<SEC-DOCUMENT>0001575872-23-000507.txt : 20230403
<SEC-HEADER>0001575872-23-000507.hdr.sgml : 20230403
<ACCEPTANCE-DATETIME>20230403171102
ACCESSION NUMBER:		0001575872-23-000507
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		59
FILED AS OF DATE:		20230403
DATE AS OF CHANGE:		20230403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			60 DEGREES PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001946563
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				452406880
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269483
		FILM NUMBER:		23793800

	BUSINESS ADDRESS:	
		STREET 1:		1025 CONNECTICUT AVENUE NW
		STREET 2:		SUITE 1000
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20036
		BUSINESS PHONE:		202-327-5422

	MAIL ADDRESS:	
		STREET 1:		1025 CONNECTICUT AVENUE NW
		STREET 2:		SUITE 1000
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20036
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>cm270_s1a.htm
<DESCRIPTION>FORM S-1/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">As filed with the U.S. Securities and Exchange
Commission on April 3, 2023</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Registration
No. 333-269483</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amendment No. 1 to<BR>
FORM S-1</B>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>60
DEGREES PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="width: 33%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>45-2406880</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or Other Jurisdiction of <BR>
    Incorporation or Organization)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Primary Standard Industrial<BR>
    Classification Code Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">1025 Connecticut Avenue
NW Suite 1000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Washington, D.C. 20036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">202-327-5422</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Geoffrey S. Dow</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>President and Chief Executive
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>60 Degrees Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>1025 Connecticut Avenue
NW Suite 1000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20036</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(202) 327-5422</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, address, including
zip code, and telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>Copies to</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Ross D. Carmel, Esq.</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: center"><FONT STYLE="font-size: 10pt"><B>David Ficksman, Esq.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Anthony Patel, Esq.</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Joilene Wood, Esq.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Carmel, Milazzo &amp; Feil LLP</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>TroyGould PC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>55 West 39<SUP>th</SUP> Street, 18th Floor</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>1801 Century Park East, Suite 1600</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>New York, New York 10018</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Los Angeles, CA 90067</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Telephone: (212) 658-0458</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Telephone: (310) 789-1290</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate date of commencement of proposed
sale to the public: <B>As soon as practicable after the effective date of this Registration Statement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on
this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following
box. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large
accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; text-align: justify"><FONT STYLE="font-size: 10pt">Large accelerated filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD>
    <TD STYLE="width: 48%; text-align: justify"><FONT STYLE="font-size: 10pt">Accelerated filer <FONT STYLE="font-family: Wingdings">&uml;</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Non-accelerated filer <FONT STYLE="font-family: Wingdings">x</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Smaller reporting company <FONT STYLE="font-family: Wingdings">x</FONT></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Emerging growth company <FONT STYLE="font-family: Wingdings">x</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with section 8(a) of the Securities
Act of 1933 or until the registration statement shall become effective on such date as the Commission acting pursuant to said section
8(a), may determine.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: red">The information in this prospectus
is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities
in any state or other jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>SUBJECT TO COMPLETION, DATED
APRIL 3, 2023</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp; <B>Units<BR>
Each Consisting of One Share of Common Stock and</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>One
Warrant to Purchase One Share of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="cm270_s1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>60 Degrees Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is an initial public offering of securities of 60 Degrees Pharmaceuticals, Inc. We are offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock. The units have no stand-alone
rights and will not be certificated or issued as stand-alone securities. The shares of common stock and the warrants comprising the units
are immediately separable and will be issued separately in this offering. Each warrant is immediately exercisable on the date of issuance
and will expire five years from the date of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering also includes the shares of common stock issuable upon the exercise of the warrants. The warrants will be issued in book-entry
form pursuant to a warrant agent agreement (the &ldquo;Warrant Agent Agreement&rdquo;) between us and Equity Stock Transfer, LLC, who
will be acting as the warrant agent (the &ldquo;Warrant Agent&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently estimate that the offering price will be between $4.15 and $6.15 per unit and the exercise price per warrant will be between
$4.7725 and $7.0725 (115% of the offering price per unit). </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prior
to this offering, there has been no public market for our common stock. We have applied to have our common stock listed on The Nasdaq
Capital Market under the symbol &ldquo;SXTP.&rdquo; This offering is contingent upon final approval of our listing application with The
Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;). There can be no assurance that we will be successful in listing our common stock on The
Nasdaq Capital Market. We have not and do not intend to apply for listing of the warrants on any exchange or market.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to use the proceeds from this offering
for general corporate purposes, including working capital. See &ldquo;<I>Use of Proceeds</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This prospectus also relates to the resale or other
disposition, from time to time, by the selling stockholders identified in this prospectus under the caption &ldquo;<I>Selling Stockholders</I>&rdquo;
(collectively, the &ldquo;Selling Stockholders&rdquo;), of up to 1,925,202 shares of our common stock. We will not receive any proceeds
from the sale or other disposition of shares by the Selling Stockholders.&nbsp;The Selling Stockholders will bear all commissions and
discounts, if any, attributable to the sale or other disposition of the shares. We will bear all costs, expenses and fees in connection
with the registration of the Selling Stockholders&rsquo; shares.</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may sell or otherwise dispose of their shares of our common stock offered by this prospectus from time to time on
terms to be determined at the time of sale through ordinary brokerage transactions or through any other means described in this prospectus
under &ldquo;<I>Selling Stockholders&mdash;Plan of Distribution</I>.&rdquo; The prices at which the Selling Stockholder may sell the
shares will be determined by the prevailing market price for the shares or in negotiated transactions. We will not receive any proceeds
from the sale of the common stock by the Selling Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Investing in our securities involves a high
degree of risk. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on page [*] of this prospectus for a discussion of information that should
be considered in connection with an investment in our securities.</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the Securities and Exchange Commission
(&ldquo;SEC&rdquo;) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
and a &ldquo;smaller reporting company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;),
and have elected to comply with certain reduced public company reporting requirements. See &ldquo;<I>Summary&mdash;Implications of Being
an Emerging Growth Company and Smaller Reporting Company</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 74%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per
    Unit</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; border-bottom: black 1pt solid; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Initial public offering price</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Underwriting discounts and commissions<SUP>(1)(2)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Proceeds, before expenses, to us</FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Represents underwriting discount and commissions
                                            equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per unit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Does not include a non-accountable expense
                                            allowance equal to 1.5% of the gross proceeds of this offering, payable to WallachBeth Capital
                                            LLC, as representative of the underwriters (the &ldquo;Representative&rdquo;), or the reimbursement
                                            of certain expenses of the underwriters. See &ldquo;<I>Underwriting</I>&rdquo; beginning
                                            on page [*] of this prospectus for additional information regarding underwriting compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the underwriting discounts listed
above and the non-accountable expense allowance described in the footnote, we have agreed to issue upon the closing of this offering
to the Representative, warrants that will expire on the fifth anniversary of the effective date of the registration statement of which
this prospectus is a part, entitling the Representative to purchase 6% of the number of shares of common stock sold in this offering
(excluding shares of common stock sold to cover over-allotments, if any) (the &ldquo;Representative Warrants&rdquo;). The registration
statement of which this prospectus is a part also covers the Representative Warrants and the shares of common stock issuable upon the
exercise thereof. For additional information regarding our arrangement with the underwriters, please see &ldquo;<I>Underwriting</I>&rdquo;
beginning on page [*].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have granted the Representative an option
to purchase from us, at the public offering price, up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares of common stock and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;warrants units, less the
underwriting discounts and commissions, within 45 days from the date of this prospectus to cover over-allotments, if any. If the Representative
exercises the option in full, the total underwriting discounts and commissions payable will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The underwriters expect to deliver the securities against payment
on or about ______________, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Sole Book-Running Manager</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WallachBeth Capital LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Prospectus dated ______________, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 94%; text-align: justify"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="width: 6%; text-align: right"><A HREF="#a_001"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">TRADEMARKS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_002"><FONT STYLE="font-size: 10pt">1</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">GLOSSARY OF SELECTED TERMS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_003"><FONT STYLE="font-size: 10pt">2</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">MARKET DATA</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_004"><FONT STYLE="font-size: 10pt">3</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_005"><FONT STYLE="font-size: 10pt">4</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">SUMMARY OF THE OFFERING</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_006"><FONT STYLE="font-size: 10pt">16</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">SUMMARY FINANCIAL DATA</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_007"><FONT STYLE="font-size: 10pt">17</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_008"><FONT STYLE="font-size: 10pt">18</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_009"><FONT STYLE="font-size: 10pt">53</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_010"><FONT STYLE="font-size: 10pt">54</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">DIVIDEND POLICY</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_011"><FONT STYLE="font-size: 10pt">55</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_012"><FONT STYLE="font-size: 10pt">55</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">CAPITALIZATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_013"><FONT STYLE="font-size: 10pt">55</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_014"><FONT STYLE="font-size: 10pt">57</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL
    CONDITION AND RESULTS OF OPERATIONS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_015"><FONT STYLE="font-size: 10pt">58</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">BUSINESS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_016"><FONT STYLE="font-size: 10pt">67</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">MANAGEMENT</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_017"><FONT STYLE="font-size: 10pt">95</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">EXECUTIVE COMPENSATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_018"><FONT STYLE="font-size: 10pt">100</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">PRINCIPAL STOCKHOLDERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_019"><FONT STYLE="font-size: 10pt">105</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_020"><FONT STYLE="font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_020"><FONT STYLE="font-size: 10pt">106</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_021"><FONT STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_021"><FONT STYLE="font-size: 10pt">106</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_022"><FONT STYLE="font-size: 10pt; text-transform: uppercase">Shares Eligible for Future
    Sale</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_022"><FONT STYLE="font-size: 10pt">109</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_023"><FONT STYLE="font-size: 10pt">UNDERWRITING</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_023"><FONT STYLE="font-size: 10pt">110</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_024"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_024">114</A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#a_025"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_025"><FONT STYLE="font-size: 10pt">114</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><A HREF="#a_026"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#a_026"><FONT STYLE="font-size: 10pt">114</FONT></A></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><A HREF="#fin_007"><FONT STYLE="font-size: 10pt">INDEX TO FINANCIAL STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#fin_007"><FONT STYLE="font-size: 10pt">F-2</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Through and including&nbsp;______________,
2023 (the 25th day after the date of this prospectus), all dealers that effect transactions in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This is in addition to the dealers&rsquo; obligation to deliver a prospectus
when acting as underwriter and with respect to their unsold allotments or subscriptions.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
should rely only on the information contained in this prospectus or any prospectus supplement or amendment. Neither we, nor the underwriters,
have authorized any other person to provide you with information that is different from, or adds to, that contained in this prospectus.
If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the underwriters take responsibility
for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the
information contained in this prospectus or any free writing prospectus is accurate only as of the date of this prospectus, regardless
of the time of delivery of this prospectus or of any sale of our securities. Our business, financial condition, results of operations
and prospects may have changed since that date. We are not making an offer of any securities in any jurisdiction in which such offer
is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">No
action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution
of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States
are required to inform themselves about and to observe any restrictions as to this public offering and the distribution of this prospectus
applicable to that jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><FONT STYLE="text-transform: uppercase"><B>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Throughout this prospectus, unless otherwise
designated or the context suggests otherwise,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">all
                                            references to the &ldquo;Company,&rdquo; &ldquo;60P,&rdquo; the &ldquo;registrant,&rdquo;
                                            &ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us&rdquo; in this prospectus mean 60 Degrees
                                            Pharmaceuticals, Inc., a Delaware corporation, and 60P Australia Pty Ltd, an Australian proprietary
                                            company limited by shares, our subsidiary;</FONT></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">assumes an initial public offering
                                            price of our units of $5.15 per unit, the midpoint of the estimated range of $4.15 and $6.15;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">&ldquo;year&rdquo; or &ldquo;fiscal
                                            year&rdquo; means the year ending December 31; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">all dollar or $ references, when
                                            used in this prospectus, refer to United States dollars.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise indicated, all information
in this prospectus assumes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">no shares of common stock have been
                                            issued pursuant to (i) the conversion of certain of our outstanding debt and (ii) certain
                                            consultant agreements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">no shares of common stock have been
                                            issued pursuant to any warrants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">no shares of common stock have been
                                            issued pursuant to the Representative&rsquo;s over-allotment option;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">no shares of common stock have been
                                            issued pursuant to the Representative Warrants; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we have filed our amended and restated
                                            certificate of incorporation to include a statement that the exclusive forum provision does
                                            not apply to claims arising under federal securities laws, of which will be filed immediately
                                            prior to the closing of this offering.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_002"></A>TRADEMARKS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Solely for convenience, our trademarks and tradenames
referred to in this prospectus, may appear without the &reg; or &trade; symbols, but such references are not intended to indicate in
any way that we will not assert, to the fullest extent under applicable law, our rights to these trademarks and tradenames. All other
trademarks, service marks and trade names included or incorporated by reference into this prospectus or the accompanying prospectus are
the property of their respective owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_003"></A><B>GLOSSARY OF SELECTED TERMS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are definitions
of certain terms that are commonly used in the medical industry and in this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;8-aminoquinoline&rdquo;
refers to the structural class of antimalarials to which Tafenoquine and Primaquine belong. 8-aminoquinolines are characterized by the
presence of an 8-amino substitution on their core quinoline ring, which confers their unique properties including an oxidative Mode of
Action and activity against the relapsing liver forms of <I>Plasmodium vivax</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;API&rdquo;
means active pharmaceutical ingredient, the active molecule contained in a pharmaceutical product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Arakoda&rdquo;
means ARAKODA<I>&reg;</I>, the 60P-owned and FDA-approved product to prevent malaria in travelers, which contains as its active pharmaceutical
ingredient, Tafenoquine succinate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Broad Spectrum of Activity&rdquo;
refers to a molecule or drug that is active against a range of different pathogens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;CAR-T&rdquo;
means chimeric antigen receptor therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;CLIA&rdquo;
means The Clinical Laboratory Improvements Amendment of 1988.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Dengue&rdquo; means
a mosquito-borne viral disease occurring in tropical and subtropical areas.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Ethics Committee&rdquo; a stand-alone or institutional committee responsible for ensuring clinical trials
are conducted ethically, and from whom permission is required for a clinical trial to proceed.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;EUA&rdquo;
means Emergency Use Authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;FDA&rdquo; refers to
the U.S. Food and Drug Administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;G6PD&rdquo; means glucose-6-phosphate dehydrogenase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;GMP&rdquo; means Good
Manufacturing Practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;IND&rdquo; means investigational
new drug application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;Kodatef&rdquo;
is the brand name of Arakoda outside the United States. Kodatef has been approved for use in Australia by the Therapeutic Goods Administration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;Legacy Studies&rdquo; is a reference to the collection of clinical and non-clinical
studies involving Tafenoquine, which were conducted by the U.S. Army prior to 2014, and which were included in the new drug application
submitted by 60P to the FDA in 2018. Some of those Legacy Studies are described in the account of the Army development program published
by Zottig et. al.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;Mode of Action&rdquo; is the process by which an anti-infective
or other pharmaceutical product is known or suspected to affect a disease process. This process is different for each drug and may or
may not be known at the time of FDA approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;Named-patient&rdquo; use of a
drug refers to the prescription by a physician of a drug to one of their patients in a jurisdiction in which the prescribed drug has not
received marketing authorization, but is believed by said physician to be safe and medically necessary. Also, sometimes referred to as
&ldquo;compassionate use.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;NIH&rdquo; means the
National Institutes of Health.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;PDUFA&rdquo; means
The Prescription Drug User Fee Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;PMA&rdquo; means Premarket Approval by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;Primaquine&rdquo; is the FDA-approved antimalarial from which
Tafenoquine is chemically derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;<I>P. vivax</I>&rdquo;
is an abbreviation for Plasmodium vivax, one of the two most important malaria parasites, characterized by its ability to relapse utilizing
a dormant life cycle stage that persists in the human liver following a bite from an infected mosquito.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; color: #212121">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in; color: #212121">&ldquo;RSV&rdquo;
means respiratory&nbsp;syncytial virus, which is a common respiratory virus that usually causes cold-like symptoms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;Repositioned Molecule&rdquo; is one which was approved by the FDA or other
regulatory authorities to treat one disease, and is being developed for a new disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Tafenoquine&rdquo; is the shortened name of the active ingredient
of Arakoda and Kodatef, tafenoquine succinate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;TGA&rdquo; is the Therapeutic Goods Administration, the Australian
equivalent of the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&ldquo;TMPRSS2&rdquo;
means transmembrane protease, serine 2, which is an enzyme that in humans is encoded by the TMPRSS2 gene, and belongs to the TMPRSS family
of proteins, whose members are transmembrane proteins which have a serine protease activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in">In connection with presentation
of scientific data, this prospectus references &ldquo;<I>P</I>-values&rdquo; at various points. These values are provided to convey the
likelihood of a particular set of data occurring by chance. For example, a <I>P</I>-value of 0.12 associated with a stand-alone, pre-conceived
hypothesis is generally understood to mean that the likelihood of that particular outcome occurring purely by chance is 12%. It is scientific
convention that a particular observation is &ldquo;proven&rdquo; if its associated <I>P</I> value is lower than 0.05 (i.e., associated
with a likelihood of occurring by chance of &lt; 5%). However, clinical observations of interest are routinely reported in the peer-reviewed
scientific literature even if their associated <I>P</I>-values are &gt; 0.05, because they may represent important therapeutic signals,
and motivate additional research. With the exception of the data reported in Figure B, the efficacy data described herein related to
our COVID-19 program and Arakoda have been published in a peer-reviewed scientific journal.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP><I>P</I>-values presented herein are not corrected for multiple comparison error, and represent the outcomes of both pre-conceived,
and post-hoc, analyses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>USE
of PRODUCT VERSUS GENERIC NAMES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus makes reference to two
commercial products owned/manufactured by 60P, Arakoda and Kodatef, which are approved by regulators in the United States and
Australia, respectively, for the prevention of malaria. The active molecule in those products is tafenoquine succinate (Tafenoquine
for short), which we are repositioning for other indications using either (i) the same dosing regimen employed in the commercial
Arakoda product (in which case reference is made to the &ldquo;Arakoda regimen of tafenoquine&rdquo; or (ii) different dosing
regimens (in which case reference is made to &ldquo;Tafenoquine&rdquo;). We also utilize the molecular name (Tafenoquine), where the
active ingredient of Arakoda and Kodatef was tested in cell culture or animal models. These different usages have been employed both
for convenience and to avoid any assertions that Arakoda or Kodatef have been granted marketing authorization by regulators for uses
other than the prevention of malaria.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_004"></A><B>MARKET DATA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market data and certain industry data and forecasts
used throughout this prospectus were obtained from internal company surveys, market research, consultant surveys, publicly available
information, reports of governmental agencies and industry publications and surveys. Industry surveys, publications, consultant surveys
and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the
accuracy and completeness of such information is not guaranteed. To our knowledge, certain third-party industry data that includes projections
for future periods does not take into account the effects of the worldwide coronavirus (COVID-19) pandemic. Accordingly, those third-party
projections may be overstated and should not be given undue weight. Forecasts are particularly likely to be inaccurate, especially over
long periods of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing
the forecasts we cite. Statements regarding our market position are based on the most currently available data. While we are not aware
of any misstatements regarding the industry data presented in this prospectus, our estimates involve risks and uncertainties and are
subject to change based on various factors, including those discussed under the heading &ldquo;<I>Risk Factors</I>&rdquo; in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1
</SUP>Dow and Smith, New Microbe and New Infect 2022; 47:100986.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_005"></A><FONT STYLE="text-transform: uppercase"><B>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary provides a brief overview of
the key aspects of our business and our securities. The reader should read the entire prospectus carefully, especially the risks of investing
in our securities discussed under &ldquo;Risk Factors.&rdquo; Some of the statements contained in this prospectus, including statements
under &ldquo;Summary&rdquo; and &ldquo;Risk Factors&rdquo; as well as those noted in the documents incorporated herein by reference,
are forward-looking statements and may involve a number of risks and uncertainties. Our actual results and future events may differ significantly
based upon a number of factors. The reader should not put undue reliance on the forward-looking statements in this document, which speak
only as of the date on the cover of this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
the context otherwise requires, references in this prospectus to &ldquo;60P,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo;
and &ldquo;our&rdquo; refer to 60 Degrees Pharmaceuticals, Inc., a Delaware corporation, and its majority ownedsubsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a growth-oriented specialty pharmaceutical company with a goal
of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and
treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that
has been on the market since late 2019. Currently, 60P&rsquo;s pipeline under development covers development programs for COVID-19, fungal,
tick-borne, and other viral diseases utilizing three of the Company&rsquo;s future products: (i) new products that contain the Arakoda
regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Mission</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our mission is to address the unmet medical need associated with infectious
diseases, through the development and commercialization of new small molecule therapeutics, focusing on synthetic drugs (made by chemists
in labs, excluding biologics) with good safety profiles based on prior clinical studies, in order to reduce cost, risk, and capitalize
on existing research. We are seeking to expand Arakoda&rsquo;s use for malaria prevention and to demonstrate clinical benefit for other
disease indications. We are further testing the viability of another product (Celgosivir) to determine whether to advance it into further
clinical development, and may seek to develop and license other molecules in the future. Celgosivir is being developed for COVID-19, RSV
and Dengue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2018, the FDA approved Arakoda for malaria
prevention in individuals 18 years and older, an indication for which there has historically been approximately 550,000 prescriptions
(one prescription per three weeks of travel) in the United States each year for the current market-leading product (atovaquone-proguanil).
Arakoda entered the U.S. supply chain in the third quarter of 2019, just prior to the COVID-19 pandemic. As the approved indication is
for travel medicine, and international travel was substantially impacted by the pandemic, we did not undertake any active marketing efforts
for Arakoda. Targeted marketing efforts will commence in the second half of 2023 to promote the malaria indication as resources permit,
although we expect our primary efforts to be developing Arakoda for other applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are repositioning the Arakoda regimen of Tafenoquine for new indications
to address several therapeutic indications that have substantial U.S. caseloads, as further described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Treatment of COVID-19</U>. According to <I>The New
    York Times</I>, the lowest daily case rate for the COVID-19 virus since March 2020 based on a seven day average has not typically
    been below 11,000 cases. Assuming this trend continues, this dynamic translates into a potential market size of at least 4,000,000
    cases per year in 2023 and future years. Paxlovid and molnupiravir have received emergency use authorization for the prevention of
    death and hospitalization in individuals with high risk of disease progression and their use for those purposes continues to be
    recommended by public health experts. However, to our knowledge, there is not published evidence from randomized controlled clinical
    trials that either drug reduces the time to sustained clinical recovery for four or more days in standard risk patients infected
    with contemporary viral strains, and Pfizer has formally abandoned efforts related to this endpoint for paxlovid.<SUP>2 </SUP>Additionally
    molnupiravir and paxlovid are not approved by FDA for use in patients without risk factors for disease progression, and that
    excluded lower risk population comprises about 25% of the U.S. population.<SUP>3</SUP> The economic value of that unsatisfied market
    may be a multi-billion-dollar opportunity, given that the value of paxlovid and molnupiravir in the 75% of the population in which
    they can be used was ~ $12 billion in 2022.<SUP>4</SUP> If proven effective for early relief of COVID-19 symptoms in standard risk
    COVID-19 patients, Tafenoquine (Arakoda regimen) could fulfill a patient&rsquo;s need unmet by the approved antivirals.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #201F1E">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #201F1E"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #201F1E"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP> Press release: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting.</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><SUP>3</SUP> See the Paxlovid (www.paxlovid.com)
and Lagevrio (www.lagevrio.com) prescribing information and epidemiology data described by Ajufo et al Am J Preventive Cardiol 2021;6:101156.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #201F1E"><SUP>4</SUP> See 2022 revenue data for Paxlovid in
Pfizer (https://investors.pfizer.com/Investors/Financials/SEC-Filings/SEC-Filings-Details/default.aspx?FilingId=16428097) and Lagevrio
(https://d18rn0p25nwr6d.cloudfront.net/CIK-0000064978/b390be48-92bf-4595-96da-ac5cd7c3d92e.pdf) in Merck financial reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #201F1E">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #201F1E"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Treatment and Post-Exposure Prevention of Tick-Borne Diseases</U>. There are at least 47,000 cases of babesiosis (red blood cell infections caused by deer tick bites) in the United States each year. This estimate is based on the observations of Krugeler who reported that 476,000 cases of Lyme disease occur in U.S. states where babesiosis is endemic and Krause et. al. who reported that 10% of Lyme disease patients are co-infected with babesiosis (thus 476,000*10% = 47,600 cases of babesiosis per year).<SUP>5</SUP> Furthermore, post-exposure prophylaxis following a tick-bite is a recognized indication to prevent Lyme disease, and it is likely that a drug proven to be effective for this indication for babesiosis would also be used in conjunction with Lyme prophylaxis. There may be more than 400,000 tick bites in the United States requiring medical treatment each year. This estimate is based on the observation that approximately 50,000 tick bites are treated in U.S. hospital emergency rooms each year but this calculation represents only about 12% of actual treated tick bites based on observations from comparable ex-U.S health systems.<SUP>6</SUP> Arakoda has the potential to be added to the existing standard of care for treatment of babesiosis, and to be a market leading product for pre- and post-exposure prophylaxis of babesiosis.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Prevention of fungal pneumonias</U>. There are up to ~ 91-92,000 new medical conditions each year in the United States including acute lymphoblastic leukemia (up to 6.540 cases) and large B-cell lymphoma (up to 18,000 cases) patients receiving CAR-T therapy, solid organ transplant patients (up to 42,887 cases), allogeneic (~ 9,000 cases) and autologous (~ 15,000 cases) hematopoietic stem cell transplant patients for whom the use of antifungal prophylaxis is recommended.<SUP>7 </SUP>Despite the availability and use of antifungal prophylaxis, the risk of some patient groups contracting fungal pneumonia exceeds the risk of contracting malaria during travel to West Africa.<SUP>6 </SUP>Arakoda has the potential to be added to existing standard of care regimens for the prevention of fungal pneumonias.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Treatment of&nbsp;<I>Candida&nbsp;</I>infections</U>. According to the Centers for Diseases Control (CDC), there are 50,000 cases of candidiasis (a type of fungal infection) each year in the United States and up to 1,900 clinical cases of <I>C</I>. <I>auris</I>, for which there are few available treatments, have been reported to date<SUP>9</SUP> Arakoda has the potential to be a market leading therapy for treatment/prevention of <I>C. auris</I>, and to be added to the standard of care regimens for other <I>Candida </I>infections.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dengue and RSV, both afflictions against which
60P&rsquo;s early clinical candidates (e.g., Celgosivir) show potential in non-clinical studies, are associated with at least 4.1 million
cases globally according to the European CDC (Dengue) <SUP>10 </SUP>and up to 240,000 hospitalizations (RSV) in children less than five
years of age and adults greater than 65 years of age in the United States each year according to the CDC.<SUP>11</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">More information about our products is provided in the next section,
and the status of various development efforts for the above-mentioned diseases is outlined in Figure A, below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>5
</SUP>Krause et al JAMA 1996;275:1657-16602. Krugeler et al&nbsp;<I>Emerg Infect Dis&nbsp;</I>2021;27:616-619</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>6
</SUP>Marx et. al., MMWR 2021;70:612-616.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>7
</SUP>See statistics for solid organ transplants at the Organ Transplant and Procurement Network at: National data - OPTN (hrsa.gov);
See statistics for hematopoietic stem cell transplant in Dsouza et al Biology of Blood and Bone Marrow Transplantation 202;26: e177-e182;
See statistics for acute lymphoblastic leukemia at: Key Statistics for Acute Lymphocytic Leukemia (ALL) (cancer.org); See statistics
for large cell large B-cell lymphoma at; Diffuse Large B-Cell Lymphoma - Lymphoma Research Foundation; Treatment guidelines recommending
antifungal prophylaxis for these diseases can be reviewed in (i) Fishman et al Clinical Transplantation. 2019;33:e13587, (ii) Hematopoietic
Cell Transplantation (cancernetwork.com), (iii) Cooper et al Journal of the National Comprehensive Cancer Network 2016;14:882-913 and
(iv) Los Arcos et al Infection (2021) 49:215&ndash;231.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>8
</SUP>Aguilar-Guisado et al Clin Transplant 2011;25:E629&ndash;38; Mace et al MMWR <FONT STYLE="background-color: white">202;70:1&ndash;35</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>9 </SUP><U>https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html.;
</U>https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-decoration: none; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-decoration: none"><SUP>10</SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>https://www.ecdc.europa.eu/en/dengue-monthly#:~:text=This%20is%20an%20increase%20of%2032%20653%20cases%20and%2032,853%20deaths%20have%20been%20reported.</U></FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>11</SUP>https://www.cdc.gov/rsv/research/index.html#:~:text=Each%20year%20in%20the%20United,younger%20than%205%20years%20old.&amp;text=58%2C000-80%2C000%20hospitalizations%20among%20children%20younger%20than%205%20years%20old.&amp;text=60%2C000-120%2C000%20hospitalizations%20among%20adults%2065%20years%20and%20older.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Figure A</U></FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="cm270_s1img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Arakoda
                                            (Tafenoquine) for malaria prevention</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
entered into a cooperative research and development agreement with the United States Army in 2014 to complete development of Arakoda
for prevention of malaria.<SUP>12</SUP> With the U.S. Army, and other private sector entities as partners, we coordinated the execution
of two clinical trials, development of a full manufacturing package, gap-filling non-clinical studies, compilation of a full regulatory
dossier, successful defense of our program at an FDA advisory committee meeting, and submitted a new drug application (&ldquo;NDA&rdquo;)
to the FDA in 2018. The history of that collaboration has been publicly communicated by the U.S. Army.<SUP>13</SUP></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA and Australia&rsquo;s medicinal regulatory
agency, Therapeutic Goods Administration, subsequently approved Arakoda and Kodatef (brand name in Australia), respectively, for prevention
of malaria in travelers in 2018. Prescribing information and guidance for patients can be found at <I>www.arakoda.com</I>. The features
and benefits of Tafenoquine for malaria prophylaxis (marketed as Arakoda in the United States), some of which have been noted by third
party experts, include: convenient once weekly dosing following a three day load; the absence of reports of drug resistance during malaria
prophylaxis; activity against liver and blood stages of malaria as well as both the major malaria species (<I>Plasmodium vivax</I> and
<I>Plasmodium falciparum);</I> absence of any black-box safety warnings; good tolerability including in women and individuals with prior
psychiatric medical history, and a comparable adverse event rate to placebo with up to 12 months continuous dosing.<SUP>14 </SUP>Tafenoquine
entered the commercial supply chains in the U.S. (as Arakoda) and Australia (as Kodatef) in the third quarter of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The only limitation of Arakoda is the requirement
for a G6PD test prior to administration.<SUP>15</SUP> The G6PD&nbsp;test must be administered to a prospective patient prior to administration
of&nbsp;Arakoda in order to prevent the potential occurrence of hemolytic anemia in individuals with G6PD deficiency.<SUP>16</SUP>&nbsp;G6PD
is one of the most common enzyme deficiencies and is implicated in hemolysis following administration/ingestion of a variety of oxidant
drugs/food. G6PD must also be ruled out as a possible cause when diagnosing neonatal jaundice. As a consequence, G6PD testing is widely
available in the United States through commercial pathology service providers (e.g., Labcorp, Quest Diagnostics, etc.). Although these
tests have a turn-around time of up to 72 hours, the test needs only to be administered once. Thus, existing U.S. testing infrastructure
is sufficient to support the FDA-approved use of the product (malaria prevention) by members of the armed forces (who automatically have
a G6PD test when they enlist), civilian travelers with a long planning horizon or repeat travelers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Tafenoquine (Arakoda regimen) for COVID-19</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the COVID-19 pandemic, since our commercial
opportunities were limited, we embarked upon an exploratory research and development campaign to identify new indications for the Arakoda
dosing regimen of Tafenoquine. In the second quarter and third quarter of 2020, we commissioned cell culture studies that showed that
Tafenoquine, the active ingredient in Arakoda, inhibited replication of SARS-CoV-2 (the virus that causes COVID-19).<SUP>17 </SUP>Then,
we commissioned computer simulations, which showed that the predicted concentration of Tafenoquine in the lungs of COVID-19 patients following
administration of the first four doses of the approved antimalarial prophylactic regimen of Arakoda exceeded those inhibiting the virus
in cell culture. The foregoing provided the rationale for seeking approval from the FDA to conduct a Phase II clinical trial in patients
with the COVID-19 disease, for which the FDA granted clearance to proceed in October 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021, with financial support from the U.S.
Army<SUP>16</SUP>, we conducted a Phase II clinical investigation of the safety and efficacy of Tafenoquine using the Arakoda regimen
in outpatients with mild-moderate COVID-19 disease (assumed to be mostly caused by the delta variant of SARS-COV-2). In summary, safety
and efficacy of Tafenoquine administered at the approved dose for malaria prevention (200 mg dose once per day on days 1, 2, 3, and 10)
was evaluated over a 28-day period in mild-moderate COVID-19 patients. The primary endpoint was day 14 clinical recovery from COVID-19
symptoms, defined as cough mild or absent, respiratory rate &lt; 24 bpm, and no shortness of breath or fever. From March 2021 through
September 2021, this study enrolled 87 of the originally planned 275 patients. In October 2021, a data safety monitoring board, after
conducting a futility analysis for the primary endpoint and reviewing adverse event data, recommended that the study be continued as planned.
However, at the time of the unblinding of this study, topline results from Phase III studies for three oral COVID-19 therapeutics in at
risk patients with mild-moderate COVID-19 disease had been announced: Fluvoxamine, molnupiravir, and paxlovid reduced the risk of hospitalization
by approximately 30%, 50% (in the first public announcement) and 90%, respectively.<SUP>19</SUP> As reported in our publication<SUP>18</SUP>,
an informal survey of potential funding/commercialization partners for a follow-on program suggested it would be important to know the
magnitude of possible benefit prior to initiating such an effort. Primarily for the above reasons, the study was terminated and unblinded
early.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
results of the study were accepted for peer-reviewed publication in May 2022.<SUP>21</SUP> For the primary endpoint, the proportion of
patients not recovered on Day 14 was numerically decreased by 27% in the intent to treat population (8/45 v 10/42 not recovered in the
Tafenoquine and placebo arms, <I>P</I> = 0.60) and 47% in the per protocol population (5/42 v 9/41, <I>P</I> = 0.25). Amongst individuals
who recorded responses in an electronic diary on day 28, all Tafenoquine patients were recovered, whereas up to 12% of placebo patients
exhibited lingering shortness of breath. Analysis of secondary/exploratory endpoints suggested Arakoda reduced time to clinical recovery
from shortness of breath, cough and fever (<I>P </I>&lt; 0.02) and numerically improved aggregate symptom scores five days after treatment
(<I>P</I> &lt; 0.1).<SUP>22</SUP> The risk of COVID-19-related hospitalization was numerically reduced in the Arakoda arm (by approximately
50%; two instances for placebo versus one for Arakoda). Mild, drug related adverse events occurred in 8.4% of individuals in the Tafenoquine
arm (v 2.4% in the placebo). We plan to confirm that Arakoda accelerates sustained recovery from COVID-19 symptoms in our next study
(described in &ldquo;<I>Prospectus Summary&mdash;Strategy</I>&rdquo; beginning on page [*]).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP></SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>12
</SUP>In 2014, we signed a cooperative research and development agreement with the United States Army Medical and Materiel Development
Activity (Agreement W81XWH-14-0313). Under this agreement, we agreed to submit an NDA for Tafenoquine to the FDA (as Arakoda), while
the US Army agreed to finance the bulk of the necessary development activities in support of that goal.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>13</SUP> Zottig et al Military Medicine 2020;
185 (S1): 687.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>14</SUP> Tan and Hwang Journal of Travel
Medicine, 2018, 1&ndash;2; Baird Journal of Travel Medicine 2018:, 1&ndash;13; Schlagenhauf et al Travel Medicine and Infectious Disease
2022; 46:102268; See Arakoda prescribing information at www.arakoda.com; McCarthy et al CID 2019:69:480-486; Dow et al. Malar J (2015)
14:473; Dow et al. Malaria Journal 2014, 13:49; Novitt-Moreno et al Travel Med Infect Dis 2022 Jan-Feb;45:102211.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>15</SUP> See prescribing information at www.arakoda.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>16</SUP> See prescribing information at www.arakoda.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>17</SUP> U.S. Patent application # 17/189,544,
Dow et. al. bioRxiv&nbsp;2020.07.12.199059;&nbsp;doi:&nbsp;https://doi.org/10.1101/2020.07.12.199059.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>18</SUP> Financial support was obtained from
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (which may be referred to as &ldquo;JPEO&rdquo;)
or JPEO via other transactional authority agreement #W911QY-21-9-0011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>19 </SUP>Reis et al Lancet Global Health
2022;10:e42-51, Bernal et al New Eng J Med 2021; https://doi.org/10.1056/NEJMoa2116044; Pfizer Inc. Press release (November 5, 2021) &ndash;
Pfizer&rsquo;s novel COVID 19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of
Phase 2/3 EPIC-HR study. Accessible at: Pfizer&rsquo;s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization
or Death by 89% in Interim Analysis of Phase 2/3 EPIC-HR Study | Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>20</SUP> Dow and Smith, New Microbe and New
Infect 2022; 47:100986.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>21</SUP> Dow and Smith, New Microbe and New
Infect 2022; 47:100986.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>22</SUP> Dow and Smith, New Microbe and New
Infect 2022; 47:100986.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2022, we conducted additional analyses of laboratory
endpoint data from the clinical study described above and are preparing a manuscript for publication. That analysis and the scientific
literature suggest two possible modes of action for Arakoda: (i) down-regulation of cytokines (immune system inflammatory proteins) associated
with severe COVID-19 and a greater risk of hospitalization or death and/or (ii) inhibition of viral entry in the lung or elsewhere in
the body, perhaps through inhibition of a host enzyme called TMPRSS2 (which facilitates entry of the virus that causes COVID-19, SARS-CoV-2,
into human cells).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming the efficacy of Tafenoquine in COVID-19
disease is proven in our next study, some of the features of the Arakoda regimen that make it ideal for malaria prophylaxis might also
make it very useful for COVID-19 related indications. Tafenoquine is slowly metabolized and has few important drug-drug interactions,
so it might be an ideal partner for standard of care oral COVID-19 therapeutics that reduce hospitalization but have no demonstrated effect
on the time to clinical recovery in non-hospitalized patients. The Arakoda regimen requires fewer tablets (8 in the first ten days versus
30 or 40 for paxlovid and molnupiravir) which should make compliance with medication easier for patients. This is an important consideration
in the attractiveness of a regimen in standard risk patients at lower risk of hospitalization, and who may be interested in taking a COVID-19
therapeutic primarily to treat early symptoms and accelerate recovery. The potential for better compliance may also suggest suitability
for outbreak control in some settings (including, for example, nursing homes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Tafenoquine for other infectious diseases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the pandemic, we also worked with NIH
to evaluate the utility of Tafenoquine as an antifungal. We, and the NIH, found that Tafenoquine exhibits a Broad Spectrum of Activity
in cell culture against <I>Candida</I> and other yeast strains via a different Mode of Action than traditional antifungals and also exhibits
antifungal activity against some fungal strains at clinically relevant doses in animal models.<SUP>23 </SUP>Our work followed Legacy
Studies that show Tafenoquine is effective for treatment and prevention of <I>Pneumocystis</I> pneumonia in animal models.<SUP>24</SUP>
We believe that if added to the standard of care for anti-fungal and yeast infection treatments for general use, Tafenoquine has the
potential to improve patient outcomes in terms of recovery from yeast infections, and prevention of fungal pneumonias in immunosuppressed
patients. There are limited treatment options available for these indications, and Tafenoquine&rsquo;s novel mechanism of action might
also mitigate problems of resistance. Clinical trial(s) to prove safety and efficacy, and approval by the FDA and other regulators, would
be required before Tafenoquine could be marketed for these indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tafenoquine
is effective in animal models of babesiosis (tick borne red blood cell infections). In two of three recent clinical case studies, Tafenoquine
administered after failure of conventional antibiotics in immunosuppressed babesiosis patients resulted in cures.<SUP>25</SUP> Consequently,
we believe that (i) if combined with standard of care products, Tafenoquine has the potential to reduce the duration of treatment with
antibiotic therapy in immunosuppressed patients and the time to parasite clearance in non-immunosuppressed patients and (ii) that once
appropriate clinical studies have been conducted, it is likely that Tafenoquine would be quickly embraced for post-exposure prophylaxis
of babesiosis in patients with tick bites and suspected of being co-infected with Lyme disease. Clinical trial(s) to prove safety and
efficacy, and approval by FDA and other regulators, would be required before Tafenoquine could be marketed for these indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Celgosivir</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Celgosivir is a host targeted glucosidase inhibitor
that was developed separately by other sponsors for HIV then for hepatitis C.<SUP>26 </SUP>The sponsors abandoned Celgosivir after completion
of Phase II clinical trials involving 700+ patients, because other antivirals in development at the time had superior activity. The National
University of Singapore initiated development of Celgosivir independently for Dengue fever. A clinical study, conducted in Singapore,
and the results of which were accepted for publication in the peer-reviewed journal Lancet Infectious Diseases, confirmed its safety
but the observed reduction in viral load was lower than what the study was powered to detect.<SUP>27</SUP> Celgosivir (as with other
Dengue antivirals) exhibits greater capacity to cure Dengue infections in animal models when administered prior to symptom onset compared
to post-symptom onset. In animal models, this problem can be addressed for Celgosivir, by administering the same dose of drug split into
four doses per day rather than two doses per day (as was the case in the Singaporean clinical trial).<SUP>28</SUP> This observation led
to the filing and approval of a patent related to Dengue, which we licensed from the National University of Singapore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>23</SUP> Dow and Smith, New Microbe and New
Infect 2022; 45: 100964.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>24</SUP> Queener et al Journal of Infectious
Diseases 1992;165:764-8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>25</SUP> Liu et al. Antimicrobial Agents
Chemo 2021;65:e00204-21, Marcos et al. IDCases 2022;27:e01460; Rogers et al. Clin Infect Dis. 2022 Jun 10:ciac473, Prasad and Wormsner.
Pathogens 2022;11:1015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>26</SUP> Sorbera et al, Drugs of the Future
2005; 30:545-552.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>27</SUP> Low et. al., Lancet ID 2014; 14:706-715.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>28</SUP> Watanabe et al, Antiviral Research
2016; 10:e19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additional clinical studies would be required to prove that such a
4x daily dosing regimen would be safe and effective in Dengue patients to regulators&rsquo; satisfaction. To that end, earlier in our
history, we, in partnership with the National University of Singapore, and Singapore General Hospital, successfully secured a grant from
the government of Singapore for a follow-on clinical trial, but were unable at that time to raise matching private sector funding. We
concluded as a result that development of Repositioned Molecules for Dengue, solely and without simultaneous development for other therapeutic
use, despite substantial morbidity and mortality in tropical countries, was an effort best suited for philanthropic entities. Accordingly,
during the pandemic, we undertook an effort (in partnership with NIH&rsquo;s Division of Microbiology and Infectious Diseases program
and Florida State University) to determine whether Celgosivir might be more broadly useful for respiratory diseases that have impact in
both tropical and temperate countries. Preliminary data suggest Celgosivir inhibits the replication of the virus that causes COVID-19
(SARS-CoV-2) in cell culture, and the RSV virus in cell culture and provides benefits in animals. We have filed and/or licensed patents
in relation to Celgosivir for these other viruses as we believe there is potential applications to fight respiratory diseases that might
have more commercial viability than historical development of Celgosivir to combat Dengue fever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competitive Strengths</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our main competitive strength has been our ability to achieve important
clinical milestones inexpensively in therapeutic areas that other entities have found extremely challenging. With a small virtual management
team, we have successfully built productive research partnerships with public and academic entities, and licensed products with well characterized
safety profiles in prior clinical studies, thereby reducing the cost and risk of clinical development. This business and product model
enabled Arakoda to be approved in 2018, with a total operating expense of &lt; $10 million. We plan to focus in the future on generating
proof of concept clinical data sets for the approved Arakoda regimen of Tafenoquine in other therapeutic areas, all of which is expected
to foster and continue our existing tradition of inexpensive product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general strategy is to demonstrate clinical proof of concept that
the FDA-approved Arakoda regimen of Tafenoquine provides clinical benefits in non-malaria therapeutic areas. Our initial focus is on COVID-19,
but additional indications have been identified for development, namely babesiosis and fungal infections, pending further data generation.
Upon demonstration of clinical proof of concept, we plan to enter into a strategic partnership with a larger entity with commercialization
capacity, or raise additional capital to facilitate commercialization of Arakoda, and any additional clinical studies that may be required
by regulators, for both travel medicine and broad infectious disease indications. We will continue to develop our portfolio products as
resources permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beginning in the second half of 2023, we plan
to execute a Phase IIB, randomized, placebo-controlled double blind clinical study powered (at 80%) to prove that the Arakoda regimen
of Tafenoquine accelerates time to sustained clinical recovery in patients with mild-moderate disease with low risk for disease progression.
This trial will utilize the bulk of proceeds raised in this offering. Based on an analysis of unpublished data from our earlier COVID-19
clinical trial,<SUP>29 </SUP>we believe that the Arakoda regimen of Tafenoquine has the potential to reduce the time to sustained clinical
recovery by about three days (see Figure B, below). The study will be conducted in out-patient clinics in the United States. The study
will utilize the majority of the proceeds of the offering reserved for research and development activities for this purpose. As of the
date of this prospectus, we have completed a clinical study synopsis. Submission of the full protocol to the Ethics Committees and to
U.S. regulators, and a subsequent posting at <I>clinicaltrials.gov</I> will follow this initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Figure B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="cm270_s1img03.jpg" ALT="" STYLE="height: 352px; width: 600px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure B: Survival curve for sustained clinical
recovery in outpatients with mild-moderate COVID-19 disease randomized to receive Tafenoquine (Arakoda regimen) or placebo. Sustained
clinical recovery was defined as the first instance of patient reported symptoms scores being &lt; 3 for four or more days, with symptoms
scores assessed according to FDA guidance.<SUP>30</SUP> This analysis utilized unpublished data from our earlier Phase II clinical trial.<SUP>31</SUP>
The analysis excludes individuals hospitalized or loss to follow-up and with a symptom score on the days of dosing &lt; 3. This analysis
represents a post-hoc analysis of our Phase II clinical trial data. If this were a formal, pre-conceived primary study endpoint, the <I>P</I>
value of 0.1209 would imply the associated difference between Tafenoquine (Arakoda regimen) and placebo has a 12.09% chance of occurring
by chance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to design the study, subject to approval by the FDA and Ethics
Committee(s) as appropriate, to include two interim endpoints to manage risk. The first will be an optional futility analysis at the earlier
of 33% enrollment or six months following the first patient enrolled, which would allow early termination of the study if the conditional
power of proving the intended hypothesis is &lt; 20%. The second, mandatory interim analysis will occur at 75% enrollment and follow a
step-wise (sponsor-blinded) process involving testing for futility, statistical significance, and sample-size reassessment if required.
The test for statistical significance would allow early termination of the study if results are unexpectedly positive and the sample size
reassessment would allow the study to enroll more patients within pre-specified limits if variability is more, and/or the magnitude of
the expected treatment effect is less, than expected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to conduct additional non-clinical studies
to clarify the process by which Tafenoquine alters the course of COVID-19 illness. Specifically, such studies will attempt to determine
whether Tafenoquine acts as an immunomodulator (by decreasing the production of immune system molecules that cause inflammation) and/or
exhibits an antiviral effect via inhibition of the host protease TMPRSS2. Antivirals are generally utilized earlier, and immunomodulators
later, in treating patients with COVID-19 disease. However, the clinical hypothesis of our planned study will be that Arakoda accelerates
clinical recovery by three days in individuals who have experienced symptoms for fewer than seven days, thereby confirming observations
from our earlier clinical study (see Figure B). Since the potential clinical benefit is already known, the primary purpose of clarifying
the manner in which Arakoda works is to (i) address anticipated regulatory questions and (ii) ascertain whether other indications, such
as relief of COVID-19 symptoms during vaccination, treatment of long COVID-19 patients, or use during hospitalization, might be plausible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following completion of our planned COVID-19 clinical
study, if warranted based on the data generated, we intend to request a change in prescribing information to facilitate an expansion of
use of Arakoda for malaria prevention from six to twelve months (mirroring our recently published post-marketing safety study) and to
include reference to the recently generated COVID-19 treatment data. Prior to doing so, we plan to discuss with the FDA additional labeling
related to COVID-19 which might be acceptable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to design and conduct feasibility assessments for one or
more additional studies in the same type of patients as the planned study and/or for a COVID 19-related indication different from that
targeted by our clinical study in 2023. One of these additional studies would be conducted in Australia, and would be a requirement to
secure tax rebates for the overall COVID-19 program (see next paragraph). A second study is likely to be required by regulators which
may or may not be the same as the study conducted in Australia. The value of conducting additional studies, in addition to securing tax
credits or for regulatory approvals, would be (i) independently confirming the therapeutic modality/clinical mode of action of Arakoda
(i.e. that it accelerates clinical recovery from COVID-19 symptoms and/or acts as an antiviral or disease modulator) and (ii) broadening
the COVID-19 indication beyond treatment of lower risk patients (i.e. potentially increasing the volume of annual prescriptions). Thus,
possible study designs could be (i) a simple repetition of the planned study with a larger sample size, (ii) a treatment study in higher
risk patients or (iii) a pre-treatment loading study in individuals known to be exposed to the virus that causes COVID-19, and/or (iv)
amelioration of COVID-19 disease-like symptoms in individuals receiving mRNA COVID-19 vaccines (if it turns out Arakoda is an immunomodulator).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to license ex-U.S. rights to COVID-19
indications to our Australian subsidiary, 60P Australia Pty Ltd. This will facilitate claiming the Australian government&rsquo;s research
tax credit for any of our COVID-19-related research activities conducted in Australia. 60P Australia has been successful in securing research
tax credits for malaria and Dengue-related research since 2013. Since conducting our planned COVID-19 study in Australia is likely to
be unfeasible and must be conducted in the U.S., we plan to apply for an overseas finding to the Australian Tax Office in the second quarter
of 2023 to request an overseas finding for the U.S. study. Should such a finding be awarded, it would allow a tax rebate of 43.5% on research
and development costs associated with the planned U.S. COVID-19 study to be claimed, but commit the Company to conduct COVID-19 research
activities in Australia of a value at least as much as the cost of the planned U.S. clinical study.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>29</SUP> Dow and Smith, New Microbe and New Infect 2022; 45: 100964.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>30</SUP> <I>FDA 2020 Guidance on Assessing COVID-19 Symptoms</I>-14
Common COVID-19 Symptoms Severity Scale.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><SUP>31</SUP> Dow and Smith, New Microbe and New Infect 2022; 45:
100964.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are planning several commercial initiatives for
the malaria market in parallel with further clinical development activities. Three routes exist for commercialization of Arakoda for the
malaria prevention market are: (i) U.S. civilian travel clinics, travel prescribing centers, and large private sector entities with employees
deployed overseas (e.g., mining companies), (ii) the prospect of additional U.S. Department of Defense (&ldquo;DoD&rdquo;) and government
agency procurement in the future (noting that as described on page [*] our existing contract with DoD has been fulfilled and has not been
extended or modified) and (iii) ex U.S. sales strategy where we currently (or in the future) have exclusive distribution arrangements
in overseas markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of the date of this prospectus, we did not have plans to hire a U.S. field sales force, but are exploring possible commercial arrangements
with contract sales organizations to target U.S. travel clinics for malaria prophylaxis. We may consummate a contract with a lobbying
firm/contract sales organization to attempt to improve the position of Arakoda in the DoD formulary and to raise awareness of Arakoda
amongst other U.S. government agencies. For such agencies, the product is expected to meet many of the requirements for occupational
malaria prevention identified by the independent parties that have endorsed the product. We have been successful in securing procurement
contracts with U.S. government agencies for Arakoda, and anticipate continued success in the future. In the third quarter of 2022, we
made our first sale to our European distributor, and made additional sales to our Australian distributor in the second quarter of 2022.
We are actively exploring the possibility of named-patient sales in jurisdictions outside Australia, Europe, and the United States. We
plan to undertake a focused marketing campaign for Arakoda for malaria prevention in the second half of 2023. This will consist of promotion
at relevant conferences, email promotion to prescribers, and target print and electronic advertisements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">It
is expected that a point of care G6PD test might be required to maximize the economic potential of a COVID-19 indication for Tafenoquine
(regardless of regimen). We do not intend to pursue independent development of such a test as there are well resourced development efforts
already underway (see &ldquo;<I>Risk Factors&mdash;Any future clinical trial for Arakoda will require screening for G6PD deficiency in
order to safely administer the product. In the United States, G6PD testing can obtained through commercial pathology services which is
associated with delays. The use of a third-party diagnostic provider of point of care testing may be required and we may not directly
control the timing, conduct and expense of such testing</I>&rdquo; beginning on page [*]). However, we will continue to monitor the progress
of development and U.S. commercialization of G6PD tests. We will seek to pursue collaborative commercial partnerships with the companies
involved in commercialization efforts, if such activities can be conducted through resource sharing efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
plan to generate additional validation data for our portfolio products if resources permit. Specifically, we will evaluate whether Celgosivir
provides therapeutic benefit in a COVID-19 animal model, and complete critical activities related to confirming GMP process feasibility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may elect, as resources permit, to undertake a clinical study of Tafenoquine in combination with standard of care for hospitalized patients
with babesiosis. We have developed such a protocol concept in partnership with academic collaborators and are planning to submit an investigational
new drug application (&ldquo;IND&rdquo;) to the FDA and pursue public and philanthropic funding to support our execution. We plan to
seek public funding to support additional non-clinical studies to validate the mechanism of action of Tafenoquine against <I>Candida
spp</I>. and further assess our utility in combination with standard of care agents in cell culture and animal studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Most
new antimalarial treatment products are developed as drug combinations to proactively combat drug resistance. Tafenoquine, due to its
long half-life and activity against all parasite species and strains, would be ideal partner in a drug combination. In the second half
of 2023, we will actively seek out a potential partner antimalarial drug for Arakoda, with the goal of pursuing licensure of a new drug
combination. We will only enter into a partnership to develop such a drug combination, if clear legal guidance can be obtained that such
a combination if developed would have a high probability of securing a priority review voucher upon FDA approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are currently efforts underway, in malaria-endemic
countries outside the U.S., to generate datasets supporting the use of Tafenoquine for mass drug administration in asymptomatic individuals
to prevent malaria transmission. We believe that such efforts are important to promote community acceptance of Tafenoquine and may eventually
support World Health Organization pre-qualification of Tafenoquine for malaria eradication efforts. To that end, we intend to support,
on a case-by-case basis, clinical studies sponsored by others, by providing commercial Arakoda and/or Kodatef for research use (provided
such product would not otherwise have been commercially salable, and the study sponsor covers shipping costs). We have previously provided
Tafenoquine for such efforts on a limited basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We have a post-marketing requirement to conduct
a malaria prophylaxis study of Arakoda in pediatric and adolescent subjects. We proposed to the FDA, in late 2021, that this might not
be safe to execute given that malaria prevention is administered to asymptomatic individuals and that methemoglobinemia (damage to the
hemoglobin in blood that carries oxygen) occurred in 5% of patients, and exceeded a level of 10% in 3% of individuals in a study conducted
by another sponsor in pediatric subjects with symptomatic vivax malaria.<SUP>32</SUP> The FDA has asked us to propose an alternate design,
for which we submitted a concept protocol in the fourth quarter of 2022, and plan to submit a full protocol by the end of the second
quarter of 2023. We estimate the cost of conducting the study proposed by the FDA, if conducted in the manner suggested by the FDA, would
be $2 million, and, due to the time periods required to secure protocol approvals from the FDA and Ethics Committees, could not be initiated
any earlier than the third quarter of 2024. The funds from this offering to be expended on such a pediatric study will be limited to
the minimum required to support protocol preparation and regulatory interactions with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP></SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>32</SUP> Velez et al 2021 - Lancet Child Adolesc Health 2022;
6: 86&ndash;95.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Intellectual Property&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are co-owners, with the U.S. Army, of patents
in the United States and certain foreign jurisdictions directed toward use of Tafenoquine for malaria and have obtained an exclusive
worldwide license from the U.S. Army to practice these inventions. We also have an exclusive worldwide license to use manufacturing information
and non-clinical and clinical data that the U.S. Army possesses relating to use of Tafenoquine for all therapeutic applications and uses
excluding radical cure of symptomatic <FONT STYLE="font-weight: normal">vivax</FONT> malaria. We have submitted patent applications in
the United States and certain foreign jurisdictions for use of Tafenoquine for COVID-19, fungal lung infections, tick-borne diseases,
and other infectious and non-infectious diseases in which induction of host cytokines/inflammation is a component of the disease process.
The United States Patent and Trademark Office (&ldquo;USPTO&rdquo;) recently allowed our first COVID-19 patent for Tafenoquine. We have
optioned or licensed patents involving Celgosivir for the treatment and prevention of Dengue (from the National University of Singapore),
COVID-19 &amp; Zika (Florida State University), and have submitted provisional patent applications related to Celgosivir for RSV. We
have optioned or own manufacturing methods related to Celgosivir. A detailed list of our intellectual property is as follows:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Patents</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 31%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Patent No.</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US Patent Date</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Application No.</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Estimated/<BR>
Anticipated<BR>
Expiration<BR>
Date</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dosing Regimen For Use Of Celgosivir As An Antiviral Therapeutic For Dengue Virus Infections</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2013203400</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2013203400<SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10-April-2033*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2014228035</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2014228035</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">MY-170991-A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Malaysia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">PI2015002372</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">378015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Mexico</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">MX/a/2015/013115</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">11201507254V</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">11201507254V</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10201908089V</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">9763921</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">9/19/2017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14/772,873</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">10517854</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">12/31/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">15/706,845</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">11219616</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">1/11/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">16/725,387</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2015358566</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2015358566</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2968694</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">10342791</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">7/9/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">15/532,280</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Naive Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">10888558</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">1/12/2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">16/504,533</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10201904908Q</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">EP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">15865264.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Hong Kong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">18103081.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Naive Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/145,530</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">New Zealand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">731813</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Prevention Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2016368580</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2016368580</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">09-Dec-2036*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Prevention Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10201912141Y</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">09-Dec-2036*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dosing Regimens Of Celgosivir For The Prevention Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">11000516</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;5/11/2011</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">16/060,945</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">09-Dec-2036<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">EP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">21764438.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;202180029643.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2021231743</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections Caused By Gram-Positive Bacteria, Fungus, Or Virus By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/189,544</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections Caused By Fungus By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/683,679</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections Caused By Sars-Cov-2 Virus By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/683,718</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Human Coronavirus Infections Using Alpha-Glucosidase Glycoprotein Processing Inhibtors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">11369592</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;6/28/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/180,140<B><SUP>#</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">19-Feb-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Human Coronavirus Infections Using Alpha-Glucosidase Glycoprotein Processing Inhibtors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/664,693<B><SUP>#</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">19-Feb-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Human Coronavirus Infections Using Alpha-Glucosidase Glycoprotein Processing Inhibtors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">EP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2021757552<B><SUP>#</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">19-Feb-2041*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Non-Viral Tick-Borne Diseases And Symptoms Thereof</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional </I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">63/337,366</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">~02-May-2043<B><SUP>&amp;</SUP></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Methods To Treat Respiratory Infection Utilizing Castanospermine Analogs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">63/358,341</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">~05-Jul-2043<B><SUP>&amp;</SUP></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Diseases Or Infections With Mcp-1 Involvement By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">63/411,654</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">~30-Sep-2043<B><SUP>&amp;</SUP></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Zika Virus Infections Using Alpha Glucosidase Inhibitors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10,328,061<SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;6-25-2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt; background-color: white">15/584,952</FONT><FONT STYLE="font-size: 10pt"><SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2-May-37</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Zika Virus Infections Using Alpha Glucosidase Inhibitors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10,561,642<SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;2-18-2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">15/856,377<SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2-May-37</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">* = </TD><TD STYLE="text-align: justify">For foreign patents and applications, the estimated and/or
anticipated patent expiration is the date that is twenty years from the PCT filing date. For all issued Australian patents, this estimated
date was also confirmed through the Australian patent office web database.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>^ = </B></TD><TD STYLE="text-align: justify">For issued U.S. patents, the estimated patent expiration was
calculated using information from the front cover of the patent, <I>i.e.</I>, 20 years from the date of the nonprovisional filing plus
any listed Patent Term Adjustment less any time disclaimed through a Terminal Disclaimer. For pending U.S. applications, the anticipated
patent expiration is the date twenty years from the earliest nonprovisional filing date and does not account for possible Patent Term
Adjustment (PTA), Patent Term Extension (PTE), or Terminal Disclaimers.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B><SUP>&amp;</SUP></B> = </TD><TD STYLE="text-align: justify">For U.S. provisional applications that are not yet the subject
of a nonprovisional or PCT application, the anticipated patent expiration was determined using the assumption that a non-provisional
application or PCT will be filed one year after filing the provisional application with a term lasting twenty years from the date of
that nonprovisional or PCT filing. This does not account for possible Patent Term Adjustment (PTA), Patent Term Extension (PTE), or Terminal
Disclaimers.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B><SUP>+</SUP> = </B></TD><TD STYLE="text-align: justify">60 Degrees Pharmaceuticals, Inc. is not a listed Applicant
and Geoffrey S. Dow, Ph.D. is not a listed inventor.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><B><SUP>#</SUP></B> = </TD><TD STYLE="text-align: justify">60 Degrees Pharmaceuticals, Inc. is not a listed Applicant,
but Geoffrey S. Dow, Ph.D. is a listed inventor.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
patents not designated with a &ldquo;+&rdquo; list Geoffrey S. Dow, Ph.D. as an inventor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
patents not designated with a &ldquo;+&rdquo; or a &ldquo;#&rdquo; list 60 Degrees Pharmaceuticals, Inc. as an applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">All estimated patent expiration dates and anticipated patent expiration
assume payment of any maintenance/annuity fees during the patent term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Trademarks</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I></I></P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 19%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>COUNTRY</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>MARK</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>STATUS</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>APPLICATION NUMBER</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>DATE FILED</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>REGISTRATION DATE</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>REGISTRATION NUMBER</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>BIR REF NUMBER</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>DUE DATE</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>DUE DATE DESCRIPTION</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1774631</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">6/2/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1774631</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000029</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1785098</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">11/26/2019</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">TMA1,064,371</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000028</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>26-Nov-29</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">ARAKODA</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1899317</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">15-May-18</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">8/20/2020</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">TMA1,081,180</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000053</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>20-Aug-30</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">20842242</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2-Aug-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/28/2017</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">20842242</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000035</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>27-Sep-27</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">European Union</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">15508872</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">3-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/21/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">15508872</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000034</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>3-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">European Union</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">ARAKODA</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">17900852</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">16-May-18</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/20/2018</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">17900852</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000054</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>16-May-28</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">285476</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">6-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">6/6/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">285476</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000033</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>6-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">New Zealand</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1044407</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">7-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">12/8/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1044407</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000031</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>6-May-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Russian Federation</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2016720181</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">6-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">7/10/2017</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">623174</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000032</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>6-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">40201707950V</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2-May-17</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">11/8/2017</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">40201707950V</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000040</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2-May-27</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United Kingdom</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">ARAKODA</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">17900852</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">16-May-18</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/20/2018</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">UK00917900852</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000054</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>16-May-28</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United Kingdom</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">15508872</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">3-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/21/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">UK009015508872</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000072</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>3-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United States of America</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">TQ 100 &amp; TABLET DESIGN</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">87608493</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">14-Sep-17</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/11/2018</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">5562900</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000037</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>11-Sep-24</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Section 8 &amp; 15 Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United States of America</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">ARAKODA</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">87688137</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">16-Nov-17</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">12/31/2019</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">5950691</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000050</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>31-Dec-25</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Section 8 &amp; 15 Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United States of America</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Allowed - &nbsp;02/16/2021</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">90072885</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">24-Jul-20</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000069</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>16-Aug-23</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Statement of Use/3rd Extension of Time Due</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Relationships &amp; Licenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2014, we entered into the Exclusive License Agreement (the &ldquo;2014 NUS-SHS Agreement&rdquo;) with National University of
Singapore (&ldquo;NUS&rdquo;) and Singapore Health Services Pte Ltd (&ldquo;SHS&rdquo;) in which we were granted a license from NUS and
SHS with respect to their share of patent rights regarding &ldquo;<FONT STYLE="color: #272727">Dosing Regimen for Use of Celgosivir as
an Antiviral Therapeutic for Dengue Virus Infection</FONT>&rdquo; to develop, market and sell licensed products. The 2014 NUS-SHS Agreement
continues in force until the expiration of the last to expire of any patents under the patent rights unless terminated earlier in accordance
with the 2014 NUS-SHS Agreement. We are obligated to pay at the rate of 1.5% of gross sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 15, 2015, we entered into the Exclusive License Agreement with the U.S. Army Medical Materiel Development Activity (the &ldquo;U.S.
Army&rdquo;), which was subsequently amended (the &ldquo;U.S. Army Agreement&rdquo;), in which we obtained a license to develop and commercialize
the licensed technology with respect to all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. This
exclusion does not impact our ability to market Arakoda for the FDA-approved use, which is the prevention of malaria utilizing the indicated
dose in asymptomatic individuals traveling to high-malaria or malaria-prone regions (whereas the license exclusion relates to its use
to treat symptomatic vivax malaria in a patient already presenting with that disease). The term of the U.S. Army Agreement will continue
until the expiration of the last to expire of the patent application or valid claim of the licensed technology, or 20 years from the
start date of the U.S. Army Agreement, unless terminated earlier by the parties. We will be required to make a minimum annual royalty
payment of 3% of net sales for net sales &lt; $35 million, and 5% of net sales greater than $35 million, with US government sales excluded
from the definition of net sales. In addition, we must pay a milestone fee of $75,000 once cumulative net sales from all sources exceeds
$6 million, $100,000 if we are acquired or merge, and regulatory approval milestone payments once marketing authorizations are achieved
in Canada ($5,000) and Europe ($5,000). Also, we will be required to obtain the U.S. Army Medical Materiel Development Activity&rsquo;s
consent prior to a change of control of the Company, which consent was obtained on September 2, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2016, we entered into the Exclusive License Agreement (the &ldquo;2016 NUS-SHS Agreement&rdquo;) with National
University of Singapore and Singapore Health Services Pte Ltd (&ldquo;SHS&rdquo;) in which we were granted a license from NUS and
SHS with respect to their share of patent rights regarding &ldquo;Novel Dosing Regimens of Celgosivir for The Prevention of
Dengue&rdquo; to develop, market and sell licensed products. The 2016 NUS-SHS Agreement continues in force until the expiration of
the last to expire of any patents under the patent rights unless terminated earlier in accordance with the 2016 NUS-SHS Agreement.
We are obligated to pay at the rate of 1.5% of gross sales or minimum annual royalty ($5,000 in 2022 and $15,000 in 2023). In July
2022, we renegotiated the timing of a license fee of $85,000 Singapore Dollars, payable to NUS, such that payment would be due at
the earlier of (i) enrollment of a patient in a Phase II clinical trial involving Celgosivir, (ii) two years from the agreement date
and (iii) an initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 4, 2020, we entered into the Other Transaction Authority for Prototype Agreement (&ldquo;OTAP Agreement&rdquo;) with the Natick
Contracting Division of the U.S. government in which we will, among other things, conduct activities for a Phase II clinical trial to
assess the safety and efficacy of Tafenoquine for the treatment of mild to moderate COVID-19 disease, with the goal of delivering Tafenoquine
with an FDA Emergency Use Authorization (&ldquo;EUA&rdquo;) approved as a countermeasure against COVID-19. The total amount of the OTAP
Agreement is $4,999,814. The term of the OTAP Agreement commences on December 4, 2020 and was completed in the third quarter of 2022.
Pursuant to the OTAP Agreement, we will not offer, sell or otherwise provide the EUA or licensed version of the prototype (Tafenoquine)
that is FDA approved for COVID-19 or any like product to any entity at a price lower than that offered to the DoD, which applies only
to products sold in the U.S., European Union and Canada related to COVID-19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 15, 2021, we entered into the Inter-Institutional Agreement (the &ldquo;FSURF Agreement&rdquo;) with the Florida State University
Research Foundation (&ldquo;FSURF&rdquo;) in which FUSRF granted us the right to manage the licensing of intellectual property created
at FSURF. The term of the FSURF Agreement expires five years from February 15, 2021. After deduction of a 5% administrative fee by FSURF,
capped at $15,000 annually, and reimbursement of patent prosecution expenses, we will receive 20% of license income and FSURF will receive
80% of license income. Payments of license income shall be paid in U.S. dollars quarterly each year. On February 19, 2021, we entered
into an agreement with FSURF, subsequently amended on February 15, 2023, that collectively granted an option, effective through August
19, 2023, to us to license methods for purifying castanospermine and its use for the treatment of COVID-19. On August 19, 2021, we entered
into an agreement with FSURF, subsequently amended on February 15, 2023, that collectively granted an option, effective through August
19, 2023, to us to license a patent relating to the use of alpha glucosidase inhibitors (including castanospermine and Celgosivir) for
treatment of Zika infections.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to the Knight Debt Conversion Agreement, for a period commencing on January 1, 2022 and ending upon
the earlier of ten years after the closing date of this offering or the conversion or redemption in full of all of the shares of Series
A Preferred Stock owned by Knight, we will pay Knight a royalty equal to 3.5% of our net sales, where &ldquo;net sales&rdquo; has the
same meaning as in our license agreement with the U.S. Army for Tafenoquine.&nbsp;Upon succeeding with the qualified IPO, at the end of
the quarter and each thereafter the royalty will be calculated, and payment will be made within fifteen days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60
Degrees Pharmaceuticals, Inc. is a Delaware corporation that was incorporated on June 1, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June 1, 2022, 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company (&ldquo;60P LLC&rdquo;), entered into
the Agreement and Plan of Merger with 60 Degrees Pharmaceuticals, Inc., pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals,
Inc. The value of each outstanding member&rsquo;s membership interest in 60P LLC was correspondingly converted into common stock of 60
Degrees Pharmaceuticals, Inc., par value $0.0001 per share, with a cost-basis equal to $5.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
majority owned subsidiary, 60P Australia Pty Ltd, an Australian proprietary company limited by shares (&ldquo;60P Australia&rdquo;),
was formed and registered in Queensland on December 3, 2013, and conducts operations in Australia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">60P
Australia previously solely owned a Singaporean subsidiary company, 60P Singapore PTE, LTD, which dissolved at our election in the second
quarter of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
independent auditors have issued a report raising substantial doubt of our ability to continue as a going concern. We anticipate that
we will require additional capital to continue as a going concern and expand our operations in accordance with our current business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Suppliers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have quality and contract manufacturing agreements relating to Arakoda in place with Piramal Enterprises Limited (API, tablets) and PCI
Pharma Services (secondary packaging) (&ldquo;PCI&rdquo;) and supply/quality/pharmacovigilance agreements in place with Biocelect Pty
Ltd, Scandinavian Biopharma, and Knight Therapeutics Inc. (to allow supply of Arakoda/Kodatef to Australia, Europe and Canada/Israel/Latin
America and Russia, respectively). As of the date of this prospectus, we have not supplied any of our products to Russia nor do we anticipate
supplying any of our products to Russia in the near future.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Effects
of COVID-19 Outbreak</I></B>. In December 2019, a novel strain of coronavirus was reported to have surfaced in Wuhan, China, which has
and is continuing to spread throughout China and other parts of the world, including the United States. On January 30, 2020, the World
Health Organization declared the outbreak of COVID-19 a &ldquo;Public Health Emergency of International Concern.&rdquo; On January 31,
2020, U.S. Health and Human Services Secretary Alex M. Azar II declared a public health emergency for the United States to aid the U.S.
healthcare community in responding to COVID-19, and on March 11, 2020 the World Health Organization characterized the outbreak as a &ldquo;pandemic.&rdquo;
A significant outbreak of COVID-19 and other infectious diseases could result in a widespread health crisis that could adversely affect
the economies and financial markets worldwide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are monitoring the global outbreak and spread of COVID-19 and taking steps in an effort to identify and mitigate the adverse impacts
on, and risks to, our business posed by its spread and the governmental and community reactions thereto. The current outbreak of COVID-19
has globally resulted in loss of life, business closures, restrictions on travel, and widespread cancellation of social gatherings. The
extent to which the COVID-19 pandemic impacts our business will depend on future developments, which are highly uncertain and cannot
be predicted at this time, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">new information which may emerge
                                            concerning the severity of the disease;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the duration and spread of the outbreak;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the severity of travel restrictions
                                            imposed by geographic areas in which we operate, mandatory or voluntary business closures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">regulatory actions taken in response
                                            to the pandemic, which may impact our product offerings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">other business disruptions that affect
                                            our workforce and supply chain;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the impact on capital and financial
                                            markets; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">actions taken throughout the world,
                                            including in markets in which we operate, to contain the COVID-19 outbreak or treat its impact.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the current outbreak of COVID-19
has resulted in a widespread global health crisis and adversely affected global economies and financial markets, and similar public health
threats could do so in the future. Such events have impacted, and could in the future impact, demand for our products, which in turn
could adversely affect our revenue and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The spread of COVID-19
has caused us to modify our business practices, including employee travel, employee work locations in certain cases, and cancellation
of physical participation in certain meetings, events and conferences and further actions may be taken as required or recommended by
government authorities or as we determine are in the best interests of our employees, customers and other business partners. We are monitoring
the global outbreak of the pandemic and are taking steps in an effort to identify and mitigate the adverse impacts on, and risks to,
our business posed by its spread and the governmental and community reactions thereto.&nbsp;See &ldquo;<I>Risk Factors&mdash;Our financial
condition and results of operations may be adversely affected by the COVID-19 pandemic</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
business is subject to a number of risks. You should be aware of these risks before making an investment decision. These risks are discussed
more fully in the section of this prospectus titled &ldquo;<I>Risk Factors,</I>&rdquo; which begins on page [*] of this prospectus. These
risks include, among others, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                            have incurred net losses since our inception and if we continue to incur net losses in the
                                            foreseeable future, the market price of our common stock may decline;</FONT></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Our financial statements have been
                                            prepared on a going-concern basis and our continued operations are in doubt;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">There is no assurance that we will
                                            be profitable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&bull;</TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0">There is no assurance that we will be eligible for Australian government research
                                    and development tax rebates;</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Our financial condition and results
                                            of operations may be adversely affected by the COVID-19 pandemic;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">If we are not able to successfully develop, obtain FDA approval for,
and provide for the commercialization of non-malaria prevention indications for Tafenoquine (Arakoda or other regimen) or Celgosivir in
a timely manner, we may not be able to expand our business operations;</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Our clinical trials for our product
                                            candidates may not yield results that will enable us to further develop our products and
                                            obtain regulatory approvals necessary to sell them;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">The mechanisms of actions of some
                                            of our products, and interactions with other antiviral products are not known, which may
                                            restrict regulatory label claims;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We expect to depend on existing and
                                            future collaborations with third parties for the development of some of our product candidates.
                                            If those collaborations are not successful, we may not be able to complete the development
                                            of these product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Even if one of our product candidates
                                            receives marketing approval, it may fail to achieve the degree of market acceptance by physicians,
                                            patients, third-party payors and others in the medical community necessary for commercial
                                            success, in which case we may not generate significant revenues or become profitable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Any future clinical trial for Arakoda
                                            will require screening for G6PD deficiency in order to safely administer the product. In
                                            the United States, G6PD testing can obtained through commercial pathology services which
                                            is associated with delays. The use of a third-party diagnostic provider of point of care
                                            testing may be required and we do not directly control the timing, conduct, expense of such
                                            testing or the timing of market entry into the US;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Our product candidates are subject
                                            to extensive regulation, which can be costly and time-consuming, and unsuccessful or delayed
                                            regulatory approvals could increase our future development costs or impair our future revenue;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">If our product candidates receive
                                            regulatory approval, we would be subject to ongoing regulatory obligations and restrictions,
                                            which will continue to change, and which may result in significant expenses and limit our
                                            ability to develop and commercialize other potential products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We have no manufacturing capacity
                                            which puts us at risk of lengthy and costly delays of bringing our products to market;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We rely on relationships with third-party
                                            contract manufacturers and raw material suppliers, which limits our ability to control the
                                            availability of, and manufacturing costs for, our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Our future growth depends on our ability to successfully commercialize
Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and our other product candidates, and
we can provide no assurance that we will successfully commercialize Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention
indications, Celgosivir and other product candidates;</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Health care reform measures could
                                            materially and adversely affect our business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Our competitors may be better positioned
                                            in the marketplace and thereby may be more successful than us at developing, manufacturing
                                            and marketing approved products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We compete in an industry characterized
                                            by extensive research and development efforts and rapid technological progress. New discoveries
                                            or commercial developments by our competitors could render our potential products obsolete
                                            or non-competitive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We would be subject to applicable
                                            regulatory approval requirements of the foreign countries in which we market our products,
                                            which are costly and may prevent or delay us from marketing our products in those countries;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Defending against claims relating
                                            to improper handling, storage or disposal of hazardous chemicals, radioactive or biological
                                            materials could be time consuming and expensive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Geopolitical conditions, including
                                            direct or indirect acts of war or terrorism could have an adverse effect on our operations
                                            and financial results;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">If product liability lawsuits are
                                            successfully brought against us, then we will incur substantial liabilities and may be required
                                            to limit commercialization of Arakoda, Celgosivir or other product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Our intellectual property rights
                                            may not preclude competitors from developing competing products and our business may suffer;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">If the manufacture, use or sale of
                                            our products infringe on the intellectual property rights of others, we could face costly
                                            litigation, which could cause us to pay substantial damages or licensing fees and limit our
                                            ability to sell some or all of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We may not be able to protect our
                                            intellectual property rights throughout the world;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Patent terms may be inadequate to
                                            protect our competitive position on our product candidates for an adequate amount of time;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&bull;</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0">The earliest Paragraph IV certification date for Arakoda
                                            has passed. Generic companies may file an ANDA at any time, and successful challenge of our
                                            malaria use patents would negatively impact our business;</P></TD></TR>
                         </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">There has been no public market for our
                                            common stock prior to this offering, and we cannot assure you that an active trading market
                                            will develop in the near future. An active market in which investors can resell their shares
                                            may not develop. If there is no viable public market for our common stock, you may be unable
                                            to sell your shares at or above the initial public offering price;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We may not be able to satisfy listing
                                            requirements of Nasdaq to maintain a listing of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
                                            is no public market for the warrants being offered in this offering;</FONT></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">The warrants may have an adverse
                                            effect on the market price of our common stock and make it more difficult to effect a business
                                            combination;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">Any failure to maintain effective
                                            internal controls over financial reporting could have an adverse impact on us; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">We are an &ldquo;emerging growth
                                            company&rdquo; and a &ldquo;smaller reporting company&rdquo; under the JOBS Act, and we cannot
                                            be certain if the reduced disclosure requirements applicable to emerging growth companies
                                            and smaller reporting companies will make our common stock less attractive to investors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Information Regarding our Capitalization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of April 3, 2023, we had 2,378,009 shares of common stock issued and outstanding. Additional information regarding our issued and outstanding
securities may be found under &ldquo;<I>Market for Common Equity and Related Stockholder Matters</I>&rdquo; and &ldquo;<I>Description
of Securities</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless otherwise specifically stated, information
throughout this prospectus does not assume the exercise of outstanding options or warrants to purchase shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located at
1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036. Our corporate website address is <I>60degreespharma.com</I>. Our telephone
number is (202) 327-5422. The information included on our website is not part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Implications of Being an Emerging Growth Company
and a Smaller Reporting Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company,&rdquo;
as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year following
the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities
Act; (ii) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (iii) the date on which
we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to
be a large accelerated filer under applicable SEC rules. We expect that we will remain an emerging growth company for the foreseeable
future, but cannot retain our emerging growth company status indefinitely and will no longer qualify as an emerging growth company on
or before the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant
to an effective registration statement under the Securities Act. For so long as we remain an emerging growth company, we are permitted
and intend to rely on exemptions from specified disclosure requirements that are applicable to other public companies that are not emerging
growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These exemptions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">being permitted to provide only two
                                            years of audited financial statements, in addition to any required unaudited interim financial
                                            statements, with correspondingly reduced &ldquo;<I>Management&rsquo;s Discussion and Analysis
                                            of Financial Condition and Results of Operations</I>&rdquo; disclosure;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">not being required to comply with
                                            the requirement of auditor attestation of our internal controls over financial reporting;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">not being required to comply with
                                            any requirement that may be adopted by the Public Company Accounting Oversight Board regarding
                                            mandatory audit firm rotation or a supplement to the auditor&rsquo;s report providing additional
                                            information about the audit and the financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">reduced disclosure obligations regarding
                                            executive compensation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">not being required to hold a nonbinding
                                            advisory vote on executive compensation and stockholder approval of any golden parachute
                                            payments not previously approved.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An emerging growth company can take advantage
of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act to comply with new or revised accounting standards.
This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply
to private companies. We have elected to avail ourselves of this extended transition period and, as a result, we will not be required
to adopt new or revised accounting standards on the dates on which adoption of such standards is required for other public reporting
companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are also a &ldquo;smaller reporting company&rdquo;
as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and have elected to take
advantage of certain of the scaled disclosure available for smaller reporting companies. We will remain a smaller reporting company until
the end of the fiscal year in which (1) we have a public common equity float of more than $250&nbsp;million, or (2) we have annual revenues
for the most recently completed fiscal year of more than $100&nbsp;million and a public common equity float or public float of more than
$700&nbsp;million. We also would not be eligible for status as a smaller reporting company if we become an investment company, an asset-backed
issuer or a majority-owned subsidiary of a parent company that is not a smaller reporting company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have elected to take advantage of certain
of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage
of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different
from what you might receive from other public reporting companies in which you hold equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 5; border: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_006"></A><B>SUMMARY OF THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60
    Degrees Pharmaceuticals, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units
    offered by us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;units,
                                            each unit consisting of one share of common stock and one warrant to purchase one share of
                                            common stock.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    units will not be certificated or issued in stand-alone form. The shares of our common stock and the warrants comprising the units
    are immediately separable upon issuance and will be issued separately in this offering.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock that may be offered by the Selling Stockholders</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">1,925,202
                                            shares.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock outstanding <BR>
    prior to the offering<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0">2,378,009 shares.</P>
</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock to be outstanding <BR>
    after the offering<SUP>(2)(3)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
    (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters exercise their option
    to purchase additional shares in full).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment
    option</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the underwriters a 45-day option to purchase up to an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
    shares of common stock and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;warrants at the public
    offering price per share of common stock and per warrant, respectively, less, in each case, underwriting discounts and commissions,
    on the same terms as set forth in this prospectus, solely to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
    of the Warrants</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            warrant will be exercisable from the date of issuance until the fifth anniversary date of
                                            issuance date for $4.7725 and $7.0725 per share (115% of the public offering price of one
                                            unit), subject to adjustment in the event of stock dividends, stock splits, stock combinations,
                                            reclassifications, reorganizations or similar events affecting our common stock as described
                                            herein.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    holder may not exercise any portion of a warrant to the extent that the holder, together with its affiliates and any other person
    or entity acting as a group, would own more than 4.99% of the outstanding common stock after exercise, as such percentage ownership
    is determined in accordance with the terms of the warrants, except that upon notice from the holder to us, the holder may waive such
    limitation up to a percentage, not in excess of 9.99%.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    terms of the warrants will be governed by the Warrant Agent Agreement. This prospectus also relates to the offering of the shares
    of common stock issuable upon exercise of the warrants. See &ldquo;<I>Description of Securities&ndash;Warrants</I>.&rdquo;</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    of Proceeds</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            principal purposes of this offering are to fund the development of new indications for our
                                            products with a focus on executing a COVID-19 clinical trial involving Arakoda, to repay
                                            debt associated with prior financing, increase our capitalization and financial flexibility,
                                            increase our visibility in the marketplace and create a public market for our common stock.
                                            As of the date of this prospectus, we cannot specify with certainty all of the particular
                                            uses for the net proceeds to us from this offering. However, we currently intend to use the
                                            net proceeds to us from this offering for research and general corporate purposes, including
                                            working capital. See &ldquo;<I>Use of Proceeds</I>&rdquo; beginning on page [*]. We will
                                            not receive any proceeds from the sale of the common stock by the Selling Stockholders.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed
    Listing</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have applied to have our common stock listed on The Nasdaq Capital Market under the symbol &ldquo;SXTP,&rdquo; which listing is a
    condition to this offering. We do not intend to apply for listing of the warrants on any exchange or market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative
    Warrants</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
    the closing of this offering, we have agreed to issue to the Representative, warrants that will expire on the fifth anniversary of
    the commencement date of sales in this offering, entitling the Representative to purchase 6% of the number of shares of common stock
    sold in this offering. The registration statement of which this prospectus is a part also covers the Representative Warrants and
    the shares of common stock issuable upon the exercise thereof. For additional information regarding our arrangement with the underwriters,
    please see &ldquo;<I>Underwriting</I>.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lock-up
    agreements</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    executive officers and directors have agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities
    for six months following the effective date of the registration statement for this offering without the prior written consent of
    WallachBeth Capital LLC. Any other holders of more than 5% of the outstanding shares of our common stock have also agreed with the
    underwriters not to sell, transfer or dispose of any shares or similar securities for six months following the effective date of
    the registration statement for this offering without the prior written consent of the underwriters. For additional information regarding
    our arrangement with the underwriters, please see &ldquo;<I>Underwriting</I>.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Knight Therapeutics Preferred Stock</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>
                                                                              <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Knight
                                            will be granted 80,965 preferred shares (share price of $100, total value $8,096,500) in
                                            consideration for extinguishment of accumulated interest associated with their loans. The
                                            preferred shares are nonvoting, have a 6% cumulative dividend accumulating annually on March
                                            31st, are not redeemable and are convertible into shares of common stock solely at the discretion
                                            of the Company, determined by (A) multiplying the number of shares of Series A Preferred
                                            Stock to be converted by $100, (B) adding to the result all accrued and accumulated and unpaid
                                            dividends on such shares to be converted, if any, and then (C) dividing the result by a price
                                            equal to the lower of (1) $100, (2) the price paid for the shares of common stock in this
                                            offering and (3) the 10-day volume weighted average share price immediately preceding our
                                            election to convert the shares of Series A Preferred Stock; provided that the conversion
                                            of the shares of Series A Preferred Stock does not result in the holder&rsquo;s ownership
                                            of common stock exceeding 19.9%.</FONT></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer
    Agent</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
    Stock Transfer, LLC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    Factors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    should carefully consider the information set forth in this prospectus and, in particular, the specific factors set forth in the
    &ldquo;<I>Risk Factors</I>&rdquo; section beginning on page [*] of this prospectus before deciding whether or not to invest in shares
    of our common stock.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">As
                                            of April 3, 2023 and excludes
                                            238,601 shares of common stock reserved for issuance under our 2022 Equity Incentive Plan.</P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
                                            of our common stock issued to BioIntelect Pty Ltd (&ldquo;BioIntelect&rdquo;) pursuant to
                                            the Master Consultancy Agreement dated as of May 29, 2013 (the &ldquo;BioIntelect Agreement&rdquo;),
                                            which provides that in connection with our initial public offering, BioIntelect will be entitled
                                            to receive deferred equity compensation in the amount equal to $155,000 (or $245,000 if Australian
                                            VC Horizon Biotech participates in the offering), (ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            shares of our common stock issued to Knight Therapeutics International S.A. (formerly known
                                            as Knight Therapeutics (Barbados) Inc.) (&ldquo;Knight&rdquo;) as a result of the conversion
                                            of certain of our outstanding debt owed to Knight pursuant to the Debt Conversion Agreement
                                            dated as of January 9, 2023, as amended on January 19, 2023 and January 27, 2023 (the &ldquo;Knight
                                            Debt Conversion Agreement&rdquo;), (iii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            shares of our common stock that are to be issued prior to the closing of this offering as
                                            a result of the conversion of our convertible promissory notes excluding the Xu Yu Note and
                                            (iv) shares of our common stock that are to be issued prior to the closing of this offering
                                            pursuant to the Equity Conversion Note dated as of October 11, 2017, as amended on December
                                            23, 2017 and December 11, 2022 (the &ldquo;Xu Yu Equity Conversion Note&rdquo;) entered into
                                            with Xu Yu.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
                                            not include (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            shares of our common stock underlying a warrant issued to Bigger Capital Fund, LP (the &ldquo;Bigger
                                            Capital Fund Warrants&rdquo;), (ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            shares of our common stock underlying a warrant issued to Cavalry Investment Fund, LP (the
                                            &ldquo;Cavalry Warrants&rdquo;), (iii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            shares of our common stock underlying a warrant issued to Walleye Opportunities Master Fund
                                            Ltd (the &ldquo;Walleye Warrants&rdquo;), (iv) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            shares of our common stock underlying a warrant issued to Geoffrey Dow (in the form of his
                                            revocable grantor trust, the Geoffrey S. Dow Revocable Trust for which Mr. Dow is the sole
                                            trustee) (the &ldquo;Dow Trust Warrants&rdquo;), (v) shares of our common stock underlying
                                            a warrant issued to Mountjoy Trust (together with the Bigger Capital Fund Warrants, the Cavalry
                                            Warrants, the Walleye Warrants and the Dow Trust Warrants, the &ldquo;Warrants&rdquo;), (vi)
                                            &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
                                            our common stock issuable upon the exercise of the Representative Warrants, (vii) 238,601
                                            shares of common stock reserved for issuance under our 2022 Equity Incentive Plan and (viii)
                                            $40,000 in value of shares of our common stock, based on the 30 day average after the IPO,
                                            to be issued pursuant to the Red Chip services agreement.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as otherwise indicated, all information
in this prospectus assumes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">a public offering price of $5.15
                                            per unit, which is the midpoint of the range of the offering price per unit;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">no shares of common stock have been issued pursuant
to the (i) conversion of certain of our outstanding debt owed to Knight, (ii) BioIntelect Agreement, (iii) conversion of our convertible
promissory notes and (iv) Xu Yu Equity Conversion Note;</P>
</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">no
                                            shares of common stock have been issued pursuant to any warrants or options; and</FONT></P></TD></TR>
          </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">no shares of common stock have been
                                            issued pursuant to the Representative&rsquo;s over-allotment option;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">no shares of common stock have been
                                            issued pursuant to the Representative Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_007"></A><FONT STYLE="text-transform: uppercase"><B>SUMMARY
FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following tables summarize our financial data.
We derived the summary financial statement data for the years ended December 31, 2022 and 2021 set forth below from our audited financial
statements and related notes contained in this prospectus. Our historical results are not necessarily indicative of the results that may
be expected in the future. You should read the information presented below together with &ldquo;<I>Management&rsquo;s Discussion and Analysis
of Financial Condition and Results of Operations</I>,&rdquo; our financial statements, the notes to those statements and the other financial
information contained in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary of Operations in U.S. Dollars</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year Ended December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Year Ended December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 70%"><FONT STYLE="font-size: 10pt">Product revenues &ndash; net of discounts and rebates</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">192,913</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1,078,440</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Service revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">30,295</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">81,900</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Product and service revenues</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">223,208</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,160,340</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Cost of revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">432,370</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">850,742</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Gross (loss) profit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(209,162</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">309,598</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Research revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">288,002</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">5,192,516</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net revenue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">78,840</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,502,114</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Operating expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Research &amp; development</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">525,563</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,510,866</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">General and administrative expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,303,722</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,115,350</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,829,285</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6,626,216</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Loss from operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,750,445</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,124,102</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Interest and other income (expense), net:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Interest expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,989,359</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,172,712</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Derivative expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(504,613</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Change in fair value of derivative liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(10,312</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt"><FONT STYLE="font-size: 10pt">Gain on debt extinguishment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">120,683</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Other (expense) income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(43,238</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">37,515</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total interest and other income (expense), net</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(4,426,839</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(3,135,197</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Loss from operations before provision for income taxes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(6,177,284</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(4,259,299</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Provision for income taxes</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">500</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 9pt"><FONT STYLE="font-size: 10pt">Net loss including noncontrolling interest</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(6,177,784</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,260,299</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Consolidated Balance Sheet Data:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 72%"><FONT STYLE="font-size: 10pt">Total assets</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">1,297,206</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-size: 10pt">1,393,527</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Total liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">25,446,266</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">19,548,011</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Total liabilities and members&rsquo; equity (deficit)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,393,527</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Total liabilities and stockholders&rsquo; equity (deficit)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,297,206</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_008"></A><FONT STYLE="text-transform: uppercase"><B>RISK
FACTORS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Our business is subject to many risks and uncertainties,
which may affect our future financial performance. If any of the events or circumstances described below occur, our business and financial
performance could be adversely affected, our actual results could differ materially from our expectations, and the price of our stock
could decline. The risks and uncertainties discussed below are not the only ones we face. There may be additional risks and uncertainties
not currently known to us or that we currently do not believe are material that may adversely affect our business and financial performance.
You should carefully consider the risks described below, together with all other information included in this prospectus, including our
financial statements and related notes, before making an investment decision. The statements contained in this prospectus that are not
historic facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially
from those set forth in or implied by forward-looking statements. If any of the following risks actually occurs, our business, financial
condition or results of operations could be harmed. In that case, the trading price of our common stock could decline, and investors
in our securities may lose all or part of their investment.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Risks Related to
Our Business</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
have incurred net losses since our inception and if we continue to incur net losses in the foreseeable future, the market price of our
common stock may decline.</I></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">To date, we have financed
our operations primarily through the issuance of equity, promissory notes and convertible notes. We incurred annual net losses of $6,177,784
in 2022 and $4,260,299 in 2021, respectively<FONT STYLE="background-color: white">&nbsp;and operating losses were $1,750,445 in 2022 and
$1,124,102 in 2021.&nbsp;We had an accumulated deficit of $28,815,148 as of December 31, 2022.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We may not achieve or
maintain profitability in the future. In particular, we expect that our expenses relating to sales and marketing and product development
and support, as well as our general and administrative costs, will increase, requiring us to increase sales in order to achieve and maintain
profitability. If we do not achieve and maintain profitability, our financial condition will be materially and adversely affected. We
would eventually be unable to continue our operations unless we were able to raise additional capital. We may not be able to raise any
necessary capital on commercially reasonable terms or at all. If we fail to achieve or maintain profitability on a quarterly or annual
basis within the timeframe expected by investors, the market price of our common stock may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our financial statements have been prepared
on a going-concern basis and our continued operations are in doubt.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements have been prepared on
a going concern basis under which an entity is considered to be able to realize its assets and satisfy its liabilities in the ordinary
course of business. Our future operations are dependent upon the identification and successful completion of equity or debt financing
and the achievement of profitable operations at an indeterminate time in the future. There can be no assurances that we will be successful
in completing an equity or debt financing or in achieving profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is no assurance that we will be profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is no assurance that we will earn profits
in the future, or that profitability will be sustained. There is no assurance that future revenues will be sufficient to generate the
funds required to continue our business and product development and marketing activities. If we do not have sufficient capital to fund
our operations, we may be required to reduce our sales and marketing efforts or forego certain business opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no assurance we will be eligible for Australian Government research and development tax credits and eligibility rules might change
in a manner that jeopardizes our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is no assurance that the Australian government
will pay research and development rebates on our research activities conducted by our subsidiary, 60P Australia Pty Ltd, in Australia.
There is no assurance that we will be able to demonstrate that our subsidiary will have &lt; $20 million AUD in aggregate turnover amongst
beneficial owners with &gt; 40% beneficial interest. If any of these risks materialize, we might not be able to complete our planned
COVID-19 clinical study, which would negatively impair our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if Australian government grants an overseas finding, if we could
not raise additional financing to fund the linked Australian research and development activities. Also, it is possible depending on evolving
interpretations by the Australian Tax Office of the legislation, that matching Australian core research might not be eligible for consideration
when a determination of an overseas finding is made. Either of these scenarios if realized might require us to refund any rebates on the
COVID-19 clinical study to the Australian government or result in us not being to obtain rebates, thereby negatively impairing our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited revenues to date, and any
potential revenues from commercial use may not materialize in the future.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have earned limited revenues to date from
Arakoda. Any potential revenues from the sale of current approved commercial use may not materialize in the future. There is no guarantee
that we will be able to generate revenue in the future. No assurance can be given that our efforts from sale of current approved products
for commercial use will be successful in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
financial condition and results of operations may be adversely affected by the COVID-19 pandemic.</I></B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A significant outbreak, epidemic or pandemic
of contagious diseases in any geographic area in which we operate or plan to operate could result in a health crisis adversely affecting
the economies, financial markets and overall demand for our services in such areas. In addition, any preventative or protective actions
that governments implement or that we take in response to a health crisis, such as travel restrictions, quarantines, or site closures,
may interfere with the ability of our employees, suppliers and customers to perform their responsibilities. Such results could have a
material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The continued global COVID-19 pandemic has created
significant volatility, uncertainty and economic disruption. To date, this pandemic has affected nearly all regions around the world.
In the United States, businesses as well as federal, state and local governments implemented significant actions to mitigate this public
health crisis. While we cannot predict the duration or scope of the COVID-19 pandemic, it may negatively impact our business and such
impact could be material to our financial results, condition and outlook related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">disruption to our operations or the
                                            operations of our suppliers, through the effects of business and facilities closures, worker
                                            sickness and COVID-19 related inability to work, social, economic, political or labor instability
                                            in affected areas, transportation delays, difficulty in enrolling patients, travel restrictions
                                            and changes in operating procedures, including for additional cleaning and safety protocols;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">increased volatility or significant
                                            disruption of global financial markets due in part to the COVID-19 pandemic, which could
                                            have a negative impact on our ability to access capital markets and other funding sources,
                                            on acceptable terms or at all and impede our ability to comply with debt covenants; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the further spread of COVID-19, and
                                            the requirements to take action to mitigate the spread of the pandemic (e.g., vaccination
                                            requirements that have been and continue to be taken in response to the pandemic and enhanced
                                            health and hygiene requirements or social distancing or other measures), will impact our
                                            ability to carry out our business as usual and may materially adversely impact global economic
                                            conditions, our business, results of operations, cash flows and financial condition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent the COVID-19 pandemic or a similar
public health threat has an impact on our business, it is likely to also have the effect of heightening many of the other risks described
in this &ldquo;<I>Risk Factors</I>&rdquo; section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If COVID-19 cases decline, it could jeopardize
our business and make us less profitable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Although the number of U.S. cases of COVID-19
remains high, it is possible that this may not be the case in the future. Since our major business objective is to conduct clinical trials
to evaluate the use of the Arakoda regimen of Tafenoquine for treatment of COVID-19, a future decline in U.S cases would reduce our sales
and profitability, and therefore harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. public sector procurement of Arakoda
might not materialize in the future, which could jeopardize our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0">Sales to the U.S. DoD were important to our revenue stream in the recent past. Although, as of the date of this
prospectus, we were not in discussions with the DoD about additional/future procurement, we anticipate that this will be feasible in the
future if one or more of the conditions/events described in this paragraph occur. First, the position of Arakoda in the DoD formulary
(Tricare, deployed personnel) needs to be improved from second/third tier to at least equivalency with competing products (as is the case
for civilian use as recommended by the CDC). Second, the shelf-life of the existing product requires extension, which is known to be technically
possible as the shelf-life of Kodatef in Australia is 48 months, but appropriate data must be generated to meet FDA requirements. Finally,
a change in the operational footprint of DoD deployments to areas with higher malaria attack rates (e.g., the Liberia deployment to manage
the Ebola outbreak in 2014) may lead to a rapid reassessment by DoD of the position of Arakoda in the formulary (advancement of the last
approved prophylactic antimalarial to co-equal standard of care took thirteen years). It is possible that none of these events would transpire,
which would reduce our revenues and jeopardize our business.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Supply chain disruptions across the globe,
including in the U.S., could jeopardize our business and harm our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Global business interruptions
may adversely impact our third-party relationships whom we rely upon in our business as well as manufacturers, suppliers, and makers
of raw materials. If any such parties are adversely impacted by supply chain restrictions, or if they cannot obtain the necessary supplies,
or if such third parties need to prioritize other products or customers over us, we may experience delays or disruptions in our supply
chain, which could have a material and adverse impact on our business. Third party manufacturers may also need to implement measures
and changes, or deviate from typical requirements because of the COVID-19 pandemic that may otherwise adversely impact our supply chain
or the quality of the resulting products or supplies. Depending on the change, we may need to obtain FDA approval or otherwise provide
the FDA with a notification of the change. As a result, we may not be able to obtain sufficient quantities of certain items, which could
impair our ability to commercialize our products and conduct the post-marketing studies requested by the FDA, in connection with the
approval of our goods. In addition, if there are continued or future disruptions, our third-party manufacturers may not be able to supply
our other potential product candidates, which would adversely affect our research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We may lose the
services of key management personnel and may not be able to attract and retain other necessary personnel.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Changes in our management
could have an adverse effect on our business. This is especially an issue while our staff is small. We are dependent upon the active
participation of several key management personnel, including Geoffrey Dow, our President and Chief Executive Officer. We also do not
carry key person life insurance on any of our senior management or other key personnel. Hence, we may suffer if the services of our management
were to become unavailable to us in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We must hire highly
skilled technical personnel as employees and as independent contractors in order to develop our products. As of the date of this prospectus,
we have two&nbsp;full-time employees, and we rely on two independent contractors to provide us with skilled technical support. The competition
for highly skilled technical, managerial and other personnel is intense and we may not be able to retain or recruit such personnel. Our
recruiting and retention success is substantially dependent on our ability to offer competitive salaries and benefits to our employees
and competitive compensation to contractors. We must compete with companies that possess greater financial and other resources than we
do and that may be more attractive to potential employees and contractors. To be competitive, we may have to increase the compensation,
bonuses, stock options and other fringe benefits offered to employees in order to attract and retain such personnel. The costs of retaining
or attracting new personnel may have a material adverse effect on our business and operating results. If we fail to attract and retain
the technical and managerial personnel needed to be successful, our business, operating results and financial condition could be materially
adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cybersecurity risks could adversely affect
our business and disrupt our operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The threats to network and data security are
increasingly diverse and sophisticated. Despite our efforts and processes to prevent breaches, our devices, as well as our servers, computer
systems, and those of third parties that we use in our operations are vulnerable to cybersecurity risks, including cyber-attacks such
as viruses and worms, phishing attacks, denial-of-service attacks, physical or electronic break-ins, employee theft or misuse, and similar
disruptions from unauthorized tampering with our servers and computer systems or those of third parties that we use in our operations,
which could lead to interruptions, delays, loss of critical data, and unauthorized access to user data. In addition, we may be the target
of email scams that attempt to acquire personal information or our assets. Despite our efforts to create security barriers to such threats,
we may not be able to entirely mitigate these risks. Any cyber-attack that attempts to obtain our or our users&rsquo; data and assets,
disrupt our service, or otherwise access our systems, or those of third parties we use, if successful, could adversely affect our business,
operating results, and financial condition, be expensive to remedy, and damage our reputation. In addition, any such breaches may result
in negative publicity, adversely affect our brand, decrease demand for our products and services, and adversely affect our operating
results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The illegal sale or distribution by third
parties of counterfeit versions of our products could have a negative impact on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pharmaceutical products are vulnerable to counterfeiting.
Third parties may illegally produce and distribute counterfeit versions of our products that are below the various manufacturing and
testing standards that our products undergo. Counterfeit products are often unsafe, ineffective and potentially life-threatening. As
many counterfeit products may be visually indistinguishable from their authentic versions, the presence of counterfeit products could
affect overall consumer confidence in the authentic product. A public loss of confidence in the integrity of pharmaceutical products
in general or in any of our products in particular due to counterfeiting could have a material adverse effect on our business, prospects,
financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we encounter difficulties enrolling
patients in any future clinical trials, our future trials could be delayed or otherwise adversely affected. Furthermore, our current
COVID-19 trials may not necessarily yield sufficient results or patient participants.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we have difficulty enrolling a sufficient
number of patients in any future clinical trial, including for COVID-19 studies for which the number of cases is unpredictable, we may
need to delay or terminate our trial, which would impair our ability to develop marketable products, and have a negative impact on our
business. Delays in enrolling patients in any future clinical trials would also adversely affect our ability to generate any product,
milestone and royalty revenues under collaboration agreements, if any, and could impose significant additional costs on us or on any
future collaborators.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our clinical trials for our product candidates
may not yield results that will enable us to further develop our products and obtain regulatory approvals necessary to sell them. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will receive regulatory approval for our product candidates only
if we can demonstrate in carefully designed and conducted clinical trials that the product candidate is safe and effective. We do not
know whether any current or future clinical trials for Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications,
or Celgosivir or any other product candidate will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals
or will result in marketable products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials are lengthy, complex and expensive
processes with uncertain results. We have spent, and expect to continue to spend, significant amounts of time and money on the clinical
development of our product candidates. The three clinical trials we conducted in the past were managed directly by us, but executed contract
research organizations (&ldquo;CROs&rdquo;). While certain of our employees have experience in designing and administering clinical trials,
our experience is limited to three clinical trials conducted by the management team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results we obtain in preclinical testing
and early clinical trials may not be predictive of results that are obtained in later studies. We may suffer significant setbacks in
advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, we
may decide to repeat or redesign a trial or discontinue development of one or more of our product candidates. If we fail to adequately
demonstrate the safety and efficacy of our products under development, we will not be able to obtain the required regulatory approvals
to commercialize our product candidates, and our business, results of operations and financial condition would be materially adversely
affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Administering our product candidates to humans
may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of our product candidates and
could result in the FDA or other regulatory authorities denying approval of our product candidates for any or all targeted indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If clinical trials for a product candidate are
unsuccessful, we will be unable to commercialize the product candidate. If one or more of our clinical trials are delayed, we will be
unable to meet our anticipated development timelines. Either circumstance could cause the market price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In planning for, and executing, clinical trials,
the targeted standard of care in the United States or other jurisdictions for the therapeutic indication may change, necessitating changes
to the design of such trials. Changes to such design trials will cause delays, and increase costs, thereby rendering us unable to meet
development timelines or complete development programs. The clinical data generated from clinical trials may not be acceptable to regulatory
agencies if changes to the standard of care occurred during trial execution, which may prevent regulatory approval, thereby damaging
our business prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because patients with COVID-19 disease enrolled in our Phase II clinical
study of Tafenoquine (Arakoda regimen) were presumed to be mostly infected with the SARS-CoV-2 delta variant, it is possible that the
results of the study might not be representative of those of future studies of Tafenoquine (Arakoda regimen) that utilize patients infected
with newer viral strains. If this risk materialized, our planned clinical trial might fail, thereby damaging our business prospects. It
should be stated that, due to the changing nature of the pandemic, this risk is common to all COVID-19 therapeutics. It is possible this
risk may be less likely to occur if the mechanism of Tafenoquine turns out not to be mediated via a direct antiviral effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our 2021 Phase II clinical study of Tafenoquine (Arakoda regimen) in COVID-19 patients was small, it is possible that the magnitude of
clinical benefit implied in Figure B listed in &ldquo;<I>Prospectus Summary&mdash;Strategy</I>&rdquo; (a three-day acceleration of recovery
in the Tafenoquine arm) may be an overestimate of the true therapeutic effect of Tafenoquine (Arakoda regimen). We have attempted to
mitigate this risk in our planned Phase IIB clinical trial design by providing for an interim analysis at 75% patient enrollment which
will include a sample size reanalysis, which would allow additional enrollment of patients if required without study termination. If
additional patients did need to be enrolled, it would increase the overall cost of the study. This risk mitigation strategy would not
work if the true therapeutic benefit of Tafenoquine (Arakoda regimen) is minimal or non-existent, or actual patient to patient variability
is larger than assumed. Any of those outcomes might result in failure of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the inclusion of a placebo arm
in our planned Phase IIB study is ethical because there are not any FDA-approved orally administered medications available for patients
with low risk of disease progression. However, because the standard of care for COVID-19 is evolving, it is possible that FDA or an Ethics
Committee may not agree with our assessment that inclusion of a placebo arm in our Phase IIB study is ethical. If this risk was realized,
it might result in (i) wasted expenditure on development of clinical sites if this was done aggressively in parallel with seeking FDA
feedback (a typical approach in the industry), and/or (ii) necessitate conducting our trial outside the United States in jurisdictions
without approved oral antivirals and accepting a greater risk of failing an FDA audit of the study in the future and/or (iii) replacement
of the placebo control with an active control arm and accepting the greater cost associated with such a study design (because they require
a higher number of patients). To mitigate against the first risk, we are planning to initiate preparations for the clinical trial at
only a small number of sites in parallel with seeking FDA and Ethics Committee feedback. If either of the second or third risks materialized,
our business might be irreparably harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Because
the number of COVID-19 cases is episodic, and the severity of the COVID-19 disease is generally perceived as being milder than it was
earlier in the pandemic meaning patients seek out medical treatment less often, it is possible that that there may be fewer COVID-19
patients available to be enrolled than expected in our study. If this risk materialized, it would result in slower recruitment in our
study than planned, forcing either a delay in the timeline for data being available, or increasing the overall cost in order to increase
the number of study sites, or both. Either eventuality would harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The mechanisms of actions of some of our
products, and interactions with other antiviral products are not known, which may restrict regulatory label claims.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA has granted full or limited marketing authority for COVID-19
products based on the clinical benefit demonstrated in clinical trials, for products that have both antiviral and non-antiviral modes
of action. However, the FDA may require specific additional evidence to grant a labeling claim of antiviral activity. We are planning
to further develop Tafenoquine (Arakoda regimen) for treatment of COVID-19 based on the observation of trends towards accelerated recovery
observed in the exploratory endpoints of a Phase II clinical trial we recently completed. We plan to undertake limited research activities
to confirm whether Tafenoquine provides clinical benefit via an antiviral or other mechanism. However, we cannot guarantee such efforts
will confirm a direct antiviral mechanism to the satisfaction of the FDA, or that any data generated will support regulatory claims of
antiviral activity in additional to whatever claims related to clinical benefit in COVID-19 treatment that the FDA may allow. Relatedly,
the FDA required warning language to be placed on the remdesivir label related to a theoretical drug-drug interaction with other antimalarials
based on in vitro (not clinical) data. Although we have conducted in vitro drug interactions studies of Tafenoquine versus molnupiravir,
remdesivir, and paxlovid, which do not suggest the possibility of clinically meaningful antagonism, we cannot guarantee these studies
will discharge any theoretical risks or concerns regulators may have (including the need for disclaimers or warning labels).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will rely on contract research organizations to conduct substantial
portions of our clinical trials, including any future clinical trial of Arakoda Tafenoquine (Arakoda or other regimen) for non-malaria
prevention indications, or Celgosivir, and as a result, we will be unable to directly control the timing, conduct and expense of all aspects
of our clinical trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not currently have sufficient staff to conduct our clinical trials
ourselves, and therefore, we will rely on third parties to conduct certain aspects of any future clinical trials. We previously contracted
with a CRO to conduct components of our clinical trials and anticipate contracting with a CRO to conduct components of any future clinical
trial for Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, or Celgosivir or any future clinical
trials for our other product candidates. As a result, we will have less control over many details and steps of any clinical trial, the
timing and completion of any clinical trial, the required reporting of adverse events and the management of data developed through any
clinical trial than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging,
potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties, such as CROs, may have staffing difficulties,
may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our
clinical trial. We may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the
work of a CRO may lead us to seek to terminate the relationship and use an alternative service provider. However, making any change may
be costly and may delay ongoing trials, if any, and contractual restrictions may make such a change difficult or impossible. Additionally,
it may be impossible to find a replacement organization that can conduct clinical trials in an acceptable manner and at an acceptable
cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even though we anticipate relying on CROs in
the future, we will likely have to devote substantial resources and rely on the expertise of our employees to manage the work being done
by the CROs. We and our management team have experience in managing clinical trials being executed on our behalf by CROs based on three
clinical studies. Therefore, we cannot guarantee that our employees will manage such studies effectively in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We expect to depend on existing and future
collaborations with third parties for the development of some of our product candidates. If those collaborations are not successful,
we may not be able to complete the development of these product candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaborations involving our product candidates
pose the following risks to us:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborators have significant discretion
                                            in determining the efforts and resources that they will apply to these collaborations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborators may not pursue development
                                            and commercialization of our product candidates or may elect not to continue or renew development
                                            or commercialization programs based on clinical trial results, changes in the collaborator&rsquo;s
                                            strategic focus or available funding, or external factors such as an acquisition that diverts
                                            resources or creates competing priorities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborators may delay clinical
                                            trials, provide insufficient funding for a clinical trial program, stop a clinical trial
                                            or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation
                                            of a product candidate for clinical testing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborators could independently
                                            develop, or develop with third parties, products that compete directly or indirectly with
                                            our product candidates if the collaborators believe that competitive products are more likely
                                            to be successfully developed or can be commercialized under terms that are more economically
                                            attractive than ours;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborators may not properly maintain
                                            or defend our intellectual property rights or may use our proprietary information in such
                                            a way as to invite litigation that could jeopardize or invalidate our proprietary information
                                            or expose us to potential litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborators may not comply with
                                            regulatory requirements and as a result their operations may be disrupted or ended until
                                            they resolve their regulatory issues with government officials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">disputes may arise between the collaborators
                                            and us that result in the delay or termination of the research, development or commercialization
                                            of our product candidates or that result in costly litigation or arbitration that diverts
                                            management attention and resources;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborations may be terminated
                                            and, if terminated, may result in a need for additional capital to pursue further development
                                            or commercialization of the applicable product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborators may elect to take over
                                            manufacturing rather than retain us as manufacturers and may encounter problems in starting
                                            up or gaining approval for their manufacturing facility and so be unable to continue development
                                            of product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we may be required to undertake the
                                            expenditure of substantial operational, financial and management resources in connection
                                            with any collaboration;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we may be required to issue equity
                                            securities to collaborators that would dilute our existing stockholders&rsquo; percentage
                                            ownership;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">we may be required to assume substantial
                                            actual or contingent liabilities;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborators may not commit adequate
                                            resources to the marketing and distribution of our product candidates, limiting our potential
                                            revenues from these products; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">collaborators may experience financial
                                            difficulties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We face a number of challenges in seeking additional collaborations.
Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether
we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&rsquo;s resources
and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&rsquo;s evaluation of a number of
factors, such as the design or results of our clinical trials, the potential market for our product candidates, the costs and complexities
of manufacturing and delivering our product candidates to patients, the potential of competing products, the existence of uncertainty
with respect to ownership or the coverage of our intellectual property, and industry and market conditions generally. If we were to determine
that additional collaborations for our Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indicationsm, or Celgosivir
development program are necessary and were unable to enter into such collaborations on acceptable terms, we might elect to delay or scale
back the development or commercialization of Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, or
Celgosivir in order to preserve our financial resources or to allow us adequate time to develop the required physical resources and systems
and expertise ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Collaboration agreements may not lead to development
or commercialization of our product candidates in the most efficient manner, or at all. In addition, there have been a significant number
of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.
If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our
product development or commercialization program could be delayed, diminished or terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any future clinical trial for Tafenoquine
(all regimens) will require screening for G6PD deficiency in order to safely administer the product. In the United States, G6PD testing
can obtained through commercial pathology services which is associated with delays. The use of a third-party diagnostic provider of point
of care testing may be required and we do not directly control the timing, conduct and expense of such testing.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to prescribing information for Arakoda, administration of
a test for G6PD deficiency is required before administration in order prevent the occurrence of hemolytic anemia that has been observed
in some patients who have G6PD deficiency and were inadvertently administered Arakoda in clinical trials. Therefore, G6PD deficiency is
an exclusion criteria in clinical trials involving Tafenoquine (all regimens).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For clinical trials administered in the United
States, G6PD testing is provided through commercial pathology companies including Labcorp and Quest Diagnostics. Such testing, while
usually available with 72-hour turnaround time, may sometimes take much longer. There is a single FDA-approved point of care test (Abbott&rsquo;s
Binax Now) but this requires administration in a CLIA-certified laboratory, which not all clinical trial sites have access to.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For many clinical trials, and in particular those
involving viral diseases, rapid administration of the investigational agent is required to maximize efficacy. Therefore, we will attempt
to import and utilize hand-held point of care tests approved elsewhere in the world in our clinical trials involving Tafenoquine (any
regimen). We may not be successful in this process, which would compromise our ability to recruit patients or result in a lower-than-expected
effect of Tafenoquine (any regimen) in such a trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Tafenoquine (all regimens) requires administration
of a G6PD test. The lack of point of care tests may negatively impair sales of Arakoda or other drug regimens containing Tafenoquine.</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A G6PD test need only be administered once and
can be recorded in electronic health records for future reference. The commercial providers of G6PD testing in the United States will
usually only commit to at best a 72-hour turn-around time for G6PD testing. Thus, while this does not present a problem in principle
for the existing malaria indication for individuals who travel frequently, or for organizations with organized occupational health and
safety programs where G6PD testing results are held on file, it may be a barrier to use of Arakoda by first time travelers or those planning
to travel and hence be a barrier to use of Arakoda if prospective patients are unwilling or unable to take the G6PD test.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If it is confirmed that the Mode of Action of Tafenoquine in COVID-19
is via a direct antiviral mechanism, it is likely that, as with other antivirals, rapid administration of the product is important to
maximize efficacy. Therefore, it is possible that the current lack of an FDA-approved, widely available point of care G6PD test will negatively
impact sales of Tafenoquine (any regimen) for COVID-19, under the assumption that the FDA eventually approves Arakoda (or other) regimen
of Tafenoquine for this indication and appropriate G6PD tests are never approved by FDA.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Several third-party diagnostic test companies
are developing point of care G6PD tests (or platforms that would accommodate them) that utilize finger stick blood samples and which
may be appropriate for use in the United States. One of these tests is approved in Brazil and Australia.<SUP>33</SUP> Another is available
for use in Europe and was recently approved by the FDA in the United States.<SUP>34</SUP> A third test is being developed with the NIH
grant support for the U.S. and ex U.S. markets and is in clinical development.<SUP>35</SUP> There is no guarantee that tests will succeed
in clinical development or ever become commercially available to the public. Having to take a test at all, or to go to a third party
lab in order to take the test, may be a hindrance to the use of Arakoda, which would negatively impact our sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our product candidates are subject to extensive
regulation, which can be costly and time-consuming, and unsuccessful or delayed regulatory approvals could increase our future development
costs or impair our future revenue. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
preclinical and clinical development, testing, manufacture, safety, efficacy, labeling, storage, recordkeeping, and subsequent advertising,
promotion, sale, marketing, and distribution, if approved, of our product candidates are subject to extensive regulation by the FDA and
other regulatory authorities in the United States and elsewhere. These regulations also vary in important, meaningful ways from country
to country. We are not permitted to market a potential new drug in the United States until we receive approval of an NDA from the FDA
for such drug. We have received an NDA approval for Arakoda for malaria prevention, but have not received approval from the FDA for any
non-malaria prevention indications for Tafenoquine (Arakoda regimen), Tafenoquine or any NDA approval from the FDA for Celgosivir or
any of our other product candidates. There can be no guarantees with respect to our product candidates that clinical studies will adequately
support an NDA, that the products will receive necessary regulatory approvals, or that they will prove to be commercially successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>33</SUP> https://www.sdbiosensor.com/product/product_view?product_no=183.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>34</SUP> Baebies Receives FDA 510(k) Clearance for G6PD Test
on FINDER Platform | Baebies.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><SUP>35</SUP> https://ivd.solutions/grant/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To receive regulatory approval for the commercial
sale of any product candidates, we must demonstrate safety and efficacy in humans to the satisfaction of regulatory authorities through
preclinical studies and adequate and well-controlled clinical trials of the product candidates. This process is expensive and can take
many years, and failure can occur at any stage of the testing. Our failure to adequately demonstrate the safety and efficacy of our product
candidates will prevent regulatory approval and commercialization of such products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event that we or our collaborators conduct
preclinical studies that do not comply with Good Laboratory Practices (&ldquo;GLP&rdquo;), or incorrectly design or carry out human clinical
trials in accordance with Good Clinical Practices (&ldquo;GCP&rdquo;), or those clinical trials fail to demonstrate clinical significance,
it is unlikely that we will be able to obtain FDA approval for product development candidates. Our inability to successfully initiate
and effectively complete clinical trials for any product candidate on schedule, or at all, will severely harm our business. Significant
delays in clinical development could materially increase product development costs or allow our competitors to bring products to market
before we do, impairing our ability to effectively commercialize any future product candidate. We do not know whether planned clinical
trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for
a variety of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">delays or failures in obtaining regulatory
                                            authorization to commence a trial because of safety concerns of regulators relating to our
                                            product candidates or similar product candidates of our competitors or failure to follow
                                            regulatory guidelines;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">delays or failures in obtaining clinical
                                            materials and manufacturing sufficient quantities of the product candidates for use in trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">delays or failures in reaching agreement
                                            on acceptable terms with prospective study sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">delays
                                            or failures in obtaining approval of our clinical trial protocol from an Institutional Review
                                            Board (&ldquo;IRB&rdquo;) to conduct a clinical trial at a prospective study site;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">delays in recruiting patients to
                                            participate in a clinical trial, which may be due to the size of the patient population,
                                            eligibility criteria, protocol design, perceived risks and benefits of the drug, availability
                                            of other approved and standard of care therapies or, availability of clinical trial sites;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">other clinical trials seeking to
                                            enroll subjects with similar profile;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">failure of our clinical trials and
                                            clinical investigators to be in compliance with GCP;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">unforeseen safety issues, including
                                            negative results from ongoing preclinical studies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">inability to monitor patients adequately
                                            during or after treatment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">difficulty recruiting and monitoring
                                            multiple study sites; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">failure of our third-party contract
                                            research organizations, clinical site organizations and other clinical trial managers, to
                                            satisfy their contractual duties, comply with regulations or meet expected deadlines; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">an insufficient number of patients
                                            who have, or are willing to have, a device implanted for monitoring and recording data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, any approvals we may obtain may
not cover all of the clinical indications for which we seek approval or permit us to make claims of superiority over currently marketed
competitive products. Also, an approval might contain significant limitations in the form of narrow indications, warnings, precautions
or contraindications with respect to conditions of use. If the FDA determines that a risk evaluation and mitigation strategy (&ldquo;REMS&rdquo;)
is necessary to ensure that the benefits of the drug outweigh the risks, we may be required to include as part of the NDA a proposed
REMS that may include a package insert directed to patients, a plan for communication with healthcare providers, restrictions on a drug&rsquo;s
distribution, or a medication guide to provide better information to consumers about the drug&rsquo;s risks and benefits. Finally, approval
could be conditioned on our commitment to conduct further clinical trials, which we may not have the resources to conduct or which may
negatively impact our financial situation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manufacture and tableting of Arakoda, Tafenoquine (all regimens)
or Celgosivir is, or will be done, by third party suppliers, who must also meet current Good Manufacturing Practices (&ldquo;cGMP&rdquo;)
requirements and pass a pre-approval inspection of their facilities before we obtain marketing approval (now or in the future). All of
our product candidates are prone to the risks of failure inherent in drug development. The results from preclinical animal testing and
early human clinical trials may not be predictive of results obtained in later human clinical trials. Further, although a new product
may show promising results in preclinical or early human clinical trials, it may subsequently prove unfeasible or impossible to generate
sufficient safety and efficacy data to obtain necessary regulatory approvals. The data obtained from preclinical and clinical studies
are susceptible to varying interpretations that may delay, limit or prevent regulatory approval, and the FDA and other regulatory authorities
in the United States and elsewhere exercise substantial discretion in the drug approval process. The numbers, size and design of preclinical
studies and clinical trials that will be required for FDA or other regulatory approval will vary depending on the product candidate, the
disease or condition for which the product candidate is intended to be used and the regulations and guidance documents applicable to any
particular product candidate. The FDA or other regulators can delay, limit or deny approval of any product candidate for many reasons,
including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">side effects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">safety and efficacy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">defects in the design of clinical
                                            trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">new understanding related to the
                                            pharmacology of other related drug products and their side effects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the fact that the FDA or other regulatory
                                            officials may not approve our or our third-party manufacturer&rsquo;s processes or facilities;
                                            or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the fact that new regulations may
                                            be enacted by the FDA or other regulators may change their approval policies or adopt new
                                            regulations requiring new or different evidence of safety and efficacy for the intended use
                                            of a product candidate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In light of widely publicized events concerning the safety of certain
drug products, regulatory authorities, members of Congress, the Government Accountability Office, medical professionals and the general
public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of certain drug products,
revisions to certain drug labeling that further limit use of the drug products and establishment of risk management programs that may,
for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach
by the FDA to clinical trials and approval. Data from clinical trials may receive greater scrutiny with respect to safety and the product&rsquo;s
risk/benefit profile, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion,
or require longer or additional clinical trials that may result in substantial additional expense, and a delay or failure in obtaining
approval or approval for a more limited indication than originally sought. Aside from issues concerning the quality and sufficiency of
submitted preclinical and clinical data, the FDA may be constrained by limited resources from reviewing and determining the approvability
of an NDA or regulatory supplement for Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications or of a Celgosivir
NDA in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In pursuing clinical development of Tafenoquine
(Arakoda or other regimen) for a non-malaria prevention indication or Celgosivir for other indications, we will be required to amend existing
prescribing information, or prepare a new NDA as appropriate. The&nbsp;FDA could approve Tafenoquine (Arakoda or other regimen) or Celgosivir,
but without including some or all of the prescribing information that we have requested. For instance, the FDA could approve Tafenoquine
(Arakoda or other regimen) or Celgosivir in&nbsp;a more limited patient population or include additional warnings in the drug&rsquo;s
label. This, in turn, could substantially and detrimentally impact our ability to successfully commercialize Tafenoquine (Arakoda or other
regimen) or Celgosivir and effectively protect our intellectual property rights in Tafenoquine (Arakoda or other regimen) or Celgosivir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are not able to successfully develop,
obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for Tafenoquine (Arakoda or other
regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We currently have only a single product (Arakoda
for malaria prevention) that has received regulatory approval for commercial sale. The process to develop, obtain regulatory approval
for and commercialize potential product candidates is long, complex and costly. Any future development of Tafenoquine (Arakoda or other
regimen for a non-malaria prevention indication) or Celgosivir, including initiating clinical trials, is dependent on obtaining additional
financing, even if we enter into a strategic collaboration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Failure to demonstrate that a product candidate,
including Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, or, in the future, Celgosivir, is safe and effective,
or significant delays in demonstrating such safety and efficacy, would adversely affect our business. Failure to obtain marketing approval
of Tafenoquine (Arakoda or other regimen for non-malaria prevention indications) or Celgosivir from appropriate regulatory authorities,
or significant delays in obtaining such approval, would also adversely affect our business and could, among other things, preclude us
from completing a strategic transaction or obtaining additional financing necessary to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Even if approved for sale, a product candidate
must be successfully commercialized to generate value. Although we plan to undertake limited efforts through a contracts sales organization
to begin commercialization activities for Arakoda for malaria prevention, we do not currently have the capital resources or management
expertise to commercialize Tafenoquine (Arakoda other regimen for non-malaria prevention indications), or Celgosivir or any of our other
product candidates and, as a result, will need to complete a strategic transaction, or, alternatively, raise substantial additional funds
to enable commercialization of Arakoda, Tafenoquine (Arakoda or other regimen for non-malaria prevention indications) or Celgosivir or
any of our other product candidates, if approved. Failure to successfully provide for the commercialization of Arakoda for its current
malaria prevention application, or Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications or Celgosivir or any
other product candidate, would damage our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If our product candidates receive regulatory
approval, we would be subject to ongoing regulatory obligations and restrictions, and possible litigation exposure, which may result in
significant expenses and limit our ability to develop and commercialize other potential products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a product candidate of ours is approved by
the FDA or by another regulatory authority, we would be held to extensive regulatory requirements over product manufacturing, testing,
distribution, labeling, packaging, adverse event reporting and other reporting to regulatory authorities, storage, advertising, marketing,
promotion, distribution, and record keeping. Regulatory approvals may also be subject to significant limitations on the indicated uses
or marketing of the product candidates. Potentially costly follow-up or post-marketing clinical studies may be required as a condition
of approval to further substantiate safety or efficacy, or to investigate specific issues of interest to the regulatory authority. Previously
unknown problems with the product candidate, including adverse events of unanticipated severity or frequency, may result in additional
regulatory controls or restrictions on the marketing or use of the product or the need for post marketing studies, and could include suspension
or withdrawal of the products from the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Furthermore, our third-party manufacturers and the manufacturing facilities
that they use to make our product candidates are regulated by the FDA. Quality control and manufacturing procedures must continue to conform
to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and products manufactured
annually with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA, state and/or other foreign
authorities. Any subsequent discovery of problems with a product, or a manufacturing or laboratory facility used by us or our collaborators,
may result in restrictions on the product, or on the manufacturing or laboratory facility, including a withdrawal of the drug from the
market or suspension of manufacturing. Any changes to an approved product, including the way it is manufactured or promoted, often require
FDA approval before the product, as modified, can be marketed. We and our third-party manufacturers will also be subject to ongoing FDA
requirements for submission of safety and other post-market information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
marketing and advertising of our drug products by our collaborators or us will be regulated by the FDA, certain state agencies or foreign
regulatory authorities including the Federal Trade Commission (&ldquo;FTC&rdquo;). Violations of these laws and regulations, including
promotion of our products for unapproved &ldquo;off-label&rdquo; uses or failing to disclose risk information, are punishable by criminal
and civil sanctions and may result in the issuance of enforcement letters or other enforcement action by the FDA, U.S. Department of
Justice, state agencies, or foreign regulatory authorities that could jeopardize our ability to market the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the FDA, state or foreign regulations,
the marketing of our drug products by us or our collaborators will be regulated by federal, state or foreign laws pertaining to health
care &ldquo;fraud and abuse,&rdquo; such as the federal anti-kickback law prohibiting bribes, kickbacks or other remuneration for the
order or recommendation of items or services reimbursed by federal health care programs. Many states have similar laws applicable to
items or services reimbursed by commercial insurers. Violations of these laws are punishable by criminal and civil sanctions, including,
in some instances, imprisonment and exclusion from participation in federal and state health care programs, including the Medicare, Medicaid
and Veterans Affairs healthcare programs. Because of the far-reaching nature of these laws, we may be required to discontinue one or
more of our practices to be in compliance with these laws. Healthcare fraud and abuse regulations are complex, and even minor irregularities
can potentially give rise to claims that a statute or prohibition has been violated. Any violations of these laws, or any action against
us for violations of these laws, even if we successfully defend against it, could have a material adverse effect on our business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we, our collaborators or our third-party manufacturers
fail to comply with applicable continuing regulatory requirements, our business could be seriously harmed because a regulatory agency
may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">issue untitled or warning letters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">suspend or withdraw our regulatory
                                            approval for approved products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">seize or detain products or recommend
                                            a product recall of a drug or medical device, or issue a mandatory recall of a medical device;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">refuse import or export of any of
                                            our drug products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">refuse to approve pending applications
                                            or supplements to approved applications filed by us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">suspend our ongoing clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">restrict our operations, including
                                            costly new manufacturing requirements, or restrict the sale, marketing and/or distribution
                                            of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">seek an injunction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">pursue criminal prosecutions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">close the facilities of our contract
                                            manufacturers; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">impose civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We could become subject to false claims
litigation under federal statutes, which can lead to civil money penalties, restitution, criminal fines and imprisonment, and exclusion
from participation in Medicare, Medicaid and other federal and state health care programs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">False claims statutes include the False Claims
Act, which allows any person to bring a suit on behalf of the federal government alleging submission of false or fraudulent claims, or
causing to present such false or fraudulent claims, under federal programs or contracts claims or other violations of the statute and
to share in any amounts paid by the entity to the government in fines or settlement. These suits against pharmaceutical companies have
increased significantly in volume and breadth in recent years. Some of these suits have been brought on the basis of certain sales practices
promoting drug products for unapproved uses. This new growth in litigation has increased the risk that a pharmaceutical company will
have to defend a false claim action, pay fines or restitution, or be excluded from the Medicare, Medicaid, Veterans Affairs and other
federal and state healthcare programs as a result of an investigation arising out of such action. We may become subject to such litigation
and, if we are not successful in defending against such actions, those actions may have a material adverse effect on our business, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We could also become subject to false claims
litigation and consumer protection claims under state statutes, which also could lead to civil monetary penalties, restitution, criminal
fines and imprisonment, and exclusion from participation in state health care programs. Of note, over the past few years there has been
an increased focus on the sales and marketing practices of the pharmaceutical industry at both the federal and state level. Additionally,
the law or regulatory policies governing pharmaceuticals may change. New statutory requirements may be enacted or additional regulations
may be adopted that could prevent or delay regulatory approval of our product candidates or limit our ability to commercialize our products.
We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative
action, either in the United States or elsewhere.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to be included in formularies developed
by MCOs and other organizations may impact the use of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Managed
Care Organizations (&ldquo;MCOs&rdquo;) and other third-party payers try to negotiate the pricing of medical services and products to
control their costs. MCOs and pharmacy benefit managers typically develop formularies to reduce their cost for medications. These formularies
can be based on the prices and therapeutic benefits of the available products. The breadth of the products covered by formularies varies
considerably from one MCO to another, and many formularies include alternative and competitive products for treatment of particular medical
conditions. Failure to be included in such formularies or to achieve favorable formulary status may negatively impact the use of our
products. If our products are not included within an adequate number of formularies, additional coverage criteria are required or if
the patient&rsquo;s cost-sharing obligations are high, our market share and gross margins could be adversely impacted, which could have
a material adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we obtain regulatory approvals
and market our products as planned, there is no guarantee of widespread market acceptance and the results of our efforts to commercialize
our products are uncertain. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Even if we are able to obtain
and maintain regulatory approvals for our products, the success of our products depends upon achieving and maintaining market acceptance.
Commercializing products is time-consuming, expensive and unpredictable. Furthermore, the market for products that address unmet medical
needs is highly speculative. If we overestimate the market opportunity for any of our products or candidates, or if we are unsuccessful
in gaining market share, these factors could have a material adverse effect on our business. There can be no assurance that we will be
able to successfully commercialize our products or gain market acceptance for such products, including in new markets. New product candidates
that appear promising in development may fail to reach the market or may have only limited or no commercial success. If any of our products
fail to gain, or lose, market acceptance, our revenues could be adversely impacted, which in turn could have a material adverse effect
on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Levels of market acceptance
for our products could be impacted by several factors, some of which are not within our control, including, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">safety, efficacy, convenience and
                                            cost-effectiveness of our products as compared to products of our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">scope of approved uses and marketing
                                            approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">availability of patent or regulatory
                                            exclusivity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">timing of market approvals and market
                                            entry;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">availability of alternative products
                                            from our competitors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">acceptance of the price of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the shelf life of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">effectiveness of our sales forces
                                            and promotional efforts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the level of reimbursement of our
                                            products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">acceptance of our products on government
                                            and private formularies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">ability to market our products effectively
                                            at the retail level or in the appropriate setting of care; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">reputation of our products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B><I>Unexpected safety, efficacy
or other concerns, whether actual or perceived, about our products may arise which could have a material adverse effect on our business
and operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Unexpected safety or efficacy
concerns can arise with respect to our products, whether or not scientifically justified. These concerns are especially more likely to
arise as our products are used or studied over longer periods of time or used by a wider group of patients, some of whom may be taking
other medicines or have additional underlying health problems. Such developments can potentially result in product recalls, withdrawals
and/or declining sales, as well as product liability, consumer fraud and/or other claims, any of which could have a material adverse
effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Any negative publicity about
any of our products, such as the discovery of safety or efficacy issues, adverse events involving our products or even public rumors
about such events, could have a material adverse effect on our business. In addition, the discovery of one or more significant problems
with a product similar to one of our products that implicates (or are perceived to implicate) an entire class of products, or the withdrawal
or recall of such similar products, could have an adverse effect on the sales of our products. New data about our products, or products
similar to our products, could also cause us reputational harm and could negatively impact demand for our products (or result in product
withdrawal), due to real or perceived side effects or uncertainty regarding safety or efficacy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Reliance on third parties to commercialize
Arakoda, Tafenoquine (Arakoda or other regimen) Celgosivir or our other product candidates could negatively impact our business. If we
are required to establish a direct sales force in the United States and are unable to do so, our business may be harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have received FDA approval of Arakoda for malaria
prevention. Arakoda entered the U.S. commercial supply chain in the third quarter of 2019. Sales have been limited due to the impact of
the COVID-19 pandemic, and we accordingly suspended our efforts to build internal sales and marketing capability. Re-establishing such
sales and marketing capability for the malaria indication would require substantial additional resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Future commercialization of Tafenoquine (Arakoda
or other regimen) for non-malaria prevention indications, or Celgosivir or any other product candidate, if approved, particularly the
establishment of a sales organization, will require substantial additional capital resources. We currently intend to pursue a strategic
partnership alternative for the commercialization of Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, or
Celgosivir, if it is approved, and we have suspended our efforts to build internal sales, marketing and distribution capabilities. If
we elect to rely on third parties to sell Arakoda, Tafenoquine (Arakoda or other regimen), or Celgosivir and any other products, then
we may receive less revenue than if we sold such products directly. In addition, we may have little or no control over the sales efforts
of those third parties. If we are unable to complete a strategic transaction, we would be unable to commercialize Arakoda, Tafenoquine
(Arakoda or other regimen) or Celgosivir or any other product candidate without substantial additional capital. Even if such capital were
secured, we would be required to rely on our existing distribution network in place through prime vendors for sales and marketing and
capabilities, since we lack our own internal resources to directly sell and market Arakoda, Tafenoquine (Arakoda or other regimen) or
Celgosivir in the United States. None of our current employees have experience in establishing and managing a sales force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event we are unable to establish an effective
sales channel for Arakoda, Tafenoquine (Arakoda or other regimen) or Celgosivir and other selected product candidates, either directly
or through third parties via a strategic transaction, the commercialization of Tafenoquine (Arakoda or other regimen) for non-malaria
prevention indications, or Celgosivir, if approved, may be delayed indefinitely and our revenues will be impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may explore new strategic collaborations
that may never materialize or may fail.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may, in the future, periodically explore a
variety of new strategic collaborations in an effort to gain access to additional product candidates or resources. At the current time,
we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking appropriate
strategic collaborators, and these strategic collaborations can be complicated and time-consuming to negotiate and document. We may not
be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into
any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing strategic collaborations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have no manufacturing capacity, which
puts us at risk of lengthy and costly delays of bringing our products to market. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
do not currently operate manufacturing facilities for clinical or commercial production of our product candidates, including their API.
We have no experience in drug formulation or manufacturing, and we lack the resources and the capabilities to manufacture any of our
product candidates on a clinical or commercial scale. We do not intend to develop Company-owned facilities for the manufacture of product
candidates for clinical trials or commercial purposes in the foreseeable future. We have contracted with Piramal to manufacture the API
for Arakoda. For drug product, we previously contracted with Piramal to manufacture the Arakoda tablets (and placebos) for commercial
and clinical use and with PCI in the United States for secondary packaging. In addition, we contracted with a separate service provider
for packaging and distribution of our clinical trial materials. We may also need to contract with similar manufacturers for similar services
in connection with any planned or future clinical trials of Arakoda and Celgosivir.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our contract manufacturers may not perform as
agreed or may not remain in the contract manufacturing business for the time required to successfully produce, store and distribute our
products. In addition, these manufacturers may have staffing difficulties, may not be able to manufacture our products on a timely basis
or may become financially distressed. In the event of errors in forecasting production quantities required to meet demand, natural disaster,
equipment malfunctions or failures, technology malfunctions, strikes, lock-outs or work stoppages, regional power outages, product tampering,
war or terrorist activities, actions of regulatory authorities, business failure, strike or other difficulty, we may be unable to find
an alternative third-party manufacturer in a timely manner and the production of our product candidates would be interrupted, resulting
in delays and additional costs, which could impact our ability to commercialize and sell our product candidates. We or our contract manufacturers
may also fail to achieve and maintain required manufacturing standards, which could result in patient injury or death, product recalls
or withdrawals, an order by governmental authorities to halt production, delays or failures in product testing or delivery, stability
testing failures, cost overruns or other problems that could seriously hurt our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Contract manufacturers also often encounter difficulties
involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. In addition, our contract
manufacturers are subject to ongoing inspections and regulation by the FDA, the U.S. Drug Enforcement Agency and corresponding foreign
and state agencies and they may fail to meet these agencies&rsquo; acceptable standards of compliance. If our contract manufacturers
fail to comply with applicable governmental regulations, such as quality control, quality assurance and the maintenance of records and
documentation, we may not be able to continue production of the API or finished product. If the safety of any API or product supplied
is compromised due to failure to adhere to applicable laws or for other reasons, this may jeopardize our regulatory approval for Arakoda,
or Celgosivir and other product candidates, and we may be held liable for any injuries sustained as a result. Upon the occurrence of
one of the aforementioned events, the ability to switch manufacturers may be difficult for a number of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the number of potential manufacturers
                                            is limited and we may not be able to negotiate agreements with alternative manufacturers
                                            on commercially reasonable terms, if at all;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">long lead times are often needed
                                            to manufacture drugs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the manufacturing process is complex
                                            and may require a significant learning curve; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the FDA must approve any replacement
                                            prior to manufacturing, which requires new testing and compliance inspections.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our contract manufacturers are subject
to significant regulation with respect to the manufacturing of our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All entities involved in the preparation of a
product candidate for clinical trials or commercial sale, including our contract manufacturing organizations used for bulk product manufacturing
and filling and finishing of our bulk product, are subject to extensive regulation. Components of a finished product approved for commercial
sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. These regulations govern manufacturing processes
and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of
investigational products and products approved for sale. The facilities and quality systems of some or all of our third-party contractors
must pass a pre-approval inspection for compliance with the applicable regulations as a condition of any regulatory approval of our product
candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation
of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The regulatory authorities also may, at any time
following approval of a product for sale, audit the manufacturing facilities of our third-party contractors or raw material suppliers.
If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications
or applicable regulations occurs independent of such an inspection or audit, the relevant regulatory authority may require remedial measures
that may be costly and time-consuming to implement and that may include the temporary or permanent suspension of a clinical trial or
commercial sales or the temporary or permanent closure of a facility. Our third-party contractors or raw material suppliers may refuse
to implement remedial measures required by regulatory authorities. Any failure to comply with applicable manufacturing regulations or
failure to implement required remedial measures imposed upon third parties with whom we contract could materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on relationships with third-party
contract manufacturers and raw material suppliers, which limits our ability to control the availability of, and manufacturing costs for,
our product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Problems with any of our contract manufacturers&rsquo;
or raw material suppliers&rsquo; facilities or processes, could prevent or delay the production of adequate supplies of finished products.
This could delay clinical trials or delay and reduce commercial sales and materially harm our business. Any prolonged delay or interruption
in the operations of our collaborators&rsquo; facilities or contract manufacturers&rsquo; facilities could result in cancellation of
shipments, loss of components in the process of being manufactured or a shortfall in availability of a product candidate or products.
A number of factors could cause interruptions, including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the inability of a supplier to provide
                                            raw materials;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">equipment malfunctions or failures
                                            at the facilities of our collaborators or suppliers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">high process failure rates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">damage to facilities due to natural
                                            or man-made disasters;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">changes in regulatory requirements
                                            or standards that require modifications to our or our collaborators&rsquo; and suppliers&rsquo;
                                            manufacturing processes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">action by regulatory authorities
                                            or by us that results in the halting or slowdown of production of components or finished
                                            product at our facilities or the facilities of our collaborators or suppliers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">problems that delay or prevent manufacturing
                                            technology transfer to another facility, contract manufacturer or collaborator with subsequent
                                            delay or inability to start up a commercial facility;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">a contract manufacturer or supplier
                                            going out of business, undergoing a capacity shortfall or otherwise failing to produce product
                                            as contractually required;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">employee or contractor misconduct
                                            or negligence; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">shipping delays, losses or interruptions;
                                            and other similar factors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because manufacturing processes are complex and
are subject to a lengthy regulatory approval process, alternative qualified production capacity and sufficiently trained or qualified
personnel may not be available on a timely or cost-effective basis or at all. Difficulties or delays in our contract manufacturers' production
of drug substances could delay our clinical trials, increase our costs, damage our reputation and cause us to lose revenue and market
share if we are unable to timely meet market demand for any products that are approved for sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The manufacturing process for our product candidates
has several components that are sourced from a single manufacturer. If we utilize an alternative manufacturer or alternative component,
we may be required to demonstrate comparability of the drug product before releasing the product for clinical use and we may not be to
find an alternative supplier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Further, if our contract manufacturers are not
in compliance with regulatory requirements at any stage, including post-marketing approval, we may be fined, forced to remove a product
from the market and/or experience other adverse consequences, including delays, which could materially harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if one of our product candidates receives
marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in
the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Physicians are often reluctant to switch their
patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients
often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products
or they are required to switch therapies due to lack of reimbursement for existing therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Efforts to educate the medical community and
third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of our
product candidates is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues
and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend
on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the efficacy and safety of the product;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the potential advantages of the product
                                            compared to competitive therapies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the prevalence and severity of any
                                            side effects;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the clinical indications for which
                                            the product is approved;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">whether the product is designated
                                            under physician treatment guidelines as a first-, second- or third-line therapy;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the product&rsquo;s convenience and
                                            ease of administration compared to alternative treatments;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the willingness of the target patient
                                            population to try, and of physicians to prescribe, the product;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">limitations or warnings, including
                                            distribution or use restrictions contained in the product&rsquo;s approved labeling;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the approval of other new products
                                            for the same indications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">changes in the standard of care for
                                            the targeted indications for the product; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">availability and amount of coverage
                                            and reimbursement from government payors, managed care plans and other third-party payors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our future growth depends on our ability
to successfully commercialize Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and our
other product candidates, and we can provide no assurance that we will successfully commercialize Arakoda, Tafenoquine (Arakoda or other
regimen) for non-malaria prevention indications, Celgosivir and other product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our future growth depends on our ability to successfully
commercialize Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and our other product
candidates, including our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">conduct additional clinical trials and develop and obtain regulatory approval for Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir or other product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">successfully partner a companion genetic test (if required by the FDA) with the commercialization of Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications and Celgosivir;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">pursue additional indications for Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications and Celgosivir and develop other product candidates, including other therapies; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">obtain commercial quantities of Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications and Celgosivir or other product candidates at acceptable cost levels.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any one of these or other factors could affect
our ability to successfully commercialize products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If approved by the FDA, Tafenoquine (Arakoda
or other regimen) for non-malaria prevention indications, and Celgosivir, will be entering a competitive marketplace and may not succeed.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our commercial opportunity may be reduced or eliminated
if competitors develop and commercialize products that are safer, more effective, have fewer side effects, are more convenient or are
less expensive than Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications and Celgosivir. If products
with any of these properties are developed, or any of the existing products are better marketed, then Arakoda, Tafenoquine (Arakoda or
other regimen) for non-malaria prevention indications and Celgosivir could be rendered obsolete and noncompetitive. Further, public announcements
regarding the development of any such competing drugs could adversely affect the market price of our common stock and the value of our
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>State-specific regulatory activities may
negatively affect our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, individual state governments
regulate certain aspects of the pharmaceutical industry including price transparency, requirements in some cases to obtain state licenses,
compliance with cGMPs, and for environmental stewardship/take-back programs. For distribution of Arakoda, we have employed a &ldquo;title
model&rdquo; approach to distribution which limits the extent of state licenses required, and we have contracted with third party organizations
to ensure we are participating in appropriate stewardship/take programs, and have complied (or have a process in place to comply) with
state licensing/price transparency requirements that we are aware of. However, we cannot guarantee that we will be compliant with all
state regulations, or that we will become aware of and act on any new requirements (which are constantly changing) in time to ensure
100% compliance at all times. State compliance is expensive and new requirements may impose new costs we were not previously aware of.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Health care reform measures could materially
and adversely affect our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The business and financial condition of pharmaceutical
and biotechnology companies are affected by the efforts of governmental and third-party payors to contain or reduce the costs of health
care. The U.S. Congress has enacted legislation to reform the health care system. While we anticipate that this legislation may, over
time, increase the number of patients who have insurance coverage for pharmaceutical products, it also imposes cost containment measures
that may adversely affect the amount of reimbursement for pharmaceutical products. These measures include increasing the minimum rebates
for products covered by Medicaid programs and extending such rebates to drugs dispensed to Medicaid beneficiaries enrolled in Medicaid
managed care organizations as well as expansion of the 340(B) Public Health Services drug discount program. In addition, such legislation
contains a number of provisions designed to generate the revenues necessary to fund the coverage expansion, including new fees or taxes
on certain health-related industries, including medical device manufacturers. Each medical device manufacturer has to pay an excise tax
(or sales tax) in an amount equal to 2.3% of the price for which such manufacturer sells its medical devices. Such excise taxes may impact
any potential sales of the genetic test if it is approved for marketing. On January&nbsp;22, 2018, legislation was enacted suspending
the medical device tax in 2018 and 2019. In December 2019, a permanent repeal of the medical device tax was enacted. The Celgosivir test
is likely to be subject to this tax if this tax is reinstated in the future. In foreign jurisdictions there have been, and we expect
that there will continue to be, a number of legislative and regulatory proposals aimed at changing the health care system. For example,
in some countries other than the United States, pricing of prescription drugs is subject to government control and we expect to see continued
efforts to reduce healthcare costs in international markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2022, the Inflation Reduction Act of
2022 was signed into law. This law requires the federal government to negotiate prices for a small number of high-cost drugs covered
under Medicare, requires drug manufacturers to pay rebates to Medicare if they increase prices faster than inflation for drugs used by
Medicare beneficiaries, and caps Medicare beneficiaries&rsquo; out-of-pocket spending under the Medicare Part D benefit. This legislation
could create more demand for negotiated drug prices and further government control of prescription drug pricing. Future legal restrictions
regarding our ability to price our drugs could affect our revenues and our business going forward.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, federal, state and local governments
continue to consider legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products.
Since 2017, several states and local governments have either implemented or are considering implementation of price transparency legislation
that may prevent or limit our ability to take price increases at certain rates or frequencies. If adequate reimbursement levels are not
maintained by government and other third-party payers for our products, our ability to sell our products may be limited and our ability
to establish acceptable pricing levels may be impaired, thereby reducing anticipated revenues and profitability. Further, the pace of
change and varying demands of state requirements may render it very difficult to comply with these various laws, and failure to comply
with these regulations could expose us to substantial financial penalties and the potential for adverse publicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some states are also considering legislation
that would control the prices of drugs, and state Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates
and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Managed
care organizations continue to seek price discounts and, in some cases, to impose restrictions on the coverage of particular drugs. Government
efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in
managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding constraint on
prices and reimbursement for drugs. It is likely that federal and state legislatures and health agencies will continue to focus on additional
health care reform in the future although we are unable to predict what additional legislation or regulation, if any, relating to the
health care industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation or regulation
would have on our business. We or any strategic partner&rsquo;s ability to commercialize Celgosivir, or any other product candidates
that we may seek to commercialize, is highly dependent on the extent to which coverage and reimbursement for these product candidates
will be available from government payors, such as Medicare and Medicaid, private health insurers, including managed care organizations,
and other third-party payors, and any change in reimbursement levels could materially and adversely affect our business. Further, the
pendency or approval of future proposals or reforms could result in a decrease in our stock price or limit our ability to raise capital
or to obtain strategic partnerships or licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our employees may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse
effect on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are exposed to the risk of employee fraud
or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information
to the FDA, comply with manufacturing standards we have established, comply with federal and state health-care fraud and abuse laws and
regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing
and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks,
self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
and promotion, sales commission, customer incentive programs and other business arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Employee misconduct could also involve the improper
use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.
It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent misconduct may
not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us,
and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business
and results of operations, including the imposition of significant civil, criminal, and administrative penalties, damages, fines, disgorgement,
individual imprisonment, exclusion from governmental funded healthcare programs, such as Medicare and Medicaid, contractual damages,
reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity
agreement or other agreement to resolve allegations of non-compliance with these laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our competitors may be better positioned
in the marketplace and thereby may be more successful than us at developing, manufacturing and marketing approved products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Many of our competitors currently have significantly
greater financial resources and expertise in conducting clinical trials, obtaining regulatory approvals, and managing manufacturing and
marketing approved products than us. Other early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. In addition, these third parties compete with us in recruiting and retaining qualified
scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
therapies and therapy licenses complementary to our programs or advantageous to our business. We expect that our ability to compete effectively
will depend upon our ability to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">successfully and rapidly complete
                                            clinical trials for any product candidates and obtain all requisite regulatory approvals
                                            in a cost-effective manner;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">build an adequate sales and marketing
                                            infrastructure, raise additional funding, or enter into strategic transactions enabling the
                                            commercialization of our products;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">develop competitive formulations
                                            of our product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">attract and retain key personnel;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">identify and obtain other product
                                            candidates on commercially reasonable terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We compete in an industry characterized
by extensive research and development efforts and rapid technological progress. New discoveries or commercial developments by our competitors
could render our potential products obsolete or non-competitive.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New developments occur and are expected to continue
to occur at a rapid pace in our industry, and there can be no assurance that discoveries or commercial developments by our competitors
will not render some or all of our potential products obsolete or non-competitive, which could have a material adverse effect on our
business, financial condition and results of operations. New data from commercial and clinical-stage products continue to emerge and
it is possible that these data may alter current standards of care, completely precluding us from further developing our product candidates
or preventing us from getting them approved by regulatory agencies. Further, it is possible that we may initiate a clinical trial or
trials for our product candidates, only to find that data from competing products make it impossible for us to complete enrollment in
these trials, resulting in our inability to file for marketing approval with regulatory agencies. Even if these products are approved
for marketing in a particular indication or indications, they may have limited sales due to particularly intense competition in these
markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect to compete with fully integrated and
well-established pharmaceutical and biotechnology companies in the near- and long-term. Most of these companies have substantially greater
financial, research and development, manufacturing and marketing experience and resources than we do and represent substantial long-term
competition for us. Such companies may succeed in discovering and developing pharmaceutical products more rapidly than we do or pharmaceutical
products that are safer, more effective or less costly than any that we may develop. Such companies also may be more successful than
we are in manufacturing, sales and marketing. Smaller companies may also prove to be significant competitors, particularly through collaborative
arrangements with large pharmaceutical and established biotechnology companies. Academic institutions, governmental agencies and other
public and private research organizations also conduct clinical trials, seek patent protection and establish collaborative arrangements
for the development of product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expect competition among products will be
based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities,
reimbursement coverage, price and patent position. There can be no assurance that our competitors will not develop safer and more effective
products, commercialize products earlier than we do, or obtain patent protection or intellectual property rights that limit our ability
to commercialize our products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that our issued patents
or pending patent applications, if issued, will not be challenged, invalidated or circumvented or that the rights granted thereunder
will provide us with proprietary protection or a competitive advantage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We would be subject to applicable regulatory
approval requirements of the foreign countries in which we market our products, which are costly and may prevent or delay us from marketing
our products in those countries. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to regulatory requirements in the
United States, we would be subject to the regulatory approval requirements in each foreign country where we market our products. Also,
we might be required to identify one or more collaborators in these foreign countries to develop, seek approval for and manufacture our
products and any companion genetic test that may be required for Arakoda or Celgosivir. If we decide to pursue regulatory approvals and
commercialization of our product candidates internationally, we may not be able to obtain the required foreign regulatory approvals on
a timely basis, if at all, and any failure to do so may cause us to incur additional costs or prevent us from marketing our products
in foreign countries, which may have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to comply with data protection
laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation,
and/or adverse publicity and could negatively affect our operating results and business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
and our partners may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that
address privacy and data security). In the United States, numerous federal and state laws and regulations, including state data breach
notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section&nbsp;5
of the FTC Act of 1914), that govern the collection, use, disclosure, and protection of health-related and other personal information
could apply to our operations or the operations of our partners. In addition, we may obtain health information from third parties (including
research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health
Insurance Portability and Accountability Act of 1996, as amended (&ldquo;HIPAA&rdquo;). Depending on the facts and circumstances, we
could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained
by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, the California Consumer Privacy Act, as amended (&ldquo;CCPA&rdquo;), became effective on January&nbsp;1, 2020. The CCPA gives
California residents expanded rights to access and delete their personal information (subject to certain exceptions), opt out of certain
personal information sharing, correct inaccurate personal information that a business has about them and limit the use and disclosure
of sensitive personal information collected about them and receive detailed information about how their personal information is used
by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such
consumers new ways to opt-out of certain sales of personal information and the right not to be discriminated against for exercising these
rights. The CCPA also gives consumers the right to request disclosure of information collected about them and whether that information
has been sold or shared with others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The CCPA provides for civil penalties for violations, as well as a private
right of action for data breaches that is expected to increase data breach litigation. Although there are limited exemptions for clinical
trial data and the CCPA&rsquo;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable
future, the CCPA may increase our compliance costs and potential liability. Many similar privacy laws have been proposed at the federal
level and in other states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Foreign data protection laws, including, without
limitation, the European Union Directive 95/46/EC, or the Directive, and the European Union&rsquo;s General Data Protection Regulation
(&ldquo;GDPR&rdquo;), that became effective in May 2018, and member state data protection legislation, may also apply to health-related
and other personal information obtained outside of the United States. These laws impose strict obligations on the ability to process
health-related and other personal information of data subjects in the European Union and the United Kingdom, including in relation to
use, collection, analysis, and transfer (including cross-border transfer) of such personal information. These laws include several requirements
relating to the consent of the individuals to whom the personal data relates, limitations on data processing, establishing a legal basis
for processing, notification of data processing obligations or security incidents to appropriate data protection authorities or data
subjects, the security and confidentiality of the personal data and various rights that data subjects may exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Directive and the GDPR prohibit, without
an appropriate legal basis, the transfer of personal data to countries outside of the European Economic Area (&ldquo;EEA&rdquo;), such
as the United States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland
has adopted similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland
to the United States, uncertainty about compliance with European Union data protection laws remains. For example, ongoing legal challenges
in Europe to the mechanisms allowing companies to transfer personal data from the EEA to the United States could result in further limitations
on the ability to transfer personal data across borders, particularly if governments are unable or unwilling to reach new or maintain
existing agreements that support cross-border data transfers, such as the European Union-U.S. and Swiss-U.S. Privacy Shield framework.
Additionally, other countries have passed or are considering passing laws requiring local data residency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the GDPR, regulators may impose substantial
fines and penalties for non-compliance. Companies that violate the GDPR can face fines of up to the greater of 20&nbsp;million Euros
or 4% of their worldwide annual turnover (revenue). The GDPR increases our responsibility and potential liability in relation to personal
data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR and other EU and
international data protection rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Compliance with U.S. and foreign privacy and
security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly
compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&rsquo; or
suppliers&rsquo; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations.
Failure to comply with U.S. and foreign data protection laws and regulations could result in government investigations and enforcement
actions (which could include civil or criminal penalties), fines, private litigation, and/or adverse publicity and could negatively affect
our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who
share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated
individuals&rsquo; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are
not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because we have multiple product candidates
in our clinical pipeline and are considering a variety of target indications, we may expend our limited resources to pursue a particular
product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which
there is a greater likelihood of success.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because we have limited financial and managerial
resources, we must focus our research and development efforts on those product candidates and specific indications that we believe are
the most promising. As a result, we may forego or delay our pursuit of opportunities with other product candidates or other indications
that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable
commercial products or profitable market opportunities. We may in the future spend our resources on other research programs and product
candidates for specific indications that ultimately do not yield any commercially viable products. Furthermore, if we do not accurately
evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product
candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us
to retain sole development and commercialization rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We must meet post-marketing requirements
associated with the Arakoda NDA imposed by the FDA. Failure to complete such requirements, or delays due to lack of resources or other
factors, may negatively impact our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">When the FDA approved the Arakoda NDA in August 2018, it imposed post-marketing
requirements on us, including associated timelines. We have made substantial progress in meeting all such requirements and recently published
data from a clinical trial related to one of them. However, we have experienced delays in our ability to execute our observational and
pediatric study requirements and are in discussion with the FDA regarding future plans relating to our pediatric program. We may experience
new or additional delays in the future on one or more of its post-marketing requirements in the future. As of the date of this prospectus,
we have not received acknowledgement from the FDA that any of the post-marketing requirements are completed nor been referred for enforcement
action due to delays in our post-marketing studies. If we fail to meet FDA requirements, experiences additional delays or is referred
for enforcement action, we might require diversion of managerial and capital resources from planned research and development to completion
of post-marketing requirements, or the FDA might revoke the NDA for Arakoda, and therefore harm the business. In the future, regulators
may impose additional post-marketing requirements for Arakoda for malaria or other indications, or in relation to our products. This situation
would require expensive clinical or non-clinical studies that might damage our financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are subject to U.S. and certain foreign
export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with
these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other
serious consequences for violations, which can harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to export control and import laws
and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions
regulations administered by the U.S. Treasury Department&rsquo;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices
Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &sect; 201, the U.S. Travel Act, the USA PATRIOT Act,
and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption
laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing,
promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or
private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter
a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have
direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities,
and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and
other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and
regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import
privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Continued uncertain economic conditions,
including inflation and the risk of a global recession could impair our ability to forecast and may harm our business, operating results,
including our revenue growth and profitability, financial condition and cash flows.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. economy is experiencing the highest
rates of inflation since the 1980s. Historically, we have not experienced significant inflation risk in our business. However, our ability
to raise our product prices depends on market conditions and there may be periods during which we are unable to fully recover increases
in our costs. In addition, the global economy suffers from slowing growth and rising interest rates, and many economists believe that
a global recession may begin in the near future. If the global economy slows, our business would likely be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Also, the global credit
and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit
availability, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration
in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely
affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Geopolitical conditions,
including direct or indirect acts of war or terrorism, could have an adverse effect on our operations and financial results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
operations could be disrupted by geopolitical conditions, political and social instability, acts of war, terrorist activity or other
similar events. In February 2022, Russia initiated significant military action against Ukraine. In response, the U.S. and certain other
countries imposed significant sanctions and export controls against Russia, Belarus and certain individuals and entities connected to
Russian or Belarusian political, business, and financial organizations, and the U.S. and certain other countries could impose further
sanctions, trade restrictions, and other retaliatory actions should the conflict continue or worsen. It is not possible to predict the
broader consequences of the conflict, including related geopolitical tensions, and the measures and retaliatory actions taken by the
U.S. and other countries in respect thereof as well as any counter measures or retaliatory actions by Russia or Belarus in response,
including, for example, potential cyberattacks or the disruption of energy exports, is likely to cause regional instability, geopolitical
shifts, and could materially adversely affect global trade, currency exchange rates, regional economies and the global economy. The situation
remains uncertain, and while it is difficult to predict the impact of any of the foregoing, the conflict and actions taken in response
to the conflict could increase our costs, disrupt our supply chain, reduce our sales and earnings, impair our ability to raise additional
capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We could be subject to lawsuits.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be party to lawsuits, settlement discussions,
mediations, arbitrations and other disputes, including patent and product liability claims, whether brought by companies, individuals
or governmental authorities. These matters may result in a loss of patent protection, reduced revenue, incurrence of significant liabilities
and diversion of our management&rsquo;s time, attention and resources. Our insurance coverage may not provide adequate protection against
actual losses. In addition, we are subject to the risk that one or more of our insurers may become insolvent and become unable to pay
claims that may be made in the future. Even if we maintain adequate insurance, claims could have a material adverse effect on our financial
condition, liquidity and results of operations and on our ability to obtain suitable, adequate or cost-effective insurance in the future.
Litigation and other disputes, including any adverse outcomes, may have an adverse impact on our business, operations or financial condition.
Even claims without merit could subject us to adverse publicity and require us to incur significant legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>We
currently, and may in the future, have assets held at financial institutions that may exceed the insurance coverage offered by the Federal
Deposit Insurance Corporation, the loss of such assets would have a severe negative affect on our operations and liquidity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may maintain our cash assets at certain financial institutions in the U.S. in amounts that may be in excess of the Federal Deposit Insurance
Corporation (&ldquo;FDIC&rdquo;) insurance limit of $250,000. In the event of a failure of any financial institutions where we maintain
our deposits or other assets, we may incur a loss to the extent such loss exceeds the FDIC insurance limitation, which could have a material
adverse effect upon our liquidity, financial condition and our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Intellectual Property and
Other Legal Matters </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If product liability lawsuits are successfully brought against us,
then we will incur substantial liabilities and may be required to limit commercialization of Arakoda, Tafenoquine (Arakoda or other regimen)
for non-malaria prevention indications, Celgosivir or other product candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may face product liability exposure related to the testing of our product candidates in human clinical trials, and may face exposure
to claims by an even greater number of persons once we begin marketing and distributing our products commercially. If we cannot successfully
defend against product liability claims, then we will incur substantial liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regardless of merit or eventual outcome, liability
claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">decreased demand for our products
                                            and product candidates;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">injury to our reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">withdrawal of clinical trial participants;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">costs of related litigation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">substantial monetary awards to patients
                                            and others;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">loss of revenues; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the inability to commercialize our
                                            products and product candidates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have obtained limited product liability insurance
coverage. Such coverage, however, may not be adequate or may not continue to be available to us in sufficient amounts or at an acceptable
cost, or at all. We may not be able to obtain commercially reasonable product liability insurance for any product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Defending against claims relating to improper
handling, storage or disposal of hazardous chemicals, radioactive or biological materials could be time consuming and expensive. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development of product candidates
may involve the controlled use of hazardous materials, including chemicals, radioactive and biological materials. We cannot eliminate
the risk of accidental contamination or discharge and any resultant injury from the materials. Various laws and regulations govern the
use, manufacture, storage, handling and disposal of hazardous materials. We may be sued or be required to pay fines for any injury or
contamination that results from our use or the use by third parties of these materials. Compliance with environmental laws and regulations
may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third parties may own or control patents
or patent applications that we may be required to license to commercialize our product candidates or that could result in litigation
that would be costly and time consuming. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our or any strategic partner&rsquo;s ability to commercialize Arakoda,
Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir and other product candidates depends upon our
ability to develop, manufacture, market and sell these drugs without infringing the proprietary rights of third parties. A number of pharmaceutical
and biotechnology companies, universities and research institutions have or may be granted patents that cover technologies similar to
the technologies owned by or licensed to us. We may choose to seek, or be required to seek, licenses under third party patents, which
would likely require the payment of license fees or royalties or both. We may also be unaware of existing patents that may be infringed
by Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications or Celgosivir, the genetic testing we intend
to use in connection with Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications, Celgosivir or our other
product candidates. Because patent applications can take many years to issue, there may be other currently pending applications that may
later result in issued patents that are infringed by Arakoda, Tafenoquine (Arakoda or other regimen) for non-malaria prevention indications,
Celgosivir or our other product candidates. Moreover, a license may not be available to us on commercially reasonable terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is a substantial amount of litigation involving
patent and other intellectual property rights in the biotechnology and biopharmaceutical industries generally. If a third party claims
that we are infringing on its technology, then our business and results of operations could be harmed by a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">infringement and other intellectual
                                            property claims, even if without merit, are expensive and time-consuming to litigate and
                                            can divert management&rsquo;s attention from our core business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">monetary damage awards for past infringement
                                            can be substantial;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">a court may prohibit us from selling
                                            or licensing product candidates unless the patent holder chooses to license the patent to
                                            us; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">if a license is available from a
                                            patent holder, we may have to pay substantial royalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may also be forced to bring an infringement
action if we believe that a competitor is infringing our protected intellectual property. Any such litigation will be costly, time-consuming
and divert management&rsquo;s attention, and the outcome of any such litigation may not be favorable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our intellectual property rights may not
preclude competitors from developing competing products and our business may suffer. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our competitive success will depend, in part,
on our ability to obtain and maintain patent protection for our inventions, technologies and discoveries, including intellectual property
that we license. The patent positions of biotechnology companies involve complex legal and factual questions, and we cannot be certain
that our patents and licenses will successfully preclude others from using our technology. Consequently, we cannot be certain that any
of our patents will provide significant market protection or will not be circumvented or challenged and found to be unenforceable or
invalid. In some cases, patent applications in the United States and certain other jurisdictions are maintained in secrecy until patents
issue, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be
certain of the priority of inventions covered by pending patent applications. An adverse outcome could subject us to significant liabilities
to third parties, require disputed rights to be licensed from third parties or require us to cease using such technology. Regardless
of merit, the listing of patents in the FDA Orange Book for Arakoda, Celgosivir may be challenged as being improperly listed. We may
have to defend against such claims and possible associated antitrust issues. We could also incur substantial costs in seeking to enforce
our proprietary rights against infringement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not be able to effectively protect our
intellectual property rights in some foreign countries, as our patents are limited by jurisdiction and many countries do not offer the
same level of legal protection for intellectual property as the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We require our employees, consultants, business
partners and members of our scientific advisory board to execute confidentiality agreements upon the commencement of employment, consulting
or business relationships with us. These agreements provide that all confidential information developed or made known during the course
of the relationship with us be kept confidential and not disclosed to third parties except in specific circumstances. In the case of
employees, the agreements provide that all inventions resulting from work performed for us, utilizing the property or relating to our
business and conceived or completed by the individual during employment shall be our exclusive property to the extent permitted by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third parties may breach these and other agreements
with us regarding our intellectual property and we may not have adequate remedies for the breach. Third parties could also fail to take
necessary steps to protect our licensed intellectual property, which could seriously harm our intellectual property position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If we are not able to protect our proprietary
technology, trade secrets and know-how, then our competitors may develop competing products. Any issued patent may not be sufficient
to prevent others from competing with us. Further, we have trade secrets relating to Arakoda, Celgosivir, and such trade secrets may
become known or independently discovered. Our issued patents and those that may issue in the future, or those licensed to us, may be
challenged, opposed, invalidated or circumvented, which could allow competitors to market similar products or limit the patent protection
term of our product candidates. All of these factors may affect our competitive position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the manufacture, use or sale of our
products infringe on the intellectual property rights of others, we could face costly litigation, which could cause us to pay substantial
damages or licensing fees and limit our ability to sell some or all of our products. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Extensive litigation regarding patents and other
intellectual property rights has been common in the biopharmaceutical industry. Litigation may be necessary to assert infringement claims,
enforce patent rights, protect trade secrets or know-how and determine the enforceability, scope and validity of certain proprietary
rights. Litigation may even be necessary to defend disputes of inventorship or ownership of proprietary rights. The defense and prosecution
of intellectual property lawsuits, U.S. Patent and Trademark Office interference proceedings, and related legal and administrative proceedings
(e.g., a reexamination, <I>inter partes</I> review, or post-grant review) in the United States and internationally involve complex legal
and factual questions. As a result, such proceedings are costly and time-consuming to pursue, and their outcome is uncertain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regardless of merit or outcome, our involvement
in any litigation, interference or other administrative proceedings could cause us to incur substantial expense and could significantly
divert the efforts of our technical and management personnel. Any public announcements related to litigation or interference proceedings
initiated or threatened against us could cause our stock price to decline. Adverse outcomes in patent litigation may potentially subject
us to antitrust litigation which, regardless of the outcome, would adversely affect our business. An adverse determination may subject
us to the loss of our proprietary position or to significant liabilities, or require us to seek licenses that may include substantial
cost and ongoing royalties. Licenses may not be available from third parties, or may not be obtainable on satisfactory terms. An adverse
determination or a failure to obtain necessary licenses may restrict or prevent us from manufacturing and selling our products, if any.
These outcomes could materially harm our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent reform legislation could increase
the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes in either the patent laws or interpretation
of the patent laws in the United States and Ex-US could increase the uncertainties and costs. Recent patent reform legislation in the
United States and other countries, including the Leahy-Smith America Invents Act (the &ldquo;Leahy-Smith Act&rdquo;), signed into law
in the United States on September 16, 2011, could increase those uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law.
These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective
avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO
during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings,
including post-grant review, inter partes review, and derivation proceedings. After March 2013, under the Leahy-Smith Act, the United
States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor
to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent
the claimed invention. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the
prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse
effect on our business, financial condition, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The U.S. Supreme Court has ruled on several patent
cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of
patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making
bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability
to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The patent protection and patent prosecution
for some of our product candidates is dependent or may be dependent in the future on third parties.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we normally seek and gain the right to
fully prosecute the patents relating to our product candidates, there may be times when platform technology patents or product-specific
patents that relate to our product candidates are controlled by our licensors. In addition, our licensors and/or licensees may have back-up
rights to prosecute patent applications in the event that we do not do so or choose not to do so, and our licensees may have the right
to assume patent prosecution rights after certain milestones are reached. If any of our licensing collaborators fails to appropriately
prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize
those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to protect our intellectual
property rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patents are of national or regional effect, and
filing, prosecuting and defending patents on all of our product candidates throughout the world would be prohibitively expensive. As
such, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from
selling or importing products made using our inventions in and into the United States or other jurisdictions. Further, the legal systems
of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property
protection, particularly those relating to pharmaceuticals or biologics, which could make it difficult for us to stop the infringement
of our patents or marketing of competing products in violation of our proprietary rights generally. In addition, certain developing countries,
including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties.
In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to
grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue
opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Patent terms may be inadequate to protect
our competitive position on our product candidates for an adequate amount of time.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent rights are of limited duration. Given
the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates
might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are
obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. A patent
term extension based on regulatory delay may be available in the U.S. However, only a single patent can be extended for each marketing
approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the
patent term extension does not extend to the full scope of the claim, but instead only to the scope of the product as approved. Laws
governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple
patents from a single patent family. Additionally, we may not receive an extension if we fail to apply within applicable deadlines, fail
to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. If we are unable to obtain patent
term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right
to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent
expiration, and our revenue could be reduced, possibly materially.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 17.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The earliest Paragraph IV certification
date for Arakoda has passed. Generic companies may file an ANDA at any time, and successful challenge of our malaria use patents would
negatively impact our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
PDUFA date for Arakoda is August 8, 2018, and the beginning date for exclusivity associated with the product&rsquo;s API is July 20,
2018. The five year data exclusivity ending date for Arakoda is July 20, 2023. Therefore, the earliest date a generic company could file
an ANDA, claiming such an application does not infringe our Orange Book listed patents was July 20, 2022. Any generic company filing
such an abbreviated new drug application (&ldquo;ANDA&rdquo;) with FDA, must notify us within 20 calendar days of receiving acknowledgement
from the FDA or receipt of such an ANDA. Thus, the earliest date we could receive such a notification was August 9, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date of this prospectus, to the best of our knowledge, no
such notice has been received by us. However, such a notice might be received at any time. Such a notice might require us to undertake
expensive litigation to defend our patents related to Arakoda&rsquo;s malaria indication, thereby diverting funds away from critical research
and development efforts for Tafenoquine (Arakoda or other regimen) for other indications. This potential litigation and the related expenditure
may harm our business. Additionally, the approval of any ANDA would increase competition and most likely drive down prices for Arakoda.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submissions, fee payment and other requirements imposed by governmental patent
agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Periodic maintenance fees on any issued patent
are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various
foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions
during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means
in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent
or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that
could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to
maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to this Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our management will have broad discretion
over the use of any net proceeds from this offering and you may not agree with how we use the proceeds, and the proceeds may not be invested
successfully.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management will have broad discretion as
to the use of any net proceeds from this offering and could use them for purposes other than those contemplated at the time of this offering
and in ways that do not necessarily improve our results of operations or enhance the value of our common stock. Accordingly, you will
be relying on the judgment of our management with regard to the use of any proceeds from this offering and you will not have the opportunity,
as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the proceeds will
be invested in a way that does not yield a favorable, or any, return for you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investors in this offering may experience
future dilution as a result of this and future equity offerings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to raise additional capital, we may
in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock.
Investors purchasing our shares or other securities in the future could have rights superior to existing common stockholders, and the
price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable for our common
stock in future transactions may be higher or lower than the price per unit in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>If we issue shares
of preferred stock your rights as a holder of our common stock or warrants may be materially adversely affected.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of the date of this prospectus, we are authorized to issue up to 1,000,000&nbsp;shares of &ldquo;blank check&rdquo; preferred stock.
Upon the consummation of this offering, we will have authorized shares of 80,965 Series A Preferred Stock, of which 80,965 shares of
Series A Preferred Stock will be issued and outstanding. The designations, rights and preferences of our other preferred stock may be
determined from time-to-time by our Board. Accordingly, our Board is empowered, without stockholder approval, to issue one or more series
of preferred stock with dividend, liquidation, conversion, voting or other rights superior to those of the holders of our common stock.
For example, an issuance of shares of preferred stock could:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">adversely affect the voting power
                                            of the holders of our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">make it more difficult for a third
                                            party to gain control of us;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">discourage bids for our common stock;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">limit or eliminate any payments that
                                            the holders of our common stock could expect to receive upon our liquidation;&nbsp;or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">adversely affect the market price
                                            of our common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Sales of a significant number of shares
of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common
stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sales of a substantial number of shares of our
common stock in the public markets could depress the market price of our common stock and impair our ability to raise capital through
the sale of additional equity securities. We cannot predict the effect that future sales of our common stock would have on the market
price of our common stock.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Existing stockholders may sell significant
quantities of common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The existing shareholders will own
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our common stock following the successful completion of this offering.
Notwithstanding that certain of our officers and directors who are shareholders will be locked up for a period of six months, and
any greater than 5% holders of our common stock will also be locked up for a period of six months, following the completion of this
offering, our existing stockholders may have acquired their shares at a lower price than that of this offering. Accordingly, they
may be incentivized to sell all or part of their holdings as soon as any applicable transfer restrictions have ended and such sales
could have a negative impact on the market price of our common stock. In addition, large number of sales of our common stock by the selling stockholders named in this prospectus could
depress the market price of our common stock and make it more difficult to sell your shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities or industry analysts do not
publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The trading market for our common stock will
depend in part on the research and reports that securities or industry analysts publish about us or our business. Several analysts may
cover our stock. If one or more of those analysts downgrade our stock or publish inaccurate or unfavorable research about our business,
our stock price would likely decline. If one or more of these analysts cease coverage of our Company or fail to publish reports on us
regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The requirements of being a public company.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
a public company, we will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act of 2002 (the &ldquo;Sarbanes-Oxley
Act&rdquo;), the Dodd-Frank Wall Street Reform and Consumer Protection Act, (the &ldquo;Dodd-Frank Act&rdquo;) and other applicable securities
rules and regulations. Compliance with these rules and regulations will increase our legal and financial compliance costs, make some
activities more difficult, time-consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among
other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley
Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting.
In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to
meet this standard, significant resources and management oversight may be required. As a result, management&rsquo;s attention may be
diverted from other business concerns, which could harm our business and operating results. We may need to hire more employees in the
future to comply with these requirements, which will increase our costs and expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, changing laws, regulations and standards
relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial
compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations,
in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance
is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs
necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws,
regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&rsquo;s
time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations,
and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory
authorities may initiate legal proceedings against us and our business may be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also expect that being a public company and
these new rules and regulations will make it more expensive for us to obtain director and officer liability insurance, and we may be
required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult
for us to attract and retain qualified members of our board of directors (&ldquo;Board&rdquo;) and qualified executive officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of disclosure of information in this
prospectus and in filings required of a public company, our business and financial condition will become more visible, which we believe
may result in increased threatened or actual litigation, including by competitors and other third parties. If such claims are successful,
our business and operating results could be harmed, and even if the claims do not result in litigation or are resolved in our favor,
these claims, and the time and resources necessary to resolve them, could divert the resources of our management and harm our business
and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Relating to Ownership of Our Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There has been no public market for our
common stock prior to this offering, and we cannot assure you that an active trading market will develop in the near future. An active
market in which investors can resell their shares may not develop. If there is no viable public market for our common stock, you may
be unable to sell your shares at or above the initial public offering price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, there has been no public
market for our common stock. All investments in securities involve the risk of loss of capital. No guarantee or representation is made
that an investor will receive a return of its capital. The value of our common stock can be adversely affected by a variety of factors,
including development problems, regulatory issues, technical issues, commercial challenges, competition, legislation, government intervention,
industry developments and trends, and general business and economic conditions. We cannot predict the extent to which an active market
for our common stock will develop or be sustained after this offering, or how the development of such a market might affect the market
price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is not quoted in the over-the-counter
markets and is not listed on any stock exchange and there is currently no active trading in our securities. We have applied to have our
common stock listed on The Nasdaq Capital Market under the symbol &ldquo;SXTP&rdquo; which listing is a condition to this offering. We
cannot assure you that an active trading market for our common stock will develop in the future due to a number of factors, including
the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors and others
in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they
tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our
shares until such time as we became more seasoned and viable. We cannot give you any assurance that an active public trading market for
our common stock will develop or be sustained. You may not be able to liquidate your shares quickly or at the market price if trading
in our common stock is not active.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may be unable to sell your shares quickly
or at the market price if trading in shares of our common stock is not active. The initial public offering price for our common stock
will be determined through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of
the common stock after the offering. As a result of these and other factors, you may be unable to resell your shares of our common stock
at or above the initial public offering price. Further, an inactive market may also impair our ability to raise capital by selling shares
of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares
of common stock as consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The public price of our common stock may
be volatile, and could, following a sale decline significantly and rapidly.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The initial public offering
price for the units will be determined by negotiations between us and the underwriters and may not be indicative of prices that will
prevail in the open market following this offering. The market price of our common stock may decline below the initial offering price,
and you may not be able to sell your shares of our common stock at or above the price you paid in the offering, or at all. Following
this offering, the public price of our common stock in the secondary market will be determined by private buy and sell transaction orders
collected from broker-dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general has experienced significant price and volume fluctuations that have often been unrelated or disproportionate
to operating performance of individual companies, particularly following an initial public offering of a company with a small public
float. There is the potential for rapid and substantial price volatility of our common stock following this offering. These broad market
factors may seriously harm the market price of our common stock, regardless of our actual or expected operating performance and financial
condition or prospects, which may make it difficult for investors to assess the rapidly changing value of our common stock. In the past,
following periods of volatility in the market price of a company&rsquo;s securities, securities class action litigation has often been
instituted. A class action suit against us could result in significant liabilities and, regardless of the outcome, could result in substantial
costs and the diversion of our management&rsquo;s resources and attention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
price run-ups followed by rapid price declines and stock price volatility may also be completely unrelated to company performance. Such
volatility, including any stock-run up, may be unrelated to our actual or expected operating performance and financial condition or prospects,
making it difficult for prospective investors to assess the rapidly changing value of our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A possible &ldquo;short squeeze&rdquo;
due to a sudden increase in demand of our common stock that largely exceeds supply may lead to price volatility in our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following this offering, investors may purchase
our common stock to hedge existing exposure in our common stock or to speculate on the price of our common stock. Speculation on the
price of our common stock may involve long and short exposures. To the extent aggregate short exposure exceeds the number of shares of
our common stock available for purchase in the open market, investors with short exposure may have to pay a premium to repurchase our
common stock for delivery to lenders of our common stock. Those repurchases may in turn dramatically increase the price of our common
stock until investors with short exposure are able to purchase additional shares of common stock to cover their short position. This
is often referred to as a &ldquo;short squeeze.&rdquo; A short squeeze could lead to volatile price movements in our common stock that
are not directly correlated to the performance or prospects of our Company and once investors purchase the shares of common stock necessary
to cover their short position, the price of our common stock may decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to satisfy listing requirements
of Nasdaq to maintain a listing of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
our common stock is listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate the
maintenance requirements for continued listing of our common stock, our common stock may be delisted. In addition, our Board may determine
that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our
common stock from Nasdaq may materially impair our stockholders&rsquo; ability to buy and sell our common stock and could have an adverse
effect on the market price of, and the efficiency of the trading market for, our common stock. In addition, the delisting of our common
stock could significantly impair our ability to raise capital.&nbsp;Although we expect our common stock will be approved for listing
on Nasdaq, an active trading market for our shares may never develop or be sustained following this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
is no public market for the warrants being offered in this offering.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no public trading market for the warrants offered by this prospectus, and we do not expect a market to develop. In addition, we do
not intend to apply to list the warrants on any exchange or market. Without an active market, the liquidity of the warrants will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Warrants
are speculative in nature.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants offered in this offering do not confer
any rights of common stock ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent
the right to acquire shares of our common stock at a fixed price for a limited period of time. Specifically, commencing on the date of
issuance, holders of the warrants may exercise their right to acquire the common stock and pay an exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share (115%
of the offering price per unit), from time to time, until the fifth anniversary from the date of issuance, after which date any unexercised
warrants will expire and have no further value. In addition, there is no established trading market for the warrants.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Since
the warrants are executory contracts, they may have no value in a bankruptcy or reorganization proceeding.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event a bankruptcy or reorganization proceeding is commenced by or against us, a bankruptcy court may hold that any unexercised warrants
are executory contracts that are subject to rejection by us with the approval of the bankruptcy court. As a result, holders of the warrants
may, even if we have sufficient funds, not be entitled to receive any consideration for their warrants or may receive an amount less
than they would be entitled to if they had exercised their warrants prior to the commencement of any such bankruptcy or reorganization
proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Holders
of our warrants will have no rights as a common stockholder until they acquire our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
investors acquire shares of our common stock upon exercise of the warrants being offered in this offering, they will have no rights with
respect to our common stock such as voting rights or the right to receive dividends. Upon exercise of such warrants, holders will be
entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
of the warrants offered by this prospectus could discourage an acquisition of us by a third party.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of the warrants offered by this prospectus could make it more difficult or expensive for a third party to acquire us. The
warrants prohibit us from engaging in certain transactions constituting &ldquo;fundamental transactions&rdquo; unless, among other things,
the surviving entity assumes our obligations under the warrants. These and other provisions of the warrants offered by this prospectus
could prevent or deter a third party from acquiring us even where the acquisition could be beneficial to you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we do not file and maintain a current and effective prospectus relating to the common stock issuable upon exercise of the warrants, holders
will only be able to exercise such warrants on a &ldquo;cashless basis.&rdquo;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not file and maintain a current and effective registration statement relating to the common stock issuable upon exercise of the
warrants at the time that holders wish to exercise such warrants, they will only be able to exercise them on a &ldquo;cashless basis&rdquo;
provided that an exemption from registration is available. As a result, the number of shares of common stock that holders will receive
upon exercise of the warrants will be fewer than it would have been had such holder exercised his, her or its warrants for cash. Further,
if an exemption from registration is not available, holders would not be able to exercise on a cashless basis and would only be able
to exercise their warrants for cash if a current and effective registration statement relating to the common stock issuable upon exercise
of the warrants is available. Under the terms of the underwriting agreement, we have agreed to use our best efforts to meet these conditions
and to file and maintain a current and effective registration statement relating to the common stock issuable upon exercise of the warrants
until the expiration of the warrants. However, we cannot assure you that we will be able to do so. If we are unable to do so, the potential
&ldquo;upside&rdquo; of the holder&rsquo;s investment in our Company may be reduced or the warrants may expire worthless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may amend the terms of the warrants in a way that may be adverse to holders with the approval by the holders of a majority of the then
outstanding warrants.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Agent Agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity
or correct any defective provision. All other modifications or amendments, including any amendment to increase the exercise price of
the warrants or shorten the exercise period of the warrants, shall require the written consent of the registered holders of a majority
of the then outstanding warrants which may be contrary to your interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
warrants may have an adverse effect on the market price of our common stock and make it more difficult to effect a business combination.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be issuing warrants to purchase shares of common stock as part of this offering. To the extent we issue shares of common stock to
effect a future business combination, the potential for the issuance of a substantial number of additional shares upon exercise of the
warrants could make us a less attractive acquisition vehicle in the eyes of a target business. Such warrants, when exercised, will increase
the number of issued and outstanding shares of common stock and reduce the value of the shares issued to complete the business combination.
Accordingly, the warrants may make it more difficult to effectuate a business combination or increase the cost of acquiring a target
business. Additionally, the sale, or even the possibility of a sale, of the shares of common stock underlying the warrants could have
an adverse effect on the market price for our securities or on our ability to obtain future financing. If and to the extent the warrants
are exercised, you may experience dilution to your holdings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Warrant Agent Agreement designate the courts of the State of New York or the United States District Court for the Southern District of
New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants,
which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Warrant Agent Agreement provides that, subject to applicable law, (i) any action, proceeding or claim against us arising out of or relating
in any way to the Warrant Agent Agreement, including under the Securities Act, will be brought and enforced in the courts of the State
of New York or the United States District Court for the Southern District of New York, and (ii) that we irrevocably submit to such jurisdiction,
which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. We will waive any objection to such exclusive
jurisdiction and that such courts represent an inconvenient forum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
the foregoing, these provisions of the Warrant Agent Agreement do not apply to suits brought to enforce any liability or duty created
by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive
forum. Any person or entity purchasing or otherwise acquiring any interest in any of our warrants shall be deemed to have notice of and
to have consented to the forum provisions in our Warrant Agent Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any action, the subject matter of which is within the scope of the forum provisions of the Warrant Agent Agreement, is filed in a court
other than courts of the State of New York or the United States District Court for the Southern District of New York (a &ldquo;foreign
action&rdquo;) in the name of any holder of our warrants, such holder shall be deemed to have consented to: (x) the personal jurisdiction
of the state and federal courts located in the State of New York in connection with any action brought in any such court to enforce the
forum provisions (an &ldquo;enforcement action&rdquo;), and (y) having service of process made upon such warrant holder in any such enforcement
action by service upon such warrant holder&rsquo;s counsel in the foreign action as an agent for such warrant holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
choice-of-forum provision may limit a warrant holder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for
disputes with our Company, which may discourage such lawsuits. Alternatively, if a court were to find this provision of our Warrant Agent
Agreement inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional
costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial
condition and results of operations and result in a diversion of the time and resources of our management and Board.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to securities litigation,
which is expensive and could divert our management&rsquo;s attention.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The market price of our securities may be volatile,
and in the past companies that have experienced volatility in the market price of their securities have been subject to securities class
action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial
costs and divert our management&rsquo;s attention from other business concerns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to maintain effective internal
controls over financial reporting could have an adverse impact on us</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are required to establish and maintain appropriate
internal controls over financial reporting. Failure to establish those controls, or any failure of those controls once established, could
adversely impact our public disclosures regarding our business, financial condition or results of operations. In addition, management&rsquo;s
assessment of internal controls over financial reporting may identify weaknesses and conditions that need to be addressed in our internal
controls over financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions
that need to be addressed in our internal control over financial reporting, disclosure of management&rsquo;s assessment of our internal
controls over financial reporting or disclosure of our public accounting firm&rsquo;s attestation to or report on management&rsquo;s
assessment of our internal controls over financial reporting may have an adverse impact on the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A control system, no matter how well conceived
and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. In addition, the
design of a control system must reflect the fact that there are resource constraints and the benefit of controls must be relative to
their costs. Because of the inherent limitations in all control systems, no system of controls can provide absolute assurance that all
control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities
that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Further, controls can
be circumvented by individual acts of some persons, by collusion of two or more persons, or by management override of the controls. The
design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can
be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control
may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because
of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At present, we are executing a plan to improve
existing internal controls by segregating accounting functions through outsourcing. For over 10 years, our Chief Executive Officer and
Treasurer have worked together in a collaborative relationship using budgets to track finances with limited resources. Our management,
including our President and Chief Executive Officer, cannot guarantee that our internal controls and disclosure controls that we have
in place will prevent all possible errors, mistakes or fraud. If we fail to have effective controls and procedures for financial reporting
in place, we could be unable to provide timely and accurate financial information and be subject to investigation by the SEC and civil
or criminal sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Our financial
controls and procedures may not be sufficient to ensure timely and reliable reporting of financial information, which, as a public company,
could materially harm our stock price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We require significant
financial resources to maintain our public reporting status. We cannot assure you we will be able to maintain adequate resources to ensure
that we will not have any future material weakness in our system of internal controls. The effectiveness of our controls and procedures
may in the future be limited by a variety of factors including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">faulty human judgment and simple
                                            errors, omissions or mistakes;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">fraudulent action of an individual
                                            or collusion of two or more people;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">inappropriate management override
                                            of procedures; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">the possibility that any enhancements
                                            to controls and procedures may still not be adequate to assure timely and accurate financial
                                            information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our internal control
over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States
of America. Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable
assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted
accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management
and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition
of our assets that could have a material effect on the financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Despite these controls,
because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even
those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Furthermore, smaller
reporting companies like us face additional limitations. Smaller reporting companies employ fewer individuals and can find it difficult
to employ resources for complicated transactions and effective risk management. Additionally, smaller reporting companies tend to utilize
general accounting software packages that lack a rigorous set of software controls.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Our status as
an &ldquo;emerging growth company&rdquo; under the JOBS Act may make it more difficult to raise capital as and when we need it.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Because of the exemptions
from various reporting requirements provided to us as an &ldquo;emerging growth company&rdquo; and because we will have an extended transition
period for complying with new or revised financial accounting standards, we may be less attractive to investors and it may be difficult
for us to raise additional capital as and when we need it. Investors may be unable to compare our business with other companies in our
industry if they believe that our financial accounting is not as transparent as other companies in our industry. If we are unable to
raise additional capital as and when we need it, our financial condition and results of operations may be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The elimination of personal liability against
our directors and officers under Delaware law and the existence of indemnification rights held by our directors, officers and employees
may result in substantial expenses. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our amended and restated certificate of incorporation
(&ldquo;Certificate of Incorporation&rdquo;) and our bylaws (&ldquo;Bylaws&rdquo;) eliminate the personal liability of our directors
and officers to us and our stockholders for damages for breach of fiduciary duty as a director or officer to the extent permissible under
Delaware law. Further, our Certificate of Incorporation provides that we are obligated to indemnify each of our directors or officers
to the fullest extent authorized by Delaware law. Those indemnification obligations could expose us to substantial expenditures to cover
the cost of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those provisions
and resulting costs may discourage us or our stockholders from bringing a lawsuit against any of our current or former directors or officers
for breaches of their fiduciary duties, even if such actions might otherwise benefit our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You should consult your own independent
tax advisor regarding any tax matters arising with respect to the securities offered in connection with this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Participation in this offering could result in
various tax-related consequences for investors. All prospective purchasers of the resold securities are advised to consult their own
independent tax advisors regarding the U.S. federal, state, local and non-U.S. tax consequences relevant to the purchase, ownership and
disposition of the resold securities in their particular situations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>We have not paid
dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our
stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never declared or paid cash dividends
on our common stock since inception as this is not how an LLC returns capital to its members and do not anticipate paying any cash dividends
on our common stock as a C-Corporation in the foreseeable future. Instead, we currently intend to retain any future earnings for working
capital and to support the growth and development of our business. Our payment of any future dividends will be at the discretion of our
Board after taking into account various factors, including, but not limited to, our earnings, capital requirements, financial condition,
prospects, operating results, cash needs, growth plans, applicable Delaware law and any other factors which our Board may deem relevant.
Our ability to pay dividends on our common stock may be limited by Delaware state law. Accordingly, investors must rely on sales of their
common stock after price appreciation, which may never occur, as the only way to realize a return on their investment. Investors seeking
cash dividends should not purchase our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an &ldquo;emerging growth company&rdquo;
and a &ldquo;smaller reporting company&rdquo; under the JOBS Act, and we cannot be certain if the reduced disclosure requirements applicable
to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are an &ldquo;emerging growth company&rdquo;
and a &ldquo;smaller reporting company&rdquo; as defined in the JOBS Act, and we may take advantage of certain exemptions from various
reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; and &ldquo;smaller
reporting companies&rdquo; including, but not limited to, not being required to comply with the auditor attestation requirements of Section
404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any
golden parachute payments not previously approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, Section 107 of the JOBS Act also
provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section 7(a)(2)(B)
of the Securities Act for complying with new or revised accounting standards. In other words, an &ldquo;emerging growth company&rdquo;
can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We are choosing
to take advantage of the extended transition period for complying with new or revised accounting standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will remain an &ldquo;emerging growth company&rdquo;
until the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an
effective registration statement under the Securities Act, although we will lose that status sooner if our revenues exceed $1.235 billion,
if we issue more than $1 billion in non-convertible debt in a three year period, or if the market value of our common stock that is held
by non-affiliates exceeds $700 million as of the last day of our most recently completed second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may continue to be a smaller reporting company
even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller
reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) the market value of our common
stock held by non-affiliates is equal to or less than $250 million as of the last business day of the most recently completed second
fiscal quarter, and (ii) our annual revenues is equal to or less than $100 million during the most recently completed fiscal year and
the market value of our common stock held by non-affiliates is equal to or less than $700 million as of the last business day of the
most recently completed second fiscal quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We cannot predict if investors will find our
common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result,
there may be a less active trading market for our common stock and our stock price may be more volatile.&nbsp;In addition, taking advantage
of reduced disclosure obligations may make comparison of our financial statements with other public companies difficult or impossible.
If investors are unable to compare our business with other companies in our industry, we may not be able to raise additional capital
as and when we need it, which may materially and adversely affect our financial condition and results of operations.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Certificate of Incorporation will designate the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation
that may be initiated by our stockholders, which could limit our stockholders&rsquo; ability to obtain a favorable judicial forum for
disputes with us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Certificate of Incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery
of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company,
(ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent of the Company to the
Company or the Company&rsquo;s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General
Corporation Law, our Certificate of Incorporation or Bylaws, or (iv) any action asserting a claim governed by the internal affairs doctrine,
in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein.
However, prior to the effectiveness of the registration statement related to this prospectus, we will amend our Certificate of Incorporation
to include a statement that this exclusive forum provision does not apply to claims arising under federal securities laws. Any person
or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have
consented to the provisions of our Certificate of Incorporation as described above.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
choice of forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims.
As such, stockholders of the Company seeking to bring a claim regarding the internal affairs of the Company may be subject to increased
costs associated with litigating in Delaware as opposed to their home state or other forum, precluded from bringing such a claim in a
forum they otherwise consider to be more favorable, and discouraged from bringing such claims as a result of the foregoing or other factors
related to forum selection. Alternatively, if a court were to find the choice of forum provision contained in our Certificate of Incorporation
to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions,
which could harm our business, operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly
experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums
and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against
our directors, officers, employees and agents as it may limit any stockholder&rsquo;s ability to bring a claim in a judicial forum that
such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. The enforceability of similar
choice of forum provisions in other companies&rsquo; certificates of incorporation has been challenged in legal proceedings, and it is
possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained
in our Certificate of Incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision
contained in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated
with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN ADDITION TO THE ABOVE RISKS, BUSINESSES
ARE OFTEN SUBJECT TO RISKS NOT FORESEEN OR FULLY APPRECIATED BY MANAGEMENT. IN REVIEWING THIS FILING, POTENTIAL INVESTORS SHOULD KEEP
IN MIND THAT OTHER POSSIBLE RISKS MAY ADVERSELY IMPACT OUR BUSINESS OPERATIONS AND THE VALUE OF OUR SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_009"></A>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus contains &ldquo;forward-looking
statements.&rdquo; Forward-looking statements reflect the current view about future events. When used in this prospectus, the words &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;future,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo;
or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements.
Such statements include, but are not limited to, statements contained in this prospectus relating to our business strategy, our future
operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions
regarding our business, the economy and other future conditions. Because forward&ndash;looking statements relate to the future, they
are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ
materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of
assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors
that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our ability to effectively operate our business segments;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our ability to manage our research, development, expansion, growth
    and operating expenses;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our ability to evaluate and measure our business, prospects and performance
    metrics;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our ability to compete, directly and indirectly, and succeed in a highly
    competitive and evolving industry;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our ability to respond and adapt to changes in technology and customer
    behavior;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our ability to protect our intellectual property and to develop, maintain
    and enhance a strong brand; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other factors (including the risks contained in the section of this
    prospectus entitled &ldquo;<I>Risk Factors</I>&rdquo;) relating to our industry, our operations and results of operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Should one or more of these risks or uncertainties
materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed,
estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Factors or events that could cause our actual
results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results,
levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States,
we do not intend to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_010"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that we will receive net proceeds
of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the underwriters&rsquo; option to purchase additional shares is exercised in full) from the sale of the units offered by us in this offering,
based on an assumed public offering price of $5.15 per unit (the midpoint of the price range set forth on the front cover page of this
prospectus), and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us.
We will not receive any of the proceeds from the sale of the common stock by the Selling Stockholders named in this prospectus. All proceeds
from the sale of the shares of our common stock offered by the Selling Stockholders will belong to the Selling Stockholders identified
in this prospectus under &ldquo;<I>Selling Stockholders</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each $1.00 increase or decrease in the assumed
initial public offering price of $5.15 per unit (the midpoint of the price range set forth on the front cover page of this prospectus)
would increase or decrease, as applicable, the net proceeds that we receive from this offering by approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;, assuming that the number of units offered by us, as set forth on the cover page of this prospectus, remains the same and after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase
or decrease of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; units offered by us would increase or decrease,
as applicable, the net proceeds that we receive from this offering by approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;, assuming the assumed initial public offering price remains the same and after deducting the estimated underwriting discounts
and commissions and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The principal purposes of this offering are to
increase our capitalization and financial flexibility, increase our visibility in the marketplace and create a public market for our
common stock. As of the date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to
us from this offering. However, we currently intend to use the majority of the net proceeds to us from this offering for executing clinical
studies and trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our strategic priority is to further develop,
through clinical studies and related activities, additional/new indications for our products. Assuming the indicated amount of funds
are raised, we anticipate up to $3.6 million will be dedicated to financing such efforts. If market conditions permit, the majority of
the available funds will be utilized for the execution of a clinical trial to confirm that Arakoda accelerates recovery from COVID-19
symptoms. Other research activities will include new product research, trial design and opening of an IND for the babesiosis indication,
protocol preparation for the pediatric post-marketing requirement, study feasibility for a second COVID-19 trial and mechanism of action
studies. If market conditions are not conducive clinical trial activities may be postponed, but the activities mentioned in the aforementioned
sentence will continue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We plan, as resources permit, to conduct additional research and development
activities including execution of animal studies to further evaluate the activities of Tafenoquine against <I>Candida </I>and Celgosivir
against COVID-19. We may also conduct a targeted promotional campaign for Arakoda for the malaria indication in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
may also retire the following cash commitments to other parties associated with the public offering: $85,000 Singapore Dollars to the
National University of Singapore as a license agreement milestone payment and $100,000 to Biointelect. Both payments are due upon the
consummation of this offering and are non-interest bearing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below sets forth the manner in which
we expect to use the net proceeds we receive from this offering. All amounts included in the table below are estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Description</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Working Capital and General
    Corporate Purposes</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="vertical-align: middle; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,200,000</FONT></TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt Repayment</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,700,000</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and Development
    (clinical trials and related activities)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,600,000</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,500,000</FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing information is an estimate based
on our current business plan. We may find it necessary or advisable to re-allocate portions of the net proceeds reserved for one category
to another, and we will have broad discretion in doing so. Pending these uses, we intend to invest the net proceeds of this offering
in a money market or other interest-bearing account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not declared any cash dividends since
inception and we do not anticipate paying any dividends in the foreseeable future. Instead, we anticipate that all of our earnings will
be used to provide working capital, to support our operations, and to finance the growth and development of our business. The payment
of dividends is within the discretion of the Board and will depend on our earnings, capital requirements, financial condition, prospects,
operating results, cash needs, growth plans, applicable Delaware law, which provides that dividends are only payable out of surplus or
current net profits, and other factors our board might deem relevant. There are no restrictions that currently limit our ability to pay
dividends on our common stock other than those generally imposed by applicable state law.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_012"></A>MARKET
FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, our common stock has
not been listed on any stock exchange or quoted on any over-the-counter market or quotation system and there has been no public market
for our common stock. We have applied to have our common stock listed on The Nasdaq Capital Market under the symbol &ldquo;SXTP,&rdquo;
which listing is a condition to this offering. There can be no assurance that our listing application will be approved. We do not intend
to apply for listing of the warrants on any exchange or market. For more information see the section &ldquo;<I>Risk Factors</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of April 3, 2023, 2,378,009 shares of our common stock were issued and outstanding and were held by fifteen stockholders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_013"></A><FONT STYLE="text-transform: uppercase"><B>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our consolidated
cash and capitalization, as of December 31, 2022. Such information is set forth on the following basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">on an actual basis;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">on a pro forma basis to reflect the
                                            (i) sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common
                                            stock by us after December 31, 2022, but prior to this offering, (ii) issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of our common stock to BioIntelect pursuant to the BioIntelect Agreement, (iii) issuance
                                            of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
                                            to Knight as a result of the conversion of certain of our outstanding debt owed to Knight
                                            pursuant to the Knight Debt Conversion Agreement, (iv) issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
                                            of our common stock as a result of the conversion of our convertible promissory notes excluding
                                            the Xu Yu Equity Conversion Note and (v) issuance of shares of our common stock pursuant
                                            to the Xu Yu Equity Conversion Note; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">on a pro forma as adjusted basis
                                            to reflect the pro forma adjustments discussed in the prior bullet and our receipt of the
                                            net proceeds our sale and issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;units
                                            in this offering at an assumed initial public offering price of $5.15 per unit (the midpoint
                                            of the price range set forth on the front cover page of this prospectus), after deducting
                                            estimated underwriting discounts and commissions and estimated offering expenses payable
                                            by us and after the use of net proceeds therefrom.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read the following table in conjunction
with &ldquo;<I>Use of Proceeds</I>,&rdquo; &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of
Operations</I>&rdquo; and our financial statements and related notes included in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The pro forma as adjusted information set forth
below is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined
at pricing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 55%; padding-bottom: 1pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; width: 12%; text-align: center"><FONT STYLE="font-size: 10pt">Actual</FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; width: 12%; text-align: center"><FONT STYLE="font-size: 10pt">Pro
    Forma </FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; width: 12%; text-align: center"><FONT STYLE="font-size: 10pt">Pro
    forma,<BR>
    as<BR>
    adjusted<SUP>(1)(2)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 1%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Cash</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Short term liabilities, including deferred
    revenue due within one year</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Long term debt, including convertible notes
    payable</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total liabilities including lease obligations
    - net of current portion</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Stockholders&rsquo; equity:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Common stock, $0.0001 par value, 150,000,000
                                    shares authorized, 2,378,009 shares issued and outstanding, actual; 150,000,000 shares authorized,
                                    [*] shares issued and outstanding, pro forma; and 150,000,000 shares authorized, [*] shares issued
                                    and outstanding, pro forma as adjusted; preferred stock, $0.0001 par value, 1,000,000 shares authorized,
                                    0 shares issued and outstanding, actual; 1,000,000 shares authorized, 0 shares issued and outstanding,
                                    pro forma; and 1,000,000 shares authorized, [*] shares issued and outstanding, pro forma as adjusted</P></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Additional paid-in capital</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Retained earnings (deficit)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Total stockholders&rsquo; equity</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Total capitalization</B></FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">The number of issued and outstanding shares as of December 31, 2022 on a pro forma as adjusted basis includes (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issued to BioIntelect pursuant to the BioIntelect Agreement, which provides that in connection with our initial public offering, BioIntelect will be entitled to receive deferred equity compensation in the amount equal to $155,000 (or $245,000 if Australian VC Horizon Biotech participates in the offering), (ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issued to Knight as a result of the conversion of certain of our outstanding debt owed to Knight pursuant to the Knight Debt Conversion Agreement, (iii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that are to be issued prior to the closing of this offering as a result of the conversion of our convertible promissory notes excluding the Xu Yu Equity Conversion Note, (iv) shares of our common stock that are to be issued prior to the closing of this offering pursuant to the Xu Yu Equity Conversion Note and (v) 100,000 shares of our common stock issued to our legal counsel and 1,343,000 shares of our common stock issued to consultants, and excludes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock underlying a warrant issued to Bigger Capital Fund, LP, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock underlying a warrant issued to Cavalry Investment Fund, LP, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock underlying a warrant issued to Walleye Opportunities Master Fund Ltd., &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock underlying a warrant issued to Geoffrey Dow, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock underlying a warrant issued to Mountjoy Trust, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock issuable upon the exercise of the Representative Warrants and 238,601 shares of common stock reserved for issuance under our 2022 Equity Incentive Plan.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Each $1.00 increase or decrease in the assumed
                                            initial public offering price of $5.15 per unit (the midpoint of the price range set forth
                                            on the front cover page of this prospectus) would increase or decrease, as applicable, the
                                            amount of our cash, additional paid-in capital and total stockholders&rsquo; equity by $
                                            &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; , assuming that
                                            the number of units offered by us, as set forth on the cover page of this prospectus, remains
                                            the same, after deducting estimated underwriting discounts and commissions payable by us.
                                            An increase or decrease of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            &nbsp; units of our common stock offered by us would increase or decrease, as applicable,
                                            the amount of our cash, additional paid-in capital and total stockholders&rsquo; equity by
                                            $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; , assuming an
                                            initial public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            &nbsp; (the midpoint of the price range set forth on the front cover page of this prospectus)
                                            after deducting estimated underwriting discounts and commissions payable by us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_014"></A><B>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Purchasers of our common stock in this offering
will experience an immediate and substantial dilution in the adjusted net tangible book value of their shares of common stock. Dilution
in as adjusted net tangible book value represents the difference between the public offering price per share that is part of the unit
and the as adjusted net tangible book value per share of our common stock immediately after the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
historical net tangible book value of our common stock as of December 31, 2022, was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share. Historical net tangible book value per
share of our common stock represents our total tangible assets (total assets less intangible assets) less total liabilities divided by
the number of shares of common stock outstanding as of that date. After giving effect to the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;shares of common stock upon the (i) issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; shares
of our common stock to BioIntelect pursuant to the BioIntelect Agreement, (ii) issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp; shares of our common stock to Knight as a result of the conversion of certain of our outstanding debt owed to Knight pursuant
to the Knight Debt Conversion Agreement, (iii) issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; shares
of our common stock as a result of the conversion of our convertible promissory notes excluding the Xu Yu Equity Conversion Note, (iv)
shares of our common stock that are to be issued prior to the closing of this offering pursuant to the Xu Yu Equity Conversion Note and
(v) issuance of 100,000 shares of our common stock to our legal counsel and 1,343,000 shares of our common stock to consultants, our
pro forma net tangible book value as of December 31, 2022 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">After giving effect to the
pro forma adjustments set forth above and the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;shares
that are part of the units in this offering at an assumed initial public offering price of $5.15&nbsp;per unit (the midpoint of the price
range set forth on the front cover page of this prospectus) for net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;, our pro forma as adjusted net tangible book value as of December 31, 2022 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp; or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;per share of our common stock. This
represents an immediate increase in pro forma net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;to the existing stockholders and an immediate dilution in pro forma net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;. The following table illustrates this per share dilution to new investors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; width: 71%; text-align: justify"><FONT STYLE="font-size: 10pt">Public offering price per share</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 12%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: top; width: 12%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">Pro forma net tangible
    book value per share as of December 31, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-left: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">Increase in pro forma
    net tangible book value per share attributable to the offering</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-size: 10pt">Pro forma as adjusted net tangible book value
    (deficit) per share as of December 31, 2022</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dilution in pro forma
    as adjusted net tangible book value per share to new investors</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Each $1.00 increase or decrease
in the assumed initial public offering price of $5.15 per unit (the midpoint of the price range set forth on the front cover page of
this prospectus) would increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share to new investors
by $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; , and would increase or decrease, as applicable, dilution
per share to new investors in this offering by $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; , assuming
that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp; units offered by us would increase or decrease, as applicable, our pro forma as adjusted net tangible book value by approximately
$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; per share and increase or decrease, as applicable, the dilution
to new investors by $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; per share, assuming the assumed initial
public offering price remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable
by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">After completion of this offering,
our existing stockholders would own approximately<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</FONT>% and our new investors would own approximately<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</FONT>% of the total number of shares of our common stock outstanding after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">To the extent that outstanding
options or warrants, if any, are exercised, you will experience further dilution. In addition, we may choose to raise additional capital
due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these
securities may result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Capitalization Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Shares Purchased</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Total Consideration</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Per Share</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 25%; text-align: justify">Existing stockholders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="white-space: nowrap; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">New Investors</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"></TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Each $1.00 increase or decrease in the assumed
initial public offering price of $5.15 per unit (the midpoint of the price range set forth on the front cover page of this prospectus)
would increase or decrease, as applicable, the total consideration paid by new investors and total consideration paid by all stockholders
by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; , assuming that the number of shares offered
by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_015"></A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS
OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The following discussion and analysis of our
financial condition and results of operations should be read in conjunction with the information presented in &ldquo;Selected Historical
Consolidated Financial Data&rdquo; and our historical consolidated financial statements and the related notes included elsewhere in this
prospectus. In addition to historical information, the following discussion contains forward-looking statements, such as statements regarding
our expectation for future performance, liquidity and capital resources, that involve risks, uncertainties and assumptions that could
cause actual results to differ materially from our expectations. Our actual results may differ materially from those contained in or
implied by any forward-looking statements. Factors that could cause such differences include those identified below and those described
in &ldquo;Cautionary Note Regarding Forward-Looking Statements,&rdquo; &ldquo;Risk Factors&rdquo; and &ldquo;Audited Consolidated Financial
Information.&rdquo; We assume no obligation to update any of these forward-looking statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
specialize in the cost-effective development and commercialization of small molecule therapeutics for infectious diseases. We have a
single FDA-approved product Arakoda, for malaria prevention in travelers. This product is revenue-generating in the United States and
foreign markets, but not yet profitable, primarily due to the lack of an active marketing campaign following its introduction into the
U.S. supply chain in late 2019. The COVID-19 pandemic curtailed foreign travel and therefore any ability to raise financing to support
an active marketing effort.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that the pathway to profitability lies through future investment in an active marketing program and recruitment of a direct sales
force to support Arakoda. However, the return on investment for such an effort is likely to be much greater if it can be shown that the
pool of potential prescriptions/patients is larger than that for malaria prevention alone. To that end, our primary operational goal
is to demonstrate the clinical effectiveness of the already approved dosing regimen of Arakoda in other disease states. Thus, in the
second half of 2023, our focus will be on executing a Phase II B clinical investigation of the efficacy of Arakoda in COVID-19 outpatients.
Other supporting activities referenced below and elsewhere in this prospectus, such as improving technical specifications, limited marketing
efforts, portfolio development, and observing the progress of foreign market growth, will be conducted as resources permit.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Key Factors Affecting our Performance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of a number of factors, our historical
results of operations may not be comparable to our results of operations in future periods, and our results of operations may not be
directly comparable from period to period. Set forth below is a brief discussion of the key factors impacting our results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Known Trends and Uncertainties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Inflation</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inflation generally affects us by increasing
our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during
the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Supply Chain</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our approved product, Arakoda, is manufactured
in India. During the audited period, our contract manufacturer experienced reduced capacity due to the COVID-19 pandemic, which in theory,
but not in practice, could have disrupted continuity of U.S. supply of Arakoda.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Geopolitical Conditions</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
February 2022, Russia initiated significant military action against Ukraine. In response, the U.S. and certain other countries imposed
significant sanctions and export controls against Russia, Belarus and certain individuals and entities connected to Russian or Belarusian
political, business, and financial organizations, and the U.S. and certain other countries could impose further sanctions, trade restrictions,
and other retaliatory actions should the conflict continue or worsen. It is not possible to predict the broader consequences of the conflict,
including related geopolitical tensions, and the measures and retaliatory actions taken by the U.S. and other countries in respect thereof
as well as any counter measures or retaliatory actions by Russia or Belarus in response, including, for example, potential cyberattacks
or the disruption of energy exports, is likely to cause regional instability, geopolitical shifts, and could materially adversely affect
global trade, currency exchange rates, regional economies and the global economy. The situation remains uncertain, and while it is difficult
to predict the impact of any of the foregoing, the conflict and actions taken in response to the conflict could increase our costs, reduce
our sales and earnings, impair our ability to raise additional capital when needed on acceptable terms, if at all, or otherwise adversely
affect our business, financial condition, and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>Effects of the COVID-19 Pandemic</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The current pandemic of COVID-19 has globally
resulted in loss of life, business closures, restrictions on travel, and widespread cancellation of social gatherings. While the disruption
is currently expected to be temporary, there is considerable uncertainty around the duration. Therefore, we expect this matter to negatively
impact our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The extent to which the COVID-19 pandemic impacts
our business will depend on future developments, which are highly uncertain and cannot be predicted at this time, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">new
                                            information which may emerge concerning the severity of the disease;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            duration and spread of the outbreak;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            severity of travel restrictions imposed by geographic areas in which we operate, mandatory
                                            or voluntary business closures;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our
                                            ability to enroll patients;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">regulatory
                                            actions taken in response to the pandemic, which may impact merchant operations, consumer
                                            and merchant pricing, and our product offerings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">other
                                            business disruptions that affect our workforce and supply chain;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            impact on capital and financial markets; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">actions
                                            taken throughout the world, including in markets in which we operate, to contain the COVID-19
                                            outbreak or treat its impact.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the current pandemic of COVID-19
has resulted in a widespread global health crisis and adversely affected global economies and financial markets, and similar public health
threats could do so in the future. Any potential impact to our results will depend on, to a large extent, future developments and new
information that may emerge regarding the duration and severity of the COVID-19 pandemic and the actions taken by government authorities
and other entities to contain the COVID-19 pandemic or treat its impact, almost all of which are beyond our control. If the disruptions
posed by the COVID-19 pandemic or other matters of global concern continue for an extensive period of time, the operations of our business
may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the extent the COVID-19 pandemic or a similar
public health threat has an impact on our business, it is likely to also have the effect of heightening many of the other risks described
in the &ldquo;<I>Risk Factors</I>&rdquo; section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Seasonality</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Our business could
be affected by seasonal variations. For instance, we expect to experience higher sales in the second and th<FONT STYLE="font-family: Times New Roman, Times, Serif">ird
quarters of the fiscal year. However, taken as a whole, seasonality does not have a material impact on our financial results.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I><U>Foreign
Currency</U></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
reporting currency is the U.S. dollar and our operations in Australia and Singapore use their local currency as their functional currencies.
We are subject to the effects of exchange rate fluctuations with respect to any of such currency. The income statements of some of our
operations are translated into U.S. dollars at the average exchange rates in each applicable period. To the extent the U.S. dollar strengthens
against foreign currencies, the translation of these foreign currencies denominated transactions results in reduced revenue, operating
expenses and net income for our international operations. We are also exposed to foreign exchange rate fluctuations as we convert the
financial statements of our foreign subsidiaries into U.S. dollars in consolidation.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><U>Concentration
of Revenues</U></I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We received the majority of our revenues from sales
of our Arakoda product to the DoD. The DoD has historically been our largest customer. Upon fulfilment of the final purchase of product
under the contract, which expired on August 31, 2022, the DoD has not issued any further contracts nor contract modifications to allow
additional procurement. Further information is provided in the &ldquo;<I>Revenue</I>&rdquo; section below. Revenues remain concentrated.
The following tables set forth our concentrations of revenues for the twelve months ended December 31, 2022 and 2021.</P>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Twelve
Months Ended December 31, 2022, and 2021</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Customers (Market)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>12/31/2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>12/31/2021</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>$ Change</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% Change</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Biocelect (Australia)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">86,763</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">37,046</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">49,717</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">134</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">DoD (US Military)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30,295</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,150,650</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,120,355</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(97</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">ICS AmerisourceBergen (US Commercial)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">88,150</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(27,356)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">115,506</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(422</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Scandinavian Biopharma Distribution AB (European Union)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">18,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">18,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">NA</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Net Sales Revenue</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">223,208</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,160,340</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(937,132</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(81</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Twelve Months Ended December 31, 2022, and
2021</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth our results of
operations for the period presented:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Twelve Months Ended <BR>
December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Consolidated Statements of Operations Data:</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 70%"><FONT STYLE="font-size: 10pt">Product revenues &ndash; net of discounts and rebates</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">192,913</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">1,078,440</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Service revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">30,295</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">81,900</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Product and service revenues</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">223,208</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,160,340</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Cost of revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">432,370</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">850,742</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Gross (loss) profit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(209,162</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">309,598</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Research revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">288,002</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">5,192,516</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Net revenue</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">78,840</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">5,502,114</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Operating expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Research and development</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">525,563</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5,510,866</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">General and administrative expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,303,722</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,115,350</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,829,285</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6,626,216</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Loss from operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,750,445</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,124,102</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Interest and other income (expense), net:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Interest expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,989,359</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,172,712</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Derivative expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(504,613</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Change in fair value of derivative liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(10,312</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Gain on Debt Extinguishment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">120,683</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Other (expense) income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(43,238</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">37,515</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Total interest and other income (expense), net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(4,426,839</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(3,135,197</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Loss from operations before provision for income taxes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(6,177,284</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(4,259,299</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Provision for income taxes</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">500</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Net loss including noncontrolling interest</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(6,177,784</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(4,260,299</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Net gain (loss) noncontrolling interest</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3,936</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(8,554</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Net loss - attributed to 60 Degrees Pharmaceuticals Inc</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(6,181,720</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,251,745</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Comprehensive loss:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net loss</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(6,177,784</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(4,260,299</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Unrealized foreign currency translation loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,127</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(3,031</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total comprehensive loss</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(6,179,911</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,263,330</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net gain (loss) &ndash; noncontrolling interest</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,936</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(8,554</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Unrealized foreign currency translation gain from noncontrolling interest</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,588</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Comprehensive loss - attributed to 60 Degrees Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(6,183,847</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,256,364</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth our results of operations as a percentage
of revenue:</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Twelve Months Ended <BR>
December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Consolidated Statements of Operations Data:</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 70%"><FONT STYLE="font-size: 10pt">Product revenues &ndash; net of discounts and rebates</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">86.43</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">92.94</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Service revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">13.57</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">7.06</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Product and service revenues</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100.00</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100.00</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Cost of revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">193.71</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">73.32</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Gross (loss) profit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(93.71</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26.68</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Research revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">129.03</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">447.50</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net revenue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">35.32</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">474.18</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Operating expenses:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Research and development</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">235.46</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">474.94</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">General and administrative expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">584.08</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">96.12</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">819.54</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">571.06</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Loss from operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(784.22</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(96.88</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Interest and other income (expense), net:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Interest expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,787.28</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(273.43</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Derivative expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(226.07</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Change in fair value of derivative liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(4.62</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Gain on debt extinguishment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54.07</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Other (expense) income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(19.37</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">3.23</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Total interest and other income (expense), net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(1,983.27</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(270.20</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Loss from operations before provision for income taxes</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,767.49</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(367.08</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Provision for income taxes</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0.22</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0.09</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Net loss including noncontrolling interest</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2,767.71</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(367.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Net gain (loss) - noncontrolling interest</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1.76</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(0.74</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Net loss &ndash; attributable to 60 Degrees Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,769.47</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(366.43</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Comprehensive loss:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net loss including noncontrolling interest</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2,767.71</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(367.17</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Unrealized foreign currency translation loss</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(0.95</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(0.26</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total comprehensive loss</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,768.66</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(367.43</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net gain (loss) &ndash; noncontrolling interest</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.76</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(0.74</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Unrealized foreign currency translation gain from noncontrolling interest</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">0.14</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Comprehensive loss - attributed to 60 Degrees Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(2,770.42</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)%</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(366.83</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Comparison of the Twelve Months Ended December&nbsp;31, 2022, and
2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Product and Service Revenue, Discounts and Rebates, Net Sales
Revenue, Cost of Goods Sold, Gross Profit, and Gross Margin</I></B></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Twelve Months Ended December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>$ Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Product revenues &ndash; net of discounts and rebates</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">192,913</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,078,440</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(885,527</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(82.11</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Service revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">30,295</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">81,900</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(51,605</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(63.01</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net product and service revenues</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">223,208</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,160,340</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(937,132</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(80.76</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Cost of revenues</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">432,370</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">850,742</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(418,372</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(49.18</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Gross (loss) profit</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(209,162</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">309,598</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(518,760</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(167.56</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Gross margin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(93.71</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">26.68</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Product Revenues &ndash; Net of Discounts and
Rebates, Service Revenue and Net Product and Service Revenues</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our product revenues were $192,913 for the twelve months ended December
31, 2022, as compared to $1,078,440 for the twelve months ended December 31, 2021. As of December 31, 2022, one government customer accounted
for 14% (and 95% as of December 31, 2021) of our total sales. The decrease in sales was mainly due to a 3-year Arakoda acquisition contract
that involved purchasing a full lot (7,500 boxes) in 2020 and a half lot (3,750 boxes) in 2021, which was fulfilled by August 31, 2021.
This contract was executed by the United States Army Medical and Materiel Development Activity (USAMMDA) to support commercialization
efforts.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
offer discounts and rebates to the civilian U.S. supply chain distribution channel. We record sales when our third-party logistics (&ldquo;3PL&rdquo;)
partner transfers boxes into their title model. Discounts and rebates are offered to our 3PL partner amounting to 2%. Then product is
transferred normally to one of the three large U.S. pharmaceutical distributors where rebates range form 10-12%. Lastly, we have relationships
with several large pharmacy benefit managers (&ldquo;PBMs&rdquo;) that allows patients to purchase Arakoda at a discount. The rebate
associated with PBMs ranges from 15% to 30% depending on the amount of coverage provided. For the twelve months ending December 31, 2022,
discounts and rebates were $59,552 compared to none for the twelve months ending December 31, 2021. There were neither discounts or rebates
on direct sales to USAMMDA.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Although, as of
the date of this prospectus, we were not in discussions with the DoD about additional/future procurement, we anticipate that this will
be feasible in the future if one or more of the conditions/events described in this paragraph occur. First, the position of Arakoda in
the DoD formulary (Tricare, deployed personnel) needs to be improved from second/third tier to at least equivalency with competing products
(as is the case for civilian use as recommended by the CDC). Second, the shelf-life of the existing product requires extension, which
is known to be technically possible as the shelf-life of Kodatef in Australia is 48 months, but appropriate data must be generated to
meet FDA requirements. Finally, a change in the operational footprint of DoD deployments to areas with higher malaria attack rates (e.g.,
the Liberia deployment to manage the Ebola outbreak in 2014) may lead to a rapid reassessment by DoD of the position of Arakoda in the
formulary (advancement of the last approved prophylactic antimalarial to co-equal standard of care took thirteen years).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">Arakoda entered the U.S. civilian supply chain in the third quarter
of 2019. For the twelve months ended December 31, 2021, 389 boxes were sold to pharmacies and dispensaries. Sales increased by 47% to
570 boxes to patients for the twelve months ended December 31, 2022. Increasing commercial sales reflect organic growth, since no active
marketing efforts were made during the pandemic and the wholesale acquisition cost has not changed from launch in 2019 through December
31, 2022.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Kodatef
sales to our distributor Biocelect in Australia for the twelve months ended December 31, 2022 were $86,763 ($37,046 for the twelve months
ended December 31, 2021). Sales to Biocelect are currently subject to a profit share distribution once the original transfer price has
been recouped. As of December 31, 2022, no profit share has been due to us, though we did settle the historical profit share through
September 30, 2022 for $24,486 (AUD$35,000) on January 16, 2023.</FONT></P>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">During 2022, we recorded our first sale of Arakoda/Kodatef to our European distributor Scandinavian Biopharma Distribution
AB. Product will be distributed there on a named patient basis. As in Australia a profit distribution share is possible depending on
the retail price established.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also earned $30,295 from storing the Army&rsquo;s
ARAKODA purchases through August 31, 2022 (when the contract ended) compared to $81,900 earned through the twelve months ended December
31, 2021 of which $57,000 of revenue was related to shipping stored ARAKODA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Cost of Revenues, Gross (Loss) Profit, and Gross
Margin</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The cost of goods sold was $432,370 for the twelve
months ended December 31, 2022, as compared to $850,742 for the twelve months ended December 31, 2021. The decrease in cost of goods sold
was primarily due to sale of a half lot to the government in 2021. The Gross Margin % fell to (94)% for the twelve months ended December
31, 2022 from 27% for the twelve months ended December 31, 2021. This is due to the current low sales volume and the fixed part of cost
of goods. As the sales volume continues to grow the gross margin will improve as the variable cost of goods of each unit sold is substantially
less than the sales price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Other Operating Revenues</I></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I></I></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Twelve Months Ended December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>$ Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Research revenues</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">288,002</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">5,192,516</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(4,904,514</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(94.45</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The research revenues earned by us were $288,002 for the twelve months
ended December 31, 2022, as compared to $5,192,516 for the twelve months ended December 31, 2021. Our research revenues are derived mostly
from a single, awarded research grant in the amount of $4,999,814 (with an additional $720,000 awarded February 26, 2021) from the Joint
Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (which may be referred to as &ldquo;JPEO&rdquo;) at
the beginning of December 2020 to study Arakoda in mild-to-moderate COVID-19 patients. The trial was actively recruiting patients from
February to September of 2021; hence the majority of the grant revenue was earned in the first nine months of 2021 ending on September
30 ($4,935,335). At the end of 2021, $245,552 remained on the grant. The study was largely completed with the planned lab data analysis
and the submission of the final study report completed during the first nine months of 2022 ending on September 30. We also earn research
revenues from the Australian Tax Authority for research expenses conducted in Australia. The revenue was $42,250 at the end of twelve
months ended December 31, 2022 compared to $19,511 at the twelve months ended December 31, 2021.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Operating Expenses</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Twelve Months Ended December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>$ Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Research and development</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">525,563</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">5,510,866</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(4,985,303</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(90.46</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">General and administrative</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,303,722</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,115,350</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">188,372</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">16.89</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total operating expenses</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,829,285</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">6,626,216</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,796,931</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(72.39</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Research and
Development Expenses</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We considerably reduced research and development costs as we completed
our Phase II COVID-19 trial in 2022. Direct COVID-19 related trial costs are 49% of the costs through the twelve months ended December
31, 2022 at $256,581 and 86% of the costs for the twelve months ended December 31, 2021 at $4,721,635. Research and development costs
are expected to increase substantially in 2023, as the second COVID-19 clinical trial and supporting activities are initiated in the second
half of the year.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>General and
Administrative Expenses</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the twelve months ended December 31, 2022, our general and administrative expenses increased by 17% or $188,372. While the net amounts
did not change substantially for the twelve months ended December 31, in 2022 we spent substantially more for accounting and auditing
at $173,975 (up from $15,071 for the twelve months ended December 31, 2021) and recorded $410,302 in professional services to be paid
in stock (none for the 12 months ended December 31, 2021). Whereas, we spent substantially less for legal, regulatory advice and insurance,
$202,974 at twelve months ended December 31, 2022 ($446,884 at twelve months ended December 31, 2021).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Interest
and Other Income (Expense), Net</I></B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Twelve Months Ended December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>$ Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% &nbsp;Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Interest expense</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(3,989,359</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(3,172,712</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(816,647</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">25.74</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Derivative expense</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(504,613</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(504,613</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">NA</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Change in fair value of derivative liabilities</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(10,312</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(10,312</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">NA</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Gain on debt extinguishment</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">120,683</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">120,683</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">NA</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Other (expense) income</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(43,238</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">37,515</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(80,753</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">215.26</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total Interest and Other Income (Expense), Net</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(4,426,839</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(3,135,197</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(1,291,642</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">41.20</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Interest Expense</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the twelve months ended December 31, 2022, we
recognized $3,989,359 of interest expense ($3,172,712 for the twelve months ended December 31, 2021). The increase is primarily related
to growing principal and interest balances with the primary lender Knight. Cash paid for interest expense was $2,193 and none for the
twelve months ended December 31, 2022 and December 31, 2021, respectively.</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>Derivative Expense</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">For the twelve months ended December 31, 2022, we recognized $504,613
of derivative expense (none for the twelve months ended December 31, 2021). The increase is related to the raising of $1,105,000 of bridge
funding.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>Change in Fair Value of Derivative
Liabilities</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the twelve months ended December 31, 2022, we
recognized a change in fair value of derivative liabilities of $10,312 (none for the twelve months ended December 31, 2021). The increase
is related to derivatives generated from the bridge funding raise.</P>
<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Gain on
debt extinguishment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the twelve months ended December 31, 2022, we recognized a $120,683 gain on debt extinguishment (none for the twelve months ended December
31, 2021). The increase is related to the renegotiation of the Xu Yu promissory note.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I>Other Income
(Expense), Net</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For the twelve months ended December 31, 2022, we recognized ($43,238)
in other (expense) income compared to $37,515 for the twelve months ended December 31, 2021. In 2022, it was uncovered that federal tax
form 8992 may have not been properly filed. We have elected to record a $30,000 tax liability for the audit of the twelve months ended
December 31, 2022, $10,000 each for the years ended December 31, 2019, 2020 and 2021 (none for the twelve months ended December 31, 2021).
For the twelve months ended December 31, 2021 we recorded $38,500 of PPA loan forgiveness income (none for the twelve months ended December
31, 2022).</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We had net cash used in operating activities of $1,009,980 for the
twelve months ended December 31, 2022, and the cash balance was $264,865 as of December 31, 2022. Based on current internal projections,
should the full amount of the proceeds from this offering be realized, and if our planned COVID-19 clinical study is eligible to receive
Australian government research and development tax rebates and it is possible to borrow and receive funds from a lender ahead of issuance
of those tax rebates, we estimate that we will have sufficient funds to remain viable through December 31, 2023 (sufficient to complete
an optional futility analysis at 33% enrolment in the clinical study if desired). However, we may not remain viable until December 31,
2023, if we end up being ineligible for research tax credits or cannot borrow against their future issuance. We cannot give assurance
that we can increase our cash balances or limit our cash consumption and thus maintain sufficient cash balances for our planned operations
or future acquisitions. Future business demands may lead to cash utilization at levels greater than recently experienced. We may need
to raise additional capital in the future. However, we cannot assure you that we will be able to raise additional capital on acceptable
terms, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To date, we have funded our operations through debt
and equity financings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2022, we had an accumulated deficit of $28,815,148. In their audit report for the fiscal year ended December 31, 2022
included in this report, our auditors have expressed their concern as to our ability to continue as a going concern. Our ability to continue
as a going concern is dependent upon our ability to generate cashflows from operations and obtain financing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The accompanying consolidated financial statements for the twelve months
ended December 31, 2022, and December 31, 2021, respectively, included an explanatory note referring to our recurring operating losses
and expressing substantial doubt in our ability to continue as a going concern. Our consolidated financial statements have been prepared
on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. To date,
we have not yet established an ongoing source of revenues and cash flows sufficient to cover our operating costs and allow us to continue
as a going concern. These factors among others raise substantial doubt about our ability to continue as a going concern for at least one
year from the date of issuance of the accompanying consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain
the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due.
The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to
continue as a going concern. Our consolidated financial statements do not include any adjustments to the amount and classification of
assets and liabilities that may be necessary should we be unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Borrowings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 10, 2015, we entered into the Loan Agreement and Engagement with Knight, as amended eight times, pursuant to which, we originally
borrowed $500,000 at a per annum interest rate of 15% (the &ldquo;Knight Loan&rdquo;) and a debenture agreement of face value $3 million
on April 24, 2018 (the &ldquo;Knight Debenture&rdquo;). As of December 31, 2022, the current outstanding balance of the Knight Loan and
Knight Debenture is $20,596,595.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Knight Debt Conversion Agreement, executed January 9, 2023 and modified on January 13, 2023, and again on January 27, 2023, Knight
and us agreed, to formalize a previously negotiated term sheet that, in the event of a successful initial public offering, we will fix
Knight&rsquo;s cumulative debt to the value as it stood on March 31, 2022, which consisted of $10,770,037 in principal and $8,096,486
in accumulated interest, and to convert the aforementioned amounts, should we consummate an initial public offering that results in gross
proceeds of at least $7,000,000 prior to December 31, 2023 as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-bottom: 12pt; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="padding-bottom: 0; font-size: 10pt; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
                                            agreed to convert the principal amount into (i) that number of shares of common stock equal
                                            to dividing the principal amount by an amount equal to the offering price of the common stock
                                            in the initial public offering discounted by 15% (the &ldquo;Conversion Common Shares&rdquo;),
                                            rounding up for fractional shares, in a number of Conversion Shares up to 19.9% of our outstanding
                                            common stock after giving effect of the initial public offering; (ii) we will make a milestone
                                            payment of $10 million to Knight if, after the date of a qualifying initial public offering,
                                            we sell ARAKODA or if a Change of Control (as per the definition included in the original
                                            loan agreement dated on&nbsp;December 10, 2015) occurs, provided that the purchaser of ARAKODA
                                            or individual or entity gaining control of us is not Knight or an affiliate of Knight; (iii)
                                            following the License and Supply agreement dated on December 10, 2015 and subsequently amended
                                            on January 21, 2019, an expansion of existing distribution rights to Tafenoquine/Arakoda
                                            to include COVID-19 indications as well as malaria prevention across the Territory as defined
                                            in said documents, subject to U.S. Army approval; and (iv) we will retain Knight or an affiliate
                                            of Knight to provide financial consulting services, management, strategic and/or regulatory
                                            advice of value $30,000 per month for five years (the parties will negotiate the terms of
                                            that consulting agreement separately in good faith).</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; padding-bottom: 12pt; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="padding-bottom: 0; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    parties agreed to convert the&nbsp;accrued interest into that number of shares (the &ldquo;Conversion Preferred Shares&rdquo; and,
    together with the Conversion Common Shares, the &ldquo;Conversion Shares&rdquo;) of a new class of preferred stock (the &ldquo;Preferred
    Stock&rdquo;) by dividing the Accrued Interest by $100.00, then rounding up. The Preferred Stock shall have the following rights,
    preferences, and designations: (i) have a 6% cumulative dividend accumulated annually on March 31; (ii) shall be non-voting stock;
    (iii) are not redeemable, (iv) be convertible to shares of common stock at a price equal to the lower of (1) the price paid for the
    shares of common stock in the initial public offering and (2) the 10 day volume weighted average share price immediately prior to
    conversion; and (v) conversion of the preferred stock to common shares will be at our sole discretion. Notwithstanding the foregoing,
    we shall not convert the Preferred Stock into shares of common stock if as a result of such conversion Knight will own 19.9% or more
    of our outstanding common stock.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition to the conversion of the debt, for a period commencing on January 1, 2022 and ending
                                            upon the earlier of 10 years after the closing of the initial public offering or the conversion
                                            or redemption in full of the Conversion Preferred Shares, we shall pay Knight a royalty equal
                                            to 3.5% of our net sales (the &ldquo;Royalty&rdquo;), where &ldquo;Net Sales&rdquo; has the
                                            same meaning as in our license agreement with the U.S. Army for Tafenoquine. Upon the qualified
                                            initial public offering, we shall calculate the royalty payable to Knight at the end of each
                                            calendar quarter. We shall pay to Knight the royalty amounts due with respect to a given
                                            calendar quarter within fifteen (15) business days after the end of such calendar quarter.
                                            Each payment of royalties due to Knight shall be accompanied by a statement specifying the
                                            total gross sales, the net sales and the deductions taken to arrive to net sales. For clarification
                                            purposes, the first royalty payment will be performed following the above instructions, on
                                            the first calendar quarter in which the qualified initial public offering takes place and
                                            will cover the sales of the period from January 1, 2022, until the end of said calendar quarter.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Should
an initial public offering not occur by January 1, 2024, then all terms of the original Knight Loan and Knight Debenture would resume
including any interest earned after March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October 11, 2017, we issued a $750,000 promissory note, as amended (the &ldquo;Avante Note&rdquo;), to Avante International Limited (&ldquo;Avante&rdquo;)
with accrued interest at an annual rate of 5.0% for the first six months, and 10% thereafter. On December 23, 2017, Avante transferred
the Avante Note to Xu Yu Equity Conversion Note.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 11, 2022, Avante and us amended the Avante Note (the &ldquo;Amendment&rdquo;). The Amendment added a provision to automatically
convert the outstanding principal and accumulated interest through March 31, 2022 to shares of common stock in the event we consummate
an initial public offering. The Amendment also provides Avante the option to convert the outstanding principal and accumulated interest
through March 31, 2022 to equity in the Company at the maturity date and will have 30 days from maturity to exercise this option. Cumulative
interest after March 31, 2022 will be forfeited should the lender elect to convert the Note into equity. We evaluated the Amendment and
determined that it constitutes an extinguishment as the option to convert interest through March 31, 2022 and is considered the addition
of a substantive conversion option. Accordingly, the Amendment resulted in extinguishment accounting and a corresponding extinguishment
gain of $120,683, which represents the difference between the carrying value of the Avante Note just prior to the Amendment and the fair
value of the Avante Note just after the Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The extinguishment accounting resulted in a fair
value of the Avante Note, including the Amendment of $1,099,578. The discount of $120,683 and costs incurred with third parties directly
related to the Amendment of $1,767 will be amortized over the remaining life of the debt using the effective interest method. Amortization
of the discount on the Avante Note, including the Amendment for the year ended December 31, 2022 was $4,955 ($0 in 2021). Interest expense
related to the Note, including the Amendment, for the year ended December 31, 2022 was $115,546 ($104,558 in 2021).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May 14, 2020, we issued the note to the U.S. Small Business Administration with a principal amount of $150,000 and a per annum interest
rate of 3.75%. The current outstanding balance of the COVID-19 Loan is $163,022 as of December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 19, 2022, we issued a Convertible Promissory
Note to Geoffrey Dow, as assigned to the Geoffrey S. Dow Revocable Trust dated August 27, 2018 on May 19, 2022 (the &ldquo;Geoffrey Dow
Trust Note&rdquo;), with a principal amount of $44,444.44 and a per annum interest rate of 6%. Upon the occurrence of our initial public
offering, the balance of such note will convert immediately prior to the initial public offering at a price equal to 80% of the price
per share of the common stock sold in the initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 19, 2022, we issued a Convertible Promissory
Note to Mountjoy Trust with a principal amount of $294,444.42 and a per annum interest rate of 6%. Upon the occurrence of our initial
public offering, the balance of such note will convert immediately prior to the initial public offering at a price equal to 80% of the
price per share of the common stock sold in the initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 24, 2022, we issued a note in the amount of
$333,333.30 to Bigger Capital Fund, LP. On the date of the pricing of our initial public offering, we will deliver to Bigger Capital
Fund, LP shares of our common stock equal to (i) 100% of the face value of the note divided by the initial public offering price per
share or (ii) if we fail to complete the initial public offering prior to May 24, 2023, the number of shares of our common stock calculated
using a $27 million pre-money valuation and the number of our outstanding shares of common stock on May 24, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 24, 2022, we issued a note in the amount of
$277,777.78 to Cavalry Investment Fund, LP. On the date of the pricing of our initial public offering, we will deliver to Cavalry Investment
Fund, LP shares of our common stock equal to (i) 100% of the face value of the note divided by the initial public offering price per
share or (ii) if we fail to complete the initial public offering prior to May 24, 2023, the number of shares of our common stock calculated
using a $27 million pre-money valuation and the number of our outstanding shares of common stock on May 24, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 24, 2022, we issued a note in the amount of
$277,777.78 to Walleye Opportunities Master Fund Ltd. On the date of the pricing of our initial public offering, we will deliver to Walleye
Opportunities Master Fund Ltd shares of our common stock equal to (i) 100% of the face value of the note divided by the initial public
offering price per share or (ii) if we fail to complete the initial public offering prior to May 24, 2023, the number of shares of our
common stock calculated using a $27 million pre-money valuation and the number of our outstanding shares of common stock on May 24, 2023.&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Contractual Obligations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes our contractual obligations as of December
31, 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Payments Due By<BR>
Period</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Less than</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>More<BR>
than</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>1 year</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>1-3 years</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>4-5 years</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>5 years</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Principal obligations on the debt arrangements</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">8,997,383</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">8,847,383</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,574</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">148,426</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Interest obligations on the debt arrangements</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15,097,215</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15,097,215</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Operating leases</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Purchase obligations</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,338,668</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">1,338,668</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">25,446,266</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">25,296,266</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,574</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">148,426</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<FONT STYLE="font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Cash Flows</B></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">The following table
sets forth the primary sources and uses of cash for each of the periods presented below:</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I><U>Twelve Months
Ended December 31, 2022, and 2021</U></I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Twelve Months Ended<BR>
    December 31,</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>$ Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>% Change</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Net cash (used in) provided by:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Operating activities</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(1,009,980</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(649,106</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">(360,874</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">56</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Investing activities</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(60,133</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(35,392</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(24,741</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(70</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Financing activities</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,221,706</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">611,226</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">610,480</FONT></P></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Effect of foreign currency translation on cash flow</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(2,127</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(3,031</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">904</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(30</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Net increase (decrease) in cash and cash equivalents</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">149,466</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(76,303</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">225,769</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">(296</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">)%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>Cash Used in Operating Activities</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT>Net cash used in operating activities was $1,009,980 for the twelve
months ended December 31, 2022, as compared to $649,106 for the twelve months ended December 31, 2021. The increase in net cash used in
operating activities was primarily due to the drop in product revenues from the end of the DoD procurement contract with none recorded
for the twelve months ended December 31, 2022 ($1,068,750 recorded for the twelve months ended December 31, 2021).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cash Used in Investing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Net cash used in investing activities was $60,133 for the twelve months
ended December 31, 2022, as compared to $35,392 for the twelve months ended December 31, 2021. The increase in net cash used in investing
activities was primarily due to the acquisition of intangibles of $27,070.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cash Provided by Financing Activities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net cash provided by financing activities was $1,221,706&nbsp;for the
twelve months ended December 31, 2022, as compared to $611,226 for the twelve months ended December 31, 2021. The increase in net cash
provided by financing activities was primarily due to $1,105,000 in bridge round financing received on May 24, 2022.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Effect of foreign currency translation on cash
flow</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
foreign operations were small relative to U.S. operations for the years ended December 31, 2022 and December 31, 2021, thus effects of
foreign currency translation have been minor.</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Critical Accounting Policies, Significant
Judgments, and Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>Use of Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
preparation of financial statements in conformity with United States generally accepted accounting principles (&ldquo;GAAP&rdquo;) requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent
assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Revenue Recognition </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We receive revenues from sales of our Arakoda
product to the DoD and resellers in the U.S. and abroad. We record deferred revenues for any advances and then recognize revenue upon
shipment to the retailer who orders product for a specific customer. We record a receivable for any amounts to be received pursuant to
such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
revenue was recognized when research expenses against the JPEO grant were recognized at the end of each month. Research revenues would
not exceed research expenses for a given period as the grant did not include the general and administrative, overhead or profit components.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Derivative Liabilities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
assessed the classification of our derivative financial instruments as of December 31, 2022, which consist of bridge shares, convertible
notes payable and certain warrants (excluding those for compensation) and have determined that such instruments qualify for treatment
as derivative liabilities as they meet the criteria for liability classification under ASC 815.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
analyze all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480,&nbsp;&ldquo;Distinguishing
Liabilities from Equity&rdquo;&nbsp;and FASB ASC Topic No. 815,&nbsp;(&ldquo;ASC 815&rdquo;) &ldquo;Derivatives and Hedging.&rdquo; Derivative
liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in
the results of operations (other income/expense) as change in fair value of derivative liabilities. We use a Monte Carlo Simulation Model
to determine the fair value of these instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon
conversion or repayment of a debt or equity instrument in exchange for shares of common stock, where the embedded conversion option has
been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), we record the shares of common
stock at fair value, relieve all related debt, derivative liabilities, and debt discounts, and recognize a net gain or loss on debt extinguishment.
In connection with the debt extinguishment, we typically record an increase to additional paid-in capital for any remaining liability
balance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
instruments that are initially classified as equity that become subject to reclassification under ASC 815 are reclassified to liabilities
at the fair value of the instrument on the reclassification date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Original
Issue Discount</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><U></U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For certain notes issued, we may provide the
debt holder with an original issue discount. The original issue discount is recorded as a debt discount, reducing the face amount of
the note, and is amortized to interest expense over the life of the debt in the Consolidated Statements of Operations and Comprehensive
Loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Debt Issue Cost</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Debt
issuance costs paid to lenders or third parties are recorded as debt discounts and amortized to interest expense over the life of the
underlying debt instrument in the Statements of Operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">From January 1, 2022 to May 31, 2022, 60 Degrees Pharmaceuticals, LLC
was a C-corporation for income tax purposes before the incorporation/merger into 60 Degrees Pharmaceuticals, Inc. on June 1, 2022. We
account for income taxes under the liability method, and deferred tax assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax
bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences
are expected to be recovered or settled. A valuation allowance is provided on deferred tax assets if it is determined that it is more
likely than not that the deferred tax asset will not be realized in the following five years. We did not realize any benefits in the year
ended December 31, 2022. Most of the deferred tax benefits are abroad and we do not project a profit in our subsidiary by 2026. We record
interest, net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We record tax positions taken or expected to
be taken in a tax return based upon the amount that is more likely than not to be realized or paid, including in connection with the
resolution of any related appeals or other legal processes. Accordingly, we recognize liabilities for certain unrecognized tax benefits
based on the amounts that are more likely than not to be settled with the relevant taxing authority. We recognize interest and/or penalties
related to unrecognized tax benefits as a component of income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Off-Balance&nbsp;Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During 2022 and 2021, we did not have any relationships with unconsolidated
organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the
purpose of facilitating&nbsp;off-balance&nbsp;sheet arrangements or other contractually narrow or limited purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>JOBS Act Accounting Election</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2012, the JOBS Act was enacted. Section&nbsp;107(b)
of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided
in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company
can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected
to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other
public companies that are not emerging growth companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recent Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Financial Accounting Standards Board (the &ldquo;FASB&rdquo;) issues
Accounting Standards Update (&ldquo;ASUs&rdquo;) to amend the authoritative literature in ASC. There have been a number of ASUs to date,
that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are
technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact on our consolidated financial
statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity, as part of its overall
simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness
of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models
for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature
is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting
the guidance, entities will no longer separately present such embedded conversion features in equity and will instead account for the
convertible debt wholly as debt. The new guidance also requires use of the &ldquo;if-converted&rdquo; method when calculating the dilutive
impact of convertible debt on earnings per share, which is consistent with our current accounting treatment under the current guidance.
The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within
those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
adopted this pronouncement on January 1, 2022; however, the adoption of this standard did not have a material effect on our consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
May 2021, the FASB issued ASUs 2021-04, Earnings Per Share (Topic 260), Debt&mdash;Modifications and Extinguishments (Subtopic 470-50),
Compensation&mdash;Stock Compensation (Topic 718), and Derivatives and Hedging&mdash;Contracts in Entity&rsquo;s Own Equity (Subtopic
815-40): Issuer&rsquo;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This
new standard provides clarification and reduces diversity in an issuer&rsquo;s accounting for modifications or exchanges of freestanding
equity-classified written call options (such as warrants) that remain equity classified after modification or exchange. This standard
is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Issuers should
apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new standard. Early adoption
is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in an interim period, the
guidance should be applied as of the beginning of the fiscal year that includes that interim period. We do not expect the adoption of
this standard to have a material effect on our consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, the FASB issued&nbsp;ASU 2021-08,&nbsp;Business
Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer
in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification
Topic 606.&nbsp;ASU 2021-08&nbsp;is effective for fiscal years beginning after December 15, 2022, and early adoption is permitted. While
we are continuing to assess the timing of adoption and the potential impacts of&nbsp;ASU 2021-08, we do not expect&nbsp;ASU 2021-08&nbsp;will
have a material effect, if any, on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_016"></A><FONT STYLE="text-transform: uppercase"><B>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a growth-oriented specialty pharmaceutical company with a goal
of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and
treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that
has been on the market since late 2019. Currently, 60P&rsquo;s pipeline under development covers development programs for COVID-19, fungal,
tick-borne, and other viral diseases utilizing three of the Company&rsquo;s future products: (i) new products that contain the Arakoda
regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In 2018, the FDA approved Arakoda for malaria prevention in individuals
18 years and older, an indication for which there has historically been approximately 550,000 prescriptions (one prescription per three
weeks of travel) in the United States each year for the current market-leading product (atovaquone-proguanil). Arakoda entered the U.S.
supply chain in the third quarter of 2019, just prior to the COVID-19 pandemic. As the approved indication is for travel medicine, and
international travel was substantially impacted by the pandemic, we did not undertake any active marketing efforts for Arakoda. Targeted
marketing efforts will commence in the second half of 2023 to promote the malaria indication as resources permit, although we expect our
primary efforts to be developing Arakoda for other applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are repositioning the Arakoda regimen of Tafenoquine for new indications
to address several therapeutic indications that have substantial U.S. caseloads, as further described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><U>Treatment
                                            of COVID-19</U>. According to <I>The New York Times</I>, the lowest daily case rate for the
                                            COVID-19 virus since March 2020 based on a seven-day average has not typically been below
                                            11,000 cases. Assuming this trend continues, this dynamic translates into a potential market
                                            size of at least 4,000,000 cases per year in 2023 and future years. Paxlovid and molnupiravir
                                            have received emergency use authorization for the prevention of death and hospitalization
                                            in individuals with high risk of disease progression and their use for those purposes continues
                                            to be recommended by public health experts. However, to our knowledge, there is not published
                                            evidence from randomized controlled clinical trials that either drug reduces the time to
                                            sustained clinical recovery for four or more days in standard risk patients infected with
                                            contemporary viral strains, and Pfizer has formally abandoned efforts related to this endpoint
                                            for paxlovid.<SUP>36 </SUP>Additionally molnupiravir and paxlovid are not approved by FDA
                                            for use in patients without risk factors for disease progression, and that excluded lower
                                            risk population comprises about 25% of the U.S. population.<SUP>37</SUP> The economic value
                                            of that unsatisfied market may be a multi-billion-dollar opportunity, given that the value
                                            of paxlovid and molnupiravir in the 75% of the population in which they can be used was ~ $12
                                            billion in 2022.<SUP>38</SUP> If proven effective for early relief of COVID-19 symptoms in
                                            standard risk COVID-19 patients, Tafenoquine (Arakoda regimen) could fulfill a patient&rsquo;s
                                            need unmet by the approved antivirals.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><SUP>36</SUP> Press release: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>37 </SUP>See the Paxlovid (www.paxlovid.com) and Lagevrio (www.lagevrio.com)
prescribing information and epidemiology data described by Ajufo et al Am J Preventive Cardiol 2021;6:101156.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>38</SUP> See 2022 revenue data for Paxlovid in Pfizer (https://investors.pfizer.com/Investors/Financials/SEC-Filings/SEC-Filings-Details/default.aspx?FilingId=16428097)
and Lagevrio (https://d18rn0p25nwr6d.cloudfront.net/CIK-0000064978/b390be48-92bf-4595-96da-ac5cd7c3d92e.pdf) in Merck financial reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><U>Treatment and Post-Exposure Prevention of Tick-Borne
    Diseases</U>. There are at least 47,000 cases of babesiosis (red blood cell infections caused by deer tick bites) in the United States
    each year. This estimate is based on the observations of Krugeler<SUP></SUP> who reported that 476,000 cases of Lyme disease occur
    in U.S. states where babesiosis is endemic and Krause et. al. who reported that 10% of Lyme disease patients are co-infected with
    babesiosis (thus 476,000*10% = 47,600 cases of babesiosis per year).<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>39
    </SUP></FONT>Furthermore, post-exposure prophylaxis following a tick-bite is a recognized indication to prevent Lyme disease, and
    it is likely that a drug proven to be effective for this indication for babesiosis would also be used in conjunction with Lyme prophylaxis.
    There may be more than 400,000 tick bites in the United States requiring medical treatment each year. This estimate is based on the
    observation that approximately 50,000 tick bites are treated in U.S. hospital emergency rooms each year but this calculation represents
    only about 12% of actual treated tick bites based on observations from comparable ex-U.S health systems.<SUP>40</SUP> Arakoda has
    the potential to be added to the existing standard of care for treatment of babesiosis, and to be a market leading product for pre-
    and post-exposure prophylaxis of babesiosis.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><U>Prevention
                                            of fungal pneumonias</U>. There are up to ~ 91-92,000 new medical conditions each year in
                                            the United States including acute lymphoblastic leukemia (up to 6.540 cases) and large B-cell
                                            lymphoma (up to 18,000 cases) patients receiving CAR-T therapy, solid organ transplant patients
                                            (up to 42,887 cases), allogeneic (~ 9,000 cases) and autologous (~ 15,000 cases) hematopoietic
                                            stem cell transplant patients for whom the use of antifungal prophylaxis is recommended.<SUP>41
                                            </SUP>Despite the availability and use of antifungal prophylaxis, the risk of some patient
                                            groups contracting fungal pneumonia exceeds the risk of contracting malaria during travel
                                            to West Africa.<SUP>42 </SUP>Arakoda has the potential to be added to existing standard of
                                            care regimens for the prevention of fungal pneumonias.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD><TD STYLE="text-align: justify"><U>Treatment
                                            of&nbsp;<I>Candida&nbsp;</I>infections</U>. According to the Centers for Diseases Control
                                            (CDC), there are 50,000 cases of candidiasis (a type of fungal infection) each year in the
                                            United States and up to 1,900 clinical cases of <I>C</I>. <I>auris</I>, for which there are
                                            few available treatments, have been reported to date<SUP>43</SUP> Arakoda has the potential
                                            to be a market leading therapy for treatment/prevention of <I>C. auris</I>, and to be added
                                            to the standard of care regimens for other <I>Candida </I>infections.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dengue and RSV, both afflictions against which 60P&rsquo;s
early clinical candidates (e.g., Celgosivir) show potential in non-clinical studies, are associated with at least 4.1 million cases globally
according to the European CDC (Dengue) <SUP>44</SUP> and up t0 200,000 hospitalizations (RSV) in children less than five years of age
and adults greater than 65 years of age in the United States each year according to the CDC.<SUP>45</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">More information about our products is provided in
the next section, and the status of various development efforts for the above-mentioned diseases is outlined in Figure A, below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>39 </SUP>Krause et al JAMA 1996;275:1657-16602; Krugeler et al.
<I>Emerg Infect Dis&nbsp;</I>2021;27:616-619</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>40</SUP> Marx et. al., MMWR 2021;70:612-616.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>41</SUP> See statistics for solid organ transplants at the Organ
Transplant and Procurement Network at: National data - OPTN (hrsa.gov); See statistics for hematopoietic stem cell transplant in Dsouza
et al Biology of Blood and Bone Marrow Transplantation 202;26: e177-e182; See statistics for acute lymphoblastic leukemia at: Key Statistics
for Acute Lymphocytic Leukemia (ALL) (cancer.org); See statistics for large cell large B-cell lymphoma at; Diffuse Large B-Cell Lymphoma
- Lymphoma Research Foundation; Treatment guidelines recommending antifungal prophylaxis for these diseases can be reviewed in [i] Fishman
et al Clinical Transplantation. 2019;33:e13587, [ii] Hematopoietic Cell Transplantation (cancernetwork.com), [iii] Cooper et al Journal
of the National Comprehensive Cancer Network 2016;14:882-913 and [iv] Los Arcos et al Infection (2021) 49:215&ndash;231.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>42</SUP> Aguilar-Guisado et al Clin Transplant 2011;25:E629&ndash;38;
Mace et al MMWR <FONT STYLE="background-color: white">202;70:1&ndash;35</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>43 </SUP>https://www.cdc.gov/fungal/diseases/candidiasis/invasive/statistics.html.;
https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>44</SUP> https://www.ecdc.europa.eu/en/dengue-monthly#:~:text=This%20is%20an%20increase%20of%2032%20653%20cases%20and%2032,853%20deaths%20have%20been%20reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>45</SUP>https://www.cdc.gov/rsv/research/index.html#:~:text=Each%20year%20in%20the%20United,younger%20than%205%20years%20old.&amp;text=58%2C000-80%2C000%20hospitalizations%20among%20children%20younger%20than%205%20years%20old.&amp;text=60%2C000-120%2C000%20hospitalizations%20among%20adults%2065%20years%20and%20older.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Figure A</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="cm270_s1img02.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Products</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Arakoda (Tafenoquine) for malaria prevention</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
entered into a cooperative research and development agreement with the United States Army in 2014<SUP>46</SUP> to complete development
of Arakoda for prevention of malaria. With the U.S. Army, and other private sector entities as partners, we coordinated the execution
of two clinical trials, development of a full manufacturing package, gap-filling non-clinical studies, compilation of a full regulatory
dossier, successful defense of its program at an FDA advisory committee meeting, and submitted an NDA to the FDA in 2018. The history
of that collaboration has been publicly communicated by the U.S. Army.<SUP>47</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA and Australia&rsquo;s medicinal regulatory
agency, Therapeutic Goods Administration, subsequently approved Arakoda and Kodatef (brand name in Australia), respectively, for prevention
of malaria in travelers in 2018. Prescribing information and guidance for patients can be found at <I>www.arakoda.com</I>. The features
and benefits of Tafenoquine for malaria prophylaxis (marketed as Arakoda in the United States), some of which have been noted by third
party experts, include: convenient once weekly dosing following a three day load; the absence of reports of drug resistance during malaria
prophylaxis; activity against liver and blood stages of malaria as well as both the major malaria species (<I>Plasmodium vivax</I> and
<I>Plasmodium falciparum);</I> absence of any black-box safety warnings; good tolerability including in women and individuals with prior
psychiatric medical history, and a comparable adverse event rate to placebo with up to 12 months continuous dosing.<SUP>48</SUP> Tafenoquine
entered the commercial supply chains in the U.S. (as Arakoda) and Australia (as Kodatef) in the third quarter of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The only limitation of&nbsp;Arakoda&nbsp;is the requirement that a&nbsp;G6PD&nbsp;test
be administered to a prospective patient prior to administration of&nbsp;Arakoda in order to prevent the potential occurrence of hemolytic
anemia in individuals with G6PD deficiency.<SUP>49</SUP>&nbsp;The G6PD&nbsp;test must be administered to a prospective patient prior to
administration of&nbsp;Arakoda in order to prevent the potential occurrence of hemolytic anemia in individuals with G6PD deficiency.<SUP>50</SUP>&nbsp;Because&nbsp;G6PD&nbsp;is
one of the most common enzyme deficiencies and is implicated in hemolysis following administration/ingestion of a variety of oxidant drugs/food,
and must also be ruled out as a possible cause when diagnosing neonatal jaundice,&nbsp;G6PD&nbsp;testing is widely available in the United
States through commercial pathology service providers (e.g.,&nbsp;Labcorp, Quest Diagnostics,&nbsp;etc.). Although these tests have a
turn-around time of up to 72 hours, the test needs only to be administered once. Thus, existing U.S. testing infrastructure is sufficient
to support the FDA-approved use of the product (malaria prevention) by members of the armed forces (who automatically have a&nbsp;G6PD&nbsp;test
when they enlist), civilian travelers with a long planning horizon or repeat travelers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>46</SUP> In 2014, we signed a cooperative research and development
agreement with the United States Army Medical and Materiel Development Activity (Agreement W81XWH-14-0313). Under this agreement, we agreed
to submit a New Drug Application for Tafenoquine to the FDA (as Arakoda), while the US Army agreed to finance the bulk of the necessary
development activities in support of that goal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>47</SUP> Zottig et al Military Medicine 2020; 185 (S1): 687.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>48</SUP> Tan and Hwang Journal of Travel
Medicine, 2018, 1&ndash;2; Baird Journal of Travel Medicine 2018:, 1&ndash;13; Schlagenhauf et al Travel Medicine and Infectious Disease
2022; 46:102268; See Arakoda prescribing information at www.arakoda.com; McCarthy et al CID 2019:69:480-486; Dow et al. Malar J (2015)
14:473; Dow et al. Malaria Journal 2014, 13:49; Novitt-Moreno et al Travel Med Infect Dis 2022 Jan-Feb;45:102211.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>49</SUP> See prescribing information at www.arakoda.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>50</SUP> See prescribing information at www.arakoda.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Tafenoquine (Arakoda regimen) for COVID-19</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the COVID-19 pandemic, since our commercial
opportunities were limited, we embarked upon an exploratory research and development campaign to identify new indications for the Arakoda
dosing regimen of Tafenoquine.. In the second quarter and third quarter of 2020, we commissioned cell culture studies that showed that
Tafenoquine, the active ingredient in Arakoda, inhibited replication of SARS-CoV-2 (the virus that causes COVID-19).<SUP>51</SUP> Then,
we commissioned computer simulations, which showed that the predicted concentration of Tafenoquine in the lungs of COVID-19 patients following
administration of the first four doses of the approved antimalarial prophylactic regimen of Arakoda exceeded those inhibiting the virus
in cell culture. This provided the rationale for seeking approval from the FDA to conduct a Phase II clinical trial in patients with the
COVID-19 disease, for which the FDA granted clearance to proceed in October 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2021, with financial support from the US Army<SUP>52</SUP>,
we conducted a Phase II clinical investigation of the safety and efficacy of Tafenoquine using the Arakoda regimen in outpatients with
mild-moderate COVID-19 disease (assumed to be mostly caused by the delta variant of SARS-COV-2). In summary, safety and efficacy of Tafenoquine
administered at the approved dose for malaria prevention (200 mg dose once per day on days 1, 2, 3, and 10) was evaluated over a 28-day
period in mild-moderate COVID-19 patients. The primary endpoint was day 14 clinical recovery from COVID-19 symptoms, defined as cough
mild or absent, respiratory rate &lt; 24 bpm, and no shortness of breath or fever. From March 2021 through September 2021, this study
enrolled 87 of an originally planned 275 patients. In October 2021, a data safety monitoring board, after conducting a futility analysis
for the primary endpoint and reviewing adverse event data, recommended that the study be continued as planned. However, at the time of
the unblinding of this study, topline results from Phase III studies for three oral COVID-19 therapeutics in at risk patients with mild-moderate
COVID-19 disease had been announced: Fluvoxamine, molnupiravir, and paxlovid reduced the risk of hospitalization by approximately 30%,
50% (in the first public announcement) and 90%, respectively.<SUP>53</SUP> As reported in our publication<SUP>54</SUP>, an informal survey
of potential funding/commercialization partners for a follow-on program suggested it would be important to know the magnitude of possible
benefit prior to initiating such an effort. Primarily for the above reasons, the study was terminated and unblinded early.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
results of the study were accepted for peer-reviewed publication in May 2022.<SUP>56</SUP> For the primary endpoint, the proportion of
patients not recovered on Day 14 was numerically decreased by 27% in the intent to treat population (8/45 v 10/42 not recovered in the
Tafenoquine and placebo arms, <I>P</I> = 0.60) and 47% in the per protocol population (5/42 v 9/41, <I>P</I> = 0.25). Amongst individuals
who recorded responses in an electronic diary at Day 28, all Tafenoquine patients were recovered, whereas up to 12% of placebo patients
exhibited lingering shortness of breath. Analysis of secondary/exploratory endpoints suggested Arakoda reduced time to clinical recovery
from shortness of breath, cough and fever (<I>P</I> &lt; 0.02) and numerically improved aggregate symptom scores five days after treatment
(<I>P</I> &lt; 0.1).<SUP>57</SUP> The risk of COVID-19-related hospitalization was numerically reduced in the Arakoda arm (by approximately
50%; two instances for placebo versus one for Arakoda). Mild, drug related adverse events occurred in 8.4% of individuals in the Tafenoquine
arm (v 2.4% in the placebo). We plan to confirm that Arakoda accelerates sustained recovery from COVID-19 symptoms in our next study
(described in &ldquo;<I>Prospectus Summary&mdash;Strategy</I>&rdquo; beginning on page [*]).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>51</SUP> U.S. Patent application # 17/189,544, Dow et. al.bioRxiv&nbsp;2020.07.12.199059;&nbsp;doi:&nbsp;https://doi.org/10.1101/2020.07.12.199059.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>52</SUP> Financial support was obtained from Joint Program Executive
Office for Chemical, Biological, Radiological and Nuclear Defense (which may be referred to as &ldquo;JPEO&rdquo;) or JPEO via other transactional
authority agreement #W911QY-21-9-0011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>53</SUP> Reis et al Lancet Global Health 2022;10:e42-51, Bernal
et al New Eng J Med 2021; https://doi.org/10.1056/NEJMoa2116044; Pfizer Inc. Press release (November 5, 2021) &ndash; Pfizer&rsquo;s novel
COVID 19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of Phase 2/3 EPIC-HR study.
Accessible at: Pfizer&rsquo;s Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk of Hospitalization or Death by 89% in Interim
Analysis of Phase 2/3 EPIC-HR Study | Pfizer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>54</SUP> Dow and Smith, New Microbe and New Infect 2022; 47:100986.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>55</SUP> Dow and Smith, New Microbe and New Infect 2022; 47:100986.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>56</SUP> Dow and Smith, New Microbe and New Infect 2022; 47:100986.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2022, we conducted additional analyses of
laboratory endpoint data from the clinical study described above and are preparing a manuscript for publication. That analysis and the
scientific literature suggest two possible modes of action for Arakoda: (i) down-regulation of cytokines (immune system inflammatory
proteins) associated with severe COVID-19 and a greater risk of hospitalization or death and/or (ii) inhibition of viral entry in the
lung or elsewhere in the body, perhaps through inhibition of a host enzyme called TMPRSS2 (which facilitates entry of the virus that
causes COVID-19, SARS-CoV-2, into human cells).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming the efficacy of Tafenoquine in COVID-19
disease is proven in our next study, some of the features of the Arakoda regimen that make it ideal for malaria prophylaxis might also
make it very useful for COVID-19 related indications. Tafenoquine is slowly metabolized and has few important drug-drug interactions,
so it might be an ideal partner for standard of care oral COVID-19 therapeutics that reduce hospitalization but have no demonstrated effect
on the time to clinical recovery in non-hospitalized patients. The Arakoda regimen requires fewer tablets (8 in the first ten days versus
30 or 40 for paxlovid and molnupiravir) which should make compliance with medication easier for patients. This is an important consideration
in the attractiveness of a regimen in standard risk patients at lower risk of hospitalization, and who may be interested in taking a COVID-19
therapeutic primarily to treat early symptoms and accelerate recovery. The potential for better compliance may also suggest suitability
for outbreak control in some settings (including, for example, nursing homes).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Tafenoquine for other infectious diseases</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the pandemic, we also worked with NIH
to evaluate the utility of Tafenoquine as an antifungal. We, and the NIH, found that Tafenoquine exhibits a Broad Spectrum of Activity
in cell culture against <I>Candida</I> and other yeast strains via a different Mode of Action than traditional antifungals and also exhibits
antifungal activity against some fungal strains at clinically relevant doses in animal models.<SUP>53</SUP> Our work followed Legacy
Studies that show Tafenoquine is effective for treatment and prevention of <I>Pneumocystis</I> pneumonia in animal models.<SUP>54</SUP>
We believe that if added to the standard of care for anti-fungal and yeast infection treatments for general use, Tafenoquine has the
potential to improve patient outcomes in terms of recovery from yeast infections, and prevention of fungal pneumonias in immunosuppressed
patients. There are limited treatment options available for these indications, and Tafenoquine&rsquo;s novel mechanism of action might
also mitigate problems of resistance. Clinical trial(s) to prove safety and efficacy, and approval by the FDA and other regulators, would
be required before Tafenoquine could be marketed for these indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Tafenoquine is effective in animal models of babesiosis
(tick borne red blood cell infections). In two of three recent clinical case studies, Tafenoquine administered after failure of conventional
antibiotics in immunosuppressed babesiosis patients resulted in cures.<SUP>55</SUP> Consequently, we believe that (i) if combined with
standard of care products, Tafenoquine has the potential to reduce the duration of treatment with antibiotic therapy in immunosuppressed
patients and the time to parasite clearance in non-immunosuppressed patients and (ii) that once appropriate clinical studies have been
conducted, it is likely that Tafenoquine would be quickly embraced for post-exposure prophylaxis of babesiosis in patients with tick bites
and suspected of being co-infected with Lyme disease. Clinical trial(s) to prove safety and efficacy, and approval by FDA and other regulators,
would be required before Tafenoquine could be marketed for these indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Celgosivir</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Celgosivir is a host targeted glucosidase inhibitor
that was developed separately by other sponsors for HIV then for hepatitis C.<SUP>60</SUP> The sponsors abandoned Celgosivir after completion
of Phase II clinical trials involving 700+ patients, because other antivirals in development at the time had superior activity. The National
University of Singapore initiated development of Celgosivir independently for Dengue fever. A clinical study, conducted in Singapore,
and the results of which were accepted for publication in the peer-reviewed journal Lancet Infectious Diseases, confirmed its safety
but the observed reduction in viral load was lower than what the study was powered to detect.<SUP>61</SUP> Celgosivir (as with other
Dengue antivirals) exhibits greater capacity to cure Dengue infections in animal models when administered prior to symptom onset compared
to post-symptom onset. In animal models, this problem can be addressed for Celgosivir, by administering the same dose of drug split into
four doses per day rather than two doses per day (as was the case in the Singaporean clinical trial).<SUP>62</SUP> This observation led
to the filing and approval of a patent related to Dengue, which we licensed from the National University of Singapore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Additional clinical studies would be required to prove that such a
4x daily dosing regimen would be safe and effective in Dengue patients to regulators&rsquo; satisfaction. To that end, earlier in our
history, we, in partnership with the National University of Singapore, and Singapore General Hospital, successfully secured a grant from
the government of Singapore for a follow-on clinical trial, but were unable at that time to raise matching private sector funding. We
concluded as a result that development of Repositioned Molecules for Dengue, solely and without simultaneous development for other therapeutic
use, despite substantial morbidity and mortality in tropical countries, was an effort best suited for philanthropic entities. Accordingly,
during the pandemic, we undertook an effort (in partnership with NIH&rsquo;s Division of Microbiology and Infectious Diseases program
and Florida State University) to determine whether Celgosivir might be more broadly useful for respiratory diseases that have impact in
both tropical and temperate countries. Preliminary data suggest Celgosivir inhibits the replication of the virus that causes COVID-19
(SARS-CoV-2) in cell culture, and the RSV virus in cell culture and provides benefits in animals. We have filed and/or licensed patents
in relation to Celgosivir for these other viruses as we believe there is potential applications to fight respiratory diseases that might
have more commercial viability than historical development of Celgosivir to combat Dengue fever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>57</SUP> Dow and Smith, New Microbe and New Infect 2022; 45: 100964.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>58</SUP> Queener et al Journal of Infectious Diseases 1992;165:764-8).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>59</SUP> Liu et al. Antimicrobial Agents Chemo 2021;65:e00204-21,
Marcos et al. IDCases 2022;27:e01460; Rogers et al. Clin Infect Dis. 2022 Jun 10:ciac473.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>60</SUP> Sorbera et al, Drugs of the Future 2005; 30:545-552.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>61</SUP> Low et. al., Lancet ID 2014; 14:706-715.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>62</SUP> Watanabe et al, Antiviral Research 2016; 10:e19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Strategy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our general strategy is to demonstrate clinical
proof of concept that the FDA-approved Arakoda regimen of Tafenoquine provides clinical benefits in non-malaria therapeutic areas. Our
initial focus is on COVID-19, but additional indications have been identified for development, namely babesiosis and fungal infections,
pending further data generation. Upon demonstration of clinical proof of concept, we plan to enter into a strategic partnership with a
larger entity with commercialization capacity, or raise additional capital to facilitate commercialization of Arakoda, and any additional
clinical studies that may be required by regulators, for both travel medicine and broad infectious disease indications. We will continue
to develop our portfolio products as resources permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Beginning in the second half of 2023, we plan
to execute a Phase IIB, randomized, placebo-controlled double blind clinical study powered (at 80%) to prove that the Arakoda regime
of Tafenoquine accelerates time to sustained clinical recovery in patients with mild-moderate disease with low risk for disease progression.
This trial will utilize the bulk of proceeds raised in this offering. Based on an analysis of unpublished data from our earlier COVID-19
clinical trial,<SUP>63</SUP> we believe that the Arakoda regimen of Tafenoquine has the potential to reduce the time to sustained clinical
recovery by about three days (see Figure B, below). The study will be conducted in out-patient clinics in the United States. The study
will utilize the majority of the proceeds of the offering reserved for research and development activities for this purpose. As of the
date of this prospectus, we have completed a clinical study synopsis. Submission of the full protocol to the Ethics Committees and to
U.S. regulators, and a subsequent posting at <I>clinicaltrials.gov</I> will follow this initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Figure
B</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="cm270_s1img04.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Figure B: Survival curve for sustained clinical
recovery in outpatients with mild-moderate COVID-19 disease randomized to receive Tafenoquine (Arakoda regimen) or placebo. Sustained
clinical recovery was defined as the first instance of patient reported symptoms scores being &lt; 3 for four or more days, with symptoms
scores assessed according to FDA guidance<SUP>64</SUP>. This analysis utilized unpublished data from our earlier Phase II clinical trial<SUP>65</SUP>.
The analysis excludes individuals hospitalized or loss to follow-up and with a symptom score on the days of dosing &lt; 3. This analysis
represents a post-hoc analysis of our Phase II clinical trial data. If this were a formal, pre-conceived primary study endpoint, the <I>P</I>
value of 0.1209 would imply the associated difference between Tafenoquine (Arakoda regimen) and placebo has a 12.09% chance of occurring
by chance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to design the study, subject to approval by the FDA and Ethics
Committee(s) as appropriate, to include two interim endpoints to manage risk. The first will be an optional futility analysis at the earlier
of 33% enrollment or six months following the first patient enrolled, which would allow early termination of the study if the conditional
power of proving the intended hypothesis is &lt; 20%. The second, mandatory interim analysis will occur at 75% enrollment and follow a
step-wise (sponsor-blinded) process involving testing for futility, statistical significance, and sample-size reassessment if required.
The test for statistical significance would allow early termination of the study if results are unexpectedly positive and the sample size
reassessment would allow the study to enroll more patients within pre-specified limits if variability is more, and/or the magnitude of
the expected treatment effect is less, than expected.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We plan to conduct additional non-clinical studies to clarify the process
by which Tafenoquine alters the course of COVID-19 illness. Specifically, such studies will attempt to determine whether Tafenoquine acts
as an immunomodulator (by decreasing the production of immune system molecules that cause inflammation) and/or exhibits an antiviral effect
via inhibition of the host protease TMPRSS2. Antivirals are generally utilized earlier, and immunomodulators later, in treating patients
infected with COVID-19. However, the clinical hypothesis of our planned study will be that Arakoda accelerates clinical recovery by three
days in individuals who have experienced symptoms for fewer than seven days, thereby confirming observations from our earlier clinical
study (see Figure B). Since the potential clinical benefit is already known, the primary purpose of clarifying the manner in which Arakoda
works is to (i) address anticipated regulatory questions and (ii) ascertain whether other indications, such as relief of COVID-19 symptoms
during vaccination, treatment of long COVID-19 patients, or use during hospitalization, might be plausible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following completion of our planned COVID-19 clinical
study, if warranted based on the data generated, we intend to request a change in prescribing information to facilitate an expansion of
use of Arakoda for malaria prevention from six to twelve months (mirroring our recently published post-marketing safety study) and to
include reference to the recently generated COVID-19 treatment data. Prior to doing so, we plan to discuss with the FDA additional labeling
related to COVID-19 which might be acceptable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to design and conduct feasibility assessments
for one or more additional studies in the same type of patients as the planned study and/or for a COVID 19-related indication different
from that targeted by our clinical study in 2023. One of these additional studies would be conducted in Australia, and would be a requirement
to secure tax rebates for the overall COVID-19 program (see next paragraph). A second study is likely to be required by regulators which
may or may not be the same as the study conducted in Australia. The value of conducting additional studies, in addition to securing tax
credits or for regulatory approvals, would be (i) independently confirming the therapeutic modality/clinical mode of action of Arakoda
(i.e. that it accelerates clinical recovery from COVID-19 symptoms and/or acts as an antiviral or disease modulator) and (ii) broadening
the COVID-19 indication beyond treatment of lower risk patients (i.e. potentially increasing the volume of annual prescriptions). Thus,
possible study designs could be (i) a simple repetition of the planned study with a larger sample size, (ii) a treatment study in higher
risk patients or (iii) a pre-treatment loading study in individuals known to be exposed to the virus that causes COVID-19, and/or (iv)
amelioration of COVID-19 disease-like symptoms in individuals receiving mRNA COVID-19 vaccines (if it turns out Arakoda is an immunomodulator).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to license ex-U.S. rights to COVID-19
indications to our Australian subsidiary, 60P Australia Pty Ltd. This will facilitate claiming the Australian government&rsquo;s research
tax credit for any of our COVID-19-related research activities conducted in Australia. 60P Australia has been successful in securing research
tax credits for malaria and Dengue-related research since 2013. Since conducting our planned COVID-19 study in Australia unlikely to be
feasible (which at the time of writing we believe to be the case) and must be conducted in the U.S., we plan to apply for an overseas
finding to the Australian Tax Office in Q1 2023 to request an overseas finding for the U.S. study. Should such a finding be awarded, it
would allow a tax rebate of 43.5% on research and development costs associated with the planned U.S. COVID-19 study to be claimed, but
commit the Company to conduct COVID-19 research activities in Australia of a value at least as much as the cost of the planned U.S. clinical
study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">We are planning several commercial initiatives for the malaria market
in parallel with further clinical development activities. Three routes exist for commercialization of Arakoda for the malaria prevention
market are: (i) U.S. civilian travel clinics, travel prescribing centers, and large private sector entities with employees deployed overseas
(e.g., mining companies), (ii) the prospect of additional DoD and government agency procurement in the future (noting that as described
on page [*] our existing contract with DoD has been fulfilled and has not been extended or modified) and (iii) ex U.S. sales strategy
where we currently (or in the future) have exclusive distribution arrangements in overseas markets.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of the date of this prospectus, we did not have plans to hire a U.S. field sales force, but may explore possible commercial arrangements
with contract sales organizations to target U.S. travel clinics for malaria prophylaxis. We will also closely monitor changes in market
share in Australia where Kodatef will be actively marketed in 2023 by the local distributor, and a point of care G6PD test is approved.
We may request that the DoD Uniform Formulary re-evaluate the formulary position of Arakoda following our recent adjustment of the U.S.
WAC pricing to reflect expected international pricing. For US government agencies such as the DoD, the product is expected to meet many
of the requirements for occupational malaria prevention identified by the independent parties that have endorsed the product, but they
are price sensitive. In the third quarter of 2022, we made our first sale to our European distributor, and made additional sales to our
Australian distributor in the second quarter of 2022. We intend to execute a contract with a distribution partner to facilitate named-patient
sales in jurisdictions outside Australia, Europe, and the United States. We plan to undertake a focused marketing campaign for Arakoda
for malaria prevention in the second half of 2023, consisting of promotion at relevant conferences, email promotion to prescribers, and
target print and electronic advertisements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>63</SUP> Dow and Smith, New Microbe and New Infect 2022; 45: 100964.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>64</SUP> <I>FDA 2020 Guidance on Assessing COVID-19 Symptoms</I>-14
Common COVID-19 Symptoms Severity Scale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>65</SUP> Dow and Smith, New Microbe and New Infect 2022; 45: 100964.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">It
is expected that a point of care G6PD test might be required to maximize the economic potential of a COVID-19 indication for Tafenoquine
(regardless of regimen). We do not intend to pursue independent development of such a test as there are well resourced development efforts
already underway or already approved by the FDA (see &ldquo;<I>Risk Factors&mdash;Any future clinical trial for Arakoda will require
screening for G6PD deficiency in order to safely administer the product. In the United States, G6PD testing can obtained through commercial
pathology services which is associated with delays. The use of a third-party diagnostic provider of point of care testing may be required
and we may not directly control the timing, conduct and expense of such testing</I>&rdquo; beginning on page [*]). However, we will continue
to monitor the progress of development and U.S. commercialization of G6PD tests. We will seek to pursue collaborative commercial partnerships
with the companies involved in commercialization efforts, if such activities can be conducted through resource sharing efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We plan to generate additional validation data
for our portfolio products if resources permit. Specifically, we will evaluate whether Celgosivir provides therapeutic benefit in a COVID-19
animal model, and complete critical activities related to confirming GMP process feasibility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may elect, as resources permit, to undertake
a clinical study of Tafenoquine in combination with standard of care for hospitalized patients with babesiosis. We have developed such
a protocol in partnership with academic collaborators and are planning to submit an IND to the FDA and pursue public and philanthropic
funding to support our execution. We plan to seek public funding to support additional non-clinical studies to validate the mechanism
of action of Tafenoquine against <I>Candida spp</I>. and further assess our utility in combination with standard of care agents in cell
culture and animal studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Most
new antimalarial treatment products are developed as drug combinations to proactively combat drug resistance. Tafenoquine, due to its
long half-life and activity against all parasite species and strains, would be ideal partner in a drug combination. In the second half
of 2023, we will actively seek out a potential partner antimalarial drug for Arakoda, with the goal of pursuing licensure of a new drug
combination. We will only enter into a partnership to develop such a drug combination, if clear legal guidance can be obtained that such
a combination if developed would have a high probability of securing a priority review voucher upon FDA approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are currently efforts underway, in malaria-endemic
countries outside the U.S., to generate datasets supporting the use of Tafenoquine for mass drug administration in asymptomatic individuals
to prevent malaria transmission. We believe that such efforts are important to promote community acceptance of Tafenoquine, and may eventually
support World Health Organization pre-qualification of Tafenoquine for malaria eradication efforts. To that end, we intend to support,
on a case-by-case basis, clinical studies sponsored by others, by providing commercial Arakoda and/or Kodatef for research use (provided
such product would not otherwise have been commercially salable, and the study sponsor covers shipping costs). We have previously provided
Tafenoquine for such efforts on a limited basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have a post-marketing requirement to conduct
a malaria prophylaxis study of Arakoda in pediatric and adolescent subjects. We proposed to the FDA, in late 2021, that this might not
be safe to execute given that malaria prevention is administered to asymptomatic individuals and that methemoglobinemia (damage to the
hemoglobin in blood that carries oxygen) occurred in 5% of patients, and exceeded a level of 10% in 3% of individuals in a study conducted
by another sponsor in pediatric subjects with symptomatic vivax malaria.<SUP>66</SUP> The FDA has asked us to propose an alternate design,
for which we submitted a concept protocol in the fourth quarter of 2022, and plan to submit a full protocol by the end of the second
quarter of 2023. We estimate the cost of conducting the study proposed by the FDA, if conducted in the manner suggested by the FDA, would
be $2 million and due to the time periods required to secure protocol approvals from the FDA and Ethics Committees, could not be initiated
any earlier than the third quarter of 2024. The funds from this offering to be expended on such a pediatric study will be limited to
the minimum required to support protocol preparation and regulatory interactions with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competitors and Competitive Advantage</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Arakoda is approved by the FDA for malaria prevention
in travelers. The major (but not only) competing products are generic atovaquone-proguanil and doxycycline &ndash; these products have
the benefit of being well established, not requiring a G6PD screen prior to travel (as is the case for Arakoda) and in the case of atovaquone-proguanil
being generally recognized as well tolerated and safe. The major limitations of these two established products are the requirement for
daily dosing including for up to 30 days post-travel in the case of doxycycline, the requirement to also take Primaquine (a medication
used to treat and prevent malaria) for post-exposure prophylaxis to prevent relapse from <I>P. vivax </I>malaria, and the potential inconvenience
for many patients of complying with a daily dosing regimen during travel. Doxycycline has the added disadvantages of a higher risk of
vaginitis, sunburn following sun exposure, contraction of malaria due to missed daily doses, and esophageal necrosis. Drug resistance
against the individual components of the atovaquone-proguanil is prevalent in some regions of the work, and the higher doses of atovaquone-proguanil
used to treat malaria, are no longer effective in some parts of Southeast Asia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>66</SUP> Velez et al 2021 - Lancet Child Adolesc Health 2022;
6: 86&ndash;95.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Arakoda has the benefit of a convenient weekly dosing
regimen following a three-day loading dose and a single day of dosing for post-exposure prophylaxis upon return from travel. It is effective
against all species of malaria everywhere in the world, which simplifies prescribing decisions. It is the only FDA-approved antimalarial
other than mefloquine with a safety profile demonstrated based on continuous dosing for 12 months, but unlike that product, it does not
have a black-box safety warning. While G6PD testing is a potential limitation for first time travelers with short planning horizons,
this is not the case for institutional occupation travel or repeat business travel, because a G6PD test need only be performed once and
can be captured in electronic health records. G6PD testing is routinely available in the United States through commercial laboratory
pathology services. Over time, Arakoda is expected to capture a significant share of the antimalarial prophylaxis market as a consequence
of these advantages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are targeting additional indications for the Arakoda regimen of Tafenoquine, of which the priority is treatment of COVID-19 in ambulatory
patients. The main competitor products for this indication are molnupiravir and paxlovid, which have been granted emergency use authorization,
and likely full marketing authorization in the future to lower the risk of hospitalization and death, principally in high-risk patients.
However, neither of these products have been shown to reduce the time to sustained clinical recovery in non-hospitalized standard risk
patients. We are targeting this therapeutic niche with the Arakoda regimen of Tafenoquine, for which we will attempt to confirm clinical
benefit in a clinical study in the second half of 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are co-owners, with the U.S. Army, of
patents in the United States and certain foreign jurisdictions directed toward use of Tafenoquine for malaria and have obtained an
exclusive worldwide license from the U.S. Army to practice these inventions. We also have an exclusive worldwide license to use
manufacturing information and non-clinical and clinical data that the U.S. Army possesses relating to use of Tafenoquine for all
therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. We have submitted patent applications in the
United States and certain foreign jurisdictions for use of Tafenoquine for COVID-19, fungal lung infections, tick-borne diseases,
and other infectious and non-infectious diseases in which induction of host cytokines/inflammation is a component of the disease
process. The United States Patent and Trademark Office (&ldquo;USPTO&rdquo;) recently allowed our first COVID-19 patent for
Tafenoquine. We have optioned or licensed patents involving Celgosivir for the treatment and prevention of Dengue (from the National
University of Singapore), COVID-19 &amp; Zika (Florida State University), and have submitted provisional patent applications related
to Celgosivir for RSV. We have optioned or own manufacturing methods related to Celgosivir. A detailed list of our intellectual
property is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Patents</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 31%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Patent No.</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>US Patent Date</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Application No.</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Estimated/<BR>
Anticipated<BR>
Expiration<BR>
Date</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dosing Regimen For Use Of Celgosivir As An Antiviral Therapeutic For Dengue Virus Infections</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2013203400</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2013203400<SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10-April-2033*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2014228035</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2014228035</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">MY-170991-A</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Malaysia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">PI2015002372</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">378015</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Mexico</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">MX/a/2015/013115</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">11201507254V</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">11201507254V</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10201908089V</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">9763921</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">9/19/2017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14/772,873</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">10517854</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">12/31/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">15/706,845</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dosing Regimens Of Celgosivir For The Treatment Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">11219616</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">1/11/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">16/725,387</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">14-Mar-2034<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2015358566</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2015358566</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2968694</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">10342791</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">7/9/2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">15/532,280</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Naive Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">10888558</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">1/12/2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">16/504,533</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10201904908Q</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">EP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">15865264.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Hong Kong</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">18103081.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Naive Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/145,530</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Regimens Of Tafenoquine For Prevention Of Malaria In Malaria-Na&iuml;ve Subjects</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">New Zealand</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">731813</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Dec-2035*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Prevention Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2016368580</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2016368580</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">09-Dec-2036*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Novel Dosing Regimens Of Celgosivir For The Prevention Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10201912141Y</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">09-Dec-2036*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Dosing Regimens Of Celgosivir For The Prevention Of Dengue</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">11000516</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;5/11/2011</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">16/060,945</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">09-Dec-2036<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">EP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">21764438.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;202180029643.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2021231743</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections Caused By Gram-Positive Bacteria, Fungus, Or Virus By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/189,544</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections Caused By Fungus By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/683,679</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Lung Infections Caused By Sars-Cov-2 Virus By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/683,718</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">02-Mar-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Human Coronavirus Infections Using Alpha-Glucosidase Glycoprotein Processing Inhibtors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">11369592</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;6/28/2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/180,140<B><SUP>#</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">19-Feb-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Human Coronavirus Infections Using Alpha-Glucosidase Glycoprotein Processing Inhibtors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">17/664,693<B><SUP>#</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">19-Feb-2041<B>^</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Human Coronavirus Infections Using Alpha-Glucosidase Glycoprotein Processing Inhibtors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">EP</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Pending</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2021757552<B><SUP>#</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">19-Feb-2041*</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Non-Viral Tick-Borne Diseases And Symptoms Thereof</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional </I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">63/337,366</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">~02-May-2043<B><SUP>&amp;</SUP></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Methods To Treat Respiratory Infection Utilizing Castanospermine Analogs</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">63/358,341</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">~05-Jul-2043<B><SUP>&amp;</SUP></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Methods For The Treatment And Prevention Of Diseases Or Infections With Mcp-1 Involvement By Administration Of Tafenoquine</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt"><I>Provisional</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">63/411,654</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">~30-Sep-2043<B><SUP>&amp;</SUP></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Zika Virus Infections Using Alpha Glucosidase Inhibitors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10,328,061<SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;6-25-2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt; background-color: white">15/584,952</FONT><FONT STYLE="font-size: 10pt"><SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2-May-37</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Treatment Of Zika Virus Infections Using Alpha Glucosidase Inhibitors</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">10,561,642<SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">&nbsp;2-18-2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">15/856,377<SUP>+</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">2-May-37</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">=  For foreign patents and applications,
the estimated and/or anticipated patent expiration is the date that is twenty years from the PCT filing date. For all issued Australian
patents, this estimated date was also confirmed through the Australian patent office web database.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B>^</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>= </B> For issued U.S. patents,
the estimated patent expiration was calculated using information from the front cover of the patent, <I>i.e.</I>, 20 years from the date
of the nonprovisional filing plus any listed Patent Term Adjustment less any time disclaimed through a Terminal Disclaimer. For pending
U.S. applications, the anticipated patent expiration is the date twenty years from the earliest nonprovisional filing date and does not
account for possible Patent Term Adjustment (PTA), Patent Term Extension (PTE), or Terminal Disclaimers.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B><SUP>&amp;</SUP></B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">=  For U.S. provisional applications
that are not yet the subject of a nonprovisional or PCT application, the anticipated patent expiration was determined using the assumption
that a non-provisional application or PCT will be filed one year after filing the provisional application with a term lasting twenty
years from the date of that nonprovisional or PCT filing. This does not account for possible Patent Term Adjustment (PTA), Patent Term
Extension (PTE), or Terminal Disclaimers.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B><SUP>+</SUP></B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>= </B> 60 Degrees Pharmaceuticals,
Inc. is not a listed Applicant and Geoffrey S. Dow, Ph.D. is not a listed inventor.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt"><B><SUP>#</SUP></B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">=  60 Degrees Pharmaceuticals,
Inc. is not a listed Applicant, but Geoffrey S. Dow, Ph.D. is a listed inventor.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All patents not designated with a &ldquo;+&rdquo;
list Geoffrey S. Dow, Ph.D. as an inventor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All patents not designated with a &ldquo;+&rdquo;
or a &ldquo;#&rdquo; list 60 Degrees Pharmaceuticals, Inc. as an applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All estimated patent expiration dates and anticipated
patent expiration assume payment of any maintenance/annuity fees during the patent term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Trademarks</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 8pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 19%; border-bottom: black 1pt solid; padding: 1.5pt"><FONT STYLE="font-size: 10pt"><B>COUNTRY</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>MARK</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>STATUS</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>APPLICATION NUMBER</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>DATE FILED</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>REGISTRATION DATE</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>REGISTRATION NUMBER</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>BIR REF NUMBER</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>DUE DATE</B></FONT></TD>
    <TD STYLE="width: 1%; padding: 1.5pt 1.5pt 1pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>DUE DATE DESCRIPTION</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1774631</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">6/2/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1774631</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000029</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1785098</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">11/26/2019</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">TMA1,064,371</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000028</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>26-Nov-29</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">ARAKODA</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1899317</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">15-May-18</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">8/20/2020</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">TMA1,081,180</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000053</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>20-Aug-30</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">China</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">20842242</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2-Aug-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/28/2017</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">20842242</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000035</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>27-Sep-27</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">European Union</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">15508872</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">3-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/21/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">15508872</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000034</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>3-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">European Union</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">ARAKODA</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">17900852</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">16-May-18</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/20/2018</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">17900852</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000054</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>16-May-28</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">285476</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">6-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">6/6/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">285476</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000033</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>6-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">New Zealand</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1044407</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">7-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">12/8/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">1044407</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000031</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>6-May-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Russian Federation</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2016720181</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">6-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">7/10/2017</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">623174</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000032</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>6-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">Singapore</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">40201707950V</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">2-May-17</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">11/8/2017</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">40201707950V</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000040</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>2-May-27</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United Kingdom</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">ARAKODA</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">17900852</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">16-May-18</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/20/2018</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">UK00917900852</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000054</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>16-May-28</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United Kingdom</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">15508872</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">3-Jun-16</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/21/2016</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">UK009015508872</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000072</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>3-Jun-26</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Renewal Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United States of America</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">TQ 100 &amp; TABLET DESIGN</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">87608493</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">14-Sep-17</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">9/11/2018</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">5562900</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000037</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>11-Sep-24</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Section 8 &amp; 15 Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United States of America</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">ARAKODA</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">87688137</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">16-Nov-17</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">12/31/2019</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">5950691</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000050</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>31-Dec-25</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Section 8 &amp; 15 Due</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding: 1.5pt"><FONT STYLE="font-size: 10pt">United States of America</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">KODATEF</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">Allowed - &nbsp;02/16/2021</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">90072885</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">24-Jul-20</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt">0081716-000069</FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>16-Aug-23</B></FONT></TD>
    <TD STYLE="padding: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding: 1.5pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Statement of Use/3rd Extension of Time Due</B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key
Relationships &amp; Licenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30, 2014, we entered into the Exclusive License Agreement (the &ldquo;2014 NUS-SHS Agreement&rdquo;) with National University of
Singapore (&ldquo;NUS&rdquo;) and Singapore Health Services Pte Ltd (&ldquo;SHS&rdquo;) in which we were granted a license from NUS and
SHS with respect to their share of patent rights regarding &ldquo;<FONT STYLE="color: #272727">Dosing Regimen for Use of Celgosivir as
an Antiviral Therapeutic for Dengue Virus Infection</FONT>&rdquo; to develop, market and sell licensed products. The 2014 NUS-SHS Agreement
continues in force until the expiration of the last to expire of any patents under the patent rights unless terminated earlier in accordance
with the 2014 NUS-SHS Agreement. We are obligated to pay at the rate of 1.5% of gross sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 15, 2015, we entered into the Exclusive License
Agreement with the U.S. Army Medical Materiel Development Activity (the &ldquo;U.S. Army&rdquo;), which was subsequently amended (the
&ldquo;U.S. Army Agreement&rdquo;), in which we obtained a license to develop and commercialize the licensed technology with respect
to all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. This exclusion does not impact our ability
to market Arakoda for the FDA-approved use, which is the prevention of malaria utilizing the indicated dose in asymptomatic individuals
traveling to malarious areas (whereas the license exclusion relates to its use to treat symptomatic vivax malaria in a patient already
presenting with that disease). The term of the U.S. Army Agreement will continue until the expiration of the last to expire of the patent
application or valid claim of the licensed technology, or 20 years from the start date of the U.S. Army Agreement, unless terminated
earlier by the parties. We will be required to make a minimum annual royalty payment of 3% of net sales for net sales &lt; $35 million,
and 5% of net sales greater than $35 million, with US government sales excluded from the definition of net sales. In addition, we must
pay a milestone fee of $75,000 once cumulative net sales from all sources exceeds $6 million, $100,000 if the company is acquired or
merges, and regulatory approval milestone payments once marketing authorizations are achieved in Canada ($5,000) and Europe ($5,000).
Also, we will be required to obtain the U.S. Army Medical Materiel Development Activity&rsquo;s consent prior to a change of control
of the Company, which consent was obtained on September 2, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2016, we entered into the Exclusive License Agreement (the &ldquo;2016 NUS-SHS Agreement&rdquo;) with National University
of Singapore (&ldquo;NUS&rdquo;) and Singapore Health Services Pte Ltd (&ldquo;SHS&rdquo;) in which we were granted a license from NUS
and SHS with respect to their share of patent rights regarding &ldquo;<FONT STYLE="color: #272727">Novel Dosing Regimens of Celgosivir
for The Prevention of Dengue</FONT>&rdquo; to develop, market and sell licensed products. The 2016 NUS-SHS Agreement continues in force
until the expiration of the last to expire of any patents under the patent rights unless terminated earlier in accordance with the 2016
NUS-SHS Agreement. We are obligated to pay at the rate of 1.5% of gross sales or minimum annual royalty ($5,000 in 2022 and $15,000 in
2023). In July 2022, the Company renegotiated the timing of a license fee of $85,000 Singapore Dollars, payable to the National University
of Singapore, such that payment would be due at the earlier of (i) enrollment of a patient in a Phase II clinical trial involving Celgosivir,
(ii) two years from the agreement date and (iii) an initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 4, 2020, we entered into the Other Transaction Authority
for Prototype Agreement (&ldquo;OTAP Agreement&rdquo;) with the Natick Contracting Division of the U.S. government in which we will, among
other things, conduct activities for a Phase II clinical trial to assess the safety and efficacy of Tafenoquine for the treatment of mild
to moderate COVID-19 disease, with the goal of delivering Tafenoquine with an FDA Emergency Use Authorization (&ldquo;EUA&rdquo;) approved
as a countermeasure against COVID-19. The total amount of the OTAP Agreement is $4,999,814. The term of the OTAP Agreement commences on
December 4, 2020 and was completed in the third quarter of 2022. The U.S. government may terminate the OTAP Agreement for any or no reason
by providing us with at least thirty (30) calendar days&rsquo; prior written notice. Pursuant to the OTAP Agreement, we will not offer,
sell or otherwise provide the EUA or licensed version of the prototype (Tafenoquine) that is FDA approved for COVID-19 or any like product
to any entity at a price lower than that offered to the DoD, which applies only to products sold in the U.S., European Union and Canada
related to COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 15, 2021, we entered into the Inter-Institutional
Agreement (the &ldquo;FSURF Agreement&rdquo;) with the Florida State University Research Foundation (&ldquo;FSURF&rdquo;) in which FUSRF
granted us the right to manage the licensing of intellectual property created at FSURF. The term of the FSURF Agreement expires five years
from February 15, 2021. After deduction of a 5% administrative fee by FSURF, capped at $15,000 annually, and reimbursement of patent prosecution
expenses, we will receive 20% of license income and FSURF will receive 80% of license income. Payments of license income shall be paid
in U.S. dollars quarterly each year. On February 19, 2021, we entered into an agreement with FSURF, subsequently amended on February 15,
2023, that collectively granted an option, effective through August 19, 2023, to us to license methods for purifying castanospermine and
its use for the treatment of COVID-19. On August 19, 2021, we entered into an agreement with FSURF, subsequently amended on February 15,
2023, that collectively granted an option, effective through August 19, 2023, to us to license a patent relating to the use of alpha glucosidase
inhibitors (including castanospermine and celgosivir) for treatment of Zika infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Knight Debt Conversion Agreement, for a period commencing on January 1, 2022 and ending upon
the earlier of ten years after the closing date of this offering or the conversion or redemption in full of all of the shares of Series
A Preferred Stock owned by Knight, we will pay Knight a royalty equal to 3.5% of our net sales, where &ldquo;net sales&rdquo; has the
same meaning as in our license agreement with the U.S. Army for Tafenoquine.&nbsp;Upon succeeding with the qualified IPO, at the end of
the quarter and each thereafter the royalty will be calculated, and payment will be made within fifteen days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Sales and Marketing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the remainder of 2023, we are committed to ensuring continuity of supply of Arakoda in the U.S. market for malaria prevention. As resources
permit, we will undertake a limited marketing campaign for Arakoda for malaria prevention in the second half of 2023. This effort would
consist of promotions at relevant conferences, email promotions to prescribers, targeted print and electronic advertisements, and outreach
via social media as appropriate. The focus of promotional efforts would be on the proven features and benefits of Arakoda, and the recent
publication demonstrating the good safety and tolerability of Arakoda for continuous weekly dosing for up to one year.<SUP>67</SUP></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><SUP></SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will be closely monitoring market share growth of Kodatef in Australia in 2023. Unlike Arakoda in the U.S., the Australian product will
be actively marketed by a sales team to travel clinics, and the same distributor is also the licensor for the SD Biosensor point of care
G6PD test (which is TGA approved). Comparison of Australian to U.S. civilian sales sector growth (the latter of which will be unsupported
by sales staff and a marketed point of care G6PD test) over the same period will inform the design of any future commercialization plan
for the malaria indication that we may wish to undertake.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective January 1, 2023, we have lowered the Arakoda WAC price to
$235 USD per 16 x 100 mg tablet box. Although international pricing is independently set by our foreign distributors, we believe that
the revised U.S. pricing will be similar relative to competitor products as it is elsewhere. Following this price adjustment, we will
attempt to improve the position of Arakoda in the DoD formulary through engagement of a consulting firm with appropriate contacts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also plan to enter into contract sales agreements with a(n) appropriate organization(s) to further (i) ex U.S. named patient use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Manufacturing </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not currently own or operate manufacturing
facilities for the production of clinical or commercial quantities of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Australian Research Tax Credit and Overseas Finding Process</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under Section 27 of the Industry Research and Development Act 1986<SUP>68</SUP>,
the Australian government offers a research tax credit of 43.5% on registered research and development activities executed in Australia
by eligible Australian domiciled entities. Companies are eligible to receive tax credits if they meet the following criteria: (i) are
domiciled in Australia, (ii) have incurred at least $20,000 in eligible research and development expenses, (iii) have conducted at least
one eligible research and development activity, (iv) beneficial owner(s) with &gt; 40 % beneficial ownership when considered together
do not have &gt; $20 million AUD aggregated turnover on an annual basis. 60P Australia Pty Ltd meets all these criteria, and will continue
to do so following this offering unless our aggregate turnover, considered together with any of our shareholders who have &gt; 40% beneficial
ownership, have &gt; $20 million AUD in aggregate annual turnover.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under Section 28D of the Industry Research and
Development Act 1986<SUP>69</SUP>, research and development activities conducted outside Australia are also potentially eligible if they
meet the following criteria: (i) they are approved in advance, (ii) they are linked to a core research and development activity conducted
in Australia, (iii) cannot be conducted in Australia for various reasons and (iv) the value of activities conducted overseas is less
than the value of activities conducted in Australia. These criteria would be met for the planned COVID-19 study if a population of suitable
patients could not be found in Australia, and we conduct research activities linked to the COVID-19 study in Australia in the future
which are greater in value than the cost of the planned COVID-19 clinical study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Government Regulation and Product Approvals </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Government authorities in the United States, at the
federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other
things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising,
promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes
for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with
applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>67</SUP> Novitt-Moreno et al. TMAID 2022;
45:102211.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>68</SUP> See Industry Research and Development
Act 1986 (legislation.gov.au).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>69</SUP> See Australian Government R&amp;D Tax Incentive &ndash;
Overseas R&amp;D: Information Sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Review and Approval of Drugs in the United States </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the United States, the FDA regulates, among
other things, the research, development, testing, manufacturing, approval, labeling, storage, recordkeeping, advertising, promotion and
marketing, distribution, post approval monitoring and reporting and import and export of drugs in the U.S. to assure the safety and effectiveness
of medical products for their intended use under the Federal Food, Drug, and Cosmetic Act (&ldquo;FDCA&rdquo;), and implementing regulations.
The failure to comply with applicable U.S. requirements at any time during the product development process, approval process or after
approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to
approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of
letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of
government contracts, denial of the ability to import and export certain products, restitution, disgorgement of profits, or civil or
criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An applicant seeking approval to market and distribute
a new drug product in the United States must typically undertake the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">completion
                                            of preclinical laboratory tests, animal studies and formulation studies in compliance with
                                            the FDA&rsquo;s good laboratory practice regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">submission
                                            to the FDA of an IND, which must take effect before human clinical trials may begin;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">approval
                                            by an independent institutional review board representing each clinical site before each
                                            clinical trial may be initiated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">performance
                                            of adequate and well-controlled human clinical trials in accordance with good clinical practices
                                            to establish the safety and efficacy of the proposed drug product for each indication;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">preparation
                                            and submission to the FDA of a new drug application;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">review
                                            of the product by an FDA advisory committee, where appropriate or if applicable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">satisfactory
                                            completion of one or more FDA inspections of the manufacturing facility or facilities at
                                            which the product, or components thereof, are produced to assess compliance with cGMP, requirements
                                            and to assure that the facilities, methods and controls are adequate to preserve the product&rsquo;s
                                            identity, strength, quality and purity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">satisfactory
                                            completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity
                                            of the clinical data;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">payment
                                            of user fees and securing FDA approval of the NDA; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">compliance
                                            with any post-approval requirements, including Risk Evaluation and Mitigation Strategies
                                            and post-approval studies required by the FDA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Preclinical Studies </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical studies include laboratory evaluation
of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient and the formulated drug or drug product,
as well as <I>in vitro</I> and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish
a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP
regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data
or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical
testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Companies usually must complete some long-term
preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and must also develop additional information
about the chemistry and physical characteristics of the investigational product and finalize a process for manufacturing the product
in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality
batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality
and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted
to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The IND and IRB Processes </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An IND is an exemption from the FDCA that allows
an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization
to administer an investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of
any new drug that is not the subject of an approved NDA. In support of a request for an IND, applicants must submit a protocol for each
clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the
preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for
clinical trials, among other things, are submitted to the FDA as part of an IND. The FDA requires a 30-day waiting period after the filing
of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether
human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, the FDA may raise concerns
or questions about the conduct of the trials as outlined in the IND and impose a clinical hold. In this case, the IND sponsor and the
FDA must resolve any outstanding concerns before clinical trials can begin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following commencement of a clinical trial under
an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA
to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay
or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not
allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold,
the FDA will provide the sponsor a written explanation of the basis for the hold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following issuance of a clinical hold or partial
clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will
base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the
FDA that the investigation can proceed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A sponsor may choose, but is not required, to
conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must
be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies
with certain FDA requirements in order to use the study as support for an IND or application for marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the IND requirements, an IRB representing
each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that
institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among
other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance
with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents,
if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements or if the product candidate has been associated
with unexpected serious harm to patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, some trials are overseen by an
independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group
provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains
to available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined
that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be
made by us based on evolving business objectives and/or competitive climate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information about certain clinical trials must
be submitted within specific timeframes to the National Institutes of Health, for public dissemination on its <I>ClinicalTrials.gov</I>
website.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Human Clinical Studies in Support of an NDA
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical trials involve the administration of
the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which
include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation
in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion
criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Human clinical trials are typically conducted
in the following sequential phases, which may overlap or be combined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phase
                                            1: The drug is initially introduced into healthy human subjects or, in certain indications
                                            such as cancer, patients with the target disease or condition and tested for safety, dosage
                                            tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early
                                            indication of its effectiveness and to determine optimal dosage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phase
                                            2: The drug is administered to a limited patient population to identify possible adverse
                                            effects and safety risks, to preliminarily evaluate the efficacy of the product for specific
                                            targeted diseases and to determine dosage tolerance and optimal dosage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phase
                                            3: The drug is administered to an expanded patient population, generally at geographically
                                            dispersed clinical trial sites, in well-controlled clinical trials to generate enough data
                                            to statistically evaluate the efficacy and safety of the product for approval, to establish
                                            the overall risk-benefit profile of the product, and to provide adequate information for
                                            the labeling of the product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phase
                                            4: Post-approval studies, which are conducted following initial approval, are typically conducted
                                            to gain additional experience and data from treatment of patients in the intended therapeutic
                                            indication.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Progress reports detailing the results of the
clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND
safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from
other studies or animal or <I>in&nbsp;vitro</I> testing that suggest a significant risk in humans exposed to the drug; and any clinically
important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase&nbsp;1,
Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore,
the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research
subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at
its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements
or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites
to assure compliance with GCP and the integrity of the clinical data submitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrent with clinical trials, companies often
complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the
drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing
process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods
for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected
and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration
over its shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Submission of an NDA to the FDA </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Assuming successful completion of required clinical
testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information relating
to the product&rsquo;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of
an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is
additionally subject to an application user fee and the sponsor of an approved NDA is also subject to annual product and establishment
user fees. These fees are typically increased annually. Certain exceptions and waivers are available for some of these fees, such as
an exception from the application fee for products with orphan designation and a waiver for certain small businesses, an exception from
the establishment fee when the establishment does not engage in manufacturing the product during a particular fiscal year, and an exception
from the product fee for a product that is the same as another product approved under an abbreviated pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA conducts a preliminary review of an NDA
within 60&nbsp;days of its receipt and strives to inform the sponsor by the 74th&nbsp;day after the FDA&rsquo;s receipt of the submission
to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information
rather than accept an NDA for filing. In this event, the application must be resubmitted with additional information. The resubmitted
application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins
an in-depth substantive review. The FDA has agreed to certain performance goals in the review process of NDAs. Most such applications
are meant to be reviewed within ten months from the date of filing, and most applications for &ldquo;priority review&rdquo; products
are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider
new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original
submission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Before approving an NDA, the FDA typically will
inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities
associated with an NDA submission, including drug component manufacturing (such as active pharmaceutical ingredients), finished drug
product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing
processes and facilities comply with cGMP requirements and adequate to assure consistent production of the product within required specifications.
Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Under
the FDA Reauthorization Act of 2017 (&ldquo;FDARA&rdquo;), the FDA must implement a protocol to expedite review of responses to inspection
reports pertaining to certain drug applications, including applications for drugs in a shortage or drugs for which approval is dependent
on remediation of conditions identified in the inspection report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, as a condition of approval, the
FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond professional labeling to ensure that the
benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population
likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of
known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication guides, physician communication
plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but is not limited to, special training
or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient
registries. The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of
the product. The requirement for a REMS can materially affect the potential market and profitability of a product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may refer an application for a novel
drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts,
including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application
should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers
such recommendations carefully when making decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fast Track, Breakthrough Therapy and Priority
Review Designations </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA is authorized to designate certain products
for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease
or condition. These programs are referred to as fast-track designation, breakthrough therapy designation and priority review designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specifically, the FDA may designate a product
for fast-track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious
or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition.
For fast-track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a fast track
product&rsquo;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary
evaluation of clinical data submitted by the sponsor, that a fast-track product may be effective. The sponsor must also provide, and
the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However,
the FDA&rsquo;s time period goal for reviewing a fast-track application does not begin until the last section of the application is submitted.
In addition, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by
data emerging in the clinical trial process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Second, a product may be designated as a breakthrough
therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease
or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA
may take certain actions with respect to breakthrough therapies, including holding meetings with the sponsor throughout the development
process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review
process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an
efficient manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Third, the FDA may designate a product for priority
review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness.
The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other
available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition,
elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may
lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended
to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&rsquo;s goal for taking action
on a marketing application from ten months to six months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Tropical
Disease PRVs</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Tropical Disease Priority Review Voucher (&ldquo;PRV&rdquo;) program
was created by Congress under the Food and Drug Administration Amendments Act of 2007 (&ldquo;FDAAA&rdquo;) in order to encourage innovation
and public access to new medicines. Pursuant to Section 1102 of FDAAA, which amended section 524 of the Federal Food, Drug, and Cosmetic
Act (&ldquo;FFDCA&rdquo;), along with later amendments, the FDA must award a PRV to certain applicants that obtain an approved NDA to
treat certain tropical diseases. Congress later expanded the scope of diseases that were eligible for a PRV (e.g., a PRV for obtaining
approval for a drug to treat rare pediatric diseases). A PRV entitles the holder of the voucher to designate a different drug application
as qualifying for priority review from FDA. When a drug application is designated for priority review through use of a priority review
voucher, that application must be reviewed by FDA no later than 6 months after receipt.<SUP>70</SUP> This guarantees a much more rapid
review by FDA compared to the standard review time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Tropical disease PRVs
were created under the FDAAA to encourage pharmaceutical companies to develop treatments for specific neglected tropical diseases. As
defined by the statute, tropical diseases refer to certain &ldquo;infectious disease[s] for which there is no significant market in developed
nations and that disproportionately affects poor and marginalized populations.&rdquo;<SUP>71</SUP> Because tropical diseases occur rarely
in the United States, obtaining approval from the FDA for treating these diseases would normally be unprofitable for pharmaceutical companies
due to the limited domestic market and the scope and significant financial costs of the post-marketing requirements imposed by FDA. Congress
intended to incentivize companies to turn their attentions to tropical diseases by providing a PRV to those companies that obtained approval
from FDA for a tropical disease drug product, and the granted PRV could then be sold to another company for money.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A PRV is an extremely valuable property interest. For example, Rhythm
Pharmaceutical, Inc. announced in 2021 that it had sold a PRV for $100,000,000.<SUP>72</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Accelerated Approval Pathway </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA may grant accelerated approval to a drug for
a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon
a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may
also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured
earlier than an effect on irreversible morbidity or mortality (&ldquo;IMM&rdquo;), and that is reasonably likely to predict an effect
on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack
of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those
granted traditional approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the purposes of accelerated approval, a surrogate
endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict
clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly
than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely
to predict the clinical benefit of a drug, such as an effect on IMM. There is limited experience with accelerated approvals by the FDA
based on intermediate clinical endpoints. However, the FDA has indicated that such endpoints generally may support accelerated approval
where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is
a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accelerated approval pathway is most often used
in settings in which the course of a disease is long, and an extended period of time is required to measure the intended clinical benefit
of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used
extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to
improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate
a clinical or survival benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>70</SUP> 21 U.S.C. &sect; 360n(a)(1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><SUP>71</SUP> 21 U.S.C. &sect; 360n(a)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>72</SUP> Ben Adams,&nbsp;<I>Newly acquired Alexion pays $100M
for Rhythm's speedy review voucher</I>, Fierce Biotech (Jan 6, 2021, 10:23 AM),&nbsp;<I>available at</I>&nbsp;https://www.fiercebiotech.com/biotech/newly-acquired-alexion-pays-100m-for-rhythm-s-speedy-review-voucher.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #242424"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accelerated approval pathway is usually contingent
on a sponsor&rsquo;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe
the drug&rsquo;s clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance
requirements, including the completion of Phase&nbsp;4 or post-approval clinical trials to confirm the effect on the clinical endpoint.
Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to
withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations
are subject to prior review by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The FDA&rsquo;s Decision on an NDA </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On the basis of the FDA&rsquo;s evaluation of
the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval
letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information
for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial
additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed
to the FDA&rsquo;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing
such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information,
the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the FDA approves a product, it may limit the
approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling,
require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess the drug&rsquo;s safety after
approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including
distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability
of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance
programs. After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional
labeling claims, are subject to further testing requirements and FDA review and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Post-Approval Requirements </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Drugs manufactured or distributed pursuant to
FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to
recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences
with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are
subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments
at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, drug manufacturers and other entities
involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies,
and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes
to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also
require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor
and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money,
and effort in the area of production and quality control to maintain cGMP compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Once an approval is granted, the FDA may withdraw
the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches
the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency,
or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling
to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution
or other restrictions under a REMS program. Other potential consequences include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">restrictions
                                            on the marketing or manufacturing of the product, complete withdrawal of the product from
                                            the market or product recalls;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">fines,
                                            warning letters or holds on post-approval clinical trials;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">refusal
                                            of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation
                                            of product license approvals;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">product
                                            seizure or detention, or refusal to permit the import or export of products; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">injunctions
                                            or the imposition of civil or criminal penalties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA strictly regulates the marketing, labeling,
advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards
and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational
activities, and promotional activities involving the Internet and social media. Promotional claims about a drug&rsquo;s safety or effectiveness
are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved
by the FDA, as reflected in the product&rsquo;s prescribing information. In the United States, healthcare professionals are generally
permitted to prescribe drugs for such uses not described in the drug&rsquo;s labeling, known as off-label uses, because the FDA does
not regulate the practice of medicine. However, the FDA&rsquo;s regulations impose rigorous restrictions on manufacturers&rsquo; communications,
prohibiting the promotion of off-label uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage
in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information.
If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial
enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services,
as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including
civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products.
The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested
that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, the distribution of prescription
pharmaceutical products is subject to the Prescription Drug Marketing Act (&ldquo;PDMA&rdquo;), and its implementation regulations, as
well as the Drug Supply Chain Security Act (&ldquo;DSCSA&rdquo;), which regulates the distribution of and tracing of prescription drugs
and prescription drug samples at the federal level, and sets minimum standards for the regulation of drug distributors by the states.
The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the
DSCSA imposes requirements to ensure accountability in distribution and to identify and remove counterfeit and other illegitimate products
from the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Abbreviated New Drug Applications for Generic
Drugs </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress authorized the FDA to approve generic drugs that are the same
as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must
submit an ANDA to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing
previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug (&ldquo;RLD&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specifically, in order for an ANDA to be approved,
the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration,
the dosage form, and the strength of the drug. At the same time, the FDA must also determine that the generic drug is &ldquo;bioequivalent&rdquo;
to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &ldquo;the rate and extent of absorption of the
drug do not show a significant difference from the rate and extent of absorption of the listed drug...&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon approval of an ANDA, the FDA indicates whether
the generic product is &ldquo;therapeutically equivalent&rdquo; to the RLD in its publication &ldquo;Approved Drug Products with Therapeutic
Equivalence Evaluations,&rdquo; also referred to as the &ldquo;Orange Book.&rdquo; Physicians and pharmacists consider a therapeutic
equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance
programs, the FDA&rsquo;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge
or consent of either the prescribing physician or patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Hatch-Waxman Amendments, the FDA may
not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five
years of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical
entity (&ldquo;NCE&rdquo;), is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An
active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where
such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission
is accompanied by a Paragraph&nbsp;IV certification, in which case the applicant may submit its application four years following the
original product approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDCA also provides for a period of three
years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence
studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity
period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination
or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety, provided
the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity
does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original
drug product. The FDA typically makes decisions about awards of data exclusivity shortly before a product is approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under FDARA, a priority review track will be
established for certain generic drugs, requiring the FDA to review a drug application within eight months for a drug that has three or
fewer approved drugs listed in the Orange Book and is no longer protected by any patent or regulatory exclusivities, or is on the FDA&rsquo;s
drug shortage list. The new legislation also authorizes the FDA to expedite review of &ldquo;competitor generic therapies&rdquo; or drugs
with inadequate generic competition, including holding meetings with or providing advice to the drug sponsor prior to submission of the
application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Hatch-Waxman Patent Certification and the
30-Month Stay </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon approval of an NDA or a supplement thereto,
NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&rsquo;s product or an approved method
of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its
application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in
the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. To the extent that
the Section&nbsp;505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify
to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Specifically, the applicant must certify with
respect to each patent that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            required patent information has not been filed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            listed patent has expired;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            listed patent has not expired, but will expire on a particular date and approval is sought
                                            after patent expiration; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            listed patent is invalid, unenforceable or will not be infringed by the new product.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A certification that the new product will not
infringe the already approved product&rsquo;s listed patents or that such patents are invalid or unenforceable is called a Paragraph&nbsp;IV
certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method
of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired (other than
method of use patents involving indications for which the ANDA applicant is not seeking approval).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the ANDA applicant has provided a Paragraph&nbsp;IV
certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA and patent holders once
the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response
to the notice of the Paragraph&nbsp;IV certification. The filing of a patent infringement lawsuit within 45&nbsp;days after the receipt
of a Paragraph&nbsp;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&nbsp;months after
the receipt of the Paragraph&nbsp;IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the
ANDA applicant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Pediatric Studies and Exclusivity </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Pediatric Research Equity Act of 2003,
an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed
indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which
the product is safe and effective. With enactment of the Food and Drug Safety and Innovation Act (&ldquo;FDASIA&rdquo;), in 2012, sponsors
must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study
or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information
required by regulation. The applicant, the FDA, and the FDA&rsquo;s internal review committee must then review the information submitted,
consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. For
drugs intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of an applicant, meet to discuss
preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, FDARA requires the FDA to meet early
in the development process to discuss pediatric study plans with drug sponsors. The legislation requires the FDA to meet with drug sponsors
no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than 90 days after the FDA&rsquo;s
receipt of the study plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FDA may, on its own initiative or at the
request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in
adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral
requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data
requirements do not apply to products with orphan designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pediatric exclusivity is another type of non-patent
marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection
to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be
granted if an NDA sponsor submits pediatric data that fairly responds to a written request from the FDA for such data. The data do not
need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond
to the FDA&rsquo;s request, additional protection is granted. If reports of requested pediatric studies are submitted to and accepted
by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product
are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA
cannot approve another application. With regard to patents, the six-month pediatric exclusivity period will not attach to any patents
for which a generic (ANDA or 505(b)(2) NDA) applicant submitted a paragraph IV patent certification, unless the NDA sponsor or patent
owner first obtains a court determination that the patent is valid and infringed by a proposed generic product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Orphan Drug Designation and Exclusivity </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Orphan Drug Act, the FDA may designate
a drug product as an &ldquo;orphan drug&rdquo; if it is intended to treat a rare disease or condition (generally meaning that it affects
fewer than 200,000&nbsp;individuals in the United States, or more in cases in which there is no reasonable expectation that the cost
of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from
sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA
will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in
or shorten the duration of the regulatory review and approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a product with orphan status receives the
first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease
or condition for which it was designated, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity
means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain
limited circumstances. Those circumstances include instances in which another sponsor&rsquo;s application for the same drug product and
indication is shown to be &ldquo;clinically superior&rdquo; to the previously approved drug. In this context, clinically superior means
that the drug provides a significant therapeutic advantage over and above the already approved drug in terms of greater efficacy, greater
safety or by providing a major contribution to patient care. Competitors may receive approval of different products for the indication
for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or
drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated
in its orphan product application, it may not be entitled to exclusivity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under FDARA, orphan exclusivity will not bar
approval of another orphan drug under certain circumstances, including if a subsequent product with the same drug for the same indication
is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution
to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. The new legislation reverses prior
precedent holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan exclusivity regardless of a showing of
clinical superiority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Patent Term Restoration and Extension </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A patent claiming a new drug product may be eligible
for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term
lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between
the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate
approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&rsquo;s
approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension
must be submitted prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought
can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and approves the application
for any patent term extension or restoration in consultation with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Review and Approval of Medical Devices in
the United States </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medical devices in the United States are strictly
regulated by the FDA. Under the FDCA, a medical device is defined as an instrument, apparatus, implement, machine, contrivance, implant,
<I>in vitro</I> reagent, or other similar or related article, including a component part, or accessory which is, among other things:
intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in
man or other animals; or intended to affect the structure or any function of the body of man or other animals, and which does not achieve
its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being
metabolized for the achievement of any of its primary intended purposes. This definition provides a clear distinction between a medical
device and other FDA regulated products such as drugs. If the primary intended use of the product is achieved through chemical action
or by being metabolized by the body, the product is usually a drug. If not, it is generally a medical device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Medical devices are classified into one of three
classes on the basis of the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness. Class&nbsp;I
devices have the lowest level or risk associated with them, and are subject to general controls, including labeling, premarket notification
and adherence to the Quality System Regulation (&ldquo;QSR&rdquo;). Class&nbsp;II devices are subject to general controls and special
controls, including performance standards. Class&nbsp;III devices, which have the highest level of risk associated with them, such as
life sustaining, life supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that
is not substantially equivalent to that of a legally marketed device, are subject to most of the aforementioned requirements as well
as to premarket approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A 510(k) must demonstrate that the proposed device
is substantially equivalent to another legally marketed device, or predicate device, which did not require premarket approval. In evaluating
a 510(k), the FDA will determine whether the device has the same intended use as the predicate device, and (a)&nbsp;has the same technological
characteristics as the predicate device, or (b)&nbsp;has different technological characteristics, and (i)&nbsp;the data supporting substantial
equivalence contains information, including appropriate clinical or scientific data, if deemed necessary by the FDA, that demonstrates
that the device is as safe and as effective as a legally marketed device, and (ii)&nbsp;does not raise different questions of safety
and effectiveness than the predicate device. Most 510(k)s do not require clinical data for clearance, but the FDA may request such data.
The FDA seeks to review and act on a 510(k) within 90 days of submission, but it may take longer if the agency finds that it requires
more information to review the 510(k). If the FDA concludes that a new device is not substantially equivalent to a predicate device,
the new device will be classified in Class&nbsp;III and the manufacturer will be most likely required to submit a PMA to market the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the PMA application process, the applicant
must demonstrate that the device is safe and effective for its intended use. This PMA approval process applies to most Class III devices,
and generally requires clinical data to support the safety and effectiveness of the device, obtained in conformance with Investigational
Device Exemption regulations. The FDA will approve a PMA application if it finds that there is a reasonable assurance that the device
is safe and effective for its intended purpose, and that the proposed manufacturing is in compliance with the QSRs. For novel technologies,
the FDA will seek input from an advisory panel of medical experts regarding the safety and effectiveness of, and their benefit-risk analysis
for the device. The PMA process is generally more detailed, lengthier and more expensive than the 510(k) process, though both processes
can be expensive and lengthy, and require payment of significant user fees, unless an exemption is available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Modifications to a 510(k)-cleared medical device
may require the submission of another 510(k) or a PMA if the changes could significantly affect safety or effectiveness or constitute
a major change in the intended use of the device. Modifications to a 510(k)-cleared device frequently require the submission of a traditional
510(k), but modifications meeting certain conditions may be candidates for FDA review under a Special 510(k). If a device modification
requires the submission of a 510(k), but the modification does not affect the intended use of the device or alter the fundamental technology
of the device, then summary information that results from the design control process associated with the cleared device can serve as
the basis for clearing the application. A Special 510(k) allows a manufacturer to declare conformance to design controls without providing
new data. When the modification involves a change in material, the nature of the &ldquo;new&rdquo; material will determine whether a
traditional or Special 510(k) is necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Review and Approval of Drug Products in
the European Union </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to market any product outside of the
United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding
quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution
of products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the comparable
foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions.
The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional
administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer
than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in
another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory
process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Procedures Governing Approval of Drug Products
in the European Union </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the European Clinical Trials Directive, a system for the
approval of clinical trials in the European Union has been implemented through national legislation of the member states. Under this system,
an applicant must obtain approval from the competent national authority of an E.U. member state in which the clinical trial is to be conducted.
Furthermore, the applicant may only start a clinical trial after a competent Ethics Committee has issued a favorable opinion. Clinical
trial application must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the European
Clinical Trials Directive and corresponding national laws of the member states and further detailed in applicable guidance documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To obtain marketing approval of a product under
European Union regulatory systems, an applicant must submit a marketing authorization application (&ldquo;MAA&rdquo;), either under a
centralized or decentralized procedure. The centralized procedure provides for the grant of a single marketing authorization by the European
Commission that is valid for all E.U. member states. The centralized procedure is compulsory for specific products, including for medicines
produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products
with a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the
treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients,
the centralized procedure may be optional.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the centralized procedure, the Committee
for Medicinal Products for Human Use (the &ldquo;CHMP&rdquo;), established at the European Medicines Agency (&ldquo;EMA&rdquo;), is responsible
for conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities,
such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the
European Union, the maximum timeframe for the evaluation of an MAA is 210&nbsp;days, excluding clock stops, when additional information
or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might
be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and
in particular from the viewpoint of therapeutic innovation. In this circumstance, the EMA ensures that the opinion of the CHMP is given
within 150&nbsp;days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The decentralized procedure is available to applicants
who wish to market a product in various E.U. member states where such a product has not previously received marketing approval in any
E.U. member states. The decentralized procedure provides for approval by one or more other, or concerned, member states of an assessment
of an application performed by one member state designated by the applicant, known as the reference member state. Under this procedure,
an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics,
and draft labeling and package leaflet, to the reference member state and concerned member states. The reference member state prepares
a draft assessment report and drafts of the related materials within 210&nbsp;days after receipt of a valid application. Within 90&nbsp;days
of receiving the reference member state&rsquo;s assessment report and related materials, each concerned member state must decide whether
to approve the assessment report and related materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a member state cannot approve the assessment
report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute
resolution mechanism and may eventually be referred to the European Commission, whose decision is binding on all member states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical Trial Approval </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Requirements for the conduct of clinical trials in the European Union
including Good Clinical Practice, are set forth in the Clinical Trials Directive 2001/20/EC and the GCP Directive 2005/28/EC. Pursuant
to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system for the approval of clinical trials in the European Union has been
implemented through national legislation of the E.U. member states. Under this system, approval must be obtained from the competent national
authority of each E.U. member state in which a study is planned to be conducted. To this end, a clinical trial application is submitted,
which must be supported by an investigational medicinal product dossier (&ldquo;IMPD&rdquo;), and further supporting information prescribed
by Directive 2001/20/EC and Directive 2005/28/EC and other applicable guidance documents. Furthermore, a clinical trial may only be started
after a competent Ethics Committee has issued a favorable opinion on the clinical trial application in that country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2014, the European Union passed the
new Clinical Trials Regulation, (EU) No 536/2014, which will replace the current Clinical Trials Directive 2001/20/EC. To ensure that
the rules for clinical trials are identical throughout the European Union, the new E.U. clinical trials legislation was passed as a regulation
that is directly applicable in all E.U. member states. All clinical trials performed in the European Union are required to be conducted
in accordance with the Clinical Trials Directive 2001/20/EC until the new Clinical Trials Regulation (EU) No 536/2014 becomes applicable.
According to the current plans of EMA, the new Clinical Trials Regulation will become applicable in 2019. The Clinical Trials Directive
2001/20/EC will, however, still apply three years from the date of entry into application of the Clinical Trials Regulation to (i)&nbsp;clinical
trials applications submitted before the entry into application and (ii)&nbsp;clinical trials applications submitted within one year
after the entry into application if the sponsor opts for old system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The new Clinical Trials Regulation aims to simplify and streamline
the approval of clinical trials in the European Union. The main characteristics of the regulation include: a streamlined application procedure
via a single entry point, the E.U. portal; a single set of documents to be prepared and submitted for the application as well as simplified
reporting procedures that will spare sponsors from submitting broadly identical information separately to various bodies and different
member states; a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts&mdash;Part
I is assessed jointly by all member states concerned. Part II is assessed separately by each member state concerned; strictly defined
deadlines for the assessment of clinical trial applications; and the involvement of the Ethics Committees in the assessment procedure
in accordance with the national law of the member state concerned but within the overall timelines defined by the Clinical Trials Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Data and Market Exclusivity in the European
Union </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Union, new chemical entities
qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. This data
exclusivity, if granted, prevents regulatory authorities in the European Union from referencing the innovator&rsquo;s data to assess
a generic (abbreviated) application for eight years, after which generic marketing authorization can be submitted, and the innovator&rsquo;s
data may be referenced, but not approved for two years. The overall ten-year period will be extended to a maximum of eleven years if,
during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic
indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in
comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the sponsor is able to gain the
prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company
can complete a full MAA with a complete database of pharmaceutical tests, preclinical tests and clinical trials and obtain marketing
approval of its product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to market any product outside of the
United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding
quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution
of drug products. Whether or not it obtains FDA approval for a product, the company would need to obtain the necessary approvals by the
comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions.
The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional
administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer
than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in
another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory
process in others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Periods of Authorization and Renewals </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketing authorization is valid for five years
in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance
by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide
the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all
variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to
be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent
authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization
which is not followed by the actual placing of the drug on the European Union market (in case of centralized procedure) or on the market
of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Orphan Drug Designation and Exclusivity </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulation&nbsp;141/2000 provides that a drug
shall be designated as an orphan drug if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment
of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Community
when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously
debilitating or serious and chronic condition in the European Community and that without incentives it is unlikely that the marketing
of the drug in the European Community would generate sufficient return to justify the necessary investment. For either of these conditions,
the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question
that has been authorized in the European Community or, if such method exists, the drug will be of significant benefit to those affected
by that condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulation&nbsp;847/2000 sets out criteria and
procedures governing designation of orphan drugs in the European Union. Specifically, an application for designation as an orphan product
can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan
drug leads to a ten-year period of market exclusivity. This period may, however, be reduced to six years if, at the end of the fifth
year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is
sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent
from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &ldquo;clinically
relevant superiority&rdquo; by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested
by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply).
Medicinal products designated as orphan drugs pursuant to Regulation&nbsp;141/2000 shall be eligible for incentives made available by
the European Community and by the member states to support research into, and the development and availability of, orphan drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Brexit and the Regulatory Framework in the
United Kingdom</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June&nbsp;23, 2016, the electorate in the
United Kingdom (U.K.) voted in favor of leaving the European Union (commonly referred to as &ldquo;Brexit&rdquo;). Thereafter, on March&nbsp;29,
2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The
withdrawal of the U.K. from the European Union will take effect either on the effective date of the withdrawal agreement or, in the absence
of agreement, two years after the U.K. provides a notice of withdrawal pursuant to the E.U. Treaty. Since the regulatory framework for
pharmaceutical products in the U.K. covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization,
commercial sales and distribution of pharmaceutical products is derived from European Union directives and regulations, Brexit could
materially impact the future regulatory regime which applies to products and the approval of product candidates in the U.K. It remains
to be seen how, if at all, Brexit will impact regulatory requirements for product candidates and products in the U.K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Regulatory Framework in Australia</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Therapeutic Goods Administration, through
the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations is responsible for the efficacy, quality, safety and timely availability
of drugs and medical devices in Australia. The mission statement of the TGA is &ldquo;To ensure the safety, quality and efficacy of therapeutic
goods available in Australia at a standard equal to that of comparable countries, and that premarket assessment of therapeutic goods
is conducted within a reasonable time.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The drug regulation process in Australia is complex
and resource intensive. It must be accountable in terms of the quality, safety and efficacy of drugs made available in Australia. This
accountability includes an acceptance of a balance between safety and efficacy. The approval process is a detailed evaluation of the
data supplied by the company sponsoring an application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A drug may first come to the attention of the TGA when an application
for marketing is received or when an Australian clinical trial is being planned. For clinical trials, the sponsoring company may submit
preliminary data for evaluation to the TGA or notify the TGA that the trial has been approved by an institutional Ethics Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The drug evaluation process for new chemical
entities is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Application</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">Check
                                            to see data complies with Australian guidelines.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">Invoice
                                            sponsor for 75% of evaluation fee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Evaluation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Evaluate
                                            pharmaceutical and chemical data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Evaluate
                                            animal pharmacology and toxicology data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Evaluate
                                            clinical data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Evaluation
                                            unit reviews reports (coordinates external evaluations if used), prepares a summary and makes
                                            an initial recommendation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Pre
                                            ADEC consultation with sponsor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prepare
                                            approved product information and consider consumer product information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Submit
                                            final package of summaries and recommendations to the ADEC (six meetings per year).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Approval</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">ADEC
                                            review and advice to the TGA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Final
                                            decision by the TGA.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Finalize
                                            conditions of registration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Advice
                                            to sponsor, invoice final 25% of evaluation fee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">For
                                            new chemical entity, advise drug information centers, forensic laboratories, etc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Registration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sponsor
                                            applies to register the product on the Australian Register of Therapeutic Goods.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Supply
                                            is permitted once the applicable number is allocated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The drug&rsquo;s chemistry, toxicology and clinical
use are evaluated using data submitted by the sponsoring company. Most of the evaluations are done within the TGA, but external evaluations
can be used. When all the data have been evaluated, the application is considered by the Australian Drug Evaluation Committee (&ldquo;ADEC&rdquo;).
This committee is a group of doctors appointed by the Minister to advise on the suitability of drugs for marketing in Australia. The
TGA takes into consideration the advice received from the ADEC when making a final recommendation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The evaluation process relates to pre-marketing
activity, but the TGA is also responsible for drugs after they are marketed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other activities under the control of the TGA
include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">maintenance of the Australian Register of Therapeutic Goods for the
registration and listing of products;</P>
</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">control
                                            of drug and device exports from Australia;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">inspection
                                            and licensing of manufacturing premises;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">post
                                            marketing surveillance;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">adverse
                                            drug reaction monitoring;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">reports
                                            were received by the Adverse Drug Reactions Advisory Committee;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">medical
                                            device complaint reporting;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">drug
                                            and device recalls;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">laboratory
                                            testing, sample testing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">complaint reporting and follow up; and</P>
</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">drug
                                            and device advertising controls</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The performance of the TGA is monitored in quarterly
performance reports which are reviewed by the Industry/Government Consultative Committee. This committee has membership from the TGA,
the Department of Finance, the Department of Industry, Science and Technology, and the peak industry organizations representing the manufacturers
of prescription drugs, non-prescription drugs, medical devices and herbal and nutritional products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the TGA does not meet the statutory timelines
in approving a drug, then it forgoes 25% of the evaluation fee as a penalty. The sponsor concerned can also consider the outcome as a
&ldquo;deemed refusal&rdquo; and appeal to the Administrative Appeals Tribunal for a resolution. For variations to the registration of
a drug, the TGA must raise an objection within 45 working days, otherwise the application is deemed to be approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Pharmaceutical Coverage, Pricing and Reimbursement
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant uncertainty exists as to the coverage
and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on
the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial
health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The
process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or
reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging
the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing
controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not
include all of the approved products for a particular indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order to secure coverage and reimbursement
for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory
approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. Additionally, a payor&rsquo;s
decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&rsquo;s
determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product.
Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in
product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The containment of healthcare costs also has
become a priority of federal, state and foreign governments and the prices of drugs have been a focus in this effort. Governments have
shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements
for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies
in jurisdictions with existing controls and measures, could further limit our net revenue and results. Coverage policies and third-party
reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products
for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be
implemented in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Outside the United States, ensuring adequate
coverage and payment for our product candidates will face challenges. Pricing of prescription pharmaceuticals is subject to governmental
control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing
approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of our product candidates
or products to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization
efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the European Union, pricing and reimbursement
schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price
has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular
drug candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the
range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal
products for human use. European Union member states may approve a specific price for a drug product or it may instead adopt a system
of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow
companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs
in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry
of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce
pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable
reimbursement and pricing arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Healthcare Law and Regulation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Healthcare providers and third-party payors play
a primary role in the recommendation and prescription of drug products that are granted regulatory approval. Arrangements with providers,
consultants, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations
that may constrain our business and/or financial arrangements. Such restrictions under applicable federal and state healthcare laws and
regulations, include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, persons and entities
                                            from knowingly and willfully soliciting, offering, receiving or providing remuneration (including
                                            any kickback, bribe or rebate), directly or indirectly, in cash or in kind, to induce or
                                            reward either the referral of an individual for, or the purchase, lease or order of, any
                                            good or service, for which payment may be made, in whole or in part, under a federal healthcare
                                            program such as Medicare and Medicaid;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            federal civil and criminal false claims laws, including the civil False Claims Act, and civil
                                            monetary penalties laws, which prohibit individuals or entities from, among other things,
                                            knowingly presenting, or causing to be presented, to the federal government, claims for payment
                                            that are false or fraudulent or making a false statement to avoid, decrease or conceal an
                                            obligation to pay money to the federal government;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            federal Health Insurance Portability and Accountability Act of 1996, which created additional
                                            federal criminal laws that prohibit, among other things, knowingly and willingly executing,
                                            or attempting to execute, a scheme or making false statements in connection with the delivery
                                            of or payment for health care benefits, items, or services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act and
                                            its implementing regulations, which also imposes obligations, including mandatory contractual
                                            terms, with respect to safeguarding the privacy, security and transmission of individually
                                            identifiable health information on covered entities and their business associates that associates
                                            that perform certain functions or activities that involve the use or disclosure of protected
                                            health information on their behalf;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            federal transparency requirements known as the federal Physician Payments Sunshine Act, under
                                            the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation
                                            Act (collectively the &ldquo;ACA&rdquo;), which requires certain manufacturers of drugs,
                                            devices, biologics and medical supplies for which payment is available under Medicare, Medicaid,
                                            or the Children&rsquo;s Health Insurance Program, with specific exceptions, to report annually
                                            to the Centers for Medicare&nbsp;&amp; Medicaid Services (&ldquo;CMS&rdquo;), within the
                                            U.S. Department of Health and Human Services, information related to payments and other transfers
                                            of value to physicians and teaching hospitals and information regarding ownership and investment
                                            interests held by physicians and their immediate family members; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">analogous
                                            state and foreign laws and regulations, such as state anti-kickback and false claims laws,
                                            which may apply to healthcare items or services that are reimbursed by non-governmental third-party
                                            payors, including private insurers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some state laws require pharmaceutical companies
to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by
the federal government in addition to requiring drug manufacturers to report information related to payments to physicians and other
health care providers or marketing expenditures. State and foreign laws also govern the privacy and security of health information in
some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating
compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Healthcare Reform </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A primary trend in the United States healthcare
industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding
the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products,
government control and other changes to the healthcare system in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2010, the United States Congress enacted
the Affordable Care Act, which, among other things, includes changes to the coverage and payment for drug products under government health
care programs. Among the provisions of the ACA of importance to our potential product candidates are: &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">an
                                            annual, nondeductible fee on any entity that manufactures or imports specified branded prescription
                                            drugs and biologic agents, apportioned among these entities according to their market share
                                            in certain government healthcare programs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">expansion
                                            of eligibility criteria for Medicaid programs by, among other things, allowing states to
                                            offer Medicaid coverage to certain individuals with income at or below 133% of the federal
                                            poverty level, thereby potentially increasing a manufacturer&rsquo;s Medicaid rebate liability;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">expanded
                                            manufacturers&rsquo; rebate liability under the Medicaid Drug Rebate Program by increasing
                                            the minimum rebate for both branded and generic drugs and revising the definition of &ldquo;average
                                            manufacturer price,&rdquo; or AMP, for calculating and reporting Medicaid drug rebates on
                                            outpatient prescription drug prices;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">addressed
                                            a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
                                            are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">expanded
                                            the types of entities eligible for the 340B drug discount program;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">established
                                            the Medicare Part&nbsp;D coverage gap discount program by requiring manufacturers to provide
                                            a 50% point-of-sale-discount off the negotiated price of applicable brand drugs to eligible
                                            beneficiaries during their coverage gap period as a condition for the manufacturers&rsquo;
                                            outpatient drugs to be covered under Medicare Part&nbsp;D; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">a
                                            new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and
                                            conduct comparative clinical effectiveness research, along with funding for such research.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other legislative changes have been proposed
and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created
measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit
reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&rsquo;s
automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2%
per fiscal year, which went into effect in April 2013 and will remain in effect through 2024 unless additional Congressional action is
taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further
reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the
statute of limitations period for the government to recover overpayments to providers from three to five years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since enactment of the ACA, there have been numerous
legal challenges and Congressional actions to repeal and replace provisions of the law. In May 2017, the U.S. House of Representatives
passed legislation known as the American Health Care Act of 2017. Thereafter, the Senate Republicans introduced and then updated a bill
to replace the ACA known as the Better Care Reconciliation Act of 2017. The Senate Republicans also introduced legislation to repeal
the ACA without companion legislation to replace it, and a &ldquo;skinny&rdquo; version of the Better Care Reconciliation Act of 2017.
In addition, the Senate considered proposed healthcare reform legislation known as the Graham-Cassidy bill. None of these measures were
passed by the U.S. Senate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2017, President Trump signed an Executive
Order directing federal agencies with authorities and responsibilities under the ACA to waive, defer, grant exemptions from, or delay
the implementation of any provision of the ACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers,
health insurers, or manufacturers of pharmaceuticals or medical devices. In October 2017, the President signed a second Executive Order
allowing for the use of association health plans and short-term health insurance, which may provide fewer health benefits than the plans
sold through the ACA exchanges. At the same time, the Administration announced that it will discontinue the payment of cost-sharing reduction
(&ldquo;CSR&rdquo;), payments to insurance companies until Congress approves the appropriation of funds for such CSR payments. The loss
of the CSR payments is expected to increase premiums on certain policies issued by qualified health plans under the ACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A bipartisan bill to appropriate funds for CSR
payments was introduced in the Senate, but the future of that bill is uncertain. Further, each chamber of Congress has put forth multiple
bills designed to repeal or repeal and replace portions of the ACA. Although none of these measures have been enacted by Congress to
date, Congress may consider other legislation to repeal and replace elements of the ACA. Congress will likely consider other legislation
to replace elements of the ACA, during the next Congressional session. We will continue to evaluate the effect that the ACA and its possible
repeal and replacement could have on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2022, the Inflation Reduction Act of
2022 was signed into law and requires the federal government to negotiate prices for some high-cost drugs covered under Medicare, requires
drug manufacturers to pay rebates to Medicare if they increase prices faster than inflation for drugs used by Medicare beneficiaries,
and caps Medicare beneficiaries&rsquo; out-of-pocket spending under the Medicare Part D benefit. We will monitor this issue to determine
the effects of this legislation on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Human Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As of December 31, 2022, we had a total of two&nbsp;employees, both
of which are full-time. We also utilize the services of two part-time contractors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing
and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans
are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase
stockholder value and the success of our Company by motivating such individuals to perform to the best of their abilities and achieve
our objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Properties </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our corporate headquarters are located at 1025 Connecticut Avenue NW
Suite 1000, Washington, D.C. 20036. We do not own any physical property, plant or labs. We currently lease two offices at the above address
and recognized a Right of Use Asset of $99,615 as of December 31, 2022 with offsetting accumulated depreciation of $86,967 ($99,615 at
December 31, 2021 with offsetting accumulated depreciation of $40,947). The current lease expired March 31, 2023 and has been renewed
for an additional two year term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Legal Proceedings </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, we may become involved in
various claims and legal proceedings. We are not currently a party to any legal proceedings that, in the opinion of our management, are
likely to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because
of defense and settlement costs, diversion of management resources and other factors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>History</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 29.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60 Degrees Pharmaceuticals, Inc. is a Delaware
corporation that was incorporated on June 1, 2022. On June 1, 2022, 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability
company (&ldquo;60P LLC&rdquo;), entered into the Agreement and Plan of Merger with 60 Degrees Pharmaceuticals, Inc., pursuant to which
60P LLC merged into 60 Degrees Pharmaceuticals, Inc. The value of each outstanding member&rsquo;s membership interest in 60P LLC was
correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc., par value $0.0001 per share, with a cost-basis equal
to $5.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also operate one subsidiary. A summary of
our majority-owned subsidiary is below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We own 88% equity in
60P Australia Pty Ltd, a Sydney-Australia based subsidiary (&ldquo;60P Australia&rdquo;). 60P Australia holds sub-licensing rights for
several ex-U.S. territories for our product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">60P Australia previously
solely owned a Singaporean subsidiary company, 60P Singapore PTE, LTD, which dissolved at our election in the second quarter of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_017"></A>MANAGEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are our executive officers and directors and their respective
ages and positions as of December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 7%"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-size: 10pt"><B>Director
    Since</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Geoffrey Dow</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">49</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Executive Officer, President and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">June 1, 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Tyrone Miller</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">48</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Treasurer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Bryan Smith</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">57</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Chief Medical Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Charles Allen</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">47</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director Nominee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Cheryl Xu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">55</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director Nominee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Stephen Toovey</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">69</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director Nominee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Paul Field</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">59</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director Nominee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Geoffrey Dow </I></B>is our Chief Executive
Officer, President, and is also our sole Director. Dr. Dow has over 20 years of product development experience in tropical diseases and
has an extensive publication and patent history. His decades of hands-on experience include 13 years in key leadership and advisory roles
in the antimalarial drug development program at the Walter Reed Army Institute of Research and at the U.S. Army Medical Materiel Development
Activity. Dr. Dow co-founded 60P in 2010. Since then, he has been involved in various projects, including leading the project development
team in securing FDA-regulatory approval for Tafenoquine (as Arakoda) for malaria prophylaxis, securing a supply chain and access relating
to Arakoda, managing post-marketing regulatory commitments, ensuring the successful prosecution of supporting patents on which Dr. Dow
was an inventor, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements. Dr. Dow has also published a number
of important safety reviews, clinical trials, non-clinical studies, on which he was a thought leader or contributor, which dispelled many
of the myths about 8-aminoquinolines. As a scientist, experienced industry project manager and inventor, Dr. Dow&rsquo;s ultimate goal
is to develop and secure the regulatory approval and commercial success of products, old and new, for new indications in infectious disease.
Dr. Dow received a B.Sc. (Hons) in Veterinary and Biomedical Science from Murdoch University, Perth, Western Australia (&ldquo;Murdoch&rdquo;)
in 1994, a Ph.D. in Veterinary and Biomedical Science from Murdoch in 2000 and an MBA from the University of Maryland at College Park
in 2012. We believe that Mr. Dow is well qualified to serve as a Director given his product development experience in tropical diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Tyrone Miller </I></B>is our Treasurer.
Mr. Miller joined us in 2014 and has held a number of roles since then, including Chief Financial Officer. He worked with the founder
and Chief Executive Officer of 60P and raised over $6 million in external financing. Mr. Miller also established a multinational financial
reporting system and worked with consultants in designing tax and credit strategies. He also provides key strategic advice in areas of
financing and business planning to 60P. In addition, he is the founder and Principal of Tax &amp; Accounting Practice at Miller Tax &amp;
Advisory since 2011. In that role, Mr. Miller advises owners of closely held businesses on accounting, financial and tax matters and
has designed accounting systems for private sector businesses. From 2002 to 2011, he was a Senior Accountant at Sachs Figurelli, LLC,
where he prepared and processed corporate and individual tax returns, consulted on reengineering accounting processes for construction,
restaurant and professional services businesses and managed staff in preparation and processing of payroll and personal property returns.
Mr. Miller is currently a Certified Public Accountant. He received a Bachelor&rsquo;s of Business Administration with a concentration
in International Business from Emory University in 1996.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Bryan Smith </I></B>is our Chief Medical
Officer. Dr. Smith is a medical doctor with expertise in clinical pharmacology, pharmacovigilance, regulatory strategy development and
translational medicine and is a retired military colonel with over 30 years of governmental research and leadership experience. He joined
us in 2016 as Chief Medical Officer and works with other members of the senior management team to establish all functional areas, including
complying with national and international laws and regulations and developing and overseeing research and development projects and agenda.
He also is currently a Senior Medical Director, Clinical and Regulatory Affairs at Fast-Track Drugs &amp; Biologics, LLC since 2019,
where he is responsible for developing clinical development plans for therapeutic products, managing clinical and regulatory projects
and designing and writing clinical trial protocols. Since 2016, Dr. Smith has been the Chief Medical Officer and member of Amivas LLC,
where he establishes all functional areas required to successfully secure FDA approvals. In addition, from 2016 to 2019, he was the Principal
Medical Consultant at Clinical Network Services, Inc., where he provided required medical, clinical pharmacology, regulatory, translational
medicine review, oversight and consultation as requested for over 25 unique clients in a range of activities and tasks for devices, small
molecules and large molecules in a range of therapeutic areas. Dr. Smith received a Bachelor of Science in General Science, with highest
honors, from Oregon State University and a Doctor of Medicine from Uniformed Services University of the Health Sciences.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Nominees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Charles Allen </I></B>is one of our director
nominees and since February 5, 2014 has served as the Chief Executive Officer of BTCS Inc. (&ldquo;BTCS&rdquo;) and the Chairman of the
Board of BTCS since September 11, 2014. Mr. Allen is responsible for BTCS&rsquo; overall corporate strategy and direction. Since December
2, 2022, Mr. Allen has been a director of Innovation1 Biotech Inc. Since January 12, 2018, Mr. Allen has been the Chief Executive Officer
of Global Bit Ventures Inc. (&ldquo;GBV&rdquo;). Since October 10, 2017, Mr. Allen has been a director of GBV. Mr. Allen has extensive
experience in business strategy and structuring and executing a variety of investment banking and capital markets transactions, including
financings, initial public offerings, and mergers and acquisitions. Prior to his work in the blockchain industry at BTCS, he worked domestically
and internationally on projects in technology, media, natural resources, logistics, medical services, and financial services. He has served
as a managing director at numerous boutique investment banks focused on advising and raising capital for small and mid-size companies.
Mr. Allen received a Bachelor of Science in Mechanical Engineering from Lehigh University and a Master of Business Administration from
the Mason School of Business at the College of William &amp; Mary. The Board concludes that Mr. Allen&rsquo;s background and leadership
experiences in the financial industry qualify him to be nominated as a potential member of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Cheryl Xu</I> </B>is one of our director
nominees and&nbsp;until recently served as Biogen&rsquo;s Vice President, Public Policy &amp; Government Affairs since 2020. Ms. Xu was
PhRMA&rsquo;s first Representative to China. Subsequently she started a consulting business in 2005,&nbsp;advising well-known multinational
companies such as Pfizer, J&amp;J and UnitedHealth Group on their market access and expansion strategies in China. Cheryl has provided
consultations to both the U.S. and Chinese governments on pharmaceutical policies including strengthening of IP protection and monitoring
system for China&rsquo;s API exports. Prior to that, she was the Director of International Finance at Pharmacia based in New Jersey from
1998 to 2003. Ms. Xu received her Bachelor of Science degree in Physics from Peking University, and Master of Business Administration
in Finance from Washington University in St. Louis.&nbsp;The Board concludes that Ms. Xu&rsquo;s background and leadership experiences
in the pharmaceutical industry qualify her to be nominated as a potential member of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Dr. Stephen Toovey</I></B> is one of our director
nominees and is an infectious and tropical disease physician. Dr. Toovey has worked in the pharmaceutical industry and academia in both
developed and developing countries, and currently specializes in the research of influenza and other respiratory viruses, malaria, rabies
and the neurological aspects of infectious diseases. He is currently the Chief Executive Officer of Pegasus, a medical and scientific
services company and has held that position since 2008. Dr. Toovey also advises a number of pharmaceutical companies and biotech organizations
on infection and immunology related matters, from translation through Phase IV, and founded numerous pharmaceutical and pharma-related
companies, with the most recent being the co-founding of Ark Biosciences in 2014. Dr. Toovey served as Chief Medical Officer of Ark Biosciences
from 2014 until 2020. In addition, he held a teaching and clinical post at the Royal Free and University College Medical School in London,
United Kingdom, Academic Centre for Travel Medicine and Vaccines, World Health Organization Collaborating Center, appointed in 2008.
He has been editor of the journal Travel Medicine and Infectious Disease since its foundation in 2003. Dr. Toovey has authored over 100
publications in peer reviewed medical journals, contributed to a number of textbooks and has presented at over 50 scientific meetings.
Dr. Toovey received his PhD from the University of Ghent. The Board concludes that Dr. Toovey&rsquo;s background and leadership experiences
in the pharmaceutical industry and academia qualify him to be nominated as a potential member of the Board.&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #201F1E">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Paul
Field</I></B> is one of our director nominees. Paul has over 30 years of business development experience across a range of disease areas,
and a deep network in the global biopharmaceutical industry.&nbsp;He is currently a corporate advisor at Imunexus since 2020, Marinova
since 2018, and GARDP (Switzerland) since 2018. He was until recently the Australian representative of FIND (Switzerland) from 2018 to
2021 and a business development advisor to the drug discovery company Biocurate from 2018 to 2020.&nbsp;Paul was previously the life
sciences specialist at Austrade from 2014 to 2018, the Australian Government&rsquo;s investment promotion agency, where he facilitated
foreign direct investment into Australian research in neglected tropical diseases, infectious diseases, autoimmune diseases, cancer and
other therapeutic areas. Paul was the founder and Executive Chairman of Bio-Link from 2005 to 2014, a privately owned biotechnology business
development company. His work at Bio-Link involved the commercialization of discovery, pre-clinical and early-stage clinical programs
undertaken by Australian biotech companies and medical research institutions. Paul has served on a number of Boards of Directors, and
he is a Fellow of the Australian Institute of Company Directors. The Board concludes that Mr. Field&rsquo;s background and leadership
experiences in the biotechnology industry qualify him to be nominated as a potential member of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Significant Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a virtually managed pharmaceutical company
for which the significant employees are its officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board has adopted a written code of business conduct and ethics
(&ldquo;Code&rdquo;) that applies to our directors, officers and employees, including our principal executive officer, principal financial
officer and principal accounting officer or controller, or persons performing similar functions. We intend to post on our website a current
copy of the Code and all disclosures that are required by law in regard to any amendments to, or waivers from, any provision of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Leadership Structure and Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board has responsibility for the oversight
of our risk management processes and, either as a whole or through its committees, regularly discusses with management our major risk
exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving
regular reports from board committees and members of senior management to enable our Board to understand our risk identification, risk
management, and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory,
cybersecurity, strategic, and reputational risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Upon the effectiveness
of the registration statement of which this prospectus forms a part, we expect that our Board will consist of five members. Our business
and affairs are managed under the direction of our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors serve until the next annual meeting
and until their successors are elected and qualified. Officers are appointed to serve until their successors have been elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board will be composed of a majority of &ldquo;independent
directors&rdquo; as defined under the rules of Nasdaq upon completion of this offering. We use the definition of &ldquo;<I>independence</I>&rdquo;
applied by Nasdaq to make this determination. Nasdaq Listing Rule 5605(a)(2) provides that an &ldquo;<I>independent director</I>&rdquo;
is a person other than an officer or employee of the company or any other individual having a relationship which, in the opinion of the
Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The Nasdaq listing
rules provide that a director cannot be considered independent if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            director is, or at any time during the past three (3) years was, an employee of the company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            director or a family member of the director accepted any compensation from the company in
                                            excess of $120,000 during any period of twelve (12) consecutive months within the three (3)
                                            years preceding the independence determination (subject to certain exemptions, including,
                                            among other things, compensation for board or board committee service);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            director or a family member of the director is a partner in, controlling shareholder of,
                                            or an executive officer of an entity to which the company made, or from which the company
                                            received, payments in the current or any of the past three fiscal years that exceed 5% of
                                            the recipient&rsquo;s consolidated gross revenue for that year or $200,000, whichever is
                                            greater (subject to certain exemptions);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            director or a family member of the director is employed as an executive officer of an entity
                                            where, at any time during the past three (3) years, any of the executive officers of the
                                            company served on the compensation committee of such other entity; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            director or a family member of the director is a current partner of the company&rsquo;s outside
                                            auditor, or at any time during the past three (3) years was a partner or employee of the
                                            company&rsquo;s outside auditor, and who worked on the company&rsquo;s audit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under such definitions, our Board has undertaken
a review of the independence of each director and director nominee. Based on information provided by each director and director nominee
concerning his or her background, employment and affiliations, our Board has determined that Charles Allen, Stephen Toovey and Paul Field,
once elected to the Board, will be independent directors of the Company. However, our common stock is not currently quoted or listed
on any national exchange or interdealer quotation system with a requirement that a majority of our Board be independent and, therefore,
we are not subject to any director independence requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Committees of the
Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the effectiveness of the registration statement
of which this prospectus forms a part, our Board will have three standing committees: (i) an audit committee (the &ldquo;Audit Committee&rdquo;);
(ii) a compensation committee (the &ldquo;Compensation Committee&rdquo;); and (iii) a nominating and corporate governance committee (the
&ldquo;Nominating and Corporate Governance Committee&rdquo;). Our Board has not yet adopted procedures by which stockholders may recommend
nominees to the Board. The composition and responsibilities of each of the committees of our Board are described below. Members serve
on these committees until their resignation or until as otherwise determined by our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Audit Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the effectiveness of the registration statement
of which this prospectus forms a part, we will establish the Audit Committee consisting of Charles Allen, who will be the Chairman of
the Audit Committee, Stephen Toovey and Paul Field. Charles Allen qualifies as an audit committee financial expert within the meaning
of Item&nbsp;407(d) of&nbsp;Regulation&nbsp;S-K&nbsp;under the Securities Act. We will also adopt an Audit Committee Charter. The Audit
Committee&rsquo;s duties, which are specified in our Audit Committee Charter, include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">reviewing
                                            and discussing with management and the independent auditor the annual audited financial statements,
                                            and recommending to the board whether the audited financial statements should be included
                                            in our annual disclosure report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">discussing
                                            with management and the independent auditor significant financial reporting issues and judgments
                                            made in connection with the preparation of our financial statements;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">discussing
                                            with management major risk assessment and risk management policies;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">monitoring
                                            the independence of the independent auditor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">verifying
                                            the rotation of the lead (or coordinating) audit partner having primary responsibility for
                                            the audit and the audit partner responsible for reviewing the audit as required by law;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">reviewing
                                            and approving all related-party transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">inquiring
                                            and discussing with management our compliance with applicable laws and regulations;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">pre-approving
                                            all audit services and permitted non-audit services to be performed by our independent auditor,
                                            including the fees and terms of the services to be performed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">appointing
                                            or replacing the independent auditor;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">determining
                                            the compensation and oversight of the work of the independent auditor (including resolution
                                            of disagreements between management and the independent auditor regarding financial reporting)
                                            for the purpose of preparing or issuing an audit report or related work;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">establishing
                                            procedures for the receipt, retention and treatment of complaints received by us regarding
                                            accounting, internal accounting controls or reports which raise material issues regarding
                                            our financial statements or accounting policies; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">approving
                                            reimbursement of expenses incurred by our management team in identifying potential target
                                            businesses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee will be composed exclusively
of &ldquo;independent directors&rdquo; who are &ldquo;financially literate&rdquo; as defined under the Nasdaq listing standards. The
Nasdaq listing standards define &ldquo;financially literate&rdquo; as being able to read and understand fundamental financial statements,
including a company&rsquo;s balance sheet, income statement and cash flow statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we intend to certify to Nasdaq that
the committee has, and will continue to have, at least one member who has past employment experience in finance or accounting, requisite
professional certification in accounting, or other comparable experience or background that results in the individual&rsquo;s financial
sophistication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the effectiveness of the registration statement
of which this prospectus forms a part, we will establish the Compensation Committee, which will be composed exclusively of independent
directors consisting of Paul Field, who will be Chairman of the Compensation Committee, Charles Allen and Stephen Toovey. Each member
of the Compensation Committee will be a&nbsp;non-employee&nbsp;director, as defined under Rule&nbsp;16b-3&nbsp;promulgated under the
Exchange Act, and an outside director, as defined pursuant to Section&nbsp;162(m) of the Code. We will also adopt a Compensation Committee
Charter. The Compensation Committee&rsquo;s duties, which are specified in our Compensation Committee Charter, include, but are not limited
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">reviews, approves and determines, or makes recommendations
    to our Board regarding, the compensation of our executive officers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">administers our equity compensation plans;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">reviews and approves, or
    makes recommendations to our Board, regarding incentive compensation and equity compensation plans; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">establishes and reviews general
    policies relating to compensation and benefits of our employees.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nominating and Corporate Governance Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon effectiveness of the registration statement
of which this prospectus forms a part, we will establish the Nominating and Corporate Governance Committee, which will be composed exclusively
of independent directors consisting of Stephen Toovey, who will be the Chairman of the Nominating and Corporate Governance Committee,
Charles Allen and Paul Field. We will also adopt the Nominating and Corporate Governance Committee Charter. The Nominating and Corporate
Governance Committee&rsquo;s duties, which are specified in our Nominating and Corporate Governance Audit Committee Charter, include,
but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">identifying,
                                            reviewing and evaluating candidates to serve on our Board consistent with criteria approved
                                            by our Board;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">evaluating
                                            director performance on our Board and applicable committees of our Board and determining
                                            whether continued service on our Board is appropriate;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">evaluating
                                            nominations by stockholders of candidates for election to our Board; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">corporate
                                            governance matters.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Family Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are no family relationships among any of
our executive officers or directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as disclosed below, to our knowledge,
none of our current directors or executive officers has, during the past ten (10) years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">been
                                            convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding
                                            traffic violations and other minor offenses);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">had
                                            any bankruptcy petition filed by or against the business or property of the person, or of
                                            any partnership, corporation or business association of which he was a general partner or
                                            executive officer, either at the time of the bankruptcy filing or within two (2) years prior
                                            to that time;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">been
                                            subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated,
                                            of any court of competent jurisdiction or federal or state authority, permanently or temporarily
                                            enjoining, barring, suspending or otherwise limiting, his or her involvement in any type
                                            of business, securities, futures, commodities, investment, banking, savings and loan, or
                                            insurance activities, or to be associated with persons engaged in any such activity;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">been
                                            found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity
                                            Futures Trading Commission to have violated a federal or state securities or commodities
                                            law, and the judgment has not been reversed, suspended, or vacated;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">been
                                            the subject of, or a party to, any federal or state judicial or administrative order, judgment,
                                            decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement
                                            of a civil proceeding among private litigants), relating to an alleged violation of any federal
                                            or state securities or commodities law or regulation, any law or regulation respecting financial
                                            institutions or insurance companies including, but not limited to, a temporary or permanent
                                            injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent
                                            cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting
                                            mail or wire fraud or fraud in connection with any business entity; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">been
                                            the subject of, or a party to, any sanction or order, not subsequently reversed, suspended
                                            or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange
                                            Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act),
                                            or any equivalent exchange, association, entity or organization that has disciplinary authority
                                            over its members or persons associated with a member.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>2022 Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
November 22, 2022, the Board and majority stockholder adopted the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan (the &ldquo;Plan&rdquo;).
The Plan provides for the grant of the following types of stock awards: (i) incentive stock options, (ii) nonstatutory stock options,
(iii) stock appreciation rights, (iv) restricted stock awards, (v) restricted stock unit awards and (vi) other stock awards. The Plan
is intended to help us secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum
efforts for our success and any of our affiliates and provide a means by which the eligible recipients may benefit from increases in
value of the common stock. The Board reserved 238,601 shares of common stock issuable upon the grant of awards under the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_018"></A><B>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table illustrates the compensation paid
by us to our executive officers. The disclosure is provided for the years ended December 31, 2022, and December 31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: justify"><FONT STYLE="font-size: 10pt">Name and Principal Position</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Year</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Base <BR>
Salary($)<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Guaranteed <BR>
Payments($)<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Stock<BR>
Award($)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-size: 10pt">Total($)</FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 43%; text-align: justify"><FONT STYLE="font-size: 10pt">Geoffrey Dow</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">54,510</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">54,510</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">519,996</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">519,996</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Tyrone Miller</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">148,672</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">148,672</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Treasurer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">363,996</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">363,996</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Bryan Smith<SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Chief Medical Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(Outsourced)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">We
                                            periodically review, and may increase, base salaries in accordance with our normal annual
                                            compensation review for each of our named executive officers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Bryan
                                            Smith&rsquo;s part time services are acquired through a contractual relationship with his
                                            direct employer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Equity Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the listing of the shares of our common stock,
(i) Dr. Dow will be granted a five-year option to purchase a total of 15,000 shares of our common stock on the last day of each quarter
in each calendar year (for a cumulative total or no more than 300,000 shares over five years) and (ii) Mr. Miller will be granted a five-year
option to purchase a total of 12,000 shares of our common stock on the last day of each quarter in each calendar year (for a cumulative
total or no more than 240,000 shares over five years). The per share exercise price of the option shall be equal to the per share closing
price of our common stock on the date of grant and shall have a cashless exercise provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Dow Employment Agreement. </I></B>We entered
into an Employment Agreement dated as of January 12, 2023, with Geoffrey Dow (the &ldquo;Dow Employment Agreement&rdquo;), our Chief
Executive Officer and Chairman of our Board. The term of the Dow Employment Agreement began on January 12, 2023, and will continue for
a period of two years, with subsequent automatic renewals unless either party thereto provides notice to terminate at least 90 days prior
to the applicable renewal date. The Dow Employment Agreement provides Dr. Dow an annual base salary of $228,000, bonuses to the extent
certain events occur or if applicable performance goals are met and employee benefits that are generally given to our senior executives.
Upon the listing of the shares of our common stock, Dr. Dow will be granted a five-year option to purchase a total of 15,000 shares of
our common stock that vest on the last day of each quarter in each calendar year (for a cumulative total or no more than 300,000 shares
over five years). The per share exercise price of the option shall be equal to the per share closing price of our common stock on the
date of the initial public offering and shall have a cashless exercise provision.<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may terminate Dr. Dow&rsquo;s employment for Cause,
as defined in the Dow Employment Agreement, at any time upon notice to Dr. Dow setting forth in reasonable detail the nature of such
Cause. We also may terminate Dr. Dow&rsquo;s employment other than for Cause at any time upon thirty&nbsp;(30)&nbsp;days&rsquo; written
notice to him. Dr. Dow may terminate his employment for Good Reason, as defined in the Dow Employment Agreement, at any time upon thirty&nbsp;(30)&nbsp;days&rsquo;
written notice to us. In the event that Dr. Dow&rsquo;s employment is terminated other than for Cause or for Good Reason, Dr. Dow will
be entitled to, among other things, a continuation of his annual salary plus health insurance benefits for a period not exceeding 18
months. In addition, in the event of a Change in Control, as defined in the Dow Employment Agreement, on, or at any time during the 24
months following, the Change in Control, (i) we terminate Dr. Dow&rsquo;s employment for any reason other than Cause or Disability, as
defined in the Dow Employment Agreement, or (ii) Dr. Dow terminates his employment for Good Reason, Dr. Dow will be entitled to Change
in Control severance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Dr. Dow is subject to non-competition and non-solicitation
during the term of his employment and for a period of 24 months after termination of his employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Miller Employment Agreement</I></B>. We entered
into an Employment Agreement dated as of January 12, 2023 with Tyrone Miller (the &ldquo;Miller Employment Agreement&rdquo;), our Chief
Financial Officer. The term of the Miller Employment Agreement began on January 12, 2023 and will continue for a period of two years,
with subsequent automatic renewals unless either party thereto provides notice to terminate at least 90 days prior to the applicable
renewal date. The Miller Employment Agreement provides Mr. Miller an annual base salary of $204,000, bonuses to the extent certain events
occur or if applicable performance goals are met and employee benefits that are generally given to our senior executives. Upon the listing
of the shares of our common stock, Mr. Miller will be granted a five-year option to purchase a total of 12,000 shares of our common stock
that vest on the last day of each quarter in each calendar year (for a cumulative total or no more than 240,000 shares over five years).
The per share exercise price of the option shall be equal to the per share closing price of our common stock on the date of the initial
public offering and shall have a cashless exercise provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may terminate Mr. Miller&rsquo;s employment hereunder
for Cause, as defined in the Miller Employment Agreement, at any time upon notice to Mr. Miller setting forth in reasonable detail the
nature of such Cause. We also may terminate Mr. Miller&rsquo;s employment other than for Cause at any time upon thirty&nbsp;(30)&nbsp;days&rsquo;
written notice to him. Mr. Miller may terminate his employment for Good Reason, as defined in the Miller Employment Agreement, at any
time upon thirty&nbsp;(30)&nbsp;days&rsquo; written notice to us. In the event that Mr. Miller&rsquo;s employment is terminated other
than for Cause or for Good Reason, Mr. Miller will be entitled to, among other things, a continuation of his annual salary plus health
insurance benefits for a period not exceeding 18 months. In addition, in the event of a Change in Control, as defined in the Miller Employment
Agreement, on, or at any time during the 24 months following, the Change in Control, (i) we terminate Mr. Miller&rsquo;s employment for
any reason other than Cause or Disability, as defined in the Dow Employment Agreement, or (ii) Mr. Miller terminates his employment for
Good Reason, Mr. Miller will be entitled to Change in Control severance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Miller is subject to non-competition and non-solicitation
during the term of his employment and for a period of 24 months after termination of his employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>2022 Equity Incentive Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
November 22, 2022, our Board and our stockholders approved the 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan. The Plan
governs equity awards to our employees, directors, officers, consultants and other eligible participants. Initially, the maximum number
of shares of our common stock that may be subject to awards under the Plan is equal to 238,601.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="background-color: lime"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The purpose of the Plan is
to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to employees,
directors and consultants, and to promote the success of our business. The administrator of the Plan may, in its sole discretion, amend,
alter, suspend or terminate the Plan, or any part thereof, at any time and for any reason. We will obtain stockholder approval of any
Plan amendment to the extent necessary and desirable to comply with legal and regulatory requirements relating to the administration of
equity-based awards. Unless earlier terminated by the administrator, the Plan will terminate ten years from the date it is adopted by
our Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Authorized Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Initially,
the maximum number of shares of our common stock that may be subject to awards under the Plan is equal 238,601.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: lime"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Plan Administration</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">One or more committees appointed
by our Board will administer the Plan. Initially, the Compensation Committee shall administer the Plan. In addition, if we determine it
is desirable to qualify transactions under the Plan as exempt under Rule 16b-3 of the Exchange Act, such transactions will be structured
with the intent that they satisfy the requirements for exemption under Rule 16b-3. Subject to the provisions of the Plan, the administrator
has the power to administer the Plan and make all determinations deemed necessary or advisable for administering the Plan, including the
power to determine the fair market value of our common stock, select the service providers to whom awards may be granted, determine the
number of shares covered by each award, approve forms of award agreements for use under the 2022 Plan, determine the terms and conditions
of awards (including the exercise price, the time or times at which the awards may be exercised, any vesting acceleration or waiver or
forfeiture restrictions and any restriction or limitation regarding any award or the shares relating thereto), construe and interpret
the terms of the Plan and awards granted under it, prescribe, amend and rescind rules relating to the Plan, rules and regulations relating
to sub-plans established for the purpose of facilitating compliance with applicable non-U.S. laws, easing the administration of the Plan
and/or for qualifying for favorable tax treatment under applicable non-U.S. laws, in each case as the administrator may deem necessary
or advisable and modify or amend each award (subject to the provisions of the Plan), including the discretionary authority to extend the
post-termination exercisability period of awards and to extend the maximum term of an option or stock appreciation right (subject to the
provisions of the Plan), to allow Participants to satisfy withholding tax obligations in a manner permissible under the Plan, to authorize
any person to execute on behalf of us any instrument required to effect the grant of an award previously granted by the administrator
and to allow a participant to defer the receipt of payment of cash or the delivery of shares that would otherwise be due to such participant
under an award. The administrator also has the authority to allow participants the opportunity to transfer outstanding awards to a financial
institution or other person or entity selected by the administrator and to institute an exchange program by which outstanding awards may
be surrendered or cancelled in exchange for awards of the same type which may have a higher or lower exercise price or different terms,
awards of a different type or cash, or by which the exercise price of an outstanding award is increased or reduced. The administrator&rsquo;s
decisions, interpretations and other actions are final and binding on all participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Eligibility</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Awards under the Plan, other
than incentive stock options, may be granted to our employees (including our officers and directors) or a parent or subsidiary, members
of our Board, or consultants engaged to render bona fide services to us or a parent or subsidiary. Incentive stock options may be granted
only to our employees or a subsidiary, provided the services (i) are not in connection with the offer or sale of securities in a capital-raising
transaction, and (ii) do not directly promote or maintain a market for our securities, in each case, within the meaning of Form S-8 promulgated
under the Securities Act, and provided further, that a consultant will include only those persons to whom the issuance of shares may be
registered under Form S-8 promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Stock Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Stock options may be granted
under the Plan. The exercise price of options granted under the Plan generally must at least be equal to the fair market value of our
common stock on the date of grant. The term of each option will be as stated in the applicable award agreement; provided, however, that
the term may be no more than 10 years from the date of grant. The administrator will determine the methods of payment of the exercise
price of an option, which may include cash, shares or other property acceptable to the administrator, as well as other types of consideration
permitted by applicable law. After the termination of service of an employee, director or consultant, they may exercise their option for
the period of time stated in their option agreement. In the absence of a specified time in an award agreement, if termination is due to
death or disability, the option will remain exercisable for six months. In all other cases, in the absence of a specified time in an award
agreement, the option will remain exercisable for three months following the termination of service. An option may not be exercised later
than the expiration of its term. Subject to the provisions of the Plan, the administrator determines the other terms of options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Stock Appreciation
Rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Stock appreciation rights
may be granted under the Plan. Stock appreciation rights allow the recipient to receive the appreciation in the fair market value of our
common stock between the exercise date and the date of grant. Stock appreciation rights may not have a term exceeding 10 years. After
the termination of service of an employee, director or consultant, they may exercise their stock appreciation right for the period of
time stated in their stock appreciation right agreement. In the absence of a specified time in an award agreement, if termination is due
to death or disability, the stock appreciation rights will remain exercisable for six months. In all other cases, in the absence of a
specified time in an award agreement, the stock appreciation rights will remain exercisable for three months following the termination
of service. However, in no event may a stock appreciation right be exercised later than the expiration of its term. Subject to the provisions
of the Plan, the administrator determines the other terms of stock appreciation rights, including when such rights become exercisable
and whether to pay any increased appreciation in cash or with shares of our common stock, or a combination thereof, except that the per
share exercise price for the shares to be issued pursuant to the exercise of a stock appreciation right will be no less than 100% of the
fair market value per share on the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Restricted Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Restricted stock may be granted
under the Plan. Restricted stock awards are grants of shares of our common stock that vest in accordance with terms and conditions established
by the administrator. The administrator will determine the number of shares of restricted stock granted to any employee, director or consultant
and, subject to the provisions of the Plan, will determine the terms and conditions of such awards. The administrator may impose whatever
conditions to vesting it determines to be appropriate (for example, the administrator may set restrictions based on the achievement of
specific performance goals or continued service to us); provided, however, that the administrator, in its sole discretion, may accelerate
the time at which any restrictions will lapse or be removed. Recipients of restricted stock awards generally will have voting and dividend
rights with respect to such shares upon grant without regard to vesting, unless the administrator provides otherwise. Shares of restricted
stock that do not vest are subject to our right of repurchase or forfeiture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Restricted Stock Units</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">RSUs may be granted under
the Plan. RSUs are bookkeeping entries representing an amount equal to the fair market value of one share of our common stock. Subject
to the provisions of the Plan, the administrator determines the terms and conditions of RSUs, including the vesting criteria and the form
and timing of payment. The administrator may set vesting criteria based upon the achievement of Company-wide, divisional, business unit
or individual goals (including continued employment or service), applicable federal or state securities laws or any other basis determined
by the administrator in its discretion. The administrator, in its sole discretion, may pay earned RSUs in the form of cash, in shares
of our common stock or in some combination thereof. Notwithstanding the foregoing, the administrator, in its sole discretion, may accelerate
the time at which any vesting requirements will be deemed satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Performance Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Performance awards may be
granted under the Plan. Performance awards are awards that will result in a payment to a participant only if performance goals established
by the administrator are achieved or the awards otherwise vest. The administrator will set objectives or vesting provisions, that, depending
on the extent to which they are met, will determine the value the payout for the performance awards. The administrator may set vesting
criteria based on the achievement of Company-wide, divisional, business unit, or individual goals (including, but not limited to, continued
employment or service), or any other basis determined by the administrator in its discretion. Each performance award&rsquo;s threshold,
target, and maximum payout values are established by the administrator on or before the grant date. After the grant of a performance award,
the administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such performance
award. The administrator, in its sole discretion, may pay earned performance awards in the form of cash, in shares, or in some combination
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Non-transferability
of Awards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Unless the administrator
provides otherwise, the Plan generally does not allow for the transfer of awards other than by will or by the laws of descent and distribution
and only the recipient of an award may exercise an award during their lifetime. If the administrator makes an award transferrable, such
award will contain such additional terms and conditions as the administrator deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Certain Adjustments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In the event of certain changes
in our capitalization, to prevent diminution or enlargement of the benefits or potential benefits available under the Plan, the administrator
will adjust the number and class of shares that may be delivered under the Plan or the number, and price of shares covered by each outstanding
award and the numerical share limits set forth in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Dissolution or Liquidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In the event of our proposed
liquidation or dissolution, the administrator will notify participants as soon as practicable and all awards will terminate immediately
prior to the consummation of such proposed transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Merger or Change in
Control</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Plan provides that in
the event of our merger with or into another corporation or entity or a &ldquo;change in control&rdquo; (as defined in the Plan), each
outstanding award will be treated as the administrator determines, including, without limitation, that (i) awards will be assumed, or
substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate
adjustments as to the number and kind of shares and prices; (ii) upon written notice to a participant, that the participant&rsquo;s awards
will terminate upon or immediately prior to the consummation of such merger or change in control; (iii) outstanding awards will vest and
become exercisable, realizable or payable, or restrictions applicable to an award will lapse, in whole or in part, prior to or upon consummation
of such merger or change in control and, to the extent the administrator determines, terminate upon or immediately prior to the effectiveness
of such merger or change in control; (iv) (A) the termination of an award in exchange for an amount of cash or property, if any, equal
to the amount that would have been attained upon the exercise of such award or realization of the participant&rsquo;s rights as of the
date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the
administrator determines in good faith that no amount would have been attained upon the exercise of such award or realization of the participant&rsquo;s
rights, then such award may be terminated by us without payment) or (B) the replacement of such award with other rights or property selected
by the administrator in its sole discretion; or (v) any combination of the foregoing. The administrator will not be obligated to treat
all awards, all awards a participant holds, or all awards of the same type, similarly. In the event that awards (or portion thereof) are
not assumed or substituted for in the event of a merger or change in control, the participant will fully vest in and have the right to
exercise all of their outstanding options and stock appreciation rights, including shares as to which such awards would not otherwise
be vested or exercisable, all restrictions on restricted stock and RSUs or performance awards will lapse and, with respect to awards with
performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all other
terms and conditions met, in all cases, unless specifically provided otherwise under the applicable award agreement or other written agreement
between the participant and us or any of our subsidiaries or parents, as applicable. If an option or stock appreciation right is not assumed
or substituted in the event of a merger or change in control, the administrator will notify the participant in writing or electronically
that the option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion
and the vested option or stock appreciation right will terminate upon the expiration of such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">For awards granted to an
outside director, the outside director will fully vest in and have the right to exercise options and/or stock appreciation rights as to
all of the shares underlying such award, including those shares which would not be vested or exercisable, all restrictions on restricted
stock and RSUs will lapse, and, with respect to awards with performance-based vesting, all performance goals or other vesting criteria
will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met, unless specifically provided
otherwise under the applicable award agreement or other written agreement between the participant and us or any of our subsidiaries or
parents, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Clawback</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Awards
will be subject to any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange
or association on which our securities are listed or as is otherwise required by the Dodd-Frank Act or other applicable laws. The administrator
also may specify in an award agreement that the participant&rsquo;s rights, payments or benefits with respect to an award will be subject
to reduction, cancellation, forfeiture or recoupment upon the occurrence of certain specified events. The administrator may require a
participant to forfeit, return or reimburse us all or a portion of the award or shares issued under the award, any amounts paid under
the award and any payments or proceeds paid or provided upon disposition of the shares issued under the award in order to comply with
such clawback policy or applicable laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B><I>Amendment and Termination</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
administrator has the authority to amend, suspend or terminate the Plan provided such action does not impair the existing rights of any
participant. The Plan automatically will terminate on November 22, 2032, unless it is terminated sooner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Board Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">In November and December 2022, we signed agreements
with four director nominees (Cheryl Xu, Paul Field, Charles Allen and Stephen Toovey) which come into effect on the date the registration
statement of which this prospectus forms a part becomes effective. Each director will receive cash compensation of $11,250 per quarter.
In addition, the two non-audit committee chairs (Mr. Toovey and Mr. Field) will receive $1,250 per quarter and the audit committee chair
(Mr. Allen) will receive an additional $2,000 per quarter. Each director will receive a one-off stock grant of [*] shares of common stock
at a per share price of $[*], [*] restricted stock units valued at $[*] per unit and a non-qualified option to purchase an additional
[*] shares of common stock at an exercise price of $[*].<B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_019"></A>PRINCIPAL STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table sets forth certain information, as of April 3, 2023 with respect to the holdings of (1) each person who is the beneficial
owner of more than 5% of our voting stock, (2) each of our directors, (3) each executive officer, and (4) all of our current directors
and executive officers as a group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial
ownership of the voting stock is determined in accordance with the rules of the SEC and includes any shares of company voting stock over
which a person exercises sole or shared voting or investment power, or of which a person has a right to acquire ownership at any time
within 60 days of April 3, 2023. Except as otherwise indicated, we believe that the persons named in this table have sole voting and
investment power with respect to all shares of voting stock held by them. Applicable percentage ownership in the following table is based
on 2,378,009 shares of common stock issued and outstanding on April 3, 2023 (excludes shares of common stock to be issued on the conversion
of our convertible notes which automatically converts upon the consummation of this offering and shares of common stock to be issued
prior to the closing of this offering as a success fee pursuant to the Investment Agreement), and after the offering assuming a common
stock offering of shares (excluding shares which may be sold upon exercise of the underwriters&rsquo; over-allotment option), plus, for
each individual, any securities that individual has the right to acquire within 60 days of April 3, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the best of our knowledge, except as otherwise
indicated, each of the persons named in the table has sole voting and investment power with respect to the shares of our common stock
beneficially owned by such person, except to the extent such power may be shared with a spouse. To our knowledge, none of the shares listed
below are held under a voting trust or similar agreement, except as noted. To our knowledge, there is no arrangement, including any pledge
by any person of our securities, the operation of which may at a subsequent date result in a change in control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name and Address<BR>
of Beneficial Owner<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Beneficially<BR>
Owned</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent of Class<BR>
Before Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent of Class<BR>
After Offering</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Officers and Directors</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; width: 30%"><FONT STYLE="font-size: 10pt">Geoffrey Dow</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 30%"><FONT STYLE="font-size: 10pt">President, Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">667,143</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt"><SUP>(2)</SUP>&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">28.05</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Tyrone Miller</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Treasurer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,928</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4.29</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Bryan Smith</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Medical Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Charles Allen</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director Nominee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Cheryl Xu</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director Nominee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Stephen Toovey</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director Nominee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Paul Field</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Director Nominee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Officers and Directors as a Group (total of [7] persons)</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">32.34</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>5% Stockholders</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Kentucky Technology INC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">525,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">22.08</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;[*] </FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Florida State University Research Foundation, INC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">405,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">17.03</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Douglas Loock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">165,938</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.98</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;[*]</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Trevally, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">120,000</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5.05</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Less than 1%&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unless
                                            otherwise indicated, the principal address of the named directors and directors and 5% stockholders
                                            of the Company is c/o 1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(2)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Includes
                                            667,143 shares of common stock held by the Geoffrey S. Dow Revocable Trust (the &ldquo;Dow
                                            Trust&rdquo;), of which Geoffrey Dow is the trustee and has control over the voting and disposition
                                            of the shares of common stock held by the Dow Trust.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_020"></A>CERTAIN RELATIONSHIPS AND
RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2022, we issued the Convertible Promissory Note to Mountjoy
Trust with a principal amount of $294,444.42 and a per annum interest rate of 6%. As of March 31, 2023, the outstanding balance
of this note was $309,705.19. Upon the occurrence of our initial public offering, the balance of such note will convert immediately prior
to the initial public offering at a price equal to 80% of the price per share of the common stock sold in the initial public offering.
We also issued to Mountjoy Trust a Common Stock Purchase Warrant to purchase a number of shares of our common stock equal to 100% of the
common stock issued to Mountjoy Trust as a result of the conversion of the note on the pricing date of our initial public offering at
the exercise price equal to 110% of the initial public offering price, or if we fail to complete the initial public offering prior to
May 31, 2023, 90% of the initial public offering price. John Dow, a relative of Geoffrey Dow, our President, Chief Executive Officer and
Director, is the trustee of the Mountjoy Trust.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 31, 2021, the majority member, Geoffrey
Dow, converted cumulative borrowings and interest into 3,942,919 member units with a par value of $1.00 and thus all debt owed to the
majority member was extinguished. We issued 37,067 shares to Geoffrey Dow (at $5.00 per share) on August 28, 2022, in recognition of capital
contributions of $185,335 made between January 1, 2022 and April 1, 2022. There are no other outstanding related party debt or obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 2, 2023, we issued a total of 100,000 shares of our common
stock to our legal counsel for payment of legal fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
March 2023, we received $200,000 paid in capital from the Geoffrey S. Dow Revocable Trust.<I>&nbsp;</I></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>The above summary description of related part
transactions includes some of the general terms and provisions of the agreements related to such transactions. For a more detailed description
of those agreements, you should refer to such agreements which are included as exhibits to the registration statement of which this prospectus
forms a part</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: center"><B>SELLING STOCKHOLDERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">This prospectus also relates to the sale or
other disposition of up to 1,925,202 shares of our common stock by the Selling Stockholders named below, and their donees, pledgees,
transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the
date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
table below sets forth information as of the date of this prospectus, to our knowledge, the Selling Stockholders and other information
regarding the beneficial ownership (as determined under Section&nbsp;13(d) of the Exchange Act and the rules and regulations thereunder)
of the shares of common stock held by the Selling Stockholders. The second column lists the number of shares of common stock beneficially
owned by the Selling Stockholders, as of April 3, 2023. The third column lists the maximum number of shares of common stock that may
be sold or otherwise disposed of by the Selling Stockholders pursuant to the registration statement of which this prospectus forms a
part. The Selling Stockholders may sell or otherwise dispose of some, all or none of their shares. Pursuant to Rules 13d-3 and 13d-5
of the Exchange Act, beneficial ownership includes any shares of our common stock as to which a stockholder has sole or shared voting
power or investment power, and also any shares of our common stock which the stockholder has the right to acquire within 60 days. The
percentage of beneficial ownership for the Selling Stockholders is based on shares of common stock outstanding as of the date of this
prospectus. Except as described below, to our knowledge, none of the Selling Stockholders have had any material relationship with us
within the past three years. Our knowledge is based on information provided by the Selling Stockholders in registration statement questionnaires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The shares of common stock being covered hereby may
be sold or otherwise disposed of from time to time during the period the registration statement of which this prospectus is a part remains
effective, by or for the account of the Selling Stockholders. After the date of effectiveness, the Selling Stockholders may have sold
or transferred, in transactions covered by this prospectus, some or all of their common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Information about the Selling Stockholders
may change over time. Any changed information will be set forth in an amendment to the registration statement or supplement to this prospectus,
to the extent required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares Beneficially</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Owned&nbsp;as&nbsp;of&nbsp;the&nbsp;date&nbsp;of<BR>
    this Prospectus</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares <BR>
    Offered by <BR>
    this</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Shares Beneficially</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>Owned After the<BR>
    Offering<SUP>(1)</SUP></B></FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Selling Stockholder</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Prospectus</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Percent</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Geoffrey S. Dow Revocable Trust<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">667,143</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">13,387</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">680,530</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Douglas Loock</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">165,938</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">165,938</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Carmel, Milazzo &amp; Feil LLP</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">100,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Florida State University Research Foundation, Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">405,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">405,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Latham BioPharm Group, LLC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">65,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">65,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Trevally, LLC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">120,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">120,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Edward Newland</FONT></P></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8,500</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">8,500</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">4C Pharma Solutions, LLC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">54,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Hybrid Financial</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">65,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">65,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Method Health Communications LLC</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">20,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Kentucky Technology Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">525,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">525,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Mountjoy Trust<SUP>(3)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">88,688</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Walleye Opportunities Master Fund Ltd.<SUP>(3)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66,934</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Bigger Capital Fund, LP<SUP>(3)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">80,321</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Cavalry Investment Fund, LP.<SUP>(3)</SUP></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">66,934</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 12pt; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Ludlow Business Services, Inc.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37,500</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">37,500</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Elliot Berman</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">30,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Delve Innovation Pty Ltd</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">13,000</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD>Less than 1%.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Assumes the sale of all shares offered pursuant to this prospectus, except that those issued to the Geoffrey S. Dow Revocable Trust upon mandatory conversion of the Geoffrey Dow Trust Note which will subject to a lock-up agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">Geoffrey S. Dow Revocable Trust owns 667,143 shares as of the date of this prospectus, and will be issued 13,387 upon mandatory conversion of its Geoffrey Dow Trust Note immediately prior to the consummation of this initial public offering. All 680,530 shares will be subject to lock-up.</FONT></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Shares offered in this prospectus and owned by these entities will be issued in conjunction with mandatory conversion or extinguishment of interim financing notes.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"><B>Plan of Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">The Selling Stockholders may, from time to
time, sell any or all of their shares of common stock on any stock exchange, market or trading facility on which the shares are traded
or in private transactions. These sales may be at fixed or negotiated prices. The Selling Stockholders may use any one or more of the
following methods when selling shares:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer
    solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">block trades in which the broker-dealer will attempt to sell the shares
    as agent but may position and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">purchases by a broker-dealer as principal and
    resale by the broker-dealer for its account;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an exchange distribution in accordance with the rules of the applicable
    exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">privately negotiated transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">short sales effected after the date the registration
    statement of which this prospectus is a part is declared effective by the SEC;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">broker-dealers may agree with the selling stockholders to sell a specified
    number of such shares at a stipulated price per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a combination of any such methods of sale; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any other method permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Broker-dealers engaged by the Selling Stockholders
may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders
(or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. The Selling Stockholders
do not expect these commissions and discounts to exceed what is customary in the types of transactions involved. Any profits on the resale
of shares of common stock by a broker-dealer acting as principal might be deemed to be underwriting discounts or commissions under the
Securities Act. Discounts, concessions, commissions and similar selling expenses, if any, attributable to the sale of shares will be
borne by a Selling Stockholder. The Selling Stockholders may agree to indemnify any agent, dealer or broker-dealer that participates
in transactions involving sales of the shares if liabilities are imposed on that person under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">The Selling Stockholders may from time to
time pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance
of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this
prospectus after we have filed a supplement to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act
supplementing or amending the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling
Stockholders under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0; text-align: justify">The Selling Stockholders also may transfer the
shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling
beneficial owners for purposes of this prospectus and may sell the shares of common stock from time to time under this prospectus after
we have filed a supplement to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act supplementing
or amending the list of Selling Stockholders to include the pledgee, transferee or other successors in interest as Selling Stockholders
under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Selling Stockholders and any broker-dealers or
agents that are involved in selling the shares of common stock held by the Selling Stockholders or its transferees, pledgees or other
successors in interest may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act in connection with such
sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares of common
stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">We are required to pay all fees and expenses
incident to the registration of the shares of common stock held by the Selling Stockholders. We have agreed to indemnify the Selling
Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">The Selling Stockholders have advised us that
they have not entered into any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale
of their shares of common stock, nor is there an underwriter or coordinating broker acting in connection with a proposed sale of common
stock by any Selling Stockholder. If we are notified by any Selling Stockholder that any material arrangement has been entered into with
a broker-dealer for the sale of shares of his, her, or its common stock, if required, we will file a supplement to this prospectus. If
the Selling Stockholders use this prospectus for any sale of their shares of common stock, they will be subject to the prospectus delivery
requirements of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">In order to comply with the securities laws
of some states, if applicable, the common stock held by the Selling Stockholders or its transferees, pledgees or other successors in
interest may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common
stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements
is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">We have advised the Selling Stockholders that
the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of
the Selling Stockholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as it may
be supplemented or amended from time to time) available to the Selling Stockholders for the purpose of satisfying the prospectus delivery
requirements of the Securities Act. The Selling Stockholders may indemnify any broker-dealer that participates in transactions involving
the sale of the shares against certain liabilities, including liabilities arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">We have agreed with the Selling Stockholders
to keep the registration statement of which this prospectus constitutes a part effective until the earliest of (1)&nbsp;such time as
all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement and
(2)&nbsp;the date on which all of the shares may be sold without restriction pursuant to Rule 144 of the Securities Act.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_021"></A>DESCRIPTION
OF SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following description of our securities is
only a summary and is qualified in its entirety by reference to the actual terms and provisions of the capital stock contained in our
Certificate of Incorporation and our Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are authorized to issue one class of stock. The total number of shares of stock which we are authorized to issue is 151,000,000 shares
of capital stock, 150,000,000 of which are common stock, $0.0001 par value per share, and 1,000,000 of which are &ldquo;blank check&rdquo;
preferred stock. As of April 3, 2023, 2,378,009 shares of common stock were issued and outstanding and held by 15 stockholders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The holders of our common stock are entitled
to the following rights:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Voting Rights</I></B>. Each share of our
common stock entitles its holder to one vote per share on all matters to be voted or consented upon by the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Dividend Rights</I></B>. Subject to limitations
under Delaware law, holders of our common stock are entitled to receive ratably such dividends or other distributions, if any, as may
be declared by our Board out of funds legally available therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Liquidation Rights</I></B>. In the event
of liquidation, dissolution or winding up of our business, the holders of our common stock are entitled to share ratably in the assets
available for distribution after the payment of all of our debts and other liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Matters</I></B>. The holders of our
common stock have no subscription, redemption or conversion privileges; in addition, such common stock does not entitle its holders to
preemptive rights. All of the outstanding shares of our common stock are fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Certificate of Incorporation authorizes 1,000,000 shares of &ldquo;blank check&rdquo; preferred stock, par value $0.0001 per share. Upon
the consummation of this initial public offering, we will have authorized 80,965 shares of Series A Preferred Stock with the following
terms and rights: (i) 6% dividend, (ii) non-voting; (iii) not redeemable; and (iv) convertible into shares of common stock, solely at
the Company&rsquo;s discretion, determined by (A) multiplying the number of shares of Series A Preferred Stock to be converted by $100,
(B) adding to the result all accrued and accumulated and unpaid dividends on such shares to be converted, if any, and then (C) dividing
the result by a price equal to the lower of (1) $100, (2) the price paid for the shares of common stock in this offering and (3) the
10-day volume weighted average share price immediately preceding our election to convert the shares of Series A Preferred Stock; provided
that the conversion of the shares of Series A Preferred Stock does not result in the holder&rsquo;s ownership of common stock exceeding
19.9%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board may provide for the issue of any or
all of the unissued and undesignated shares of the preferred stock in one or more series, and to fix the number of shares and to determine
or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative,
participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed
in the resolution or resolutions adopted by the Board providing for the issuance of such shares and as may be permitted by law, without
stockholder approval. Our Board is able to determine, with respect to any series of preferred stock, the terms and rights of that series,
including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            designation of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            number of shares of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">whether
                                            dividends, if any, will be cumulative or non-cumulative and the dividend rate, if any, of
                                            the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            dates at which dividends, if any, will be payable;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            redemption rights and price or prices, if any, for shares of the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            terms and amounts of any sinking fund provided for the purchase or redemption of shares of
                                            the series;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            amounts payable on shares of the series in the event of any voluntary or involuntary liquidation,
                                            dissolution or winding-up of the affairs of our Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">whether
                                            the shares of the series will be convertible into shares of any other class or series, or
                                            any other security, of our Company or any other entity, and, if so, the specification of
                                            the other class or series or other security, the conversion price or prices or rate or rates
                                            and provisions for any adjustments to such prices or rates, the date or dates as of which
                                            the shares will be convertible, and all other terms and conditions upon which the conversion
                                            may be made;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            ranking of such series with respect to dividends and amounts payable on our liquidation,
                                            dissolution or winding-up, which may include provisions that such series will rank senior
                                            to our common stock with respect to dividends and those distributions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">restrictions
                                            on the issuance of shares of the same series or any other class or series; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">voting
                                            rights, if any, of the holders of the series.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of preferred stock could adversely
affect, among other things, the voting power of holders of common stock and the likelihood that stockholders will receive dividend payments
and payments upon our liquidation, dissolution or winding up. The issuance of preferred stock could also have the effect of delaying,
deferring or preventing a change in control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Warrants Issued in this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Overview</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summary of certain terms and provisions
of the warrants offered hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Warrant Agent
Agreement and the form of warrant, both of which are filed as exhibits to the registration statement of which this prospectus is a part.
Prospective investors should carefully review the terms and provisions set forth in the Warrant Agent Agreement, including the annexes
thereto, and form of warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The warrants issued in this offering entitle the
registered holder to purchase one share of our common stock at an assumed exercise price of $5.9225 per share, 115% of the assumed public
offering price of $5.15 per unit, the midpoint of the offering price per unit, subject to adjustment as discussed below, immediately
following the issuance of such warrant and terminating at 5:00 p.m., New York City time, on the fifth anniversary of the date of issuance.
We will not apply to have the warrants underlying the units listed on any exchange or market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The exercise price and number of shares of common
stock issuable upon exercise of the warrants may be adjusted in certain circumstances, including in the event of a stock dividend or
recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of common stock at
prices below its exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Exercisability</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The warrants are exercisable at any time after their
original issuance and at any time up to the date that is five years after their original issuance. The warrants may be exercised upon
surrender of the warrant certificate on or prior to the expiration date at the offices of the Warrant Agent, by utilizing the exercise
form on the reverse side of the warrant certificate completing and executing as indicated, accompanied by full payment of the exercise
price, by certified or official bank check payable to us, for the number of warrants being exercised. Under the terms of the Warrant
Agent Agreement, we must use our best efforts to maintain the effectiveness of the registration statement and current prospectus relating
to common stock issuable upon exercise of the warrants until the expiration of the warrants. If we fail to maintain the effectiveness
of the registration statement and current prospectus relating to the common stock issuable upon exercise of the warrants, the holders
of the warrants shall have the right to exercise the warrants solely via a cashless exercise feature provided for in the warrants, until
such time as there is an effective registration statement and current prospectus relating to common stock issuable upon exercise of the
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Exercise Limitation</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A holder may not exercise any portion of a warrant
to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99%
of the outstanding common stock after exercise, as such percentage ownership is determined in accordance with the terms of the warrant,
except that upon prior notice from the holder to us, the holder may waive such limitation up to a percentage not in excess of 9.99%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Exercise Price</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The exercise price per whole share of common stock
purchasable upon exercise of the warrants is $5.9225 per share (based on an assumed public offering price of $5.15 per unit) or 115%
of the public offering price of the common stock. The exercise price is subject to appropriate adjustment in the event of certain stock
dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also
upon any distributions of assets, including cash, stock or other property to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Fractional Shares</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No fractional shares of common stock will be issued
upon exercise of the warrants. If, upon exercise of the warrant, a holder would be entitled to receive a fractional interest in a share,
we will, upon exercise, pay a cash adjustment in respect of such fraction in an amount equal to such fraction multiplied by the exercise
price. If multiple warrants are exercised by the holder at the same time, we shall pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Transferability</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Subject to applicable laws, the warrants may be offered
for sale, sold, transferred or assigned without our consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Warrant Agent; Global Certificate</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The warrants will be issued in registered form under
a Warrant Agent Agreement between the Warrant Agent and us. The warrants shall initially be represented only by one or more global warrants
deposited with the Warrant Agent, as custodian on behalf of The Depository Trust Company (&ldquo;DTC&rdquo;) and registered in the name
of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC. Our transfer agent, Equity Stock Transfer, LLC, will serve as the
Warrant Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Fundamental Transactions</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the event of a fundamental transaction, as described
in the warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer
or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person,
the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the
voting power represented by our outstanding common stock, the holders of the warrants will be entitled to receive the kind and amount
of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such
fundamental transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Rights as a Stockholder</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The warrant holders do not have the rights or privileges
of holders of common stock or any voting rights until they exercise their warrants and receive shares of common stock. After the issuance
of shares of common stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record on all
matters to be voted on by stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I><U>Governing Law </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The warrants and the Warrant Agent Agreement are
governed by New York law.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Notes Outstanding</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 10, 2015, we entered into the Loan Agreement and Engagement with Knight, as amended eight times, pursuant to which, we originally
borrowed $500,000 at a per annum interest rate of 15% (the &ldquo;Knight Loan&rdquo;) and a debenture agreement of face value $3 million
on April 24, 2018. As of December 31, 2022, the current outstanding balance of the Knight Loan and Knight Debenture is $20,596,595.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the Knight Debt Conversion Agreement, executed January 9, 2023 and modified on January 13, 2023, and again on January 27, 2023, Knight
and us agreed, to formalize a previously negotiated term sheet that, in the event of a successful initial public offering, we will fix
Knight&rsquo;s cumulative debt to the value as it stood on March 31, 2022, which consisted of $10,770,037 in principal and $8,096,486
in accumulated interest, and to convert the aforementioned amounts, should we consummate an initial public offering that results in gross
proceeds of at least $7,000,000 prior to December 31, 2023 as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 35px; padding-bottom: 12pt; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We agreed
    to convert the principal amount into (i) that number of shares of common stock equal to dividing the principal amount by an amount
    equal to the offering price of the common stock in the initial public offering discounted by 15% (the &ldquo;Conversion Common Shares&rdquo;),
    rounding up for fractional shares, in a number of Conversion Shares up to 19.9% of our outstanding common stock after giving effect
    of the initial public offering; (ii) we will make a milestone payment of $10 million to Knight if, after the date of a qualifying
    initial public offering, we sell ARAKODA or if a Change of Control (as per the definition included in the original loan agreement
    dated on&nbsp;December 10, 2015) occurs, provided that the purchaser of ARAKODA or individual or entity gaining control of us is
    not Knight or an affiliate of Knight; (iii) following the License and Supply agreement dated on December 10, 2015 and subsequently
    amended on January 21, 2019, an expansion of existing distribution rights to Tafenoquine/Arakoda to include COVID-19 indications
    as well as malaria prevention across the Territory as defined in said documents, subject to U.S. Army approval; and (iv) we will
    retain Knight or an affiliate of Knight to provide financial consulting services, management, strategic and/or regulatory advice
    of value $30,000 per month for five years (the parties will negotiate the terms of that consulting agreement separately in good faith).</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 33px"></TD><TD STYLE="width: 35px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            parties agreed to convert the&nbsp;accrued interest into that number of shares of a new class
                                            of preferred stock by dividing the Accrued Interest by $100.00, then rounding up. The Preferred
                                            Stock shall have the following rights, preferences, and designations: (i) have a 6% cumulative
                                            dividend accumulated annually on March 31; (ii) shall be non-voting stock; (iii) are not
                                            redeemable, (iv) be convertible to shares of common stock at a price equal to the lower of
                                            (1) the price paid for the shares of common stock in the initial public offering and (2)
                                            the 10 day volume weighted average share price immediately prior to conversion; and (v) conversion
                                            of the preferred stock to common shares will be at our sole discretion. Notwithstanding the
                                            foregoing, we shall not convert the Preferred Stock into shares of common stock if as a result
                                            of such conversion Knight will own 19.9% or more of our outstanding common stock.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 33px"></TD><TD STYLE="width: 35px; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition to the conversion of the debt, for a period commencing on January 1, 2022 and ending
                                            upon the earlier of 10 years after the closing of the initial public offering or the conversion
                                            or redemption in full of the Conversion Preferred Shares, we shall pay Knight a royalty equal
                                            to 3.5% of our net sales, where &ldquo;Net Sales&rdquo; has the same meaning as in our license
                                            agreement with the U.S. Army for Tafenoquine. Upon the qualified initial public offering,
                                            we shall calculate the royalty payable to Knight at the end of each calendar quarter. We
                                            shall pay to Knight the royalty amounts due with respect to a given calendar quarter within
                                            fifteen (15) business days after the end of such calendar quarter. Each payment of royalties
                                            due to Knight shall be accompanied by a statement specifying the total gross sales, the net
                                            sales and the deductions taken to arrive to net sales. For clarification purposes, the first
                                            royalty payment will be performed following the above instructions, on the first calendar
                                            quarter in which the qualified initial public offering takes place and will cover the sales
                                            of the period from January 1, 2022, until the end of said calendar quarter.</FONT></P><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Should
an initial public offering not occur by January 1, 2024, then all terms of the original Knight Loan and Knight Debenture would resume
including any interest earned after March 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October 11, 2017, we issued a $750,000 promissory note, as amended, to Avante International Limited with accrued interest at an annual
rate of 5.0% for the first six months, and 10% thereafter. On December 23, 2017, Avante transferred the Avante Note to Xu Yu Equity Conversion
Note. On December 11, 2022, Avante and us amended the Avante Note. The Amendment added a provision to automatically convert the outstanding
principal and accumulated interest through March 31, 2022 to shares of common stock in the event we consummate an initial public offering.
The Amendment also provides Avante the option to convert the outstanding principal and accumulated interest through March 31, 2022 to
equity in the Company at the maturity date and will have 30 days from maturity to exercise this option. Cumulative interest after March
31, 2022 will be forfeited should the lender elect to convert the Note into equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
evaluated the Amendment and determined that it constitutes an extinguishment as the option to convert interest through March 31, 2022
and is considered the addition of a substantive conversion option. Accordingly, the Amendment resulted in extinguishment accounting and
a corresponding extinguishment gain of $120,683, which represents the difference between the carrying value of the Avante Note just prior
to the Amendment and the fair value of the Avante Note just after the Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The extinguishment accounting resulted in a fair value of the Avante
Note, including the Amendment of $1,099,578. The discount of $120,683 and costs incurred with third parties directly related to the Amendment
of $1,767 will be amortized over the remaining life of the debt using the effective interest method. Amortization of the discount on the
Avante Note, including the Amendment for the year ended December 31, 2022 was $4,955 ($0 in 2021). Interest expense related to the Note,
including the Amendment, for the year ended December 31, 2022 was $115,546 ($104,558 in 2021).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May 14, 2020, we issued the note to the U.S. Small Business Administration with a principal amount of $150,000 and a per annum interest
rate of 3.75%. The current outstanding balance of the COVID-19 Loan is $163,022 as of December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May 19, 2022, we issued a Convertible Promissory Note to Geoffrey Dow, as assigned to the Geoffrey S. Dow Revocable Trust dated August
27, 2018 on May 19, 2022 (the &ldquo;Geoffrey Dow Trust Note&rdquo;), with a principal amount of $44,444.44 and a per annum interest
rate of 6%. Upon the occurrence of our initial public offering, the balance of such note will convert immediately prior to the initial
public offering at a price equal to 80% of the price per share of the common stock sold in the initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
May 19, 2022, we issued a Convertible Promissory Note to Mountjoy Trust with a principal amount of $294,444.42 and a per annum interest
rate of 6%. Upon the occurrence of our initial public offering, the balance of such note will convert immediately prior to the initial
public offering at a price equal to 80% of the price per share of the common stock sold in the initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 24, 2022, we issued a note in the amount of
$333,333.30 to Bigger Capital Fund, LP. On the date of the pricing of our initial public offering, we will deliver to Bigger Capital
Fund, LP shares of our common stock equal to (i) 100% of the face value of the note divided by the initial public offering price per
share or (ii) if we fail to complete the initial public offering prior to May 24, 2023, the number of shares of our common stock calculated
using a $27 million pre-money valuation and the number of our outstanding shares of common stock on May 24, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2022, we issued a note in the amount
of $277,777.78 to Cavalry Investment Fund, LP. On the date of the pricing of our initial public offering, we will deliver to Cavalry
Investment Fund, LP shares of our common stock equal to (i) 100% of the face value of the note divided by the initial public offering
price per share or (ii) if we fail to complete the initial public offering prior to May 24, 2023, the number of shares of our common
stock calculated using a $27 million pre-money valuation and the number of our outstanding shares of common stock on May 24, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2022, we issued a note in the amount
of $277,777.78 to Walleye Opportunities Master Fund Ltd. On the date of the pricing of our initial public offering, we will deliver to
Walleye Opportunities Master Fund Ltd shares of our common stock equal to (i) 100% of the face value of the note divided by the initial
public offering price per share or (ii) if we fail to complete the initial public offering prior to May 24, 2023, the number of shares
of our common stock calculated using a $27 million pre-money valuation and the number of our outstanding shares of common stock on May
24, 2023.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2022, we issued to Geoffrey Dow a right
to receive five-year (5) warrants upon the closing of an IPO, with an exercise price of 110% of the IPO price. If the IPO is not completed
by May 31, 2023, the exercise price is 90% of the IPO price.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 19, 2022, we issued to Mountjoy Trust a right to receive five-year
(5) warrants upon the closing of an IPO, with an exercise price of 110% of the IPO price. If the IPO is not completed by May 31, 2023,
the exercise price is 90% of the IPO price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2022, we issued to Bigger Capital Fund,
LP a right to receive five-year (5) warrants upon the closing of an IPO, with an exercise price of 110% of the IPO price.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2022, we issued to Cavalry Investment
Fund, LP a right to receive five-year (5) warrants upon the closing of an IPO, with an exercise price of 110% of the IPO price.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2022, we issued to Walleye Opportunities
Master Fund Ltd a right to receive five-year (5) warrants upon the closing of an IPO, with an exercise price of 110% of the IPO price.<B><I>&nbsp;</I></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Section 203 of the Delaware General Corporation
Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are subject to the provisions of Section 203
of the DGCL regulating corporate takeovers. This statute prevents certain Delaware corporations, under certain circumstances, from engaging
in a &ldquo;business combination&rdquo; with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">a
                                            stockholder who owns 15% or more of our outstanding voting stock (otherwise known as an &ldquo;interested
                                            stockholder&rdquo;);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">an
                                            affiliate of an interested stockholder; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">an
                                            associate of an interested stockholder, for three years following the date that the stockholder
                                            became an interested stockholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A &ldquo;business combination&rdquo; includes
a merger or sale of more than 10% of our assets. However, the above provisions of Section 203 do not apply if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our
                                            Board approves the transaction that made the stockholder an &ldquo;interested stockholder,&rdquo;
                                            prior to the date of the transaction; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">after
                                            the completion of the transaction that resulted in the stockholder becoming an interested
                                            stockholder, that stockholder owned at least 85% of our voting stock outstanding at the time
                                            the transaction commenced, other than statutorily excluded shares of common stock.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Potential Effects of Authorized but Unissued Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our shares of common and preferred stock are
available for future issuance without stockholder approval. We may utilize these additional shares for a variety of corporate purposes,
including future public offerings to raise additional capital, to facilitate corporate acquisitions, payment as a dividend on the capital
stock or as equity compensation to our service providers under our equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The existence of unissued and unreserved common
stock and preferred stock may enable our Board to issue shares to persons friendly to current management or to issue preferred stock
with terms that could render more difficult or discourage a third-party attempt to obtain control by means of a merger, tender offer,
proxy contest or otherwise, thereby protecting the continuity of our management. In addition, our Board has the discretion to determine
designations, rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption
privileges and liquidation preferences of each series of preferred stock, all to the fullest extent permissible under the Delaware General
Corporation Law and subject to any limitations set forth in our Certificate of Incorporation. The purpose of authorizing the Board to
issue preferred stock and to determine the rights and preferences applicable to such preferred stock is to eliminate delays associated
with a stockholder vote on specific issuances. The issuance of preferred stock, while providing desirable flexibility in connection with
possible financings, acquisitions and other corporate purposes, could have the effect of making it more difficult for a third party to
acquire, or could discourage a third party from acquiring, a majority of our outstanding voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also, if we issue additional shares of our authorized,
but unissued, common stock, these issuances will dilute the voting power and distribution rights of our existing common stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent and registrar for our common
stock will be Equity Stock Transfer, LLC (&ldquo;Equity Stock Transfer&rdquo;), located at 237 West 37th Street, Suite 602, New York,
NY 10018. The phone number and facsimile number for Equity Stock Transfer are (212) 575-5757 and (347) 584-3644, respectively. Additional
information about Equity Stock Transfer can be found on its website at <I>www.equitystock.com</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have applied to have our common stock listed on
The Nasdaq Capital Market under the symbol &ldquo;SXTP,&rdquo; which listing is a condition to this offering. We do not intend to apply
for listing of the warrants on any exchange or market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><A NAME="a_022"></A><B>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There is not currently an established U.S. trading
market for our common stock. We cannot predict the effect, if any, that market sales of shares of our common stock or the availability
of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Sales of substantial
amounts of our common stock, including shares issued upon exercise of outstanding warrants, in the public market after this offering,
could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through the sale of our
equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon completion of the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock pursuant to this offering, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock issued and outstanding. In the event the underwriters exercise the over-allotment option in full, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock issued and outstanding. The common stock sold in this offering will be freely tradable without restriction or
further registration or qualification under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All previously issued shares of common stock
that were not offered and sold in this offering, are or will be upon issuance, &ldquo;restricted securities,&rdquo; as that term is defined
in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if such public resale is registered
under the Securities Act or if the resale qualifies for an exemption from registration under Rule 144 under the Securities Act, which
are summarized below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In general, a person who has beneficially owned
restricted shares of our common stock for at least six months in the event we have been a reporting company under the Exchange Act for
at least ninety (90) days before the sale, would be entitled to sell such securities, provided that such person is not deemed to be an
affiliate of ours at the time of sale or to have been an affiliate of ours at any time during the ninety (90) days preceding the sale.
A person who is an affiliate of ours at such time would be subject to additional restrictions, by which such person would be entitled
to sell within any three-month period only a number of shares that does not exceed the greater of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1% of the number of shares of our common stock
then outstanding; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1% of the average weekly trading volume of our
common stock during the four calendar weeks preceding the filing by such person of a notice on Form 144 with respect to the sale;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided that, in each case, we are subject to
the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Rule 144 trades must also comply with the
manner of sale, notice and other provisions of Rule 144, to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-Up Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our executive officers and directors have agreed
with the underwriters not to sell, transfer or dispose of any shares or similar securities for six months following the effective date
of the registration statement for this offering. Any other holders of more than 5% of the outstanding shares of our common stock have
also agreed with the underwriters not to sell, transfer or dispose of any shares or similar securities for six months following the effective
date of the registration statement for this offering without the prior written consent of the underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_023"></A><FONT STYLE="text-transform: uppercase"><B>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are offering our securities described in this
prospectus through the underwriters named below. WallachBeth Capital LLC is acting as representative of the underwriters. We have entered
into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, each of the
underwriters has severally agreed to purchase, and we have agreed to sell to the underwriters, the number of common stock and warrants
listed next to its name in the following table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 68%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Underwriters</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 13%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of<BR>
    Shares</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 13%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of<BR>
    Warrants</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCECFF">
    <TD><FONT STYLE="font-size: 10pt">WallachBeth Capital LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">[&bull;]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">[&bull;]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 17.95pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCECFF">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">[&bull;]</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">[&bull;]</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The underwriting agreement provides that the underwriters
must buy all of the securities being sold in this offering if they buy any of them. However, the underwriters are not required to take
or pay for the securities covered by the underwriters&rsquo; option to purchase additional securities as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our securities are offered subject to a number of
conditions, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">receipt
                                            and acceptance of our common stock and warrants by the underwriters; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">the
                                            underwriters&rsquo; right to reject orders in whole or in part.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this offering, certain of
the underwriters or securities dealers may distribute prospectuses electronically.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Over-Allotment Option</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0">We have granted the underwriters
an option exercisable for 45 days after the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate
of (i) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock included in the Units and/or (ii) Warrants to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
of common stock included in the Units (15% of the shares of common stock and Warrants included in Units sold in this offering) from us
in any combination thereof to cover over allotments, if any, at the public offering price, less underwriting discounts and commissions
and the non-accountable expense allowance payable to the underwriters. To the extent that this option is exercised, each underwriter will
be obligated, subject to certain conditions, to purchase its pro rata portion of these additional shares or Warrants based on the underwriter&rsquo;s
percentage underwriting commitment in this offering as indicated in the table at the beginning of this Underwriting Section.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Underwriting Discount</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Securities sold by the underwriters to the public
will initially be offered at the initial unit offering price set forth on the cover of this prospectus. Any securities sold by the underwriters
to securities dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per unit from
the initial public offering price. The underwriters may offer the securities through one or more of their affiliates or selling agents.
If all the units are not sold at the initial public offering price, WallachBeth Capital LLC may change the offering price and the other
selling terms. Upon execution of the underwriting agreement, the underwriters will be obligated to purchase the securities at the prices
and upon the terms stated therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the per unit and total
underwriting discount we will pay to the underwriters assuming both no exercise and full exercise of the underwriters&rsquo; option to
purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional common stock and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
additional warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 55%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per
    Unit</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total
    without</B><BR>
    <B>Over-Allotment</B><BR>
    <B>Option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total
    with</B><BR>
    <B>Over-Allotment</B><BR>
    <B>Option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top; width: 1%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Public
    offering price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Underwriting
    discounts and commissions (8%)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-size: 10pt">Proceeds,
    before expenses to us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: right">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have agreed to pay WallachBeth Capital LLC a non-accountable expense allowance of 1.5% of the gross proceeds of the offering. We also
have agreed to pay WallachBeth Capital LLC&rsquo;s fees and expenses up to a maximum amount of $145,000. We have paid $10,000 to WallachBeth
Capital LLC as an advance to be applied towards reasonable out-of-pocket expenses, or the advance. Any portion of the advance shall be
returned back to us to the extent not actually incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We estimate that the total expenses of the offering
payable by us, not including the underwriting discount, will be approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
We have also agreed to reimburse the underwriters for certain expenses incurred by them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Right of First Refusal</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For a period of one year from the closing of
this offering, we will grant to WallachBeth Capital LLC an irrevocable right of first refusal to act as lead underwriter or book-running
manager or placement agent for each and every future public and private equity and debt offerings of the Company, or any successor to
or any subsidiary of the Company in any stock exchange during such one-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to indemnify the several underwriters
against certain liabilities, including certain liabilities under the Securities Act. If we are unable to provide this indemnification,
we have agreed to contribute to payments the underwriters may be required to make in respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Relationships</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Some of the underwriters and their affiliates
have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business
with us or our affiliates. They have received, or may in the future receive, customary fees and commissions for these transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>No Public Market</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, there has not been a
public market for our securities in the U.S. and the public offering price for our units will be determined through negotiations between
us and the underwriters. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial
information, market valuations of other companies that we and the underwriters believe to be comparable to us, estimates of our business
potential, the present state of our development and other factors deemed relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We offer no assurances that the initial public
offering price will correspond to the price at which our common stock will trade in the public market subsequent to this offering or
that an active trading market for our common stock will develop and continue after this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock Exchange</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have applied to have our common stock listed
on The Nasdaq Capital Market under the symbol &ldquo;SXTP.&rdquo; There can be no assurance that we will be successful in listing our
common stock on The Nasdaq Capital Market. We do not intend to apply for listing of the warrants on any exchange or market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Electronic Distribution</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A prospectus in electronic format may be made
available on websites or through other online services maintained by one or more of the underwriters of this offering, or by their affiliates.
Other than the prospectus in electronic format, the information on any underwriter&rsquo;s website and any information contained in any
other website maintained by an underwriter is not part of this prospectus or the registration statement of which this prospectus forms
a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter, and should not be relied upon
by investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Price Stabilization, Short Positions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with this offering, the underwriters
may engage in activities that stabilize, maintain or otherwise affect the price of our common stock during and after this offering, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">stabilizing
                                            transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">short
                                            sales;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">purchases
                                            to cover positions created by short sales;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">imposition
                                            of penalty bids; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">syndicate
                                            covering transactions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Stabilizing transactions consist of bids or purchases
made for the purpose of preventing or retarding a decline in the market price of our common stock while this offering is in progress.
Stabilization transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified
maximum. These transactions may also include making short sales of our common stock, which involve the sale by the underwriters of a
greater number of common stock than they are required to purchase in this offering and purchasing common stock on the open market to
cover short positions created by short sales. Short sales may be &ldquo;covered short sales,&rdquo; which are short positions in an amount
not greater than the underwriters&rsquo; option to purchase additional shares referred to above, or may be &ldquo;naked short sales,&rdquo;
which are short positions in excess of that amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters may close out any covered short
position by either exercising their option, in whole or in part, or by purchasing shares in the open market. In making this determination,
the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the
price at which they may purchase shares through the over-allotment option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Naked short sales are short sales made in excess
of the over-allotment option. The underwriters must close out any naked short position by purchasing shares in the open market. A naked
short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the
common stock in the open market that could adversely affect investors who purchased in this offering.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters also may impose a penalty bid.
This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because has
repurchased shares sold by or for the account of that underwriter in stabilizing or short covering transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These stabilizing transactions, short sales,
purchases to cover positions created by short sales, the imposition of penalty bids and syndicate covering transactions may have the
effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our
common stock. As a result of these activities, the price of our common stock may be higher than the price that otherwise might exist
in the open market. The underwriters may carry out these transactions on The Nasdaq Capital Market, in the over-the-counter market or
otherwise. Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above
may have on the price of the shares. Neither we, nor any of the underwriters make any representation that the underwriters will engage
in these stabilization transactions or that any transaction, once commenced, will not be discontinued without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Determination of Offering Price</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Prior to this offering, there was no public market
for our common stock. The initial public offering price will be determined by negotiation between us and WallachBeth Capital LLC. The
principal factors to be considered in determining the initial public offering price include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            information set forth in this prospectus and otherwise available to WallachBeth Capital LLC;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our
                                            history and prospects and the history and prospects for the industry in which we compete;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our
                                            past and present financial performance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">our
                                            prospects for future earnings and the present state of our development;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            general condition of the securities market at the time of this offering;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">the
                                            recent market prices of, and demand for, publicly traded shares of generally comparable companies;
                                            and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&bull;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">other
                                            factors deemed relevant by the underwriters and us.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The estimated public offering price range set
forth on the cover page of this preliminary prospectus is subject to change as a result of market conditions and other factors. Neither
we nor the underwriters can assure investors that an active trading market will develop for our common stock or that the common stock
will trade in the public market at or above the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Affiliations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The underwriters and their respective affiliates
are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities.
The underwriters and their affiliates may from time to time in the future engage with us and perform services for us or in the ordinary
course of their business for which they will receive customary fees and expenses. In the ordinary course of their various business activities,
the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities
(or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their
customers, and such investment and securities activities may involve securities and/or instruments of us. The underwriters and their
respective affiliates may also make investment recommendations and/or publish or express independent research views in respect of these
securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in these securities
and instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Offer Restrictions Outside the United States</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">No action has been taken
in any jurisdiction (except in the United States) that would permit a public offering of the common stock the possession, circulation
or distribution of this prospectus or any other material relating to us or the common stock in any jurisdiction where action for that
purpose is required. Accordingly, the common stock may not be offered or sold, directly or indirectly, and neither this prospectus nor
any other material or advertisements in connection with the common stock may be distributed or published, in or from any country or jurisdiction
except in compliance with any applicable laws, rules and regulations of any such country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INTERESTS OF NAMED EXPERTS AND COUNSEL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Carmel,
Milazzo &amp; Feil LLP, New York, New York, our counsel, owns 100,000 shares of our common stock for payment of legal fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_024"></A><FONT STYLE="text-transform: uppercase"><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">RBSM LLP, an independent registered public accounting
firm, audited our financial statements for the years ended December 31, 2022 and 2021, respectively. We have included our financial statements
in this prospectus and elsewhere in the registration statement in reliance on the reports of RBSM LLP, given their authority as experts
in accounting and auditing.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_025"></A><FONT STYLE="text-transform: uppercase"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain legal matters with respect to the validity of the securities
being offered by this prospectus will be passed upon by Carmel, Milazzo &amp; Feil LLP, New York, New York. TroyGould PC, Los Angeles,
California, is acting as counsel for the underwriters with respect to the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_026"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have filed with the
SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of our common stock offered by this prospectus.
This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration
statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC.
For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed
as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other
document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see
the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed
as an exhibit is qualified in all respects by the filed exhibit. You may obtain copies of this information by mail from the Public Reference
Section of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549, at prescribed rates. You may obtain information on the operation
of the public reference rooms by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website that contains reports,
proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is
<I>www.sec.gov</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We are subject to the
information and reporting requirements of the Exchange Act and, in accordance with this law, are required to file periodic reports, proxy
statements and other information with the SEC. These periodic reports, proxy statements and other information are available for inspection
and copying at the SEC&rsquo;s public reference facilities and the website of the SEC referred to above. We also maintain a website at
<I>https://60degreespharma.com/</I>. You may access these materials free of charge as soon as reasonably practicable after they are electronically
filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our
website address in this prospectus is an inactive textual reference only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Consolidated
Financial Statements </B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Years
Ended December 31, 2022 and 2021</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 118 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="fin_007"></A>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Index to Financial Statements</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Page</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">FINANCIAL STATEMENTS:</FONT></TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><A HREF="#fin_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">Report of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#fin_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="#fin_002"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Balance Sheets</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#fin_002"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><A HREF="#fin_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Statements of Operations and Comprehensive Loss</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#fin_003"><FONT STYLE="font-family: Times New Roman, Times, Serif">3</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="#fin_004"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Statements
    of Changes in Shareholders&rsquo; and Members&rsquo; Deficit</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#fin_004"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.25in"><A HREF="#fin_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Statements of Cash Flows</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#fin_005"><FONT STYLE="font-family: Times New Roman, Times, Serif">5</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in"><A HREF="#fin_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: right"><A HREF="#fin_006"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 119 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><A NAME="fin_001"></A>report
of INDEPENDENT registered public ACCOUNTing firm</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the Board of Directors and Stockholders of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">60 Degrees Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying consolidated
balance sheets of 60 Degrees Pharmaceuticals, Inc. (formerly known as 60 Degrees Pharmaceuticals, LLC) and subsidiaries (&ldquo;the Company&rdquo;)
as of December 31, 2022 and 2021, and the related statements of operations and comprehensive loss, shareholders&rsquo; and members&rsquo;
deficit, and cash flows for each of the years in the two-year period ended December 31, 2022, and the related notes (collectively referred
to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position
of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the two-year
period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Change in Reporting Entity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As described in Note 6, the
Company operated as a Limited Liability Company, LLC, from January 1, 2022 to May 31, 2022 and converted to a &ldquo;C&rdquo; Corporation
starting from June 1, 2022 through December 31, 2022. Prior to the Company&rsquo;s conversion from a LLC to a Corporation, the LLC equity
structure consisted of &ldquo;Membership Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Company&rsquo;s Ability to Continue as a Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements,
the Company has an accumulated deficit, recurring losses and expects future losses that raise substantial doubt about the Company&rsquo;s
ability to continue as a going concern. Management&rsquo;s evaluation of the events and conditions and management&rsquo;s plans regarding
these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from
the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s
internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ RBSM LLP</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have served as the Company&rsquo;s auditor since 2022.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Las Vegas, Nevada</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">April 3, 2023</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<BR></P>


<!-- Field: Page; Sequence: 120; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="fin_002"></A>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Consolidated Balance Sheets</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; font-weight: bold">December 31,</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center; font-weight: bold">December 31,</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; padding-left: 9pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">264,865</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">115,399</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts Receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,965</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">146,362</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Prepaid and Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,967</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225,869</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred Offering Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68,629</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Inventory (Note 3)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">518,578</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">689,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,099,004</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,176,672</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Property and Equipment, net (Note 4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,948</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Right of Use Asset (Note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,647</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58,667</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Intangible Assets, net (Note 5)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">164,255</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">109,240</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Other Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">176,902</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">167,907</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,297,206</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,393,527</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND SHAREHOLDERS' DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Accounts Payable and Accrued Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">758,668</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">588,678</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Lease Liability (Note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,795</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred Compensation (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related Party Notes, net <I>(including accrued interest) </I>(Note 9)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">195,097</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Debenture (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,276,609</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBA EIDL <I>(including accrued interest) </I>(Note 8)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Notes <I>(including accrued interest) </I>(Notes 8 and 9)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,855,887</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Derivative Liabilities (Note 9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,129,840</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Derivative Liabilities &ndash; Related Parties (Note 9)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">364,360</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Current Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">23,921,211</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">635,473</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Long-Term Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Deferred Compensation (Note 7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">255,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,743</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Lease Liability (Note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 9pt">Debenture (Note 8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,388,570</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SBA EIDL <I>(including accrued interest) </I>(Note 8)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">160,272</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159,161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Notes <I>(including accrued interest) </I>(Note 8)</FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,109,783</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">15,197,064</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Long-Term Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,525,055</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">18,912,538</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">25,446,266</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">19,548,011</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Commitments and Contingencies (Note 11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">SHAREHOLDERS&rsquo; DEFICIT</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Members&rsquo; Capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,979,365</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Preferred stock, $0.0001 par value, 1,000,000 shares authorized; no shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Class A common stock, $0.0001 par value, 150,000,000 shares authorized; 2,386,009 and no shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively (Note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">239</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Additional Paid-in-Capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,164,461</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated Other Comprehensive Income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">73,708</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75,835</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated Deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28,815,148</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(22,633,428</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">60P Shareholders&rsquo; Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23,576,740</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(17,578,228</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Noncontrolling interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(572,320</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(576,256</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Shareholders' Deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(24,149,060</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(18,154,484</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Shareholders' Deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,297,206</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,393,527</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The accompanying notes are an integral part
of these audited consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="fin_003"></A>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">For Fiscal Years Ended December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Product Revenues &ndash; net of Discounts and Rebates</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">192,913</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,078,440</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Service Revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30,295</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">81,900</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Product and Service Revenues</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223,208</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,160,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Cost of Revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">432,370</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">850,742</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gross (Loss) Profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(209,162</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">309,598</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Research Revenues</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">288,002</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,192,516</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net Revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">78,840</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,502,114</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and Development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">525,563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,510,866</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">General and Administrative Expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,303,722</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,115,350</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total Operating Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,829,285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,626,216</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from Operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,750,445</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,124,102</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,989,359</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,172,712</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Derivative Expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(504,613</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in Fair Value of Derivative Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(10,312</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gain on Debt Extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other (Expense) Income</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(43,238</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">37,515</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total Interest and Other Expense (Income), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,426,839</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,135,197</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from Operations before Provision for Income Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,177,284</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,259,299</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Provision for Income Taxes (Note 10)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">500</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net Loss including Noncontrolling interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,177,784</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,260,299</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net Gain (Loss) &ndash; Noncontrolling Interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,936</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,554</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net Loss &ndash; attributed to 60 Degrees Pharmaceuticals, Inc.</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,181,720</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,251,745</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Comprehensive Loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Net Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,177,784</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,260,299</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 9pt">Unrealized Foreign Currency Translation Gain (Loss)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,127</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,031</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total Comprehensive Loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,179,911</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,263,330</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Net Gain (Loss) &ndash; Noncontrolling Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,936</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8,554</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Unrealized Foreign Currency Translation (Loss) Gain from Noncontrolling Interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,588</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Comprehensive Loss &ndash; attributed to 60 Degrees Pharmaceuticals, Inc.</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,183,847</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(4,256,364</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Net loss (June 1 &ndash; December 31, 2022) per common share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Basic and Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.78</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average number of common shares outstanding (June 1 &ndash; December 31, 2022)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Basic and Diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,380,986</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The accompanying notes are an integral part
of these audited consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="fin_004"></A>60 DEGREES PHARMACEUTICALS, INC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Consolidated Statements of
Shareholders&rsquo;and Members&rsquo; Deficit</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Fiscal Years Ended December 31, 2022 and 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Members&rsquo;
    Equity</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Common Stock</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Additional<BR>
    Paid-in</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Accumulated</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Accumulated<BR>
    Other<BR>
    Comprehensive</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Total Shareholders&rsquo;<BR>
    Equity (Deficit)</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Noncontrolling<BR>
    Interest on</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Total<BR>
    Shareholders&rsquo; </B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Units</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Amount</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Shares</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Amount</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Capital</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Deficit</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Income
    (Loss)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Attributable
    to 60P</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Shareholders</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Deficit</B></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Balance&mdash;December&nbsp;31,&nbsp;2020</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>14,675,500</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>799,700</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>-</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>-</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>-</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(18,381,683</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>80,454</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(17,501,529</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(569,290</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(18,070,819</B></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">Conversion of Debt into Member Units</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">4,179,665</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">4,179,665</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">4,179,665</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">4,179,665</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">Foreign Translation (Loss) Gain</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(4,619</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(4,619</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">1,588</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(3,031</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">Net loss</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(4,251,745</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(4,251,745</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(8,554</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(4,260,299</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Balance&mdash;December 31, 2021</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>18,855,165</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>4,979,365</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>-</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>-</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>-</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(22,633,428</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>75,835</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(17,578,228</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(576,256</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(18,154,484</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">Net Foreign Translation Loss through May 31, 2022</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(28,654</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(28,654</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(611</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(29,265</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">Net (Loss) Gain through May 31, 2022</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(1,949,246</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(1,949,246</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">1,370</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(1,947,876</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">Business Combination: June 1, 2022 (60P, LLC into 60P,
    Inc.)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(18,855,165</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(4,979,365</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">2,348,942</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">235</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">4,979,130</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">Issuance of Shares June 30, 2022</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">37,067</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">4</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">185,331</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">185,335</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">185,335</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">Net Foreign Translation Gain after June 1, 2022</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">26,527</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">26,527</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">611</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">27,138</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">Net (Loss) Gain after June 1, 2022</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(4,232,474</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">-</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(4,232,474</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">2,566</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">(4,229,908</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>Balance&mdash;December 31, 2022</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>-</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>-</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>2,386,009</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>239</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>5,164,461</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(28,815,148</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>73,708</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(23,576,740</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(572,320</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 6pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>(24,149,060</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt"><B>)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The accompanying notes are an integral part
of these audited consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="fin_005"></A>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Consolidated Statements of
Cash Flows</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold">For the Years Ended December 31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left; padding-left: 9pt">Net Loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(6,177,784</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(4,260,299</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,648</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,528</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in">Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,118</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,310</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Amortization of Debt Discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,090,387</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">604,595</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Amortization of ROU Asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">40,947</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Amortization of Note Issuance Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">74,496</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Gain on Debt Extinguishment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(120,683</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Derivative expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">504,613</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Change in fair value of derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,312</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Inventory Reserve</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">223,400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,322</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 9pt">Changes in Operating Assets and Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts Receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,397</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">713,063</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Prepaid and Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,902</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">135,844</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(52,936</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">312,226</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accounts Payable and Accrued Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">169,990</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(844,670</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Accrued Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,685,678</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,568,118</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Reduction of Lease Liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46,795</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(39,820</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Deferred Compensation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">425,257</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">51,730</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Cash Used in Operating Activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,009,980</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(649,106</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in">Capitalization of Patents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(33,063</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(32,324</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Purchases of Property and Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,068</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.25in">Acquisition of Intangibles</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(27,070</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Cash Used in Investing Activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(60,133</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(35,392</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Payment of Deferred Offering Costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(68,629</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Proceeds from Notes Payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in">Proceeds from Notes Payable &ndash; Related Parties</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">305,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">683,226</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in">Repayments on Notes Payable &ndash; Related Party</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(72,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Proceeds from Advances &ndash; Related Party</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">185,335</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Cash Provided by Financing Activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,221,706</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">611,226</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Foreign Currency Translation Loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,127</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(3,031</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in Cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">149,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(76,303</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Cash&mdash;Beginning of Year</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">115,399</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">191,702</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">Cash&mdash;End of Year</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">264,865</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">115,399</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash paid During the Year for Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,193</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash paid During the Year for Income Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">NONCASH INVESTING/FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Right-of-use asset obtained in exchange for new operating lease liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,615</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Debt discount recorded in connection with derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,105,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Conversion of Debt into Shares</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">185,335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Conversion of Debt into Member Units</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,179,665</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>The accompanying notes are an integral part
of these audited consolidated financial statements.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="fin_006"></A>60 DEGREES PHARMACEUTICALS, INC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">NATURE OF OPERATIONS</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60 Degrees Pharmaceuticals, Inc. was incorporated
in Delaware on June 1, 2022 and merged on the same day with 60<SUP>o</SUP> Pharmaceuticals, LLC which was organized on September 9, 2010
in the District of Columbia. The financial statements of 60 Degrees Pharmaceuticals, Inc. and its subsidiaries (which may be referred
to as the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, &ldquo;60P&rdquo; or &ldquo;60 Degrees Pharmaceuticals&rdquo;)
are prepared in accordance with accounting principles generally accepted in the United States of America (&ldquo;U.S. GAAP&rdquo;). The
Company&rsquo;s headquarters are located in Washington, DC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60 Degrees Pharmaceuticals, Inc. was formed to
develop new medicines for the treatment and prevention of infectious diseases. Since its founding, the Company has developed Arakoda&trade;
for the prevention of malaria. The Company continues to develop its novel products targeting the effects and treatment of diseases such
as Coronaviruses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Going Concern</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company's financial statements are prepared
on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business.
However, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated
losses to date. This condition, among others, raises substantial doubt about the ability of the Company to continue as a going concern
for one year from the date the financial statements are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In view of these matters, continuation as a going
concern is dependent upon continued operations of the Company, which in turn is dependent upon the Company&rsquo;s ability to meet its
financial requirements, raise additional capital, and the success of its future operations. The financial statements do not include any
adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going
concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management plans to fund operations of the Company
through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a public
offering until such a time as a business combination or other profitable investment may be achieved. There currently is a plan in place
to take the Company public in an IPO transaction in the first half of 2023. Management believes that this plan provides an opportunity
for the Company to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">summary of SIGNIFICANT ACCOUNTING POLICIES</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Basis of Presentation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounting and reporting policies of the Company
and its subsidiaries are presented on a consolidated basis and conform to accounting principles generally accepted in the United States
of America (&ldquo;US GAAP&rdquo;) after elimination of intercompany transactions and accounts. These consolidated financial statements
are presented in US Dollars, which is the Company&rsquo;s functional currency. The Company has adopted the calendar year as its basis
of reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Principles of Consolidation and Non-Controlling
Interest</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s consolidated financial statements
include the financial statements of its majority owned (87.53%) subsidiary 60P Australia Pty Ltd, as well as the financial statements
of 60P Singapore Pty Lte, a wholly owned subsidiary of 60P Australia Pty Ltd. 60P Singapore Pty Lte was closed via dissolution as of March
31, 2022. All significant intercompany accounts and transactions have been eliminated in consolidation. 60P Singapore Pty Lte was originally
set up to conduct research in Singapore. The entity had no assets and its liabilities were to both 60P Australia Pty Ltd, its direct owner,
and 60P. Through consolidation accounting the closure of the business unit resulted in a currency exchange gain.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2.</TD><TD>summary of SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Principles of Consolidation and Non-Controlling
Interest (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For entities that are consolidated, but not 100%
owned, a portion of the income or loss and corresponding equity is allocated to owners other than the Company. The aggregate of the income
or loss and corresponding equity that is not owned by us is included in Non-controlling Interest in the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Use of Estimates</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with United States GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant
estimates include the reserve for inventory, deferred compensation, derivative liabilities and valuation allowance for the deferred tax
asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Cash and Cash Equivalents</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents include all cash in
banks and short-term highly liquid investments (with original maturities of three months or less) as cash equivalents. The Company&rsquo;s
cash is deposited in demand accounts at financial institutions that management believes are creditworthy. The Company&rsquo;s cash and
cash equivalents in bank deposit accounts, at times, may exceed federally insured limits. On December 31, 2022, the Company&rsquo;s cash
and cash equivalents did not exceed FDIC insured limits (did not exceed FDIC insured limits at December 31, 2021). The Company also held
cash at its subsidiaries in Australia and Singapore though the amounts were minimal. <FONT STYLE="background-color: white">The Company
has not experienced any losses related to amounts in excess of FDIC limits. The Company does not hold any cash equivalents, which would
consist of highly liquid investments with original maturities of three months or less at the time of purchase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Accounts Receivable and Allowance for Doubtful
Accounts</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company records accounts receivable at net
realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on
the trade accounts receivable balances and charged to the provision for doubtful accounts. Based on the Company&rsquo;s history there
has been no need to make a recording to allowance for doubtful accounts. Most of the Company&rsquo;s revenue has been earned via government
contracts, and with a large American pharmaceutical distributor. As the Company continues to engage with smaller distributors, we will
continue to analyze whether an entry should be recorded in Allowance for Doubtful Accounts. There was no allowance as of December 31,
2022 and December 31, 2021. At the year ended December 31, 2022, the US government accounted for 66% of the outstanding AR balance (84%
at December 31, 2021) and the American pharmaceutical distributor accounted for 30% of the outstanding AR balance at the year ended December
31, 2022 (15% at the year ended December 31, 2021).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Inventory</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventories are stated at the lower of cost or
net realizable value. Cost comprises direct materials and, where applicable, costs that have been incurred in bringing the inventories
to their present location and condition. The Company uses the Specific Identification method per lot. A box price is calculated per lot
number and sales are recognized by their lot number.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Property and Equipment</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment are stated at cost. Normal
repairs and maintenance costs are charged to earnings as incurred and additions and major improvements are capitalized. The cost of assets
retired or otherwise disposed of and the related depreciation are eliminated from the accounts in the period of disposal and the resulting
gain or loss is credited or charged to earnings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 23.75pt">2.</TD><TD>summary of SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Property and Equipment (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation is computed over the estimated useful
lives of the related asset type or term of the operating lease using the straight-line method for financial statement purposes. The estimated
service lives for Property and Equipment is either three (3), five (5) or seven (7) years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>I<B>mpairment of Long-lived Assets</B></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Long-lived assets, such as property and equipment
and identifiable intangibles with finite useful lives, are periodically evaluated for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable. We look for indicators of a trigger event for asset impairment and
pay attention to any adverse change in the extent or manner in which the asset is being used or in its physical condition. Assets are
grouped and evaluated for impairment at the lowest level of which there are identifiable cash flows, which is generally at a location
level. Assets are reviewed using factors including, but not limited to, our future operating plans and projected cash flows. The determination
of whether impairment has occurred is based on an estimate of undiscounted future cash flows directly related to the assets, compared
to the carrying value of the assets. If the sum of the undiscounted future cash flows of the assets does not exceed the carrying value
of the assets, full or partial impairment may exist. If the asset&rsquo;s carrying amount exceeds its fair value, an impairment charge
is recognized in the amount by which the carrying amount exceeds the fair value of the asset. Fair value is determined using an income
approach, which requires discounting the estimated future cash flows associated with the asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Intangible Assets</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company capitalizes
its patent and filing fees and legal patent and prosecution fees in connection with internally developed pending patents. When pending
patents are issued, patents will be amortized over the expected period to be benefitted, not to exceed the patent lives, which may be
as long as ten to fifteen years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Website Development Costs</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for&nbsp;website development
costs&nbsp;in accordance with ASC 350-50 &ldquo;Website Development Costs&rdquo;. Accordingly, all costs incurred in the planning stage
are expensed as incurred, costs incurred in the website application and infrastructure development stage that meet specific criteria are
capitalized and costs incurred in the day-to-day operation of the website are expensed as incurred. All costs associated with the websites
are subject to straight-line amortization over a three-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the years ended December 31, 2022 and 2021,
the Company capitalized website development or related costs of $27,070 and none, respectively, in connection with the upgrade and enhancement
of functionality of corporate website at www.60-p.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Derivative Liabilities</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company assessed the classification of its
derivative financial instruments as of December 31, 2022 and December 31, 2021, which consist of bridge shares, convertible notes payable
and certain warrants (excluding those for compensation) and has determined that such instruments qualify for treatment as derivative liabilities
as they meet the criteria for liability classification under ASC 815.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2.</TD><TD>summary of SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Derivative Liabilities (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company analyzes all financial instruments
with features of both liabilities and equity under FASB ASC Topic No. 480, (&ldquo;ASC 480&rdquo;),&nbsp;&ldquo;Distinguishing Liabilities
from Equity&rdquo;&nbsp;and FASB ASC Topic No. 815,&nbsp;(&ldquo;ASC 815&rdquo;) &ldquo;Derivatives and Hedging&rdquo;. Derivative liabilities
are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of
operations (other income/expense) as change in fair value of derivative liabilities. The Company uses a Monte Carlo Simulation Model (&ldquo;MCSM&rdquo;)
to determine the fair value of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon conversion or repayment of a debt or equity
instrument in exchange for shares of common stock, where the embedded conversion option has been bifurcated and accounted for as a derivative
liability (generally convertible debt and warrants), the Company records the shares of common stock at par value, relieves all related
debt, derivative liabilities, and debt discounts, and recognizes a net gain or loss on debt extinguishment. In connection with the debt
extinguishment, the Company typically records an increase to additional paid-in capital for any remaining liability balance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity instruments that are initially classified
as equity that become subject to reclassification under ASC Topic 815 are reclassified to liabilities at the fair value of the instrument
on the reclassification date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Original Issue Discount (&ldquo;OID&rdquo;)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For certain notes issued, the Company may provide
the debt holder with an original issue discount. The original issue discount is recorded as a debt discount, and is amortized to interest
expense over the life of the debt, in the Consolidated Statements of Operations and Comprehensive Loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Debt Issuance Cost</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Debt issuance costs paid to lenders, or third
parties are recorded as debt discounts and amortized to interest expense over the life of the underlying debt instrument, in the Consolidated
Statements of Operations and Comprehensive Loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Income Taxes</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60 Degrees Pharmaceuticals, Inc. is a corporation
and has accepted the default taxation status of C corporation. The merger does not materially impact tax matters in 2022 as the LLC had
elected to be taxed as a C corporation for income tax purposes at the beginning of 2022. Previously, the LLC was taxed as a partnership
in which for federal purposes, all income tax benefits of a partnership are passed through to the members. The District of Columbia taxes
partnerships on form D-30 (District of Columbia Unincorporated Business Franchise Tax Return) and corporations on form D-20 (District
of Columbia (DC) Corporation Franchise Tax Return) and both returns have a minimum tax due of $250 if gross receipts are at $1 million
or less and a $1,000 if above. The tax years that remain subject to examination by major tax jurisdictions include the years ended December
31, 2019, 2020 and 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60P Australia Pty Ltd is subject to the taxes
of the Australian Taxation Office and the now closed 60P Singapore Pte Ltd was subject to the taxes of the Inland Revenue Authority of
Singapore.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Concentrations</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject
the Company to concentrations of credit risk consist primarily of cash, accounts receivable, inventory purchases, and lending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2.</TD><TD>summary of SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Concentrations (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant customers represent any customer whose business makes up
10% of our receivables or revenues. 96% of receivables (consisting of three customers and two significant at 66% and 30%) and 100% of
revenues (consisting of four customers and three significant at 40%, 39% and 14% respectively) were generated by significant customers
for the year ended December 31, 2022. 99% of the Company&rsquo;s receivables (consisting of three customers and two significant at 84%
and 15%) and 100% of the revenues (consisting of three customers and all of them significant at 95%, 3% and 2% respectively) were generated
by the Company from significant customers during the year ended December 31, 2021. Currently, the Company has exclusive relationships
with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients
in those markets. The US government has historically been the Company&rsquo;s largest customer through a purchase support contract and
a clinical study. Both of those activities ended as during 2022 and near-term receivables and revenues from the government are not anticipated
to be significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since the Company first started working on tafenoquine
all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine it would
take time and be expensive to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (API).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 31, 2022, 85% (93% at December
31, 2021) of the Company&rsquo;s non-related party debt is held by Knight Therapeutics, the senior secured lender and also a publicly
traded Canadian company. The amount of senior secured debt with Knight Therapeutics currently limits the Company&rsquo;s ability to access
additional credit and management has been informed that additional lending with Knight Therapeutics is not currently possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Business Segments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company uses the &ldquo;management approach&rdquo;
to identify its reportable segments. The management approach requires companies to report segment financial information consistent with
information used by management for making operating decisions and assessing performance as the basis for identifying the Company&rsquo;s
reportable segments. The Company manages its business in one identifiable segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Revenue Recognition</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes revenue in accordance with
the Financial Accounting Standards Board&rsquo;s (&ldquo;FASB&rdquo;), Accounting Standards Codification (&ldquo;ASC&rdquo;) ASC 606,
Revenue from Contracts with Customers (&ldquo;ASC 606&rdquo;). Revenues are recognized when control is transferred to customers in amounts
that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated
through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance
obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance
obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company received the majority of its revenues
from sales of its Arakoda&trade; product to the US Department of Defense (the &ldquo;DoD&rdquo;) and resellers in the US and abroad. The
Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for
60P. Sales to the DoD are recognized upon their acceptance after product is shipped to them. Foreign sales to both Australia and Europe
are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject
to profit sharing agreements for boxes sold to customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2.</TD><TD>summary of SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Research and Development Costs </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">T<FONT STYLE="font-family: Times New Roman, Times, Serif">he
Company accounts for research and development costs in accordance with ASC subtopic 730-10, Research and Development (&ldquo;ASC 730-10&rdquo;).
Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development
costs are expensed as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded $525,563 in research and
development costs during the year ended December 31, 2022 ($5,510,866 for the year ended December 31, 2021).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Fair Value of Financial Instruments</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying value of the Company&rsquo;s financial
instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable,
and accrued expenses) approximate their fair value due to the short-term nature of such instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The inputs used to measure fair value are based
on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to
lowest priority, are described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Level&nbsp;1</I></B>&mdash;Quoted prices
(unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Level&nbsp;2</I></B>&mdash;Observable prices
that are based on inputs not quoted on active markets but corroborated by market data</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Level&nbsp;3</I></B>&mdash;Unobservable
inputs reflecting the Company&rsquo;s assumptions, consistent with reasonably available assumptions made by other market participants.
These valuations require significant judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Note 9 regarding Derivative Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Liabilities measured at fair value at December 31, 2022 and December
31, 2021 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 1</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 2</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Level 3</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Total</TD><TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; text-align: left; padding-bottom: 1pt">Derivative Liabilities</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-align: right">1,494,200</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; width: 10%; text-align: right">1,494,200</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,494,200</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,494,200</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Foreign Currency Transactions and Translation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The individual financial statements of each group
entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency).
The consolidated financial statements of the group and the statement of financial position and equity of the company are presented in
US dollars, which is the functional currency of the Company and the presentation currency for the consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 23.75pt">2.</TD><TD>summary of SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Foreign Currency Transactions and Translation
(Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the purpose of presenting consolidated financial
statements, the assets and liabilities of the group&rsquo;s foreign operations are mostly translated at exchange rates prevailing on the
reporting date. Income and expense items are</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">translated at the average exchange rates for the
period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions
are used. Exchange differences arising, if any, are recognized in other income. Exchange rates along with historical rates used in these
financial statements are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Average Exchange Rate as of December 31,</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>December 31,</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>December 31,</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt"><B>Currency</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 12%"><FONT STYLE="font-size: 10pt">1 AUD =</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: right"><FONT STYLE="font-size: 10pt">0.6948 USD</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 19%; text-align: right"><FONT STYLE="font-size: 10pt">0.7513 USD</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right"><FONT STYLE="font-size: 10pt">0.6805 USD</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 21%; text-align: right"><FONT STYLE="font-size: 10pt">0.72644959 USD</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">1 SGD =</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.015 AUD*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.9912 AUD</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.023 AUD*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.02069301 AUD</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="5" STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">* Through 4/30/2022 (account closure date)</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Reclassifications</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year amounts have been reclassified
for consistency with the current year presentation. These reclassifications had no material effect on the consolidated results of operations
and comprehensive loss, shareholders&rsquo; deficit, or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Accumulated Comprehensive Income (Loss)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other comprehensive loss&nbsp;consists of foreign
currency translation adjustments, unrealized gains and losses from cash flow hedges.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>2022 Equity Incentive Plan</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 22, 2022, the Company adopted a 2022
Equity Incentive Plan also referred to as (&ldquo;2022 Plan&rdquo;). The maximum shares available under the 2022 Plan is equal to 10%
of the currently outstanding shares or 238,601.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Subsequent Events</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers events or transactions that
occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain
estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through April 3, 2023, which
is the date the financial statements were issued.</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Recently Issued and Adopted Accounting Pronouncements</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The FASB issues ASUs to amend the authoritative
literature in ASC. There have been a number of ASUs to date, that amend the original text of ASC. Management believes that those issued
to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected
to have a significant impact on our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">2.</TD><TD>summary of SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Recently Issued and Adopted Accounting Pronouncements
(Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, FASB issued ASU 2020-06, Accounting
for Convertible Instruments and Contracts in an Entity; Own Equity (&ldquo;ASU 2020-06&rdquo;), as part of its overall simplification
initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information
provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt
that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated
and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will
no longer separately present such embedded conversion features in equity and will instead account for the convertible debt wholly as debt.
The new guidance also requires use of the &ldquo;if-converted&rdquo; method when calculating the dilutive impact of convertible debt on
earnings per share, which is consistent with the Company&rsquo;s current accounting treatment under the current guidance. The guidance
is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal
years, with early adoption permitted, but only at the beginning of the fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We adopted this pronouncement on January 1, 2022;
however, the adoption of this standard did not have a material effect on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the Financial Accounting Standards
Board (the &ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2021-04, Earnings Per Share (Topic 260), Debt&mdash;Modifications
and Extinguishments (Subtopic 470-50), Compensation&mdash;Stock Compensation (Topic 718), and Derivatives and Hedging&mdash;Contracts
in Entity&rsquo;s Own Equity (Subtopic 815-40): Issuer&rsquo;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options. This latter standard provides clarification and reduces diversity in an issuer&rsquo;s accounting for modifications
or exchanges of freestanding equity-classified written call options (such as warrants) that remain equity classified after modification
or exchange. This standard is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal
years. Issuers should apply the new standard prospectively to modifications or exchanges occurring after the effective date of the new
standard. Early adoption is permitted, including adoption in an interim period. If an issuer elects to early adopt the new standard in
an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company
does not expect the adoption of this standard to have a material effect on the Company&rsquo;s consolidated financial statements.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In October 2021, the FASB issued&nbsp;ASU 2021-08,&nbsp;Business
Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires an acquirer
in a business combination to recognize and measure contract assets and contract liabilities in accordance with Accounting Standards Codification
Topic 606.&nbsp;ASU 2021-08&nbsp;is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. While
the Company is continuing to assess the timing of adoption and the potential impacts of&nbsp;ASU 2021-08, it does not expect&nbsp;ASU
2021-08&nbsp;will have a material effect, if any, on its consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Related Parties</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Parties are considered to be related to the Company
if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with
the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal
owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly
influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully
pursuing its own separate interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">3.</TD><TD>INVENTORY</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of the following major classes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">December, 31 2022</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">December 31, 2021</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Raw Material (API)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">397,487</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">538,320</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Packaging</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">97,486</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">88,468</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Finished Goods</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">183,943</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,514</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Clinical Trial Supplies</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">63,062</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">63,062</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Total Inventory</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">741,978</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">727,364</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Reserve for Expiring Inventory</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(223,400</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,322</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Inventory, net</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">518,578</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">689,042</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">4.</TD><TD>PROPERTY AND EQUIPMENT</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2022 and December 31, 2021, Property and Equipment
consists of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">December 31, 2022</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">December 31, 2021</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Lab Equipment</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">132,911</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">132,911</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Computer Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,261</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,261</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">Furniture</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,030</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,030</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Property and Equipment, at Cost</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">148,202</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">148,202</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(126,902</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(99,254</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Property and Equipment, Net</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">21,300</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">48,948</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses for Lab and Computer Equipment
for the years ended December 31, 2022, and 2021 were in the amount of $27,648 and $27,528 respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">5.</TD><TD>INTANGIBLE ASSETS</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">As
of December 31, 2022 and December 31, 2021, Intangible Assets consist of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">December 31, 2022</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">December 31, 2021</TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%">Patents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">145,613</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">112,550</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Website Development Costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">27,070</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Intangible Assets, at Cost</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">172,683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated Amortization</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,428</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,310</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Intangible Assets, Net</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">164,255</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">109,240</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amortization expense for the years ended December
31, 2022, and 2021 was in the amount of $5,118 and $3,310, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">5.</TD><TD>INTANGIBLE ASSETS (continued)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the estimated future
amortization expense related to our patents and website development costs for the years ended December 31:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left; font-weight: bold">Year</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">Patents</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">Website Development <BR>
Costs</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">2023</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">4,033</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">9,023</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,023</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,520</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,345</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; font-weight: bold; padding-bottom: 1pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">47,477</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">25,566</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company additionally has $91,644 in capitalized patent expenses
that will be amortizable as the patents they are associated with are awarded.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">6.</TD><TD>CAPITALIZATION and equity transactions</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Business Combination &ndash; Subsidiary</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2022, 60 Degrees Pharmaceuticals, LLC,
a District of Columbia limited liability company (&ldquo;60P LLC&rdquo;), entered into the Agreement and Plan of Merger with 60 Degrees
Pharmaceuticals, Inc, pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. The value of each outstanding member&rsquo;s
membership interest in 60P LLC was correspondingly converted into common stock of 60 Degrees Pharmaceuticals, Inc, par value $0.0001 per
share, with a cost basis equal to $5 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2022 the Company issued 37,067 shares
of common stock to its Chief Executive Officer for $185,335 ($5/share).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">7.</TD><TD>deferred COMPENSATION</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2020, the Company received consulting services
from Biointelect Pty Ltd of Australia with a value of $100,000, which is payable contingent upon a future capital raise and is non-interest
bearing. On May 5, 2022, the Company agreed to modify their contract with Biointelect Pty Ltd. Previously, Biointelect potentially could
earn $60,000 in deferred cash compensation and $400,000 in warrants in connection with a fundraise and other services provided. As the
Company considered this compensation unlikely, it agreed to restructure by increasing the cash component to $100,000, tying $155,000 in
equity compensation to an IPO/future qualifying transaction while leaving $245,000 in equity compensation with the original triggering
events. The Company took a deferred compensation charge for the $155,000 in equity compensation in Q2 of 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">7.</TD><TD>deferred COMPENSATION (continued)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also in 2020, the Company entered into an agreement with Latham Biopharma
for contingent compensation. As of June 17, 2022, $57,198 had been earned and was due ($54,743 was earned as of December 31, 2021). On
June 17, 2022 the Company and Latham Biopharma agreed to convert the deferred compensation of $57,198 and $12,500 of accrued expense into
a 100% contingent deferred compensation amount of $38,900 in cash and $60,000 in shares of the Company if within the next five years the
Company nets at least $10,000,000 in an IPO or any private financing that secures the retirement and/or conversion to equity of all secured
debt excluding the loans advanced by the Small Business Administration. Then before the end of the year the Company and Latham Biopharma
initiated an agreement that converted the entire deferred compensation into 65,000 shares valued at $5 per share. The Company has taken
a contingent deferred compensation charge of $226,100 in Q4 of 2022 to reflect this subsequent agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in">8.</TD><TD>DEBT</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Promissory Notes</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 27, 2019 the Company restructured
its cumulative borrowing with its senior secured lender, Knight Therapeutics, Inc, into a note for the principal amount of $6,309,823
and accrued interest of $4,160,918 and a debenture of $3,483,851, collectively referred to as the &lsquo;Knight Loan&rsquo;. The Knight
Loan matures on December 31, 2023. The Knight Loan bears an annual interest rate of 15% compounded quarterly. Under the Knight Loan, the
Company is required to pay the lender 15% of cumulative gross profits of above $7,000,000. At the end of December 31, 2022, the Company
had reached cumulative gross profits of $1,583,231 ($1,790,744 at December 31, 2021).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">On October 11, 2017 the Company issued a promissory note (&ldquo;Note&rdquo;)
with an individual investor in the amount of $750,000. The Note matures 60 days after the Knight Loan is repaid. The Note bore an interest
rate of 5% from inception for the first six months and 10% per annum thereafter both compounded quarterly on a calendar basis. The lender
has an option to convert the Note into equity in the Company at the maturity date and will have 30 days from maturity to exercise this
option. Cumulative interest would have originally been forfeited prior to the Amendment (discussed below), should the lender have elected
to convert the Note into equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">On
December 11, 2022, the Company and the individual investor amended the Note (&ldquo;the Amendment&rdquo;). The Amendment added a provision
to automatically convert the outstanding principal and accumulated interest through March 31, 2022 into common shares in the event the
Company consummates an IPO. The Amendment also provides the lender the option to convert the outstanding principal and accumulated interest
through March 31, 2022 into equity in the Company at the maturity date and will have 30 days from maturity to exercise this option. Cumulative
interest after March 31, 2022 will be forfeited should the lender elect to convert the Note into equity. The Company evaluated the Amendment
and determined that it constitutes an extinguishment as the option to convert interest through March 31, 2022 is considered the addition
of a substantive conversion option. Accordingly, the Amendment resulted in extinguishment accounting and a corresponding extinguishment
gain of $120,683, which represents the difference between the carrying value of the Note just prior to the Amendment and the fair value
of the Note just after the Amendment. The extinguishment accounting resulted in a fair value of the Note, including the Amendment of $1,099,578.
The discount of $120,683 and costs incurred with third parties directly related to the Amendment of $1,767 will be amortized over the
remaining life of the debt using the effective interest method. Amortization of the discount on the Note for the year ended December 31,
2022 was $4,955 ($0 in 2021). Interest expense related to the Note, including the Amendment, for the year ended December 31, 2022 was
$115,546 ($104,558 in 2021).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Promissory notes are summarized as follows at December 31, 2022:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Knight Therapeutics</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Note, including amendment</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Bridge Notes</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Promissory Notes and Interest less Discounts</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">16,319,986</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,109,783</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">535,901</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">17,965,670</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Less Current Maturities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">16,319,986</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">535,901</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">16,855,887</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Long Term Promissory Notes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,109,783</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,109,783</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-weight: normal; text-transform: none"><I>Notes
to the Consolidated Financial Statements&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal; text-transform: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60 DEGREES PHARMACEUTICALS, INC </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Notes to Consolidated Financial
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>For Years Ended December
31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 23.75pt">8.</TD><TD STYLE="text-align: justify">DeBT (CONTINUED)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Promissory Notes (Continued)</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Promissory notes are summarized as follows at December 31, 2021:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Knight Therapeutics</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Note, including amendment</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%"><FONT STYLE="font-size: 10pt">Promissory Notes and Interest less Discounts</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">14,085,333</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,111,731</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">15,197,064</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Less Current Maturities</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Long Term Promissory Notes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">14,085,333</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,111,731</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">15,197,064</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="text-transform: none"><U>Debenture</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2019 60P entered into the Knight
debenture of $3,000,000 with an original issue discount (&ldquo;OID&rdquo;) of $2,100,000. The OID is being amortized using the effective
interest method. The Company subsequently restructured the Knight Loan (see Subsequent Events footnote 13). $500,103 of the original issue
discount was amortized to interest expense during the twelve months ended December 31, 2022 ($431,625 during twelve months ended December
31, 2021) and the unamortized original issue discount at December 31, 2022 was $279,061 ($779,164 at December 31, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: center">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold"><P STYLE="margin-top: 0; margin-bottom: 0">December 31,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2022</P></TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: center; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold"><P STYLE="margin-top: 0; margin-bottom: 0">December 31,</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">2021</P></TD><TD STYLE="white-space: nowrap; text-align: center; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left">Original Debenture</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">3,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Unamortized debt discount</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(279,061</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(779,164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Debenture Prior to Accumulated Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,720,939</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,220,836</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accumulated Interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,555,670</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,167,734</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">Debenture</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">4,276,609</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,388,570</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>SBA COVID-19 EIDL</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2020, the Company received COVID-19 EIDL lending from the
Small Business Administration (SBA) in the amount of $150,000. The loan bears interest at an annual rate of 3.75% calculated on a monthly
basis. The Company was committed to make $731 monthly payments first due June 4, 2021. On March 31, 2021, the SBA announced the deferment
period has been extended an additional eighteen months. Thus, the Company was first obligated to start making payments of $731 on November
4, 2022. The current balance is $163,022 for the year ended December 31, 2022 ($159,161 at December 31, 2021). The current maturity is
$2,750 and the long-term liability is $160,272. The current future payment obligations of the principal are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: left; font-weight: bold">Period</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font-weight: bold">Principal Payments</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: left">2024</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">2026</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Thereafter</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">150,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; font-weight: bold">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">150,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to the deferral, the Company is expected to
make a balloon payment of $36,643 to be due on 11/4/2050.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Notes to the Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60
DEGREES PHARMACEUTICALS, INC </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>For
Years Ended December 31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DERIVATIVE
LIABILITIES</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><U>Promissory
Notes, Bridge Shares and Warrants</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
May 2022, the Company executed promissory notes having a face amount of $888,889. The notes contain an original issue discount of 10%
($88,889) and debt issuance costs of $91,436, resulting in net proceeds of $708,564. These notes bear interest at 10% with a default
interest rate of 15% and are unsecured. The notes are due at the earlier of one-year (1) from the issuance date or the closing of an
initial public offering (&quot;IPO&quot;). In connection with the issuance of these notes, the Company will also issue common stock to
each note holder equivalent to (a) 100% of the face amount of the note divided by the IPO price per share, or (b) if the Company fails
to complete the IPO prior to May 24, 2023, the number of shares of the Company's common stock calculated using a $27,000,000 pre-money
valuation of the Company and the number of the Company's outstanding shares of common stock on May 24, 2023. Additionally, each of these
note holders are entitled to receive five-year (5) fully vested warrants upon the closing of an IPO, with an exercise price of 110% of
the IPO price.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><U>Convertible
Promissory Notes and Warrants - Related Parties</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
May 2022, the Company executed convertible promissory notes with the Company's Chief Executive Officer and a family member related to
the Chief Executive Officer, having a face amount of $338,888. The notes contain an original issue discount of 10% ($33,888) and debt
issuance costs of $34,289, resulting in net proceeds of $270,711. These notes bear interest at 6% with a default interest rate of 15%
and are unsecured. The notes are due at the earlier of one-year (1) from the issuance date or the closing of an IPO. Upon the closing
of an IPO, these notes are mandatorily redeemable at the lesser of (a) 20% discount to the IPO price or (b) $27,000,000 pre-money valuation.
Additionally, each of these note holders are entitled to receive five-year (5) fully vested warrants upon the closing of an IPO, with
an exercise price of 110% of the IPO price. If the IPO is not completed by May 31, 2023, the exercise price is 90% of the IPO price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory
notes and Convertible notes &ndash; related parties are summarized as follows at December 31, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Promissory Notes</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Convertible Notes</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Issuance date of promissory notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">May 2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">May 2022</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 74%; text-align: left">Maturity date of promissory notes</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">1</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-weight: bold; text-align: right">1</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Default interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Collateral</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Unsecured</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">Unsecured</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Conversion Rate</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Balance - December 31, 2021</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Face amount of notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">888,889</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">338,888</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Less: unamortized debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(407,555</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(155,443</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;Add: accrued interest on promissory notes</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">54,567</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,651</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;Balance - December 31, 202</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">535,901</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">195,097</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 100%; font-size: 10pt"><FONT STYLE="font-size: 10pt">For the twelve months ended December 31, 2022, the Company recorded amortization of debt discount of $664,780.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1
</B>- earlier of 1 year from date of issuance or closing of IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2
</B>- see discussion above in (a) and (b)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to the Consolidated Financial Statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60
DEGREES PHARMACEUTICALS, INC </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>For
Years Ended December 31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DERIVATIVE
                                            LIABILITIES (CONTINUED)</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><U>Convertible
Promissory Notes and Warrants - Related Parties (Continued)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">As
noted above, certain of the Company&rsquo;s bridge shares, warrants and convertible notes (containing an embedded conversion feature)
are accounted for as derivative liabilities since there is an unknown exercise price associated with each instrument. The exercise price
is dependent upon a yet to be completed IPO or a failed IPO. In both cases, the possible exercise prices contain different conditions
(related to the success or failure of the IPO) that could result in issuing an undeterminable amount of common stock to settle any conversions.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using
significant unobservable inputs (Level 3) is as follows at December 31, 2022 and December 31, 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 92%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Convertible</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Bridge Shares</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Warrants</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Notes Payable</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Derivative&nbsp;liabilities - December 31, 2021</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">Fair value - commitment date</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">823,687</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">565,007</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">95,194</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">1,483,888</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Fair value - mark to market adjustment</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">10,665</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">13,157</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(13,510</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">10,312</FONT></TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-size: 10pt">Derivative&nbsp;liabilities - December 31, 2022</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">834,352</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">578,164</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">81,684</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">1,494,200</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in fair value of derivative liabilities (mark to market adjustment) are included in other income (expense) in the accompanying consolidated
statements of operations and comprehensive loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2022, the Company recorded a change in fair of derivative liabilities of $10,312. In connection with the
valuation of the Company&rsquo;s derivative liabilities, and accounting for these instruments at fair value, the Company computed a fair
value on the commitment date of $1,483,888, and upon the initial valuation of these instruments, determined that the fair value of the
liabilities exceeded the cash value raised of $979,275. As a result, the Company recorded a debt discount at the maximum amount allowed
(the face amount of the debt less the OID and debt issuance costs), which required the excess to be recorded as a derivative expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2022, the Company recorded a derivative expense of $504,613.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
expense is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 82%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Commitment Date</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">May 2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Fair value of derivative liabilities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">1,483,888</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less: face amount of debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(979,275</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Derivative expense</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">504,613</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the commitment date (Day 1 valuation), the fair value of the Company's potential future issuances of common stock related to common stock
issued with promissory notes, warrants and embedded conversion features in convertible promissory notes is established with an estimate
using the Monte Carlo Simulation Model to compute fair value. The</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monte
Carlo simulation requires the input of assumptions, including our stock price, the volatility of our stock price, remaining term in years,
expected dividend yield, and risk-free rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the valuation model considers the probability of the occurrence or nonoccurrence of an IPO within the terms of our liability-classified
financial instruments, as an IPO event can potentially impact the settlement.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal"><I>Notes
to the consolidated financial statements</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-align: justify; text-indent: -23.75pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-align: justify; text-indent: -23.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60
DEGREES PHARMACEUTICALS, INC </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>For
Years Ended December 31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-align: justify; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Derivative
                                            liabilities (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: none"><U>Convertible
Promissory Notes and Warrants - Related Parties (Continued)</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
at each subsequent reporting period, we remeasure the fair value of our liability-classified bridge shares, warrants and embedded conversion
features in convertible promissory notes using the Monte Carlo simulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
assumptions used to perform the Monte-Carlo Simulation were as follows at the Commitment Date as well as for the year ended December
31, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 40pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Commitment Date</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>May 2022</B></FONT></TD>
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 87%"><FONT STYLE="font-size: 10pt">Stock price</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-size: 10pt">5.00</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Volatility</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">99.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Expected term (in years) &ndash; Notes</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">1.00 - 1.03</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Expected term (in years) &ndash; Warrants</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">Risk-free interest rate</FONT></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">2.76% - 2.84</FONT></TD>
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-size: 10pt">Dividend yield</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">IPO probability (prior to note maturity date)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">95</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 40pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold">Mark to Market</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,&nbsp;2022</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%">Stock price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">5.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">101.9</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Expected term (in years) &ndash; Notes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.39 - 0.41</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected term (in years) &ndash; Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.39</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.06</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">IPO probability (prior to note maturity date)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">95</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
                                            Taxes</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company currently pays taxes at the federal level as a &ldquo;C Corporation&rdquo;. Previously, for federal income tax purposes, 60 Degrees
Pharmaceuticals, LLC filed as a partnership whereby all liability and benefit was attached to the Members&rsquo; returns through December
31, 2021. The District of Columbia, however, taxed the entity separately as an unincorporated business on a D-30 franchise tax return
when income was over $12,000 annually. Additionally, there was a minimum tax of $250 for revenues at and below $1,000,0000 and $1,000
for those revenues above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">60P, LLC elected to be taxed as a C-Corporation
as of January 1, 2022. A final DC return of the LLC (five-month period ended May 31, 2022) will be filed on the District of Columbia&rsquo;s
D-20 Corporation Franchise Tax Return, which also has minimum taxes for revenues above $1,000,000 ($1,000) and at or below ($250). As
a result of the merger of 60P, LLC into 60P, Inc., all accumulated DC net operating losses incurred prior to January 1, 2022 are not
transferable (irreversibly vacated). Prospectively, DC net operating loss will not be considered in deferred tax asset computations as
the 12/31/2021 balance of $577,978 has been written off to reflect the relinquished DC net operating loss. The provision for income taxes
for the year ended December&nbsp;31, 2022 consists of the following:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to the consolidated financial statements</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-align: justify; text-indent: -23.75pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60
DEGREES PHARMACEUTICALS, INC </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>For
Years Ended December 31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
                                            Taxes (CONTINUED)</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Federal</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">DC</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 1.5pt">Taxable loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(5,807,867</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(5,807,367</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.5pt">DC Franchise tax</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 1.5pt">Provision (added) used</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,219,652</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(479,108</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Allowance added (used)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,219,652</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">479,108</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Net Provision for income tax</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">500</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federally
the Company has a cumulative net loss of $5,807,867 as of December 31, 2022 (none as of December 31, 2021). The net tax benefit associated
with loss accumulated through the year ending December 31, 2022 is $1,219,652 (none as of December 31, 2021) with the federal tax rate
of 21%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has cumulative net loss in DC of $5,807,367 for the twelve months ended December 31, 2022 ($6,996,799 as of December 31, 2021).
The net tax benefit is the cumulative net loss multiplied by the District of Columbia corporate tax rate of 8.25%. The Company&rsquo;s
net tax benefit at December 31, 2022 is $479,108 ($577,978 at December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australian
subsidiary has cumulative losses of AUD9,640,315 at December 31, 2022 (and AUD8,997,499 at December 31, 2021). The Australian subsidiary
has also measured a deferred tax benefit associated with the cumulative losses of AUD2,410,079 at December 31, 2022 (and AUD2,249,375
at December 31, 2021). The current tax rate in Australia is now 25% for businesses with an aggregated turnover (ordinary income of the
Company and its affiliates) of AUD50 million. The Company projects to continue to qualify for the lower tax rate in the near future.&quot;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none">Management
assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing
deferred tax assets. On the basis of this evaluation, the Company has determined that it is more likely than not that the Company will
not recognize the benefits of the foreign and state net deferred tax assets, and, as a result, full valuation allowance has been set
against its net deferred tax assets as of December&nbsp;31, 2022, and December 31, 2021. The amount of the deferred tax asset to be realized
could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased. </FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">As of the Period Ended</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&nbsp;31, 2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&nbsp;31, 2021</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; text-align: left; padding-left: 1.5pt">Federal Deferred Tax Asset</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,219,652</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.5pt">DC Deferred Tax Asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">479,108</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">577,978</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Australian Deferred Tax Asset (USD)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,640,059</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,634,058</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,338,819</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,212,036</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 1.5pt">Allowance</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3,338,819</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,212,036</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Net Value of Deferred Tax Asset</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes the impact of a tax position in the financial statements if that position is more likely than not to be sustained
on a tax return upon examination by the relevant taxing authority, based on the technical merits of the position. As of December&nbsp;31,
2022, and December 31, 2021, the Company had no recognized tax benefits. The Company recognizes interest and penalties related to income
tax matters as other expense and nondeductible penalties, respectively. As of December 31, 2022, the Company has recognized a potential
tax penalty regarding a US foreign tax reporting form of $30,000 and none at December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to the Consolidated Financial Statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60
DEGREES PHARMACEUTICALS, INC </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>For
Years Ended December 31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments
                                            and Contingencies</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Operating
Lease</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
February 3, 2016, the Company entered into the lease agreement with CXI Corp to rent business premises. The contract most recently
amended on December 10, 2020 with an additional term of twenty-four months <FONT STYLE="background-color: white">that was set to
expire </FONT> on March 31, 2023 has been extended for an additional two year term until March 31, 2025. We have renewed the lease for an additional two years. As a result of our adoption of ASC 842,
the operating leases are reflected on our balance sheet within operating lease right-of-use (ROU) assets and the related current and
non-current operating lease liabilities. ROU assets represent the right to use an underlying asset for the lease term, and lease
liabilities represent the obligation to make lease payments arising from lease agreement. Lease expense is recognized on a
straight-line basis over the lease term, subject to any changes in the lease or expectation regarding the terms. Variable lease
costs such as common area maintenance, property taxes and insurance are expensed as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">When
the new accounting standard was adopted on December 31, 2021 the Company had current and long-term operating lease liabilities of $46,795
and $13,000, respectively, and right of use of asset of $58,667.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Future
minimum lease payments on a discounted and undiscounted basis under this lease are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 2.5pt double; text-align: center; white-space: nowrap; font-weight: bold">Undiscounted Cash Flows</TD><TD STYLE="white-space: nowrap; padding-bottom: 2.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 87%; font-weight: normal; text-transform: none; text-align: left; text-indent: 0in">Discount rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">15.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 1.5pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 1.5pt">2023 (January 1 to March 31)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,326</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.5pt">Total undiscounted minimum future payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,326</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Imputed interest</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(326</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 1.5pt">Total operating lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Short-term lease liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 1.5pt">Long-term lease liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Other
information related to our operating lease is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; padding-bottom: 1pt; text-align: justify">&nbsp;</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">December&nbsp;31, 2022</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Weighted average remaining lease term in years</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">0.25 years</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 87%; text-align: justify">Weighted average discount rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">15.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rent
expenses were in the amount of $51,894 and $51,894 as of the years ended December 31, 2022, and December 31, 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Board
of Directors</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November and December 2022, the Company signed agreements with four director nominees (Cheryl Xu, Paul Field, Charles Allen and Stephen
Toovey) which come into effect on the date the Company&rsquo;s S-1 becomes effective. Each director will receive cash compensations of
$11,250 quarterly. In addition, the two non-audit committee chairs (Toovey, Field) will receive $1,250 per quarter and the audit committee
chair (Allen) will receive an additional $2,000 per quarter. Each director will receive a one-off issuance of common stock of value $50,000
and a non-qualified option to purchase an additional $50,000 of common stock. Each director will receive equity compensation in the form
of restricted stock units valued at $40,000 and a non-qualified option to purchase $40,000 of common stock.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><I>Notes
to the Consolidated Financial Statements</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60
DEGREES PHARMACEUTICALS, INC </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>For
Years Ended December 31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments
                                            and Contingencies (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Contingencies</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations
could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Contingent
Compensation </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to 2015 the Company agreed with certain vendors, advisors and employees to deferred compensation that expires on December 31, 2023. The
net amount of these contingent payments is $43,581. The Company does not anticipate the trigger for these payments to be reached prior
to expiration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2020, the Company engaged with two vendors to help secure COVID-19 trial funding for the Company&rsquo;s Phase II COVID trial. Ultimately,
the efforts were unsuccessful but a tail does remain. If one Australian fund participates in the Company&rsquo;s IPO a maximum of $520,000
would be due as of December 31, 2021. Due to subsequent agreement the maximum amount due would be $305,000 as of December 31, 2022. Currently,
the Company is not engaged with the Australian fund to solicit their participation in the Company&rsquo;s IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Litigation,
Claims and Assessments</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business.
As of December 31, 2022, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on
the results of the Company&rsquo;s operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSEQUENT
                                            EVENTS</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated subsequent events through April 3, 2023, which is the date the financial statements were issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 1, 2023 the Company lowered the wholesale acquisition cost [WAC] price of a box of Arakoda&trade; [16 x 100 mg tablets] from
$285 to $235 per box, to better align the cost of utilizing Arakoda&trade; for malaria prophylaxis with competing products including
atovaquone-proguanil.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 9, 2023, and in two subsequent amendments, the Company and Knight Therapeutics agreed to extinguish Knight's debt in the event
of an IPO. Key points of this agreement are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Parties agreed to fix Knight&rsquo;s cumulative debt to the value as it stood on March 31,
                                            2022, which consisted of $10,770,037 in principal and $8,096,486 in accumulated interest
                                            should the Company execute an IPO that results in gross proceeds of at least $7,000,000 prior
                                            to December 31, 2023. Should an IPO not occur by January 1, 2024 then all terms of the original
                                            loans would resume including any interest earned after March 31, 2022. From April 1, 2022
                                            through December 31, 2022 the Company has recorded $2,009,133 in accumulated Interest that
                                            would be subject to reversal should the IPO be successfully executed.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Parties agreed to convert the Principal Amount into (i) that number of shares of Common Stock
                                            equal to dividing the Principal Amount by an amount equal to the offering price of the Common
                                            Stock in the IPO discounted by 15% (the &ldquo;Conversion Common Shares&rdquo;), rounding
                                            up for fractional shares, in a number of Conversion Shares up to 19.9% of the Company&rsquo;s
                                            outstanding Common Stock after giving effect of the IPO; (ii) the Company will make a milestone
                                            payment of $10 million to Knight if, after the date of a Qualifying IPO, the Company
sells Arakoda&trade; or if a Change of Control (as per the definition included in the original loan agreement dated on December 10, 2015)
occurs, provided that the purchaser of Arakoda&trade; or individual or entity gaining control of the Borrower is not the Lender or an
affiliate of the Lender; (iii) following the License and Supply agreement dated on December 10, 2015 and subsequently amended on January
21, 2019, an expansion of existing distribution rights to tafenoquine/Arakoda&trade; to include COVID-19 indications as well as malaria
prevention across the Territory as defined in said documents, subject to US Army approval; and (iv) Company will retain Lender or an
affiliate to provide financial consulting services, management, strategic and/or regulatory advice of value $30,000 per month for five
years (the parties will negotiate the terms of that consulting agreement separately in good faith).</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><I>Notes
to the Consolidated Financial Statements</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60
DEGREES PHARMACEUTICALS, INC </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>For
Years Ended December 31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSEQUENT
                                            EVENTS (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Parties agreed to convert the accrued interest into that number of shares (the &ldquo;Conversion
                                            Preferred Shares&rdquo; and, together with the Conversion Common Shares, the &ldquo;Conversion
                                            Shares&rdquo;) of a new class of preferred stock (the &ldquo;Preferred Stock&rdquo;) by dividing
                                            the Accrued Interest by [$100.00], then rounding up (resulting in the issuance of 80,965
                                            preferred shares at the IPO). The Preferred Stock shall have the following rights, preferences,
                                            and designations: (i) have a 6% [cumulative] dividend accumulated annually on March 31; (ii)
                                            shall be non-voting stock; (iii) are not redeemable, (iv) be convertible to shares of Common
                                            Stock at a price equal to the lower of (1) the price paid for the shares of Common Stock
                                            in the IPO and (2) the 10 day volume weighted average share price immediately prior to conversion;
                                            and (v) conversion of the preferred stock to common shares will be at the sole discretion
                                            of the Company. Notwithstanding the foregoing, the Company shall not convert the Preferred
                                            Stock into shares of Common Stock if as a result of such conversion Lender will own 19.9%
                                            or more of the Company&rsquo;s outstanding Common Stock.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition to the conversion of the Debt, for a period commencing on January 1, 2022 and ending
                                            upon the earlier of 10 years after the Closing or the conversion or redemption in full of
                                            the Conversion Preferred Shares, Company shall pay Lender a royalty equal to 3.5% of the
                                            Company&rsquo;s net sales (the &ldquo;Royalty&rdquo;), where &ldquo;Net Sales&rdquo; has
                                            the same meaning as in the Company&rsquo;s license agreement with the U.S. Army for tafenoquine.
                                            Upon success of the Qualified IPO, the Company shall calculate the royalty payable to Knight
                                            Therapeutics International S.A. (&ldquo;Knight&rdquo;) at the end of each calendar quarter.
                                            The Company shall pay to Knight the royalty amounts due with respect to a given calendar
                                            quarter within fifteen (15) Business Days after the end of such calendar quarter. Each payment
                                            of royalties due to Knight shall be accompanied by a statement specifying the total gross
                                            sales, the net sales and the deductions taken to arrive to net sales. For clarification purposes,
                                            the first royalty payment will be performed following the above instructions, on the first
                                            calendar quarter in which the Qualified IPO takes place and will cover the sales of the period
                                            from January 1, 2022 until the end of said calendar quarter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2023 Geoff Dow signed an updated employment agreement as Chief Executive Officer with a two-year agreement subject to automatic
annual renewals unless either party provides notice within 90 days of expiration. Notable provisions are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
                                            salary will be $228,000 per year with a cash bonus of up to 25% of base pay should performance
                                            goals be met. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            the Company becoming public, Geoff Dow will be awarded 300,000 options which will vest at
                                            the end of each quarter over five years. The exercise price will be the closing price of
                                            the stock on the day of the IPO. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Executive will be awarded a two times base salary cash bonus if in a change of control transaction,
                                            the Company&rsquo;s share price is two times the closing price on the day of the IPO. </FONT></TD></TR></TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><I>Notes to the Consolidated Financial Statements</I></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60
DEGREES PHARMACEUTICALS, INC </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>For
Years Ended December 31, 2022 AND December 31, 2021 (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-transform: uppercase; text-indent: -23.75pt"></P>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; text-transform: uppercase; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSEQUENT
                                            EVENTS (continued)</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2023 Tyrone Miller signed an updated employment agreement as Chief Financial Officer with a two-year agreement subject to
automatic annual renewals unless either party provides notice within 90 days of expiration. Notable provisions are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
salary will be $204,000 per year with a cash bonus of up to 25% of base pay should performance goals be met.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
                                            the Company becoming public, Tyrone Miller will be awarded 240,000 options which will vest
                                            at the end of each quarter over five years. The exercise price will be the closing price
                                            of the stock on the day of the IPO.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Executive will be awarded a two times base salary cash bonus if in a change of control transaction,
                                            the Company&rsquo;s share price is two times the closing price on the day of the IPO.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company must meet a NASDAQ listing requirement of a minimum public float of $15 million. As of December 31, 2022, the value of the Company&rsquo;s
potentially freely tradable shares was $1,715,246 representing 165,938 shares of value $829,690 owned by Douglas Loock, and an obligation
to the three interim investors (Bigger, Calvary and Walleye) to issue common shares of value $885,556 at the IPO. Subsequently the Company
issued common shares in exchange for services to the following organizations in the indicated amounts: Carmel, Milazzo &amp; Feil LLP
(100,000 shares), Florida State University Research Foundation (405,000 shares), Trevally LLC (120,000 shares), ENA Healthcare Communications
LLC (8,500 shares), 4C Pharma Solutions LLC (54,000 shares), Hybrid Financial Inc. (65,000 shares), Method Health Communications LLC
(20,000 shares)<FONT STYLE="background-color: white">, Kentucky Technology Inc. (525,000), Ludlow Business Services Inc. (37,500), and
Delve Innovation Pty Ltd (13,000). We also issued 30,000 shares of our common shares to Elliot Berman in exchange for services provided
by Berman Accounting &amp; Advisory P.A. </FONT>Additionally, the Company issued Latham BioPharm Group LLC 65,000 common shares in exchange
for extinguishment of $98,900 in deferred compensation that would otherwise have been payable in the event of an IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2023 the Company and their Australian distributor agreed to settle historical profit share through September 30, 2022 for
$24,486 (AUD$35,000) through the issuance of a onetime pandemic credit of $18,637 (AUD$26,640). <FONT STYLE="background-color: white">On
March 3, 2023, the Company&rsquo;s Board, with the consent of Geoffrey S. Dow decided to cancel 18,217 common shares issued to the Geoffrey
S. Dow Revocable Trust and, with the consent of Tyrone Miller, decided to cancel 2,783 shares issued to Tyrone Miller.</FONT>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 21, 2023, the Company&rsquo;s Board, with the consent of Geoffrey S. Dow decided to cancel 1,240,682 common shares issued to
the Geoffrey S. Dow Revocable Trust and, with the consent of Tyrone Miller, decided to cancel 189,318 shares issued to Tyrone Miller.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 1, 2023, the Company signed an investment relations consulting agreement with Red Chip. This Agreement obligates the Company to
issue Red Chip $40,000 of Rule 144 stock, based on the 30-day average of the publicly traded common shares after the IPO. All shares
are deemed earned immediately upon signing, acceptance, and execution of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023, the Company received $200,000 in paid-in capital from the Geoffrey S. Dow Revocable Trust. As of the day of finalization
of these statements, the Board had not made a decision regarding the capitalization of the aforementioned paid-in capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no other events or transactions during this time which would have a material effect on these financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to the Consolidated Financial Statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There have been no other events or transactions during
this time which would have a material effect on these financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>Each Consisting of One Share of Common Stock and<BR>
One Warrant to Purchase One Share of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><IMG SRC="cm270_s1img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><B>60 Degrees Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><B>WallachBeth Capital LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through and including, <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2023, (the 25th day after the date of this prospectus), all dealers effecting transactions in the common stock, whether or not participating
in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer&rsquo;s obligation to
deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Part II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>INFORMATION NOT REQUIRED
IN PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Item 13. Other Expenses
of Issuance and Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table
indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting
discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission (&ldquo;SEC&rdquo;)
registration fee and the Financial Industry Regulatory Authority, Inc. (&ldquo;FINRA&rdquo;) filing.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 57%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 29%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Amount</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Securities
    and Exchange Commission registration fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 16.5pt; text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">FINRA
    filing fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">NASDAQ
    listing fee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Accountants&rsquo;
    fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Legal
    fees and expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Printing
    and engraving expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Miscellaneous</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 12pt; text-align: justify; text-indent: -12pt"><FONT STYLE="font-size: 10pt">Total
    expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double; text-align: right"><FONT STYLE="font-size: 10pt">[*]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Item 14. Indemnification
of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Section 102 of the General
Company Law of the State of Delaware (&ldquo;DGCL&rdquo;) permits a company to eliminate the personal liability of directors of a company
to the company or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached
his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment
of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our charter
provides that none of our directors shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary
duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination
or limitation of liability of directors for breaches of fiduciary duty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Section 145 of the DGCL
provides that a company has the power to indemnify a director, officer, employee, or agent of the company, or a person serving at the
request of the company for another company, partnership, joint venture, trust or other enterprise in related capacities against expenses
(including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in
connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending
or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably
believed to be in or not opposed to the best interests of the company, and, in any criminal action or proceeding, had no reasonable cause
to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the company, no indemnification
shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the company
unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability
but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which
the Court of Chancery or such other court shall deem proper.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our charter provides that we will indemnify to
the fullest extent permitted from time to time by the DGCL or any other applicable laws as presently or hereafter in effect, any person
who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether
civil, criminal, administrative or investigative, including, without limitation, an action by or in the right of the Company, by reason
of his acting as a director or officer of the Company or any of its subsidiaries (and the Company, in the discretion of the Board, may
so indemnify a person by reason of the fact that he is or was an employee or agent of the Company or any of its subsidiaries or is or
was serving at the request of the Company in any other capacity for or on behalf of the Company) against any liability or expense actually
and reasonably incurred by such person in respect thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 146; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In any underwriting
agreement we enter into in connection with the sale of common stock being registered hereby, the underwriters will agree to indemnify,
under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act of 1933
(the &ldquo;Securities Act&rdquo;), against certain liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Item 15. Recent Sales
of Unregistered Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Set forth below is information
regarding securities issued by us within the last three years which were not registered under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(a) Issuance of Capital
Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">On June 1, 2022, 60 Degrees Pharmaceuticals, LLC,
    a District of Columbia limited liability company (&ldquo;60P LLC&rdquo;), entered into the Agreement and Plan of Merger with 60 Degrees
    Pharmaceuticals, Inc., a Delaware corporation, pursuant to which 60P LLC merged into 60 Degrees Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;).
    The value of each outstanding members&rsquo; membership interest in 60P LLC was automatically converted into common stock of the
    Company, par value $0.0001 per share, with a cost-basis equal to $5.00 per share.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">We issued 37,067 shares to Geoffrey Dow (at $5.00 per share) on August
    28, 2022 in recognition of capital contributions of $185,335 made between January 1, 2022 and April 1, 2022. There are no other outstanding
    related party debt or obligations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On January 2, 2023, we issued a total of 100,000 shares of our common
stock to our legal counsel for payment of certain legal fees.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 21, 2023, we cancelled 1,240,682 common shares owned by
    the Geoffrey S. Dow Revocable Trust.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 21, 2023, we cancelled 189,318 common shares owned by Tyrone
    Miller.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 26, 2023, we issued 405,000 shares of our common stock to
    Florida State University Research Foundation Inc. in exchange for its services.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 26, 2023, we issued 65,000 shares of our common stock to
    Latham BioPharm Group, LLC in exchange for its services.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 26, 2023, we issued 120,000 shares of our common stock to
    Trevally, LLC in exchange for its services.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 26, 2023, we issued 8,500 shares of our common stock to
    ENA Healthcare Communications, LLC in exchange for its services.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 26, 2023, we issued 54,000 shares of our common stock to
    4C Pharma Solutions, LLC in exchange for the cancellation of debt and credit.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 26, 2023, we issued 65,000 shares of our common stock to
    Hybrid Financial in exchange for its services.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On January 26, 2023, we issued 20,000 shares of our common stock to
    Sheila Burke in exchange for services provided by Method Health Communications LLC.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">On January 26, 2023, we issued 525,000 shares of our common stock to University of Kentucky School of Pharmacy in exchange for its services.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 26, 2023, we
issued 37,500 shares of our common stock to Ludlow Business Services, Inc. in exchange for its services.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 26, 2023, we
    issued 30,000 shares of our common stock to Elliot Berman in exchange for services provided by Berman Accounting &amp; Advisory P.A.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 19, 2023, we issued
    13,000 shares of our common stock to a consultant. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 22, 2023, we cancelled
    18,217 shares of our common stock owned by Geoffrey Dow.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 22, 2023, we cancelled 2,783 shares of our
    common stock owned by Ty Miller.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On the effective date of this registration statement, we issued 13,980
    of our common stock to Geoffrey S. Dow Revocable Trust as a result of the conversion of the Convertible Promissory Note we issued
    to the Geoffrey S. Dow Revocable Trust on May 19, 2022 (the &ldquo;Geoffrey S. Dow Revocable Trust Note&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On the effective date of this registration statement, we issued 92,620
    shares of our common stock to Mountjoy Trust as a result of the conversion of the Convertible Promissory Note we issued to Mountjoy
    Trust on May 19, 2022 (the &ldquo;Mountjoy Note&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On the effective date of this registration statement, we issued 66,934
    shares of our common stock to Walleye Opportunities Master Fund Ltd. as a result of the conversion of the Convertible Promissory
    Note we issued to Walleye Opportunities Master Fund Ltd. on May 24, 2022 (the &ldquo;Walleye Note&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On the effective date of this registration statement, we issued 80,321
    shares of our common stock to Bigger Capital Fund, LP as a result of the conversion of the Convertible Promissory Note we issued
    to Bigger Capital Fund, LP on May 24, 2022 (the &ldquo;Bigger Capital Fund Note&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On the effective date of this registration statement, we issued 66,934
    shares of our common stock to Cavalry Investment Fund, LP. as a result of the conversion of the Convertible Promissory Note we issued
    to Cavalry Investment Fund, LP. on May 24, 2022 (the &ldquo;Cavalry Note&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The issuance of the capital stock listed above
was deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance
of securities were made to an accredited investor and did not involve a public offering. The recipient of such securities represented
its intention to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution
thereof.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2022, we issued to Geoffrey Dow a
Common Stock Purchase Warrant to purchase a number of shares of our common stock equal to (i) the total number of common stock issued
to Geoffrey Dow as a result of the conversion of the Dow Note, which will occur on the pricing date of our initial public offering, at
the exercise price equal to 110% of the initial public offering price, or (ii) if we fail to complete the initial public offering prior
to May 31, 2023, 90% of the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2022, we issued to Mountjoy Trust
a Common Stock Purchase Warrant to purchase a number of shares of our common stock equal to (i) the total number of common stock issued
to Mountjoy Trust as a result of the conversion of the Mountjoy Note, which is to occur on the pricing date of our initial public offering,
at the exercise price equal to 110% of the initial public offering price, or (ii) if we fail to complete the initial public offering
prior to May 31, 2023, 90% of the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2022, we issued to Bigger Capital
Fund, LP a Common Stock Purchase Warrant to purchase a number of shares of our common stock equal to 50% of the total number of common
stock issued to Bigger Capital Fund, LP as a result of the conversion of the Bigger Capital Fund Note, which is to occur on the pricing
date of our initial public offering, at the exercise price equal to 110% of the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2022, we issued to Cavalry Investment
Fund, LP a Common Stock Purchase Warrant to purchase a number of shares of our common stock equal to 50% of the total number of common
stock issued to Cavalry Investment Fund, LP as a result of the conversion of the Cavalry Investment Fund Note, which is to occur on the
pricing date of our initial public offering, at the exercise price equal to 110% of the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 24, 2022, we issued to Walleye Opportunities
Master Fund Ltd a Common Stock Purchase Warrant to purchase a number of shares of our common stock equal to 50% of the total number of
common stock issued to Walleye Opportunities Master Fund Ltd as a result of the conversion of the Walleye Note, which is to occur on
the pricing date of our initial public offering, at the exercise price equal to 110% of the initial public offering price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The warrants described above were deemed exempt
from registration in reliance on Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of
securities were made to an accredited investor and did not involve a public offering. The recipients of such securities represented its
intention to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(c) Option Grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Issuance of Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 14, 2020, we issued the Note to the U.S.
Small Business Administration with a principal amount of $150,000 and a per annum interest rate of 3.75%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 19, 2022, we issued the Convertible Promissory
Note to Geoffrey Dow, as assigned to the Geoffrey S. Dow Revocable Trust dated August 27, 2018 on May 19, 2022 (the &ldquo;Dow Note&rdquo;),
with a principal amount of $44,444.44 and a per annum interest rate of 6%. Upon the occurrence of our initial public offering, the balance
of the Dow Note will convert immediately prior to the initial public offering at a price equal to 80% of the price per share of the common
stock sold in the initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">On May 19, 2022, we issued the Mountjoy Note with a principal amount
of $294,444.42 and a per annum interest rate of 6%. Upon the occurrence of our initial public offering, the balance of the Mountjoy Note
will convert immediately prior to the initial public offering at a price equal to 80% of the price per share of the common stock sold
in the initial public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 24, 2022, we issued the Bigger Capital Fund
Note in the amount of $333,333.30 to Bigger Capital Fund, LP. On the date of the pricing of our initial public offering, we will deliver
to Bigger Capital Fund, LP shares of our common stock equal to (i) 100% of the face value of the note divided by the initial public offering
price per share or (ii) if we fail to complete the initial public offering prior to May 24, 2023, the number of shares of common stock
calculated using a $27 million pre-money valuation and the number of outstanding shares of common stock on May 24, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 24, 2022, we issued the Cavalry Investment
Fund Note a note in the amount of $277,777.78 to Cavalry Investment Fund, LP. On the date of the pricing of our initial public offering,
we will deliver to Cavalry Investment Fund, LP shares of our common stock equal to (i) 100% of the face value of the note divided by
the initial public offering price per share or (ii) if we fail to complete the initial public offering prior to May 24, 2023, the number
of shares of common stock calculated using a $27 million pre-money valuation and the number of outstanding shares of common stock on
May 24, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 24, 2022, we issued the Walleye Note in the
amount of $277,777.78 to Walleye Opportunities Master Fund Ltd. On the date of the pricing of our initial public offering, we will deliver
to Walleye Opportunities Master Fund Ltd shares of our common stock equal to (i) 100% of the face value of the note divided by the initial
public offering price per share or (ii) if we fail to complete the initial public offering prior to May 24, 2023, the number of shares
of common stock calculated using a $27 million pre-money valuation and the number of outstanding shares of common stock on May 24, 2023.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The notes described above were deemed exempt from
registration in reliance on Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of securities
were made to an accredited investor and did not involve a public offering. The recipients of such securities represented its intention
to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Item 16. Exhibits
and Financial Statement Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) <B><I>Exhibits</I></B>: Reference is made
to the Exhibit Index following Item 17 of Part II hereto, which Exhibit Index is hereby incorporated into this Item.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) <B><I>Financial Statement Schedules</I></B>:
All schedules are omitted because the required information is inapplicable or the information is presented in the financial statements
and the related notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
To include any prospectus required by section 10(a)(3) of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range
may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate,
the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation
of Registration Fee&rdquo; table in the effective registration statement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement; provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii)
above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports
filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities
Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed
pursuant to Rule 424(b) that is part of the registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be
a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
That, for the purpose of determining liability under the Securities Act to any purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
date the filed prospectus was deemed part of and included in the registration statement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements
relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration
statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement
or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into
the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of
sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part
of the registration statement or made in any such document immediately prior to such date of first use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
That for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
of securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
424;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
the undersigned registrant;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
or its securities provided by or on behalf of the undersigned registrant; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant
to any charter provision, by law or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">The undersigned registrant
hereby undertakes that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">(1) For purposes of determining
any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h)
under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt; text-align: justify">(2) For the purpose of determining
any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to
be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 89%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Underwriting Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex3-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.1</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex3-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Certificate
    of Incorporation of the Registrant</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designation of Series A Preferred Stock</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Certificate of Incorporation of
    the Registrant</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex3-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.4</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex3-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bylaws of the
    Registrant</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Representative Warrant</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Agent Agreement</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Counsel to the Registrant</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
    Purchase Agreement dated as of May 19, 2022, by and between the Registrant and Geoffrey Dow</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-2.htm">10.2**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock
    Purchase Warrant dated as of May 19, 2022, issued by the Registrant to Geoffrey Dow, as assigned to the Geoffrey S. Dow Revocable
    Trust dated August 27, 2018</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.3**</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    Promissory Note dated as of May 19, 2022, issued by the Registrant to Geoffrey Dow</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-4.htm">10.4**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
    Purchase Agreement dated as of May 19, 2022, by and between Registrant and Mountjoy Trust</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.5</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-5.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock
    Purchase Warrant dated as of May 19, 2022, issued by the Registrant to Mountjoy Trust</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-6.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.6</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-6.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    Promissory Note dated as of May 19, 2022, issued by the Registrant to Mountjoy Trust</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-7.htm">10.7**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-7.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
    Purchase Agreement dated as of May 24, 2022, by and between Registrant and Bigger Capital Fund, LP</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-8.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.8</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-8.htm">Common Stock Purchase Warrant dated as of May 24, 2022, issued by the
    Registrant to Bigger Capital Fund, LP</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-9.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.9</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-9.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Promissory
    Note dated as of May 24, 2022, issued by the Registrant to Bigger Capital Fund, LP</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-10.htm">10.10**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-10.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
    Purchase Agreement dated as of May 24, 2022, by and between Registrant and Cavalry Investment Fund, LP</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-11.htm">10.11</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-11.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock
    Purchase Warrant dated as of May 24, 2022, issued by the Registrant to Cavalry Investment Fund, LP</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-12.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.12</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-12.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Promissory
    Note dated as of May 24, 2022, issued by the Registrant to Cavalry Investment Fund, LP</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-13.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.13**</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-13.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
    Purchase Agreement dated as of May 24, 2022, by and between Registrant and Walleye Opportunities Master Fund Ltd</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-14.htm">10.14</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-14.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common Stock
    Purchase Warrant dated as of May 24, 2022, issued by the Registrant to Walleye Opportunities Master Fund Ltd</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-15.htm">10.15</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-15.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Promissory
    Note dated as of May 24, 2022, issued by the Registrant to Walleye Opportunities Master Fund Ltd</FONT></A></FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-16.htm">10.16**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-16.htm">Debt Conversion Agreement dated as of January 9, 2023, by and between
    the Registrant to Knight Therapeutics International S.A.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-17.htm">10.17**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-17.htm">First Amendment to the Debt Conversion Agreement dated as of January
    19, 2023, by and between the Registrant to Knight Therapeutics International S.A.</A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-18.htm">10.18**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-18.htm">Second Amendment to The Debt Conversion Agreement dated as of January
    27, 2023, by and between the Registrant to Knight Therapeutics International S.A.</A></FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-19.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.19**</FONT></A></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 89%"><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-19.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Inter-Institutional
    Agreement dated as of February 15, 2021, by the Registrant and Florida State University Research Foundation</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-20.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.20**</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-20.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exclusive
    License Agreement dated as of September 15, 2016, between National University of Singapore, Singapore Health Services Pte Ltd, the
    Registrant and 60P Australia Pty Ltd</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-21.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.21**</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-21.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Master Consultancy
    Agreement dated as of May 29, 2013, by and between the Registrant and BioIntelect Pty Ltd</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-22.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.22+</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-22.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Employment
    Agreement dated as of January 12, 2023, between the Registrant and Geoffrey Dow</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-23.htm">10.23+</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-23.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Employment
    Agreement dated as of January 12, 2023, between the Registrant and Tyrone Miller</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-24.htm">10.24**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-24.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subscription
    Agreement dated as of October 11, 2017, by and between the Registrant and Avante International Limited</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-25.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.25**</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-25.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Promissory
    Note dated as of October 11, 2017, issued by the Registrant to Avante International Limited</FONT></A></FONT></TD></TR>

  </TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 150; Options: NewSection; Value: 5 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-26.htm">10.26**</A></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 89%"><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-26.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    Promissory Note dated as of December 31, 2016, issued by the Registrant to Geoffrey Dow</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-27.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.27**</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-27.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Agreement
    to Consolidate and Convert Existing Debt dated as of December 31, 2021, between the Registrant and Geoffrey Dow</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-28.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.28**</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-28.htm"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Agreement
    to Convert Debt to Equity dated as of December 31, 2021, issued by the Registrant to Geoffrey Dow</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-29.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.29**</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-29.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    Promissory Note dated as of December 31, 2016, issued by the Registrant to Tyrone Miller</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-30.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.30**</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-30.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Agreement
    to Convert Debt to Equity dated as of December 31, 2021, issued by the Registrant to Tyrone Miller</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-31.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.31</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-31.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Convertible
    Promissory Note dated as of December 31, 2016, issued by the Registrant to Douglas Loock</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-32.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.32</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-32.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Agreement
    to Convert Debt to Equity dated as of August 31, 2021, issued by the Registrant to Douglas Loock</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-33.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">10.33</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-33.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Agreement
    and Plan of Merger dated as of June 1, 2022, by and between the Registrant and 60 Degrees Pharmaceuticals, LLC</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-34.htm">10.34**</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-34.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exclusive
    License Agreement dated as of May 30, 2014, between National University of Singapore, Singapore Health Services Pte Ltd, the Registrant
    and 60P Australia Pty Ltd</FONT></A></FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-35.htm">10.35+</A></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex10-35.htm">2022 Equity Incentive Plan</A></FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex21-1.htm">21.1</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex21-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">List of Subsidiaries
    of the Registrant</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="cm270_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">23.1</FONT></A></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><A HREF="cm270_ex23-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consent of
    RBSM LLP dated as of April 3, 2023</FONT></FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Counsel to the Registrant (included in Exhibit
    5.1)</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#yas_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">24.1</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="#yas_001"><FONT STYLE="font-family: Times New Roman, Times, Serif">Power of Attorney (included
    in signature page)</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consent of
    Director Nominee of Charles Allen</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex99-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.2</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex99-2.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consent of
    Director Nominee of Cheryl Xu</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex99-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.3</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex99-3.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consent of
    Director Nominee of Stephen Toovey</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex99-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.4</FONT></A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex99-4.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consent of
    Director Nominee of Paul Field</FONT></A></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex107.htm">107</A></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="cm270_ex107.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Filing Fee Table</FONT></A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">*To be filed by amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">**Parts of certain information have been redacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">+ Management contract or compensatory plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 151 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Act of 1933, as amended,
the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in
the City of Washington, District of Columbia, on&nbsp;April 3, 2023.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 3%; text-align: justify"><FONT STYLE="font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><FONT STYLE="font-size: 10pt">/s/
<I>Geoffrey Dow</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">President and Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">(Principal Executive Officer)</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><B><A NAME="yas_001"></A>POWER
OF ATTORNEY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">KNOW ALL PERSONS BY THESE PRESENTS, that
each person whose signature appears below constitutes and appoints Geoffrey Dow and Tyrone Miller his or her true and lawful attorney-in-fact,
with full power of substitution and re-substitution for him or her and in his or her name, place and stead, in any and all capacities
to sign any and all amendments including pre- and post-effective amendments to this registration statement, any subsequent registration
statement for the same offering which may be filed pursuant to Rule&nbsp;462(b) under the Securities Act of 1933, as amended, and pre-
or post-effective amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with
the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his or her substitute, each
acting alone, may lawfully do or cause to be done by virtue thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 36%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 18%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ <I>Geoffrey Dow</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President, Chief Executive Officer and Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 3, 2023</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Geoffrey Dow</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ <I>Tyrone Miller</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Treasurer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">April 3, 2023</FONT></TD></TR>
  <TR>
    <TD><FONT STYLE="font-size: 10pt">Tyrone Miller</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 152; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>cm270_ex3-1.htm
<DESCRIPTION>EXHIBIT 3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt"><B>Exhibit 3.1</B></P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 34%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 24pt"><U>Delaware</U></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 1</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The First State</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B><I>I, JEFFREY W. BULLOCK, SECRETARY OF STATE
OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF &ldquo;60 DEGREES
PHARMACEUTICALS, INC.&quot;, FILED IN THIS OFFICE ON THE FIRST DAY OF JUNE, A.D. 2022, AT 8 O'CLOCK A.M.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; font-size: 10pt">/<FONT STYLE="font-family: Times New Roman, Times, Serif">s</FONT>/
    <FONT STYLE="font-family: Times New Roman, Times, Serif">Jeffrey W. Bullock</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Jeffrey W. Bullock, Secretary Of State</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 30%; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6829222 8100</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SR# 20222549773</P></TD>
    <TD STYLE="vertical-align: bottom; width: 30%; text-align: center; font-size: 10pt"><IMG SRC="cm270_ex3-1img01.jpg" ALT=""></TD>
    <TD STYLE="width: 5%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 35%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Authentication: 203562558</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Date: 06-01-22</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may verify this certificate online at corp.delaware.gov/authver.shtml</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATE OF INCORPORATION OF 60 DEGREES<BR>
PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">I, </FONT>the
undersigned, for the purpose of creating and organizing a corporation under the provisions of and subject to the requirements of the General
Corporation Law of the State of Delaware (the &quot;<B>DGCL&quot;), </B>certify as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
name of the corporation is 60 Degrees Pharmaceuticals, Inc. (the <B>&quot;Corporation&quot;).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
address of the registered office of the Corporation in the State of Delaware is 251 Little Falls Drive, Wilmington, New Castle County,
Delaware 19808. The name of the registered agent of the Corporation at such address is Corporation Service Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
nature of the business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which
corporations may be organized under the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
total number of shares of common stock which the Corporation is authorized to issue is 150,000,000, at a par value of $.0001 per share,
and the total number of shares of preferred stock which the Corporation is authorized to issue is 1,000,000, at a par value of $.0001
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
board of directors is hereby expressly authorized to provide, out of the unissued shares of preferred stock, for one or more series of
preferred stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such
series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional or other special
rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series. The powers, preferences and
relative, participating, optional and other special rights of each series of preferred stock, and the qualifications, limitations or restrictions
thereof, if any, may differ from those of any and all other series at any time outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
name and mailing address of the incorporator of the Corporation are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Name</U></FONT></TD>
    <TD STYLE="width: 64%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mailing Address</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEOFFREYS, DOW</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1025 Connecticut Avenue, NW</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suite 1000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington, District of Columbia 20036</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Unless
and except to the extent that the by-laws of the Corporation (the <B>&quot;By-laws&quot;) </B>shall so require, the election of directors
of the Corporation need not be by written ballot.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State of Delaware</B></FONT></TD>
    <TD STYLE="width: 65%; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Secretary of State</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Division of Corporations</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delivered 07:56 AM 06/01/2022</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FILED 08:00 AM 06/01/2022</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SR 20222549773 - File Number 6829222</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or to its stockholders
for monetary damages for any breach of fiduciary duty as a director. No amendment to, modification of or repeal of this paragraph 8 shall
apply to or have any effect on the liability or alleged liability of any director of the Corporation for or with respect to any acts or
omissions of such director occurring prior to such amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation shall indemnify, advance expenses, and hold harmless, to the fullest extent permitted by applicable law as it presently exists
or may hereafter be amended, any person (a <B>&ldquo;Covered Person&rdquo;) </B>who was or is made or is threatened to be made a party
or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a <B>&ldquo;Proceeding&rdquo;),
</B>by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer
of the Corporation or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director,
officer, employee or agent of another corporation or of a partnership, joint venture, trust, enterprise or nonprofit entity, including
service with respect to employee benefit plans, against all liability and loss suffered and expenses (including attorneys' fees) reasonably
incurred by such Covered Person. Notwithstanding the preceding sentence, except for claims for indemnification (following the final disposition
of such Proceeding) or advancement of expenses not paid in full, the Corporation shall be required to indemnify a Covered Person in connection
with a Proceeding (or part thereof) commenced by such Covered Person only if the commencement of such Proceeding (or part thereof) by
the Covered Person was authorized in the specific case by the board of directors of the Corporation. Any amendment, repeal or modification
of this paragraph 9 shall not adversely affect any right or protection hereunder of any person in respect of any act or omission occurring
prior to the time of such repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
furtherance and not in limitation of the powers conferred by statute, the board of directors is expressly authorized to adopt, amend or
repeal the By-laws or adopt new By-laws without any action on the part of the stockholders; provided that any By-law adopted or amended
by the board of directors, and any powers thereby conferred, may be amended, altered or repealed by the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Corporation shall have the right, subject to any express provisions or restrictions contained in this Certificate of Incorporation of
the Corporation (the <B>&quot;Certificate of Incorporation&quot;) </B>or the By-laws, from time to time, to amend, alter or repeal any
provision of the Certificate of Incorporation in any manner now or hereafter provided by law, and all rights and powers of any kind conferred
upon a director or stockholder of the Corporation by this Certificate of Incorporation or any amendment thereof are conferred subject
to such right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to
the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of
the Corporation, (ii) any action asserting a claim for breach of a fiduciary duty owed by any director, officer, employee or agent of
the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (iii) any action asserting a claim arising pursuant to any
provision of the DGCL, this Certificate of Incorporation or the By-laws or (iv) any action asserting a claim governed by the internal
affairs doctrine, in each case subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as
defendants therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, THE UNDERSIGNED, being the incorporator, for
the purpose of forming a corporation pursuant to the DGCL, do make this Certificate of Incorporation, hereby acknowledging, declaring,
and certifying that the foregoing Certificate of Incorporation is my act and deed and that the facts herein stated are true, and have
accordingly hereunto set my hand this 1st day of June, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporator</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEOFFREY S. DOW</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GEOFFREY S. DOW</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.4
<SEQUENCE>3
<FILENAME>cm270_ex3-4.htm
<DESCRIPTION>EXHIBIT 3.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BY-LAWS OF 60 DEGREES PHARMACEUTICALS, INC.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 177.3pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OFFICES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 1.01 Offices.</B>
The address of the registered office of 60 DEGREES PHARMACEUTICALS, INC (hereinafter called the &quot;<B>Corporation</B>&quot;) in the
State of Delaware shall be at 251 Little Falls Drive, Wilmington, Delaware 19808. The Corporation may have other offices, both within
and without the State of Delaware, as the board of directors of the Corporation (the &quot;<B>Board of Directors</B>&quot;) from time
to time shall determine or the business of the Corporation may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 1.02 Books and
Records.</B> Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger,
books of account, and minute books, may be maintained on any information storage device, method, or one or more electronic networks or
databases (including one or more distributed electronic networks or databases); <I>provided that</I> the records so kept can be converted
into clearly legible paper form within a reasonable time, and, with respect to the stock ledger, the records so kept comply with Section
224 of the Delaware General Corporation Law. The Corporation shall so convert any records so kept upon the request of any person entitled
to inspect such records pursuant to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"><B>ARTICLE II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"><B>MEETINGS OF THE
STOCKHOLDERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.01 Place of Meetings.</B>
All meetings of the stockholders shall be held at such place, if any, either within or without the State of Delaware, or by means of remote
communication, as shall be designated from time to time by resolution of the Board of Directors and stated in the notice of meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.02 Annual Meeting.</B>
The annual meeting of the stockholders for the election of directors and for the transaction of such other business as may properly come
before the meeting shall be held at such date, time and place, if any, as shall be determined by the Board of Directors and stated in
the notice of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.03 Special Meetings.</B>
Special meetings of stockholders for any purpose or purposes shall be called pursuant to a resolution approved by the Board of Directors
and may not be called by any other person or persons. The only business which may be conducted at a special meeting shall be the matter
or matters set forth in the notice of such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.04 Adjournments.
</B>Any meeting of the stockholders, annual or special, may be adjourned from time to time to reconvene at the same or some other place,
if any, and notice need not be given of any such adjourned meeting if the time, place, if any, thereof, and the means of remote communication,
if any, are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Corporation may transact any business
which might have been transacted at the original meeting. If the adjournment is for more than 30 days, a notice of the adjourned meeting
shall be given to each stockholder of record entitled to vote at the meeting. If after the adjournment a new record date is fixed for
stockholders entitled to vote at the adjourned meeting, the Board of Directors shall fix a new record date for notice of the adjourned
meeting and shall give notice of the adjourned meeting to each stockholder of record entitled to vote at the adjourned meeting as of
the record date fixed for notice of the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.05 Notice of
Meetings.</B> Notice of the place, if any, date, hour, the record date for determining the stockholders entitled to vote at the meeting
(if such date is different from the record date for stockholders entitled to notice of the meeting) and means of remote communication,
if any, of every meeting of stockholders shall be given by the Corporation not less than 10 days nor more than 60 days before the meeting
(unless a different time is specified by law) to every stockholder entitled to vote at the meeting as of the record date for determining
the stockholders entitled to notice of the meeting. Notices of special meetings shall also specify the purpose or purposes for which the
meeting has been called. Notices of meetings to stockholders may be given by mailing the same, addressed to the stockholder entitled thereto,
at such stockholder's mailing address as it appears on the records of the corporation and such notice shall be deemed to be given when
deposited in the U.S. mail, postage prepaid. Without limiting the manner by which notices of meetings otherwise may be given effectively
to stockholders, any such notice may be given by electronic transmission in accordance with applicable law. Notice of any meeting need
not be given to any stockholder who shall, either before or after the meeting, submit a waiver of notice or who shall attend such meeting,
except when the stockholder attends for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business
because the meeting is not lawfully called or convened. Any stockholder so waiving notice of the meeting shall be bound by the proceedings
of the meeting in all respects as if due notice thereof had been given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.06 List of Stockholders.</B>
The Corporation shall prepare a complete list of the stockholders entitled to vote at any meeting of stockholders (provided, however,
if the record date for determining the stockholders entitled to vote is less than ten days before the date of the meeting, the list shall
reflect the stockholders entitled to vote as of the tenth day before the meeting date), arranged in alphabetical order, and showing the
address of each stockholder and the number of shares of each class of capital stock of the Corporation registered in the name of each
stockholder at least ten days before any meeting of the stockholders. Such list shall be open to the examination of any stockholder, for
any purpose germane to the meeting, on a reasonably accessible electronic network if the information required to gain access to such list
was provided with the notice of the meeting or during ordinary business hours, at the principal place of business of the Corporation for
a period of at least ten days before the meeting. If the meeting is to be held at a place, the list shall also be produced and kept at
the time and place of the meeting the whole time thereof and may be inspected by any stockholder who is present. If the meeting is held
solely by means of remote communication, the list shall also be open for inspection by any stockholder during the whole time of the meeting
as provided by applicable law. Except as provided by applicable law, the stock ledger of the Corporation shall be the only evidence as
to who are the stockholders entitled to examine the stock ledger and the list of stockholders or to vote in person or by proxy at any
meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.07 Quorum.</B>
Unless otherwise required by law, the Corporation's Certificate of Incorporation (the &quot;<B>Certificate of Incorporation</B>&quot;)
or these by-laws, at each meeting of the stockholders, stockholders holding at least thirty-three and 34/100ths of shares of the Corporation
entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum. If, however, such quorum shall
not be present or represented at any meeting of the stockholders, the stockholders entitled to vote thereat, present in person or represented
by proxy, shall have power, by the affirmative vote of a majority in voting power thereof, to adjourn the meeting from time to time, in
the manner provided in Section 2.04, until a quorum shall be present or represented. A quorum, once established, shall not be broken by
the subsequent withdrawal of enough votes to leave less than a quorum. At any such adjourned meeting at which there is a quorum, any business
may be transacted that might have been transacted at the meeting originally called.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.08 Conduct of
Meetings.</B> The Board of Directors may adopt by resolution such rules and regulations for the conduct of the meeting of the stockholders
as it shall deem appropriate. At every meeting of the stockholders, the Chair of the Board, or in his or her absence or inability to act,
the president, or in his or her absence or inability to act, a quorum of stockholders present shall appoint a director to act as chair
of, and preside at, the meeting. The secretary or, in his or her absence or inability to act, the person whom the chair of the meeting
shall appoint secretary of the meeting, shall act as secretary of the meeting and keep the minutes thereof. Except to the extent inconsistent
with such rules and regulations as adopted by the Board of Directors, the chair of any meeting of the stockholders shall have the right
and authority to prescribe such rules, regulations, and procedures and to do all such acts as, in the judgment of such chair, are appropriate
for the proper conduct of the meeting. Such rules, regulations, or procedures, whether adopted by the Board of Directors or prescribed
by the chair of the meeting, may include, without limitation, the following: (a) the establishment of an agenda or order of business for
the meeting; (b) the determination of when the polls shall open and close for any given matter to be voted on at the meeting; (c) rules
and procedures for maintaining order at the meeting and the safety of those present; (d) limitations on attendance at or participation
in the meeting to stockholders of record of the corporation, their duly authorized and constituted proxies or such other persons as the
chair of the meeting shall determine; (e) restrictions on entry to the meeting after the time fixed for the commencement thereof; and
(f) limitations on the time allotted to questions or comments by participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.09 Voting; Proxies.</B>
Unless otherwise required by law or the Certificate of Incorporation, the election of directors shall be decided by a plurality of the
votes cast at a meeting of the stockholders by the holders of stock, at which a quorum is present in person or represented by proxy entitled
to vote in the election. Unless otherwise required by law, the Certificate of Incorporation, or these by-laws, any matter, other than
the election of directors, brought before any meeting of stockholders, at which a quorum is present in person or represented by proxy
at the meeting entitled to vote on the matter, shall be decided by the affirmative vote of a majority of such stockholders. Each stockholder
entitled to vote at a meeting of stockholders or to express consent to corporate action without a meeting may authorize another person
or persons to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after one year from its date, unless the
proxy provides for a longer period. The authorization of a person to act as proxy may be documented, signed, and delivered in accordance
with Section 116 of the General Corporation Law of the State of Delaware (the &quot;<B>DGCL</B>&quot;) provided that such authorization
shall set forth, or be delivered with, information enabling the Corporation to determine the identity of the stockholder granting such
authorization. A proxy shall be irrevocable if it states that it is irrevocable and if, and only as long as, it is coupled with an interest
sufficient in law to support an irrevocable power. A stockholder may revoke any proxy which is not irrevocable by attending the meeting
and voting in person or by delivering to the secretary of the Corporation a revocation of the proxy or a new proxy bearing a later date.
Voting at meetings of stockholders need not be by written ballot.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.10 Inspectors
at Meetings of Stockholders.</B> The Board of Directors, in advance of any meeting of stockholders, may, and shall if required by law,
appoint one or more inspectors, who may be employees of the Corporation, to act at the meeting or any adjournment thereof and make a written
report thereof. The Board of Directors may designate one or more persons as alternate inspectors to replace any inspector who fails to
act. If no inspector or alternate is able to act at a meeting, the person presiding at the meeting shall appoint one or more inspectors
to act at the meeting. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully
to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors shall (a)
ascertain the number of shares outstanding and the voting power of each, (b) determine the shares represented at the meeting, the existence
of a quorum and the validity of proxies and ballots, (c) count all votes and ballots, (d) determine and retain for a reasonable period
a record of the disposition of any challenges made to any determination by the inspectors, and (e) certify their determination of the
number of shares represented at the meeting and their count of all votes and ballots. The inspectors may appoint or retain other persons
or entities to assist the inspectors in the performance of their duties. Unless otherwise provided by the Board of Directors, the date
and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced
at the meeting. No ballot, proxies, votes, or any revocation thereof or change thereto, shall be accepted by the inspectors after the
closing of the polls unless the Court of Chancery of the State of Delaware upon application by a stockholder shall determine otherwise.
In determining the validity and counting of proxies and ballots cast at any meeting of stockholders, the inspectors may consider such
information as is permitted by applicable law. No person who is a candidate for office at an election may serve as an inspector at such
election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 2.11 Consent of
Stockholders Without a Meeting.</B> Any action to be taken at any annual or special meeting of stockholders may be taken without a meeting,
without prior notice and without a vote, if a consent or consents in writing or by electronic transmission, setting forth the action to
be so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary
to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered
to the Corporation by delivery to its registered office in the State of Delaware (by hand or by certified or registered mail, return receipt
requested), its principal place of business, an officer or agent of the Corporation having custody of the book in which proceedings of
meetings of stockholders are recorded, or to an information processing system designated by the corporation for receiving such consents
in accordance with applicable law. Every consent shall bear the date of signature of each stockholder who signs the consent, and no consent
shall be effective to take the corporate action referred to therein unless, within 60 days of the earliest dated consent delivered in
the manner required by this Section 2.11, consents signed by a sufficient number of holders to take action are delivered to the Corporation
as aforesaid. Prompt notice of the taking of the corporate action without a meeting by less than unanimous consent shall, to the extent
required by applicable law, be given to those stockholders who have not consented in writing, and who, if the action had been taken at
a meeting, would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date that consents
signed by a sufficient number of holders to take the action were delivered to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Section 2.12 Fixing the Record Date. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment
thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the
record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than ten days before the date
of such meeting. If the Board of Directors so fixes a date, such date shall also be the record date for determining the stockholders entitled
to vote at such meeting unless the Board of Directors determines, at the time it fixes such record date, that a later date on or before
the date of the meeting shall be the date for making such determination. If no record date is fixed by the Board of Directors, the record
date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the
day next preceding the day on which notice is given, or, if notice is waived, at the close of business on the day next preceding the day
on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders
shall apply to any adjournment of the meeting; <I>provided, however,</I> that the Board of Directors may fix a new record date for the
determination of stockholders entitled to vote at the adjourned meeting and in such case shall also fix as the record date for stockholders
entitled to notice of such adjourned meeting the same or an earlier date as that fixed for the determination of stockholders entitled
to vote therewith at the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order that the Corporation may determine the stockholders entitled to consent to corporate action without a meeting, the Board of Directors
may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the
Board of Directors, and which record date shall not be more than ten days after the date upon which the resolution fixing the record date
is adopted by the Board of Directors. If no record date has been fixed by the Board of Directors, the record date for determining stockholders
entitled to consent to corporate action without a meeting: (i) when no prior action by the Board of Directors is required by law, the
record date for such purpose shall be the first date on which a signed consent setting forth the action taken or proposed to be taken
is delivered to the Corporation by delivery (by hand, or by certified or registered mail, return receipt requested) to its registered
office in the State of Delaware, its principal place of business, or an officer or agent of the Corporation having custody of the book
in which proceedings of meetings of stockholders are recorded and (ii) if prior action by the Board of Directors is required by law, the
record date for such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution taking
such prior action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment
of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion, or exchange of stock, or for the
purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which
the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record
date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which
the Board of Directors adopts the resolution relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.45pt; text-align: right; text-indent: -22.45pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"><B>ARTICLE III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"><B>BOARD OF DIRECTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.01 General Powers.</B>
The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors. The Board of Directors
may adopt such rules and procedures, not inconsistent with the Certificate of Incorporation, these by-laws, or applicable law, as it may
deem proper for the conduct of its meetings and the management of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.02 Number; Term
of Office.</B> The Board of Directors shall consist of one or more members, the number thereof to be determined from time to time by resolution
of the Board of Directors. Each director shall hold office until a successor is duly elected and qualified or until the director's earlier
death, resignation, disqualification, or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.03 Newly Created
Directorships and Vacancies.</B> Any newly created directorships resulting from an increase in the authorized number of directors and
any vacancies occurring in the Board of Directors, may be filled by the affirmative votes of a majority of the remaining members of the
Board of Directors, although less than a quorum, or by a sole remaining director prior to the next meeting of the Board of Directors.
A director so elected shall be elected to hold office until the earlier of the expiration of the term of office of the director whom he
or she has replaced, a successor is duly elected and qualified, or the earlier of such director's death, resignation, or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.04 Resignation.</B>
Any director may resign at any time by notice given in writing or by electronic transmission to the Corporation. Such resignation shall
take effect at the date of receipt of such notice by the Corporation or at such later time as is therein specified. A verbal resignation
shall not be deemed effective until confirmed by the director in writing or by electronic transmission to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.05 Removal.</B>
Except as prohibited by applicable law or the Certificate of Incorporation, the stockholders entitled to vote in an election of directors
may remove any director from office at any time, with or without cause, by the affirmative vote of a majority in voting power thereof;
provided, however, until the Corporation&rsquo;s shares are traded freely on a stock exchange Geoffrey S. Dow shall not be removed from
his office as director or any other elected office except for cause.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.06 Fees and Expenses.</B>
Directors shall receive such fees and expenses as the Board of Directors shall from time to time prescribe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.07 Regular Meetings.</B>
Regular meetings of the Board of Directors may be held without notice at such times and at such places as may be determined from time
to time by the Board of Directors or the Chair of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.08 Special Meetings.</B>
Special meetings of the Board of Directors may be held at such times and at such places as may be determined by the Chair of the Board,
or in his or her absence or inability to act, the president, or in his or her absence or inability to act, a majority of directors present
shall appoint a director to act as chair of, and preside at, the meeting, on at least 24 hours' notice to each director given by one of
the means specified in Section 3.11 hereof other than by mail or on at least three days' notice if given by mail. Special meetings shall
be called by the chairman, or in his or her absence or inability to act, the president, in like manner and on like notice on the written
request of any two or more directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.09 Telephone
Meetings.</B> Board of Directors or Board of Directors committee meetings may be held by means of telephone conference or other communications
equipment by means of which all persons participating in the meeting can hear each other and be heard. Participation by a director in
a meeting pursuant to this Section 3.09 shall constitute presence in person at such meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.10 Adjourned
Meetings.</B> A majority of the directors present at any meeting of the Board of Directors, including an adjourned meeting, whether a
quorum is present, may adjourn and reconvene such meeting to another time and place. At least 24 hours' notice of any adjourned meeting
of the Board of Directors shall be given to each director whether present at the time of the adjournment, if such notice shall be given
by one of the means specified in Section 3.11 hereof other than by mail, or at least three days' notice if by mail. Any business may be
transacted at an adjourned meeting that might have been transacted at the meeting as originally called.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.11 Notices.</B>
Subject to Section 3.08, Section 3.10, and Section 3.12 hereof, whenever notice is required to be given to any director by applicable
law, the Certificate of Incorporation, or these by-laws, such notice shall be deemed given effectively if given in person or by telephone,
mail addressed to such director at such director's address as it appears on the records of the Corporation, facsimile, email, or by other
means of electronic transmission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.12 Waiver of
Notice.</B> Whenever notice to directors is required by applicable law, the Certificate of Incorporation, or these by-laws, a waiver thereof,
in writing signed by, or by electronic transmission by, the director entitled to the notice, whether before or after such notice is required,
shall be deemed equivalent to notice. Attendance by a director at a meeting shall constitute a waiver of notice of such meeting except
when the director attends a meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business
on the ground that the meeting was not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any
regular or special Board of Directors or committee meeting need be specified in any waiver of notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.13 Organization.
</B>At each meeting of the Board of Directors, the chairman or, in his or her absence, another director selected by the Board of Directors
shall preside. The secretary shall act as secretary at each meeting of the Board of Directors. If the secretary is absent from any meeting
of the Board of Directors, an assistant secretary shall perform the duties of secretary at such meeting; and in the absence from any such
meeting of the secretary and all assistant secretaries, the person presiding at the meeting may appoint any person to act as secretary
of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.14 Quorum of
Directors.</B> Except as otherwise permitted by the Certificate of Incorporation, these by-laws, or applicable law, the presence of a
majority of the Board of Directors shall be necessary and sufficient to constitute a quorum for the transaction of business at any meeting
of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.15 Action by
Majority Vote.</B> Except as otherwise expressly required by these by-laws, the Certificate of Incorporation, or by applicable law, the
vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.16 Action Without
Meeting.</B> Unless otherwise restricted by the Certificate of Incorporation or these by-laws, any action required or permitted to be
taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting if all directors or members
of such committee, as the case may be, consent thereto in writing or by electronic transmission and any consent may be documented, signed,
and delivered in any manner permitted by Section 116 of the DGCL. After an action is taken, the consent or consents relating thereto shall
be filed with the minutes of proceedings of the Board of Directors or committee in accordance with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 3.17 Committees
of the Board of Directors.</B> The Board of Directors may designate one or more committees, each committee to consist of one or more of
the directors of the Corporation. The Board of Directors may designate one or more directors as alternate members of any committee, who
may replace any absent or disqualified member at any meeting of the committee. If a member of a committee shall be absent from any meeting,
or disqualified from voting thereat, the remaining member or members present at the meeting and not disqualified from voting, whether
such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors to act at the meeting in
the place of any such absent or disqualified member. Any such committee, to the extent permitted by applicable law, shall have and may
exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation and may
authorize the seal of the Corporation to be affixed to all papers that may require it to the extent so authorized by the Board of Directors.
Unless the Board of Directors provides otherwise, at all meetings of such committee, a majority of the then authorized members of the
committee shall constitute a quorum for the transaction of business, and the vote of a majority of the members of the committee present
at any meeting at which there is a quorum shall be the act of the committee. Each committee shall keep regular minutes of its meetings.
Unless the Board of Directors provides otherwise, each committee designated by the Board of Directors may make, alter, and repeal rules
and procedures for the conduct of its business. In the absence of such rules and procedures each committee shall conduct its business
in the same manner as the Board of Directors conducts its business pursuant to this Article III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OFFICERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.01 Positions
and Election.</B> The officers of the Corporation shall be elected by the Board of Directors and shall include a Chair of the Board of
Directors (who must be a director), a president, a treasurer, and a secretary. The Board of Directors, in its discretion, may also elect
one or more vice chairs (who must be directors), and one or more vice presidents, assistant treasurers, assistant secretaries, and other
officers. Any two or more offices may be held by the same person. Except as otherwise provided in these by-laws, the Chair of the Board
shall preside at all meetings of the Board of Directors and of stockholders. The Chair of the Board shall perform such other duties and
services as shall be assigned to or required of the Chair of the Board by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.02 Term. </B>Each
officer of the Corporation shall hold office until such officer's successor is elected and qualified or until such officer's earlier death,
resignation, or removal. Any officer elected or appointed by the Board of Directors may be removed by the Board of Directors at any time,
with or without cause, by the majority vote of the members of the Board of Directors then in office. The removal of an officer shall be
without prejudice to his or her contract rights, if any. The election or appointment of an officer shall not of itself create contract
rights. Any officer of the Corporation may resign at any time by giving written notice of his or her resignation to the president or the
secretary. Any such resignation shall take effect at the time specified therein or, if the time when it shall become effective shall not
be specified therein, immediately upon its receipt. Unless otherwise specified therein, the acceptance of such resignation shall not be
necessary to make it effective. Should any vacancy occur among the officers, the position shall be filled for the unexpired portion of
the term by appointment made by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.03 The President.</B>
The president shall have general supervision over the business of the Corporation and other duties incident to the office of president,
and any other duties as may be from time to time assigned to the president by the Board of Directors and subject to the control of the
Board of Directors in each case.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.04 Vice Presidents.</B>
Each vice president shall have such powers and perform such duties as may be assigned to him or her from time to time by the Chair of
the Board of Directors or the president.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.05 The Secretary.</B>
The secretary shall attend all sessions of the Board of Directors and all meetings of the stockholders and record all votes and the minutes
of all proceedings and shall perform like duties for committees when required. He or she shall give, or cause to be given, notice of all
meetings of the stockholders and meetings of the Board of Directors, and shall perform such other duties as may be prescribed by the Board
of Directors or the president. The secretary shall keep in safe custody the seal of the Corporation and have authority to affix the seal
to all documents requiring it and attest to the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.06 The Treasurer.</B>
The treasurer shall have the custody of the corporate funds and securities, except as otherwise provided by the Board of Directors, and
shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all moneys
and other valuable effects in the name and to the credit of the Corporation in such depositories as may be designated by the Board of
Directors. The treasurer shall disburse the funds of the Corporation as may be ordered by the Board of Directors, taking proper vouchers
for such disbursements, and shall render to the president and the directors, at the regular meetings of the Board of Directors, or whenever
they may require it, an account of all his or her transactions as treasurer and of the financial condition of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 4.07 Duties of
Officers May Be Delegated.</B> In case any officer is absent, or for any other reason that the Board of Directors may deem sufficient,
the president or the Board of Directors may delegate for the time being the powers or duties of such officer to any other officer or to
any director.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>STOCK CERTIFICATES AND THEIR TRANSFER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.01 Certificates
Representing Shares.</B> The shares of stock of the Corporation shall be represented by certificates; provided that the Board of Directors
may provide by resolution or resolutions that some or all of any class or series shall be uncertificated shares that may be evidenced
by a book-entry system maintained by the registrar of such stock. If shares are represented by certificates, such certificates shall be
in the form, other than bearer form, approved by the Board of Directors. The certificates representing shares of stock of each class shall
be signed by, or in the name of, the Corporation by any two authorized officers of the Corporation. Any or all such signatures may be
facsimiles. Although any officer, transfer agent, or registrar whose manual or facsimile signature is affixed to such a certificate ceases
to be such officer, transfer agent, or registrar before such certificate has been issued, it may nevertheless be issued by the Corporation
with the same effect as if such officer, transfer agent, or registrar were still such at the date of its issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.02 Transfers
of Stock.</B> Stock of the Corporation shall be transferable in the manner prescribed by law and in these by-laws. Transfers of stock
shall be made on the books of the Corporation only by the holder of record thereof, by such person's attorney lawfully constituted in
writing and, in the case of certificated shares, upon the surrender of the certificate thereof, which shall be cancelled before a new
certificate or uncertificated shares shall be issued. No transfer of stock shall be valid as against the Corporation for any purpose until
it shall have been entered in the stock records of the Corporation by an entry showing from and to whom transferred. To the extent designated
by the president or any vice president or the treasurer of the Corporation, the Corporation may recognize the transfer of fractional uncertificated
shares but shall not otherwise be required to recognize the transfer of fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.03 Transfer Agents
and Registrars.</B> The Board of Directors may appoint, or authorize any officer or officers to appoint, one or more transfer agents and
one or more registrars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 5.04 Lost, Stolen,
or Destroyed Certificates.</B> The Board of Directors may direct a new certificate or uncertificated shares to be issued in place of any
certificate theretofore issued by the Corporation alleged to have been lost, stolen, or destroyed upon the making of an affidavit of that
fact by the owner of the allegedly lost, stolen, or destroyed certificate. When authorizing such issue of a new certificate or uncertificated
shares, the Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of the lost,
stolen, or destroyed certificate, or the owner's legal representative to give the Corporation a bond sufficient to indemnify it against
any claim that may be made against the Corporation with respect to the certificate alleged to have been lost, stolen, or destroyed or
the issuance of such new certificate or uncertificated shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VI</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>GENERAL PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.01 Seal. </B>The
seal of the Corporation shall be in such form as shall be approved by the Board of Directors. The seal may be used by causing it or a
facsimile thereof to be impressed or affixed or reproduced or otherwise, as may be prescribed by law or custom or by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.02 Fiscal Year.
</B>The fiscal year of the Corporation shall be determined by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.03 Checks, Notes,
Drafts, Etc. </B>All checks, notes, drafts, or other orders for the payment of money of the Corporation shall be signed, endorsed, or
accepted in the name of the Corporation by such officer, officers, person, or persons as from time to time may be designated by the Board
of Directors or by an officer or officers authorized by the Board of Directors to make such designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.04 Dividends.
</B>Subject to applicable law and the Certificate of Incorporation, dividends upon the shares of capital stock of the Corporation may
be declared by the Board of Directors at any regular or special meeting of the Board of Directors. Dividends may be paid in cash, in property,
or in shares of the Corporation's capital stock, unless otherwise provided by applicable law or the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 6.05 Conflict with
Applicable Law or Certificate of Incorporation. </B>These by-laws are adopted subject to any applicable law and the Certificate of Incorporation.
Whenever these by-laws may conflict with any applicable law or the Certificate of Incorporation, such conflict shall be resolved in favor
of such law or the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VII</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Section 7.01 Amendments.
</B>These by-laws may be adopted, amended, or repealed or new by-laws adopted by the Board of Directors. The stockholders may make additional
by-laws and may adopt, amend, or repeal any by-laws whether such by-laws were originally adopted by them or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 70%; text-align: center"><FONT STYLE="font-size: 10pt">Adopted by Sole Director effective June 1, 2022</FONT></TD>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;/s/ Geoff Dow</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Secretary</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>cm270_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: right">Exhibit 10.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">SECURITIES PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of May 19, 2022, by and between 60 Degrees Pharmaceuticals, LLC, a limited liability
company (the &ldquo;<U>Company</U>&rdquo;), and each lender party that executes the signature page hereto as a purchaser (each, a &ldquo;Purchaser&rdquo;
and collectively, the &ldquo;Purchasers&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms and
conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities
Act, as defined, contained in Section 4(a)(2) thereof and/or Rule 506(b) thereunder, the Company desires to issue and sell to the Purchaser,
and the Purchaser desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and the Purchaser agree as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE I.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1 <U>Definitions</U>. In addition
to the words and terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Acquiring Person&rdquo; shall
have the meaning ascribed to such term in Section 5.5. &ldquo;Action&rdquo; shall have the meaning ascribed to such term in Section 3.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Affiliate&rdquo; means any
Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a
Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&ldquo;Board of Directors&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Closing&rdquo; means the
closing of the purchase and sale of the Notes pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Closing Date&rdquo;
means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto,
and all conditions precedent to (i) the Purchaser&rsquo;s obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities to be issued and sold, in each case, have been satisfied or waived, but in no event later than
the second Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Common Stock&rdquo; means
the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Common Stock Equivalents&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Evaluation Date&rdquo; shall
have the meaning ascribed to such term in Section 3.19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Exchange Act&rdquo; means
the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Exempt Issuance&rdquo; means
the issuance of (a) shares of Common Stock, restricted stock units or options, and the underlying shares of Common Stock to consultants,
employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the
non- employee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for
such purpose for services rendered to the Company, (b) securities issued upon the exercise or exchange of or conversion of any Securities
issued hereunder and/or other securities issuable pursuant to existing agreements, exercisable or exchangeable for or convertible into
shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since
the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price
of such securities (other than in connection with stock dividends, stock splits or combinations) or to extend the term of such securities,
(c) securities issued pursuant, acquisitions or strategic transactions approved by a majority of the directors of the Company, provided
that any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and which shall reasonably be
expected to provide to the Company additional benefits, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, (d) securities issued
pursuant to any purchase money equipment loan or capital leasing arrangement, purchasing agent or debt financing from a commercial bank
or similar financial institution, (e) securities issued pursuant to any presently outstanding warrants or this Agreement; and (f) securities
upon a stock split, stock dividend or subdivision of the Common Stock and shares of common stock in a public offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">(g) non-convertible loans from traditional
commercials banks with interest per annum not to exceed 12% which will rank <B><I>pari passu </I></B>with the Notes issued to investors
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Face Value&rdquo; means
the Subscription Amount plus original issue discount as described in the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;FCPA&rdquo; means the Foreign
Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;GAAP&rdquo; shall have the
meaning ascribed to such term in Section 3.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Indebtedness&rdquo; shall
have the meaning ascribed to such term in Section 3.27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Intellectual Property&rdquo;
means all of the following in any jurisdiction throughout the world: (a) all inventions (whether patentable or unpatentable and whether
or not reduced to practice), all improvements thereto, and all U.S. and foreign patents, patent applications, and patent disclosures,
together with all reissuances, continuations, continuations-in-part, revisions, extensions, and reexaminations thereof, (b) all trademarks,
service marks, brand names, certification marks, trade dress, logos, trade names, domain names, assumed names and corporate names, together
with all colorable imitations thereof, and including all goodwill associated therewith, and all applications, registrations, and renewals
in connection therewith, (c) all copyrights, and all applications, registrations, and renewals in connection therewith, (d) all trade
secrets under applicable state laws and the common law and know-how (including formulas, techniques, technical data, designs, drawings,
specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), (e) all computer
software (including source code, object code, diagrams, data and related documentation), and (f) all copies and tangible embodiments of
the foregoing (in whatever form or medium).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;IPO&rdquo; shall mean an
initial public offering by the Company that results in a listing of the Company&rsquo;s Common Stock on a national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Licensed Intellectual Property
Agreement&rdquo; means all licenses, sublicenses, agreements and permissions (each as amended to date) that any third party owns and that
the Company uses, including off- the-shelf software purchased or licensed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Liens&rdquo; means a lien,
charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Material Adverse Effect&rdquo;
shall have the meaning assigned to such term in Section 3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Notes&rdquo; means the Original
Issue Discount Convertible Promissory Notes issued to the Purchaser, in the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0.5in">&ldquo;Note Conversion Price&rdquo;
means the Note Conversion Price provided in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Original Issue Date&rdquo;
means the date of the first issuance of the Notes, regardless of any transfers of any Note and regardless of the number of instruments
which may be issued to evidence such Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Person&rdquo; means an individual
or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock
company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Proceeding&rdquo; means
an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such
as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Purchaser Party&rdquo; shall
have the meaning ascribed to such term in Section 5.8. &ldquo;Registrable Securities&rdquo; shall mean, collectively, the Shares and the
Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Regulation FD&rdquo; means
Regulation FD promulgated by the SEC pursuant to the Exchange Act, as such Regulation may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Required Approvals&rdquo;
shall have the meaning ascribed to such term in Section 3.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Rule 144&rdquo; means Rule
144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar
rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;SEC&rdquo; means the United
States Securities and Exchange Commission. &ldquo;Securities&rdquo; means the Notes, the Warrants and the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Securities Act&rdquo; means
the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Shares&rdquo; means the Common
Stock issuable upon conversion of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Short Sales&rdquo; means
all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the
location and/or reservation of borrowable shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Subscription Amount&rdquo;
means, as to the Purchaser, the aggregate amount to be paid for the Note purchased hereunder as specified below the Purchaser&rsquo;s
name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in
immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Subsidiary&rdquo; means
with respect to any entity at any date, any direct or indirect corporation, limited or general partnership, limited liability company,
trust, estate, association, joint venture or other business entity of which (A) more than 50% of (i) the outstanding capital stock having
(in the absence of contingencies) ordinary voting power to elect a majority of the Board of Directors or other managing body of such entity,
(ii) in the case of a partnership or limited liability company, the interest in the capital or profits of such partnership or limited
liability company or (iii) in the case of a trust, estate, association, joint venture or other entity, the beneficial interest in such
trust, estate, association or other entity business is, at the time of determination, owned or controlled directly or indirectly through
one or more intermediaries, by such entity, or (B) is under the actual control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Trading Day&rdquo; means
a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Trading Market&rdquo; means
any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE
American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the OTCQB,
the OTCQX, or the OTC Pink Marketplace (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Transaction Documents&rdquo;
means this Agreement, the Notes, the Warrants, and any other documents or agreements executed in connection with the transactions contemplated
hereunder, including, but not limited to, the documents referenced in Section 2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Transfer Agent&rdquo; means
Equity Transfer, LLC with a mailing address of 18 Lafayette Place, Woodmere, NY 11598, and a facsimile number of (646) 536-3179, and any
successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Variable Rate Transaction&rdquo;
means any Equity Line of Credit or similar agreement, nor issue nor agree to issue any Common Stock, floating or Variable Priced Equity
Linked Instruments nor any of the foregoing or equity with price reset rights (subject to adjustment for stock splits, distributions,
dividends, recapitalizations and the like) (collectively, the &ldquo;Variable Rate Transaction&rdquo;). For purposes of this Agreement,
&ldquo;Equity Line of Credit&rdquo; shall include any transaction involving a written agreement between the Company and an investor or
underwriter whereby the Company has the right to &ldquo;put&rdquo; its securities to the investor or underwriter over an agreed period
of time and at an agreed price or price formula, and &ldquo;Variable Priced Equity Linked Instruments&rdquo; shall include: (A) any debt
or equity securities which are convertible into, exercisable or exchangeable for, or carry the right to receive additional shares of Common
Stock either (1) at any conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices
of or quotations for Common Stock at any time after the initial issuance of such debt or equity security, or (2) with a fixed conversion,
exercise or exchange price that is subject to being reset at some future date at any time after the initial issuance of such debt or equity
security due to a change in the market price of the Company&rsquo;s Common Stock since date of initial issuance, and (B) any amortizing
convertible security which amortizes prior to its maturity date, where the Company is required or has the option to (or any investor in
such transaction has the option to require the Company to) make such amortization payments in shares of Common Stock which are valued
at a price that is based upon and/or varies with the trading prices of or quotations for Common Stock at any time after the initial issuance
of such debt or equity security (whether or not such payments in stock are subject to certain equity conditions). For purposes of determining
the total consideration for a convertible instrument (including a right to purchase equity of the Company) issued, subject to an original
issue or similar discount or which principal amount is directly or indirectly increased after issuance, the consideration will be deemed
to be the actual cash amount received by the Company in consideration of the original issuance of such convertible instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Warrants&rdquo; means, collectively,
the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants
shall be exercisable immediately and have a term of exercise equal to five years from such initial exercise date, in the form of <U>Exhibit
B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Warrant Exercise Price&rdquo;
means the exercise price provided in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Warrant Shares&rdquo; means
the shares of Common Stock issuable upon exercise of the Warrants at the Warrant Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE II. <BR>
PURCHASE AND
SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Dates, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and
delivery of this Agreement by the parties hereto, the Company agrees to sell, and each Purchaser, severally and not jointly, agrees
to purchase an aggregate of (i) Notes with a Face Value listed on the Purchaser&rsquo;s signature page and (ii) Warrants to purchase
shares equal to 100% of the Shares issuable upon conversion of the Note at a price equal to 110% of the IPO price or, if the Company
fails to complete the IPO before May 31, 2023, 90% of the IPO price. On the Closing Date, the Purchaser shall deliver to the Company
a signed copy of the Transaction Documents and, via wire transfer, immediately available funds equal to the Purchaser&rsquo;s
Subscription Amount. After receipt of the Subscription Amount, the Company shall deliver to the Purchaser countersigned copies of
the Transaction Documents. Upon satisfaction of the closing conditions set forth in Section 2.3, the Closing shall occur at the
Company&rsquo;s offices or such other location as the parties shall mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="text-decoration: none">2.2</FONT> <FONT STYLE="text-decoration: none">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deliveries.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(i)&nbsp;&nbsp;&nbsp;this
Agreement duly executed by the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(ii)&nbsp;&nbsp;a
Note in the principal amount of $44,444, convertible at the Note Conversion Price, registered in the name of the Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(iii)&nbsp;an
original Warrant to purchase &lt;WARRANT SHARES&gt; shares of Common Stock, exercisable at the Warrant Exercise Price, registered in the
name of such Purchaser;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(iv)&nbsp;a
Board Consent approving the issuance of the Notes and the execution of the Transaction Documents listed above on behalf of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date each Purchaser shall deliver or cause to be delivered to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -18pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="text-decoration: none">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-decoration: none">this Agreement duly executed by the Purchaser; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -18pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 50pt"></TD><TD STYLE="width: 20pt"><FONT STYLE="text-decoration: none">(ii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-decoration: none">the Purchaser&rsquo;s Subscription Amount by wire transfer to the
Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="text-decoration: none">2.3</FONT> <FONT STYLE="text-decoration: none">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Closing Conditions.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(i)&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) on the Closing Date of the representations and warranties of the Purchaser contained herein (unless as of a specific
date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(ii)&nbsp;&nbsp;all
obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -18pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(iii)&nbsp;the
delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 53.95pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(i)&nbsp;&nbsp;&nbsp;accuracy
in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in
all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a
specific date therein in which case they shall be accurate as of such date);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(ii)&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -18pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(iii)&nbsp;the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -18pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(iv)&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 0 0 169.25pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ARTICLE III.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES OF COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company hereby makes the following
representations and warranties to each Purchaser as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or Articles of Incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. Subject to obtaining the Required Approvals, this Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. Except as set forth in <U>Schedule 3.3</U>, the execution, delivery and performance by the Company of this Agreement and
the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions
contemplated hereby and thereby do not and will not (i) subject to the Required Approvals, conflict with or violate any provision of the
Company&rsquo;s or any Subsidiary&rsquo;s Certificate or Articles of Incorporation, bylaws or other organizational or charter documents,
or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result
in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party
or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any
property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not have or reasonably <FONT STYLE="letter-spacing: -0.15pt">be </FONT>expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. Except as set forth on <U>Schedule 3.4</U>, the Company is not required to obtain any consent, waiver, authorization
or order of, give any notice to, or make any filing <FONT STYLE="letter-spacing: -0.15pt">or </FONT>registration with, any court or other
federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the
Company of the Transaction Documents, other than: (i) blue sky filings or a Form D filing and (ii) such filings as are required to be
made under applicable state securities laws (the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Shares,
when issued upon conversion of the Notes will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by
the Company. The Company shall reserve from its duly authorized capital stock a number <FONT STYLE="letter-spacing: -0.15pt">of </FONT>shares
of Common Stock issuable pursuant to the Notes and Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The capitalization of the Company is as set forth on <U>Schedule 3.6</U>. The Company has not issued any capital stock since its most
recently filed periodic report under the Exchange </FONT>Act, other than pursuant to the exercise of employee stock awards under the Company&rsquo;s
equity incentive plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans
and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic
report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as set forth on <U>Schedule 3.6</U>, as a result
of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of
Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate
the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchaser) and will not
result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities.
There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound
to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo;
plans <FONT STYLE="letter-spacing: -0.15pt">or </FONT>agreements or any similar plan or agreement. All of the outstanding shares of capital
stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal
and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe
for or purchase securities. No further approval or authorization of any stockholder, the Board of Directors or others is required for
the issuance and sale of the Securities. There are no stockholders&rsquo; agreements, voting agreements or other similar agreements with
respect to the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any
of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect Subsidiaries of the Company are set forth in Schedule 3.7. The Company owns, directly or indirectly, all
of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares
of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Statements</U>. The consolidated financial statements of the Company, together with the related notes and schedules, present fairly, in
all material respects, the consolidated financial position of the Company and any of its Subsidiaries as of the dates indicated and the
consolidated results of operations, cash flows and changes in stockholders&rsquo; equity of the Company for the periods specified and
have been prepared in compliance with United States generally accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;) applied on a
consistent basis during the periods involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest financial statements: (i) there has been no
event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company
has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary
course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements
pursuant to GAAP, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares
of its capital stock and (v) the Company has not issued any equity securities to any officer, director </FONT>or Affiliate, except pursuant
to existing Company equity incentive plans. Other than as disclosed on <U>Schedule 3.9</U>, except for the issuance of the Securities
contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably
expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations,
assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this
representation is made or deemed made that has not been publicly disclosed at least one Trading Day prior to the date that this representation
is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
Except as set forth on <U>Schedule 3.10</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation,
inquiry or other similar proceeding of any federal or state government unit pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an
&ldquo;<U>Action</U>&rdquo;) which (i) adversely affects or challenges the legality, validity or enforceability of any of the
Transaction Documents or the issuance of the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be
expected to result in a Material Adverse Effect. The Company has no reason to believe that an Action will be filed against it in the
future except as disclosed on <U>Schedule 3.10</U>. Neither the Company nor any Subsidiary, nor any director or officer thereof, is
or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a
claim for fraud or breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or
contemplated, any investigation or inquiry by the SEC involving the Company or any current or former director or officer of the
Company. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by
the Company or any Subsidiary under the Securities Act, and the Company has no reason to believe it will do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no effort is underway to unionize or organize the employees of the Company
or any Subsidiary. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be,
in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition
agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of
each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing
matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating
to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance
could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. There is no workmen&rsquo;s compensation
liability matter, employment-related charge, complaint, grievance, investigation, inquiry or obligation of any kind pending, or to the
Company&rsquo;s knowledge, threatened, relating to an alleged violation or breach by the Company or its Subsidiaries of any law, regulation
or contract that could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Except as set forth on <U>Schedule 3.12</U>, neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no
event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in </FONT>violation
of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties
is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court,
arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;Hazardous Materials&rdquo;) into the environment, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations,
codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations,
issued, entered, promulgated or approved thereunder (&ldquo;Environmental Laws&rdquo;); (ii) have received all permits licenses or other
approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with
all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could
be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate regulatory
authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations or
permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any Subsidiary has received
any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. There is no agreement,
commitment, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries or to which the Company or any of
its Subsidiaries is a party which has or would reasonably be expected to have the effect of prohibiting or materially impairing any business
practice of the Company or any of its Subsidiaries, any acquisition of property by the Company or any of its Subsidiaries or the conduct
of business by the Company or any of its Subsidiaries as currently conducted other than such effects, individually or in the aggregate,
which have not had and would not reasonably be expected to have a Material Adverse Effect on the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. Subject to the Liens of the outstanding secured senior debt, the Company and the Subsidiaries have good and marketable
title in fee simple to all personal property owned by them that is material to the business of the Company and the Subsidiaries. The Company
owns no real property. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid,
subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the Liens of the outstanding secured senior debt, to the Company&rsquo;s knowledge, the Company owns or possesses or has the right
to use pursuant to a valid and enforceable written license, sublicense, agreement, or permission all Intellectual Property necessary for
the operation of the business of the Company as presently conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company&rsquo;s knowledge, the Intellectual Property does not interfere with, infringe upon, misappropriate, or otherwise come into
conflict with, any Intellectual Property rights of third parties, and the Company has no knowledge that facts exist which indicate a likelihood
of the foregoing. The Company has not received any charge, complaint, claim, demand, or notice alleging any such interference, infringement,
misappropriation, or conflict (including any claim that the Company must license or refrain from using any Intellectual Property rights
of any third party). To the knowledge of the Company, no third party has interfered with, infringed upon, misappropriated, or otherwise
come into conflict with, any Intellectual Property rights of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -18pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.05pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="text-decoration: none">(iii)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-decoration: none">With respect to each Licensed Intellectual Property Agreement:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72.05pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72.05pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.1pt">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="text-decoration: none">The
Licensed Intellectual Property Agreement is legal, valid, binding, enforceable, and in full force and effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.1pt">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="text-decoration: none">To
the Company&rsquo;s knowledge, no party to the Licensed Intellectual Property Agreement is in breach or default, and no event has occurred
that with notice or lapse of time would constitute a breach or default or permit termination, modification, or acceleration thereunder,
which as to any such breach, default or event could have a Material Adverse Effect on the Company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.1pt">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="text-decoration: none">No
party to such Licensed Intellectual Property Agreement has repudiated any provision thereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.1pt">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="text-decoration: none">Except
as set forth in such Licensed Intellectual Property Agreement, the Company has not received written or verbal notice or otherwise has
knowledge that the underlying item of Intellectual Property is subject to any outstanding injunction, judgment, order, decree, ruling,
or charge; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.1pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt"><FONT STYLE="letter-spacing: -0.1pt">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Except
as set forth on <U>Schedule 3.16</U>, the Company has not granted any sublicense or similar right with respect to the license, sublicense,
agreement, or permission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 53.95pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 53.95pt"><FONT STYLE="text-decoration: none">(iv)&nbsp;The
Company has complied with and is presently in compliance with all foreign, federal, state, local, governmental (including, but not limited
to, the Federal Trade Commission and State Attorneys General), administrative, or regulatory laws, regulations, guidelines, and rules
applicable to any personal identifiable information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">(v)&nbsp;&nbsp;Each
Person who participated in the creation, conception, invention or development of the Intellectual Property currently used in the business
of the Company (each, a &ldquo;Developer&rdquo;) which is not licensed from third parties has executed one or more agreements containing
industry standard confidentiality, work for hire and assignment provisions, whereby the Developer has assigned to the Company all copyrights,
patent rights, Intellectual Property rights and other rights in the Intellectual Property, including all rights in the Intellectual Property
that existed prior to the assignment of rights <FONT STYLE="letter-spacing: -0.15pt">by </FONT>such Person to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -18.7pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60.05pt"></TD><TD STYLE="width: 18.7pt"><FONT STYLE="text-decoration: none">(vi)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="text-decoration: none">Each Developer has signed a perpetual non-disclosure agreement with
the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor
any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as disclosed in Schedule 3.18, none of the officers or directors of the Company or any
Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such
employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of
$120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) other employee benefits, including stock award agreements under any equity incentive plan of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. Except as disclosed in the Schedule 3.19, the Company and the Subsidiaries are in compliance with any
and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable
rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof and as of the Closing Date. The Company
and the Subsidiaries maintain a system of internal accounting controls. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently
filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most
recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in
the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have
materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its
Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth on <U>Schedule 3.20</U>, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the
Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person
with respect to the transactions contemplated by the Transaction Documents. The Purchaser shall have no obligation with respect to any
fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due
by the Company in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company
shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the
Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. Except as disclosed on <U>Schedule 3.22, n</U>o Person has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements; Shell Company</U>. The Company&rsquo;s Common Stock is not quoted or listed on any Trading Market. The Company
is not and has never been a shell company as such term is defined in Rule 12(b)(2) under the Securities Exchange Act of 1934, as amended
and the rules and regulations of the Securities and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">3.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchaser as a result of the Purchaser <FONT STYLE="letter-spacing: -0.15pt">and
</FONT>the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation
as a result of the Company&rsquo;s issuance of the Securities and the Purchaser&rsquo;s ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided the Purchaser or its agent or counsel with any information that
it believes constitutes or might constitute material, non-public information which is not otherwise disclosed on <U>Schedule 3.25</U>.
The Company understands and confirms that the Purchaser will rely on the foregoing representation in effecting transactions in securities
of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchaser regarding the Company and its Subsidiaries,
their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and
correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in light of the circumstances under which they were made not misleading. The press releases disseminated by the
Company during the 12 months preceding the date of this Agreement do not contain any untrue statement of a material fact or omit to state
a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under
which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Article IV hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchaser&rsquo;s representations and warranties set forth in Article IV, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be
integrated with prior offerings by the Company for purposes of any applicable stockholder approval provisions of any Trading Market on
which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i) the Company&rsquo;s assets do not constitute unreasonably small capital
to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (ii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all
of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of
its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts
as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge
of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.27</U> sets forth as of the date hereof all outstanding
secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the
purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in excess of
$100,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect </FONT>of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $100,000 due under leases
required to be capitalized in accordance with GAAP. Except as set forth on <U>Schedule 3.27</U>, neither the Company nor any Subsidiary
is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been required
to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being
contested in good faith, except where the failure to so file or pay would not have a Material Adverse Effect. Except as otherwise disclosed
in <U>Schedule 3.28</U>, no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had, or would
have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state or other governmental
tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which would have a Material Adverse
Effect</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign
or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)
failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the
Company is aware) which is in violation of law, or (iv) violated any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgment
Regarding Purchaser&rsquo;s Purchase of Securities</U>. The Company acknowledges and agrees that the Purchaser is acting solely in the
capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company
further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective
representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental
to the Purchaser&rsquo;s purchase of the Securities. The Company further represents to the Purchaser that the Company&rsquo;s decision
to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">3.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgement
Regarding Purchaser&rsquo;s Trading Activity</U>. Notwithstanding anything in this Agreement or elsewhere to the contrary (except for
Sections 4.7 and 5.12 hereof), it is understood and acknowledged by the Company that: (i) the Purchaser has not been asked by the Company
to agree, nor has the Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo;
securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open market
or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions,
before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s
publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which the Purchaser is
a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) the Purchaser shall not
be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction.
The Company further understands and acknowledges that (y) the Purchaser may engage in hedging activities at various times during the period
that the Securities are outstanding, </FONT>including, without limitation, during the periods that the value of the Shares deliverable
with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&rsquo;
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such
aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation
M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of <FONT STYLE="letter-spacing: -0.15pt">the
</FONT>Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Private
Placement</U>. Assuming the accuracy of each Purchaser&rsquo;s representations and warranties set forth in Article IV, no registration
under the Securities Act is required for the offer and sale of the Notes or the Shares issuable upon conversion thereof by the Company
to the Purchasers as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
General Solicitation</U>. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company offered the Securities for sale only to the Purchaser and certain
other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506(b) under the Securities
Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company
participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities,
calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with
the Company in any capacity at the time of sale, nor any Person, including a placement agent, who will receive a commission or fees for
soliciting purchasers (each, an &ldquo;Issuer Covered Person&rdquo; and, together, &ldquo;Issuer Covered Persons&rdquo;) is subject to
any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;Disqualification
Event&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine
whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its
disclosure obligations under Rule 506(e), and has furnished to the Purchaser a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Disqualification Events</U>. The Company will notify the Purchaser in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;OFAC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation.</U> The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the &ldquo;BHCA&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;Federal Reserve&rdquo;).
Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the
outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is
subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises
a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal
Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;Money Laundering Laws&rdquo;), and
no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any
Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE IV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES
OF PURCHASERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchaser</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date
hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. The Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under
the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar
power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and performance by the Purchaser of the transactions contemplated
by this Agreement have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable,
on the part of the Purchaser. Each Transaction Document to which it is a party has been duly executed by the Purchaser, and when delivered
by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the Purchaser, enforceable
against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. The Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting the Purchaser&rsquo;s right to sell the Securities in compliance with applicable federal and state securities laws). The
Purchaser is acquiring the Securities hereunder in the ordinary course of its business. The Purchaser understands that the Securities
are &ldquo;restricted securities&rdquo; and have not been registered under the Securities Act or any applicable state securities law and
is acquiring such Securities as principal for its own account and not with a view to or for distributing or reselling such Securities
or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing
any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such </FONT>Securities in violation of the Securities
Act or any applicable state securities law (this representation and warranty not limiting the Purchaser&rsquo;s right to sell such Securities
in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time the Purchaser was offered the Securities, it was, and as of the date hereof it is, an accredited investor within
the meaning of Rule 501 under the Securities Act. The Purchaser is not subject to any of the &ldquo;Bad Actor&rdquo; disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;Disqualification Event&rdquo;), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of the Purchaser</U>. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. The Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and has been afforded, subject to Regulation FD, (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment; provided, however, that the Purchaser has not requested nor been
provided by the Company with any non-public information regarding the Company, its financial condition, results of operations, business,
properties, management and prospects. The Purchaser acknowledges and agrees that neither the Company nor anyone else has provided the
Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, the Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with the Purchaser, directly or indirectly executed any purchases or sales,
including Short Sales, of the securities of the Company during the period commencing as of the time that the Purchaser first received
a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions
contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Purchaser&rsquo;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of the Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons
party to this Agreement or to the Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners,
legal and other advisors, employees, agents and Affiliates, the Purchaser has maintained the confidentiality of all disclosures made to
it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance
of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification
of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company acknowledges and agrees
that the representations contained in this Article 4 shall not modify, amend or affect the Purchaser&rsquo;s right to rely on the Company&rsquo;s
representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document
or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transaction
contemplated hereby.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal
of Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Shares, the Warrants and Warrant
Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of the Shares, Warrants
or Warrant Shares other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser
or in connection with a pledge as contemplated in Section 5.1(b), the Company may require the transferor to provide to the Company an
opinion of counsel selected by the transferor and reasonably acceptable to the Company at the cost of the Company, the form and substance
of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such
transferred Shares, Warrants or Warrant Shares under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">(a)&nbsp;Each
Purchaser agrees to the imprinting, so long as is required by this Section 5.1, of a legend on any of the Shares, the Warrants or Warrant
Shares in the following form:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 18pt; text-align: justify; text-indent: 0cm">NEITHER THIS SECURITY NOR THE
SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY
BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT
IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">(b)&nbsp;The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Shares or Warrant Shares to a financial institution that is an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and,
if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Shares or Warrant Shares to the pledgees
or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of
the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge.
At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured
party of Shares and Warrant Shares may reasonably request in connection with a pledge or transfer of the Shares or Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">(c)
Certificates evidencing the Shares and the Warrant Shares (or the Transfer Agent&rsquo;s records if held in book entry form) shall
not contain any legend (including the legend set forth in Section 5.1(a) hereof): (i) while a registration statement covering the
resale of such securities is effective under the Securities Act (the &ldquo;Effective Date&rdquo;), (ii) following any sale of such
Shares or Warrant Shares pursuant to Rule 144, (iii) if such Shares or Warrant Shares are eligible for sale under Rule 144, without
the requirement for the Company to be in compliance with the current public information required under Rule 144 as to such Shares or
Warrant Shares and without volume or manner-of-sale restrictions or (iv) if such legend is not required under applicable
requirements of the Securities Act (including Sections 4(a)(1) and 4(a)(7) judicial interpretations and pronouncements issued by the
staff of the SEC). The Company shall, if any of the provisions in clause (i) &ndash;(iv) above are applicable, at its expense, cause
its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date if required by the Transfer Agent to
effect the removal of the legend hereunder. If all or any portion of a Note is converted or a Warrant is exercised at a time when
there is an effective registration statement to cover the resale of the Shares or the Warrant Shares, or if such Shares or Warrant
Shares may be sold under Rule 144 and the Company is then in compliance with the current public information required under Rule 144,
or if the Shares or Warrant Shares may be sold under Rule 144 without the requirement for the Company to be in compliance with the
current public information required under Rule 144 as to such Shares or Warrant Shares and without volume or manner-of-sale
restrictions or if such legend is not otherwise required under applicable requirements of the Securities Act (including Sections
4(a)(1) and 4(a)(7), judicial interpretations and pronouncements issued by the staff of the SEC) then such Shares or Warrant Shares
shall be issued or reissued free of all legends. The Company agrees that following the effective date of any registration statement
or at such time as such legend is no longer required under this Section 5.1(c), it will, no later than two Trading Days following
the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing restricted Shares or Warrant Shares,
as applicable, issued with a restrictive legend (such second Trading Day, the &ldquo;Legend Removal Date&rdquo;), deliver or cause
to be delivered to such Purchaser a certificate representing such Shares or Warrant Shares that is free from all restrictive and
other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the
restrictions on transfer set forth in this Section 5.1. Certificates for Shares or Warrant Shares subject to legend removal
hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker
with the Depository Trust Company system as directed by such Purchaser. The Company shall be responsible for any delays caused by
its Transfer Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="font-size: 10pt">(d)
In addition to such Purchaser&rsquo;s other available remedies, (i) the Company shall pay to a Purchaser, in cash, as partial
liquidated damages and not as a penalty, for each $1,000 of the principal amount of the Notes being converted or the value of the
Warrant Shares for which a Warrant is being exercised (based on the Warrant Exercise Price), $20 per Trading Day for each Trading
Day after the Legend Removal Date (increasing to $20 per Trading Day after the fifth Trading Day) until such certificate is
delivered without a legend. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Company&rsquo;s
failure to deliver certificates representing any Securities as required by the Transaction Documents, and such Purchaser shall have
the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief, and (ii) if after the Legend Removal Date such Purchaser purchases (in an open market transaction or
otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of
shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion <FONT STYLE="letter-spacing: -0.15pt">of </FONT>the
number of shares of Common Stock that such Purchaser anticipated receiving from the Company without any restrictive legend, then,
the Company shall pay to such Purchaser, in cash, an amount equal to the excess of such Purchaser&rsquo;s total purchase price
(including brokerage commissions and other out-of- pocket expenses, if any) for the shares of Common Stock so purchased (including
brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;Buy-In Price&rdquo;) over the product of (A) such number <FONT STYLE="letter-spacing: -0.15pt">of </FONT>Shares
or Warrant Shares that the Company was required to deliver to such Purchaser by the Legend </FONT>Removal Date multiplied by (B) the
highest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such
Purchaser to the Company of the applicable Shares or Warrant Shares (as the case may be) and ending on the date of such delivery and
payment under this Section 5.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt"><FONT STYLE="text-decoration: none">(e)
In the event a Purchaser shall request delivery of unlegended shares as described in this Section 5.1 and the Company is required to
deliver such unlegended shares, (i) it shall pay all fees and expenses associated with or required by the legend removal and/or
transfer including but not limited to legal fees, Transfer Agent fees and overnight delivery charges and taxes, if any, imposed by
any applicable government upon the issuance of Common Stock; and (ii) the Company may not refuse to deliver unlegended shares based
on any claim that such Purchaser or anyone associated or affiliated with such Purchaser has not complied with Purchaser&rsquo;s
obligations under the Transaction Documents, or for any other reason, unless, an injunction or temporary restraining order from a
court, on notice, restraining and or enjoining delivery of such unlegended shares shall have been sought and obtained by the Company
and the Company has posted a surety bond for the benefit of such Purchaser in the amount of the greater of (i) 150% of the amount of
the aggregate purchase price of the Shares (based on amount of principal and/or interest of the Note which was converted) and
Warrant Shares (based on exercise price in effect upon exercise) which is subject to the injunction or temporary restraining order,
or (ii) the VWAP of the Common Stock on the Trading Day before the issue date of the injunction multiplied by the number of
unlegended shares to be subject to the injunction, which bond shall remain in effect until the completion of the litigation of the
dispute and the proceeds of which shall be payable to such Purchaser to the extent Purchaser obtains judgment in Purchaser&rsquo;s
favor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -16.55pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 5.2&nbsp; <U>Furnishing of Information</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none">(a)
Until the earliest of the time that (i) no Purchaser owns Shares and Warrant Shares or (ii) the Warrants have expired, the Company
covenants to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required
to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the
reporting requirements of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none; letter-spacing: -0.15pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="font-size: 10pt; letter-spacing: -0.15pt">(b) </FONT><FONT STYLE="font-size: 10pt">At
any time during the period commencing from the six month anniversary of the date hereof and ending at such time on the earlier to
occur that the Warrants are not outstanding, terminated or that all of the Warrant Shares (assuming cashless exercise) may be sold
without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation
pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule
144(c) for a period of more than 30 consecutive days or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an
issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) for a period of more than 30
consecutive days (a &ldquo;Public Information Failure&rdquo;) then, in addition to such Purchaser&rsquo;s other available remedies,
the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or
reduction of its ability to sell the Shares and/or Warrant Shares, an amount in cash equal to two percent of the aggregate Note
Conversion Price of such Purchaser&rsquo;s Note(s) and/or Warrant Exercise Price of such Purchaser&rsquo;s Warrants on the day of a
Public Information Failure and on every 30</FONT><FONT STYLE="font-size: 7pt">th </FONT><FONT STYLE="font-size: 10pt">day (pro-rated
for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured
and (b) such time that such public information is no longer required for the Purchasers to transfer the Shares and/or Warrant Shares
pursuant to Rule 144. Public Information Failure Payments shall be paid on the earlier <FONT STYLE="letter-spacing: -0.15pt">of </FONT>(i)
the last day of the calendar month during which such Public Information Failure Payments are incurred and (ii) the second Trading
Day after the event or failure giving rise to the Public Information Failure payments is cured. In the event the Company fails to
make Public Information Failure payments in a timely </FONT>manner, such Public Information Failure payments shall bear interest at
the rate of one and one-half percent per month (prorated for partial months) until paid in full. Nothing herein shall limit such
Purchaser&rsquo;s right to pursue actual damages for the Public Information Failure, and such Purchaser shall have the right to
pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section
2(a)(1) of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations
of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder
approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the SEC or any regulatory agency or Trading Market, without the prior written consent of the Purchaser, except (a)
as required by federal securities law in connection with the filing of final Transaction Documents with the SEC and (b) to the extent
such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchaser with prior notice
of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. When the Company&rsquo;s Common Stock is quoted or listed on a Trading Market, to the extent that any notice provided
pursuant to any Transaction Document or any other communications made by the Company, or information provided, to the Purchaser constitutes,
or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice
or other material information with the SEC pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company. In addition to any other remedies provided
by this Agreement or other Transaction Documents, if the Company knowingly provides any material, non- public information to the Purchasers
without their prior written consent, and it fails to immediately (no later than that Trading Day) file a Form 8-K, once it is required
to do so, disclosing this material, non-public information, it shall pay the Purchasers as partial liquidated damages and not as a penalty
a sum equal to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">$1,000 per day for each $100,000
of each Purchaser&rsquo;s Subscription Amount beginning with the day the information is disclosed to the Purchaser and ending and including
the day the Form 8-K disclosing this information is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes, and shall
not use such proceeds: (a) for the satisfaction of any Indebtedness as defined in the Note, (b) for the redemption of any Common Stock
or Common Stock Equivalents, (c) in violation of FCPA or OFAC regulations, or (d) to lend money, give credit, or make advances to any
officers, directors, employees or affiliates of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchaser</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to the provisions of this
Section 5.8, the Company will indemnify and hold each Purchaser and its directors, officers, stockholders, members, partners, employees
and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title), each Person who controls the Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of
the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each,
a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs
and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation
(including local counsel, if retained) that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach
of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents,
(b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder
of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction
Documents (unless such action is solely based upon a breach of such Purchaser Party&rsquo;s representations, warranties or covenants under
the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence,
willful misconduct or malfeasance) or (c) any untrue or alleged untrue statement of a material fact contained in any registration statement,
any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of
or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein
(in the case of any prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading. If any
action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser
Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of
its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in
any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser
Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company
has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable
opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party,
in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel (in addition
to local counsel, if retained). The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a
Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (z)
to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of
any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction
Documents. The Purchaser Parties shall have the right to settle any action against any of them by the payment of money provided that they
cannot agree to any equitable relief and the Company, its officers, directors and Affiliates receive unconditional releases in customary
form. The indemnification required by this Section 5.8 shall be made by periodic payments of the amount thereof during the investigation
or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause
of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant
to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement
Without Consent if Failure to Reimburse</U>. If an indemnified party shall have requested an indemnifying party to reimburse the indemnified
party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature
contemplated </FONT>by Section 5.8 effected without its written consent if (1) such settlement is entered into more than 45 days after
receipt by such indemnifying party of the aforesaid request, (2) such indemnifying party shall have received notice of the terms of such
settlement at least 30 days prior to such settlement being entered into and (3) such indemnifying party shall not have reimbursed such
indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company agrees, if the Company applies to have the Common Stock traded on any Trading Market, it will then include
in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted
on such other Trading Market as promptly as possible. The Company will then take all action necessary to continue the listing and trading
of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer
through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of
fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Senior
Debt</U>. The Company shall not issue any new indebtedness which is senior in rank to the Notes while the Notes are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. The Purchaser covenants that neither it nor any Affiliate acting on its behalf or pursuant to any
understanding with it will execute any purchases or sales, including Short Sales of any of the Company&rsquo;s securities during the period
commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first
publicly announced pursuant to the initial press release. Each Purchaser covenants that until such time as the transactions contemplated
by this Agreement are publicly disclosed by the Company pursuant to the initial press release, the Purchaser will maintain the confidentiality
of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing
and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser
makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release,
(ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with
applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant
to the initial press release and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company or its Subsidiaries after the issuance of the initial press release. Notwithstanding the foregoing, in the case
of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of the Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio
manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion
Procedures</U>. The forms of Conversion Notice included in the Notes set forth the totality of the procedures required of the Purchaser
to exercise the Notes. No additional legal opinion, other information or instructions shall be required of the Purchaser to convert their
Note. Without limiting the preceding sentences, no ink-original Conversion Notice shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Conversion Notice form be required to convert the Notes. The Company shall honor conversions
of the Notes and shall deliver Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DTC
Program</U>. For so long as any of the Notes are outstanding, the Company will employ as the Transfer Agent for the Common Stock and Shares
a participant in the Depository Trust Company Automated Securities Transfer Program and cause the Common Stock to be transferable pursuant
to such program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance
of Property</U>. The Company shall keep all of its property necessary for the operations of its business, which is necessary or useful
to the conduct of its business, in good working order and condition, ordinary wear and tear excepted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Preservation
of Corporate Existence</U>. The Company shall preserve and maintain its corporate existence, rights, privileges and franchises in the
jurisdiction of its incorporation, and qualify and remain qualified, as a foreign corporation in each jurisdiction in which such qualification
is necessary in view of its business or operations and where the failure to qualify or remain qualified might reasonably have a Material
Adverse Effect upon the financial condition, business or operations of the Company taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Registration of Securities on Form S-1.</U> Other than the registration rights provided hereunder, for the initial six months the Notes
are outstanding, the Company will not file any registration statements on Form S-1. For the avoidance of doubt, the foregoing shall not
prevent the Company from filing a Registration Statement on Form S-8 with respect to equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Variable
Rate Transactions</U>. While any of the Notes are outstanding, the Company shall be prohibited from entering a Variable Rate Transaction
without the prior consent of the holders of more than 50% in principal amount of the then outstanding Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights and Lock-Up Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.7pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 33.7pt"><FONT STYLE="text-decoration: none">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to the Shares and Warrant Shares, the Company shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.7pt"><FONT STYLE="text-decoration: none">(1)
With the next Registration Statement on Form S-1 filed by the Company, include the Registrable Securities in such Registration
Statement and use its best efforts to cause the Registration Statement to become effective and remain effective as provided
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.7pt"><FONT STYLE="text-decoration: none">(2)
Prepare and file with the SEC such amendments, including post-effective amendments, to the Registration Statement as may be
necessary to keep the Registration Statement continuously effective as to the applicable Registrable Securities until such time as
all of the Registerable Securities have been sold by the Holder or he is eligible to otherwise remove the restrictive legend and
effect a sale other than through the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.7pt"><FONT STYLE="text-decoration: none">(3)
Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of, (i) any order suspending the effectiveness
of the Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the
Registrable Securities for sale in any U.S. jurisdiction, at the earliest practicable moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.7pt"><FONT STYLE="text-decoration: none">(4)
Furnish to the Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto,
including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference, and all
exhibits to the extent requested by the Holder (including those previously furnished or incorporated by reference) promptly after
the filing of such documents with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 33.7pt"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Purchaser agrees that, without the prior written consent of the Company, the Purchaser shall not, during the period ending 90 days after
the date of the prospectus filed with the SEC in connection with the Registration Statement on Form S-1 described in Section 5.19(a):
<FONT STYLE="letter-spacing: -0.05pt">(1) </FONT>offer, pledge, announce the intention to sell, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer
or dispose of, directly or indirectly, any Registrable Securities or (2) enter into any swap or other agreement that transfers, in whole
or in part, any of the economic consequences of ownership of the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE IV.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
This Agreement may be terminated by the Purchaser by written notice to the other parties, if the Closing has not been consummated on or
before June 30, 2022; provided, however, that no such termination will affect the right of any party to sue for any breach by any other
party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth below and in the Transaction Documents to the contrary, each party shall pay the fees
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to
the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including,
without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice
delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered by email
attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. ( Eastern Standard or Daylight
Savings Time, as applicable) on a Trading Day, (b) the next Trading Day after the date <FONT STYLE="letter-spacing: -0.15pt">of </FONT>transmission,
if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached hereto
on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second Trading Day following
the date of transmission, if sent by U.S. nationally recognized overnight delivery service or (d) upon actual receipt by the party to
whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages
attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public
information regarding the Company or any Subsidiaries, the Company shall, if the Company&rsquo;s Common Stock is quoted or listed on a
Trading Market, simultaneously file such notice with the SEC pursuant to a Current Report on Form 8-K, or which failure to do so will
subject the Company to the liquidated damages provided for in Article 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. Except as provided in the last sentence of this Section 6.5, <FONT STYLE="letter-spacing: -0.15pt">no </FONT>provision of
this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by
the Company and a majority in interest of the outstanding balance of the Note or, in the case of a waiver, by the party against whom enforcement
of any </FONT>such waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the
exercise of any such right. Any amendment effected in accordance with accordance with this Section 6.5 shall be binding upon the Purchaser
and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser.
Each Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any
Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions
of the Transaction Documents that apply to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
Section 6.7 and this Section 6.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law; Exclusive Jurisdiction; Attorneys&rsquo; Fees</U>. All questions concerning the construction, validity, enforcement and interpretation
of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New
York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against
a party hereto or its respective affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the New York County, New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the New York County, New York for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any
of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it
is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue
for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such
Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents,
then, in addition to the obligations of the Company elsewhere in this Agreement, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when </FONT>counterparts have been signed by each party and delivered to each other party, it being understood
that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail
delivery of a &ldquo;.pdf' format data file, such signature shall create a valid and binding obligation of the party executing (or on
whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf' signature page were an original
thereof.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
the Company does not timely perform its related obligations within the periods therein provided, then that Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part
without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an conversion of a Note, the
Purchaser shall be required to return any Shares subject to any such rescinded Conversion Notice concurrently with the restoration of
such Purchaser&rsquo;s right to acquire such shares pursuant to the Purchaser&rsquo;s Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction without requiring the posting of any bond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each Purchaser
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside.</U> To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser
enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part
thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required
to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without
limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration
the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other </FONT>Purchaser, and no Purchaser shall be responsible in any way for the performance or
non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction
Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership,
an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert
or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be
entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out
of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding
for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction
Documents. The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the
Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each
provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between
the Company and the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been
paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due
and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule <FONT STYLE="letter-spacing: -0.15pt">of </FONT>construction to the effect that any ambiguities are to
be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto.
In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment
for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur
after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver
of jury trial</U>. In any action, suit, or proceeding in any jurisdiction brought by any party against any other party, the parties each
knowingly and intentionally, to the greatest extent permitted by applicable law, hereby absolutely, unconditionally, irrevocably and expressly
waive forever trial by jury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">6.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Circumvention</U>.
The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation, including any Certificates
of Designation, or Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of
this Agreement, and will at all times in good faith carry out all of the provision of this Agreement and take all action as may be required
to protect the rights of all holders of the Securities. Without limiting the generality of the foregoing or any other provision of this
Agreement or the other Transaction Documents, the Company (a) shall not increase the par value of any Shares issuable upon conversion
of the Notes above the Note Conversion Price then in effect and (b) shall take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable Shares upon the conversion of the Notes. Notwithstanding anything
herein to the contrary, if after 180 days from the original issuance date, the Purchasers are not permitted to convert the Note, in full,
for any reason, subject to the Purchaser&rsquo;s compliance with Rule 144 the Company shall use its best </FONT>efforts to promptly remedy
such failure, including, without limitation, obtaining such consent or approvals as necessary to permit such conversion or exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">(Signature Pages Follow)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none; color: #28212F">IN
WITNESS <FONT STYLE="text-decoration: none; letter-spacing: 0pt">WHEREOF</FONT></FONT><FONT STYLE="text-decoration: none; color: #75696B; letter-spacing: -0.25pt">, </FONT><FONT STYLE="text-decoration: none; color: #28212F">the </FONT><FONT STYLE="text-decoration: none; color: #150F1C; letter-spacing: -0.15pt">p</FONT><FONT STYLE="text-decoration: none; color: rgb(65,56,70); letter-spacing: 0pt">arties </FONT><FONT STYLE="text-decoration: none; color: #28212F">here </FONT><FONT STYLE="text-decoration: none; color: #263152">t</FONT><FONT STYLE="text-decoration: none; color: #28212F">o
have caused </FONT><FONT STYLE="text-decoration: none; color: #263152; letter-spacing: -0.2pt">t</FONT><FONT STYLE="text-decoration: none; color: #28212F; letter-spacing: -0.2pt">h</FONT><FONT STYLE="text-decoration: none; color: #05010C; letter-spacing: -0.2pt">i</FONT><FONT STYLE="text-decoration: none; color: #413846; letter-spacing: -0.2pt">s </FONT><FONT STYLE="text-decoration: none; color: #28212F">Securities </FONT><FONT STYLE="text-decoration: none; color: #150F1C; letter-spacing: -0.2pt">Purcha</FONT><FONT STYLE="text-decoration: none; color: #413846; letter-spacing: -0.2pt">se </FONT><FONT STYLE="text-decoration: none; color: #28212F">Agreement
to </FONT><FONT STYLE="text-decoration: none; color: #150F1C">be</FONT> <FONT STYLE="text-decoration: none; color: #28212F">du</FONT><FONT STYLE="text-decoration: none; color: #05010C">l</FONT><FONT STYLE="text-decoration: none; color: #413846">y</FONT> <FONT STYLE="text-decoration: none; color: #28212F">executed
by</FONT> <FONT STYLE="text-decoration: none; color: #263152">t</FONT><FONT STYLE="text-decoration: none; color: #28212F">heir
respec</FONT><FONT STYLE="text-decoration: none; color: #263152">t</FONT><FONT STYLE="text-decoration: none; color: #05010C">i</FONT><FONT STYLE="text-decoration: none; color: #28212F">ve</FONT> <FONT STYLE="text-decoration: none; color: #413846">aut</FONT><FONT STYLE="text-decoration: none; color: #150F1C">horized</FONT> <FONT STYLE="text-decoration: none; color: #413846">signatories</FONT> <FONT STYLE="text-decoration: none; color: #28212F">as
of the date</FONT> <FONT STYLE="text-decoration: none; color: #150F1C">fir</FONT><FONT STYLE="text-decoration: none; color: #413846">st</FONT> <FONT STYLE="text-decoration: none; color: #28212F">ind</FONT><FONT STYLE="text-decoration: none; color: #05010C">i</FONT><FONT STYLE="text-decoration: none; color: #28212F">cated <FONT STYLE="letter-spacing: -0.15pt">above</FONT></FONT><FONT STYLE="text-decoration: none; color: #593121; letter-spacing: -0.15pt">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #263152; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt; color: #28212F"><U>Address for No</U></FONT><U><FONT STYLE="font-size: 10pt; color: #263152">t</FONT></U><U><FONT STYLE="font-size: 10pt; color: #28212F">ice</FONT></U><FONT STYLE="font-size: 10pt; color: #263152"></FONT>:</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; padding-left: 10pt; text-indent: -10pt">&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 5%"></TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 25%"><FONT STYLE="color: #28212F">Name</FONT><FONT STYLE="color: #05010C">:
  T</FONT><FONT STYLE="color: #413846">yro</FONT><FONT STYLE="color: #150F1C">ne Miller</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 65%"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"></TD>
  <TD STYLE="text-align: justify; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="text-decoration: none; color: #28212F">Title:</FONT>
  Ch<FONT STYLE="text-decoration: none; color: #05010C">i</FONT><FONT STYLE="text-decoration: none; color: #28212F">ef
  F</FONT><FONT STYLE="text-decoration: none; color: #05010C">in</FONT><FONT STYLE="text-decoration: none; color: #28212F">ancial
  Office</FONT><FONT STYLE="text-decoration: none; color: #05010C">r</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #05010C; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -16.8pt"><FONT STYLE="text-decoration: none; color: #593121">[</FONT><FONT STYLE="text-decoration: none; color: #28212F">REMAINDER
</FONT><FONT STYLE="text-decoration: none; color: #150F1C">OF </FONT><FONT STYLE="text-decoration: none; color: #28212F">PAGE INTENTIONALLY
LEFT BLANK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #28212F; text-align: center; text-indent: -16.8pt"><FONT STYLE="text-decoration: none">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #28212F; text-align: center; text-indent: -16.8pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">PURCHASER SIGNATURE PAGE TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; text-indent: 0cm">Name of Purchaser: Geoffrey Dow</TD>
    <TD STYLE="width: 50%; text-align: justify; text-indent: 0cm"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt; background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0cm"><I>Signature of Authorized Signatory of Purchaser</I>:</TD>
    <TD STYLE="text-align: justify; text-indent: 0cm"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">Name of Authorized Signatory: <U>Geoffrey
Dow</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">Title of Authorized Signatory: Dr.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">Email Address of Authorized Signatory
<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">Facsimile Number of Authorized Signatory:NA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">Address for Notice to Purchaser:
<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">Address for Delivery of Securities
to Purchaser (if not same as address for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">Face Value_$44,444</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">Subscription Amount: __________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">SS Number: <FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">Purchaser Signature Page</P>


<!-- Field: Page; Sequence: 30; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>5
<FILENAME>cm270_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 10.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR
WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Warrant Shares: &lt;WARRANT SHARES&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Initial Exercise Date: May 19, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;Warrant&rdquo;) certifies that, for value received, Geoffrey Dow., or its assigns (the &ldquo;Holder&rdquo;) is entitled,
upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof
(the &ldquo;Initial Exercise Date&rdquo;) and on or prior to the close of business on the fifth year anniversary of the Initial Exercise
Date (the &ldquo;Termination Date&rdquo;) but not thereafter, to subscribe for and purchase from 60 Degrees Pharmaceuticals, LLC, a limited
liability company (the &ldquo;Company&rdquo;), up to &lt;WARRANT SHARES&gt; shares of Common Stock (subject to adjustment hereunder, the
&ldquo;Warrant Shares&rdquo;). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b). This Warrant issued pursuant to a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) entered into as
of the Initial Exercise Date between the Company and the initial Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;), dated May 19th, 2022 among the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise
Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate
by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed copy
of the Notice of Exercise Form annexed hereto. Within two Trading Days following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn
on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice
of Exercise. Notwithstanding anything herein to the contrary (although the Holder may surrender the Warrant to, and receive a replacement
Warrant from, the Company), the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has
purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within two Trading Days of the date the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one Trading Day of delivery of such
notice. The Holder by acceptance of this Warrant or any transferee, acknowledges and agrees that, by reason of the provisions of this
Section 2(a), following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <U>Exercise Price.</U> The
initial exercise price per share of the Common Stock under this Warrant shall be equal to 110% of the IPO (as defined in the Purchase
Agreement) price or, if the Company fails to complete the IPO before May 31, 2023, 90% of the IPO price , subject to adjustment under
Section 3 (the &ldquo;Exercise Price&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Cashless Exercise.</U>
Other than as provided for in Section 2(f), if at any time after the six month anniversary of the Initial Exercise Date, there is no
effective Registration Statement covering the resale of the Warrant Shares by the Holder (or the prospectus does not meet the requirements
of Section 10 of the Securities Act), then this Warrant may also be exercised at the Holder&rsquo;s election, in whole or in part and
in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the number obtained by dividing
[(A - B) times (C)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in">(A) =</TD><TD STYLE="text-align: justify">the greater of (i) the arithmetic average of the VWAPs for the five consecutive Trading Days ending on
the date immediately preceding the date on which the Holder elects to exercise this Warrant by means of a &ldquo;cashless exercise,&rdquo;
as set forth in the applicable Notice of Exercise or (ii) the VWAP for the Trading Day immediately prior to the date on which the Holder
makes such &ldquo;cashless exercise&rdquo; election;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 90pt; text-align: justify; text-indent: -36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder, at the time of such exercise; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 90pt; text-align: justify; text-indent: -36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in">(C) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&ldquo;VWAP&rdquo; means, for any date, the
price determined by the first of the following clauses that applies: (a) if the Common
Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or
the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P.
(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)) (or a similar organization or agency
succeeding to its functions of reporting prices), (b) if no volume weighted average price of the Common Stock is reported for the
Trading Market, the most recent reported bid price per share of the Common Stock, or (c) in all other cases, the fair market value
of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest
of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued in
such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant
Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrants being exercised may be
tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything herein
to the contrary, if on the Termination Date (unless the Holder notifies the Company otherwise) if there is no effective Registration Statement
covering the resale of the Warrant Shares by the Holder, then this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Mechanics of Exercise.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(i) <U>Delivery of Certificates
Upon Exercise.</U> Certificates for the shares of Common Stock purchased hereunder shall be transmitted to the Holder by the Transfer
Agent by crediting the account of the Holder&rsquo;s prime broker with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&ldquo;DWAC&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being
exercised via cashless exercise and Rule 144 is available, or otherwise by physical delivery to the address specified by the Holder in
the Notice of Exercise by the date that is two Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise
and (B) payment of the aggregate Exercise Price as set forth above (unless by cashless exercise, if permitted) (such date, the &ldquo;Warrant
Share Delivery Date&rdquo;). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to
be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been
exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted). The Company understands that a
delay in the delivery of the Warrant Shares after the Warrant Share Delivery Date could result in economic loss to the Holder. As compensation
to the Holder for such loss, the Company agrees to pay (as liquidated damages and not as a penalty) to the Holder for late issuance of
Warrant Shares upon exercise of this Warrant the proportionate amount of $10 per Trading Day (increasing to $20 per Trading Day after
the fifth Trading Day) after the Warrant Share Delivery Date for each $1,000 of the value of the Warrant Shares for which this Warrant
is exercised (based on the Exercise Price) which are not timely delivered. In no event shall liquidated damages for any one transaction
exceed $1,000 for the first 10 Trading Days. Furthermore, in addition to any other remedies which may be available to the Holder, in
the event that the Company fails for any reason to effect delivery of the Warrant Shares by the Warrant Share Delivery Date, the Holder
may revoke all or part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon the Company
and the Holder shall each be restored to their respective positions immediately prior to the exercise of the relevant portion of this
Warrant, except that the liquidated damages described above shall be payable through the date notice of revocation or rescission is given
to the Company or the date the Warrant Shares are delivered to the Holder, whichever date is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(ii) <U>Delivery of New Warrants
Upon Exercise.</U> If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender
of this Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant
shall in all other respects be identical to this Warrant. Unless the Warrant has been fully exercised, the Holders shall not be required
to surrender this Warrant as a condition of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iii) <U>Rescission Rights.</U>
If the Company fails to deliver the Warrant Shares or cause the Transfer Agent to transmit to the Holder a certificate or the certificates
representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right,
at any time prior to issuance of such Warrant Shares, to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iv) <U>Compensation for Buy-In
on Failure to Timely Deliver Certificates Upon Exercise.</U> In addition to any other rights available to the Holder, if the Company
fails to deliver the Warrant Shares, or cause the Transfer Agent to transmit to the Holder the certificate or certificates representing
the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;Buy-In&rdquo;), then the Company shall pay in cash to the Holder the amount as provided under Section 4.1(e)
of the Purchase Agreement. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder,
at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(v) <U>No Fractional Shares or
Scrip.</U> No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any
fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(vi) <U>Charges, Taxes and Expenses.
</U>Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such certificate including any charges of any clearing firm, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by
the Holder. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise. The Company shall
(A) pay the reasonable legal fees of the Holder&rsquo;s choice (in an amount not to exceed $500 per opinion, and not more often than
once per week) in connection with the exercise of the Warrants, (B) cause its attorneys to promptly provide any reliance opinion to the
Transfer Agent, and (C) pay the Holder the sums required under Section 2(d)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(vii) <U>Closing of Books.</U>
The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant
to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>Holder&rsquo;s Exercise
Limitations.</U> The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion
of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth
on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group
together with the Holder or any of the Holder&rsquo;s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation
(as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and
its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act
and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned
by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is
exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is
exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm
the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section
2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common
Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B)
a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth
the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;Beneficial Ownership Limitation&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon not less than
61 days&rsquo; prior notice to the Company, may increase the Beneficial Ownership Limitation provisions of this Section 2(e) solely with
respect to the Holder&rsquo;s Warrant, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares
of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held
by the Holder and the provisions of this Section 2(e) shall continue to apply. Any such increase will not be effective until the 61st
day after such notice is delivered to the Company. The Holder may also decrease the Beneficial Ownership Limitation provisions of this
Section 2(e) solely with respect to the Holder&rsquo;s Warrant at any time, which decrease shall be effectively immediately upon delivery
of notice to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the
intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect
to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Stock Dividends and Splits.
</U>If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions
on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance
of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant or pursuant to any of the
other Transaction Documents), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification
of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by
a fraction of which the numerator shall be the number of shares of <FONT STYLE="letter-spacing: -0.1pt">Common </FONT>Stock (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common
Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately
adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section
3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <U>Subsequent Equity Sales.
</U>If and whenever on or after the Initial Exercise Date, the Company issues or sells, or in accordance with this Section 3 is deemed
to have issued or sold, any shares of Common Stock (including the issuance or sale of shares of Common Stock owned or held by or for
the account of the Company, issued or sold or deemed to have been issued or sold) for a consideration per share (the &ldquo;<U>Base Share
Price</U>&rdquo;) less than a price equal to the Exercise Price in effect immediately prior to such issuance or sale or deemed issuance
or sale (such Exercise Price then in effect is referred to herein as the &ldquo;<U>Applicable Price</U>&rdquo;) (the foregoing a &ldquo;<U>Dilutive
Issuance</U>&rdquo;), then immediately after such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount
equal to the Base Share Price. For all purposes of the foregoing (including, without limitation, determining the adjusted Exercise Price
and the Base Share Price under this Section 3(b)), the following shall be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(i) <U>Issuance of Options.</U>
If the Company in any manner grants or sells any Options and the lowest price per share for which one share of Common Stock is at any
time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities issuable upon
exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock
shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale of such Option
for such price per share. For purposes of this Section 3(b)(i), the &ldquo;lowest price per share for which one share of Common Stock
is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities issuable upon
exercise of any such Option or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the sum of the lowest
amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock upon the granting
or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon
exercise of such Option or otherwise pursuant to the terms thereof and (y) the lowest exercise price set forth in such Option for which
one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible
Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid
or payable to the holder of such Option (or any other Person) upon the granting or sale of such Option, upon exercise of such Option
and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise pursuant to
the terms thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option
(or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance
of such shares of Common Stock or of such Convertible Securities upon the exercise of such Options or otherwise pursuant to the terms
of or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(ii) <U>Issuance of Convertible
Securities.</U> If the Company in any manner issues or sells any Convertible Securities and the lowest price per share for which one
share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof
is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold
by the Company at the time of the issuance or sale of such Convertible Securities for such price per share. For the purposes of this
Section 3(b)(ii), the &ldquo;lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or
exchange thereof or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the sum of the lowest amounts
of consideration (if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale of
the Convertible Security and upon conversion, exercise or exchange of such Convertible Security or otherwise pursuant to the terms thereof
and (y) the lowest conversion price set forth in such Convertible Security for which one share of Common Stock is issuable upon conversion,
exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder
of such Convertible Security (or any other Person) upon the issuance or sale of such Convertible Security plus the value of any other
consideration received or receivable by, or benefit conferred on, the holder of such Convertible Security (or any other Person). Except
as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock
upon conversion, exercise or exchange of such Convertible Securities or otherwise pursuant to the terms thereof, and if any such issuance
or sale of such Convertible Securities is made upon exercise of any Options for which adjustment of this Warrant has been or is to be
made pursuant to other provisions of this Section 3(b), except as contemplated below, no further adjustment of the Exercise Price shall
be made by reason of such issuance or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iii) <U>Change in Option Price
or Rate of Conversion.</U> &ldquo;Convertible Securities&rdquo; means any stock or other security (other than Options) that is at any
time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles
the holder thereof to acquire, any shares of Common Stock. If the purchase or exercise price provided for in any Options, the additional
consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any
Convertible Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time
(other than proportional changes in conversion or exercise prices, as applicable, in connection with an event referred to in Section
3(a)), the Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which would have
been in effect at such time had such Options or Convertible Securities provided for such increased or decreased purchase price, additional
consideration or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold. For purposes
of this Section 3(b)(iii), if the terms of any Option or Convertible Security that was outstanding as of the Closing Date are increased
or decreased in the manner described in the immediately preceding sentence, then such Option or Convertible Security and the shares of
Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such
increase or decrease. No adjustment pursuant to this Section 3(b) shall be made if such adjustment would result in an increase of the
Exercise Price then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iv) <U>Calculation of Consideration
Received.</U> If any Option is issued in connection with the issuance or sale of any other securities of the Company together comprising
one integrated transaction in which no specific consideration is allocated to such Option by the parties thereto, the Options will be
deemed to have been issued for a consideration of par value of the Company&rsquo;s Common Stock. If any shares of Common Stock, Options
or Convertible Securities are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor will
be deemed to be the net amount of consideration received by the Company therefor. If any shares of Common Stock, Options or Convertible
Securities are issued or sold for a consideration other than cash, the amount of such consideration received by the Company will be the
fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of
consideration received by the Company for such securities will be the arithmetic average of the VWAPs of such security for each of the
five Trading Days immediately preceding the date of receipt. If any shares of Common Stock, Options or Convertible Securities are issued
to the owners of the non-surviving entity in connection with any merger in which the Company is the surviving entity, the amount of consideration
therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity as is attributable
to such shares of Common Stock, Options or Convertible Securities. The fair value of any consideration other than cash or publicly traded
securities will be determined jointly by the Company and the Holder. If such parties are unable to reach agreement within 10 days after
the occurrence of an event requiring valuation (the &ldquo;Valuation Event&rdquo;), the fair value of such consideration will be determined
within five Trading Days after the 10<FONT STYLE="font-size: 7pt">th </FONT>day following such Valuation Event by an independent, reputable
appraiser jointly selected by the Company and the Holder. The determination of such appraiser shall be final and binding upon all parties
absent manifest error. If such appraiser&rsquo;s valuation differs by less than 5% from the Company&rsquo;s proposed valuation, the fees
and expenses of such appraiser shall be borne by the Holder, and if such appraiser&rsquo;s valuation differs by more than 5% from the
Company&rsquo;s proposed valuation, the fees and expenses of such appraiser shall be borne by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(v) <U>Record Date.</U> If the
Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other
distribution payable in shares of Common Stock, Options or in Convertible Securities or (B) to subscribe for or purchase shares of Common
Stock, Options or Convertible Securities, then such record date will be deemed to be the date of the issuance or sale of the shares of
Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the
date of the granting of such right of subscription or purchase (as the case may be).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin-top: 0pt; margin-bottom: 0pt"> (vi) Notwithstanding the foregoing, this Section 3(b) shall not apply to any Exempt Issuances.</P>



<P STYLE="text-indent: 0.75in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Full Ratchet Increase
in Warrant Shares.</U> Until the Notes are no longer outstanding, whenever the Exercise Price is adjusted under Section 3(b), the number
of Warrant Shares shall be increased on a full ratchet basis to the number of shares of Common Stock determined by multiplying the Exercise
Price then in effect immediately prior to such adjustment by the number of Warrant Shares issuable upon exercise of this Warrant immediately
prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. By way of example, if
E is the total number of Warrant Shares in effect immediately prior to such Dilutive Issuance, F is the Exercise Price in effect immediately
prior to such Dilutive Issuance, and G is the Dilutive Issuance Price, the adjustment to the number of Warrant Shares can be expressed
in the following formula: Total number of Warrant Shares after such Dilutive Issuance = the number obtained from dividing [E x F] by
G. Notwithstanding the foregoing, if the Exercise Price is being adjusted as a result of a sale of securities, this Section 3(c) shall
NOT apply if the Holder is offered the right to participate (in an amount not to exceed $50,000 unless agreed to by the Holder and the
Company) and does not participate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(d) <U>Subsequent Rights Offerings.
</U>In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock
Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares
of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to
such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares
of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale
of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be
determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). Notwithstanding
the foregoing, no Purchase Rights will be made under this Section 3(d) in respect of an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>Pro Rata Distributions.
</U>If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock (and not to the Holder)
evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security
other than the Common Stock (which shall be subject to Section 3(d)), then in each such case the Exercise Price shall be adjusted by
multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive
such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which
the numerator shall be such VWAP on such record date less the then per share fair market value at such record date of the portion of
such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined by the Board
of Directors in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the portion of
assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment
shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(f) <U>Fundamental Transaction.</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(i) If,
at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions engages in
any Fundamental Transaction, as defined in the Purchase Agreement, then, upon any subsequent exercise of this Warrant, the Holder shall
have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence
of such Fundamental Transaction (without regard to any limitation on the exercise of this Warrant), at the option of the Holder the number
of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional
consideration (the &ldquo;Alternate Consideration&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number
of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any
limitation on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall not effect a Fundamental Transaction unless it gives the Holder at least 10 Trading Days prior notice together with sufficient details
so the Holder can make an informed decision as to whether it elects to accept the Alternative Consideration. If a public announcement
of the Fundamental Transaction has not been made, the notice to the Holder may not be given until the Company files a Form 8-K or other
report disclosing the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(ii) Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, provided that the Warrant Shares are not registered under an effective
registration statement, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the
date of the consummation of such Fundamental Transaction or (ii) the positive difference between the cash per share paid in such Fundamental
Transaction minus the then in effect Exercise Price. &ldquo;Black Scholes Value&rdquo; means the value of the unexercised portion of this
Warrant based on the Black and Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. determined as
of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from
the HVT function on Bloomberg L.P. as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus
the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iii) If
Section 3(f)(i) and (ii) are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
and the other Transaction Documents in accordance with the provisions of this Section 3(f)(iii) pursuant to written agreements in form
and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant prior to such Fundamental Transaction (without regard to any limitation on the exercise of
this Warrant), and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into
account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital
stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring
to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor
Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g) <U>Calculations.</U> All
calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares <FONT STYLE="letter-spacing: -0.15pt">of </FONT>Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(h) <U>Notice to Holder</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(i) <U>Adjustment to Exercise
Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly email to the
Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and
setting forth a brief statement of the facts requiring such adjustment. The Holder may supply an email address to the Company and change
such address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(ii) <U>Notice to Allow Exercise
by the Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B)
the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize
the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class
or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets
of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, or (E) the Company shall
authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the
Company shall deliver to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 5 calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are
to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected
to become effective <FONT STYLE="letter-spacing: -0.15pt">or </FONT>close, and the date as of which it is expected that holders of the
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to email such notice or
any defect therein or in the emailing thereof shall not affect the validity of the corporate action required to be specified in such
notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any of the Subsidiaries (as determined in good faith by the Company), the Company shall simultaneously file such notice with the Commission
pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>Transferability</U>. Subject
to compliance with any applicable securities laws and the provisions of the Purchase Agreement, this Warrant and all rights hereunder
(including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the
principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form
attached hereto duly executed by the Holder or its agent or attorney. Upon such surrender, the Company shall execute and deliver a new
Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new Holder for the
purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <U>New Warrants</U>. This
Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with
a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or
attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;Warrant Register&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a) <U>No Rights as Stockholder
Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the
Company prior to the exercise hereof other than as explicitly set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b) <U>Loss, Theft, Destruction
or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss,
theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or
stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate. In no event shall the Holder be required to deliver a bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(c) <U>Saturdays, Sundays, Holidays,
etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not
be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(d) <U>Authorized Shares</U>.</P>



<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its Articles of
Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at
all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such
exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and
(iii) use best efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(e) <U>Jurisdiction</U>. All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with
the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(f) <U>Restrictions</U>. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered or if not exercised on a cashless
basis when Rule 144 (or any successor law or rule) is available, may have restrictions upon resale imposed by state and federal securities
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(g) <U>Non-waiver and Expenses</U>.
No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate as a waiver of such
right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant or the
Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(h) <U>Notices</U>. Any notice,
request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance
with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(i) <U>Limitation of Liability</U>.
No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and
no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price
of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(j) <U>Remedies</U>. The Holder,
in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance
of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by
reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for
specific performance that a remedy at law would be adequate or that there is no irreparable harm and not to require the posting of a
bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(k) <U>Successors and Assigns</U>.
Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and
be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(l) <U>Amendment</U>. This Warrant
may be modified or amended or the provisions hereof waived with the written consent of the Company and Holders of 75% of the outstanding
Warrants issued pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(m) <U>Severability</U>. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if
any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent
of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(n) <U>Headings</U>. The headings
used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: justify"><B>60 Deg</B></TD>
    <TD STYLE="width: 43%; font-weight: bold; text-align: justify"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">Name:</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">Title:</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">TO: <B>60 Degrees Pharmaceuticals, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(1) The undersigned hereby
elects to purchase________________Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in
full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-indent: 72pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> (2) Payment shall take the form of (check applicable box):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 100pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 100pt; text-indent: 0pt; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(3) Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified
below:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
giving effect to this Notice of Exercise, the undersigned will not have exceeded the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">SIGNATURE OF HOLDER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-underline-color: black; text-align: justify">Name of Investing Entity:</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><I>Signature of Authorized Signatory of Investing Entity</I>:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">Name of Authorized Signatory:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">Title of Authorized Signatory:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">Date:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-underline-color: black; text-align: center">&nbsp;</TD>
    <TD STYLE="text-indent: 0.125in; width: 40%; text-underline-color: black; text-align: left">(To assign the foregoing warrant, execute </TD>
    <TD STYLE="width: 30%; text-underline-color: black; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: center">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: left">this form and supply required information. Do </TD>
    <TD STYLE="text-underline-color: black; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: center">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: left">not use this form to exercise the warrant.)</TD>
    <TD STYLE="text-underline-color: black; text-align: center">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">60 Degrees Pharmaceuticals, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">FOR VALUE RECEIVED,<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>all
of or<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>shares of the foregoing Warrant and all rights evidenced
thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-underline-color: black; text-align: justify">&nbsp;whose address is</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 49%; text-underline-color: black; text-align: justify">Dated:<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
    <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 20%; text-underline-color: black; text-align: justify">Holder&rsquo;s Signature: &nbsp;</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 25%; text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">Holder&rsquo;s Address: &nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-underline-color: black; text-align: justify">Signature Guaranteed: &nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed
by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.</P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>6
<FILENAME>cm270_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.3&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH
THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Original Issue Date: May 19, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">$44,444 Principal and Face Value</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">$40,000 Purchase Price and Subscription Amount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">$4,444 Original Issue Discount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ORIGINAL ISSUE DISCOUNT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONVERTIBLE PROMISSORY NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE
PROMISSORY NOTE is duly authorized and validly issued at a 10% original issue discount by 60 Degrees Pharmaceuticals, LLC, a Washington
DC limited liability corporation (the &ldquo;Company&rdquo;) (the &ldquo;Note&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">FOR VALUE RECEIVED, the Company
promises to pay to Geoffrey Dow, or its permitted assigns (the &ldquo;Holder&rdquo;), the principal sum of $44,444 on May 31, 2023 (the
&ldquo;Maturity Date&rdquo;) or such earlier date as this Note is required or permitted to be repaid as provided hereunder, and to pay
interest to the Holder on the aggregate unconverted and then outstanding principal amount of this Note in accordance with the provisions
hereof. This Note is subject to the following additional provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Section 1</U>. <U>Definitions</U>. For the purposes
hereof, (a) capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement and (b) the following
words and phrases shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Alternate Consideration&rdquo;
shall have the meaning set forth in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Bankruptcy Event&rdquo;
means any of the following events: (a) the Company or any Subsidiary thereof commences a case or other proceeding under any bankruptcy,
reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction
relating to the Company or any Subsidiary thereof, (b) there is commenced against the Company or any Subsidiary thereof any such case
or proceeding that is not dismissed within 60 days after commencement, (c) the Company or any Subsidiary thereof is adjudicated insolvent
or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Company or any Subsidiary
thereof suffers any appointment of any custodian or the like for it or any substantial part of its property that is not discharged or
stayed within 60 calendar days after such appointment, (e) the Company or any Subsidiary thereof makes a general assignment for the benefit
of creditors, (f) the Company or any Subsidiary thereof calls a meeting of its creditors with a view to arranging a composition, adjustment
or restructuring of its debts or (g) the Company or any Subsidiary thereof, by any act or failure to act, expressly indicates its consent
to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting any of the
foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Base Conversion Price&rdquo;
shall have the meaning set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Beneficial Ownership Limitation&rdquo;
shall have the meaning set forth in Section 4(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Black Scholes Value&rdquo;
means the value of the outstanding principal amount of this Note, plus all accrued and unpaid interest hereon based on the Black and Scholes
Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) determined as of the day
of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction
and the Maturity Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying
price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any
non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to the time between
the date of the public announcement of the applicable Fundamental Transaction and the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Buy-In&rdquo; shall have
the meaning set forth in Section 4(d)(v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Change of Control Transaction&rdquo;
means the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an individual or legal entity or &ldquo;group&rdquo;
(as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership
of capital stock of the Company, by contract or otherwise) of in excess of 50% of the voting securities of the Company (other than by
means of conversion, exercise or exchange of this Note or the Warrants issued together with this Note), (b) the Company merges into or
consolidates with any other Person, or any Person merges into or consolidates with the Company and, after giving effect to such transaction,
the shareholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power <FONT STYLE="letter-spacing: -0.15pt">of
</FONT>the Company or the successor entity of such transaction, (c) the Company sells or transfers all or substantially all of its assets
to another Person, (d) a replacement at one time or within a three year period of more than one-half of the members of the Board of Directors
which is not approved by a majority of those individuals who are members of the Board of Directors on the Original Issue Date (or by those
individuals who are serving as members of the Board of Directors on any date whose nomination to the Board of Directors was approved by
a majority of the members of the Board of Directors who are members on the date hereof), or (d) the execution by the Company of an agreement
to which the Company is a party or by which it is bound, providing for any of the events set forth in clauses (a) through (d) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Conversion&rdquo; shall
have the meaning ascribed to such term in Section 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Conversion Date&rdquo; shall
have the meaning set forth in Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Conversion Price&rdquo;
shall have the meaning set forth in Section 4(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Conversion Shares&rdquo;
means, collectively, the shares of Common Stock issuable upon conversion of this Note in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Default Interest Rate&rdquo;
shall have the meaning set forth in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Dilutive Issuance&rdquo;
shall have the meaning set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Dilutive Issuance Notice&rdquo;
shall have the meaning set forth in Section 5(b)(5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;DWAC&rdquo; means the Deposit
or Withdrawal at Custodian system at The Depository Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Event of Default&rdquo;
shall have the meaning set forth in Section 7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Exchange Act&rdquo; means
the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Fundamental Transaction&rdquo;
shall have the meaning set forth in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;IPO&rdquo; shall have the
meaning set forth in Section 4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Liens&rdquo; shall have
the meaning set forth in the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Note Register&rdquo; shall
have the meaning set forth in Section 3(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Notice of Conversion&rdquo;
shall have the meaning set forth in Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Mandatory Default Amount&rdquo;
shall have the meaning set forth in Section 7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Option Value&rdquo; means
the value of a Common Stock Equivalent based on the Black Scholes Option Pricing model obtained from the &ldquo;OV&rdquo; function on
Bloomberg determined as of (A) the Trading Day prior to the public announcement of the issuance of the applicable Common Stock Equivalent,
if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day immediately following the issuance of the
applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is not publicly announced, for pricing purposes and
reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of the applicable
Common Stock Equivalent as of the applicable date of determination, (ii) an expected volatility equal to the greater of 100% and the 100
day volatility obtained from the HVT function on Bloomberg as of (A) the Trading Day immediately following the public announcement of
the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day immediately
following <FONT STYLE="letter-spacing: -0.15pt">the </FONT>issuance of the applicable Common Stock Equivalent if the issuance of such
Common Stock Equivalent is not publicly announced, (iii) the underlying price per share used in such calculation shall be the highest
VWAP of the Common Stock during the period beginning on the Trading Day prior to the execution of definitive documentation relating to
the issuance of the applicable Common Stock Equivalent and ending on (A) the Trading Day immediately following the public announcement
of such issuance, if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day immediately following the
issuance of the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is not publicly announced, (iv) a zero
cost of borrow and (v) a 360 day annualization factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Original Issue Date&rdquo;
means the date of the first issuance of this Note, regardless of any transfers of this Note and regardless of the number of instruments
which may be issued to evidence this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Permitted Indebtedness&rdquo;
means (a) the indebtedness evidenced by this Note, (b) senior secured non-convertible loans from traditional commercials banks with interest
per annum not to exceed 12%, (c) capital lease obligations and purchase money indebtedness incurred in connection with the acquisition
of machinery and equipment as long as such capital leases and indebtedness are approved in advance by the Holder and (d) the Indebtedness
set forth on Schedule 3.27 to the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Permitted Lien&rdquo; means
the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental charges or levies not
yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good faith and by appropriate proceedings
for which adequate reserves (in the good faith judgment of the management of the Company) have been established in accordance with GAAP,
(b) Liens imposed by law which were incurred in the ordinary course of the Company&rsquo;s business, such as carriers&rsquo;, warehousemen&rsquo;s
and mechanics&rsquo; Liens, statutory landlords&rsquo; Liens, and other similar Liens arising in the ordinary course of the Company&rsquo;s
business, and which (x) do not individually or in the aggregate materially detract from the value of such property or assets or materially
impair the use thereof in the operation of the business of the Company and its consolidated Subsidiaries or (y) are being contested in
good faith by appropriate proceedings, which proceedings have the effect of preventing for the foreseeable future the forfeiture or sale
of the property or asset subject to such Lien, (c) Liens incurred in connection with Permitted Indebtedness under clauses (a) through
(d) thereunder, and Liens set forth on Schedule 3.1(aa) to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Purchase Agreement&rdquo;
means the Securities Purchase Agreement, dated as of May [*], 2022, among the Company and the original Holders, as amended, modified or
supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Share Delivery Date&rdquo;
shall have the meaning set forth in Section 4(d)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Successor Entity&rdquo;
shall have the meaning set forth in Section 5(e)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;Transaction Documents&rdquo;
means the Note, the Purchase Agreement and the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;VWAP&rdquo; means, for any
date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading
Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market
on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)) (or a similar organization or agency succeeding to its functions of reporting prices), (b) if
no volume weighted average price of the Common Stock is reported for the Trading Market, the most recent bid price per share of the Common
Stock so reported, or (c) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Section 2</U>. <U>Interest</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Interest shall accrue to the Holder on the aggregate
unconverted and then outstanding principal amount of this Note at the rate of 6% per annum, calculated on the basis of a 360-day year
and shall accrue daily commencing on the Original Issue Date until payment in full of the outstanding principal (or conversion to the
extent applicable), together with all accrued and unpaid interest, liquidated damages and other amounts which may become due hereunder,
has been made. During the existence of an Event of Default, interest shall accrue at the lesser of (i) the rate of 15% per annum, or (ii)
the maximum amount permitted by law (the lesser of clause (i) or (ii), the &ldquo;<U>Default Interest Rate</U>&rdquo;). Once an Event
of Default is cured, the interest rate shall return to 6%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Section 3</U>. <U>Registration of Transfers and
Exchanges</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a) <U>Different Denominations</U>.
This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as requested by the
Holder surrendering the same. No service charge or other fees will be payable for such registration of transfer or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) <U>Investor Representations</U>.
This Note has been issued subject to certain investment representations of the original Holder set forth in the Purchase Agreement and
may be transferred or exchanged only in compliance with the Purchase Agreement and applicable federal and state securities laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c) <U>Reliance on Note Register</U>.
Prior to due presentment for transfer to the Company of this Note, the Company and any agent of the Company may treat the Person in whose
name this Note is duly registered on the Note Register as the owner hereof for the purpose of receiving payment as herein provided and
for all other purposes, whether or not this Note is overdue, and neither the Company nor any such agent shall be affected by notice to
the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Section 4. Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><B>(a) </B><U>Voluntary Conversion</U>.
After the Original Issue Date until this Note is no longer outstanding, this Note shall be convertible, in whole or in part, at any time,
and from time to time, into Conversion Shares at the option of the Holder. The Holder shall effect conversions by delivering to the Company
a Notice of Conversion, the form of which is attached hereto as Annex A (each, a &ldquo;Notice of Conversion&rdquo;), specifying therein
the principal amount of this Note to be converted and the date on which such conversion shall be effected (such date, the &ldquo;Conversion
Date&rdquo;). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of
Conversion is deemed delivered hereunder. No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or
other type of guarantee or notarization) of any Notice of Conversion form be required. To effect conversions hereunder, the Holder shall
not be required to physically surrender this Note to the Company unless the entire principal amount of this Note, plus all accrued and
unpaid interest thereon, has been so converted. Conversions hereunder shall have the effect of lowering the outstanding principal amount
of this Note in an amount equal to the applicable conversion. The Holder and the Company shall maintain records showing the principal
amount(s) converted in each conversion, the date of each conversion, and the Conversion Price in effect at the time of each conversion.
The Company may deliver an objection to any Notice of Conversion within two Trading Days of delivery of such Notice of Conversion. In
the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest error.
<B>The Holder, and any assignee by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph,
following conversion of a portion of this Note, the unpaid and unconverted principal amount of this Note may be less than the amount stated
on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) <U>Mandatory Conversion</U>.
This Note shall convert into Conversion Shares upon the completion of an initial public offering by the Company that results in a listing
of the Company&rsquo;s Common Stock on a national securities exchange (the &ldquo;IPO&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c) <U>Conversion Price</U>. The
&ldquo;Conversion Price&rdquo; shall be at the lesser of a 20% discount to the IPO price or a $27 million pre-money valuation. All such
Conversion Price determinations are to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification
or similar transaction that proportionately decreases or increases the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(d) <U>Mechanics of Conversion
or Prepayment</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(i) <U>Conversion Shares Issuable
Upon Conversion of Principal Amount</U>. The number <FONT STYLE="letter-spacing: -0.15pt">of </FONT>Conversion Shares issuable upon a
conversion hereunder shall be determined by the quotient obtained by dividing (x) the outstanding principal amount of this Note to be
converted by (y) the Conversion Price in effect at the time of such conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(ii) <U>Delivery of Certificate
Upon Conversion</U>. Not later than two Trading Days after each Conversion Date (the &ldquo;Share Delivery Date&rdquo;), the Company shall
deliver, or cause to be delivered, to the Holder any certificate or certificates required to be delivered by the Company under this Section
4(d) which shall be free of restrictive legends and trading restrictions except as provided by the Securities Act (other than those which
may then be required by the Purchase Agreement) and such shares shall be delivered electronically through the Depository Trust Company
or another established clearing corporation performing similar functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iii) <U>Failure to Deliver Conversion
Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as directed by the applicable
Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Company at any time on or before its
receipt of such Conversion Shares, to rescind such conversion, in which event the Company shall promptly return to the Holder any original
Note delivered to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iv) <U>Obligation Absolute; Partial
Liquidated Damages</U>. The Company&rsquo;s obligations to issue and deliver the Conversion Shares upon conversion of this Note in accordance
with the terms hereof, are absolute and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver
or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or
any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of
any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective of any
other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of such Conversion
Shares. In the event the Holder of this Note shall elect to convert any or all of the outstanding principal amount hereof, the Company
may not refuse conversion based on any claim that the Holder or anyone associated or affiliated with the Holder has been engaged in any
violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining and or enjoining
conversion of all or part of this Note shall have been sought and obtained, and the Company posts a surety bond for the benefit of the
Holder in accordance with Section 5.1(d) of the Purchase Agreement. The exercise of any such rights shall not prohibit the Holder from
seeking to collect damages under this Note, the Purchase Agreement or under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(v) <U>Compensation for Buy-In
on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available to the Holder, if the Company
fails for any reason to deliver to the Holder such Conversion Shares by the Share Delivery Date pursuant to Section 4(d)(ii), and if after
such Share Delivery Date the Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise), or the
Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Conversion
Shares which the Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &ldquo;Buy-In&rdquo;), then
the Company shall have the remedies provided for in accordance with Section 5.1(d) of the Purchase Agreement. Nothing herein or therein
shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver Conversion Shares
upon conversion of this Note as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(vi) <U>Fractional Shares</U>.
No fractional shares or scrip representing fractional shares shall be issued upon the conversion of this Note. As to any fraction of a
share which the Holder would otherwise be entitled to purchase upon such conversion, the Company shall at its election, either pay a cash
adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up to the
next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(vii) <U>Transfer Taxes and Expenses</U>.
The issuance of Conversion Shares on conversion of this Note shall be made without charge to the Holder hereof for any documentary stamp
or similar taxes that may be payable in respect of the issue or delivery of such certificates. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Conversion and all fees to the Depository Trust Company (or another established
clearing corporation performing similar functions) required for same-day electronic delivery of the Conversion Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(viii) <U>Attorneys&rsquo; Fees
etc</U>. The Company shall (A) pay the reasonable fees of the law firm of the Holder&rsquo;s choice (in an amount not to exceed $500 per
opinion) in connection with the conversion of the Note, (B) cause its attorneys to promptly provide any reliance opinion to the Transfer
Agent, and (C) pay the Holder the sums required under Section 4(d)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(e) <U>Holder&rsquo;s Conversion
Limitations</U>. The Company shall not effect any conversion of this Note, and a Holder shall not have the right to convert any portion
of this Note, to the extent that after giving effect to the conversion set forth on the applicable Notice of Conversion, the Holder (together
with the Holder&rsquo;s Affiliates, and any Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates)
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock
issuable upon conversion of this Note with respect to which such determination is being made, but shall exclude the number of shares of
Common Stock which are issuable upon (i) conversion of the remaining, unconverted principal amount of this Note beneficially owned by
the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities
of the Company subject to a limitation on conversion <FONT STYLE="letter-spacing: -0.15pt">or </FONT>exercise analogous to the limitation
contained herein (including, without limitation, any other Notes or the Warrants) beneficially owned by the Holder or any of its Affiliates.
Except as set forth in the preceding sentence, for purposes of this Section 4(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained
in this Section 4(e) applies, the determination of whether this Note is convertible (in relation to other securities owned by the Holder
together with any Affiliates) and of which principal amount of this Note is convertible shall be in the sole discretion of the Holder,
and the submission of a Notice of Conversion shall be deemed to be the Holder&rsquo;s determination of whether this Note may be converted
(in relation to other securities owned by the Holder together with any Affiliates) and which principal amount of this Note is convertible,
in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, the Holder will be deemed to
represent to the Company each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions
set forth in this Section 4(e) and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition,
a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this Section 4(e), in determining the number of outstanding shares
of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following:
(i) the Company&rsquo;s most recent periodic or annual report filed with the SEC, as the case may be, (ii) a more recent public announcement
by the Company, or (iii) a more recent written notice by the Company or the Company&rsquo;s transfer agent setting forth the number of
shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally
and in writing to the Holder the number of shares of Common Stock then outstanding. <FONT STYLE="letter-spacing: -0.2pt">In </FONT>any
case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Note, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common
Stock was reported. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of this Note held by the Holder. The
Holder, upon not less than 61 days&rsquo; prior notice to the Company, may increase the Beneficial Ownership Limitation provisions of
this Section 4(e) to 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon conversion of this Note held by the Holder. In all events, the provisions of this Section 4(e) shall continue to
apply. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the Company. The Holder
may also decrease the Beneficial Ownership Limitation provisions of this Section 4(e) solely with respect to the Holder&rsquo;s Note at
any time, which decrease shall be effectively immediately upon delivery of notice to the Company. The Beneficial Ownership Limitation
provisions of this Section 4(e) shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
Section 4(e) to correct any portion which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained
herein or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this Section 4(d) shall apply to a successor holder of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Section 5</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a) <U>Stock Dividends and Stock
Splits</U>. If the Company, at any time while this Note is outstanding: (i) pays a stock dividend or otherwise makes a distribution or
distributions payable in shares of Common Stock on shares of Common Stock or any Common Stock Equivalents, (ii) subdivides outstanding
shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding shares of
Common Stock into a smaller number of shares or (iv) issues, in the event of a reclassification of shares of the Common Stock, any shares
of capital stock of the Company, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be the number
of shares of Common Stock (excluding any treasury shares of the Company) outstanding immediately before such event, and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to this Section 5(a)
shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) <U>Subsequent Equity Sales</U>.
(1) At any time, for so long as the Note or any amounts accrued and payable thereunder remain outstanding, the Company or any Subsidiary,
as applicable, sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or
announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents entitling any
Person to acquire shares of Common Stock at an effective price per share that is lower than the Conversion Price then in effect (such
lower price, the &ldquo;Base Conversion Price&rdquo; and each such issuance or announcement a &ldquo;<U>Dilutive Issuance</U>&rdquo;),
then the Conversion Price shall be immediately reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such
Common Stock or Common Stock Equivalents are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">(2) If any Common Stock Equivalent
is amended or adjusted, and such price as so amended shall be less than the Conversion Price in effect at the time of such amendment or
adjustment, then the Conversion Price shall be adjusted upon each such issuance or amendment as provided in this Section 5(b). In case
any Common Stock Equivalent is issued in connection with the issue or sale of other securities of the Company, together comprising one
integrated transaction, (x) the Common Stock Equivalents will be deemed to have been issued for the Option Value of such Common Stock
Equivalents and (y) the other securities issued or sold in such integrated transaction shall be deemed to have been issued or sold for
the difference of (I) the aggregate consideration received by the Company less any consideration paid or payable by the Company pursuant
to the terms of such other securities of the Company, less (II) the Option Value. If any shares of Common Stock or Common Stock Equivalents
are issued or sold or deemed to have been issued or sold for cash, the amount of such consideration received by the Company will be deemed
to be the net amount received by the Company therefor. If any shares of Common Stock or Common Stock Equivalents are issued or sold for
a consideration other than cash, the amount of such consideration received by the Company will be the fair value of such consideration,
except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company
will be the average VWAP of such public traded securities for the ten days prior to the date of receipt. If any shares of Common Stock
or Common Stock Equivalents are issued to the owners of the non-surviving entity in connection with any merger in which the Company is
the surviving entity, the amount of consideration therefor will be deemed to be the fair value of such portion of the net assets and business
of the non-surviving entity as is attributable to such shares of Common Stock or Common Stock Equivalents, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt">(3) If the holder of Common
Stock or Common Stock Equivalents outstanding on the Original Issue Date or issued after the Original Issuance Date shall at any time,
whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or
due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common
Stock at an effective price per share that is lower than the Conversion Price then in effect, such issuance shall be deemed to have occurred
for less than the Conversion Price on such date and such issuance shall be deemed to be a Dilutive Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(4) If the Company enters into
a Variable Rate Transaction despite the prohibition set forth in the Purchase Agreement, the Company shall be deemed to have issued Common
Stock or Common Stock Equivalents at the lowest possible conversion price at which such securities may be converted or exercised under
the terms of such Variable Rate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(5) The Company shall notify the
Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject to this
Section 5(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other
pricing terms (such notice, the &ldquo;Dilutive Issuance Notice&rdquo;). For purposes of clarification, whether or not the Company provides
a Dilutive Issuance Notice pursuant to this Section 5(b), upon the occurrence of any Dilutive Issuance, the Holder is entitled to receive
a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive Issuance, regardless of whether
the Holder accurately refers to the Base Conversion Price in the Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(6) The provisions of this Section
5(b) shall apply each time a Dilutive Issuance occurs after the Original Issue Date for so long as the Note or any amounts accrued and
payable thereunder remain outstanding, but any adjustment of the Conversion Price pursuant to this Section 5(b) shall be downward only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">(7) The provisions of this Section
5(b) shall not apply to Exempt Issuances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c) <U>Subsequent Rights
Offerings</U>. In addition to any adjustments pursuant to Section 5(a) above, if at any time the Company grants, issues or sells
any Common Stock, Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the
record holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete conversion of this Note (without regard to
any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
<U>(provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would
result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right
thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(d) <U>Pro Rata Distributions</U>.
During such time as this Note is outstanding, if the Company shall declare or make any dividend or other distribution of its assets or
rights or warrants to acquire its assets, or subscribe for or purchase any security other than Common Stock, to holders of shares of Common
Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property
or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction)
(a &ldquo;Distribution&rdquo;), at any time after the issuance of this Note, then, in each such case, the Holder shall be entitled to
participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number
of shares of Common Stock acquirable upon complete conversion of this Note (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, to the extent that the Holder's right to participate in any such Distribution would
result in the Holder exceeding the Beneficial Ownership Limitation with respect to the Company or any other publicly-traded corporation
subject to Section 13(d) of the Exchange Act, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in
the Holder exceeding the Beneficial Ownership Limitation with respect to the Company or any other publicly-traded corporation subject
to Section 13(d) of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(e) <U>Fundamental Transaction</U>.
(1) If, at any time while this Note is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related
transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person)
is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash
or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, (v)
the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person
whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held
by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock
or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent
conversion of this Note, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such
conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation on the conversion of
this Note), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable as a result of such Fundamental Transaction by
a holder of the number of shares of Common Stock for which this Note is convertible immediately prior to such Fundamental Transaction
(without regard to any limitation on the conversion of this Note). For purposes of any such conversion, the determination of the Conversion
Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Conversion Price among the
Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion of this Note following such
Fundamental Transaction. The Company shall not effect a Fundamental Transaction unless it gives the Holder at least 10 Trading Days prior
notice together with sufficient details so the Holder can make an informed decision as to whether it elects to accept the Alternative
Consideration. If a public announcement of the Fundamental Transaction has not been made, the notice to the Holder may not be given until
the Company files a Form 8-K or other report disclosing the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(2) Notwithstanding anything to
the contrary, provided that the Warrant Shares are not registered under an effective registration statement, in the event of a Fundamental
Transaction that is (x) an all cash transaction, (y) a &ldquo;Rule 13e-3 transaction&rdquo; as defined in Rule 13e-3 under the Exchange
Act, or (z) a Fundamental Transaction involving a person or entity not traded on a national securities exchange or trading market (with
such exchange or market including, without limitation, the Nasdaq Global Select Trading Market, the Nasdaq Global Market, or the Nasdaq
Capital Market, the New York Stock Exchange, Inc., the NYSE American or any market operated by the OTC Markets, Inc.), the Company or
any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, concurrently with the consummation of the Fundamental Transaction,
purchase this Note from the Holder by paying to the Holder the higher of (i) an amount of cash equal to the Black Scholes Value of the
outstanding principal of this Note on the date of the consummation of such Fundamental Transaction, or (ii) the product of (a) the number
of Conversion Shares issuable upon full conversion of this Note (without regard to any limitation on conversion of this Note) and (b)
the positive difference between the cash per share paid in such Fundamental Transaction minus the then in effect Conversion Price. (3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(3) If Section 5(e)(1) and (2)
are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under this Note and the other Transaction
Documents in accordance with the provisions of this Section 5(e) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Note a security of the Successor Entity evidenced by a written instrument substantially
similar in form and substance to this Note which is convertible for a corresponding number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Note (without
regard to any limitations on the conversion of this Note) prior to such Fundamental Transaction, and with a conversion price which applies
the Conversion Price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
conversion price being for the purpose of protecting the economic value of this Note immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Note and the other
Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. Notwithstanding anything
in this Section 5(e), an Exempt Issuance (as defined in the Purchase Agreement) shall not be deemed a Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(f) <U>Calculations</U>. All calculations
under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section
5, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares
of Common Stock (excluding any treasury shares of the Company) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(g) <U>Notice to the Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 53.95pt">(i) <U>Adjustment to Conversion
Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 5, the Company shall promptly deliver to
each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement of the facts requiring
such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 54pt">(ii) <U>Notice to Allow Conversion
by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on its Common Stock, (B) the Company
shall declare a special nonrecurring cash dividend on or a redemption of its Common Stock, (C) the Company shall authorize the granting
to all holders of its Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any
rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of its Common Stock,
any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company,
or any compulsory share exchange whereby its Common Stock is converted into other securities, cash or property or (E) the Company shall
authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be filed at each office or agency maintained for the purpose of conversion of this Note, and shall cause to be delivered
to the Holder at its last address as it shall appear upon the Note Register, at least 5 calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend,
distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of its Common Stock
of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date
as of which it is expected that holders of its Common Stock of record shall be entitled to exchange their shares of the Common Stock for
securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public
information regarding the Company or any of the Subsidiaries (as determined in good faith by the Company), the Company or its successor
shall simultaneously file such notice with the SEC pursuant to a Current Report on Form 8-K. If the Company does not simultaneously file
the required Form 8-K, the Holder shall be entitled penalties in accordance with Section 5.6 of the Purchase Agreement The Holder shall
remain entitled to convert this Note during the 20-day period commencing on the date of such notice through the effective date of the
event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Section 6</U>. <U>Negative Covenants</U>. As long
as any portion of this Note remains outstanding, unless the holders of at least 50% in principal amount of the then outstanding Notes
shall have otherwise given prior written consent, the Company shall not, and shall not permit any of the Subsidiaries to, directly or
indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a) other than Permitted Indebtedness,
enter into, create, incur, assume, guarantee or suffer to exist any indebtedness for borrowed money of any kind, including, but not limited
to, a guarantee, on or with respect to any of its property or assets now owned or hereafter acquired or any interest therein or any income
or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) other than Permitted Liens,
enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to any of its property or assets now owned
or hereafter acquired or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c) amend
its charter documents, including, without limitation, its articles of incorporation and bylaws, in any manner that materially and adversely
affects any rights of the Holder, increases in authorized shares and stock splits shall not be deemed to materially and adversely affects
any rights of the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(d) purchase or otherwise
acquire more than a <U>de minimis</U> number of shares of its Common Stock or Common Stock Equivalents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt">(e) repay, or offer to repay,
any Indebtedness, other than Permitted Indebtedness, as such terms Indebtedness and Permitted Indebtedness are in effect as of the Original
Issue Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(f) pay cash dividends or distributions
on any equity securities of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36.05pt">(g) enter into any transaction
with any Affiliate of the Company which would be required to <FONT STYLE="letter-spacing: -0.15pt">be </FONT>disclosed in any public filing
with the SEC assuming that the Company is subject to the Securities Act or the Exchange Act, unless such transaction is made on an arm&rsquo;s-length
basis and expressly approved by a majority of the disinterested directors of the Company (even if less than a quorum otherwise required
for board approval);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(h) issue any equity securities
of the Company other than pursuant to the provisions of the Purchase Agreement or an Exempt Issuance; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(i) enter into any agreement with
respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Section 7</U>. <U>Events of Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a) &ldquo;<U>Event of Default</U>&rdquo;
means, wherever used herein, any of the following events (whatever the reason for such event and whether such event shall be voluntary
or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order, rule or regulation
of any administrative or governmental body):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(i) any default in the payment
of (A) principal and interest payment under this Note or any other Indebtedness, or (B) late fees, liquidated damages and other amounts
owing to the Holder of this Note, as and when the same shall become due and payable (whether on a Conversion Date, or the Maturity Date,
or by acceleration or otherwise), which default, solely in the case of a default under clause (B) above, is not cured within five Trading
Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(ii) the Company shall fail to
observe or perform any other covenant or agreement contained in this Note (other than a breach by the Company of its obligations to deliver
Conversion Shares, which breach is addressed in clause (x) below) or any Transaction Document which failure is not cured, if possible
to cure, within the earlier to occur of 15 Trading Days after notice of such failure is sent by the Holder or by any other Holder to the
Company and (B) 10 Trading Days after the Company has become aware of such failure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iii) except for payment defaults
covered under Section 7(a)(i), the Company shall breach, or a default or event of default (subject to any grace or cure period provided
in the applicable agreement, document or instrument) shall occur under, (A) any of the Transaction Documents or (B) any other material
agreement, lease, document or instrument to which the Company or any Subsidiary is obligated (and not covered by any other clause of this
Section 7) which default or event of default if not cured, if possible to cure, within the earlier to occur of (i) 10 Trading Days after
notice of such default sent by Holder or by any other holder to the Company and (ii) five Trading Days after the Company has become aware
of such default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.95pt">(iv) any representation or warranty
made in this Note, any other Transaction Document, any written statement pursuant hereto or thereto or any other report, financial statement
or certificate made or delivered to the Holder or any other Holder shall be untrue or incorrect in any material respect as of the date
when made or deemed made, which failure is not cured, if possible to cure, within the earlier to occur of 10 Trading Days after notice
of such failure is sent by the Holder or by any other Holder to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(v) the Company or any Subsidiary
shall be subject to a Bankruptcy Event;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(vi) the Company or any Subsidiary
shall: (A) apply for or consent to the appointment of a receiver, trustee, custodian or liquidator of it or any of its properties; (B)
admit in writing its inability to pay its debts as they mature; (C) make a general assignment for the benefit of creditors; (D) be adjudicated
as bankrupt or insolvent or be the subject of an order for relief under Title 11 of the United States Code or any bankruptcy, reorganization,
insolvency, readjustment of debt, dissolution or liquidation law or statute of any other jurisdiction or foreign country; or (E) file
a voluntary petition in bankruptcy, or a petition or an answer seeking reorganization or an arrangement with creditors or to take advantage
or any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law or statute, or an answer admitting
the material allegations of a petition filed against it in any proceeding under any such law, or (F) take or permit to be taken any action
in furtherance of or for the purpose of effecting any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(vii) if any order, judgment or
decree shall be entered, without the application, approval or consent of the Company or any Subsidiary, by any court of competent jurisdiction,
approving a petition seeking liquidation or reorganization of the Company or any Subsidiary, or appointing a receiver, trustee, custodian
or liquidator of the Company or any Subsidiary, or of all or any substantial part of its assets, and such order, judgment or decree shall
continue unstayed and in effect for any period of 60 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(viii) the occurrence of any levy
upon or seizure or attachment of, or any uninsured loss of or damage to, any property of the Company or any Subsidiary having an aggregate
fair value or repair cost (as the case may be) in excess of $100,000 individually or in the aggregate, and any such levy, seizure or attachment
shall not be set aside, bonded or discharged within 45 days after the date thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.95pt">(ix) any monetary judgment,
writ or similar final process shall be entered or filed against the Company, any Subsidiary or any of their respective property or other
assets for more than $100,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or unstayed for a period
of 30 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(x) any Material Adverse Effect
occurs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(xi) any provision of any Transaction
Document shall at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding on or enforceable
against the parties thereto, or the validity or enforceability thereof shall be contested by any party thereto, or a proceeding shall
be commenced by the Company or any Subsidiary or any governmental authority having jurisdiction over any of them, seeking to establish
the invalidity or unenforceability thereof, or the Company or any Subsidiary shall deny in writing that it has any liability or obligation
purported to be created under any Transaction Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(xii) the Company fails to use
the proceeds in the manner as described in Section 5.7 of the Purchase Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(xiii) the Company shall be a party
to any Change of Control Transaction or shall agree to sell or dispose of all or in excess of 50% of its assets in one transaction or
a series of related transactions (whether or not such sale would constitute a Change of Control Transaction);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(xiv) from and after 90 days after
the Original Issue Date, the Company fails to have authorized and reserved the amount of shares designated in Section 3.5 of the Purchase
Agreement (without regard to any limitations on conversion hereof, including without limitation, the Beneficial Ownership Limitation);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(xv) the Company shall fail for
any reason, except if caused by the action or inaction of the Holder to deliver Conversion Shares to the Holder prior to the third Trading
Day after a Conversion Date pursuant to Section 4 or the Company shall provide at any time notice to the Holder, including by way of public
announcement, of the Company&rsquo;s intention to not honor requests for conversions of this Note in accordance with the terms hereof;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.95pt">(xvi) the Company fails to file
with the SEC any required reports under Section 13 or 15(d) of the Exchange Act within the time required (including any applicable extension
period) by the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) <U>Remedies Upon Event of Default</U>.
If any Event of Default occurs, the outstanding principal amount of this Note, plus liquidated damages and other amounts owing in respect
thereof through the date of acceleration, shall become, at the Holder&rsquo;s election, immediately due and payable in cash (the &ldquo;Mandatory
Default Amount&rdquo;). Upon the payment in full of the Mandatory Default Amount, the Holder shall promptly surrender this Note to or
as directed by the Company. In connection with such acceleration described herein, the Holder need not provide, and the Company hereby
waives, any presentment, demand, protest or other notice of any kind, and the Holder may immediately and without expiration of any grace
period enforce any and all of its rights and remedies hereunder and all other remedies available to it under applicable law. Such acceleration
may be rescinded and annulled by Holder at any time prior to payment hereunder and the Holder shall have all rights as a holder of the
Note until such time, if any, as the Holder receives full payment pursuant to this Section 7(b). No such rescission or annulment shall
affect any subsequent Event of Default or impair any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c) <U>Interest Rate Upon Event
of Default</U>. Commencing on the occurrence of any Event of Default and until such Event of Default is cured, this Note shall accrue
interest at an interest rate equal to the Default Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(d) <U>Conversion Price Upon Event
of Default</U>. Commencing on the occurrence of any Event <FONT STYLE="letter-spacing: -0.25pt">of </FONT>Default and until such Event
of Default is cured, this Note shall be convertible at the Default Conversion Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><U>Section 8</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a) <U>No Rights as Stockholder
Until Conversion</U>. This Note does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company
prior to the conversion hereof other than as explicitly set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) <U>Notices</U>. All notices,
offers, acceptance and any other acts under this Agreement (except payment) shall be in writing, and shall be sufficiently given if delivered
to the addressees in person, by FedEx or similar receipted next day delivery, or at the Company&rsquo;s registered address or such other
address as any of them, by notice to the other may designate from time to time. Time shall be counted to, or from, as the case may be,
the date of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c) <U>Absolute Obligation</U>.
Except as expressly provided herein, no provision of this Note shall alter or impair the obligation of the Company, which is absolute
and unconditional, to pay the principal of, liquidated damages and accrued interest and late fees, as applicable, on this Note at the
time, place, and rate, and in the coin or currency, herein prescribed. This Note is a direct debt obligation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(d) <U>Lost or Mutilated Note</U>.
If this Note shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver, in exchange and substitution for and
upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost, stolen or destroyed Note, a new Note for the principal
amount of this Note so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of this
Note, and of the ownership hereof, reasonably satisfactory to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(e) <U>Exclusive Jurisdiction;
Governing Law; Prevailing Party Attorneys&rsquo; Fees</U>. All questions concerning the construction, validity, enforcement and interpretation
of this Note and venue shall be governed by and construed and enforced in accordance with Section 6.9 of the Purchase Agreement. If any
party shall commence an Action or Proceeding to enforce or otherwise relating to this Note, then, in addition to the other obligations
of the Company elsewhere in this Note, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party
for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of
such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(f) <U>Waiver</U>. Any waiver by
the Company or the Holder of a breach of any provision of this Note shall not operate as or be construed to be a waiver of any other breach
of such provision or of any breach of any other provision of this Note. The failure of the Company or the Holder to insist upon strict
adherence to any term of this Note on one or more occasions shall not be considered a waiver or deprive that party of the right thereafter
to insist upon strict adherence to that term or any other term of this Note on any other occasion. Any waiver by the Company or the Holder
must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(g) <U>Severability</U>. If any
provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain in effect, and if any provision is
inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall
be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate
of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law. The Company
covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner whatsoever claim
or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit or forgive the Company from paying
all or any portion of the principal of or interest on this Note as contemplated herein, wherever enacted, now or at any time hereafter
in force, or which may affect the covenants or the performance of this Note, and the Company (to the extent it may lawfully do so) hereby
expressly waives all benefits or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or
impede the execution <FONT STYLE="letter-spacing: -0.15pt">of </FONT>any power herein granted to the Holder, but will suffer and permit
the execution of every such as though no such law has been enacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(h) <U>Remedies, Characterizations,
Other Obligations, Breaches and Injunctive Relief</U>. The remedies provided in this Note shall be cumulative and in addition to all other
remedies available under this Note and any of the other Transaction Documents at law or in equity (including a decree of specific performance
and/or other injunctive relief), and nothing herein shall limit the Holder&rsquo;s right to pursue actual and consequential damages for
any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be no characterization
concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with respect to payments,
conversion and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall not, except as expressly
provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company acknowledges that a breach
by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such breach would be inadequate.
The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder shall be entitled, in addition to
all other available remedies, to an injunction restraining any such breach or any such threatened breach, without the necessity of showing
economic loss and without any bond or other security being required. The Company shall provide all information and documentation to the
Holder that is requested by the Holder to enable the Holder to confirm the Company&rsquo;s compliance with the terms and conditions of
this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(i) <U>Next Trading Day</U>. Whenever
any payment or other obligation hereunder shall be due on a day other than a Trading Day, such payment shall be made on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(j) <U>Headings</U>. The headings
contained herein are for convenience only, do not constitute a part of this Note and shall not be deemed to limit or affect any of the
provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">IN WITNESS WHEREOF, the Company
has caused this Note to be duly executed by a duly authorized officer as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; font-weight: bold; text-align: justify">60 De</TD>
    <TD STYLE="width: 45%; font-weight: bold; text-align: justify"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Name: </TD>
    <TD STYLE="text-align: justify">Tyrone Miller</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">Title: </TD>
    <TD STYLE="text-align: justify">Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ANNEX A</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTICE OF CONVERSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The undersigned hereby elects to
convert principal under the Original Issue Discount Convertible Note due May 31, 2023 of 60 Degrees Pharmaceuticals, LLC, a limited liability
company (the &ldquo;Company&rdquo;), into shares of common stock (the &ldquo;Common Stock&rdquo;), of the Company according to the conditions
hereof, as of the date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">By the delivery of this Notice
of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed the amounts
specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">The undersigned agrees to comply
with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid shares
of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">Conversion calculations:</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Date to Effect Conversion:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Principal Amount of Note to be Converted:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Number of shares of Common Stock to be issued:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Signature:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Name:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">DWAC Instructions:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 15%">Broker No:</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Account No:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>7
<FILENAME>cm270_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">Exhibit 10.4</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">SECURITIES PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of May 19, 2022, by and between 60 Degrees Pharmaceuticals, LLC, a limited liability
company (the &ldquo;<U>Company</U>&rdquo;), and each lender party that executes the signature page hereto as a purchaser (each, a &ldquo;Purchaser&rdquo;
and collectively, the &ldquo;Purchasers&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities
Act, as defined, contained in Section 4(a)(2) thereof and/or Rule 506(b) thereunder, the Company desires to issue and sell to the Purchaser,
and the Purchaser desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and the Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE I. DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1 <U>Definitions</U>. In addition
to the words and terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings
set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Acquiring Person&rdquo; shall
have the meaning ascribed to such term in Section 5.5. &ldquo;Action&rdquo; shall have the meaning ascribed to such term in Section 3.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Affiliate&rdquo; means
any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with
a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Board of Directors&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Closing&rdquo; means the closing
of the purchase and sale of the Notes pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Closing Date&rdquo;
means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto,
and all conditions precedent to (i) the Purchaser&rsquo;s obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities to be issued and sold, in each case, have been satisfied or waived, but in no event later than
the second Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Common Stock&rdquo; means
the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Common Stock Equivalents&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Evaluation Date&rdquo; shall
have the meaning ascribed to such term in Section 3.19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Exchange Act&rdquo; means
the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Exempt
Issuance&rdquo; means the issuance of (a) shares of Common Stock, restricted stock units or options, and the underlying shares of
Common Stock to consultants, employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for
such purpose, by a majority of the non- employee members of the Board of Directors or a majority of the members of a committee of
non-employee directors established for such purpose for services rendered to the Company, (b) securities issued upon the exercise or
exchange of or conversion of any Securities issued hereunder and/or other securities issuable pursuant to existing agreements,
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement,
provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to
decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock dividends,
stock splits or combinations) or to extend the term of such securities, (c) securities issued pursuant, acquisitions or strategic
transactions approved by a majority of the directors of the Company, provided that any such issuance shall only be to a Person (or
to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a
business synergistic with the business of the Company and which shall reasonably be expected to provide to the Company additional
benefits, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising
capital or to an entity whose primary business is investing in securities, (d) securities issued pursuant to any purchase money
equipment loan or capital leasing arrangement, purchasing agent or debt financing from a commercial bank or similar financial
institution, (e) securities issued pursuant to any presently outstanding warrants or this Agreement; and (f) securities upon a stock
split, stock dividend or subdivision of the Common Stock and shares of common stock in a public offering; (g) non-convertible loans
from traditional commercials banks with interest per annum not to exceed 12% which will rank <B><I>pari passu </I></B>with the Notes
issued to investors by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Face Value&rdquo; means the
Subscription Amount plus original issue discount as described in the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;FCPA&rdquo; means the Foreign
Corrupt Practices Act of 1977, as amended. &ldquo;GAAP&rdquo; shall have the meaning ascribed to such term in Section 3.8. &ldquo;Indebtedness&rdquo;
shall have the meaning ascribed to such term in Section 3.27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Intellectual
Property&rdquo; means all of the following in any jurisdiction throughout the world: (a) all inventions (whether patentable or
unpatentable and whether or not reduced to practice), all improvements thereto, and all U.S. and foreign patents, patent
applications, and patent disclosures, together with all reissuances, continuations, continuations-in-part, revisions, extensions,
and reexaminations thereof, (b) all trademarks, service marks, brand names, certification marks, trade dress, logos, trade names,
domain names, assumed names and corporate names, together with all colorable imitations thereof, and including all goodwill
associated therewith, and all applications, registrations, and renewals in connection therewith, (c) all copyrights, and all
applications, registrations, and renewals in connection therewith, (d) all trade secrets under applicable state laws and the common
law and know-how (including formulas, techniques, technical data, designs, drawings, specifications, customer and supplier lists,
pricing and cost information, and business and marketing plans and proposals), (e) all computer software (including source code,
object code, diagrams, data and related documentation), and (f) all copies and tangible embodiments of the foregoing (in whatever
form or medium).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;IPO&rdquo; shall mean an initial
public offering by the Company that results in a listing of the Company&rsquo;s Common Stock on a national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Licensed Intellectual Property
Agreement&rdquo; means all licenses, sublicenses, agreements and permissions (each as amended to date) that any third party owns and that
the Company uses, including off- the-shelf software purchased or licensed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Liens&rdquo; means a lien,
charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Material Adverse Effect&rdquo;
shall have the meaning assigned to such term in Section 3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Notes&rdquo; means the
Original Issue Discount Convertible Promissory Notes issued to the Purchaser, in the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Note Conversion Price&rdquo;
means the Note Conversion Price provided in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Original Issue Date&rdquo;
means the date of the first issuance of the Notes, regardless of any transfers of any Note and regardless of the number of instruments
which may be issued to evidence such Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Person&rdquo; means an
individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint
stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Proceeding&rdquo; means
an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such
as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Purchaser Party&rdquo; shall
have the meaning ascribed to such term in Section 5.8. &ldquo;Registrable Securities&rdquo; shall mean, collectively, the Shares and the
Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Regulation FD&rdquo; means
Regulation FD promulgated by the SEC pursuant to the Exchange Act, as such Regulation may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Required Approvals&rdquo;
shall have the meaning ascribed to such term in Section 3.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Rule 144&rdquo; means Rule
144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar
rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;SEC&rdquo; means the United
States Securities and Exchange Commission. &ldquo;Securities&rdquo; means the Notes, the Warrants and the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Securities Act&rdquo; means
the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Shares&rdquo; means the Common
Stock issuable upon conversion of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Short Sales&rdquo; means
all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include the
location and/or reservation of borrowable shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Subscription Amount&rdquo;
means, as to the Purchaser, the aggregate amount to be paid for the Note purchased hereunder as specified below the Purchaser&rsquo;s
name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in
immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Subsidiary&rdquo; means
with respect to any entity at any date, any direct or indirect corporation, limited or general partnership, limited liability company,
trust, estate, association, joint venture or other business entity of which (A) more than 50% of (i) the outstanding capital stock having
(in the absence of contingencies) ordinary voting power to elect a majority of the Board of Directors or other managing body of such entity,
(ii) in the case of a partnership or limited liability company, the interest in the capital or profits of such partnership or limited
liability company or (iii) in the case of a trust, estate, association, joint venture or other entity, the beneficial interest in such
trust, estate, association or other entity business is, at the time of determination, owned or controlled directly or indirectly through
one or more intermediaries, by such entity, or (B) is under the actual control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Trading Day&rdquo; means a
day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Trading Market&rdquo; means
any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE
American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the OTCQB,
the OTCQX, or the OTC Pink Marketplace (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Transaction Documents&rdquo;
means this Agreement, the Notes, the Warrants, and any other documents or agreements executed in connection with the transactions contemplated
hereunder, including, but not limited to, the documents referenced in Section 2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Transfer Agent&rdquo; means
Equity Stock Transfer, LLC with a mailing address of, and any
successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Variable Rate
Transaction&rdquo; means any Equity Line of Credit or similar agreement, nor issue nor agree to issue any Common Stock, floating or
Variable Priced Equity Linked Instruments nor any of the foregoing or equity with price reset rights (subject to adjustment for
stock splits, distributions, dividends, recapitalizations and the like) (collectively, the &ldquo;Variable Rate Transaction&rdquo;).
For purposes of this Agreement, &ldquo;Equity Line of Credit&rdquo; shall include any transaction involving a written agreement
between the Company and an investor or underwriter whereby the Company has the right to &ldquo;put&rdquo; its securities to the
investor or underwriter over an agreed period of time and at an agreed price or price formula, and &ldquo;Variable Priced Equity
Linked Instruments&rdquo; shall include: (A) any debt or equity securities which are convertible into, exercisable or exchangeable
for, or carry the right to receive additional shares of Common Stock either (1) at any conversion, exercise or exchange rate or
other price that is based upon and/or varies with the trading prices of or quotations for Common Stock at any time after the initial
issuance of such debt or equity security, or (2) with a fixed conversion, exercise or exchange price that is subject to being reset
at some future date at any time after the initial issuance of such debt or equity security due to a change in the market price of
the Company&rsquo;s Common Stock since date of initial issuance, and (B) any amortizing convertible security which amortizes prior
to its maturity date, where the Company is required or has the option to (or any investor in such transaction has the option to
require the Company to) make such amortization payments in shares of Common Stock which are valued at a price that is based upon
and/or varies with the trading prices of or quotations for Common Stock at any time after the initial issuance of such debt or
equity security (whether or not such payments in stock are subject to certain equity conditions). For purposes of determining the
total consideration for a convertible instrument (including a right to purchase equity of the Company) issued, subject to an
original issue or similar discount or which principal amount is directly or indirectly increased after issuance, the consideration
will be deemed to be the actual cash amount received by the Company in consideration of the original issuance of such convertible
instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Warrants&rdquo; means,
collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof,
which Warrants shall be exercisable immediately and have a term of exercise equal to five years from such initial exercise date, in the
form of <U>Exhibit B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&ldquo;Warrant Exercise Price&rdquo;
means the exercise price provided in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&ldquo;Warrant Shares&rdquo; means
the shares of Common Stock issuable upon exercise of the Warrants at the Warrant Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE II. PURCHASE AND SALE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Dates, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and
delivery of this Agreement by the parties hereto, the Company agrees to sell, and each Purchaser, severally and not jointly, agrees to
purchase an aggregate of (i) Notes with a Face Value listed on the Purchaser&rsquo;s signature page and (ii) Warrants to purchase shares
equal to 100% of the Shares issuable upon conversion of the Note at a price equal to 110% of the IPO price or, if the Company fails to
complete the IPO before May 31, 2023, 90% of the IPO price. On the Closing Date, the Purchaser shall deliver to the Company a signed
copy of the Transaction Documents and, via wire transfer, immediately available funds equal to the Purchaser&rsquo;s Subscription Amount.
After receipt of the Subscription Amount, the Company shall deliver to the Purchaser countersigned copies of the Transaction Documents.
Upon satisfaction of the closing conditions set forth in Section 2.3, the Closing shall occur at the Company&rsquo;s offices or such
other location as the parties shall mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deliveries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On or
prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this Agreement
duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a Note
in the principal amount of $294,444, convertible at the Note Conversion Price, registered in the name of the Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an original
Warrant to purchase &lt;WARRANT SHARES&gt; shares of Common Stock, exercisable at the Warrant Exercise Price, registered in the name of
such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a Board
Consent approving the issuance of the Notes and the execution of the Transaction Documents listed above on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On or
prior to the Closing Date each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this Agreement
duly executed by the Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Purchaser&rsquo;s
Subscription Amount by wire transfer to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Closing
Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligations
of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) on the Closing Date of the representations and warranties of the Purchaser contained herein (unless as of a specific
date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The respective
obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;accuracy
in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in
all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a
specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES
OF COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company hereby makes the following
representations and warranties to each Purchaser as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or Articles of Incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse
effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in
any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. Subject to obtaining the Required Approvals, this Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. Except as set forth in <U>Schedule 3.3</U>, the execution, delivery and performance by the Company of this Agreement
and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it
of the transactions contemplated hereby and thereby do not and will not (i) subject to the Required Approvals, conflict with or
violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s Certificate or Articles of Incorporation, bylaws or other
organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of
time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company
or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice,
lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or
otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company
or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of
any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. Except as set forth on <U>Schedule 3.4</U>, the Company is not required to obtain any consent, waiver,
authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local
or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the
Transaction Documents, other than: (i) blue sky filings or a Form D filing and (ii) such filings as are required to be made under
applicable state securities laws (the &ldquo;Required Approvals&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Shares,
when issued upon conversion of the Notes will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by
the Company. The Company shall reserve from its duly authorized capital stock a number of shares of Common Stock issuable pursuant to
the Notes and Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The capitalization of the Company is as set forth on <U>Schedule 3.6</U>. The Company has not issued any capital stock since its
most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock awards under
the Company&rsquo;s equity incentive plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s
employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the
date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right,
right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except
as set forth on <U>Schedule 3.6</U>, as a result of the purchase and sale of the Securities, there are no outstanding options,
warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any
shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which
the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or
capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue
shares of Common Stock or other securities to any Person (other than the Purchaser) and will not result in a right of any holder
of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no outstanding
securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no
contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem
a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo;
plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized,
validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none
of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale
of the Securities. There are no stockholders&rsquo; agreements, voting agreements or other similar agreements with respect to
the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of
the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect Subsidiaries of the Company are set forth in Schedule 3.7. The Company owns, directly or indirectly, all
of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Statements</U>. The consolidated financial statements of the Company, together with the related notes and schedules, present fairly,
in all material respects, the consolidated financial position of the Company and any of its Subsidiaries as of the dates indicated and
the consolidated results of operations, cash flows and changes in stockholders&rsquo; equity of the Company for the periods specified
and have been prepared in compliance with United States generally accepted accounting principles (&ldquo;GAAP&rdquo;) applied on a consistent
basis during the periods involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest financial statements: (i) there has been
no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii)
the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred
in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the
Company&rsquo;s financial statements pursuant to GAAP, (iii) the Company has not altered its method of accounting, (iv) the Company
has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made
any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any
officer, director or Affiliate, except pursuant to existing Company equity incentive plans. Other than as disclosed on <U>Schedule
3.9</U>, except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its
Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required
to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not
been publicly disclosed at least one Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
Except as set forth on Schedule 3.10, there is no action, suit, inquiry, notice of violation, proceeding or investigation, inquiry
or other similar proceeding of any federal or state government unit pending or, to the knowledge of the Company, threatened against
or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the
issuance of the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a
Material Adverse Effect. The Company has no reason to believe that an Action will be filed against it in the future except as
disclosed on <U>Schedule</U> <U>3.10</U>. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has
been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim
for fraud or breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation or inquiry by the SEC involving the Company or any current or former director or officer of the Company. The
SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company
or any Subsidiary under the Securities Act, and the Company has no reason to believe it will do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their
relationships with their employees are good. To the knowledge of the Company, no effort is underway to unionize or organize the employees
of the Company or any Subsidiary. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now
expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information
agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and
the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with
respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign
laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except
where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. There is no workmen&rsquo;s compensation liability matter, employment-related charge, complaint, grievance, investigation, inquiry
or obligation of any kind pending, or to the Company&rsquo;s knowledge, threatened, relating to an alleged violation or breach by the
Company or its Subsidiaries of any law, regulation or contract that could, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Except as set forth on <U>Schedule 3.12</U>, neither the Company nor any Subsidiary: (i) is in default under or in violation of
(and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the
Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under
or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party
or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation
of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation
of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal,
state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and
employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;Hazardous Materials&rdquo;) into the environment, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations,
codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations,
issued, entered, promulgated or approved thereunder (&ldquo;Environmental Laws&rdquo;); (ii) have received all permits licenses or other
approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with
all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could
be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations
or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any Subsidiary has
received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. There
is no agreement, commitment, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries or to which the
Company or any of its Subsidiaries is a party which has or would reasonably be expected to have the effect of prohibiting or materially
impairing any business practice of the Company or any of its Subsidiaries, any acquisition of property by the Company or any of its Subsidiaries
or the conduct of business by the Company or any of its Subsidiaries as currently conducted other than such effects, individually or
in the aggregate, which have not had and would not reasonably be expected to have a Material Adverse Effect on the Company or any of
its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. Subject to the Liens of the outstanding secured senior debt, the Company and the Subsidiaries have good and marketable
title in fee simple to all personal property owned by them that is material to the business of the Company and the Subsidiaries. The
Company owns no real property. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them
under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the Liens of the outstanding secured senior debt, to the Company&rsquo;s knowledge, the Company owns or possesses or has the right
to use pursuant to a valid and enforceable written license, sublicense, agreement, or permission all Intellectual Property necessary for
the operation of the business of the Company as presently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company&rsquo;s knowledge, the Intellectual Property does not interfere with, infringe upon, misappropriate, or otherwise come into
conflict with, any Intellectual Property rights of third parties, and the Company has no knowledge that facts exist which indicate a likelihood
of the foregoing. The Company has not received any charge, complaint, claim, demand, or notice alleging any such interference, infringement,
misappropriation, or conflict (including any claim that the Company must license or refrain from using any Intellectual Property rights
of any third party). To the knowledge of the Company, no third party has interfered with, infringed upon, misappropriated, or otherwise
come into conflict with, any Intellectual Property rights of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each Licensed Intellectual Property Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Licensed Intellectual Property Agreement is legal, valid, binding, enforceable, and in full force and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company&rsquo;s knowledge, no party to the Licensed Intellectual Property Agreement is in breach or default, and no event has occurred
that with notice or lapse of time would constitute a breach or default or permit termination, modification, or acceleration thereunder,
which as to any such breach, default or event could have a Material Adverse Effect on the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
party to such Licensed Intellectual Property Agreement has repudiated any provision thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in such Licensed Intellectual Property Agreement, the Company has not received written or verbal notice or otherwise has
knowledge that the underlying item of Intellectual Property is subject to any outstanding injunction, judgment, order, decree, ruling,
or charge; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth on <U>Schedule 3.16</U>, the Company has not granted any sublicense or similar right with respect to the license,
sublicense, agreement, or permission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has complied with and is presently in compliance with all foreign, federal, state, local, governmental (including, but not limited
to, the Federal Trade Commission and State Attorneys General), administrative, or regulatory laws, regulations, guidelines, and rules
applicable to any personal identifiable information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Person who participated in the creation, conception, invention or development of the Intellectual Property currently used in the business
of the Company (each, a &ldquo;Developer&rdquo;) which is not licensed from third parties has executed one or more agreements containing
industry standard confidentiality, work for hire and assignment provisions, whereby the Developer has assigned to the Company all copyrights,
patent rights, Intellectual Property rights and other rights in the Intellectual Property, including all rights in the Intellectual Property
that existed prior to the assignment of rights by such Person to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Developer has signed a perpetual non-disclosure agreement with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company
nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as disclosed in Schedule 3.18, none of the officers or directors of the Company or any
Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such
employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of
$120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) other employee benefits, including stock award agreements under any equity incentive plan of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. Except as disclosed in the Schedule 3.19, the Company and the Subsidiaries are in compliance with any
and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable
rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof and as of the Closing Date. The Company
and the Subsidiaries maintain a system of internal accounting controls. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently
filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most
recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in
the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that
have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company
and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth on <U>Schedule 3.20</U>, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the
Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person
with respect to the transactions contemplated by the Transaction Documents. The Purchaser shall have no obligation with respect to any
fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be
due by the Company in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. Except as disclosed on <U>Schedule 3.22</U>, no Person has any right to cause the Company or any Subsidiary to effect
the registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Listing
and Maintenance Requirements; Shell Company</U>. The Company&rsquo;s Common Stock is not quoted or listed on any Trading Market. The
Company is not and has never been a shell company as such term is defined in Rule 12(b)(2) under the Securities Exchange Act of 1934,
as amended and the rules and regulations of the Securities and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchaser as a result of the Purchaser and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance
of the Securities and the Purchaser&rsquo;s ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided the Purchaser or its agent or counsel with any information that
it believes constitutes or might constitute material, non-public information which is not otherwise disclosed on <U>Schedule 3.25</U>.
The Company understands and confirms that the Purchaser will rely on the foregoing representation in effecting transactions in securities
of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchaser regarding the Company and its Subsidiaries,
their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and
correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in light of the circumstances under which they were made not misleading. The press releases disseminated by
the Company during the 12 months preceding the date of this Agreement do not contain any untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances
under which they were made and when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any
representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Article
IV hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchaser&rsquo;s representations and warranties set forth in Article IV, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable stockholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i) the Company&rsquo;s assets do not constitute unreasonably
small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into
account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (ii) the current cash flow of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. <U>Schedule 3.27</U> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the
Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo;
means (x) any liabilities for borrowed money or amounts owed in excess of $100,000 (other than trade accounts payable incurred
in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes
thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the
ordinary course of business; and (z) the present value of any lease payments in excess of $100,000 due under leases required to
be capitalized in accordance with GAAP. Except as set forth on <U>Schedule 3.27</U>, neither the Company nor any Subsidiary is
in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been required
to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being
contested in good faith, except where the failure to so file or pay would not have a Material Adverse Effect. Except as otherwise disclosed
in <U>Schedule 3.28</U>, no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had, or
would have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state or other
governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which would have a Material
Adverse Effect</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law, or (iv) violated any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgment
Regarding Purchaser&rsquo;s Purchase of Securities</U>. The Company acknowledges and agrees that the Purchaser is acting solely in the
capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The
Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchaser&rsquo;s purchase of the Securities. The Company further represents to the Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgement
Regarding Purchaser&rsquo;s Trading Activity</U>. Notwithstanding anything in this Agreement or elsewhere to the contrary (except
for Sections 4.7 and 5.12 hereof), it is understood and acknowledged by the Company that: (i) the Purchaser has not been asked by
the Company to agree, nor has the Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any
specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation,
Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions,
may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties
in &ldquo;derivative&rdquo; transactions to which the Purchaser is a party, directly or indirectly, presently may have a
&ldquo;short&rdquo; position in the Common Stock, and (iv) the Purchaser shall not be deemed to have any affiliation with or control
over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands and
acknowledges that (y) the Purchaser may engage in hedging activities at various times during the period that the Securities are
outstanding, including, without limitation, during the periods that the value of the Shares deliverable with respect to Securities
are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&rsquo; equity
interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such
aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation
M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the
Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Private
Placement</U>. Assuming the accuracy of each Purchaser&rsquo;s representations and warranties set forth in Article IV, no registration
under the Securities Act is required for the offer and sale of the Notes or the Shares issuable upon conversion thereof by the Company
to the Purchasers as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
General Solicitation</U>. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company offered the Securities for sale only to the Purchaser and certain
other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506(b) under the Securities
Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company
participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities,
calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with
the Company in any capacity at the time of sale, nor any Person, including a placement agent, who will receive a commission or fees for
soliciting purchasers (each, an &ldquo;Issuer Covered Person&rdquo; and, together, &ldquo;Issuer Covered Persons&rdquo;) is subject to
any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;Disqualification
Event&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to
determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable,
with its disclosure obligations under Rule 506(e), and has furnished to the Purchaser a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Disqualification Events</U>. The Company will notify the Purchaser in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;OFAC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of
1956, as amended (the &ldquo;BHCA&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;Federal
Reserve&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Money
Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;Money Laundering Laws&rdquo;), and
no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any
Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE IV.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>REPRESENTATIONS AND WARRANTIES OF PURCHASERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchaser</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. The Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry
out its obligations hereunder and thereunder. The execution and delivery of this Agreement and performance by the Purchaser of the transactions
contemplated by this Agreement have been duly authorized by all necessary corporate, partnership, limited liability company or similar
action, as applicable, on the part of the Purchaser. Each Transaction Document to which it is a party has been duly executed by the Purchaser,
and when delivered by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of
the Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable
bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights
generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies
and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements.</U> The Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this
representation and warranty not limiting the Purchaser&rsquo;s right to sell the Securities in compliance with applicable federal
and state securities laws). The Purchaser is acquiring the Securities hereunder in the ordinary course of its business. The
Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not been registered under the Securities
Act or any applicable state securities law and is acquiring such Securities as principal for its own account and not with a view to
or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state
securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable
state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding
the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation
and warranty not limiting the Purchaser&rsquo;s right to sell such Securities in compliance with applicable federal and state
securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time the Purchaser was offered the Securities, it was, and as of the date hereof it is, an accredited investor within
the meaning of Rule 501 under the Securities Act. The Purchaser is not subject to any of the &ldquo;Bad Actor&rdquo; disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;Disqualification Event&rdquo;), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of the Purchaser</U>. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. The Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and has been afforded, subject to Regulation FD, (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment; provided, however, that the Purchaser has not requested nor been
provided by the Company with any non-public information regarding the Company, its financial condition, results of operations, business,
properties, management and prospects. The Purchaser acknowledges and agrees that neither the Company nor anyone else has provided the
Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, the Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with the Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that the Purchaser first received
a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the
transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case
of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of the Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed
by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other
Persons party to this Agreement or to the Purchaser&rsquo;s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, the Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Company acknowledges and agrees
that the representations contained in this Article 4 shall not modify, amend or affect the Purchaser&rsquo;s right to rely on the Company&rsquo;s
representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document
or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transaction
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE V.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal
of Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Shares, the Warrants and Warrant
Shares may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of the Shares, Warrants
or Warrant Shares other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser
or in connection with a pledge as contemplated in Section 5.1(b), the Company may require the transferor to provide to the Company an
opinion of counsel selected by the transferor and reasonably acceptable to the Company at the cost of the Company, the form and substance
of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such
transferred Shares, Warrants or Warrant Shares under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Purchaser agrees to the imprinting, so long as is required by this Section 5.1, of a legend on any of the Shares, the Warrants or Warrant
Shares in the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NEITHER THIS SECURITY NOR THE
SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY
BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT
IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Shares or Warrant Shares to a financial institution that is an &ldquo;accredited
investor&rdquo; as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and,
if required under the terms of such arrangement, such Purchaser may transfer pledged or secured Shares or Warrant Shares to the pledgees
or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of
the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge.
At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured
party of Shares and Warrant Shares may reasonably request in connection with a pledge or transfer of the Shares or Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates
evidencing the Shares and the Warrant Shares (or the Transfer Agent&rsquo;s records if held in book entry form) shall not contain any
legend (including the legend set forth in Section 5.1(a) hereof): (i) while a registration statement covering the resale of such securities
is effective under the Securities Act (the &ldquo;Effective Date&rdquo;), (ii) following any sale of such Shares or Warrant Shares pursuant
to Rule 144, (iii) if such Shares or Warrant Shares are eligible for sale under Rule 144, without the requirement for the Company to be
in compliance with the current public information required under Rule 144 as to such Shares or Warrant Shares and without volume or manner-of-sale
restrictions or (iv) if such legend is not required under applicable requirements of the Securities Act (including Sections 4(a)(1) and
4(a)(7) judicial interpretations and pronouncements issued by the staff of the SEC). The Company shall, if any of the provisions in clause
(i) &ndash;(iv) above are applicable, at its expense, cause its counsel to issue a legal opinion to the Transfer Agent promptly after
the Effective Date if required by the Transfer Agent to effect the removal of the legend hereunder. If all or any portion of a Note is
converted or a Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Shares or the
Warrant Shares, or if such Shares or Warrant Shares may be sold under Rule 144 and the Company is then in compliance with the current
public information required under Rule 144, or if the Shares or Warrant Shares may be sold under Rule 144 without the requirement for
the Company to be in compliance with the current public information required under Rule 144 as to such Shares or Warrant Shares and without
volume or manner-of-sale restrictions or if such legend is not otherwise required under applicable requirements of the Securities Act
(including Sections 4(a)(1) and 4(a)(7), judicial interpretations and pronouncements issued by the staff of the SEC) then such Shares
or Warrant Shares shall be issued or reissued free of all legends. The Company agrees that following the effective date of any registration
statement or at such time as such legend is no longer required under this Section 5.1(c), it will, no later than two Trading Days following
the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing restricted Shares or Warrant Shares, as
applicable, issued with a restrictive legend (such second Trading Day, the &ldquo;Legend Removal Date&rdquo;), deliver or cause to be
delivered to such Purchaser a certificate representing such Shares or Warrant Shares that is free from all restrictive and other legends.
The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer
set forth in this Section 5.1. Certificates for Shares or Warrant Shares subject to legend removal hereunder shall be transmitted by the
Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with the Depository Trust Company system
as directed by such Purchaser. The Company shall be responsible for any delays caused by its Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to such Purchaser&rsquo;s other available remedies, (i) the Company shall pay to a Purchaser, in cash, as partial
liquidated damages and not as a penalty, for each $1,000 of the principal amount of the Notes being converted or the value of the
Warrant Shares for which a Warrant is being exercised (based on the Warrant Exercise Price), $20 per Trading Day for each Trading
Day after the Legend Removal Date (increasing to $20 per Trading Day after the fifth Trading Day) until such certificate is
delivered without a legend. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Company&rsquo;s
failure to deliver certificates representing any Securities as required by the Transaction Documents, and such Purchaser shall have
the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief, and (ii) if after the Legend Removal Date such Purchaser purchases (in an open market transaction or
otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of
shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of
Common Stock that such Purchaser anticipated receiving from the Company without any restrictive legend, then, the Company shall pay
to such Purchaser, in cash, an amount equal to the excess of such Purchaser&rsquo;s total purchase price (including brokerage
commissions and other out-of- pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions
and other out-of-pocket expenses, if any) (the &ldquo;Buy-In Price&rdquo;) over the product of (A) such number of Shares or Warrant
Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied by (B) the highest closing
sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such Purchaser to the
Company of the applicable Shares or Warrant Shares (as the case may be) and ending on the date of such delivery and payment under
this Section 5.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.75in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event a Purchaser shall request delivery of unlegended shares as described in this Section 5.1 and the Company is required to deliver
such unlegended shares, (i) it shall pay all fees and expenses associated with or required by the legend removal and/or transfer including
but not limited to legal fees, Transfer Agent fees and overnight delivery charges and taxes, if any, imposed by any applicable government
upon the issuance of Common Stock; and (ii) the Company may not refuse to deliver unlegended shares based on any claim that such Purchaser
or anyone associated or affiliated with such Purchaser has not complied with Purchaser&rsquo;s obligations under the Transaction Documents,
or for any other reason, unless, an injunction or temporary restraining order from a court, on notice, restraining and or enjoining delivery
of such unlegended shares shall have been sought and obtained by the Company and the Company has posted a surety bond for the benefit
of such Purchaser in the amount of the greater of (i) 150% of the amount of the aggregate purchase price of the Shares (based on amount
of principal and/or interest of the Note which was converted) and Warrant Shares (based on exercise price in effect upon exercise) which
is subject to the injunction or temporary restraining order, or (ii) the VWAP of the Common Stock on the Trading Day before the issue
date of the injunction multiplied by the number of unlegended shares to be subject to the injunction, which bond shall remain in effect
until the completion of the litigation of the dispute and the proceeds of which shall be payable to such Purchaser to the extent Purchaser
obtains judgment in Purchaser&rsquo;s favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnishing
of Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
the earliest of the time that (i) no Purchaser owns Shares and Warrant Shares or (ii) the Warrants have expired, the Company covenants
to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed
by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time during the period commencing from the six month anniversary of the date hereof and ending at such time on the earlier to
occur that the Warrants are not outstanding, terminated or that all of the Warrant Shares (assuming cashless exercise) may be sold
without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation
pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule
144(c) for a period of more than 30 consecutive days or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an
issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) for a period of more than 30
consecutive days (a &ldquo;Public Information Failure&rdquo;) then, in addition to such Purchaser&rsquo;s other available remedies,
the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or
reduction of its ability to sell the Shares and/or Warrant Shares, an amount in cash equal to two percent of the aggregate Note
Conversion Price of such Purchaser&rsquo;s Note(s) and/or Warrant Exercise Price of such Purchaser&rsquo;s Warrants on the day of a
Public Information Failure and on every 30<FONT STYLE="font-size: 10pt">th </FONT>day (pro-rated for periods totaling less than
thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such
public information is no longer required for the Purchasers to transfer the Shares and/or Warrant Shares pursuant to Rule 144.
Public Information Failure Payments shall be paid on the earlier of (i)&nbsp;the last day of the calendar month during which such
Public Information Failure Payments are incurred and (ii) the second Trading Day after the event or failure giving rise to the
Public Information Failure payments is cured. In the event the Company fails to make Public Information Failure payments in a timely
manner, such Public Information Failure payments shall bear interest at the rate of one and one-half percent per month (prorated for
partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public
Information Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2(a)(1) of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and
regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless
stockholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the SEC or any regulatory agency or Trading Market, without the prior written consent of the Purchaser, except (a)
as required by federal securities law in connection with the filing of final Transaction Documents with the SEC and (b) to the extent
such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchaser with prior notice
of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that
any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted
by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of
receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. When the Company&rsquo;s Common Stock is quoted or listed on a Trading Market, to the extent that any notice
provided pursuant to any Transaction Document or any other communications made by the Company, or information provided, to the
Purchaser constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall
simultaneously file such notice or other material information with the SEC pursuant to a Current Report on Form 8-K. The Company
understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of
the Company. In addition to any other remedies provided by this Agreement or other Transaction Documents, if the Company knowingly
provides any material, non- public information to the Purchasers without their prior written consent, and it fails to immediately
(no later than that Trading Day) file a Form 8-K, once it is required to do so, disclosing this material, non-public information, it
shall pay the Purchasers as partial liquidated damages and not as a penalty a sum equal to $1,000 per day for each $100,000 of each
Purchaser&rsquo;s Subscription Amount beginning with the day the information is disclosed to the Purchaser and ending and including
the day the Form 8-K disclosing this information is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes, and shall
not use such proceeds: (a) for the satisfaction of any Indebtedness as defined in the Note, (b) for the redemption of any Common Stock
or Common Stock Equivalents, (c) in violation of FCPA or OFAC regulations, or (d) to lend money, give credit, or make advances to any
officers, directors, employees or affiliates of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchaser</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Subject to the provisions of this
Section 5.8, the Company will indemnify and hold each Purchaser and its directors, officers, stockholders, members, partners, employees
and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title), each Person who controls the Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of
the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other Persons with a functionally
equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each,
a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs
and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and costs of investigation
(including local counsel, if retained) that any such Purchaser Party may suffer or incur as a result of or relating to (a) any breach
of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents,
(b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder
of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction
Documents (unless such action is solely based upon a breach of such Purchaser Party&rsquo;s representations, warranties or covenants under
the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations
by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes fraud, gross negligence,
willful misconduct or malfeasance) or (c) any untrue or alleged untrue statement of a material fact contained in any registration statement,
any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of
or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein
(in the case of any prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading. If any
action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser
Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of
its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in
any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser
Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company
has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable
opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party,
in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such separate counsel (in addition
to local counsel, if retained). The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a
Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not be unreasonably withheld or delayed; or (z)
to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&rsquo;s breach of
any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction
Documents. The Purchaser Parties shall have the right to settle any action against any of them by the payment of money provided that they
cannot agree to any equitable relief and the Company, its officers, directors and Affiliates receive unconditional releases in customary
form. The indemnification required by this Section 5.8 shall be made by periodic payments of the amount thereof during the investigation
or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause
of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant
to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement
Without Consent if Failure to Reimburse</U>. If an indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any
settlement of the nature contemplated by Section 5.8 effected without its written consent if (1) such settlement is entered into
more than 45 days after receipt by such indemnifying party of the aforesaid request, (2) such indemnifying party shall have received
notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (3) such indemnifying party
shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company agrees, if the Company applies to have the Common Stock traded on any Trading Market, it will then include
in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted
on such other Trading Market as promptly as possible. The Company will then take all action necessary to continue the listing and trading
of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer
through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of
fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Senior
Debt</U>. The Company shall not issue any new indebtedness which is senior in rank to the Notes while the Notes are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. The Purchaser covenants that neither it nor any Affiliate acting on its behalf or pursuant to any
understanding with it will execute any purchases or sales, including Short Sales of any of the Company&rsquo;s securities during the
period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are
first publicly announced pursuant to the initial press release. Each Purchaser covenants that until such time as the transactions contemplated
by this Agreement are publicly disclosed by the Company pursuant to the initial press release, the Purchaser will maintain the confidentiality
of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing
and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser
makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release,
(ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with
applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company or its Subsidiaries after the issuance of the initial press release. Notwithstanding the foregoing, in
the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the
Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of the Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of
assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion
Procedures</U>. The forms of Conversion Notice included in the Notes set forth the totality of the procedures required of the Purchaser
to exercise the Notes. No additional legal opinion, other information or instructions shall be required of the Purchaser to convert their
Note. Without limiting the preceding sentences, no ink-original Conversion Notice shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Conversion Notice form be required to convert the Notes. The Company shall honor
conversions of the Notes and shall deliver Shares in accordance with the terms, conditions and time periods set forth in the Transaction
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DTC
Program</U>. For so long as any of the Notes are outstanding, the Company will employ as the Transfer Agent for the Common Stock and
Shares a participant in the Depository Trust Company Automated Securities Transfer Program and cause the Common Stock to be transferable
pursuant to such program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance
of Property</U>. The Company shall keep all of its property necessary for the operations of its business, which is necessary or useful
to the conduct of its business, in good working order and condition, ordinary wear and tear excepted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Preservation
of Corporate Existence</U>. The Company shall preserve and maintain its corporate existence, rights, privileges and franchises in the
jurisdiction of its incorporation, and qualify and remain qualified, as a foreign corporation in each jurisdiction in which such qualification
is necessary in view of its business or operations and where the failure to qualify or remain qualified might reasonably have a Material
Adverse Effect upon the financial condition, business or operations of the Company taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Registration of Securities on Form S-1</U>. Other than the registration rights provided hereunder, for the initial six months the Notes
are outstanding, the Company will not file any registration statements on Form S-1. For the avoidance of doubt, the foregoing shall not
prevent the Company from filing a Registration Statement on Form S-8 with respect to equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Variable
Rate Transactions</U>. While any of the Notes are outstanding, the Company shall be prohibited from entering a Variable Rate Transaction
without the prior consent of the holders of more than 50% in principal amount of the then outstanding Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights and Lock-Up Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect
to the Shares and Warrant Shares, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
the next Registration Statement on Form S-1 filed by the Company, include the Registrable Securities in such Registration Statement and
use its best efforts to cause the Registration Statement to become effective and remain effective as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepare
and file with the SEC such amendments, including post-effective amendments, to the Registration Statement as may be necessary to keep
the Registration Statement continuously effective as to the applicable Registrable Securities until such time as all of the Registerable
Securities have been sold by the Holder or he is eligible to otherwise remove the restrictive legend and effect a sale other than through
the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of, (i) any order suspending the effectiveness of the
Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities
for sale in any U.S. jurisdiction, at the earliest practicable moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furnish
to the Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto, including financial
statements and schedules, all documents incorporated or deemed to be incorporated therein by reference, and all exhibits to the extent
requested by the Holder (including those previously furnished or incorporated by reference) promptly after the filing of such documents
with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Purchaser agrees that, without the prior written consent of the Company, the Purchaser shall not, during the period ending 90 days after
the date of the prospectus filed with the SEC in connection with the Registration Statement on Form S-1 described in Section 5.19(a):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;offer,
pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Registrable
Securities or (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership
of the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">ARTICLE IV. MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
This Agreement may be terminated by the Purchaser by written notice to the other parties, if the Closing has not been consummated on
or before June 30, 2022; provided, however, that no such termination will affect the right of any party to sue for any breach by any
other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth below and in the Transaction Documents to the contrary, each party shall pay the fees
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any
exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities
to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered by email
attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. ( Eastern Standard or Daylight
Savings Time, as applicable) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication
is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second Trading Day following the date of transmission, if
sent by U.S. nationally recognized overnight delivery service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall, if the Company&rsquo;s Common Stock is quoted or listed on a Trading Market, simultaneously
file such notice with the SEC pursuant to a Current Report on Form 8-K, or which failure to do so will subject the Company to the liquidated
damages provided for in Article 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. Except as provided in the last sentence of this Section 6.5, no provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and a majority in
interest of the outstanding balance of the Note or, in the case of a waiver, by the party against whom enforcement of any such
waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair
the exercise of any such right. Any amendment effected in accordance with accordance with this Section 6.5 shall be binding upon the
Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser.
Each Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any
Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions
of the Transaction Documents that apply to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
Section 6.7 and this Section 6.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law; Exclusive Jurisdiction; Attorneys&rsquo; Fees</U>. All questions concerning the construction, validity, enforcement and interpretation
of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New
York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against
a party hereto or its respective affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the New York County, New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the New York County, New York for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company elsewhere in this Agreement, the prevailing party in such Action or Proceeding
shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a &ldquo;.pdf' format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf' signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
and Withdrawal Righ</U>t. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then that Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an conversion
of a Note, the Purchaser shall be required to return any Shares subject to any such rescinded Conversion Notice concurrently with the
restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to the Purchaser&rsquo;s Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction without requiring the posting of any bond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies.
</U>In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each Purchaser
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The
Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not
because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained
in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company
and the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have
been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver
of jury trial</U>. In any action, suit, or proceeding in any jurisdiction brought by any party against any other party, the parties each
knowingly and intentionally, to the greatest extent permitted by applicable law, hereby absolutely, unconditionally, irrevocably and
expressly waive forever trial by jury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Circumvention</U>.
The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation, including any
Certificates of Designation, or Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of
arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Agreement, and will at all times in good faith carry out all of the provision of this
Agreement and take all action as may be required to protect the rights of all holders of the Securities. Without limiting the
generality of the foregoing or any other provision of this Agreement or the other Transaction Documents, the Company (a) shall not
increase the par value of any Shares issuable upon conversion of the Notes above the Note Conversion Price then in effect and (b)
shall take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
nonassessable Shares upon the conversion of the Notes. Notwithstanding anything herein to the contrary, if after 180 days from the
original issuance date, the Purchasers are not permitted to convert the Note, in full, for any reason, subject to the
Purchaser&rsquo;s compliance with Rule 144 the Company shall use its best efforts to promptly remedy such failure, including,
without limitation, obtaining such consent or approvals as necessary to permit such conversion or exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Signature Pages Follow)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties here to have caused
this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60 Degree Pharmaceuticals, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for Notice</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0pt; width: 3%">&nbsp;</TD>
    <TD STYLE="background-color: Black; border-bottom: black 1pt solid; padding-left: 0pt; width: 40%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0pt; width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Geoffrey Dow</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">SIGNATURE
PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">5/24/22, 5:12 AM</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Mail </B>- Geoff Dow - Outlook</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; width: 100%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="background-color: Black; text-align: center; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 30; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>8
<FILENAME>cm270_ex10-5.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 10.5</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES FOR
WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Warrant Shares: &lt;WARRANT SHARES&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Initial Exercise Date: May 19, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;Warrant&rdquo;) certifies that, for value received, Geoffrey Dow., or its assigns (the &ldquo;Holder&rdquo;) is entitled,
upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof
(the &ldquo;Initial Exercise Date&rdquo;) and on or prior to the close of business on the fifth year anniversary of the Initial Exercise
Date (the &ldquo;Termination Date&rdquo;) but not thereafter, to subscribe for and purchase from 60 Degrees Pharmaceuticals, LLC, a limited
liability company (the &ldquo;Company&rdquo;), up to &lt;WARRANT SHARES&gt; shares of Common Stock (subject to adjustment hereunder, the
&ldquo;Warrant Shares&rdquo;). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined
in Section 2(b). This Warrant issued pursuant to a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) entered into as
of the Initial Exercise Date between the Company and the initial Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;), dated May 19, 2022 among the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a) Exercise of the purchase rights
represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before
the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in writing
to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed copy of the Notice of
Exercise Form annexed hereto. Within two Trading Days following the date of exercise as aforesaid, the Holder shall deliver the aggregate
Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United
States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise.
Notwithstanding anything herein to the contrary (although the Holder may surrender the Warrant to, and receive a replacement Warrant from,
the Company), the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within two Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial
exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the
effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such
purchases. The Company shall deliver any objection to any Notice of Exercise Form within one Trading Day of delivery of such notice. The
Holder by acceptance of this Warrant or any transferee, acknowledges and agrees that, by reason of the provisions of this Section 2(a),
following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) <U>Exercise Price</U>. The
initial exercise price per share of the Common Stock under this Warrant shall be equal to 110% of the IPO (as defined in the Purchase
Agreement) price or, if the Company fails to complete the IPO before May 31, 2023, 90% of the IPO price , subject to adjustment under
Section 3 (the &ldquo;Exercise Price&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c) <U>Cashless Exercise</U>. Other
than as provided for in Section 2(f), if at any time after the six month anniversary of the Initial Exercise Date, there is no effective
Registration Statement covering the resale of the Warrant Shares by the Holder (or the prospectus does not meet the requirements of Section
10 of the Securities Act), then this Warrant may also be exercised at the Holder&rsquo;s election, in whole or in part and in lieu of
making the cash payment otherwise contemplated to be made to the Company upon such exercise, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the number obtained by dividing [(A
- B) times (C)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="white-space: nowrap; width: 0.4in">(A) =</TD><TD STYLE="text-align: justify">the greater of (i) the arithmetic average of the VWAPs for the five consecutive Trading Days ending on
the date immediately preceding the date on which the Holder elects to exercise this Warrant by means of a &ldquo;cashless exercise,&rdquo;
as set forth in the applicable Notice of Exercise or (ii) the VWAP for the Trading Day immediately prior to the date on which the Holder
makes such &ldquo;cashless exercise&rdquo; election;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 90pt; text-indent: -36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder, at the time of such exercise; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 90pt; text-indent: -36pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.4in">(C) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the
terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&ldquo;VWAP&rdquo; means, for any
date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading
Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market
on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)) (or a similar organization or agency succeeding to its functions of reporting prices), (b) if
no volume weighted average price of the Common Stock is reported for the Trading Market, the most recent reported bid price per share
of the Common Stock, or (c) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">If Warrant Shares are issued in
such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant
Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrants being exercised may be
tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Notwithstanding anything herein
to the contrary, if on the Termination Date (unless the Holder notifies the Company otherwise) if there is no effective Registration Statement
covering the resale of the Warrant Shares by the Holder, then this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">(d) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72.05pt">(i) <U>Delivery of Certificates
Upon Exercise</U>. Certificates for the shares of Common Stock purchased hereunder shall be transmitted to the Holder by the Transfer
Agent by crediting the account of the Holder&rsquo;s prime broker with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&ldquo;DWAC&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being
exercised via cashless exercise and Rule 144 is available, or otherwise by physical delivery to the address specified by the Holder in
the Notice of Exercise by the date that is two Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise
and (B) payment of the aggregate Exercise Price as set forth above (unless by cashless exercise, if permitted) (such date, the &ldquo;Warrant
Share Delivery Date&rdquo;). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to be
named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been exercised,
with payment to the Company of the Exercise Price (or by cashless exercise, if permitted). The Company understands that a delay in the
delivery of the Warrant Shares after the Warrant Share Delivery Date could result in economic loss to the Holder. As compensation to the
Holder for such loss, the Company agrees to pay (as liquidated damages and not as a penalty) to the Holder for late issuance of Warrant
Shares upon exercise of this Warrant the proportionate amount of $10 per Trading Day (increasing to $20 per Trading Day after the fifth
Trading Day) after the Warrant Share Delivery Date for each $1,000 of the value of the Warrant Shares for which this Warrant is exercised
(based on the Exercise Price) which are not timely delivered. In no event shall liquidated damages for any one transaction exceed $1,000
for the first 10 Trading Days. Furthermore, in addition to any other remedies which may be available to the Holder, in the event that
the Company fails for any reason to effect delivery of the Warrant Shares by the Warrant Share Delivery Date, the Holder may revoke all
or part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon the Company and the Holder shall
each be restored to their respective positions immediately prior to the exercise of the relevant portion of this Warrant, except that
the liquidated damages described above shall be payable through the date notice of revocation or rescission is given to the Company or
the date the Warrant Shares are delivered to the Holder, whichever date is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.95pt">(ii) <U>Delivery of New Warrants
Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender
of this Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical to this Warrant. Unless the Warrant has been fully exercised, the Holders shall not be required to surrender
this Warrant as a condition of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iii) <U>Rescission Rights</U>.
If the Company fails to deliver the Warrant Shares or cause the Transfer Agent to transmit to the Holder a certificate or the certificates
representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right, at
any time prior to issuance of such Warrant Shares, to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iv) <U>Compensation for
Buy-In on Failure to Timely Deliver Certificates Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to deliver the Warrant Shares, or cause the Transfer Agent to transmit to the Holder the certificate or certificates
representing the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the
Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm
otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the
Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall pay in cash to the Holder
the amount as provided under Section 4.1(e) of the Purchase Agreement. Nothing herein shall limit a Holder&rsquo;s right to pursue
any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver certificates representing shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(v) <U>No Fractional Shares or
Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction
of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay
a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to
the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(vi) <U>Charges, Taxes and Expenses</U>.
Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such certificate including any charges of any clearing firm, all of which taxes and expenses shall
be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by
the Holder. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise. The Company shall
(A) pay the reasonable legal fees of the Holder&rsquo;s choice (in an amount not to exceed $500 per opinion, and not more often than once
per week) in connection with the exercise of the Warrants, (B) cause its attorneys to promptly provide any reliance opinion to the Transfer
Agent, and (C) pay the Holder the sums required under Section 2(d)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(vii) <U>Closing of Books</U>.
The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant
to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(e) <U>Holder&rsquo;s Exercise
Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion
of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth
on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting as a group
together with the Holder or any of the Holder&rsquo;s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation
(as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and
its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination
is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act
and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned
by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the
Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable,
in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy
of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance with
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;Beneficial
Ownership Limitation&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days&rsquo; prior notice
to the Company, may increase the Beneficial Ownership Limitation provisions of this Section 2(e) solely with respect to the Holder&rsquo;s
Warrant, provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(e) shall continue to apply. Any such increase will not be effective until the 61st day after such notice is delivered
to the Company. The Holder may also decrease the Beneficial Ownership Limitation provisions of this Section 2(e) solely with respect to
the Holder&rsquo;s Warrant at any time, which decrease shall be effectively immediately upon delivery of notice to the Company. The provisions
of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e)
to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a) <U>Stock Dividends and Splits</U>.
If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions
on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance
of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant or pursuant to any of the other
Transaction Documents), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by
way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of
shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) <U>Subsequent Equity
Sales</U>. If and whenever on or after the Initial Exercise Date, the Company issues or sells, or in accordance with this Section
3 is deemed to have issued or sold, any shares of Common Stock (including the issuance or sale of shares of Common Stock owned
or held by or for the account of the Company, issued or sold or deemed to have been issued or sold) for a consideration per share
(the &ldquo;<U>Base Share Price</U>&rdquo;) less than a price equal to the Exercise Price in effect immediately prior to such
issuance or sale or deemed issuance or sale (such Exercise Price then in effect is referred to herein as the &ldquo;<U>Applicable
Price</U>&rdquo;) (the foregoing a &ldquo;<U>Dilutive Issuance</U>&rdquo;), then immediately after such Dilutive Issuance, the
Exercise Price then in effect shall be reduced to an amount equal to the Base Share Price. For all purposes of the foregoing (including,
without limitation, determining the adjusted Exercise Price and the Base Share Price under this Section 3(b)), the following shall
be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(i) <U>Issuance of Options</U>.
If the Company in any manner grants or sells any Options and the lowest price per share for which one share of Common Stock is at any
time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities issuable upon
exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock
shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale of such Option for
such price per share. For purposes of this Section 3(b)(i), the &ldquo;lowest price per share for which one share of Common Stock is issuable
upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities issuable upon exercise of
any such Option or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the sum of the lowest amounts
of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock upon the granting or sale
of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise
of such Option or otherwise pursuant to the terms thereof and (y) the lowest exercise price set forth in such Option for which one share
of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities
issuable upon exercise of any such Option or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable
to the holder of such Option (or any other Person) upon the granting or sale of such Option, upon exercise of such Option and upon conversion,
exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise pursuant to the terms thereof plus
the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option (or any other Person).
Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common
Stock or of such Convertible Securities upon the exercise of such Options or otherwise pursuant to the terms of or upon the actual issuance
of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(ii) <U>Issuance of Convertible
Securities</U>. If the Company in any manner issues or sells any Convertible Securities and the lowest price per share for which one share
of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof is
less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold by
the Company at the time of the issuance or sale of such Convertible Securities for such price per share. For the purposes of this Section
3(b)(ii), the &ldquo;lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or exchange
thereof or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the sum of the lowest amounts of consideration
(if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale of the Convertible
Security and upon conversion, exercise or exchange of such Convertible Security or otherwise pursuant to the terms thereof and (y) the
lowest conversion price set forth in such Convertible Security for which one share of Common Stock is issuable upon conversion, exercise
or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder of such
Convertible Security (or any other Person) upon the issuance or sale of such Convertible Security plus the value of any other consideration
received or receivable by, or benefit conferred on, the holder of such Convertible Security (or any other Person). Except as contemplated
below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock upon conversion,
exercise or exchange of such Convertible Securities or otherwise pursuant to the terms thereof, and if any such issuance or sale of such
Convertible Securities is made upon exercise of any Options for which adjustment of this Warrant has been or is to be made pursuant to
other provisions of this Section 3(b), except as contemplated below, no further adjustment of the Exercise Price shall be made by reason
of such issuance or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72.05pt">(iii) <U>Change in Option Price
or Rate of Conversion</U>. &ldquo;Convertible Securities&rdquo; means any stock or other security (other than Options) that is at any
time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise entitles
the holder thereof to acquire, any shares of Common Stock. If the purchase or exercise price provided for in any Options, the additional
consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate at which any
Convertible Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases at any time
(other than proportional changes in conversion or exercise prices, as applicable, in connection with an event referred to in Section 3(a)),
the Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which would have been in
effect at such time had such Options or Convertible Securities provided for such increased or decreased purchase price, additional consideration
or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold. For purposes of this Section
3(b)(iii), if the terms of any Option or Convertible Security that was outstanding as of the Closing Date are increased or decreased in
the manner described in the immediately preceding sentence, then such Option or Convertible Security and the shares of Common Stock deemed
issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease.
No adjustment pursuant to this Section 3(b) shall be made if such adjustment would result in an increase of the Exercise Price then in
effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 71.95pt">(iv) <U>Calculation
of Consideration Received</U>. If any Option is issued in connection with the issuance or sale of any other securities of the
Company together comprising one integrated transaction in which no specific consideration is allocated to such Option by the parties
thereto, the Options will be deemed to have been issued for a consideration of par value of the Company&rsquo;s Common Stock.
If any shares of Common Stock, Options or Convertible Securities are issued or sold or deemed to have been issued or sold for
cash, the consideration received therefor will be deemed to be the net amount of consideration received by the Company therefor.
If any shares of Common Stock, Options or Convertible Securities are issued or sold for a consideration other than cash, the amount
of such consideration received by the Company will be the fair value of such consideration, except where such consideration consists
of publicly traded securities, in which case the amount of consideration received by the Company for such securities will be the
arithmetic average of the VWAPs of such security for each of the five Trading Days immediately preceding the date of receipt.
If any shares of Common Stock, Options or Convertible Securities are issued to the owners of the non-surviving entity in connection
with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be the fair
value of such portion of the net assets and business of the non-surviving entity as is attributable to such shares of Common Stock,
Options or Convertible Securities. The fair value of any consideration other than cash or publicly traded securities will be determined
jointly by the Company and the Holder. If such parties are unable to reach agreement within 10 days after the occurrence of an
event requiring valuation (the &ldquo;<U>Valuation Event</U>&rdquo;), the fair value of such consideration will be determined
within five Trading Days after the 10<FONT STYLE="font-size: 10pt">th </FONT>day following such Valuation Event by an independent,
reputable appraiser jointly selected by the Company and the Holder. The determination of such appraiser shall be final and binding
upon all parties absent manifest error. If such appraiser&rsquo;s valuation differs by less than 5% from the Company&rsquo;s proposed
valuation, the fees and expenses of such appraiser shall be borne by the Holder, and if such appraiser&rsquo;s valuation differs
by more than 5% from the Company&rsquo;s proposed valuation, the fees and expenses of such appraiser shall be borne by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(v) <U>Record Date</U>. If the
Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other distribution
payable in shares of Common Stock, Options or in Convertible Securities or (B) to subscribe for or purchase shares of Common Stock, Options
or Convertible Securities, then such record date will be deemed to be the date of the issuance or sale of the shares of Common Stock deemed
to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of the granting
of such right of subscription or purchase (as the case may be).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 72pt">(vi) Notwithstanding the foregoing, this Section 3(b) shall not
apply to any Exempt Issuances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c) <U>Full Ratchet Increase in
Warrant Shares</U>. Until the Notes are no longer outstanding, whenever the Exercise Price is adjusted under Section 3(b), the number
of Warrant Shares shall be increased on a full ratchet basis to the number of shares of Common Stock determined by multiplying the Exercise
Price then in effect immediately prior to such adjustment by the number of Warrant Shares issuable upon exercise of this Warrant immediately
prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. By way of example, if
E is the total number of Warrant Shares in effect immediately prior to such Dilutive Issuance, F is the Exercise Price in effect immediately
prior to such Dilutive Issuance, and G is the Dilutive Issuance Price, the adjustment to the number of Warrant Shares can be expressed
in the following formula: Total number of Warrant Shares after such Dilutive Issuance = the number obtained from dividing [E x F] by G.
Notwithstanding the foregoing, if the Exercise Price is being adjusted as a result of a sale of securities, this Section 3(c) shall NOT
apply if the Holder is offered the right to participate (in an amount not to exceed $50,000 unless agreed to by the Holder and the Company)
and does not participate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(d) <U>Subsequent Rights Offerings</U>.
In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents
or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock
(the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights,
the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant,
issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s right to participate in
any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase
Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). Notwithstanding the foregoing, no Purchase
Rights will be made under this Section 3(d) in respect of an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(e) <U>Pro Rata Distributions</U>.
If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock (and not to the Holder)
evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security
other than the Common Stock (which shall be subject to Section 3(d)), then in each such case the Exercise Price shall be adjusted by multiplying
the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution
by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which the numerator
shall be such VWAP on such record date less the then per share fair market value at such record date of the portion of such assets or
evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined by the Board of Directors
in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the portion of assets or evidences
of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment shall be made whenever
any such distribution is made and shall become effective immediately after the record date mentioned above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">(f) <U>Fundamental Transaction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(i) If, at any time while this
Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions engages in any Fundamental Transaction,
as defined in the Purchase Agreement, then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive,
for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction
(without regard to any limitation on the exercise of this Warrant), at the option of the Holder the number of shares of Common Stock of
the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;Alternate
Consideration&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which
this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall not effect a Fundamental Transaction
unless it gives the Holder at least 10 Trading Days prior notice together with sufficient details so the Holder can make an informed decision
as to whether it elects to accept the Alternative Consideration. If a public announcement of the Fundamental Transaction has not been
made, the notice to the Holder may not be given until the Company files a Form 8-K or other report disclosing the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(ii) Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, provided that the Warrant Shares are not registered under an effective registration
statement, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently
with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant from the Holder by paying to the
Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction or (ii) the positive difference between the cash per share paid in such Fundamental Transaction minus
the then in effect Exercise Price. &ldquo;Black Scholes Value&rdquo; means the value of the unexercised portion of this Warrant based
on the Black and Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. determined as of the day of
consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction
and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg L.P. as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the
underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value
of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to the time
between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(iii) If Section 3(f)(i) and (ii)
are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction
Documents in accordance with the provisions of this Section 3(f)(iii) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at
the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant prior to such Fundamental Transaction (without regard to any limitation on the exercise of this Warrant), and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value
of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares
of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence
of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of
such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(g) <U>Calculations</U>. All calculations
under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section
3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares
of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt">(h) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(i) <U>Adjustment to Exercise Price</U>.
Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly email to the Holder a
notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting
forth a brief statement of the facts requiring such adjustment. The Holder may supply an email address to the Company and change such
address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 72pt">(ii) <U>Notice to Allow Exercise
by the Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the
Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the
granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or
of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common
Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of
the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, or (E) the Company shall authorize
the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall
deliver to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 5 calendar days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders
of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)
the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close,
and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to email such notice or any defect therein or in the emailing thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public
information regarding the Company or any of the Subsidiaries (as determined in good faith by the Company), the Company shall simultaneously
file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant
during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a) <U>Transferability</U>. Subject
to compliance with any applicable securities laws and the provisions of the Purchase Agreement, this Warrant and all rights hereunder
(including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the
principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form
attached hereto duly executed by the Holder or its agent or attorney. Upon such surrender, the Company shall execute and deliver a new
Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new Holder for the
purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) <U>New Warrants</U>. This Warrant
may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written
notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject
to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and
deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All
Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant
except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt">(c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;Warrant Register&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(a) <U>No Rights as Stockholder
Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company
prior to the exercise hereof other than as explicitly set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(b) <U>Loss, Theft, Destruction
or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft
or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or stock certificate,
if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in
lieu of such Warrant or stock certificate. In no event shall the Holder be required to deliver a bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(c) <U>Saturdays, Sundays, Holidays,
etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not
be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt">(d) <U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Except and to the extent as waived
or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its Articles of Incorporation
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights
of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not
increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in
par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and nonassessable Warrant Shares upon the exercise of this Warrant and <U>(iii) </U>use best efforts to obtain all such authorizations,
exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform
its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt">(e) <U>Jurisdiction</U>. All
questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with
the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.95pt">(f) <U>Restrictions</U>. The
Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered or if not exercised on a cashless
basis when Rule 144 (or any successor law or rule) is available, may have restrictions upon resale imposed by state and federal securities
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(g) <U>Non-waiver and Expenses</U>.
No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate as a waiver of such
right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant or the
Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(h) <U>Notices</U>. Any notice,
request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance
with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(i) <U>Limitation of Liability</U>.
No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of
any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(j) <U>Remedies</U>. The Holder,
in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance
of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by
reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for
specific performance that a remedy at law would be adequate or that there is no irreparable harm and not to require the posting of a bond
or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(k) <U>Successors and Assigns</U>.
Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and
be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(l) <U>Amendment</U>. This Warrant
may be modified or amended or the provisions hereof waived with the written consent of the Company and Holders of 75% of the outstanding
Warrants issued pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(m) <U>Severability</U>. Wherever
possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if
any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent
of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">(n) <U>Headings</U>. The headings
used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P>Warrant</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">IN WITNESS WHEREOF, the Company has caused this Warrant
to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">60 Degrees Pharmaceuticals, LLC</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 5%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 45%; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">&nbsp;</TD>
    <TD STYLE="text-underline-color: black">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black">/s/ Geoffrey Dow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">&nbsp;</TD>
    <TD STYLE="text-underline-color: black">Name:</TD>
    <TD STYLE="text-underline-color: black">Geoffrey Dow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">&nbsp;</TD>
    <TD STYLE="text-underline-color: black">Title:</TD>
    <TD STYLE="text-underline-color: black">Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">TO: <B>60 Degrees Pharmaceuticals, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(1) The undersigned hereby elects to purchase _______________
Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment
of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(2) Payment shall take the form of (check applicable
box):</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 100pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744; </FONT>in
lawful money of the United States; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 100pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744; </FONT>if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(3) Please issue a certificate or certificates representing
said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 55%; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(4) After giving effect to this Notice of Exercise,
the undersigned will not have exceeded the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Warrant Shares shall be delivered to the following DWAC Account Number
or by physical delivery of a certificate to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; width: 15%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; width: 30%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; width: 55%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">SIGNATURE OF HOLDER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-underline-color: black">Name of Investing Entity:</TD>
    <TD STYLE="width: 40%; text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><I>Signature of Authorized Signatory of Investing Entity</I>:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">Name of Authorized Signatory:</TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">Title of Authorized Signatory:</TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">Date:</TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; padding-left: 9pt; text-underline-color: black; text-align: justify">(To assign the foregoing warrant, execute </TD>
    <TD STYLE="width: 30%; text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">this form and supply required information. Do </TD>
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">not use this form to exercise the warrant.)</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">60 Degrees Pharmaceuticals, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">FOR VALUE RECEIVED,_______all of or ________
shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="width: 50%; text-underline-color: black">&nbsp;whose address is</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="width: 49%; text-underline-color: black">Dated:______________, ______&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="width: 20%; text-underline-color: black">Holder&rsquo;s Signature: &nbsp;</TD>
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="width: 25%; text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">&nbsp;</TD>
    <TD STYLE="text-underline-color: black">Holder&rsquo;s Address: &nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-underline-color: black">Signature Guaranteed: &nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 40%; text-underline-color: black">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed
by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>9
<FILENAME>cm270_ex10-6.htm
<DESCRIPTION>EXHIBIT 10.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: right"><B>Exhibit 10.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify"><B>NEITHER THIS SECURITY NOR THE SECURITIES
INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">Original Issue Date: May 19, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">$294,444 Principal and Face Value</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">$265,000 Purchase Price and Subscription
Amount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">$29,444 Original Issue Discount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ORIGINAL ISSUE DISCOUNT<BR>
CONVERTIBLE PROMISSORY NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE PROMISSORY NOTE
is duly authorized</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify">and validly issued at a 10% original
issue discount by 60 Degrees Pharmaceuticals, LLC, a Washington DC limited liability corporation (the &ldquo;Company&rdquo;) (the &ldquo;Note&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED,
the Company promises to pay to Geoffrey Dow, or its permitted assigns (the &ldquo;Holder&rdquo;), the principal sum of $294,444 on May
31, 2023 (the &ldquo;Maturity Date&rdquo;) or such earlier date as this Note is required or permitted to be repaid as provided hereunder,
and to pay interest to the Holder on the aggregate unconverted and then outstanding principal amount of this Note in accordance with the
provisions hereof. This Note is subject to the following additional provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify"><U>Section 1</U>. <U>Definitions</U>.
For the purposes hereof, (a) capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement
and (b) the following words and phrases shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&ldquo;Alternate Consideration&rdquo; shall have the meaning
set forth in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify; text-indent: 0.5in">&ldquo;Bankruptcy
Event&rdquo; means any of the following events: (a) the Company or any Subsidiary thereof commences a case or other proceeding under any
bankruptcy, reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law
of any jurisdiction relating to the Company or any Subsidiary thereof, (b) there is commenced against the Company or any Subsidiary thereof
any such case or proceeding that is not dismissed within 60 days after commencement, (c) the Company or any Subsidiary thereof is adjudicated
insolvent or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Company or any Subsidiary
thereof suffers any appointment of any custodian or the like for it or any substantial part of its property that is not discharged or
stayed within 60 calendar days after such appointment, (e) the Company or any Subsidiary thereof makes a general assignment for the benefit
of creditors, (f) the Company or any Subsidiary thereof calls a meeting of its creditors with a view to arranging a composition, adjustment
or restructuring of its debts or (g) the Company or any Subsidiary thereof, by any act or failure to act, expressly indicates its consent
to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting any of the
foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Base Conversion Price&rdquo; shall have the meaning
set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Beneficial Ownership Limitation&rdquo; shall have
the meaning set forth in Section 4(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&ldquo;Black Scholes
Value&rdquo; means the value of the outstanding principal amount of this Note, plus all accrued and unpaid interest hereon based on the
Black and Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Maturity Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the
HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus
the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Buy-In&rdquo; shall have the meaning set forth in
Section 4(d)(v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&ldquo;Change of
Control Transaction&rdquo; means the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an individual
or legal entity or &ldquo;group&rdquo; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether
through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of 50% of the voting securities
of the Company (other than by means of conversion, exercise or exchange of this Note or the Warrants issued together with this Note),
(b) the Company merges into or consolidates with any other Person, or any Person merges into or consolidates with the Company and, after
giving effect to such transaction, the shareholders of the Company immediately prior to such transaction own less than 50% of the aggregate
voting power of the Company or the successor entity of such transaction, (c) the Company sells or transfers all or substantially all of
its assets to another Person, (d) a replacement at one time or within a three year period of more than one-half of the members of the
Board of Directors which is not approved by a majority of those individuals who are members of the Board of Directors on the Original
Issue Date (or by those individuals who are serving as members of the Board of Directors on any date whose nomination to the Board of
Directors was approved by a majority of the members of the Board of Directors who are members on the date hereof), or (d) the execution
by the Company of an agreement to which the Company is a party or by which it is bound, providing for any of the events set forth in clauses
(a) through (d) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Conversion&rdquo; shall have the meaning ascribed
to such term in Section 4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Conversion Date&rdquo; shall have the meaning set forth in Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Conversion Price&rdquo;
shall have the meaning set forth in Section 4(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&ldquo;Conversion
Shares&rdquo; means, collectively, the shares of Common Stock issuable upon conversion of this Note in accordance with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Default Interest Rate&rdquo; shall have the meaning
set forth in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Dilutive Issuance&rdquo; shall have the meaning set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Dilutive Issuance Notice&rdquo; shall have the meaning
set forth in Section 5(b)(5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&ldquo;DWAC&rdquo;
means the Deposit or Withdrawal at Custodian system at The Depository Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Event of Default&rdquo; shall have the meaning set
forth in Section 7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify; text-indent: 35.95pt">&ldquo;Exchange
Act&rdquo; means the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Fundamental Transaction&rdquo; shall have the meaning
set forth in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;IPO&rdquo; shall have the meaning set forth in Section 4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Liens&rdquo; shall have the meaning set forth in
the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Note Register&rdquo; shall have the meaning set forth in Section 3(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Notice of Conversion&rdquo;
shall have the meaning set forth in Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&ldquo;Mandatory Default Amount&rdquo; shall have the meaning
set forth in Section 7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify; text-indent: 0.5in">&ldquo;Option Value&rdquo;
means the value of a Common Stock Equivalent based on the Black Scholes Option Pricing model obtained from the &ldquo;OV&rdquo; function
on Bloomberg determined as of (A) the Trading Day prior to the public announcement of the issuance of the applicable Common Stock Equivalent,
if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day immediately following the issuance of the
applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is not publicly announced, for pricing purposes and
reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of the applicable
Common Stock Equivalent as of the applicable date of determination, (ii) an expected volatility equal to the greater of 100% and the 100
day volatility obtained from the HVT function on Bloomberg as of (A) the Trading Day immediately following the public announcement of
the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day immediately
following the issuance of the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is not publicly announced,
(iii) the underlying price per share used in such calculation shall be the highest VWAP of the Common Stock during the period beginning
on the Trading Day prior to the execution of definitive documentation relating to the issuance of the applicable Common Stock Equivalent
and ending on (A) the Trading Day immediately following the public announcement of such issuance, if the issuance of such Common Stock
Equivalent is publicly announced or (B) the Trading Day immediately following the issuance of the applicable Common Stock Equivalent if
the issuance of such Common Stock Equivalent is not publicly announced, (iv) a zero cost of borrow and (v) a 360 day annualization factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify; text-indent: 0.5in">&ldquo;Original Issue
Date&rdquo; means the date of the first issuance of this Note, regardless of any transfers of this Note and regardless of the number of
instruments which may be issued to evidence this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify; text-indent: 0.5in">&ldquo;Permitted Indebtedness&rdquo;
means (a) the indebtedness evidenced by this Note, (b) senior secured non-convertible loans from traditional commercials banks with interest
per annum not to exceed 12%, (c) capital lease obligations and purchase money indebtedness incurred in connection with the acquisition
of machinery and equipment as long as such capital leases and indebtedness are approved in advance by the Holder and (d) the Indebtedness
set forth on Schedule 3.27 to the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify; text-indent: 0.5in">&ldquo;Permitted
Lien&rdquo; means the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental charges
or levies not yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good faith and by appropriate
proceedings for which adequate reserves (in the good faith judgment of the management of the Company) have been established in accordance
with GAAP, (b) Liens imposed by law which were incurred in the ordinary course of the Company&rsquo;s business, such as carriers&rsquo;,
warehousemen&rsquo;s and mechanics&rsquo; Liens, statutory landlords&rsquo; Liens, and other similar Liens arising in the ordinary course
of the Company&rsquo;s business, and which (x) do not individually or in the aggregate materially detract from the value of such property
or assets or materially impair the use thereof in the operation of the business of the Company and its consolidated Subsidiaries or (y)
are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing for the foreseeable future
the forfeiture or sale of the property or asset subject to such Lien, (c) Liens incurred in connection with Permitted Indebtedness under
clauses (a) through (d) thereunder, and Liens set forth on Schedule 3.1(aa) to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&ldquo;Purchase
Agreement&rdquo; means the Securities Purchase Agreement, dated as of May [*], 2022, among the Company and the original Holders, as amended,
modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Share Delivery Date&rdquo; shall have the meaning
set forth in Section 4(d)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Successor Entity&rdquo; shall have the meaning set forth in Section 5(e)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;Transaction Documents&rdquo; means the Note, the
Purchase Agreement and the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&ldquo;VWAP&rdquo; means, for any date, the price
determined by the first of the following clauses that applies: (a)&nbsp;if the Common Stock is then listed or quoted on a Trading
Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New
York City time) to 4:02 p.m. (New York City time)) (or a similar organization or agency succeeding to its functions of reporting
prices), (b) if no volume weighted average price of the Common Stock is reported for the Trading Market, the most recent bid price
per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of
which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify"><U>Section 2</U>. <U>Interest</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">Interest shall accrue to the Holder on
the aggregate unconverted and then outstanding principal amount of this Note at the rate of 6% per annum, calculated on the basis of a
360-day year and shall accrue daily commencing on the Original Issue Date until payment in full of the outstanding principal (or conversion
to the extent applicable), together with all accrued and unpaid interest, liquidated damages and other amounts which may become due hereunder,
has been made. During the existence of an Event of Default, interest shall accrue at the lesser of (i) the rate of 15% per annum, or (ii)
the maximum amount permitted by law (the lesser of clause (i) or (ii), the &ldquo;<U>Default Interest Rate</U>&rdquo;). Once an Event
of Default is cured, the interest rate shall return to 6%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify"><U>Section 3</U>. <U>Registration of
Transfers and Exchanges</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(a)&nbsp;&nbsp;<U>Different
Denominations</U>. This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as
requested by the Holder surrendering the same. No service charge or other fees will be payable for such registration of transfer or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(b)&nbsp;&nbsp;<U>Investor
Representations</U>. This Note has been issued subject to certain investment representations of the original Holder set forth in the
Purchase Agreement and may be transferred or exchanged only in compliance with the Purchase Agreement and applicable federal and
state securities laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">(c)&nbsp;&nbsp;&nbsp;<U>Reliance
on Note Register</U>. Prior to due presentment for transfer to the Company of this Note, the Company and any agent of the Company may
treat the Person in whose name this Note is duly registered on the Note Register as the owner hereof for the purpose of receiving payment
as herein provided and for all other purposes, whether or not this Note is overdue, and neither the Company nor any such agent shall be
affected by notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"><U>Section 4. Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;<U>Voluntary
Conversion</U>. After the Original Issue Date until this Note is no longer outstanding, this Note shall be convertible, in whole or in
part, at any time, and from time to time, into Conversion Shares at the option of the Holder. The Holder shall effect conversions by delivering
to the Company a Notice of Conversion, the form of which is attached hereto as <U>Annex A</U> (each, a &ldquo;Notice of Conversion&rdquo;),
specifying therein the principal amount of this Note to be converted and the date on which such conversion shall be effected (such date,
the &ldquo;Conversion Date&rdquo;). If no Conversion Date is specified in a Notice of Conversion, the Conversion Date shall be the date
that such Notice of Conversion is deemed delivered hereunder. No ink-original Notice of Conversion shall be required, nor shall any medallion
guarantee (or other type of guarantee or notarization) of any Notice of Conversion form be required. To effect conversions hereunder,
the Holder shall not be required to physically surrender this Note to the Company unless the entire principal amount of this Note, plus
all accrued and unpaid interest thereon, has been so converted. Conversions hereunder shall have the effect of lowering the outstanding
principal amount of this Note in an amount equal to the applicable conversion. The Holder and the Company shall maintain records showing
the principal amount(s) converted in each conversion, the date of each conversion, and the Conversion Price in effect at the time of each
conversion. The Company may deliver an objection to any Notice of Conversion within two Trading Days of delivery of such Notice of Conversion.
In the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative in the absence of manifest
error. <B>The Holder, and any assignee by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph,
following conversion of a portion of this Note, the unpaid and unconverted principal amount of this Note may be less than the amount stated
on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;<U>Mandatory
Conversion</U>. This Note shall convert into Conversion Shares upon the completion of an initial public offering by the Company that results
in a listing of the Company&rsquo;s Common Stock on a national securities exchange (the &ldquo;IPO&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;<U>Conversion
Price</U>. The &ldquo;Conversion Price&rdquo; shall be at the lesser of a 20% discount to the IPO price or a $27 million pre-money valuation.
All such Conversion Price determinations are to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification
or similar transaction that proportionately decreases or increases the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;<U>Mechanics of Conversion
or Prepayment</U>.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;<U>Conversion
Shares Issuable Upon Conversion of Principal Amount</U>. The number of Conversion Shares issuable upon a conversion hereunder shall be
determined by the quotient obtained by dividing (x) the outstanding principal amount of this Note to be converted by (y) the Conversion
Price in effect at the time of such conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;<U>Delivery of
Certificate Upon Conversion</U>. Not later than two Trading Days after each Conversion Date (the &ldquo;Share Delivery Date&rdquo;),
the Company shall deliver, or cause to be delivered, to the Holder any certificate or certificates required to be delivered by the
Company under this Section 4(d) which shall be free of restrictive legends and trading restrictions except as provided by the
Securities Act (other than those which may then be required by the Purchase Agreement) and such shares shall be delivered
electronically through the Depository Trust Company or another established clearing corporation performing similar functions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 71.95pt">(iii)&nbsp;&nbsp;&nbsp;<U>Failure
to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as directed
by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Company at any time
on or before its receipt of such Conversion Shares, to rescind such conversion, in which event the Company shall promptly return to the
Holder any original Note delivered to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;<U>Obligation
Absolute; Partial Liquidated Damages</U>. The Company&rsquo;s obligations to issue and deliver the Conversion Shares upon conversion of
this Note in accordance with the terms hereof, are absolute and unconditional, irrespective of any action or inaction by the Holder to
enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action
to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder
or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the
issuance of such Conversion Shares. In the event the Holder of this Note shall elect to convert any or all of the outstanding principal
amount hereof, the Company may not refuse conversion based on any claim that the Holder or anyone associated or affiliated with the Holder
has been engaged in any violation of law, agreement or for any other reason, unless an injunction from a court, on notice to Holder, restraining
and or enjoining conversion of all or part of this Note shall have been sought and obtained, and the Company posts a surety bond for the
benefit of the Holder in accordance with Section 5.1(d) of the Purchase Agreement. The exercise of any such rights shall not prohibit
the Holder from seeking to collect damages under this Note, the Purchase Agreement or under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available to the Holder,
if the Company fails for any reason to deliver to the Holder such Conversion Shares by the Share Delivery Date pursuant to Section 4(d)(ii),
and if after such Share Delivery Date the Holder is required by its brokerage firm to purchase (in an open market transaction or otherwise),
or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Conversion Shares which the Holder was entitled to receive upon the conversion relating to such Share Delivery Date (a &ldquo;Buy-In&rdquo;),
then the Company shall have the remedies provided for in accordance with Section 5.1(d) of the Purchase Agreement. Nothing herein or therein
shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver Conversion Shares
upon conversion of this Note as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 1in">(vi)&nbsp;&nbsp;&nbsp;<U>Fractional
Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of this Note. As to any fraction
of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Company shall at its election, either pay
a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion Price or round up
to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 1in">(vii)&nbsp;&nbsp;&nbsp;<U>Transfer
Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of this Note shall be made without charge to the Holder hereof
for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such certificates. The Company shall
pay all Transfer Agent fees required for same-day processing of any Notice of Conversion and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Conversion
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 6pt; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 71.95pt">(viii)&nbsp;&nbsp;&nbsp;<U>Attorneys&rsquo;
Fees etc</U>. The Company shall (A) pay the reasonable fees of the law firm of the Holder&rsquo;s choice (in an amount not to exceed $500
per opinion) in connection with the conversion of the Note, (B) cause its attorneys to promptly provide any reliance opinion to the Transfer
Agent, and (C) pay the Holder the sums required under Section 4(d)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Conversion Limitations</U>. The Company shall not effect any conversion of this Note, and a Holder shall not have the right to
convert any portion of this Note, to the extent that after giving effect to the conversion set forth on the applicable Notice of
Conversion, the Holder (together with the Holder&rsquo;s Affiliates, and any Persons acting as a group together with the Holder or
any of the Holder&rsquo;s Affiliates) would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).
For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
shall include the number of shares of Common Stock issuable upon conversion of this Note with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which are issuable upon (i) conversion of the remaining,
unconverted principal amount of this Note beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion
of the unexercised or unconverted portion of any other securities of the Company subject to a limitation on conversion or exercise
analogous to the limitation contained herein (including, without limitation, any other Notes or the Warrants) beneficially owned by
the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 4(e), beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. To the extent that the limitation contained in this Section 4(e) applies, the determination of whether this Note is
convertible (in relation to other securities owned by the Holder together with any Affiliates) and of which principal amount of this
Note is convertible shall be in the sole discretion of the Holder, and the submission of a Notice of Conversion shall be deemed to
be the Holder&rsquo;s determination of whether this Note may be converted (in relation to other securities owned by the Holder
together with any Affiliates) and which principal amount of this Note is convertible, in each case subject to the Beneficial
Ownership Limitation. To ensure compliance with this restriction, the Holder will be deemed to represent to the Company each time it
delivers a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this Section 4(e) and
the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any
group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. For purposes of this Section 4(e), in determining the number of outstanding shares of Common
Stock, the Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following: (i)
the Company&rsquo;s most recent periodic or annual report filed with the SEC, as the case may be, (ii) a more recent public
announcement by the Company, or (iii) a more recent written notice by the Company or the Company&rsquo;s transfer agent setting
forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within two
Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the
number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including this Note, by the Holder or its Affiliates since the date as of which such number of outstanding shares of
Common Stock was reported. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be 4.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of this Note
held by the Holder. The Holder, upon not less than 61 days&rsquo; prior notice to the Company, may increase the Beneficial Ownership
Limitation provisions of this Section 4(e) to 9.99% of the number of shares of Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock upon conversion of this Note held by the Holder. In all events, the provisions of
this Section 4(e) shall continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice
is delivered to the Company. The Holder may also decrease the Beneficial Ownership Limitation provisions of this Section 4(e) solely
with respect to the Holder&rsquo;s Note at any time, which decrease shall be effectively immediately upon delivery of notice to the
Company. The Beneficial Ownership Limitation provisions of this Section 4(e) shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 4(e) to correct any portion which may be defective or
inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes or supplements necessary or
desirable to properly give effect to such limitation. The limitations contained in this Section 4(d) shall apply to a successor
holder of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify"><U>Section 5</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Stock Splits</U>. If the Company, at any time while this Note is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any Common Stock Equivalents,
(ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse
stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues, in the event of a reclassification
of shares of the Common Stock, any shares of capital stock of the Company, then the Conversion Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Company)
outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to this Section 5(a) shall become effective immediately after the record
date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>. (1) At any time, for so long as the Note or any amounts accrued and payable thereunder remain outstanding, the Company
or any Subsidiary, as applicable, sells or grants any option to purchase or sells or grants any right to reprice, or otherwise disposes
of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents
entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the Conversion Price then in
effect (such lower price, the &ldquo;Base Conversion Price&rdquo; and each such issuance or announcement a &ldquo;<U>Dilutive Issuance</U>&rdquo;),
then the Conversion Price shall be immediately reduced to equal the Base Conversion Price. Such adjustment shall be made whenever such
Common Stock or Common Stock Equivalents are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;If
any Common Stock Equivalent is amended or adjusted, and such price as so amended shall be less than the Conversion Price in effect at
the time of such amendment or adjustment, then the Conversion Price shall be adjusted upon each such issuance or amendment as provided
in this Section 5(b). In case any Common Stock Equivalent is issued in connection with the issue or sale of other securities of the Company,
together comprising one integrated transaction, (x) the Common Stock Equivalents will be deemed to have been issued for the Option Value
of such Common Stock Equivalents and (y) the other securities issued or sold in such integrated transaction shall be deemed to have been
issued or sold for the difference of (I) the aggregate consideration received by the Company less any consideration paid or payable by
the Company pursuant to the terms of such other securities of the Company, less (II) the Option Value. If any shares of Common Stock
or Common Stock Equivalents are issued or sold or deemed to have been issued or sold for cash, the amount of such consideration received
by the Company will be deemed to be the net amount received by the Company therefor. If any shares of Common Stock or Common Stock Equivalents
are issued or sold for a consideration other than cash, the amount of such consideration received by the Company will be the fair value
of such consideration, except where such consideration consists of publicly traded securities, in which case the amount of consideration
received by the Company will be the average VWAP of such public traded securities for the ten days prior to the date of receipt. If any
shares of Common Stock or Common Stock Equivalents are issued to the owners of the non-surviving entity in connection with any merger
in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be the fair value of such portion
of the net assets and business of the non-surviving entity as is attributable to such shares of Common Stock or Common Stock Equivalents,
as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;If
the holder of Common Stock or Common Stock Equivalents outstanding on the Original Issue Date or issued after the Original Issuance Date
shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices
or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive
shares of Common Stock at an effective price per share that is lower than the Conversion Price then in effect, such issuance shall be
deemed to have occurred for less than the Conversion Price on such date and such issuance shall be deemed to be a Dilutive Issuance.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;If
the Company enters into a Variable Rate Transaction despite the prohibition set forth in the Purchase Agreement, the Company shall be
deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion price at which such securities may be
converted or exercised under the terms of such Variable Rate Transaction.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 0.5in">(5)&nbsp;&nbsp;&nbsp;The
Company shall notify the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents
subject to this Section 5(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion
price and other pricing terms (such notice, the &ldquo;Dilutive Issuance Notice&rdquo;). For purposes of clarification, whether or not
the Company provides a Dilutive Issuance Notice pursuant to this Section 5(b), upon the occurrence of any Dilutive Issuance, the Holder
is entitled to receive a number of Conversion Shares based upon the Base Conversion Price on or after the date of such Dilutive Issuance,
regardless of whether the Holder accurately refers to the Base Conversion Price in the Notice of Conversion.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 0.5in">(6)&nbsp;&nbsp;&nbsp;The
provisions of this Section 5(b) shall apply each time a Dilutive Issuance occurs after the Original Issue Date for so long as the Note
or any amounts accrued and payable thereunder remain outstanding, but any adjustment of the Conversion Price pursuant to this Section
5(b) shall be downward only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 0.5in">(7)&nbsp;&nbsp;&nbsp;The provisions of this Section 5(b) shall not
apply to Exempt Issuances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">(c)&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 5(a) above, if at any time the Company grants, issues or sells
any Common Stock, Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled to acquire, upon
the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held
the number of shares of Common Stock acquirable upon complete conversion of this Note (without regard to any limitations on conversion
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, to the extent
that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. During such time as this Note is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets or rights or warrants to acquire its assets, or subscribe for or purchase any security other than Common
Stock, to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any
distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate
rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;Distribution&rdquo;), at any time after the issuance of
this Note, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the
Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
conversion of this Note (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken,
the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<U>provided</U>, <U>however</U>, to the extent that the Holder's right to participate in any such Distribution would result in the
Holder exceeding the Beneficial Ownership Limitation with respect to the Company or any other publicly-traded corporation subject to
Section 13(d) of the Exchange Act, then the Holder shall not be entitled to participate in such Distribution to such extent (or in
the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation with respect to the Company or any other publicly-traded corporation
subject to Section 13(d) of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>. (1) If, at any time while this Note is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or
indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or
exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property, (v) the Company, directly or indirectly, in one or
more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person
acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person
or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share
purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent
conversion of this Note, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon
such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation on the
conversion of this Note), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is
the surviving corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable as a result of
such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Note is convertible immediately
prior to such Fundamental Transaction (without regard to any limitation on the conversion of this Note). For purposes of any such
conversion, the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based
on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities,
cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any conversion of this Note following such Fundamental Transaction. The Company shall not effect a
Fundamental Transaction unless it gives the Holder at least 10 Trading Days prior notice together with sufficient details so the
Holder can make an informed decision as to whether it elects to accept the Alternative Consideration. If a public announcement of
the Fundamental Transaction has not been made, the notice to the Holder may not be given until the Company files a Form 8-K or other
report disclosing the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary, provided that the Warrant Shares are not registered under an effective registration statement, in the event
of a Fundamental Transaction that is (x) an all cash transaction, (y) a &ldquo;Rule 13e-3 transaction&rdquo; as defined in Rule 13e-3
under the Exchange Act, or (z) a Fundamental Transaction involving a person or entity not traded on a national securities exchange or
trading market (with such exchange or market including, without limitation, the Nasdaq Global Select Trading Market, the Nasdaq Global
Market, or the Nasdaq Capital Market, the New York Stock Exchange, Inc., the NYSE American or any market operated by the OTC Markets,
Inc.), the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, concurrently with the consummation
of the Fundamental Transaction, purchase this Note from the Holder by paying to the Holder the higher of (i) an amount of cash equal to
the Black Scholes Value of the outstanding principal of this Note on the date of the consummation of such Fundamental Transaction, or
(ii) the product of (a) the number of Conversion Shares issuable upon full conversion of this Note (without regard to any limitation on
conversion of this Note) and (b) the positive difference between the cash per share paid in such Fundamental Transaction minus the then
in effect Conversion Price. (3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;If
Section 5(e)(1) and (2) are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under this Note and
the other Transaction Documents in accordance with the provisions of this Section 5(e) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Note a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Note which is convertible for a corresponding number of shares
of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon
conversion of this Note (without regard to any limitations on the conversion of this Note) prior to such Fundamental Transaction, and
with a conversion price which applies the Conversion Price hereunder to such shares of capital stock (but taking into account the relative
value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such conversion price being for the purpose of protecting the economic value of this Note immediately prior
to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the
occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after
the date of such Fundamental Transaction, the provisions of this Note and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Note and the other Transaction Documents with the same effect as if such Successor Entity had been named as
the Company herein. Notwithstanding anything in this Section 5(e), an Exempt Issuance (as defined in the Purchase Agreement) shall not
be deemed a Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">(f)&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding any treasury shares of the Company) issued and outstanding.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">(g)&nbsp;&nbsp;&nbsp;<U>Notice to the Holder</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 53.95pt">(i)&nbsp;&nbsp;&nbsp;<U>Adjustment
to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 5, the Company shall
promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief
statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 53.95pt">(ii)&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Conversion by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on its Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of its Common Stock, (C) the Company shall
authorize the granting to all holders of its Common Stock of rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification
of its Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby its Common Stock is converted into other securities, cash or property
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be filed at each office or agency maintained for the purpose of conversion of this Note,
and shall cause to be delivered to the Holder at its last address as it shall appear upon the Note Register, at least 5 calendar days
prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken
for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which
the holders of its Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined
or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective
or close, and the date as of which it is expected that holders of its Common Stock of record shall be entitled to exchange their shares
of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer
or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect
the validity of the corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes,
or contains, material, non-public information regarding the Company or any of the Subsidiaries (as determined in good faith by the Company),
the Company or its successor shall simultaneously file such notice with the SEC pursuant to a Current Report on Form 8-K. If the Company
does not simultaneously file the required Form 8-K, the Holder shall be entitled penalties in accordance with Section 5.6 of the Purchase
Agreement The Holder shall remain entitled to convert this Note during the 20-day period commencing on the date of such notice through
the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify"><U>Section 6</U>. <U>Negative Covenants</U>.
As long as any portion of this Note remains outstanding, unless the holders of at least 50% in principal amount of the then outstanding
Notes shall have otherwise given prior written consent, the Company shall not, and shall not permit any of the Subsidiaries to, directly
or indirectly:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">(a)&nbsp;&nbsp;&nbsp;other
than Permitted Indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any indebtedness for borrowed money of any
kind, including, but not limited to, a guarantee, on or with respect to any of its property or assets now owned or hereafter acquired
or any interest therein or any income or profits therefrom;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;other
than Permitted Liens, enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to any of its property
or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;amend
its charter documents, including, without limitation, its articles of incorporation and bylaws, in any manner that materially and adversely
affects any rights of the Holder, increases in authorized shares and stock splits shall not be deemed to materially and adversely affects
any rights of the Holder;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;purchase
or otherwise acquire more than a <U>de minimis </U>number of shares of its Common Stock or Common Stock Equivalents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">(e)&nbsp;&nbsp;&nbsp;repay,
or offer to repay, any Indebtedness, other than Permitted Indebtedness, as such terms Indebtedness and Permitted Indebtedness are in effect
as of the Original Issue Date;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">(f)&nbsp;&nbsp;&nbsp;pay cash dividends or distributions on any equity
securities of the Company;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;enter
into any transaction with any Affiliate of the Company which would be required to be disclosed in any public filing with the SEC assuming
that the Company is subject to the Securities Act or the Exchange Act, unless such transaction is made on an arm&rsquo;s-length basis
and expressly approved by a majority of the disinterested directors of the Company (even if less than a quorum otherwise required for
board approval);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;issue
any equity securities of the Company other than pursuant to the provisions of the Purchase Agreement or an Exempt Issuance; or</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">(i)&nbsp;&nbsp;&nbsp;enter
into any agreement with respect to any of the foregoing. <U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt"><U>&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><U>Section 7</U>. <U>Events of Default</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&ldquo;<U>Event
of Default</U>&rdquo; means, wherever used herein, any of the following events (whatever the reason for such event and whether such event
shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order,
rule or regulation of any administrative or governmental body):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 71.95pt">(i)&nbsp;&nbsp;&nbsp;any
default in the payment of (A) principal and interest payment under this Note or any other Indebtedness, or (B) late fees, liquidated damages
and other amounts owing to the Holder of this Note, as and when the same shall become due and payable (whether on a Conversion Date, or
the Maturity Date, or by acceleration or otherwise), which default, solely in the case of a default under clause (B) above, is not cured
within five Trading Days;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;the
Company shall fail to observe or perform any other covenant or agreement contained in this Note (other than a breach by the Company of
its obligations to deliver Conversion Shares, which breach is addressed in clause (x) below) or any Transaction Document which failure
is not cured, if possible to cure, within the earlier to occur of 15 Trading Days after notice of such failure is sent by the Holder or
by any other Holder to the Company and (B) 10 Trading Days after the Company has become aware of such failure;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;except
for payment defaults covered under Section 7(a)(i), the Company shall breach, or a default or event of default (subject to any grace or
cure period provided in the applicable agreement, document or instrument) shall occur under, (A) any of the Transaction Documents or (B)
any other material agreement, lease, document or instrument to which the Company or any Subsidiary is obligated (and not covered by any
other clause of this Section 7) which default or event of default if not cured, if possible to cure, within the earlier to occur of (i)
10 Trading Days after notice of such default sent by Holder or by any other holder to the Company and (ii) five Trading Days after the
Company has become aware of such default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 71.95pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;any
representation or warranty made in this Note, any other Transaction Document, any written statement pursuant hereto or thereto or any
other report, financial statement or certificate made or delivered to the Holder or any other Holder shall be untrue or incorrect in any
material respect as of the date when made or deemed made, which failure is not cured, if possible to cure, within the earlier to occur
of 10 Trading Days after notice of such failure is sent by the Holder or by any other Holder to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 71.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 71.95pt">(v)&nbsp;&nbsp;&nbsp;the Company or any Subsidiary shall be subject
to a Bankruptcy Event;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 71.95pt">(vi)&nbsp;&nbsp;&nbsp;the
Company or any Subsidiary shall: (A) apply for or consent to the appointment of a receiver, trustee, custodian or liquidator of it or
any of its properties; (B) admit in writing its inability to pay its debts as they mature; (C) make a general assignment for the benefit
of creditors; (D) be adjudicated as bankrupt or insolvent or be the subject of an order for relief under Title 11 of the United States
Code or any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law or statute of any other jurisdiction
or foreign country; or (E) file a voluntary petition in bankruptcy, or a petition or an answer seeking reorganization or an arrangement
with creditors or to take advantage or any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law
or statute, or an answer admitting the material allegations of a petition filed against it in any proceeding under any such law, or (F)
take or permit to be taken any action in furtherance of or for the purpose of effecting any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 1in">(vii)&nbsp;&nbsp;&nbsp;if
any order, judgment or decree shall be entered, without the application, approval or consent of the Company or any Subsidiary, by any
court of competent jurisdiction, approving a petition seeking liquidation or reorganization of the Company or any Subsidiary, or appointing
a receiver, trustee, custodian or liquidator of the Company or any Subsidiary, or of all or any substantial part of its assets, and such
order, judgment or decree shall continue unstayed and in effect for any period of 60 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 1in">(viii)   &nbsp;the
occurrence of any levy upon or seizure or attachment of, or any uninsured loss of or damage to, any property of the Company or any Subsidiary
having an aggregate fair value or repair cost (as the case may be) in excess of $100,000 individually or in the aggregate, and any such
levy, seizure or attachment shall not be set aside, bonded or discharged within 45 days after the date thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 71.95pt">(ix)   &nbsp;any
monetary judgment, writ or similar final process shall be entered or filed against the Company, any Subsidiary or any of their respective
property or other assets for more than $100,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or
unstayed for a period of 30 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 71.95pt">(x)&nbsp;&nbsp;&nbsp;any Material Adverse Effect occurs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 71.95pt">(xi)   &nbsp;any
provision of any Transaction Document shall at any time for any reason (other than pursuant to the express terms thereof) cease to be
valid and binding on or enforceable against the parties thereto, or the validity or enforceability thereof shall be contested by any party
thereto, or a proceeding shall be commenced by the Company or any Subsidiary or any governmental authority having jurisdiction over any
of them, seeking to establish the invalidity or unenforceability thereof, or the Company or any Subsidiary shall deny in writing that
it has any liability or obligation purported to be created under any Transaction Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 1in">(xii)   &nbsp;the
Company fails to use the proceeds in the manner as described in Section 5.7 of the Purchase Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 1in">(xiii)   &nbsp;the
Company shall be a party to any Change of Control Transaction or shall agree to sell or dispose of all or in excess of 50% of its assets
in one transaction or a series of related transactions (whether or not such sale would constitute a Change of Control Transaction);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 71.95pt">(xiv)   &nbsp;from
and after 90 days after the Original Issue Date, the Company fails to have authorized and reserved the amount of shares designated in
Section 3.5 of the Purchase Agreement (without regard to any limitations on conversion hereof, including without limitation, the Beneficial
Ownership Limitation);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 71.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 5.95pt; text-indent: 1in">(xv)   &nbsp;the
Company shall fail for any reason, except if caused by the action or inaction of the Holder to deliver Conversion Shares to the Holder
prior to the third Trading Day after a Conversion Date pursuant to Section 4 or the Company shall provide at any time notice to the Holder,
including by way of public announcement, of the Company&rsquo;s intention to not honor requests for conversions of this Note in accordance
with the terms hereof; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 71.95pt">(xvi)   &nbsp;the
Company fails to file with the SEC any required reports under Section 13 or 15(d) of the Exchange Act within the time required (including
any applicable extension period) by the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(b)   &nbsp;<U>Remedies
Upon Event of Default</U>. If any Event of Default occurs, the outstanding principal amount of this Note, plus liquidated damages and
other amounts owing in respect thereof through the date of acceleration, shall become, at the Holder&rsquo;s election, immediately due
and payable in cash (the &ldquo;Mandatory Default Amount&rdquo;). Upon the payment in full of the Mandatory Default Amount, the Holder
shall promptly surrender this Note to or as directed by the Company. In connection with such acceleration described herein, the Holder
need not provide, and the Company hereby waives, any presentment, demand, protest or other notice of any kind, and the Holder may immediately
and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all other remedies available to
it under applicable law. Such acceleration may be rescinded and annulled by Holder at any time prior to payment hereunder and the Holder
shall have all rights as a holder of the Note until such time, if any, as the Holder receives full payment pursuant to this Section 7(b).
No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(c)   &nbsp;<U>Interest
Rate Upon Event of Default</U>. Commencing on the occurrence of any Event of Default and until such Event of Default is cured, this Note
shall accrue interest at an interest rate equal to the Default Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(d)   &nbsp;<U>Conversion
Price Upon Event of Default</U>. Commencing on the occurrence of any Event of Default and until such Event of Default is cured, this Note
shall be convertible at the Default Conversion Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt"><U>Section 8</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(a)   &nbsp;<U>No
Rights as Stockholder Until Conversion</U>. This Note does not entitle the Holder to any voting rights, dividends or other rights as a
stockholder of the Company prior to the conversion hereof other than as explicitly set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(b)   &nbsp;<U>Notices</U>.
All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing, and shall be sufficiently
given if delivered to the addressees in person, by FedEx or similar receipted next day delivery, or at the Company&rsquo;s registered
address or such other address as any of them, by notice to the other may designate from time to time. Time shall be counted to, or from,
as the case may be, the date of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(c)   &nbsp;<U>Absolute
Obligation</U>. Except as expressly provided herein, no provision of this Note shall alter or impair the obligation of the Company, which
is absolute and unconditional, to pay the principal of, liquidated damages and accrued interest and late fees, as applicable, on this
Note at the time, place, and rate, and in the coin or currency, herein prescribed. This Note is a direct debt obligation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(d)
&nbsp;<U>Lost or Mutilated Note</U>. If this Note shall be mutilated, lost, stolen or destroyed, the Company shall execute and
deliver, in exchange and substitution for and upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost,
stolen or destroyed Note, a new Note for the principal amount of this Note so mutilated, lost, stolen or destroyed, but only upon
receipt of evidence of such loss, theft or destruction of this Note, and of the ownership hereof, reasonably satisfactory to the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 35.95pt">(e)   &nbsp;<U>Exclusive
Jurisdiction; Governing Law; Prevailing Party Attorneys&rsquo; Fees</U>. All questions concerning the construction, validity, enforcement
and interpretation of this Note and venue shall be governed by and construed and enforced in accordance with Section 6.9 of the Purchase
Agreement. If any party shall commence an Action or Proceeding to enforce or otherwise relating to this Note, then, in addition to the
other obligations of the Company elsewhere in this Note, the prevailing party in such action or proceeding shall be reimbursed by the
non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(f)   &nbsp;<U>Waiver</U>.
Any waiver by the Company or the Holder of a breach of any provision of this Note shall not operate as or be construed to be a waiver
of any other breach of such provision or of any breach of any other provision of this Note. The failure of the Company or the Holder to
insist upon strict adherence to any term of this Note on one or more occasions shall not be considered a waiver or deprive that party
of the right thereafter to insist upon strict adherence to that term or any other term of this Note on any other occasion. Any waiver
by the Company or the Holder must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(g)   &nbsp;<U>Severability</U>.
If any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain in effect, and if any provision
is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances. If it shall
be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury, the applicable rate
of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under applicable law. The Company
covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or in any manner whatsoever claim
or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit or forgive the Company from paying
all or any portion of the principal of or interest on this Note as contemplated herein, wherever enacted, now or at any time hereafter
in force, or which may affect the covenants or the performance of this Note, and the Company (to the extent it may lawfully do so) hereby
expressly waives all benefits or advantage of any such law, and covenants that it will not, by resort to any such law, hinder, delay or
impede the execution of any power herein granted to the Holder, but will suffer and permit the execution of every such as though no such
law has been enacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">(h)   &nbsp;<U>Remedies,
Characterizations, Other Obligations, Breaches and Injunctive Relief. </U>The remedies provided in this Note shall be cumulative and in
addition to all other remedies available under this Note and any of the other Transaction Documents at law or in equity (including a decree
of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder&rsquo;s right to pursue actual and
consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there
shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein
with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the Holder and
shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for
any such breach would be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder
shall be entitled, in addition to all other available remedies, to an injunction restraining any such breach or any such threatened breach,
without the necessity of showing economic loss and without any bond or other security being required. The Company shall provide all information
and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company&rsquo;s compliance with the
terms and conditions of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 6pt; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 35.95pt">(i)   &nbsp;<U>Next
Trading Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Trading Day, such payment shall
be made on the next succeeding Trading Day.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 0.5in">(j)   &nbsp;<U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Note and shall not be deemed to limit or affect
any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Promissory Note</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has caused
this Note to be duly executed by a duly authorized officer as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">60 Degrees Pharmaceuticals, LLC</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; width: 50%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; width: 5%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Geoffrey Dow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    <TD>Geoffrey Dow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 256.15pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 256.15pt">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 169.5pt; text-indent: 44.5pt">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">ANNEX A NOTICE OF CONVERSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 0.5in">The undersigned hereby
elects to convert principal under the Original Issue Discount Convertible Note due May 31, 2023 of 60 Degrees Pharmaceuticals, LLC, a
limited liability company (the &ldquo;Company&rdquo;), into shares of common stock (the &ldquo;Common Stock&rdquo;), of the Company according
to the conditions hereof, as of the date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 0.5in">By the delivery of
this Notice of Conversion the undersigned represents and warrants to the Company that its ownership of the Common Stock does not exceed
the amounts specified under Section 4 of this Note, as determined in accordance with Section 13(d) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 0.5in">The undersigned agrees
to comply with the prospectus delivery requirements under the applicable securities laws in connection with any transfer of the aforesaid
shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">Conversion calculations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">Date to Effect Conversion:</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Principal Amount of Note to be Converted: </TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Number of shares of Common Stock to be issued:</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Signature:</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>DWAC Instructions:</TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 15%">Broker No:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Account No:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>10
<FILENAME>cm270_ex10-7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">Exhibit 10.7</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of May 24, 2022, by and between 60&deg; Pharmaceuticals, LLC, a limited
liability company, and each investor that executes the signature page hereto as a purchaser (each, a &ldquo;Purchaser&rdquo; and
collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities
Act, as defined, contained in Section 4(a)(2) thereof and/or Rule 506(b) thereunder, the Company desires to issue and sell to the Purchaser,
and the Purchaser desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and the Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE I. DEFINITIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1 <U>Definitions</U>. In
addition to the words and terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Acquiring Person&rdquo;
shall have the meaning ascribed to such term in Section 5.5. &ldquo;Action&rdquo; shall have the meaning ascribed to such term in Section
3.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Affiliate&rdquo; means
any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with
a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Bridge Shares&rdquo;
means shares of the Company&rsquo;s Common Stock issued to each Purchaser equal to and based on (A) 100% of the Face Value of each Purchaser&rsquo;s
Note divided by the Company&rsquo;s IPO price upon the pricing of the Company&rsquo;s IPO or (B) if the Company fails to complete the
IPO before the Maturity Date, the number of shares calculated using a $27 million pre-money valuation for the Company and the number of
the Company&rsquo;s shares outstanding on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Board of Directors&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Closing&rdquo; means the
closing of the purchase and sale of the Notes pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Closing Date&rdquo;
means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto,
and all conditions precedent to (i) the Purchaser&rsquo;s obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities to be issued and sold, in each case, have been satisfied or waived, but in no event later than
the second Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Common Stock&rdquo;
means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Common Stock Equivalents&rdquo;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Company&rdquo; means
60&deg; Pharmaceuticals, LLC and any successor company after conversion from a limited liability company to a corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Evaluation Date&rdquo;
shall have the meaning ascribed to such term in Section 3.19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Exchange Act&rdquo;
means the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Exempt
Issuance&rdquo; means the issuance of (a) shares of Common Stock, restricted stock units or options, and the underlying shares of
Common Stock to consultants, employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for
such purpose, by a majority of the non- employee members of the Board of Directors or a majority of the members of a committee of
non-employee directors established for such purpose for services rendered to the Company, (b) securities issued upon the exercise or
exchange of or conversion of any Securities issued hereunder and/or other securities issuable pursuant to existing agreements,
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement,
provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to
decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock dividends,
stock splits or combinations) or to extend the term of such securities, (c) securities issued pursuant, acquisitions or strategic
transactions approved by a majority of the directors of the Company, provided that any such issuance shall only be to a Person (or
to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a
business synergistic with the business of the Company and which shall reasonably be expected to provide to the Company additional
benefits, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising
capital or to an entity whose primary business is investing in securities, (d) securities issued pursuant to any purchase money
equipment loan or capital leasing arrangement, purchasing agent or debt financing from a commercial bank or similar financial
institution, (e) securities issued pursuant to any presently outstanding warrants or this Agreement; and (f) securities upon a stock
split, stock dividend or subdivision of the Common Stock and shares of common stock in a public offering; (g) non-convertible loans
from traditional commercials banks with interest per annum not to exceed 12% which will rank <B><I>pari passu </I></B>with the Notes
issued to investors by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Face Value&rdquo; means
the Subscription Amount plus original issue discount as described in the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;FCPA&rdquo; means the
Foreign Corrupt Practices Act of 1977, as amended. &ldquo;GAAP&rdquo; shall have the meaning ascribed to such term in Section 3.8. &ldquo;Indebtedness&rdquo;
shall have the meaning ascribed to such term in Section 3.27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Intellectual
Property&rdquo; means all of the following in any jurisdiction throughout the world: (a) all inventions (whether patentable or
unpatentable and whether or not reduced to practice), all improvements thereto, and all U.S. and foreign patents, patent
applications, and patent disclosures, together with all reissuances, continuations, continuations-in-part, revisions, extensions,
and reexaminations thereof, (b) all trademarks, service marks, brand names, certification marks, trade dress, logos, trade names,
domain names, assumed names and corporate names, together with all colorable imitations thereof, and including all goodwill
associated therewith, and all applications, registrations, and renewals in connection therewith, (c) all copyrights, and all
applications, registrations, and renewals in connection therewith, (d) all trade secrets under applicable state laws and the common
law and know-how (including formulas, techniques, technical data, designs, drawings, specifications, customer and supplier lists,
pricing and cost information, and business and marketing plans and proposals), (e) all computer software (including source code,
object code, diagrams, data and related documentation), and (f) all copies and tangible embodiments of the foregoing (in whatever
form or medium).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;IPO&rdquo; shall mean
an initial public offering by the Company that results in a listing of the Company&rsquo;s Common Stock on a national securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Licensed Intellectual
Property Agreement&rdquo; means all licenses, sublicenses, agreements and permissions (each as amended to date) that any third party owns
and that the Company uses, including off- the-shelf software purchased or licensed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Liens&rdquo; means
a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Material Adverse Effect&rdquo;
shall have the meaning assigned to such term in Section 3.1. &ldquo;Maturity Date&rdquo; shall have the meaning assigned to such term
in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Notes&rdquo; means
the Original Issue Discount Promissory Notes issued to the Purchaser, in the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Original Issue Date&rdquo;
means the date of the first issuance of the Notes, regardless of any transfers of any Note and regardless of the number of instruments
which may be issued to evidence such Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Person&rdquo; means
an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Proceeding&rdquo; means
an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such
as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Purchaser Party&rdquo;
shall have the meaning ascribed to such term in Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Registrable
Securities&rdquo; shall mean, collectively, the Bridge Shares and the Warrant Shares. &ldquo;Regulation FD&rdquo; means Regulation
FD promulgated by the SEC pursuant to the Exchange Act, as such Regulation may be amended or interpreted from time to time, or any
similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Required Approvals&rdquo;
shall have the meaning ascribed to such term in Section 3.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Rule 144&rdquo; means
Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar
rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;SEC&rdquo; means the United
States Securities and Exchange Commission. &ldquo;Securities&rdquo; means the Notes, the Warrants and the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Securities Act&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Shares&rdquo; means the
Bridge Shares and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Short Sales&rdquo;
means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include
the location and/or reservation of borrowable shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Subscription Amount&rdquo;
means, as to the Purchaser, the aggregate amount to be paid for the Note purchased hereunder as specified below the Purchaser&rsquo;s
name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in
immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Subsidiary&rdquo; means
with respect to any entity at any date, any direct or indirect corporation, limited or general partnership, limited liability company,
trust, estate, association, joint venture or other business entity of which (A) more than 50% of (i) the outstanding capital stock having
(in the absence of contingencies) ordinary voting power to elect a majority of the Board of Directors or other managing body of such entity,
(ii) in the case of a partnership or limited liability company, the interest in the capital or profits of such partnership or limited
liability company or (iii) in the case of a trust, estate, association, joint venture or other entity, the beneficial interest in such
trust, estate, association or other entity business is, at the time of determination, owned or controlled directly or indirectly through
one or more intermediaries, by such entity, or (B) is under the actual control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Trading Day&rdquo; means
a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Trading Market&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
OTCQB, the OTCQX, or the OTC Pink Marketplace (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Transaction Documents&rdquo;
means this Agreement, the Notes, the Warrants, and any other documents or agreements executed in connection with the transactions contemplated
hereunder, including, but not limited to, the documents referenced in Section 2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Transfer Agent&rdquo;
means [*], and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Variable Rate Transaction&rdquo;
means any Equity Line of Credit or similar agreement, nor issue nor agree to issue any Common Stock, floating or Variable Priced Equity
Linked Instruments nor any of the foregoing or equity with price reset rights (subject to adjustment for stock splits, distributions,
dividends, recapitalizations and the like) (collectively, the &ldquo;Variable Rate Transaction&rdquo;). For purposes of this Agreement,
&ldquo;Equity Line of Credit&rdquo; shall include any transaction involving a written agreement between the Company and an investor or
underwriter whereby the Company has the right to &ldquo;put&rdquo; its securities to the investor or underwriter over an agreed period
of time and at an agreed price or price formula, and &ldquo;Variable Priced Equity Linked Instruments&rdquo; shall include: (A) any debt
or equity securities which are convertible into, exercisable or exchangeable for, or carry the right to receive additional shares of Common
Stock either (1) at any conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices
of or quotations for Common Stock at any time after the initial issuance of such debt or equity security, or (2) with a fixed conversion,
exercise or exchange price that is subject to being reset at some future date at any time after the initial issuance of such debt or equity
security due to a change in the market price of the Company&rsquo;s Common Stock since date of initial issuance, and (B) any amortizing
convertible security which amortizes prior to its maturity date, where the Company is required or has the option to (or any investor in
such transaction has the option to require the Company to) make such amortization payments in shares of Common Stock which are valued
at a price that is based upon and/or varies with the trading prices of or quotations for Common Stock at any time after the initial issuance
of such debt or equity security (whether or not such payments in stock are subject to certain equity conditions). For purposes of determining
the total consideration for a convertible instrument (including a right to purchase equity of the Company) issued, subject to an original
issue or similar discount or which principal amount is directly or indirectly increased after issuance, the consideration will be deemed
to be the actual cash amount received by the Company in consideration of the original issuance of such convertible instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Warrants&rdquo;
means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a)
hereof, which Warrants shall be exercisable immediately and have a term of exercise equal to five years from such initial exercise
date, in the form of <U>Exhibit B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Warrant Exercise Price&rdquo;
means the exercise price provided in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&ldquo;Warrant Shares&rdquo;
means the shares of Common Stock issuable upon exercise of the Warrants at the Warrant Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE II. PURCHASE AND
SALE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Dates, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and
delivery of this Agreement by the parties hereto, the Company agrees to sell, and each Purchaser, severally and not jointly, agrees to
purchase an aggregate of (i) Notes with a Face Value listed on the Purchaser&rsquo;s signature page and (ii) Warrants to purchase shares
equal to 50% of the Bridge Shares. On the Closing Date, the Purchaser shall deliver to the Company a signed copy of the Transaction Documents
and, via wire transfer, immediately available funds equal to the Purchaser&rsquo;s Subscription Amount. After receipt of the Subscription
Amount, the Company shall deliver to the Purchaser countersigned copies of the Transaction Documents. Upon satisfaction of the closing
conditions set forth in Section 2.3, the Closing shall occur at the Company&rsquo;s offices or such other location as the parties shall
mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deliveries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
Note with a Face Value of $330,000 registered in the name of the Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
original Warrant to purchase shares of Common Stock, exercisable at the Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0">Exercise Price, registered in
the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
Board Consent approving the issuance of the Notes and the execution of the Transaction Documents listed above on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by the Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Purchaser&rsquo;s Subscription Amount by wire transfer to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the (i) date of the pricing of the Company&rsquo;s IPO, the Company shall deliver to each Purchaser shares of the Company&rsquo;s common
stock equal to 100% of the Face Value of each Purchaser&rsquo;s Note divided by the Company&rsquo;s IPO price upon or (ii) if the Company
fails to complete the IPO before the Maturity Date, the number of shares of the Company&rsquo;s common stock calculated using a $27 million
pre- money valuation for the Company and the number of the Company&rsquo;s shares outstanding on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Closing
Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) on the Closing Date of the representations and warranties of the Purchaser contained herein (unless as of a specific
date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;accuracy
in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in
all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a
specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPRESENTATIONS AND WARRANTIES
OF COMPANY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company hereby makes the
following representations and warranties to each Purchaser as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary
is in violation nor default of any of the provisions of its respective certificate or Articles of Incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material
adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the
Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect
on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;)
and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the
consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part
of the Company and no further action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in
connection herewith or therewith other than in connection with the Required Approvals. Subject to obtaining the Required Approvals,
this Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed
by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation
of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of
creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief
or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. Except as set forth in <U>Schedule 3.3</U>, the execution, delivery and performance by the Company of this Agreement
and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it
of the transactions contemplated hereby and thereby do not and will not (i) subject to the Required Approvals, conflict with or
violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s Certificate or Articles of Incorporation, bylaws or other
organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of
time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company
or any Subsidiary, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice,
lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or
otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company
or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation of
any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to
which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. Except as set forth on <U>Schedule 3.4</U>, the Company is not required to obtain any consent, waiver,
authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local
or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the
Transaction Documents, other than: (i) blue sky filings or a Form D filing and (ii) such filings as are required to be made under
applicable state securities laws (the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Shares,
when issued will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company shall
reserve from its duly authorized capital stock a number of shares of Common Stock issuable pursuant to the Notes and Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The capitalization of the Company is as set forth on <U>Schedule 3.6</U>. The Company has not issued any capital stock since its
most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock awards under
the Company&rsquo;s equity incentive plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s
employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the
date of the most recently filed periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right,
right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except
as set forth on <U>Schedule 3.6</U>, as a result of the purchase and sale of the Securities, there are no outstanding options,
warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any
shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which
the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or
capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue
shares of Common Stock or other securities to any Person (other than the Purchaser) and will not result in a right of any holder
of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. There are no outstanding
securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no
contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem
a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo;
plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized,
validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none
of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.
No further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale
of the Securities. There are no stockholders&rsquo; agreements, voting agreements or other similar agreements with respect to
the Company&rsquo;s capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of
the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect Subsidiaries of the Company are set forth in Schedule 3.7. The Company owns, directly or indirectly, all
of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Statements</U>. The consolidated financial statements of the Company, together with the related notes and schedules, present fairly,
in all material respects, the consolidated financial position of the Company and any of its Subsidiaries as of the dates indicated
and the consolidated results of operations, cash flows and changes in stockholders&rsquo; equity of the Company for the periods
specified and have been prepared in compliance with United States generally accepted accounting principles (&ldquo;<U>GAAP</U>&rdquo;)
applied on a consistent basis during the periods involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest financial statements: (i) there has
been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect,
(ii) the Company has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses
incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in
the Company&rsquo;s financial statements pursuant to GAAP, (iii) the Company has not altered its method of accounting, (iv) the
Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed
or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities
to any officer, director or Affiliate, except pursuant to existing Company equity incentive plans. Other than as disclosed on
<U>Schedule 3.9</U>, except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance,
occurrence or development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its
Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required
to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has
not been publicly disclosed at least one Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Litigation</U>.
Except as set forth on <U>Schedule 3.10</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation,
inquiry or other similar proceeding of any federal or state government unit pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;)
which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the
issuance of the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a
Material Adverse Effect. The Company has no reason to believe that an Action will be filed against it in the future except as
disclosed on <U>Schedule &nbsp;3.10</U>. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has
been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim
for fraud or breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation or inquiry by the SEC involving the Company or any current or former director or officer of the Company. The
SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company
or any Subsidiary under the Securities Act, and the Company has no reason to believe it will do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their
relationships with their employees are good. To the knowledge of the Company, no effort is underway to unionize or organize the employees
of the Company or any Subsidiary. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now
expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information
agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and
the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with
respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign
laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except
where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. There is no workmen&rsquo;s compensation liability matter, employment-related charge, complaint, grievance, investigation, inquiry
or obligation of any kind pending, or to the Company&rsquo;s knowledge, threatened, relating to an alleged violation or breach by the
Company or its Subsidiaries of any law, regulation or contract that could, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Except as set forth on <U>Schedule 3.12</U>, neither the Company nor any Subsidiary: (i) is in default under or in violation of
(and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the
Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under
or that it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party
or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation
of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii) is or has been in violation
of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal,
state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and
employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to
pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or
subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants,
contaminants, or toxic or hazardous substances or wastes (collectively, &ldquo;Hazardous Materials&rdquo;) into the environment, or
otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of
Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses,
notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder
(&ldquo;Environmental Laws&rdquo;); (ii) have received all permits licenses or other approvals required of them under applicable
Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such
permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably expected to have,
individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations
or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any Subsidiary has
received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. There
is no agreement, commitment, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries or to which the
Company or any of its Subsidiaries is a party which has or would reasonably be expected to have the effect of prohibiting or materially
impairing any business practice of the Company or any of its Subsidiaries, any acquisition of property by the Company or any of its Subsidiaries
or the conduct of business by the Company or any of its Subsidiaries as currently conducted other than such effects, individually or
in the aggregate, which have not had and would not reasonably be expected to have a Material Adverse Effect on the Company or any of
its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. Subject to the Liens of the outstanding secured senior debt, the Company and the Subsidiaries have good and marketable
title in fee simple to all personal property owned by them that is material to the business of the Company and the Subsidiaries. The
Company owns no real property. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them
under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the Liens of the outstanding secured senior debt, to the Company&rsquo;s knowledge, the Company owns or possesses or has the right
to use pursuant to a valid and enforceable written license, sublicense, agreement, or permission all Intellectual Property necessary for
the operation of the business of the Company as presently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company&rsquo;s knowledge, the Intellectual Property does not interfere with, infringe upon, misappropriate, or otherwise come into
conflict with, any Intellectual Property rights of third parties, and the Company has no knowledge that facts exist which indicate a likelihood
of the foregoing. The Company has not received any charge, complaint, claim, demand, or notice alleging any such interference, infringement,
misappropriation, or conflict (including any claim that the Company must license or refrain from using any Intellectual Property rights
of any third party). To the knowledge of the Company, no third party has interfered with, infringed upon, misappropriated, or otherwise
come into conflict with, any Intellectual Property rights of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each Licensed Intellectual Property Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Licensed Intellectual Property Agreement is legal, valid, binding, enforceable, and in full force and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company&rsquo;s knowledge, no party to the Licensed Intellectual Property Agreement is in breach or default, and no event has
occurred that with notice or lapse of time would constitute a breach or default or permit termination, modification, or acceleration
thereunder, which as to any such breach, default or event could have a Material Adverse Effect on the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
party to such Licensed Intellectual Property Agreement has repudiated any provision thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in such Licensed Intellectual Property Agreement, the Company has not received written or verbal notice or otherwise has
knowledge that the underlying item of Intellectual Property is subject to any outstanding injunction, judgment, order, decree, ruling,
or charge; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth on <U>Schedule 3.16</U>, the Company has not granted any sublicense or similar right with respect to the license,
sublicense, agreement, or permission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has complied with and is presently in compliance with all foreign, federal, state, local, governmental (including, but not limited
to, the Federal Trade Commission and State Attorneys General), administrative, or regulatory laws, regulations, guidelines, and rules
applicable to any personal identifiable information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Person who participated in the creation, conception, invention or development of the Intellectual Property currently used in the business
of the Company (each, a &ldquo;Developer&rdquo;) which is not licensed from third parties has executed one or more agreements containing
industry standard confidentiality, work for hire and assignment provisions, whereby the Developer has assigned to the Company all copyrights,
patent rights, Intellectual Property rights and other rights in the Intellectual Property, including all rights in the Intellectual Property
that existed prior to the assignment of rights by such Person to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Developer has signed a perpetual non-disclosure agreement with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company
nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as disclosed in Schedule 3.18, none of the officers or directors of the Company or any
Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such
employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of
$120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) other employee benefits, including stock award agreements under any equity incentive plan of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. Except as disclosed in the Schedule 3.19, the Company and the Subsidiaries are in compliance with
any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all
applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof and as of the Closing
Date. The Company and the Subsidiaries maintain a system of internal accounting controls. The Company&rsquo;s certifying officers
have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the
period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the
Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such
term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to
materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth on <U>Schedule 3.20</U>, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank
or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchaser shall have no obligation
with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in
this Section that may be due by the Company in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. Except as disclosed on <U>Schedule 3.22</U>, no Person has any right to cause the Company or any Subsidiary to effect
the registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements; Shell Company</U>. The Company&rsquo;s Common Stock is not quoted or listed on any Trading Market. The
Company is not and has never been a shell company as such term is defined in Rule 12(b)(2) under the Securities Exchange Act of 1934,
as amended and the rules and regulations of the Securities and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchaser as a result of the Purchaser and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance
of the Securities and the Purchaser&rsquo;s ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided the Purchaser or its agent or counsel with any
information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed
on <U>Schedule 3.25</U>. The Company understands and confirms that the Purchaser will rely on the foregoing representation in
effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchaser
regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the
Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit
to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they
were made not misleading. The press releases disseminated by the Company during the 12 months preceding the date of this Agreement
do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading.
The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the
transactions contemplated hereby other than those specifically set forth in Article IV hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering.</U> Assuming the accuracy of the Purchaser&rsquo;s representations and warranties set forth in Article IV, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable stockholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the
Company of the proceeds from the sale of the Securities hereunder, (i) the Company&rsquo;s assets do not constitute unreasonably
small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into
account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements
and capital availability thereof, and (ii) the current cash flow of the Company, together with the proceeds the Company would
receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient
to pay all amounts on or in respect of its liabilities when such amounts are required to be paid. The Company does not intend
to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable
on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe that it will
file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the
Closing Date. <U>Schedule 3.27</U> sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the
Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo;
means (x) any liabilities for borrowed money or amounts owed in excess of $100,000 (other than trade accounts payable incurred
in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes
thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the
ordinary course of business; and (z) the present value of any lease payments in excess of $100,000 due under leases required to
be capitalized in accordance with GAAP. Except as set forth on <U>Schedule 3.27</U>, neither the Company nor any Subsidiary is
in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been
required to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and
are not being contested in good faith, except where the failure to so file or pay would not have a Material Adverse Effect. Except
as otherwise disclosed in <U>Schedule 3.28</U>, no tax deficiency has been determined adversely to the Company or any of its Subsidiaries
which has had, or would have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any
federal, state or other governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against
it which would have a Material Adverse Effect</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law, or (iv) violated any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgment
Regarding Purchaser&rsquo;s Purchase of Securities</U>. The Company acknowledges and agrees that the Purchaser is acting solely in the
capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The
Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchaser&rsquo;s purchase of the Securities. The Company further represents to the Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgement
Regarding Purchaser&rsquo;s Trading Activity</U>. Notwithstanding anything in this Agreement or elsewhere to the contrary (except for
Sections 4.7 and 5.12 hereof), it is understood and acknowledged by the Company that: (i) the Purchaser has not been asked by the Company
to agree, nor has the Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo;
securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open market
or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions,
before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s
publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which the Purchaser
is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) the Purchaser shall
not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction.
The Company further understands and acknowledges that (y) the Purchaser may engage in hedging activities at various times during the
period that the Securities are outstanding, including, without limitation, during the periods that the value of the Shares deliverable
with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&rsquo;
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that
such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation
M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the
Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Private
Placement</U>. Assuming the accuracy of each Purchaser&rsquo;s representations and warranties set forth in Article IV, no registration
under the Securities Act is required for the offer and sale of the Notes or the Shares issuable upon conversion thereof by the Company
to the Purchasers as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
General Solicitation</U>. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company offered the Securities for sale only to the Purchaser and certain
other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506(b) under the
Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer
of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding
voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the
Securities Act) connected with the Company in any capacity at the time of sale, nor any Person, including a placement agent, who
will receive a commission or fees for soliciting purchasers (each, an &ldquo;Issuer Covered Person&rdquo; and, together,
&ldquo;Issuer Covered Persons&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule
506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;Disqualification Event&rdquo;), except for a Disqualification Event
covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is
subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule
506(e), and has furnished to the Purchaser a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Disqualification Events</U>. The Company will notify the Purchaser in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;OFAC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning
of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of
1956, as amended (the &ldquo;BHCA&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;Federal
Reserve&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;Money Laundering Laws&rdquo;), and
no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any
Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE IV.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>REPRESENTATIONS AND WARRANTIES OF PURCHASERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchaser</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. The Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and performance by the Purchaser
of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate, partnership, limited
liability company or similar action, as applicable, on the part of the Purchaser. Each Transaction Document to which it is a party
has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms, except: (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. The Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting the Purchaser&rsquo;s right to sell the Securities in compliance with applicable federal and state securities laws). The
Purchaser is acquiring the Securities hereunder in the ordinary course of its business. The Purchaser understands that the Securities
are &ldquo;restricted securities&rdquo; and have not been registered under the Securities Act or any applicable state securities law
and is acquiring such Securities as principal for its own account and not with a view to or for distributing or reselling such Securities
or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing
any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities
Act or any applicable state securities law (this representation and warranty not limiting the Purchaser&rsquo;s right to sell such Securities
in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time the Purchaser was offered the Securities, it was, and as of the date hereof it is, an accredited investor within
the meaning of Rule 501 under the Securities Act. The Purchaser is not subject to any of the &ldquo;Bad Actor&rdquo; disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;Disqualification Event&rdquo;), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of the Purchaser</U>. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. The Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and has been afforded, subject to Regulation FD, (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment; provided, however, that the Purchaser has not requested nor been
provided by the Company with any non-public information regarding the Company, its financial condition, results of operations, business,
properties, management and prospects. The Purchaser acknowledges and agrees that neither the Company nor anyone else has provided the
Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, the Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with the Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that the Purchaser first received
a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the
transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case
of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other
portions of the Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed
by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other
Persons party to this Agreement or to the Purchaser&rsquo;s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, the Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions
in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company acknowledges and
agrees that the representations contained in this Article 4 shall not modify, amend or affect the Purchaser&rsquo;s right to rely on the
Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any other
Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transaction contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE V.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal
of Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Shares and the Warrants
may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of the Shares or Warrants
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection
with a pledge as contemplated in Section 5.1(b), the Company may require the transferor to provide to the Company an opinion of counsel
selected by the transferor and reasonably acceptable to the Company at the cost of the Company, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Shares
or Warrants under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Purchaser agrees to the imprinting, so long as is required by this Section 5.1, of a legend on any of the Shares or the Warrants in the
following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY
NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES
ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER
OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE
SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Shares to a financial institution that is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and, if required under
the terms of such arrangement, such Purchaser may transfer pledged or secured Shares to the pledgees or secured parties. Such a pledge
or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor
shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s expense,
the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Shares may reasonably request in connection
with a pledge or transfer of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates
evidencing the Shares (or the Transfer Agent&rsquo;s records if held in book entry form) shall not contain any legend (including the legend
set forth in Section 5.1(a) hereof): (i) while a registration statement covering the resale of such securities is effective under the
Securities Act (the &ldquo;Effective Date&rdquo;), (ii) following any sale of such Shares pursuant to Rule 144, (iii) if such Shares are
eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required
under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or (iv) if such legend is not required under applicable
requirements of the Securities Act (including Sections 4(a)(1) and 4(a)(7) judicial interpretations and pronouncements issued by the staff
of the SEC). The Company shall, if any of the provisions in clause (i) &ndash;(iv) above are applicable, at its expense, cause its counsel
to issue a legal opinion to the Transfer Agent promptly after the Effective Date if required by the Transfer Agent to effect the removal
of the legend hereunder. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to
cover the resale of the Shares, or if such Shares may be sold under Rule 144 and the Company is then in compliance with the current public
information required under Rule 144, or if the Shares may be sold under Rule 144 without the requirement for the Company to be in compliance
with the current public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or if
such legend is not otherwise required under applicable requirements of the Securities Act (including Sections 4(a)(1) and 4(a)(7), judicial
interpretations and pronouncements issued by the staff of the SEC) then such Shares shall be issued or reissued free of all legends. The
Company agrees that following the effective date of any registration statement or at such time as such legend is no longer required under
this Section 5.1(c), it will, no later than two Trading Days following the delivery by a Purchaser to the Company or the Transfer Agent
of a certificate representing restricted Shares, as applicable, issued with a restrictive legend (such second Trading Day, the &ldquo;Legend
Removal Date&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing such Shares that is free from all
restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge
the restrictions on transfer set forth in this Section 5.1. Certificates for Shares subject to legend removal hereunder shall be transmitted
by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with the Depository Trust Company
system as directed by such Purchaser. The Company shall be responsible for any delays caused by its Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to such Purchaser&rsquo;s other available remedies, (i) the Company shall pay to a Purchaser, in cash, as partial
liquidated damages and not as a penalty, for the value of the Warrant Shares for which a Warrant is being exercised (based on the
Warrant Exercise Price), $20 per Trading Day for each Trading Day after the Legend Removal Date (increasing to $20 per Trading Day
after the fifth Trading Day) until such certificate is delivered without a legend. Nothing herein shall limit such Purchaser&rsquo;s
right to pursue actual damages for the Company&rsquo;s failure to deliver certificates representing any Securities as required by
the Transaction Documents, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief, and (ii) if after the Legend Removal Date
such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by
such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal
to all or any portion of the number of shares of Common Stock that such Purchaser anticipated receiving from the Company without any
restrictive legend, then, the Company shall pay to such Purchaser, in cash, an amount equal to the excess of such Purchaser&rsquo;s
total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so
purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;Buy-In Price&rdquo;) over the
product of (A) such number of Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date
multiplied by (B) the highest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of
the delivery by such Purchaser to the Company of the applicable Shares (as the case may be) and ending on the date of such delivery
and payment under this Section 5.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event a Purchaser shall request delivery of unlegended shares as described in this Section 5.1 and the Company is required to deliver
such unlegended shares, (i) it shall pay all fees and expenses associated with or required by the legend removal and/or transfer including
but not limited to legal fees, Transfer Agent fees and overnight delivery charges and taxes, if any, imposed by any applicable government
upon the issuance of Common Stock; and (ii) the Company may not refuse to deliver unlegended shares based on any claim that such Purchaser
or anyone associated or affiliated with such Purchaser has not complied with Purchaser&rsquo;s obligations under the Transaction Documents,
or for any other reason, unless, an injunction or temporary restraining order from a court, on notice, restraining and or enjoining delivery
of such unlegended shares shall have been sought and obtained by the Company and the Company has posted a surety bond for the benefit
of such Purchaser in the amount of the greater of (i) 150% of the amount of the aggregate purchase price of the Bridge Shares (based on
the market price of the Bridge Shares) and Warrant Shares (based on exercise price in effect upon exercise) which is subject to the injunction
or temporary restraining order, or (ii) the VWAP of the Common Stock on the Trading Day before the issue date of the injunction multiplied
by the number of unlegended shares to be subject to the injunction, which bond shall remain in effect until the completion of the litigation
of the dispute and the proceeds of which shall be payable to such Purchaser to the extent Purchaser obtains judgment in Purchaser&rsquo;s
favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnishing
of Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
the earliest of the time that (i) no Purchaser owns Shares or (ii) the Warrants have expired, the Company covenants to timely file (or
obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after
the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time during the period commencing from the six month anniversary of the date hereof and ending at such time on the earlier to
occur that the Warrants are not outstanding, terminated or that all of the Warrant Shares (assuming cashless exercise) may be sold
without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation
pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule
144(c) for a period of more than 30 consecutive days or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an
issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) for a period of more than 30
consecutive days (a &ldquo;Public Information Failure&rdquo;) then, in addition to such Purchaser&rsquo;s other available remedies,
the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or
reduction of its ability to sell the Shares and/or Warrant Shares, an amount in cash equal to two percent of the aggregate Note
Conversion Price of such Purchaser&rsquo;s Note(s) and/or Warrant Exercise Price of such Purchaser&rsquo;s Warrants on the day of a
Public Information Failure and on every 30<FONT STYLE="font-size: 10pt">th </FONT>day (pro-rated for periods totaling less than
thirty days) thereafter until the earlier of (a) the date such Public Information Failure is cured and (b) such time that such
public information is no longer required for the Purchasers to transfer the Shares and/or Warrant Shares pursuant to Rule 144.
Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public
Information Failure Payments are incurred and (ii) the second Trading Day after the event or failure giving rise to the Public
Information Failure payments is cured. In the event the Company fails to make Public Information Failure payments in a timely
manner, such Public Information Failure payments shall bear interest at the rate of one and one-half percent per month (prorated for
partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public
Information Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including,
without limitation, a decree of specific performance and/or injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in
Section 2(a)(1) of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and
regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless
stockholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the SEC or any regulatory agency or Trading Market, without the prior written consent of the Purchaser, except (a)
as required by federal securities law in connection with the filing of final Transaction Documents with the SEC and (b) to the extent
such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchaser with prior notice
of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that
any Purchaser is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted
by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of
receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. When the Company&rsquo;s Common Stock is quoted or listed on a Trading Market, to the extent that any notice provided
pursuant to any Transaction Document or any other communications made by the Company, or information provided, to the Purchaser constitutes,
or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice
or other material information with the SEC pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company. In addition to any other remedies
provided by this Agreement or other Transaction Documents, if the Company knowingly provides any material, non- public information to
the Purchasers without their prior written consent, and it fails to immediately (no later than that Trading Day) file a Form 8-K, once
it is required to do so, disclosing this material, non-public information, it shall pay the Purchasers as partial liquidated damages
and not as a penalty a sum equal to $1,000 per day for each $100,000 of each Purchaser&rsquo;s Subscription Amount beginning with the
day the information is disclosed to the Purchaser and ending and including the day the Form 8-K disclosing this information is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes, and shall
not use such proceeds: (a) for the satisfaction of any Indebtedness as defined in the Note, (b) for the redemption of any Common Stock
or Common Stock Equivalents, (c) in violation of FCPA or OFAC regulations, or (d) to lend money, give credit, or make advances to any
officers, directors, employees or affiliates of the Company.</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchaser</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of this Section 5.8, the Company will indemnify and hold each Purchaser and its directors, officers, stockholders, members, partners,
employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title), each Person who controls the Purchaser (within the meaning of Section 15 of the Securities Act and
Section 20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling
persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo; fees and
costs of investigation (including local counsel, if retained) that any such Purchaser Party may suffer or incur as a result of or relating
to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other
Transaction Documents, (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates,
by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated
by the Transaction Documents (unless such action is solely based upon a breach of such Purchaser Party&rsquo;s representations, warranties
or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder
or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes
fraud, gross negligence, willful misconduct or malfeasance) or (c) any untrue or alleged untrue statement of a material fact contained
in any registration statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary
prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein (in the case of any prospectus or supplement thereto, in light of the circumstances under which they were
made) not misleading. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant
to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the
defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right
to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall
be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the
Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii)
in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company
and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel (in addition to local counsel, if retained). The Company will not be liable to any Purchaser Party under
this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not
be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable
to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party
in this Agreement or in the other Transaction Documents. The Purchaser Parties shall have the right to settle any action against any of
them by the payment of money provided that they cannot agree to any equitable relief and the Company, its officers, directors and Affiliates
receive unconditional releases in customary form. The indemnification required by this Section 5.8 shall be made by periodic payments
of the amount thereof during the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement
Without Consent if Failure to Reimburse</U>. If an indemnified party shall have requested an indemnifying party to reimburse the indemnified
party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature
contemplated by Section 5.8 effected without its written consent if (1) such settlement is entered into more than 45 days after receipt
by such indemnifying party of the aforesaid request, (2) such indemnifying party shall have received notice of the terms of such settlement
at least 30 days prior to such settlement being entered into and (3) such indemnifying party shall not have reimbursed such indemnified
party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company agrees, if the Company applies to have the Common Stock traded on any Trading Market, it will then include
in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted
on such other Trading Market as promptly as possible. The Company will then take all action necessary to continue the listing and trading
of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer
through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of
fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Senior
Debt</U>. The Company shall not issue any new indebtedness which is senior in rank to the Notes while the Notes are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. The Purchaser covenants that neither it nor any Affiliate acting on its behalf or pursuant to any
understanding with it will execute any purchases or sales, including Short Sales of any of the Company&rsquo;s securities during the
period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are
first publicly announced pursuant to the initial press release. Each Purchaser covenants that until such time as the transactions contemplated
by this Agreement are publicly disclosed by the Company pursuant to the initial press release, the Purchaser will maintain the confidentiality
of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing
and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser
makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release,
(ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with
applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities
of the Company to the Company or its Subsidiaries after the issuance of the initial press release. Notwithstanding the foregoing, in
the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the
Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of the Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of
assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DTC
Program</U>. For so long as any of the Notes are outstanding, the Company will employ as the Transfer Agent for the Common Stock and
Shares a participant in the Depository Trust Company Automated Securities Transfer Program and cause the Common Stock to be transferable
pursuant to such program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance
of Property</U>. The Company shall keep all of its property necessary for the operations of its business, which is necessary or useful
to the conduct of its business, in good working order and condition, ordinary wear and tear excepted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Preservation
of Corporate Existence</U>. The Company shall preserve and maintain its corporate existence, rights, privileges and franchises in
the jurisdiction of its incorporation, and qualify and remain qualified, as a foreign corporation in each jurisdiction in which such
qualification is necessary in view of its business or operations and where the failure to qualify or remain qualified might
reasonably have a Material Adverse Effect upon the financial condition, business or operations of the Company taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Registration of Securities on Form S-1</U>. Other than the registration rights provided hereunder, for the initial six months the Notes
are outstanding, the Company will not file any registration statements on Form S-1. For the avoidance of doubt, the foregoing shall not
prevent the Company from filing a Registration Statement on Form S-8 with respect to equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Variable
Rate Transactions</U>. While any of the Notes are outstanding, the Company shall be prohibited from entering a Variable Rate Transaction
without the prior consent of the holders of more than 50% in principal amount of the then outstanding Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights and Lock-Up Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to the Shares, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
the next Registration Statement on Form S-1 filed by the Company, include the Registrable Securities in such Registration Statement and
use its best efforts to cause the Registration Statement to become effective and remain effective as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepare
and file with the SEC such amendments, including post-effective amendments, to the Registration Statement as may be necessary to keep
the Registration Statement continuously effective as to the applicable Registrable Securities until such time as all of the Registerable
Securities have been sold by the Holder or he is eligible to otherwise remove the restrictive legend and effect a sale other than through
the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of, (i) any order suspending the effectiveness of the
Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities
for sale in any U.S. jurisdiction, at the earliest practicable moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furnish
to the Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto, including financial
statements and schedules, all documents incorporated or deemed to be incorporated therein by reference, and all exhibits to the extent
requested by the Holder (including those previously furnished or incorporated by reference) promptly after the filing of such documents
with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser agrees that, without the prior written consent of the Company, the Purchaser shall not, during the period ending 90 days after
the date of the prospectus filed with the SEC in connection with the Registration Statement on Form S-1 described in Section 5.18(a):
(1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any
Registrable Securities or (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences
of ownership of the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion
to a Corporation</U>. The Company shall convert from a limited liability company to a corporation on or before June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Right
of Participation</U>. For so long as Notes are outstanding, the Purchasers shall be given the right to purchase 20% of the shares issued
in the Company&rsquo;s IPO on a pro rata basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE IV. MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
This Agreement may be terminated by the Purchaser by written notice to the other parties, if the Closing has not been consummated on
or before June 15, 2022; provided, however, that no such termination will affect the right of any party to sue for any breach by any
other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth below and in the Transaction Documents to the contrary, each party shall pay the fees
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any
exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities
to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered by email
attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. ( Eastern Standard or Daylight
Savings Time, as applicable) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication
is delivered via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second Trading Day following the date of transmission, if
sent by U.S. nationally recognized overnight delivery service or (d) upon actual receipt by the party to whom such notice is required
to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent
that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the
Company or any Subsidiaries, the Company shall, if the Company&rsquo;s Common Stock is quoted or listed on a Trading Market, simultaneously
file such notice with the SEC pursuant to a Current Report on Form 8-K, or which failure to do so will subject the Company to the liquidated
damages provided for in Article 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. Except as provided in the last sentence of this Section 6.5, no provision of this Agreement may be waived, modified, supplemented
or amended except in a written instrument signed, in the case of an amendment, by the Company and a majority in interest of the outstanding
balance of the Note or, in the case of a waiver, by the party against whom enforcement of any such waived provision is sought. No waiver
of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in
the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay
or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any amendment effected
in accordance with accordance with this Section 6.5 shall be binding upon the Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each
Purchaser. Each Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or
transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
Section 6.7 and this Section 6.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law; Exclusive Jurisdiction; Attorneys&rsquo; Fees</U>. All questions concerning the construction, validity, enforcement and interpretation
of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New
York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against
a party hereto or its respective affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the New York County, New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the New York County, New York for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company elsewhere in this Agreement, the prevailing party in such Action or Proceeding
shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a &ldquo;.pdf' format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf
such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf' signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any
of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document
and the Company does not timely perform its related obligations within the periods therein provided, then that Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in
whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an conversion
of a Note, the Purchaser shall be required to return any Shares subject to any such rescinded Conversion Notice concurrently with the
restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to the Purchaser&rsquo;s Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction without requiring the posting of any bond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each Purchaser
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law
would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a
Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or
any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or
are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The
Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not
because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained
in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company
and the Purchasers collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have
been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts
are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver
of jury trial</U>. In any action, suit, or proceeding in any jurisdiction brought by any party against any other party, the parties each
knowingly and intentionally, to the greatest extent permitted by applicable law, hereby absolutely, unconditionally, irrevocably and
expressly waive forever trial by jury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Circumvention</U>.
The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation, including any Certificates
of Designation, or Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Agreement, and will at all times in good faith carry out all of the provision of this Agreement and take all action as may be
required to protect the rights of all holders of the Securities. Without limiting the generality of the foregoing or any other provision
of this Agreement or the other Transaction Documents, the Company (a) shall not increase the par value of any Shares and (b) shall take
all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Signature Pages Follow)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="4" STYLE="padding-left: 10pt; text-indent: -10pt"><B>60 Degrees Pharmaceuticals, LLC</B></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for Notice</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0pt; width: 3%">&nbsp;</TD>
    <TD STYLE="background-color: Black; border-bottom: black 1pt solid; padding-left: 0pt; width: 40%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-left: 0pt; width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Geoffrey Dow</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Office</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;<FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURCHASER SIGNATURE PAGE TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">SECURITIES PURCHASE
AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to
be duly executed by their respective authorized signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Purchaser: Bigger Capital Fund, LP</FONT></TD>
    <TD STYLE="background-color: Black; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Purchaser</I>:</FONT></TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory: Michael Bigger</FONT></TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory: Managing Member of the GP</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address of Authorized Signatory:</FONT></TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile Number of Authorized Signatory: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice to Purchaser:</FONT></TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 67%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Face Value $330,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Amount: $300,000</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN Number:</FONT></TD>
    <TD STYLE="background-color: Black; width: 15%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">Purchaser Signature Page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>11
<FILENAME>cm270_ex10-8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; text-indent: 0.5in"><B>Exhibit 10.8</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="text-decoration: none">EXHIBIT B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY
NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Warrant Shares: &lt;WARRANT SHARES&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Initial
Exercise Date: [*], 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS COMMON STOCK PURCHASE
WARRANT (the &ldquo;Warrant&rdquo;) certifies that, for value received, Bigger Capital Fund LP, or its assigns (the &ldquo;Holder&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;Initial Exercise Date&rdquo;) and on or prior to the close of business on the fifth year anniversary of the
Initial Exercise Date (the &ldquo;Termination Date&rdquo;) but not thereafter, to subscribe for and purchase from 60&deg; Pharmaceuticals,
LLC, a limited liability company (the &ldquo;Company&rdquo;), up to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&lt;WARRANT SHARES&gt; shares
of Common Stock (subject to adjustment hereunder, the &ldquo;Warrant Shares&rdquo;). The purchase price of one Warrant Share under this
Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant issued pursuant to a Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;) entered into as of the Initial Exercise Date between the Company and the initial Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;), dated May 24, 2022 among the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it
may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a
duly executed copy of the Notice of Exercise Form annexed hereto. Within two Trading Days following the date of exercise as
aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by
wire transfer or cashier&rsquo;s check drawn on a United States bank, unless the cashless exercise procedure specified in Section
2(c) below is specified in the applicable Notice of Exercise. Notwithstanding anything herein to the contrary (although the Holder
may surrender the Warrant to, and receive a replacement Warrant from, the Company), the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within two
Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in
purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise Form within one Trading Day of delivery of such notice. The Holder by
acceptance of this Warrant or any transferee, acknowledges and agrees that, by reason of the provisions of this Section 2(a),
following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;<U>Exercise
Price</U>. The initial exercise price per share of the Common Stock under this Warrant shall be equal to 110% of the IPO (as defined in
the Purchase Agreement) price (the &ldquo;Exercise Price&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;<U>Cashless
Exercise</U>. Other than as provided for in Section 2(f), if at any time after the six month anniversary of the Initial Exercise Date,
there is no effective Registration Statement covering the resale of the Warrant Shares by the Holder (or the prospectus does not meet
the requirements of Section 10 of the Securities Act), then this Warrant may also be exercised at the Holder&rsquo;s election, in whole
or in part and in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise, at such time by
means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the number
obtained by dividing [(A - B) times (C)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in; text-align: left">(A) =</TD><TD STYLE="text-align: justify">the greater of (i) the arithmetic average of the VWAPs for the
five consecutive Trading Days ending on the date immediately preceding the date on which the Holder elects to exercise this Warrant by
means of a &ldquo;cashless exercise,&rdquo; as set forth in the applicable Notice of Exercise or (ii) the VWAP for the Trading Day immediately
prior to the date on which the Holder makes such &ldquo;cashless exercise&rdquo; election;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in; text-align: left">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder, at
the time of such exercise; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in; text-align: left">(C) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;VWAP&rdquo; means, for any date, the
price determined by the first of the following clauses that applies: <FONT STYLE="text-decoration: none">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such
date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by
Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)) (or a similar
organization or agency succeeding to its functions of reporting prices), (b) if no volume weighted average price of the Common Stock
is reported for the Trading Market, the most recent reported bid price per share of the Common Stock, or (c) in all other cases, the
fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a
majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall
be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant
Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrants being exercised may be
tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything
herein to the contrary, if on the Termination Date (unless the Holder notifies the Company otherwise) if there is no effective
Registration Statement covering the resale of the Warrant Shares by the Holder, then this Warrant shall be automatically exercised
via cashless exercise pursuant to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;<U>Delivery
of Certificates Upon Exercise</U>. Certificates for the shares of Common Stock purchased hereunder shall be transmitted to the Holder
by the Transfer Agent by crediting the account of the Holder&rsquo;s prime broker with The Depository Trust Company through its Deposit
or Withdrawal at Custodian system (&ldquo;DWAC&rdquo;) if the Company is then a participant in such system and either (A) there is an
effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)
this Warrant is being exercised via cashless exercise and Rule 144 is available, or otherwise by physical delivery to the address specified
by the Holder in the Notice of Exercise by the date that is two Trading Days after the latest of (A) the delivery to the Company of the
Notice of Exercise and (B) payment of the aggregate Exercise Price as set forth above (unless by cashless exercise, if permitted) (such
date, the &ldquo;Warrant Share Delivery Date&rdquo;). The Warrant Shares shall be deemed to have been issued, and Holder or any other
person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the
date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted). The Company
understands that a delay in the delivery of the Warrant Shares after the Warrant Share Delivery Date could result in economic loss to
the Holder. As compensation to the Holder for such loss, the Company agrees to pay (as liquidated damages and not as a penalty) to the
Holder for late issuance of Warrant Shares upon exercise of this Warrant the proportionate amount of $10 per Trading Day (increasing to
$20 per Trading Day after the fifth Trading Day) after the Warrant Share Delivery Date for each $1,000 of the value of the Warrant Shares
for which this Warrant is exercised (based on the Exercise Price) which are not timely delivered. In no event shall liquidated damages
for any one transaction exceed $1,000 for the first 10 Trading Days. Furthermore, in addition to any other remedies which may be available
to the Holder, in the event that the Company fails for any reason to effect delivery of the Warrant Shares by the Warrant Share Delivery
Date, the Holder may revoke all or part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon
the Company and the Holder shall each be restored to their respective positions immediately prior to the exercise of the relevant portion
of this Warrant, except that the liquidated damages described above shall be payable through the date notice of revocation or rescission
is given to the Company or the date the Warrant Shares are delivered to the Holder, whichever date is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the
Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical to this Warrant. Unless the Warrant has been fully exercised, the Holders shall not
be required to surrender this Warrant as a condition of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;<U>Rescission
Rights</U>. If the Company fails to deliver the Warrant Shares or cause the Transfer Agent to transmit to the Holder a certificate or
the certificates representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will
have the right, at any time prior to issuance of such Warrant Shares, to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Certificates Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to deliver the Warrant Shares, or cause the Transfer Agent to transmit to the Holder the certificate or
certificates representing the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such
date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage
firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the
Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall pay in cash to the Holder
the amount as provided under Section 4.1(e) of the Purchase Agreement. Nothing herein shall limit a Holder&rsquo;s right to pursue
any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver certificates representing shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such certificate including any charges of any clearing firm, all of which
taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names
as may be directed by the Holder. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise.
The Company shall (A) pay the reasonable legal fees of the Holder&rsquo;s choice (in an amount not to exceed $500 per opinion, and not
more often than once per week) in connection with the exercise of the Warrants, (B) cause its attorneys to promptly provide any reliance
opinion to the Transfer Agent, and (C) pay the Holder the sums required under Section 2(d)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii)&nbsp;&nbsp;&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates), would beneficially own in excess
of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which
would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any
of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to
the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding
sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this
Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and
the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is
exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or
confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be
determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the
Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the
Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a
Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the
conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of
which such number of outstanding shares of Common Stock was reported. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be
4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days&rsquo; prior notice to the Company, may
increase the Beneficial Ownership Limitation provisions of this Section 2(e) solely with respect to the Holder&rsquo;s Warrant,
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the
provisions of this Section 2(e) shall continue to apply. Any such increase will not be effective until the 61st day after such
notice is delivered to the Company. The Holder may also decrease the Beneficial Ownership Limitation provisions of this Section 2(e)
solely with respect to the Holder&rsquo;s Warrant at any time, which decrease shall be effectively immediately upon delivery of
notice to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or
inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or
desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder
of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant or pursuant to any of the other Transaction Documents), (ii) subdivides outstanding shares of Common Stock into a larger number
of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares,
or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise
Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that
the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>. If and whenever on or after the Initial Exercise Date, the Company issues or sells, or in accordance with this
Section 3 is deemed to have issued or sold, any shares of Common Stock (including the issuance or sale of shares of Common Stock
owned or held by or for the account of the Company, issued or sold or deemed to have been issued or sold) for a consideration per
share (the &ldquo;<U>Base Share Price</U>&rdquo;) less than a price equal to the Exercise Price in effect immediately prior to such
issuance or sale or deemed issuance or sale (such Exercise Price then in effect is referred to herein as the &ldquo;<U>Applicable
Price</U>&rdquo;) (the foregoing a &ldquo;<U>Dilutive Issuance</U>&rdquo;), then immediately after such Dilutive Issuance, the
Exercise Price then in effect shall be reduced to an amount equal to the Base Share Price. For all purposes of the foregoing
(including, without limitation, determining the adjusted Exercise Price and the Base Share Price under this Section 3(b)), the
following shall be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of Options</U>. If the Company in any manner grants or sells any Options and the lowest price per share for which one share of Common
Stock is at any time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities
issuable upon exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share
of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale
of such Option for such price per share. For purposes of this Section 3(b)(i), the &ldquo;lowest price per share for which one share of
Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities
issuable upon exercise of any such Option or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the
sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock
upon the granting or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security
issuable upon exercise of such Option or otherwise pursuant to the terms thereof and (y) the lowest exercise price set forth in such Option
for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any
Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof minus (2) the sum of all amounts
paid or payable to the holder of such Option (or any other Person) upon the granting or sale of such Option, upon exercise of such Option
and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise pursuant to the
terms thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option
(or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance
of such shares of Common Stock or of such Convertible Securities upon the exercise of such Options or otherwise pursuant to the terms
of or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;<U>Issuance
of Convertible Securities</U>. If the Company in any manner issues or sells any Convertible Securities and the lowest price per share
for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to
the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been
issued and sold by the Company at the time of the issuance or sale of such Convertible Securities for such price per share. For the purposes
of this Section 3(b)(ii), the &ldquo;lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise
or exchange thereof or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the sum of the lowest amounts
of consideration (if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale of
the Convertible Security and upon conversion, exercise or exchange of such Convertible Security or otherwise pursuant to the terms thereof
and (y) the lowest conversion price set forth in such Convertible Security for which one share of Common Stock is issuable upon conversion,
exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder
of such Convertible Security (or any other Person) upon the issuance or sale of such Convertible Security plus the value of any other
consideration received or receivable by, or benefit conferred on, the holder of such Convertible Security (or any other Person). Except
as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock
upon conversion, exercise or exchange of such Convertible Securities or otherwise pursuant to the terms thereof, and if any such issuance
or sale of such Convertible Securities is made upon exercise of any Options for which adjustment of this Warrant has been or is to be
made pursuant to other provisions of this Section 3(b), except as contemplated below, no further adjustment of the Exercise Price shall
be made by reason of such issuance or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;<U>Change
in Option Price or Rate of Conversion</U>. &ldquo;Convertible Securities&rdquo; means any stock or other security (other than Options)
that is at any time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which otherwise
entitles the holder thereof to acquire, any shares of Common Stock. If the purchase or exercise price provided for in any Options, the
additional consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the rate
at which any Convertible Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or decreases
at any time (other than proportional changes in conversion or exercise prices, as applicable, in connection with an event referred to
in Section 3(a)), the Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which
would have been in effect at such time had such Options or Convertible Securities provided for such increased or decreased purchase price,
additional consideration or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold.
For purposes of this Section 3(b)(iii), if the terms of any Option or Convertible Security that was outstanding as of the Closing Date
are increased or decreased in the manner described in the immediately preceding sentence, then such Option or Convertible Security and
the shares of Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the
date of such increase or decrease. No adjustment pursuant to this Section 3(b) shall be made if such adjustment would result in an increase
of the Exercise Price then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;<U>Calculation
of Consideration Received</U>. If any Option is issued in connection with the issuance or sale of any other securities of the Company
together comprising one integrated transaction in which no specific consideration is allocated to such Option by the parties thereto,
the Options will be deemed to have been issued for a consideration of par value of the Company&rsquo;s Common Stock. If any shares of
Common Stock, Options or Convertible Securities are issued or sold or deemed to have been issued or sold for cash, the consideration received
therefor will be deemed to be the net amount of consideration received by the Company therefor. If any shares of Common Stock, Options
or Convertible Securities are issued or sold for a consideration other than cash, the amount of such consideration received by the Company
will be the fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the
amount of consideration received by the Company for such securities will be the arithmetic average of the VWAPs of such security for each
of the five Trading Days immediately preceding the date of receipt. If any shares of Common Stock, Options or Convertible Securities are
issued to the owners of the non-surviving entity in connection with any merger in which the Company is the surviving entity, the amount
of consideration therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving entity
as is attributable to such shares of Common Stock, Options or Convertible Securities. The fair value of any consideration other than cash
or publicly traded securities will be determined jointly by the Company and the Holder. If such parties are unable to reach agreement
within 10 days after the occurrence of an event requiring valuation (the &ldquo;<U>Valuation Event</U>&rdquo;), the fair value of such
consideration will be determined within five Trading Days after the 10th day following such Valuation Event by an independent, reputable
appraiser jointly selected by the Company and the Holder. The determination of such appraiser shall be final and binding upon all parties
absent manifest error. If such appraiser&rsquo;s valuation differs by less than 5% from the Company&rsquo;s proposed valuation, the fees
and expenses of such appraiser shall be borne by the Holder, and if such appraiser&rsquo;s valuation differs by more than 5% from the
Company&rsquo;s proposed valuation, the fees and expenses of such appraiser shall be borne by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;<U>Record
Date</U>. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend
or other distribution payable in shares of Common Stock, Options or in Convertible Securities or (B) to subscribe for or purchase shares
of Common Stock, Options or Convertible Securities, then such record date will be deemed to be the date of the issuance or sale of the
shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution
or the date of the granting of such right of subscription or purchase (as the case may be).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(vi)&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, this Section 3(b) shall not apply to any Exempt Issuances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;<U>Full
Ratchet Increase in Warrant Shares</U>. Until the Notes are no longer outstanding, whenever the Exercise Price is adjusted under Section
3(b), the number of Warrant Shares shall be increased on a full ratchet basis to the number of shares of Common Stock determined by multiplying
the Exercise Price then in effect immediately prior to such adjustment by the number of Warrant Shares issuable upon exercise of this
Warrant immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. By
way of example, if E is the total number of Warrant Shares in effect immediately prior to such Dilutive Issuance, F is the Exercise Price
in effect immediately prior to such Dilutive Issuance, and G is the Dilutive Issuance Price, the adjustment to the number of Warrant Shares
can be expressed in the following formula: Total number of Warrant Shares after such Dilutive Issuance = the number obtained from dividing
[E x F] by G. Notwithstanding the foregoing, if the Exercise Price is being adjusted as a result of a sale of securities, this Section
3(c) shall NOT apply if the Holder is offered the right to participate (in an amount not to exceed $50,000 unless agreed to by the Holder
and the Company) and does not participate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). Notwithstanding
the foregoing, no Purchase Rights will be made under this Section 3(d) in respect of an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock
(and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe
for or purchase any security other than the Common Stock (which shall be subject to Section 3(d)), then in each such case the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders
entitled to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned
above, and of which the numerator shall be such VWAP on such record date less the then per share fair market value at such record date
of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined
by the Board of Directors in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the
portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such
adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;<U>Fundamental
Transaction</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(i)&nbsp;&nbsp;&nbsp;If,
at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions engages in
any Fundamental Transaction, as defined in the Note, then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction (without regard to any limitation on the exercise of this Warrant), at the option of the Holder the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the &ldquo;Alternate Consideration&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall not effect a Fundamental Transaction unless it gives the Holder at least 10 Trading Days prior notice together with sufficient details
so the Holder can make an informed decision as to whether it elects to accept the Alternative Consideration. If a public announcement
of the Fundamental Transaction has not been made, the notice to the Holder may not be given until the Company files a Form 8-K or other
report disclosing the Fundamental Transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(ii)&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, provided that the Warrant Shares are not registered under an effective
registration statement, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the
date of the consummation of such Fundamental Transaction or (ii) the positive difference between the cash per share paid in such Fundamental
Transaction minus the then in effect Exercise Price. &ldquo;Black Scholes Value&rdquo; means the value of the unexercised portion of this
Warrant based on the Black and Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. determined as
of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from
the HVT function on Bloomberg L.P. as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus
the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="text-decoration: none">(iii)&nbsp;&nbsp;&nbsp;If
Section 3(f)(i) and (ii) are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the
Company is not the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under
this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(f)(iii) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior
to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a
security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
the shares of Common Stock acquirable and receivable upon exercise of this Warrant prior to such Fundamental Transaction (without
regard to any limitation on the exercise of this Warrant), and with an exercise price which applies the exercise price hereunder to
such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental
Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for
the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the
provisions of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the
Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company
under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the
Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
email to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant
Shares and setting forth a brief statement of the facts requiring such adjustment. The Holder may supply an email address to the Company
and change such address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by the Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of
all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into
other securities, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the
affairs of the Company, then, in each case, the Company shall deliver to the Holder at its last address as it shall appear upon the
Warrant Register of the Company, at least 5 calendar days prior to the applicable record or effective date hereinafter specified, a
notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to email such notice or any defect therein or in the emailing thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries (as determined in good faith by the Company), the
Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event
triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;<U>Transferability</U>.
Subject to compliance with any applicable securities laws and the provisions of the Purchase Agreement, this Warrant and all rights hereunder
(including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the
principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form
attached hereto duly executed by the Holder or its agent or attorney. Upon such surrender, the Company shall execute and deliver a new
Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new Holder for the
purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;Warrant
Register&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes,
absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;<U>No
Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof other than as explicitly set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant
or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of
such cancellation, in lieu of such Warrant or stock certificate. In no event shall the Holder be required to deliver a bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except and to the extent
as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its Articles
of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities
or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at
all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such
exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and <FONT STYLE="text-decoration: none">(iii)&nbsp;&nbsp;use
best efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered or if not exercised on a
cashless basis when Rule 144 (or any successor law or rule) is available, may have restrictions upon resale imposed by state and federal
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;<U>Non-waiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which
results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs
and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the
Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate or that there is no irreparable harm and not to require the posting
of a bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and Holders of 75% of
the outstanding Warrants issued pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">TO: <B>60&deg; Pharmaceuticals, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1)&nbsp;The undersigned hereby elects to
purchase_______Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="text-decoration: none">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-decoration: none">&#9744;&nbsp;</FONT><FONT STYLE="text-decoration: none">in
lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-decoration: none">&#9744;&nbsp;</FONT><FONT STYLE="text-decoration: none">if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="text-decoration: none">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 2in; font: 10pt Times New Roman, Times, Serif; width: 30%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; width: 100%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="text-decoration: none">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
giving effect to this Notice of Exercise, the undersigned will not have exceeded the Beneficial Ownership Limitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">The Warrant Shares shall be delivered to the following
DWAC Account Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 2in; font: 10pt Times New Roman, Times, Serif; width: 30%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0pt 0">&nbsp;<FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE OF HOLDER</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(To assign the foregoing warrant,
execute<BR>
 this form and supply required information. <BR>
Do not use this form to exercise the warrant.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">60&deg; Pharmaceuticals, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">FOR VALUE RECEIVED,_______all of or______<U></U>shares
of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whose address is</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5in">Dated: ___________, _____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature: </FONT></TD>
    <TD STYLE="width: 70%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Signature Guaranteed: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 30%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0">NOTE: The signature to this
Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change
whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>12
<FILENAME>cm270_ex10-9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><B>Exhibit 10.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THIS SECURITY NOR THE SECURITIES INTO
WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Original Issue Date: May 24, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$330,000 Principal and Face Value</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$300,000 Purchase Price and Subscription Amount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$ 30,000 Original Issue Discount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE PROMISSORY NOTE is duly
authorized and validly issued at a 10% original issue discount by 60&deg; Pharmaceuticals, LLC, a limited liability company (the
&ldquo;Company&rdquo;) (the &ldquo;Note&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the Company
promises to pay to Bigger Capital Fund, LP, or its permitted assigns (the &ldquo;Holder&rdquo;), the principal sum of $330,000 on the
earlier of May 24, 2023, the date of the Company&rsquo;s IPO, or such earlier date as this Note is required or permitted to be repaid
as provided hereunder, and to pay interest to the Holder on the aggregate then outstanding principal amount of this Note in accordance
with the provisions hereof. This Note is subject to the following additional provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 1</U>. <U>Definitions</U>. For the
purposes hereof, (a) capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement and (b)
the following words and phrases shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;Alternate Consideration&rdquo; shall have the meaning set forth
in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Bankruptcy Event&rdquo;
means any of the following events: (a) the Company or any Subsidiary thereof commences a case or other proceeding under any bankruptcy,
reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction
relating to the Company or any Subsidiary thereof, (b) there is commenced against the Company or any Subsidiary thereof any such case
or proceeding that is not dismissed within 60 days after commencement, (c) the Company or any Subsidiary thereof is adjudicated insolvent
or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Company or any Subsidiary
thereof suffers any appointment of any custodian or the like for it or any substantial part of its property that is not discharged or
stayed within 60 calendar days after such appointment, (e) the Company or any Subsidiary thereof makes a general assignment for the benefit
of creditors, (f) the Company or any Subsidiary thereof calls a meeting of its creditors with a view to arranging a composition, adjustment
or restructuring of its debts or (g) the Company or any Subsidiary thereof, by any act or failure to act, expressly indicates its consent
to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting any of the
foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Base Conversion Price&rdquo; shall have the meaning set forth
in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Beneficial Ownership Limitation&rdquo; shall have the meaning set forth in Section 4(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Black Scholes Value&rdquo;
means the value of the outstanding principal amount of this Note, plus all accrued and unpaid interest hereon based on the Black and Scholes
Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) determined as of the day
of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction
and the Maturity Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying
price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any
non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to the time between
the date of the public announcement of the applicable Fundamental Transaction and the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Buy-In&rdquo; shall have the meaning set forth in Section 4(d)(v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Change of Control Transaction&rdquo;
means the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an individual or legal entity or &ldquo;group&rdquo;
(as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership
of capital stock of the Company, by contract or otherwise) of in excess of 50% of the voting securities of the Company (other than by
means of conversion, exercise or exchange of this Note or the Warrants issued together with this Note), (b) the Company merges into or
consolidates with any other Person, or any Person merges into or consolidates with the Company and, after giving effect to such transaction,
the shareholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power of the Company or
the successor entity of such transaction, (c) the Company sells or transfers all or substantially all of its assets to another Person,
(d) a replacement at one time or within a three year period of more than one-half of the members of the Board of Directors which is not
approved by a majority of those individuals who are members of the Board of Directors on the Original Issue Date (or by those individuals
who are serving as members of the Board of Directors on any date whose nomination to the Board of Directors was approved by a majority
of the members of the Board of Directors who are members on the date hereof), or (d) the execution by the Company of an agreement to which
the Company is a party or by which it is bound, providing for any of the events set forth in clauses (a) through (d) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Default Interest Rate&rdquo; shall have the meaning set forth
in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Dilutive Issuance&rdquo; shall have the meaning set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Dilutive Issuance Notice&rdquo; shall have the meaning set forth
in Section 5(b)(5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;DWAC&rdquo; means the Deposit or Withdrawal
at Custodian system at The Depository Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Event of Default&rdquo; shall have the meaning set forth in
Section 7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Exchange Act&rdquo; means the Securities
Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Fundamental Transaction&rdquo; shall have the meaning set forth
in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;IPO&rdquo; shall have the meaning set forth in Section 4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Liens&rdquo; shall have the meaning set forth in the Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Note Register&rdquo; shall have the meaning set forth in Section 3(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Notice of Conversion&rdquo; shall have
the meaning set forth in Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Mandatory Default Amount&rdquo; shall have the meaning set forth
in Section 7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Option
Value&rdquo; means the value of a Common Stock Equivalent based on the Black Scholes Option Pricing model obtained from the
&ldquo;OV&rdquo; function on Bloomberg determined as of (A) the Trading Day prior to the public announcement of the issuance of the
applicable Common Stock Equivalent, if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day
immediately following the issuance of the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is not
publicly announced, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a
period equal to the remaining term of the applicable Common Stock Equivalent as of the applicable date of determination, (ii) an
expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of (A)
the Trading Day immediately following the public announcement of the applicable Common Stock Equivalent if the issuance of such
Common Stock Equivalent is publicly announced or (B) the Trading Day immediately following the issuance of the applicable Common
Stock Equivalent if the issuance of such Common Stock Equivalent is not publicly announced, (iii) the underlying price per share
used in such calculation shall be the highest VWAP of the Common Stock during the period beginning on the Trading Day prior to the
execution of definitive documentation relating to the issuance of the applicable Common Stock Equivalent and ending on (A) the
Trading Day immediately following the public announcement of such issuance, if the issuance of such Common Stock Equivalent is
publicly announced or (B) the Trading Day immediately following the issuance of the applicable Common Stock Equivalent if the
issuance of such Common Stock Equivalent is not publicly announced, (iv) a zero cost of borrow and (v) a 360 day annualization
factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Original Issue Date&rdquo;
means the date of the first issuance of this Note, regardless of any transfers of this Note and regardless of the number of instruments
which may be issued to evidence this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.95pt">&ldquo;Permitted Indebtedness&rdquo;
means (a) the indebtedness evidenced by this Note, (b) senior secured non-convertible loans from traditional commercials banks with interest
per annum not to exceed 12%, (c) capital lease obligations and purchase money indebtedness incurred in connection with the acquisition
of machinery and equipment as long as such capital leases and indebtedness are approved in advance by the Holder and (d) the Indebtedness
set forth on Schedule 3.27 to the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Permitted
Lien&rdquo; means the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental
charges or levies not yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good faith
and by appropriate proceedings for which adequate reserves (in the good faith judgment of the management of the Company) have been
established in accordance with GAAP, (b) Liens imposed by law which were incurred in the ordinary course of the Company&rsquo;s
business, such as carriers&rsquo;, warehousemen&rsquo;s and mechanics&rsquo; Liens, statutory landlords&rsquo; Liens, and other
similar Liens arising in the ordinary course of the Company&rsquo;s business, and which (x) do not individually or in the aggregate
materially detract from the value of such property or assets or materially impair the use thereof in the operation of the business
of the Company and its consolidated Subsidiaries or (y) are being contested in good faith by appropriate proceedings, which
proceedings have the effect of preventing for the foreseeable future the forfeiture or sale of the property or asset subject to such
Lien, (c) Liens incurred in connection with Permitted Indebtedness under clauses (a) through (d) thereunder, and Liens set forth on
Schedule 3.1(aa) to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Purchase Agreement&rdquo;
means the Securities Purchase Agreement, dated as of May 24, 2022, among the Company and the original Holders, as amended, modified or
supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Share Delivery Date&rdquo; shall have the meaning set forth
in Section 4(d)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Successor Entity&rdquo; shall have the meaning set forth in Section 5(e)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Transaction Documents&rdquo; means the Note, the Purchase Agreement
and the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;VWAP&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)) (or a similar organization or agency succeeding to its
functions of reporting prices), (b) if no volume weighted average price of the Common Stock is reported for the Trading Market, the
most recent bid price per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of
Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 2</U>. <U>Payments of Principal and
Interest</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All principal, accrued interest and other amounts
due shall be paid in U.S. Dollars by wire transfer of immediately available funds. The Company may repay the Holder before the Maturity
Date without penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest shall accrue to the Holder on
the aggregate then outstanding principal amount of this Note at the rate of 10% per annum, calculated on the basis of a 360-day
year and shall accrue daily commencing on the Original Issue Date until payment in full of the outstanding principal, together
with all accrued and unpaid interest, liquidated damages and other amounts which may become due hereunder, has been made. During
the existence of an Event of Default, interest shall accrue at the lesser of (i) the rate of 15% per annum, or (ii) &nbsp;the
maximum amount permitted by law (the lesser of clause (i) or (ii), the &ldquo;<U>Default Interest Rate</U>&rdquo;). Once an Event
of Default is cured, the interest rate shall return to 10%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 3</U>. <U>Registration of Transfers
and Exchanges</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;<U>Different
Denominations</U>. This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations,
as requested by the Holder surrendering the same. No service charge or other fees will be payable for such registration of transfer
or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;<U>Investor
Representations</U>. This Note has been issued subject to certain investment representations of the original Holder set forth
in the Purchase Agreement and may be transferred or exchanged only in compliance with the Purchase Agreement and applicable federal
and state securities laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;<U>Reliance
on Note Register</U>. Prior to due presentment for transfer to the Company of this Note, the Company and any agent of the Company
may treat the Person in whose name this Note is duly registered on the Note Register as the owner hereof for the purpose of receiving
payment as herein provided and for all other purposes, whether or not this Note is overdue, and neither the Company nor any such
agent shall be affected by notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Section 4. Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Note does not have a conversion feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Section 5</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a)&nbsp;&nbsp;<U>Stock Dividends and Stock
Splits</U>. If the Company, at any time while this Note is outstanding:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) pays a stock dividend or otherwise makes a
distribution or distributions payable in shares of Common Stock on shares of Common Stock or any Common Stock Equivalents, (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock split) outstanding
shares of Common Stock into a smaller number of shares or (iv) issues, in the event of a reclassification of shares of the Common Stock,
any shares of capital stock of the Company, then the Conversion Price shall be multiplied by a fraction of which the numerator shall be
the number of shares of Common Stock (excluding any treasury shares of the Company) outstanding immediately before such event, and of
which the denominator shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant
to this Section 5(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>. (1) At any time, for so long as the Note or any amounts accrued and payable thereunder remain outstanding, the
Company or any Subsidiary, as applicable, sells or grants any option to purchase or sells or grants any right to reprice, or otherwise
disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common
Stock Equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the
Conversion Price then in effect (such lower price, the &ldquo;Base Conversion Price&rdquo; and each such issuance or announcement
a &ldquo;<U>Dilutive Issuance</U>&rdquo;), then the Conversion Price shall be immediately reduced to equal the Base Conversion
Price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;If any Common
Stock Equivalent is amended or adjusted, and such price as so amended shall be less than the Conversion Price in effect at the time of
such amendment or adjustment, then the Conversion Price shall be adjusted upon each such issuance or amendment as provided in this Section
5(b). In case any Common Stock Equivalent is issued in connection with the issue or sale of other securities of the Company, together
comprising one integrated transaction, (x) the Common Stock Equivalents will be deemed to have been issued for the Option Value of such
Common Stock Equivalents and (y) the other securities issued or sold in such integrated transaction shall be deemed to have been issued
or sold for the difference of (I) the aggregate consideration received by the Company less any consideration paid or payable by the Company
pursuant to the terms of such other securities of the Company, less (II) the Option Value. If any shares of Common Stock or Common Stock
Equivalents are issued or sold or deemed to have been issued or sold for cash, the amount of such consideration received by the Company
will be deemed to be the net amount received by the Company therefor. If any shares of Common Stock or Common Stock Equivalents are issued
or sold for a consideration other than cash, the amount of such consideration received by the Company will be the fair value of such
consideration, except where such consideration consists of publicly traded securities, in which case the amount of consideration received
by the Company will be the average VWAP of such public traded securities for the ten days prior to the date of receipt. If any shares
of Common Stock or Common Stock Equivalents are issued to the owners of the non-surviving entity in connection with any merger in which
the Company is the surviving entity, the amount of consideration therefor will be deemed to be the fair value of such portion of the
net assets and business of the non-surviving entity as is attributable to such shares of Common Stock or Common Stock Equivalents, as
the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;If
the holder of Common Stock or Common Stock Equivalents outstanding on the Original Issue Date or issued after the Original Issuance Date
shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices
or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive
shares of Common Stock at an effective price per share that is lower than the Conversion Price then in effect, such issuance shall be
deemed to have occurred for less than the Conversion Price on such date and such issuance shall be deemed to be a Dilutive Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;If
the Company enters into a Variable Rate Transaction despite the prohibition set forth in the Purchase Agreement, the Company shall be
deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion price at which such securities may be
converted or exercised under the terms of such Variable Rate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)&nbsp;&nbsp;The
Company shall notify the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents
subject to this Section 5(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion
price and other pricing terms (such notice, the &ldquo;Dilutive Issuance Notice&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)&nbsp;&nbsp;The
provisions of this Section 5(b) shall apply each time a Dilutive Issuance occurs after the Original Issue Date for so long as the Note
or any amounts accrued and payable thereunder remain outstanding, but any adjustment of the Conversion Price pursuant to this Section
5(b) shall be downward only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(7)&nbsp;&nbsp;The provisions of this
Section 5(b) shall not apply to Exempt Issuances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 5(a) above, if at any time the Company grants, issues
or sells any Common Stock, Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of Bridge Shares, including without limitation, the Beneficial Ownership Limitation) immediately
before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken,
the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right
to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;<U>Pro Rata
Distributions</U>. During such time as this Note is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets or rights or warrants to acquire its assets, or subscribe for or purchase any security other than Common Stock, to holders
of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or
other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement
or other similar transaction) (a &ldquo;Distribution&rdquo;), at any time after the issuance of this Note, then, in each such case, the
Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the
Holder had held the number of Bridge Shares (without regard to any limitations on exercise hereof, including without limitation, the
Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<U>provided</U>, <U>however</U>, to the extent that the Holder's right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation with respect to the Company or any other publicly-traded corporation subject to Section
13(d) of the Exchange Act, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial
ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be
held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation with respect to the Company or any other publicly-traded corporation subject to Section 13(d) of
the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;<U>Fundamental
Transaction</U>. (1) If, at any time while this Note is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or
other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent conversion of this
Note, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion
immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation on the conversion of this
Note), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this Note is convertible immediately prior to such Fundamental
Transaction (without regard to any limitation on the conversion of this Note). For purposes of any such conversion, the determination
of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any conversion of this Note following such Fundamental Transaction. The Company shall not effect a Fundamental Transaction unless
it gives the Holder at least 10 Trading Days prior notice together with sufficient details so the Holder can make an informed
decision as to whether it elects to accept the Alternative Consideration. If a public announcement of the Fundamental Transaction
has not been made, the notice to the Holder may not be given until the Company files a Form 8-K or other report disclosing the
Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(2)&nbsp;&nbsp;Notwithstanding
anything to the contrary, provided that the Warrant Shares are not registered under an effective registration statement, in the event
of a Fundamental Transaction that is (x) an all cash transaction, (y) a &ldquo;Rule 13e-3 transaction&rdquo; as defined in Rule 13e-3
under the Exchange Act, or (z) a Fundamental Transaction involving a person or entity not traded on a national securities exchange or
trading market (with such exchange or market including, without limitation, the Nasdaq Global Select Trading Market, the Nasdaq Global
Market, or the Nasdaq Capital Market, the New York Stock Exchange, Inc., the NYSE American or any market operated by the OTC Markets,
Inc.), the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, concurrently with the consummation
of the Fundamental Transaction, purchase this Note from the Holder by paying to the Holder the higher of (i) an amount of cash equal to
the Black Scholes Value of the outstanding principal of this Note on the date of the consummation of such Fundamental Transaction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(3)&nbsp;&nbsp;If
Section 5(e)(1) and (2) are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under this Note and
the other Transaction Documents in accordance with the provisions of this Section 5(e) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Note a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Note. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Note and the other
Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. Notwithstanding anything
in this Section 5(e), an Exempt Issuance (as defined in the Purchase Agreement) shall not be deemed a Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding any treasury shares of the Company) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&nbsp;<U>&nbsp;Notice
to the Holder</U>.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 53.95pt">(i)&nbsp;&nbsp;<U>Adjustment
to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 5, the Company shall
promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 53.95pt">(ii)&nbsp;&nbsp;<U>Notice
to Allow Conversion by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
its Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of its Common Stock, (C)
the Company shall authorize the granting to all holders of its Common Stock of rights or warrants to subscribe for or purchase
any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required
in connection with any reclassification of its Common Stock, any consolidation or merger to which the Company is a party, any
sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby its Common
Stock is converted into other securities, cash or property or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be filed at each office
or agency maintained, and shall cause to be delivered to the Holder at its last address as it shall appear upon the Note Register,
at least 5 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date
on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record
is not to be taken, the date as of which the holders of its Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale,
transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of its
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such
notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any of the Subsidiaries (as determined in good faith by the Company), the Company or its successor shall simultaneously
file such notice with the SEC pursuant to a Current Report on Form 8-K. If the Company does not simultaneously file the required
Form 8-K, the Holder shall be entitled penalties in accordance with Section 5.6 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 6</U>. <U>Negative Covenants</U>. As
long as any portion of this Note remains outstanding, unless all of the Holders of the then outstanding Notes shall have otherwise given
prior written consent, the Company shall not, and shall not permit any of the Subsidiaries to, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;other
than Permitted Indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any indebtedness for borrowed money of any
kind, including, but not limited to, a guarantee, on or with respect to any of its property or assets now owned or hereafter acquired
or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;other
than Permitted Liens, enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to any of its property
or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)  &nbsp;amend
its charter documents, including, without limitation, its articles of incorporation and bylaws, in any manner that materially and adversely
affects any rights of the Holder, increases in authorized shares and stock splits shall not be deemed to materially and adversely affects
any rights of the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) &nbsp;purchase
or otherwise acquire more than a <U>de minimis</U> number of shares of its Common Stock or Common Stock Equivalents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(e)  &nbsp;repay,
or offer to repay, any Indebtedness, other than Permitted Indebtedness, as such terms Indebtedness and Permitted Indebtedness are in effect
as of the Original Issue Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(f)&nbsp;&nbsp;pay cash dividends or
distributions on any equity securities of the Company;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(g)  &nbsp;enter
into any transaction with any Affiliate of the Company which would be required to be disclosed in any public filing with the SEC assuming
that the Company is subject to the Securities Act or the Exchange Act, unless such transaction is made on an arm&rsquo;s-length basis
and expressly approved by a majority of the disinterested directors of the Company (even if less than a quorum otherwise required for
board approval);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(h)  &nbsp;issue
any equity securities of the Company other than pursuant to the provisions of the Purchase Agreement or an Exempt Issuance; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(i)&nbsp;&nbsp;enter into any agreement
with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 7</U>. <U>Events of Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)  &nbsp;&ldquo;Event
of Default&rdquo; means, wherever used herein, any of the following events (whatever the reason for such event and whether such event
shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order,
rule or regulation of any administrative or governmental body):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)  &nbsp;any
default in the payment of (A) principal and interest payment under this Note or any other Indebtedness, or (B) late fees, liquidated damages
and other amounts owing to the Holder of this Note, as and when the same shall become due and payable (whether on a Conversion Date, or
the Maturity Date, or by acceleration or otherwise), which default, solely in the case of a default under clause (B) above, is not cured
within five Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)  &nbsp;the
Company shall fail to observe or perform any other covenant or agreement contained in this Note (other than a breach by the Company of
its obligations to deliver Shares, which breach is addressed in clause (x) below) or any Transaction Document which failure is not cured,
if possible to cure, within the earlier to occur of 15 Trading Days after notice of such failure is sent by the Holder or by any other
Holder to the Company and (B) 10 Trading Days after the Company has become aware of such failure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)  &nbsp;except
for payment defaults covered under Section 7(a)(i), the Company shall breach, or a default or event of default (subject to any grace or
cure period provided in the applicable agreement, document or instrument) shall occur under, (A) any of the Transaction Documents or (B)
any other material agreement, lease, document or instrument to which the Company or any Subsidiary is obligated (and not covered by any
other clause of this Section 7) which default or event of default if not cured, if possible to cure, within the earlier to occur of (i)
10 Trading Days after notice of such default sent by Holder or by any other holder to the Company and (ii) five Trading Days after the
Company has become aware of such default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)  &nbsp;any
representation or warranty made in this Note, any other Transaction Document, any written statement pursuant hereto or thereto or any
other report, financial statement or certificate made or delivered to the Holder or any other Holder shall be untrue or incorrect in any
material respect as of the date when made or deemed made, which failure is not cured, if possible to cure, within the earlier to occur
of 10 Trading Days after notice of such failure is sent by the Holder or by any other Holder to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&nbsp;&nbsp;the Company or any Subsidiary
shall be subject to a Bankruptcy Event;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)  &nbsp;the
Company or any Subsidiary shall: (A) apply for or consent to the appointment of a receiver, trustee, custodian or liquidator of it or
any of its properties; (B) admit in writing its inability to pay its debts as they mature; (C) make a general assignment for the benefit
of creditors; (D) be adjudicated as bankrupt or insolvent or be the subject of an order for relief under Title 11 of the United States
Code or any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law or statute of any other jurisdiction
or foreign country; or (E) file a voluntary petition in bankruptcy, or a petition or an answer seeking reorganization or an arrangement
with creditors or to take advantage or any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law
or statute, or an answer admitting the material allegations of a petition filed against it in any proceeding under any such law, or (F)
take or permit to be taken any action in furtherance of or for the purpose of effecting any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii)  &nbsp;if
any order, judgment or decree shall be entered, without the application, approval or consent of the Company or any Subsidiary, by any
court of competent jurisdiction, approving a petition seeking liquidation or reorganization of the Company or any Subsidiary, or appointing
a receiver, trustee, custodian or liquidator of the Company or any Subsidiary, or of all or any substantial part of its assets, and such
order, judgment or decree shall continue unstayed and in effect for any period of 60 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(viii)  &nbsp;the
occurrence of any levy upon or seizure or attachment of, or any uninsured loss of or damage to, any property of the Company or any Subsidiary
having an aggregate fair value or repair cost (as the case may be) in excess of $100,000 individually or in the aggregate, and any such
levy, seizure or attachment shall not be set aside, bonded or discharged within 45 days after the date thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(ix)  &nbsp;any
monetary judgment, writ or similar final process shall be entered or filed against the Company, any Subsidiary or any of their respective
property or other assets for more than $100,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or
unstayed for a period of 30 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(x)&nbsp;&nbsp;any Material Adverse Effect
occurs;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xi)  &nbsp;any
provision of any Transaction Document shall at any time for any reason (other than pursuant to the express terms thereof) cease to be
valid and binding on or enforceable against the parties thereto, or the validity or enforceability thereof shall be contested by any party
thereto, or a proceeding shall be commenced by the Company or any Subsidiary or any governmental authority having jurisdiction over any
of them, seeking to establish the invalidity or unenforceability thereof, or the Company or any Subsidiary shall deny in writing that
it has any liability or obligation purported to be created under any Transaction Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xii)  &nbsp;the
Company fails to use the proceeds in the manner as described in Section 5.7 of the Purchase Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xiii)  &nbsp;the
Company shall be a party to any Change of Control Transaction or shall agree to sell or dispose of all or in excess of 50% of its assets
in one transaction or a series of related transactions (whether or not such sale would constitute a Change of Control Transaction);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xiv)  &nbsp;from
and after 90 days after the Original Issue Date, the Company fails to have authorized and reserved the amount of shares designated in
Section 3.5 of the Purchase Agreement (including without limitation, the Beneficial Ownership Limitation);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xv)  &nbsp;the
Company fails to file with the SEC any required reports under Section 13 or 15(d) of the Exchange Act within the time required (including
any applicable extension period) by the rules and regulations thereunder; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xvi)  &nbsp;the
Company fails to convert from a limited liability company to a corporation on or before June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) &nbsp;<U>Remedies Upon
Event of Default</U>. If any Event of Default occurs, the outstanding principal amount of this Note, plus liquidated damages and other
amounts owing in respect thereof through the date of acceleration, shall become, at the Holder&rsquo;s election, immediately due and
payable in cash (the &ldquo;Mandatory Default Amount&rdquo;). Upon the payment in full of the Mandatory Default Amount, the Holder shall
promptly surrender this Note to or as directed by the Company. In connection with such acceleration described herein, the Holder need
not provide, and the Company hereby waives, any presentment, demand, protest or other notice of any kind, and the Holder may immediately
and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all other remedies available
to it under applicable law. Such acceleration may be rescinded and annulled by Holder at any time prior to payment hereunder and the
Holder shall have all rights as a holder of the Note until such time, if any, as the Holder receives full payment pursuant to this Section
7(b). No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>&nbsp;Interest Rate
Upon Event of Default</U>. Commencing on the occurrence of any Event of Default and until such Event of Default is cured, this Note shall
accrue interest at an interest rate equal to the Default Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Section 8</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) &nbsp;<U>No Rights as
Stockholder Until Conversion</U>. This Note does not entitle the Holder to any voting rights, dividends or other rights as a stockholder
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) &nbsp;<U>Notices</U>.
All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing, and shall be sufficiently
given if delivered to the addressees in person, by FedEx or similar receipted next day delivery, or at the Company&rsquo;s registered
address or such other address as any of them, by notice to the other may designate from time to time. Time shall be counted to, or from,
as the case may be, the date of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) &nbsp;<U>Absolute Obligation</U>.
Except as expressly provided herein, no provision of this Note shall alter or impair the obligation of the Company, which is absolute
and unconditional, to pay the principal of, liquidated damages and accrued interest and late fees, as applicable, on this Note at the
time, place, and rate, and in the coin or currency, herein prescribed. This Note is a direct debt obligation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) &nbsp;<U>Lost or Mutilated
Note</U>. If this Note shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver, in exchange and substitution
for and upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost, stolen or destroyed Note, a new Note for
the principal amount of this Note so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction
of this Note, and of the ownership hereof, reasonably satisfactory to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(e) <U>Exclusive Jurisdiction;
Governing Law; Prevailing Party Attorneys&rsquo; Fees</U>. All questions concerning the construction, validity, enforcement and interpretation
of this Note and venue shall be governed by and construed and enforced in accordance with Section 6.9 of the Purchase Agreement. If any
party shall commence an Action or Proceeding to enforce or otherwise relating to this Note, then, in addition to the other obligations
of the Company elsewhere in this Note, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party
for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution of
such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) &nbsp;<U>Waiver</U>.
Any waiver by the Company or the Holder of a breach of any provision of this Note shall not operate as or be construed to be a waiver
of any other breach of such provision or of any breach of any other provision of this Note. The failure of the Company or the Holder
to insist upon strict adherence to any term of this Note on one or more occasions shall not be considered a waiver or deprive that party
of the right thereafter to insist upon strict adherence to that term or any other term of this Note on any other occasion. Any waiver
by the Company or the Holder must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)
&nbsp;<U>Severability</U>. If any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain
in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other
Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the
applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum
rate of interest permitted under applicable law. The Company covenants (to the extent that it may lawfully do so) that it shall not
at any time insist upon, plead, or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury
law or other law which would prohibit or forgive the Company from paying all or any portion of the principal of or interest on this
Note as contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the
performance of this Note, and the Company (to the extent it may lawfully do so) hereby expressly waives all benefits or advantage of
any such law, and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein
granted to the Holder, but will suffer and permit the execution of every such as though no such law has been enacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) &nbsp;<U>Remedies, Characterizations,
Other Obligations, Breaches and Injunctive Relief</U>. The remedies provided in this Note shall be cumulative and in addition to all
other remedies available under this Note and any of the other Transaction Documents at law or in equity (including a decree of specific
performance and/or other injunctive relief), and nothing herein shall limit the Holder&rsquo;s right to pursue actual and consequential
damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder that there shall be
no characterization concerning this instrument other than as expressly provided herein. Amounts set forth or provided for herein with
respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be received by the Holder and shall
not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance thereof). The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for
any such breach would be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the Holder
shall be entitled, in addition to all other available remedies, to an injunction restraining any such breach or any such threatened breach,
without the necessity of showing economic loss and without any bond or other security being required. The Company shall provide all information
and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company&rsquo;s compliance with the
terms and conditions of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) &nbsp;<U>Next Trading
Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Trading Day, such payment shall be made
on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) &nbsp;<U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Note and shall not be deemed to limit or affect
any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.95pt">IN WITNESS WHEREOF, the Company has caused this
Note to be duly executed by a duly authorized officer as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>13
<FILENAME>cm270_ex10-10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.10</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of May 24, 2022, by and between 60&deg; Pharmaceuticals, LLC, a limited liability
company, and each investor that executes the signature page hereto as a purchaser (each, a &ldquo;Purchaser&rdquo; and collectively,
the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, subject
to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of
the Securities Act, as defined, contained in Section 4(a)(2) thereof and/or Rule 506(b) thereunder, the Company desires to issue and sell
to the Purchaser, and the Purchaser desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy
of which are hereby acknowledged, the Company and the Purchaser agree as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE I.<BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">1.1 <U>Definitions</U>.
In addition to the words and terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">&ldquo;Acquiring Person&rdquo;
shall have the meaning ascribed to such term in Section 5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">&ldquo;Action&rdquo;
shall have the meaning ascribed to such term in Section 3.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Affiliate&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Bridge Shares&rdquo;
means shares of the Company&rsquo;s Common Stock issued to each Purchaser equal to and based on (A) 100% of the Face Value of each Purchaser&rsquo;s
Note divided by the Company&rsquo;s IPO price upon the pricing of the Company&rsquo;s IPO or (B) if the Company fails to complete the
IPO before the Maturity Date, the number of shares calculated using a $27 million pre-money valuation for the Company and the number of
the Company&rsquo;s shares outstanding on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Board of Directors&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Closing&rdquo;
means the closing of the purchase and sale of the Notes pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Closing
Date&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all conditions precedent to (i) the Purchaser&rsquo;s obligations to pay the Subscription Amount and (ii) the
Company&rsquo;s obligations to deliver the Securities to be issued and sold, in each case, have been satisfied or waived, but in no
event later than the second Trading Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Common Stock&rdquo;
means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Common Stock
Equivalents&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time
convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 9pt"><TR STYLE="font-size: 9pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 9pt; width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Company&rdquo;
means 60&deg; Pharmaceuticals, LLC and any successor company after conversion from a limited liability company to a corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Evaluation Date&rdquo;
shall have the meaning ascribed to such term in Section 3.19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Exchange
Act&rdquo; means the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Exempt
Issuance&rdquo; means the issuance of (a) shares of Common Stock, restricted stock units or options, and the underlying shares of
Common Stock to consultants, employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for
such purpose, by a majority of the non- employee members of the Board of Directors or a majority of the members of a committee of
non-employee directors established for such purpose for services rendered to the Company, (b) securities issued upon the exercise or
exchange of or conversion of any Securities issued hereunder and/or other securities issuable pursuant to existing agreements,
exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement,
provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to
decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock dividends,
stock splits or combinations) or to extend the term of such securities, (c) securities issued pursuant, acquisitions or strategic
transactions approved by a majority of the directors of the Company, provided that any such issuance shall only be to a Person (or
to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a
business synergistic with the business of the Company and which shall reasonably be expected to provide to the Company additional
benefits, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising
capital or to an entity whose primary business is investing in securities, (d) securities issued pursuant to any purchase money
equipment loan or capital leasing arrangement, purchasing agent or debt financing from a commercial bank or similar financial
institution, (e) securities issued pursuant to any presently outstanding warrants or this Agreement; and (f) securities upon a stock
split, stock dividend or subdivision of the Common Stock and shares of common stock in a public offering; (g) non-convertible loans
from traditional commercials banks with interest per annum not to exceed 12% which will rank <B><I>pari passu </I></B>with the Notes
issued to investors by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Face Value&rdquo;
means the Subscription Amount plus original issue discount as described in the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;FCPA&rdquo; means
the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;GAAP&rdquo; shall have the meaning ascribed to such term in Section 3.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Indebtedness&rdquo; shall have the meaning ascribed to such term in Section 3.27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Intellectual
Property&rdquo; means all of the following in any jurisdiction throughout the world: (a) all inventions (whether patentable or
unpatentable and whether or not reduced to practice), all improvements thereto, and all U.S. and foreign patents, patent
applications, and patent disclosures, together with all reissuances, continuations, continuations-in-part, revisions, extensions,
and reexaminations thereof, (b) all trademarks, service marks, brand names, certification marks, trade dress, logos, trade names,
domain names, assumed names and corporate names, together with all colorable imitations thereof, and including all goodwill
associated therewith, and all applications, registrations, and renewals in connection therewith, (c) all copyrights, and all
applications, registrations, and renewals in connection therewith, (d) all trade secrets under applicable state laws and the common
law and know-how (including formulas, techniques, technical data, designs, drawings, specifications, customer and supplier lists,
pricing and cost information, and business and marketing plans and proposals), (e) all computer software (including source code,
object code, diagrams, data and related documentation), and (f) all copies and tangible embodiments of the foregoing (in whatever
form or medium).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;IPO&rdquo;
shall mean an initial public offering by the Company that results in a listing of the Company&rsquo;s Common Stock on a national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Licensed
Intellectual Property Agreement&rdquo; means all licenses, sublicenses, agreements and permissions (each as amended to date) that any
third party owns and that the Company uses, including off- the-shelf software purchased or licensed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Liens&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Material Adverse
Effect&rdquo; shall have the meaning assigned to such term in Section 3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Maturity Date&rdquo;
shall have the meaning assigned to such term in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Notes&rdquo;
means the Original Issue Discount Promissory Notes issued to the Purchaser, in the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Original
Issue Date&rdquo; means the date of the first issuance of the Notes, regardless of any transfers of any Note and regardless of the number
of instruments which may be issued to evidence such Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Person&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Proceeding&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Purchaser Party&rdquo;
shall have the meaning ascribed to such term in Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Registrable
Securities&rdquo; shall mean, collectively, the Bridge Shares and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Regulation
FD&rdquo; means Regulation FD promulgated by the SEC pursuant to the Exchange Act, as such Regulation may be amended or interpreted from
time to time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such
Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Required Approvals&rdquo;
shall have the meaning ascribed to such term in Section 3.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Rule 144&rdquo;
means Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or
any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;SEC&rdquo; means
the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Securities&rdquo;
means the Notes, the Warrants and the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Securities
Act&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Shares&rdquo;
means the Bridge Shares and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Short Sales&rdquo;
means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include
the location and/or reservation of borrowable shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Subscription
Amount&rdquo; means, as to the Purchaser, the aggregate amount to be paid for the Note purchased hereunder as specified below the Purchaser&rsquo;s
name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in United States dollars and in
immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Subsidiary&rdquo;
means with respect to any entity at any date, any direct or indirect corporation, limited or general partnership, limited liability company,
trust, estate, association, joint venture or other business entity of which (A) more than 50% of (i) the outstanding capital stock having
(in the absence of contingencies) ordinary voting power to elect a majority of the Board of Directors or other managing body of such entity,
(ii) in the case of a partnership or limited liability company, the interest in the capital or profits of such partnership or limited
liability company or (iii) in the case of a trust, estate, association, joint venture or other entity, the beneficial interest in such
trust, estate, association or other entity business is, at the time of determination, owned or controlled directly or indirectly through
one or more intermediaries, by such entity, or (B) is under the actual control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Trading Day&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Trading
Market&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in
question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock
Exchange, the OTCQB, the OTCQX, or the OTC Pink Marketplace (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Transaction
Documents&rdquo; means this Agreement, the Notes, the Warrants, and any other documents or agreements executed in connection with the
transactions contemplated hereunder, including, but not limited to, the documents referenced in Section 2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Transfer Agent&rdquo;
means [*], and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Variable
Rate Transaction&rdquo; means any Equity Line of Credit or similar agreement, nor issue nor agree to issue any Common Stock, floating
or Variable Priced Equity Linked Instruments nor any of the foregoing or equity with price reset rights (subject to adjustment for stock
splits, distributions, dividends, recapitalizations and the like) (collectively, the &ldquo;Variable Rate Transaction&rdquo;). For purposes
of this Agreement, &ldquo;Equity Line of Credit&rdquo; shall include any transaction involving a written agreement between the Company
and an investor or underwriter whereby the Company has the right to &ldquo;put&rdquo; its securities to the investor or underwriter over
an agreed period of time and at an agreed price or price formula, and &ldquo;Variable Priced Equity Linked Instruments&rdquo; shall include:
(A) any debt or equity securities which are convertible into, exercisable or exchangeable for, or carry the right to receive additional
shares of Common Stock either (1) at any conversion, exercise or exchange rate or other price that is based upon and/or varies with the
trading prices of or quotations for Common Stock at any time after the initial issuance of such debt or equity security, or (2) with a
fixed conversion, exercise or exchange price that is subject to being reset at some future date at any time after the initial issuance
of such debt or equity security due to a change in the market price of the Company&rsquo;s Common Stock since date of initial issuance,
and (B) any amortizing convertible security which amortizes prior to its maturity date, where the Company is required or has the option
to (or any investor in such transaction has the option to require the Company to) make such amortization payments in shares of Common
Stock which are valued at a price that is based upon and/or varies with the trading prices of or quotations for Common Stock at any time
after the initial issuance of such debt or equity security (whether or not such payments in stock are subject to certain equity conditions).
For purposes of determining the total consideration for a convertible instrument (including a right to purchase equity of the Company)
issued, subject to an original issue or similar discount or which principal amount is directly or indirectly increased after issuance,
the consideration will be deemed to be the actual cash amount received by the Company in consideration of the original issuance of such
convertible instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Warrants&rdquo;
means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a)
hereof, which Warrants shall be exercisable immediately and have a term of exercise equal to five years from such initial exercise
date, in the form of <U>Exhibit B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&ldquo;Warrant Exercise
Price&rdquo; means the exercise price provided in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0.5in">&ldquo;Warrant Shares&rdquo;
means the shares of Common Stock issuable upon exercise of the Warrants at the Warrant Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE II.<BR>
PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing</U>.
On the Closing Dates, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution
and delivery of this Agreement by the parties hereto, the Company agrees to sell, and each Purchaser, severally and not jointly,
agrees to purchase an aggregate of (i) Notes with a Face Value listed on the Purchaser&rsquo;s signature page and (ii) Warrants
to purchase shares equal to 50% of the Bridge Shares. On the Closing Date, the Purchaser shall deliver to the Company a signed
copy of the Transaction Documents and, via wire transfer, immediately available funds equal to the Purchaser&rsquo;s Subscription
Amount. After receipt of the Subscription Amount, the Company shall deliver to the Purchaser countersigned copies of the Transaction
Documents. Upon satisfaction of the closing conditions set forth in Section 2.3, the Closing shall occur at the Company&rsquo;s
offices or such other location as the parties shall mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"> 2.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deliveries.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.75in"> (ii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a Note in the principal amount of $250,000.00 registered in the name of the Purchaser;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;
an original Warrant to purchase shares of Common Stock, exercisable at the Warrant Exercise Price, registered in the name of
such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.75in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
Board Consent approving the issuance of the Notes and the execution of the Transaction Documents listed above on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 55pt"></TD><TD STYLE="width: 18pt">(i)</TD><TD>this Agreement duly executed by the Purchaser; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 55pt"></TD><TD STYLE="width: 18pt">(ii)</TD><TD>the Purchaser&rsquo;s Subscription Amount by wire transfer to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the (i) date of the pricing of the Company&rsquo;s IPO, the Company shall deliver to each Purchaser shares of the Company&rsquo;s common
stock equal to 100% of the Face Value of each Purchaser&rsquo;s Note divided by the Company&rsquo;s IPO price upon or (ii) if the Company
fails to complete the IPO before the Maturity Date, the number of shares of the Company&rsquo;s common stock calculated using a $27 million
pre- money valuation for the Company and the number of the Company&rsquo;s shares outstanding on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41.95pt"></TD><TD STYLE="width: 36pt">2.3</TD><TD>Closing Conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) on the Closing Date of the representations and warranties of the Purchaser contained herein (unless as of a specific
date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 54.05pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 55pt"></TD><TD STYLE="width: 18pt">(iii)</TD><TD>the delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;accuracy
in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in
all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a
specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 55pt"></TD><TD STYLE="width: 18pt">(iii)</TD><TD>the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 77.95pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 55pt"></TD><TD STYLE="width: 18pt">(iv)</TD><TD>there shall have been no Material Adverse Effect with respect to the Company since the</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0in">date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;ARTICLE III.<BR>
REPRESENTATIONS AND WARRANTIES OF COMPANY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Company hereby
makes the following representations and warranties to each Purchaser as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power
and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company
nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or Articles of Incorporation,
bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted
or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as
the case may be, could not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity
or enforceability of any Transaction Document, (ii) a material adverse effect on the results of operations, assets, business,
prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse
effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its obligations under any Transaction
Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding has been instituted in
any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. Subject to obtaining the Required Approvals, this Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. Except as set forth in <U>Schedule 3.3</U>, the execution, delivery and performance by the Company of this Agreement and
the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions
contemplated hereby and thereby do not and will not (i) subject to the Required Approvals, conflict with or violate any provision of
the Company&rsquo;s or any Subsidiary&rsquo;s Certificate or Articles of Incorporation, bylaws or other organizational or charter documents,
or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under,
result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights
of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility,
debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required
Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses
(ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. Except as set forth on <U>Schedule 3.4</U>, the Company is not required to obtain any consent, waiver, authorization
or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental
authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other
than: (i) blue sky filings or a Form D filing and (ii) such filings as are required to be made under applicable state securities laws
(the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Shares,
when issued will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company shall
reserve from its duly authorized capital stock a number of shares of Common Stock issuable pursuant to the Notes and Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The capitalization of the Company is as set forth on <U>Schedule 3.6</U>. The Company has not issued any capital stock since its most
recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock awards under the Company&rsquo;s
equity incentive plans, the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans
and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic
report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as set forth on <U>Schedule 3.6</U>, as a result
of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares
of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate
the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchaser) and will not
result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities.
There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound
to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo;
plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized,
validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of
such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No
further approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities.
There are no stockholders&rsquo; agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital
stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect Subsidiaries of the Company are set forth in Schedule 3.7. The Company owns, directly or indirectly, all
of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Statements</U>. The consolidated financial statements of the Company, together with the related notes and schedules, present fairly,
in all material respects, the consolidated financial position of the Company and any of its Subsidiaries as of the dates indicated and
the consolidated results of operations, cash flows and changes in stockholders&rsquo; equity of the Company for the periods specified
and have been prepared in compliance with United States generally accepted accounting principles (&ldquo;GAAP&rdquo;) applied on a consistent
basis during the periods involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest financial statements: (i) there has been no
event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company
has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary
course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements
pursuant to GAAP, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company equity incentive plans. Other than as disclosed on Schedule 3.9, except for the issuance of the Securities contemplated
by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected
to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations,
assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this
representation is made or deemed made that has not been publicly disclosed at least one Trading Day prior to the date that this representation
is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
Except as set forth on <U>Schedule 3.10</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation,
inquiry or other similar proceeding of any federal or state government unit pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an
&ldquo;<U>Action</U>&rdquo;) which (i) adversely affects or challenges the legality, validity or enforceability of any of the
Transaction Documents or the issuance of the Securities or (ii) could, if there were an unfavorable decision, have or reasonably be
expected to result in a Material Adverse Effect. The Company has no reason to believe that an Action will be filed against it in the
future except as disclosed on <U>Schedule 3.10</U>. Neither the Company nor any Subsidiary, nor any director or officer thereof, is
or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a
claim for fraud or breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or
contemplated, any investigation or inquiry by the SEC involving the Company or any current or former director or officer of the
Company. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement filed by
the Company or any Subsidiary under the Securities Act, and the Company has no reason to believe it will do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their
relationships with their employees are good. To the knowledge of the Company, no effort is underway to unionize or organize the employees
of the Company or any Subsidiary. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now
expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information
agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and
the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with
respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign
laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except
where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect. There is no workmen&rsquo;s compensation liability matter, employment-related charge, complaint, grievance, investigation, inquiry
or obligation of any kind pending, or to the Company&rsquo;s knowledge, threatened, relating to an alleged violation or breach by the
Company or its Subsidiaries of any law, regulation or contract that could, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Except as set forth on <U>Schedule 3.12</U>, neither the Company nor any Subsidiary: (i) is in default under or in violation of (and
no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or
any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in
violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any
of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or
order of any court, arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or
regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes,
environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each
case as could not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;Hazardous Materials&rdquo;) into the environment, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations,
codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations,
issued, entered, promulgated or approved thereunder (&ldquo;Environmental Laws&rdquo;); (ii) have received all permits licenses or other
approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with
all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could
be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates, authorizations
or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor any Subsidiary has
received any notice of proceedings relating to the revocation or modification of any such certificate, authorization or permit. There
is no agreement, commitment, judgment, injunction, order or decree binding upon the Company or any of its Subsidiaries or to which the
Company or any of its Subsidiaries is a party which has or would reasonably be expected to have the effect of prohibiting or materially
impairing any business practice of the Company or any of its Subsidiaries, any acquisition of property by the Company or any of its Subsidiaries
or the conduct of business by the Company or any of its Subsidiaries as currently conducted other than such effects, individually or
in the aggregate, which have not had and would not reasonably be expected to have a Material Adverse Effect on the Company or any of
its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. Subject to the Liens of the outstanding secured senior debt, the Company and the Subsidiaries have good and marketable
title in fee simple to all personal property owned by them that is material to the business of the Company and the Subsidiaries. The
Company owns no real property. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them
under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Intellectual Property</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the Liens of the outstanding secured senior debt, to the Company&rsquo;s knowledge, the Company owns or possesses or has the right
to use pursuant to a valid and enforceable written license, sublicense, agreement, or permission all Intellectual Property necessary for
the operation of the business of the Company as presently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 54.05pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company&rsquo;s knowledge, the Intellectual Property does not interfere with, infringe upon, misappropriate, or otherwise come into
conflict with, any Intellectual Property rights of third parties, and the Company has no knowledge that facts exist which indicate a likelihood
of the foregoing. The Company has not received any charge, complaint, claim, demand, or notice alleging any such interference, infringement,
misappropriation, or conflict (including any claim that the Company must license or refrain from using any Intellectual Property rights
of any third party). To the knowledge of the Company, no third party has interfered with, infringed upon, misappropriated, or otherwise
come into conflict with, any Intellectual Property rights of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 54.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 54.05pt"> (iii) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect
to each Licensed Intellectual Property Agreement:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Licensed Intellectual Property Agreement is legal, valid, binding, enforceable, and in full force and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 120pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company&rsquo;s knowledge, no party to the Licensed Intellectual Property Agreement is in breach or default, and no event has
occurred that with notice or lapse of time would constitute a breach or default or permit termination, modification, or acceleration
thereunder, which as to any such breach, default or event could have a Material Adverse Effect on the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
party to such Licensed Intellectual Property Agreement has repudiated any provision thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 72.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 72.05pt">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in such Licensed Intellectual Property Agreement, the Company has not received written or verbal notice or otherwise has
knowledge that the underlying item of Intellectual Property is subject to any outstanding injunction, judgment, order, decree, ruling,
or charge; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth on Schedule 3.16, the Company has not granted any sublicense or similar right with respect to the license, sublicense, agreement,
or permission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 53.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 53.95pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has complied with and is presently in compliance with all foreign, federal, state, local, governmental (including, but not limited
to, the Federal Trade Commission and State Attorneys General), administrative, or regulatory laws, regulations, guidelines, and rules
applicable to any personal identifiable information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 53.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Person who participated in the creation, conception, invention or development of the Intellectual Property currently used in the business
of the Company (each, a &ldquo;Developer&rdquo;) which is not licensed from third parties has executed one or more agreements containing
industry standard confidentiality, work for hire and assignment provisions, whereby the Developer has assigned to the Company all copyrights,
patent rights, Intellectual Property rights and other rights in the Intellectual Property, including all rights in the Intellectual Property
that existed prior to the assignment of rights by such Person to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78.7pt; text-indent: -18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in"> (vi) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Developer has signed a perpetual non-disclosure agreement with the Company.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company
nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase
in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as disclosed in Schedule 3.18, none of the officers or directors of the Company or any
Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal
property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any
officer, director or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such
employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of
$120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on
behalf of the Company and (iii) other employee benefits, including stock award agreements under any equity incentive plan of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. Except as disclosed in the Schedule 3.19, the Company and the Subsidiaries are in compliance with any
and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable
rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof and as of the Closing Date. The Company
and the Subsidiaries maintain a system of internal accounting controls. The Company&rsquo;s certifying officers have evaluated the effectiveness
of the disclosure controls and procedures of the Company and the Subsidiaries
as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &ldquo;<U>Evaluation
Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since
the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange
Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth on <U>Schedule 3.20</U>, no brokerage or finder&rsquo;s fees or commissions are or will be payable by the
Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person
with respect to the transactions contemplated by the Transaction Documents. The Purchaser shall have no obligation with respect to any
fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be
due by the Company in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The
Company shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration
under the Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. Except as disclosed on <U>Schedule 3.22</U>, no Person has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements; Shell Company</U>. The Company&rsquo;s Common Stock is not quoted or listed on any Trading Market. The
Company is not and has never been a shell company as such term is defined in Rule 12(b)(2) under the Securities Exchange Act of 1934,
as amended and the rules and regulations of the Securities and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchaser as a result of the Purchaser and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance
of the Securities and the Purchaser&rsquo;s ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided the Purchaser or its agent or counsel with any information that
it believes constitutes or might constitute material, non-public information which is not otherwise disclosed on <U>Schedule 3.25</U>.
The Company understands and confirms that the Purchaser will rely on the foregoing representation in effecting transactions in securities
of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchaser regarding the Company and its Subsidiaries,
their respective businesses and the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and
correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in light of the circumstances under which they were made not misleading. The press releases disseminated by
the Company during the 12 months preceding the date of this Agreement do not contain any untrue statement of a material fact or omit
to state a material fact required
to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made and
when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in Article IV hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchaser&rsquo;s representations and warranties set forth in Article IV, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities
to be integrated with prior offerings by the Company for purposes of any applicable stockholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i) the Company&rsquo;s assets do not constitute unreasonably small capital
to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (ii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all
of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of
its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such
debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has
no knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy
or reorganization laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.27</U> sets forth as of the date hereof
all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments.
For the purposes of this Agreement, &ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money or amounts owed in
excess of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements
and other contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection
or similar transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $100,000 due
under leases required to be capitalized in accordance with GAAP. Except as set forth on <U>Schedule 3.27</U>, neither the Company nor
any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been required
to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being
contested in good faith, except where the failure to so file or pay would not have a Material Adverse Effect. Except as otherwise disclosed
in <U>Schedule 3.28</U>, no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had, or
would have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state or other
governmental tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which would have a Material
Adverse Effect</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds,
(iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of
which the Company is aware) which is in violation of law, or (iv) violated any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgment
Regarding Purchaser&rsquo;s Purchase of Securities</U>. The Company acknowledges and agrees that the Purchaser is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in
any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given
by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Purchaser&rsquo;s purchase of the Securities. The Company further represents
to the Purchaser that the Company&rsquo;s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Acknowledgement
Regarding Purchaser&rsquo;s Trading Activity</U>. Notwithstanding anything in this Agreement or elsewhere to the contrary (except
for Sections 4.7 and 5.12 hereof), it is understood and acknowledged by the Company that: (i) the Purchaser has not been asked
by the Company to agree, nor has the Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of
the Company, or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any
specified term; (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation,
Short Sales or &ldquo;derivative&rdquo; transactions, before or after the closing of this or future private placement transactions,
may negatively impact the market price of the Company&rsquo;s publicly-traded securities; (iii) any Purchaser, and counter-parties
in &ldquo;derivative&rdquo; transactions to which the Purchaser is a party, directly or indirectly, presently may have a &ldquo;short&rdquo;
position in the Common Stock, and (iv) the Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s
length counter-party in any &ldquo;derivative&rdquo; transaction. The Company further understands and acknowledges that (y) the
Purchaser may engage in hedging activities at various times during the period that the Securities are outstanding, including,
without limitation, during the periods that the value of the Shares deliverable with respect to Securities are being determined,
and (z) such hedging activities (if any) could reduce the value of the existing stockholders&rsquo; equity interests in the Company
at and after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging
activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation
M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to
facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting
purchases of, any of the Securities, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase
any other securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Private
Placement</U>. Assuming the accuracy of each Purchaser&rsquo;s representations and warranties set forth in Article IV, no registration
under the Securities Act is required for the offer and sale of the Notes or the Shares issuable upon conversion thereof by the
Company to the Purchasers as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;No
General Solicitation</U>. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company offered the Securities for sale only to the Purchaser
and certain other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506(b) under
the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other
officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding
voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under
the Securities Act) connected with the Company in any capacity at the time of sale, nor any Person, including a placement agent,
who will receive a commission or fees for soliciting purchasers (each, an &ldquo;Issuer Covered Person&rdquo; and, together, &ldquo;Issuer
Covered Persons&rdquo;) is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii)
under the Securities Act (a &ldquo;Disqualification Event&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2)
or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification
Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished
to the Purchaser a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Disqualification Events</U>. The Company will notify the Purchaser in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to
become a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer,
agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office
of Foreign Assets Control of the U.S. Treasury Department (&ldquo;OFAC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the
meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the &ldquo;BHCA&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the
&ldquo;Federal Reserve&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total
equity of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any
of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that
is subject to the BHCA and to regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">3.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970,
as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;Money
Laundering Laws&rdquo;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company
or any Subsidiary, threatened.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 182.75pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE IV.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>REPRESENTATIONS AND WARRANTIES OF PURCHASERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 35.95pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Representations
and Warranties of the Purchaser</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as
of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. The Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability
company or similar power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and performance by the Purchaser
of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate, partnership, limited
liability company or similar action, as applicable, on the part of the Purchaser. Each Transaction Document to which it is a party
has been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms, except: (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. The Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect
arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation
and warranty not limiting the Purchaser&rsquo;s right to sell the Securities in compliance with applicable federal and state securities
laws). The Purchaser is acquiring the Securities hereunder in the ordinary course of its business. The Purchaser understands that
the Securities are &ldquo;restricted securities&rdquo; and have not been registered under the Securities Act or any applicable
state securities law and is acquiring such Securities as principal for its own account and not with a view to or for distributing
or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has
no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities
law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution
of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty
not limiting the Purchaser&rsquo;s right to sell such Securities in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time the Purchaser was offered the Securities, it was, and as of the date hereof it is, an accredited investor
within the meaning of Rule 501 under the Securities Act. The Purchaser is not subject to any of the &ldquo;Bad Actor&rdquo; disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &ldquo;Disqualification Event&rdquo;), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of the Purchaser</U>. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. The Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and has been afforded, subject to Regulation FD, (i) the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the
Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable
it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can
acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment;
provided, however, that the Purchaser has not requested nor been provided by the Company with any non-public information regarding
the Company, its financial condition, results of operations, business, properties, management and prospects. The Purchaser acknowledges
and agrees that neither the Company nor anyone else has provided the Purchaser with any information or advice with respect to
the Securities nor is such information or advice necessary or desired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, the Purchaser has not,
nor has any Person acting on behalf of or pursuant to any understanding with the Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that the
Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting
forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding
the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of the Purchaser&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions
made by the portfolio managers managing other portions of the Purchaser&rsquo;s assets, the representation set forth above shall
only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase
the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to the Purchaser&rsquo;s representatives,
including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates,
the Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein
shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability
of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Company acknowledges
and agrees that the representations contained in this Article 4 shall not modify, amend or affect the Purchaser&rsquo;s right to rely
on the Company&rsquo;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transaction contemplated hereby.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 182.7pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ARTICLE V.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Removal
of Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">The Shares and
the Warrants may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of the Shares
or Warrants other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or
in connection with a pledge as contemplated in Section 5.1(b), the Company may require the transferor to provide to the Company an opinion
of counsel selected by the transferor and reasonably acceptable to the Company at the cost of the Company, the form and substance of which
opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred
Shares or Warrants under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.75in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Purchaser agrees to the imprinting, so long as is required by this Section 5.1, of a legend on any of the Shares or the Warrants in the
following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 0in">NEITHER THIS SECURITY
NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY
BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION
THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Shares to a financial institution that is an &ldquo;accredited investor&rdquo;
as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and, if required under
the terms of such arrangement, such Purchaser may transfer pledged or secured Shares to the pledgees or secured parties. Such a pledge
or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor
shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&rsquo;s expense,
the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Shares may reasonably request in connection
with a pledge or transfer of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 54.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 54.05pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates
evidencing the Shares (or the Transfer Agent&rsquo;s records if held in book entry form) shall not contain any legend (including the legend
set forth in Section 5.1(a) hereof): (i) while a registration statement covering the resale of such securities is effective under the
Securities Act (the &ldquo;Effective Date&rdquo;), (ii) following any sale of such Shares pursuant to Rule 144, (iii) if such Shares are
eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information required
under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or (iv) if such legend is not required under applicable
requirements of the Securities Act (including Sections 4(a)(1) and 4(a)(7) judicial interpretations and pronouncements issued by the staff
of the SEC). The Company shall, if any of the provisions in clause (i) &ndash;(iv) above are applicable, at its expense, cause its counsel
to issue a legal opinion to the Transfer Agent promptly after the Effective Date if required by the Transfer Agent to effect the removal
of the legend hereunder. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to
cover the resale of the Shares, or if such Shares may be sold under Rule 144 and the Company is then in compliance with the current public
information required under Rule 144, or if the Shares may be sold under Rule 144 without the requirement for the Company to be in compliance
with the current public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or if
such legend is not otherwise required under applicable requirements of the Securities Act (including Sections 4(a)(1) and 4(a)(7), judicial
interpretations and pronouncements issued by the staff of the SEC) then such Shares shall be issued or reissued free of all legends. The
Company agrees that following the effective date of any registration statement or at such time as such legend is no longer required under
this Section 5.1(c), it will, no later than two Trading Days following the delivery by a Purchaser to the Company or the Transfer Agent
of a certificate representing restricted Shares, as applicable, issued with a restrictive legend (such second Trading Day, the &ldquo;Legend
Removal Date&rdquo;), deliver or cause to be delivered to such Purchaser a certificate representing such Shares that is free from all
restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge
the restrictions on transfer set forth in this Section 5.1. Certificates for Shares subject to legend removal hereunder shall be transmitted
by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&rsquo;s prime broker with the Depository Trust Company
system as directed by such Purchaser. The Company shall be responsible for any delays caused by its Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.75in"></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 54.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 54.05pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to such Purchaser&rsquo;s other available remedies, (i) the Company shall pay to a Purchaser, in cash, as partial liquidated
damages and not as a penalty, for the value of the Warrant Shares for which a Warrant is being exercised (based on the Warrant Exercise
Price), $20 per Trading Day for each Trading Day after the Legend Removal Date (increasing to $20 per Trading Day after the fifth Trading
Day) until such certificate is delivered without a legend. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages
for the Company&rsquo;s failure to deliver certificates representing any Securities as required by the Transaction Documents, and such
Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief, and
(ii) if after the Legend Removal Date such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to
deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number
of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such Purchaser anticipated receiving
from the Company without any restrictive legend, then, the Company shall pay to such Purchaser, in cash, an amount equal to the excess
of such Purchaser&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares
of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;Buy-In Price&rdquo;)
over the product of (A) such number of Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied
by (B) the highest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery
by such Purchaser to the Company of the applicable Shares (as the case may be) and ending on the date of such delivery and payment under
this Section 5.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 54.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 53.95pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event a Purchaser shall request delivery of unlegended shares as described in this Section 5.1 and the Company is required to deliver
such unlegended shares, (i) it shall pay all fees and expenses associated with or required by the legend removal and/or transfer including
but not limited to legal fees, Transfer Agent fees and overnight delivery charges and taxes, if any, imposed by any applicable government
upon the issuance of Common Stock; and (ii) the Company may not refuse to deliver unlegended shares based on any claim that such Purchaser
or anyone associated or affiliated with such Purchaser has not complied with Purchaser&rsquo;s obligations under the Transaction Documents,
or for any other reason, unless, an injunction or temporary restraining order from a court, on notice, restraining and or enjoining delivery
of such unlegended shares shall have been sought and obtained by the Company and the Company has posted a surety bond for the benefit
of such Purchaser in the amount of the greater of (i) 150% of the amount of the aggregate purchase price of the Bridge Shares (based on
the market price of the Bridge Shares) and Warrant Shares (based on exercise price in effect upon exercise) which is subject to the injunction
or temporary restraining order, or (ii) the VWAP of the Common Stock on the Trading Day before the issue date of the injunction multiplied
by the number of unlegended shares to be subject to the injunction, which bond shall remain in effect until the completion of the litigation
of the dispute and the proceeds of which shall be payable to such Purchaser to the extent Purchaser obtains judgment in Purchaser&rsquo;s
favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.55pt; text-indent: -16.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in"> 5.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Furnishing of Information.</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
the earliest of the time that (i) no Purchaser owns Shares or (ii) the Warrants have expired, the Company covenants to timely file (or
obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after
the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time during the period commencing from the six month anniversary of the date hereof and ending at such time on the earlier to occur
that the Warrants are not outstanding, terminated or that all of the Warrant Shares (assuming cashless exercise) may be sold without
the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule
144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule 144(c) for a period
of more than 30 consecutive days or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and
the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) for a period of more than 30 consecutive days (a &ldquo;Public
Information Failure&rdquo;) then, in addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser,
in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Shares
and/or Warrant Shares, an amount in cash equal to two percent of the aggregate Note Conversion Price of such Purchaser&rsquo;s Note(s)
and/or Warrant Exercise Price of such Purchaser&rsquo;s Warrants on the day of a Public Information Failure and on every 30<FONT STYLE="font-size: 10pt">th
</FONT>day (pro-rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information
Failure is cured and (b) such time that such public information is no longer required for the Purchasers to transfer the Shares and/or
Warrant Shares pursuant to Rule 144. Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar
month during which such Public Information Failure Payments are incurred and (ii) the second Trading Day after the event or failure giving
rise to the Public Information Failure payments is cured. In the event the Company fails to make Public Information Failure payments
in a timely manner, such Public Information Failure payments shall bear interest at the rate of one and one-half percent per month (prorated
for partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public
Information Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt"></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined
in Section 2(a)(1) of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the
rules and regulations of any Trading Market such that it would require stockholder approval prior to the closing of such other
transaction unless stockholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Securities
Laws Disclosure; Publicity</U>. The Company shall not publicly disclose the name of any Purchaser, or include the name of any
Purchaser in any filing with the SEC or any regulatory agency or Trading Market, without the prior written consent of the Purchaser,
except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the SEC and
(b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the
Purchaser with prior notice of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that
any Purchaser is an &ldquo;Acquiring Person&rdquo; under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the
Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Securities under the Transaction Documents or under any other agreement between the Company and the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. When the Company&rsquo;s Common Stock is quoted or listed on a Trading Market, to the extent that any notice
provided pursuant to any Transaction Document or any other communications made by the Company, or information provided, to the
Purchaser constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall
simultaneously file such notice or other material information with the SEC pursuant to a Current Report on Form 8-K. The Company
understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities
of the Company. In addition to any other remedies provided by this Agreement or other Transaction Documents, if the Company knowingly
provides any material, non- public information to the Purchasers without their prior written consent, and it fails to immediately
(no later than that Trading Day) file a Form 8-K, once it is required to do so, disclosing this material, non-public information,
it shall pay the Purchasers as partial liquidated damages and not as a penalty a sum equal to $1,000 per day for each $100,000
of each Purchaser&rsquo;s Subscription Amount beginning with the day the information is disclosed to the Purchaser and ending
and including the day the Form 8-K disclosing this information is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes,
and shall not use such proceeds: (a) for the satisfaction of any Indebtedness as defined in the Note, (b) for the redemption of
any Common Stock or Common Stock Equivalents, (c) in violation of FCPA or OFAC regulations, or (d) to lend money, give credit,
or make advances to any officers, directors, employees or affiliates of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.8 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchaser</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Subject to the
provisions of this Section 5.8, the Company will indemnify and hold each Purchaser and its directors, officers, stockholders, members,
partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title), each Person who controls the Purchaser (within the meaning of Section 15 of the Securities Act
and Section 20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other
Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of
such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses, liabilities, obligations, claims,
contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&rsquo;
fees and costs of investigation (including local counsel, if retained) that any such Purchaser Party may suffer or incur as a result of
or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents, (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is solely based upon a breach of such Purchaser Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which
constitutes fraud, gross negligence, willful misconduct or malfeasance) or (c) any untrue or alleged untrue statement of a material fact
contained in any registration statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in any
preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein
or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in light of the circumstances under
which they were made) not misleading. If any action shall be brought against any Purchaser Party in respect of which indemnity may be
sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right
to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall
have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized
by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel
or (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position
of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses
of no more than one such separate counsel (in addition to local counsel, if retained). The Company will not be liable to any Purchaser
Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which
shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is
attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser
Party in this Agreement or in the other Transaction Documents. The Purchaser Parties shall have the right to settle any action against
any of them by the payment of money provided that they cannot agree to any equitable relief and the Company, its officers, directors and
Affiliates receive unconditional releases in customary form. The indemnification required by this Section 5.8 shall be made by periodic
payments of the amount thereof during the investigation or defense, as and when bills are received or are incurred. The indemnity agreements
contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and
any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Settlement
Without Consent if Failure to Reimburse</U>. If an indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any
settlement of the nature contemplated by Section 5.8 effected without its written consent if (1) such settlement is entered into
more than 45 days after receipt by such indemnifying party of the aforesaid request, (2) such indemnifying party shall have received
notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (3) such indemnifying
party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company agrees, if the Company applies to have the Common Stock traded on any Trading Market, it will
then include in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares
to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action necessary to
continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s
reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility
of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation,
including, without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation
in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Senior
Debt</U>. The Company shall not issue any new indebtedness which is senior in rank to the Notes while the Notes are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. The Purchaser covenants that neither it nor any Affiliate acting on its behalf or pursuant
to any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&rsquo;s securities
during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by
this Agreement are first publicly announced pursuant to the initial press release. Each Purchaser covenants that until such time
as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release,
the Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in
the Disclosure Schedules. Notwithstanding the foregoing and notwithstanding anything contained in this Agreement to the contrary,
the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that
it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated
by this Agreement are first publicly announced pursuant to the initial press release, (ii) no Purchaser shall be restricted or
prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from
and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press
release and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to
the Company or its Subsidiaries after the issuance of the initial press release. Notwithstanding the foregoing, in the case of
a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of the Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DTC
Program</U>. For so long as any of the Notes are outstanding, the Company will employ as the Transfer Agent for the Common Stock
and Shares a participant in the Depository Trust Company Automated Securities Transfer Program and cause the Common Stock to be
transferable pursuant to such program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance
of Property</U>. The Company shall keep all of its property necessary for the operations of its business, which is necessary or
useful to the conduct of its business, in good working order and condition, ordinary wear and tear excepted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Preservation
of Corporate Existence</U>. The Company shall preserve and maintain its corporate existence, rights, privileges and franchises
in the jurisdiction of its incorporation, and qualify and remain qualified, as a foreign corporation in each jurisdiction in which
such qualification is necessary in view of its business or operations and where the failure to qualify or remain qualified might
reasonably have a Material Adverse Effect upon the financial condition, business or operations of the Company taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Registration of Securities on Form S-1</U>. Other than the registration rights provided hereunder, for the initial six months
the Notes are outstanding, the Company will not file any registration statements on Form S-1. For the avoidance of doubt, the
foregoing shall not prevent the Company from filing a Registration Statement on Form S-8 with respect to equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Variable
Rate Transactions</U>. While any of the Notes are outstanding, the Company shall be prohibited from entering a Variable Rate Transaction
without the prior consent of the holders of more than 50% in principal amount of the then outstanding Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights and Lock-Up Agreement.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 33.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With respect to
the Shares, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
the next Registration Statement on Form S-1 filed by the Company, include the Registrable Securities in such Registration Statement and
use its best efforts to cause the Registration Statement to become effective and remain effective as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepare
and file with the SEC such amendments, including post-effective amendments, to the Registration Statement as may be necessary to keep
the Registration Statement continuously effective as to the applicable Registrable Securities until such time as all of the Registerable
Securities have been sold by the Holder or he is eligible to otherwise remove the restrictive legend and effect a sale other than through
the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of, (i) any order suspending the effectiveness of the
Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities
for sale in any U.S. jurisdiction, at the earliest practicable moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furnish
to the Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto, including financial
statements and schedules, all documents incorporated or deemed to be incorporated therein by reference, and all exhibits to the extent
requested by the Holder (including those previously furnished or incorporated by reference) promptly after the filing of such documents
with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Purchaser agrees that, without the prior written consent of the Company, the Purchaser shall not, during the period ending 90 days after
the date of the prospectus filed with the SEC in connection with the Registration Statement on Form S-1 described in Section 5.18(a):
(1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option
or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any
Registrable Securities or (2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences
of ownership of the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion
to a Corporation</U>. The Company shall convert from a limited liability company to a corporation on or before June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">5.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Right
of Participation</U>. For so long as Notes are outstanding, the Purchasers shall be given the right to purchase 20% of the shares
issued in the Company&rsquo;s IPO on a pro rata basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0">ARTICLE IV.
MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 35.95pt">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
This Agreement may be terminated by the Purchaser by written notice to the other parties, if the Closing has not been consummated
on or before June 15, 2022; provided, however, that no such termination will affect the right of any party to sue for any breach
by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees
and Expenses</U>. Except as expressly set forth below and in the Transaction Documents to the contrary, each party shall pay the
fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party
incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer
Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the
Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the
delivery of any Securities to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral
or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered
by email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. ( Eastern
Standard or Daylight Savings Time, as applicable) on a Trading Day, (b) the next Trading Day after the date of transmission, if
such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached
hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second Trading
Day following the date of transmission, if sent by U.S. nationally recognized overnight delivery service or (d) upon actual receipt
by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth
on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes,
or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall, if the Company&rsquo;s
Common Stock is quoted or listed on a Trading Market, simultaneously file such notice with the SEC pursuant to a Current Report
on Form 8-K, or which failure to do so will subject the Company to the liquidated damages provided for in Article 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments;
Waivers</U>. Except as provided in the last sentence of this Section 6.5, no provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and a majority in interest
of the outstanding balance of the Note or, in the case of a waiver, by the party against whom enforcement of any such waived provision
is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or
requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise
of any such right. Any amendment effected in accordance with accordance with this Section 6.5 shall be binding upon the Purchaser
and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted
assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of
each Purchaser. Each Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities,
by the provisions of the Transaction Documents that apply to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as
otherwise set forth in Section 6.7 and this Section 6.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law; Exclusive Jurisdiction; Attorneys&rsquo; Fees</U>. All questions concerning the construction, validity, enforcement and interpretation
of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State
of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning
the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents
(whether brought against a party hereto or its respective affiliates, directors, officers, stockholders, partners, members, employees
or agents) shall be commenced exclusively in the state and federal courts sitting in the New York County, New York. Each party
hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the New York County, New York
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees
not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.
Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition
to the obligations of the Company elsewhere in this Agreement, the prevailing party in such Action or Proceeding shall be reimbursed
by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a &ldquo;.pdf' format data file, such signature shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf'
signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain
in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be
hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then that Purchaser
may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand
or election in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission
of an conversion of a Note, the Purchaser shall be required to return any Shares subject to any such rescinded Conversion Notice
concurrently with the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to the Purchaser&rsquo;s Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction without requiring the posting of any bond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each Purchaser
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages
may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents
and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy
at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any
other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the
Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers
are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser
to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate
legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers with
the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do
so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each
other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively
and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction
Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other
amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages
or other amounts are due and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 36.05pt">6.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and
every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after
the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver
of jury trial</U>. In any action, suit, or proceeding in any jurisdiction brought by any party against any other party, the parties
each knowingly and intentionally, to the greatest extent permitted by applicable law, hereby absolutely, unconditionally, irrevocably
and expressly waive forever trial by jury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">6.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Circumvention</U>.
The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation, including any
Certificates of Designation, or Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement,
dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms of this Agreement, and will at all times in good faith carry out all of the provision of this Agreement and
take all action as may be required to protect the rights of all holders of the Securities. Without limiting the generality of
the foregoing or any other provision of this Agreement or the other Transaction Documents, the Company (a) shall not increase
the par value of any Shares and (b) shall take all such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and nonassessable Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 182.75pt; text-align: center; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">(Signature Pages Follow)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Securities Purchase Agreement</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 35.95pt">IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of
the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 Degree Pharmaceuticals, LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Address for Notice</U>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 47%; border-bottom: black 1pt solid">/s/ Geoffrey Dow</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Geoffrey Dow</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD>
    <TD STYLE="padding-left: 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: black">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.85pt; text-align: left; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">SIGNATURE PAGE FOR PURCHASER
FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 9pt"><TR STYLE="font-size: 9pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 9pt; width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">PURCHASER SIGNATURE PAGE TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">SECURITIES PURCHASE
AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><FONT STYLE="font-size: 10pt">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to
be duly executed by their respective authorized signatories as of the date first indicated above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Purchaser:</FONT><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%">Cavalry Investment Fund, LP</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Purchaser</I>:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">Thomas Walsh</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">Managing Member</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address of Authorized Signatory:</FONT></TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile Number of Authorized Signatory: </FONT></TD>
    <TD STYLE="background-color: Black; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice to Purchaser:</FONT></TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 67%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Delivery of Securities to Purchaser (if not same as address for notice):</FONT></TD>
    <TD STYLE="width: 33%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Face Value</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$277,777.78</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subscription Amount: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250,000.00</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN Number:</FONT></TD>
    <TD STYLE="background-color: Black; width: 15%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">Purchaser Signature Page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 9pt"><TR STYLE="font-size: 9pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 9pt; width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>14
<FILENAME>cm270_ex10-11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">EXHIBIT B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant Shares: &lt;WARRANT SHARES&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Initial Exercise Date: [*],
2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS COMMON STOCK PURCHASE
WARRANT (the &ldquo;Warrant&rdquo;) certifies that, for value received, Cavalry Investment Fund LP, or its assigns (the &ldquo;Holder&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;Initial Exercise Date&rdquo;) and on or prior to the close of business on the fifth year anniversary of the
Initial Exercise Date (the &ldquo;Termination Date&rdquo;) but not thereafter, to subscribe for and purchase from 60&deg; Pharmaceuticals,
LLC, a limited liability company (the &ldquo;Company&rdquo;), up to &lt;WARRANT SHARES&gt; shares of Common Stock (subject to adjustment
hereunder, the &ldquo;Warrant Shares&rdquo;). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b). This Warrant issued pursuant to a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;)
entered into as of the Initial Exercise Date between the Company and the initial Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;Purchase Agreement&rdquo;), dated May 24, 2022 among the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) Exercise of the
purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise
Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may
designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a
duly executed copy of the Notice of Exercise Form annexed hereto. Within two Trading Days following the date of exercise as
aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by
wire transfer or cashier&rsquo;s check drawn on a United States bank, unless the cashless exercise procedure specified in Section
2(c) below is specified in the applicable Notice of Exercise. Notwithstanding anything herein to the contrary (although the Holder
may surrender the Warrant to, and receive a replacement Warrant from, the Company), the Holder shall not be required to physically
surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant
has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within two
Trading Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in
purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding
number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder
and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company
shall deliver any objection to any Notice of Exercise Form within one Trading Day of delivery of such notice. The Holder by
acceptance of this Warrant or any transferee, acknowledges and agrees that, by reason of the provisions of this Section 2(a),
following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder
at any given time may be less than the amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Exercise Price</U>.
The initial exercise price per share of the Common Stock under this Warrant shall be equal to 110% of the IPO (as defined in the Purchase
Agreement) price (the &ldquo;Exercise Price&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Cashless Exercise</U>.
Other than as provided for in Section 2(f), if at any time after the six month anniversary of the Initial Exercise Date, there is no
effective Registration Statement covering the resale of the Warrant Shares by the Holder (or the prospectus does not meet the requirements
of Section 10 of the Securities Act), then this Warrant may also be exercised at the Holder&rsquo;s election, in whole or in part and
in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the number obtained by dividing
[(A - B) times (C)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in; text-align: left">(A) =</TD><TD STYLE="text-align: justify">the greater of (i) the arithmetic average of the VWAPs for the
five consecutive Trading Days ending on the date immediately preceding the date on which the Holder elects to exercise this Warrant by
means of a &ldquo;cashless exercise,&rdquo; as set forth in the applicable Notice of Exercise or (ii) the VWAP for the Trading Day immediately
prior to the date on which the Holder makes such &ldquo;cashless exercise&rdquo; election;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in; text-align: left">(B) =</TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder, at
the time of such exercise; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in; text-align: left">(C) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;VWAP&rdquo; means, for any date, the price determined by the
first of the following clauses that applies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)  if
the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date
(or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P.
(based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)) (or a similar organization or agency succeeding
to its functions of reporting prices), (b) if no volume weighted average price of the Common Stock is reported for the Trading Market,
the most recent reported bid price per share of the Common Stock, or (c) in all other cases, the fair market value of a share of Common
Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding
and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Warrant Shares are issued
in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant
Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrants being exercised may be
tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding anything
herein to the contrary, if on the Termination Date (unless the Holder notifies the Company otherwise) if there is no effective
Registration Statement covering the resale of the Warrant Shares by the Holder, then this Warrant shall be automatically exercised
via cashless exercise pursuant to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(d) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.05pt">(i) <U>Delivery of Certificates
Upon Exercise</U>. Certificates for the shares of Common Stock purchased hereunder shall be transmitted to the Holder by the Transfer
Agent by crediting the account of the Holder&rsquo;s prime broker with The Depository Trust Company through its Deposit or Withdrawal
at Custodian system (&ldquo;DWAC&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration
statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) this Warrant is being
exercised via cashless exercise and Rule 144 is available, or otherwise by physical delivery to the address specified by the Holder in
the Notice of Exercise by the date that is two Trading Days after the latest of (A) the delivery to the Company of the Notice of Exercise
and (B) payment of the aggregate Exercise Price as set forth above (unless by cashless exercise, if permitted) (such date, the &ldquo;Warrant
Share Delivery Date&rdquo;). The Warrant Shares shall be deemed to have been issued, and Holder or any other person so designated to
be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the date the Warrant has been
exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted). The Company understands that a
delay in the delivery of the Warrant Shares after the Warrant Share Delivery Date could result in economic loss to the Holder. As compensation
to the Holder for such loss, the Company agrees to pay (as liquidated damages and not as a penalty) to the Holder for late issuance of
Warrant Shares upon exercise of this Warrant the proportionate amount of $10 per Trading Day (increasing to $20 per Trading Day after
the fifth Trading Day) after the Warrant Share Delivery Date for each $1,000 of the value of the Warrant Shares for which this Warrant
is exercised (based on the Exercise Price) which are not timely delivered. In no event shall liquidated damages for any one transaction
exceed $1,000 for the first 10 Trading Days. Furthermore, in addition to any other remedies which may be available to the Holder, in
the event that the Company fails for any reason to effect delivery of the Warrant Shares by the Warrant Share Delivery Date, the Holder
may revoke all or part of the relevant Warrant exercise by delivery of a notice to such effect to the Company, whereupon the Company
and the Holder shall each be restored to their respective positions immediately prior to the exercise of the relevant portion of this
Warrant, except that the liquidated damages described above shall be payable through the date notice of revocation or rescission is given
to the Company or the date the Warrant Shares are delivered to the Holder, whichever date is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) <U>Delivery of New Warrants
Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender
of this Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant
shall in all other respects be identical to this Warrant. Unless the Warrant has been fully exercised, the Holders shall not be required
to surrender this Warrant as a condition of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) <U>Rescission Rights</U>.
If the Company fails to deliver the Warrant Shares or cause the Transfer Agent to transmit to the Holder a certificate or the certificates
representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right,
at any time prior to issuance of such Warrant Shares, to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv) <U>Compensation
for Buy-In on Failure to Timely Deliver Certificates Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to deliver the Warrant Shares, or cause the Transfer Agent to transmit to the Holder the certificate or certificates
representing the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the
Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm
otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the
Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall pay in cash to the Holder
the amount as provided under Section 4.1(e) of the Purchase Agreement. Nothing herein shall limit a Holder&rsquo;s right to pursue
any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance
and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver certificates representing shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v) <U>No Fractional Shares
or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any
fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi) <U>Charges, Taxes and
Expenses</U>. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or
other incidental expense in respect of the issuance of such certificate including any charges of any clearing firm, all of which taxes
and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as
may be directed by the Holder. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise.
The Company shall (A) pay the reasonable legal fees of the Holder&rsquo;s choice (in an amount not to exceed $500 per opinion, and not
more often than once per week) in connection with the exercise of the Warrants, (B) cause its attorneys to promptly provide any reliance
opinion to the Transfer Agent, and (C) pay the Holder the sums required under Section 2(d)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii) <U>Closing of Books</U>.
The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant
to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates), would beneficially own in excess
of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which
would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any
of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to
the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding
sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this
Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and
the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is
exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or
confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be
determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the
Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the
Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a
Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the
conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates since the date as of
which such number of outstanding shares of Common Stock was reported. The &ldquo;Beneficial Ownership Limitation&rdquo; shall be
4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days&rsquo; prior notice to the Company, may
increase the Beneficial Ownership Limitation provisions of this Section 2(e) solely with respect to the Holder&rsquo;s Warrant,
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the
provisions of this Section 2(e) shall continue to apply. Any such increase will not be effective until the 61st day after such
notice is delivered to the Company. The Holder may also decrease the Beneficial Ownership Limitation provisions of this Section 2(e)
solely with respect to the Holder&rsquo;s Warrant at any time, which decrease shall be effectively immediately upon delivery of
notice to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or
inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or
desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder
of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Stock Dividends and
Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock
(which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant or pursuant
to any of the other Transaction Documents), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)
combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues
by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall
be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any)
outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate
Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective
immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Subsequent
Equity Sales</U>. If and whenever on or after the Initial Exercise Date, the Company issues or sells, or in accordance with this
Section 3 is deemed to have issued or sold, any shares of Common Stock (including the issuance or sale of shares of Common Stock
owned or held by or for the account of the Company, issued or sold or deemed to have been issued or sold) for a consideration
per share (the &ldquo;<U>Base Share Price</U>&rdquo;) less than a price equal to the Exercise Price in effect immediately prior
to such issuance or sale or deemed issuance or sale (such Exercise Price then in effect is referred to herein as the &ldquo;<U>Applicable
Price</U>&rdquo;) (the foregoing a &ldquo;<U>Dilutive Issuance</U>&rdquo;), then immediately after such Dilutive Issuance, the
Exercise Price then in effect shall be reduced to an amount equal to the Base Share Price. For all purposes of the foregoing (including,
without limitation, determining the adjusted Exercise Price and the Base Share Price under this Section 3(b)), the following shall
be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) <U>Issuance of Options</U>.
If the Company in any manner grants or sells any Options and the lowest price per share for which one share of Common Stock is at any
time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities issuable upon
exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share of Common Stock
shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale of such Option
for such price per share. For purposes of this Section 3(b)(i), the &ldquo;lowest price per share for which one share of Common Stock
is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities issuable upon
exercise of any such Option or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the sum of the lowest
amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock upon the granting
or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon
exercise of such Option or otherwise pursuant to the terms thereof and (y) the lowest exercise price set forth in such Option for which
one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible
Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid
or payable to the holder of such Option (or any other Person) upon the granting or sale of such Option, upon exercise of such Option
and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise pursuant to
the terms thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder of such Option
(or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance
of such shares of Common Stock or of such Convertible Securities upon the exercise of such Options or otherwise pursuant to the terms
of or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) <U>Issuance of Convertible
Securities</U>. If the Company in any manner issues or sells any Convertible Securities and the lowest price per share for which one
share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to the terms thereof
is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been issued and sold
by the Company at the time of the issuance or sale of such Convertible Securities for such price per share. For the purposes of this
Section 3(b)(ii), the &ldquo;lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise or
exchange thereof or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the sum of the lowest amounts
of consideration (if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale of
the Convertible Security and upon conversion, exercise or exchange of such Convertible Security or otherwise pursuant to the terms thereof
and (y) the lowest conversion price set forth in such Convertible Security for which one share of Common Stock is issuable upon conversion,
exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder
of such Convertible Security (or any other Person) upon the issuance or sale of such Convertible Security plus the value of any other
consideration received or receivable by, or benefit conferred on, the holder of such Convertible Security (or any other Person). Except
as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock
upon conversion, exercise or exchange of such Convertible Securities or otherwise pursuant to the terms thereof, and if any such issuance
or sale of such Convertible Securities is made upon exercise of any Options for which adjustment of this Warrant has been or is to be
made pursuant to other provisions of this Section 3(b), except as contemplated below, no further adjustment of the Exercise Price shall
be made by reason of such issuance or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) <U>Change in Option
Price or Rate of Conversion</U>. &ldquo;Convertible Securities&rdquo; means any stock or other security (other than Options) that
is at any time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which
otherwise entitles the holder thereof to acquire, any shares of Common Stock. If the purchase or exercise price provided for in
any Options, the additional consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible
Securities, or the rate at which any Convertible Securities are convertible into or exercisable or exchangeable for shares of
Common Stock increases or decreases at any time (other than proportional changes in conversion or exercise prices, as applicable,
in connection with an event referred to in Section 3(a)), the Exercise Price in effect at the time of such increase or decrease
shall be adjusted to the Exercise Price which would have been in effect at such time had such Options or Convertible Securities
provided for such increased or decreased purchase price, additional consideration or increased or decreased conversion rate, as
the case may be, at the time initially granted, issued or sold. For purposes of this Section 3(b)(iii), if the terms of any Option
or Convertible Security that was outstanding as of the Closing Date are increased or decreased in the manner described in the
immediately preceding sentence, then such Option or Convertible Security and the shares of Common Stock deemed issuable upon exercise,
conversion or exchange thereof shall be deemed to have been issued as of the date of such increase or decrease. No adjustment
pursuant to this Section 3(b) shall be made if such adjustment would result in an increase of the Exercise Price then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 72.05pt">(iv) <U>Calculation
of Consideration Received</U>. If any Option is issued in connection with the issuance or sale of any other securities of the
Company together comprising one integrated transaction in which no specific consideration is allocated to such Option by the parties
thereto, the Options will be deemed to have been issued for a consideration of par value of the Company&rsquo;s Common Stock.
If any shares of Common Stock, Options or Convertible Securities are issued or sold or deemed to have been issued or sold for
cash, the consideration received therefor will be deemed to be the net amount of consideration received by the Company therefor.
If any shares of Common Stock, Options or Convertible Securities are issued or sold for a consideration other than cash, the amount
of such consideration received by the Company will be the fair value of such consideration, except where such consideration consists
of publicly traded securities, in which case the amount of consideration received by the Company for such securities will be the
arithmetic average of the VWAPs of such security for each of the five Trading Days immediately preceding the date of receipt.
If any shares of Common Stock, Options or Convertible Securities are issued to the owners of the non-surviving entity in connection
with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be the fair
value of such portion of the net assets and business of the non-surviving entity as is attributable to such shares of Common Stock,
Options or Convertible Securities. The fair value of any consideration other than cash or publicly traded securities will be determined
jointly by the Company and the Holder. If such parties are unable to reach agreement within 10 days after the occurrence of an
event requiring valuation (the &ldquo;<U>Valuation Event</U>&rdquo;), the fair value of such consideration will be determined
within five Trading Days after the 10<FONT STYLE="font-size: 10pt">th </FONT>day following such Valuation Event by an independent,
reputable appraiser jointly selected by the Company and the Holder. The determination of such appraiser shall be final and binding
upon all parties absent manifest error. If such appraiser&rsquo;s valuation differs by less than 5% from the Company&rsquo;s proposed
valuation, the fees and expenses of such appraiser shall be borne by the Holder, and if such appraiser&rsquo;s valuation differs
by more than 5% from the Company&rsquo;s proposed valuation, the fees and expenses of such appraiser shall be borne by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v) <U>Record Date</U>. If
the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend or other
distribution payable in shares of Common Stock, Options or in Convertible Securities or (B) to subscribe for or purchase shares of Common
Stock, Options or Convertible Securities, then such record date will be deemed to be the date of the issuance or sale of the shares of
Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the
date of the granting of such right of subscription or purchase (as the case may be).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)&nbsp;&nbsp;Notwithstanding the
foregoing, this Section 3(b) shall not apply to any Exempt Issuances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Full Ratchet Increase
in Warrant Shares</U>. Until the Notes are no longer outstanding, whenever the Exercise Price is adjusted under Section 3(b), the number
of Warrant Shares shall be increased on a full ratchet basis to the number of shares of Common Stock determined by multiplying the Exercise
Price then in effect immediately prior to such adjustment by the number of Warrant Shares issuable upon exercise of this Warrant immediately
prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. By way of example, if
E is the total number of Warrant Shares in effect immediately prior to such Dilutive Issuance, F is the Exercise Price in effect immediately
prior to such Dilutive Issuance, and G is the Dilutive Issuance Price, the adjustment to the number of Warrant Shares can be expressed
in the following formula: Total number of Warrant Shares after such Dilutive Issuance = the number obtained from dividing [E x F] by
G. Notwithstanding the foregoing, if the Exercise Price is being adjusted as a result of a sale of securities, this Section 3(c) shall
NOT apply if the Holder is offered the right to participate (in an amount not to exceed $50,000 unless agreed to by the Holder and the
Company) and does not participate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues
or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date
as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would
result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right
thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). Notwithstanding the foregoing, no Purchase
Rights will be made under this Section 3(d) in respect of an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Pro Rata Distributions</U>.
If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock (and not to the Holder)
evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe for or purchase any security
other than the Common Stock (which shall be subject to Section 3(d)), then in each such case the Exercise Price shall be adjusted by
multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders entitled to receive
such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned above, and of which
the numerator shall be such VWAP on such record date less the then per share fair market value at such record date of the portion of
such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined by the Board
of Directors in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the portion of
assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such adjustment
shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;<U>Fundamental
Transaction</U>.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)  If,
at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions engages in
any Fundamental Transaction, as defined in the Note, then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction (without regard to any limitation on the exercise of this Warrant), at the option of the Holder the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the &ldquo;Alternate Consideration&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall not effect a Fundamental Transaction unless it gives the Holder at least 10 Trading Days prior notice together with sufficient details
so the Holder can make an informed decision as to whether it elects to accept the Alternative Consideration. If a public announcement
of the Fundamental Transaction has not been made, the notice to the Holder may not be given until the Company files a Form 8-K or other
report disclosing the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)  Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, provided that the Warrant Shares are not registered under an effective
registration statement, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the
date of the consummation of such Fundamental Transaction or (ii) the positive difference between the cash per share paid in such Fundamental
Transaction minus the then in effect Exercise Price. &ldquo;Black Scholes Value&rdquo; means the value of the unexercised portion of this
Warrant based on the Black and Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. determined as
of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from
the HVT function on Bloomberg L.P. as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus
the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii) If Section 3(f)(i)
and (ii) are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the Company is not
the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and
the other Transaction Documents in accordance with the provisions of this Section 3(f)(iii) pursuant to written agreements in form
and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such
Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the
Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of
Common Stock acquirable and receivable upon exercise of this Warrant prior to such Fundamental Transaction (without regard to any
limitation on the exercise of this Warrant), and with an exercise price which applies the exercise price hereunder to such shares of
capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and
the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is
reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor
Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of
this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this
Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;<U>Notice
to Holder</U>.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i) <U>Adjustment to Exercise
Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly email to the
Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and
setting forth a brief statement of the facts requiring such adjustment. The Holder may supply an email address to the Company and change
such address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii) <U>Notice to Allow
Exercise by the Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company
shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of
all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into
other securities, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the
affairs of the Company, then, in each case, the Company shall deliver to the Holder at its last address as it shall appear upon the
Warrant Register of the Company, at least 5 calendar days prior to the applicable record or effective date hereinafter specified, a
notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or
warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such
dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to email such notice or any defect therein or in the emailing thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries (as determined in good faith by the Company), the
Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain
entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event
triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the provisions of the Purchase Agreement, this Warrant and all rights hereunder
(including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the
principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form
attached hereto duly executed by the Holder or its agent or attorney. Upon such surrender, the Company shall execute and deliver a new
Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new Holder for the
purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>New Warrants</U>.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;Warrant Register&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>No Rights as Stockholder
Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the
Company prior to the exercise hereof other than as explicitly set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Loss, Theft, Destruction
or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss,
theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant or
stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate. In no event shall the Holder be required to deliver a bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Saturdays, Sundays,
Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except and to the extent as
waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its Articles of Incorporation
or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith
assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights
of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not
increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in
par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and nonassessable Warrant Shares upon the exercise of this Warrant and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(iii)  use
best efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as
may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company
shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or
bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered or if not exercised on
a cashless basis when Rule 144 (or any successor law or rule) is available, may have restrictions upon resale imposed by state and federal
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) <U>Non-waiver and Expenses</U>.
No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate as a waiver of such
right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant or the
Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) <U>Notices</U>. Any notice,
request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance
with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) <U>Limitation of Liability</U>.
No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and
no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price
of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) <U>Remedies</U>. The
Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate or that there is no irreparable harm and not to require the posting
of a bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(k) <U>Successors and Assigns</U>.
Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and
be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(l) <U>Amendment</U>. This
Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and Holders of 75% of the
outstanding Warrants issued pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(n) <U>Headings</U>. The
headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.95pt">IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TO: <B>60&deg; Pharmaceuticals, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(1)&nbsp;The undersigned hereby elects
to purchase _______&#9;Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and
tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(2)&nbsp;Payment shall take the
form of (check applicable box):</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;</FONT>in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;</FONT>if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(3)  Please
issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is specified
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 2in; font: 10pt Times New Roman, Times, Serif; width: 30%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 100%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(4)  After
giving effect to this Notice of Exercise, the undersigned will not have exceeded the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Warrant Shares shall be delivered to the following DWAC Account
Number or by physical delivery of a certificate to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="margin-left: 2in; font: 10pt Times New Roman, Times, Serif; width: 30%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0">&nbsp;<FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE OF HOLDER</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity</I>:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(To assign the foregoing warrant,
execute <BR>
this form and supply required information. Do <BR>
not use this form to exercise the warrant.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">60&deg; Pharmaceuticals, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">FOR VALUE RECEIVED,_____all of or____shares
of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whose address is</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 264.45pt"><P STYLE="margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 5in">Dated: ___________, _____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Signature: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 70%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s Address: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="text-decoration: none">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Signature Guaranteed: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 30%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOTE: The signature to this Assignment Form must
correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must
be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should
file proper evidence of authority to assign the foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>15
<FILENAME>cm270_ex10-12.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 430.3pt"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><B>NEITHER THIS SECURITY NOR THE
SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">Original Issue Date: May 24, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">$277,777.78 Principal and Face Value</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">$250,000.00 Purchase Price and Subscription
Amount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">$27,777.78 Original Issue Discount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">ORIGINAL ISSUE DISCOUNT
<BR>
PROMISSORY NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.6pt 0pt 0pt; text-align: justify; text-indent: 0.5in">THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE PROMISSORY
NOTE is duly authorized and validly issued at a 10% original issue discount by 60&deg; Pharmaceuticals, LLC, a limited liability
company (the &ldquo;Company&rdquo;) (the &ldquo;Note&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.6pt 0pt 0pt; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED,
the Company promises to pay to Cavalry Investment Fund, LP, or its permitted assigns (the &ldquo;Holder&rdquo;), the principal sum of
$277,777.78 on the earlier of May 24, 2023, the date of the Company&rsquo;s IPO, or such earlier date as this Note is required or permitted
to be repaid as provided hereunder, and to pay interest to the Holder on the aggregate then outstanding principal amount of this Note
in accordance with the provisions hereof. This Note is subject to the following additional provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"><U>Section 1</U>. <U>Definitions</U>.
For the purposes hereof, (a) capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement
and (b) the following words and phrases shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.6pt 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Alternate Consideration&rdquo; shall have the meaning
set forth in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.6pt 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Bankruptcy
Event&rdquo; means any of the following events: (a) the Company or any Subsidiary thereof commences a case or other proceeding under any
bankruptcy, reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law
of any jurisdiction relating to the Company or any Subsidiary thereof, (b) there is commenced against the Company or any Subsidiary thereof
any such case or proceeding that is not dismissed within 60 days after commencement, (c) the Company or any Subsidiary thereof is adjudicated
insolvent or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Company or any Subsidiary
thereof suffers any appointment of any custodian or the like for it or any substantial part of its property that is not discharged or
stayed within 60 calendar days after such appointment, (e) the Company or any Subsidiary thereof makes a general assignment for the benefit
of creditors, (f) the Company or any Subsidiary thereof calls a meeting of its creditors with a view to arranging a composition, adjustment
or restructuring of its debts or (g) the Company or any Subsidiary thereof, by any act or failure to act, expressly indicates its consent
to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting any of the
foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.55pt 0pt 5.95pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.8pt 0pt 42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Base Conversion Price&rdquo; shall have the meaning
set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 71.8pt 0pt 42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Beneficial Ownership Limitation&rdquo; shall
have the meaning set forth in Section 4(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Black
Scholes Value&rdquo; means the value of the outstanding principal amount of this Note, plus all accrued and unpaid interest hereon based
on the Black and Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. (&ldquo;Bloomberg&rdquo;)
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable Fundamental Transaction and the Maturity Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility
obtained from the HVT function on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental
Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option
time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Buy-In&rdquo; shall have the meaning set forth in
Section 4(d)(v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Change
of Control Transaction&rdquo; means the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an individual
or legal entity or &ldquo;group&rdquo; (as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether
through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of in excess of 50% of the voting securities
of the Company (other than by means of conversion, exercise or exchange of this Note or the Warrants issued together with this Note),
(b) the Company merges into or consolidates with any other Person, or any Person merges into or consolidates with the Company and, after
giving effect to such transaction, the shareholders of the Company immediately prior to such transaction own less than 50% of the aggregate
voting power of the Company or the successor entity of such transaction, (c) the Company sells or transfers all or substantially all of
its assets to another Person, (d) a replacement at one time or within a three year period of more than one-half of the members of the
Board of Directors which is not approved by a majority of those individuals who are members of the Board of Directors on the Original
Issue Date (or by those individuals who are serving as members of the Board of Directors on any date whose nomination to the Board of
Directors was approved by a majority of the members of the Board of Directors who are members on the date hereof), or (d) the execution
by the Company of an agreement to which the Company is a party or by which it is bound, providing for any of the events set forth in clauses
(a) through (d) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Default Interest Rate&rdquo; shall have the
meaning set forth in Section 2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Dilutive Issuance&rdquo; shall have the meaning set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Dilutive Issuance Notice&rdquo; shall have the meaning
set forth in Section 5(b)(5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;DWAC&rdquo; means the Deposit
or Withdrawal at Custodian system at The Depository Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Event of Default&rdquo; shall have the meaning set
forth in Section 7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Exchange Act&rdquo; means the
Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Fundamental Transaction&rdquo; shall have the meaning
set forth in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;IPO&rdquo; shall have the meaning set forth in Section
4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Liens&rdquo; shall have the meaning set forth in
the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 122pt 0pt 42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Note Register&rdquo; shall have the meaning set forth in Section 3(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 122pt 0pt 42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Notice of Conversion&rdquo;
shall have the meaning set forth in Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Mandatory Default Amount&rdquo; shall have the meaning
set forth in Section 7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Option Value&rdquo;
means the value of a Common Stock Equivalent based on the Black Scholes Option Pricing model obtained from the &ldquo;OV&rdquo;
function on Bloomberg determined as of (A) the Trading Day prior to the public announcement of the issuance of the applicable Common
Stock Equivalent, if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day immediately following
the issuance of the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is not publicly announced,
for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the
remaining term of the applicable Common Stock Equivalent as of the applicable date of determination, (ii) an expected volatility
equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of (A) the Trading Day
immediately following the public announcement of the applicable Common Stock Equivalent if the issuance of such Common Stock
Equivalent is publicly announced or (B) the Trading Day immediately following the issuance of the applicable Common Stock Equivalent
if the issuance of such Common Stock Equivalent is not publicly announced, (iii) the underlying price per share used in such
calculation shall be the highest VWAP of the Common Stock during the period beginning on the Trading Day prior to the execution of
definitive documentation relating to the issuance of the applicable Common Stock Equivalent and ending on (A) the Trading Day
immediately following the public announcement of such issuance, if the issuance of such Common Stock Equivalent is publicly
announced or (B) the Trading Day immediately following the issuance of the applicable Common Stock Equivalent if the issuance of
such Common Stock Equivalent is not publicly announced, (iv) a zero cost of borrow and (v) a 360 day annualization factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Original
Issue Date&rdquo; means the date of the first issuance of this Note, regardless of any transfers of this Note and regardless of the number
of instruments which may be issued to evidence this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Permitted
Indebtedness&rdquo; means (a) the indebtedness evidenced by this Note, (b) senior secured non-convertible loans from traditional commercials
banks with interest per annum not to exceed 12%, (c) capital lease obligations and purchase money indebtedness incurred in connection
with the acquisition of machinery and equipment as long as such capital leases and indebtedness are approved in advance by the Holder
and (d) the Indebtedness set forth on Schedule 3.27 to the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Permitted
Lien&rdquo; means the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental
charges or levies not yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good faith
and by appropriate proceedings for which adequate reserves (in the good faith judgment of the management of the Company) have been
established in accordance with GAAP, (b) Liens imposed by law which were incurred in the ordinary course of the Company&rsquo;s
business, such as carriers&rsquo;, warehousemen&rsquo;s and mechanics&rsquo; Liens, statutory landlords&rsquo; Liens, and other
similar Liens arising in the ordinary course of the Company&rsquo;s business, and which (x) do not individually or in the aggregate
materially detract from the value of such property or assets or materially impair the use thereof in the operation of the business
of the Company and its consolidated Subsidiaries or (y) are being contested in good faith by appropriate proceedings, which
proceedings have the effect of preventing for the foreseeable future the forfeiture or sale of the property or asset subject to such
Lien, (c) Liens incurred in connection with
Permitted Indebtedness under clauses (a) through (d) thereunder, and Liens set forth on Schedule 3.1(aa) to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.9pt 0pt 6pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Purchase
Agreement&rdquo; means the Securities Purchase Agreement, dated as of May 24, 2022, among the Company and the original Holders, as amended,
modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Share Delivery Date&rdquo; shall have the
meaning set forth in Section 4(d)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Successor Entity&rdquo; shall have the meaning set forth in Section 5(e)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;Transaction Documents&rdquo; means the Note, the
Purchase Agreement and the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41.95pt">&ldquo;VWAP&rdquo; means, for any date, the price determined
by the first of the following clauses that applies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)) (or a similar organization or agency succeeding to its functions of
reporting prices), (b) if no volume weighted average price of the Common Stock is reported for the Trading Market, the most recent bid
price per share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which
shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><U>Section 2</U>. <U>Payments of Principal
and Interest</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All principal, accrued interest and
other amounts due shall be paid in U.S. Dollars by wire transfer of immediately available funds. The Company may repay the Holder before
the Maturity Date without penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest shall accrue to the Holder on the
aggregate then outstanding principal amount of this Note at the rate of 10% per annum, calculated on the basis of a 360-day year and
shall accrue daily commencing on the Original Issue Date until payment in full of the outstanding principal, together with all
accrued and unpaid interest, liquidated damages and other amounts which may become due hereunder, has been made. During the
existence of an Event of Default, interest shall accrue at the lesser of (i) the rate of 15% per annum, or (ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT>the
maximum amount permitted by law (the lesser of clause (i) or (ii), the &ldquo;<U>Default Interest Rate</U>&rdquo;). Once an Event of
Default is cured, the interest rate shall return to 10%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><U>Section 3</U>. <U>Registration of Transfers
and Exchanges</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(a) <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp; </FONT><U>
Different Denominations</U>. This Note is exchangeable for an equal aggregate principal amount of Notes of different
authorized denominations, as requested by the Holder surrendering the same. No service charge or other fees will be payable
for such registration of transfer or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Investor
Representations</U>. This Note has been issued subject to certain investment representations of the original Holder set forth
in the Purchase Agreement and may be transferred or exchanged only in compliance with the Purchase Agreement and applicable federal
and state securities laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp; &nbsp; <U>Reliance
on Note Register</U>. Prior to due presentment for transfer to the Company of this Note, the Company and any agent of the
Company may treat the Person in whose name this Note is duly registered on the Note Register as the owner hereof for the
purpose of receiving payment as herein provided and for all other purposes, whether or not this Note is overdue, and neither
the Company nor any such agent shall be affected by notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.25pt 0pt 6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"><U>Section 4. Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Note does not have a conversion feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Section
5</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp; </FONT><U>Stock
Dividends and Stock Splits</U>. If the Company, at any time while this Note is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any Common Stock Equivalents,
(ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse
stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues, in the event of a reclassification
of shares of the Common Stock, any shares of capital stock of the Company, then the Conversion Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Company)
outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to this Section 5(a) shall become effective immediately after the record
date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Subsequent Equity Sales</U>. (1) At any time, for so long as the Note or any amounts accrued and payable thereunder remain outstanding,
the Company or any Subsidiary, as applicable, sells or grants any option to purchase or sells or grants any right to reprice, or otherwise
disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common Stock
Equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the Conversion Price
then in effect (such lower price, the &ldquo;Base Conversion Price&rdquo; and each such issuance or announcement a &ldquo;<U>Dilutive
Issuance</U>&rdquo;), then the Conversion Price shall be immediately reduced to equal the Base Conversion Price. Such adjustment shall
be made whenever such Common Stock or Common Stock Equivalents are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>If any Common Stock Equivalent is amended or adjusted, and such price as so amended shall be less than the Conversion Price in
effect at the time of such amendment or adjustment, then the Conversion Price shall be adjusted upon each such issuance or amendment as
provided in this Section 5(b). In case any Common Stock Equivalent is issued in connection with the issue or sale of other securities
of the Company, together comprising one integrated transaction, (x) the Common Stock Equivalents will be deemed to have been issued for
the Option Value of such Common Stock Equivalents and (y) the other securities issued or sold in such integrated transaction shall be
deemed to have been issued or sold for the difference of (I) the aggregate consideration received by the Company less any consideration
paid or payable by the Company pursuant to the terms of such other securities of the Company, less (II) the Option Value. If any shares
of Common Stock or Common Stock Equivalents are issued or sold or deemed to have been issued or sold for cash, the amount of such consideration
received by the Company will be deemed to be the net amount received by the Company therefor. If any shares of Common Stock or Common
Stock Equivalents are issued or sold for a consideration other than cash, the amount of such consideration received by the Company will
be the fair value of such consideration, except where such consideration consists of publicly traded securities, in which case the amount
of consideration received by the Company will be the average VWAP of such public traded securities for the ten days prior to the date
of receipt. If any shares of Common Stock or Common Stock Equivalents are issued to the owners of the non-surviving entity in connection
with any merger in which the Company is the surviving entity, the amount of consideration therefor will be deemed to be the fair value
of such portion of the net assets and business of the non-surviving entity as is attributable to such shares of Common
Stock or Common Stock Equivalents, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(3)&nbsp;&nbsp; If the holder of Common Stock or Common Stock Equivalents outstanding on the Original Issue Date or issued after the Original Issuance
Date shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange
prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to
receive shares of Common Stock at an effective price per share that is lower than the Conversion Price then in effect, such issuance shall
be deemed to have occurred for less than the Conversion Price on such date and such issuance shall be deemed to be a Dilutive Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(4)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>If the Company enters into a Variable Rate Transaction despite the prohibition set forth in the Purchase Agreement, the Company
shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion price at which such securities
may be converted or exercised under the terms of such Variable Rate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(5)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The Company shall notify the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common
Stock Equivalents subject to this Section 5(b), indicating therein the applicable issuance price, or applicable reset price, exchange
price, conversion price and other pricing terms (such notice, the &ldquo;Dilutive Issuance Notice&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(6)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The provisions of this Section 5(b) shall apply each time a Dilutive Issuance occurs after the Original Issue Date for so long
as the Note or any amounts accrued and payable thereunder remain outstanding, but any adjustment of the Conversion Price pursuant to this
Section 5(b) shall be downward only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> (7) &nbsp;&nbsp;The provisions of this Section 5(b) shall not apply to Exempt Issuances.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 5(a) above, if at any time the Company grants,
issues or sells any Common Stock, Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the
Holder had held the number of Bridge Shares, including without limitation, the Beneficial Ownership Limitation) immediately before the
date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of
which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall
be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial
Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. During such time as this Note is outstanding, if the Company shall declare or make any dividend
or other distribution of its assets or rights or warrants to acquire its assets, or subscribe for or purchase any security other than
Common Stock, to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution
of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme
of arrangement or other similar transaction) (a &ldquo;Distribution&rdquo;), at any time after the issuance of this Note, then, in each
such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated
therein if the Holder had held the number of Bridge Shares (without regard to
any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of
which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common
Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent that the Holder's
right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation with respect to
the Company or any other publicly-traded corporation subject to Section 13(d) of the Exchange Act, then the Holder shall not be entitled
to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution
to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever,
as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation with respect to the Company or any other
publicly-traded corporation subject to Section 13(d) of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><U>Fundamental Transaction</U>. (1) If, at any time while this Note is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv)
the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or
share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or
scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock
(not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with
the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent conversion of this Note, the Holder shall have the right to receive, for each Conversion
Share that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without
regard to any limitation on the conversion of this Note), the number of shares of Common Stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable
as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Note is convertible immediately
prior to such Fundamental Transaction (without regard to any limitation on the conversion of this Note). For purposes of any such conversion,
the determination of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount
of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any conversion
of this Note following such Fundamental Transaction. The Company shall not effect a Fundamental Transaction unless it gives the Holder
at least 10 Trading Days prior notice together with sufficient details so the Holder can make an informed decision as to whether it elects
to accept the Alternative Consideration. If a public announcement of the Fundamental Transaction has not been made, the notice to the
Holder may not be given until the Company files a Form 8-K or other report disclosing the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.6pt 0pt 0pt; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>Notwithstanding anything to the contrary, provided that the Warrant Shares are not registered under an effective registration statement,
in the event of a Fundamental Transaction that is (x) an all cash transaction, (y) a &ldquo;Rule 13e-3 transaction&rdquo; as defined in
Rule 13e-3 under the Exchange Act, or (z) a Fundamental Transaction involving a person or entity not traded on a national securities exchange
or trading market (with such exchange or market including, without limitation, the Nasdaq Global Select Trading Market, the Nasdaq Global
Market, or the Nasdaq Capital Market, the New York Stock Exchange, Inc., the NYSE American or any market operated by the OTC Markets,
Inc.), the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, concurrently with the consummation
of the Fundamental Transaction, purchase this Note from the Holder by paying to the Holder the higher of (i) an amount of cash equal to
the Black Scholes Value of the outstanding principal of this Note on the date of the consummation of such Fundamental Transaction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>If Section 5(e)(1) and (2) are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which
the Company is not the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under
this Note and the other Transaction Documents in accordance with the provisions of this Section 5(e) pursuant to written agreements in
form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Note a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Note. Upon the occurrence of any such Fundamental
Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction,
the provisions of this Note and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Note
and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. Notwithstanding
anything in this Section 5(e), an Exempt Issuance (as defined in the Purchase Agreement) shall not be deemed a Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding any treasury shares of the Company) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> (g) <U>Notice to the Holder</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 53.95pt">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Adjustment to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 5, the
Company shall promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief
statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.65pt 0pt 6pt; text-align: justify; text-indent: 53.95pt"></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 53.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 53.95pt">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><U>Notice to Allow Conversion by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever
form) on its Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of its Common Stock,
(C) the Company shall authorize the granting to all holders of its Common Stock of rights or warrants to subscribe for or purchase any
shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection
with any reclassification of its Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all
or substantially all of the assets of the Company, or any compulsory share exchange whereby its Common Stock is converted into other securities,
cash or property or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be filed at each office or agency maintained, and shall cause to be delivered
to the Holder at its last address as it shall appear upon the Note Register, at least 5 calendar days prior to the applicable record or
effective date hereinafter specified, a notice stating (x) the date on
which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to
be taken, the date as of which the holders of its Common Stock of record to be entitled to such dividend, distributions, redemption, rights
or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange
is expected to become effective or close, and the date as of which it is expected that holders of its Common Stock of record shall be
entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange, provided that the failure to deliver such notice or any defect therein or in the delivery thereof
shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries (as determined in
good faith by the Company), the Company or its successor shall simultaneously file such notice with the SEC pursuant to a Current Report
on Form 8-K. If the Company does not simultaneously file the required Form 8-K, the Holder shall be entitled penalties in accordance with
Section 5.6 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 6</U>. <U>Negative Covenants</U>.
As long as any portion of this Note remains outstanding, unless all of the Holders of the then outstanding Notes shall have otherwise
given prior written consent, the Company shall not, and shall not permit any of the Subsidiaries to, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>other than Permitted Indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any indebtedness for borrowed
money of any kind, including, but not limited to, a guarantee, on or with respect to any of its property or assets now owned or hereafter
acquired or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>other than Permitted Liens, enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to any
of its property or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>amend its charter documents, including, without limitation, its articles of incorporation and bylaws, in any manner that materially
and adversely affects any rights of the Holder, increases in authorized shares and stock splits shall not be deemed to materially and
adversely affects any rights of the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>purchase or otherwise acquire more than a <U>de minimis</U> number of shares of its Common Stock or Common Stock Equivalents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>repay, or offer to repay, any Indebtedness, other than Permitted Indebtedness, as such terms Indebtedness and Permitted Indebtedness
are in effect as of the Original Issue Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> (f) pay cash dividends or distributions on any equity securities of the Company;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>enter into any transaction with any Affiliate of the Company which would be required to be disclosed in any public filing with
the SEC assuming that the Company is subject to the Securities Act or the Exchange Act, unless such transaction is made on an arm&rsquo;s-length
basis and expressly approved by a majority of the disinterested directors of the Company (even if less than a quorum otherwise required
for board approval);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>issue any equity securities of the Company other than pursuant to the provisions of the Purchase Agreement or an Exempt Issuance;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"> (i) enter into any agreement with respect to any of the foregoing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.95pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0"><U>Section 7</U>. <U>Events of Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>&ldquo;<U>Event of Default</U>&rdquo; means, wherever used herein, any of the following events (whatever the reason for such event
and whether such event shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order
of any court, or any order, rule or regulation of any administrative or governmental body):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>any default in the payment of (A) principal and interest payment under this Note or any other Indebtedness, or (B) late fees, liquidated
damages and other amounts owing to the Holder of this Note, as and when the same shall become due and payable (whether on a Conversion
Date, or the Maturity Date, or by acceleration or otherwise), which default, solely in the case of a default under clause (B) above, is
not cured within five Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT>the Company shall fail to observe or perform any other covenant or agreement contained in this Note (other than a breach by the
Company of its obligations to deliver Shares, which breach is addressed in clause (x) below) or any Transaction Document which failure
is not cured, if possible to cure, within the earlier to occur of 15 Trading Days after notice of such failure is sent by the Holder or
by any other Holder to the Company and (B) 10 Trading Days after the Company has become aware of such failure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>except for payment defaults covered under Section 7(a)(i), the Company shall breach, or a default or event of default (subject
to any grace or cure period provided in the applicable agreement, document or instrument) shall occur under, (A) any of the Transaction
Documents or (B) any other material agreement, lease, document or instrument to which the Company or any Subsidiary is obligated (and
not covered by any other clause of this Section 7) which default or event of default if not cured, if possible to cure, within the earlier
to occur of (i) 10 Trading Days after notice of such default sent by Holder or by any other holder to the Company and (ii) five Trading
Days after the Company has become aware of such default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>any representation or warranty made in this Note, any other Transaction Document, any written statement pursuant hereto or thereto
or any other report, financial statement or certificate made or delivered to the Holder or any other Holder shall be untrue or incorrect
in any material respect as of the date when made or deemed made, which failure is not cured, if possible to cure, within the earlier to
occur of 10 Trading Days after notice of such failure is sent by the Holder or by any other Holder to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"> (v) the Company or any Subsidiary shall be subject to a Bankruptcy Event;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>the Company or any Subsidiary shall: (A) apply for or consent to the appointment of a receiver, trustee, custodian or liquidator
of it or any of its properties; (B) admit in writing its inability to pay its debts as they mature; (C) make a general assignment for
the benefit of creditors; (D) be adjudicated as bankrupt or insolvent or be the subject of an order for relief under Title 11 of the United
States Code or any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law or statute of any other
jurisdiction or foreign country; or (E) file a voluntary petition in bankruptcy, or a petition or an answer seeking reorganization or
an arrangement with creditors or to take advantage or any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or
liquidation law or statute, or an answer admitting the material allegations of a petition filed against it in any proceeding under any
such law, or (F) take or permit to be taken any action in furtherance of or for the purpose of effecting any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>if any order, judgment or decree shall be entered, without the application, approval or consent of the Company or any Subsidiary,
by any court of competent jurisdiction, approving a petition seeking liquidation or reorganization of the Company or any Subsidiary, or
appointing a receiver, trustee, custodian or liquidator of the Company or any Subsidiary, or of all or any substantial part of its assets,
and such order, judgment or decree shall continue unstayed and in effect for any period of 60 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.75pt 0pt 5.95pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>the occurrence of any levy upon or seizure or attachment of, or any uninsured loss of or damage to, any property of the Company
or any Subsidiary having an aggregate fair value or repair cost (as the case may be) in excess of $100,000 individually or in the aggregate,
and any such levy, seizure or attachment shall not be set aside, bonded or discharged within 45 days after the date thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 71.95pt">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>any monetary judgment, writ or similar final process shall be entered or filed against the Company, any Subsidiary or any of their
respective property or other assets for more than $100,000, and such judgment, writ or similar final process shall remain unvacated, unbonded
or unstayed for a period of 30 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 71.95pt"> (x) any Material Adverse Effect occurs;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 71.95pt">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>any provision of any Transaction Document shall at any time for any reason (other than pursuant to the express terms thereof) cease
to be valid and binding on or enforceable against the parties thereto, or the validity or enforceability thereof shall be contested by
any party thereto, or a proceeding shall be commenced by the Company or any Subsidiary or any governmental authority having jurisdiction
over any of them, seeking to establish the invalidity or unenforceability thereof, or the Company or any Subsidiary shall deny in writing
that it has any liability or obligation purported to be created under any Transaction Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 71.95pt">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>the Company fails to use the proceeds in the manner as described in Section 5.7 of the Purchase Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 71.95pt">(xiii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>the Company shall be a party to any Change of Control Transaction or shall agree to sell or dispose of all or in excess of 50%
of its assets in one transaction or a series of related transactions (whether or not such sale would constitute a Change of Control Transaction);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 71.95pt">(xiv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>from and after 90 days after the Original Issue Date, the Company fails to have authorized and reserved the amount of shares designated
in Section 3.5 of the Purchase Agreement (including without limitation, the Beneficial Ownership Limitation);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 71.95pt">(xv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>the Company fails to file with the SEC any required reports under Section 13 or 15(d) of the Exchange Act within the time required
(including any applicable extension period) by the rules and regulations thereunder; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 71.95pt">(xvi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT>the Company fails to convert from a limited liability company to a corporation on or before June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><U>Remedies Upon Event of Default</U>. If any Event of Default occurs, the outstanding principal amount of this Note, plus liquidated
damages and other amounts owing in respect thereof through the date of acceleration, shall become, at the Holder&rsquo;s election, immediately
due and payable in cash (the &ldquo;Mandatory Default Amount&rdquo;). Upon the payment in full of the Mandatory Default Amount, the Holder
shall promptly surrender this Note to or as directed by the Company. In connection with such acceleration described herein, the Holder
need not provide, and the Company hereby waives, any presentment, demand, protest or other notice of any kind, and the Holder may immediately
and without expiration of any grace period enforce any and all of its rights and remedies hereunder and all other remedies available to
it under applicable law. Such acceleration may be rescinded and annulled by Holder at any time prior to payment hereunder and the Holder
shall have all rights as a holder of the Note until such time, if any, as the Holder receives full payment pursuant to this Section 7(b).
No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT><U>Interest Rate Upon Event of Default</U>. Commencing on the occurrence of any Event of Default and until such Event of Default
is cured, this Note shall accrue interest at an interest rate equal to the Default Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Section 8</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>No Rights as Stockholder Until Conversion</U>. This Note does not entitle the Holder to any voting rights, dividends or other
rights as a stockholder of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing, and
shall be sufficiently given if delivered to the addressees in person, by FedEx or similar receipted next day delivery, or at the Company&rsquo;s
registered address or such other address as any of them, by notice to the other may designate from time to time. Time shall be counted
to, or from, as the case may be, the date of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Absolute Obligation</U>. Except as expressly provided herein, no provision of this Note shall alter or impair the obligation
of the Company, which is absolute and unconditional, to pay the principal of, liquidated damages and accrued interest and late fees, as
applicable, on this Note at the time, place, and rate, and in the coin or currency, herein prescribed. This Note is a direct debt obligation
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Lost or Mutilated Note</U>. If this Note shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver,
in exchange and substitution for and upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost, stolen or destroyed
Note, a new Note for the principal amount of this Note so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such
loss, theft or destruction of this Note, and of the ownership hereof, reasonably satisfactory to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><U>Exclusive
Jurisdiction; Governing Law; Prevailing Party Attorneys&rsquo; Fees</U>. All questions concerning the construction, validity,
enforcement and interpretation of this Note and venue shall be governed by and construed and enforced in accordance with Section
6.9 of the Purchase Agreement. If any party shall commence an Action or Proceeding to enforce or otherwise relating to this Note,
then, in addition to the other obligations of the Company elsewhere in this Note, the prevailing party in such action or proceeding
shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Waiver</U>. Any waiver by the Company or the Holder of a breach of any provision of this Note shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this Note. The failure of the Company
or the Holder to insist upon strict adherence to any term of this Note on one or more occasions shall not be considered a waiver or deprive
that party of the right thereafter to insist upon strict adherence to that term or any other term of this Note on any other occasion.
Any waiver by the Company or the Holder must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Severability</U>. If any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain
in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons
and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing
usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under
applicable law. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead, or
in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would prohibit
or forgive the Company from paying all or any portion of the principal of or interest on this Note as contemplated herein, wherever enacted,
now or at any time hereafter in force, or which may affect the covenants or the performance of this Note, and the Company (to the extent it may lawfully
do so) hereby expressly waives all benefits or advantage of any such law, and covenants that it will not, by resort to any such law, hinder,
delay or impede the execution of any power herein granted to the Holder, but will suffer and permit the execution of every such as though
no such law has been enacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Remedies, Characterizations, Other Obligations, Breaches and Injunctive Relief.</U> The remedies provided in this Note shall
be cumulative and in addition to all other remedies available under this Note and any of the other Transaction Documents at law or in
equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder&rsquo;s
right to pursue actual and consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants
to the Holder that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set
forth or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to be
received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company (or the performance
thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that
the remedy at law for any such breach would be inadequate. The Company therefore agrees that, in the event of any such breach or threatened
breach, the Holder shall be entitled, in addition to all other available remedies, to an injunction restraining any such breach or any
such threatened breach, without the necessity of showing economic loss and without any bond or other security being required. The Company
shall provide all information and documentation to the Holder that is requested by the Holder to enable the Holder to confirm the Company&rsquo;s
compliance with the terms and conditions of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Next Trading Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Trading Day, such
payment shall be made on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0pt; text-align: justify; text-indent: 0.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;
</FONT><U>Headings</U>. The headings contained herein are for convenience only, do not constitute a part of this Note and shall not be
deemed to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 165.65pt 0pt 163.75pt; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 165.65pt 0pt 163.75pt; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 35.95pt">IN WITNESS WHEREOF, the Company has caused
this Note to be duly executed by a duly authorized officer as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>16
<FILENAME>cm270_ex10-13.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: right; text-indent: 0.25in"><B>Exhibit 10.13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES PURCHASE
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">This Securities Purchase
Agreement (this &#8220;<U>Agreement</U>&#8221;) is dated as of May [*], 2022, by and between 60&deg; Pharmaceuticals, LLC, a limited liability
company, and each investor that executes the signature page hereto as a purchaser (each, a &#8220;Purchaser&#8221; and collectively, the
&#8220;<U>Purchasers</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">WHEREAS, subject to the
terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities
Act, as defined, contained in Section 4(a)(2) thereof and/or Rule 506(b) thereunder, the Company desires to issue and sell to the Purchaser,
and the Purchaser desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and the Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE I. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><B>DEFINITIONS</B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">1.1 <U>Definitions</U>.
In addition to the words and terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&#8220;Acquiring
Person&#8221; shall have the meaning ascribed to such term in Section 5.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&#8220;Action&#8221;
shall have the meaning ascribed to such term in Section 3.10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Affiliate&#8221;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Bridge Shares&#8221;
means shares of the Company&#8217;s Common Stock issued to each Purchaser equal to and based on (A) 100% of the Face Value of each Purchaser&#8217;s
Note divided by the Company&#8217;s IPO price upon the pricing of the Company&#8217;s IPO or (B) if the Company fails to complete the
IPO before the Maturity Date, the number of shares calculated using a $27 million pre-money valuation for the Company and the number of
the Company&#8217;s shares outstanding on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&#8220;Board of
Directors&#8221; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&#8220;Closing&#8221;
means the closing of the purchase and sale of the Notes pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Closing Date&#8221;
means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and
all conditions precedent to (i) the Purchaser&#8217;s obligations to pay the Subscription Amount and (ii) the Company&#8217;s obligations
to deliver the Securities to be issued and sold, in each case, have been satisfied or waived, but in no event later than the second Trading
Day following the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Common Stock&#8221;
means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Common Stock Equivalents&#8221;
means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including,
without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. &#8220;Company&#8221; means 60&deg; Pharmaceuticals,
LLC and any successor company after conversion from a limited liability company to a corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;Evaluation
Date&#8221; shall have the meaning ascribed to such term in Section 3.19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Exchange Act&#8221;
means the Securities Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Exempt Issuance&#8221;
means the issuance of (a) shares of Common Stock, restricted stock units or options, and the underlying shares of Common Stock to consultants,
employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the
nonemployee members of the Board of Directors or a majority of the members of a committee of non-employee directors established for such
purpose for services rendered to the Company, (b) securities issued upon the exercise or exchange of or conversion of any Securities issued
hereunder and/or other securities issuable pursuant to existing agreements, exercisable or exchangeable for or convertible into shares
of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date
of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such
securities (other than in connection with stock dividends, stock splits or combinations) or to extend the term of such securities, (c)
securities issued pursuant, acquisitions or strategic transactions approved by a majority of the directors of the Company, provided that
any such issuance shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating
company or an owner of an asset in a business synergistic with the business of the Company and which shall reasonably be expected to provide
to the Company additional benefits, but shall not include a transaction in which the Company is issuing securities primarily for the purpose
of raising capital or to an entity whose primary business is investing in securities, (d) securities issued pursuant to any purchase money
equipment loan or capital leasing arrangement, purchasing agent or debt financing from a commercial bank or similar financial institution,
(e) securities issued pursuant to any presently outstanding warrants or this Agreement; and (f) securities upon a stock split, stock dividend
or subdivision of the Common Stock and shares of common stock in a public offering; (g) non-convertible loans from traditional commercials
banks with interest per annum not to exceed 12% which will rank <B><I>pari passu</I></B> with the Notes issued to investors by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Face Value&#8221;
means the Subscription Amount plus original issue discount as described in the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;FCPA&#8221;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;GAAP&#8221;
shall have the meaning ascribed to such term in Section 3.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;Indebtedness&#8221;
shall have the meaning ascribed to such term in Section 3.27.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Intellectual Property&#8221;
means all of the following in any jurisdiction throughout the world: (a) all inventions (whether patentable or unpatentable and whether
or not reduced to practice), all improvements thereto, and all U.S. and foreign patents, patent applications, and patent disclosures,
together with all reissuances, continuations, continuations-in-part, revisions, extensions, and reexaminations thereof, (b) all trademarks,
service marks, brand names, certification marks, trade dress, logos, trade names, domain names, assumed names and corporate names, together
with all colorable imitations thereof, and including all goodwill associated therewith, and all applications, registrations, and renewals
in connection therewith, (c) all copyrights, and all applications, registrations, and renewals in connection therewith, (d) all trade
secrets under applicable state laws and the common law and know-how (including formulas, techniques, technical data, designs, drawings,
specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), (e) all computer
software (including source code, object code, diagrams, data and related documentation), and (f) all copies and tangible embodiments of
the foregoing (in whatever form or medium).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">Securities Purchase
Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;IPO&#8221; shall
mean an initial public offering by the Company that results in a listing of the Company&#8217;s Common Stock on a national securities
exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Licensed Intellectual
Property Agreement&#8221; means all licenses, sublicenses, agreements and permissions (each as amended to date) that any third party owns
and that the Company uses, including offthe-shelf software purchased or licensed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Liens&#8221; means
a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&#8220;Material
Adverse Effect&#8221; shall have the meaning assigned to such term in Section 3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;Maturity Date&#8221;
shall have the meaning assigned to such term in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Notes&#8221; means
the Original Issue Discount Promissory Notes issued to the Purchaser, in the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Original Issue Date&#8221;
means the date of the first issuance of the Notes, regardless of any transfers of any Note and regardless of the number of instruments
which may be issued to evidence such Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Person&#8221; means
an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Proceeding&#8221;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;Purchaser Party&#8221;
shall have the meaning ascribed to such term in Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;Registrable
Securities&#8221; shall mean, collectively, the Bridge Shares and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Regulation FD&#8221;
means Regulation FD promulgated by the SEC pursuant to the Exchange Act, as such Regulation may be amended or interpreted from time to
time, or any similar rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Regulation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;Required Approvals&#8221;
shall have the meaning ascribed to such term in Section 3.4.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Rule 144&#8221; means
Rule 144 promulgated by the SEC pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar
rule or regulation hereafter adopted by the SEC having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;SEC&#8221;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;Securities&#8221;
means the Notes, the Warrants and the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Securities Act&#8221;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#8220;Shares&#8221;
means the Bridge Shares and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Short Sales&#8221;
means all &#8220;short sales&#8221; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include
the location and/or reservation of borrowable shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Subscription Amount&#8221;
means, as to the Purchaser, the aggregate amount to be paid for the Note purchased hereunder as specified below the Purchaser&#8217;s
name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in
immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Subsidiary&#8221;
means with respect to any entity at any date, any direct or indirect corporation, limited or general partnership, limited liability company,
trust, estate, association, joint venture or other business entity of which (A) more than 50% of (i) the outstanding capital stock having
(in the absence of contingencies) ordinary voting power to elect a majority of the Board of Directors or other managing body of such entity,
(ii) in the case of a partnership or limited liability company, the interest in the capital or profits of such partnership or limited
liability company or (iii) in the case of a trust, estate, association, joint venture or other entity, the beneficial interest in such
trust, estate, association or other entity business is, at the time of determination, owned or controlled directly or indirectly through
one or more intermediaries, by such entity, or (B) is under the actual control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&#8220;Trading Day&#8221;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Trading Market&#8221;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
OTCQB, the OTCQX, or the OTC Pink Marketplace (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Transaction Documents&#8221;
means this Agreement, the Notes, the Warrants, and any other documents or agreements executed in connection with the transactions contemplated
hereunder, including, but not limited to, the documents referenced in Section 2.2(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&#8220;Transfer
Agent&#8221; means [*], and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Variable Rate
Transaction&#8221; means any Equity Line of Credit or similar agreement, nor issue nor agree to issue any Common Stock, floating or
Variable Priced Equity Linked Instruments nor any of the foregoing or equity with price reset rights (subject to adjustment for
stock splits, distributions, dividends, recapitalizations and the like) (collectively, the &#8220;Variable Rate Transaction&#8221;).
For purposes of this Agreement, &#8220;Equity Line of Credit&#8221; shall include any transaction involving a written agreement
between the Company and an investor or underwriter whereby the Company has the right to &#8220;put&#8221; its securities to the
investor or underwriter over an agreed period of time and at an agreed price or price formula, and &#8220;Variable Priced Equity
Linked Instruments&#8221; shall include: (A) any debt or equity securities which are convertible into, exercisable or exchangeable
for, or carry the right to receive additional shares of Common Stock either (1) at any conversion, exercise or exchange rate or
other price that is based upon and/or varies with the trading prices of or quotations for Common Stock at any time after the initial
issuance of such debt or equity security, or (2) with a fixed conversion, exercise or exchange price that is subject to being reset
at some future date at any time after the initial issuance of such debt or equity security due to a change in the market price of
the Company&#8217;s Common Stock since date of initial issuance, and (B) any amortizing convertible security which amortizes prior
to its maturity date, where the Company is required or has the option to (or any investor in such transaction has the option to
require the Company to) make such amortization payments in shares of Common Stock which are valued at a price that is based upon
and/or varies with the trading prices of or quotations for Common Stock at any time after the initial issuance of such debt or
equity security (whether or not such payments in stock are subject to certain equity conditions). For purposes of determining the
total consideration for a convertible instrument (including a right to purchase equity of the Company) issued, subject to an
original issue or similar discount or which principal amount is directly or indirectly increased after issuance, the consideration
will be deemed to be the actual cash amount received by the Company in consideration of the original issuance of such convertible
instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Warrants&#8221; means,
collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof,
which Warrants shall be exercisable immediately and have a term of exercise equal to five years from such initial exercise date, in the
form of <U>Exhibit B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: justify; text-indent: 0in">&#8220;Warrant Exercise
Price&#8221; means the exercise price provided in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&#8220;Warrant Shares&#8221;
means the shares of Common Stock issuable upon exercise of the Warrants at the Warrant Exercise Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE II. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURCHASE
AND SALE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">2.1 <U>Closing</U>. On the
Closing Dates, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery
of this Agreement by the parties hereto, the Company agrees to sell, and each Purchaser, severally and not jointly, agrees to purchase
an aggregate of (i) Notes with a Face Value listed on the Purchaser&#8217;s signature page and (ii) Warrants to purchase shares equal
to 50% of the Bridge Shares. On the Closing Date, the Purchaser shall deliver to the Company a signed copy of the Transaction Documents
and, via wire transfer, immediately available funds equal to the Purchaser&#8217;s Subscription Amount. After receipt of the Subscription
Amount, the Company shall deliver to the Purchaser countersigned copies of the Transaction Documents. Upon satisfaction of the closing
conditions set forth in Section 2.3, the Closing shall occur at the Company&#8217;s offices or such other location as the parties shall
mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">2.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deliveries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;this
Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
Note in the principal amount of $250,000.00 registered in the name of the Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;an
original Warrant to purchase shares of Common Stock, exercisable at the Warrant Exercise Price, registered in the name of such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a
Board Consent approving the issuance of the Notes and the execution of the Transaction Documents listed above on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to the Closing Date each Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">(i)</TD><TD STYLE="text-align: justify">this Agreement duly executed by the Purchaser; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">the Purchaser&#8217;s Subscription Amount by wire transfer to the Company.</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
the (i) date of the pricing of the Company&#8217;s IPO, the Company shall deliver to each Purchaser shares of the Company&#8217;s common
stock equal to 100% of the Face Value of each Purchaser&#8217;s Note divided by the Company&#8217;s IPO price upon or (ii) if the Company
fails to complete the IPO before the Maturity Date, the number of shares of the Company&#8217;s common stock calculated using a $27 million
premoney valuation for the Company and the number of the Company&#8217;s shares outstanding on the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">2.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Closing
Conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) on the Closing Date of the representations and warranties of the Purchaser contained herein (unless as of a specific
date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
respective obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;accuracy
in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in
all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a
specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify; text-indent: 0.75in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;there
shall have been no Material Adverse Effect with respect to the Company since the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE III.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPRESENTATIONS
AND WARRANTIES OF COMPANY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">The Company hereby makes
the following representations and warranties to each Purchaser as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or Articles of Incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt"></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. Subject to obtaining the Required Approvals, this Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U>. Except as set forth in <U>Schedule 3.3</U>, the execution, delivery and performance by the Company of this Agreement and
the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions
contemplated hereby and thereby do not and will not (i) subject to the Required Approvals, conflict with or violate any provision of the
Company&#8217;s or any Subsidiary&#8217;s Certificate or Articles of Incorporation, bylaws or other organizational or charter documents,
or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result
in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination,
amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other
instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party
or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental
authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any
property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could
not have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Filings,
Consents and Approvals</U>. Except as set forth on <U>Schedule 3.4</U>, the Company is not required to obtain any consent, waiver,
authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or
other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the
Transaction Documents, other than: (i) blue sky filings or a Form D filing and (ii) such filings as are required to be made under
applicable state securities laws (the &#8220;<U>Required Approvals</U>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Shares,
when issued will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company shall
reserve from its duly authorized capital stock a number of shares of Common Stock issuable pursuant to the Notes and Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Capitalization</U>.
The capitalization of the Company is as set forth on <U>Schedule 3.6</U>. The Company has not issued any capital stock since its most
recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock awards under the Company&#8217;s
equity incentive plans, the issuance of shares of Common Stock to employees pursuant to the Company&#8217;s employee stock purchase plans
and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic
report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right
to participate in the transactions contemplated by the Transaction Documents. Except as set forth on <U>Schedule 3.6</U>, as a result
of the purchase and sale of the Securities, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments
of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts,
commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to issue additional shares of
Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate
the Company or any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchaser) and will not
result in a right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities.
There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions,
and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound
to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221;
plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized,
validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and none of such
outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further
approval or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities.
There are no stockholders&#8217; agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital
stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsidiaries</U>.
All of the direct and indirect Subsidiaries of the Company are set forth in Schedule 3.7. The Company owns, directly or indirectly, all
of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares
of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Statements</U>. The consolidated financial statements of the Company, together with the related notes and schedules, present fairly,
in all material respects, the consolidated financial position of the Company and any of its Subsidiaries as of the dates indicated
and the consolidated results of operations, cash flows and changes in stockholders&#8217; equity of the Company for the periods
specified and have been prepared in compliance with United States generally accepted accounting principles
(&#8220;<U>GAAP</U>&#8221;) applied on a consistent basis during the periods involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest financial statements: (i) there has been no
event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company
has not incurred any liabilities (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary
course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements
pursuant to GAAP, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares
of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to
existing Company equity incentive plans. Other than as disclosed on <U>Schedule 3.9</U>, except for the issuance of the Securities contemplated
by this Agreement, no event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected
to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets
or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation
is made or deemed made that has not been publicly disclosed at least one Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Litigation</U>.
Except as set forth on <U>Schedule 3.10</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation, inquiry
or other similar proceeding of any federal or state government unit pending or, to the knowledge of the Company, threatened against or
affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative
agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<U>Action</U>&#8221;) which (i) adversely
affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the issuance of the Securities or
(ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. The Company
has no reason to believe that an Action will be filed against it in the future except as disclosed on <U>Schedule 3.10</U>. Neither the
Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation
of or liability under federal or state securities laws or a claim for fraud or breach of fiduciary duty. There has not been, and to the
knowledge of the Company, there is not pending or contemplated, any investigation or inquiry by the SEC involving the Company or any current
or former director or officer of the Company. The SEC has not issued any stop order or other order suspending the effectiveness of any
registration statement filed by the Company or any Subsidiary under the Securities Act, and the Company has no reason to believe it will
do so in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the
Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&#8217;s or its
Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such
Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and
its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no effort is
underway to unionize or organize the employees of the Company or any Subsidiary. To the knowledge of the Company, no executive
officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment
contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or
agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does
not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and
its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and
employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. There is no workmen&#8217;s
compensation liability matter, employment-related charge, complaint, grievance, investigation, inquiry or obligation of any kind
pending, or to the Company&#8217;s knowledge, threatened, relating to an alleged violation or breach by the Company or its
Subsidiaries of any law, regulation or contract that could, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance</U>.
Except as set forth on <U>Schedule 3.12</U>, neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no
event has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any
Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation
of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties
is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court,
arbitrator or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &#8220;Hazardous Materials&#8221;) into the environment, or otherwise relating to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations,
codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations,
issued, entered, promulgated or approved thereunder (&#8220;Environmental Laws&#8221;); (ii) have received all permits licenses or other
approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with
all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could
be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulatory
Permits</U>. The Company and each of its Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
regulatory authorities necessary to conduct their respective businesses, except where the failure to possess such certificates,
authorizations or permits would not have, individually or in the aggregate, a Material Adverse Effect, and neither the Company nor
any Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate,
authorization or permit. There is no agreement, commitment, judgment, injunction, order or decree binding upon the Company or any of
its Subsidiaries or to which the Company or any of its Subsidiaries is a party which has or would reasonably be expected to have the
effect of prohibiting or materially impairing any business practice of the Company or any of its Subsidiaries, any acquisition of
property by the Company or any of its Subsidiaries or the conduct of business by the Company or any of its Subsidiaries as currently
conducted other than such effects, individually or in the aggregate, which have not had and would not reasonably be expected to have
a Material Adverse Effect on the Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Title
to Assets</U>. Subject to the Liens of the outstanding secured senior debt, the Company and the Subsidiaries have good and marketable
title in fee simple to all personal property owned by them that is material to the business of the Company and the Subsidiaries. The Company
owns no real property. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid,
subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the Liens of the outstanding secured senior debt, to the Company&rsquo;s knowledge, the Company owns or possesses or has the right
to use pursuant to a valid and enforceable written license, sublicense, agreement, or permission all Intellectual Property necessary for
the operation of the business of the Company as presently conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1.5in; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company&rsquo;s knowledge, the Intellectual Property does not interfere with, infringe upon, misappropriate, or otherwise come into
conflict with, any Intellectual Property rights of third parties, and the Company has no knowledge that facts exist which indicate a likelihood
of the foregoing. The Company has not received any charge, complaint, claim, demand, or notice alleging any such interference, infringement,
misappropriation, or conflict (including any claim that the Company must license or refrain from using any Intellectual Property rights
of any third party). To the knowledge of the Company, no third party has interfered with, infringed upon, misappropriated, or otherwise
come into conflict with, any Intellectual Property rights of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 81pt; text-align: justify; text-indent: -0.25in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each Licensed Intellectual Property Agreement:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 1in">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Licensed Intellectual Property Agreement is legal, valid, binding, enforceable, and in full force and effect;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 1in">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the Company&#8217;s knowledge, no party to the Licensed Intellectual Property Agreement is in breach or default, and no event has occurred
that with notice or lapse of time would constitute a breach or default or permit termination, modification, or acceleration thereunder,
which as to any such breach, default or event could have a Material Adverse Effect on the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 1in">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
party to such Licensed Intellectual Property Agreement has repudiated any provision thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 1in">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth in such Licensed Intellectual Property Agreement, the Company has not received written or verbal notice or otherwise has
knowledge that the underlying item of Intellectual Property is subject to any outstanding injunction, judgment, order, decree, ruling,
or charge; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84pt; text-align: justify; text-indent: 1in">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as set forth on <U>Schedule 3.16</U>, the Company has not granted any sublicense or similar right with respect to the license, sublicense,
agreement, or permission.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has complied with and is presently in compliance with all foreign, federal, state, local, governmental (including, but not limited
to, the Federal Trade Commission and State Attorneys General), administrative, or regulatory laws, regulations, guidelines, and rules
applicable to any personal identifiable information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Person who participated in the creation, conception, invention or development of the Intellectual Property currently used in the business
of the Company (each, a &#8220;Developer&#8221;) which is not licensed from third parties has executed one or more agreements containing
industry standard confidentiality, work for hire and assignment provisions, whereby the Developer has assigned to the Company all copyrights,
patent rights, Intellectual Property rights and other rights in the Intellectual Property, including all rights in the Intellectual Property
that existed prior to the assignment of rights by such Person to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Developer has signed a perpetual non-disclosure agreement with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor
any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transactions
With Affiliates and Employees</U>. Except as disclosed in Schedule 3.18, none of the officers or directors of the Company or any Subsidiary
and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any transaction with
the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing
for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee
or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is
an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary
or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits,
including stock award agreements under any equity incentive plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Sarbanes-Oxley;
Internal Accounting Controls</U>. Except as disclosed in the Schedule 3.19, the Company and the Subsidiaries are in compliance with
any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all
applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof and as of the Closing
Date. The Company and the Subsidiaries maintain a system of internal accounting controls. The Company&#8217;s certifying officers
have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the
period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;<U>Evaluation
Date</U>&#8221;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the
Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such
term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to
materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Fees</U>. Except as set forth on <U>Schedule 3.20</U>, no brokerage or finder&#8217;s fees or commissions are or will be payable by the
Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person
with respect to the transactions contemplated by the Transaction Documents. The Purchaser shall have no obligation with respect to any
fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due
by the Company in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended. The Company
shall conduct its business in a manner so that it will not become an &#8220;investment company&#8221; subject to registration under the
Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights</U>. Except as disclosed on <U>Schedule 3.22, n</U>o Person has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
and Maintenance Requirements; Shell Company</U>. The Company&#8217;s Common Stock is not quoted or listed on any Trading Market. The Company
is not and has never been a shell company as such term is defined in Rule 12(b)(2) under the Securities Exchange Act of 1934, as amended
and the rules and regulations of the Securities and Exchange Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchaser as a result of the Purchaser and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s issuance of
the Securities and the Purchaser&#8217;s ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor any other Person acting on its behalf has provided the Purchaser or its agent or counsel with any
information that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed on <U>Schedule
3.25</U>. The Company understands and confirms that the Purchaser will rely on the foregoing representation in effecting
transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchaser regarding
the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby, including the Disclosure
Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made not
misleading. The press releases disseminated by the Company during the 12 months preceding the date of this Agreement do not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make
the statements therein, in light of the circumstances under which they were made and when made, not misleading. The Company
acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Article IV hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Integrated Offering</U>. Assuming the accuracy of the Purchaser&#8217;s representations and warranties set forth in Article IV, neither
the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales
of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be
integrated with prior offerings by the Company for purposes of any applicable stockholder approval provisions of any Trading Market on
which any of the securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder, (i) the Company&#8217;s assets do not constitute unreasonably small capital
to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular
capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability
thereof, and (ii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all
of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of
its liabilities when such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts
as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge
of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.27</U> sets forth as of the date hereof all outstanding
secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the
purposes of this Agreement, &#8220;<U>Indebtedness</U>&#8221; means (x) any liabilities for borrowed money or amounts owed in excess of
$100,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#8217;s consolidated
balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar
transactions in the ordinary course of business; and (z) the present value of any lease payments in excess of $100,000 due under leases
required to be capitalized in accordance with GAAP. Except as set forth on <U>Schedule 3.27</U>, neither the Company nor any Subsidiary
is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Tax
Status</U>. The Company and each of its Subsidiaries have filed all federal, state, local and foreign tax returns which have been required
to be filed and paid all taxes shown thereon through the date hereof, to the extent that such taxes have become due and are not being
contested in good faith, except where the failure to so file or pay would not have a Material Adverse Effect. Except as otherwise disclosed
in <U>Schedule 3.28</U>, no tax deficiency has been determined adversely to the Company or any of its Subsidiaries which has had, or would
have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state or other governmental
tax deficiency, penalty or assessment which has been or might be asserted or threatened against it which would have a Material Adverse
Effect</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Foreign
Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or
other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any
unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or
campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by
any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated any provision of
FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgment
Regarding Purchaser&#8217;s Purchase of Securities</U>. The Company acknowledges and agrees that the Purchaser is acting solely in the
capacity of an arm&#8217;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company
further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with
respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective
representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental
to the Purchaser&#8217;s purchase of the Securities. The Company further represents to the Purchaser that the Company&#8217;s decision
to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Acknowledgement
Regarding Purchaser&#8217;s Trading Activity</U>. Notwithstanding anything in this Agreement or elsewhere to the contrary (except for
Sections 4.7 and 5.12 hereof), it is understood and acknowledged by the Company that: (i) the Purchaser has not been asked by the Company
to agree, nor has the Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#8220;derivative&#8221;
securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open market
or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#8220;derivative&#8221; transactions,
before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#8217;s
publicly-traded securities; (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221; transactions to which the Purchaser is
a party, directly or indirectly, presently may have a &#8220;short&#8221; position in the Common Stock, and (iv) the Purchaser shall not
be deemed to have any affiliation with or control over any arm&#8217;s length counter-party in any &#8220;derivative&#8221; transaction.
The Company further understands and acknowledges that (y) the Purchaser may engage in hedging activities at various times during the period
that the Securities are outstanding, including, without limitation, during the periods that the value of the Shares deliverable with respect
to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&#8217;
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such
aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Regulation
M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Private
Placement</U>. Assuming the accuracy of each Purchaser&#8217;s representations and warranties set forth in Article IV, no registration
under the Securities Act is required for the offer and sale of the Notes or the Shares issuable upon conversion thereof by the Company
to the Purchasers as contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
General Solicitation</U>. Neither the Company nor any person acting on behalf of the Company has offered or sold any of the Securities
by any form of general solicitation or general advertising. The Company offered the Securities for sale only to the Purchaser and certain
other &#8220;accredited investors&#8221; within the meaning of Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Disqualification Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506(b) under the Securities
Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company
participating in the offering hereunder, any beneficial owner of 20% or more of the Company&#8217;s outstanding voting equity securities,
calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with
the Company in any capacity at the time of sale, nor any Person, including a placement agent, who will receive a commission or fees for
soliciting purchasers (each, an &#8220;Issuer Covered Person&#8221; and, together, &#8220;Issuer Covered Persons&#8221;) is subject to
any of the &#8220;Bad Actor&#8221; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &#8220;Disqualification
Event&#8221;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine
whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its
disclosure obligations under Rule 506(e), and has furnished to the Purchaser a copy of any disclosures provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
of Disqualification Events</U>. The Company will notify the Purchaser in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become
a Disqualification Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company's knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&#8220;OFAC&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>U.S.
Real Property Holding Corporation.</U> The Company is not and has never been a U.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">real property holding corporation
within the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&#8217;s
request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Bank
Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956,
as amended (the &#8220;BHCA&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;Federal Reserve&#8221;).
Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the
outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any entity that is
subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises
a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal
Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">3.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;Money
Laundering Laws&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the
Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE IV. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPRESENTATIONS
AND WARRANTIES OF PURCHASERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Purchaser</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date
hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization;
Authority</U>. The Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under
the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar
power and authority to enter into and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement and performance by the Purchaser of the transactions contemplated
by this Agreement have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable,
on the part of the Purchaser. Each Transaction Document to which it is a party has been duly executed by the Purchaser, and when delivered
by the Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of the Purchaser, enforceable
against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Understandings
or Arrangements</U>. The Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty
not limiting the Purchaser&#8217;s right to sell the Securities in compliance with applicable federal and state securities laws). The
Purchaser is acquiring the Securities hereunder in the ordinary course of its business. The Purchaser understands that the Securities
are &#8220;restricted securities&#8221; and have not been registered under the Securities Act or any applicable state securities law and
is acquiring such Securities as principal for its own account and not with a view to or for distributing or reselling such Securities
or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing
any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement
or understandings with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities
Act or any applicable state securities law (this representation and warranty not limiting the Purchaser&#8217;s right to sell such Securities
in compliance with applicable federal and state securities laws).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchaser
Status</U>. At the time the Purchaser was offered the Securities, it was, and as of the date hereof it is, an accredited investor within
the meaning of Rule 501 under the Securities Act. The Purchaser is not subject to any of the &#8220;Bad Actor&#8221; disqualifications
described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &#8220;Disqualification Event&#8221;), except for a Disqualification
Event covered by Rule 506(d)(2) or (d)(3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Experience
of the Purchaser</U>. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in
the Securities, and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk of an
investment in the Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Access
to Information</U>. The Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and has been afforded, subject to Regulation FD, (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment; provided, however, that the Purchaser has not requested nor been
provided by the Company with any non-public information regarding the Company, its financial condition, results of operations, business,
properties, management and prospects. The Purchaser acknowledges and agrees that neither the Company nor anyone else has provided the
Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, the Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with the Purchaser, directly or indirectly executed any purchases or sales,
including Short Sales, of the securities of the Company during the period commencing as of the time that the Purchaser first received
a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions
contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Purchaser&#8217;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of the Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons
party to this Agreement or to the Purchaser&#8217;s representatives, including, without limitation, its officers, directors, partners,
legal and other advisors, employees, agents and Affiliates, the Purchaser has maintained the confidentiality of all disclosures made to
it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance
of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification
of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">The Company acknowledges
and agrees that the representations contained in this Article 4 shall not modify, amend or affect the Purchaser&#8217;s right to rely
on the Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transaction contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE V. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OTHER AGREEMENTS
OF THE PARTIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">5.1
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Removal of Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">The Shares and the Warrants
may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of the Shares or Warrants
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection
with a pledge as contemplated in Section 5.1(b), the Company may require the transferor to provide to the Company an opinion of counsel
selected by the transferor and reasonably acceptable to the Company at the cost of the Company, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Shares
or Warrants under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Purchaser agrees to the imprinting, so long as is required by this Section 5.1, of a legend on any of the Shares or the Warrants in the
following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.05pt; text-align: justify; text-indent: 0in">NEITHER THIS SECURITY
NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES
ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY
BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT
IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.05pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered
broker-dealer or grant a security interest in some or all of the Shares to a financial institution that is an &#8220;accredited investor&#8221;
as defined in Rule 501(a) under the Securities Act and who agrees to be bound by the provisions of this Agreement and, if required under
the terms of such arrangement, such Purchaser may transfer pledged or secured Shares to the pledgees or secured parties. Such a pledge
or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor
shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&#8217;s expense,
the Company will execute and deliver such reasonable documentation as a pledgee or secured party of Shares may reasonably request in connection
with a pledge or transfer of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.05pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certificates
evidencing the Shares (or the Transfer Agent&#8217;s records if held in book entry form) shall not contain any legend (including the
legend set forth in Section 5.1(a) hereof): (i) while a registration statement covering the resale of such securities is effective
under the Securities Act (the &#8220;Effective Date&#8221;), (ii) following any sale of such Shares pursuant to Rule 144, (iii) if
such Shares are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current
public information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or (iv) if such
legend is not required under applicable requirements of the Securities Act (including Sections 4(a)(1) and 4(a)(7) judicial
interpretations and pronouncements issued by the staff of the SEC). The Company shall, if any of the provisions in clause (i)
&#8211;(iv) above are applicable, at its expense, cause its counsel to issue a legal opinion to the Transfer Agent promptly after
the Effective Date if required by the Transfer Agent to effect the removal of the legend hereunder. If all or any portion of a
Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Shares, or if such
Shares may be sold under Rule 144 and the Company is then in compliance with the current public information required under Rule 144,
or if the Shares may be sold under Rule 144 without the requirement for the Company to be in compliance with the current public
information required under Rule 144 as to such Shares and without volume or manner-of-sale restrictions or if such legend is not
otherwise required under applicable requirements of the Securities Act (including Sections 4(a)(1) and 4(a)(7), judicial
interpretations and pronouncements issued by the staff of the SEC) then such Shares shall be issued or reissued free of all legends.
The Company agrees that following the effective date of any registration statement or at such time as such legend is no longer
required under this Section 5.1(c), it will, no later than two Trading Days following the delivery by a Purchaser to the Company or
the Transfer Agent of a certificate representing restricted Shares, as applicable, issued with a restrictive legend (such second
Trading Day, the &#8220;Legend Removal Date&#8221;), deliver or cause to be delivered to such Purchaser a certificate representing
such Shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give
instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 5.1. Certificates for Shares
subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the
Purchaser&#8217;s prime broker with the Depository Trust Company system as directed by such Purchaser. The Company shall be
responsible for any delays caused by its Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to such Purchaser&#8217;s other available remedies, (i) the Company shall pay to a Purchaser, in cash, as partial liquidated
damages and not as a penalty, for the value of the Warrant Shares for which a Warrant is being exercised (based on the Warrant Exercise
Price), $20 per Trading Day for each Trading Day after the Legend Removal Date (increasing to $20 per Trading Day after the fifth Trading
Day) until such certificate is delivered without a legend. Nothing herein shall limit such Purchaser&#8217;s right to pursue actual damages
for the Company&#8217;s failure to deliver certificates representing any Securities as required by the Transaction Documents, and such
Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief, and (ii) if after the Legend Removal Date such Purchaser purchases (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares
of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that
such Purchaser anticipated receiving from the Company without any restrictive legend, then, the Company shall pay to such Purchaser, in
cash, an amount equal to the excess of such Purchaser&#8217;s total purchase price (including brokerage commissions and other out-of-pocket
expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any)
(the &#8220;Buy-In Price&#8221;) over the product of (A) such number of Shares that the Company was required to deliver to such Purchaser
by the Legend Removal Date multiplied by (B) the highest closing sale price of the Common Stock on any Trading Day during the period commencing
on the date of the delivery by such Purchaser to the Company of the applicable Shares (as the case may be) and ending on the date of such
delivery and payment under this Section 5.1(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 63pt; text-align: justify; text-indent: 0.75in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event a Purchaser shall request delivery of unlegended shares as described in this Section 5.1 and the Company is required to deliver
such unlegended shares, (i) it shall pay all fees and expenses associated with or required by the legend removal and/or transfer including
but not limited to legal fees, Transfer Agent fees and overnight delivery charges and taxes, if any, imposed by any applicable government
upon the issuance of Common Stock; and (ii) the Company may not refuse to deliver unlegended shares based on any claim that such Purchaser
or anyone associated or affiliated with such Purchaser has not complied with Purchaser&#8217;s obligations under the Transaction Documents,
or for any other reason, unless, an injunction or temporary restraining order from a court, on notice, restraining and or enjoining delivery
of such unlegended shares shall have been sought and obtained by the Company and the Company has posted a surety bond for the benefit
of such Purchaser in the amount of the greater of (i) 150% of the amount of the aggregate purchase price of the Bridge Shares (based on
the market price of the Bridge Shares) and Warrant Shares (based on exercise price in effect upon exercise) which is subject to the injunction
or temporary restraining order, or (ii) the VWAP of the Common Stock on the Trading Day before the issue date of the injunction multiplied
by the number of unlegended shares to be subject to the injunction, which bond shall remain in effect until the completion of the litigation
of the dispute and the proceeds of which shall be payable to such Purchaser to the extent Purchaser obtains judgment in Purchaser&#8217;s
favor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: justify; text-indent: -0.5pt">5.2 <U>Furnishing
of Information</U>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
the earliest of the time that (i) no Purchaser owns Shares or (ii) the Warrants have expired, the Company covenants to timely file (or
obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after
the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
any time during the period commencing from the six month anniversary of the date hereof and ending at such time on the earlier to
occur that the Warrants are not outstanding, terminated or that all of the Warrant Shares (assuming cashless exercise) may be sold
without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation
pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule
144(c) for a period of more than 30 consecutive days or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an
issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) for a period of more than 30
consecutive days (a &#8220;Public Information Failure&#8221;) then, in addition to such Purchaser&#8217;s other available remedies,
the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or
reduction of its ability to sell the Shares and/or Warrant Shares, an amount in cash equal to two percent of the aggregate Note
Conversion Price of such Purchaser&#8217;s Note(s) and/or Warrant Exercise Price of such Purchaser&#8217;s Warrants on the day of a
Public Information Failure and on every 30<SUP>th</SUP> day (pro-rated for periods totaling less than thirty days) thereafter until
the earlier of (a) the date such Public Information Failure is cured and (b) such time that such public information is no longer
required for the Purchasers to transfer the Shares and/or Warrant Shares pursuant to Rule 144. Public Information Failure Payments
shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure Payments are
incurred and (ii) the second Trading Day after the event or failure giving rise to the Public Information Failure payments is cured.
In the event the Company fails to make Public Information Failure payments in a timely manner, such Public Information Failure
payments shall bear interest at the rate of one and one-half percent per month (prorated for partial months) until paid in full.
Nothing herein shall limit such Purchaser&#8217;s right to pursue actual damages for the Public Information Failure, and such
Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of
specific performance and/or injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section
2(a)(1) of the Securities Act) that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations
of any Trading Market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder
approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities
Laws Disclosure; Publicity</U>. The Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser
in any filing with the SEC or any regulatory agency or Trading Market, without the prior written consent of the Purchaser, except (a)
as required by federal securities law in connection with the filing of final Transaction Documents with the SEC and (b) to the extent
such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchaser with prior notice
of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stockholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &#8220;<U>Acquiring Person</U>&#8221; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-Public
Information</U>. When the Company&#8217;s Common Stock is quoted or listed on a Trading Market, to the extent that any notice provided
pursuant to any Transaction Document or any other communications made by the Company, or information provided, to the Purchaser constitutes,
or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice
or other material information with the SEC pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company. In addition to any other remedies provided
by this Agreement or other Transaction Documents, if the Company knowingly provides any material, nonpublic information to the Purchasers
without their prior written consent, and it fails to immediately (no later than that Trading Day) file a Form 8-K, once it is required
to do so, disclosing this material, non-public information, it shall pay the Purchasers as partial liquidated damages and not as a penalty
a sum equal to $1,000 per day for each $100,000 of each Purchaser&#8217;s Subscription Amount beginning with the day the information is
disclosed to the Purchaser and ending and including the day the Form 8-K disclosing this information is filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds</U>. The Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes, and shall
not use such proceeds: (a) for the satisfaction of any Indebtedness as defined in the Note, (b) for the redemption of any Common Stock
or Common Stock Equivalents, (c) in violation of FCPA or OFAC regulations, or (d) to lend money, give credit, or make advances to any
officers, directors, employees or affiliates of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
of Purchaser</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">Subject to the provisions
of this Section 5.8, the Company will indemnify and hold each Purchaser and its directors, officers, stockholders, members, partners,
employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack
of such title or any other title), each Person who controls the Purchaser (within the meaning of Section 15 of the Securities Act and
Section 20 of the Exchange Act), and the directors, officers, stockholders, agents, members, partners or employees (and any other Persons
with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling
persons (each, a &#8220;<U>Purchaser Party</U>&#8221;) harmless from any and all losses, liabilities, obligations, claims, contingencies,
damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#8217; fees and
costs of investigation (including local counsel, if retained) that any such Purchaser Party may suffer or incur as a result of or relating
to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other
Transaction Documents, (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their respective Affiliates,
by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated
by the Transaction Documents (unless such action is solely based upon a breach of such Purchaser Party&#8217;s representations, warranties
or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder
or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which constitutes
fraud, gross negligence, willful misconduct or malfeasance) or (c) any untrue or alleged untrue statement of a material fact contained
in any registration statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary
prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein (in the case of any prospectus or supplement thereto, in light of the circumstances under which they were
made) not misleading. If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant
to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the
defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right
to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall
be at the expense of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the
Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii)
in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company
and the position of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel (in addition to local counsel, if retained). The Company will not be liable to any Purchaser Party under
this Agreement (y) for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent, which shall not
be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable
to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party
in this Agreement or in the other Transaction Documents. The Purchaser Parties shall have the right to settle any action against any of
them by the payment of money provided that they cannot agree to any equitable relief and the Company, its officers, directors and Affiliates
receive unconditional releases in customary form. The indemnification required by this Section 5.8 shall be made by periodic payments
of the amount thereof during the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained
herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities
the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Settlement
Without Consent if Failure to Reimburse</U>. If an indemnified party shall have requested an indemnifying party to reimburse the
indemnified party for reasonable fees and expenses of counsel, such indemnifying party agrees that it shall be liable for any
settlement of the nature contemplated by Section 5.8 effected without its written consent if (1) such settlement is entered into
more than 45 days after receipt by such indemnifying party of the aforesaid request, (2) such indemnifying party shall have received
notice of the terms of such settlement at least 30 days prior to such settlement being entered into and (3) such indemnifying party
shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Listing
of Common Stock</U>. The Company agrees, if the Company applies to have the Common Stock traded on any Trading Market, it will then include
in such application all of the Shares, and will take such other action as is necessary to cause all of the Shares to be listed or quoted
on such other Trading Market as promptly as possible. The Company will then take all action necessary to continue the listing and trading
of its Common Stock on a Trading Market and will comply in all respects with the Company&#8217;s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer
through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of
fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Senior
Debt</U>. The Company shall not issue any new indebtedness which is senior in rank to the Notes while the Notes are outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Transactions and Confidentiality</U>. The Purchaser covenants that neither it nor any Affiliate acting on its behalf or pursuant to any
understanding with it will execute any purchases or sales, including Short Sales of any of the Company&#8217;s securities during the period
commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first
publicly announced pursuant to the initial press release. Each Purchaser covenants that until such time as the transactions contemplated
by this Agreement are publicly disclosed by the Company pursuant to the initial press release, the Purchaser will maintain the confidentiality
of the existence and terms of this transaction and the information included in the Disclosure Schedules. Notwithstanding the foregoing
and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser
makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company
after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release,
(ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with
applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant
to the initial press release and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the
Company to the Company or its Subsidiaries after the issuance of the initial press release. Notwithstanding the foregoing, in the case
of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of the Purchaser&#8217;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of the Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio
manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DTC
Program</U>. For so long as any of the Notes are outstanding, the Company will employ as the Transfer Agent for the Common Stock and Shares
a participant in the Depository Trust Company Automated Securities Transfer Program and cause the Common Stock to be transferable pursuant
to such program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maintenance
of Property</U>. The Company shall keep all of its property necessary for the operations of its business, which is necessary or useful
to the conduct of its business, in good working order and condition, ordinary wear and tear excepted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Preservation
of Corporate Existence</U>. The Company shall preserve and maintain its corporate existence, rights, privileges and franchises in the
jurisdiction of its incorporation, and qualify and remain qualified, as a foreign corporation in each jurisdiction in which such qualification
is necessary in view of its business or operations and where the failure to qualify or remain qualified might reasonably have a Material
Adverse Effect upon the financial condition, business or operations of the Company taken as a whole.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Registration of Securities on Form S-1.</U> Other than the registration rights provided hereunder, for the initial six months the Notes
are outstanding, the Company will not file any registration statements on Form S-1. For the avoidance of doubt, the foregoing shall not
prevent the Company from filing a Registration Statement on Form S-8 with respect to equity compensation plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Variable
Rate Transactions</U>. While any of the Notes are outstanding, the Company shall be prohibited from entering a Variable Rate Transaction
without the prior consent of the holders of more than 50% in principal amount of the then outstanding Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">5.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration
Rights and Lock-Up Agreement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to the Shares, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
the next Registration Statement on Form S-1 filed by the Company, include the Registrable Securities in such Registration Statement and
use its best efforts to cause the Registration Statement to become effective and remain effective as provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33.75pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepare
and file with the SEC such amendments, including post-effective amendments, to the Registration Statement as may be necessary to keep
the Registration Statement continuously effective as to the applicable Registrable Securities until such time as all of the Registerable
Securities have been sold by the Holder or he is eligible to otherwise remove the restrictive legend and effect a sale other than through
the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33.75pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of, (i) any order suspending the effectiveness of the
Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities
for sale in any U.S. jurisdiction, at the earliest practicable moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33.75pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furnish
to the Holder, without charge, at least one conformed copy of each Registration Statement and each amendment thereto, including financial
statements and schedules, all documents incorporated or deemed to be incorporated therein by reference, and all exhibits to the extent
requested by the Holder (including those previously furnished or incorporated by reference) promptly after the filing of such documents
with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33.75pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">(b) The Purchaser
agrees that, without the prior written consent of the Company, the Purchaser shall not, during the period ending 90 days after the
date of the prospectus filed with the SEC in connection with the Registration Statement on Form S-1 described in Section 5.18(a):
(1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or
indirectly, any Registrable Securities or (2) enter into any swap or other agreement that transfers, in whole or in part, any of the
economic consequences of ownership of the Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33.75pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">5.19 <U>Conversion to a
Corporation</U>. The Company shall convert from a limited liability company to a corporation on or before June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">5.20 <U>Right of Participation</U>.
For so long as Notes are outstanding, the Purchasers shall be given the right to purchase 20% of the shares issued in the Company&#8217;s
IPO on a pro rata basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.1 <U>Termination</U>.
This Agreement may be terminated by the Purchaser by written notice to the other parties, if the Closing has not been consummated on or
before June 15, 2022; provided, however, that no such termination will affect the right of any party to sue for any breach by any other
party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.2 <U>Fees and Expenses</U>.
Except as expressly set forth below and in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its
advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any
fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser),
stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.3 <U>Entire Agreement</U>.
The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect
to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such
matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.4 <U>Notices</U>. Any
and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be
deemed given and effective on the earliest of: (a) the date of transmission, if such notice or communication is delivered by email attachment
at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. ( Eastern Standard or Daylight Savings
Time, as applicable) on a Trading Day, (b) the next Trading Day after the date of transmission, if such notice or communication is delivered
via email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later
than 5:30 p.m. (New York City time) on any Trading Day, (c) the second Trading Day following the date of transmission, if sent by U.S.
nationally recognized overnight delivery service or (d) upon actual receipt by the party to whom such notice is required to be given.
The address for such notices and communications shall be as set forth on the signature pages attached hereto. To the extent that any notice
provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any
Subsidiaries, the Company shall, if the Company&#8217;s Common Stock is quoted or listed on a Trading Market, simultaneously file such
notice with the SEC pursuant to a Current Report on Form 8-K, or which failure to do so will subject the Company to the liquidated damages
provided for in Article 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.5 <U>Amendments;
Waivers</U>. Except as provided in the last sentence of this Section 6.5, no provision of this Agreement may be waived, modified,
supplemented or amended except in a written instrument signed, in the case of an amendment, by the Company and a majority in
interest of the outstanding balance of the Note or, in the case of a waiver, by the party against whom enforcement of any such
waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall
be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision,
condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair
the exercise of any such right. Any amendment effected in accordance with accordance with this Section 6.5 shall be binding upon the
Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.6 <U>Headings</U>. The
headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of
the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.7 <U>Successors and Assigns</U>.
This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may
not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser. Each Purchaser may
assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided
that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction Documents
that apply to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.8 <U>No Third-Party Beneficiaries</U>.
This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for
the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section 6.7 and this Section
6.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.9 <U>Governing Law; Exclusive
Jurisdiction; Attorneys&#8217; Fees</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction
Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard
to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, stockholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the New York County, New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the New York County, New York for the adjudication of any dispute hereunder or in connection
herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject
to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing
a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.
If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations
of the Company elsewhere in this Agreement, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.10 <U>Survival</U>. The
representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.11 <U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being
understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile
transmission or by e-mail delivery of a &#8220;.pdf' format data file, such signature shall create a valid and binding obligation of
the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or
&#8220;.pdf' signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.13 <U>Rescission and Withdrawal
Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction
Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not
timely perform its related obligations within the periods therein provided, then that Purchaser may rescind or withdraw, in its sole discretion
from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to
its future actions and rights; provided, however, that in the case of a rescission of an conversion of a Note, the Purchaser shall be
required to return any Shares subject to any such rescinded Conversion Notice concurrently with the restoration of such Purchaser&#8217;s
right to acquire such shares pursuant to the Purchaser&#8217;s Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.14 <U>Replacement of Securities</U>.
If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to
be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor,
a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction
without requiring the posting of any bond.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.15 <U>Remedies</U>. In
addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each Purchaser and
the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not
be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.16 <U>Payment Set Aside.</U>
To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces
or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are
subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded,
repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any
bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation
or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.17 <U>Independent
Nature of Purchasers&#8217; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or
non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers
as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in
any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other
Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own
separate legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to provide all Purchasers
with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do
so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other
Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and
not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.18 <U>Liquidated Damages</U>.
The Company&#8217;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing
obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding
the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and payable shall
have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.19 <U>Saturdays, Sundays,
Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.20 <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.21 <U>Waiver of jury trial</U>.
In any action, suit, or proceeding in any jurisdiction brought by any party against any other party, the parties each knowingly and intentionally,
to the greatest extent permitted by applicable law, hereby absolutely, unconditionally, irrevocably and expressly waive forever trial
by jury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">6.22 <U>Non-Circumvention</U>.
The Company hereby covenants and agrees that the Company will not, by amendment of its Articles of Incorporation, including any Certificates
of Designation, or Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution,
issue or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of
this Agreement, and will at all times in good faith carry out all of the provision of this Agreement and take all action as may be required
to protect the rights of all holders of the Securities. Without limiting the generality of the foregoing or any other provision of this
Agreement or the other Transaction Documents, the Company (a) shall not increase the par value of any Shares and (b) shall take all such
action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Signature Pages
Follow)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Securities Purchase Agreement</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the parties
hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first
indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in"><B>60 Degrees Pharmaceuticals, LLC</B></TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; text-indent: 0in">Address for Notice:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify; text-indent: 0in"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; width: 5%">By:&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; width: 35%">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Name: Geoffrey Dow</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">1025 Connecticut Avenue NW, Suite 1000</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Title: Chief Executive Officer</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Washington, D.C. 20036</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURE PAGE FOR PURCHASER
FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><BR STYLE="clear: both"></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">PURCHASER SIGNATURE PAGE TO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">SECURITIES PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.55pt">IN WITNESS WHEREOF, the
undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date
first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-align: justify; text-indent: -0.5pt">Name
of Purchaser: <U>Walleye Opportunities Master Fund Ltd</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><I>Signature of Authorized
Signatory of Purchaser</I>: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Name of Authorized Signatory:
William England</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Title of Authorized Signatory:
Chief Investment Officer of the Manager</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Email Address of Authorized
Signatory: wengland@walleyecapital.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Facsimile Number of Authorized
Signatory: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Address for Notice to Purchaser:
<U>legal@walleyecapital.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">2800 Niagara Lane No.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Plymouth, MN 55447</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Address for Delivery of Securities
to Purchaser (if not same as address for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Face Value: <U>$277,777.78</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Subscription
Amount: <U>$250,000.00</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">EIN Number: <FONT STYLE="background-color: Black"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Purchaser Signature
Page</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.95pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>17
<FILENAME>cm270_ex10-14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="text-decoration: none"><B>Exhibit
10.14</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="text-decoration: none">EXHIBIT B</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE
STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY
ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH
A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Warrant Shares: &lt;WARRANT SHARES&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Initial Exercise Date: May [*], 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">THIS COMMON STOCK
PURCHASE WARRANT (the &ldquo;Warrant&rdquo;) certifies that, for value received, &lt;HOLDER&gt;., or its assigns (the &ldquo;Holder&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;Initial Exercise Date&rdquo;) and on or prior to the close of business on the fifth year anniversary of the
Initial Exercise Date (the &ldquo;Termination Date&rdquo;) but not thereafter, to subscribe for and purchase from 60&deg; Pharmaceuticals,
LLC, a limited liability company (the &ldquo;Company&rdquo;), up to &lt;WARRANT SHARES&gt; shares of Common Stock (subject to adjustment
hereunder, the &ldquo;Warrant Shares&rdquo;). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b). This Warrant issued pursuant to a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;)
entered into as of the Initial Exercise Date between the Company and the initial Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.
<U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities
Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;), dated May [*], 2022 among the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise
of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise
Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate
by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed copy
of the Notice of Exercise Form annexed hereto. Within two Trading Days following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn
on a United States bank, unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice
of Exercise. Notwithstanding anything herein to the contrary (although the Holder may surrender the Warrant to, and receive a replacement
Warrant from, the Company), the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has
purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within two Trading Days of the date the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within one Trading Day of delivery of such
notice. The Holder by acceptance of this Warrant or any transferee, acknowledges and agrees that, by reason of the provisions of this
Section 2(a), following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise
Price. The initial exercise price per share of the Common Stock under this Warrant shall be equal to 110% of the IPO (as defined in the
Purchase Agreement) price (the &ldquo;Exercise Price&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cashless
Exercise. Other than as provided for in Section 2(f), if at any time after the six month anniversary of the Initial Exercise Date, there
is no effective Registration Statement covering the resale of the Warrant Shares by the Holder (or the prospectus does not meet the requirements
of Section 10 of the Securities Act), then this Warrant may also be exercised at the Holder&rsquo;s election, in whole or in part and
in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise, at such time by means of a &ldquo;cashless
exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the number obtained by dividing [(A
- B) times (C)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 30pt; text-align: left">(A) =</TD><TD STYLE="text-align: justify">the greater of (i) the arithmetic average
of the VWAPs for the five consecutive Trading Days ending on the date immediately preceding the date on which the Holder elects to exercise
this Warrant by means of a &ldquo;cashless exercise,&rdquo; as set forth in the applicable Notice of Exercise or (ii) the VWAP for the
Trading Day immediately prior to the date on which the Holder makes such &ldquo;cashless exercise&rdquo; election;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 30pt; text-align: left">(B) =</TD><TD STYLE="text-align: justify"> the Exercise Price of this Warrant, as
adjusted hereunder, at the time of such exercise; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 30pt; text-align: left">(C) =</TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&ldquo;VWAP&rdquo; means, for any date, the price
determined by the first of the following clauses that applies: (a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if the Common Stock is
then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a
Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)) (or a similar organization or agency succeeding
to its functions of reporting prices), (b) if no volume weighted average price of the Common Stock is reported for the Trading
Market, the most recent reported bid price per share of the Common Stock, or (c) in all other cases, the fair market value of a
share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of
the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrants being exercised
may be tacked on to the holding period of the Warrant Shares. The Company agrees not to take any position contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, if on the Termination Date (unless the Holder notifies the Company otherwise) if there is no effective
Registration Statement covering the resale of the Warrant Shares by the Holder, then this Warrant shall be automatically
exercised via cashless exercise pursuant to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 72.05pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of Certificates Upon Exercise</U>. Certificates for the shares of Common Stock purchased hereunder shall be transmitted to the Holder
by the Transfer Agent by crediting the account of the Holder&rsquo;s prime broker with The Depository Trust Company through its Deposit
or Withdrawal at Custodian system (&ldquo;DWAC&rdquo;) if the Company is then a participant in such system and either (A) there is an
effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)
this Warrant is being exercised via cashless exercise and Rule 144 is available, or otherwise by physical delivery to the address specified
by the Holder in the Notice of Exercise by the date that is two Trading Days after the latest of (A) the delivery to the Company of the
Notice of Exercise and (B) payment of the aggregate Exercise Price as set forth above (unless by cashless exercise, if permitted) (such
date, the &ldquo;Warrant Share Delivery Date&rdquo;). The Warrant Shares shall be deemed to have been issued, and Holder or any other
person so designated to be named therein shall be deemed to have become a holder of record of such shares for all purposes, as of the
date the Warrant has been exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted). The Company
understands that a delay in the delivery of the Warrant Shares after the Warrant Share Delivery Date could result in economic loss to
the Holder. As compensation to the Holder for such loss, the Company agrees to pay (as liquidated damages and not as a penalty) to the
Holder for late issuance of Warrant Shares upon exercise of this Warrant the proportionate amount of $10 per Trading Day (increasing
to $20 per Trading Day after the fifth Trading Day) after the Warrant Share Delivery Date for each $1,000 of the value of the Warrant
Shares for which this Warrant is exercised (based on the Exercise Price) which are not timely delivered. In no event shall liquidated
damages for any one transaction exceed $1,000 for the first 10 Trading Days. Furthermore, in addition to any other remedies which may
be available to the Holder, in the event that the Company fails for any reason to effect delivery of the Warrant Shares by the Warrant
Share Delivery Date, the Holder may revoke all or part of the relevant Warrant exercise by delivery of a notice to such effect to the
Company, whereupon the Company and the Holder shall each be restored to their respective positions immediately prior to the exercise
of the relevant portion of this Warrant, except that the liquidated damages described above shall be payable through the date notice
of revocation or rescission is given to the Company or the date the Warrant Shares are delivered to the Holder, whichever date is earlier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares, deliver to the
Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical to this Warrant. Unless the Warrant has been fully exercised, the Holders shall
not be required to surrender this Warrant as a condition of exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rescission
Rights</U>. If the Company fails to deliver the Warrant Shares or cause the Transfer Agent to transmit to the Holder a certificate or
the certificates representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will
have the right, at any time prior to issuance of such Warrant Shares, to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Certificates Upon Exercise</U>. In addition to any other rights available to the Holder, if the
Company fails to deliver the Warrant Shares, or cause the Transfer Agent to transmit to the Holder the certificate or certificates representing
the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;Buy-In&rdquo;), then the Company shall pay in cash to the Holder
the amount as provided under Section 4.1(e) of the Purchase Agreement. Nothing herein shall limit a Holder&rsquo;s right to pursue any
other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive
relief with respect to the Company&rsquo;s failure to timely deliver certificates representing shares of Common Stock upon exercise of
the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such certificate including any charges of any clearing firm, all of which
taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names
as may be directed by the Holder. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise.
The Company shall (A) pay the reasonable legal fees of the Holder&rsquo;s choice (in an amount not to exceed $500 per opinion, and not
more often than once per week) in connection with the exercise of the Warrants, (B) cause its attorneys to promptly provide any reliance
opinion to the Transfer Agent, and (C) pay the Holder the sums required under Section 2(d)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates), would beneficially own in excess
of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which
would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any
of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company
(including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to
the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding
sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not
representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely
responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this
Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and
the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Warrant is
exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or
confirm the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be
determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the
number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)
the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement
by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock
outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the
Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;Beneficial Ownership Limitation&rdquo;
shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days&rsquo; prior notice to the Company, may increase
the Beneficial Ownership Limitation provisions of this Section 2(e) solely with respect to the Holder&rsquo;s Warrant, provided that the
Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e)
shall continue to apply. Any such increase will not be effective until the 61st day after such notice is delivered to the Company. The
Holder may also decrease the Beneficial Ownership Limitation provisions of this Section 2(e) solely with respect to the Holder&rsquo;s
Warrant at any time, which decrease shall be effectively immediately upon delivery of notice to the Company. The provisions of this paragraph
shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this
paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained
or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this
paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant or pursuant to any of the other Transaction Documents), (ii) subdivides outstanding shares of Common Stock into a larger number
of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares,
or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise
Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such
that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become
effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and
shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Equity Sales</U>. If and whenever on or after the Initial Exercise Date, the Company issues or sells, or in accordance with this Section
3 is deemed to have issued or sold, any shares of Common Stock (including the issuance or sale of shares of Common Stock owned or held
by or for the account of the Company, issued or sold or deemed to have been issued or sold) for a consideration per share (the &ldquo;Base
Share Price&rdquo;) less than a price equal to the Exercise Price in effect immediately prior to such issuance or sale or deemed issuance
or sale (such Exercise Price then in effect is referred to herein as the &ldquo;Applicable Price&rdquo;) (the foregoing a &ldquo;Dilutive
Issuance&rdquo;), then immediately after such Dilutive Issuance, the Exercise Price then in effect shall be reduced to an amount equal
to the Base Share Price. For all purposes of the foregoing (including, without limitation, determining the adjusted Exercise Price and
the Base Share Price under this Section 3(b)), the following shall be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of Options</U>. If the Company in any manner grants or sells any Options and the lowest price per share for which one share of Common
Stock is at any time issuable upon the exercise of any such Option or upon conversion, exercise or exchange of any Convertible Securities
issuable upon exercise of any such Option or otherwise pursuant to the terms thereof is less than the Applicable Price, then such share
of Common Stock shall be deemed to be outstanding and to have been issued and sold by the Company at the time of the granting or sale
of such Option for such price per share. For purposes of this Section 3(b)(i), the &ldquo;lowest price per share for which one share
of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange of any Convertible Securities
issuable upon exercise of any such Option or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the
sum of the lowest amounts of consideration (if any) received or receivable by the Company with respect to any one share of Common Stock
upon the granting or sale of such Option, upon exercise of such Option and upon conversion, exercise or exchange of any Convertible Security
issuable upon exercise of such Option or otherwise pursuant to the terms thereof and (y) the lowest exercise price set forth in such
Option for which one share of Common Stock is issuable upon the exercise of any such Options or upon conversion, exercise or exchange
of any Convertible Securities issuable upon exercise of any such Option or otherwise pursuant to the terms thereof minus (2) the sum
of all amounts paid or payable to the holder of such Option (or any other Person) upon the granting or sale of such Option, upon exercise
of such Option and upon conversion, exercise or exchange of any Convertible Security issuable upon exercise of such Option or otherwise
pursuant to the terms thereof plus the value of any other consideration received or receivable by, or benefit conferred on, the holder
of such Option (or any other Person). Except as contemplated below, no further adjustment of the Exercise Price shall be made upon the
actual issuance of such shares of Common Stock or of such Convertible Securities upon the exercise of such Options or otherwise pursuant
to the terms of or upon the actual issuance of such shares of Common Stock upon conversion, exercise or exchange of such Convertible
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance
of Convertible Securities</U>. If the Company in any manner issues or sells any Convertible Securities and the lowest price per share
for which one share of Common Stock is at any time issuable upon the conversion, exercise or exchange thereof or otherwise pursuant to
the terms thereof is less than the Applicable Price, then such share of Common Stock shall be deemed to be outstanding and to have been
issued and sold by the Company at the time of the issuance or sale of such Convertible Securities for such price per share. For the purposes
of this Section 3(b)(ii), the &ldquo;lowest price per share for which one share of Common Stock is issuable upon the conversion, exercise
or exchange thereof or otherwise pursuant to the terms thereof&rdquo; shall be equal to (1) the lower of (x) the sum of the lowest amounts
of consideration (if any) received or receivable by the Company with respect to one share of Common Stock upon the issuance or sale of
the Convertible Security and upon conversion, exercise or exchange of such Convertible Security or otherwise pursuant to the terms thereof
and (y) the lowest conversion price set forth in such Convertible Security for which one share of Common Stock is issuable upon conversion,
exercise or exchange thereof or otherwise pursuant to the terms thereof minus (2) the sum of all amounts paid or payable to the holder
of such Convertible Security (or any other Person) upon the issuance or sale of such Convertible Security plus the value of any other
consideration received or receivable by, or benefit conferred on, the holder of such Convertible Security (or any other Person). Except
as contemplated below, no further adjustment of the Exercise Price shall be made upon the actual issuance of such shares of Common Stock
upon conversion, exercise or exchange of such Convertible Securities or otherwise pursuant to the terms thereof, and if any such issuance
or sale of such Convertible Securities is made upon exercise of any Options for which adjustment of this Warrant has been or is to be
made pursuant to other provisions of this Section 3(b), except as contemplated below, no further adjustment of the Exercise Price shall
be made by reason of such issuance or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Change
in Option Price or Rate of Conversion</U>. &ldquo;Convertible Securities&rdquo; means any stock or other security (other than Options)
that is at any time and under any circumstances, directly or indirectly, convertible into, exercisable or exchangeable for, or which
otherwise entitles the holder thereof to acquire, any shares of Common Stock. If the purchase or exercise price provided for in any Options,
the additional consideration, if any, payable upon the issue, conversion, exercise or exchange of any Convertible Securities, or the
rate at which any Convertible Securities are convertible into or exercisable or exchangeable for shares of Common Stock increases or
decreases at any time (other than proportional changes in conversion or exercise prices, as applicable, in connection with an event referred
to in Section 3(a)), the Exercise Price in effect at the time of such increase or decrease shall be adjusted to the Exercise Price which
would have been in effect at such time had such Options or Convertible Securities provided for such increased or decreased purchase price,
additional consideration or increased or decreased conversion rate, as the case may be, at the time initially granted, issued or sold.
For purposes of this Section 3(b)(iii), if the terms of any Option or Convertible Security that was outstanding as of the Closing Date
are increased or decreased in the manner described in the immediately preceding sentence, then such Option or Convertible Security and
the shares of Common Stock deemed issuable upon exercise, conversion or exchange thereof shall be deemed to have been issued as of the
date of such increase or decrease. No adjustment pursuant to this Section 3(b) shall be made if such adjustment would result in an increase
of the Exercise Price then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 72.05pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculation
of Consideration Received</U>. If any Option is issued in connection with the issuance or sale of any other securities of the Company
together comprising one integrated transaction in which no specific consideration is allocated to such Option by the parties thereto,
the Options will be deemed to have been issued for a consideration of par value of the Company&rsquo;s Common Stock. If any shares of
Common Stock, Options or Convertible Securities are issued or sold or deemed to have been issued or sold for cash, the consideration
received therefor will be deemed to be the net amount of consideration received by the Company therefor. If any shares of Common Stock,
Options or Convertible Securities are issued or sold for a consideration other than cash, the amount of such consideration received by
the Company will be the fair value of such consideration, except where such consideration consists of publicly traded securities, in
which case the amount of consideration received by the Company for such securities will be the arithmetic average of the VWAPs of such
security for each of the five Trading Days immediately preceding the date of receipt. If any shares of Common Stock, Options or Convertible
Securities are issued to the owners of the non-surviving entity in connection with any merger in which the Company is the surviving entity,
the amount of consideration therefor will be deemed to be the fair value of such portion of the net assets and business of the non-surviving
entity as is attributable to such shares of Common Stock, Options or Convertible Securities. The fair value of any consideration other
than cash or publicly traded securities will be determined jointly by the Company and the Holder. If such parties are unable to reach
agreement within 10 days after the occurrence of an event requiring valuation (the &ldquo;<U>Valuation Event</U>&rdquo;), the fair value
of such consideration will be determined within five Trading Days after the 10<FONT STYLE="font-size: 10pt">th </FONT>day following such
Valuation Event by an independent, reputable appraiser jointly selected by the Company and the Holder. The determination of such appraiser
shall be final and binding upon all parties absent manifest error. If such appraiser&rsquo;s valuation differs by less than 5% from the
Company&rsquo;s proposed valuation, the fees and expenses of such appraiser shall be borne by the Holder, and if such appraiser&rsquo;s
valuation differs by more than 5% from the Company&rsquo;s proposed valuation, the fees and expenses of such appraiser shall be borne
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Record
Date</U>. If the Company takes a record of the holders of shares of Common Stock for the purpose of entitling them (A) to receive a dividend
or other distribution payable in shares of Common Stock, Options or in Convertible Securities or (B) to subscribe for or purchase shares
of Common Stock, Options or Convertible Securities, then such record date will be deemed to be the date of the issuance or sale of the
shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution
or the date of the granting of such right of subscription or purchase (as the case may be).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(vi) Notwithstanding the foregoing, this Section 3(b) shall not apply to any Exempt</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt">Issuances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Full
Ratchet Increase in Warrant Shares</U>. Until the Notes are no longer outstanding, whenever the Exercise Price is adjusted under Section
3(b), the number of Warrant Shares shall be increased on a full ratchet basis to the number of shares of Common Stock determined by multiplying
the Exercise Price then in effect immediately prior to such adjustment by the number of Warrant Shares issuable upon exercise of this
Warrant immediately prior to such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. By
way of example, if E is the total number of Warrant Shares in effect immediately prior to such Dilutive Issuance, F is the Exercise Price
in effect immediately prior to such Dilutive Issuance, and G is the Dilutive Issuance Price, the adjustment to the number of Warrant
Shares can be expressed in the following formula: Total number of Warrant Shares after such Dilutive Issuance = the number obtained from
dividing [E x F] by G. Notwithstanding the foregoing, if the Exercise Price is being adjusted as a result of a sale of securities, this
Section 3(c) shall NOT apply if the Holder is offered the right to participate (in an amount not to exceed $50,000 unless agreed to by
the Holder and the Company) and does not participate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable
to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares
of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale
of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be
determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&rsquo;s right to participate
in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled
to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase
Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). Notwithstanding the foregoing, no Purchase
Rights will be made under this Section 3(d) in respect of an Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Pro
Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock
(and not to the Holder) evidences of its indebtedness or assets (including cash and cash dividends) or rights or warrants to subscribe
for or purchase any security other than the Common Stock (which shall be subject to Section 3(d)), then in each such case the Exercise
Price shall be adjusted by multiplying the Exercise Price in effect immediately prior to the record date fixed for determination of stockholders
entitled to receive such distribution by a fraction of which the denominator shall be the VWAP determined as of the record date mentioned
above, and of which the numerator shall be such VWAP on such record date less the then per share fair market value at such record date
of the portion of such assets or evidence of indebtedness so distributed applicable to one outstanding share of the Common Stock as determined
by the Board of Directors in good faith. In either case the adjustments shall be described in a statement provided to the Holder of the
portion of assets or evidences of indebtedness so distributed or such subscription rights applicable to one share of Common Stock. Such
adjustment shall be made whenever any such distribution is made and shall become effective immediately after the record date mentioned
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f) <U>Fundamental
Transaction</U>.</P>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If,
at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions engages in
any Fundamental Transaction, as defined in the Note, then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction (without regard to any limitation on the exercise of this Warrant), at the option of the Holder the number of shares of Common
Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration
(the &ldquo;Alternate Consideration&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted
to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock
in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable
manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same
choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company
shall not effect a Fundamental Transaction unless it gives the Holder at least 10 Trading Days prior notice together with sufficient details
so the Holder can make an informed decision as to whether it elects to accept the Alternative Consideration. If a public announcement
of the Fundamental Transaction has not been made, the notice to the Holder may not be given until the Company files a Form 8-K or other
report disclosing the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary, in the event of a Fundamental Transaction, provided that the Warrant Shares are not registered under an effective
registration statement, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the
date of the consummation of such Fundamental Transaction or (ii) the positive difference between the cash per share paid in such Fundamental
Transaction minus the then in effect Exercise Price. &ldquo;Black Scholes Value&rdquo; means the value of the unexercised portion of this
Warrant based on the Black and Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. determined as
of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate
corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental
Transaction and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from
the HVT function on Bloomberg L.P. as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus
the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to
the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in"></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Section 3(f)(i) and (ii) are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under this Warrant
and the other Transaction Documents in accordance with the provisions of this Section 3(f)(iii) pursuant to written agreements in form
and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor
Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant prior to
such Fundamental Transaction (without regard to any limitation on the exercise of this Warrant), and with an exercise price which applies
the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock
pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such
exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"> (h) <U>Notice to Holder</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
email to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant
Shares and setting forth a brief statement of the facts requiring such adjustment. The Holder may supply an email address to the Company
and change such address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice
to Allow Exercise by the Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company
shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, or (E) the Company
shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case,
the Company shall deliver to the Holder at its last address as it shall appear upon the Warrant Register of the Company, at least 5 calendar
days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are
to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected
to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation,
merger, sale, transfer or share exchange; provided that the failure to email such notice or any defect therein or in the emailing thereof
shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided
hereunder constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries (as determined
in good faith by the Company), the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on
Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice
to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transferability</U>.
Subject to compliance with any applicable securities laws and the provisions of the Purchase Agreement, this Warrant and all rights hereunder
(including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the
principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form
attached hereto duly executed by the Holder or its agent or attorney. Upon such surrender, the Company shall execute and deliver a new
Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such
instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this
Warrant shall promptly be cancelled. The Warrant, if properly assigned in accordance herewith, may be exercised by a new Holder for the
purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;Warrant
Register&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of
this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as Stockholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof other than as explicitly set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon surrender and cancellation of such Warrant
or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of
such cancellation, in lieu of such Warrant or stock certificate. In no event shall the Holder be required to deliver a bond or other
security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Authorized
Shares</U>.</P>



<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Except and to
the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its
Articles of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of
securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be
necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the
generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor
upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in
order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;use best efforts to obtain all such authorizations, exemptions or consents from
any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered or if not exercised on
a cashless basis when Rule 144 (or any successor law or rule) is available, may have restrictions upon resale imposed by state and federal
securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Non-waiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of the Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant,
which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover
any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred
by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate or that there is no irreparable harm and not to require the posting
of a bond or other security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and Holders of 75% of
the outstanding Warrants issued pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.5in">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Warrant</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 35.95pt">IN WITNESS WHEREOF, the Company has caused
this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 35.95pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 241.85pt"></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">TO: <B>60 Degrees Pharmaceuticals, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(1) The undersigned hereby elects to purchase _______________
Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment
of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(2) Payment shall take the form of (check applicable
box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 100pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744; </FONT>in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 100pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744; </FONT>if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(3) Please issue a certificate or certificates representing
said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 30%; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 55%; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">(4) After giving effect to this Notice of Exercise,
the undersigned will not have exceeded the Beneficial Ownership Limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Warrant Shares shall be delivered to the following DWAC Account Number
or by physical delivery of a certificate to:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; width: 15%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black; width: 30%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black; width: 55%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">SIGNATURE OF HOLDER</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-underline-color: black">Name of Investing Entity:</TD>
    <TD STYLE="width: 40%; text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><I>Signature of Authorized Signatory of Investing Entity</I>:</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">Name of Authorized Signatory:</TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">Title of Authorized Signatory:</TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">Date:</TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; padding-left: 9pt; text-underline-color: black; text-align: justify">(To assign the foregoing warrant, execute </TD>
    <TD STYLE="width: 30%; text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">this form and supply required information. Do </TD>
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">not use this form to exercise the warrant.)</TD>
    <TD STYLE="text-underline-color: black; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0">60 Degrees Pharmaceuticals, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 72pt">FOR VALUE RECEIVED,_______all of or ________
shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="width: 50%; text-underline-color: black">&nbsp;whose address is</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="width: 49%; text-underline-color: black">Dated:______________, ______&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="width: 20%; text-underline-color: black">Holder&rsquo;s Signature: &nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="width: 25%; text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black">&nbsp;</TD>
    <TD STYLE="text-underline-color: black">Holder&rsquo;s Address: &nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black">&nbsp;</TD>
    <TD STYLE="text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-underline-color: black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-underline-color: black">Signature Guaranteed: &nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 40%; text-underline-color: black">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOTE: The signature to this Assignment Form must correspond
with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever, and must be guaranteed
by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper
evidence of authority to assign the foregoing Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-decoration: none"><B></B></FONT></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>18
<FILENAME>cm270_ex10-15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXHIBIT A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NEITHER THIS SECURITY NOR THE SECURITIES INTO
WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED
IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Original Issue Date: May [*], 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$&lt;Amount&gt; Principal and Face Value</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$&lt;Amount&gt; Purchase Price and Subscription
Amount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$&lt;Amount&gt; Original Issue Discount</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ORIGINAL ISSUE DISCOUNT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PROMISSORY NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS ORIGINAL ISSUE DISCOUNT CONVERTIBLE PROMISSORY NOTE is duly
authorized and validly issued at a 10% original issue discount by 60&deg; Pharmaceuticals, LLC, a limited liability company (the
&ldquo;Company&rdquo;) (the &ldquo;Note&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the Company
promises to pay to &lt;Holder Name&gt;, or its permitted assigns (the &ldquo;Holder&rdquo;), the principal sum of &lt;Amount&gt; on the
earlier of May [*], 2023, the date of the Company&rsquo;s IPO, or such earlier date as this Note is required or permitted to be repaid
as provided hereunder, and to pay interest to the Holder on the aggregate then outstanding principal amount of this Note in accordance
with the provisions hereof. This Note is subject to the following additional provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 1</U>. <U>Definitions</U>. For the
purposes hereof, (a) capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement and (b)
the following words and phrases shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Alternate Consideration&rdquo; shall have the meaning set forth
in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Bankruptcy Event&rdquo;
means any of the following events: (a) the Company or any Subsidiary thereof commences a case or other proceeding under any bankruptcy,
reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction
relating to the Company or any Subsidiary thereof, (b) there is commenced against the Company or any Subsidiary thereof any such case
or proceeding that is not dismissed within 60 days after commencement, (c) the Company or any Subsidiary thereof is adjudicated insolvent
or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Company or any Subsidiary
thereof suffers any appointment of any custodian or the like for it or any substantial part of its property that is not discharged or
stayed within 60 calendar days after such appointment, (e) the Company or any Subsidiary thereof makes a general assignment for the benefit
of creditors, (f) the Company or any Subsidiary thereof calls a meeting of its creditors with a view to arranging a composition, adjustment
or restructuring of its debts or (g) the Company or any Subsidiary thereof, by any act or failure to act, expressly indicates its consent
to, approval of or acquiescence in any of the foregoing or takes any corporate or other action for the purpose of effecting any of the
foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Base Conversion Price&rdquo; shall have the meaning set forth
in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Beneficial Ownership Limitation&rdquo; shall have the meaning set forth in Section 4(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Black Scholes Value&rdquo;
means the value of the outstanding principal amount of this Note, plus all accrued and unpaid interest hereon based on the Black and Scholes
Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg L.P. (&ldquo;Bloomberg&rdquo;) determined as of the day
of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction
and the Maturity Date, (B) an expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function
on Bloomberg as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction, (C) the underlying
price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any
non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to the time between
the date of the public announcement of the applicable Fundamental Transaction and the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Buy-In&rdquo; shall have the meaning set forth in Section 4(d)(v).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Change of Control Transaction&rdquo;
means the occurrence after the date hereof of any of (a) an acquisition after the date hereof by an individual or legal entity or &ldquo;group&rdquo;
(as described in Rule 13d-5(b)(1) promulgated under the Exchange Act) of effective control (whether through legal or beneficial ownership
of capital stock of the Company, by contract or otherwise) of in excess of 50% of the voting securities of the Company (other than by
means of conversion, exercise or exchange of this Note or the Warrants issued together with this Note), (b) the Company merges into or
consolidates with any other Person, or any Person merges into or consolidates with the Company and, after giving effect to such transaction,
the shareholders of the Company immediately prior to such transaction own less than 50% of the aggregate voting power of the Company or
the successor entity of such transaction, (c) the Company sells or transfers all or substantially all of its assets to another Person,
(d) a replacement at one time or within a three year period of more than one-half of the members of the Board of Directors which is not
approved by a majority of those individuals who are members of the Board of Directors on the Original Issue Date (or by those individuals
who are serving as members of the Board of Directors on any date whose nomination to the Board of Directors was approved by a majority
of the members of the Board of Directors who are members on the date hereof), or (d) the execution by the Company of an agreement to which
the Company is a party or by which it is bound, providing for any of the events set forth in clauses (a) through (d) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Default Interest Rate&rdquo; shall have the meaning set forth
in Section 2(a). &ldquo;Dilutive Issuance&rdquo; shall have the meaning set forth in Section 5(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Dilutive Issuance Notice&rdquo; shall have the meaning set forth
in Section 5(b)(5).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;DWAC&rdquo; means the Deposit or Withdrawal
at Custodian system at The Depository Trust Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Event of Default&rdquo; shall have the meaning set forth in
Section 7(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Exchange Act&rdquo; means the Securities
Exchange Act of 1934, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Fundamental Transaction&rdquo; shall have the meaning set forth
in Section 5(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;IPO&rdquo; shall have the meaning set forth in Section 4(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Liens&rdquo; shall have the meaning set forth in the Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Note Register&rdquo; shall have the meaning set forth in Section 3(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Notice of Conversion&rdquo; shall have
the meaning set forth in Section 4(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Mandatory Default Amount&rdquo; shall have the meaning set forth
in Section 7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Option
Value&rdquo; means the value of a Common Stock Equivalent based on the Black Scholes Option Pricing model obtained from the
&ldquo;OV&rdquo; function on Bloomberg determined as of (A) the Trading Day prior to the public announcement of the issuance of the
applicable Common Stock Equivalent, if the issuance of such Common Stock Equivalent is publicly announced or (B) the Trading Day
immediately following the issuance of the applicable Common Stock Equivalent if the issuance of such Common Stock Equivalent is not
publicly announced, for pricing purposes and reflecting (i) a risk-free interest rate corresponding to the U.S. Treasury rate for a
period equal to the remaining term of the applicable Common Stock Equivalent as of the applicable date of determination, (ii) an
expected volatility equal to the greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of (A)
the Trading Day immediately following the public announcement of the applicable Common Stock Equivalent if the issuance of such
Common Stock Equivalent is publicly announced or (B) the Trading Day immediately following the issuance of the applicable Common
Stock Equivalent if the issuance of such Common Stock Equivalent is not publicly announced, (iii) the underlying price per share
used in such calculation shall be the highest VWAP of the Common Stock during the period beginning on the Trading Day prior to the
execution of definitive documentation relating to the issuance of the applicable Common Stock Equivalent and ending on (A) the
Trading Day immediately following the public announcement of such issuance, if the issuance of such Common Stock Equivalent is
publicly announced or (B) the Trading Day immediately following the issuance of the applicable Common Stock Equivalent if the
issuance of such Common Stock Equivalent is not publicly announced, (iv) a zero cost of borrow and (v) a 360 day annualization
factor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Original Issue Date&rdquo;
means the date of the first issuance of this Note, regardless of any transfers of this Note and regardless of the number of instruments
which may be issued to evidence this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.95pt">&ldquo;Permitted Indebtedness&rdquo;
means (a) the indebtedness evidenced by this Note, (b) senior secured non-convertible loans from traditional commercials banks with interest
per annum not to exceed 12%, (c) capital lease obligations and purchase money indebtedness incurred in connection with the acquisition
of machinery and equipment as long as such capital leases and indebtedness are approved in advance by the Holder and (d) the Indebtedness
set forth on Schedule 3.27 to the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Permitted
Lien&rdquo; means the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental
charges or levies not yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good faith
and by appropriate proceedings for which adequate reserves (in the good faith judgment of the management of the Company) have been
established in accordance with GAAP, (b) Liens imposed by law which were incurred in the ordinary course of the Company&rsquo;s
business, such as carriers&rsquo;, warehousemen&rsquo;s and mechanics&rsquo; Liens, statutory landlords&rsquo; Liens, and other
similar Liens arising in the ordinary course of the Company&rsquo;s business, and which (x) do not individually or in the aggregate
materially detract from the value of such property or assets or materially impair the use thereof in the operation of the business
of the Company and its consolidated Subsidiaries or (y) are being contested in good faith by appropriate proceedings, which
proceedings have the effect of preventing for the foreseeable future the forfeiture or sale of the property or asset subject to such
Lien, (c) Liens incurred in connection with Permitted Indebtedness under clauses (a) through (d) thereunder, and Liens set forth on
Schedule 3.1(aa) to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Purchase Agreement&rdquo;
means the Securities Purchase Agreement, dated as of May [*], 2022, among the Company and the original Holders, as amended, modified or
supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Share Delivery Date&rdquo; shall have the meaning set forth
in Section 4(d)(ii). &ldquo;Successor Entity&rdquo; shall have the meaning set forth in Section 5(e)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;Transaction Documents&rdquo; means the Note, the Purchase Agreement
and the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;VWAP&rdquo; means, for any date, the price determined by the
first of the following clauses that applies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) if the Common Stock is then listed or quoted
on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the
Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)) (or a similar organization or agency succeeding to its functions of reporting
prices), (b) if no volume weighted average price of the Common Stock is reported for the Trading Market, the most recent bid price per
share of the Common Stock so reported, or (c) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall
be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 2</U>. <U>Payments of Principal and
Interest</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">All principal, accrued interest and other amounts
due shall be paid in U.S. Dollars by wire transfer of immediately available funds. The Company may repay the Holder before the Maturity
Date without penalty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest shall accrue to the Holder on the aggregate
then outstanding principal amount of this Note at the rate of 10% per annum, calculated on the basis of a 360-day year and shall accrue
daily commencing on the Original Issue Date until payment in full of the outstanding principal, together with all accrued and unpaid interest,
liquidated damages and other amounts which may become due hereunder, has been made. During the existence of an Event of Default, interest
shall accrue at the lesser of (i) the rate of 15% per annum, or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii)  the
maximum amount permitted by law (the lesser of clause (i) or (ii), the &ldquo;Default Interest Rate&rdquo;). Once an Event of Default
is cured, the interest rate shall return to 10%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 3</U>. <U>Registration of Transfers
and Exchanges</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>Different Denominations</U>.
This Note is exchangeable for an equal aggregate principal amount of Notes of different authorized denominations, as requested
by the Holder surrendering the same. No service charge or other fees will be payable for such registration of transfer or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Investor Representations</U>.
This Note has been issued subject to certain investment representations of the original Holder set forth in the Purchase Agreement
and may be transferred or exchanged only in compliance with the Purchase Agreement and applicable federal and state securities
laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Reliance on
Note Register</U>. Prior to due presentment for transfer to the Company of this Note, the Company and any agent of the Company
may treat the Person in whose name this Note is duly registered on the Note Register as the owner hereof for the purpose of receiving
payment as herein provided and for all other purposes, whether or not this Note is overdue, and neither the Company nor any such
agent shall be affected by notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Section 4. Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Note does not have a conversion feature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Section 5</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">(a) <U>Stock Dividends
and Stock Splits</U>. If the Company, at any time while this Note is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any Common Stock Equivalents, (ii)
subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of a reverse stock
split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues, in the event of a reclassification of
shares of the Common Stock, any shares of capital stock of the Company, then the Conversion Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares of the Company) outstanding
immediately before such event, and of which the denominator shall be the number of shares of Common Stock outstanding immediately
after such event. Any adjustment made pursuant to this Section 5(a) shall become effective immediately after the record date for
the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Subsequent
Equity Sales</U>. (1) At any time, for so long as the Note or any amounts accrued and payable thereunder remain outstanding, the
Company or any Subsidiary, as applicable, sells or grants any option to purchase or sells or grants any right to reprice, or otherwise
disposes of or issues (or announces any sale, grant or any option to purchase or other disposition), any Common Stock or Common
Stock Equivalents entitling any Person to acquire shares of Common Stock at an effective price per share that is lower than the
Conversion Price then in effect (such lower price, the &ldquo;Base Conversion Price&rdquo; and each such issuance or announcement
a &ldquo;<U>Dilutive Issuance</U>&rdquo;), then the Conversion Price shall be immediately reduced to equal the Base Conversion
Price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) If any Common Stock Equivalent
is amended or adjusted, and such price as so amended shall be less than the Conversion Price in effect at the time of such amendment
or adjustment, then the Conversion Price shall be adjusted upon each such issuance or amendment as provided in this Section 5(b). In
case any Common Stock Equivalent is issued in connection with the issue or sale of other securities of the Company, together comprising
one integrated transaction, (x) the Common Stock Equivalents will be deemed to have been issued for the Option Value of such Common Stock
Equivalents and (y) the other securities issued or sold in such integrated transaction shall be deemed to have been issued or sold for
the difference of (I) the aggregate consideration received by the Company less any consideration paid or payable by the Company pursuant
to the terms of such other securities of the Company, less (II) the Option Value. If any shares of Common Stock or Common Stock Equivalents
are issued or sold or deemed to have been issued or sold for cash, the amount of such consideration received by the Company will be deemed
to be the net amount received by the Company therefor. If any shares of Common Stock or Common Stock Equivalents are issued or sold for
a consideration other than cash, the amount of such consideration received by the Company will be the fair value of such consideration,
except where such consideration consists of publicly traded securities, in which case the amount of consideration received by the Company
will be the average VWAP of such public traded securities for the ten days prior to the date of receipt. If any shares of Common Stock
or Common Stock Equivalents are issued to the owners of the non-surviving entity in connection with any merger in which the Company is
the surviving entity, the amount of consideration therefor will be deemed to be the fair value of such portion of the net assets and
business of the non-surviving entity as is attributable to such shares of Common Stock or Common Stock Equivalents, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(3)  If
the holder of Common Stock or Common Stock Equivalents outstanding on the Original Issue Date or issued after the Original Issuance Date
shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices
or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive
shares of Common Stock at an effective price per share that is lower than the Conversion Price then in effect, such issuance shall be
deemed to have occurred for less than the Conversion Price on such date and such issuance shall be deemed to be a Dilutive Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(4)  If
the Company enters into a Variable Rate Transaction despite the prohibition set forth in the Purchase Agreement, the Company shall be
deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion price at which such securities may be
converted or exercised under the terms of such Variable Rate Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(5)  The
Company shall notify the Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents
subject to this Section 5(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion
price and other pricing terms (such notice, the &ldquo;Dilutive Issuance Notice&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(6)  The
provisions of this Section 5(b) shall apply each time a Dilutive Issuance occurs after the Original Issue Date for so long as the Note
or any amounts accrued and payable thereunder remain outstanding, but any adjustment of the Conversion Price pursuant to this Section
5(b) shall be downward only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> (7) The provisions
of this Section 5(b) shall not apply to Exempt Issuances.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 5(a) above, if at any time the Company grants, issues
or sells any Common Stock, Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata
to the record holders of any class of shares of Common Stock (the &ldquo;Purchase Rights&rdquo;), then the Holder will be entitled
to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired
if the Holder had held the number of Bridge Shares, including without limitation, the Beneficial Ownership Limitation) immediately
before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken,
the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase
Rights (<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right
to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its
right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>Pro Rata Distributions</U>.
During such time as this Note is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
or rights or warrants to acquire its assets, or subscribe for or purchase any security other than Common Stock, to holders of
shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock
or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of
arrangement or other similar transaction) (a &ldquo;Distribution&rdquo;), at any time after the issuance of this Note, then, in
each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of Bridge Shares (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for
such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be
determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, to the extent that the Holder's right
to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation with respect
to the Company or any other publicly-traded corporation subject to Section 13(d) of the Exchange Act, then the Holder shall not
be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as
a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation
with respect to the Company or any other publicly-traded corporation subject to Section 13(d) of the Exchange Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e) <U>Fundamental
Transaction</U>. (1) If, at any time while this Note is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets
in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether
by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making
or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or
other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent conversion of this
Note, the Holder shall have the right to receive, for each Conversion Share that would have been issuable upon such conversion
immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation on the conversion of this
Note), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving
corporation, and any additional consideration (the &ldquo;Alternate Consideration&rdquo;) receivable as a result of such Fundamental
Transaction by a holder of the number of shares of Common Stock for which this Note is convertible immediately prior to such Fundamental
Transaction (without regard to any limitation on the conversion of this Note). For purposes of any such conversion, the determination
of the Conversion Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion
the Conversion Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components
of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon
any conversion of this Note following such Fundamental Transaction. The Company shall not effect a Fundamental Transaction unless
it gives the Holder at least 10 Trading Days prior notice together with sufficient details so the Holder can make an informed
decision as to whether it elects to accept the Alternative Consideration. If a public announcement of the Fundamental Transaction
has not been made, the notice to the Holder may not be given until the Company files a Form 8-K or other report disclosing the
Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(2)  Notwithstanding
anything to the contrary, provided that the Warrant Shares are not registered under an effective registration statement, in the event
of a Fundamental Transaction that is (x) an all cash transaction, (y) a &ldquo;Rule 13e-3 transaction&rdquo; as defined in Rule 13e-3
under the Exchange Act, or (z) a Fundamental Transaction involving a person or entity not traded on a national securities exchange or
trading market (with such exchange or market including, without limitation, the Nasdaq Global Select Trading Market, the Nasdaq Global
Market, or the Nasdaq Capital Market, the New York Stock Exchange, Inc., the NYSE American or any market operated by the OTC Markets,
Inc.), the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, concurrently with the consummation
of the Fundamental Transaction, purchase this Note from the Holder by paying to the Holder the higher of (i) an amount of cash equal to
the Black Scholes Value of the outstanding principal of this Note on the date of the consummation of such Fundamental Transaction</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(3)  If
Section 5(e)(1) and (2) are not applicable, the Company shall cause any successor entity in a Fundamental Transaction in which the Company
is not the survivor (the &ldquo;Successor Entity&rdquo;) to assume in writing all of the obligations of the Company under this Note and
the other Transaction Documents in accordance with the provisions of this Section 5(e) pursuant to written agreements in form and substance
reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and
shall, at the option of the Holder, deliver to the Holder in exchange for this Note a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Note. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Note and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity),
and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Note and the other
Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein. Notwithstanding anything
in this Section 5(e), an Exempt Issuance (as defined in the Purchase Agreement) shall not be deemed a Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) <U>Calculations</U>.
All calculations under this Section 5 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be.
For purposes of this Section 5, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall
be the sum of the number of shares of Common Stock (excluding any treasury shares of the Company) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) <U>Notice to the
Holder</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 53.95pt">(i) <U>Adjustment
to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 5, the Company shall
promptly deliver to each Holder a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 53.95pt">(ii) <U>Notice to
Allow Conversion by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on its
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of its Common Stock, (C) the
Company shall authorize the granting to all holders of its Common Stock of rights or warrants to subscribe for or purchase any
shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in
connection with any reclassification of its Common Stock, any consolidation or merger to which the Company is a party, any sale
or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby its Common Stock
is converted into other securities, cash or property or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be filed at each office
or agency maintained, and shall cause to be delivered to the Holder at its last address as it shall appear upon the Note Register,
at least 5 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date
on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record
is not to be taken, the date as of which the holders of its Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale,
transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of its
Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange, provided that the failure to deliver such
notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified
in such notice. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding
the Company or any of the Subsidiaries (as determined in good faith by the Company), the Company or its successor shall simultaneously
file such notice with the SEC pursuant to a Current Report on Form 8-K. If the Company does not simultaneously file the required
Form 8-K, the Holder shall be entitled penalties in accordance with Section 5.6 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 6</U>. <U>Negative Covenants</U>. As
long as any portion of this Note remains outstanding, unless all of the Holders of the then outstanding Notes shall have otherwise given
prior written consent, the Company shall not, and shall not permit any of the Subsidiaries to, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)  other
than Permitted Indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any indebtedness for borrowed money of any
kind, including, but not limited to, a guarantee, on or with respect to any of its property or assets now owned or hereafter acquired
or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)  other
than Permitted Liens, enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to any of its property
or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)  amend
its charter documents, including, without limitation, its articles of incorporation and bylaws, in any manner that materially and adversely
affects any rights of the Holder, increases in authorized shares and stock splits shall not be deemed to materially and adversely affects
any rights of the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)  purchase
or otherwise acquire more than a de minimis number of shares of its Common Stock or Common Stock Equivalents;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(e)  repay,
or offer to repay, any Indebtedness, other than Permitted Indebtedness, as such terms Indebtedness and Permitted Indebtedness are in effect
as of the Original Issue Date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt"> (f) pay cash dividends or distributions on any equity securities of the Company;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(g)  enter
into any transaction with any Affiliate of the Company which would be required to be disclosed in any public filing with the SEC assuming
that the Company is subject to the Securities Act or the Exchange Act, unless such transaction is made on an arm&rsquo;s-length basis
and expressly approved by a majority of the disinterested directors of the Company (even if less than a quorum otherwise required for
board approval);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(h)  issue
any equity securities of the Company other than pursuant to the provisions of the Purchase Agreement or an Exempt Issuance; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt"> (i) enter into any agreement with respect to any of the foregoing.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>Section 7</U>. <U>Events of Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) &ldquo;<U>Event
of Default</U>&rdquo; means, wherever used herein, any of the following events (whatever the reason for such event and whether
such event shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any
court, or any order, rule or regulation of any administrative or governmental body):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)  any
default in the payment of (A) principal and interest payment under this Note or any other Indebtedness, or (B) late fees, liquidated damages
and other amounts owing to the Holder of this Note, as and when the same shall become due and payable (whether on a Conversion Date, or
the Maturity Date, or by acceleration or otherwise), which default, solely in the case of a default under clause (B) above, is not cured
within five Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)  the
Company shall fail to observe or perform any other covenant or agreement contained in this Note (other than a breach by the Company of
its obligations to deliver Shares, which breach is addressed in clause (x) below) or any Transaction Document which failure is not cured,
if possible to cure, within the earlier to occur of 15 Trading Days after notice of such failure is sent by the Holder or by any other
Holder to the Company and (B) 10 Trading Days after the Company has become aware of such failure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)  except
for payment defaults covered under Section 7(a)(i), the Company shall breach, or a default or event of default (subject to any grace or
cure period provided in the applicable agreement, document or instrument) shall occur under, (A) any of the Transaction Documents or (B)
any other material agreement, lease, document or instrument to which the Company or any Subsidiary is obligated (and not covered by any
other clause of this Section 7) which default or event of default if not cured, if possible to cure, within the earlier to occur of (i)
10 Trading Days after notice of such default sent by Holder or by any other holder to the Company and (ii) five Trading Days after the
Company has become aware of such default;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)  any
representation or warranty made in this Note, any other Transaction Document, any written statement pursuant hereto or thereto or any
other report, financial statement or certificate made or delivered to the Holder or any other Holder shall be untrue or incorrect in any
material respect as of the date when made or deemed made, which failure is not cured, if possible to cure, within the earlier to occur
of 10 Trading Days after notice of such failure is sent by the Holder or by any other Holder to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> (v) the Company or any Subsidiary shall be subject to a Bankruptcy Event;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)  the
Company or any Subsidiary shall: (A) apply for or consent to the appointment of a receiver, trustee, custodian or liquidator of it or
any of its properties; (B) admit in writing its inability to pay its debts as they mature; (C) make a general assignment for the benefit
of creditors; (D) be adjudicated as bankrupt or insolvent or be the subject of an order for relief under Title 11 of the United States
Code or any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law or statute of any other jurisdiction
or foreign country; or (E) file a voluntary petition in bankruptcy, or a petition or an answer seeking reorganization or an arrangement
with creditors or to take advantage or any bankruptcy, reorganization, insolvency, readjustment of debt, dissolution or liquidation law
or statute, or an answer admitting the material allegations of a petition filed against it in any proceeding under any such law, or (F)
take or permit to be taken any action in furtherance of or for the purpose of effecting any of the foregoing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vii)  if
any order, judgment or decree shall be entered, without the application, approval or consent of the Company or any Subsidiary, by any
court of competent jurisdiction, approving a petition seeking liquidation or reorganization of the Company or any Subsidiary, or appointing
a receiver, trustee, custodian or liquidator of the Company or any Subsidiary, or of all or any substantial part of its assets, and such
order, judgment or decree shall continue unstayed and in effect for any period of 60 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(viii)  the
occurrence of any levy upon or seizure or attachment of, or any uninsured loss of or damage to, any property of the Company or any Subsidiary
having an aggregate fair value or repair cost (as the case may be) in excess of $100,000 individually or in the aggregate, and any such
levy, seizure or attachment shall not be set aside, bonded or discharged within 45 days after the date thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 71.95pt">(ix)  any
monetary judgment, writ or similar final process shall be entered or filed against the Company, any Subsidiary or any of their respective
property or other assets for more than $100,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or
unstayed for a period of 30 days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 78.05pt"></TD><TD STYLE="width: 15.7pt">(x)</TD><TD>any Material Adverse Effect occurs;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xi)  any
provision of any Transaction Document shall at any time for any reason (other than pursuant to the express terms thereof) cease to be
valid and binding on or enforceable against the parties thereto, or the validity or enforceability thereof shall be contested by any party
thereto, or a proceeding shall be commenced by the Company or any Subsidiary or any governmental authority having jurisdiction over any
of them, seeking to establish the invalidity or unenforceability thereof, or the Company or any Subsidiary shall deny in writing that
it has any liability or obligation purported to be created under any Transaction Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xii)  the
Company fails to use the proceeds in the manner as described in Section 5.7 of the Purchase Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xiii)  the
Company shall be a party to any Change of Control Transaction or shall agree to sell or dispose of all or in excess of 50% of its assets
in one transaction or a series of related transactions (whether or not such sale would constitute a Change of Control Transaction);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xiv)  from
and after 90 days after the Original Issue Date, the Company fails to have authorized and reserved the amount of shares designated in
Section 3.5 of the Purchase Agreement (including without limitation, the Beneficial Ownership Limitation);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xv)  the
Company fails to file with the SEC any required reports under Section 13 or 15(d) of the Exchange Act within the time required (including
any applicable extension period) by the rules and regulations thereunder; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(xvi)  the
Company fails to convert from a limited liability company to a corporation on or before June 30, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Remedies Upon
Event of Default</U>. If any Event of Default occurs, the outstanding principal amount of this Note, plus liquidated damages and
other amounts owing in respect thereof through the date of acceleration, shall become, at the Holder&rsquo;s election, immediately
due and payable in cash (the &ldquo;Mandatory Default Amount&rdquo;). Upon the payment in full of the Mandatory Default Amount,
the Holder shall promptly surrender this Note to or as directed by the Company. In connection with such acceleration described
herein, the Holder need not provide, and the Company hereby waives, any presentment, demand, protest or other notice of any kind,
and the Holder may immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder
and all other remedies available to it under applicable law. Such acceleration may be rescinded and annulled by Holder at any
time prior to payment hereunder and the Holder shall have all rights as a holder of the Note until such time, if any, as the Holder
receives full payment pursuant to this Section 7(b). No such rescission or annulment shall affect any subsequent Event of Default
or impair any right consequent thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Interest Rate
Upon Event of Default</U>. Commencing on the occurrence of any Event of Default and until such Event of Default is cured, this
Note shall accrue interest at an interest rate equal to the Default Interest Rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Section 8</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a) <U>No Rights as
Stockholder Until Conversion</U>. This Note does not entitle the Holder to any voting rights, dividends or other rights as a stockholder
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b) <U>Notices</U>.
All notices, offers, acceptance and any other acts under this Agreement (except payment) shall be in writing, and shall be sufficiently
given if delivered to the addressees in person, by FedEx or similar receipted next day delivery, or at the Company&rsquo;s registered
address or such other address as any of them, by notice to the other may designate from time to time. Time shall be counted to,
or from, as the case may be, the date of delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c) <U>Absolute Obligation</U>.
Except as expressly provided herein, no provision of this Note shall alter or impair the obligation of the Company, which is absolute
and unconditional, to pay the principal of, liquidated damages and accrued interest and late fees, as applicable, on this Note
at the time, place, and rate, and in the coin or currency, herein prescribed. This Note is a direct debt obligation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d) <U>Lost or Mutilated
Note</U>. If this Note shall be mutilated, lost, stolen or destroyed, the Company shall execute and deliver, in exchange and substitution
for and upon cancellation of a mutilated Note, or in lieu of or in substitution for a lost, stolen or destroyed Note, a new Note
for the principal amount of this Note so mutilated, lost, stolen or destroyed, but only upon receipt of evidence of such loss,
theft or destruction of this Note, and of the ownership hereof, reasonably satisfactory to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">(e) <U>Exclusive
Jurisdiction; Governing Law; Prevailing Party Attorneys&rsquo; Fees</U>. All questions concerning the construction, validity,
enforcement and interpretation of this Note and venue shall be governed by and construed and enforced in accordance with Section
6.9 of the Purchase Agreement. If any party shall commence an Action or Proceeding to enforce or otherwise relating to this Note,
then, in addition to the other obligations of the Company elsewhere in this Note, the prevailing party in such action or proceeding
shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f) <U>Waiver</U>.
Any waiver by the Company or the Holder of a breach of any provision of this Note shall not operate as or be construed to be a
waiver of any other breach of such provision or of any breach of any other provision of this Note. The failure of the Company
or the Holder to insist upon strict adherence to any term of this Note on one or more occasions shall not be considered a waiver
or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Note on any
other occasion. Any waiver by the Company or the Holder must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g) <U>Severability</U>.
If any provision of this Note is invalid, illegal or unenforceable, the balance of this Note shall remain in effect, and if any
provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to all other Persons and circumstances.
If it shall be found that any interest or other amount deemed interest due hereunder violates the applicable law governing usury,
the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate of interest permitted under
applicable law. The Company covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, plead,
or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law or other law which would
prohibit or forgive the Company from paying all or any portion of the principal of or interest on this Note as contemplated herein,
wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Note, and
the Company (to the extent it may lawfully do so) hereby expressly waives all benefits or advantage of any such law, and covenants
that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Holder,
but will suffer and permit the execution of every such as though no such law has been enacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h) <U>Remedies, Characterizations,
Other Obligations, Breaches and Injunctive Relief</U>. The remedies provided in this Note shall be cumulative and in addition
to all other remedies available under this Note and any of the other Transaction Documents at law or in equity (including a decree
of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder&rsquo;s right to pursue actual
and consequential damages for any failure by the Company to comply with the terms of this Note. The Company covenants to the Holder
that there shall be no characterization concerning this instrument other than as expressly provided herein. Amounts set forth
or provided for herein with respect to payments, conversion and the like (and the computation thereof) shall be the amounts to
be received by the Holder and shall not, except as expressly provided herein, be subject to any other obligation of the Company
(or the performance thereof). The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable
harm to the Holder and that the remedy at law for any such breach would be inadequate. The Company therefore agrees that, in the
event of any such breach or threatened breach, the Holder shall be entitled, in addition to all other available remedies, to an
injunction restraining any such breach or any such threatened breach, without the necessity of showing economic loss and without
any bond or other security being required. The Company shall provide all information and documentation to the Holder that is requested
by the Holder to enable the Holder to confirm the Company&rsquo;s compliance with the terms and conditions of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i) <U>Next Trading
Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Trading Day, such payment shall
be made on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(j) <U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Note and shall not be deemed to limit
or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">Promissory Note</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.95pt">IN WITNESS WHEREOF, the Company has caused this
Note to be duly executed by a duly authorized officer as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>19
<FILENAME>cm270_ex10-16.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: right; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: right; text-indent: -0.5pt"><B>Exhibit 10.16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center"><B>DEBT
CONVERSION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt">This Debt Conversion Agreement
(the &#8220;<B><I>Agreement</I></B>&#8221;), dated as of January 9, 2023, is by and between Knight Therapeutics International S.A., a
corporation formed under the laws of Uruguay, and formerly known as Knight Therapeutics (Barbados) Inc. (the &#8220;<B><I>Lender</I></B>&#8221;),
and 60 Degrees Pharmaceuticals, Inc., a Delaware corporation and successor by merger of 60&deg;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">Pharmaceuticals, LLC, a District
of Columbia limited liability company (the &#8220;<B><I>Company</I></B>&#8221;). Lender and the Company are each referred to as a &#8220;<B><I>Party</I></B>&#8221;
and together as the &#8220;<B><I>Parties</I></B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>WHEREAS</B>, Lender extended
the Company a line of credit up to $7,000,000 pursuant to the terms of that certain Loan Agreement and Engagement, dated December 10,
2015, by and between the Company and Lender (as amended, the &#8220;<B><I>Loan Agreement</I></B>&#8221;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>WHEREAS</B>, on April 24,
2018, Company, in connection with one tranche of funding provided by Lender, issued to Lender a Secured Convertible Debenture with a face
value of $3,000,000 (as amended, the &#8220;<B><I>Note</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>WHEREAS</B>, in connection
with the Loan Agreement, the Company delivered to Lender a Security Agreement, dated December 10, 2015, pursuant to which the Company
granted a security interest in its assets to Lender (the &#8220;<B><I>Security Agreement</I></B>&#8221; and together with the Loan Agreement
and the Note, the &#8220;<B><I>Loan Documents</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>WHEREAS</B>, the Company is
the process of conducting an initial public offering on Nasdaq of its common stock (&#8220;Nasdaq listed&#8221;), par value $0.0001 per
share (the &#8220;<B><I>Common Stock</I></B>&#8221;) pursuant to an underwritten offering (the &#8220;<B><I>IPO</I></B>&#8221;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>WHEREAS</B>, as at 31
March 2022, the aggregate principal amount outstanding under the Loan Documents is $10,770,037 (&#8220;<B><I>Principal
Amount</I></B>&#8221;), and the accrued interest under the Loan Documents is $8,096,486 (the &#8220;<B><I>Accrued
Interest</I></B>&#8221; and together with the Principal Amount, the &#8220;<B><I>Debt</I></B>&#8221;),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>WHEREAS</B>, Lender and the
Company desire to convert a portion of the Debt into shares of the Common Stock and desire to convert the remaining portion of the Debt
into shares of a new class of preferred stock as more fully described in this Agreement, to fully satisfy the Company&#8217;s obligations
under the Loan Documents, provided that the IPO results in gross proceeds to the Company of at least $7,000,000 (a &#8220;<B><I>Qualified
IPO</I></B>&#8221;) and occurs before December 31, 2023. For clarification purposes, if the IPO does not meet the before mentioned results
by the end of 2023, the conversion in this document will have no effect, the Company will continue to be obliged by the Loan Documents
and the interest calculation shall be resumed under original terms of loan (including default interest) since March 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt">NOW, THEREFORE, for good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.25pt"></TD><TD STYLE="width: 36pt">1.</TD><TD STYLE="text-align: left"><B>Conversion of the Debt</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Conversion
of the Principal Amount</I></B>. Subject to the terms and conditions hereof, at the Closing (as defined below), Lender hereby elects
to convert the Principal Amount into (i) that number of shares of Common Stock equal to dividing the Principal Amount by an amount
equal to the offering price of the Common Stock in the IPO discounted by 15% (the &#8220;<B><I>Conversion Common
Shares</I></B>&#8221;), rounding up for fractional shares, in a number of Conversion Shares up to 19.9% of the Company&#8217;s
outstanding Common Stock after giving effect of the IPO; and (ii) the balance into a convertible promissory note (the
&#8220;<B><I>Conversion Note</I></B>&#8221;), in substantially the form attached hereto as <U>Exhibit A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Conversion
of the Accrued Interest</I></B>. Subject to the terms and conditions hereof, at the Closing (as defined below), Lender hereby elects to
convert the Accrued Interest into that number of shares (the &#8220;<B><I>Conversion Preferred Shares</I></B>&#8221; and, together with
the Conversion Common Shares, the &#8220;<B><I>Conversion Shares</I></B>&#8221;) of a new class of preferred stock (the &#8220;<B><I>Preferred
Stock</I></B>&#8221;) by dividing the Accrued Interest by [$1.00]. The Preferred Stock shall have the following rights, preferences, and
designations: (i) have a 6% [cumulative] dividend accumulated annually on March 31, (ii) shall be non-voting stock; and (iii) be convertible
in shares of Common Stock at a price equal to the lower of (1) the price paid for the shares of Common Stock in the IPO and (2) the 10
day volume weighted average share price immediately preceding the Company&#8217;s election to convert the Preferred Stock. Notwithstanding
the foregoing, the Company shall not convert the Preferred Stock into shares of Common Stock if as a result of such conversion Lender
will own 19.9% or more of the Company&#8217;s outstanding Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 35.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Royalty</I></B>.
In addition to the conversion of the Debt, for a period commencing on January 1, 2022 and ending upon the earlier of 10 years after the
Closing or the conversion or redemption in full of the Conversion Preferred Shares, Company shall pay Lender a royalty equal to 3.5%
of the Company&rsquo;s net sales (the &ldquo;<B><I>Royalty</I></B>&rdquo;), where &ldquo;<B><I>Net Sales&rdquo;</I></B> has the same
meaning as in the Company&rsquo;s license agreement with the U.S. Army for Tafenoquine. Upon succeeding the Qualified IPO, the Company
shall calculate the royalty payable to Knight Therapeutics International S.A. (&ldquo;Knight&rdquo;) at the end of each calendar quarter.
The Company shall pay to Knight the royalty amounts due with respect to a given calendar quarter within fifteen (15) Business Days after
the end of such calendar quarter. Each payment of royalties due to Knight shall be accompanied by a statement specifying the total gross
sales, the net sales and the deductions taken to arrive to net sales. For clarification purposes, the first royalty payment will be performed
following the above instructions, on the first calendar quarter in which the Qualified IPO took place and will cover the sales of the
period from January 1, 2022 until the end of said calendar quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Effect
of Conversion</I></B>. At the Closing, Lender shall deliver to the Company the Notes for conversion into the Conversion Shares and
the Conversion Note, if any. After the conversion of the Debt into the Conversion Shares and the Conversion Note, if any, the Loan
Documents shall terminate and be of no further force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.25pt"></TD><TD STYLE="width: 36pt">2.</TD><TD STYLE="text-align: left"><B>Closing; Conditions to Closing</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Closing</I></B>.
The consummation of the transactions contemplated by this Agreement (the &#8220;<B><I>Closing</I></B>&#8221;) shall take place contemporaneously
with the consummation of the Qualified IPO, which Closing shall be held in the offices of the Company or such other place as may be mutually
agreeable to the Parties. The date on which the Closing occurs is referred to as the &#8220;<B><I>Closing Date</I></B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Conditions
to Closing</I></B>. The Closing shall be subject to the satisfaction or waiver by the Company, on the one hand, and Lender, on the other,
of the conditions that, on the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
consummation of the Qualified IPO;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
acceptance by the Secretary of State of the State of Delaware of an Amended and Restated Certificate of Incorporation of the Company creating
the Preferred Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that
all representations and warranties of the Parties contained in this Agreement shall be true and correct in all material respects at and
as of the Closing Date (except to the extent expressly made as of an earlier date, in which case only as of such date); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Parties shall have performed, satisfied, and complied in all material respects with all covenants, agreements and conditions required
by this Agreement to be performed, satisfied or complied with by the Parties at or prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Closing
Deliveries</I></B>. At the Closing,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 23.05pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
Company shall issue certificates representing the Conversion Shares in the name of Lender, and shall issue and deliver the Conversion
Note, if any, to the Lender; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 23.05pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
shall deliver to the Company (A) the Note and other documents evidencing the Debt, which shall be marked &#8220;Cancelled&#8221; by the
Company, and (B) such instruments and documents as may be necessary to effect the full and complete release of the security interest pursuant
to the Security Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.25pt"></TD><TD STYLE="width: 36pt">3.</TD><TD STYLE="text-align: left"><B>Representations and Warranties</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Of
the Company</I></B>. The Company hereby represents and warrants to Lender that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 21.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 21.35pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is duly organized, validly existing, and good standing under the laws of the State of Delaware with the power to own its assets
and to transact business in Delaware, and in such other states where its business is conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in"><FONT STYLE="font-size: 10pt"><BR STYLE="clear: both">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 21.35pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has all requisite limited liability company power and authority to enter into this Agreement, and this Agreement, when executed
and delivered, will constitute a valid and legally binding obligation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 21.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 21.35pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Conversion Shares to be issued upon conversion of the Principal Amount have been duly authorized for issuance by all corporate action
and no approval by the Company&#8217;s stockholders or any third party, including any government agency, is required for the issuance
of the Conversion Shares pursuant to this Agreement. The Conversion Shares, when issued pursuant to this Agreement, will be duly and validly
authorized and issued, fully paid and nonassessable, and free and clear of all liens and encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Of Lender</I></B>.
Lender hereby represents and warrants to the Company that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
is duly organized, validly existing, and good standing under the laws of the State of Delaware with the power to own its assets and to
transact business in Delaware, and in such other states where its business is conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
has all requisite limited liability company power and authority to enter into this Agreement, and this Agreement, when executed and delivered,
will constitute a valid and legally binding obligation of Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
is the owner of the Notes and owns such Notes free and clear of all liens, claims and encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
hereby confirms, that the Conversion Shares, the Conversion Note, if any, and the shares of Common Stock into which they convert (the
&#8220;<B><I>Conversion Securities</I></B>&#8221;) to be purchased by it are being and will be acquired for investment for its own account,
not as nominee or agent, and not with a view to the resale or distribution of any part thereof, and that neither Lender nor any of its
officers, members, managers or representatives with the authority, responsibility or power to make a decision with regard to the purchase
or sale of the Conversion Securities or any portion thereof has any present intention of selling, granting any participation in or otherwise
distributing the same. Lender is familiar with the phrase &#8220;acquired for investment and not with a view to distribution&#8221; as
it relates to the Securities Act of 1933, as amended (the &#8220;<B><I>Securities Act</I></B>&#8221;) and state securities laws and the
special meaning given to such term by the Securities and Exchange Commission (the &#8220;<B><I>SEC</I></B>&#8221;). By executing this
Agreement, Lender further represents that it does not have any contract, undertaking, agreement or arrangement with any person to sell,
transfer or grant participations to such person or to any third person, with respect to any of the Conversion Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
understands that the Conversion Securities will not be at the time of issuance, registered under the Securities Act on the ground that
the sale provided for in this Agreement and the issuance of securities hereunder is exempt from registration under the Securities Act,
and that the Company&#8217;s reliance on such exemption is predicated on Lender&#8217; representations and warranties set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
represents that it is experienced in evaluating and investment in private placement transactions of securities of companies in a similar
stage of development as the Company and acknowledges that it can bear the economic risk of its investment and that it has such knowledge
and experience in financial and business matters that it is capable of evaluating the merits and risks of the investment in the Conversion
Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
is an Accredited Investor, as such term is defined in Regulation D promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.25pt; text-align: justify; text-indent: 18.7pt">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lender
understands that the neither the Conversion Securities nor any portion thereof may be sold, transferred or otherwise disposed of without
registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement covering
the Conversion Securities (or such portion thereof) or an available exemption from registration under the Securities Act, the Conversion
Securities and each portion thereof must be held indefinitely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35.25pt; text-align: right"></TD><TD STYLE="text-align: left; width: 36pt">4.</TD><TD STYLE="text-align: justify"><B>Miscellaneous</B>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Governing
Law</I></B>. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Entire
Agreement</I></B>. This Agreement constitutes the entire agreement between the Parties and supersedes all prior oral or written negotiations
and agreements between the Parties with respect to the subject matter hereof. No modification, variation or amendment of this Agreement
(including any exhibit hereto) shall be effective unless made in writing and signed by both Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Attorneys&#8217;
Fees</I></B>. In the event any Party hereto fails to perform any of its obligations under this Agreement or the transactions contemplated
hereby or in the event a dispute arises concerning the meaning or interpretation of any provision of this Agreement, the defaulting Party
or the Party not prevailing in such dispute, as the case may be, shall pay any and all reasonable costs and expenses incurred by the other
Party in enforcing or establishing its rights hereunder, including court costs and reasonable attorneys&#8217; fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Successors
and Assigns</I></B>. This Agreement shall be binding upon each Party hereto and its respective successors and assigns. The Company shall
not assign this Agreement without the prior written consent of Lender, in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Severability</I></B>.
If any term of provision of this Agreement or any application thereof shall be held invalid or unenforceable, the remainder of this Agreement
and any other application of such term or provision shall not be affected thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 35.5pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Counterparts;
Electronic Signature</I></B>. This Agreement may be executed in one or more counterparts, each of which shall be an original, but all
of which, taken together, shall constitute one agreement. The Parties acknowledge and agree that this Agreement may be signed and/or transmitted
by e-mail or a .pdf document or using electronic signature technology (e.g., via DocuSign, Adobesign, or other electronic signature technology),
and that such signed electronic record shall be valid and as effective to bind the Party so signing as a paper copy bearing such Party&#8217;s
handwritten signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>[Signature Page Follows]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt">IN WITNESS WHEREOF, the Parties
have executed this Debt Conversion Agreement as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: left; text-indent: 0in"><B>LENDER: </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><B>KNIGHT THERAPEUTICS INTERNATIONAL S.A. </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: normal 18pt Calibri, Helvetica, Sans-Serif; text-align: center"></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left">Arvind Utchanah</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: left; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: left; text-indent: 0in">By:&nbsp;&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">/s/ Arvind Utchanah</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Name:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Arvind Utchanah</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">CFO</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: left; text-indent: 0in"><B>COMPANY: </B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in"><B>60 DEGREES PHARMACEUTICALS, INC. </B></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 180.05pt; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 180.05pt; text-align: left; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%; text-align: left; text-indent: 0in">By: <U></U></TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">[<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Name:&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Geoffrey S. Dow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">CEO&nbsp;&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>Signature Page to
Debt Conversion Agreement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>Exhibit A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>Form of Convertible
Promissory Note</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">NEITHER THE ISSUANCE AND SALE OF
THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED
OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR (B) AN OPINION OF COUNSEL TO THE HOLDER (IF REQUESTED BY THE COMPANY), IN A FORM REASONABLY ACCEPTABLE TO THE COMPANY, THAT REGISTRATION
IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD OR ELIGIBLE TO BE SOLD PURSUANT TO RULE 144 UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING,
THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.
ANY TRANSFEREE OF THIS PROMISSORY NOTE SHOULD CAREFULLY REVIEW THE TERMS OF THIS PROMISSORY NOTE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>60 DEGREES PHARMACEUTICALS,
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.7pt; text-align: center; text-indent: -0.5pt"><B>CONVERTIBLE PROMISSORY
NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.05pt; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 67%; text-align: left; text-indent: 0in"><B>$[__________________]</B></TD>
    <TD STYLE="width: 33%; text-align: left; text-indent: 0in"><B>Issue Date:</B>&nbsp;&nbsp;[IPO DATE], 2023</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt"><B>FOR VALUE RECEIVED</B>, 60 Degrees
Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), hereby promises to pay to the order of Knight
Therapeutics (Barbados) Inc. or its registered assigns (&#8220;<B><I>Holder</I></B>&#8221;), the principal amount set forth above, together
with accrued and unpaid interest thereon, each due and payable on the date and in the manner set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Repayment</B>.
All payments of interest and principal under this Convertible Promissory Note (this &#8220;<B><I>Note</I></B>&#8221;) shall be in
lawful money of the United States of America. All payments shall be applied first to accrued interest, and thereafter to principal.
The outstanding principal amount of this Note, together with all accrued but unpaid interest thereon, shall be due and payable on
the second anniversary of the Issue Date (the &#8220;<B><I>Maturity Date</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Prepayment</B>.
The Company may prepay all or any portion of the principal amount or accrued interest of this Note prior to the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Interest
Rate</B>. The Company promises to pay simple interest on the outstanding principal amount hereof from the date hereof until payment in
full, which interest shall be payable at the rate of 10.0% per annum or the maximum rate permissible by law, whichever is less. Interest
shall be due and payable on the Maturity Date and shall be calculated on the basis of a 365-day year for the actual number of days elapsed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0in">Exhibit A to Debt Conversion Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conversion</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Conversion
Upon Maturity</I></B>. In the event that this Note is not repaid in full prior to the Maturity Date, then the entire outstanding principal
amount of this Note, together with all accrued but unpaid interest thereon, shall automatically convert in whole without any further action
by Holder into shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<B><I>Common Stock</I></B>&#8221;).
The number of shares of Common Stock into which the amounts due under this Note shall be converted shall be calculated using a conversion
price per share of Common Stock equal to the lower of: (i) the price of the Company&#8217;s Common Stock in its initial public offering,
and (ii) the 10-day weighted average price of the Common Stock traded on the Nasdaq Capital Market or any other national securities exchange
on which the shares of Common Stock are then trading, for the 10 trading days ending on the first trading day immediately preceding the
Maturity Date (the &#8220;<B><I>Conversion Price</I></B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Limitations
to Conversion</I></B>. Notwithstanding the foregoing anything to the contrary contained in this Note, no amounts under this Note shall
be converted to the extent (but only to the extent) that, after giving effect to such conversion, the Holder would beneficially own 19.9%
(the &#8220;<B><I>Maximum Percentage</I></B>&#8221;) or more of the outstanding Common Stock (calculated on an as-converted basis, fully
diluted basis) of the Company. To the extent the above limitation applies, no amounts under this Note shall be converted and the Maturity
Date of this Note shall be automatically extended by 12 months. After which time, this Note shall be converted up to the Maximum Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>No
Fractional Shares</I></B>. If the conversion of this Note would result in the issuance of a fractional share, the Company shall, in lieu
of issuance of any fractional share, pay Holder a sum in cash equal to the product resulting from multiplying the Conversion Price by
such fractional share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Default</B>.
If there shall be any Event of Default (defined below) hereunder, at the option of, and upon the declaration of the Holder and upon written
notice to the Company (which election and notice shall not be required in the case of an Event of Default under <U>Section 5(c),</U> or
5<U>(d</U>)), this Note shall accelerate and all principal and unpaid accrued interest shall become immediately due and payable. The occurrence
of any one or more of the following shall constitute an &#8220;<B><I>Event of Default</I></B>&#8221;:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company fails to pay timely any of the principal amount due under this Note on the date the same becomes due and payable or any accrued
interest or other amounts due under this Note on the date the same becomes due and payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: right; text-indent: 35.5pt">Exhibit A to Debt Conversion Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company files any petition or action for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for
the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any
corporate action in furtherance of any of the foregoing; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 35.5pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
involuntary petition is filed against the Company (unless such petition is dismissed or discharged within 60 days) under any bankruptcy
statute now or hereafter in effect, or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official)
is appointed to take possession, custody or control of any property of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Waiver</B>.
The Company hereby waives demand, notice, presentment, protest and notice of dishonor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Governing
Law. </B>This Note shall be governed by and construed under the laws of the State of Delaware, as applied to agreements among Delaware
residents, made and to be performed entirely within the State of Delaware, without giving effect to conflicts of laws principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Modification;
Waiver.</B> Any term of this Note may be amended or waived only with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Assignment.</B>
This Note may be transferred by Holder only with the consent of the Company and upon its surrender to the Company for registration of
transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon,
this Note shall be reissued to, and registered in the name of, the transferee, or a new Note for like principal amount and interest shall
be issued to, and registered in the name of, the transferee. Interest and principal shall be paid solely to the registered holder of this
Note. Such payment shall constitute full discharge of the Company&#8217;s obligation to pay such interest and principal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Expenses</B>.
In the event of any default hereunder, the Company shall pay all reasonable attorneys&#8217; fees and court costs incurred by Holder in
enforcing and collecting this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Voting
Rights</B>. The Holder shall have no voting rights as a stockholder with respect to the shares of Common Stock issuable upon conversion
of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 35.5pt">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Security</B>.
The obligation of the Company under this Note are not secured. The Holder shall have rights in this respect pari passu with the Company&#8217;s
senior most unsecured debt issued after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: right; text-indent: 35.5pt">Exhibit A to Debt Conversion Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35.5pt"><B>IN WITNESS WHEREOF</B>, the
Company has caused this Convertible Promissory Note to be duly executed as of the Issuance Date set out above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 180.55pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left; text-indent: 0in"><B>60 DEGREES PHARMACEUTICALS, INC.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Name:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Geoffrey S. Dow</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: left; text-indent: 0in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5pt; text-align: right; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5pt; text-align: right; text-indent: -0.5pt">Exhibit A to Debt Conversion Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5pt; text-align: right; text-indent: -0.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>20
<FILENAME>cm270_ex10-17.htm
<DESCRIPTION>EXHIBIT 10.17
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.35pt; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.35pt; text-align: right; text-indent: 0in"><B>Exhibit 10.17</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.35pt; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.35pt; text-align: center; text-indent: 0in"><B>AMMENDMENT TO THE DEBT
CONVERSION AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">This amendment to
the Debt Conversion Agreement (the &ldquo;<B>Amendment Agreement</B>&rdquo;) is made and entered into on this 19th day of January 2023,
by and between Knight Therapeutics International S.A. (the &ldquo;<B>Lender</B>&rdquo;) and 60 Degrees Pharmaceuticals, INC (the &ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>WHEREAS</B> the
Borrower and Lender entered into a Debt Conversion Agreement (&ldquo;<B>the Initial Agreement</B>&rdquo;) as of January 9<SUP>th</SUP>,
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>WHEREAS</B> the
Borrower and Lender wish to amend the agreement as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>NOW THEREFORE</B>,
for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Borrower and Lender, intending to
be legally bound, hereby agree and contract as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify"><U>Amendment to Initial Agreement.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20.4pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Clause 1b will be deleted and replaced with&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">&ldquo;Conversion
of the Accrued Interest. Subject to the terms and conditions hereof, at the Closing (as defined below), Lender hereby elects to convert
the Accrued Interest into that number of shares (the &ldquo;Conversion Preferred Shares&rdquo; and, together with the Conversion Common
Shares, the &ldquo;Conversion Shares&rdquo;) of a new class of preferred stock (the &ldquo;Preferred Stock&rdquo;) by dividing the Accrued
Interest by [$100.00], then rounding up. The Preferred Stock shall have the following rights, preferences, and designations: (i) have
a 6% [cumulative] dividend accumulated annually on March 31, (ii) shall be nonvoting stock; and (iii) be convertible in shares of Common
Stock at a price equal to the lower of (1) the price paid for the shares of Common Stock in the IPO and (2) the 10 day volume weighted
average share price immediately preceding the Company&rsquo;s election to convert the Preferred Stock. Notwithstanding the foregoing,
the Company shall not convert the Preferred Stock into shares of Common Stock if as a result of such conversion Lender will own 19.9%
or more of the Company&rsquo;s outstanding Common Stock.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify"><U>Definitions.</U> All capitalized terms not defined in this Amendment Agreement will have the meaning
ascribed to them in the Debt Conversion Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">3.</TD><TD STYLE="text-align: justify"><U>Modification.</U> Except as explicitly modified and amended hereby, the Initial Agreement remains and
unchanged and unmodified and in full force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">4.</TD><TD STYLE="text-align: justify"><U>Governing Law.</U> This Amendment Agreement will be governed and interpreted in accordance with the
state of Delaware.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">5.</TD><TD STYLE="text-align: justify"><U>Counterparts,</U> Electronic Signature. This Amendment Agreement may be executed in one or more counterparts
which together shall be deemed to constitute one valid and binding agreement and delivery of the counterparts may be effected by means
of a telecopier transmission, electronically or in a portable document format (pdf.)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.55pt; text-align: justify; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.55pt; text-align: center; text-indent: 0in"><B><I>[Signature Page
Follows]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>IN WITNESS THEREOF</B>,
the undersigned have executed this Amendment Agreement as of the date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: left; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Lender:</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: left; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><B>KNIGHT THERAPEUTICS
INTERNATIONAL S. A. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">/s/ Arvind Utchanah&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; width: 6%">Name:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; width: 44%">Arvind Utchanah&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;CFO</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Borrower:</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: left; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><B>60 DEGREES PHARMACEUTICALS,
INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: left; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: left; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%; font-size: 10pt">[<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>]</TD>
    <TD STYLE="width: 65%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-indent: -0.5pt"><B> </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-indent: -0.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-indent: 0in">Name:</TD>
    <TD STYLE="width: 44%; text-indent: 0in">Geoffrey S. Dow</TD>
    <TD STYLE="width: 50%; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Title:</TD>
    <TD STYLE="text-indent: 0in">CEO</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>21
<FILENAME>cm270_ex10-18.htm
<DESCRIPTION>EXHIBIT 10.18
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.55pt; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.55pt; text-align: right; text-indent: 0in"><B>Exhibit 10.18</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.55pt; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.55pt; text-align: center; text-indent: 0in"><B>AMMENDMENT TWO TO THE
DEBT CONVERSION AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">This second amendment
to the Debt Conversion Agreement (the &ldquo;<B>Second Amendment Agreement</B>&rdquo;) is made and entered into on this 27<SUP>th</SUP>
day of January 2023, by and between Knight Therapeutics International S.A. (the &ldquo;<B>Lender</B>&rdquo;) and 60 Degrees Pharmaceuticals,
INC. (the &ldquo;<B>Borrower</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>WHEREAS</B> the
Borrower and Lender entered into a Debt Conversion Agreement (&ldquo;<B>the Initial Agreement</B>&rdquo;) as of January 9<SUP>th</SUP>,
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>WHEREAS</B> the
Borrower and Lender entered into an Amendment to the Debt Conversion Agreement (the &ldquo;<B>Amending Agreement</B>&rdquo;) as of January
19<SUP>th</SUP>, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>WHEREAS</B> the
Borrower and Lender wish to further amend the Initial Agreement and Amendment to the Debt Conversion Agreement as set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>NOW THEREFORE</B>,
for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Borrower and Lender, intending to
be legally bound, hereby agree and contract as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.9pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify"><U>Amendment to Initial Agreement.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">a.</TD><TD STYLE="text-align: justify">Clause 1a will be deleted and replaced with:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.65pt; text-align: justify; text-indent: -0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;<B>Conversion
of the Principal Amount.</B> Subject to the terms and conditions hereof, at the Closing (as defined below), Lender hereby elects to convert
the Principal Amount into (i) that number of shares of Common Stock equal to dividing the Principal Amount by an amount equal to the
offering price of the Common Stock in the IPO discounted by 15% (the &ldquo;Conversion Common Shares&rdquo;), rounding up for fractional
shares, in a number of Conversion Shares up to 19.9% of the Company&rsquo;s outstanding Common Stock after giving effect of the IPO;
(ii) the Company will make a milestone payment of $10 million to Knight if, after the date of a Qualifying IPO, the Company sells ARAKODA
or if a Change of Control (as per the definition included in the original loan agreement dated on December 10<SUP>th</SUP>, 2015) occurs,
provided that the purchaser of ARAKODA or individual or entity gaining control of the Borrower is not the Lender or an affiliate of the
Lender; (iii) following the License and Supply agreement dated on December 10<SUP>th</SUP>, 2015 and subsequently amended on January
21<SUP>st</SUP>, 2019, an expansion of existing distribution rights to Tafenoquine/Arakoda to include COVID-19 indications as well as
malaria prevention across the Territory as defined in said documents, subject to US Army approval; and (iv) Company will retain Lender
or an affiliate to provide financial consulting services, management, strategic and/or regulatory advice of value $30,000 per month for
five years (the parties will negotiate the terms of that consulting agreement separately in good faith).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">b.</TD><TD STYLE="text-align: justify">Clause 1b will be deleted and replaced with:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">&ldquo;<B>Conversion
of the Accrued Interest.</B> Subject to the terms and conditions hereof, at the Closing, Lender hereby elects to convert the Accrued Interest
into that number of shares (the &ldquo;Conversion Preferred Shares&rdquo; and, together with the Conversion Common Shares, the &ldquo;Conversion
Shares&rdquo;) of a new class of preferred stock (the &ldquo;Preferred Stock&rdquo;) by dividing the Accrued Interest by [$100.00], then
rounding up. The Preferred Stock shall have the following rights, preferences, and designations: (i) have a 6% [cumulative] dividend accumulated
annually on March 31; (ii) shall be non-voting stock; (iii) are not redeemable, (iv) be convertible to shares of Common Stock at a price
equal to the lower of (1) the price paid for the shares of Common Stock in the IPO and (2) the 10 day volume weighted average share price
immediately prior to conversion; and (v) conversion of the preferred stock to common shares will be at the sole discretion of the Company.
Notwithstanding the foregoing, the Company shall not convert the Preferred Stock into shares of Common Stock if as a result of such conversion
Lender will own 19.9% or more of the Company&rsquo;s outstanding Common Stock.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">c.</TD><TD STYLE="text-align: justify">Exhibit A will be deleted.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">d.</TD><TD STYLE="text-align: justify">Any references to the Conversion Note shall be deleted and inapplicable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">e.</TD><TD STYLE="text-align: justify">For the avoidance of doubt, the parties agree that all debt obligations of Borrower to Lender shall be
deemed satisfied pursuant to the conversion of the Principal Amount and Accrued Interest as specified herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">2.</TD><TD STYLE="text-align: justify"><U>Definitions.</U> All capitalized terms not defined in this Second Amendment Agreement will have the
meaning ascribed to them in the Debt Conversion Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">3.</TD><TD STYLE="text-align: justify"><U>Modification.</U> Except as explicitly modified and amended hereby, the Initial Agreement and Amendment
to the Debt Conversion Agreement remain and unchanged and unmodified and in full force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: left; text-indent: 0in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">4.</TD><TD STYLE="text-align: justify"><U>Governing Law.</U> This Second Amendment Agreement will be governed and interpreted in accordance with
the State of Delaware, excluding its conflict of law provisions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37.9pt; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.9pt"></TD><TD STYLE="width: 18pt">5.</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Second Amendment Agreement may be executed in one or more counterparts which
together shall be deemed to constitute one valid and binding agreement and delivery of the counterparts may be effected by means of a
telecopier transmission, electronically or in a portable document format (pdf.)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in"><B><I>[Signature Page Follows]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"><B>IN WITNESS THEREOF</B>,
the undersigned have executed this Second Amendment Agreement as of the date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Lender:</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: left; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><B>KNIGHT THERAPEUTICS
INTERNATIONAL S. A. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left; text-indent: 0in">/s/ Arvind Utchanah&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in; width: 6%">Name:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; width: 44%">Arvind Utchanah&nbsp;&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;CFO</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Borrower:</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: left; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left; text-indent: 0pt"><B>60 DEGREES PHARMACEUTICALS,
INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: left; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: left; text-indent: 0in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; border-bottom: Black 1pt solid; font-size: 10pt">[<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>]</TD>
    <TD STYLE="width: 65%; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-indent: 0in">Name:</TD>
    <TD STYLE="width: 44%; text-indent: 0in">Geoffrey S. Dow</TD>
    <TD STYLE="width: 50%; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Title:</TD>
    <TD STYLE="text-indent: 0in">CEO</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.65pt; text-align: justify; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.9pt; text-align: left; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: left; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>22
<FILENAME>cm270_ex10-19.htm
<DESCRIPTION>EXHIBIT 10.19
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.35pt; text-align: right; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.35pt; text-align: right; text-indent: -0.5pt"><B>Exhibit 10.19</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.35pt; text-align: center; text-indent: -0.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.35pt; text-align: center; text-indent: -0.5pt"><B>INTER-INSTITUTIONAL
AGREEMENT BETWEEN </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.35pt; text-align: center; text-indent: -0.5pt"><B>60 DEGREE, INC.
</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 0 19.35pt; text-align: center; text-indent: -0.5pt">AND FLORIDA STATE
UNIVERSITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">This Inter-Institutional Agreement (hereinafter &ldquo;Agreement&rdquo;)
is entered into by 60 Degree, Inc., having a principal business address at 1025 Connecticut Avenue NW, Suite 1000, Washington D.C., hereinafter
referred to as &ldquo;60 Degree&rdquo; and Florida State University Research Foundation, Inc. (&ldquo;FSURF&rdquo;), a direct support
organization created by Florida State University (&ldquo;FSU&rdquo;) to, among other things, manage the licensing of intellectual property
created at FSU. FSURF is located at <FONT STYLE="color: #222222">2000 Levy Ave. Suite 351, Tallahassee, FL 32310. </FONT>The signatories
to this</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">Agreement are collectively referred to as &ldquo;Parties&rdquo;
and individually as a &ldquo;Party&rdquo; hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">WHEREAS, 60 Degree has developed the Enabling Data
described in Appendix A; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">WHEREAS, 60 Degree and FSURF seek to work together
to market the Intellectual Property</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">(&ldquo;Technology&rdquo;) and in sharing in any royalties
or other consideration resulting from such commercialization; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">WHEREAS, FSURF desires to lead the licensing effort
for technology commercialization from the collaboration between FSURF and 60 Degree; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">WHEREAS, FSURF is willing to undertake the commercial
licensing of the Intellectual Property that is jointly or solely owned by the Parties, and 60 Degree is willing to refrain from licensing
such Intellectual Property, prosecuting patent(s) of this Intellectual Property and/or pursuing infringement actions against such Licensee(s)
in return for prescribed shares in any License Income or equity stake received by FSURF as a result of licensing this Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">NOW, THEREFORE, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">1. DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">1.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Intellectual
Property</B> is defined and outlined in Appendix A, incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">1.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Licensed
Intellectual Property</B> is defined as the specific Intellectual Property for which license or option rights are granted in a License
Agreement with a third party Licensee. Such Intellectual Property shall be identified in an appendix to each License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">1.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>License
Agreement </B>is any license or option agreement that is entered into by FSURF under the provisions of this Agreement and that grants
to a third party the right to make, have made, use, have used, import, sell, and/or have sold products or practice methods claimed by
one or more piece(s) of Licensed Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">1.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Licensee
</B>is any licensee or optionee to a License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0cm"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>License
Income</B> is defined as any consideration, including but not limited to license issue fees, annual license fees, earned royalties or
equity, received as a result of License Agreements using the specific Licensed Intellectual Property or optioning of Licensed Intellectual
Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0cm">1.6 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Patent Prosecution Expenses</B>
shall mean all out-of-pocket expenses incurred by FSURF for the preparation, filing, prosecution, maintenance, inventorship determination,
licensing, and defense or endorsement of patent applications that include Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LICENSING
AND COMMERCIALIZATION OF THE TECHNOLOGY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80.75pt"></TD><TD STYLE="width: 24pt">2.1</TD><TD>60 Degree hereby grants to FSURF the right to exclusively or nonexclusively license Intellectual Property listed in Appendix A on
60 Degree&rsquo;s behalf during the term of this agreement. 60 Degree designates FSURF as the sole negotiating and licensing agent for
any License Agreements involving the subject Intellectual Property. All licensing decisions shall be at the sole discretion of FSURF.
However, FSURF may solicit input from 60 Degree regarding its licensing decisions and, to the extent such input is provided by 60 Degree,
FSURF will take such input into consideration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80.75pt"></TD><TD STYLE="width: 24pt">2.2</TD><TD>Subject to the rights granted in Paragraph 2.1, FSURF will undertake reasonable efforts to commercialize said Intellectual Property
and to grant an exclusive or nonexclusive license to the Intellectual Property to one or more qualified Licensees and manage existing
License Agreements, including distribution of License Income. FSURF agrees to provide an annual accounting to 60 Degree for all License
Income received as a result of the commercialization of said Intellectual Property, to the extent that each entity is owed a proportionate
share of License Income. FSURF agrees to pay 60 Degree its respective share of License Income on an annual basis each year. The determination
of each Party&rsquo;s share of License Income derived from each License Agreement shall be calculated and distributed in accordance with
the formula provided in Appendix B of this Agreement, incorporated herein by reference. Each Party shall distribute to its own Inventors
according to its policy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80.75pt"></TD><TD STYLE="width: 24pt">2.3</TD><TD>For any License Agreement that FSURF negotiates and executes, FSURF will seek the same protections, in the terms and conditions of
the License Agreement, for 60 Degree that it does for itself.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80.75pt"></TD><TD STYLE="width: 24pt">2.4</TD><TD>FSURF will provide 60 Degree with a copy of each fully executed License Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80.75pt"></TD><TD STYLE="width: 24pt">2.5</TD><TD>FSURF shall keep books and records sufficient to verify the accounting referred to above, including without limitation, records relating
to license revenues. Such books and records shall be preserved for a period of not less than five (5) years after they are created, during
and after the term of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80.75pt"></TD><TD STYLE="width: 24pt">2.6</TD><TD>In consideration of a proportionate percentage share of License Income received by FSURF, 60 Degree agrees not to license the Intellectual
Property, as defined herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80.75pt"></TD><TD STYLE="width: 24pt">2.7</TD><TD>This Inter-Institutional Agreement may be assigned by 60 Degree or FSURF in conjunction with an assignment or transfer of their rights
in the Licensed Intellectual Property, with written authorization from the other Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80.75pt"></TD><TD STYLE="width: 24pt">2.8</TD><TD>The Parties may add new Intellectual Property or remove existing Intellectual Property from Appendix A through an amendment to this
Agreement in accordance with Article 11. In no case will the removal of Intellectual Property from
Appendix A nor termination of this Agreement remove Licensed Intellectual Property from an existing License Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80.75pt"></TD><TD STYLE="width: 24pt">2.9</TD><TD>FSURF will be responsible for costs associated with patent prosecution of the Intellectual Property and will require a licensee to
reimburse FSURF for Patent Prosecution Expenses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt; font-weight: normal">&#9;</FONT>3.
&#9;RELATIONSHIP BETWEEN THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">3.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Party
is and shall remain an independent contractor as long as this Agreement is in effect and no Party shall act as an agent, legal representative,
partner, or joint venturer of the other Party for any purpose whatsoever. The employees of one Party shall not be deemed employees of
any other Party. Except as provided in Paragraph 2.1, neither of the Parties shall have any right, power, or authority to make any contract
or other agreement to assume or create any obligation or responsibility, express or implied, on behalf of or in the name of the other
Party, or to bind the other Party in any way. Except as provided in Paragraph 2.1, none of the Parties to this Agreement shall represent
to any other person that such Party has any such right, power, or authority. This Agreement is not intended to constitute, create, give
effect to, or otherwise contemplate a joint venture, partnership, or formal business entity of any kind and the rights and obligations
of the Parties shall not be construed as providing for a sharing of profits or losses arising out of the efforts of either of the Parties
other than that which is specifically provided herein. The Parties retain the right to practice their invention for internal research
and educational purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0cm">3.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties agree to assist each other in achieving the purpose of this Agreement, including the sharing of information relating to entities
that may have an interest in commercializing and/or sponsoring further research relating to the Technology. Notwithstanding such mutual
assistance, it is further understood and agreed that neither this Agreement nor the Parties&rsquo; performance hereunder shall establish
any contract, express or implied, between the U.S. Government, 60 Degree, and FSURF, and this Agreement is not intended to restrict or
confine any Party in their independent development of the underlying Technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Calibri, Helvetica, Sans-Serif; font-size: 11pt; font-weight: normal">&#9;</FONT>4.
&#9;EFFECTIVE DATE AND TERMINATION OF AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 4.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement is effective only upon the signature of duly authorized representatives of the Parties (&ldquo;Effective Date&rdquo;) and may be modified only in writing with the consent of both Parties.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 4.2 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This agreement shall not be in effect and will terminate should 60 Degree enter into a license agreement with FSURF for the technology described in Appendix A.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 4.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement shall automatically expire five (5) years after the Effective Date if no License Agreement has been executed, or sooner at the mutual will of the Parties, as expressed in writing. If a License Agreement has been executed the Agreement shall expire upon the expiration date of the License Agreement. The terms of any Non-Disclosure or Proprietary Information Agreements executed under Article 5 hereof shall survive such termination of interest by a Party hereto.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 4.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination or expiration of this Agreement will not relieve either Party of any obligation or liability which arises under this Agreement including management of any existing License Agreements including distribution of License Income before expiration or termination, including without limitation any obligation to distribute License Income. Termination shall not affect any License Agreement granted prior to termination.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The following terms shall survive expiration or termination of this Agreement, Sections 4, 5, 6, 8, 9 and 10 in their entirety.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"> <B>5.</B> <B>NON-DISCLOSURE AGREEMENTS </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Parties anticipate that under this Agreement it may be necessary for the Parties to transfer information of a proprietary nature. The Parties further agree to execute mutually agreeable Non-Disclosure Agreements if necessary, to protect such information.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">6. LIMITATION
OF LIABILITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 6.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in this Agreement shall be construed against any Party as (1) a warranty or representation as to the validity or scope of the Intellectual Property; (2) granting by implication, estoppel, or otherwise, any licenses or rights to manufacture, use, or sell intellectual property, as distinct from the rights to enter into License Agreements as set forth in Article 2 of this Agreement; (3) a requirement to file any patent applications, or maintain any patents in force; (4) an obligation to bring or prosecute actions against third parties; (5) an obligation to furnish any manufacturing or technical information or technical assistance; or (6) conferring any immunity from or defenses under antitrust laws, patent misuse laws, or any other state or federal law.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">7. EXCHANGE OF
INFORMATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any notice or payment given to either Party pursuant to the terms of this Agreement will be deemed to have been properly given and to be effective on the date of:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 144.05pt"></TD><TD STYLE="width: 18pt">a.</TD><TD>delivery if delivered in person;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 144.05pt"></TD><TD STYLE="width: 18pt">b.</TD><TD>mailing if mailed by first-class certified mail; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 144.05pt"></TD><TD STYLE="width: 18pt">c.</TD><TD>mailing if mailed by any express carrier service that requires the recipient to sign the documents demonstrating the delivery of such
notice of payment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">to the respective addresses provided in Paragraph
7.2 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All notices, correspondence, and/or transmittal of information shall be addressed as follows:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-indent: 0cm">&#9;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-indent: 0cm"><B><U>For 60 Degree, Inc.:</U></B></TD>
    <TD STYLE="width: 45%; text-indent: 0cm"><B><U>For FSURF:</U></B></TD>
    <TD STYLE="width: 5%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0cm"><I>Mailing and Courier Address:</I></TD>
    <TD STYLE="text-indent: 0cm"><I>Mailing and Courier Address: </I></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">Chief Executive Officer </TD>
    <TD STYLE="text-indent: 0cm">President, FSURF </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">Attn: Geoff Dow</TD>
    <TD STYLE="text-indent: 0cm">Attn: Laurel Fulkerson </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">1025 Connecticut Ave. NW, Suite 1000 </TD>
    <TD STYLE="text-indent: 0cm">2000 Levy Ave., Suite 351 </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">Washington D.C. 20036</TD>
    <TD STYLE="text-indent: 0cm">Tallahassee, FL 32310 </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">Telephone:&nbsp;&nbsp;(240) 351-1167</TD>
    <TD STYLE="text-indent: 0cm">Telephone: (850) 644-8650 </TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">Facsimile:&nbsp;&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">Facsimile:&nbsp;&nbsp;(850) 644-3658 </TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">8. GOVERNING
LAW/ENFORCEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt">THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF FLORIDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0cm"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">9. PUBLICITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">9.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neither Party shall use, or grant the right to
use, the name or insignia of the other Party or the name of any staff member, officer, employee or student of the other Party or any adaptation
thereof in any advertising, promotional or sales literature, publicity or in any document employed to obtain funds (except as may be required
under SEC stock registration requirements) without the prior written approval of the Party or individual whose name is to be used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">10. U.S. GOVERNMENT
INTERESTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">Nothing in this Agreement shall be construed to limit
in any way the rights of the U.S. Government or other state or local government organizations under applicable federal, state or local
regulations, rules or laws. Each party shall be separately responsible for complying with all reporting and other requirements of any
governmental entity with an interest in the joint inventions or joint patent rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm"><B>11. INTEGRATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">The foregoing contains the entire Agreement between
the Parties, and supersedes any prior oral or written agreements, commitments, understandings, or communications with respect to the subject
matter of the Agreement. No amendment or modification of this Agreement shall be effective unless set forth in writing by duly authorized
representatives of each Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">IN WITNESS WHEREOF, the Parties to this Agreement have
executed this Agreement in duplicate originals, by their respective officers on the day and year hereinafter written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-indent: 0cm">Signature:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0in; width: 45%; text-indent: 0cm">/s/ Geoff Dow</TD>
    <TD STYLE="width: 50%; text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0cm">Geoff Dow</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-indent: 0cm; text-underline-color: black">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: normal; text-indent: 0cm; text-underline-color: black">Chief Executive Officer </TD>
    <TD STYLE="font-weight: normal; text-indent: 0cm; text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm">Date<U STYLE="text-decoration: none">: </U></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-indent: 0cm">2/11/2021 6:31 AM PST</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-indent: 0cm"><B><U>Florida State University Research Foundation, Inc.</U>&nbsp;&nbsp;</B></TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm"></TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm">Signature:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0cm">&nbsp;/s/ Laurel Fulkerson</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm">Name:</TD>
    <TD STYLE="text-indent: 0cm"><U>Laurel Fulkerson </U></TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: normal; text-indent: 0cm; text-underline-color: black">Title:</TD>
    <TD STYLE="font-weight: normal; text-indent: 0cm; text-underline-color: black">President</TD>
    <TD STYLE="font-weight: normal; text-indent: 0cm; text-underline-color: black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0cm">Date<U STYLE="text-decoration: none">:</U></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0cm">2/15/2021  2:02 PM EST</TD>
    <TD STYLE="text-indent: 0cm">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0cm">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0cm"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><B>APPENDIX A </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">INTELLECTUAL
PROPERTY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt"><U>FSU Contribution</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">Technology 20-037: Treatment of COVID19 Infections
with Castanospermine</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">Provisional patent application 62/979,855 and US and
foreign patent applications and issued patents based on this Provisional patent application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt"><U>Sixty Degree Pharmaceuticals Contribution</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -0.5pt">In vitro susceptibility data for castanospermine and
celgosivir against respiratory viruses including SARS-CoV-2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt"><B>APPENDIX B </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0pt">ROYALTY-SHARING/
DISTRIBUTION FORMULA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm"><U>Distribution of License Income </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5pt">After deduction of a five percent
(5%) administrative fee by FSURF, capped at fifteen thousand dollars ($15,000) annually, and reimbursement of Patent Prosecution Expenses,
60 Degree shall receive Twenty percent (20%) of License Income and FSURF? shall receive eighty percent (80%) of License Income. Payments
of License Income shall be paid in U.S. dollars quarterly each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0cm">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>23
<FILENAME>cm270_ex10-20.htm
<DESCRIPTION>EXHIBIT 10.20
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.20</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXCLUSIVE LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">This <B>EXCLUSIVE LICENSE AGREEMENT (&ldquo;Agreement&rdquo;) </B>is made
on the 15th day of September 2016 between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NATIONAL UNIVERSITY OF SINGAPORE, </B>(Company
Registration Number: 200604346E), a company limited by guarantee incorporated in Singapore, having its registered address at 21 Lower
Kent Ridge Road, Singapore 119077 <B>(&ldquo;NUS&rdquo; </B>which expression shall include its successors and assigns)of the first part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>SINGAPORE HEALTH SERVICES PTE LTD </B>(Company
Registration Number: 200002698Z), a company incorporated in Singapore, having its registered address at 31 Third Hospital Avenue #03-03,
Singapore 168753 <B>(&ldquo;SHS&rdquo; </B>which expression shall include its successors and assigns) of the second part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(NUS and SHS hereinafter collectively referred to as <B>&ldquo;Licensor&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">60&deg; <B>PHARMACEUTICALS, LLC, </B>an American company
having its registered office address at 1025 Connecticut Avenue NW, Suite 1000, Washington DC, USA 20036 (hereinafter referred to as &ldquo;60P&rdquo;
which expression shall include its successors and assigns) of the third part</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>60P AUSTRALIA PTY LTD </B>(Company Registration
No. 167060219) a company incorporated in Australia and having its registered office at 105 North Steyne Manly New South Wales 2095, <B>(&ldquo;60P
Australia&rdquo; </B>which expression shall include its successors and assigns) of the fourth part</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(60P </B>and <B>60P Australia </B>hereinafter collectively referred
to as <B>&ldquo;Licensee&rdquo;).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in"><B>A.</B></TD><TD STYLE="text-align: justify"><B>NUS, SHS, 60P, </B>and <B>60P Australia
                                            </B>have agreed that all <B>Patent Rights </B>as described in <B>Schedule 2 </B>are owned
                                            as legal and equitable owners in the following proportions [i.e. NUS owns<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="background-color: Navy">&nbsp;</FONT>&nbsp;%;
                                            SHS owns<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;</FONT> %; 60P owns<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;
                                            </FONT>% and 60P Australia owns %].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><B>B.</B></TD><TD STYLE="text-align: justify"><B>Licensor </B>has the right to grant licenses under its share
of the said <B>Patent Rights.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left"><B>D.</B></TD><TD STYLE="text-align: justify"><B>Licensee </B>is interested in obtaining and <B>Licensor </B>is
desirous of granting an exclusive, sub&nbsp;licensable license from <B>Licensor </B>in respect of <B>Licensor&rsquo;s </B>share of <B>the
Patent Rights </B>to develop, market and sell <B>Licensed Products </B>in the <B>Field of Use </B>in the <B>Territory </B>in accordance
with the terms of this Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOW, THEREFORE, in consideration of the premises and
the mutual covenants contained herein, <B>Licensor </B>and <B>Licensee </B>(hereinafter collectively referred to as <B>&ldquo;Parties&rdquo;
</B>and singularly as <B>&ldquo;Party&rdquo;) </B>hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify"><B>DEFINITIONS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In this Agreement, unless the context otherwise requires, the following
expressions have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Academic</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Purposes</B></P></TD>
    <TD STYLE="text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 78%">
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">academic research (including sponsored research),scholarly
publications, educational purposes, and medical services.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Affiliate</B></FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, with respect to any entity, any other entity directly or indirectly controlling, controlled by, or under common control with, such entity. The expression &quot;control&quot; (including its correlative meanings, &quot;controlled by&quot;, &quot;controlling&quot; and &quot;under common control with&quot;) shall mean, with respect to a corporation, the right to exercise, directly or indirectly, more than 50 per cent, of the voting rights attributable to the shares of the controlled corporation and, with respect to any entity other than a corporation, the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such entity.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Confidential</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Information</B></P></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">any information disclosed by one <B>Party </B>to the other&nbsp;<B>Party
</B>in any form, which, if disclosed in tangible form, is marked at the time of disclosure as being confidential or proprietary or with
words of similar import, and if disclosed orally or visually or in other intangible form, is described as confidential at the time of
such disclosure and confirmed in writing as confidential within thirty (30) days of such disclosure.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective Date</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15 September 2016</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Field of Use</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic and prophylactic use for human and veterinary diseases.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">exclusive, sub-licensable and transferable license in&nbsp;respect of the
<B>Patent Rights </B>to develop, manufacture, market and sell products worldwide.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Licensee&rsquo;s</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Improvements</B></P></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any modifications, additions, &nbsp;alterations,enhancements, upgrades or new versions made by <B>Licensee </B>of the <B>Invention </B>under the <B>Patent Rights, </B>including without limitation those made by <B>Licensee </B>under <B>Licensee&rsquo;s </B>sponsorship research programs other than <B>Licensor Improvements, NUS Improvements, SHS Improvements </B>and/or and <B>Joint Improvements.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Invention</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the invention as described in <B>Schedule 1 Part A.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inventors</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satoru Watanabe, Kitti Wing Ki Chan, Geoffrey Dow,Eng Eong Ooi, Jenny G Low, and Subhash Vasudevan.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Licensed</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Process(es)</B></P></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">any and all processes or methods that incorporate,utilize or are made
with the use of the <B>Invention </B>or whose use or practice, but for the rights granted <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hereunder,
would constitute an infringement of any claim within the <B>Patent Rights.</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensed Product(s)</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 78%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(a)&nbsp;&nbsp;any product: (i) which incorporates, utilizes or is made
    with the use of the <B>Invention; </B>or, (ii) which, but for the rights granted hereunder, the manufacture, use or sale thereof would
    constitute an infringement of any claim within the <B>Patent Rights;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Or</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(b)&nbsp;&nbsp;any article, composition, apparatus, chemical, substance
    or any other materials made, used or sold for use with a <B>Licensed Process.</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Licensee&rsquo;s</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Representative</B></P></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any agent who is engaged by <B>Licensee </B>to act on behalf of the <B>Licensee, </B>for the purposes of this Agreement, to provide certain services, including the selling of <B>Licensed Products, </B>but shall not include <B>SubLicensees.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gross Sales</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the gross amount of monies, cash, or non-cash consideration equivalent received for the treatment or prophylaxis of dengue in humans only, with the exception of data, drug, drug product, or in kind services or access to any of the foregoing provided by third parties, that is paid to <B>Licensee </B>and/or its <B>Related Company </B>for the <B>Licensed Products, Licensed Processes </B>or any products manufactured by <B>Licensee </B>that contain celgosivir. by sale or any other mode of transfer in the countries considered by the World Bank to be &ldquo;high income&rdquo; (ie per capita income over US $12,615) in 2012 (as annexed in <B>Schedule 5), </B>and such other countries as may be added by the World Bank from time to time <B>BUT EXCLUDING ALL </B>sales made which are intended for non-profit NonGovernment Organisations and charities worldwide notwithstanding that such sales are made in high income countries and <B>Licensee&rsquo;s </B>subsidiaries and any <B>Sub-licensing Revenue.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joint Improvements</B></FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">any modifications, addition, alterations, enhancements, upgrades or new
    versions of the <B>Invention </B>under the <B>Patent Rights </B>made through any consultancy agreement or arrangement between:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the <B>Licensee; </B>and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any current or past employee, student or intern of NUS who terminated
    his employment with NUS within twelve (12) months after entering into the consultancy arrangement; and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any current or past employee, student or intern of SHS who terminated
    his employment&nbsp;with SHS within twelve (12) months after entering into the consultancy arrangement.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensor Improvements</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any modifications, addition, alterations, enhancements, upgrades or new versions of the <B>Invention </B>under the <B>Patent Rights </B>made by <B>NUS </B>and/or <B>SHS.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUS Improvements</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any modifications, addition, alterations, enhancements, upgrades or new versions of the <B>Invention </B>under the <B>Patent Rights </B>made through any consultancy agreement or arrangement between the <B>Licensee </B>and any current or past employee, student or intern of NUS who terminated his employment with NUS within twelve (12) months after entering into the consultancy arrangement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patents</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all or any of the patents and all continuations, divisions, and reissues thereof, and any corresponding foreign patent applications and any patents, or other equivalent foreign patent rights issuing, granted, or registered thereon granted pursuant to the <B>Patent Applications, </B>short particulars of which are set out in <B>Schedule 2 Part A.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent Applications</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all applications for patents and rights of a similar nature, filed and to be filed, in respect of the <B>Invention, </B>including, but not limited to, patent applications the short particulars of which are set out in <B>Schedule 2 Part B, </B>and/or any <B>Joint Improvements, </B>and in the event of any amendment of or a division of the same, such amended applications or divided applications.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent Rights</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights under all <B>Patents </B>and <B>Patent Applications.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Phase III</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Clinical Trial</B></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A study in humans of the safety, dose ranging and efficacy of <B>a Licensed Product, </B>which is prospectively designed to generate sufficient data (if successful) to commence pivotal clinical trials, as further defined in 21 C.F.R. &sect; 312.21(b), or a similar study in a country other than the United States.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulatory Approval</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means the approval, registration, license, or authorization of a regulatory authority necessary for the manufacture, distribution, use, promotion and sale of a pharmaceutical or biological product for one or more indications in a country or other regulatory jurisdiction in the Field.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related Company</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any entity which directly or indirectly controls, is controlled by, or is under common control with <B>Licensee, </B>including <B>Licensee's </B>related corporations within the meaning of Section 6 of the Singapore Companies Act (Cap. 50).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<IMG SRC="cm270_ex10-20img01.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHS Improvements</B></FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify; width: 78%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any modifications, addition, alterations, enhancements, upgrades or new versions of the <B>Invention </B>under the <B>Patent Rights </B>made through any consultancy agreement or arrangement between the <B>Licensee </B>and any current or past employee, student or intern of SHS who terminated his employment with SHS within twelve (12) months after entering into the consultancy arrangement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sub-licensing Revenue</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all upfront fees, sub-licensing fees, royalties and all other amounts in cash and cash equivalent which are paid to the <B>Licensee </B>by any <B>Sub-Licensee </B>of its rights hereunder, with the exception of data, drug, drug product, or in kind services or access to any of the foregoing provided by third parties and any revenue paid to the <B>Licensee </B>by any <B>Sub-Licensee </B>in relation to treatment or prophylaxis of dengue in humans.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sub-Licensee</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any person, company or other legal entity, other than <B>Licensee, </B>who has the right, granted by <B>Licensee, </B>to make, have made, use, sell or import for sale the <B>Licensed Product </B>or <B>Licensed Process.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Technology Rights</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all technical information, formulations, know-how, processes, procedures, compositions, devices, methods, formulae, materials, tests, data, designs, other information and <B>Confidential Information </B>related to the <B>Patent Rights, </B>that are not described by <B>Patent Rights </B>but that are necessary for practicing the invention covered by the <B>Patent Rights.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the period during which this Agreement is in force pursuant to <B>Section 6.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Territory</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Worldwide</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>INTERPRETATION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left">2.1</TD><TD STYLE="text-align: justify">In this Agreement:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Words importing the singular shall include the plural and vice versa, and words that are gender specific or neuter shall include the other gender and the neuter.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">References to a person shall be construed as references to an individual, corporation, company, firm, incorporated body of persons of any country, or any agency, thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The headings in this Agreement are for convenience only and shall not affect its interpretation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 49px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to Sections and Schedules refer, unless the context otherwise requires, to Sections and Schedules of this Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 130.5pt; text-indent: -58pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 130.5pt; text-indent: -58pt"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 130.5pt; text-indent: -58pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 130.5pt; text-indent: -58pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 49px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references to statutes or statutory provisions shall be taken to be a reference to the statutes or provisions as revised, amended, supplemented
or re-enacted from time to time, and shall include any subsidiary legislation made thereunder.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>GRANT OF LICENSE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensor
</B>hereby grants to <B>Licensee </B>and <B>Licensee hereby </B>accepts, subject to the terms and conditions hereof, and subject to <B>Licensor&rsquo;s
</B>rights under <B>Section 3.2 </B>an exclusive, sublicensable, license of the <B>Licensor&rsquo;s </B>rights in the <B>Patent Rights
</B>to make, use, sell, offer to sell, and import any <B>Licensed Products </B>in the <B>Field of Use </B>in the <B>Territory </B>during
the <B>Term.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nothing
in this Agreement shall prejudice <B>NUS' </B>and <B>SHS&rsquo; </B>right to use / practice the <B>Patent Rights </B>for <B>Academic
Purposes.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensor
</B>shall be obliged under this Agreement to render reasonable technical assistance, or support, or provide training to <B>60P, </B>for
purposes of using / practicing the <B>Patent Rights </B>granted hereunder, such assistance or support not to exceed 10 hours per month.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall own all rights, title and interests in and to all of <B>Licensee&rsquo;s Improvements. </B>For clarity, neither <B>NUS </B>nor
<B>SHS </B>has any rights to the <B>Licensee&rsquo;s Improvements </B>and no <B>Royalty, </B>fee or any fees cost or expense shall be
payable to <B>NUS </B>and/or <B>SHS </B>in respect of <B>Licensee&rsquo;s Improvements.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>agrees that all rights, title and interests in and to all <B>Joint Improvements </B>shall be co-owned by <B>60P, 60P Australia, NUS,
</B>and <B>SHS </B>as tenants in common in the following proportions: <B>60P Australia: <FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;%,
60P: <FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</B></FONT>%, NUS:&nbsp;<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;</FONT>&nbsp;%,
SHS:&nbsp;<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>%</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall be entitled to use and practice <B>Joint Improvements </B>and such use and practice shall be subject to the same terms and
conditions as the use and practice of <B>Patent Rights </B>licensed under this Agreement unless terms and conditions for the use and
practice of <B>Joint Improvements </B>are separately negotiated and agreed in writing by <B>Licensor </B>and <B>Licensee.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUS
</B>hereby grants to Licensee a right of first refusal to negotiate a separate license agreement for any <B>NUS Improvements. </B>Ownership
of all rights, title and interest in and to all <B>NUS Improvements </B>shall be determined by inventive contributions</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHS
</B>hereby grants to <B>Licensee </B>a right of first refusal to negotiate a separate license agreement for any <B>SHS Improvements.
</B>Ownership of all rights, title and interest in and to all <B>SHS Improvements </B>shall be determined by inventive contributions.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to <B>Sections 3.2 and 3.4</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee </B>hereby grants to NUS and SHS a non-exclusive, royalty-free license under all rights protecting <B>Licensee&rsquo;s Improvements </B>to practice the same for <B>Academic Purposes </B>during the <B>Term </B>of this Agreement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee </B>hereby grants to NUS and SHS a non-exclusive, royalty-free license under all <B>Licensee&rsquo;s </B>share in the rights protecting <B>Joint Improvements </B>to practise the same for <B>Academic Purposes </B>during the <B>Term </B>of this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: right; text-indent: -35pt"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left">3.10</TD><TD STYLE="text-align: justify">Subject always to the written consent of the <B>Licensee</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 46px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee </B>further grants to <B>NUS </B>and <B>SHS </B>the non-exclusive, royalty-free right to sublicense the <B>Licensee&rsquo;s Improvements </B>to other non-profit academic institutions and to SHS&rsquo;s <B>Affiliates </B>for <B>Academic Purposes; </B>and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 46px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee </B>further grants to <B>NUS </B>and <B>SHS </B>the non-exclusive, royalty-free right to sublicense the <B>Licensee&rsquo;s </B>share in the <B>Joint Improvements </B>to other non-profit academic institutions and to SHS&rsquo;s <B>Affiliates </B>for <B>Academic Purposes.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><B>3A.</B></TD><TD STYLE="text-align: justify"><B>NOT IN USE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>NOT IN USE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>SUB-LICENCES</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.1</B></TD><TD STYLE="text-align: justify"><B>60P </B>and <B>60P Australia </B>shall each have the right to grant sub-licences of the <B>Patent Rights
</B>under its license in this Agreement to <B>Sub-licensees </B>on an arm&rsquo;s length basis, provided that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 35pt">i.</TD><TD STYLE="text-align: justify">neither <B>60P </B>nor <B>60P Australia </B>shall grant any rights to its <B>Sub-licensees </B>which are
inconsistent with the rights granted to and obligations of the <B>Licensee </B>hereunder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 35pt">ii</TD><TD STYLE="text-align: justify">any act or omission of a <B>Sub-licensee </B>which would be a breach of this Agreement if performed by
the <B>Licensee </B>shall be deemed to be a breach by <B>Licensee </B>of this Agreement, unless such breach, if capable of remedy, shall
have been remedied by the <B>Sub-licensee </B>within a period of ninety (90) days after notice of that breach has been provided by <B>Licensor
</B>to <B>60P </B>in writing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 46px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each sub-licence granted by <B>60P </B>and/or <B>60P Australia </B>shall include an audit right in favour of the <B>Licensor </B>of at least the same scope as provided in <B>Section 9.1(c) </B>hereof with respect to the Licensee;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 46px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each sub-licence granted by <B>60P </B>and/or <B>60P Australia </B>shall include an indemnity clause from the <B>Sub-licensee </B>for costs, claims, damages or expenses directly incurred or suffered by the <B>Licensor, </B>or for which the <B>Licensor </B>may become liable, as a result of the default or negligence of such <B>Sub-licensee;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 35pt">v</TD><TD STYLE="text-align: justify">upon the termination of this Agreement under <B>Section 19, </B>the <B>Licensor </B>shall have the right
and option to require an assignment to it or its nominee of each sublicence between <B>60P </B>and/or <B>60P Australia </B>and its/their
<B>Sub-licensees, </B>and for these purposes, both <B>60P </B>and <B>60P Australia </B>shall procure that all sub-licences granted hereunder
shall contain express terms that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 107pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 98px">&nbsp;</TD>
    <TD STYLE="width: 46px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">permit the assignment of the sub-license to the <B>Licensor </B>under the circumstances specified in this <B>Section 5.1(v) </B>and require <B>60P </B>and/or <B>60P Australia </B>and <B>Sub-licensee </B>to consent to such assignment;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: 1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 98px"></TD><TD STYLE="width: 46px; text-align: left">(b)</TD><TD STYLE="text-align: justify">in the event that the <B>Licensor </B>does not exercise its
option to require an assignment under this <B>Section 5.1(v), </B>or if for any reason the assignment cannot be effected, the sub-licence agreement
will automatically be terminated; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 109pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 98px"></TD><TD STYLE="width: 46px; text-align: left">(c)</TD><TD STYLE="text-align: justify"><B>60P, 60P Australia </B>and the <B>Sub-licensee </B>in question
shall bear their own expenses in relation to such assignment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60P
</B>shall within thirty (30) days of the grant of any sub-licence (which shall be in writing) provide the <B>Licensor </B>with a true
copy of the sub-licence at <B>60P&rsquo;s </B>own expense.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
sub-licences granted to any <B>Sub-licensee </B>by <B>60P </B>and/or <B>60P Australia </B>shall not be transferable and shall not permit
further sub-licensing of the <B>Patent Rights, Invention </B>or <B>Technology </B>by the <B>Sub-licensee.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Parties agree that <B>Sub-Licensing Revenue </B>received from a <B>Related Company </B>of <B>60P </B>and/or <B>60P Australia </B>shall
not be considered to be <B>Sub-Licensing Revenue </B>for the purposes of <B>Section 8.3 </B>herein.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 48px; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>COMMENCEMENT DATE AND TERM</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall come into effect on the date that this Agreement is signed and shall continue in force until the expiration of the last
to expire of any patents under the <B>Patent Rights </B>unless terminated earlier in accordance with this Agreement <B>(&ldquo;Term&rdquo;).</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;OBLIGATIONS
OF LICENSEE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>hereby undertakes and agrees with <B>Licensor </B>that it will at all times during the <B>Term </B>observe and perform the terms
and conditions set out in this Agreement and in particular shall:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">use diligent efforts to effect introduction of the <B>Licensed Products </B>into the commercial market as soon as practicable, consistent with reasonable and sound business practice and judgment in order the achieve the <B>Performance Objectives </B>by the respective <B>Dates of Achievement </B>specified in <B>Section </B>7.2;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deliver to <B>NUS, </B>such part of the <B>Licensee&rsquo;s </B>annual audited financial statements which pertain to the <B>Gross Sales </B>of the <B>Licensed Products </B>and <B>Licensed Processes </B>and <B>Sub-licensing Revenue, </B>at the end of the first quarter following the end of each financial year of <B>Licensee </B>during the <B>Term. </B>For clarity, <B>NUS </B>is only entitled to view and review (if necessary) <B>Licensee&rsquo;s </B>financial statements which pertain to the <B>Gross Sales </B>of the <B>Licensed Products </B>and <B>Sub-licensing Revenue </B>and no other financial statements of <B>Licensee </B>whatsoever.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">deliver to <B>NUS, Licensee&rsquo;s </B>annual budget for the subsequent financial year as well as a technical/development update, no later than the end of <B>Licensee&rsquo;s </B>financial year commencing the first year from the introduction of the <B>Licensed Products </B>into the commercial market in the <B>Territory </B>or <B>31 December 2014 </B>whichever is the later and thereafter based on the <B>Licensee&rsquo;s </B>financial year.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>also undertakes to meet the following <B>Performance Objectives </B>by the respective <B>Dates of Achievement </B>whether by the
<B>Licensee, </B>the <B>Sub-Licensees </B>or the <B>Licensee&rsquo;s </B>assignees:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; border: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Performance Objectives:</B></FONT></TD>
    <TD STYLE="width: 30%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date of Achievement</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Commencement of a Phase II Clinical Trial involving</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Licensed Product or Process</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">3 years from <B>Effective</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Date</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Commencement of a Phase III Clinical Trial involving</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Licensed Product </B>or <B>Process</B></P></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years from <B>Effective Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission for Regulatory Approval involving <B>Licensed Product </B>or <B>Licensed Process</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years from Completion of Phase III Clinical Program</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market Launch </B>of <B>Licensed Product </B>or <B>Licensed Process</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9 months from the date of Regulatory Approval involving <B>Licensed Product or Licensed Process.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Within
twelve (12) months the date of <B>Market Launch of Licensed Product </B>or <B>Licensed Process, Licensee </B>and <B>Licensor </B>shall
have good faith discussions on projected sales of the <B>Licensed Products </B>for the next three (3) years and mutually agree on the
performance objectives of Licensee.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
<B>Licensee </B>fails to fulfill the performance objectives mutually agreed between <B>Licensee </B>and <B>Licensor </B>pursuant to Section
<B>7.2 </B>above, the <B>Parties </B>shall have good faith discussions on the reasons for such failure to meet the mutually agreed performance
objectives. If <B>Licensee </B>is unable to provide any valid reasons reasonably satisfactory to <B>Licensor, Licensor </B>shall grant
to <B>Licensee </B>a further grace period of <B>9 months </B>for each of the respective dates of achievement set out in <B>Section </B>7.2
and in the event that <B>Licensee </B>is still unable to meet the respective dates of achievement, <B>Licensors, </B>at its option, have
the right, by notice in writing to <B>Licensee, </B>to immediately: (i) terminate the exclusivity, sublicensing right and transferability
of the <B>License </B>granted under <B>Section </B>3.1 and grant licenses to other third party licensees in the <B>Territory; </B>or
(ii) terminate this Agreement pursuant to <B>Section 19.1(a).</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>FINANCIAL PROVISIONS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            consideration for the exclusive sub-licensable grant of <B>the License </B>under the <B>Patent
                                            Rights </B>by <B>Licensor </B>to <B>Lic<U>ensee </U></B><U>unde</U>r <B>Section 3, 60P </B>shall
                                            pay to <B>NUS </B>an agreed non- refundable upfront fee of <B>S$<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>(&ldquo;Upfront
                                            Fee&rdquo;) </B>in two (2) instalments as follows:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35pt"></TD><TD STYLE="width: 36.75pt">(a)</TD><TD STYLE="text-align: justify">the first instalment of <B>S$<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            </FONT>upon the signing of this Agreement; and</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71.75pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt"></TD><TD STYLE="width: 36.75pt; text-align: left">(b)</TD><TD STYLE="text-align: justify">the second instalment
                                            of <B>S$</B><FONT STYLE="background-color: Black"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>upon enrolment of the first volunteer in a Phase II Clinical Trial of the <B>Licensed
                                            Product </B>or 3 years from the <B>Effective </B>Date, whichever is earlier.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the <B>Upfront </B>Fee under <B>Section 8.1, 60P </B>shall pay to <B>NUS </B>during the <B>Term </B>of this Agreement, the
<U>greater</U> of the amounts in Section 8.2(a) and <B>Section 8.2(b) </B>below, which, unless otherwise stated, shall be payable no
later than within ten (10) business days of the start of each calendar year during the <B>Term </B>of this <B>Agreement:</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5pt; text-indent: 35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35.5pt"></TD><TD STYLE="width: 18pt">(a)</TD><TD>royalty (&ldquo;Royalty&rdquo;) at the rate of <FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;%
                                            of <B>Gross Sales; </B>or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">minimum annual royalty for each calendar year during the <B>Term ( Minimum Annual Royalty&quot;) </B>as follows :</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; width: 43%; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Minimum Annual Royalty</B></FONT></TD>
    <TD STYLE="width: 50%; border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dates</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: black 1pt solid; border-left: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><B>S$<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting on the <B>Effective Date </B>and ending on 31 December 2022.</FONT></TD></TR>
  <TR STYLE="background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><B>S$<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></B></TD>
    <TD STYLE="vertical-align: bottom; border: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting on 1 January 2023 and ending at the end of the Term of this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">8.3</TD><TD STYLE="text-align: justify"><B>60P</B> shall further pay to <B>NUS:</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of all <B>Sub-licensing Revenue </B>where <B>Licensee </B>has not commenced a Phase III clinical trial on the <B>Licensed Products </B>before sub-licensing its rights under the <B>Section 3.1 </B>to its <B>Sub-licensees; </B>or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of all <B>Sub-licensing Revenue where Licensee </B>has commenced a Phase III clinical trial on the <B>Licensed Products </B>before sub-licensing its rights under <B>Section 3.1 </B>to its <B>Sub-Licensees.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<B>Upfront Fee, </B>the <B>Royalty </B>and all other sums payable under this Agreement shall be paid in Singapore Dollars in favour of
<B>NUS </B>in cleared funds to such bank account or in such other manner as NUS may specify from time to time to <B>Licensee </B>without
any set-off, deduction or withholding of taxes, charges and other duties. Where the <B>Upfront Fee </B>and/or <B>Royalty </B>and/or any
other sums payable under this Agreement are subject to goods and services taxes <B>(&ldquo;GST&rdquo;), these GST </B>shall be borne
by the <B>Licensee. Licensee </B>agrees to hold harmless from, and indemnify <B>Licensor </B>against all liabilities, costs, damages
suffered by <B>Licensor </B>of whatever nature resulting from 60P's failure duly and timely to pay and discharge its liability for any
<B>GST.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
<B>60P </B>fails to pay in full to <B>NUS, </B>the <B>Upfront </B>Fee and/or <B>Royalty </B>and/or any other sums payable under this
Agreement by their respective due dates, the amount outstanding shall bear interest, both before and after any judgment, at the rate
of percent (%) per month, from such date until the said amounts are paid in full to <B>Licensor.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>ACCOUNTS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">9.1</TD><TD STYLE="text-align: justify"><B>60P </B>shall:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide financial statements pertaining to the Gross Sales of the <B>Licensed Products </B>with accompanying <B>Royalty </B>under this Agreement, showing all items of account from which such Royalty and other payment are calculated, such statements to be certified by an authorized officer of 60P as properly reflecting all amounts due to <B>Licensor </B>in accordance with the relevant provisions under this Agreement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">keep true, accurate and complete accounts and records in sufficient detail to enable the amount of <B>Royalty </B>and other sums payable under this Agreement to be determined by <B>Licensor;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the reasonable request of <B>Licensor </B>from time to time, but no more than once annually, and upon not less than ten (10) days&rsquo; prior written notice, allow NUS or its agent (or enable NUS or its agent), at NUS&rsquo;s expense, to inspect, audit and copy those accounts and records pertaining to the items shown on the statements provided under <B>Section 7.1(b)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
following any inspection and audit pursuant to <B>Section 9.1(c) </B>which audit shall be limited to the documents in respect of the
<B>Gross Sales </B>of the <B>Licensed Products </B>and <B>Sublicensing Revenue, NUS </B>discovers a discrepancy, in <B>NUS&rsquo; </B>disfavour,
between the amount of <B>Royalty </B>and other sums actually paid by <B>60P </B>and those which should have been payable under this Agreement,
which is in excess ol'^^ percent %) of those that should have been payable under this Agreement, <B>60P </B>shall, within seven (7) days
of the date of <B>NUS&rsquo; </B>notification thereof, reimburse NUS for any such deficiency and for any professional fees and expenses
incurred by NUS for such audit and inspection.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
provisions of this <B>Section 9 </B>shall remain in full force and effect after the termination of this Agreement for any reason until
the settlement of all subsisting claims of <B>NUS </B>under this Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSECUTION
OF PATENT APPLICATIONS AND MAINTENANCE OF PATENTS</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall not do anything which might bring into question <B>NUS&rsquo; and SHS&rsquo; </B>respective ownership of their share of the
intellectual property rights in and relating to the <B>Patent Rights </B>or their validity.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60P
Australia </B>shall, from the <B>Effective Date, </B>be responsible for the management and further prosecution of the <B>Patent Rights.
</B>All such <B>Patent Rights </B>shall be in the names of <B>NUS, SHS, 60P </B>and <B>60P Australia </B>as the proprietors thereof.
<B>60P Australia </B>shall:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be responsible for all costs, expenses and fees relating to the preparation, filing, prosecution and maintenance of such <B>Patent Rights (&ldquo;Patent Costs&rdquo;) </B>from the <B>Effective Date., </B>and reimburse NUS for any and all costs, expenses and fees relating to the preparation, filing, prosecution and maintenance of the <B>Patent Rights </B>incurred by <B>Licensor </B>from the first filing date to date immediately before the <B>Effective Date </B>of this Agreement;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek and maintain the strongest and broadest patent claims practicable in the best interest of <B>NUS, SHS, 60P </B>and <B>60P Australia </B>and use patent attorneys acceptable to <B>Licensor, </B>such acceptance not to be unreasonably withheld;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">copy <B>Licensor </B>on all patent prosecution documents and give <B>Licensor </B>reasonable opportunities to advise <B>60P Australia </B>on such preparation, filing, prosecution and maintenance;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">keep <B>Licensor </B>informed of the status of such <B>Patent Rights </B>from time to time, and shall promptly furnish <B>Licensor </B>with copies of all grants or certificates of registration of any <B>Patent;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not abandon or allow to lapse any such <B>Patent Rights, </B>or to amend or re-file the patent specifications of any <B>Patent Applications </B>within the scope of the license granted under this Agreement, without the prior written consent of <B>Licensor;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do all such other acts and things as may be necessary, as <B>Licensor </B>may reasonably request, at Licensee&rsquo;s cost and expense, to assist or enable Licensor and Licensee to maintain the <B>Patent Rights.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensor
</B>shall, at any time and from time to time, at <B>Licensee&rsquo;s </B>cost and expense, execute and do all such assurances, acts and
things, and execute all such documents as <B>60P</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1pt"><B>Australia </B>may reasonably
require to prosecute each of the <B>Patent Applications </B>to grant and to maintain each of the <B>Patents </B>in force.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is hereby agreed and understood that, notwithstanding <B>Section 10.2, 60P Australia </B>shall, by giving three (3) months&rsquo; written
notice to <B>Licensor </B>prior to the relevant deadline for the payment of any fees, have the right and option not to pay for the prosecution
of any <B>Patent Application </B>or patent maintenance in any country determined by <B>60P Australia. </B>If <B>60P Australia </B>elects
not to pay for the prosecution of any such <B>Patent Application </B>in a particular country or countries as aforesaid:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the license granted pursuant to this Agreement in respect of the country or countries of which <B>60P Australia </B>has made the election, shall automatically terminate and revert to <B>Licensor.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon receipt of such notice pursuant to <B>Section 10.4, Licensor </B>may prosecute the <B>Patent Applications </B>in such country or countries in respect of which <B>60P Australia </B>has made the election, at its own cost and expense, and notwithstanding <B>Section 3, </B>to thereafter deal with the same and the related <B>Technology Rights </B>in that country or countries as <B>Licensor </B>deems fit without having to account to <B>Licensee </B>therefor and <B>Licensee </B>shall do all such other acts and things as may be necessary, as <B>Licensor </B>may reasonably request, at <B>Licensor&rsquo;s </B>cost and expense, to assist or enable <B>Licensor </B>and <B>Licensee </B>to maintain the <B>Patent Rights.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
<B>60P Australia </B>fails to notify <B>NUS </B>of its intention to cease prosecuting any <B>Patent Applications </B>or maintaining any
<B>Patents </B>in any country pursuant to <B>Section 10.4 </B>and the <B>Patent Application </B>or the <B>Patent </B>lapses then :</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the license granted pursuant to this Agreement in respect of such country shall automatically terminate; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 49px"></TD><TD STYLE="width: 48px; text-align: left">(d)</TD><TD STYLE="text-align: justify"><B>Licensee </B>shall pay to <B>Licensors </B>a sum of&#9;which
<B>Licensor </B>and <B>Licensee </B>agree is a genuine pre-estimate of the loss suffered by <B>Licensor </B>arising from lapse of such
<B>Patent </B>or <B>Patent Application </B>in such country. For clarity, <B>Licensee </B>is neither obliged nor required to pay <B>Licensor
</B>any further sum in respect of the loss suffered by <B>Licensor </B>herein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>11.</B></TD><TD STYLE="text-align: justify"><B>FORMAL LICENSE FOR REGISTRATION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
and when required by <B>Licensee, </B>subject to the requirements of the relevant government authority of the <B>Territory, NUS </B>and
<B>SHS </B>shall execute, within thirty (30) days of the grant of a patent pursuant to any of the <B>Patent Applications, </B>a separate
formal licence document in <B>Licensee&rsquo;s </B>favour in respect of such patent for registration in all or any competent registries
within such countries as may be determined by <B>Licensee, </B>each such license to be in the form set out in <B>Schedule 3 </B>or as
nearly in such form as may be required under the laws of such country in which it is to be registered.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of such formal licenses shall operate subject to and with the benefit of all the terms of this Agreement, the terms of which shall be
deemed to be incorporated in their entirety into each of such formal licenses. In the event of any conflict in meaning between any such
formal license and the provisions of this Agreement, lhe provisions of this Agreement shall prevail.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<B>Parties </B>shall use reasonable endeavours to ensure that, to the extent permitted by relevant authorities, this Agreement shall
not form part of any public record.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the <B>Parties </B>shall, at the request of the other <B>Party, </B>execute any further document that may be necessary to:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 35pt"></TD><TD STYLE="width: 18pt">(a)</TD><TD STYLE="text-align: justify">give effect to this Agreement; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35pt">&nbsp;</TD>
    <TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">protect in any country the rights of the other Party under this Agreement and/or in relation to the <B>Patent Rights </B>from time to time; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 35pt"></TD><TD STYLE="width: 18pt; text-align: left">(c)</TD><TD STYLE="text-align: justify">procure the grant of <B>Patents </B>pursuant to each of the
<B>Patent Applications.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>12.</B></TD><TD STYLE="text-align: justify"><B>INFRINGEMENT OF PATENTS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
the <B>Effective Date, Licensee </B>shall forthwith notify <B>Licensor </B>in writing of any infringement, or suspected or threatened
infringement, of any of the <B>Patents </B>by any third party that shall at any time come to its knowledge.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>may in its sole discretion, take all appropriate steps (including all legal proceedings) as may be necessary to prevent or restrain
any infringement by a third party of any of the <B>Patents </B>and shall be responsible for all costs and fees incurred by it in the
taking of any such steps.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall not be obliged to undertake any legal action. <B>60P </B>shall indemnify <B>Licensor </B>against all costs, expenses, losses,
damages, claims and counter-claims issued or made against <B>Licensor </B>as a result of, or in the course of, such action taken by <B>Licensee
</B>under <B>Section 12.2 </B>on a full indemnity basis.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUS
</B>and <B>SHS </B>shall (at <B>60P&rsquo;s </B>cost and expense) provide or procure the provision of such assistance in taking such
steps (including any proceedings) as <B>Licensee </B>shall reasonably require.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
<B>Licensee </B>decides not to or fails to take appropriate steps to prevent or restrain any infringement by any third party of any of
the <B>Patent Rights </B>(but not otherwise), <B>Licensor </B>shall be entitled to take action to prevent or restrain such infringement.
In the event that <B>Licensor </B>decides to take action under this Section:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 46px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensor </B>shall have full control over, and shall conduct at its own cost, any such action as it deems fit;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 46px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee </B>shall, at <B>Licensor&rsquo;s </B>cost, provide or procure the provision of such assistance as <B>Licensor </B>shall reasonably require in taking such action; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 46px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensor </B>shall be entitled to retain any award of damages or other compensation obtained as a result of any such action (including any proceedings) being taken by <B>Licensor.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="text-align: left; width: 48px"><B>13.</B></TD><TD STYLE="text-align: justify"><B>INFRINGEMENT OF THIRD PARTY RIGHTS</B></TD>
</TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any proceedings are brought against <B>Licensee </B>on grounds that the use or exploitation by <B>Licensee </B>of any of the <B>Patent
Rights </B>and <B>Technology Rights </B>infringes the rights of any third party, <B>Licensee </B>shall forthwith notify <B>Licensor </B>of
the same. <B>Licensee </B>shall have the exclusive control of the defense of such proceedings.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60P
</B>shall indemnify <B>Licensor </B>and keep <B>Licensor </B>indemnified against, and hold <B>Licensor </B>harmless from, all costs,
expenses, losses, damages, claims and counter-claims issued or made against <B>Licensor </B>in respect of such proceedings in <B>Section
13.1.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">14</TD><TD STYLE="text-align: justify"><B>TRADE MARKS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall have the absolute right and discretion to manufacture, have manufactured, or use <B>Licensed Products </B>under any trade marks
designated by <B>Licensee (&ldquo;Licensee&rsquo;s Trade Marks&rdquo;) </B>provided that the <B>Licensee&rsquo;s Trade Marks </B>shall
be readily distinguishable from, and not confusingly similar to, any trade mark or trade name, whether registered or not, of <B>NUS.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUS
</B>hereby agrees that it shall have no claim, right, title or interest in or to the <B>Licensee&rsquo;s Trade Marks </B>(except where
any of such <B>Licensee&rsquo;s Trade Marks </B>is not readily distinguishable from, or is confusingly similar to, any trade mark or
trade name of <B>NUS), </B>and that all goodwill accruing thereto shall belong to <B>Licensee </B>absolutely.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall have the sole conduct of all proceedings relating to the <B>Licensee&rsquo;s Trade Marks.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall have the sole right to decide what action, if any, to take in respect of any infringement or alleged infringement of the <B>Licensee&rsquo;s
Trade Marks </B>or any other claim or counterclaim brought or threatened in respect of the use or registration of any of the <B>Licensee&rsquo;s
Trade Marks.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall not be obliged to bring or defend any proceedings in relation to the <B>Licensee&rsquo;s Trade Marks.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUS
</B>shall not be entitled to bring any proceedings in respect of any infringement or alleged infringement of any of the <B>Licensee&rsquo;s
Trade Marks.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>15.</B></TD><TD STYLE="text-align: justify"><B>CONFIDENTIALITY</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
<B>Party </B>hereby agrees to use all reasonable efforts to maintain the secrecy of any and all <B>Confidential Information </B>disclosed
to it by the other <B>Party </B>under the terms of this Agreement, or developed pursuant to this Agreement, and not to disclose, without
the express, written consent of the disclosing <B>Party, </B>such <B>Confidential Information </B>to any third party.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
receiving <B>Party </B>agrees to maintain the <B>Confidential Information </B>of the disclosing <B>Party </B>in confidence with the same
degree of care as it holds its own confidential and proprietary information and in any event with no less than a reasonable standard
of care. The receiving <B>Party </B>will use such <B>Confidential Information </B>for the performance of this Agreement only. The receiving
<B>Party </B>may disclose such <B>Confidential Information </B>on a need-to-know basis only to its directors, officers, employees, contractors,
consultants, advisors, authorised representatives, agents, investors or potential investors (each a <B>&ldquo;Representative&rdquo;,
</B>and collectively <B>&ldquo;Representatives&rdquo;) </B>who have undertaken obligations of confidentiality for the benefit of receiving
<B>Party </B>which are substantially similar to those contained in this <B>Section 15 </B>and will not disclose such <B>Confidential
Information </B>to any third party, or use the <B>Confidential Information </B>for any other purpose. The receiving <B>Party </B>undertakes
that its <B>Representatives </B>shall make use of such <B>Confidential Information </B>only for the performance of this Agreement and
receiving <B>Party </B>shall be responsible for any unauthorized use or disclosure of disclosing <B>Party&rsquo;s Confidential Information
</B>by its <B>Representatives.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
receiving <B>Party </B>shall take all reasonable steps, including, but not limited to, those steps taken to protects its own information,
data or other tangible or intangible property that it regards as proprietary or confidential, to ensure that the <B>Confidential Information
</B>of the other <B>Party </B>is not disclosed or duplicated for the use of any third <B>Party, </B>and shall take all reasonable steps
to prevent its officers and employees, or any other persons having access to the <B>Confidential Information, </B>from disclosing or
making unauthorized use of any <B>Confidential Information, </B>or from committing any acts or omissions that may result in a violation
of this Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preceding obligations of non-disclosure and the limitation on the right to use the <B>Confidential Information </B>shall not apply to
the extent that the receiving <B>Party </B>can demonstrate that the <B>Confidential Information:</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">was already in the possession or control of the receiving <B>Party </B>prior to the time of disclosure by disclosing <B>Party, </B>as evidenced by written records; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">was at the time of disclosure by the disclosing <B>Party </B>or thereafter becomes public knowledge through no fault or omission of the receiving Party; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is lawfully obtained by the receiving <B>Party </B>from a third party under no obligation of confidentiality to the disclosing <B>Party; </B>or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is developed by the receiving <B>Party </B>independently of the <B>Confidential Information, </B>as evidenced by written records; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is required to be disclosed by court rule or governmental law or regulation, including for the purposes of seeking regulatory advice and marketing authorization from national health authorities provided that the receiving <B>Party </B>gives the disclosing <B>Party </B>prompt notice of any such requirement and cooperated with the disclosing <B>Party </B>in attempting to limit such disclosure; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">was disclosed by the receiving <B>Party </B>with the disclosing <B>Party&rsquo;s </B>prior written approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
to, and all rights emanating from the ownership of, all <B>Confidential Information </B>disclosed under this Agreement shall remain vested
in the disclosing <B>Party. </B>Nothing herein shall be construed as granting any license or other right to use the <B>Confidential Information
</B>of the other <B>Party </B>other than as specifically agreed upon by the <B>Parties.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
written request of the disclosing <B>Party </B>given after termination of the Agreement, the receiving <B>Party </B>shall promptly return
to the disclosing <B>Party </B>all written materials and documents, as well as other media, made available or supplied by the disclosing
<B>Party </B>to the receiving <B>Party </B>that contains <B>Confidential Information, </B>together with any copies thereof, except that
the receiving <B>Party </B>may retain one copy each of such document or other media for archival purposes, subject to protection and
nondisclosure in accordance with the terms of this Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>16.</B></TD><TD STYLE="text-align: justify"><B>DISCLAIMER OF WARRANTIES</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
<B>Licensor </B>nor any of its trustees, directors, employees, or agents assumes any responsibility for the manufacture, production,
specifications, sale or use of the <B>Patent Rights </B>or <B>Licensed Products </B>by <B>Licensee </B>or any <B>Sub-licensees.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
for the warranties of <B>Section 4.1, </B>the <B>Licensor </B>makes no representations, and provides no warranties, express or implied:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">including, but not limited to, warranties of fitness for purpose or merchantability or satisfactory quality or compliance with any description, or any implied warranty arising from course of performance, course of dealing, usage of trade or otherwise, regarding or with respect to the <B>Patent Rights </B>or <B>Licensed Products;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on the patentability of the <B>Licensed Products </B>or of the enforceability of any <B>Patents, </B>if any, and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that the <B>Patent Rights </B>or <B>Licensed Products </B>are or shall be free from infringement of any patent or other rights of third parties, and to the fullest extent permitted by law, all such warranties and representations are hereby excluded.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 43pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>17.</B></TD><TD STYLE="text-align: justify"><B>INDEMNITIES; INSURANCE; LIMITATION OF LIABILITY</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">17.1</TD><TD STYLE="text-align: justify"><B>60P </B>and <B>60P Australia </B>hereby jointly and severally
indemnify, hold harmless and defend <B>NUS and SHS </B>jointly and severally from and against any and all claims, demands, actions, losses,
damages, costs (including legal costs on a full indemnity basis), expenses and liabilities whatsoever which <B>NUS </B>and/or <B>SHS
</B>may incur or suffer in connection with:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the manufacture, marketing, distribution and sale of the <B>Licensed Products </B>or any product for human use manufactured by the <B>Licensee </B>containing celgosivir by <B>Licensee </B>directly or through <B>Licensee's Representatives, </B>or otherwise by or through any <B>Sub-Licensees; </B>or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other agreements entered into by <B>Licensee </B>or <B>Licensee's Representatives </B>or any <B>Sub-licensees </B>relating to the <B>Licensed Products, </B>any product for human use manufactured by the <B>Licensee </B>containing celgosivir, and <B>Invention </B>or the performance or non-performance of the terms of such agreements or any representations or statements made by <B>Licensee </B>or <B>Licensee's Representatives </B>or any <B>Sub-Licensees </B>relating to the <B>Invention, </B>any product for human use manufactured by the <B>Licensee </B>containing celgosivir, or <B>Licensed Products; </B>or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any claim that any modification(s) made by or on behalf of <B>Licensee </B>or any <B>SubLicensees </B>infringes any trademark, trade secret, confidential information, copyright or patent or any other proprietary rights of any third party; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 47px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all taxes of any kind (except Singapore income tax in respect of consideration received by <B>NUS and SHS </B>under this Agreement), payments in lieu of taxes, import duties, assessments, fees, charges and withholdings of any nature whatsoever, and all penalties, fines, additions to tax or interest thereon, however imposed, whether levied or asserted against <B>NUS and SHS </B>by any tax authority of any country in connection with this Agreement or any matters arising therefrom including any payments received by <B>NUS </B>and <B>SHS </B>hereunder; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all charges, fines or any liability arising from any default or failure by <B>Licensee </B>and/or <B>Licensee's Representatives </B>or any <B>Sub-Licensees </B>to comply with and observe all laws and regulations referred to in <B>Section 18; </B>or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any action or omission of <B>Licensee, </B>or <B>Licensee&rsquo;s Representatives </B>or any <B>SubLicensees, </B>or any of their employees, agents or contractors in the performance of its obligations or the exercise of any of its rights under this Agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.2</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall obtain and maintain adequate product liability insurance within (15) days from the date of Regulatory Approval referred in
<B>Section 7.2 </B>and shall ensure that <B>NUS </B>and SHS are named as additional insured on the policy subject always to the terms
and conditions specified by the insurers. <B>Licensee </B>shall supply <B>Licensor </B>with a copy of such insurance policy upon written
request.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.3</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
<B>NUS </B>nor <B>SHS </B>shall have any liability to the <B>Licensee </B>for any indirect, consequential, special or incidental loss,
damage, expense or liability (including lost profit and loss of goodwill, opportunity costs, loss of business, damage to reputation,
claims by third parties or customers), or any exemplary or punitive damages, regardless of the form of action, whether in contract or
tort (including negligence), arising from or caused by <B>NUS </B>or <B>SHS </B>or its employees and contractors or from the <B>Licensee&rsquo;s
</B>use or exploitation of the <B>Patent Rights.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.4</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS&rsquo;s
and SHS&rsquo;s total liability to <B>Licensee </B>for direct damages or losses for any cause arising from the acts or omissions of <B>NUS
</B>and/or <B>SHS </B>including any failure by <B>NUS </B>and SHS or their affiliated related companies in complying with statutory requirements
or in complying and adhering to Guidelines and Procedures for Good Clinical Practice in the conduct of a the clinical trials shall be
limited to the total amount of funds payable by the <B>60P </B>in the form of <B>Upfront Payments </B>and <B>Royalties.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>18.</B></TD><TD STYLE="text-align: justify"><B>COMPLIANCE WITH LAW</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18.1</B></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall observe, and shall ensure that all <B>Sub-Licensees </B>observe, all applicable laws and regulations and obtain all necessary
licenses, consents and permissions required in respect of the manufacture, storage, marketing, distribution, sale (including export),
and importation of the <B>Licensed Products </B>within the <B>Territory.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>19.</B></TD><TD STYLE="text-align: justify"><B>TERMINATION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUS
</B>shall be entitled forthwith to terminate this Agreement immediately by notice in writing if:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60P </B>or <B>60P Australia </B>fails, or refuses, to perform or comply with any one or more of its obligations under this Agreement, and, if in the opinion of <B>NUS </B>that default is capable of remedy, <B>Licensee, 60P </B>or <B>60P Australia, </B>as the case may be, fails to remedy such default within 90 days after written notice of such default has been given to <B>Licensee, 60P </B>or <B>60P Australia, </B>as the case may be, by <B>NUS;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee, 60P </B>or <B>60P Australia, </B>ceases or, in <B>NUS&rsquo; </B>reasonable opinion, may cease, to carry on its business;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee, 60P </B>or <B>60P Australia, </B>becomes insolvent or is unable to pay its debts as they fall due or suspends or threatens to suspend making payments with respect to all or any class of its debts or enters into any composition or arrangement with its creditors or makes a general assignment for the benefit of its creditors;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee, 60P </B>or <B>60P Australia, </B>goes into liquidation or if an order is made or a resolution is passed for the winding up of <B>Licensee, 60P </B>or <B>60P Australia,, </B>whether voluntarily or compulsorily (except for the purpose of a bona fide reconstruction or amalgamation); or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee, 60P </B>or <B>60P Australia, </B>has a receiver or receiver and manager or judicial manager appointed over any part of its assets or undertaking.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall be entitled forthwith to terminate this Agreement immediately by notice in writing if <B>NUS </B>and <B>SHS </B>are in breach
of their obligations under this Agreement and shall fail to remedy any such default within the prescribed period in the notice given
by Licensee.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>shall be entitled to terminate this Agreement if the <B>Licensee </B>determines that further commercialization of celgosivir for
the treatment of acute dengue fever is no longer viable.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination
of this Agreement howsoever caused shall not prejudice any other right or remedy of the <B>Parties </B>in respect of any antecedent breach.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">19.5</TD><TD STYLE="text-align: justify">Upon the termination of this Agreement:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee </B>shall be entitled to continue to exercise the rights granted to it under this Agreement to such extent and for such further period, not exceeding twelve (12) months from the date of termination, reasonably necessary to enable <B>Licensee </B>to satisfy any orders placed prior to such termination date or scheduled for delivery within such twelve(12)-month period;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to <B>Section 19.5 (a) </B>above, <B>Licensee </B>shall forthwith cease to and shall not manufacture, market, distribute, sell, import, or use, until the expiration of the last to expire of any <B>Patents </B>under <B>Patent Rights </B>any product or process or method that incorporates utilizes or is made with the use of the <B>Invention </B>or which, but for the rights granted under this Agreement would constitute an infringement of any claim within the <B>Patent Rights;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each receiving <B>Party </B>shall forthwith return to each disclosing <B>Party </B>all <B>Confidential Information </B>pursuant to <B>Section 15.5;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60P </B>shall promptly pay all amounts due less all deductions due to <B>Licensee </B>under this Agreement to <B>NUS </B>and shall submit a declaration in writing signed by a duly authorized officer that it has complied with such payment obligations, along with a copy of all materials reasonably necessary to support such declaration.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee </B>shall provide <B>Licensor </B>with all data and know-how developed by <B>Licensee </B>in the course of <B>Licensee's </B>efforts to develop <B>Licensed Product(s) </B>and <B>Licensed Process(es); Licensor </B>shall have the right to use such data and knowhow for academic purpose on such terms and conditions mutually agreed between <B>Licensor </B>and <B>Licensee;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: right; text-indent: -35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: right; text-indent: -35pt"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: right; text-indent: -35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee </B>shall provide <B>Licensor </B>access to any regulatory information filed with any U.S. or foreign government agency with respect to <B>Licensed Product(s) </B>and <B>Licensed Process(es); </B>and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 48px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If <B>Licensee </B>has filed patent applications or obtained patents to any <B>Licensee&rsquo;s Improvements, Joint Improvements, NUS Improvements </B>and/or <B>SHS Improvements </B>to <B>Licensed Product(s) </B>or <B>Licensed Process(es) </B>within the scope of the <B>Patent Rights, Licensee </B>agrees upon request to enter into good faith negotiations with <B>Licensor </B>or <B>Licensor's </B>future licensee(s) for the purpose of granting licensing rights to said modifications or improvements in a timely fashion and under commercially reasonable terms</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.6</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
termination of this Agreement under any of its provision, Sections 3A3 (Provisions Relating to Essential and Other documents), 9 (Accounts),
15 (Confidentiality), 16 (Disclaimer of Warranties), 17 (Indemnities; Insurance; Limitation of Liability), 19 (Termination), 20 (Use
of Licensor&rsquo;s Name), and 22 to 29 and any other Sections of this Agreement which from their context are intended to survive the
termination of this Agreement, shall survive the Term or the termination of this Agreement and shall be deemed to remain in full force
and effect.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">20.</TD><TD STYLE="text-align: justify"><B>USE OF LICENSOR&rsquo;S NAME</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee
</B>agrees that it shall not use in any way the name of <B>Licensor </B>or any logotypes or symbols associated with <B>Licensor </B>or
the names of any directors or employees of <B>Licensor </B>without the prior written consent of <B>Licensor.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">21.</TD><TD STYLE="text-align: justify"><B>FORCE MAJEURE EVENTS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything else in this Agreement, no default, delay or failure to perform on the part of either <B>Party </B>shall be construed a breach
of this Agreement if such default delay or failure to perform is shown to be due entirely to causes beyond the control of the <B>Party
</B>charged with a default, delay or failure to perform <B>(&ldquo;Force Majeure Events&rdquo;), </B>including but not limited to, causes
such as strikes, lockouts or other labour disputes to perform, including, without limitation, riots, civil disturbances, actions or inaction
of governmental authorities, epidemics, war, embargoes, severe weather, fire, earthquakes, acts or God or the public enemy and nuclear
disasters (each a <B>&ldquo;Force Majeure Event&rdquo;).</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">22.</TD><TD STYLE="text-align: justify"><B>NO PARTNERSHIP OR AGENCY</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
agency, partnership or joint venture is created hereby. <B>Licensee </B>does not have any authority of any kind to bind <B>Licensor </B>in
any respect whatsoever.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">23.</TD><TD STYLE="text-align: justify"><B>ASSIGNMENT AND CHANGE OF CONTROLLING INTEREST</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
rights and obligations hereunder are personal to the <B>Parties </B>and no <B>Party </B>shall assign any such rights, or novate its rights
and obligations to any third party without the prior consent in writing of the other <B>Party </B>on terms to be agreed by the <B>Parties.
</B>Where such consent is given, the <B>Party, </B>which is the assignor, shall procure that such third party covenants with the other
<B>Party </B>to be bound by the terms of this Agreement as if it had been a party hereto in place of the assignor.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<B>Licensee </B>shall notify <B>Licensor </B>no later than thirty (30) days prior to any intended issuance or transfer of shares which
would result in a change in the control of <B>Licensee </B>to another party. <B>Licensor </B>shall, within thirty (30) days of receiving
such notice, inform <B>Licensee </B>in writing whether or not <B>Licensor </B>consents to such issuance or transfer of shares, such consent
not to be unreasonably withheld.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>24.</B></TD><TD STYLE="text-align: justify"><B>NO WAIVER</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure or delay by a <B>Party </B>in enforcing an obligation, or exercising a right or remedy under this Agreement shall not be construed
or deemed to be a waiver of that obligation, right or remedy. A waiver of a breach of a term under this Agreement shall not amount to
a waiver of a breach of any other term in this Agreement and a waiver of a particular obligation in one circumstance will not prevent
a <B>Party </B>from subsequently requiring compliance with the obligation on other occasions. Any waiver by a <B>Party </B>of any right
under this Agreement shall be made in writing and signed by the authorized representative of such <B>Party.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>25.</B></TD><TD STYLE="text-align: justify"><B>NOTICES</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices, demands or other communications required or permitted to be given or made hereunder shall be in writing and delivered personally,
or sent by prepaid registered post, email, or by telefax, addressed to the intended recipient thereof at its address or telefax number
as set out below (or to such other address or telefax number as any <B>Party </B>may from time to time notify the other <B>Party). </B>Any
such notice, demand or communication shall be deemed to have been duly served on and received by the addressee:</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">if delivered by hand, at the time of delivery;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">if sent by prepaid registered post, within ten days of dispatch; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">if transmitted by way of telefax or email, at the time of transmission.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">25.2</TD><TD STYLE="text-align: justify">In proving the giving of a notice or other communication, it
shall be sufficient to show:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of registered post, that the notice or other communication was contained in an envelope which was duly addressed, sufficient postage paid and posted; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52px">&nbsp;</TD>
    <TD STYLE="width: 45px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case of telefax that the telefax transmission was duly transmitted from the dispatching terminal as evidenced by a transmission report generated by the transmitting equipment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUS:</B></FONT></TD>
    <TD STYLE="width: 46%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry Liaison Office</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60&deg; Pharmaceuticals LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National University of Singapore</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1025 Connecticut Ave NW Suite 1000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 5</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington DC, 20036</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iCube Building</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21 Heng Mui Keng Terrace</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore 119613</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: 1.202.688.2832</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: (65) 6777 6990</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHS:</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SingHealth Intellectual Property (SHIP)</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore Health Services Pte Ltd</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20 College Road, The Academia</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 7, Discovery Tower</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore 169856</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: 62215472</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>26.</B></TD><TD STYLE="text-align: justify"><B>ENTIRE AGREEMENT</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement contains the entire agreement between the <B>Parties </B>hereto regarding the subject matter hereof, and supersedes all prior
agreements, understandings and negotiations regarding the same. No modification, variation or amendment shall be made to this Agreement
unless made in writing, specifically referring to this Agreement and signed by the authorized representatives of both <B>Parties.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>27.</B></TD><TD STYLE="text-align: justify"><B>SEVERABILITY</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
any one or more of the provisions of this Agreement be held to be invalid or unenforceable by a court of competent jurisdiction, it shall
be considered severed from this Agreement and shall not serve to invalidate the remaining provisions hereof. The <B>Parties </B>shall
make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the objectives
contemplated by them when entering into this Agreement may be realized.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">28.</TD><TD STYLE="text-align: justify"><B>DISPUTE RESOLUTION</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">28.1</TD><TD STYLE="text-align: justify"><U>Informal Resolution</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Any dispute, controversy or claim arising
out of or in connection with this Agreement shall be resolved in the following manner:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 49px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the aggrieved <B>Party (&ldquo;Claimant&rdquo;) </B>shall notify the responding <B>Party (&ldquo;Respondent&rdquo;) </B>in writing <B>(&ldquo;Resolution Notice&rdquo;), </B>setting forth in detail the nature of its dispute, controversy or claim <B>(&ldquo;Claim&rdquo;) </B>and requesting a meeting <B>(&ldquo;Resolution Meeting&rdquo;) </B>of a senior representative from each <B>Party </B>to be held on a date not less than fifteen (15) nor more than thirty (30) days thereafter <B>(&ldquo;Resolution Period&rdquo;) </B>for the purpose of resolving such <B>Claim;</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 49px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the <B>Respondent </B>shall issue and deliver a written response to <B>Claimant </B>not later than five (5) days before the <B>Resolution Meeting, </B>setting forth in detail its response to such <B>Claim, </B>failing which the <B>Resolution Meeting </B>shall not proceed and the <B>Claimant </B>shall be entitled to submit the dispute to arbitration/mediation as provided under <B>Section 28.2 </B>below;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 49px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the senior representative from each <B>Party </B>shall meet to resolve such <B>Claim </B>amicably between the <B>Claimant </B>and the <B>Respondent </B>in good faith; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49px">&nbsp;</TD>
    <TD STYLE="width: 49px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if such <B>Claim </B>is not resolved by the end of fifteen (15) days after the <B>Resolution Period, </B>then either <B>Claimant </B>or <B>Respondent </B>shall be entitled to submit the dispute to arbitration, as provided under <B>Section 28.2 </B>below.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: right; text-indent: -37pt"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -37pt">&nbsp;</P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-align: justify; text-indent: -37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">28.2</TD><TD STYLE="text-align: justify"><U>Mediation</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48px; text-align: justify; text-indent: 1pt">If such efforts taken under
<B>Section 28.1 </B>above fail, then the <B>Parties </B>shall refer the matter to mediation in accordance with the rules and procedures
of the Singapore Mediation Centre. The language of the mediation shall be English.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48px; text-align: justify; text-indent: 1pt">If mediation fails, then
the dispute shall be referred to and resolved by arbitration in Singapore at the Singapore Arbitration Centre <B>(&ldquo;S1AC&rdquo;)
</B>in accordance with the Arbitration Rules of the <B>S1AC </B>for the time being in force, which rules are deemed to be incorporated
by reference to <B>Section 28.2 </B>herein. A tribunal consisting of a single arbitrator to be appointed by the Chairman of the <B>SIAC
</B>shall be convened. The language of the arbitration is in English. Any arbitral award made hereunder shall be final and binding upon
the <B>Parties </B>hereto and judgment on such award may be entered into any court or tribunal having jurisdiction thereof. The <B>Parties
</B>hereto undertake to keep the mediation and arbitration proceedings and all information, pleadings, documents, evidence and all matters
relating thereto confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: 1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>29.</B></TD><TD STYLE="text-align: justify"><B>GOVERNING LAW</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement shall be governed by, interpreted and construed in accordance with the laws of the Republic of Singapore and the <B>Parties
</B>hereby submit to the exclusive jurisdiction of the courts of the Republic of Singapore.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>30.</B></TD><TD STYLE="text-align: justify"><B>GENERAL</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.1</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stamp
duty or fees, if any, payable in respect of this Agreement shall be borne wholly by <B>60P.</B></FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.2</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
<B>Party </B>shall from time to time do all acts and execute all such documents as may be reasonable necessary in order to give effect
to the provisions of this Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.3</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in this Agreement, the <B>Parties </B>shall bear their own costs of and incidental to the preparation execution
and implementation of this Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30.4</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement may be executed in one or more counterparts by the <B>Parties </B>by signature of a person having authority to bind the <B>Party,
</B>each of which when executed and delivered, by facsimile transmission or other electronic modes of delivery, will be an original and
all of which will constitute but one and the same Agreement.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">AS WITNESS the hands of the <B>Parties </B>hereto the day and year first
above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">SIGNED by for and on behalf of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>NATIONAL UNIVERSITY OF SINGAPORE</B></P></TD>
    <TD STYLE="width: 38%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 36%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED by for and on behalf of<BR>
<B>60&deg; PHARMACEUTICAL LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lily CHAN</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey DOW, CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO, NUS Enterprise</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the presence of:</FONT></TD>
    <TD STYLE="width: 5%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the presence of: &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Jackson, Manager</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyrone MILLER, CFO &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED by for and on behalf of</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR>
SINGAPORE HEALTH SERVICES</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PTE LTD</B></FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED by for and on behalf of <BR>
<B>60P AUSTRALIA PTY LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof Ivy NG</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey DOW, CEO &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group CEO</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the presence of:</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the presence of: &nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:Koh</FONT> &nbsp;Choon Heng</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Tyrone MILLER,CFO</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation:Asst Dir</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONFIDENTIAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Bart A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INTELLECTUAL PROPERTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NUS Ref: 15301N: Novel Dosing Regimens of Celgosivir
For The Prevention of Dengue </B>Methods of preventing a disease resulting from a dengue virus (DENV) infection in a human subject, comprising
administering to the human subject a compound of Formula (I), or pharmaceutical composition comprising a compound of Formula (I): A compound
of Formula (1) can be first administered to an asymptomatic human subject followed by subsequent doses administered at least once daily.
The methods of the invention can be used to prevent a disease resulting from primary and secondary DENV1-4 viral infections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Part A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Patents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NOT IN USE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Part B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Patent Applications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Novel Dosing Regimens of Celgosivir For The
Prevention of Dengue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1.US Provisional Patent Application Number 62/266,119</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONFIDENTIAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>SCHEDULE 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>FORMAL LICENSE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>PATENT LICENSE FOR REGISTRATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>THIS AGREEMENT </B>is made on the [&#9;] day of [&#9;J 20</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NATIONAL
UNIVERSITY OF SINGAPORE, </B>(Company Registration Number: 200604346E), a company limited by guarantee incorporated in Singapore and
having its registered office at 21 Lower Kent Ridge Road, Singapore 119260 <B>(&ldquo;NUS&rdquo; </B>which expression shall include its
successors and assigns);</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SINGAPORE
HEALTH SERVICES PTE LTD </B>(Company Registration Number: 200002698Z), a company incorporated in Singapore, having its registered address
at 31 Third Hospital Avenue #03-03, Singapore 168753 <B>(&ldquo;SHS&rdquo; </B>which expression shall include its successors and assigns;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60&deg;
PHARMACEUTICALS LLC </B>a company incorporated in Washington DC and having its registered office at 1025 Connecticut Ave NW Suite 1000,
Washington DC 20036 United States (&ldquo;60P&rdquo; which expression shall include its successors and assigns).</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60P
AUSTRALIA PTY LTD </B>(Company Registration No. 167060219) a company incorporated in Australia and having its registered office at 105
North Steyne Manly New South Wales 2095, <B>(&ldquo;60P Australia&rdquo; </B>which expression shall include its successors and assigns)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>(60P </B>and <B>60P Australia </B>hereinafter collectively
referred to as <B>&ldquo;Licensee&rdquo;).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">(A)</TD><TD STYLE="text-align: justify"><B>NUS </B>and <B>SHS </B>are the registered joint proprietors
in <I>[country]</I> of patent number <B>(&ldquo;Patent&rdquo;) </B>for an invention entitled [&#9;<B>] (&ldquo;Invention&quot;).</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 71pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><B>(B)</B></TD><TD STYLE="text-align: justify"><B>By </B>an agreement dated [&#9;<B>] (&ldquo;Principal Agreement&rdquo;)
</B>it was agreed between the <B>Parties</B> &nbsp;that <B>NUS </B>and <B>SHS
</B>would grant to the <B>Licensee </B>an exclusive sub-licensable transferable license under the <B>Patent </B>on the terms and for the
consideration set out in the <B>Principal Agreement.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: 2pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NOW IT IS HEREBY AGREED </B>as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left">I.</TD><TD STYLE="text-align: justify">Pursuant to and for the consideration specified in the <B>Principal
Agreement, NUS </B>and <B>SHS </B>grant [and shall from the date of the publication of the application for the <B>Patent </B>be deemed
to have granted] to the <B>Licensee </B>an exclusive, sublicensable transferable license under the Patent to manufacture, use, sell,
and import <I>[describe the Products using the same wording as in the Principal Agreement]</I> made in accordance with the provisions
of the <B>Principal Agreement </B>and to do all other things within the scope of the <B>Patent </B>on the terms and conditions of the
<B>Principal Agreement,</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<B>License </B>granted by Section 1 <B>(&ldquo;License&rdquo;) </B>shall automatically terminate and cease to have effect if terminated
at any time under the provisions of the <B>Principal Agreement, </B>or on the expiration or termination of the <B>Principal Agreement
</B>for any cause or reason whatsoever.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-align: justify; text-indent: -35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0px"></TD><TD STYLE="width: 48px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<B>License </B>is granted pursuant to the terms of the <B>Principal Agreement </B>and not in substitution for any license or licenses
granted under the <B>Principal Agreement. </B>Nothing contained in this Agreement shall in any way derogate from the <B>Principal Agreement,
</B>which shall remain in full force and effect in accordance with its terms.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>IN WITNESS WHEREOF </B>the parties hereto have caused this Agreement
to be executed on the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensor</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 50%"><U>&nbsp;</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><U>&nbsp;</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NATIONAL UNIVERSITY</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD><U>&nbsp;</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF SINGAPORE</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.Lily Chan</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SINGAPORE HEALTH SERVICES</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO, NUS Enterprise</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PTE LTD</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Licensee</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60&deg; PHARMACEUTICALS LLC</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60P AUSTRALIA PTY LTD</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><U></U></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONFIDENTIAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="cm270_ex10-20img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONFIDENTIAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE 5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>LIST OF COUNTRIES CONSIDERED &ldquo;HIGH INCOME&rdquo;
BY WORLD BANK IN 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONFIDENTIAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-20img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>24
<FILENAME>cm270_ex10-21.htm
<DESCRIPTION>EXHIBIT 10.21
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.21</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Master Consultancy Agreement</B></FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; width: 15%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company</B></FONT></TD>
    <TD STYLE="padding-top: 1pt; width: 15%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Name:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; width: 70%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60<SUP>0</SUP> Pharmaceuticals LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ABN:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Address:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1025 Connecticut Avenue NW, Suite 1000, Washington DC, 20036 United States</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Email:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">geoffdow@60degreespharma.com</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consultant</B></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Contact:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey S Dow, CEO &amp; Principal</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Name:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Biointelect Pty Ltd</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>ABN:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17 154 647 051&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17 154 647 051</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Address:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15 Boden Place, Castle Hill NSW 2154</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Email:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jherz@biointelect.com.au</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Contact:</I></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jennifer Herz</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commencement Date</B></FONT></TD>
    <TD STYLE="padding-top: 1pt; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29 May 2013</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Background:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company wishes to engage the Consultant to provide services to it from
time to time and the Consultant has agreed to accept such engagement on the terms and conditions set out in this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Operative Part:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.95pt">1.</TD><TD>The Company agrees to engage the Consultant to provide the Services on the terms and conditions set out in this agreement and any
Work Order under this agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 30.95pt">2.</TD><TD>The Consultant agrees to provide the Services to the Company and comply with the terms and conditions set out in this agreement and
any Work Order under this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By signing below the Company and the Consultant (as defined above) agree
to be bound by the terms of the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signed for and on behalf of Biointelect Pty Limited by:</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signed for and on behalf of 60&deg; Pharmaceut LLC by:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>By:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jennifer Herz</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print or Type</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print or Type</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-4-2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-3-2013</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Terms and Conditions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>1</B></TD><TD STYLE="text-align: justify"><B>Definitions &amp; Interpretation</B></TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">1.1</TD><TD STYLE="text-align: justify">In this agreement:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Business Day</B> means a day which is not
a Saturday, Sunday or bank or public holiday in Sydney, Australia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Confidential Information</B> means any information
relating to the Company, the Company&rsquo;s business and financial affairs, the existence and terms of this agreement and information,
including information of the Company&rsquo;s clients, provided to the Consultant of a confidential nature</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28pt"><B>Corporations Act</B> means the <I>Corporations Act</I>
2001 (Cth).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Fees</B> mean the fees and other amounts
payable by the Company to the Consultant for providing the Services as specified in the Work Order relating to those Services</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28pt"><B>GST</B> has the meaning given in the GST Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>GST Law</B> has the meaning given to that
expression in the A <I>New Tax System (Goods and Services Tax) Act</I> 1999.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Insolvency Event</B> means, in respect of
a party, if that party enters into bankruptcy, provisional liquidation, liquidation, voluntary administration or if a &quot;controller'&rsquo;
(as defined in the Corporations Act 2001 (Cth)) is appointed to that party or if a receiver or receiver and manager is appointed to that
party, or if a mortgagee takes possession of any assets of that party whether by itself or by an agent or if that party ceases to trade
or is unable to pay its debts as they fall due or if that party makes a compromise with its creditors or enters into a scheme of arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Intellectual Property Rights</B> means all
registered and unregistered rights in relation to present and future copyrights, trademarks, designs, know-how, patents, plant varieties
and all other intellectual property as defined in article 2 of the Convention establishing the World Intellectual Property Organisation
1967</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Key Person</B> means the person(s) delivering
the Services on behalf of the Consultant as specified in a Work Order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Moral Rights</B> means the right of integrity
of authorship, the right of attribution of authorship and the right not to have authorship falsely attributed, more particularly as conferred
by the <I>Copyright Act</I> 1968 (Cth), and rights of a similar nature anywhere in the world whether existing presently or which may in
the future come into existence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Personnel</B> mean all employees (fulltime,
parttime or casual) employed by, seconded to or otherwise working for a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Services</B> means the services described
in a Work Order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28pt"><B>Special Conditions</B> means the special conditions
(if any) detailed in a Work Order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Term</B> means the period from the Commencement
Date until the agreement is terminated under clause 11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.4in; text-indent: 0pt"><B>Work Order</B> means a document in the form
of the Schedule 1 (<B>Work Order</B>) (with such changes to the form as the parties may agree), containing details of the Services to
be provided by the Consultant to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">1.2</TD><TD STYLE="text-align: justify">In this agreement unless the contrary intention appears:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 66pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>a reference to a statute or other law includes regulations and other instruments under it and consolidations, amendments, re-enactments
or replacements or any of them;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(b)</TD><TD STYLE="text-align: justify">singular includes the plural number and vice versa</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 66pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD>a reference to any one gender includes each other gender (as the case may require);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 66pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(d)</TD><TD>the word &quot;person&quot; includes a firm, corporation, body corporate, unincorporated association or any governmental authority;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 66pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(e)</TD><TD>a reference to a person includes a reference to the person's executors, administrators, legal personal representatives, successors
and permitted assigns; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 66pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(f)</TD><TD>all headings in this agreement have been inserted for the purpose of ease of reference only, they do not affect the meaning or interpretation
of it</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">1.3</TD><TD STYLE="text-align: justify">Any schedule attached to this agreement forms part of it.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>2</B></TD><TD STYLE="text-align: justify"><B>Services</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">2.1</TD><TD STYLE="text-align: justify">The Company engages the Consultant to provide and the Consultant
agrees to provide the Services as agreed in writing from time to time during the Term by the parties signing a Work Order in which details
of the Services will be recorded</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">2.2</TD><TD STYLE="text-align: justify">The Company makes no promises to the Consultant as to the
quantity of Services it will be retained by the Company to provide</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">2.3</TD><TD STYLE="text-align: justify">The term of this agreement wil commence on the Commencement
Date and will continue until terminated under clause 11.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>3</B></TD><TD STYLE="text-align: justify"><B>Work Order</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">3.1</TD><TD STYLE="text-align: justify">When the Company requires the Consultant to provide Services
it will submit a Work Order by email to the Consultant in the form set out in Schedule 1.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">3.2</TD><TD>A Work Order will not be binding until the Company receives from the Consultant an acceptance of that Work Order, which acceptance
must be in writing and may be given by email</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">3.3</TD><TD STYLE="text-align: justify">A Work Order issued by the Company will form part of this
agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">3.4</TD><TD STYLE="text-align: justify">Each party must act in accordance with any Special Conditions
detailed in a Work Order.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">3.5</TD><TD>The Consultant must procure the Key Person and any other of its Personnel who provide the Services to sign the personal undertaking
in Schedule 2, before the Key Person or Personnel commence the performance of any Services under a Work Order</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>4</B></TD><TD STYLE="text-align: justify"><B>Performance of Services</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">4.1</TD><TD>The Services are to be performed at the times and to achieve the business outcomes reasonably required by the Company as specified
in a Work Order and as notified from time to time by the Company to Consultant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">4.2</TD><TD>The Services are to be provided on behalf of the Consultant by the Key Person. The Consultant warrants that the Key Person has the
skills, qualifications and experience necessary to provide the Services to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">4.3</TD><TD>Where the Key Person is unable to provide the Services the Services are to be provided by a replacement as approved by the Company,
which approval may be given subject to conditions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">4.4</TD><TD>The Consultant must perform the Services in a proper, workmanlike and professional manner.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">4.5</TD><TD>The Consultant must comply with all of the Company&rsquo;s reasonable requests about the performance of the Services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>5</B></TD><TD STYLE="text-align: justify"><B>Fees and Expenses</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">5.1</TD><TD>In consideration of the Services provided by the Consultant, the Company must pay the Consultant the Fees.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">5.2</TD><TD>The Fees cover time spent on work for the Company whether carried out on the Company&rsquo;s premises or elsewhere.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">5.3</TD><TD>Unless otherwise expressly stated, all Fees and other amounts payable in respect of the provision of Services are exclusive of GST.
GST must be paid in addition to the stated amount payable</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">5.4</TD><TD>Subject to clause 5.5, the Company must reimburse the reasonable expenses of travel, meals and other related expenses provided that
the Consultant obtained the Company's prior written approval for the Consultant to incur the expense on behalf of the Company</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">5.5</TD><TD STYLE="text-align: justify">Expenses are payable after receipt by the Company of a note
of the expenses incurred accompanied by supporting vouchers</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>6</B></TD><TD STYLE="text-align: justify"><B>Consultants Status</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">6.1</TD><TD>The Consultant is an independent contractor without authority to bind the Company by contract or otherwise</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">6.2</TD><TD>The Consultant and Consultant's Personnel are not agents or employees of the Company by virtue of this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">6.3</TD><TD>The Consultant also agrees that neither it nor its Personnel have, under this agreement, any entitlement from the Company in relation
to employment or related benefits.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">6.4</TD><TD>At all times throughout the Term, the Consultant warrants that it has paid or will pay, on or before the due date for payment all:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(a)</TD><TD STYLE="text-align: justify">remuneration, superannuation and other benefits payable or
to be provided to;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>payroll tax payable by the Consultant in respect of wages paid or payable in respect of;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(c)</TD><TD STYLE="text-align: justify">workers compensation insurance premiums payable by the Consultant
in respect of,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-indent: 0pt">employees (or deemed employees) of the Consultant
in respect of work done in connection with this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">6.5</TD><TD>The Consultant indemnifies the Company against any loss or liability (including statutory liability for unpaid wages, workers compensation
insurance premiums, workers compensation liability and unpaid payroll tax) directly or indirectly arising from breach of this clause 6
or failure to pay the foregoing when due</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">6.6</TD><TD STYLE="text-align: justify">The Consultant must not, and mustensure that the Consultant
s Personnel do not</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>make any representations, promises or public statements about the Company or its business, without the prior written approval of the
Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>make any false, misleading or deceptive statements with respect to the Company or its business</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">6.7</TD><TD>The Consultant must not engage in any activity which is likely to result in a conflict of interest with its role under this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">7</TD><TD STYLE="text-align: justify">Intellectual Property Rights</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">7.1</TD><TD>The Intellectual Property Rights in all written reports (whether final or interim) created by or on behalf of the Contractor and delivered
to the Company as a result of the provision of the Services to the Company, will vest in the Company, after delivery of the report and
payment of all fees due by the Company to the Contractor in respect of the work undertaken by the Contractor to which the report relates</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">7.2</TD><TD>The Intellectual Property Rights in all other materials (in whatever form they exist) brought into existence, by or on behalf of the
Contractor, as a result of the provisions of the Services to the Company shall be and remain the property of the Contractor and the Company
shall receive no right, title or interest in such Intellectual Property Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">7.3</TD><TD>For the avoidance of doubt, the Intellectual Property Rights in those materials provided by the Company to the Contractor during the
Term of this Agreement remain with the Company or entity which licensed those materials to the Company and the Contractor acknowledges
that it acquires no right or ownership of any such of the Intellectual Property Rights by virtue of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>8</B></TD><TD STYLE="text-align: justify"><B>Warranties</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">8.1</TD><TD STYLE="text-align: justify">The Consultant and the Company each represent and warrant
to the other that:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>it is a corporation with limited liability registered (or taken to be registered) and validly existing under the Corporations Act:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>it has full power and authority to enter into and perform its obligations under this agreement in accordance with the terms of this
agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD>it has taken all necessary action to authorise the execution, delivery and performance of the agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(d)</TD><TD>this agreement constitutes legal, valid and binding obligations on the party and is enforceable against it in accordance with the
terms of this agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">8.2</TD><TD STYLE="text-align: justify">The Consultant warrants to the Company that:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>the information provided to the Company in relation to the subject matter of this agreement before the date of this agreement is true
and correct;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>the business of the Consultant is registered with the Australian Business Number set out in this agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(c)</TD><TD STYLE="text-align: justify">the Consultant is registered for the purposes of GST.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>9</B></TD><TD STYLE="text-align: justify"><B>Confidentiality</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">9.1</TD><TD>Each party must treat as confidential the Confidential Information and will treat the Confidential Information with the same level
of care and protection as they would their own confidential information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">9.2</TD><TD STYLE="text-align: justify">Subject to clause 9 3, each party must not, without the prior
written consent of the other party, use the Confidential Information except in performing its obligations under this agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">9.3</TD><TD STYLE="text-align: justify">Each party may disclose any Confidential Information:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(a)</TD><TD STYLE="text-align: justify">with the prior written consent of the other party;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 68pt; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>if the Confidential lnformation has come within the public domain, other than by a breach of this clause 9 by either party; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(c)</TD><TD STYLE="text-align: justify">if required to do so by a Governmental Agency,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in; text-indent: 0pt">but, to the extent possible, must consult with
the other party before making the disclosure and use reasonable endeavours to agree on the form and content of the disclosure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">9.4</TD><TD>The obligations set out in this clause 9 are in addition to, and not in substitution for any confidentiality agreements entered into
between the Company and the Consultant (if any) prior to this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">9.5</TD><TD>On termination of this agreement, each party will promptly return to the other all Confidential Information, in whatever form, in
its possession, custody or control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>10</B></TD><TD STYLE="text-align: justify"><B>Costs</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">10.1</TD><TD>Except as expressly stated otherwise in this agreement each party must pay its own legal and other costs and expenses of negotiating,
preparing, executing and performing its obligations under this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>11</B></TD><TD STYLE="text-align: justify"><B>Termination</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">11.1</TD><TD>Either party may terminate a Work Order, without cause at any time, by giving the other party written notice which may take effect
immediately.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">11.2</TD><TD>Either party may terminate this agreement, without cause at any time, by giving the other party 10 days written notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>12</B></TD><TD STYLE="text-align: justify"><B>Limitation of Liability</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">12.1</TD><TD STYLE="text-align: justify">Subject to clause 12.2, the Consultant's aggregate liability
(whether for breach of contract, breach of statutory duty or negligence or other tort) for loss or damage suffered or incurred by the
Company in connection with any Services provided under this agreement by the Consultant is limited to the total amount of the Fees received
by the Consultant under this agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">12.2</TD><TD STYLE="text-align: justify">The limitation in clause 12.1 and the exclusion in clause
12.3 do not apply in relation to liability:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(a)</TD><TD STYLE="text-align: justify">for personal injury (including sickness or death), or damage
to tangible property; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>wilful breach of this agreement, gross misconduct, fraud or dishonesty of the Consultant or its personnel</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">12.3</TD><TD>Subject to clause 12.1, neither party is liable to the other party for any loss of profits or income (actual or anticipated), loss
of business or of goodwill, loss of data (and cost of data re-entry) or loss arising out of business interruption or delay in the performance
of any obligation and includes costs and expenses incurred in connection with such loss or in connection with the mitigation (or attempted
mitigation) of such loss</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>13</B></TD><TD STYLE="text-align: justify"><B>Insurance</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">13.1</TD><TD>The Consultant must during the term of its appointment under this agreement effect and maintain with a reputable insurer licensed
to conduct business in Australia a professional indemnity insurance policy. This policy must be maintained for a period of three years
after the end of the Term. The policy must provide cover of not less than $1 million and must provide for at least one reinstatement of
the policy during each policy year. The Consultant must promptly, on request from the Company, provide evidence of the currency of this
insurance.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>14</B></TD><TD STYLE="text-align: justify"><B>Restraint</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">14.1</TD><TD>The Consultant agrees that neither it nor the Key Person nor its other Personnel providing the Services (directly or indirectly, or
through any interposed body corporate, trust, principal, agent, shareholder, beneficiary or in any other capacity) will, during the Restraint
Period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>promote, participate in, operate or engage in a business in competition with the Company in the Territory;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>solicit, canvass or secure the custom of a person who is or was, during the Term, a supplier of goods or services to the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD>solicit, canvass or secure the custom of a person who is or was, during the Term, a customer of, the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(d)</TD><TD>solicit, employ or engage the services of any employee of the Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(e)</TD><TD>use any information concerning the business or affairs of the Company which may have been acquired by the Consultant for Consultant's
own benefit or to the detriment or intended or probably detriment of the Company</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">14.2</TD><TD STYLE="text-align: justify">In this clause 14 a reference to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><B>Company</B> includes the Company and any of its related
bodies corporate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD><B>Restraint Period</B> means the period commencing on the Commencement Date and ending 12 months after the Term of this agreement
ends; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 65pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD><B>Territory</B> means Australia, and any countries in which work was conducted by the Consultant or its sub contractors on behalf
of the Company (this list includes but is not necessarily limited to Brazil, Thailand, United States and France)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.2pt"></TD><TD STYLE="width: 30.9pt">14.3</TD><TD>Each of the restraint obligations imposed by this agreement is a separate and independent obligation from the other restraint obligations
imposed (although they are cumulative in effect)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">14.4</TD><TD STYLE="text-align: justify">The parties agree that each of the restraint obligations
imposed by this clause:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>is reasonable in its extent (as to duration and restrained conduct) having regard to the interests of each party to this agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(b)</TD><TD STYLE="text-align: justify">extends no further (in any respect) than is reasonably necessary;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(c)</TD><TD STYLE="text-align: justify">is to protect the goodwill of the Company&rsquo;s business.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">14.5</TD><TD>If any of the restraint obligations imposed by this clause 14 is judged to go beyond what is reasonable in the circumstances and necessary
to protect the goodwill of the business of the Company but would be judged reasonable and necessary if any activity were deleted or a
period were reduced, then the restraint obligations apply with that activity deleted or area reduced by the minimum amount necessary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>15</B></TD><TD STYLE="text-align: justify"><B>Notices</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">15.1</TD><TD>Any notice given in accordance with this agreement will be correctly given if it is in writing and is left at or sent by email or
by pre-paid security post addressed to a party at its registered office or principal place of business for the time being or at any other
address as may be notified pursuant to this clause 15 for the purpose of the service of notices.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">15.2</TD><TD>A notice will be regarded to have been given on the date of delivery, in the case of a notice being sent by email, on the earlier
of the receipt by the sender of an automated message confirming delivery or four hours after the time (as recorded on the sender&rsquo;s
email system) unless the sender receives an automated message that the email has not been delivered and in the case of a notice being
sent by post, it will be deemed to have been given two Business Days after the date of posting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><B>16</B></TD><TD STYLE="text-align: justify"><B>Invalidity</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">16.1</TD><TD>If a provision of this agreement is void or voidable against, or is unenforceable by, a party but would not be void or voidable or
unenforceable if it were read down and is capable of being read down, it is to be read down accordingly.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">16.2</TD><TD>If a provision of this agreement is read down and is still void or voidable against, or is unenforceable by, a party:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 67pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>if the provision would not be void or voidable or unenforceable if a word or words were omitted, that word or those words are to be
severed; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(b)</TD><TD STYLE="text-align: justify">in any other case, the whole provision is to be severed,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 33pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.4in">and the remainder of this agreement has full effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>17</B></TD><TD STYLE="text-align: justify"><B>Waiver</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">17.1</TD><TD STYLE="text-align: justify">The failure of either party to enforce any provision of this
agreement shall not be construed as a waiver or limitation of that party's right to subsequently enforce and compel strict compliance
with every provision of this agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>18</B></TD><TD STYLE="text-align: justify"><B>Non Solicitation</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">18.1</TD><TD>During the Term of this agreement, neither party will solicit for hire any employee of the other who was involved in Services provided
under this agreement. In the event either party permits the other to hire one of its employees, the parties agree to negotiate a reasonable
placement fee in good faith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>19</B></TD><TD STYLE="text-align: justify"><B>Remedies</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">19.1</TD><TD STYLE="text-align: justify">The rights and remedies contained in this agreement are cumulative
and are not exclusive of any rights and remedies provided by law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">19.2</TD><TD>A party is entitled to enforce or take action in respect of, to the extent permitted by law, any breach of another party's obligations
under this agreement notwithstanding the termination of this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>20</B></TD><TD STYLE="text-align: justify"><B>Further Assurances</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">20.1</TD><TD STYLE="text-align: justify">Each party must do and perform all such other acts matters
and things as may be necessary or convenient to implement the provisions of this agreement so as to give effect to the intentions of
the parties as expressed in this agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>21</B></TD><TD STYLE="text-align: justify"><B>Assignment</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left">21.1</TD><TD STYLE="text-align: justify">A party may not assign or deal with any right under this
agreement without the prior written consent of the other party. Any purported dealing in breach of this clause is of no effect</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>22</B></TD><TD STYLE="text-align: justify"><B>Severability</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">22.1</TD><TD>If any provision of this agreement shall be held to be invalid or unenforceable for any reason, the remaining provisions shall continue
to be valid and enforceable. If a court finds that any provision of this agreement is invalid or unenforceable, but that by limiting such
provision it would become valid and enforceable, then such provision shall be deemed to be written, construed, and enforced as so limited.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>23</B></TD><TD STYLE="text-align: justify"><B>Whole Agreement</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">23.1</TD><TD>No modification of this agreement is binding unless it is in writing and signed by or on behalf of each party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">23.2</TD><TD>In relation to the subject matter of this agreement, this document embodies the entire understanding of the parties and constitutes
the entire terms agreed on between them.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">23.3</TD><TD>The Consultant acknowledges and confirms that it does not enter into this agreement in reliance on any representation or other inducement
by or on behalf of the Company (or any person acting on its behalf) except as expressly set out in this document</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in; text-align: left"><B>24</B></TD><TD STYLE="text-align: justify"><B>Governing Law</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.4in">24.1</TD><TD>The contents of this document, its meaning and interpretation and the relationship of the parties are to be governed by the laws of
this State of New South Wales, Australia. The parties submit to the exclusive jurisdiction of the courts of that State.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border: Black 1pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Work Order</B></FONT></P>
                                                                        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biointelect Pty Limited ABN 17 154 647 051</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 27%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key Person</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="width: 73%; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jennifer Herz. Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Services</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#[lnsert]#</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Timetable</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#[lnsert]#</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees and manner of payment</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#[lnsert]#</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Special Conditions (if any)</B></FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#[lnsert]#</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 31.7pt">(a)</TD><TD>This Work Order is made pursuant to and is governed by the terms and conditions of the Master Agreement between the Company and the
Consultant dated <B>#(Insert]# 2013 (Agreement).</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 31.7pt">(b)</TD><TD>Any terms used but not defined in this Work Order have the meaning given to them in the Agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 31.7pt">(c)</TD><TD>This Work Order forms part of the Agreement and all provisions of the Agreement are applicable to this Work Order</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNED for <I>Biointelect Pty Limited</I></B> by its authorised officer:</FONT></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNED for <I>60&deg; Pharmaceuticals LLC</I></B><I> by</I> its authorised officer:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name (please print)</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name (please print)</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title (please print)</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title (please print)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SCHEDULE 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Undertaking</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">From:&#9;<B>#[lnsert full name of Individual]# of #[lnsert address]# (Individual)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To:&#9;<B>#[Name of Company-ACN if applicable]# of #[lnsert address]# (Company)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>BACKGROUND</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 187pt"><B>Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW Australia
2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 187pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left">A</TD><TD STYLE="text-align: justify">The Company and Biointelect Pty Limited (ABN 346245)of 15
Boden Place, Castle Hill, NSW, 17 154 647 051 2154 have entered into a Master Consultancy Agreement
dated #[Insert]#2013 (Agreement).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 32pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-indent: -32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">B</TD><TD>The Individual is an employee of Biointelect to whom either Biointelect or the Company will disclose Confidential Information to enable
Biointelect to fulfil contractual obligations it has to the Company under the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>OPERATIVE PROVISIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><B>1</B></TD><TD STYLE="text-align: justify"><B>Definitions</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left">1.1</TD><TD STYLE="text-align: justify">In this deed:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 32pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.4in">Confidential Information means all information of the
Company which:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">is disclosed to or observed by the Individual in the course of the Individual
fulfilling the contractual obligations Biointelect has to the Company under the Agreement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">is
regarded by the Company as being confidential, including any information relating to:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.8in"></TD><TD STYLE="width: 0.4in; text-align: left">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
Company, its business and financial affairs;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.8in"></TD><TD STYLE="width: 0.4in; text-align: left">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
business and financial affairs of Company's clients.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in">intellectual Property Rights means all registered and unregistered
rights in relation to present and future copyrights, trademarks, designs, know-how, patents, plant varieties and all other intellectual
property as defined in article 2 of the Convention establishing the World Intellectual Property Organisation 1967.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.4in">Moral Rights means the right of integrity of authorship, the right
of attribution of authorship and the right not to have authorship falsely attributed, more particularly as conferred by the <I>Copyright
Act </I>1968 (Cth), and rights of a similar nature anywhere in the world whether existing presently or which may in the future come into
existence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><B>2</B></TD><TD STYLE="text-align: justify"><B>Confidential information</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left">2.1</TD><TD STYLE="text-align: justify">Subject to clause 2.2, the Individual must:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 32pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">not
disclose the Confidential Information without the Company's consent;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">keep the Confidential Information secure and prevent third parties from gaining
access to the Confidential Information;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">use the Confidential Information only for the purpose of enabling the Individual
to fulfil the obligations and exercising the rights of Biointelect under the Agreement; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(d)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">promptly return to the Company all Confidential information within 30 days
of written request from the Company to do so.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left">2.2</TD><TD STYLE="text-align: justify">Clause 2.1 does not apply where:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 38pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">disclosure
is required by law;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 38pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
relevant information is in the public domain; or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the relevant information was received in good faith by the Individual from
a third party who did not prohibit the proposed disclosure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left">2.3</TD><TD STYLE="text-align: justify">The Individual acknowledges that:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any breach of the confidentiality obligations under this deed may not be
adequately compensated by an award of damages; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 73pt; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">any breach will entitle the Company, in addition to any other remedies available
at law or in equity, to seek an injunction to restrain the committing of any breach (or continuing breach).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><B>3</B></TD><TD STYLE="text-align: justify"><B>Intellectual Property</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38pt; text-indent: -30pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">3.1</TD><TD>The individual must immediately disclose to Biointelect in writing any and all new materials, in which Intellectual Property Rights
subsist, developed by him or her in the course of performing the obligations of Biointelect under the Agreement (Works).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38pt; text-indent: -30pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">3.2</TD><TD>The Individual acknowledges thatthe Intellectual Property Rights in all written reports (whether final or interim) created by him
or her on behalf of the Contractor and delivered to the Company as a result of the provision of the Services to the Company, will vest
in the Company, after delivery of the report and payment of all fees due by the Company to the Contractor in respect of the work undertaken
by the Contractor to which the report relates.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38pt; text-indent: -30pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">3.3</TD><TD>The Intellectual Property Rights in all other materials (in whatever form they exist) brought into existence, by him or her on behalf
of the Contractor, as a result of the provisions of the Services to the Company shall be and remain the property of the Contractor and
the Company shall receive no right, title or interest in such Intellectual Property Rights.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38pt; text-indent: -30pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">3.4</TD><TD>For the avoidance of doubt, the Intellectual Property Rights in those materials provided by the Company to the Contractor during the
Term of the Agreement remain with the Company or entity which licensed those materials to the Company and the Individual acknowledges
that he or she acquires no right or ownership of any such of the Intellectual Property Rights of the Company by virtue of this undertaking.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 38pt; text-indent: -30pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">3.5</TD><TD>The Individual acknowledges he or she must do all acts, matters and things and execute all documents that are necessary or desirable
for:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69pt; text-indent: -29pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">perfecting the title and interest of Biointelect to the intellectual Property
Rights arising in the Works assigned under clause 3.2; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69pt; text-indent: -29pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">enabling Biointelect to procure registration of any of the Intellectual Property
Rights that subsist in the Works in any jurisdiction</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left">3.6</TD><TD STYLE="text-align: justify">The Individual warrants that:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 38pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(a)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">he
or she is the author of the Works;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 38pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
Works are original and will not infringe or violate the rights of any third party;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 38pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">he
or she not aware of the Works infringing the rights of any third party; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 69pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(d)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">the Intellectual Property Rights in the Works vested under the Agreement
in Biointelect are free from encumbrances and that the individual is free to assign the Intellectual Property Rights in the Works to Biointelect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">3.7</TD><TD>The Individual must provide such consents as are reasonably required by Biointelect in relation to any existing or future Moral Rights
in respect of any Works developed by him or her in the course of performing the obligations of Biointelect under the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">3.8</TD><TD>Individual acknowledges that it has no rights or ownership of any aspect of the Intellectual Property Rights of the Company, or any
of its clients, in any aspect or regard.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><B>4</B></TD><TD STYLE="text-align: justify"><B>Restraint</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">4.1</TD><TD>The Individual (directly or indirectly, or through any interposed body corporate, trust, principal, agent, shareholder, beneficiary
or in any other capacity) must not, during the Restraint Period:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 64pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(c)</TD><TD>promote, participate in, operate or engage in a business in competition with the Company in the Territory;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 64pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(d)</TD><TD>solicit, canvass or secure the custom of a person who is or was, during the term of the Agreement, a supplier of goods or services
to the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 64pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(e)</TD><TD>solicit, canvass or secure the custom of a person who is or was, during the term of the Agreement, a customer of, the Company;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(f)</TD><TD STYLE="text-align: justify">solicit, employ or engage the services of any employee of
the Company; or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 64pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(g)</TD><TD>use any information concerning the business or affairs of the Company which may have been acquired by the Individual for individual's
own benefit or to the detriment or intended or probably detriment of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left">4.2</TD><TD STYLE="text-align: justify">In this clause 14 a reference to:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(h)</TD><TD STYLE="text-align: justify">#[lnsert name of Company]# includes the Company and any of
its related bodies corporate;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 64pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(i)</TD><TD>Restraint Period means the period commencing on the Commencement Date and ending 12 months after the Term of this agreement ends;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(j)</TD><TD STYLE="text-align: justify">Territory means Australia, and any countries in which work
was conducted by the Consultant or its sub contractors on behalf of the Company (this list includes but is not necessarily limited to
Brazil. Thailand, United States and France)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">4.3</TD><TD>Each of the restraint obligations imposed by this deed is a separate and independent obligation from the other restraint obligations
imposed (although they are cumulative in effect).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left">4.4</TD><TD STYLE="text-align: justify">The Individual agrees that each of the restraint obligations
imposed by this clause 4:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 64pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">is reasonable in its extent (as to duration and restrained conduct) having
regard to the interests of the party to the Agreement;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">extends
no further (in ary respect) than is reasonably necessary; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left">(c)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">is
to protect the goodwill of the Company's business.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">4.5</TD><TD>If any of the restraint obligations imposed by this clause 4 is fudged to go beyond what is reasonable in the circumstances and necessary
to protect the goodwill of the business of the Company but would be judged reasonable and necessary if any activity were deleted or a
period were reduced, then the restraint obligations apply with that activity deleted or area reduced by the minimum amount necessary.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><B>5</B></TD><TD STYLE="text-align: justify"><B>General</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">5.1</TD><TD>All obligations in this deed will remain valid and binding upon the Individual following expiry or termination of the Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 31pt; text-indent: -31pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in">5.2</TD><TD>If any part or a provision of this deed is judged invalid or unenforceable in a jurisdiction it is severed for that jurisdiction and
the remainder of this deed will continue to operate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left">5.3</TD><TD STYLE="text-align: justify">The laws in force in New South Wales govern this deed and
the Individual submits to the non-exclusive jurisdiction of the courts in NewSouth Wales.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">SIGNED SEALED and DELIVERED by the Individual as a deed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Individual</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Individual</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIANA MILLS</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JENNIFER HERZ</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-4-2013</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6-4-2013</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; width: 60%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Work Order #1 pursuant to Master Consultancy Agreement</B></FONT></TD>
    <TD STYLE="width: 40%; text-align: right"><IMG SRC="cm270_ex10-21img02.jpg" ALT="">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Dated #[lnsert date]#</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60&deg; Pharmaceuticals LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biointelect Pty Limited ABN 17 154 647 051</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key Person</B></FONT></TD>
    <TD STYLE="width: 80%; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jennifer Herz, Director</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Services</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>As set out in proposal letter dated 28 May 2013</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Background:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">60&deg; Pharmaceuticals are developing products for treatment of dengue
    fever including celgosivir, an anti-viral for early treatment of infection with dengue, and a novel disease modifying agent which may
    be used for later state treatment and/or for treatment of severe dengue. 60&deg; Pharmaceuticals are in need of the following consultancy
    services:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A) Initial approach and liaison with sanofi to negotiate access to any
    relevant non-clinical and clinical data related to the early development of celgosivir for HIV and HCV</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">B) Analysis of market access environment and assessment of market demand
    forecast for both products in selected countries. Countries included initialy are Brazil and Thailand.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mexico, Singapore, Vietnam, Malaysia and India may be added at a later
    date.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Proposal:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A) Liaison with Sanofi</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Methodology:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Initially, an approach will be made by J Herz to selected key sanofi personnel
    to seek informal advice on the best approach for 60&deg; Pharmaceuticals. The overall objective is to rapidly access al relevant data
    for celgosivir at a minimum cost for 60&deg; Pharmaceuticals.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Cost:
    USD$300per hour,</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial
    contacts and written report with recommendation of initial formal approach capped at 4 hours or USD$1,200, actual hours if less to be
    charged.</FONT></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent
    steps and costs to be agreed at each stage by the CEO of 60&deg; Pharmaceuticals</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">B)&nbsp;Country analysis and market
    demand forecast</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Methodology:</B></P>
    <P STYLE="text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">1)&nbsp;&nbsp;&nbsp;&nbsp;Phase 1: Secondary research
    will be conducted to understand the market access environment in Brazil and Thailand and will include a review of publicly available information
    on the regulatory, reimbursement and policy environment related to the pharmaceutical industry in each country. Estimate 12 hours per
    country.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">2)&nbsp;&nbsp;&nbsp;&nbsp;Phase 2:
An analysis of the healthcare systems in Brazil and Thailand, with a specific emphasis on the management of dengue fever and the use
of antivirals and other relevant treatments. This will include patient flow, decision-making and pharmaceutical procurement. It will
also include where possible information on mild versus severe dengue and attempt to assess the hidden burden. Publicly available information
will be supplemented and validated by primary research with relevant health care professionals and decision makers from each country.
This primary research will be conducted by email and telephone 12 hours per country. Consolidation and report writing for Phase 1 &amp;
2 estimated at <U STYLE="text-decoration: none">6 hours</U> per Country.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; vertical-align: top; width: 27%">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; padding-left: 0.25in; text-indent: -0.25in; width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Phase 3: Forecast estimate - publications on dengue epidemiology and disease burden for each country will be reviewed from the literature to estimate patient numbers. Where possible, market intelligence on current use of pharmaceuticals which may provide analogues and be relevant for predicting uptake, usage and compliance estimates for both dengue products will be sought. In particular, 60&deg; Pharmaceuticals would like to understand the trade-off between demand and price In both markets This information may be enhanced by purchase of local pharmaceutical market data from IMS. Quotations for this data will be sought separately and approved by the CEO of 60&deg; Pharmaceuticals in advance.</FONT></TD></TR>

<TR>
    <TD STYLE="border-left: Black 1pt solid; vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; padding-left: 0.25in; text-indent: -0.25in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-left: 9pt">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Costs proposal:</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; width: 27%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; width: 61%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Literature searching and sourcing relevant articles for secondary research will be conducted by CNS library service @ $85 per hour, estimated at2 hours per country, total 14 hours (NB passed through at cost from CNS)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; text-align: right; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD$1,190</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 1 &amp; 2 are estimated to take 30 hours per country with a total consulting cost of USD$9,000 per country. This estimate is based on actual hours for a similar project. Actual hours will be charged (if less than 30 hours) but capped at USD$9,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD$18,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase 3 - Market forecast. In order to be more efficient it is recommended to prepare this in detail for one major market and then apply the forecasting model with variations for known key variables, to the other countries. Estimate 8 hours to prepare and adapt model @ $300 per hour </FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USD$2,400</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total project costs (excluding expenses)</B></FONT></TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[ USD$21,590</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; width: 27%">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; width: 73%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Payment schedule:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"><FONT STYLE="font-family: Symbol">&middot;&#9;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">40%
    to be invoiced on acceptance and signature of this proposal</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"><FONT STYLE="font-family: Symbol">&middot;&nbsp;
    &nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">30% to be invoiced at the end of June</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-indent: -15pt"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">30%
    to be invoiced on submission of the final report to 60&deg; Pharmaceuticals</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-indent: -15pt"><FONT STYLE="font-family: Symbol">&middot;&#9;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Terms
    30 days, payable by wire transfer to the following bank account:</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; text-indent: 35pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35pt">Bank Name: Commonwealth Bank of Australia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35pt">Bank/Branch Code: 062 347</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35pt">Account: BIOINTELECT PTY LTD</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35pt">Account number: 1054 2500</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 35pt">SWIFT code CTBA AU 2S 3FX</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Expenses:</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-indent: -15pt"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Normal
    telephone, stationery, printing, postage and internet costs are included.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-indent: -15pt"><FONT STYLE="font-family: Symbol">&middot;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">International
    phone calls to be recharged at cost (Skype will be used where possible)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 35pt; text-indent: -15pt"><FONT STYLE="font-family: Symbol">&middot;
    &nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Travel expenses to be recharged at cost but to be approved in
    advance by the CEO of 60&deg; Pharmaceuticals.</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; padding-left: 35pt; text-indent: -15pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Timetable</B></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; padding-left: 35pt; text-indent: -15pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Draft report to be provided 60 days after acceptance of this Work Order. Final report to be completed subject to feedback from 60&deg; Pharmaceuticals</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees and manner of payment</B></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; border-right: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">40% to be invoiced upon acceptance of this work order</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">30% to be invoiced at the end of June</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">30% to be invoiced upon submission offinal report by the Consultant to
    the Company</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Payment of Fees to be made by wire transfer within 30 days of presentation
    of a Tax Invoice by the Consultant to the Company</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special Conditions (if any)</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 73%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Payment to the following bank account:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Biointelect Pty Ltd</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Bank Name: Commonwealth Bank of Australia</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Bank/Branch Code 062 347</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Account: BIOINTELECT PTY LTD</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Account number: 1054 2500</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">SWIFT code CTBAAU 2S 3FX</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; width: 94%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
    Work Order is made pursuant to and is governed by the terms and conditions of the Master Agreement between the Company and the
    Consultant dated June 2013 (Agreement)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any terms used but not defined in this Work Order have the meaning given to them in the Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Work Order forms part of the Agreement and all provisions of the Agreement are applicable to this Work Order</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Tims, Serif; font-size: 10pt"><B>SIGNED for <I>Biointelect Pty Limited</I></B> by its</FONT></P>
                           <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorised Officer</FONT></P></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Tmes, Serif; font-size: 10pt"><B>SIGNED for 60<SUP>o</SUP> <I>Pharmaceuticals LLC</I></B> by</FONT></P>
                           <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its authorised Officer</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jennifer Herz</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Don</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name (please print)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name (please print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title (please print)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title (please print)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-21img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="2" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD COLSPAN="2" STYLE="border: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Work Order #11</B></FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biointelect Pty Limited ABN 17 154 647 051</B></FONT></TD></TR>
  <TR>
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 Degrees Pharmaceuticals LLC [Client]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 26%; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key Persons</B></FONT></TD>
    <TD STYLE="width: 74%; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jennifer Herz, in her role as Director of 60P Australia Pty Ltd</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Services</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 19pt">Support capital raising activities with the following
    activities:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Identify
    and outreach to potential investors in Australia and overseas</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Preparation
    of pitch deck and other supporting materials</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Presentation
    of opportunity to potential investors</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Participation
    in webinar and preparation of content</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Outreach
    to media and response to media enquiries</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 23pt"><FONT STYLE="font-family: Symbol">&middot;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">Support
    CEO and Torreya with negotiations, due diligence and investor relations activities.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 19pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Project
    Management of activities related to agreed in vitro, preclinical and clinical studies related to testing of Tafenoquine against SARS-CoV2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37pt"><FONT STYLE="font-family: Symbol">&middot;
    &nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Introductions to Certara and 360biolabs</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37pt"><FONT STYLE="font-family: Symbol">&middot;
    &nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Liaison
with Australia investigators, CRO's, health, defence, DFAT and TGA</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37pt"><FONT STYLE="font-family: Symbol">&middot;
    &nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Local
project management and coordination as required</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 37pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Timetable</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From March 2020 until deal concludes.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees and manner of payment</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">$245,000 USD in deferred compensation paid in shares of 60 Degrees Pharmaceuticals
    [with the number of shares to be defined by dividing $245,000 by the fair market value at the time of payment] for any deal involving
    an investor introduced by Biointelect which results in consummation of &gt;$1 million USD in financing.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">$100,000 USD and $155,000 USD deferred compensation paid in shares of 60
    Degrees Pharmaceuticals [with the number of shares to be defined by dividing $155,000 by the fair market value at the time of payment]
    if the Company consummates an IPO or for any deal which results in additional $7.5 million USD or more in financing from an investor OR
    that results in i) sponsorship of a clinical trial for COVID19 by the 60P group and ii) that results in indefeasible retirement and conversion
    to equity of Knights principle, interest and debenture as a condition of closing.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Resident Director fees will be increased to $40,000 AUD p.a. in the event
    an IPO in consummated by 60 Degrees Pharmaceuticals LLC.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For clarity, compensation will be paid by 60 Degrees Pharmaceuticals (located
    at 1025 Connecticut Avenue NW, Suite 1000, Washington DC, United States) and the shares described above are in reference to shares in
    the same entity, and/or a successor entity and/or the entity owning 100% of 60 Degrees Pharmaceuticals LLC that will be listed in the
    event of an IPO.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares not issued within five years of execution of this work agreement
    will expire. The obligation of 60 Degrees Pharmaceuticals LLC to pay the cash compensation will expire withing three years of the date
    of execution of this agreement.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">To be invoiced on completion of deal as specified above.</P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Special Conditions (if any)</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Work is conducted at risk with payment contingent on successful funding outcome as defined above.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Work Order is made pursuant to and is governed by the terms and conditions of the Master Agreement between the Company and the Consultant dated 29<SUP>th</SUP> May 2013 (Agreement).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any terms used but not defined in this Work Order have the meaning given to them in the Agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Work Order forms part of the Agreement and all provisions of the Agreement are applicable to this Work Order.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times Serif; font-size: 10pt"><B>SIGNED</B> for <B><I>Biointelect Pty Limited</I></B> by its</FONT></P>
                           <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorised officer:</FONT></P></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNED</B> for 60 Degrees Pharmaceuticals LLC by its authorised officer:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Biointelect Pty Ltd. Suite 110, 117 Old Pittwater Road, Brookvale NSW 2100
Australia, ABN: 17 154 647 051</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">T <U>1300 800 984</U> E <U>office@biointelect.com</U> Sydney | Lyon <U>www.biointelect.com
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="cm270_ex10-21img01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jennifer Herz</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name (please print)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name (please print)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Biointelect Pty Ltd. Suite 110, 117 Old Pittwater Road, Brookvale NSW 2100
Australia, ABN: 17 154 647 051</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">T <U>1300 800 984</U> E <U>office@biointelect.com</U> Sydney | Lyon <U>www.biointelect.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>25
<FILENAME>cm270_ex10-22.htm
<DESCRIPTION>EXHIBIT 10.22
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.22</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>EMPLOYMENT AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">This Employment Agreement, dated
as of January 12, 2023 (this <B>&ldquo;Agreement&rdquo;</B>), is made and entered into by and between 60 Degrees Pharmaceuticals Inc.,
a De corporation (the <B>&ldquo;Company&rdquo;</B>), and Geoffrey Dow (the <B>&ldquo;Executive&rdquo;</B> and together with the Company,
the &ldquo;<B>Parties</B>&rdquo; and individually a &ldquo;<B>Party</B>&rdquo;<B>).</B> Capitalized terms used herein and not otherwise
defined shall have the meanings set forth in Section 11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>RECITALS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, subject to the
terms and conditions hereinafter set forth, Company wishes to employ Executive as its Chief Executive Officer and Executive wishes to
be employed by Company as its Chief Executive Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration
of the foregoing premises and the mutual promises, terms, provisions, and conditions set forth in this Agreement, the adequacy and sufficiency
of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><U>Employment</U>. Subject to the terms and conditions set forth in this Agreement, Company hereby offers,
and Executive hereby accepts employment with Company, as of the date first above written (the <B>&ldquo;Effective Date&rdquo;</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><U>Term</U>. The Executive&rsquo;s employment hereunder shall be effective as of the Effective Date and
shall continue until the second (2nd) anniversary thereof (the &ldquo;<B>Initial Term</B>&rdquo;), unless terminated earlier pursuant
to the terms of this Agreement; provided that, on such second (2nd) anniversary of the Effective Date and each annual anniversary thereafter
(such date and each annual anniversary thereof, a &ldquo;<B>Renewal Date</B>&rdquo;), the Agreement shall be deemed to be automatically
extended, upon the same terms and conditions, for successive periods of one (1) year (each &ldquo;<B>Renewal Term</B>&rdquo;), unless
either Party provides written notice of its intention not to extend the term of the Agreement at least 90 days prior to the applicable
Renewal Date. The Initial Term and each Renewal Term is hereinafter referred to as the &ldquo;<B>Term</B>.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><U>Capacity and Performance</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">During the Term, the Executive shall be employed by Company on a full-time basis as its Chief Executive
Officer and Board Chairman. Executive shall perform such duties and responsibilities as directed by the Board of Directors of the Company
(the &ldquo;<B>Board</B>&rdquo;), consistent with Executive&rsquo;s position on behalf of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Executive shall devote his full business time, attention, skill, and best efforts to the performance of
his duties under this Agreement and shall not engage in any other business or occupation during the Term of Employment, including, without
limitation, any activity that: (x) conflicts with the interests of the Company or any other member of the Company Group, (y) interferes
with the proper and efficient performance of Executive&rsquo;s duties for the Company, or (z) interferes with Executive&rsquo;s exercise
of judgment in the Company&rsquo;s best interests. Notwithstanding the foregoing, nothing herein shall preclude Executive from: (i) serving,
with the prior written consent of the Board, as a member of the Board of Directors or Advisory Board (or the equivalent in the case of
a non-corporate entity) of a noncompeting for-profit business and one or more charitable organizations, (ii) engaging in charitable activities
and community affairs, and (iii) managing Executive&rsquo;s personal investments and affairs; <I>provided, however,</I> that the activities
set out in clauses (i), (ii), and (iii) shall be limited by Executive so as not to materially interfere, individually or in the aggregate,
with the performance of his duties and responsibilities hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Executive&rsquo;s employment with Company shall be exclusive with respect to the business of Company.
Accordingly, during the Term, Executive shall devote Executive&rsquo;s full business time and Executive&rsquo;s best efforts, business
judgment, skill and knowledge to the advancement of the business and interests of Company and the discharge of Executive&rsquo;s duties
and responsibilities hereunder, except for permitted vacation (and other paid time off) periods, reasonable periods of illness or incapacity,
and reasonable and customary time spent on civic, charitable and religious activities, in each case such activities shall not interfere
in any material respect with Executive&rsquo;s duties and responsibilities hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">During the Term, the Executive will report directly to the Board.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">On the Effective Date, the Board shall appoint Executive as the Chief Executive Officer &amp; Chairman
of the Board of Directors of the Company and shall, during the Term, nominate and recommend Executive for election as a director. Executive
acknowledges and agrees that Executive is not entitled to any additional compensation in respect of Executive&rsquo;s appointment as a
director of Company. If during the Term, Executive ceases to be a director of Company for any reason, Executive&rsquo;s employment with
the Company will continue (unless terminated under Section 5), and all terms of this Agreement (other than those relating to Executive&rsquo;s
position as a director of Company) will continue in full force, and effect and Executive will have no claims in respect of such cessation
of office. Executive agrees to abide by all statutory, fiduciary or common law duties arising under applicable law that apply to Executive
as a director of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">Executive shall be employed to perform his duties under this Agreement at the primary office location
of Company, or at such other location or locations as may be mutually agreeable to Executive and Company (including reasonable provisions
during the COVID-19 national public health emergency). Notwithstanding this, it is expected that the Executive shall be required to travel
a reasonable amount of time in the performance of his duties under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><U>Compensation and Benefits</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Base Salary</U>. For services performed by Executive under this Agreement, Company shall pay Executive
an annual base salary during the Term at the rate of $228,000 per year, minus applicable withholdings and deductions, payable at the same
times as salaries are payable to other executives of Company (the <B>&ldquo;Base Salary&rdquo;</B>). During the Term, the Base Salary
shall be reviewed by the Compensation Committee and/or the Board each year, and the Board may, from time to time, increase such Base Salary
and any reference to <B>&ldquo;Base Salary&rdquo;</B> herein shall refer to such Base Salary, as increased.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Annual Bonus</U>. For each fiscal year of the Company during the Term, the Company shall afford Executive
the opportunity to earn an incentive bonus (<B>&ldquo;Bonus&rdquo;</B>) as described in this Section 4(b). The aggregate target Bonus
payable to Executive under such program(s) shall equal 25% percent (25%) of the Base Salary for such fiscal year and shall be payable
to the extent the applicable performance goals are achieved (which goals and payment matrices shall be set by the Compensation Committee
of the Board in its discretion). amount of the Bonus will be determined by certification by the Board that the applicable goals have been
achieved, and the Board shall promptly provide such certification following achievement of the applicable goals. The amount payable under
this Section 4(b) shall be paid by the seventh (7<FONT STYLE="font-size: 10pt">th</FONT>) day following the approval of the annual audited
financial statements by the Board or its audit committee, as applicable, for the calendar year in which the Bonus is earned or if later,
the fifteenth (15<FONT STYLE="font-size: 10pt">th</FONT>) day of the third month following the end of the Company&rsquo;s fiscal year
in which the Bonus is earned..</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Equity Awards</U>. During the Term, the Executive shall be entitled to receive equity awards either
now or in the future, on terms and conditions similar to those applicable to other executive officers of the Company generally, inside
or outside of any established equity plan. The amount and terms of the long-term incentive awards awarded to the Executive shall be set
by the Compensation Committee in its discretion, except</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><U>Annual Stock Option</U><B>.</B>
Upon the Company becoming publicly traded on a national exchange, Executive shall be granted a five-year option (the &ldquo;<U>Option</U>&rdquo;)
to purchase a total of 15,000 shares of the Company&rsquo;s common stock on the last day of each quarter, or March 31, June 30, September
30 and December 31, in each calendar year (for a cumulative total or no more than 300,000 shares over five years). The per share exercise
price of the Option shall be equal to the per share closing price of the Company&rsquo;s common stock on the date of grant, and shall
have a cashless exercise provision. The Option shall vest and become exercisable subject to the terms set forth in the 2022 Equity Incentive
Plan approved by the Board and effectuated prior to the Company going public by way of Initial Public Offering of its common stock on
a national exchange. The Option shall otherwise be subject to the terms of the plan pursuant to which it is granted and/or an option agreement
to be entered into between Executive and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>Other Executive Benefits</U>. During the Term, the Executive shall be entitled to participate in all
Executive benefit plans, including health and 401(k) plans, from time to time generally in effect for Company&rsquo;s Executives (collectively,
<B>&ldquo;Benefit Plans&rdquo;</B>). If the Company does not implement a health plan, it will compensate Executive $1,100.00 per month.
Such participation and receipt of benefits under any such Benefit Plans shall be on the same terms (including cost-sharing between Company
and Executive) as are applicable to other Company Executives and shall be subject to the terms of the applicable plan documents and generally
applicable Company policies. The Company may alter, modify, add to or delete the Benefit Plans in a manner nondiscriminatory to Executive
at any time in accordance with applicable plan rules.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>Vacation</U>. The Executive shall be entitled to an annual vacation of 28 days plus ten established
holiday days per full calendar year of his employment with the Company hereunder. Any unused vacation in one accrued calendar year may
not be carried over to any subsequent calendar year. However, the Company shall pay the Executive (based on the Executive&rsquo;s Base
Salary) for any such unused vacation days within 30 days of the end of any such calendar year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>Business and Travel Expenses</U>. Company shall pay or reimburse Executive for all reasonable, customary
and necessary business expenses (including cell phone, travel, lodging, and entertainment expenses) which are correctly documented and
incurred or paid by Executive in the performance of Executive&rsquo;s duties and responsibilities hereunder, subject to the rules, regulations,
and procedures of Company and in effect from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify"><U>Change in Control Transaction Bonus</U>. During Executive&rsquo;s employment, if (i) a Change in Control
has occurred, and (ii) as of such Change in Control, the price per share of Company&rsquo;s common stock is two (2) times or more than
the closing price per share of the common stock of the Company upon listing on an exchange, Executive shall be paid a bonus (the <B>&ldquo;Change
in Control Transaction Bonus&rdquo;</B>), in cash, equal to two (2) times the Base Salary as in effect immediately before such Change
in Control. If applicable, the Change in Control Transaction Bonus shall be paid in a lump sum within fifteen (15) days after the consummation
of such Change in Control and the following certification by the Board of the occurrence of clauses (i) and (ii) above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><U>Termination of Employment; Severance Benefits</U>. Notwithstanding the provisions of Section 2, the
Executive&rsquo;s employment hereunder shall terminate under the following circumstances:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Death</U>. If Executive&rsquo;s dies during the Term, Executive&rsquo;s employment hereunder shall
immediately and automatically terminate. In such event, Company shall pay to Executive&rsquo;s designated beneficiary or, if no beneficiary
has been selected by Executive, to Executive&rsquo;s estate, the Final Compensation. Company shall have no further obligation hereunder
to Executive, Executive&rsquo;s beneficiary, or Executive&rsquo;s estate upon the termination of Executive&rsquo;s employment under this
Section 5(a) including, specifically, that the provisions of Section 5(d) shall not apply.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Disability</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Company may terminate Executive&rsquo;s employment hereunder due to Executive&rsquo;s Disability during
the Term by giving Executive thirty (30) days&rsquo; written notice of its intent to terminate, but in no event shall such termination
be effective prior to the expiration of the time periods in the definition of <B>&ldquo;Disability.&rdquo;</B> Notwithstanding the foregoing,
Company will, after engaging in an interactive process with Executive to discern whether reasonable accommodation(s) can be provided without
undue hardship upon Company, offer Executive reasonable accommodation(s) to enable Executive to perform the essential functions of Executive&rsquo;s
position to the extent required by applicable law (if any) before terminating Executive&rsquo;s employment hereunder. Executive may decline
such reasonable accommodation, in which case Executive&rsquo;s employment hereunder will terminate as provided in this subsection.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">In the event of such termination for Disability, Executive will receive Executive&rsquo;s Final
                                                                 Compensation. Company shall have
no further obligation hereunder to Executive upon termination of Executive&rsquo;s employment under this Section 5(d), including, specifically,
that the provisions of Section 5(d) shall not apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">Subject to Executive&rsquo;s rights under the Family and Medical Leave Act (FMLA) and the Americans with
Disabilities Act (ADA), Company may designate another Executive to act in Executive&rsquo;s place during any period of Executive&rsquo;s
Disability during which Executive is unable to perform the essential functions of Executive&rsquo;s position with or without a reasonable
accommodation. Notwithstanding any such designation, Executive shall continue to receive the Base Salary in accordance with Section 4(a)
and coverage under the Benefit Plans in accordance with Section 4(b), to the extent permitted by the then- current terms of the applicable
benefit plans and as provided under the FMLA, if applicable, until the earliest to occur of: (A) the end of the Term, (B) Executive becomes
eligible for disability income benefits under Company&rsquo;s disability income plan, or (C) the termination of Executive&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iv)</TD><TD STYLE="text-align: justify">While receiving disability income payments under Company&rsquo;s disability income plan (if applicable),
Company will continue to pay to Executive Executive&rsquo;s Base Salary under Section 4(a), but may offset any such disability income
payments Executive receives against the Base Salary payments. Executive will also continue to participate in the Benefit Plans in accordance
with Section 4(b) and the terms of such Benefit Plans, until the end of the Term or until the termination of Executive&rsquo;s employment,
whichever occurs first.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(v)</TD><TD STYLE="text-align: justify">If any question arises as to whether during any period Executive has a Disability as defined herein, Executive
may, and at the request of Company shall, submit to a medical examination by a qualified, unbiased physician selected by Company and reasonably
acceptable to Executive or Executive&rsquo;s duly appointed guardian, if any, to determine whether Executive has a Disability and such
determination shall for the purposes of this Agreement be conclusive of the issue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>By Company for Cause</U>. Company may terminate Executive&rsquo;s employment hereunder for Cause, as
defined in Section 11(c), at any time upon notice to Executive setting forth in reasonable detail the nature of such Cause. Upon the giving
of notice of termination of Executive&rsquo;s employment hereunder for Cause, Executive will receive Executive&rsquo;s Final Compensation.
Except as provided herein, Company will have no further obligation to Executive upon termination of Executive&rsquo;s employment under
this Section 5(c). Any notice of termination of Executive&rsquo;s employment hereunder for Cause, or any notice to Executive regarding
any event, condition or circumstance that, if not cured, if applicable, in accordance with the above, could give rise to a termination
of Executive&rsquo;s employment hereunder for Cause, shall set forth in detail the applicable event(s), condition(s) or circumstance(s)
constituting reason(s) or potential reason(s) for such termination hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>By Company Other than for Cause or by Executive for Good Reason</U>. Company may terminate Executive&rsquo;s
employment hereunder other than for Cause at any time upon thirty (30) days&rsquo; written notice to Executive and Executive may terminate
Executive&rsquo;s employment hereunder for Good Reason at any time upon thirty (30) days&rsquo; written notice to Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">In the event of a termination of Executive&rsquo;s employment under this Section 5(d), in addition to
the Final Compensation, Executive shall receive:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">continuation of Executive&rsquo;s Base Salary, at the rate in effect as of the date immediately preceding
the date of termination, until the earlier of: (x) the Term End Date and (y) the first anniversary of the date of termination (<I><U>provided</U></I>,
<I><U>however,</U></I> if the date of termination is after the first anniversary of the Effective Date, the period pursuant to this subsection
shall be eighteen (18) months after the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices,
less applicable withholdings, commencing at the conclusion of the period set forth in Section 5(d)(iii), provided that the first installment
of such payments shall include all amounts which would have been paid during the period between Executive&rsquo;s date of termination
and the date of such first installment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">if the date of termination occurs after the end of a calendar year but prior to the date on which a Bonus
is paid under Section 4(d), payment of such Bonus as determined under Section 4(d) shall be at the time proscribed by Section 4(b); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">payment of a <I>pro-rata</I> portion of the amount of Executive&rsquo;s Bonus for the year in which termination
occurs that would have been payable based on actual performance determined under the terms of the Bonus as then in effect for such year,
with such <I>pro-rata</I> portion calculated by multiplying the amount of such bonus for the year in which such termination occurs (as
determined by the Board based on actual performance for such year) by a number: (x) the numerator of which is the number of days worked
by Executive during the year of such termination, and (y) the denominator of which is three hundred sixty-five (365), with such payment
to be made after the determination of the Bonus pursuant to Section 4(b).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">If the Executive timely and properly elects health continuation coverage under the Consolidated Omnibus
Budget Reconciliation Act of 1985 (<B>&ldquo;COBRA&rdquo;</B>), the Company shall reimburse the Executive for the monthly COBRA premium
paid by the Executive for himself and his dependents. Such reimbursement shall be paid to the Executive on the 1st day of the month immediately
following the month in which the Executive timely remits the premium payment. The Executive shall be eligible to receive such reimbursement
until the earliest of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">the first anniversary of the date of termination (provided, however, if the date of termination is after
the first anniversary of the Effective Date, the period pursuant to this subsection (1) shall be eighteen (18) months after the date of
termination);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">the date the Executive is no longer eligible to receive COBRA continuation coverage; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">the date on which the Executive receives substantially similar coverage from another employer or other
source.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">Any obligation of Company to Executive
                                            under this Section 5(d) (other than for the Final Compensation or for benefits required by
                                            law) is conditioned upon Executive&rsquo;s execution and delivery to Company and the expiration
                                            of all applicable statutory revocation periods of a release of claims in the form attached
                                            hereto as <U>Exhibit A</U> (the &ldquo;<B>Executive Release</B>&rdquo;), provided, that the
                                            terms of such Executive Release shall be subject to modification to the extent necessary
                                            to comply with: (a) the fact that Company is simultaneously terminating more than one executive
                                            as part of a group termination decision or (b) changes in applicable law, if any, occurring
                                            after the date hereof, and prior to the date such Executive Release is executed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>By Executive Other than for Good Reason</U>. Executive may terminate Executive&rsquo;s employment hereunder
other than for Good Reason upon thirty (30) days&rsquo; written notice to Company; <I><U>provided</U></I>, that Company may, in its sole
and absolute discretion, by written notice accelerate such date of termination. In the event of a termination of Executive&rsquo;s employment
under this Section 5(e), Executive will receive the Final Compensation. Company shall have no further obligation hereunder to Executive
upon termination of Executive&rsquo;s employment under this Section 5(e).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>Change in Control Severance</U>. Except as otherwise set forth herein, if a Change in Control occurs,
and on, or at any time during the 24 months following, the Change in Control, (i) the Company terminates Executive&rsquo;s employment
for any reason other than Cause or Disability, or (ii) Executive terminates Executive&rsquo;s employment for Good Reason, Executive shall
be entitled to the following benefits:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">The Company shall pay Executive, in a lump sum within 60 days following termination of Executive&rsquo;s
employment, severance equal to two times the sum of Executive&rsquo;s Base Salary and Bonus (the full, non- prorated Bonus for the year
of termination assuming attainment of the targeted performance goals at the 100% payout level).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">Executive also shall be entitled to receive any and all vested benefits accrued under any other incentive
plans to the date of termination of employment, the amount, entitlement to, form, and time of payment of such benefits to be determined
by the terms of such incentive plans. For purposes of calculating Executive&rsquo;s benefits under the incentive plans, Executive&rsquo;s
employment shall be deemed to have terminated under circumstances that have the most favorable result for Executive under the applicable
incentive plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">If, upon the date of termination of
                                            Executive&rsquo;s employment, Executive holds any awards with respect to securities of the
                                            Company, (i) all such awards that are options shall immediately become vested and exercisable
                                            upon such date and shall be exercisable thereafter until the <U>earlier</U> of the third
                                            (3rd) year anniversary of Executive&rsquo;s termination of employment or the expiration of
                                            the term of the options; (ii) all restrictions on any such awards of restricted stock, restricted
                                            stock units or other awards shall terminate or lapse, and all such awards of restricted stock,
                                            restricted stock units or other awards shall be vested and payable; and (iii) all performance
                                            goals applicable to any such performance-based awards that are &ldquo;in cycle&rdquo; (i.e.,
                                            the performance period is not yet complete) shall be deemed satisfied at the &ldquo;target&rdquo;
                                            level (assuming 100% payout), and (iv) all such awards shall be paid in accordance with the
                                            terms of the applicable award agreement. The provisions of this subsection shall be subject
                                            (and defer) to the provisions of any incentive plan, award agreement or other agreement as
                                            it relates to an individual award to the extent such provisions provide treatment that is
                                            more favorable to Executive than the treatment described in this subsection and such more
                                            favorable provisions in such incentive plan, award agreement or other agreement shall supersede
                                            any inconsistent or contrary provision of this subsection. All of Executive&rsquo;s awards
                                            with respect to securities of the Company that are outstanding upon the date of termination
                                            of Executive&rsquo;s employment shall continue to be subject to, and enjoy the benefits and
                                            protections under, the terms of the incentive plan, the award agreement and any other plan,
                                            agreement, policy or other arrangement to which such awards are subject as of the effective
                                            date of Executive&rsquo;s participation, including any employment security agreement or other
                                            written compensation arrangement (even if the remaining terms thereof are waived), without
                                            application of this subsection.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iv)</TD><TD STYLE="text-align: justify">Executive and Executive&rsquo;s spouse and other qualified beneficiaries shall be eligible for continued
coverage as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(A)</TD><TD STYLE="text-align: justify">If the Executive, Executive&rsquo;s spouse and/or Executive&rsquo;s other qualified beneficiaries are
enrolled under a group health plan as defined by COBRA, on the date of termination of Executive&rsquo;s employment, Executive, Executive&rsquo;s
spouse and/or Executive&rsquo;s qualified beneficiaries may elect to continue such coverage under COBRA, except that the maximum coverage
period shall be extended to no less than the Severance Period (but no more than 2 years) for that Executive, unless, after electing COBRA,
the individual attains age 65 and becomes eligible for Medicare, in which case COBRA shall end for that individual. If Executive, Executive&rsquo;s
spouse and/or Executive&rsquo;s other qualified beneficiaries elect COBRA coverage, the Company shall pay a portion of the COBRA costs
for the Severance Period for that Executive (subject to any earlier termination of COBRA). The portion to be paid by the Company shall
equal the amount necessary so that the total of the COBRA costs paid by Executive is equal to the costs that would have been paid by Executive
for such coverage as an active employee immediately prior to termination of Executive&rsquo;s employment or, if less, prior to the Change
in Control. The cost of COBRA coverage paid by the Company may be taxable income to the Executive and reported on Executive&rsquo;s Internal
Revenue Service Form W-2. Executive, Executive&rsquo;s spouse and/or Executive&rsquo;s qualified beneficiaries may continue coverage under
COBRA after the Severance Period for that Executive, provided they pay the full COBRA costs and COBRA otherwise remains available.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(B)</TD><TD STYLE="text-align: justify">The benefits and/or extended coverage provided under this subsection shall cease prior to the date such
benefits and/or extended coverage would otherwise end under subsection if and when Executive (A) obtains employment with another employer
during the Severance Period and becomes eligible for coverage under any substantially similar plan provided by his/her new employer or
(B) fails to pay the required active employee portion of the cost of coverage provided under this subsection in the time and manner specified
by the Company or its designee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(v)</TD><TD STYLE="text-align: justify">Executive shall be entitled to payment for any accrued but unused vacation in accordance with the Company&rsquo;s
policy in effect at the time of termination of Executive&rsquo;s employment, in a lump sum within 60 days following such termination.
Executive shall not be entitled to receive any payments or other compensation attributable to vacation that would have been earned had
Executive&rsquo;s employment continued during the Severance Period, and Executive waives any right to receive any such compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(vi)</TD><TD STYLE="text-align: justify">The Company shall, at the Company&rsquo;s expense, provide Executive with 12 months of executive outplacement
services with a professional outplacement firm selected by the Company; provided that Executive must use the outplacement services by
no later than the end of the second calendar year following the calendar year in which the termination of Executive&rsquo;s employment
occurred and the total cost of such outplacement services must not exceed any per individual cap on such amounts in the Company&rsquo;s
agreement with the professional outplacement firm selected by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(vii)</TD><TD STYLE="text-align: justify">Executive shall not be entitled to reimbursement for any other fringe benefits or perquisite payments
during the Severance Period, including but not limited to dues and expenses related to club memberships, automobile, cell phone, expenses
for professional services, executive physicals, and other similar perquisites.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(viii)</TD><TD STYLE="text-align: justify">The Company shall pay as incurred (within ten calendar days following the Company&rsquo;s receipt of an
invoice from Executive) Executive&rsquo;s out-of-pocket expenses, including attorneys&rsquo; fees, incurred by Executive at any time from
the date of this Agreement through Executive&rsquo;s remaining lifetime or, if longer, the statute of limitations for contract claims
under applicable state law, in connection with any action taken to enforce the Executive&rsquo;s rights under this Agreement or construe
or determine the validity of this Agreement or otherwise in connection herewith, including any claim or legal action or proceeding, whether
brought by Executive or the Company or another party; provided, Executive must be successful through judgment in his/her favor with respect
to such action in order to recover fees under this Section 5(f)(viii); provided further, that Executive shall have submitted an invoice
for such fees and expenses at least fifteen calendar days before the end of the calendar year next following the calendar year in which
such fees and expenses were incurred. The amount of such legal fees and expenses that the Company is obligated to pay in any given calendar
year shall not affect the legal fees and expenses that the Company is obligated to pay in any other calendar year, and Executive&rsquo;s
right to have the Company pay such legal fees and expenses may not be liquidated or exchanged for any other benefit. The Company&rsquo;s
obligation to pay Executive&rsquo;s eligible legal fees and expenses under this Section 5(f)(viii) shall not be conditioned upon the termination
of Executive&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><U>Effect of Termination</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Upon termination of Executive&rsquo;s employment hereunder and subject to the provisions of Section 5
and Section 6(c), Company&rsquo;s entire obligation to Executive shall be payment of Final Compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">In connection with the cessation of Executive&rsquo;s service as Chief Executive Officer of Company for
any reason, except as may otherwise be requested by the Company in writing and agreed upon in writing by Executive, Executive shall be
deemed to have resigned from any and all directorships, committee memberships, and any other positions Executive holds with the Company
or any other member of the Company Group. Executive hereby agrees that no further action is required by Executive or any of the preceding
to make the transitions and resignations provided for in this paragraph effective, but Executive nonetheless agrees to execute any documentation
Company reasonably requests at the time to confirm it and to not reassume any such service or position without the written consent of
Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Except as otherwise required by Consolidated Omnibus Budget Reconciliation Act or any similar federal
or state law, benefits shall continue or terminate pursuant to the terms of the applicable benefit plan or agreement, without regard to
any continuation of Base Salary or other payment to Executive following such date of termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">The provisions of this Section 6 shall apply to any termination of employment. Provisions of this Agreement
will survive any termination if so provided herein or if necessary or desirable to accomplish the purposes of other surviving provisions,
including, without limitation, the obligations of Executive under Section 7 through Section 9.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">Any termination of Executive&rsquo;s employment with Company under this Agreement shall automatically
be deemed to be simultaneous resignation of all other positions and titles (including any director positions) that Executive holds with
Company and any Affiliate or subsidiary thereof. This Section 6(e) shall constitute a resignation notice for such purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">Upon termination of the Executive&rsquo;s employment or upon the Company&rsquo;s request at any other
time, the Executive will deliver to the Company all of the Company&rsquo;s property, equipment, and documents, together with all copies
thereof, and any other material containing or disclosing any Intellectual Property or Confidential Information and certify in writing
that the Executive has fully complied with the foregoing obligation. The Executive agrees that the Executive will not copy, delete, or
alter any Company computer equipment information before the Executive returns it to the Company. In addition, if the Executive has used
any personal computer, server, or email system to receive, store, review, prepare or transmit any Company information, including but not
limited to, Confidential Information, the Executive agrees to provide the Company with a computer-usable copy of all such Confidential
Information and then permanently delete and expunge such Confidential Information from those systems; and the Executive agrees to provide
the Company access to the Executive&rsquo;s system as reasonably requested to verify that the necessary copying and/or deletion is completed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify"><U>Confidential Information</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Executive acknowledges that Company continually develops Confidential Information, that Executive may
develop Confidential Information for Company and that Executive may learn of Confidential Information during the course of employment
with Company. Executive will comply with the policies and procedures of Company for protecting Confidential Information and shall not
disclose to any Person or use, other than as required by applicable law, regulation or process or for the proper performance of Executive&rsquo;s
duties and responsibilities to Company, any Confidential Information obtained by Executive incident to Executive&rsquo;s employment or
other association with Company. Executive understands that this restriction shall continue to apply after Executive&rsquo;s employment
terminates, regardless of the reason for such termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding anything contained in this Section 7 to the contrary, nothing contained herein shall prevent
Executive from disclosing any Confidential Information required by law, subpoena, court order or other legal processes to be disclosed;
provided, that, Executive shall give prompt written notice to Company of such requirement, disclose no more information than is so required
and cooperate, at Company&rsquo;s cost and expense, with any attempt by Company to obtain a protective order or similar treatment with
respect to such information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Pursuant to the Defend Trade Secrets Act of 2016, Executive understands that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Executive may not be held criminally or civilly liable under any federal or state trade secret law for
the disclosure of a trade secret that is made in confidence to a federal, state, or local government official, either directly or indirectly,
or to an attorney and solely for the purpose of reporting or investigating a suspected violation of law; or is made in a complaint or
other document that is filed under seal in a lawsuit or other proceeding; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law,
Executive may disclose the employer&rsquo;s trade secrets to Executive&rsquo;s attorney and use the trade secret information in the court
proceeding if Executive files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant
to court order.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><U>Assignment of Rights to Intellectual Property</U>. Executive shall promptly and fully disclose to Company
all Intellectual Property developed for the benefit of Company in the course of Executive&rsquo;s employment by Company. Executive hereby
assigns and agrees to assign to Company (or as otherwise directed by Company) Executive&rsquo;s full right, title, and interest in and
to all such Intellectual Property. Executive agrees to execute any and all applications for domestic and foreign patents, copyrights or
other proprietary rights and to do such other acts (including without limitation the execution and delivery of instruments of further
assurance or confirmation) requested by Company (at Company&rsquo;s expense) to assign to Company the Intellectual Property developed
for the benefit of Company in the course of Executive&rsquo;s employment by Company and to permit Company to enforce any patents, copyrights
or other proprietary rights to the Intellectual Property. Executive will not charge Company for time spent in complying with these obligations.
All copyrightable works that Executive creates developed for the benefit of Company in the course of Executive&rsquo;s employment by Company
shall be considered <B>&ldquo;</B>work made for hire<B>.&rdquo;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><U>Restricted Activities</U>. Executive agrees that the restrictions on Executive&rsquo;s activities during
and after Executive&rsquo;s employment set forth below are necessary to protect the goodwill, Confidential Information and other legitimate
interests of Company and its successors and assigns:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">During the Term of this Agreement and during the Restricted Period following termination of employment,
Executive will not, without the prior written consent of Company, directly or indirectly, and whether as principal or investor or as an
Executive, officer, director, manager, partner, consultant, agent, or otherwise, alone or in association with any other Person, firm,
corporation, or other business organization, engage or otherwise become involved in a Competing Business (as defined below) in any country
in which the Company conducted business during the Term; provided, however, that the provisions of this Section 9 shall apply solely to
those activities of a Competing Business which are congruent with those activities with which Executive was personally involved or for
which Executive was responsible while employed by the Company or its subsidiaries during the twelve (12) month period preceding termination
of Executive&rsquo;s employment. This Section 9 will not be violated, however, by Executive&rsquo;s investment of up to $500,000 in the
aggregate in one or more publicly-traded companies that engage in a Competing Business. <B>&ldquo;Competing Business&rdquo;</B> means
a business or enterprise (other than Company or its subsidiaries) engaged in development and commercialization of therapeutics for COVID-19
or malaria and any other business directly competing with the business of the Company as currently conducted or otherwise conducted by
the Company during the Term. <B>&ldquo;Restricted Period&rdquo;</B> means twenty-four (24) months.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">During the Term of this Agreement and during the Restricted Period (as defined above), Executive will
not engage in any Wrongful Solicitation. A <B>&ldquo;Wrongful Solicitation&rdquo;</B> shall be deemed to occur when Executive directly
or indirectly (except in the course of Executive&rsquo;s employment with Company), for the purpose of conducting or engaging in a Competing
Business, calls upon, solicits, advises or otherwise does, or attempts to do, business with any Person who is, or was, during the then
most recent 12-month period, a customer of Company or any of its subsidiaries, or takes away or interferes or attempts to take away or
interfere with any custom, trade, business, patronage or affairs of Company or any of its subsidiaries, or hires or attempts to hire any
Person who is, or was during the most recent 12-month period, an Executive, officer, representative or agent of Company or any of its
subsidiaries, or solicits, induces, or attempts to solicit or induce any Person who is an Executive, officer, representative or agent
of Company or any of its subsidiaries to leave the employ or agency of the Company or any of its subsidiaries, or violate the terms of
their contract, or any employment consulting or agent agreement, with it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">It is expressly understood and agreed that although Executive and Company consider the restrictions contained
in this Section 9 to be reasonable if a court makes a final judicial determination of competent jurisdiction that the time or territory
or any other restriction contained in this Agreement is an unenforceable restriction against Executive, the provisions of this Agreement
shall not be rendered void but shall be deemed amended to apply as to such maximum time and territory and to such maximum extent as the
court may judicially determine or indicate to be enforceable. Alternatively, if any court of competent jurisdiction finds that any restriction
contained in this Agreement is unenforceable, and such restriction cannot be amended so as to make it enforceable, such finding shall
not affect the enforceability of any of the other restrictions contained herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Executive expressly understands that in the event of a violation of any period specified in this Section
9, such period shall be extended by a period of time equal to that period beginning with the commencement of any such violation and ending
when such violation shall have been finally terminated in good faith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify"><U>Enforcement of Covenants</U>. Executive
                                            acknowledges that Executive has carefully read and considered all the terms and conditions
                                            of this Agreement, including the restraints imposed upon Executive pursuant to Sections 7,
                                            8 and 9<I>,</I> and Executive agrees that these restraints are necessary for the reasonable
                                            and proper protection of Company and its successors and assigns and that each and every one
                                            of the restraints is reasonable in respect to the subject matter, length of time and geographic
                                            area. Executive further acknowledges that, were Executive to breach any of the covenants
                                            in Section 7, Section 8 and/or Section 9 the damage to the Company would be irreparable.
                                            Executive therefore agrees that Company, in addition to any other remedies available to it,
                                            shall be entitled to preliminary and permanent injunctive relief against any breach or threatened
                                            breach by Executive of any of the covenants herein, without any requirement to post a bond
                                            or similar security. The Parties further agree that in the event that any provision of Section
                                            7, Section 8 and/or Section 9 shall be determined by any court of competent jurisdiction
                                            to be unenforceable by reason of its being extended over too great a time, too large a geographic
                                            area or too great a range of activities, such provision shall be deemed to be modified to
                                            permit its enforcement to the maximum extent permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">11.</TD><TD STYLE="text-align: justify"><U>Definitions</U>. Words or phrases that are initially capitalized or within quotation marks shall have
the meanings provided in this Section 11 and as provided elsewhere. For purposes of this Agreement, the following definitions apply:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><B>&ldquo;$&rdquo;</B> refers to U.S. Dollars.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><B>&ldquo;Affiliate&rdquo;</B> means, with respect to any specified Person, any other Person which directly
or indirectly through one or more intermediaries controls, or is controlled by, or is under common control with, such specified Person
(for the purposes of this definition, <B>&ldquo;control&rdquo;</B> (including, with correlative meanings, the terms <B>&ldquo;controlling,&rdquo;
&ldquo;controlled by&rdquo;</B> and <B>&ldquo;under common control with&rdquo;</B>), as used with respect to any Person, means the possession,
directly or indirectly, of the power to either: (i) direct or cause the direction of the management or policies of such Person, whether
through the ownership of voting securities, by agreement or otherwise, or (ii) vote at least fifty percent (50%) or more of the securities
having voting power for the election of a majority of the directors (or Persons performing similar functions) of such Person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><B>&ldquo;Cause&rdquo; </B>means if Executive is discharged by Company on account of the occurrence of
one or more of the following events:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Executive&rsquo;s continued refusal or failure to perform (other than by reason of Disability) Executive&rsquo;s
material duties and responsibilities to Company if such refusal or failure is not cured within thirty (30) days following written notice
of such refusal or failure by Company to Executive, or Executive&rsquo;s continued refusal or failure to follow any reasonable lawful
direction of the Board if such refusal or failure is not cured within thirty (30) days following written notice of such refusal or failure
by Company to Executive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">a material breach of this Agreement (other than Section 7, Section 8 and/or Section 9) by Executive that,
if capable of being cured, is not cured within thirty (30) days following written notice of such breach by Company to Executive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">an intentional and material breach of Section 7, Section 8 and/or Section 9 hereof by Executive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iv)</TD><TD STYLE="text-align: justify">willful, grossly negligent or unlawful misconduct by Executive which causes material harm to Company or
its reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(v)</TD><TD STYLE="text-align: justify">any conduct engaged in by Executive that is materially detrimental to the business or reputation of Company
as determined by the Board in good faith using its reasonable business judgment that is not cured within thirty (30) days following written
notice from Company to Executive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(vi)</TD><TD STYLE="text-align: justify">the Company is directed in writing by regulatory or governmental authorities to terminate the employment
of Executive or Executive engages in activities that: (i) are not approved or authorized by the Board, and (ii) cause actions to be taken
by regulatory or governmental authorities that have a material adverse effect on Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: right"></TD><TD STYLE="width: 0.25in">(vii)</TD><TD STYLE="text-align: justify">a conviction, plea of guilty, or plea of <I>nolo contendere</I> by Executive, of or with
respect to a criminal offense which is a felony or other crime involving dishonesty, disloyalty, fraud, embezzlement, theft, or similar
action(s) (including, without limitation, acceptance of bribes, kickbacks or self-dealing), or the material breach of Executive&rsquo;s
fiduciary duties with respect to Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><B>&ldquo;Change in Control&rdquo;</B> means the occurrence, in a single transaction or in a series of
related transactions, of any one or more of the following events:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">A transaction or series of transactions (other than an offering of common stock to the general public
through a registration statement filed by the Company with the Securities and Exchange Commission) whereby any &ldquo;Person&rdquo; or
related &ldquo;group&rdquo; of &ldquo;persons&rdquo; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other
than the Company, any of its subsidiaries, an Executive benefit plan maintained by the Company or any of its subsidiaries or a &ldquo;Person&rdquo;
that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly
or indirectly acquires beneficial ownership (within the meaning of Rule 13(d)(3) under the Exchange Act) of securities of the Company
possessing more than fifty percent (50%) of the total combined voting power of the Company&rsquo;s securities outstanding immediately
after such acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">The consummation by the Company (whether directly involving the Company or indirectly involving the Company
through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination, or (y) a sale or other disposition
of all or substantially all of the Company&rsquo;s assets in any single transaction or series of related transactions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(A)</TD><TD STYLE="text-align: justify">which results in the Company&rsquo;s voting securities outstanding immediately before the transaction
continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the Person that,
as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all
of the Company&rsquo;s assets or otherwise succeeds to the business of the Company (the Company or such Person, the <B>&ldquo;Successor
Entity&rdquo;</B>) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&rsquo;s outstanding
voting securities immediately after the transaction, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(B)</TD><TD STYLE="text-align: justify">after which no Person or group beneficially owns voting securities representing fifty percent (50%) or
more of the combined voting power of the Successor Entity; <I><U>provided</U>, <U>however</U>,</I> that no Person or group shall be treated
for purposes of this Section 11(d) as beneficially owning fifty percent (50%) or more of the combined voting power of the Successor Entity
solely as a result of the voting power held in the Company prior to the consummation of the transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">A transaction shall not constitute
a Change in Control if its sole purpose is to change the State of the Company&rsquo;s incorporation or to create a holding company that
will be owned in substantially the same proportions by the persons who held the Company&rsquo;s securities immediately before such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><B>&ldquo;Code&rdquo;</B> means the Internal Revenue Code of 1986, as amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><B>&ldquo;Company&rdquo;</B> has the meaning ascribed to it in the preamble of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">&ldquo;<B>Company Group&rdquo;</B> shall mean the Company together with any of its direct or indirect
subsidiaries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify"><B>&ldquo;Compensation Committee&rdquo;</B> shall mean the committee of the Board designated to make compensation
decisions relating to senior executive officers of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify"><B>&ldquo;Confidential Information&rdquo;</B> means any and all nonpublic information of the Company.
Confidential Information includes, without limitation, such information relating to (i) the development, research, testing, manufacturing,
marketing, and financial activities of the Company, (ii) the Services, (iii) the costs, sources of supply, financial performance, and
strategic and/or business plans of Company, (iv) the identity and special needs of the customers and prospective customers of Company,
and (v) the people and organizations with whom Company has business relationships and those relationships. Confidential Information also
includes any information that Company has received, or may receive hereafter, belonging to customers or others with any understanding,
express or implied, that the information would not be disclosed. Notwithstanding the foregoing, <B>&ldquo;</B>Confidential Information<B>&rdquo;</B>
does not include (x) any information that is or becomes generally known to the industry or the public through no wrongful act of Executive
or any representative of Executive and (y) any information that is made legitimately available to Executive by a third Party without breach
of any confidentiality obligation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(j)</TD><TD STYLE="text-align: justify"><B>&ldquo;Disability&rdquo;</B> means Executive&rsquo;s inability, due to any illness, injury, accident
or condition of either a physical or psychological nature, to substantially perform Executive&rsquo;s duties and responsibilities hereunder
for a period of one hundred twenty (120) consecutive days, or for any one hundred and eighty (180) days during any period of three hundred
and sixty-five (365) consecutive calendar days, exclusive of any leave Executive may take under the Family and Medical Leave Act, 29 U.S.C.
&sect; 12101 <I>et seq. (</I><B>&ldquo;FMLA&rdquo;</B><I>)</I> or as a reasonable accommodation under the Americans with Disabilities
Act, 29 U.S.C. &sect; 2601 <I>et seq. (</I><B>&ldquo;ADA&rdquo;</B><I>).</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(k)</TD><TD STYLE="text-align: justify"><B>&ldquo;Final Compensation&rdquo;</B> means the amount equal to the sum of: (i) the Base Salary earned
but not paid through the date of termination of employment, payable not later than the next scheduled payroll date, (ii) any business
and related expenses and allowances incurred by Executive or to which Executive is entitled under Section 4(f) but unreimbursed on the
date of termination of employment; provided that with respect to business expenses unreimbursed under Section 4(f), such expenses and
required substantiation and documentation are submitted within one hundred eighty (180) days of termination in the case of termination
on account of Executive&rsquo;s death, or thirty (30) days on account of termination for any reason other than death, and that such expenses
are reimbursable under Company&rsquo;s applicable reimbursement policy, and (iii) any other supplemental compensation, insurance, retirement
or other benefits due and payable or otherwise required to be provided under Section 4 in accordance with the terms and conditions of
the applicable plan or agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(l)</TD><TD STYLE="text-align: justify"><B>&ldquo;Good Reason&rdquo;</B> means, without Executive&rsquo;s express written consent: (i) a material
reduction in the Base Salary, then in effect, except a material diminution generally affecting all of the members of the Company&rsquo;s
management, (ii) a material reduction in job title, position or responsibility, (iii) a material breach of any term or condition contained
in this Agreement, or (iv) a relocation of Executive&rsquo;s principal worksite that is more than fifty (50) miles from Executive&rsquo;s
principal worksite as of the Effective Date. However, none of the foregoing events or conditions will constitute <B>&ldquo;Good Reason&rdquo;</B>
unless (i) Executive provides Company with written notice of the existence of Good Reason within ninety (90) days following the occurrence
thereof, (ii) Company does not reverse or otherwise cure the event or condition within thirty (30) days of receiving that written notice,
and (iii) Executive resigns Executive&rsquo;s employment within thirty (30) days following the expiration of that cure period.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(m)</TD><TD STYLE="text-align: justify"><B>&ldquo;Intellectual Property&rdquo;</B> means inventions, discoveries, developments, methods, processes,
compositions, works, concepts and ideas (whether or not patentable or copyrightable or constituting trade secrets) conceived, made, created,
developed or reduced to practice by Executive (whether alone or with others, whether or not during normal business hours or on or off
Company premises) during Executive&rsquo;s employment that relate to either the Services or any prospective activity of Company or that
make use of Confidential Information or any of the equipment or facilities of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(n)</TD><TD STYLE="text-align: justify"><B>&ldquo;Person&rdquo;</B> means an individual, a corporation, a limited liability company, an association,
a partnership, an estate, a trust, and any other entity or organization other than Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(o)</TD><TD STYLE="text-align: justify"><B>&ldquo;Sale of Company&rdquo; </B>means the sale of Company to an independent third Party or group
of independent third Parties pursuant to which such Party or Parties acquire: (i) equity interests possessing the voting power under normal
circumstances to elect a majority of the Board of Directors or similar governing body of Company (whether by merger, consolidation or
sale or transfer of such equity interests), or (ii) all or substantially all of Company&rsquo;s assets determined on a consolidated basis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(p)</TD><TD STYLE="text-align: justify"><B>&ldquo;Services&rdquo;</B> means all services planned, researched, developed, tested, manufactured,
sold, licensed, leased or otherwise distributed or put into use by Company, together with all products provided or planned by Company,
during Executive&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(q)</TD><TD STYLE="text-align: justify"><B>&ldquo;Severance Period</B>&rdquo; shall mean that number of years or partial years following termination
of Executive&rsquo;s employment equal to the number of years or partial years of Base Salary that the Executive receives under Section
5(f)..</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(r)</TD><TD STYLE="text-align: justify"><B>&ldquo;Term End Date&rdquo;</B> shall mean the last day of the Term of this Employment Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify"><U>Withholding</U>. All payments made by Company under this Agreement may be reduced by any tax or other
amounts required to be withheld by Company under applicable law or by any amounts authorized in writing by Executive.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">13.</TD><TD STYLE="text-align: justify"><U>Assignment</U>. Neither Company nor Executive may make any assignment of this Agreement or any interest
herein, by operation of law or otherwise, without the prior written consent of the other; provided, however, that Company may assign its
rights and obligations under this Agreement without the consent of Executive in the event of a Sale of Company. This Agreement shall inure
to the benefit of and be binding upon Company and Executive, their respective successors, executors, administrators, heirs and permitted
assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">14.</TD><TD STYLE="text-align: justify"><U>Compliance with Code Section 409A</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Notwithstanding any provision of this Agreement to the contrary, Executive&rsquo;s employment will be
deemed to have terminated on the date of Executive &ldquo;separation from service&rdquo; (within the meaning of Treas. Reg. Section 1.409A-1(h))
with Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">It is intended that this Agreement will comply with Section 409A of the Code, and any regulations and
guideline issued thereunder (<B>&ldquo;Section 409A&rdquo;</B>) to the extent that any compensation and benefits provided hereunder constitute
deferred compensation subject to Section 409A. This Agreement shall be interpreted on a basis consistent with this intent. The Parties
will negotiate in good faith to amend this Agreement as necessary to comply with Section 409A in a manner that preserves the original
intent of the Parties to the extent reasonably possible. No action or failure to act, pursuant to this Section 14 shall subject Company
to any claim, liability, or expense, and Company shall not have any obligation to indemnify or otherwise protect Executive from the obligation
to pay any taxes pursuant to Section 409A of the Code.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">For purposes of the application of Treas. Reg. &sect; 1.409A-1(b)(4)(or any successor provision), each
payment in a series of payments will be deemed a separate payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Notwithstanding anything in this Agreement to the contrary, if any amount or benefit that would constitute
non-exempt &ldquo;deferred compensation&rdquo; for purposes of Section 409A of the Code would otherwise be payable or distributable under
this Agreement by reason of Executive&rsquo;s separation from service during a period in which Executive is a &ldquo;specified Executive&rdquo;
(as defined under Code Section 409A and the final regulations thereunder), then, subject to any permissible acceleration of payment by
Company under Treas. Reg. Section 1.409A-3(j)(4)(ii) (domestic relations order), (j)(4)(iii) (conflicts of interest), or (j)(4)(vi) (payment
of employment taxes):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">if the payment or distribution is payable in a lump sum, the Executive&rsquo;s right to receive payment
or distribution of such non-exempt deferred compensation will be delayed until the earlier of Executive&rsquo;s death or the first day
of the seventh month following Executive&rsquo;s separation from service; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">if the payment or distribution is payable over time, the amount of such non-exempt deferred compensation
that would otherwise be payable during the six months immediately following Executive&rsquo;s separation from service will be accumulated,
and the Executive&rsquo;s right to receive payment or distribution of such accumulated amount will be delayed until the earlier of Executive&rsquo;s
death or the first day of the seventh month following Executive&rsquo;s separation from service, whereupon the accumulated amount will
be paid or distributed to Executive and the normal payment or distribution schedule for any remaining payments or distributions will resume.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">This Section 14(d) should not be
construed to prevent the application of Treas. Reg &sect; 1.409A-1(b)(9)(iii)(or any successor provision) to amounts payable hereunder
(or any portion thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">15.</TD><TD STYLE="text-align: justify"><U>Golden Parachute Limitation</U>. Notwithstanding anything in this Section or elsewhere in this Agreement
to the contrary, in the event the payments and benefits payable hereunder to or on behalf of Executive (which the Parties agree will not
include any portion of payments allocated to the non-competition and non-solicitation provisions of Section 9) that are classified as
payments of reasonable compensation for purposes of Section 280G of the Code, when added to all other amounts and benefits payable to
or on behalf of Executive, would result in the loss of a deduction under Code Section 280G, or the imposition of an excise tax under Code
Section 4999, the amounts and benefits payable hereunder shall be reduced to such extent as may be necessary to avoid such loss of deduction
or imposition of excise tax. In applying this principle, the reduction shall be made in a manner consistent with the requirements of Code
Section 409A and where two or more economically equivalent amounts are subject to reduction, but payable at different times, such amounts
shall be reduced on a <I>pro-rata</I> basis. All calculations required to be made under this subsection will be made by the Company&rsquo;s
independent public accountants, subject to the right of Executive&rsquo;s professional advisors to review the same. The Parties recognize
that the actual implementation of the provisions of this subsection are complex and agree to deal with each other in good faith to resolve
any questions or disagreements arising hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">16.</TD><TD STYLE="text-align: justify"><U>Successors.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Company&rsquo;s Successors.</U> Subject to Section 5(f),, any successor to the Company (whether
direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&rsquo;s
business and/or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement
in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.
For all purposes under this Agreement, the term &ldquo;Company&rdquo; shall include any successor to the Company&rsquo;s business and/or
assets which executes and delivers the assumption agreement described in this Section 16 or which becomes bound by the terms of this Agreement
by operation of law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Executive&rsquo;s Successors.</U> The terms of this Agreement and all rights of Executive hereunder
shall inure to the benefit of, and be enforceable by, Executive&rsquo;s personal or legal representatives, executors, administrators,
successors, heirs, distributees, devisees and legatees</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">17.</TD><TD STYLE="text-align: justify"><U>Clawback Provisions</U>. Any amounts payable under this Agreement are subject to any policy (whether
in existence as of the Effective Date or later adopted) established by the Company providing for clawback or recovery of amounts that
were paid to the Executive. The Company will make any determination for clawback or recovery in its sole discretion and in accordance
with any applicable law or regulation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">18.</TD><TD STYLE="text-align: justify"><U>Indemnification</U>. Company will indemnify Executive to the fullest extent permitted by law, for all
amounts (including, without limitation, judgments, fines, settlement payments, expenses and reasonable out-of-pocket attorneys&rsquo;
fees) incurred or paid by Executive in connection with any action, suit, investigation or proceeding, or threatened action, suit, investigation
or proceeding, arising out of or relating to the performance by Executive of services for, or the acting by Executive as a director, officer
or Executive of, Company, or any subsidiary of Company. Any fees or other necessary expenses incurred by Executive in defending any such
action, suit, investigation or proceeding shall be paid by Company in advance, subject to Company&rsquo;s right to seek repayment from
Executive if a determination is made that Executive was not entitled to indemnification.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">19.</TD><TD STYLE="text-align: justify"><U>Severability</U>. If any portion or provision of this Agreement shall to any extent be declared illegal
or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision
in the circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each
portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">20.</TD><TD STYLE="text-align: justify"><U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed
by the waiving Party. The failure of either Party to require the performance of any term or obligation of this Agreement, or the waiver
by either Party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed
a waiver of any subsequent breach.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">21.</TD><TD STYLE="text-align: justify"><U>Survival</U>. Section 6 through and including Section 32 shall survive and continue in full force in
accordance with their terms notwithstanding the termination of Executive&rsquo;s employment (and hence the Term of this Agreement) for
any reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">22.</TD><TD STYLE="text-align: justify"><U>Notices</U>. Any and all notices, requests, demands and other communications provided for by this Agreement
shall be in writing and shall be effective when delivered in Person, with respect to notices delivered personally, or upon confirmed receipt
when delivered by facsimile or deposited with a reputable, nationally recognized overnight courier service and addressed or faxed to Executive
at Executive&rsquo;s last known address on the books of Company or, in the case of Company, at its principal place of business, attention:
Secretary, Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">23.</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the Parties (including
with respect to Company, its successors and assigns) with respect to Executive&rsquo;s employment and supersedes all prior communications,
agreements and understandings, written or oral, with respect to the terms and conditions of Executive&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">24.</TD><TD STYLE="text-align: justify"><U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by Executive
and by an expressly authorized representative of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">25.</TD><TD STYLE="text-align: justify"><U>Headings</U>. The headings and captions in this Agreement are for convenience only and in no way define
or describe the scope or content of any provision of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">26.</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be
an original and all of which together shall constitute one and the same instrument. Furthermore, the delivery of a copy of such signature
by facsimile transmission or other electronic exchange methodology shall constitute a valid and binding execution and delivery of this
Agreement by such Party, and such electronic copy shall constitute an enforceable original document. Counterpart signatures need not be
on the same page and shall be deemed effective upon receipt.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">27.</TD><TD STYLE="text-align: justify"><U>Additional Obligations</U>. Without implication that the contrary would otherwise be true, Executive&rsquo;s
obligations under Section 7, Section 8 and Section 9 are in addition to, and not in limitation of, any obligations that Executive may
have under applicable law (including any law regarding trade secrets, duty of loyalty, fiduciary duty, unfair competition, unjust enrichment,
slander, libel, conversion, misappropriation and fraud).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">28.</TD><TD STYLE="text-align: justify"><U>Attorneys&rsquo; Fees</U> . In any action or proceeding brought to enforce any provision of this
Agreement, the prevailing Party shall be entitled to recover reasonable attorneys&rsquo; fees, costs, and expenses from the other Party
to the action or proceeding. For purposes of this Agreement, the <B>&ldquo;prevailing Party&rdquo;</B> shall be deemed to be that Party
who obtains substantially the result sought, whether by settlement, mediation, judgment or otherwise, and <B>&ldquo;attorneys&rsquo; fees&rdquo;</B>
shall include, without limitation, the reasonable out-of-pocket attorneys&rsquo; fees incurred in retaining counsel for advice, negotiations,
suit, appeal or other legal proceeding, including mediation and arbitration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">29.</TD><TD STYLE="text-align: justify"><U>Confidentiality</U>. The Parties acknowledge and agree that this Agreement and each of its provisions
are and shall be treated strictly confidential. During the Term and thereafter, Executive shall not disclose any terms of this Agreement
to any Person or entity without the prior written consent of Company, with the exception of Executive&rsquo;s tax, legal or accounting
advisors or for legitimate business purposes of Executive, or as otherwise required by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">30.</TD><TD STYLE="text-align: justify"><U>No Rule of Construction</U>. This Agreement shall be construed to be neither against nor in favor of
any Party hereto based upon any Party&rsquo;s role in drafting this Agreement, but rather in accordance with the fair meaning hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">31.</TD><TD STYLE="text-align: justify"><U>Governing Law</U>. The validity, interpretation, construction and performance of this Agreement shall
be governed by the laws of the state of Florida.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">32.</TD><TD STYLE="text-align: justify"><U>WAIVER OF JURY TRIAL</U>. EXECUTIVE AND THE COMPANY EXPRESSLY WAIVE ANY RIGHT EITHER MAY HAVE TO A
JURY TRIAL CONCERNING ANY CIVIL ACTION THAT MAY ARISE FROM THIS AGREEMENT OR THE RELATIONSHIP OF THE PARTIES HERETO.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">33.</TD><TD STYLE="text-align: justify"><U>Conditions</U>. This Agreement and the Executive&rsquo;s continued employment hereunder is conditional
on the Company&rsquo;s satisfaction (determined in the Company&rsquo;s sole discretion) that the Executive has met the legal requirements
to perform the Executive&rsquo;s role, including but not limited to satisfactory results of a background and/or credit search or any other
applicable security clearance checks and criminal record checks and other reference checks that the Company performs. The Executive acknowledges
and agrees that in signing this Agreement, and providing the Company with the necessary documentation to perform the checks required for
the Executive&rsquo;s role and with references, the Executive is providing consent to the Company or its agent, to performs such checks
and contact the references the Executive provided to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">34.</TD><TD STYLE="text-align: justify"><U>Prior Restrictions</U>. By signing below, the Executive represents that the Executive is not bound
by the terms of any agreement with any Person which restricts in any way the Executive&rsquo;s hiring by the Company and the performance
of the Executive&rsquo;s expected job duties; the Executive also represents that, during the Executive&rsquo;s employment with the Company,
the Executive shall not disclose or make use of any confidential information of any other persons or entities in violation of any of their
applicable policies or agreements and/or applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">35.</TD><TD STYLE="text-align: justify"><U>Independent Legal Counsel</U>. By signing below, the Executive hereby acknowledges that the Executive
has been encouraged to obtain independent legal advice regarding the execution of this Agreement, and that the Executive has either obtained
such advice or voluntarily chosen not to do so, and hereby waives any objections or claims the Executive may make resulting from any failure
on the Executive&rsquo;s part to obtain such advice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">36.</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be
deemed an original when executed, but all of which taken together shall constitute the same Agreement. Delivery of an executed counterpart
of a signature page to this Agreement by electronic transmission, including in portable document format (.pdf), shall be deemed as effective
as delivery of an original executed counterpart of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><B>IN WITNESS WHEREOF</B>, this
Agreement has been executed by Company (by its duly authorized representative) and by Executive, as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: justify">60 Degrees Pharmaceuticals Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Ty Miller</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify; text-indent: 0in">Name:</TD>
    <TD STYLE="width: 40%; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">Ty Miller</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">Title:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 10pt">CFO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: justify">EXECUTIVE<FONT STYLE="font-weight: normal">:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Geoff Dow</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><U>EXHIBIT A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><U>Release of Claims</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">FOR AND IN CONSIDERATION OF the
benefits to be provided me in<FONT STYLE="font-size: 10pt">1</FONT>c<FONT STYLE="font-size: 10pt">/</FONT>o<FONT STYLE="font-size: 10pt">1</FONT>n<FONT STYLE="font-size: 10pt">2</FONT>n<FONT STYLE="font-size: 10pt">/</FONT>e<FONT STYLE="font-size: 10pt">2</FONT>ct<FONT STYLE="font-size: 10pt">0</FONT>io<FONT STYLE="font-size: 10pt">2</FONT>n<FONT STYLE="font-size: 10pt">3</FONT>
with the termination of my employment, as set forth in that certain Employment Agreement, dated as of<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2022 (the <B>&ldquo;Agreement&rdquo;</B>), between me and 60 Degrees Pharmaceuticals Inc. (the <B>&ldquo;Company&rdquo;</B>), or under
any severance pay plan applicable to me, which benefits are conditioned on my signing this Release of Claims and to which I am not otherwise
entitled, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I, on my own behalf
and on behalf of my heirs, executors, administrators, beneficiaries, representatives and assigns, and all others connected with me, hereby
release and forever discharge Company and any of its subsidiaries and Affiliates (as that term is defined in Section 11(b) of the Agreement)
and all of their respective past, present and future officers, directors, trustees, equity holders, Executives, agents, managers, joint
venturers, representatives, successors and assigns, and all others connected with any of them (collectively, the <B>&ldquo;Released Parties&rdquo;</B>),
both individually and in their official capacities, from any and all causes of action, rights and claims of any type or description, known
or unknown, which I have had in the past, now have, or might now have, through the date of my signing of this Release of Claims, in any
way resulting from, arising out of or connected with my employment by the Company or any of its Affiliates or the termination of that
employment, including, but not limited to, any allegation, claim or violation arising under: Title VII of the Civil Rights Act of 1964,
as amended; the Civil Rights Act of 1991; the Age Discrimination in Employment Act of 1967, as amended (including the Older Worker Benefit
Protection Act); the Equal Pay Act of 1963, as amended; the Americans with Disabilities Act of 1990; the Family and Medical Leave Act
of 1993; the Worker Adjustment Retraining and Notification Act; Executive Retirement Income Security Act of 1974; the Fair Labor Standards
Act; any applicable Executive Orders; or their state or local counterparts; or under any other federal, state or local civil or human
rights law, or under any other federal, state or local law, regulation or ordinance; or under any public policy, contract or tort, or
under common law; or arising under any policies, practices or procedures of the Company; or any claim for wrongful discharge, breach of
contract, intentional infliction of emotional distress or defamation; or any claim for costs, fees or other expenses, including attorneys&rsquo;
fees incurred in these matters (all of the foregoing collectively referred to herein as <B>&ldquo;Claims&rdquo;</B>), other than (i) the
right to payment of any vested or accrued benefits under any supplemental compensation, insurance, retirement and/or other benefit plan
or agreement applicable to Executive, (ii) the right to payment of any amounts owed to me by Company pursuant to Section 5 of the Agreement,
(iii) any rights under applicable workers compensation or unemployment compensation laws, (iv) any rights that survive termination of
my employment pursuant to an option grant agreement or certificate to purchase the Company&rsquo;s (or an Affiliate&rsquo;s) capital stock,
(v) any rights with respect to the Company&rsquo;s (or an Affiliate&rsquo;s) capital stock owned by Executive, or (vi) any rights to indemnification
under the Agreement, the Company&rsquo;s by-laws or any other applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">In signing this Release of Claims,
I acknowledge my understanding that I may not sign it prior to the termination of my employment, but that I may consider the terms of
this Release of Claims for up to twenty-one (21) days (or such longer period as the Company may specify) from the later of the date my
employment with the Company terminates or the date I receive this Release of Claims. I also acknowledge that I am advised by the Company
and its Affiliates to seek the advice of an attorney prior to signing this Release of Claims; that I have had sufficient time to consider
this Release of Claims and to consult with an attorney, if I wished to do so, or to consult with any other Person of my choosing before
signing; and that I am signing this Release of Claims voluntarily and with a full understanding of its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">I represent that I have not filed
against the Released Parties any complaints, charges, or lawsuits arising out of my employment, or any other matter arising on or prior
to the date of this Release of Claims, and covenant and agree that I will never individually or with any Person file, or commence the
filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect
to any of the matters released by me pursuant to this Release of Claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">I further acknowledge that, in signing
this Release of Claims, I have not relied on any promises or representations, express or implied, that are not set forth expressly in
the Agreement. I understand that I may revoke this Release of Claims at any time within seven (7) days of the date of my signing by written
notice to the Secretary, Board of Directors of the Company (or such other Person as the Company may specify by notice to me given in accordance
with the Agreement) and that this Release of Claims will take effect only upon the expiration of such seven-day revocation period and
only if I have not timely revoked it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5pt">Intending to be legally bound,
I have signed this Release of Claims as of the date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify; text-indent: 0in">Signature:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 40%; text-align: justify; text-indent: 0in">/s/ Geoff Dow</TD>
    <TD STYLE="width: 50%; text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoff Dow</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/12/2023</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; text-indent: 0in">Signed:</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-align: justify; text-indent: 0in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>26
<FILENAME>cm270_ex10-23.htm
<DESCRIPTION>EXHIBIT 10.23
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit 10.23</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B><U>EMPLOYMENT AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">This Employment Agreement, dated
as of January 12, 2023 (this <B>&ldquo;Agreement&rdquo;</B>), is made and entered into by and between 60 Degrees Pharmaceuticals Inc.,
a Delaware corporation (the <B>&ldquo;Company&rdquo;</B>), and Tyrone Miller (the <B>&ldquo;Executive&rdquo;</B> and together with the
Company, the &ldquo;<B>Parties</B>&rdquo; and individually a &ldquo;<B>Party</B>&rdquo;<B>).</B> Capitalized terms used herein and not
otherwise defined shall have the meanings set forth in Section 11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>RECITALS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>, subject to the terms
and conditions hereinafter set forth, Company wishes to employ Executive as its Chief Financial Officer and Executive wishes to be employed
by Company as its Chief Financial Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>, in consideration
of the foregoing premises and the mutual promises, terms, provisions, and conditions set forth in this Agreement, the adequacy and sufficiency
of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: .25in">1.</TD><TD STYLE="text-align: justify"><U>Employment</U>. Subject to the terms and conditions set forth in this Agreement, Company hereby offers, and Executive hereby accepts
employment with Company, as of the date first above written (the <B>&ldquo;Effective Date&rdquo;</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><U>Term</U>. The Executive&rsquo;s employment hereunder shall be effective as of the Effective Date and shall continue until the second
(2nd) anniversary thereof (the &ldquo;<B>Initial Term</B>&rdquo;), unless terminated earlier pursuant to the terms of this Agreement;
provided that, on such second (2nd) anniversary of the Effective Date and each annual anniversary thereafter (such date and each annual
anniversary thereof, a &ldquo;<B>Renewal Date</B>&rdquo;), the Agreement shall be deemed to be automatically extended, upon the same terms
and conditions, for successive periods of one (1) year (each &ldquo;<B>Renewal Term</B>&rdquo;), unless either Party provides written
notice of its intention not to extend the term of the Agreement at least 90 days prior to the applicable Renewal Date. The Initial Term
and each Renewal Term is hereinafter referred to as the &ldquo;<B>Term</B>.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">3.</TD><TD><U>Capacity and Performance</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">During the Term, the Executive shall be employed by Company on a full-time basis as its Chief Financial Officer. Executive shall perform
such duties and responsibilities as directed by the Board of Directors of the Company (the &ldquo;<B>Board</B>&rdquo;), consistent with
Executive&rsquo;s position on behalf of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Executive shall devote his full business time, attention, skill, and best efforts to the performance of his duties under this Agreement
and shall not engage in any other business or occupation during the Term of Employment, including, without limitation, any activity that:
(x) conflicts with the interests of the Company or any other member of the Company Group, (y) interferes with the proper and efficient
performance of Executive&rsquo;s duties for the Company, or (z) interferes with Executive&rsquo;s exercise of judgment in the Company&rsquo;s
best interests. Notwithstanding the foregoing, nothing herein shall preclude Executive from: (i) serving, with the prior written consent
of the Board, as a member of the Board of Directors or Advisory Board (or the equivalent in the case of a non-corporate entity) of a noncompeting
for-profit business and one or more charitable organizations, (ii) engaging in charitable activities and community affairs, and (iii)
managing Executive&rsquo;s personal investments and affairs and (iv) continuing tax advisory work for existing clients; <I>provided, however,</I>
that the activities set out in clauses (i), (ii), (iii) and (iv) shall be limited by Executive so as not to materially interfere, individually
or in the aggregate, with the performance of his duties and responsibilities hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Executive&rsquo;s employment with Company shall be exclusive
with respect to the business of Company. Accordingly, during the Term, Executive shall devote Executive&rsquo;s full business time and
Executive&rsquo;s best efforts, business judgment, skill and knowledge to the advancement of the business and interests of Company and
the discharge of Executive&rsquo;s duties and responsibilities hereunder, except for permitted vacation (and other paid time off) periods,
reasonable periods of illness or incapacity, and reasonable and customary time spent on civic, charitable and religious activities, in
each case such activities shall not interfere in any material respect with Executive&rsquo;s duties and responsibilities hereunder.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>During the Term, the Executive will report directly to the Chief Executive Officer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD>On the Effective Date, the Board shall appoint Executive as the Chief Financial Officer</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">Executive shall be employed to perform his duties under this Agreement at the primary office location of Company, or at such other
location or locations as may be mutually agreeable to Executive and Company. Notwithstanding this, it is expected that the Executive shall
be required to travel a reasonable amount of time in the performance of his duties under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: .25in">4.</TD><TD><U>Compensation and Benefits</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Base Salary</U>. For services performed by Executive under this Agreement, Company shall pay Executive an annual base salary during
the Term at the rate of $204,000 per year, minus applicable withholdings and deductions, payable at the same times as salaries are payable
to other executives of Company (the <B>&ldquo;Base Salary&rdquo;</B>). During the Term, the Base Salary shall be reviewed by the Compensation
Committee and/or the Board each year, and the Board may, from time to time, increase such Base Salary and any reference to <B>&ldquo;Base
Salary&rdquo;</B> herein shall refer to such Base Salary, as increased.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Annual Bonus</U>. For each fiscal year of the Company during the Term, the Company shall afford Executive the opportunity to earn
an incentive bonus (<B>&ldquo;Bonus&rdquo;</B>) as described in this Section 4(b). The aggregate target Bonus payable to Executive under
such program(s) shall equal 25% percent (25%) of the Base Salary for such fiscal year and shall be payable to the extent the applicable
performance goals are achieved (which goals and payment matrices shall be set by the Compensation Committee of the Board in its discretion).
The amount of the Bonus will be determined by certification by the Board that the applicable goals have been achieved, and the Board shall
promptly provide such certification following achievement of the applicable goals. The amount payable under this Section 4(b) shall be
paid by the seventh (7<FONT STYLE="font-size: 10pt">th</FONT>) day following the approval of the annual audited financial statements by
the Board or its audit committee, as applicable, for the calendar year in which the Bonus is earned or if later, the fifteenth (15<FONT STYLE="font-size: 10pt">th</FONT>)
day of the third month following the end of the Company&rsquo;s fiscal year in which the Bonus is earned.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>Equity Awards</U>. During the Term, the Executive shall be entitled to receive equity awards either now or in the future, on terms
and conditions similar to those applicable to other executive officers of the Company generally, inside or outside of any established
equity plan. The amount and terms of the long-term incentive awards awarded to the Executive shall be set by the Compensation Committee
in its discretion, except</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in"><U>Annual Stock Option</U><B>.</B>
Upon the Company becoming publicly traded on a national exchange, Executive shall be granted a five-year option (the &ldquo;<U>Option</U>&rdquo;)
to purchase a total of 12,000 shares of the Company&rsquo;s common stock on the last day of each quarter, or March 31, June 30, September
30 and December 31, in each calendar year (for a cumulative total or no more than 240,000 shares over five years). The per share exercise
price of the Option shall be equal to the per share closing price of the Company&rsquo;s common stock on the date of grant, and shall
have a cashless exercise provision. The Option shall vest and become exercisable subject to the terms set forth in the 2022 Equity Incentive
Plan approved by the Board and effectuated prior to the Company going public by way of Initial Public Offering of its common stock on
a national exchange. The Option shall otherwise be subject to the terms of the plan pursuant to which it is granted and/or an option agreement
to be entered into between Executive and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 96pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 96pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify"><U>Other Executive Benefits</U>. During the Term, the Executive
shall be entitled to participate in all Executive benefit plans, including health and 401(k) plans, from time to time generally in effect
for Company&rsquo;s Executives (collectively, <B>&ldquo;Benefit Plans&rdquo;</B>). If the Company does not implement a health plan, it
will compensate Executive $1,100.00 per month. Such participation and receipt of benefits under any such Benefit Plans shall be on the
same terms (including cost-sharing between Company and Executive) as are applicable to other Company Executives and shall be subject
to the terms of the applicable plan documents and generally applicable Company policies. The Company may alter, modify, add to or delete
the Benefit Plans in a manner nondiscriminatory to Executive at any time in accordance with applicable plan rules.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>Vacation</U>. The Executive shall be entitled to an annual vacation of 28 days plus ten established holiday days per full calendar
year of his employment with the Company hereunder. Any unused vacation in one accrued calendar year may not be carried over to any subsequent
calendar year. However, the Company shall pay the Executive (based on the Executive&rsquo;s Base Salary) for any such unused vacation
days within 30 days of the end of any such calendar year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>Business and Travel Expenses</U>. Company shall pay or reimburse Executive for all reasonable, customary and necessary business
expenses (including cell phone, travel, lodging, and entertainment expenses) which are correctly documented and incurred or paid by Executive
in the performance of Executive&rsquo;s duties and responsibilities hereunder, subject to the rules, regulations, and procedures of Company
and in effect from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify"><U>Change in Control Transaction Bonus</U>. During Executive&rsquo;s employment, if (i) a Change in Control has occurred, and (ii)
as of such Change in Control, the price per share of Company&rsquo;s common stock is two (2) times or more than the closing price per
share of the common stock of the Company upon listing on an exchange, Executive shall be paid a bonus (the <B>&ldquo;Change in Control
Transaction Bonus&rdquo;</B>), in cash, equal to two (2) times the Base Salary as in effect immediately before such Change in Control.
If applicable, the Change in Control Transaction Bonus shall be paid in a lump sum within fifteen (15) days after the consummation of
such Change in Control and the following certification by the Board of the occurrence of clauses (i) and (ii) above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: .25in">5.</TD><TD STYLE="text-align: justify"><U>Termination of Employment; Severance Benefits</U>. Notwithstanding the provisions of Section 2, the Executive&rsquo;s employment
hereunder shall terminate under the following circumstances:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Death</U>. If Executive&rsquo;s dies during the Term, Executive&rsquo;s employment hereunder shall immediately and automatically
terminate. In such event, Company shall pay to Executive&rsquo;s designated beneficiary or, if no beneficiary has been selected by Executive,
to Executive&rsquo;s estate, the Final Compensation. Company shall have no further obligation hereunder to Executive, Executive&rsquo;s
beneficiary, or Executive&rsquo;s estate upon the termination of Executive&rsquo;s employment under this Section 5(a) including, specifically,
that the provisions of Section 5(d) shall not apply.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD><U>Disability</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Company may terminate Executive&rsquo;s employment hereunder due to Executive&rsquo;s Disability during the Term by giving Executive
thirty (30) days&rsquo; written notice of its intent to terminate, but in no event shall such termination be effective prior to the expiration
of the time periods in the definition of <B>&ldquo;Disability.&rdquo;</B> Notwithstanding the foregoing, Company will, after engaging
in an interactive process with Executive to discern whether reasonable accommodation(s) can be provided without undue hardship upon Company,
offer Executive reasonable accommodation(s) to enable Executive to perform the essential functions of Executive&rsquo;s position to the
extent required by applicable law (if any) before terminating Executive&rsquo;s employment hereunder. Executive may decline such reasonable
accommodation, in which case Executive&rsquo;s employment hereunder will terminate as provided in this subsection.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">In the event of such termination for Disability, Executive will
receive Executive&rsquo;s Final Compensation. Company shall have no further obligation hereunder to Executive upon termination of Executive&rsquo;s
employment under this Section 5(d), including, specifically, that the provisions of Section 5(d) shall not apply.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">Subject to Executive&rsquo;s rights under the Family and Medical
Leave Act (FMLA) and the Americans with Disabilities Act (ADA), Company may designate another Executive to act in Executive&rsquo;s place
during any period of Executive&rsquo;s Disability during which Executive is unable to perform the essential functions of Executive&rsquo;s
position with or without a reasonable accommodation. Notwithstanding any such designation, Executive shall continue to receive the Base
Salary in accordance with Section 4(a) and coverage under the Benefit Plans in accordance with Section 4(b), to the extent permitted
by the then- current terms of the applicable benefit plans and as provided under the FMLA, if applicable, until the earliest to occur
of: (A) the end of the Term, (B) Executive becomes eligible for disability income benefits under Company&rsquo;s disability income plan,
or (C) the termination of Executive&rsquo;s employment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iv)</TD><TD STYLE="text-align: justify">While receiving disability income payments under Company&rsquo;s disability income plan (if applicable), Company will continue to
pay to Executive Executive&rsquo;s Base Salary under Section 4(a), but may offset any such disability income payments Executive receives
against the Base Salary payments. Executive will also continue to participate in the Benefit Plans in accordance with Section 4(b) and
the terms of such Benefit Plans, until the end of the Term or until the termination of Executive&rsquo;s employment, whichever occurs
first.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(v)</TD><TD STYLE="text-align: justify">If any question arises as to whether during any period Executive has a Disability as defined herein, Executive may, and at the request
of Company shall, submit to a medical examination by a qualified, unbiased physician selected by Company and reasonably acceptable to
Executive or Executive&rsquo;s duly appointed guardian, if any, to determine whether Executive has a Disability and such determination
shall for the purposes of this Agreement be conclusive of the issue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><U>By Company for Cause</U>. Company may terminate Executive&rsquo;s employment hereunder for Cause, as defined in Section 11(c),
at any time upon notice to Executive setting forth in reasonable detail the nature of such Cause. Upon the giving of notice of termination
of Executive&rsquo;s employment hereunder for Cause, Executive will receive Executive&rsquo;s Final Compensation. Except as provided herein,
Company will have no further obligation to Executive upon termination of Executive&rsquo;s employment under this Section 5(c). Any notice
of termination of Executive&rsquo;s employment hereunder for Cause, or any notice to Executive regarding any event, condition or circumstance
that, if not cured, if applicable, in accordance with the above, could give rise to a termination of Executive&rsquo;s employment hereunder
for Cause, shall set forth in detail the applicable event(s), condition(s) or circumstance(s) constituting reason(s) or potential reason(s)
for such termination hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><U>By Company Other than for Cause or by Executive for Good Reason</U>. Company may terminate Executive&rsquo;s employment hereunder
other than for Cause at any time upon thirty (30) days&rsquo; written notice to Executive and Executive may terminate Executive&rsquo;s
employment hereunder for Good Reason at any time upon thirty (30) days&rsquo; written notice to Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">In the event of a termination of Executive&rsquo;s employment under this Section 5(d), in addition to the Final Compensation, Executive
shall receive:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">continuation of Executive&rsquo;s Base Salary, at the rate in effect as of the date immediately preceding the date of termination,
until the earlier of: (x) the Term End Date and (y) the first anniversary of the date of termination (<I><U>provided</U></I>, <I><U>however,</U></I>
if the date of termination is after the first anniversary of the Effective Date, the period pursuant to this subsection shall be eighteen
(18) months after the date of termination), payable in accordance with the Company&rsquo;s regular payroll practices, less applicable
withholdings, commencing at the conclusion of the period set forth in Section 5(d)(iii), provided that the first installment of such payments
shall include all amounts which would have been paid during the period between Executive&rsquo;s date of termination and the date of such
first installment; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">if the date of termination occurs after the end of a calendar year but prior to the date on which a Bonus is paid under Section 4(d),
payment of such Bonus as determined under Section 4(d) shall be at the time proscribed by Section 4(b); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">payment of a <I>pro-rata</I> portion of the amount of Executive&rsquo;s Bonus for the year in which termination occurs that would
have been payable based on actual performance determined under the terms of the Bonus as then in effect for such year, with such <I>pro-rata</I>
portion calculated by multiplying the amount of such bonus for the year in which such termination occurs (as determined by the Board based
on actual performance for such year) by a number: (x) the numerator of which is the number of days worked by Executive during the year
of such termination, and (y) the denominator of which is three hundred sixty-five (365), with such payment to be made after the determination
of the Bonus pursuant to Section 4(b).</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">If the Executive timely and properly elects health continuation coverage under the Consolidated Omnibus Budget Reconciliation Act
of 1985 (<B>&ldquo;COBRA&rdquo;</B>), the Company shall reimburse the Executive for the monthly COBRA premium paid by the Executive for
himself and his dependents. Such reimbursement shall be paid to the Executive on the 1st day of the month immediately following the month
in which the Executive timely remits the premium payment. The Executive shall be eligible to receive such reimbursement until the earliest
of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">the first anniversary of the date of termination (provided, however, if the date of termination is after the first anniversary of
the Effective Date, the period pursuant to this subsection (1) shall be eighteen (18) months after the date of termination);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">the date the Executive is no longer eligible to receive COBRA continuation coverage; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">the date on which the Executive receives substantially similar coverage from another employer or other source.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">Any obligation of Company to Executive under this Section 5(d) (other than for the Final Compensation or for benefits required by
law) is conditioned upon Executive&rsquo;s execution and delivery to Company and the expiration of all applicable statutory revocation
periods of a release of claims in the form attached hereto as <U>Exhibit A</U> (the <B>&ldquo;Executive Release&rdquo;</B>), provided,
that the terms of such Executive Release shall be subject to modification to the extent necessary to comply with: (a) the fact that Company
is simultaneously terminating more than one executive as part of a group termination decision or (b) changes in applicable law, if any,
occurring after the date hereof, and prior to the date such Executive Release is executed.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><U>By Executive Other than for Good Reason</U>. Executive may terminate Executive&rsquo;s employment hereunder other than for Good
Reason upon thirty (30) days&rsquo; written notice to Company; <I><U>provided</U></I>, that Company may, in its sole and absolute discretion,
by written notice accelerate such date of termination. In the event of a termination of Executive&rsquo;s employment under this Section
5(e), Executive will receive the Final Compensation. Company shall have no further obligation hereunder to Executive upon termination
of Executive&rsquo;s employment under this Section 5(e).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><U>Change in Control Severance</U>. Except as otherwise set forth herein, if a Change in Control occurs, and on, or at any time during
the 24 months following, the Change in Control, (i) the Company terminates Executive&rsquo;s employment for any reason other than Cause
or Disability, or (ii) Executive terminates Executive&rsquo;s employment for Good Reason, Executive shall be entitled to the following
benefits:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">The Company shall pay Executive, in a lump sum within 60 days following termination of Executive&rsquo;s employment, severance equal
to two times the sum of Executive&rsquo;s Base Salary and Bonus (the full, non- prorated Bonus for the year of termination assuming attainment
of the targeted performance goals at the 100% payout level).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">Executive also shall be entitled to receive any and all vested benefits accrued under any other incentive plans to the date of termination
of employment, the amount, entitlement to, form, and time of payment of such benefits to be determined by the terms of such incentive
plans. For purposes of calculating Executive&rsquo;s benefits under the incentive plans, Executive&rsquo;s employment shall be deemed
to have terminated under circumstances that have the most favorable result for Executive under the applicable incentive plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">If, upon the date of termination of Executive&rsquo;s employment,
Executive holds any awards with respect to securities of the Company, (i) all such awards that are options shall immediately become vested
and exercisable upon such date and shall be exercisable thereafter until the <U>earlier</U> of the third (3<FONT STYLE="font-size: 10pt">rd</FONT>)
year anniversary of Executive&rsquo;s termination of employment or the expiration of the term of the options; (ii) all restrictions on
any such awards of restricted stock, restricted stock units or other awards shall terminate or lapse, and all such awards of restricted
stock, restricted stock units or other awards shall be vested and payable; and (iii) all performance goals applicable to any such performance-based
awards that are &ldquo;in cycle&rdquo; (i.e., the performance period is not yet complete) shall be deemed satisfied at the &ldquo;target&rdquo;
level (assuming 100% payout), and (iv) all such awards shall be paid in accordance with the terms of the applicable award agreement.
The provisions of this subsection shall be subject (and defer) to the provisions of any incentive plan, award agreement or other agreement
as it relates to an individual award to the extent such provisions provide treatment that is more favorable to Executive than the treatment
described in this subsection and such more favorable provisions in such incentive plan, award agreement or other agreement shall supersede
any inconsistent or contrary provision of this subsection. All of Executive&rsquo;s awards with respect to securities of the Company
that are outstanding upon the date of termination of Executive&rsquo;s employment shall continue to be subject to, and enjoy the benefits
and protections under, the terms of the incentive plan, the award agreement and any other plan, agreement, policy or other arrangement
to which such awards are subject as of the effective date of Executive&rsquo;s participation, including any employment security agreement
or other written compensation arrangement (even if the remaining terms thereof are waived), without application of this subsection.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iv)</TD><TD STYLE="text-align: justify">Executive and Executive&rsquo;s spouse and other qualified beneficiaries shall be eligible for continued coverage as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD><TD STYLE="text-align: justify">If the Executive, Executive&rsquo;s spouse and/or Executive&rsquo;s
other qualified beneficiaries are enrolled under a group health plan as defined by COBRA, on the date of termination of Executive&rsquo;s
employment, Executive, Executive&rsquo;s spouse and/or Executive&rsquo;s qualified beneficiaries may elect to continue such coverage
under COBRA, except that the maximum coverage period shall be extended to no less than the Severance Period (but no more than 2 years)
for that Executive, unless, after electing COBRA, the individual attains age 65 and becomes eligible for Medicare, in which case COBRA
shall end for that individual. If Executive, Executive&rsquo;s spouse and/or Executive&rsquo;s other qualified beneficiaries elect COBRA
coverage, the Company shall pay a portion of the COBRA costs for the Severance Period for that Executive (subject to any earlier termination
of COBRA). The portion to be paid by the Company shall equal the amount necessary so that the total of the COBRA costs paid by Executive
is equal to the costs that would have been paid by Executive for such coverage as an active employee immediately prior to termination
of Executive&rsquo;s employment or, if less, prior to the Change in Control. The cost of COBRA coverage paid by the Company may be taxable
income to the Executive and reported on Executive&rsquo;s Internal Revenue Service Form W-2. Executive, Executive&rsquo;s spouse and/or
Executive&rsquo;s qualified beneficiaries may continue coverage under COBRA after the Severance Period for that Executive, provided they
pay the full COBRA costs and COBRA otherwise remains available.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(B)</TD><TD STYLE="text-align: justify">The benefits and/or extended coverage provided under this subsection shall cease prior to the date such benefits and/or extended coverage
would otherwise end under subsection if and when Executive (A) obtains employment with another employer during the Severance Period and
becomes eligible for coverage under any substantially similar plan provided by his/her new employer or (B) fails to pay the required active
employee portion of the cost of coverage provided under this subsection in the time and manner specified by the Company or its designee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(v)</TD><TD STYLE="text-align: justify">Executive shall be entitled to payment for any accrued but unused vacation in accordance with the Company&rsquo;s policy in effect
at the time of termination of Executive&rsquo;s employment, in a lump sum within 60 days following such termination. Executive shall not
be entitled to receive any payments or other compensation attributable to vacation that would have been earned had Executive&rsquo;s employment
continued during the Severance Period, and Executive waives any right to receive any such compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(vi)</TD><TD STYLE="text-align: justify">The Company shall, at the Company&rsquo;s expense, provide Executive with 12 months of executive outplacement services with a professional
outplacement firm selected by the Company; provided that Executive must use the outplacement services by no later than the end of the
second calendar year following the calendar year in which the termination of Executive&rsquo;s employment occurred and the total cost
of such outplacement services must not exceed any per individual cap on such amounts in the Company&rsquo;s agreement with the professional
outplacement firm selected by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(vii)</TD><TD STYLE="text-align: justify">Executive shall not be entitled to reimbursement for any other fringe benefits or perquisite payments during the Severance Period,
including but not limited to dues and expenses related to club memberships, automobile, cell phone, expenses for professional services,
executive physicals, and other similar perquisites.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(viii)</TD><TD STYLE="text-align: justify">The Company shall pay as incurred (within ten calendar days following the Company&rsquo;s receipt of an invoice from Executive) Executive&rsquo;s
out-of-pocket expenses, including attorneys&rsquo; fees, incurred by Executive at any time from the date of this Agreement through Executive&rsquo;s
remaining lifetime or, if longer, the statute of limitations for contract claims under applicable state law, in connection with any action
taken to enforce the Executive&rsquo;s rights under this Agreement or construe or determine the validity of this Agreement or otherwise
in connection herewith, including any claim or legal action or proceeding, whether brought by Executive or the Company or another party;
provided, Executive must be successful through judgment in his/her favor with respect to such action in order to recover fees under this
Section 5(f)(viii); provided further, that Executive shall have submitted an invoice for such fees and expenses at least fifteen calendar
days before the end of the calendar year next following the calendar year in which such fees and expenses were incurred. The amount of
such legal fees and expenses that the Company is obligated to pay in any given calendar year shall not affect the legal fees and expenses
that the Company is obligated to pay in any other calendar year, and Executive&rsquo;s right to have the Company pay such legal fees and
expenses may not be liquidated or exchanged for any other benefit. The Company&rsquo;s obligation to pay Executive&rsquo;s eligible legal
fees and expenses under this Section 5(f)(viii) shall not be conditioned upon the termination of Executive&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: .25in">6.</TD><TD><U>Effect of Termination</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: .25in">(a)</TD><TD STYLE="text-align: justify">Upon termination of Executive&rsquo;s employment hereunder and subject to the provisions of Section 5 and Section 6(c), Company&rsquo;s
entire obligation to Executive shall be payment of Final Compensation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">In connection with the cessation of Executive&rsquo;s service as Chief Financial Officer of Company for any reason, except as may
otherwise be requested by the Company in writing and agreed upon in writing by Executive, Executive shall be deemed to have resigned from
any and all directorships, committee memberships, and any other positions Executive holds with the Company or any other member of the
Company Group. Executive hereby agrees that no further action is required by Executive or any of the preceding to make the transitions
and resignations provided for in this paragraph effective, but Executive nonetheless agrees to execute any documentation Company reasonably
requests at the time to confirm it and to not reassume any such service or position without the written consent of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Except as otherwise required by Consolidated Omnibus Budget Reconciliation Act or any similar federal or state law, benefits shall
continue or terminate pursuant to the terms of the applicable benefit plan or agreement, without regard to any continuation of Base Salary
or other payment to Executive following such date of termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">The provisions of this Section 6 shall apply to any termination of employment. Provisions of this Agreement will survive any termination
if so provided herein or if necessary or desirable to accomplish the purposes of other surviving provisions, including, without limitation,
the obligations of Executive under Section 7 through Section 9.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">Any termination of Executive&rsquo;s employment with Company under this Agreement shall automatically be deemed to be simultaneous
resignation of all other positions and titles (including any director positions) that Executive holds with Company and any Affiliate or
subsidiary thereof. This Section 6(e) shall constitute a resignation notice for such purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">Upon termination of the Executive&rsquo;s employment or upon the Company&rsquo;s request at any other time, the Executive will deliver
to the Company all of the Company&rsquo;s property, equipment, and documents, together with all copies thereof, and any other material
containing or disclosing any Intellectual Property or Confidential Information and certify in writing that the Executive has fully complied
with the foregoing obligation. The Executive agrees that the Executive will not copy, delete, or alter any Company computer equipment
information before the Executive returns it to the Company. In addition, if the Executive has used any personal computer, server, or email
system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information,
the Executive agrees to provide the Company with a computer-usable copy of all such Confidential Information and then permanently delete
and expunge such Confidential Information from those systems; and the Executive agrees to provide the Company access to the Executive&rsquo;s system
as reasonably requested to verify that the necessary copying and/or deletion is completed.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: .25in">7.</TD><TD><U>Confidential Information</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Executive acknowledges that Company continually develops Confidential Information, that Executive may develop Confidential Information
for Company and that Executive may learn of Confidential Information during the course of employment with Company. Executive will comply
with the policies and procedures of Company for protecting Confidential Information and shall not disclose to any Person or use, other
than as required by applicable law, regulation or process or for the proper performance of Executive&rsquo;s duties and responsibilities
to Company, any Confidential Information obtained by Executive incident to Executive&rsquo;s employment or other association with Company.
Executive understands that this restriction shall continue to apply after Executive&rsquo;s employment terminates, regardless of the reason
for such termination.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Notwithstanding anything contained in this Section 7 to the contrary, nothing contained herein shall prevent Executive from disclosing
any Confidential Information required by law, subpoena, court order or other legal processes to be disclosed; provided, that, Executive
shall give prompt written notice to Company of such requirement, disclose no more information than is so required and cooperate, at Company&rsquo;s
cost and expense, with any attempt by Company to obtain a protective order or similar treatment with respect to such information.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>Pursuant to the Defend Trade Secrets Act of 2016, Executive understands that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Executive may not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret
that is made in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and solely
for the purpose of reporting or investigating a suspected violation of law; or is made in a complaint or other document that is filed
under seal in a lawsuit or other proceeding; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the
employer&rsquo;s trade secrets to Executive&rsquo;s attorney and use the trade secret information in the court proceeding if Executive
files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><U>Assignment of Rights to Intellectual Property</U>. Executive shall promptly and fully disclose to Company all Intellectual Property
developed for the benefit of Company in the course of Executive&rsquo;s employment by Company. Executive hereby assigns and agrees to
assign to Company (or as otherwise directed by Company) Executive&rsquo;s full right, title, and interest in and to all such Intellectual
Property. Executive agrees to execute any and all applications for domestic and foreign patents, copyrights or other proprietary rights
and to do such other acts (including without limitation the execution and delivery of instruments of further assurance or confirmation)
requested by Company (at Company&rsquo;s expense) to assign to Company the Intellectual Property developed for the benefit of Company
in the course of Executive&rsquo;s employment by Company and to permit Company to enforce any patents, copyrights or other proprietary
rights to the Intellectual Property. Executive will not charge Company for time spent in complying with these obligations. All copyrightable
works that Executive creates developed for the benefit of Company in the course of Executive&rsquo;s employment by Company shall be considered
<B>&ldquo;</B>work made for hire<B>.&rdquo;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><U>Restricted Activities</U>. Executive agrees that the restrictions on Executive&rsquo;s activities during and after Executive&rsquo;s
employment set forth below are necessary to protect the goodwill, Confidential Information and other legitimate interests of Company and
its successors and assigns:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">During the Term of this Agreement and during the Restricted Period
following termination of employment, Executive will not, without the prior written consent of Company, directly or indirectly, and whether
as principal or investor or as an Executive, officer, director, manager, partner, consultant, agent, or otherwise, alone or in association
with any other Person, firm, corporation, or other business organization, engage or otherwise become involved in a Competing Business
(as defined below) in any country in which the Company conducted business during the Term; provided, however, that the provisions of
this Section 9 shall apply solely to those activities of a Competing Business which are congruent with those activities with which Executive
was personally involved or for which Executive was responsible while employed by the Company or its subsidiaries during the twelve (12)
month period preceding termination of Executive&rsquo;s employment. This Section 9 will not be violated, however, by Executive&rsquo;s
investment of up to $500,000 in the aggregate in one or more publicly-traded companies that engage in a Competing Business. <B>&ldquo;Competing
Business&rdquo;</B> means a business or enterprise (other than Company or its subsidiaries) engaged in the development and commercialization
of therapeutics for malaria or COVID-19 and any other business directly competing with the business of the Company as currently conducted
or otherwise conducted by the Company during the Term. <B>&ldquo;Restricted Period&rdquo;</B> means twenty-four (24) months.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">During the Term of this Agreement and during the Restricted Period (as defined above), Executive will not engage in any Wrongful Solicitation.
A <B>&ldquo;Wrongful Solicitation&rdquo;</B> shall be deemed to occur when Executive directly or indirectly (except in the course of Executive&rsquo;s
employment with Company), for the purpose of conducting or engaging in a Competing Business, calls upon, solicits, advises or otherwise
does, or attempts to do, business with any Person who is, or was, during the then most recent 12-month period, a customer of Company or
any of its subsidiaries, or takes away or interferes or attempts to take away or interfere with any custom, trade, business, patronage
or affairs of Company or any of its subsidiaries, or hires or attempts to hire any Person who is, or was during the most recent 12-month
period, an Executive, officer, representative or agent of Company or any of its subsidiaries, or solicits, induces, or attempts to solicit
or induce any Person who is an Executive, officer, representative or agent of Company or any of its subsidiaries to leave the employ or
agency of the Company or any of its subsidiaries, or violate the terms of their contract, or any employment consulting or agent agreement,
with it.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">It is expressly understood and agreed that although Executive and Company consider the restrictions contained in this Section 9 to
be reasonable if a court makes a final judicial determination of competent jurisdiction that the time or territory or any other restriction
contained in this Agreement is an unenforceable restriction against Executive, the provisions of this Agreement shall not be rendered
void but shall be deemed amended to apply as to such maximum time and territory and to such maximum extent as the court may judicially
determine or indicate to be enforceable. Alternatively, if any court of competent jurisdiction finds that any restriction contained in
this Agreement is unenforceable, and such restriction cannot be amended so as to make it enforceable, such finding shall not affect the
enforceability of any of the other restrictions contained herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Executive expressly understands that in the event of a violation of any period specified in this Section 9, such period shall be extended
by a period of time equal to that period beginning with the commencement of any such violation and ending when such violation shall have
been finally terminated in good faith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Sans-Serif; font-size: 9pt; color: Red"><B></B></FONT><U>Enforcement of Covenants</U>. Executive
acknowledges that Executive has carefully read and considered all the terms and conditions of this Agreement, including the restraints
imposed upon Executive pursuant to Sections 7, 8 and 9<I>,</I> and Executive agrees that these restraints are necessary for the reasonable
and proper protection of Company and its successors and assigns and that each and every one of the restraints is reasonable in respect
to the subject matter, length of time and geographic area. Executive further acknowledges that, were Executive to breach any of the covenants
in Section 7, Section 8 and/or Section 9 the damage to the Company would be irreparable. Executive therefore agrees that Company, in addition
to any other remedies available to it, shall be entitled to preliminary and permanent injunctive relief against any breach or threatened
breach by Executive of any of the covenants herein, without any requirement to post a bond or similar security. The Parties further agree
that in the event that any provision of Section 7, Section 8 and/or Section 9 shall be determined by any court of competent jurisdiction
to be unenforceable by reason of its being extended over too great a time, too large a geographic area or too great a range of activities,
such provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: .25in">11.</TD><TD STYLE="text-align: justify"><U>Definitions</U>. Words or phrases that are initially capitalized or within quotation marks shall have the meanings provided in
this Section 11 and as provided elsewhere. For purposes of this Agreement, the following definitions apply:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD><B>&ldquo;$&rdquo;</B> refers to U.S. Dollars.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify"><B>&ldquo;Affiliate&rdquo;</B> means, with respect to any specified
Person, any other Person which directly or indirectly through one or more intermediaries controls, or is controlled by, or is under common
control with, such specified Person (for the purposes of this definition, <B>&ldquo;control&rdquo;</B> (including, with correlative meanings,
the terms <B>&ldquo;controlling,&rdquo; &ldquo;controlled by&rdquo;</B> and <B>&ldquo;under common control with&rdquo;</B>), as used
with respect to any Person, means the possession, directly or indirectly, of the power to either: (i) direct or cause the direction of
the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise, or (ii) vote
at least fifty percent (50%) or more of the securities having voting power for the election of a majority of the directors (or Persons
performing similar functions) of such Person.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD><B>&ldquo;Cause&rdquo;</B> means if Executive is discharged by Company on account of the occurrence of one or more of the following
events:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">Executive&rsquo;s continued refusal or failure to perform (other than by reason of Disability) Executive&rsquo;s material duties and
responsibilities to Company if such refusal or failure is not cured within thirty (30) days following written notice of such refusal or
failure by Company to Executive, or Executive&rsquo;s continued refusal or failure to follow any reasonable lawful direction of the Board
if such refusal or failure is not cured within thirty (30) days following written notice of such refusal or failure by Company to Executive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">a material breach of this Agreement (other than Section 7, Section 8 and/or Section 9) by Executive that, if capable of being cured,
is not cured within thirty (30) days following written notice of such breach by Company to Executive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">an intentional and material breach of Section 7, Section 8 and/or Section 9 hereof by Executive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iv)</TD><TD STYLE="text-align: justify">willful, grossly negligent or unlawful misconduct by Executive which causes material harm to Company or its reputation;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(v)</TD><TD STYLE="text-align: justify">any conduct engaged in by Executive that is materially detrimental to the business or reputation of Company as determined by the Board
in good faith using its reasonable business judgment that is not cured within thirty (30) days following written notice from Company to
Executive;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(vi)</TD><TD STYLE="text-align: justify">the Company is directed in writing by regulatory or governmental authorities to terminate the employment of Executive or Executive
engages in activities that: (i) are not approved or authorized by the Board, and (ii) cause actions to be taken by regulatory or governmental
authorities that have a material adverse effect on Company; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(vii)</TD><TD STYLE="text-align: justify">a conviction, plea of guilty, or plea of <I>nolo contendere</I>
by Executive, of or with respect to a criminal offense which is a felony or other crime involving dishonesty, disloyalty, fraud, embezzlement,
theft, or similar action(s) (including, without limitation, acceptance of bribes, kickbacks or self-dealing), or the material breach
of Executive&rsquo;s fiduciary duties with respect to Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><B>&ldquo;Change in Control&rdquo;</B> means the occurrence, in a single transaction or in a series of related transactions, of any
one or more of the following events:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">A transaction or series of transactions (other than an offering of common stock to the general public through a registration statement
filed by the Company with the Securities and Exchange Commission) whereby any &ldquo;Person&rdquo; or related &ldquo;group&rdquo; of &ldquo;persons&rdquo;
(as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than the Company, any of its subsidiaries, an Executive
benefit plan maintained by the Company or any of its subsidiaries or a &ldquo;Person&rdquo; that, prior to such transaction, directly
or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership
(within the meaning of Rule 13(d)(3) under the Exchange Act) of securities of the Company possessing more than fifty percent (50%) of
the total combined voting power of the Company&rsquo;s securities outstanding immediately after such acquisition;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries)
of (x) a merger, consolidation, reorganization, or business combination, or (y) a sale or other disposition of all or substantially all
of the Company&rsquo;s assets in any single transaction or series of related transactions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">(A)</TD><TD STYLE="text-align: justify">which results in the Company&rsquo;s voting securities outstanding
immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities
of the Company or the Person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or
indirectly, all or substantially all of the Company&rsquo;s assets or otherwise succeeds to the business of the Company (the Company
or such Person, the <B>&ldquo;Successor Entity&rdquo;) </B>directly or indirectly, at least a majority of the combined voting power of
the Successor Entity&rsquo;s outstanding voting securities immediately after the transaction, and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(B)</TD><TD STYLE="text-align: justify">after which no Person or group beneficially owns voting securities representing fifty percent (50%) or more of the combined voting
power of the Successor Entity; <I><U>provided</U>, <U>however</U>,</I> that no Person or group shall be treated for purposes of this Section
11(d) as beneficially owning fifty percent (50%) or more of the combined voting power of the Successor Entity solely as a result of the
voting power held in the Company prior to the consummation of the transaction.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in">A transaction shall not
constitute a Change in Control if its sole purpose is to change the State of the Company&rsquo;s incorporation or to create a holding
company that will be owned in substantially the same proportions by the persons who held the Company&rsquo;s securities immediately before
such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="padding-left: -0.375in; width: 0.25in"></TD><TD STYLE="padding-left: -0.375in; width: 0.25in">(e)</TD><TD><B>&ldquo;Code&rdquo;</B> means the Internal Revenue Code of 1986, as amended.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD><B>&ldquo;Company&rdquo;</B> has the meaning ascribed to it in the preamble of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD>&ldquo;<B>Company Group&rdquo;</B> shall mean the Company together with any of its direct or indirect subsidiaries.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(h)</TD><TD STYLE="text-align: justify"><B>&ldquo;Compensation Committee&rdquo;</B> shall mean the committee of the Board designated to make compensation decisions relating
to senior executive officers of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify"><B>&ldquo;Confidential Information&rdquo;</B> means any and all nonpublic information of the Company. Confidential Information includes,
without limitation, such information relating to (i) the development, research, testing, manufacturing, marketing, and financial activities
of the Company, (ii) the Services, (iii) the costs, sources of supply, financial performance, and strategic and/or business plans of Company,
(iv) the identity and special needs of the customers and prospective customers of Company, and (v) the people and organizations with whom
Company has business relationships and those relationships. Confidential Information also includes any information that Company has received,
or may receive hereafter, belonging to customers or others with any understanding, express or implied, that the information would not
be disclosed. Notwithstanding the foregoing, <B>&ldquo;</B>Confidential Information<B>&rdquo;</B> does not include (x) any information
that is or becomes generally known to the industry or the public through no wrongful act of Executive or any representative of Executive
and (y) any information that is made legitimately available to Executive by a third Party without breach of any confidentiality obligation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(j)</TD><TD STYLE="text-align: justify"><B>&ldquo;Disability&rdquo;</B> means Executive&rsquo;s inability, due to any illness, injury, accident or condition of either a physical
or psychological nature, to substantially perform Executive&rsquo;s duties and responsibilities hereunder for a period of one hundred
twenty (120) consecutive days, or for any one hundred and eighty (180) days during any period of three hundred and sixty-five (365) consecutive
calendar days, exclusive of any leave Executive may take under the Family and Medical Leave Act, 29 U.S.C. &sect; 12101 <I>et seq. (</I><B>&ldquo;FMLA&rdquo;</B><I>)</I>
or as a reasonable accommodation under the Americans with Disabilities Act, 29 U.S.C. &sect; 2601 <I>et seq. (</I><B>&ldquo;ADA&rdquo;</B><I>).</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(k)</TD><TD STYLE="text-align: justify"><B>&ldquo;Final Compensation&rdquo;</B> means the amount equal to the sum of: (i) the Base Salary earned but not paid through the
date of termination of employment, payable not later than the next scheduled payroll date, (ii) any business and related expenses and
allowances incurred by Executive or to which Executive is entitled under Section 4(f) but unreimbursed on the date of termination of employment;
provided that with respect to business expenses unreimbursed under Section 4(f), such expenses and required substantiation and documentation
are submitted within one hundred eighty (180) days of termination in the case of termination on account of Executive&rsquo;s death, or
thirty (30) days on account of termination for any reason other than death, and that such expenses are reimbursable under Company&rsquo;s
applicable reimbursement policy, and (iii) any other supplemental compensation, insurance, retirement or other benefits due and payable
or otherwise required to be provided under Section 4 in accordance with the terms and conditions of the applicable plan or agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(l)</TD><TD STYLE="text-align: justify"><B>&ldquo;Good Reason&rdquo;</B> means, without Executive&rsquo;s express written consent: (i) a material reduction in the Base Salary,
then in effect, except a material diminution generally affecting all of the members of the Company&rsquo;s management, (ii) a material
reduction in job title, position or responsibility, (iii) a material breach of any term or condition contained in this Agreement, or (iv)
a relocation of Executive&rsquo;s principal worksite that is more than fifty (50) miles from Executive&rsquo;s principal worksite as of
the Effective Date. However, none of the foregoing events or conditions will constitute <B>&ldquo;Good Reason&rdquo;</B> unless (i) Executive
provides Company with written notice of the existence
of Good Reason within ninety (90) days following the occurrence thereof, (ii) Company does not reverse or otherwise cure the event or
condition within thirty (30) days of receiving that written notice, and (iii) Executive resigns Executive&rsquo;s employment within thirty
(30) days following the expiration of that cure period.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(m)</TD><TD STYLE="text-align: justify"><B>&ldquo;Intellectual Property&rdquo;</B> means inventions, discoveries, developments, methods, processes, compositions, works, concepts
and ideas (whether or not patentable or copyrightable or constituting trade secrets) conceived, made, created, developed or reduced to
practice by Executive (whether alone or with others, whether or not during normal business hours or on or off Company premises) during
Executive&rsquo;s employment that relate to either the Services or any prospective activity of Company or that make use of Confidential
Information or any of the equipment or facilities of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(n)</TD><TD STYLE="text-align: justify"><B>&ldquo;Person&rdquo;</B> means an individual, a corporation, a limited liability company, an association, a partnership, an estate,
a trust, and any other entity or organization other than Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(o)</TD><TD STYLE="text-align: justify"><B>&ldquo;Sale of Company&rdquo; </B>means the sale of Company to an independent third Party or group of independent third Parties
pursuant to which such Party or Parties acquire: (i) equity interests possessing the voting power under normal circumstances to elect
a majority of the Board of Directors or similar governing body of Company (whether by merger, consolidation or sale or transfer of such
equity interests), or (ii) all or substantially all of Company&rsquo;s assets determined on a consolidated basis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(p)</TD><TD STYLE="text-align: justify"><B>&ldquo;Services&rdquo;</B> means all services planned, researched, developed, tested, manufactured, sold, licensed, leased or otherwise
distributed or put into use by Company, together with all products provided or planned by Company, during Executive&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(q)</TD><TD STYLE="text-align: justify"><B>&ldquo;Severance Period</B>&rdquo; shall mean that number of years or partial years following termination of Executive&rsquo;s
employment equal to the number of years or partial years of Base Salary that the Executive receives under Section 5(f)..</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(r)</TD><TD><B>&ldquo;Term End Date&rdquo;</B> shall mean the last day of the Term of this Employment Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify"><U>Withholding</U>. All payments made by Company under this Agreement may be reduced by any tax or other amounts required to be withheld
by Company under applicable law or by any amounts authorized in writing by Executive.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">13.</TD><TD STYLE="text-align: justify"><U>Assignment</U>. Neither Company nor Executive may make any assignment of this Agreement or any interest herein, by operation of
law or otherwise, without the prior written consent of the other; provided, however, that Company may assign its rights and obligations
under this Agreement without the consent of Executive in the event of a Sale of Company. This Agreement shall inure to the benefit of
and be binding upon Company and Executive, their respective successors, executors, administrators, heirs and permitted assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">14.</TD><TD><U>Compliance with Code Section 409A</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Notwithstanding any provision of this Agreement to the contrary, Executive&rsquo;s employment will be deemed to have terminated on
the date of Executive &ldquo;separation from service&rdquo; (within the meaning of Treas. Reg. Section 1.409A-1(h)) with Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">It is intended that this Agreement will comply with Section 409A of the Code, and any regulations and guideline issued thereunder
(<B>&ldquo;Section 409A&rdquo;</B>) to the extent that any compensation and benefits provided hereunder constitute deferred compensation
subject to Section 409A. This Agreement shall be interpreted on a basis consistent with this intent. The Parties will negotiate in good
faith to amend this Agreement as necessary to comply with Section 409A in a manner that preserves the original intent of the Parties to
the extent reasonably possible. No action or failure to act, pursuant to this Section 14 shall subject Company to any claim, liability,
or expense, and Company shall not have any obligation to indemnify or otherwise protect Executive from the obligation to pay any taxes
pursuant to Section 409A of the Code.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">For purposes of the application of Treas. Reg. &sect; 1.409A-1(b)(4)(or any successor provision), each payment in a series of payments
will be deemed a separate payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Notwithstanding anything in this Agreement to the contrary, if
any amount or benefit that would constitute non-exempt &ldquo;deferred compensation&rdquo; for purposes of Section 409A of the Code would
otherwise be payable or distributable under this Agreement by reason of Executive&rsquo;s separation from service during a period in
which Executive is a &ldquo;specified Executive&rdquo; (as defined under Code Section 409A and the final regulations thereunder), then,
subject to any permissible acceleration of payment by Company under Treas. Reg. Section 1.409A-3(j)(4)(ii) (domestic relations order),
(j)(4)(iii) (conflicts of interest), or (j)(4)(vi) (payment of employment taxes):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">if the payment or distribution is payable in a lump sum, the Executive&rsquo;s right to receive payment or distribution of such non-exempt
deferred compensation will be delayed until the earlier of Executive&rsquo;s death or the first day of the seventh month following Executive&rsquo;s
separation from service; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">if the payment or distribution is payable over time, the amount of such non-exempt deferred compensation that would otherwise be payable
during the six months immediately following Executive&rsquo;s separation from service will be accumulated, and the Executive&rsquo;s right
to receive payment or distribution of such accumulated amount will be delayed until the earlier of Executive&rsquo;s death or the first
day of the seventh month following Executive&rsquo;s separation from service, whereupon the accumulated amount will be paid or distributed
to Executive and the normal payment or distribution schedule for any remaining payments or distributions will resume.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in">This Section 14(d) should not be construed to
prevent the application of Treas. Reg &sect; 1.409A-1(b)(9)(iii)(or any successor provision) to amounts payable hereunder (or any portion
thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">15.</TD><TD STYLE="text-align: justify"><U>Golden Parachute Limitation</U>. Notwithstanding anything in this Section or elsewhere in this Agreement to the contrary, in the
event the payments and benefits payable hereunder to or on behalf of Executive (which the Parties agree will not include any portion of
payments allocated to the non-competition and non-solicitation provisions of Section 9) that are classified as payments of reasonable
compensation for purposes of Section 280G of the Code, when added to all other amounts and benefits payable to or on behalf of Executive,
would result in the loss of a deduction under Code Section 280G, or the imposition of an excise tax under Code Section 4999, the amounts
and benefits payable hereunder shall be reduced to such extent as may be necessary to avoid such loss of deduction or imposition of excise
tax. In applying this principle, the reduction shall be made in a manner consistent with the requirements of Code Section 409A and where
two or more economically equivalent amounts are subject to reduction, but payable at different times, such amounts shall be reduced on
a <I>pro-rata</I> basis. All calculations required to be made under this subsection will be made by the Company&rsquo;s independent public
accountants, subject to the right of Executive&rsquo;s professional advisors to review the same. The Parties recognize that the actual
implementation of the provisions of this subsection are complex and agree to deal with each other in good faith to resolve any questions
or disagreements arising hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">16.</TD><TD><U>Successors.</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><U>Company&rsquo;s Successors.</U> Subject to Section 5(f),, any successor to the Company (whether direct or indirect and
whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&rsquo;s business and/or
assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same
manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession. For all purposes
under this Agreement, the term &ldquo;Company&rdquo; shall include any successor to the Company&rsquo;s business and/or assets which executes
and delivers the assumption agreement described in this Section 16 or which becomes bound by the terms of this Agreement by operation
of law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><U>Executive&rsquo;s Successors.</U> The terms of this Agreement and all rights of Executive hereunder shall inure to the
benefit of, and be enforceable by, Executive&rsquo;s personal or legal representatives, executors, administrators, successors, heirs,
distributees, devisees and legatees</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">17.</TD><TD STYLE="text-align: justify"><U>Clawback Provisions</U>. Any amounts payable under this Agreement are subject to any policy (whether in existence as of the Effective
Date or later adopted) established by the Company providing for clawback or recovery of amounts that were paid to the Executive. The Company
will make any determination for clawback or recovery in its sole discretion and in accordance with any applicable law or regulation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">18.</TD><TD STYLE="text-align: justify"><U>Indemnification</U>. Company will indemnify Executive to the
fullest extent permitted by law, for all amounts (including, without limitation, judgments, fines, settlement payments, expenses and
reasonable out-of-pocket attorneys&rsquo; fees) incurred or paid by Executive in connection with any action, suit, investigation or proceeding,
or threatened action, suit, investigation or proceeding, arising out of or relating to the performance by Executive of services for,
or the acting by Executive as a director, officer or Executive of, Company, or any subsidiary of Company. Any fees or other necessary
expenses incurred by Executive in defending any such action, suit, investigation or proceeding shall be paid by Company in advance, subject
to Company&rsquo;s right to seek repayment from Executive if a determination is made that Executive was not entitled to indemnification.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">19.</TD><TD STYLE="text-align: justify"><U>Severability</U>. If any portion or provision of this Agreement shall to any extent be declared illegal or unenforceable by a court
of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in the circumstances
other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision
of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">20.</TD><TD STYLE="text-align: justify"><U>Waiver</U>. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving Party. The failure
of either Party to require the performance of any term or obligation of this Agreement, or the waiver by either Party of any breach of
this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">21.</TD><TD STYLE="text-align: justify"><U>Survival</U>. Section 6 through and including Section 32 shall survive and continue in full force in accordance with their terms
notwithstanding the termination of Executive&rsquo;s employment (and hence the Term of this Agreement) for any reason.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">22.</TD><TD STYLE="text-align: justify"><U>Notices</U>. Any and all notices, requests, demands and other communications provided for by this Agreement shall be in writing
and shall be effective when delivered in Person, with respect to notices delivered personally, or upon confirmed receipt when delivered
by facsimile or deposited with a reputable, nationally recognized overnight courier service and addressed or faxed to Executive at Executive&rsquo;s
last known address on the books of Company or, in the case of Company, at its principal place of business, attention: Secretary, Board
of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">23.</TD><TD STYLE="text-align: justify"><U>Entire Agreement</U>. This Agreement constitutes the entire agreement between the Parties (including with respect to Company, its
successors and assigns) with respect to Executive&rsquo;s employment and supersedes all prior communications, agreements and understandings,
written or oral, with respect to the terms and conditions of Executive&rsquo;s employment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">24.</TD><TD STYLE="text-align: justify"><U>Amendment</U>. This Agreement may be amended or modified only by a written instrument signed by Executive and by an expressly authorized
representative of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">25.</TD><TD STYLE="text-align: justify"><U>Headings</U>. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or
content of any provision of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">26.</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which
together shall constitute one and the same instrument. Furthermore, the delivery of a copy of such signature by facsimile transmission
or other electronic exchange methodology shall constitute a valid and binding execution and delivery of this Agreement by such Party,
and such electronic copy shall constitute an enforceable original document. Counterpart signatures need not be on the same page and shall
be deemed effective upon receipt.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">27.</TD><TD STYLE="text-align: justify"><U>Additional Obligations</U>. Without implication that the contrary would otherwise be true, Executive&rsquo;s obligations under
Section 7, Section 8 and Section 9 are in addition to, and not in limitation of, any obligations that Executive may have under applicable
law (including any law regarding trade secrets, duty of loyalty, fiduciary duty, unfair competition, unjust enrichment, slander, libel,
conversion, misappropriation and fraud).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">28.</TD><TD STYLE="text-align: justify"><U>Attorneys&rsquo; Fees</U>. In any action or proceeding brought to enforce any provision of this Agreement, the prevailing
Party shall be entitled to recover reasonable attorneys&rsquo; fees, costs, and expenses from the other Party to the action or proceeding.
For purposes of this Agreement, the <B>&ldquo;prevailing Party&rdquo;</B> shall be deemed to be that Party who obtains substantially the
result sought, whether by settlement, mediation, judgment or otherwise, and <B>&ldquo;attorneys&rsquo; fees&rdquo;</B> shall include,
without limitation, the reasonable out-of-pocket attorneys&rsquo; fees incurred in retaining counsel for advice, negotiations, suit, appeal
or other legal proceeding, including mediation and arbitration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">29.</TD><TD STYLE="text-align: justify"><U>Confidentiality</U>. The Parties acknowledge and agree that
this Agreement and each of its provisions are and shall be treated strictly confidential. During the Term and thereafter, Executive shall
not disclose any terms of this Agreement to any Person or entity without the prior written consent of Company, with the exception of
Executive&rsquo;s tax, legal or accounting advisors or for legitimate business purposes of Executive, or as otherwise required by law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">30.</TD><TD STYLE="text-align: justify"><U>No Rule of Construction</U>. This Agreement shall be construed to be neither against nor in favor of any Party hereto based upon
any Party&rsquo;s role in drafting this Agreement, but rather in accordance with the fair meaning hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">31.</TD><TD STYLE="text-align: justify"><U>Governing Law</U>. The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of
the state of Florida.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">32.</TD><TD STYLE="text-align: justify"><U>WAIVER OF JURY TRIAL</U>. EXECUTIVE AND THE COMPANY EXPRESSLY WAIVE ANY RIGHT EITHER MAY HAVE TO A JURY TRIAL CONCERNING ANY CIVIL
ACTION THAT MAY ARISE FROM THIS AGREEMENT OR THE RELATIONSHIP OF THE PARTIES HERETO.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">33.</TD><TD STYLE="text-align: justify"><U>Conditions</U>. This Agreement and the Executive&rsquo;s continued employment hereunder is conditional on the Company&rsquo;s satisfaction
(determined in the Company&rsquo;s sole discretion) that the Executive has met the legal requirements to perform the Executive&rsquo;s
role, including but not limited to satisfactory results of a background and/or credit search or any other applicable security clearance
checks and criminal record checks and other reference checks that the Company performs. The Executive acknowledges and agrees that in
signing this Agreement, and providing the Company with the necessary documentation to perform the checks required for the Executive&rsquo;s
role and with references, the Executive is providing consent to the Company or its agent, to performs such checks and contact the references
the Executive provided to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">34.</TD><TD STYLE="text-align: justify"><U>Prior Restrictions</U>. By signing below, the Executive represents that the Executive is not bound by the terms of any agreement
with any Person which restricts in any way the Executive&rsquo;s hiring by the Company and the performance of the Executive&rsquo;s expected
job duties; the Executive also represents that, during the Executive&rsquo;s employment with the Company, the Executive shall not disclose
or make use of any confidential information of any other persons or entities in violation of any of their applicable policies or agreements
and/or applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">35.</TD><TD STYLE="text-align: justify"><U>Independent Legal Counsel</U>. By signing below, the Executive hereby acknowledges that the Executive has been encouraged to obtain
independent legal advice regarding the execution of this Agreement, and that the Executive has either obtained such advice or voluntarily
chosen not to do so, and hereby waives any objections or claims the Executive may make resulting from any failure on the Executive&rsquo;s
part to obtain such advice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in">36.</TD><TD STYLE="text-align: justify"><U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original when executed,
but all of which taken together shall constitute the same Agreement. Delivery of an executed counterpart of a signature page to this Agreement
by electronic transmission, including in portable document format (.pdf), shall be deemed as effective as delivery of an original executed
counterpart of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 78pt; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in"><B>IN WITNESS WHEREOF</B>, this Agreement has
been executed by Company (by its duly authorized representative) and by Executive, as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold">60 Degrees Pharmaceuticals Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 5%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 6%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 39%; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Geoff Dow</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoff Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">Title:</TD>
    <TD STYLE="text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 50%; font-weight: bold">EXECUTIVE<FONT STYLE="font-weight: normal">:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Tyrone Miller</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><U>EXHIBIT A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><U>Release of Claims</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">FOR AND IN CONSIDERATION OF the
benefits to be provided me in connection with the termination of my employment, as set forth in that certain Employment Agreement, dated
as of<U>_______</U>, 2022 (the <B>&ldquo;Agreement&rdquo;</B>), between me and 60 Degrees Pharmaceuticals Inc. (the <B>&ldquo;Company&rdquo;</B>),
or under any severance pay plan applicable to me, which benefits are conditioned on my signing this Release of Claims and to which I am
not otherwise entitled, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, I,
on my own behalf and on behalf of my heirs, executors, administrators, beneficiaries, representatives and assigns, and all others connected
with me, hereby release and forever discharge Company and any of its subsidiaries and Affiliates (as that term is defined in Section 11(b)
of the Agreement) and all of their respective past, present and future officers, directors, trustees, equity holders, Executives, agents,
managers, joint venturers, representatives, successors and assigns, and all others connected with any of them (collectively, the <B>&ldquo;Released
Parties&rdquo;</B>), both individually and in their official capacities, from any and all causes of action, rights and claims of any type
or description, known or unknown, which I have had in the past, now have, or might now have, through the date of my signing of this Release
of Claims, in any way resulting from, arising out of or connected with my employment by the Company or any of its Affiliates or the termination
of that employment, including, but not limited to, any allegation, claim or violation arising under: Title VII of the Civil Rights Act
of 1964, as amended; the Civil Rights Act of 1991; the Age Discrimination in Employment Act of 1967, as amended (including the Older Worker
Benefit Protection Act); the Equal Pay Act of 1963, as amended; the Americans with Disabilities Act of 1990; the Family and Medical Leave
Act of 1993; the Worker Adjustment Retraining and Notification Act; Executive Retirement Income Security Act of 1974; the Fair Labor Standards
Act; any applicable Executive Orders; or their state or local counterparts; or under any other federal, state or local civil or human
rights law, or under any other federal, state or local law, regulation or ordinance; or under any public policy, contract or tort, or
under common law; or arising under any policies, practices or procedures of the Company; or any claim for wrongful discharge, breach of
contract, intentional infliction of emotional distress or defamation; or any claim for costs, fees or other expenses, including attorneys&rsquo;
fees incurred in these matters (all of the foregoing collectively referred to herein as <B>&ldquo;Claims&rdquo;</B>), other than (i) the
right to payment of any vested or accrued benefits under any supplemental compensation, insurance, retirement and/or other benefit plan
or agreement applicable to Executive, (ii) the right to payment of any amounts owed to me by Company pursuant to Section 5 of the Agreement,
(iii) any rights under applicable workers compensation or unemployment compensation laws, (iv) any rights that survive termination of
my employment pursuant to an option grant agreement or certificate to purchase the Company&rsquo;s (or an Affiliate&rsquo;s) capital stock,
(v) any rights with respect to the Company&rsquo;s (or an Affiliate&rsquo;s) capital stock owned by Executive, or (vi) any rights to indemnification
under the Agreement, the Company&rsquo;s by-laws or any other applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">In signing this Release of Claims,
I acknowledge my understanding that I may not sign it prior to the termination of my employment, but that I may consider the terms of
this Release of Claims for up to twenty-one (21) days (or such longer period as the Company may specify) from the later of the date my
employment with the Company terminates or the date I receive this Release of Claims. I also acknowledge that I am advised by the Company
and its Affiliates to seek the advice of an attorney prior to signing this Release of Claims; that I have had sufficient time to consider
this Release of Claims and to consult with an attorney, if I wished to do so, or to consult with any other Person of my choosing before
signing; and that I am signing this Release of Claims voluntarily and with a full understanding of its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">I represent that I have not filed
against the Released Parties any complaints, charges, or lawsuits arising out of my employment, or any other matter arising on or prior
to the date of this Release of Claims, and covenant and agree that I will never individually or with any Person file, or commence the
filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect
to any of the matters released by me pursuant to this Release of Claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">I further acknowledge that, in signing
this Release of Claims, I have not relied on any promises or representations, express or implied, that are not set forth expressly in
the Agreement. I understand that I may revoke this Release of Claims at any time within seven (7) days of the date of my signing by written
notice to the Secretary, Board of Directors of the Company (or such other Person as the Company may specify by notice to me given in accordance
with the Agreement) and that this Release of Claims will take effect only upon the expiration of such seven-day revocation period and
only if I have not timely revoked it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Intending to be legally bound, I have signed this Release
of Claims as of the date written below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-indent: 0in">Signature:</TD>
    <TD STYLE="width: 38%; border-bottom: Black 1pt solid; text-indent: 0in">/s/ Ty Miller</TD>
    <TD STYLE="width: 50%; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ty Miller</FONT></TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 0in">Date Signed:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/12/2023</FONT></TD>
    <TD STYLE="text-indent: 0in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>27
<FILENAME>cm270_ex10-24.htm
<DESCRIPTION>EXHIBIT 10.24
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.24</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">600
PHARMACEUTICALS,LLC<FONT STYLE="text-decoration: none">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSCRIPTION
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITH</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Avante
International </B>Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October
11, 2017</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE
TO <B>INVESTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
RESIDENTS OF ALL STATES AND THE DISTRICT OF COLUMBIA:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
OFFERING IS BEING MADE SOLELY TO &ldquo;ACCREDITED INVESTORS,&rdquo; AS SUCH TERM IS DEFINED INRULE 501 OF REGULATION D UNDER THE SECURITIES
ACT. THE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE AND WILL BE OFFERED AND SOLD
IN RELIANCE ON THE EXEMPTION FROM REGISTRATION AFFORDED BY SECTION 4(2) AND REGUlATION D (RULE 506) OF THE SECURITIES ACT AND CORRESPONDING
PROVISIONS OF STATE SECURITIES LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SECURITIES ARE SUBJECT TO RESTRICTION ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE
SECURITIES ACT AND STATE LAW, PURSUANT TO REGISTRATION THEREUNDER OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY WILL BE
REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR ANY OTHER REGULATORY AUTHORITY, NOR HAVE
ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THIS OFFERING OR THE ACCURACY, COMPLETENESS OR ADEQUACY OF THIS
MEMORANDUM. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 0; text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 80%"></TD>
    <TD STYLE="background-color: white; text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Issuance,
    Purchase and Sale of the Note</U></B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Purchase and Sale</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>The Closing</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investor Rights</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
    and Warranties of Company</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Organization; Authority</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Conflicts</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Capitalization</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business/Financial Projections</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Litigation</U></B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Taxes</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Intellectual Property</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Contracts and Commitments</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compliance with Law</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Employee Matters</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Debts and Security Interests</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Business</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
    of Investors</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Qmanization of Investor; Authorization</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Conflict as to Investor</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investment Intent</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reliance upon Investor&rsquo;s Representation</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Investment Experience</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Restricted Securities</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Legends</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Financial Books and Records</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reliance</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations
    to Continue in Effect; Indemnification</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Continued Effect</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification by Company</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Indemnification by Investor</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions
    to Closing of Investors</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5.1</I></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><U>Conditions </U></I><U>to <I>Closing</I></U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conditions
    to Closing of Company</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Use
    of Proceeds</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Notices</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Miscellaneous</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expenses</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Captions</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Waiver</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exclusive Agreement; <I>Amendment</I></U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Counterparts</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing Law</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7</FONT></TD>
    <TD STYLE="width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Attorney&rsquo;s Fees</U></FONT></TD>
    <TD STYLE="text-align: right; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Designation of Forum and Consent to Jurisdiction</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Waiver of Jury Trial</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No Assignment</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9 11</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General Cooperation</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-indent: 10pt; text-align: left; padding-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Definitions</U></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  </TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">APPENDICES:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXHIBIT
A.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
of Note</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUBSCRIPTION
AGREEMENT</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 33.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Subscription Agreement (this &ldquo;Agreement&rdquo;) is made as of October II, 2017 (the <U>&ldquo;Effective Date&rdquo;),</U> by and
between The 60 Degrees Pharmaceuticals, LLC., a limited liability company organized and operating in Washington, District of Columbia,
USA (the &ldquo;Company&rdquo;), and Avante International Limited, a family company based in Hong Kong, (&ldquo;Investor&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>RECITALS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 34.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is engaged in development and commercialization of drugs to treat and prevent tropical diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company desires to issue and sell to Investor, and Investor desires to purchase, an unsecured non-convertible promissory note of the
Company in the form as the attached <U>EXHIBIT A</U> (the &ldquo;Note&rdquo;), pursuant to the terms and conditions of this Agreement
and the Note of even date herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
capitalized terms used herein without definition have the meanings ascribed thereto in <U>Section 10</U> hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>AGREEMENT</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the premises and the mutual promises and covenants herein contained, the sufficiency of which is hereby acknowledged,
the Parties agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance,
Purchase and Sale of the Note.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 32.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 67.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase
and Sale</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 101.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms and conditions of this Agreement, Investor hereby agrees to purchase from Company, and Company agrees to issue and sell
to Investor, the Notes at a price of Seven Hundred and Fifty Thousand Dollars($ 750,000.00).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 101.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
consideration of the foregoing issuance and sale of the Note, Investor agrees to pay to Company the sum of Seven Hundred and Fifty Thousand
Dollars ($750,000.00) (the &ldquo;Purchase Price&rdquo;) as provided in <U>Section 1.2</U> below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 67.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>The
Closing.</U></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 100.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor
shall purchase from the Company, and the Company shall issue and sell to Investor, the Note as set forth in Section 1. l(a) above. The
Purchase Price for the Note shall be paid by Investor in one lump sum payment, without notice, demand, deduction or offset, by ACH, wire
transfer or check to the bank account of the Company at B11nk of <B>America. </B>The Note is issued and sold as part of an offering of
convertible and non-convertible promissory notes in the aggregate principal amount of up to $2,500,000 (the &ldquo;Offering&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 104.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 104.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Place</U>.
The purchase and sale of the Note (hereinafter referred to as a <U>&ldquo;Closing&rdquo;)</U> shall take place once all documents are
signed and delivered to the Company&rsquo;s legal counsel, C. Thomas Hicks III, at DiMuro Ginsberg, PC, t 101 King Street, Suite 610,
Alexandria, Virginia 22314. If Investor fails to pay the Purchase Price after all such documents</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">are
signed and delivered as set out above then this Agreement shall terminate immediately. Upon such termination Investor&rsquo;s right to
purchase the Note shall be null and void and Investor s hall reimburse the Company within three (3) calendar days following the Company&rsquo;s
written demand for such reimbursement, for all reasonable out-of.pocket costs and expenses (including reasonable attorneys&rsquo; fees)
incurred by or on behalf of the Company in connection with this Agreement and the sale of the Note contemplated herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 100.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deliveries
at Closing</U>. Promptly following the Closing but not later than thirty (30) calendar days, subject to receipt of the Purchase Price,
the Company shall deliver to Investor documentation reflecting the purchased Note has been reflected in the Company&rsquo;s electronic
record-keeping of its debt. The Note shall be subject to the rights and conditions set forth in <U>Sections 1.3</U>, ll and hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 100.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investor
Rights to information.</U> Investor will have access, upon written request, to regularly prepared financial statements, Company Manager
and Member resolutions and access to the Company&rsquo;s Manager, Geoffrey S. Dow or his successor(s,) with reasonable notice at reasonable
times at the Company&rsquo;s principal place of business, on a best efforts basis, except that access to information which is confidential
under third-party contract and/or Company research and development and other proprietary information will not be accessible. Investor
herby agrees that in the event any confidential and/or proprietary information is provided to or learned by Investor, such information
shall <B>be kept </B>strictly confidential by Investor and may not disclosed, disseminated, distributed, divulged, used or reproduced
in any manner without the prior written consent of the Company, which consent may be withheld in the Company&rsquo;s sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 33pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of Company.</U> Company represents and warrants to Investor as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>0rW}i7,ation;
Authority.</U> Company is a limited liability company duly organized and validly existing under the laws of Washington, District of Columbia,
USA, with full company power and authority to execute, deliver and perfom1 this Agreement, to conduct the Business, to own its properties
and to consummate the transactions contemplated by this Agreement. The Company was fanned on September 9, 2010, and since the time of
its formation has not owned any assets not related to the Business or engaged in any business other than the Business . This Agreement
has been duly authorized by all necessary actions of Company and its members and the Manager and constitutes legal, valid and binding
obligations of Company , enforceable against it in accordance with their respective teams, except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors&rsquo; rights generally,
and (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflicts</U> . Neither the execution and delivery of this Agreement nor performance by the Company of any or all of the transactions
contemplated hereby will violate, conflict with, or give rise to any termination right under (a) any provision of the Articles of Organization,
as amended, or the Amended and Restated Operating Agreement of the Company, (b) any material agreement or commitment to which Company
is a party, or (c) any law, rule , regulation or order of any court or other Governmental Agency applicable to Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Business/Financial
Projections/RISK FACTORS.</U> The Company has provided Investor with a briefing document describing in general the Business and the non
convertible note investment opportunity. However, Investor acknowledges and agrees that such briefing document provided to Investor in
connection with the transactions contemplated hereunder contains forward looking statements concerning future events that involve material
risks and uncertainty, including that. if for any reason. including insufficient available funds, the Company is unable to obtain United
States Food and Drug Administration confirmation of the Borrower&rsquo;s eligibility for a New Drug Application for a Tafenoquine prophylactic
antimalarial drug and/or there is no PRV Voucher Presale or Priority Voucher Sale, the remaining Note proceeds shall be applied to other
drug development projects of the Company. Other financial risks may apply, and Investor is responsible for doing its own due diligence
and investigation as to any additional risk factors prior to making this investment.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I><U>Litigation.
</U>There is no litigation or governmental or administrative proceeding or, to the knowledge of the Company, any investigation pending
or threatened against the Company or affecting the properties or assets of the Company, or, as to matters related to the Company, against
any member, manager or key employee of the Company, nor, to the knowledge of the Company (a) bas any material event occurred, or (b)
does any material condition exist, on the basis of which any such claim may be asserted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>-
.. The Company has filed on a timely basis all Tax Returns required to be filed on or before the date hereof pursuant to all applicable
laws or regulations of each Governmental Agency having jurisdiction over it. AJl Taxes that Company has been required by law to withhold
or collect have been duly withheld or collected and paid or will be timely paid to the proper Governmental Agency. All Tax Returns filed
by Company are true, complete and complete in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.7</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Intellectual
Property.</U></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 100.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of the time of the execution of this Agreement, the Company has the right to use all of the intellectual property which is used by the
Company in the Business . Details regarding intellectual property used by the Company are available upon request from the Manager, provided
that this does not violate confidentiality provisions of third party agreements, or reveal trade secrets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I><U>Contracts
and Commitments.</U> All of the material contracts to which the Company is a party are valid, binding, in full force and effect in all
material respects and enforceable by Company in accordance with their respective terms in all material respects, subject to applicable
bankruptcy, insolvency, reorganization, moratorium. and other laws of general application affecting enforcement of creditors&rsquo; rights
generally. The Company is not in default under any of the material contracts and no other party to any of the material contracts is in
default thereunder. The execution and delivery of this Agreement and the consummation of the transactions contemplated thereby will not
conflict with or result in any violation or default under, or give rise to a right of termination, contract. cancellation or acceleration
under any material</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.9</I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance
with Law</U>.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.4in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
operations of the Company have been conducted in accordance with, and the Company is in compliance with, all applicable laws and regulations.
The Company has not received any notification of any asserted present or past failure to comply with any such law or regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 100.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of the Company&rsquo;s books and records are complete and correct in all material respects, and are available to Investor for inspection
and review at the Company&rsquo;s principal place of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I><U>Employee
Matters.</U> The Company is in compliance with all applicable laws and regulations (including those of the United States) respecting
labor, employment, fair employment practices, terms and conditions of employment. and wages and hours, except for violations, individually
or in the aggregate, which are not reasonably likely to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.l
l <U>Debts and Security Interests</U>. The company is subject to the repayment of approximately $6,7000,000 in loan principal plus accrued
interest to Knight Therapeutics (Barbados), Inc.&bull; and to $1,596,750 in notes payable to Geoffrey S. Dow. The company also has three
convertible notes outstanding to Geoffrey Dow ($377,000), Tyrone Miller ($20,000) and Douglas Loock ($32,000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.12
<U>Business</U>. Company is not engaged in any business or operations other than the Business and associated events and activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Representations of lnvestor</U>. Investor hereby represents to Company as follows as to itself:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Organization
of <B>Investor; </B>Authorization.</U> This Agreement constitutes the legal. valid and binding obligations of Investor , enforceable
against him in accordance with their terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and
other laws of general application affecting enforcement of creditors&rsquo; rights generally, and (ii) as limited by laws relating to
the availability of specific performance, injunctive relief, or other equitable remedies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Conflict as to Investor.</U> Neither the execution and delivery of this Agreement by Investor nor the performance of (investor&rsquo;s
obligations hereunder will violate (a) any material agreement or commitment to which Investor is a party or (c) any law or order of any
court or other Governmental Agency applicable to Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment
Intent</U>. This Agreement is made with Investor in reliance upon Investor&rsquo; s representation to Company, which by Investor&rsquo;s
execution of this Agreement Investor hereby confirms, that the Note to be purchased by and issued to Investor (collectively, the <U>&ldquo;Securities&rdquo;)
</U>will be acquired for investment for Investor&rsquo;s own account, not as a nominee or agent, and not with a view to the resale or
distribution of any part thereof, and that Investor has no present intention of selling, granting any participation in, or otherwise
distributing the same. By executing this Agreement, Investor hereby further represents that Investor does not have any contract, undertaking,
agreement or arrangement with any person to sell. transfer or grant participations to such person or to any third person, with respect
to any of the Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reliance
upon Investor&rsquo;s Representations.</U> Investor understands that the Note is not registered under the Securities Act of 1933 (the
<U>&quot;1933 Act&quot;).</U>&middot; Investor hereby acknowledges that the Note has not been reviewed by the United States Securities
and Exchange Commission (&quot;the SEC&quot;) because of Company's representations that this is intended to be a nonpublic offering pursuant
to Sections 4(2) and 4(6) of the Act and Regulation D promulgated thereunder, as wen as under exemptions provided for in state laws.
Investor represents that the Note is being purchased for his/ her/its own account, for investment and not for distribution or resale
to others. Investor agrees that he or she will not transfer, sell, or otherwise dispose of the Note unless it is registered under the
Act or unless an exemption from such registration is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Investment</U>.
Investor acknowledges this purchase of the Note is suitable only for highly sophisticated &quot;accredited investors&quot; (as defined
below) and that the Company has no independently audited financial statements and full and complete disclosure concerning its financial
condition cannot therefore be made. The Company is an early development stage company and has no significant revenues or earnings to
date. The purchase of the Note involves a high degree of risk and only investors who can withstand a complete loss of their investment
should consider investing in the Company. In this regard, Investor represents that Investor is experienced in evaluating and investing
in private placement transactions of securities of companies in a similar stage of development and acknowledges that Investor is able
to fend for itself, can bear the economic risk of Investor's investment, and <I>has </I>such knowledge and experience in financial and
business matters that Investor is capable of evaluating the merits and risks of the investment in the Note. In furtherance of Investor's
due diligence in evaluating the merits and risks of this investment in the Note, Investor represents that Investor has had full and complete
access to all documents containing certain organizational, business and financial information about the Company as well as the right
to ask for and receive additional information from the Company's management, which Investor has either requested and received, or [investor
has chosen to not ask for after the opportunity to review any such information or requests for information with Investor's counsel and/or
advisors. Investor specifically represents and wants to the Company the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 100.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor
is not an &quot;investment company&quot; within the meaning of the Investment Company Act of 1940, as amended (hereinafter. the <U>&quot;1940
Act&quot;),</U> or a company that is excluded from the definition of an investment company solely by reason of the provisions of Sections
3(c)(l) or 3(cX7) of the 1940 Act;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 100.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor
has such knowledge and experience in financial and business matters that he/she/it is capable of evaluating the merits and risks of an
investment in the Company and the capacity to protect his/her/its interest in connection with the proposed investment in the Company
and bas obtained, in his/her/its judgment, sufficient information from the Company to evaluate the merits and risks of such investment;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 101.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor
is acquiring the Note for his/her/its own account, for investment purposes only and not with a view toward distribution or resale of
the Note in whole or in part; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 101.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investor
represents that he/she/it is an &quot;accredited investor&quot; as such term is defined in Rule 501 of Regulation D promulgated under
the Securities Act of 1933, as amended (the &quot;Act&quot;). The definition of &quot;accredited investor&quot; includes, but is not
limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -34.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#9;A&#9;bank,&#9;insurance
 company,&#9;registered&#9;investment</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">company,
business development company, or small business investment company;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 133.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">{ii)
An employee benefit plan, within the meaning of the Employee Retirement Income Security Act, if a bank, insurance company, or registered
investment adviser makes the investment decisions, or if the plan has total assets in excess of $5 million;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 133.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
charitable organization, corporation, or partnership with</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assets
exceeding <I>$5 </I>million;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 133.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
director, executive officer, or <B>general </B>partner of the company selling the securities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 133.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
business in which all the equity owners are accredited investors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 134.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
natural person who bas individual net worth, or joint net worth with the person's spouse, that exceeds $1 million at the time of the
purchase, excluding the value of the primary residence of such person;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 134.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii}
A natural person with income exceeding $200,000 in each of the two most recent years or joint in me with a spouse: exceeding $300,000
for those years and a reasonable expectation of the same income level in the current year; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 134.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
A trust with assets in excess of <I>$5 </I>million, not formed to acquire the securities offered, whose purchases a sophisticated person
makes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 68.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restricted
Securities</U>. Investor understands that the Note may not be sold, transferred. or otherwise disposed of without registration under
the 1933 Act or an exemption therefrom, and that in the absence of an effective registration statement covering tile Note or an available
exemption from registration wider the 1933 Act, the Note must be held indefinitely. In particular, Investor is aware that the Note may
not be sold pursuant to Rule 144 promulgated under the 1933 Act unless all of the conditions of that Rule are met. Among the conditions
for use of Rule 144 may be the availability of current information to the public about the Company. Such information is not now available
and the Company has no present plans to make such information available. In this connection, Investor represents that he/she/it is familiar
with and understands the resale limitations imposed by Rule 144 under the 1933 Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
acknowledges that the Note has not been registered under the Act by reason of a claimed exemption under the provisions of the Act that
depends, in part, upon his investment intention. Investor understands that, if the Note is sold in the United States or to United States
residents, it is the position of the SEC that the statutory basis for such exemption would not be present if his/ her/its representation
merely meant that his/her/its present intention was to hold the Note for a short period, for a deferred sale, for a market rise, or for
any other fixed period. Investor realizes that, in the view of the SEC, a purchase now with an intent to resell would represent a purchase
with an intent inconsistent with his/ her/its representation to the Company, and the SEC might regard such a sale, transfer, or other
disposition as a deferred sale for which the exemption is not available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
agrees that the Company may, if it desires, permit the transfer of the Note by Investor out of his/ her/its name only when his or her
request for transfer is accompanied by an opinion of counsel reasonably satisfactory to the Company that the proposed sale, transfer,
or disposition does not result in a violation of the Act or any applicable state or province &quot;blue sky&quot; laws (collectively
&quot;S securities Laws.&quot;) Investor agrees to hold the Company and its directors, officers, controlling persons, and their respective
heirs, representatives, successors and assigns harmless to indemnify them against all liabilities, costs and expenses incurred by them
as a result of any sale, transfer, or disposition of the Note by the undersigned Investor in violation of any Securities Laws or misrepresentation
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
acknowledges and agrees that the Company is relying on Investor's representations contained in this Agreement in determining whether
to accept this subscription. Investor agrees that the Company has the unrestricted right to reject or limit any subscription and to cl9se
the offer at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
represents and warrants that all representations made by Investor hereunder are true and correct in all material respects as of the date
of execution hereof: and Investor further agrees that until the closing on the Note subscribed for he shall inform the Company immediately
of any changes in any of the representations provided by Investor herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Legends.
</U>To the extent applicable, each document (whether electronic or on paper) evidencing the Note shall be endorsed with a legend substantially
in the form set forth below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.65pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">'TIIB
NOTE REPRESENTED HEREBY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED,
PLEDGED, OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECE&pound;VED AN OPINION OF COUNSEL OR
OTHER EVIDENCE, SATISFACTORY TO TIIE COMPANY AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.&quot;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Financial
Books and Records.</U> Investor acknowledges that he/she/it has had the opportunity to review the Company's financial books and records
but Investor understands and acknowledges that the Company has no independently audited financial statements and full and complete disclosure
concerning its financial condition cannot therefore be made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Reliance.</U>&nbsp;&nbsp;&nbsp;&nbsp;The
foregoing representations and warranties are made by Investor with the knowledge and expectation that the Company is placing reliance
thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Representations
</U></B><U>to Continue in Effect; Indemnification</U>.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Continued Effect</U>. All representations and warranties contained in this Agreement shall be true as of the date of this Agreement
and, except where limited, shall continue in effect notwithstanding any investigation conducted or knowledge acquired with respect thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
by Company</U>. The Company shall indemnify and hold harmless and reimburse Investor for any loss, liability, claim , damage, cost, expense
(including, but not limited to, costs of investigation and reasonable attorneys' fees) or diminution of value of the Note, but excluding
any punitive or consequential damages (collectively, <B><U>&quot;Damages&quot;)</U></B> arising from any (a) material inaccuracy in any
of the representations or warranties of the Company in this Agreement or (b) material failure by the Company to comply with any agreement
or obligation in this Agreement, in each case when proven and adjudicated in a final, non appealable decision of a court of competent
jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
by Investor</U>. [investor shall indemnify and hold harmless and reimburse the Company for any Damages arising from (a) any inaccuracy
in any of the representations and warranties of Investor in this Agreement, (b) any failure by Investor to comply with any agreement
or obligation in this Agreement, or (c) any claim by any Person for brokerage fees, commissions or similar payments based upon any agreement
or understanding made by such Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
to Closing of lnvestor.</U></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>5</I>.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;<U>Condition&sect;
to Closing.</U> The obligations of Investor under <U>Section 1. I</U> ere subject to the fulfillment on or before the Closing of each
of the following conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of the representations and warranties of the Company set forth in <U>Section 2</U> hereof shall be true in all material respects at the
Closing as if then made and Investor shall have received a certificate of the Manager to that eff t.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall have made available to Investor all other documents required by this Agreement or otherwise reasonably requested by Investor
in connection with the transactions contemplated hereunder. Investor acknowledges and agrees that some or all of such documents made
available to Investor in connection with the transactions contemplated hereunder contain forward looking statements concerning future
events that involve material</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks
and uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
to Closing of Company.</U> The obligations of the Company to Investor under this Agreement are subject to the fulfillment on or before
the Closing of each of the following conditions by Investor:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 67.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
representations and warranties of Investor contained in <U>Section 3</U> shall be true in an material respects as of the Closing as though
such representations and warranties had been made on and as of the date of Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
authorizations, approvals or permits,, ;'if any* , of' any governmental authority or regulatory body of the United States or of any state
that acquired in connection with the lawful issuance and sale of the Note pursuant to this Agreement sq l have been duly obtained and
effective as of the Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Use
of Proceeds.</U></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company shall use the proceeds from the sale of the Note to fund the prosecution of its New Drug Application with the United States Food
and Drug Administration for a determination of eligibility for priority review and to obtain a priority review voucher for a Tafenoquine
prophylactic antimalarial drug developed by the Company, and general operating and capital expenditures as reasonably determined by management,
in furtherance of the Business.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices.</U></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.55pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices, consents and other communications under this agreement shall be in writing or other electronic form and shall be deemed to have
been duly given when (a) sent by Certified and Registered U.S. Mail, return receipt requested, or (b) delivered by hand or by recognized overnight
courier, or (c) sent by facsimile (with receipt confirmed) or (d) sent via e mail (with acknowledgment of receipt by recipient}, in
each case to the appropriate postal addresses. email and facsimile numbers set forth below (or to such other addresses, and facsimile
numbers as a party may designate as to itself by notice to the other Parties):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to Investor:</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address on Signature Page Below</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Geoffrey S. Dow</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy to:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>C. Thomas Hicks III, Esq</B>.</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses.
</U>Each party shall bear its own expenses incident to the preparation, negotiation, execution and delivery of this Agreement and the
performance of its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Captions.
</U>The captions in this Agreement are for convenience of reference only and shall not be given any effect in the interpretation of
this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Waiver.</U> The failure of a party to insist upon strict adherence to any obligation of this Agreement shall not be considered a waiver
or deprive that party of the right thereafter to insist upon strict adherence to that term or any other term of this Agreement Any waiver
must be in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 68.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exclusive
Agreement; Amendment.</U> This Agreement and the other agreements and documents delivered pursuant hereto supersedes any and all
other prior or contemporaneous written or oral understandings or agreements among the Parties with respect to its subject matter. This
Agreement is intended (with the documents referred to herein) as a complete and exclusive statement of <B>the </B>terms of the agreement
among the Parties with respect thereto and cannot be changed or terminated orally. This Agreement may only be amended with prior written
consent of the Company and Investor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts.
</U>This Agreement may be executed electronically and/or in two (2) or more counterparts, all of which shall be considered an original.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 66.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. This Agreement shall be governed by the internal laws of Washington, District of Columbia, USA, without regard to the conflicts
of law principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Attorney's
Fees</U>. In any action or proceeding brought by a party to enforce any provision of this Agreement, the prevailing party shall be entitled
to recover the reasonable costs and expenses incurred by it in connection with that action or proceeding (including. but not limited
to, attorneys' fees).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Designation
of Forum and Consent to Jurisdiction.</U> The Parties hereto (a) designate any state or federal court of competent jurisdiction in Washington,
District of Columbia, USA, as a forum where all matters pertaining to this Agreement may be adjudicated, and (b) by the foregoing designation,
consent to the exclusive jurisdiction and venue of such Court for the purpose of adjudicating all matters pertaining to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Waiver
of Jury Trial</U>. As a specifically bargained inducement for the other Parties to enter into this Agreement, each of the Parties waives
any right it may have to have a jury participate in resolving any dispute arising out of or related to this Agreement. Instead, any such
disputes resolved in court shall be resolved in a bench trial without a jury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.7pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Assignment.</U> No party may assign its rights and obligations under this Agreement without obtaining the prior written consent of the
other party (which consent may be withheld by such party in his/her/its sole and absolute discretion), <U>provided, however,</U> the
Parties agree that Investor shall have the right at any time and from time to time to assign his/her/its rights under this Agreement
or any instrument or document executed in connection herewith for estate planning purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 67.9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>General
Cooperation.</U> Upon request from the other party following the Closing, each party will do, execute, acknowledge and deliver or cause
to be done, executed, acknowledged and delivered all and every further act, deed, conveyance, transfer and assurance necessary to better
assure compliance with the terms, provisions, purposes and intents of this Agreement and all other agreements, securities and instruments
contemplated hereby and thereby, and the effectiveness of the rights, benefits and remedies provided for hereby and thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l0.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this Agreement, the following terms have the meanings specified in this Section 10:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Business&quot;
- Development of drugs to treat and prevent tropical diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Business
Days&quot; -&#9;any day other than a Saturday, Sunday or nationally recognized holiday or other day when banks are closed for business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Closing&quot;
- See Section 1.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Note&quot;
- See Recital C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Company&quot;
&mdash; See the first paragraph of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Effective
Date&quot; &mdash; See the first paragraph of this Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Governmental
Agency&quot; &mdash; The United States, any state or municipality, the government of any foreign country, any subdivision of any of the
foregoing or any authority, department, commission, board, bureau, agency, court or instrumentality of any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt">&ldquo;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor&quot;
- See the first paragraph of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Material
Adverse Effect&quot; - A material adverse effect on the business, assets, results of operations, financial condition or prospects of
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Party&quot;
or &quot;Parties&quot; - the Company or the Investor, or both, as the case may be.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Person&quot;
&mdash; Any individual or legal entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Securities
Act&quot; &middot;- The Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.65pt"></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Truces&quot;
- All taxes, penalties, interest, or other assessments or charges including, without limitation, income, transfer, excise, franchise,
sales, use, property, employment, withholding. social security, workers' compensation., and <B>_value added taxes and customs duties,
imposed by any Governmental Agency.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&quot;Tax
Returns&quot; -&middot; Any return, report, information return or other document (including any related or supporting information) filed
or required to be filed with any Governmental Agency in connection with any Taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
capitalized terms used in this Agreement have the meanings ascribed to them elsewhere in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
<B>WITNESS WHEREOF, </B>the Parties have executed this Agreement as of the date and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY:</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS,</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AVENTE INTERNATIONAL LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LLC</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7/F D1, KIN ON COMMERCIAL</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BUILDING. SHEUNG WAN, HONG </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>HONG</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&quot;For and on behalf of</I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>By Geoffrey S. Dow, Manager</U></B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black; width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITNESS:</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITNESS:</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="background-color: Black"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;<FONT STYLE="text-decoration: none">&nbsp;</FONT></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form of Note</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-decoration: none"><B>&nbsp;&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>28
<FILENAME>cm270_ex10-25.htm
<DESCRIPTION>EXHIBIT 10.25
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.25</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.4pt">THE NOTE REPRESENTED HEREBY HAS
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,AS AMENDED, ANO MAY NOT BE SOLO, TRANSFERRED, ASSIGN ED, PLEDGED, OR
HYPOTHECATEO UNLESS AND UNTIL REGISTERED UNDER SUCH ACT, OR UNLESS THE COMPANY HAS RECEIVED AN OPINION Of COUNSEL OR OTHER EVIDENCE,
SATISFACTORY TO THE COMPANY ANO ITS COUNSEL. THAT SUCH REGISTRATION IS NOT REQUIRED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify; text-indent: 0.4pt">THE PAYMENT OF
THIS NOTE ANO THE RIGHTS OF THE LENDER UNDER THIS NOTE ARE SUBORDINATED TO THE PAYMENT OF SENIOR INDEBTEDNESS (AS DEFINED IN THE SUBORDINATION
AGREEMENT REFERRED TO BELOW) (&quot;SENIOR INDEBTEDNESS&quot;) AND THE RIGHTS OF THE HOLDERS OF SENIOR INDEBTEDNESS PURSUANT TO THE TERMS
OF THE SUBORDINATlON AGREEMENT DATED AS OF THE DATE HEREOF (THE &quot;SUBORDINATION AGREEMENT&quot;) BY AND AMONG 60 DEGREES PHARMACEUTICALS,
LLC, KNIGHT THERAPEUTICS (BARBADOS) INC. (THE &quot;SENIOR LENDER&quot;) AND EACH OF THE CREDITORS REFERRED TO THEREIN, INCLUDING THE
LENDER UNDER THIS NOTE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMISSORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ORIGINAL ISSUE DATE: OCTOBER 11, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMOUNT PER UNIT: $250,000.00 USO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NUMBER OF UNITS: 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PRINCIPAL AMOUNT OF NOTE: $750,000.00 USO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 129.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify"><B>FOR VALUE RECEIVED, </B><FONT STYLE="font-size: 10pt">60
DEGREES PHARMACEUTICALS, LLC, a District of Columbia </FONT>limited liability company the &quot;Borrower&quot;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ited
&nbsp;&nbsp;&nbsp;&nbsp;(the &quot;Lender&quot;), located at &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;r at such other location &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as the om 1me o 1me m a written notice provided to the
Borrower, or to any subsequent holder or permitted assignee of this promissory note (this &quot;Note&quot;), the principal
amount of Seven Hundred Fifty Thousand and 00/100 DOLLARS ($750,000.00) (the &quot;Principal Amount'&quot;), upon the terms
and conditions specified below. This Note is issued as part of an offering of convertible and non-convertible promissory
notes (the &quot; Offering&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: justify">The Borrower is not permitted to
issue more than ten discrete units for Two Hundred and Fifty Thousand and 00/100 DOLLARS ($250,000.00) each (each, a
&quot;Unit&quot;) for a total Offering of Two Million Five Hundred Thousand and 00/100 DOLLARS ($2,500 ,000.00) in convertible and
non convertible promissory notes (including this Note) as part of the Offering without the prior written consent of all existing
holders of such promissory notes. All promissory notes issued for Units as part of the Offering will be issued in the principal
amount of Two Hundred Fifty Thousand and 00/100 DOLLARS ($250,000.00). This Note represents three (3) Units of non-convertible
promissory notes combined into one instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD><U>Maturity Date</U>. The &quot;Maturity Date&quot; of the Note shall be the earlier of:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">a.</TD><TD>the presale of a Priority Review Voucher (&quot;PRV Presale&quot;) by the Borrower after the United States Food and Drug Administration
(USFDA) confirms the Borrower's eligibility for a New Drug Application (NOA); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 337.05pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 337.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 59.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">b.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            sale of a Priority Review Voucher (&quot;'PRV&quot; ) by the Borrower previously granted
                                            by the USF DA to the Borrower for a Tafenoquine prophylactic antimalarial drug (&quot;PRV
                                            Voucher Sale&quot;); or</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">c.</TD><TD STYLE="text-align: justify">Sixty (60) days after the date on which the Senior indebtedness is indefeasibly paid in full and the Senior
Lender has terminated the Subordination Agreement pursuant to Section 2 2 thereof. For the avoidance of doubt, no payments of principal,
pursuant to this Section I or of interest, pursuant to Section 2 below, shall be made by Borrower to Lender unless permitted by the terms
of the Subordination Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Interest.</U>
The outstanding Principal Amount and accrued interest of this Note shall bear interest from the date the Note is issued at the rate of
five percent (5%) per annum for the first six months, and thereafter at the rate of ten percent ( I 0%) per annum. Interest shall accrue
on a calendar year quarterly basis (Mar 31, Jun 30, Sep 30, Dec 31) and at Maturity and be payable in arrears on Maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Preferred
Units.</U> If proceeds of at least Seven Hundred Fifty Thousand and 00/100 DOLLARS ($750,000.00) from the sale of Units as part of the
Offering are received by the Borrower by October 13, 2017 or in case of wire transfer delays proof of copy of remittance that funds were
sent on October 13, 2017 and received no later than October 18 , 20 17, then all Units (both convertible and non-convertible) for which
the proceeds are received by the Borrower prior to that date will be deemed Preferred Units eligible to receive an exclusive <I>pro rata</I>
bonus share of2% of the gross proceeds of a PRV Sale or a PRV Presale. If the minimum offering proceeds of Seven Hundred Fifty Thousand
and 00/100 DOLLARS ($750,000.00) are not received by October 13, 2017 or proof of remittance on that date, then all Units issued under
this offering will be deemed to be Preferred Units .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0"> 4. <U>PRV Distributions, Repayment of Principal, and Interest.</U> Immediately following the date of closing a PRV Voucher Sale or PRY Pre-sale, the Borrower will satisfy its Knight Obligation, and thereafter make, within ten (10) days, the following distributions to each holder of one or more Units issued as part of the Offering (both convertible and non-convertible), including the Lender and the Founders, in the event either or both purchase such Units:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.95pt; text-align: justify; text-indent: -0.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD>payment in full of the Principal Amount of each Unit; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD>payment in full of the interest accrued under each Unit; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD>and one percent (1%) of the gross proceeds from any PRV Sale or PRV Presale for each Unit owned; and if</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">D.</FONT></TD><TD><FONT STYLE="font-size: 10pt">the Unit is deemed to be a Preferred Unit then the Lender will receive a bonus <I>pro </I></FONT><I>rata</I>
<FONT STYLE="font-size: 10pt">share of two percent (2%) of gross proceeds from the PRV Sale or PRV Presale calculated as follows: amount
of the gross proceeds from the PRV Sale or PRV Pre-</FONT> Sale in US dollars ($US), multiplied by two percent (2%), multiplied by a quotient
equal to the number of Preferred Units held by the Lender, divided by the total number of Preferred Units purchased under the Offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 91.65pt; text-align: justify; text-indent: -32.9pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 91.65pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0"> 5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prepayment.</U> Borrower may not prepay any portion of the Principal Amount of this Note prior to the Maturity Date.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion
Option</U>. The Lender shall have the option to exercise a conversion of their debt into shares of the Borrower:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 95.55pt; text-indent: -16.55pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">A.</TD><TD><U>Exercise Price:</U> Pre-money value of the Borrower will be set at the lower of $32.835M USO (approximately 16,417,500 units outstanding
at $2 per unit) or a valuation agreed with a third party that is lower than $32.835M. In the event the agreed valuation is $32.835M, each
$250,000 USO note will convert to 125,000 units of Borrower stock.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Option Period:</U> The Lender's option to convert begins at the Maturity
date and shall expire 30 days later.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify"><U>No Interest Payment and Conversion of Principal:</U> Interest will not be paid if Lender elects to
convert the outstanding Principal of this Note to Equity. In the event the Lender elects to convert, the Principal will be converted to
equity in the Borrower per above and the Note will be retired.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">D.</TD><TD STYLE="text-align: justify"><U>Subscription Agreement:</U> Investor will sign a stand-alone subscription agreement which will contain
the form for the Lender to exercise its right of conversion and to join in the operating agreement of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rank</U>.
The right to payment under this Note will be in priority relative to the right to payment under other non-convertible promissory notes
issued by the Borrower as part of the Offering that have substantially the same terms and conditions as this Note other than principal
amount (together with this Note, the &quot; Borrower Issued Notes&quot;). The Borrower will inform the Lender when/if additional Notes
arc subscribed under this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0"> 8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Events of Acceleration.</U> The entire unpaid Principal Amount under this Note shall become immediately due and payable, subordinate to the Borrower's obligation to pay in full the First Knight Obligation, upon (i) admission by the Borrower of its inability to pay its debts generally as they become due, (ii) the filing of a petition in bankruptcy by the Borrower, (iii) the execution by the Borrower of a general assignment for the benefit of creditors, or (iv) the filing by or against the Borrower of a petition in bankruptcy or a petition for relief under the provisions of the federal bankruptcy code or another state or federal law for the relief of debtors and the continuation of such petition without dismissal for a period of ninety (90) days or more.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0"> 9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Amendment and Waiver.</U> This Note may be amended or a provision hereof waived only in a writing signed by both the Borrower and the Lender.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
The unenforceability or invalidity of any provision or provisions of this Note as to any person, entity, or circumstance shall
not render that provision or those provisions unenforceable or invalid as to any other provisions or circumstances, and all provisions
hereof, in </FONT>all other respects, shall remain valid and enforceable.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment.
</U>This Note is not assignable by the Lender without the Borrower's prior written consent, which consent may be withheld in the
Borrower's sole and absolute discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
All notices, demands and requests of any kind to be delivered to any party in connection with this Note shall be in writing and shall
be deemed to have been duly given if personally delivered, sent by facsimile or electronic mail, or if sent by nationally-recognized
overnight courier or by registered or certified mail, return receipt requested and postage prepaid, to the address set forth in this Note
or to such other address as the party to whom notice is to be given may have furnished to the other party hereto in writing in accordance
with the provisions of this Section 12. Any such notice or communication shall be deemed to have been received (i) in the case of personal
delivery, on the date of such delivery, (ii) in the case of facsimile or electronic mail, when receipt is confirmed, (iii) in the case
of nationally-recognized overnight courier, on the next business day after the date when sent, and (iv) in the case of mailing, on the
third business day following that on which the piece of mail containing such communication is posted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.1pt; text-align: justify; text-indent: 0.9pt">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Legal
Matters</U>. The validity, construction, enforcement, and interpretation of this Note are governed by the laws of Washington,
District of Columbia, USA and the federal laws of the United States of America, without regard to principles of conflict of laws.
The Borrower and the Lender (a) consent to the personal jurisdiction of the city and federal courts having jurisdiction in
Washington, District of Columbia, USA, (b) stipulate that the proper, exclusive and convenient venue of any legal proceeding arising
out of this Note is Washington, District of Columbia, USA, for city court proceedings, and the U.S. District Court for the District
of Columbia, for federal district court proceedings, and (c) waive any defense, whether asserted by a motion or pleading, that
Washington, District of Columbia, USA or the U.S. District Court for the District of Columbia is an improper or inconvenient
venue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.9pt; text-align: justify; text-indent: 0.6pt">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Rights as a Member.</U> Nothing contained in this Note shall be construed as conferring upon the Lender or any other person the right
to vote or to consent or to receive notices as a member in respect of meetings of members of the Borrower or any other matters or any
rights whatsoever as a member of the Borrower, and no distributions shall be payable or accrued in respect of this Note or the interest
represented hereby until Maturity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.35pt; text-align: justify; text-indent: 0.65pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Further
Assurances.</U> From time to time, the Lender, at the Borrower's reasonable request, shall execute and deliver such other instruments
and do and perform such other acts as required to confirm the Lender' s rights under this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.35pt; text-align: justify; text-indent: 0.65pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0"> 16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Deposit Upon Closing.</U>. Upon closing the purchase of this Note, the full Principle Amount shall be sent via wire transfer by the Lender to the Bank of America, N.A. Account of the Borrower.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 15.8pt; text-indent: -0.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE PAGE FOLLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 139.55pt; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IN WITNESS HEREOF</B> <FONT STYLE="font-size: 10pt">,this Note has
been executed by the Borrower and delivered to the </FONT>Lender as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BORROWER</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LENDER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, LLC</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a District of Columbia </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">limited liability company<FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="background-color: Black; width: 43%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="background-color: Black; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey. Dow, Manager</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITNESS:</FONT></TD>
    <TD STYLE="background-color: Black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITNESS:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JUN
    ZOV</U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>TYRONE MILLER</U></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>29
<FILENAME>cm270_ex10-26.htm
<DESCRIPTION>EXHIBIT 10.26
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.26&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONVERTIBLE PROMISSORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Original
Issue Date: December <FONT STYLE="font-size: 10pt">31<SUP>st</SUP></FONT></B></FONT><B> 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Principal
Amount:</B></FONT><B> $ <U>346,000.00</U> <FONT STYLE="font-size: 10pt">USD</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FOR
VALUE RECEIVED, 60 DEGREES PHARMACEUTICALS, LLC, a District of Columbia limited liability company (the &quot;Borrower&quot;),
promises to pay to </FONT><FONT STYLE="font-size: 10pt"><U>Geoffrey S. Dow</U></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><I>, </I>or
any subsequent holder or permitted assignee of this Note (the &quot;Lender&quot;), located at <U>&nbsp;<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</U>or
at such other location as the Lender may designate from time to time in a written notice provided to the Borrower, the principal
amount of <U>three hundred forty six</U> Thousand and 00/100 DOLLARS ($ <U>346,000.00</U>) (the &quot;Principal Amount&rdquo;), upon
the terms and conditions specified below. Notwithstanding the foregoing, no payment of the Principal Amount under this Note shall be
required to the extent that such Principal Amount has been converted pursuant to Section 4 of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower is not permitted to issue more than
$750,000 in convertible notes (including this Note) issued as part of the offering under which this Note was issued (the &quot;Offering&quot;)
without the prior written consent of all existing holders of such convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <U>Maturity Date</U>. The &quot;Maturity Date&quot;
of the Note shall be the earlier of the date on which payment in full is made under a loan of up to $5,000,000 to the Borrower from Knight
Therapeutics (Barbados), Inc. under that certain Loan Agreement and Engagement dated as of December 10, 2015 (the &quot;First Knight Obligation&quot;),
and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.55pt"></TD><TD STYLE="width: 15.75pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">a.</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            sale of a Priority Review Voucher (&quot;PRV&quot;) by the Borrower previously granted by
                                            the United States Food and Drug Administration (USFDA) to the Borrower for a Tafenoquine
                                            prophylactic antimalarial drug (the &quot;PRV Voucher Sale&quot;); or</FONT></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.55pt"></TD><TD STYLE="width: 15.75pt">b.</TD><TD STYLE="text-align: justify">the presale of such a PRV to someone other than the Borrower, or another business transaction or agreement
that would prevent the Borrower from obtaining a PRV; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.55pt"></TD><TD STYLE="width: 15.75pt">c.</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tafenoquine
                                            has been approved by the USFDA for use for another indication but not for malaria prophylaxis;</FONT></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <U>Interest</U>. The outstanding Principal
Amount of this Note shall not bear interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <U>Distributions.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 38.45pt"></TD><TD STYLE="width: 17.25pt">a.</TD><TD STYLE="text-align: justify">The Lender shall be eligible for certain distributions with respect to this Note until it is fully converted
to Class II Units (defined below). After payment from net proceeds of a PRV of the First Knight Obligation and up to an additional $3,000,000
and accrued interest from Knight Therapeutics (Barbados), Inc. under further Knight loans, the Borrower shall distribute, prior to conversion
of the convertible notes (including this Note) issued as part of the Offering, the remaining net proceeds of the PRV Voucher Sale in the
manner and priority as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71pt; text-align: justify; text-indent: -19pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52pt"></TD><TD STYLE="width: 17.85pt"><B>(i)</B></TD><TD STYLE="text-align: justify">to the Lender his/her/its pro rata share, together with payments to other holders of all convertible notes
(including the Note) issued as part of the Offering, as payment in full of the entire outstanding Principal Amount under the Note (therefore,
since the maximum permitted value of convertible notes issued as part of the Offering is $750,000, then a maximum aggregate amount of
up to $750,000 may be distributed);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71pt; text-align: justify; text-indent: -19pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt"><B>(ii)</B></TD><TD STYLE="text-align: justify">to the Lender his/her/its pro rata share, together with payments to other holders of all convertible notes
(including the Note) issued as part of the Offering, in an amount up to the principal amount of convertible notes issued as part of the
Offering multiplied by four (4) (therefore, since the maximum permitted value of convertible notes issued as part of the Offering is $750,000
then a maximum aggregate amount of up to $3,000,000 of the principal amounts under such convertible notes may be distributed); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71pt; text-align: justify; text-indent: -19pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52pt"></TD><TD STYLE="width: 19pt"><B>(iii)</B></TD><TD STYLE="text-align: justify">to the Lender his/her/its pro rata share, <FONT STYLE="font-size: 10pt"><I>pari passu,</I></FONT> together
with distributions to all other holders of convertible notes (including the Founders, in the event either or both purchase such convertible
notes) issued as part of the Offering in proportion to their percentage of the Offering, of up to 5.03% of remaining net proceeds of the
PRV Voucher Sale available for distribution to existing holders of Class I and II units immediately prior to the Offering and the holders
of convertible notes (including this Note) issued under the Offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-indent: -15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.4pt"></TD><TD STYLE="width: 13.3pt">b.</TD><TD>Following the Principal Amount being converted pursuant to Section 5 below, all distributions to the Lender set forth in Section 3.a.,
if any, which could have been made because sufficient &quot;net proceeds&quot; (as defined in Section 3.c.) were available, but have not
yet been distributed, shall be made with respect to Class II Units into which the Principal Amount has been converted. For the purpose
of avoiding doubt, holders of convertible notes will be eligible for payment in full of the distributions required under Section 3.a.
only if sufficient &quot;net proceeds&quot; as defined in Section 3.c. are derived from a PRV sale as defined in Section 1.a.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-indent: -15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 39.4pt"></TD><TD STYLE="width: 13.3pt">c.</TD><TD>The term &quot;net proceeds&rdquo; of a PRV Voucher Sale for the
                                            purpose of subsection 3.a. shall mean the proceeds available to the Borrower to distribute
                                            from gross proceeds of the PRV Voucher Sale after first repaying loans as described in 3a.,
                                            and making distributions to other parties as required by contract. <FONT STYLE="font-size: 10pt">In
                                            </FONT>the event of a PRV Voucher Sale no greater than $22,500,000, net proceeds available
                                            to the Borrower to distribute to holders of convertible notes issued as part of the Offering
                                            will represent 81% of the gross proceeds of sale. In addition in the event of a PRV Voucher
                                            Sale greater than $22,500,000 but no greater than $60,000,000, the Borrower will have available
                                            for distribution to such holders of convertible notes an additional 41% of every $1.00 over
                                            $22,500,000, up to $60,000,000. <FONT STYLE="font-size: 10pt">In addition in the event of
                                            a PRV Voucher Sale greater than $60,000,000, the Borrower will have available for distribution
                                            to such holders of convertible notes an additional 31% of every $1.00 over $60,000,000.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. &quot;<U>Prepayment.</U> Borrower may not prepay
any portion of the Principal Amount of this Note prior to the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <U>Conversion.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a. <U>Conversion.</U> The Principal Amount shall
be converted at and as of the Maturity Date into fully paid and non-assessable non-voting Class II Units of the Borrower (&quot;Class
II Units&quot;) that have identical rights, restrictions, preferences and privileges as all other holders of Class II Units of the Borrower
outstanding as of the conversion date pursuant to the Lender transmitting to the Borrower a copy of an executed notice of conversion,
in the form attached hereto as <FONT STYLE="font-size: 10pt"><B><U>Exhibit-A<I>.</I></U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b. <U>Conversion Ratio.</U> The number of Class
II Units into which this Note shall be converted pursuant to this Section 5 shall be the number determined by dividing the Principal of
this note by $1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c. <U>Fractional Shares</U>. If the conversion
of this Note in accordance with this Section 5 would result in the issuance of a fraction of a Class II Unit, then the Borrower shall
round such fraction of a Class II Unit to the nearest whole Class II Unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">d. <U>Joinder to Operating Agreement.</U> As a
condition to receiving Class II Units from the Borrower, upon the Lender&rsquo;s conversion of this Note, the Lender shall execute and
transmit to the Borrower a joinder, in the form attached hereto as Exhibit B, to the Borrower&rsquo;s then existing Operating Agreement,
and shall agree to be bound by its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. <U>Rank.</U> The right to payment under this
Note will be <I>pari passu</I> with the right to payment under all other notes issued by the Borrower as part of the Offering that have
substantially the same terms and conditions as this Note other than principal amount (together with this Note, the &quot;Borrower Issued
Convertible Notes&quot;). Any payments on the Borrower Issued Convertible Notes will be made pro rata to all the holders of the Borrower
Issued Convertible Notes based on the principal amounts of such Borrower Issued Convertible Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <U>Events of Acceleration.</U> The entire unpaid
Principal Amount under this Note shall become immediately due and payable, subordinate to the Borrower&rsquo;s obligation to pay in full
the First Knight Obligation, upon (i) admission by the Borrower of its inability to pay its debts generally as they become due, (ii) the
filing of a petition in bankruptcy by the Borrower, (iii) the execution by the Borrower of a general assignment for the benefit of creditors,
or (iv) the filing by or against the Borrower of a petition in bankruptcy or a petition for relief under the provisions of the federal
bankruptcy code or another state or federal law for the relief of debtors and the continuation of such petition without dismissal for
a period of ninety (90) days or more.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9<FONT STYLE="font-family: Times New Roman, Times, Serif"><B>.
</B><U>Amendment and Waiver.</U> This Note may be amended or a provision hereof waived only in a writing signed by both the Borrower and
the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. <U>Severability.</U> The unenforceability
or invalidity of any provision or provisions of this Note as to any person, entity, or circumstance shall not render that provision or
those provisions unenforceable or invalid as to any other provisions or circumstances, and all provisions hereof, in all other respects,
shall remain valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR STYLE="clear: both">
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. <U>Assignment.</U> This Note is not assi<FONT STYLE="font-size: 10pt">gn</FONT>able
by the Lender without the Borrower&rsquo;s prior written consent, which consent may be withheld in the Borrower&rsquo;s sole and absolute
discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12. <U>Notices.</U> All notices, demands and requests
of any kind to be delivered to any party in connection with this Note shall be in writing and shall be deemed to have been duly given
if personally delivered, sent by facsimile or if sent by nationally-recognized overnight courier or by registered or certified mail, return
receipt requested and postage prepaid, to the address set forth in this Note or to such other address as the party to whom notice is to
be given may have furnished to the other party hereto in writing in accordance with the provisions of this Section 12. Any such notice
or communication shall be deemed to have been received (i) in the case of personal delivery, on the date of such delivery, (ii) in the
case of facsimile, when receipt is confirmed, (iii) in the case of nationally-recognized overnight courier, on the next business day after
the date when sent, and (iv) in the case of mailing, on the third business day following that on which the piece of mail containing such
communication is posted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13. <U>Legal Matters.</U> The validity, construction,
enforcement, and interpretation of this Note are governed by the laws of Washington, District of Columbia, USA and the federal laws of
the United States of America, without regard to principles of conflict of laws. The Borrower and the Lender (a) consent to the personal
jurisdiction of the state and federal courts having jurisdiction in Washington, District of Columbia, USA, (b) stipulate that the proper,
exclusive and convenient venue of any legal proceeding arising out of this Note is Washington, District of Columbia, USA, for state court
proceedings, and the U.S District Court for the District of Columbia, for federal district court proceedings, and (c) waive any defense,
whether asserted by a motion or pleading, that Washington, District of Columbia, USA or the U.S. District Court for the District of Columbia
is an improper or inconvenient venue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. <U>No Rights as a Member.</U> Nothing contained
in this Note shall be construed as conferring upon the Lender or any other person the right to vote or to consent or to receive notices
as a member in respect of meetings of members of the Borrower or any other matters or any rights whatsoever as a member of the Borrower,
and no distributions shall be payable or accrued in respect of this Note or the interest represented hereby or the Class II Units obtainable
hereunder, until, and only to the extent that, this Note shall have been converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15. <U>Further Assurances.</U> From time to time,
the Lender, at the Borrower&rsquo;s reasonable request, shall execute and deliver such other instruments and do and perform such other
acts as required to confirm the Lender&rsquo;s rights under this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16. <U>Escrow.</U> Upon closing the purchase of
this Note, the full Principle Amount shall be sent via wire transfer by the Lender to the Bank of America, N.A. Account of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS HEREOF, this Note has been executed
by the Borrower and delivered to the Lender as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BORROWER </B></FONT></TD>
    <TD STYLE="width: 47%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LENDER</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>60 DEGREES PHARMACEUTICALS, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">a District of Columbia limited liability company</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyrone Miller</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Geoffrey S. Dow</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>60 DEGREES PHARMACEUTICALS, LLC CONVERSION NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Reference is made to the Convertible Promissory
Note (the &ldquo;Note&rdquo;) issued to the undersigned by 60 DEGREES PHARMACEUTICALS, LLC (the &quot;Company&quot;). In accordance with
and pursuant to the Note, the undersigned hereby elects to convert the Principal Amount (as defined in the Note) indicated below into
non-voting Class II Units of membership (&quot;Class II Units&quot;) of the Company as of the date specified below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date of Conversion: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aggregate Principal Amount to be converted: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please confirm the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of Class II Units to be issued: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please issue the Class II Units into which the Note is being converted
in the following name and to the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>60 DEGREES PHARMACEUTICALS, LLC JOINDER TO
OPERATING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned acknowledges that he, she or it
has been provided with a copy of the 60 DEGREES PHARMACEUTICALS, LLC Operating Agreement in effect as of the date below (the &quot;Operating
Agreement&quot;). The undersigned further acknowledges and agrees to be bound by all of the terms of the Operating Agreement to the same
extent as if he, she or it had been an original party thereto. All capitalized terms not defined herein have the meaning set forth in
the Operating Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IN WITNESS WHEREOF</B>, the undersigned has (have) executed this
Joinder to the Operating Agreement this <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> day of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Printed Name of Member: </FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Printed Name of Co-Member (if any) <I>If an Entity: </I></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Printed Name of Entity:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature of Member:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature of Co-Member:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Signature of Authorized</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Person Print Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Print Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>30
<FILENAME>cm270_ex10-27.htm
<DESCRIPTION>EXHIBIT 10.27
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.27</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B><U>AGREEMENT TO CONSOLIDATE AND CONVERT EXISTING DEBT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">This Agreement to Consolidate and Convert Related
Party Debt (the &ldquo;<B>Agreement</B>&rdquo;) is made effective as 31<FONT STYLE="font-size: 10pt">st </FONT>December 2021 between 60&deg;
Pharmaceuticals, LLC, a limited liability company organized and operating under the laws of Washington, District of Columbia (&ldquo;Company&rdquo;),
and Geoffrey Dow (&ldquo;Creditor&rdquo;), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt">A.</TD><TD>Creditor has made the following loans, totaling $3,445,489 to the Company:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt">1. Dow Long Term Loan
($1,596,750 Principal; $259,058 Interest at 12/31/21)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt">2. Dow 2019 &amp; 2020
Paid In Capital @ AFR ($450,000 Principal, $25,008 interest at 12/31/21)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt">3. Dow Debenture ($596,389 at 12/31/21)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt">4. Dow 300K Loan associated with debenture ($300,000 Principal,
$218,284 Interest at 12/31/21)</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt">B.</TD><TD>Company requires consolidation then conversion of all related party debt to prepare for future financing events.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt">C.</TD><TD>The Creditor agrees to this consolidation and conversion of debt into 3,426,489 new membership interest in 60 Degree Pharmaceuticals,
effective as of 12/31/21.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt">D.</TD><TD>The Creditor is already a member of 60 Degrees Pharmaceuticals LLC</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0in">NOW, THEREFORE, in consideration of the premises, the mutual promises
contained herein, and other good and valuable consideration, receipt and sufficiency is acknowledged by the Parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt">1.</TD><TD>Creditor hereby agrees to permit Company to convert the Debt to equity in Company in the form of an economic interest in Company on
the books of Company (&rdquo;Economic Interest&rdquo;) measured in terms of percentage of equity in Company held <I>pari passu </I>by
Members and holders of Economic Interests who are not Members.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 23pt"></TD><TD STYLE="width: 18pt">2.</TD><TD>Economic Interest in Company is defined under Company&rsquo;s Eight Amended and Restated Operating Agreement dated as of 31 December
2021 (the &ldquo;Operating Agreement&rdquo;) as the (a) right to a distributive
share of the income, gain, losses and deductions of the Company in accordance with this Agreement, and (b) right to a distributive share
of Company Assets. This constitutes all financial benefits available from Company which are allocated and distributed under the terms
of the Operating Agreement. The difference between Members and mere holders of an Economic Interest is that the latter have no right to
vote or participate in management of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">60&deg; PHARMACEUTICALS, LLC</TD>
    <TD COLSPAN="2">for CRE</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="background-color: Black; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="background-color: Black; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:_</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">Authorized Agent</TD>
    <TD COLSPAN="2">Geoffrey Dow</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P>60&deg; Pharmaceuticals, LLC Agreement to Convert Debt to Equity</P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>31
<FILENAME>cm270_ex10-28.htm
<DESCRIPTION>EXHIBIT 10.28
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 83.4pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 83.4pt; text-align: right"><B>Exhibit 10.28</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 83.4pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><U>AGREEMENT TO CONVERT DEBT TO EQUITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 83.4pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt">This Agreement to Convert Debt to Equity
(the &ldquo;<B>Agreement</B>&rdquo;) effective as of the 31<FONT STYLE="font-size: 10pt">st </FONT>day of December, 2021 between 60&deg;
Pharmaceuticals, LLC, a limited liability company organized and operating under the laws of Washington, District of Columbia (&ldquo;Company&rdquo;),
and Geoffrey Dow (&ldquo;Creditor&rdquo;), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41.95pt; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD>Creditor has loaned US $448,500 (the &ldquo;Debt&rdquo;) to Company in consideration of receiving a promissory note. The terms of
that Promissory note require conversion to equity, and the Company has administratively considered the Debt to be converted for tax purposes.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD>Company requires all debt-related administrative paperwork to be updated in preparation for future financing events</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD>As a component of updating the Companies&rsquo; administrative paperwork, Company has requested that Creditor agree to convert the
Debt to membership interests in the partnership and Creditor has agreed to do so.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">D.</TD><TD>The Creditor is already a member of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">NOW, THEREFORE, in consideration of the premises, the mutual promises
contained herein, and other good and valuable consideration, receipt and sufficiency is acknowledged by the Parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-indent: -18pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Creditor hereby agrees to permit Company to convert the Debt to equity in Company in the form of an economic interest in Company on
the books of Company (&rdquo;Economic Interest&rdquo;) measured in terms of percentage of equity in Company held <I>pari passu </I>by
Members and holders of Economic Interests who are not Members.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Economic Interest in Company is defined under Company&rsquo;s Seventh Amended and Restated Operating Agreement dated as of 26 September
2018 (the &ldquo;Operating Agreement&rdquo;) as the (a) right to a distributive share of the income, gain, losses and deductions of the
Company in accordance with this Agreement, and (b) right to a distributive share of Company Assets. This constitutes all financial benefits
available from Company which are allocated and distributed under the terms of the Operating Agreement. The difference between Members
and mere holders of an Economic Interest is that the latter have no right to vote or participate in management of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 42pt; text-indent: -18pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD>&nbsp;</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P>60&deg; Pharmaceuticals, LLC Agreement to Convert Debt to Equity</P></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD>All capitalized terms in this Agreement shall have the meaning ascribed to such terms in the Operating Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">60&deg; PHARMACEUTICALS, LLC</TD>
    <TD COLSPAN="2">for CREDITOR</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="background-color: Black; width: 35%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="background-color: Black; width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:_</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="background-color: Black">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">Authorized Agent</TD>
    <TD COLSPAN="2">Geoffrey Dow</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 6pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center">2</TD></TR><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%"><P>60&deg; Pharmaceuticals, LLC Agreement to Convert Debt to Equity</P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>32
<FILENAME>cm270_ex10-29.htm
<DESCRIPTION>EXHIBIT 10.29
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.29</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>CONVERTIBLE PROMISSORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 130pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps">Original
Issue Date: December</FONT> 31<SUP>ST</SUP> 2016<BR>
PRINCIPAL AMOUNT: $ <U>20,000.00</U> USD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.2pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">FOR
VALUE RECEIVED, 60 DEGREES PHARMACEUTICALS, LLC, a District of Columbia limited liability company (the &quot;Borrower&quot;),
promises to pay to <U>Tyrone Miler</U><FONT STYLE="font-size: 10pt"><I>,</I></FONT> or any subsequent holder or permitted assignee
of this Note (the &ldquo;Lender&rdquo;), located at </FONT> <U>7/4 Gist Ave, Silver Spring, MD, 20910</U> <FONT STYLE="font-family: Times New Roman, Times, Serif">or
at such other location as the Lender may designate from time to time in a written notice provided to the Borrower, the principal
amount of <U>Twenty</U> Thousand and 00/100 DOLLARS ($ <U>20,000.00</U>) (the &ldquo;Principal Amount&rdquo;), upon the terms and
conditions specified below. Notwithstanding the foregoing, no payment of the Principal Amount under this Note shall be required to
the extent that such Principal Amount has been converted pursuant to Section 4 of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Borrower is not permitted to issue more than
$750,000 in convertible notes (including this Note) issued as part of the offering under which this Note was issued (the &ldquo;Offering&rdquo;)
without the prior written consent of all existing holders of such convertible notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <U>Maturity Date</U>. The &ldquo;Maturity Date&rdquo;
of the Note shall be the earlier of the date on which payment in full is made under a loan of up to $5,000,000 to the Borrower from Knight
Therapeutics (Barbados), Inc. under that certain Loan Agreement and Engagement dated as of December 10, 2015 (the &ldquo;First Knight
Obligation&rdquo;), and:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.25pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">a.</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            sale of a Priority Review Voucher (&ldquo;PRV&rdquo;) by the Borrower previously granted
                                            by the United States Food and Drug Administration (USFDA) to the Borrower for a Tafenoquine
                                            prophylactic antimalarial drug (the &ldquo;PRV Voucher Sale&rdquo;); or</FONT></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.35pt"></TD><TD STYLE="width: 17.8pt">b.</TD><TD STYLE="text-align: justify">the presale of such a PRV to someone other than the Borrower, or another business transaction or agreement
that would prevent the Borrower from obtaining a PRV; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19.35pt"></TD><TD STYLE="width: 17.8pt">c.</TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tafenoquine
                                            has been approved by the USFDA for use for another indication but not for malaria prophylaxis;</FONT></P></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Interest</U>. The outstanding
Principal Amount of this Note shall not bear interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Distributions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 37pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-size: 10pt">a.</FONT></TD><TD STYLE="text-align: justify">The Lender shall be eligible for certain distributions with respect to this Note until it is fully converted
to Class II Units (defined below). After payment from net proceeds of a PRV of the First Knight Obligation and up to an additional $3,000,000
and accrued interest from Knight Therapeutics (Barbados), Inc. under further Knight loans, the Borrower shall distribute, prior to conversion
of the convertible notes (including this Note) issued as part of the Offering, the remaining net proceeds of the PRV Voucher Sale in the
manner and priority as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56.05pt"></TD><TD STYLE="width: 17.75pt">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to the Lender his/her/its pro rata share, together with payments to other holders of all convertible
notes (including the Note) issued as part of the Offering, as payment in full of the entire outstanding Principal Amount under the Note
(therefore, since the maximum permitted value of convertible notes issued as part of the Offering is $750,000, then a maximum aggregate
amount of up to $750,000 may be distributed);</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56pt"></TD><TD STYLE="width: 18pt">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to the Lender his/her/its pro rata share, together with payments to other holders of all convertible
notes (including the Note) issued as part of the Offering, in an amount up to the principal amount of convertible notes issued as part
of the Offering multiplied by four (4) (therefore, since the maximum permitted value of convertible notes issued as part of the Offering
is $750,000 then a maximum aggregate amount of up to $3,000,000 of the principal amounts under such convertible notes may be distributed);
and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 56pt"></TD><TD STYLE="width: 18pt">(iii)</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">to the Lender his/her/its pro rata share, <I>pari passu,</I> together with distributions to all other
holders of convertible notes (including the Founders, in the event either or both purchase such convertible notes) issued as part of the
Offering in proportion to their percentage of the Offering, of up to 5.03% of remaining net proceeds of the PRV Voucher Sale available
for distribution to existing holders of Class I and II units immediately prior to the Offering and the holders of convertible notes (including
this Note) issued under the Offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55pt; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.4pt"></TD><TD STYLE="width: 15.3pt">b.</TD><TD>Following the Principal Amount being converted pursuant to Section 5 below, all distributions to the Lender set forth in Section 3.a.,
if any, which could have been made because sufficient &ldquo;net proceeds&quot; (as defined in Section 3.c.) were available, but have
not yet been distributed, shall be made with respect to Class II Units into which the Principal Amount has been converted. For the purpose
of avoiding doubt, holders of convertible notes will be eligible for payment in full of the distributions required under Section 3.a.
only if sufficient &ldquo;net proceeds&quot; as defined in Section 3.c. are derived from a PRV sale as defined in Section 1.a.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.4pt"></TD><TD STYLE="width: 15.3pt">c.</TD><TD>The term &ldquo;net proceeds&quot; of a PRV Voucher Sale for the purpose of subsection 3.a. shall mean the proceeds available to the
Borrower to distribute from gross proceeds of the PRV Voucher Sale after first repaying loans as described in 3a., and making distributions
to other parties as required by contract. In the event of a PRV Voucher Sale no greater than $22,500,000, net proceeds available to the
Borrower to distribute to holders of convertible notes issued as part of the Offering will represent 81% of the gross proceeds of sale.
In addition in the event of a PRV Voucher Sale greater than $22,500,000 but no greater than $60,000,000, the Borrower will have available
for distribution to such holders of convertible notes an additional 41% of every $1.00 over $22,500,000, up to $60,000,000. In addition
in the event of a PRV Voucher Sale greater than $60,000,000, the Borrower will have available for distribution to such holders of convertible
notes an additional 31% of every $1.00 over $60,000,000.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 55pt; text-indent: -16pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <U>Prepayment</U>. Borrower may not prepay
any portion of the Principal Amount of this Note prior to the Maturity Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <U>Conversion.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">a. <U>Conversion.</U> The Principal Amount shall
be converted at and as of the Maturity Date into fully paid and non-assessable non-voting Class II Units of the Borrower (&quot;Class
II Units&quot;) that have identical rights, restrictions, preferences and privileges as all other holders of Class II Units of the Borrower
outstanding as of the conversion date pursuant to the Lender transmitting to the Borrower a copy of an executed notice of conversion,
in the form attached hereto as <FONT STYLE="font-size: 10pt"><B><U>Exhibit A.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">b. <U>Conversion Ratio.</U> The number of Class
II Units into which this Note shall be converted pursuant to this Section 5 shall be the number determined by dividing the Principal of
this note by $1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">c. <U>Fractional Shares.</U> If the conversion
of this Note in accordance with this Section 5 would result in the issuance of a fraction of a Class II Unit, then the Borrower shall
round such fraction of a Class II Unit to the nearest whole Class II Unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">d. <U>Joinder to Operating Agreement.</U> As a
condition to receiving Class II Units from the Borrower, upon the Lender&rsquo;s conversion of this Note, the Lender shall execute and
transmit to the Borrower a joinder, in the form attached hereto as Exhibit B, to the Borrower&rsquo;s then existing Operating Agreement,
and shall agree to be bound by its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. <U>Rank.</U> The right to payment under this
Note will be <I>pari passu</I> with the right to payment under all other notes issued by the Borrower as part of the Offering that have
substantially the same terms and conditions as this Note other than principal amount (together with this Note, the &quot;Borrower Issued
Convertible Notes&quot;). Any payments on the Borrower Issued Convertible Notes will be made pro rata to all the holders of the Borrower
Issued Convertible Notes based on the principal amounts of such Borrower Issued Convertible Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <U>Events of Acceleration.</U> The entire unpaid
Principal Amount under this Note shall become immediately due and payable, subordinate to the Borrower&rsquo;s obligation to pay in full
the First Knight Obligation, upon (i) admission by the Borrower of its inability to pay its debts generally as they become due, (ii) the
filing of a petition in bankruptcy by the Borrower, (iii) the execution by the Borrower of a general assignment for the benefit of creditors,
or (iv) the filing by or against the Borrower of a petition in bankruptcy or a petition for relief under the provisions of the federal
bankruptcy code or another state or federal law for the relief of debtors and the continuation of such petition without dismissal for
a period of ninety (90) days or more.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. <U>Amendment and Waiver.</U> This Note may
be amended or a provision hereof waived only in a writing signed by both the Borrower and the Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. <U>Severability.</U> The unenforceability
or invalidity of any provision or provisions of this Note as to any person, entity, or circumstance shall not render that provision or
those provisions unenforceable or invalid as to any other provisions or circumstances, and all provisions hereof, in all other respects,
shall remain valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both">
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. <U>Assi<FONT STYLE="font-size: 10pt">gn</FONT>ment</U>.
This Note is not assignable by the Lender without the Borrower&rsquo;s prior written consent, which consent may be withheld in the Borrower's
sole and absolute discretion.</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12. <U>Notices.</U> All notices, demands and requests
of any kind to be delivered to any party in connection with this Note shall be in writing and shall be deemed to have been duly given
if personally delivered, sent by facsimile or if sent by nationally-recognized overnight courier or by registered or certified mail, return
receipt requested and postage prepaid, to the address set forth in this Note or to such other address as the party to whom notice is to
be given may have furnished to the other party hereto in writing in accordance with the provisions of this Section 12. Any such notice
or communication shall be deemed to have been received (i) in the case of personal delivery, on the date of such delivery, (ii) in the
case of facsimile, when receipt is confirmed, (iii) in the case of nationally-recognized overnight courier, on the next business day after
the date when sent, and (iv) in the case of mailing, on the third business day following that on which the piece of mail containing such
communication is posted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13. <U>Legal Matters.</U> The validity, construction,
enforcement, and interpretation of this Note are governed by the laws of Washington, District of Columbia, USA and the federal laws of
the United States of America, without regard to principles of conflict of laws. The Borrower and the Lender (a) consent to the personal
jurisdiction of the state and federal courts having jurisdiction in Washington, District of Columbia, USA, (b) stipulate that the proper,
exclusive and convenient venue of any legal proceeding arising out of this Note is Washington, District of Columbia, USA, for state court
proceedings, and the U.S District Court for the District of Columbia, for federal district court proceedings, and (c) waive any defense,
whether asserted by a motion or pleading, that Washington, District of Columbia, USA or the U.S. District Court for the District of Columbia
is an improper or inconvenient venue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. <U>No Rights as a Member.</U> Nothing contained
in this Note shall be construed as conferring upon the Lender or any other person the right to vote or to consent or to receive notices
as a member in respect of meetings of members of the Borrower or any other matters or any rights whatsoever as a member of the Borrower,
and no distributions shall be payable or accrued in respect of this Note or the interest represented hereby or the Class II Units obtainable
hereunder, until, and only to the extent that, this Note shall have been converted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15. <U>Further Assurances.</U> From time to time,
the Lender, at the Borrower&rsquo;s reasonable request, shall execute and deliver such other instruments and do and perform such other
acts as required to confirm the Lender&rsquo;s rights under this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16. <U>Escrow.</U> Upon closing the purchase of
this Note, the fall Principle Amount shall be sent via wire transfer by the Lender to the Bank of America, N.A. Account of the Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: 2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS HEREOF, this Note has been executed
by the Borrower and delivered to the Lender as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-align: justify; text-indent: 2pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BORROWER</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LENDER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, LLC</B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>a District of Columbia limited liability company</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 40%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid"><FONT STYLE="background-color: Black"></FONT><FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey S. Dow</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top">Tyrone Miller</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; text-indent: 40pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manager</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>60 DEGREES PHARMACEUTICALS, LLC CONVERSION NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Reference is made to the Convertible
Promissory Note (the &quot;Note&quot;) issued to the undersigned by 60 DEGREES PHARMACEUTICALS, LLC (the &quot;Company&quot;). <FONT STYLE="font-size: 10pt"><B>In </B></FONT>accordance
with and pursuant to the Note, the undersigned hereby elects to convert the Principal Amount (as defined in the Note) indicated
below into non-voting Class II Units of membership (&ldquo;Class II Units&rdquo;) of the Company as of the dale specified below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date of Conversion: <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate Principal Amount to be converted<FONT STYLE="font-size: 10pt"><I>:</I></FONT>
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please confirm the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of Class <FONT STYLE="font-size: 10pt">II</FONT> Units to be
issued<FONT STYLE="font-size: 10pt"><I>: </I></FONT><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please issue the Class II Units into which the Note is being converted
in the following name and to the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding-bottom: 4pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid; padding-bottom: 4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; padding-bottom: 4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 42%; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>60 DEGREES PHARMACEUTICALS, LLC JOINDER TO
OPERATING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned acknowledges that he, she or it
has been provided with a copy of the 60 DEGREES PHARMACEUTICALS, LLC Operating Agreement in effect as of the date below (the &quot;Operating
Agreement&quot;). The undersigned further acknowledges and agrees to be bound by all of the terms of the Operating Agreement to the same
extent as if he, she or it had been an original party thereto. All capitalized terms not defined herein have the meaning set forth in
the Operating Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>IN WITNESS WHEREOF, </B>the undersigned has (have) executed this
Joinder to the Operating Agreement this <U>&nbsp;&nbsp;&nbsp;&nbsp;</U> day of <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><B>Printed Name of Member: </B></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Printed Name of Co-Member (if any) </B><I>If an Entity:</I></FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Printed Name of Entity:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Address:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Signature of Member:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Signature of Co-Member:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Signature of Authorized</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Person Print Name:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Print Title:</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>33
<FILENAME>cm270_ex10-30.htm
<DESCRIPTION>EXHIBIT 10.30
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.30</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>AGREEMENT TO CONVERT DEBT TO EQUITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 82.4pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt; text-align: justify; text-indent: 35.95pt">This Agreement to Convert
Debt to Equity (the &ldquo;<B>Agreement</B>&rdquo;) is made effective as of the 31<FONT STYLE="font-size: 10pt">st </FONT>day of December,
2021 between 60&deg; Pharmaceuticals, LLC, a limited liability company organized and operating under the laws of Washington, District
of Columbia ( &ldquo;Company&rdquo;), and Ty Miller (&ldquo;Creditor&rdquo;), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">Creditor has loaned US $20,000 (the &ldquo;Debt&rdquo;) to Company in consideration of receiving a promissory
note. The terms of that Promissory note require conversion to equity, and the Company has administratively considered the Debt to be converted
for tax purposes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">Company requires all debt-related administrative paperwork to be updated in preparation for future financing
events</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify">As a component of updating the Companies&rsquo; administrative paperwork, Company has requested that Creditor
agree to convert the Debt to membership units in the partnership and Creditor has agreed to do so.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">D.</TD><TD STYLE="text-align: justify">The Creditor is already a member of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">NOW, THEREFORE, in consideration of the
premises, the mutual promises contained herein, and other good and valuable consideration, receipt and sufficiency is acknowledged by
the Parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 41.05pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">Creditor hereby agrees to permit Company to convert the Debt to equity in Company in the form of an economic
interest in Company on the books of Company (&rdquo;Economic Interest&rdquo;) measured in terms of percentage of equity in Company held
<I>pari passu </I>by Members and holders of Economic Interests who are not Members.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Economic Interest in Company is defined under Company&rsquo;s Seventh Amended and Restated Operating Agreement
dated as of 26 September 2018 (the &ldquo;Operating Agreement&rdquo;) as the (a) right to a distributive share of the income, gain, losses
and deductions of the Company in accordance with this Agreement, and (b) right to a distributive share of Company Assets. This constitutes
all financial benefits available from Company which are allocated and distributed under the terms of the Operating Agreement. The difference
between Members and mere holders of an Economic Interest is that the latter have no right to vote or participate in management of Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0 1pt">60&deg; Pharmaceuticals, LLC Agreement to Convert Debt to Equity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">All capitalized terms in this Agreement shall have the meaning ascribed to such terms in the Operating
Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60&deg; PHARMACEUTICALS, LLC</FONT></TD>
    <TD STYLE="width: 49%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for CREDITOR</FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">[<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>]</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">[<FONT STYLE="background-color: Black">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Founder</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ty Mille</FONT>r</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: -1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0 1pt">60&deg; Pharmaceuticals, LLC Agreement to Convert Debt to Equity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>34
<FILENAME>cm270_ex10-31.htm
<DESCRIPTION>EXHIBIT 10.31
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.31</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CONVERTIBLE PROMISSORY NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Original Issue Date: December 3 1<SUP>st</SUP> 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Principal Amount: $ <U>32,000,00</U> USD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">FOR VALUE RECEIVED,
60 DEGREES PHARMACEUTICALS, LLC, a District of Columbia limited liability company (the &ldquo;Borrower&rdquo;), promises to pay to <U>Doug
Loock</U></FONT> , <FONT STYLE="background-color: white">or any subsequent holder or permitted assignee of this Note (the &ldquo;Lender&rdquo;),
located at <U>6213 Red wivy ct Bethesda,20817 MD</U> or at such other location as the Lender may designate from time to time in a written
notice provided to the Borrower, the principal amount of <U>thirty two</U> Thousand and 00/100 DOLLARS ($ <U>32,000</U>.00) (the &ldquo;Principal
Amount&rdquo;), upon the terms and conditions specified below. Notwithstanding the foregoing, no payment of the Principal Amount under
this Note shall be required to the extent that such Principal Amount has been converted pursuant to Section 4 of this Note. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">The Borrower
is not permitted to issue more than $750,000 in convertible notes (including this Note) issued as part of the offering under which this
Note was issued (the &ldquo;Offering&rdquo;) without the prior written consent of all existing holders of such convertible notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Maturity
Date</U>. The &ldquo;Maturity Date&rdquo; of the Note shall be the earlier of the date on which payment in full is made under a loan of
up to $5,000,000 to the Borrower from Knight Therapeutics (Barbados), Inc. under that certain Loan Agreement and Engagement dated as of
December 10, 2015 (the &ldquo;First Knight Obligation&rdquo;), and:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">the
    sale of a Priority Review Voucher (&ldquo;PRV&rdquo;) by the Borrower previously granted by the United States Food and Drug Administration
    (USFDA) to the Borrower for a Tafenoquine prophylactic antimalarial drug (the &ldquo;PRV Voucher Sale&rdquo;); or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">the presale of such a PRV to someone other than the Borrower, or another business transaction or agreement that would prevent the Borrower from obtaining a PRV; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">c.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Tafenoquine
    has been approved by the USFDA for use for another indication but not for malaria prophylaxis;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Interest</U>.
The outstanding Principal Amount of this Note shall not bear interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Distributions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">a.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">The Lender shall be eligible for certain distributions with respect to this Note until it is fully converted to Class II Units (defined below). After payment from net proceeds of a PRV of the First Knight Obligation and up to an additional $3,000,000 and accrued interest from Knight Therapeutics (Barbados), Inc. under further Knight loans, the Borrower shall distribute, prior to conversion of the convertible notes (including this Note) issued as part of the Offering, the remaining net proceeds of the PRV Voucher Sale in the manner and priority as follows:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29px">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">(i)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">to the Lender his/her/its pro rata share, together with payments to other holders of all convertible notes (including the Note) issued as part of the Offering, as payment in full of the entire outstanding Principal Amount under the Note (therefore, since the maximum permitted value of convertible notes issued as part of the Offering is $750,000, then a maximum aggregate amount of up to $750,000 may be distributed);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29px">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">(ii)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">to the Lender his/her/its pro rata share, together with payments to other holders of all convertible notes (including the Note) issued as part of the Offering, in an amount up to the principal amount of convertible notes issued as part of the Offering multiplied by four (4) (therefore, since the maximum permitted value of convertible notes issued as part of the Offering is $750,000 then a maximum aggregate amount of up to $3,000,000 of the principal amounts under such convertible notes may be distributed); and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29px">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">(iii)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">to the Lender his/her/its pro rata share, </FONT><FONT STYLE="font-size: 10pt">pari passu, <FONT STYLE="background-color: white">together with distributions to all other holders of convertible notes (including the Founders, in the event either or both purchase such convertible notes) issued as part of the Offering in proportion to their percentage of the Offering, of up to 5.03% of remaining net proceeds of the PRV Voucher Sale available for distribution to existing holders of Class I and II units immediately prior to the Offering and the holders of convertible notes (including this Note) issued under the Offering.</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">b.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Following the Principal Amount being converted pursuant to Section 5 below, all distributions to the Lender set forth in Section 3.a., if any, which could have been made because sufficient &ldquo;net proceeds&rdquo; (as defined in Section 3.c.) were available, but have not yet been distributed, shall be made with respect to Class II Units into which the Principal Amount has been converted. For the purpose of avoiding doubt, holders of convertible notes will be eligible for payment in full of the distributions required under Section 3.a. only if sufficient &ldquo;net proceeds&rdquo; as defined in Section 3.c. are derived from a PRV sale as defined in Section 1 .a.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt; background-color: white">c.</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">The term &ldquo;net proceeds&rdquo; of a PRV Voucher Sale for the purpose of subsection 3.a. shall mean the proceeds available to the Borrower to distribute from gross proceeds of the PRV Voucher Sale after first repaying loans as described in 3a., and making distributions to other parties as required by contract. In the event of a PRV Voucher Sale no greater than $22,500,000, net proceeds available to the Borrower to distribute to holders of convertible notes issued as part of the Offering will represent 81% of the gross proceeds of sale. In addition in the event of a PRV Voucher Sale greater than $22,500,000 but no greater than $60,000,000, the Borrower will have available for distribution to such holders of convertible notes an additional 41% of every $1.00 over $22,500,000, up to $60,000,000. In addition in the event of a PRV Voucher Sale greater than $60,000,000, the Borrower will have available for distribution to such holders of convertible notes an additional 31% of every $1.00 over $60,000,000.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Prepayment</U>.
Borrower may not prepay any portion of the Principal Amount of this Note prior to the Maturity Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion</U>.
The Principal Amount shall be converted at and as of the Maturity Date into fully paid and non-assessable non-voting Class II Units of
the Borrower (&ldquo;Class II Units&rdquo;) that have identical rights, restrictions, preferences and privileges as all other holders
of Class II Units of the Borrower outstanding as of the conversion date pursuant to the Lender transmitting to the Borrower a copy of
an executed notice of conversion, in the form attached hereto as </FONT><B><U>Exhibit <FONT STYLE="background-color: white">A</FONT></U></B><FONT STYLE="background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">b.&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Conversion
Ratio</U>. The number of Class II Units into which this Note shall be converted pursuant to this Section 5 shall be the number determined
by dividing the Principal of this note by $1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">c.&nbsp;&nbsp;&nbsp;&nbsp;<U>Fractional
Shares</U>. If the conversion of this Note in accordance with this Section 5 would result in the issuance of a fraction of a Class II
Unit, then the Borrower shall round such fraction of a Class II Unit to the nearest whole Class II Unit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">d.&nbsp;&nbsp;&nbsp;&nbsp;<U>&nbsp;Joinder
to Operating Agreement</U>. As a condition to receiving Class II Units from the Borrower, upon the Lender&rsquo;s conversion of this Note,
the Lender shall execute and transmit to the Borrower a joinder, in the form attached hereto as Exhibit B, to the Borrower&rsquo;s then
existing Operating Agreement, and shall agree to be bound by its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rank</U>.
The right to payment under this Note will be </FONT>pari passu <FONT STYLE="background-color: white">with the right to payment under all
other notes issued by the Borrower as part of the Offering that have substantially the same terms and conditions as this Note other than
principal amount (together with this Note, the &ldquo;Borrower Issued Convertible Notes&rdquo;). Any payments on the Borrower Issued Convertible
Notes will be made pro rata to all the holders of the Borrower Issued Convertible Notes based on the principal amounts of such Borrower
Issued Convertible Notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Events
of Acceleration</U>. The entire unpaid Principal Amount under this Note shall become immediately due and payable, subordinate to the Borrower&rsquo;s
obligation to pay in full the First Knight Obligation, upon (i) admission by the Borrower of its inability to pay its debts generally
as they become due, (ii) the filing of a petition in bankruptcy by the Borrower, (iii) the execution by the Borrower of a general assignment
for the benefit of creditors, or (iv) the filing by or against the Borrower of a petition in bankruptcy or a petition for relief under
the provisions of the federal bankruptcy code or another state or federal law for the relief of debtors and the continuation of such petition
without dismissal for a period of ninety (90) days or more.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment
and Waiver</U>. This Note may be amended or a provision hereof waived only in a writing signed by both the Borrower and the Lender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">10.&nbsp;&nbsp;<U>Severability</U>.
The unenforceability or invalidity of any provision or provisions of this Note as to any person, entity, or circumstance shall not render
that provision or those provisions unenforceable or invalid as to any other provisions or circumstances, and all provisions hereof, in
all other respects, shall remain valid and enforceable.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">11.&nbsp;&nbsp;
<U>Assignment</U>. This Note is not assignable by the Lender without the Borrower&rsquo;s prior written consent, which consent may be
withheld in the Borrower&rsquo;s sole and absolute discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">12&nbsp; &nbsp;<U>&nbsp;Notices</U>.
All notices, demands and requests of any kind to be delivered to any party in connection with this Note shall be in writing and shall
be deemed to have been duly given if personally delivered, sent by facsimile or if sent by nationally-recognized overnight courier or
by registered or certified mail, return receipt requested and postage prepaid, to the address set forth in this Note or to such other
address as the party to whom notice is to be given may have furnished to the other party hereto in writing in accordance with the provisions
of this Section 12. Any such notice or communication shall be deemed to have been received (i) in the case of personal delivery, on the
date of such delivery, (ii) in the case of facsimile, when receipt is confirmed, (iii) in the case of nationally-recognized overnight
courier, on the next business day after the date when sent, and in the case of mailing, on the third business day following that on which
the piece of mail containing such communication is posted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">13.&nbsp;&nbsp;
<U>Legal Matters</U>. The validity, construction, enforcement, and interpretation of this Note are governed by the laws of Washington,
District of Columbia, USA and the federal laws of the United States of America, without regard to principles of conflict of laws. The
Borrower and the Lender (a) consent to the personal jurisdiction of the state and federal courts having jurisdiction in Washington, District
of Columbia, USA, (b) stipulate that the proper, exclusive and convenient venue of any legal proceeding arising out of this Note is Washington,
District of Columbia, USA, for state court proceedings, and the U.S District Court for the District of Columbia, for federal district
court proceedings, and (c) waive any defense, whether asserted by a motion or pleading, that Washington, District of Columbia, USA or
the U.S. District Court for the District of Columbia is an improper or inconvenient venue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">14.&nbsp;&nbsp;
<U>No Rights as a Member</U>. Nothing contained in this Note shall be construed as conferring upon the Lender or any other person the
right to vote or to consent or to receive notices as a member in respect of meetings of members of the Borrower or any other matters or
any rights whatsoever as a member of the Borrower, and no distributions shall be payable or accrued in respect of this Note or the interest
represented hereby or the Class II Units obtainable hereunder, until, and only to the extent that, this Note shall have been converted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">15.&nbsp;&nbsp;
<U>Further Assurances</U>. From time to time, the Lender, at the Borrower&rsquo;s reasonable request, shall execute and deliver such other
instruments and do and perform such other acts as required to confirm the Lender&rsquo;s rights under this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">16.&nbsp;&nbsp;
<U>Escrow</U>. Upon closing the purchase of this Note, the full Principle Amount shall be sent via wire</FONT>&nbsp;<FONT STYLE="background-color: white">transfer
by the Lender to the Bank of America, N. A. Account of the Borrower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">IN WITNESS HEREOF,
this Note has been executed by the Borrower and delivered to the Lender as of the date first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 40%; padding-right: 0.5pt; padding-left: 0.5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>BORROWER</B></FONT></TD>
    <TD STYLE="width: 60%; padding-right: 0.5pt; padding-left: 0.5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LENDER</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>60 DEGREES PHARMACEUTICALS, LLC</B></FONT></TD>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">a District of Columbia limited liability company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>By.</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"><B>Name: </B></FONT></TD>
    <TD STYLE="width: 44%; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"><B>Geoffrey S. Dow</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"><B>Name:</B></FONT></TD>
    <TD STYLE="width: 44%; border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"><B>Manager</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white"><B>Exhibit A</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="background-color: white"><B>60 DEGREES
PHARMACEUTICALS,LLC CONVERSION NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Reference is
made to the Convertible Promissory Note (the &ldquo;Note&rdquo;) issued to the undersigned by 60 DEGREES PHARMACEUTICALS, LLC (the &ldquo;Company&rdquo;).
In accordance with and pursuant to the Note, the undersigned hereby elects to convert the Principal Amount (as defined in the Note) indicated
below into non-voting Class II Units of membership (&ldquo;Class II Units&rdquo;) of the Company as of the date specified below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Date of Conversion:</FONT></TD>
    <TD STYLE="width: 60%; border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Aggregate Principal Amount to be converted:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Please confirm the following information:</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Number of Class II Units to be issued:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Please issue the Class II Units into which the Note is being converted in the following name and to the following address:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Name:</FONT></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white">Dated:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">The undersigned acknowledges that
he, she or it has been provided with a copy of the 60 DEGREES PHARMACEUTICALS, LLC Operating Agreement in effect as of the date below
(the &ldquo;Operating Agreement&rdquo;). The undersigned further acknowledges and agrees to be bound by all of the terms of the Operating
Agreement to the same extent as if he, she or it had been an original party thereto. All capitalized terms not defined herein have the
meaning set forth in the Operating Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">IN WITNESS WHEREOF, <FONT STYLE="background-color: white">the
undersigned has (have) executed this Joinder to the Operating Agreement this__________day of__________</FONT>, <FONT STYLE="background-color: white">2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 50%; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt; background-color: white">Printed Name of Member:</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt; background-color: white">Printed Name of Co-Member (if any) </FONT><FONT STYLE="font-size: 10pt">If an Entity:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt; background-color: white">Printed Name of Entity:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt; background-color: white">Address:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="width: 50%; padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt; background-color: white">Signature of Member:</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt; background-color: white">Signature of Co-Member:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt; background-color: white">Signature of Authorized</FONT></TD>
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt; background-color: white">Person Print Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding-right: 0.5pt; padding-left: 0.5pt"><FONT STYLE="font-size: 10pt; background-color: white">Print Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.5pt; padding-left: 0.5pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>35
<FILENAME>cm270_ex10-32.htm
<DESCRIPTION>EXHIBIT 10.32
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.32</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>AGREEMENT TO CONVERT DEBT TO EQUITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 41pt">This Agreement to Convert Debt to Equity (the &ldquo;Agreement&rdquo;)
is made as of the 3l<SUP>st</SUP> day of August, 2021 between 60&deg; Pharmaceuticals, LLC, a limited liability company organized and
operating under the laws of Washington, District of Columbia ( &ldquo;Company&quot;), and Dong Loock (&ldquo;Creditor&quot;), as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 41pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">A<B>.</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Creditor has loaned US S32,000 (the &quot;Debt&quot;) to Company in consideration of receiving a promissory note.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Company has entered into an agreement with HORIZON 3 BIOTECH FUND (&quot;Fund&quot;) to initially borrow US $1.5 Million (the &quot;Loan&quot;) under terms of a Convertible Promissory Note.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">C<B>.</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">As a condition to Fund making the Loan, Company has agreed with Fund to restructure debt and equity of Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">D.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">As part of the restructure of debt and equity of Company, Company has requested that Creditor agree to convert the Debt to equity ownership of Company and Creditor has agreed to do so.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">NOW, THEREFORE, in consideration of the premises, the mutual promises contained
herein, and other good and valuable consideration, receipt and sufficiency is acknowledged by the Pities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Creditor hereby agrees to permit Company to convert the Debt to equity in Company in the form of an economic interest in Company on the books of Company upon closing the investment of Fund in Company (&ldquo;Closing&rdquo;) with all proportionate rights to financial and income tax benefits generated by Company (&quot;Economic lnterest&quot;) measured in terms of percentage of equity in Company held <I>pari passu</I> by Members and holders of Economic Interests who are not Members.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Economic Interest in Company is defined under Company&rsquo;s Eighth Amended and Restated Operating Agreement dated as of 31 August 2021 (the &quot;Operating Agreement&quot;) as the (a) right to a distributive share of the income, gain, losses and deductions of the Company in accordance with this Agreement, and (b) right to a distributive share of Company Assets. This constitutes all financial benefits available from Company which are allocated and distributed under the terms of the Operating Agreement. The difference between Members and mere holders of an Economic Interest is that the latter have no right to vote or participate in management of Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">60&deg; Pharmaceuticals, LLC Agreement to Convert Debt to Equity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="text-align: right; width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 39pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Holders of Economic Interests, including Creditor, shall sign Joinder Agreements in the form attached as ADDENDUM III of the Operating Agreement at Closing agreeing to be admitted as Members of the Company and shall be fully bound by, and subject to, all of the covenants, terms and conditions of the Operating Agreement as though they were original parties to the Agreement, and shall be subject to all obligations and entitled to all the rights incidental to Members under the terms of the Operating Agreement, with their financial benefits maintained in accordance with their percentage Interests relative to Interests of other Members and non-Member holders of Economic Interests.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 37pt; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20pt">&nbsp;</TD>
    <TD STYLE="width: 20pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">All capitalized terms in this Agreement shall have the meaning ascribed to such terms in the Operating Agreement.s</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 19pt; text-indent: -19pt">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">60&deg; PHARMACEUTICALS, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">For Creditor</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Founder</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Doug Loock</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">60&deg; Pharmaceuticals, LLC Agreement to Convert Debt to Equity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>


<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="font-size: 10pt; vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>36
<FILENAME>cm270_ex10-33.htm
<DESCRIPTION>EXHIBIT 10.33
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.7pt; text-align: center; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.7pt; text-align: right; text-indent: -0.5pt"><B>Exhibit 10.33</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.7pt; text-align: center; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>AGREEMENT
and PLAN OF MERGER </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>of&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>60
DEGREES PHARMACEUTICALS, LLC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">This
Agreement and Plan of Merger (the &ldquo;<B>Plan</B>&rdquo;) for 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited
liability company (the &ldquo;<B>Company</B>&rdquo;), is made and entered into effective as of June 1, 2022 in accordance with the
terms of the Company&rsquo;s Eighth Amended and Restated Operating Agreement, dated as of December 31, 2021 (the &ldquo;<B>LLC
Agreement</B>&rdquo;), the District of Columbia Limited Liability Company Act (the &ldquo;<B>DC Act</B>&rdquo;), and the Delaware
General Corporation Law (the &ldquo;<B>DGCL</B>&rdquo;). Capitalized terms used but not otherwise defined in this Plan have the
meanings ascribed to such terms in the LLC Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 2.75pt; text-align: center; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B>RECITALS</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Company is a limited
liability company, formed on September 9, 2010 by the filing of Articles of Organization with the District of Columbia Department of
Consumer and Regulatory Affairs Corporations Division (the &ldquo;<B>DCRA</B>&rdquo;) pursuant to and in accordance with the DC
Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.7in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, under the terms of the LLC Agreement,
the Company is managed by the manager;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.7in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Company has incorporated as a Delaware
corporation effective June 1, 2022, as managed by the sole director;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the Company wishes to merge with the
Delaware corporation effective June 1, 2022;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50.05pt; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, a District of Columbia limited
liability company may merge into a Delaware corporation under Title 8, Section 264(c) of the DGCL and Section &sect; 29&ndash;809.02
of the DC Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, it is intended that the merger of
the Company will be treated as an exchange pursuant to Section 351 of the Internal Revenue Code of 1986, as amended (the
&ldquo;<B>Code</B>&rdquo;) for US federal income tax purposes; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">WHEREAS, the manager and the members have
approved the merger of the Company into a Delaware corporation (the &ldquo;<B>Merger</B>&rdquo;) and the terms of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">NOW, THEREFORE, the Company does hereby
adopt this Plan to effect the merger as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: center; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Article 1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">TERMS
AND CONDITIONS OF CONVERSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Name
of Converting Entity</U>. The name of the converting entity is 60 Degrees Pharmaceuticals, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Name
of Converted Entity</U>. The name of the converted entity is 60 Degrees Pharmaceuticals, Inc. (the &ldquo;<B>Corporation</B>&rdquo;), which
is incorporated in Delaware concurrent with the filing of the Certificate of Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate
of Merger</U>. Pursuant to Title 8, Section 264(c) of the DGCL, the Company shall cause to be filed with the Delaware Secretary of State
a certificate of merger in substantially the form attached hereto as Exhibit A (the &ldquo;<B>Certificate of Merger</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective
Date</U>. The Merger shall become effective at the time of filing the Certificate of Merger with the Secretary of State (the &ldquo;<B>Effective
Time</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Merger</U>.
At the Effective Time, the Company shall continue its existence in the organizational form of a Delaware corporation. The Company&rsquo;s LLC
Agreement shall be terminated and of no further force or effect and shall be superseded in their entirety by the Certificate of Incorporation
(as defined in Section 9 below) and the By-Laws (as defined in Section 10 below), and no party shall have any further rights, duties,
or obligations pursuant to the Company&rsquo;s LLC Agreement. Notwithstanding the foregoing, the termination of the LLC Agreement shall not
relieve any party thereto from any liability arising in connection with any breach by such party of the LLC Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Approval</U>.
This Plan has been approved by the Manager and by the Members holding more than fifty percent (50%) of all outstanding membership interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Merger
of Membership Interests</U>. The value of each outstanding members &lsquo;membership interest in the Company as set forth in the LLC Agreement
shall, without any action on the part of any holder thereof, be automatically converted into common stock in the Corporation, par value
$.0001 (the &ldquo;<B>Common Stock</B>&rdquo;), equal to five dollars ($5.00) per share of Common Stock. No fractional shares shall be issued
in connection with the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; width: 68%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Shares</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; width: 15%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Percentage Ownership</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Geoffrey Dow</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">1,888,975</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">80.42%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Douglas Look</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">165,938</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">7.06%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">Tyrone Miller</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">294,029</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">12.52%</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">TOTAL</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">2,348,942</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 11pt">100%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5pt; text-indent: -0.5pt">The shares of Common Stock into
which the membership interests shall be converted at the Effective Time have not been registered under the Securities Act of 1933,
as amended (the &ldquo;<B>Securities Act</B>&rdquo;) or the securities laws of the District of Columbia or any state and may not be
transferred, pledged, or hypothecated except as permitted under the Securities Act and applicable state securities laws pursuant to
registration or exemption therefrom; any certificates evidencing the Common Stock, if any, or any other securities issued in respect
of the Common Stock upon any split, dividend, recapitalization, merger, consolidation, or similar event shall bear any legend
required by the Corporation, required under the Securities Act and application state securities laws, or called for by an agreement
between the Corporation and any stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Rights
and Liabilities</U>. At the Effective Time:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.4in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 60pt">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
the rights, privileges, and powers of the Company and all property and all debts due to the Company, as well as all other things and causes
of action belonging to the Company, shall remain vested in the Corporation and shall be the property of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.4in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 60pt">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
actions and resolutions of the manager and the member, as applicable, taken or adopted from the inception of the Company prior to the
Effective Time shall continue in full force and effect as if the Corporation&rsquo;s board of directors and the stockholders, respectively,
had taken such actions and adopted such resolutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in; text-indent: 0.4in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 60pt">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
rights of creditors and all liens upon any property of the Company shall be preserved unimpaired, and all debts, liabilities, and duties
of the Company shall remain attached to the Corporation and may be enforced against the Corporation to the same extent as if said debts,
liabilities, and duties had originally been incurred or contracted by the Corporation in its capacity as a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certificate
of Incorporation</U>. A certificate of incorporation of the Corporation in substantially the form attached hereto as Exhibit B (the &ldquo;<B>Certificate
of Incorporation</B>&rdquo;) shall be filed with the Secretary of State.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>By-Laws</U>.
The by-laws of the Corporation shall be substantially in the form attached hereto as Exhibit C (the &ldquo;<B>By-Laws</B>&rdquo;).]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Board
of Directors; Officers</U>. Pursuant to an Organizational Action by Sole Incorporator substantially in the form attached hereto as
D, which shall be executed immediately following the filing of the Certificate of Incorporation, the initial directors of the
Corporation shall be elected and shall hold such office until the first annual meeting of stockholders, or until his or her
successor shall have been duly elected and qualified, or until his or her earlier death, resignation, or removal. Thereafter,
immediately following the filing of the Organizational Action by Sole Incorporator, the initial director shall ratify and approve
the by-laws of the Corporation substantially in the form attached hereto as Exhibit C (the &ldquo;<B>By-Laws</B>&rdquo;) and elect the
officers of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>US
Federal Income Tax Consequences</U>. The Merger has been structured to be treated, for US federal income tax purposes, as if the Company
transferred its assets to the Corporation for shares of the Corporation&rsquo;s common stock pursuant to an exchange described in Section 351
of the Code, followed by a distribution of the shares of the Corporation&rsquo;s common stock to the members in liquidation of the Company,
as described in Rev. Rul. 2004-59.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendment
or Termination</U>. This Plan may be amended or terminated by the Company and the Merger may be abandoned at any time prior to the Effective
Date by the managers, except that the Plan may not be so amended without the written consent of the Members if the effect of such amendment
materially alters the rights and obligations of the Members after the Merger.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Counterparts</U>.
This Plan may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be
one and the same agreement. A signed copy of this Plan delivered by facsimile, email, or other means of Electronic Transmission shall
be deemed to have the same legal effect as delivery of an original signed copy of this Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.1pt; text-indent: 0.3in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All issues and questions concerning the application, construction, validity, interpretation, and enforcement of this Plan shall
be governed by and construed in accordance with the internal laws of the State of Delaware, without giving effect to any choice or conflict
of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any
jurisdiction other than those of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.35pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT
A</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATE OF MERGER </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"> [ATTACHMENT]</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT B</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CERTIFICATE OF INCORPORATION OF 60
DEGREES PHARMACEUTICALS, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"> [ATTACHMENT]</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT
C</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>BY-LAWS OF 60 DEGREES PHARMACEUTICALS,
INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">[ATTACHMENT]</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT
D</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ORGANIZATIONAL ACTION
BY SOLE INCORPORATOR </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"> [ATTACHMENT]</P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">IN WITNESS WHEREOF,
the undersigned, having been duly authorized, hereby adopt this Plan as of the date set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>60 Degrees Pharmaceuticals, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-size: 10pt">GEOFF DOW</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">GEOFF DOW, SOLE MANAGER </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>&nbsp;</B></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>60 Degrees Pharmaceuticals, Inc.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ <FONT STYLE="font-size: 10pt">GEOFF DOW</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">GEOFF DOW, SOLE DIRECTOR</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>37
<FILENAME>cm270_ex10-34.htm
<DESCRIPTION>EXHIBIT 10.34
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;Exhibit 10.34</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXCLUSIVE LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">This <B>EXCLUSIVE LICENSE AGREEMENT (&quot;Agreement&quot;)
</B>is made on the 30<SUP>th </SUP>day of <B>May 2014 </B>between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NATIONAL UNIVERSITY OF SINGAPORE, </B>(Company
Registration Number: 200604346E), a company limited by guarantee incorporated in Singapore, having its registered address at 21 Lower
Kent Ridge Road, Singapore 119077 <B>(&quot;NUS&quot; </B>which expression shall include its successors and assigns)of the first part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SINGAPORE HEALTH SERVICES PTE LTD </B>(Company
Registration Number: 200002698Z), a company incorporated in Singapore, having its registered address at 31 Third Hospital Avenue #03-03,
Singapore 168753 <B>(&quot;SHS&rdquo; </B>which expression shall include its successors and assigns) of the second part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(NUS </B>and <B>SHS </B>hereinafter collectively referred to as
<B>&ldquo;Licensor&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>60</B>&deg; <B>PHARMACEUTICALS, LLC, </B>an
American company having its registered office address at 1025 Connecticut Avenue NW, Suite 1000, Washington DC, USA 20036 <B>(&quot;60P&rdquo;
</B>which expression shall include its successors and assigns) of the third part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">And</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>60P AUSTRALIA PTY LTD </B>(Company Registration
No. 167060219) a company incorporated in Australia and having its registered office at 105 North Steyne Manly New South Wales 2095, <B>(&ldquo;60P
Australia&rdquo; </B>which expression shall include its successors and assigns) of the fourth part</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(60P </B>and <B>60P Australia </B>hereinafter collectively referred
to as <B>&ldquo;Licensee&rdquo;).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: -17pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.7pt"></TD><TD STYLE="width: 15.15pt"><B>A.</B></TD><TD STYLE="text-align: justify"><B>NUS </B>and <B>Singapore General Hospital Pte Ltd (&quot;SGH&rdquo;) </B>(UEN Number: 198703907Z),
a company incorporated in Singapore and having its registered office at 31 Third Hospital Avenue #03-03 Singapore 168753 and Tan Tock
Seng Hospital Pte Ltd (Company Registration No.199003683N), a company incorporated in Singapore and having its registered office at 11
Jalan Tan Tock Seng, Singapore 308433 <B>(&quot;TTSH&rdquo;) </B>had entered into a <B>Project Agreement dated 27 July 2012 </B>(hereinafter
referred as <B>&quot;the Project Agreement&rdquo;) </B>wherein <B>NUS, SGH, </B>and <B>TTSH </B>inter alia agreed to folfill their respective
roles in the project entitled <B><I>&quot;CELGOSIVIR PROOF OF CONCEPT TRIAL FOR TREATMENT OF ACUTE DENGUE FEVER&quot;</I> (&quot;the Celaden
Project&quot;).</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-align: justify; text-indent: -17pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.7pt"></TD><TD STYLE="width: 15.15pt"><B>B.</B></TD><TD STYLE="text-align: justify">Pursuant to the Project Agreement, <B>NUS, SHS </B>and <B>TTSH </B>have agreed that all <B>Patent Rights
</B>as described in <B>Schedule 2 </B>are owned by <B>Licensor </B>as legal and equitable owners in the following proportions [i.e. NUS
owns <FONT STYLE="background-color: black">c&nbsp;</FONT>% and SHS owns <FONT STYLE="background-color: black">c&nbsp;</FONT>%].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 21.7pt"></TD><TD STYLE="width: 15.15pt; text-align: left"><B>C.</B></TD><TD STYLE="text-align: justify"><B>Licensor </B>has the right to grant licenses under the said
<B>Patent Rights.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 21.7pt"></TD><TD STYLE="width: 15.15pt"><B>D.</B></TD><TD STYLE="text-align: justify">Licensee is interested in obtaining and <B>Licensor </B>is desirous of granting an exclusive, sublicensable
license from <B>Licensor </B>in <B>respect</B> of the <B>Patent Rights </B>to develop, market and sell <B>Licensed Products </B>in the
<B>Field of Use </B>in the <B>Territory </B>in accordance with the terms of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 74%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 26%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 1 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -17pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 19pt"></TD><TD STYLE="width: 17pt"><B>E.</B></TD><TD STYLE="text-align: justify">Except where they are public records, the <B>Licensee </B>is interested in obtaining and <B>Licensor </B>is
desirous of granting access to the <B>Essential Documents </B>of the <B>CELADEN </B>study for the purpose of developing, marketing, and
selling <B>Licensed Products </B>in the <B>Field of Use </B>in the <B>Territory </B>in accordance with the terms of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NOW, THEREFORE, in consideration of the premises
and the mutual covenants contained herein, <B>Licensor </B>and <B>Licensee </B>(hereinafter collectively referred to as <B>&ldquo;Parties&rdquo;
</B>and singularly as <B>&ldquo;Party&rdquo;) </B>hereto agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD><B>DEFINITIONS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In this Agreement, unless the context otherwise requires,
the following expressions have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Academic</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Purposes</B></P></TD>
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 55%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">academic research (including sponsored research), scholarly publications, educational purposes, and medical services.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Affiliate</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, with respect to any entity, any other entity directly or indirectly controlling, controlled by, or under common control with, such entity. The expression &quot;control&quot; (including its correlative meanings, &quot;controlled by&quot;, &quot;controlling&quot; and &quot;under common control with&quot;) shall mean, with respect to a corporation, the right to exercise, directly or indirectly, more than 50 per cent. of the voting rights attributable to the shares of the controlled corporation and, with respect to any entity other than a corporation, the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such entity.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Confidential</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Information</B></P></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any information disclosed by one <B>Party </B>to the other <B>Party </B>in any form, which, if disclosed in tangible form, is marked at the time of disclosure as being confidential or proprietary or with words of similar import, and if disclosed orally or visually or in other intangible form, is described as confidential at the time of such disclosure and confirmed in writing as confidential within thirty (30) days of such disclosure.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effective Date </B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 30<SUP>th</SUP>,2014</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Field of Use</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therapeutic and prophylactic use for human and veterinary diseases.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exclusive, sub-licensable and transferable license in respect of the <B>Patent Rights </B>to develop, manufacture, market and sell products worldwide.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Licensee&rsquo;s</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Improvements</B></P></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any modifications,&nbsp;&nbsp;additions,&nbsp;&nbsp;alterations, enhancements, upgrades or new versions made by <B>Licensee </B>of the <B>Invention </B>under the <B>Patent Rights, </B>including without limitation those made by <B>Licensee </B>under <B>Licensee&rsquo;s </B>sponsorship research programs other than <B>Licensor Improvements, NUS Improvements, SHS Improvements </B>and/or and <B>Joint Improvements.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 71%; padding-right: 13pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 29%; padding-right: 13pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 13pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) 173900</FONT></TD>
    <TD STYLE="padding-right: 13pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 2 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
  <TR>
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Invention</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 55%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the invention
    as described in <B>Schedule 1 Part A.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inventors</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drs Subhash Vasudevan,
    Cynthia Sung, Abhay Rathore, Satoru Watanabe, Eng Eong Ooi and Jenny Low, assignors under the Deeds of Assignments dated 21 May2013
    and26June2013.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Essential</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Documents</B></P></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Essential Documents
    </B>of the <B>Celaden Project </B>conducted by <B>NUS, SGH, and TTSH </B>under the Project Agreement. For the avoidance of doubt,
    <B>Essential Documents </B>for the purpose of this Agreement shall include the &ldquo;Essential Documents for the Conduct of a Clinical
    Trial&rdquo; as defined in ICH Guidelines for Good Clinical Practice E6 (Rl) and those documents particularly described in <B>Schedule
    4.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Licensed</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Process(es)</B></P></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any and all processes or
    methods that incorporate, utilize or are made with the use of the <B>Invention </B>or whose use or practice, but for the rights granted
    hereunder, would constitute an infringement of any claim within the <B>Patent Rights.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensed Product(s)</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a)&nbsp;&nbsp;any product: (i) which
        incorporates, utilizes or is made with the use of the <B>Invention; </B>or, (ii) which, but for the rights granted hereunder,
        the manufacture, use or sale thereof would constitute an infringement of any claim within the <B>Patent Rights;</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b)&nbsp;&nbsp;any article, composition,
    apparatus, chemical, substance or any other materials made, used or sold for use with a <B>Licensed Process.</B></P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Licensee&rsquo;s</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Representative</B></P></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any agent who is engaged
    by <B>Licensee </B>to act on behalf of the <B>Licensee, </B>for the purposes of this Agreement, to provide certain services, including
    the selling of <B>Licensed Products, </B>but shall not include <B>Sub-Licensees.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gross Sales</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    gross amount of monies, cash, or non-cash consideration equivalent received for the treatment or prophylaxis of dengue in humans
    only, with the exception of data, drug, drug product, or in kind services or access to any of the foregoing provided by third parties,
    that is paid to <B>Licensee </B>and/or its <B>Related Company </B>for the <B>Licensed Products, Licensed Processes </B>or any products
    manufactured by <B>Licensee </B>that contain celgosivir. by sale or any other mode of transfer in the countries considered by the
    World Bank to be &ldquo;high income&rdquo; (ie per capita income over US $12,615) in 2012 (as annexed in <B>Schedule 5),</B> and
    such other countries as may be added by the World Bank from time to time <B>BUT EXCLUDING ALL</B> sales made which are intended for
    non-profit NonGovernment Organisations and charities worldwide notwithstanding that such sales are made in high income countries
    and <B>Licensee&rsquo;s</B> subsidiaries and any <B>Sub-licensing Revenue.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 72%; padding-right: 13pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 28%; padding-right: 13pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 13pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="padding-right: 13pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 3 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
  <TR>
    <TD STYLE="vertical-align: top; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joint Improvements</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 55%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">any modifications,
                           addition, alterations, enhancements, upgrades or new versions of the <B>Invention</B> under the <B>Patent
                           Rights</B> made through any consultancy agreement or arrangement between:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
    <B>Licensee;</B> and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(ii)&nbsp;&nbsp;&nbsp;&nbsp;any
    current or past employee, student or intern of <B>NUS</B> who terminated his employment with <B>NUS</B> within twelve (12) months
    after entering into the consultancy arrangement; and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">(iii)&nbsp;&nbsp;&nbsp;any
    current or past employee, student or intern of <B>SHS</B> who terminated his employment with <B>SHS</B> within twelve (12) months
    after entering into the consultancy arrangement,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">including US provisional application 61/911795
    and PCT/US2014/028076 filed on March 14, 2014.</P></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensor Improvements</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any modifications, addition,
    alterations, enhancements, upgrades or new versions of the <B>Invention</B> under the <B>Patent Rights</B> made by <B>NUS</B> and/or
    <B>SHS.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NUS</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Improvements</B></P></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any modifications, addition,
    alterations, enhancements, upgrades or new versions of the <B>Invention</B> under the <B>Patent Rights</B> made through any consultancy
    agreement or arrangement between the <B>Licensee</B> and any current or past employee, student or intern of <B>NUS </B>who terminated
    his employment with <B>NUS</B> within twelve (12) months after entering into the consultancy arrangement.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patents</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all or any of the patents
    and all continuations, divisions, and reissues thereof, and any corresponding foreign patent applications and any patents, or other
    equivalent foreign patent rights issuing, granted, or registered thereon granted pursuant to the <B>Patent Applications,</B> short
    particulars of which are set out in <B>Schedule 2 Part A.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent Applications</B></FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">--</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all applications for patents
    and rights of a similar nature, filed and to be filed, in respect of the</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14</FONT></TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 4 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%">&nbsp;</TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 55%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Invention, </B>including, but not limited to, patent applications the short particulars of which are set out in <B>Schedule 2 Part B, </B>and/or any <B>Joint Improvements, </B>and in the event of any amendment of or a division of the same, such amended applications or divided applications.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent Rights</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rights under all <B>Patents </B>and <B>Patent Applications.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Related Company</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any entity which directly or indirectly controls, is controlled by, or is under common control with <B>Licensee, </B>including <B>Licensee's </B>related corporations within the meaning of Section 6 of the Singapore Companies Act (Cap. 50).</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHS Improvements</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any modifications, addition, alterations, enhancements, upgrades or new versions of the <B>Invention </B>under the <B>Patent Rights </B>made through any consultancy agreement or arrangement between the <B>Licensee </B>and any current or past employee, student or intern of SHS who terminated his employment with <B>SHS </B>within twelve (12) months after entering into the consultancy arrangement.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sub-licensing Revenue</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all upfront fees, sub-licensing fees, royalties and all other amounts in cash and cash equivalent which are paid to the <B>Licensee </B>by any <B>Sub-Licensee </B>of its rights hereunder, with the exception of data, drug, drug product, or in kind services or access to any of the foregoing provided by third parties and any revenue paid to the <B>Licensee </B>by any <B>Sub-Licensee </B>in relation to treatment or prophylaxis of dengue in humans.</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sub-Licensee</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any person, company or other legal entity, other than <B>Licensee, </B>who has the right, granted by <B>Licensee, </B>to make, have made, use, sell or import for sale the <B>Licensed Product or Licensed Process.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Technology Rights</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all technical infomation, formulations, know-how, processes, procedures, compositions, devices, methods, formulae, materials, tests, data, designs, other information and <B>Confidential Information </B>related to the <B>Patent Rights, </B>that are not described by <B>Patent Rights </B>but that are necessary for practicing the invention covered by the <B>Patent Rights.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the period during which this Agreement is in force pursuant to <B>Section 6.</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Territory</B></FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>-</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Worldwide</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Celaden Project</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14 </FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 5 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify; font-style: normal; font-weight: normal"><B>INTERPRETATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.1.</TD><TD STYLE="text-align: justify">In this Agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: -20pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Words importing the singular shall include the plural and vice versa, and words that are gender specific
or neuter shall include the other gender and the neuter.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">References to a person shall be construed as references to an individual, corporation, company, firm,
incorporated body of persons of any country, or any agency, thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">The headings in this Agreement are for convenience only and shall not affect its interpretation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">All references to Sections and Schedules refer, unless the context otherwise requires, to Sections and
Schedules of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">All references to statutes or statutory provisions shall be taken to be a reference to the statutes or
provisions as revised, amended, supplemented or re-enacted from time to time, and shall include any subsidiary legislation made thereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD STYLE="text-align: justify"><B>GRANT OF LICENSE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: -38pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.1.</TD><TD STYLE="text-align: justify"><B>Licensor </B>hereby grants to <B>Licensee and Licensee hereby </B>accepts, subject to the terms and
conditions hereof, and subject to <B>Licensor&rsquo;s </B>rights under <B>Section 3.2 </B>an exclusive, sub-licensable, license of the
<B>Patent Rights </B>to make, use, sell, offer to sell, and import any <B>Licensed Products </B>in the <B>Field of Use </B>in the <B>Territory
</B>during the <B>Term.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.2.</TD><TD STYLE="text-align: justify">Nothing in this Agreement shall prejudice <B>NUS', SHS', </B>and/or <B>TTSH&rsquo;s </B>right to use /
practice the <B>Patent Rights for Academic Purposes.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.3.</TD><TD STYLE="text-align: justify"><B>Licensor </B>shall be obliged under this Agreement to render reasonable technical assistance, or support,
or provide training to <B>60P, </B>for purposes of using / practicing the <B>Patent Rights </B>granted hereunder, such assistance or support
not to exceed 10 hours per month.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.4.</TD><TD STYLE="text-align: justify"><B>Licensee </B>shall own all rights, title and interests in and to all of <B>Licensee&rsquo;s Improvements.
</B>For clarity, neither <B>NUS </B>nor <B>SHS </B>has any rights to the <B>Licensee&rsquo;s Improvements </B>and no <B>Royalty, </B>fee
or any fees cost or expense shall be payable to <B>NUS </B>and/or <B>SHS </B>in respect <B>of Licensee&rsquo;s Improvements.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-size: 10pt">3.5</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Licensee </B>agrees that all rights, title and interests in and to all
<B>Joint Improvements </B>shall be co-owned by <B>60P, 60P Australia, NUS, and SHS </B>as tenants in common in the following proportions:
<B>60P Australia: <FONT STYLE="background-color: black">__</FONT> %, </B></FONT><B>60P: <FONT STYLE="font-size: 10pt; background-color: black">__</FONT>
%,NUS: <FONT STYLE="font-size: 10pt; background-color: black">__</FONT> %, SHS: <FONT STYLE="font-size: 10pt; background-color: black">__</FONT></B>
%</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.6</TD><TD STYLE="text-align: justify"><B>Licensee </B>shall be entitled to use and practice <B>Joint Improvements </B>and such use and practice
shall be subject to the same terms and conditions as the use and practice of <B>Patent Rights </B>licensed under this Agreement unless
terms and conditions for the use and practice of <B>Joint Improvements </B>are separately negotiated and agreed in writing by <B>Licensor
and Licensee.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.7</TD><TD STYLE="text-align: justify"><B>NUS </B>hereby grants to <B>Licensee </B>a right of first refusal to negotiate a separate license agreement
for any <B>NUS Improvements. </B>Ownership of all rights, title and interest in and to all <B>NUS Improvements </B>shall be determined
by inventive contributions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 6 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: center; text-indent: -40pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.8</TD><TD STYLE="text-align: justify"><B>SHS </B>hereby grants to <B>Licensee </B>a right of first refusal to negotiate a separate license agreement
for any <B>SHS Improvements. </B>Ownership of all rights, title and interest in and to all <B>SHS Improvements </B>shall be determined
by inventive contributions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.9</TD><TD STYLE="text-align: justify">Subject to <B>Sections 3.2 </B>and <B>3.4, Licensee </B>hereby grants to <B>NUS and SHS </B>a nonexclusive,
royalty-free license under all rights protecting <B>Licensee&rsquo;s Improvements </B>and <B>Joint Improvements </B>to practice the same
for <B>Academic Purposes </B>during the <B>Term </B>of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.10</TD><TD STYLE="text-align: justify">Subject always to the written consent of the <B>Licensee, Licensee </B>further grants to <B>NUS </B>and
<B>SHS </B>the non-exclusive, royalty-free right to sublicense the <B>Licensee&rsquo;s Improvements </B>and <B>Joint Improvements </B>to
other non-profit academic institutions and to <B>SHS's Affiliates </B>for <B>Academic Purposes.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt"><B>3A.</B></TD><TD STYLE="text-align: justify"><B>ACCESS TO ALL OF ESSENTIAL DOCUMENTS AND ANY OTHER DOCUMENTS RELATED TO THE CELADEN PROJECT TO LICENSEE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">3A.l</TD><TD STYLE="text-align: justify"><B>Licensor </B>shall furnish to the <B>Licensee </B>all of the <B>Essential Documents </B>in complete
and readable format per industry practices in respect of commercialization of clinical trials and programs data and, subject always to
the obligations of disclosure to the relevant authorities and the right of access granted to <B>SGH </B>and <B>TTSH </B>as participants
in the <B>Celaden Project, </B>each of <B>NUS </B>and <B>SHS </B>hereby jointly and severally undertake that they shall not, from the
<B>Effective Date </B>and during the <B>Term </B>of this Agreement, grant any third party access to the <B>Essential Documents </B>for
commercial purposes. <B>Licensee, </B>its <B>Related Companies </B>and <B>Sub-Licensees </B>may utilize the <B>Essential Documents </B>to
make, seek and maintain regulatory approval for the use, sale, offer to sell, and import of any products for human use manufactured by
<B>Licensee </B>that contain celgosivir.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt">3A.2</TD><TD STYLE="text-align: justify"><B>Licensee </B>may, from time to time, request for access to documents related to the <B>Celaden Project
</B>which are not <B>Essential Documents (&quot;Other Documents&quot;). </B>If the <B>Other Documents </B>are within the possession, custody
and control of <B>Licensor, Licensor </B>may, in its sole and unfettered discretion, grant to <B>Licensee </B>access to the <B>Other Documents.
</B>If further requested by <B>Licensee </B>and subject always to the obligations of disclosure to the relevant authorities and the right
of access granted to <B>SGH </B>and <B>TTSH </B>as participants in the <B>Celaden Project, Licensor </B>may, it its sole and unfettered
discretion, undertake in writing not to grant during the <B>Term </B>any third party access to the <B>Other Documents </B>for commercial
purposes. If such undertaking is given by <B>Licensor, Licensee, </B>its <B>Related Companies </B>and <B>Sub-Licensees </B>may utilize
such <B>Other Documents </B>as are described in the undertaking to make, seek and maintain regulatory approval for the use, sale, offer
to sell, and import of any products for human use manufactured by the <B>Licensee </B>that contain celgosivir.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 34pt; text-align: left">3A.3</TD><TD STYLE="text-align: justify"><B>Licensee </B>may request
                                            that <B>Licensor </B>continue not to grant to any third party access to the <B>Essential
                                            Documents </B>and the <B>Other Documents </B>in respect of which <B>Licensor </B>has given
                                            a written undertaking pursuant to <B>Section 3A.2 </B>after the expiry of the <B>Term </B>of
                                            this Agreement. <B>Licensor </B>may, in its sole and unfettered discretion, agree and undertake
                                            in writing to continue not granting any third party access to such <B>Essential Documents
                                            </B><U>and </U><B>Other Documents </B>subject to payment of an annual fee of Singapore Dollars
                                            <FONT STYLE="background-color: black">__ __</FONT> <B>(S$ </B><FONT STYLE="background-color: black">__
                                            __</FONT>) for each year that the <B>Licensee </B>requires the <B>Licensor </B>to give such
                                            undertaking. If such undertaking is given by <B>Licensor, Licensee, </B>its <B>Related Companies
                                            </B>and <B>Sub-Licensees </B>may utilize the <B>Essential Documents </B>and such <B>Other
                                            Documents </B>as are described in the undertaking to make, seek and maintain regulatory approval
                                            for the use, sale, offer to sell, and import of any product containing celgosivir for each
                                            year that the undertaking is given. In the event that such an undertaking is not given, the
                                            <B>Licensee</B> may continue to use, on a non-exclusive basis, the <B>Essential Documents
                                            </B>and such <B>Other Documents</B> to make, seek, and maintain regulatory approval for the
                                            use, sale, offer to sell, and import of any product for human use manufactured by <B>Licensee
                                            </B>containing celgosivir.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 7 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.9pt"><B>4.</B></TD><TD><B>WARRANTIES OF NUS AND SHS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.9pt">4.1</TD><TD>Both <B>NUS</B> and <B>SHS</B> hereby jointly and severally warrant to <B>Licensee</B> as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52pt; text-align: justify; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(a)</TD><TD STYLE="text-align: justify"><B>NUS</B> and <B>SHS</B> have legal and equitable ownership of the <B>Patent Rights</B> in the following
proportions :</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 20pt"><B>(i)</B></TD><TD STYLE="text-align: justify"><B>NUS</B> <B>- <FONT STYLE="background-color: black">__</FONT>%;
                                            </B>and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 20pt"><B>(ii)</B></TD><TD STYLE="text-align: justify"><B>SHS - <FONT STYLE="background-color: black">__</FONT>%.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 52pt; text-align: justify; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(b)</TD><TD STYLE="text-align: justify">Neither <B>NUS</B> nor <B>SHS</B> has received any claim or notice of claim of ownership and infringement
whatsoever in respect of the <B>Patent Rights;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(c)</TD><TD STYLE="text-align: justify">To the best of <B>NUS</B>&rsquo; and <B>SHS</B>&rsquo; knowledge, the <B>Patent Rights</B> are in full
force and effect and free from all liens and encumbrances.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(d)</TD><TD STYLE="text-align: justify">To the best of <B>NUS</B>&rsquo; and <B>SHS</B>&rsquo; knowledge, there are no restrictions or prohibitions
affecting their respective rights in licensing the <B>Patent Rights</B> to <B>Licensee;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(e)</TD><TD STYLE="text-align: justify">To the best of <B>NUS&rsquo;</B> and <B>SHS</B>&rsquo; knowledge, there are no claims or notice of claims
by any of the participants involved in the clinical trial in the <B>Celaden Project;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(f)</TD><TD STYLE="text-align: justify">To give <B>Licensee</B> the first right of refusal to license in respect of any <B>Licensor Improvements.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.9pt"><B>5.</B></TD><TD><B>SUB-LICENCES</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.9pt">5.1</TD><TD><B>60P</B> and <B>60P Australia</B> shall each have the right to grant sub-licences ofthe <B>Patent Rights </B>under its license in
this Agreement to <B>Sub-licensees</B> on an arm's length basis, provided that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 20pt">i.</TD><TD STYLE="text-align: justify">neither <B>60P</B> nor <B>60P Australia</B> shall grant any rights to its <B>Sub-licensees</B> which are
inconsistent with the rights granted to and obligations of the <B>Licensee </B>hereunder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 20pt">ii.</TD><TD STYLE="text-align: justify">any act or omission of a <B>Sub-licensee</B> which would be a breach of this Agreement if performed by
the <B>Licensee</B> shall be deemed to be a breach by <B>Licensee</B> of this Agreement, unless such breach, if capable of remedy, shall
have been remedied by the <B>Sub-licensee</B> within a period of ninety (90) days after notice of that breach has been provided by <B>Licensor</B>
to <B>60P</B> in writing;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 20pt">iii.</TD><TD STYLE="text-align: justify">each sub-licence granted by <B>60P</B> and/or <B>60P Australia</B> shall include an audit right in favour
of the <B>Licensor</B> of at least the same scope as provided in <B>Section 9.1(c) </B>hereof with respect to the Licensee;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 20pt">iv.</TD><TD STYLE="text-align: justify">each sub-licence granted by <B>60P</B> and/or <B>60P Australia</B> shall include an indemnity clause from
the <B>Sub-licensee</B> for costs, claims, damages or expenses directly incurred or suffered by the <B>Licensor, </B>or for which the
<B>Licensor </B>may become liable, as a result of the default or negligence of such <B>Sub-licensee;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 8 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 69pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 60pt"></TD><TD STYLE="width: 20pt">v.</TD><TD STYLE="text-align: justify">upon the termination of this Agreement under <B>Section 19, </B>the <B>Licensor </B>shall have the right
and option to require an assignment to it or its nominee of each sublicence between <B>60P </B>and/or <B>60P Australia </B>and its/their
<B>Sub-licensees, </B>and for these purposes, both <B>60P and 60P Australia </B>shall procure that all sub-licences granted hereunder
shall contain express terms that:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 104pt; text-align: justify; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80pt"></TD><TD STYLE="width: 40pt">(a)</TD><TD STYLE="text-align: justify">permit the assignment of the sub-license to the <B>Licensor </B>under the circumstances specified in this
<B>Section 5.l(v) </B>and require <B>60P </B>and/or <B>60P Australia and Sub-licensee </B>to consent to such assignment;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80pt"></TD><TD STYLE="width: 40pt">(b)</TD><TD STYLE="text-align: justify">in the event that the <B>Licensor </B>does not exercise its option to require an assignment under this
<B>Section 5.l(v), </B>or if for any reason the assignment cannot be effected, the sub-licence agreement will automatically be terminated;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 80pt"></TD><TD STYLE="width: 40pt">(c)</TD><TD STYLE="text-align: justify"><B>60P, 60P Australia </B>and the <B>Sub-licensee </B>in question shall bear their own expenses in relation
to such assignment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt">5.2</TD><TD STYLE="text-align: justify"><B>60P </B>shall within thirty (30) days of the grant of any sub-licence (which shall be in writing) provide
the <B>Licensor </B>with a true copy of the sub-licence at <B>60P's </B>own expense.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.3</TD><TD STYLE="text-align: justify">The sub-licences granted to any <B>Sub-licensee </B>by <B>60P </B>and/or <B>60P Australia </B>shall not
be transferable and shall not permit further sub-licensing of the <B>Patent Rights, Invention </B>or <B>Technology </B>by the <B>Sub-licensee.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt">5.4</TD><TD STYLE="text-align: justify">The Parties agree that <B>Sub-Licensing Revenue </B>received from a <B>Related Company of 60P </B>and/or
<B>60P Australia </B>shall not be considered to be <B>Sub-Licensing Revenue </B>for the purposes of <B>Section 8.3 </B>herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt"><B>6.</B></TD><TD STYLE="text-align: justify"><B>COMMENCEMENT DATE AND TERM</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt">6.1</TD><TD STYLE="text-align: justify">This Agreement shall come into effect on the date that this Agreement is signed and shall continue in
force until the expiration of the last to expire of any patents under the <B>Patent Rights </B>unless terminated earlier in accordance
with this Agreement <B>(&ldquo;Term&rdquo;).</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt"><B>7.</B></TD><TD STYLE="text-align: justify"><B>OBLIGATIONS OF LICENSEE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt">7.1</TD><TD STYLE="text-align: justify"><B>Licensee </B>hereby undertakes and agrees with <B>Licensor </B>that it will at all times during the
<B>Term </B>observe and perform the terms and conditions set out in this Agreement and in particular shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 69pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17pt">(a)</TD><TD STYLE="text-align: justify">use diligent efforts to effect introduction of the <B>Licensed Products </B>into the commercial market
as soon as practicable, consistent with reasonable and sound business practice and judgment in order the achieve the <B>Performance Objectives
</B>by the respective <B>Dates of Achievement </B>specified in <B>Section 7.2;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.5pt"></TD><TD STYLE="width: 17.75pt">(b)</TD><TD STYLE="text-align: justify">deliver to <B>NUS, </B>such part of the <B>Licensee&rsquo;s </B>annual audited financial statements which
pertain to the <B>Gross Sales </B>of the <B>Licensed Products </B>and <B>Licensed Processes and Sub-licensing Revenue, </B>at the end
of the first quarter following the end of each financial year of <B>Licensee </B>during the <B>Term. </B>For clarity, <B>NUS </B>is only
entitled to view and review (if necessary) <B>Licensee&rsquo;s </B>financial statements which pertain to the <B>Gross Sales </B>of the
<B>Licensed Products </B>and <B>Sub-licensing Revenue </B>and no other financial statements of <B>Licensee </B>whatsoever.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 75%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 9 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 69pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.55pt">(c)</TD><TD STYLE="text-align: justify">deliver to <B>NUS, Licensee&rsquo;s </B>annual budget for the subsequent financial year as well as a technical/development
update, no later than the end of <B>Licensee's </B>financial year commencing the first year from the introduction of the <B>Licensed Products
</B>into the commercial market in the <B>Territory </B>or <B>31 December 2014 </B>whichever is the later and thereafter based on the <B>Licensee's
</B>financial year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 69pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33pt">7.2</TD><TD STYLE="text-align: justify"><B>Licensee </B>also undertakes to meet the following <B>Performance Objectives </B>by the respective
<B>Dates of Achievement </B>whether by the <B>Licensee, </B>the <B>Sub-Licensees </B>or the <B>Licensee's </B>assignees:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: 1pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; border: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Performance Objectives:</B></FONT></TD>
    <TD STYLE="width: 40%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date of Achievement</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Commencement of a Phase II Clinical Trial involving</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Licensed Product </B>or <B>Process</B></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 years from <B>Effective Date</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Commencement of a Phase III Clinical Trial involving</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Licensed Product </B>or <B>Process</B></P></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 years from <B>Effective Date</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Submission for Regulatory Approval involving</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Licensed Product </B>or <B>Licensed Process</B></P></TD>
    <TD STYLE="vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2 years from Completion of Phase III Clinical Program</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market Launch </B>of <B>Licensed Product </B>or <B>Licensed Process</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9 months from the date of Regulatory Approval involving <B>Licensed&nbsp;&nbsp;Product </B>or <B>Licensed Process.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33pt">7.3</TD><TD STYLE="text-align: justify">Within twelve (12) months the date of <B>Market Launch of Licensed Product </B>or <B>Licensed Process,
Licensee </B>and <B>Licensor </B>shall have good faith discussions on projected sales of the <B>Licensed Products </B>for the next three
(3) years and mutually agree on the performance objectives of <B>Licensee.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33pt">7.4</TD><TD STYLE="text-align: justify">If <B>Licensee </B>fails to fulfill the performance objectives mutually agreed between <B>Licensee </B>and
<B>Licensor </B>pursuant to <B>Section 7.2 </B>above, the <B>Parties </B>shall have good faith discussions on the reasons for such failure
to meet the mutually agreed performance objectives. If <B>Licensee </B>is unable to provide any valid reasons reasonably satisfactory
to <B>Licensor, Licensor </B>shall grant to <B>Licensee </B>a further grace period of <B>9 months </B>for each of the respective dates
of achievement set out in <B>Section 7.2 </B>and in the event that <B>Licensee </B>is still unable to meet the respective dates of achievement,
<B>Licensors, </B>at its option, have the right, by notice in writing to <B>Licensee, </B>to immediately: (i) terminate the exclusivity,
sublicensing right and transferability of the <B>License </B>granted under <B>Section 3.1 </B>and grant licenses to other third party
licensees in the <B>Territory; </B>or (ii) terminate this Agreement pursuant to <B>Section 19.1(a).</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33pt"><B>8.</B></TD><TD><B>FINANCIAL PROVISIONS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33pt">8.1</TD><TD STYLE="text-align: justify">In consideration for the exclusive sub-licensable grant of the <B>License </B>under the <B>Patent Rights
</B>by <B>Licensor </B>to <B>Licensee </B>under <B>Section 3, 60P </B>shall pay to <B>NUS </B>an agreed non- refundable upfront fee of
<B>S<FONT STYLE="background-color: black">_______</FONT> (&quot;Upfront Fee&quot;) </B>as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 27%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 10 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -29pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt">(a)</TD><TD STYLE="text-align: justify"><B>S<FONT STYLE="background-color: black">________</FONT></B> being the Option Fee which was paid on execution
of the Intellectual Property Option Agreement made between <B>NUS</B> and <B>60P</B> dated 1 April 2013 (the receipt of which <B>NUS</B>
hereby acknowledges);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt">(b)</TD><TD STYLE="text-align: justify">S<FONT STYLE="background-color: black"><B>________</B></FONT> on the signing of this Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 40pt">(c)</TD><TD STYLE="text-align: justify">the balance S<FONT STYLE="background-color: black"><B>________</B></FONT> upon enrolment of the first
volunteer in a Phase II Clinical Trial of the <B>Licensed Product</B> or 3 years from the <B>Effective Date, </B>whichever is earlier.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -29pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">8.2</TD><TD STYLE="text-align: justify">In addition to the <B>Upfront Fee</B> under <B>Section 8.1, 60P</B> shall, commencing from nine (9) months
from the date of Regulatory Approval referred in <B>Section 7.2,</B> pay to <B>NUS</B> during the <B>Term</B> of this <B>Agreement,</B>
no later than by the end of the first quarter following the relevant financial year of <B>60P</B> in respect of which such amounts are
payable:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: -38pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">(a)</TD><TD STYLE="text-align: justify">a royalty fee <B>(&ldquo;Royalty&rdquo;)</B> at the rate of <FONT STYLE="background-color: black"><B>__</B></FONT>%
of <B>Gross Sales</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">8.3</TD><TD STYLE="text-align: justify"><B>60P</B> shall, commencing from the first (1<SUP>st</SUP>) year anniversary of the date of Market
Launch of <B>Licensed Product</B>
or <B>Licensed Process,</B> further pay to <B>NUS:</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: black"><B>__</B></FONT> % of all <B>Sub-licensing Revenue</B> where <B>Licensee</B>
has not commenced a Phase III clinical trial on the <B>Licensed Products</B> before sub-licensing its rights under the <B>Section 3.1</B>
to its <B>Sub-licensees;</B> or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: black"><B>__</B></FONT> % of all <B>Sub-licensing Revenue</B> where <B>Licensee</B>
has commenced a Phase III clinical trial on the <B>Licensed Products</B> before sub-licensing its rights under <B>Section 3.1</B> to its
<B>Sub-Licensees</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">8.4</TD><TD STYLE="text-align: justify">The <B>Upfront Fee,</B> the <B>Royalty</B> and all other sums payable under this Agreement shall be paid
in Singapore Dollars in favour of <B>NUS</B> in cleared funds to such bank account or in such other manner as <B>NUS</B> may specify from
time to time to <B>Licensee</B> without any set-off, deduction or withholding of taxes, charges and other duties. Where the <B>Upfront
Fee </B>and/or <B>Royalty</B> and/or any other sums payable under this Agreement are subject to goods and services taxes <B>(&ldquo;GST&rdquo;),</B>
these <B>GST</B> shall be borne by the <B>Licensee. Licensee</B> agrees to hold harmless from, and indemnify <B>Licensor</B> against all
liabilities, costs, damages suffered by <B>Licensor</B> of whatever nature resulting from <B>60P&rsquo;s</B> failure duly and timely to
pay and discharge its liability for any <B>GST.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">8.5</TD><TD STYLE="text-align: justify">If <B>60P</B> fails to pay in full to <B>NUS,
                                            </B>the <B>Upfront Fee</B> and/or <B>Royalty</B> and/or any other sums payable under this
                                            Agreement by their respective due dates, the amount outstanding shall bear interest, both
                                            before and after any judgment, at the rate of <FONT STYLE="background-color: Black"><B>___
                                            </B></FONT>percent <FONT STYLE="background-color: Black"><B>__ </B></FONT>%) per month, from
                                            such date until the said amounts are paid in full to <B>Licensor.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt"><B>9.</B></TD><TD STYLE="text-align: justify"><B>ACCOUNTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">9.1</TD><TD STYLE="text-align: justify"><B>60P shall:</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 15.6pt">(a)</TD><TD STYLE="text-align: justify">provide financial statements pertaining to the <B>Gross Sales</B> of the <B>Licensed Products</B> with
accompanying <B>Royalty</B> under this Agreement, showing all items of account from which such <B>Royalty</B> and other payment are calculated,
such statements to be certified by an authorized officer of <B>60P</B> as properly reflecting all amounts due to <B>Licensor</B> in accordance
with the relevant provisions under this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 74%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14</FONT></TD>
    <TD STYLE="width: 26%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pagse 11 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 37pt; text-indent: -37pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52pt"></TD><TD STYLE="width: 16pt">(b)</TD><TD STYLE="text-align: justify">keep true, accurate and complete accounts and records in sufficient detail to enable the amount of <B>Royalty</B>
and other sums payable under this Agreement to be determined by <B>Licensor;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 52pt"></TD><TD STYLE="width: 16pt">(c)</TD><TD STYLE="text-align: justify">at the reasonable request of <B>Licensor</B> from time to time, but no more than once annually, and upon
not less than ten (10) days' prior written notice, allow <B>NUS</B> or its agent (or enable <B>NUS</B> or its agent), at <B>NUS&rsquo;s</B>
expense, to inspect, audit and copy those accounts and records pertaining to the items shown on the statements provided under <B>Section
7.1(b)</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.9pt">9.2</TD><TD STYLE="text-align: justify">If, following any inspection and audit pursuant to <B>Section 9.1(c)</B> which audit shall be limited
to the documents in respect of the <B>Gross Sales</B> of the <B>Licensed Products</B> and <B>Sublicensing Revenue, NUS</B> discovers a
discrepancy, in NUS&rsquo; disfavour, between the amount of <B>Royalty</B> and other sums actually paid by <B>60P</B> and those which
should have been payable under this Agreement, which is in excess of <FONT STYLE="background-color: black">__</FONT> percent (<FONT STYLE="background-color: black">_</FONT>%)
of those that should have been payable under this Agreement, <B>60P</B> shall, within seven (7) days of the date of <B>NUS&rsquo; </B>notification
thereof, reimburse <B>NUS</B> for any such deficiency and for any professional fees and expenses incurred by <B>NUS</B> for such audit
and inspection.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.9pt">9.3</TD><TD STYLE="text-align: justify">The provisions of this <B>Section 9</B> shall remain in fall force and effect after the termination of
this Agreement for any reason until the settlement of all subsisting claims of <B>NUS</B> under this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.9pt"><B>10.</B></TD><TD STYLE="text-align: justify"><B>PROSECUTION OF PATENT APPLICATIONS AND MAINTENANCE OF PATENTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 39pt; text-align: justify; text-indent: -39pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.9pt">10.1</TD><TD STYLE="text-align: justify"><B>Licensee</B> acknowledges that all intellectual property rights in and relating to the <B>Patent Rights</B>
belongs to both <B>NUS and SHS</B> and <B>Licensee</B> shall not do anything which might bring into question <B>NUS&rsquo; and SHS&rsquo;</B>
respective ownership of the intellectual property rights in and relating to the <B>Patent Rights</B> or their validity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.9pt">10.2</TD><TD STYLE="text-align: justify"><B>60P Australia</B> shall, from the <B>Effective Date,</B> be responsible for the management and farther
prosecution of the <B>Patent Rights.</B> All such <B>Patent Rights</B> shall be in the names of <B>NUS</B> and <B>SHS</B> as the proprietors
thereof. <B>60P Australia</B> shall:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.7pt">(a)</TD><TD STYLE="text-align: justify">be responsible for all costs, expenses and fees relating to the preparation, filing, prosecution and maintenance
of such <B>Patent Rights (&ldquo;Patent Costs&rdquo;)</B> from the <B>Effective Date.,</B> and reimburse <B>NUS</B> for any and all costs,
expenses and fees relating to the preparation, filing, prosecution and maintenance of the <B>Patent Rights</B> incurred by <B>Licensor</B>
from the first filing date to date immediately before the <B>Effective Date</B> of this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.75pt">(b)</TD><TD STYLE="text-align: justify">seek and maintain the strongest and broadest patent claims practicable in the best interest of <B>NUS
and SHS</B> and use patent attorneys acceptable to <B>Licensor,</B> such acceptance not to be unreasonably withheld;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.75pt">(c)</TD><TD STYLE="text-align: justify">copy <B>Licensor</B> on all patent prosecution documents and give <B>Licensor</B> reasonable opportunities
to advise <B>60P Australia</B> on such preparation, filing, prosecution and maintenance;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17.5pt">(d)</TD><TD STYLE="text-align: justify">keep <B>Licensor</B> informed of the status of such <B>Patent Rights</B> from time to time, and shall
promptly furnish <B>Licensor</B> with copies of all grants or certificates of registration of any <B>Patent;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 12 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.3pt">(e)</TD><TD STYLE="text-align: justify">not abandon or allow to lapse any such <B>Patent Rights, </B>or to amend or re-file the patent specifications
of any <B>Patent Applications </B>within the scope of the license granted under this Agreement, without the prior written consent of <B>Licensor;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">do all such other acts and things as may be necessary, as <B>Licensor </B>may reasonably request, at <B>Licensee&rsquo;s
</B>cost and expense, to assist or enable <B>Licensor </B>maintain the <B>Patent Rights.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">10.3</TD><TD STYLE="text-align: justify"><B>Licensor </B>shall, at any time and from time to time, at <B>60P Australia&rsquo;s </B>cost and expense,
execute and do all such assurances, acts and things, and execute all such documents as <B>60P Australia </B>may reasonably require to
prosecute each of the <B>Patent Applications </B>to grant and to maintain each of the <B>Patents </B>in force.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">10.4</TD><TD STYLE="text-align: justify">It is hereby agreed and understood that, notwithstanding <B>Section 10.2, 60P Australia </B>shall, by
giving three (3) months&rsquo; written notice to <B>Licensor </B>prior to the relevant deadline for the payment of any fees, have the
right and option not to pay for the prosecution of any <B>Patent Application </B>or patent maintenance in any country determined by <B>60P
Australia. </B>If <B>60P Australia </B>elects not to pay for the prosecution of any such <B>Patent Application </B>in a particular country
or countries as aforesaid:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.05pt">(a)</TD><TD STYLE="text-align: justify">the license granted pursuant to this Agreement in respect of the country or countries of which <B>60P
Australia </B>has made the election, shall automatically terminate and revert to <B>NUS.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17pt">(b)</TD><TD STYLE="text-align: justify">upon receipt of such notice pursuant to <B>Section 10.4, Licensor </B>may prosecute the <B>Patent Applications
</B>in such country or countries in respect of which <B>60P Australia </B>has made the election, at its own cost and expense, and notwithstanding
<B>Section 3, </B>to thereafter deal with the same and the related <B>Technology Rights </B>in that country or countries as <B>Licensor
</B>deems fit without having to account to <B>Licensee </B>therefore.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">For the avoidance of doubt, any <B>Patent </B>obtained pursuant to <B>Section 10.4(b) </B>shall be or
remain the absolute property of <B>Licensor.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">10.5</TD><TD STYLE="text-align: justify">If <B>60P Australia </B>fails to notify <B>NUS </B>of its intention to cease prosecuting any <B>Patent
Applications </B>or maintaining any <B>Patents </B>in any country pursuant to <B>Section 10.4 </B>and the <B>Patent Application </B>or
the <B>Patent </B>lapses then :</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -33pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 34.05pt">(a)</TD><TD STYLE="text-align: justify">the license granted pursuant to this Agreement in respect of such country shall automatically terminate;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 34.05pt">(b)</TD><TD STYLE="text-align: justify"><B>60P Australia </B>shall pay to <B>Licensors </B>a sum of <B>S<FONT STYLE="background-color: black">_______</FONT></B>
which <B>Licensor </B>and <B>Licensee </B>agree is a genuine pre-estimate of the loss suffered by <B>Licensor </B>arising from lapse of
such <B>Patent </B>or <B>Patent Application </B>in such country. For clarity, <B>60P Australia </B>is neither obliged nor required to
pay <B>Licensor </B>any farther sum in respect ofthe loss suffered by <B>Licensor </B>herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt"><B>11.</B></TD><TD STYLE="text-align: justify"><B>FORMAL LICENSE FOR REGISTRATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.1</TD><TD STYLE="text-align: justify">As and when required by <B>Licensee, </B>subject to the requirements of the relevant government authority
of the <B>Territory, NUS </B>and <B>SHS </B>shall execute, within thirty (30) days of the grant of a patent pursuant to any of the <B>Patent
Applications, </B>a separate formal licence document th <B>Licensee&rsquo;s </B>favour in respect of such patent for registration in all
or any competent registries within such countries as may be determined by <B>Licensee, </B>each such license to be in the form set out
in <B><I>Schedule 3</I></B> or as nearly in such form as may be required under the laws of such country in which it is to be registered.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 74%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 26%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 13 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">11.2</TD><TD STYLE="text-align: justify">Each of such formal licenses shall operate subject to and with the benefit of all the terms of this Agreement,
the terms of which shall be deemed to be incorporated in their entirety into each of such formal licenses. In the event of any conflict
in meaning between any such formal license and the provisions of this Agreement, the provisions of this Agreement shall prevail.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">11.3</TD><TD STYLE="text-align: justify">The <B>Parties</B> shall use reasonable endeavours to ensure that, to the extent permitted by relevant
authorities, this Agreement shall not form pant of any public record.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">11.4</TD><TD STYLE="text-align: justify">Each of the <B>Parties</B> shall, at the request of the other <B>Party,</B> execute any further document
that may be necessary to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(a)</TD><TD STYLE="text-align: justify">give effect to this Agreement; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(b)</TD><TD STYLE="text-align: justify">protect in any country the rights of the other <B>Party</B> under this Agreement and/or in relation to
the <B>Patent Rights</B> from time to time; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40pt"></TD><TD STYLE="width: 20pt">(c)</TD><TD STYLE="text-align: justify">procure the grant of <B>Patents</B> pursuant to each of the <B>Patent Applications.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt"><B>12.</B></TD><TD STYLE="text-align: justify"><B>INFRINGEMENT OF PATENTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">12.1</TD><TD STYLE="text-align: justify">From the <B>Effective Date, Licensee</B> shall forthwith notify <B>Licensor</B> in writing of any infringement,
or suspected or threatened infringement, of any of the <B>Patents</B> by any third party that shall at any time come to its knowledge.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">12.2</TD><TD STYLE="text-align: justify"><B>Licensee</B> may in its sole discretion, take all appropriate steps (including all legal proceedings)
as may be necessary to prevent or restrain any infringement by a third party of any of the <B>Patents</B> and shall be responsible for
all costs and fees incurred by it in the taking of any such steps.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">12.3</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall not be obliged to undertake any legal action. <B>60P</B> shall indemnify <B>Licensor
</B>against all costs, expenses, losses, damages, claims and counter-claims issued or made against <B>Licensor</B> as a result of, or
in the course of, such action taken by <B>Licensee</B> under <B>Section 12.2</B> on a full indemnity basis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">12.4</TD><TD STYLE="text-align: justify"><B>NUS</B> and <B>SHS</B> shall (at <B>60P&rsquo;s</B> cost and expense) provide or procure the provision
of such assistance in taking such steps (including any proceedings) as <B>Licensee</B> shall reasonably require.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 40pt">12.5</TD><TD STYLE="text-align: justify">If <B>Licensee</B> decides not to or fails to take appropriate steps to prevent or restrain any infringement
by any third party of any of the <B>Patent Rights</B> (but not otherwise), <B>Licensor </B>shall be entitled to take action to prevent
or restrain such infringement. In the event that <B>Licensor</B> decides to take action under this Section:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 51pt; text-align: justify; text-indent: -11pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><B>Licensor</B> shall have full control over, and shall conduct at its own cost, any such action as it
deems fit;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall, at <B>Licensor&rsquo;s</B> cost, provide or procure the provision of such assistance
as <B>Licensor</B> shall reasonably require in taking such action; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 73%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14</FONT></TD>
    <TD STYLE="width: 27%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 14 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -13pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify"><B>Licensor</B> shall be entitled to
                                            retain any award of damages or other compensation obtained as a result of any such action
                                            (including any proceedings) being taken by <B>Licensor.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt"><B>13.</B></TD><TD STYLE="text-align: justify"><B>INFRINGEMENT OF THIRD PARTY RIGHTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">13.1</TD><TD STYLE="text-align: justify">If any proceedings are brought against <B>Licensee</B> on grounds that the use or exploitation by <B>Licensee</B>
of any of the <B>Patent Rights</B> and <B>Technology Rights</B> infringes the rights of any third party, <B>Licensee</B> shall forthwith
notify <B>Licensor</B> of the same. <B>Licensee</B> shall have the exclusive control of the defense of such proceedings.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">13.2</TD><TD STYLE="text-align: justify"><B>60P</B> shall indemnify <B>Licensor</B> and keep <B>Licensor</B> indemnified against, and hold <B>Licensor
</B>harmless from, all costs, expenses, losses, damages, claims and counter-claims issued or made against <B>Licensor</B> in respect of
such proceedings in <B>Section 13.1.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt"><B>14.</B></TD><TD STYLE="text-align: justify"><B>TRADE MARKS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">14.1</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall have the absolute right and discretion to manufacture, have manufactured, or use
<B>Licensed Products</B> under any trade marks designated by <B>Licensee (&ldquo;Licensee&rsquo;s Trade Marks&rdquo;)</B> provided that
the <B>Licensee&rsquo;s Trade Marks</B> shall be readily distinguishable from, and not confusingly similar to, any trade mark or trade
name, whether registered or not, of <B>NUS.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">14.2</TD><TD STYLE="text-align: justify"><B>NUS</B> hereby agrees that it shall have no claim, right, title or interest in or to the <B>Licensee&rsquo;s
Trade Marks</B> (except where any of such <B>Licensee&rsquo;s Trade Marks</B> is not readily distinguishable from, or is confusingly similar
to, any trade mark or trade name of <B>NUS), </B>and that all goodwill accruing thereto shall belong to <B>Licensee</B> absolutely.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">14.3</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall have the sole conduct of all proceedings relating to the <B>Licensee&rsquo;s Trade
Marks.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">14.4</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall have the sole right to decide what action, if any, to take in respect of any infringement
or alleged infringement of the <B>Licensee&rsquo;s Trade Marks</B> or any other claim or counterclaim brought or threatened in respect
of the use or registration of any of the <B>Licensee&rsquo;s Trade Marks.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">14.5</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall not be obliged to bring or defend any proceedings in relation to the <B>Licensee&rsquo;s
Trade Marks.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">14.6</TD><TD STYLE="text-align: justify"><B>NUS</B> shall not be entitled to bring any proceedings in respect of any infringement or alleged infringement
of any of the <B>Licensee&rsquo;s Trade Marks.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt"><B>15.</B></TD><TD STYLE="text-align: justify"><B>CONFIDENTIALITY</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">15.1</TD><TD STYLE="text-align: justify">Each <B>Party</B> hereby agrees to use all reasonable efforts to maintain the secrecy of any and all <B>Confidential
Information</B> disclosed to it by the other <B>Party</B> under the terms of this Agreement, or developed pursuant to this Agreement,
and not to disclose, without the express, written consent of the disclosing <B>Party,</B> such <B>Confidential Information</B> to any
third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 32.45pt">15.2</TD><TD STYLE="text-align: justify">The receiving <B>Party</B> agrees to maintain the <B>Confidential Information</B> of the disclosing <B>Party</B>
in confidence with the same degree of care as it holds its own confidential and proprietary information and in any event with no less
than a reasonable standard of care.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14 </FONT></TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 15 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The receiving <B>Party </B>will use
such <B>Confidential Information </B>for the performance of this Agreement only. The receiving <B>Party </B>may disclose such <B>Confidential
Information </B>on a need-to-know basis only to its directors, officers, employees, contractors, consultants, advisors, authorised representatives,
agents, investors or potential investors (each a <B>&ldquo;Representative&rdquo;, </B>and collectively <B>&ldquo;Representatives&rdquo;)
</B>who have undertaken obligations of confidentiality for the benefit of receiving <B>Party </B>which are substantially similar to those
contained in this <B>Section 15 </B>and will not disclose such <B>Confidential Information </B>to any third party, or use the <B>Confidential
Information </B>for any other purpose. The receiving <B>Party </B>undertakes that its <B>Representatives </B>shall make use of such <B>Confidential
Information </B>only for the performance of this Agreement and receiving <B>Party </B>shall be responsible for any unauthorized use or
disclosure of disclosing <B>Party's Confidential Information </B>by its <B>Representatives.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.5pt">15.3</TD><TD STYLE="text-align: justify">The receiving <B>Party </B>shall take all reasonable steps, including, but not limited to, those steps
taken to protects its own information, data or other tangible or intangible property that it regards as proprietary or confidential, to
ensure that the <B>Confidential Information </B>of the other <B>Party </B>is not disclosed or duplicated for the use of any third <B>Party,
</B>and shall take all reasonable steps to prevent its officers and employees, or any other persons having access to the <B>Confidential
Information, </B>from disclosing or making unauthorized use of any <B>Confidential Information, </B>or from committing any acts or omissions
that may result in a violation of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">15.4</TD><TD STYLE="text-align: justify">The preceding obligations of non-disclosure and the limitation on the right to use the <B>Confidential
Information </B>shall not apply to the extent that the receiving <B>Party </B>can demonstrate that the <B>Confidential Information:</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 15.8pt">(a)</TD><TD STYLE="text-align: justify">was already in the possession or control of the receiving <B>Party </B>prior to the time of disclosure
by disclosing <B>Party, </B>as evidenced by written records; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 15.9pt">(b)</TD><TD STYLE="text-align: justify">was at the time of disclosure by the disclosing <B>Party </B>or thereafter becomes public knowledge through
no fault or omission of the receiving Party; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.05pt">(c)</TD><TD STYLE="text-align: justify">is lawfully obtained by the receiving <B>Party </B>from a third party under no obligation of confidentiality
to the disclosing <B>Party; </B>or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.75pt">(d)</TD><TD STYLE="text-align: justify">is developed by the receiving <B>Party </B>independently of the <B>Confidential Information, </B>as evidenced
by written records; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify">is required to be disclosed by court rule or governmental law or regulation, including for the purposes
of seeking regulatory advice and marketing authorization from national health authorities provided that the receiving <B>Party </B>gives
the disclosing <B>Party </B>prompt notice of any such requirement and cooperated with the disclosing <B>Party </B>in attempting to limit
such disclosure; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">was disclosed by the receiving <B>Party </B>with the disclosing <B>Party's </B>prior written approval.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 38pt; text-align: justify; text-indent: -38pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.5pt">15.5</TD><TD STYLE="text-align: justify">Title to, and all rights emanating from the ownership of, all <B>Confidential Information </B>disclosed
under this Agreement shall remain vested in the disclosing <B>Party. </B>Nothing herein shall be construed as granting any license or
other right to use the <B>Confidential Information </B>of the other <B>Party </B>other than as specifically agreed upon by the <B>Parties.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.5pt">15.6</TD><TD STYLE="text-align: justify">Upon written request of the disclosing <B>Party </B>given after termination of the Agreement, the receiving
<B>Party </B>shall promptly return to the disclosing <B>Party </B>all written materials and documents, as well as other media, made available
or supplied by the disclosing <B>Party </B>to the receiving <B>Party </B>that contains <B>Confidential Information, </B>together with
any copies thereof, except that the receiving <B>Party </B>may retain one copy each of such document or other media for archival purposes,
subject to protection and nondisclosure in accordance with the terms of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14 </FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 16 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3.9pt"></TD><TD STYLE="width: 34.05pt"><B>16.</B></TD><TD STYLE="text-align: justify"><B>DISCLAIMER OF WARRANTIES</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3.9pt"></TD><TD STYLE="width: 34.05pt">16.1</TD><TD STYLE="text-align: justify">Neither <B>Licensor </B>nor any of its trustees, directors, employees, or agents assumes any responsibility
for the manufacture, production, specifications, sale or use of the <B>Patent Rights or Licensed Products </B>by <B>Licensee </B>or any
<B>Sub-licensees.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3.9pt"></TD><TD STYLE="width: 34.05pt">16.2</TD><TD STYLE="text-align: justify">Save for the warranties of <B>Section 4.1, </B>the <B>Licensor </B>makes no representations, and provides
no warranties, express or implied:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt; text-align: justify; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17.75pt">(a)</TD><TD STYLE="text-align: justify">including, but not limited to, warranties of fitness for purpose or merchantability or satisfactory quality
or compliance with any description, or any implied warranty arising from course of performance, course of dealing, usage of trade or otherwise,
regarding or with respect to the <B>Patent Rights or Licensed Products;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17.85pt">(b)</TD><TD STYLE="text-align: justify">on the patentability of the <B>Licensed Products </B>or of the enforceability of any <B>Patents, </B>if
any, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17.85pt">(c)</TD><TD STYLE="text-align: justify">that the <B>Patent Rights or Licensed Products </B>are or shall be free from infringement of any patent
or other rights of third parties,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40pt; text-align: justify; text-indent: 1pt">and to the fullest
extent permitted by law, all such warranties and representations are hereby excluded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3.9pt"></TD><TD STYLE="width: 34.05pt"><B>17.</B></TD><TD STYLE="text-align: justify"><B>INDEMNITIES; INSURANCE; LIMITATION OF LIABILITY</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3.9pt"></TD><TD STYLE="width: 34.05pt">17.1.</TD><TD STYLE="text-align: justify"><B>60P and 60P Australia </B>hereby jointly and severally indemnify, hold harmless and defend <B>NUS and
SHS </B>from and against any and all claims, demands, actions, losses, damages, costs (including legal costs on a full indemnity basis),
expenses and liabilities whatsoever which <B>NUS </B>and/or <B>SHS </B>may incur or suffer in connection with:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt; text-align: justify; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17.75pt">(a)</TD><TD STYLE="text-align: justify">the manufacture, marketing, distribution and sale of the <B>Licensed Products </B>or any product for human
use manufactured by the <B>Licensee </B>containing celgosivir by <B>Licensee </B>directly or through <B>Licensee's Representatives, </B>or
otherwise by or through any <B>Sub-Licensees; </B>or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17.85pt">(b)</TD><TD STYLE="text-align: justify">any other agreements entered into by <B>Licensee or Licensee's Representatives </B>or any <B>Sub-licensees
</B>relating to the <B>Licensed Products, </B>any product for human use manufactured by the <B>Licensee </B>containing celgosivir, and
<B>Invention </B>or the performance or non-performance of the terms of such agreements or any representations or statements made by <B>Licensee
or Licensee's Representatives </B>or any <B>Sub-Licensees </B>relating to the <B>Invention, </B>any product for human use manufactured
by the <B>Licensee </B>containing celgosivir, or <B>Licensed Products; </B>or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17.85pt">(c)</TD><TD STYLE="text-align: justify">any claim that any modification(s) made by or on behalf of <B>Licensee </B>or any <B>SubLicensees </B>infringes
any trademark, trade secret, confidential information, copyright or patent or any other proprietary rights of any third party; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.2pt"></TD><TD STYLE="width: 17.9pt">(d)</TD><TD STYLE="text-align: justify">all taxes of any kind (except Singapore
                                            income tax in respect of consideration received by <B>NUS and SHS </B>under this Agreement),
                                            payments in lieu of taxes, import duties, assessments, fees, charges and withholdings of
                                            any nature whatsoever, and all penalties, fines, additions to tax or interest thereon, however
                                            imposed, whether levied or asserted against <B>NUS and SHS</B> by any tax authority of any
                                            country in connection with this Agreement or any matters arising therefrom including any
                                            payments received by <B>NUS</B> and <B>SHS</B> hereunder; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 17 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT="" STYLE="width: 139px; height: 86px"></B></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70pt; text-align: justify; text-indent: 1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.55pt">(e)</TD><TD STYLE="text-align: justify">all charges, fines or any liability arising from any default or failure by <B>Licensee </B>and/or <B>Licensee's
Representatives</B> or any <B>Sub-Licensees</B> to comply with and observe all laws and regulations referred to in <B>Section 18;</B>
or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify">any action or omission of <B>Licensee,</B> or <B>Licensee&rsquo;s Representatives</B> or any <B>Sub-Licensees,</B>
or any of their employees, agents or contractors in the performance of its obligations or the exercise of any of its rights under this
Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 41pt; text-align: justify; text-indent: -41pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.2</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall obtain and maintain adequate product liability insurance within (15) days from the
date of Regulatory Approval referred in <B>Section 7.2</B> and shall ensure that <B>NUS </B>and <B>SHS</B> are named as additional insured
on the policy subject always to the terms and conditions specified by the insurers. <B>Licensee</B> shall supply <B>Licensor</B> with
a copy of such insurance policy upon written request.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.3</TD><TD STYLE="text-align: justify">Neither <B>NUS</B> nor <B>SHS</B> shall have any liability to the <B>Licensee</B> for any indirect, consequential,
special or incidental loss, damage, expense or liability (including lost profit and loss of goodwill, opportunity costs, loss of business,
damage to reputation, claims by third parties or customers), or any exemplary or punitive damages, regardless of the form of action, whether
in contract or tort (including negligence), arising from or caused by <B>NUS</B> or <B>SHS</B> or its employees and contractors or from
the <B>Licensee&rsquo;s</B> use or exploitation of the <B>Patent Rights.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.4</TD><TD STYLE="text-align: justify"><B>NUS&rsquo;s</B> and <B>SHS&rsquo;s</B> total liability to <B>Licensee</B> for direct damages or losses
for any cause arising from the acts or omissions of <B>NUS</B> and/or <B>SHS</B> including any failure by <B>NUS</B> and <B>SHS</B> or
their affiliated related companies in complying with statutory requirements or in complying and adhering to Guidelines and Procedures
for Good Clinical Practice in the conduct of a the clinical trials shall be limited to the total amount of funds payable by the <B>60P</B>
in the form of <B>Upfront Payments</B> and <B>Royalties.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>18.</B></TD><TD STYLE="text-align: justify"><B>COMPLIANCE WITH LAW</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.1</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall observe, and shall ensure that all <B>Sub-Licensees</B> observe, all applicable
laws and regulations and obtain all necessary licenses, consents and permissions required in respect of the manufacture, storage, marketing,
distribution, sale (including export), and importation of the <B>Licensed Products</B> within the <B>Territory.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>19.</B></TD><TD STYLE="text-align: justify"><B>TERMINATION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.1</TD><TD STYLE="text-align: justify">NUS shall be entitled forthwith to terminate this Agreement immediately by notice in writing if:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><B>Licensee, 60P</B> or <B>60P Australia</B> fails, or refuses, to perform or comply with any one or more
of its obligations under this Agreement, and, if in the opinion of <B>NUS </B>that default is capable of remedy, <B>Licensee, 60P</B>
or <B>60P Australia,</B> as the case may be, fails to remedy such default within 90 days after written notice of such default has been
given to <B>Licensee, 60P</B> or <B>60P Australia,</B> as the case may be, by <B>NUS;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -15pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 18 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 69pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(b)</TD><TD STYLE="text-align: justify"><B>Licensee, 60P or 60P Australia, </B>ceases or, in <B>NUS&rsquo; </B>reasonable opinion, may cease,
to carry on its business;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(c)</TD><TD STYLE="text-align: justify"><B>Licensee, 60P or 60P Australia, </B>becomes insolvent or is unable to pay its debts as they fall due
or suspends or threatens to suspend making payments with respect to all or any class of its debts or enters into any composition or arrangement
with its creditors or makes a general assignment for the benefit of its creditors;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(d)</TD><TD STYLE="text-align: justify"><B>Licensee, 60P or 60P Australia, </B>goes into liquidation or if an order is made or a resolution is
passed for the winding up of <B>Licensee, 60P or 60P Australia, </B>whether voluntarily or compulsorily (except for the purpose of a bona
fide reconstruction or amalgamation); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(e)</TD><TD STYLE="text-align: justify"><B>Licensee, 60P or 60P Australia, </B>has a receiver or receiver and manager or judicial manager appointed
over any part of its assets or undertaking.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44pt; text-align: justify; text-indent: -44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.2</TD><TD STYLE="text-align: justify"><B>Licensee </B>shall be entitled forthwith to terminate this Agreement immediately by notice in writing
if</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 69pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(a)</TD><TD STYLE="text-align: justify"><B>NUS&rsquo; and SHS&rsquo;s </B>breach their respective warranties referred in <B>Section 4 </B>in this
Agreement; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(b)</TD><TD STYLE="text-align: justify"><B>NUS and SHS </B>are in breach of their obligations under this Agreement and shall fail to remedy any
such default within the prescribed period in the notice given by <B>Licensee.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44pt; text-align: justify; text-indent: -44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.3</TD><TD STYLE="text-align: justify"><B>Licensee </B>shall be entitled to terminate this Agreement upon the occurrence of any of the following:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 69pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(a)</TD><TD STYLE="text-align: justify">if the <B>Licensee </B>determines that farther commercialization of celgosivir for the treatment of acute
dengue fever is no longer viable.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(b)</TD><TD STYLE="text-align: justify"><B>Licensee </B>is unable to complete satisfactory due diligence in respect of the clinical data relating
to the <B>Celaden Project;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 44pt; text-align: justify; text-indent: -44pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.4</TD><TD STYLE="text-align: justify">Termination of this Agreement howsoever caused shall not prejudice any other right or remedy of the <B>Parties
</B>in respect of any antecedent breach.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.5</TD><TD STYLE="text-align: justify">Upon the termination of this Agreement:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 69pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(a)</TD><TD STYLE="text-align: justify"><B>Licensee </B>shall be entitled to continue to exercise the rights granted to it under this Agreement
to such extent and for such further period, not exceeding twelve (12) months from the date of termination, reasonably necessary to enable
<B>Licensee </B>to satisfy any orders placed prior to such termination date or scheduled for delivery within such twelve(12)-month period;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">subject to <B>Section 19.5 (a) </B>above, <B>Licensee </B>shall forthwith cease to and shall not manufacture,
market, distribute, sell, import, or use, until the expiration of the last to expire of any <B>Patents </B>under <B>Patent Rights </B>any
product or process or method that incorporates utilizes or is made with the use of the <B>Invention </B>or which, but for the rights granted
under this Agreement would constitute an infringement of any claim within the <B>Patent Rights;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54.9pt"></TD><TD STYLE="width: 17.55pt">(c)</TD><TD STYLE="text-align: justify">Each receiving <B>Party </B>shall forthwith return to each disclosing <B>Party </B>all <B>Confidential
Information </B>pursuant to <B>Section 15.5;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 19 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify"><B>60P</B> shall promptly pay all amounts
                                            due less all deductions due to <B><I>Licensee</I></B> under this Agreement to <B><I>NUS</I></B>
                                            and shall submit a declaration in writing signed by a duly authorized officer that it has
                                            complied with such payment obligations, along with a copy of all materials reasonably necessary
                                            to support such declaration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall provide <B>Licensor</B> with all data and know-how developed by <B>Licensee</B>
in the course of <B>Licensee's</B> efforts to develop <B>Licensed Product(s)</B> and <B>Licensed Process(es); Licensor</B> shall have
the right to use such data and knowhow for academic purpose on such terms and conditions mutually agreed between <B>Licensor</B> and <B>Licensee;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: justify"><B>Licensee</B> shall provide <B>Licensor</B> access to any regulatory infomation filed with any U.S.
or foreign government agency with respect to <B>Licensed Product(s)</B> and <B>Licensed Process(es);</B> and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(g)</TD><TD STYLE="text-align: justify">If <B>Licensee</B> has filed patent applications or obtained patents to any <B>Licensee&rsquo;s Improvements,
Joint Improvements, NUS Improvements</B> and/or <B>SHS Improvements</B> to <B>Licensed Product(s)</B> or <B>Licensed Process(es)</B> within
the scope of the <B>Patent Rights, Licensee</B> agrees upon request to enter into good faith negotiations with <B>Licensor</B> or <B>Licensor's</B>
future licensee(s) for the purpose of granting licensing rights to said modifications or improvements in a timely fashion and under commercially
reasonable terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46pt; text-align: justify; text-indent: -46pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.6.</TD><TD STYLE="text-align: justify">Notwithstanding termination of this Agreement under any of its provision, <B>Sections 3A3 (Provisions
Relating to Essential and Other documents), 9 (Accounts), 15 (Confidentiality), 16 (Disclaimer of Warranties), 17 (Indemnities; Insurance;
Limitation of Liability), 19 (Termination), 20 (Use of Licensor&rsquo;s Name), and 22 to 29</B> and any other Sections of this Agreement
which from their context are intended to survive the termination of this Agreement, shall survive the <B>Term</B> or the termination of
this Agreement and shall be deemed to remain in full force and effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>20.</B></TD><TD STYLE="text-align: justify"><B>USE OF LICENSOR&rsquo;S NAME</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.1</TD><TD STYLE="text-align: justify"><B>Licensee</B> agrees that it shall not use in any way the name of <B>Licensor</B> or any logotypes or
symbols associated with <B>Licensor</B> or the names of any directors or employees of <B>Licensor</B> without the prior written consent
of <B>Licensor.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>21.</B></TD><TD STYLE="text-align: justify"><B>FORCE MAJEURE EVENTS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.1</TD><TD STYLE="text-align: justify">Notwithstanding anything else in this Agreement, no default, delay or failure to perform on the part of
either <B>Party</B> shall be construed a breach of this Agreement if such default delay or failure to perform is shown to be due entirely
to causes beyond the control of the <B>Party</B> charged with a default, delay or failure to perform <B>(&ldquo;Force Majeure Events&rdquo;),
</B>including but not limited to, causes such as strikes, lockouts or other labour disputes to perform, including, without limitation,
riots, civil disturbances, actions or inaction of governmental authorities, epidemics, war, embargoes, severe weather, fire, earthquakes,
acts or God or the public enemy and nuclear disasters (each a <B>&ldquo;Force Majeure Event&rdquo;).</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>22.</B></TD><TD STYLE="text-align: justify"><B>NO PARTNERSHIP OR AGENCY</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">22.1</TD><TD STYLE="text-align: justify">No agency, partnership or joint venture is created hereby. <B>Licensee</B> does not have any authority
of any kind to bind <B>Licensor</B> in any respect whatsoever.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14 </FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 20 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>23.</B></TD><TD STYLE="text-align: justify"><B>ASSIGNMENT AND CHANGE OF CONTROLLING INTEREST</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23.1</TD><TD STYLE="text-align: justify">All rights and obligations hereunder are personal to the <B>Parties </B>and no <B>Party </B>shall assign
any such rights, or novate its rights and obligations to any third party without the prior consent in writing of the other <B>Party </B>on
terms to be agreed by the <B>Parties. </B>Where such consent is given, the <B>Party, </B>which is the assignor, shall procure that such
third party covenants with the other <B>Party </B>to be bound by the terms of this Agreement as if it had been a party hereto in place
of the assignor.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23.2</TD><TD STYLE="text-align: justify">The <B>Licensee </B>shall notify <B>Licensor </B>no later than thirty (30) days prior to any intended
issuance or transfer of shares which would result in a change in the control of <B>Licensee </B>to another party. <B>Licensor </B>shall,
within thirty (30) days of receiving such notice, inform <B>Licensee </B>in writing whether or not <B>Licensor </B>consents to such issuance
or transfer of shares, such consent not to be unreasonably withheld.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>24.</B></TD><TD STYLE="text-align: justify"><B>NO WAIVER</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">24.1</TD><TD STYLE="text-align: justify">The failure or delay by a <B>Party </B>in enforcing an obligation, or exercising a right or remedy under
this Agreement shall not be construed or deemed to be a waiver of that obligation, right or remedy. A waiver of a breach of a term under
this Agreement shall not amount to a waiver of a breach of any other term in this Agreement and a waiver of a particular obligation in
one circumstance will not prevent a <B>Party </B>from subsequently requiring compliance with the obligation on other occasions. Any waiver
by a <B>Party </B>of any right under this Agreement shall be made in writing and signed by the authorized representative of such <B>Party.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>25.</B></TD><TD STYLE="text-align: justify"><B>NOTICES</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">25.1</TD><TD STYLE="text-align: justify">All notices, demands or other communications required or permitted
to be given or made hereunder shall be in writing and delivered personally, or sent by prepaid registered post, email, or by telefax,
addressed to the intended recipient thereof at its address or telefax number as set out below (or to such other address or telefax number
as any <B>Party </B>may from time to time notify the other <B>Party). </B>Any such notice, demand or communication shall be deemed to
have been duly served on and received by the addressee:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.8pt">(a)</TD><TD>if delivered by hand, at the time of delivery;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>if sent by prepaid registered post, within ten days of dispatch; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>if transmitted by way of telefax or email, at the time of transmission.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">25.2</TD><TD STYLE="text-align: justify">In proving the giving of a notice or other communication, it shall be sufficient to show:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 71pt; text-align: justify; text-indent: -17pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 53.95pt"></TD><TD STYLE="width: 17.1pt">(a)</TD><TD>in the case of registered post, that the notice or other communication was contained in an envelope which was duly addressed, sufficient
postage paid and posted; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 17.3pt">(b)</TD><TD>in the case of telefax that the telefax transmission was duly transmitted from the dispatching terminal as evidenced by a transmission
report generated by the transmitting equipment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUS:</B></FONT></TD>
    <TD STYLE="width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensee:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Industry Liaison Office</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60&deg; Pharmaceuticals LLC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14 </FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 21 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 0.5in">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National University of Singapore</FONT></TD>
    <TD STYLE="width: 65%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1025 Connecticut Ave NW Suite 1000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington DC, 20036</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iCube Building</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21 Heng Mui Keng Terrace</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore 119613</FONT></P>
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: (65) 6777 6990</FONT></P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax: 1.202.688.2832</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.95pt"><B>26.</B></TD><TD STYLE="text-align: justify"><B>ENTIRE AGREEMENT</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.95pt">26.1</TD><TD STYLE="text-align: justify">This Agreement contains the entire agreement between the <B>Parties</B> hereto regarding the subject matter
hereof, and supersedes all prior agreements, understandings and negotiations regarding the same. No modification, variation or amendment
shall be made to this Agreement unless made in writing, specifically referring to this Agreement and signed by the authorized representatives
of both <B>Parties.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.95pt"><B>27.</B></TD><TD><B>SEVERABILITY</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.95pt">27.1</TD><TD STYLE="text-align: justify">Should any one or more of the provisions of this Agreement be held to be invalid or unenforceable by a
court of competent jurisdiction, it shall be considered severed from this Agreement and shall not serve to invalidate the remaining provisions
hereof. The <B>Parties </B>shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable
one such that the objectives contemplated by them when entering into this Agreement may be realized.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.95pt"><B>28.</B></TD><TD><B>DISPUTE RESOLUTION</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.95pt">28.1</TD><TD STYLE="text-align: justify"><U>Informal Resolution</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Any dispute, controversy or claim arising
out of or in connection with this Agreement shall be resolved in the following manner:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 68pt; text-align: justify; text-indent: -16pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.35pt">(a)</TD><TD STYLE="text-align: justify">the aggrieved <B>Party (&ldquo;Claimant&rdquo;)</B> shall notify the responding <B>Party (&ldquo;Respondent&rdquo;)</B>
in writing <B>(&ldquo;Resolution Notice&rdquo;),</B> setting forth in detail the nature of its dispute, controversy or claim <B>(&ldquo;Claim&rdquo;)</B>
and requesting a meeting <B>(&ldquo;Resolution Meeting&rdquo;)</B> of a senior representative from each <B>Party</B> to be held on a date
not less than fifteen (15) nor more than thirty (30) days thereafter <B>(&ldquo;Resolution Period&rdquo;)</B> for the purpose of resolving
such <B>Claim;</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.5pt">(b)</TD><TD STYLE="text-align: justify">the <B>Respondent</B> shall issue and deliver a written response to <B>Claimant</B> not later than five
(5) days before the <B>Resolution Meeting,</B> setting forth in detail its response to such <B>Claim,</B> failing which the <B>Resolution
Meeting</B> shall not proceed and the <B>Claimant</B> shall be entitled to submit the dispute to arbitration/mediation as provided under
<B>Section 28.2</B> below;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.5pt">(c)</TD><TD STYLE="text-align: justify">the senior representative from each <B>Party</B> shall meet to resolve such <B>Claim </B>amicably between
the <B>Claimant</B> and the <B>Respondent</B> in good faith; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 16.5pt">(d)</TD><TD STYLE="text-align: justify">if such <B>Claim</B> is not resolved by the end of fifteen (15) days after the <B>Resolution Period,</B>
then either <B>Claimant or Respondent</B> shall be entitled to submit the dispute to arbitration, as provided under <B>Section 28.2</B>
below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 22 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">28.2</TD><TD STYLE="text-align: justify"><U>Mediation</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If such efforts taken under <B>Section
28.1</B> above fail, then the <B>Parties</B> shall refer the matter to mediation in accordance with the rules and procedures of the Singapore
Mediation Centre. The language of the mediation shall be English.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">If mediation fails, then the dispute
shall be referred to and resolved by arbitration in Singapore at the Singapore Arbitration Centre <B>(&ldquo;SIAC&rdquo;) </B>in accordance
with the Arbitration Rules of the SIAC for the time being in force, which rules are deemed to be incorporated by reference to <B>section
28.2</B> herein. A tribunal consisting of a single arbitrator to be appointed by the Chairman of the <B>SIAC </B>shall be convened. The
language of the arbitration is in English. Any arbitral award made hereunder shall be final and binding upon the <B>Parties</B> hereto
and judgment on such award may be entered into any court or tribunal having jurisdiction thereof. The <B>Parties</B> hereto undertake
to keep the mediation and arbitration proceedings and all information, pleadings, documents, evidence and all matters relating thereto
confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>29.</B></TD><TD STYLE="text-align: justify"><B>GOVERNING LAW</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">29.1</TD><TD STYLE="text-align: justify">This Agreement shall be governed by, interpreted and construed in accordance with the laws of the Republic
of Singapore and the <B>Parties</B> hereby submit to the exclusive jurisdiction of the courts of the Republic of Singapore.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>30.</B></TD><TD STYLE="text-align: justify"><B>GENERAL</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">30.1</TD><TD STYLE="text-align: justify">Stamp duty or fees, if any, payable in respect of this Agreement shall be borne wholly by <B>60P.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">30.2</TD><TD STYLE="text-align: justify">Each <B>Party</B> shall from time to time do all acts and execute all such documents as may be reasonable
necessary in order to give effect to the provisions of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">30.3</TD><TD STYLE="text-align: justify">Except as otherwise provided in this Agreement, the <B>Parties</B> shall bear their own costs of and incidental
to the preparation execution and implementation of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">30.4</TD><TD STYLE="text-align: justify">This Agreement may be executed in one or more counterparts by the <B>Parties</B> by signature of a person
having authority to bind the <B>Party,</B> each of which when executed and delivered, by facsimile transmission or other electronic modes
of delivery, will be an original and all of which will constitute but one and the same Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 23 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AS WITNESS the hands of the <B>Parties </B>hereto the day and year
first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED by for and on behalf of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NATIONAL UNIVERSITY OF </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SINGAPORE</B></P></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNED by for and on behalf of</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>60<SUP>o</SUP> PHARMACEUTICAL LLC</B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: black">_________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lily CHAN</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey DOW, CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO, NUS Enterprise</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the presence of:</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the presence of:</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: black">_________________</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian WONG, Manager</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyrone MILLER, CFO</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED by for and on behalf of </FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNED by for and on behalf of </FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SINGAPORE HEALTH SERVICES</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60P AUSTRALIA PTY LTD</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PTE LTD</B></FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: black">_________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prof Ivy NG</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Geoffrey DOW, CEO</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Group CEO</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the presence of:</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the presence of:</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: black">_________________</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tyrone MILLER, CFO</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation:</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 24 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Part A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INTELLECTUAL PROPERTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NUS Ref: 11325N: Dosing Regimen for Use of
Celgosivir as an Antiviral Therapeutic For Dengue Virus Infection </B>The present invention pertains to methods of treating a dengue virus
(DENY) infection in a human subject, comprising administering to the human subject an initial dose of about 100 to 600 mg of a compound
of Celgosivir or a pharmaceutical composition comprising a compound of Celgosivir, within from about 48 to about 72 hours of fever onset
due to dengue infection and administering to the human subject a dose of about 25 to about 300 mg per day of Celgosivir or a pharmaceutical
composition comprising Celgosivir at intervals of from about 6 to about 12 hours until there is an improvement in the infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 2</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Part A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Patents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NOT IN USE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Part B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patent Applications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dosing Regimen/or Use of Celgosivir as an Antiviral Therapeutic
For Dengue Virus Infection</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 16.95pt">1.</TD><TD>Patent Cooperation Treaty Serial No. IB2013/001634 Filed on 26, July 2013</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Australia Serial No. 201 3203400, filed on 10, April 2013</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD>PCT/US2014/028076 filed on March 14, 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 77%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUSRef: LL2013-14 </FONT></TD>
    <TD STYLE="width: 23%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 25 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FORMAL LICENSE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>PATENT LICENSE FOR REGISTRATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS AGREEMENT </B>is made on the [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
day of [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] 20</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt">(1)</TD><TD STYLE="text-align: justify"><B>NATIONAL UNIVERSITY OF SINGAPORE, </B>(Company Registration Number: 200604346E), a company limited
by guarantee incorporated in Singapore and having its registered office at 21 Lower Kent Ridge Road, Singapore 119260 <B>(&ldquo;NUS&rdquo;
</B>which expression shall include its successors and assigns);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify"><B>SINGAPORE HEALTH SERVICES PTE LTD </B>(Company Registration Number: 200002698Z), a company incorporated
in Singapore, having its registered address at 31 Third Hospital Avenue #03-03, Singapore 168753 <B>(&ldquo;SHS&rdquo; </B>which expression
shall include its successors and assigns;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD STYLE="text-align: justify"><B>60</B>&deg; <B>PHARMACEUTICALS LLC </B>a company incorporated in Washington DC and having its registered
office at 1025 Connecticut Ave NW Suite 1000, Washington DC 20036 United States <B>(&ldquo;60P&rdquo; </B>which expression shall include
its successors and assigns).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt">(4)</TD><TD STYLE="text-align: justify"><B>60P AUSTRALIA PTY LTD </B>(Company Registration No. 167060219) a company incorporated in Australia
and having its registered office at 105 North Steyne Manly New South Wales 2095, <B>(&quot;60P Australia&rdquo; </B>which expression shall
include its successors and assigns)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(60P </B>and <B>60P Australia </B>hereinafter
collectively referred to as <B>&quot;Licensee&rdquo;).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt">(A)</TD><TD STYLE="text-align: justify"><B>NUS </B>and <B>SHS </B>are the registered joint proprietors in <I>[country] of</I> patent number [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
<B>(&ldquo;Patent&rdquo;) </B>for an invention entitled [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] <B>(&ldquo;Invention&rdquo;).</B></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt">(B)</TD><TD STYLE="text-align: justify">By an agreement dated [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] <B>(&ldquo;Principal
Agreement&rdquo;) </B>it was agreed between the <B>Parties </B>that <B>NUS </B>and <B>SHS </B>would grant to the <B>Licensee </B>an exclusive
sub-licensable transferable license under the <B>Patent </B>on the terms and for the consideration set out in the <B>Principal Agreement.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW IT IS HEREBY AGREED </B>as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34pt; text-align: justify; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 33.4pt">1.</TD><TD STYLE="text-align: justify">Pursuant to and for the consideration specified in the <B>Principal Agreement, NUS </B>and <B>SHS </B>grant
[and shall from the date of the publication of the application for the <B>Patent </B>be deemed to have granted] to the <B>Licensee </B>an
exclusive, sublicensable transferable license under the Patent to manufacture, use, sell, and import <I>[describe the Products using the
same wording as in the Principal Agreement]</I> made in accordance with the provisions of the <B>Principal Agreement </B>and to do all
other things within the scope of the <B>Patent </B>on the terms and conditions of the <B>Principal Agreement.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 231pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14</FONT></TD>
    <TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 26 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 231pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -34pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 35pt">2.</TD><TD STYLE="text-align: justify">The <B>License </B>granted by Section 1 <B>(&ldquo;License&rdquo;) </B>shall automatically terminate and cease to have effect if terminated
at any time under the provisions of the <B>Principal Agreement, </B>or on the expiration or termination of the <B>Principal Agreement
</B>for any cause or reason whatsoever.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 35pt">3.</TD><TD STYLE="text-align: justify">The <B>License </B>is granted pursuant to the terms of the <B>Principal Agreement </B>and not in substitution for any license or licenses
granted under the <B>Principal Agreement. </B>Nothing contained in this Agreement shall in any way derogate from the <B>Principal Agreement,
</B>which shall remain in foil force and effect in accordance with its terms.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 2pt">IN <B>WITNESS WHEREOF </B>the patties hereto
have caused this Agreement to be executed on the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Licensor</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NATIONAL UNIVERSITY</B></FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF SINGAPORE</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SINGAPORE HEALTH SERVICES</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PTE LTD</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Licensee</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60</B>&deg; <B>PHARMACEUTICALS LLC</B></FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>60P AUSTRALIA PTY LTD</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref: LL2013-14 </FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GHMatters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 27 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ESSENTIAL DOCUMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;<IMG SRC="cm270_ex10-34img02.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GI (Matters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 28 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;<IMG SRC="cm270_ex10-34img03.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GI (Matters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 29 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>LIST OF COUNTRIES CONSIDERED &quot;HIGH INCOME&quot; BY WORLD BANK
IN 2012</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="cm270_ex10-34img04.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GI (Matters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 30 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CONFIDENTIAL</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="cm270_ex10-34img05.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NUS Ref LL2013-14</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105313372_1 (GI (Matters) L73900</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page 31 of 31</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;<IMG SRC="cm270_ex10-34img01.jpg" ALT=""></B></P>


<!-- Field: Page; Sequence: 31; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="text-align: center; width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>38
<FILENAME>cm270_ex10-35.htm
<DESCRIPTION>EXHIBIT 10.35
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><B>Exhibit 10.35</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">60 DEGREES PHARMACEUTICALS, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2022 EQUITY INCENTIVE PLAN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Purposes
of the Plan</B>. The purposes of this Plan are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to attract and retain the best available personnel for positions of substantial responsibility,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to provide additional incentive to Employees, Directors and Consultants, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">to promote the success of the Company&rsquo;s business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Plan permits the grant of
Incentive Stock Options, Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units and Performance
Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Definitions</B>.
As used herein, the following definitions will apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Administrator</B>&rdquo;
means the Board or any of its Committees as will be administering the Plan, in accordance with Section&nbsp;4 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Applicable
Laws</B>&rdquo; means the legal and regulatory requirements relating to the administration of equity-based awards, including but not limited
to the related issuance of shares of Common Stock, including but not limited to, under U.S. federal and state corporate laws, U.S. federal
and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable
laws of any non-U.S. country or jurisdiction where Awards are, or will be, granted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Award</B>&rdquo;
means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock
Units, or Performance Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Award
Agreement</B>&rdquo; means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted
under the Plan. The Award Agreement is subject to the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Board</B>&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Change
in Control</B>&rdquo; means the occurrence of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Change
in Ownership of the Company</B>. A change in the ownership of the Company which occurs on the date that any one person, or more than one
person acting as a group (&ldquo;<B>Person</B>&rdquo;), acquires ownership of the stock of the Company that, together with the stock held
by such Person, constitutes more than fifty percent (50%)&nbsp;of the total voting power of the stock of the Company; provided, however,
that for purposes of this subsection&nbsp;(a), the acquisition of additional stock by any one Person, who is considered to own more than
fifty percent (50%)&nbsp;of the total voting power of the stock of the Company will not be considered a Change in Control; provided, further,
that any change in the ownership of the stock of the Company as a result of a private financing of the Company that is approved by the
Board also will not be considered a Change in Control. Further, if the stockholders of the Company immediately before such change in ownership
continue to retain immediately after the change in ownership, in substantially the same proportions as their ownership of shares of the
Company&rsquo;s voting stock immediately prior to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%)
or more of the total voting power of the stock of the Company or of the ultimate parent entity of the Company, such event will not be
considered a Change in Control under this subsection (a). For this purpose, indirect beneficial ownership will include, without limitation,
an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company,
as the case may be, either directly or through one or more subsidiary corporations or other business entities; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Change
in Effective Control of the Company</B>. If the Company has a class of securities registered pursuant to Section 12 of the Exchange Act,
a change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any
twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to
the date of the appointment or election. For purposes of this subsection (b), if any Person is considered to be in effective control of
the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Change
in Ownership of a Substantial Portion of the Company&rsquo;s Assets</B>. A change in the ownership of a substantial portion of the Company&rsquo;s
assets which occurs on the date that any Person acquires (or has acquired during the twelve (12)&nbsp;month period ending on the date
of the most recent acquisition by such Person or Persons)&nbsp;assets from the Company that have a total gross fair market value equal
to or more than fifty percent (50%)&nbsp;of the total gross fair market value of all of the assets of the Company immediately prior to
such acquisition or acquisitions; provided, however, that for purposes of this subsection (c), the following will not constitute a change
in the ownership of a substantial portion of the Company&rsquo;s assets: (i)&nbsp;a transfer to an entity that is controlled by the Company&rsquo;s
stockholders immediately after the transfer, or (ii)&nbsp;a transfer of assets by the Company to: (A)&nbsp;a stockholder of the Company
(immediately before the asset transfer)&nbsp;in exchange for or with respect to the Company&rsquo;s stock, (B)&nbsp;an entity, fifty percent
(50%)&nbsp;or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (C)&nbsp;a Person, that
owns, directly or indirectly, fifty percent (50%)&nbsp;or more of the total value or voting power of all the outstanding stock of the
Company, or (D)&nbsp;an entity, at least fifty percent (50%)&nbsp;of the total value or voting power of which is owned, directly or indirectly,
by a Person described in this subsection (c)(ii)(C). For purposes of this subsection (c), gross fair market value means the value of the
assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">For purposes of this Section
2.6, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation,
purchase or acquisition of stock, or similar business transaction with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Notwithstanding the foregoing,
a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning
of Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;&nbsp;Further and for the avoidance
of doubt, a transaction will not constitute a Change in Control if: (x) its primary purpose is to change the jurisdiction of the Company&rsquo;s
incorporation, or (y) its primary purpose is to create a holding company that will be owned in substantially the same proportions by the
persons who held the Company&rsquo;s securities immediately before such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Code</B>&rdquo;
means the U.S. Internal Revenue Code of 1986, as amended. Reference to a specific section of the Code or regulation thereunder will include
such section or regulation, any valid regulation or other formal guidance of general or direct applicability promulgated under such section,
and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Committee</B>&rdquo;
means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board, or by a duly authorized committee
of the Board, in accordance with Section&nbsp;4 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Common
Stock</B>&rdquo; means the common stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Company</B>&rdquo;
means 60 Degrees Pharmaceuticals, Inc., a Delaware corporation, or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Consultant</B>&rdquo;
means any natural person, including an advisor, engaged by the Company or any of its Parent or Subsidiaries to render bona fide services
to such entity, provided the services (a)&nbsp;are not in connection with the offer or sale of securities in a capital-raising transaction,
and (b)&nbsp;do not directly promote or maintain a market for the Company&rsquo;s securities, in each case, within the meaning of Form
S-8 promulgated under the Securities Act, and provided further, that a Consultant will include only those persons to whom the issuance
of Shares may be registered under Form S-8 promulgated under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Director</B>&rdquo;
means a member of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Disability</B>&rdquo;
means total and permanent disability as defined in Code Section&nbsp;22(e)(3), provided that in the case of Awards other than Incentive
Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform
and non-discriminatory standards adopted by the Administrator from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Employee</B>&rdquo;
means any person, including Officers and Directors, employed by the Company or any Parent or Subsidiary of the Company. Neither service
as a Director nor payment of a director&rsquo;s fee by the Company will be sufficient to constitute &ldquo;employment&rdquo; by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Exchange
Act</B>&rdquo; means the U.S. Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Exchange
Program</B>&rdquo; means a program under which (a) outstanding Awards are surrendered or cancelled in exchange for awards of the same
type (which may have higher or lower exercise prices and different terms), awards of a different type, and/or cash, (b) Participants would
have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Administrator,
and/or (c) the exercise price of an outstanding Award is reduced or increased. The Administrator will determine the terms and conditions
of any Exchange Program in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Fair
Market Value</B>&rdquo; means, as of any date and unless the Administrator determines otherwise, the value of Common Stock determined
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Common Stock is listed on any established stock exchange or a national market system, including without limitation the New York Stock
Exchange or the Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market of The Nasdaq Stock Market, its Fair
Market Value will be the closing sales price for such stock (or, if no closing sales price was reported on that date, as applicable, on
the last Trading Day such closing sales price was reported) as quoted on such exchange or system on the date of determination, as reported
in <I>The Wall Street Journal</I> or such other source as the Administrator deems reliable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a
Share will be the mean between the high bid and low asked prices for the Common Stock on the day of determination (or, if no bids and
asks were reported on that date, as applicable, on the last Trading Day such bids and asks were reported), as reported in <I>The Wall
Street Journal</I> or such other source as the Administrator deems reliable; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of any Awards granted on the Registration Date, the Fair Market Value will be the initial price to the public as set forth in
the final prospectus included within the registration statement on Form S-1 filed with the Securities and Exchange Commission for the
initial public offering of the Common Stock; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In addition, for purposes of
determining the fair market value of shares for any reason other than the determination of the exercise price of Options or Stock Appreciation
Rights, fair market value will be determined by the Administrator in a manner compliant with Applicable Laws and applied consistently
for such purpose. The determination of fair market value for purposes of tax withholding may be made in the Administrator&rsquo;s sole
discretion subject to Applicable Laws and is not required to be consistent with the determination of fair market value for other purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Fiscal
Year</B>&rdquo; means the fiscal year of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Incentive
Stock Option</B>&rdquo; means an Option that by its terms qualifies and is otherwise intended to qualify as an incentive stock option
within the meaning of Code Section&nbsp;422 and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Nonstatutory
Stock Option</B>&rdquo; means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Officer</B>&rdquo;
means a person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act and the rules and regulations
promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Option</B>&rdquo;
means a stock option granted pursuant to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Outside
Director</B>&rdquo; means a Director who is not an Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Parent</B>&rdquo;
means a &ldquo;parent corporation,&rdquo; whether now or hereafter existing, as defined in Code Section&nbsp;424(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Participant</B>&rdquo;
means the holder of an outstanding Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="background-color: white"><U>&ldquo;<B>Performance
Awards</B></U></FONT>&rdquo; means an Award which may be earned in whole or in part upon attainment of performance goals or other vesting
criteria as the Administrator may determine and which may be <FONT STYLE="background-color: white">cash- or stock-denominated and may
be </FONT>settled for cash, Shares or other securities or a combination of the foregoing <FONT STYLE="background-color: white">under</FONT>
Section <FONT STYLE="background-color: white">10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Performance
Period</B>&rdquo; means Performance Period as defined in Section 10.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Period
of Restriction</B>&rdquo; means the period (if any) during which the transfer of Shares of Restricted Stock are subject to restrictions
and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the
achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Plan</B>&rdquo;
means this 60 Degrees Pharmaceuticals, Inc. 2022 Equity Incentive Plan, as may be amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Registration
Date</B>&rdquo; means the effective date of the first registration statement that is filed by the Company and declared effective pursuant
to Section 12(b)&nbsp;of the Exchange Act, with respect to any class of the Company&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Restricted
Stock</B>&rdquo; means Shares issued pursuant to an Award of Restricted Stock under Section&nbsp;8 of the Plan, or issued pursuant to
the early exercise of an Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Restricted
Stock Unit</B>&rdquo; means a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to
Section&nbsp;9. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Rule&nbsp;16b-3</B>&rdquo;
means Rule&nbsp;16b-3 of the Exchange Act or any successor to Rule&nbsp;16b-3, as in effect when discretion is being exercised with respect
to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Section&nbsp;16b</B>&rdquo;
means Section&nbsp;16(b) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Section
409A</B>&rdquo; means Code Section&nbsp;409A and the U.S. Treasury Regulations and guidance thereunder, and any applicable state law equivalent,
as each may be promulgated, amended or modified from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Securities
Act</B>&rdquo; means the U.S. Securities Act of 1933, as amended, including the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Service
Provider</B>&rdquo; means an Employee, Director or Consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Share</B>&rdquo;
means a share of the Common Stock, as adjusted in accordance with Section 15 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Stock
Appreciation Right</B>&rdquo; means an Award, granted alone or in connection with an Option, that pursuant to Section&nbsp;7 is designated
as a Stock Appreciation Right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Subsidiary</B>&rdquo;
means a &ldquo;subsidiary corporation,&rdquo; whether now or hereafter existing, as defined in Code Section&nbsp;424(f).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Trading
Day</B>&rdquo; means a day that the primary stock exchange, national market system, or other trading platform, as applicable, upon which
the Common Stock is listed (or otherwise trades regularly, as determined by the Administrator, in its sole discretion) is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">2.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>U.S.
Treasury Regulations</B>&rdquo; means the Treasury Regulations of the Code. Reference to a specific Treasury Regulation or Section of
the Code will include such Treasury Regulation or Section, any valid regulation promulgated under such Section, and any comparable provision
of any future legislation or regulation amending, supplementing or superseding such Section or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock&nbsp;Subject&nbsp;to&nbsp;the&nbsp;Plan</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock
Subject to the Plan</B>. Subject to adjustment upon changes in capitalization of the Company as provided in Section 15 of the Plan and
the automatic increase set forth in Section&nbsp;3.2 of the Plan, the maximum aggregate number of Shares that may be subject to Awards
and sold under the Plan will be equal to 238,601<FONT STYLE="font-size: 10pt">&nbsp;</FONT>Shares, In addition, Shares may become available
for issuance under Sections&nbsp;3.2 and&nbsp;3.2 of the Plan. The Shares may be authorized but unissued, or reacquired Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Automatic
Share Reserve Increase</B>. Subject to adjustment upon changes in capitalization of the Company as provided in Section 15, the number
of Shares available for issuance under the Plan will be increased on the first day of each Fiscal Year beginning with the 2023 Fiscal
Year, in an amount equal to the least of (a)&nbsp;a number of Shares equal to four&nbsp;percent (4%) of the total number of shares of
all classes of common stock of the Company outstanding on the last day of the immediately preceding Fiscal Year, or (b)&nbsp;such number
of Shares determined by the Administrator no later than the last day of the immediately preceding Fiscal Year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Lapsed
Awards</B>. If an Award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an Exchange
Program, or, with respect to Restricted Stock, Restricted Stock Units, or Performance Awards is forfeited to or repurchased by the Company
due to the failure to vest, the unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights the forfeited or repurchased
Shares) which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated). With
respect to Stock Appreciation Rights, only Shares actually issued (i.e., the net Shares issued) pursuant to a Stock Appreciation Right
will cease to be available under the Plan; all remaining Shares under Stock Appreciation Rights will remain available for future grant
or sale under the Plan (unless the Plan has terminated). Shares that actually have been issued under the Plan under any Award will not
be returned to the Plan and will not become available for future distribution under the Plan; provided, however, that if Shares issued
pursuant to Awards of Restricted Stock, Restricted Stock Units or Performance Awards are repurchased by the Company or are forfeited to
the Company due to the failure to vest, such Shares will become available for future grant under the Plan. Shares used to pay the exercise
price of an Award or to satisfy the tax liabilities or withholdings related to an Award will become available for future grant or sale
under the Plan. To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not result in reducing
the number of Shares available for issuance under the Plan. Notwithstanding the foregoing and, subject to adjustment as provided in Section
15, the maximum number of Shares that may be issued upon the exercise of Incentive Stock Options will equal the aggregate Share number
stated in Section 3.1, plus, to the extent allowable under Code Section 422 and the U.S. Treasury Regulations promulgated thereunder,
any Shares that become available for issuance under the Plan pursuant to Sections 3.2 and 3.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Share
Reserve</B>. The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be
sufficient to satisfy the requirements of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Administration
of the Plan</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Procedure</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Multiple
Administrative Bodies</B>. Different Committees with respect to different groups of Service Providers may administer the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Rule
16b-3</B>. To the extent desirable to qualify transactions hereunder as exempt under Rule&nbsp;16b-3, the transactions contemplated hereunder
will be structured to satisfy the requirements for exemption under Rule&nbsp;16b-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">4.1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Other
Administration</B>. Other than as provided above, the Plan will be administered by (A)&nbsp;the Board or (B)&nbsp;a Committee, which Committee
will be constituted to comply with Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;Powers
of the Administrator</B>. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated
by the Board to such Committee, the Administrator will have the authority, in its discretion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the Fair Market Value;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
select the Service Providers to whom Awards may be granted hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the number of Shares or dollar amounts to be covered by each Award granted hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
approve forms of Award Agreements for use under the Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and conditions
include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance
criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the
Shares relating thereto (including but not limited to, temporarily suspending the exercisability of an Award if the Administrator deems
such suspension to be necessary or appropriate for administrative purposes or to comply with Applicable Laws, provided that such suspension
must be lifted prior to the expiration of the maximum term and post-termination exercisability period of an Award), based in each case
on such factors as the Administrator will determine;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
institute and determine the terms and conditions of an Exchange Program, including, subject to Section 20.3, to unilaterally implement
an Exchange Program without the consent of the applicable Award holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
construe and interpret the terms of the Plan and Awards granted pursuant to the Plan;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established
for the purpose of facilitating compliance with applicable non-U.S. laws, easing the administration of the Plan and/or for qualifying
for favorable tax treatment under applicable non-U.S. laws, in each case as the Administrator may deem necessary or advisable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
modify or amend each Award (subject to Section&nbsp;20.3), including but not limited to the discretionary authority to extend the post-termination
exercisability period of Awards and to extend the maximum term of an Option or Stock Appreciation Right (subject to Sections 6.4 and 7.5);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
allow Participants to satisfy withholding tax obligations in a manner prescribed in Section 16;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by
the Administrator;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise would be due to such Participant
under an Award; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to
make all other determinations deemed necessary or advisable for administering the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Effect
of Administrator&rsquo;s&nbsp;Decision</B>. The Administrator&rsquo;s decisions, determinations and interpretations will be final and
binding on all Participants and any other holders of Awards and will be given the maximum deference permitted by Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Eligibility</B>.
Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units and Performance Awards may be granted
to Service Providers. Incentive Stock Options may be granted only to Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Options</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Grant
of Options</B>. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant Options
to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Option
Agreement</B>. Each Award of an Option will be evidenced by an Award Agreement that will specify the exercise price, the term of the Option,
the number of Shares subject to the Option, the exercise restrictions, if any, applicable to the Option, and such other terms and conditions
as the Administrator, in its sole discretion, will determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Limitations</B>.
Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. Notwithstanding
such designation, however, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options
are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary)
exceeds <FONT STYLE="background-color: yellow">one hundred thousand dollars ($100,000),</FONT> such Options will be treated as nonstatutory
stock options. For purposes of this Section&nbsp;6.3, incentive stock options will be taken into account in the order in which they were
granted, the fair market value of the Shares will be determined as of the time the Option with respect to such Shares is granted, and
calculation will be performed in accordance with Code Section&nbsp;422 and the U.S. Treasury Regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Term
of Option</B>. The term of each Option will be stated in the Award Agreement; provided, however, that the term will be no more than <FONT STYLE="background-color: yellow">ten
(10)</FONT> years from the date of grant thereof. In the case of an Incentive Stock Option granted to a Participant who, at the time the
Incentive Stock Option is granted, owns stock representing more than ten percent (<FONT STYLE="background-color: yellow">10%</FONT>) of
the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary of the Company, the term of the Incentive
Stock Option will be <FONT STYLE="background-color: yellow">five (5)</FONT> years from the date of grant or such shorter term as may be
provided in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;Option
Exercise Price and Consideration</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exercise
Price</B>. The per Share exercise price for the Shares to be issued pursuant to the exercise of an Option will be determined by the Administrator,
but will be no less than one hundred percent (<FONT STYLE="background-color: yellow">100</FONT>%) of the Fair Market Value per Share on
the date of grant. In addition, in the case of an Incentive Stock Option granted to an Employee who owns stock representing more than
ten percent (<FONT STYLE="background-color: yellow">10</FONT>%) of the voting power of all classes of stock of the Company or any Parent
or Subsidiary of the Company, the per Share exercise price will be no less than one hundred ten percent (<FONT STYLE="background-color: yellow">110</FONT>%)
of the Fair Market Value per Share on the date of grant. Notwithstanding the foregoing provisions of this Section&nbsp;6.5.1, Options
may be granted with a per Share exercise price of less than one hundred percent (<FONT STYLE="background-color: yellow">100</FONT>%) of
the Fair Market Value per Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Code Section&nbsp;424(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Waiting
Period and Exercise Dates</B>. At the time an Option is granted, the Administrator will fix the period within which the Option may be
exercised and will determine any conditions that must be satisfied before the Option may be exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Form
of Consideration</B>. The Administrator will determine the acceptable form of consideration for exercising an Option, including the method
of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of consideration at the time
of grant. Such consideration may consist entirely of: (a) cash (including cash equivalents); (b) check; (c) promissory note, to the extent
permitted by Applicable Laws, (d) other Shares, provided that such Shares have a Fair Market Value on the date of surrender equal to
the aggregate exercise price of the Shares as to which such Option will be exercised and provided further that accepting such Shares
will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion; (e) consideration
received by the Company under a cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection
with the Plan; (f) by net exercise; (g) such other consideration and method of payment for the issuance of Shares to the extent permitted
by Applicable Laws, or (h) any combination of the foregoing methods of payment. In making its determination as to the type of consideration
to accept, the Administrator will consider if acceptance of such consideration may be reasonably expected to benefit the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exercise
of Option</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Procedure
for Exercise; Rights as a Stockholder</B>. Any Option granted hereunder will be exercisable according to the terms of the Plan and at
such times and under such conditions as determined by the Administrator and set forth in the Award Agreement. An Option may not be exercised
for a fraction of a Share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">An Option will be deemed exercised
when the Company receives: (a)&nbsp;notice of exercise (in such form as the Administrator may specify from time to time) from the person
entitled to exercise the Option, and (b)&nbsp;full payment for the Shares with respect to which the Option is exercised (together with
applicable tax withholdings). Full payment may consist of any consideration and method of payment authorized by the Administrator and
permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant
or, if requested by the Participant, in the name of the Participant and his or her spouse. Until the Shares are issued (as evidenced by
the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive
dividends or any other rights as a stockholder will exist with respect to the Shares subject to an Option, notwithstanding the exercise
of the Option. The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised. No adjustment will be
made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section
15 of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">Exercising an Option in any
manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number
of Shares as to which the Option is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination
of Relationship as a Service Provider</B>. If a Participant ceases to be a Service Provider, other than upon such cessation as the result
of the Participant&rsquo;s death or Disability, the Participant may exercise his or her Option within three&nbsp;(3) months of such cessation,
or such shorter or longer period of time, as is specified in the Award Agreement, in no event later than the expiration of the term of
such Option as set forth in the Award Agreement or Section&nbsp;6.4. Unless otherwise provided by the Administrator or set forth in the
Award Agreement or other written agreement authorized by the Administrator between the Participant and the Company or any of its Subsidiaries
or Parents, as applicable, if on such date of cessation the Participant is not vested as to his or her entire Option, the Shares covered
by the unvested portion of the Option will revert to the Plan immediately. If after such cessation the Participant does not exercise his
or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered by such Option will revert
to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Disability
of Participant</B>. If a Participant ceases to be a Service Provider as a result of the Participant&rsquo;s Disability, the Participant
may exercise his or her Option <FONT STYLE="background-color: yellow">within six (6) months</FONT> of such cessation, or such longer
or shorter period of time as is specified in the Award Agreement (but in no event later than the expiration of the term of such Option
as set forth in the Award Agreement or Section&nbsp;6.4, as applicable) to the extent the Option is vested on such date of cessation.
Unless otherwise provided by the Administrator or set forth in the Award Agreement or other written agreement authorized by the Administrator
between the Participant and the Company or any of its Subsidiaries or Parents, as applicable, if on the date of such cessation the Participant
is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan immediately.
If after such cessation the Participant does not exercise his or her Option within the time specified herein, the Option will terminate,
and the Shares covered by such Option will revert to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Death
of Participant</B>. If a Participant dies while a Service Provider, the Option may be exercised <FONT STYLE="background-color: yellow">within
six (6) months</FONT> following the Participant&rsquo;s death, or within such longer or shorter period of time as is specified in the
Award Agreement (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement or Section&nbsp;6.4,
as applicable), by the Participant&rsquo;s designated beneficiary, provided such beneficiary has been designated prior to the Participant&rsquo;s
death in a form (if any) acceptable to the Administrator. If the Administrator has not permitted the designation of a beneficiary or if
no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant&rsquo;s
estate or by the person(s) to whom the Option is transferred pursuant to the Participant&rsquo;s will or in accordance with the laws of
descent and distribution (each, a &ldquo;<B>Legal Representative</B>&rdquo;). If the Option is exercised pursuant to this Section 6.6.4,
Participant&rsquo;s designated beneficiary or Legal Representative shall be subject to the terms of this Plan and the Award Agreement,
including but not limited to the restrictions on transferability and forfeitability applicable to the Service Provider. Unless otherwise
provided by the Administrator or set forth in the Award Agreement or other written agreement authorized by the Administrator between the
Participant and the Company or any of its Subsidiaries or Parents, as applicable, if at the time of death Participant is not vested as
to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan immediately. If the Option
is not so exercised within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to
the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">6.6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Tolling
Expiration</B>. A Participant&rsquo;s Award Agreement may also provide that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.9in">&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the exercise of the Option following the cessation of Participant&rsquo;s status as a Service Provider (other than upon the Participant&rsquo;s
death or Disability) would result in liability under Section 16b, then the Option will terminate on the earlier of (i) the expiration
of the term of the Option set forth in the Award Agreement, or (ii) the <FONT STYLE="background-color: yellow">tenth (10<SUP>th</SUP>)</FONT>
day after the last date on which such exercise would result in liability under Section 16b; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if
the exercise of the Option following the cessation of the Participant&rsquo;s status as a Service Provider (other than upon the Participant&rsquo;s
death or Disability) would be prohibited at any time solely because the issuance of Shares would violate the registration requirements
under the Securities Act, then the Option will terminate on the earlier of (i) the expiration of the term of the Option or (ii) the expiration
of a period of thirty (30) days after the cessation of the Participant&rsquo;s status as a Service Provider during which the exercise
of the Option would not be in violation of such registration requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock
Appreciation Rights</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Grant
of Stock Appreciation Rights</B>. Subject to the terms and conditions of the Plan, a Stock Appreciation Right may be granted to Service
Providers at any time and from time to time as will be determined by the Administrator, in its sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Number
of Shares</B>. The Administrator will have complete discretion to determine the number of Shares subject to any Award of Stock Appreciation
Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exercise
Price and Other Terms</B>. The per Share exercise price for the Shares that will determine the amount of the payment to be received upon
exercise of a Stock Appreciation Right as set forth in Section 7.6 will be determined by the Administrator and will be no less than one
hundred percent (<FONT STYLE="background-color: yellow">100</FONT>%) of the Fair Market Value per Share on the date of grant. Otherwise,
the Administrator, subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions of Stock
Appreciation Rights granted under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock
Appreciation Right Agreement</B>. Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will specify the exercise
price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions as the Administrator,
in its sole discretion, will determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Expiration
of Stock Appreciation Rights</B>. A Stock Appreciation Right granted under the Plan will expire upon the date determined by the Administrator,
in its sole discretion, and set forth in the Award Agreement. Notwithstanding the foregoing, the rules of Section 6.4 relating to the
maximum term and Section 6.6 relating to exercise also will apply to Stock Appreciation Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Payment
of Stock Appreciation Right Amount</B>. Upon exercise of a Stock Appreciation Right, a Participant will be entitled to receive payment
from the Company in an amount determined by multiplying:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of Shares with respect to which the Stock Appreciation Right is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">At the discretion of the Administrator,
the payment upon Stock Appreciation Right exercise may be in cash, in Shares of equivalent value, or in some combination thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted
Stock</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Grant
of Restricted Stock</B>. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time, may grant
Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Restricted
Stock Agreement</B>. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction
(if any), the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine.
Unless the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock until the restrictions
on such Shares have lapsed. The Administrator, in its sole discretion, may determine that an Award of Restricted Stock will not be subject
to any Period of Restriction and consideration for such Award is paid for by past services rendered as a Service Provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Transferability</B>.
Except as provided in this Section 8 or as the Administrator determines, Shares of Restricted Stock may not be sold, transferred, pledged,
assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Other
Restrictions</B>. The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as it may
deem advisable or appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Removal
of Restrictions</B>. Except as otherwise provided in this Section 8, Shares of Restricted Stock covered by each Restricted Stock grant
made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other
time as the Administrator may determine. The Administrator, in its discretion, may accelerate the time at which any restrictions will
lapse or be removed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Voting
Rights</B>. During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full
voting rights with respect to those Shares, unless the Administrator determines otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Dividends
and Other Distributions</B>. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to
receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise. If any such
dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability
as the Shares of Restricted Stock with respect to which they were paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">8.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;Return
of Restricted Stock to Company</B>. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not
lapsed will revert to the Company and again will become available for grant under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Restricted
Stock Units</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Grant</B>.
Restricted Stock Units may be granted at any time and from time to time as determined by the Administrator. After the Administrator determines
that it will grant Restricted Stock Units, it will advise the Participant in an Award Agreement of the terms, conditions, and restrictions
related to the grant, including the number of Restricted Stock Units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Vesting
Criteria and Other Terms</B>. The Administrator will set vesting criteria in its discretion, which, depending on the extent to which the
criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant. The Administrator may
set vesting criteria based upon the achievement of Company-wide, divisional, business unit, or individual goals (including, but not limited
to, continued employment or service), applicable federal or state securities laws or any other basis determined by the Administrator in
its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Earning
Restricted Stock Units</B>. Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a payout as determined
by the Administrator. Notwithstanding the foregoing, at any time after the grant of Restricted Stock Units, the Administrator, in its
sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;&nbsp;Form
and Timing of Payment</B>. Payment of earned Restricted Stock Units will be made at the time(s) determined by the Administrator and set
forth in the Award Agreement. The Administrator, in its sole discretion, may settle earned Restricted Stock Units in cash, Shares, or
a combination of both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Cancellation</B>.
On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;<U STYLE="text-decoration: none">Performance
Awards</U></B><U>.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><U STYLE="text-decoration: none">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Award
Agreement</B>. Each Performance Award will be evidenced by an Award Agreement that will specify any time period during which any performance
objectives or other vesting provisions will be measured (&ldquo;Performance Period&rdquo;), and such other terms and conditions as the
Administrator determines. Each Performance Award will have an initial value that is determined by the Administrator on or before its date
of grant. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><U STYLE="text-decoration: none">Objectives
or Vesting Provisions and Other Terms. </U></B>The Administrator will set any objectives or vesting provisions that, depending on the
extent to which any such objectives or vesting provisions are met, <FONT STYLE="background-color: white">will determine the value of the
payout for the Performance Awards. </FONT>The Administrator may set vesting criteria based upon the achievement of Company-wide, divisional,
business unit, or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities
laws,&nbsp;or any other basis determined by the Administrator in its discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Earning
Performance <U STYLE="text-decoration: none">Awards</U></B>. After an applicable Performance Period has ended, the holder of a Performance Award will be entitled to
receive a payout for the Performance Award earned by the Participant over the Performance Period. The Administrator, in its discretion,
may reduce or waive any performance objectives or other vesting provisions for such Performance Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;Form
and Timing of Payment</B>. Payment of earned Performance Awards will be made at the time(s) determined by the Administrator and set forth
in the Award Agreement. The Administrator, in its sole discretion, may settle earned Performance Awards in cash, Shares, or a combination
of both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;Cancellation
of Performance Awards</B>. On the date set forth in the Award Agreement, all unearned or unvested Performance Awards will be forfeited
to the Company, and again will be available for grant under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;Outside
Director Award Limitations</B>. No Outside Director may be granted, in any Fiscal Year, equity awards (including any Awards granted under
this Plan), the value of which will be based on their grant date fair value determined in accordance with U.S. generally accepted accounting
principles, and be provided any other compensation (including without limitation any cash retainers or fees) in amounts that, in the aggregate,
exceed $<FONT STYLE="background-color: yellow">500,000</FONT>, provided that such amount is increased to $<FONT STYLE="background-color: yellow">750,000</FONT>&nbsp;in
the Fiscal Year of such individual&rsquo;s initial service as an Outside Director. Any Awards granted or other compensation provided to
an individual (a)&nbsp;for such individual&rsquo;s services as an Employee, or for such individual&rsquo;s services as a Consultant (other
than as an Outside Director), or (b)&nbsp;prior to the Registration Date, will be excluded for purposes of this Section&nbsp;11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;Compliance
With Section&nbsp;409A</B>. Awards will be designed and operated in such a manner that they are either exempt from the application of,
or comply with, the requirements of Section&nbsp;409A such that the grant, payment, settlement or deferral will not be subject to the
additional tax or interest applicable under Section&nbsp;409A, except as otherwise determined in the sole discretion of the Administrator.
The Plan and each Award Agreement under the Plan is intended to be exempt from or meet the&nbsp;requirements of Section&nbsp;409A and
will be construed and interpreted in accordance with such intent (including with respect to any ambiguities or ambiguous terms), except
as otherwise determined in the sole discretion of the Administrator. To the extent that an Award or payment, or the settlement or deferral
thereof, is subject to Section&nbsp;409A the Award will be granted, paid, settled or deferred in a manner that will meet the requirements
of Section&nbsp;409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable
under Section&nbsp;409A. In no event will the Company or any of its Parent or Subsidiaries have any responsibility, liability, or obligation
to reimburse, indemnify, or hold harmless a Participant (or any other person) in respect of Awards, for any taxes, penalties or interest
that may be imposed on, or other costs incurred by, Participant (or any other person) as a result of Section 409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Leaves
of Absence/Transfer Between Locations</B>. Unless the Administrator provides otherwise or as otherwise required by Applicable Laws, vesting
of Awards granted hereunder will be suspended during any unpaid leave of absence. A Participant will not cease to be an Employee in the
case of (a)&nbsp;any leave of absence approved by the Company or (b)&nbsp;transfers between locations of the Company or between the Company,
its Parent, or any of its Subsidiaries. For purposes of Incentive Stock Options, no such leave may exceed three (3) months, unless reemployment
upon expiration of such leave is guaranteed by statute or contract. If reemployment upon expiration of a leave of absence approved by
the Company is not so guaranteed, then six (6) months following the first (1<SUP>st</SUP>) day of such leave, any Incentive Stock Option
held by the Participant will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock
Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&nbsp;&nbsp;<B>Limited
Transferability of Awards</B>. <FONT STYLE="text-underline-style: double"><U STYLE="text-decoration: none">Unless determined otherwise by the Administrator, Awards</U></FONT>
may not be <FONT STYLE="text-underline-style: double"><U STYLE="text-decoration: none">sold, pledged, assigned, hypothecated, </U></FONT>transferred, or disposed of
in any manner other than by will or by the laws of descent and distribution (which, for purposes of clarification, shall be deemed to
include through a beneficiary designation if available in accordance with Section 6.6.4), and may be exercised, during the lifetime of
the Participant, only by the Participant. If the Administrator makes an Award transferable, such Award will contain such additional terms
and conditions as the Administrator deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;Adjustments;
Dissolution or Liquidation; Merger or Change in Control</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">15.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;Adjustments</B>.
In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization,
stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, reclassification, repurchase,
or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares
occurs (other than any ordinary dividends or other ordinary distributions), the Administrator, in order to prevent diminution or enlargement
of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and class of shares of stock
that may be delivered under the Plan and/or the number, class, and price of shares of stock covered by each outstanding Award, and numerical
Share limits in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">15.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Dissolution
or Liquidation</B>. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant
as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an
Award will terminate immediately prior to the consummation of such proposed action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">15.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;Merger
or Change in Control</B>. In the event of a merger of the Company with or into another corporation or other entity or a Change in Control,
each outstanding Award will be treated as the Administrator determines (subject to the provisions of the following paragraph) without
a Participant&rsquo;s consent, including, without limitation, that (a)&nbsp;Awards will be assumed, or substantially equivalent awards
will be substituted, by the acquiring or successor corporation (or an affiliate thereof) with appropriate adjustments as to the number
and kind of shares and prices; (b) upon written notice to a Participant, that the Participant&rsquo;s Awards will terminate upon or immediately
prior to the consummation of such merger or Change in Control; (c)&nbsp;outstanding Awards will vest and become exercisable, realizable,
or payable, or restrictions applicable to an Award will lapse, in whole or in part prior to or upon consummation of such merger or Change
in Control, and, to the extent the Administrator determines, terminate upon or immediately prior to the effectiveness of such merger or
Change in Control; (d) (i) the termination of an Award in exchange for an amount of cash and/or property, if any, equal to the amount
that would have been attained upon the exercise of such Award or realization of the Participant&rsquo;s rights as of the date of the occurrence
of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the Administrator determines
in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&rsquo;s rights,
then such Award may be terminated by the Company without payment), or (ii)&nbsp;the replacement of such Award with other rights or property
selected by the Administrator in its sole discretion; or (e) any combination of the foregoing. In taking any of the actions permitted
under this Section&nbsp;15.3, the Administrator will not be obligated to treat all Awards, all Awards held by a Participant, all Awards
of the same type, or all portions of Awards, similarly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In the event that the acquiring
or successor corporation (or an affiliate thereof) does not assume the Award (or portion thereof) as described below or substitute for
the Award (or portion thereof) as described above, then the Participant will fully vest in and have the right to exercise his or her outstanding
Options and Stock Appreciation Rights (or portions thereof) not assumed or substituted for, including Shares as to which such Awards would
not otherwise be vested or exercisable, all restrictions on Restricted Stock, Restricted Stock Units, or Performance Awards (or portions
thereof) not assumed or substituted for will lapse, and, with respect to Awards with performance-based vesting (or portions thereof) not
assumed or substituted for, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target
levels and all other terms and conditions met, in each case, unless specifically provided otherwise under the applicable Award Agreement
or other written agreement authorized by the Administrator between the Participant and the Company or any of its Subsidiaries or Parents,
as applicable. In addition, unless specifically provided otherwise under the applicable Award Agreement or other written agreement authorized
by the Administrator between the Participant and the Company or any of its Subsidiaries or Parents, as applicable, if an Option or Stock
Appreciation Right (or portion thereof) is not assumed or substituted in the event of a merger or Change in Control, the Administrator
will notify the Participant in writing or electronically that the Option or Stock Appreciation Right (or its applicable portion) will
be exercisable for a period of time determined by the Administrator in its sole discretion, and the Option or Stock Appreciation Right
(or its applicable portion) will terminate upon the expiration of such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">For the purposes of this Section&nbsp;15.3
and Section&nbsp;15.4 below, an Award will be considered assumed if, following the merger or Change in Control, the Award confers the
right to purchase or receive, for each Share subject to the Award immediately prior to the merger or Change in Control, the consideration
(whether stock, cash, or other securities or property) received in the merger or Change in Control by holders of Common Stock for each
Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration
chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the merger or
Change in Control is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the
successor corporation, provide for the consideration to be received upon the exercise of an Option or Stock Appreciation Right or upon
the payout of a Restricted Stock Unit or Performance Award, for each Share subject to such Award, to be solely common stock of the successor
corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the merger
or Change in Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Notwithstanding anything in
this Section&nbsp;15.3 to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance goals
will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant&rsquo;s
consent, in all cases, unless specifically provided otherwise under the applicable Award Agreement or other written agreement authorized
by the Administrator between the Participant and the Company or any of its Subsidiaries or Parents, as applicable; provided, however,
a modification to such performance goals only to reflect the successor corporation&rsquo;s post-Change in Control corporate structure
will not be deemed to invalidate an otherwise valid Award assumption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Notwithstanding anything in
this Section&nbsp;15.3 to the contrary, and unless otherwise provided in an Award Agreement, if an Award that vests, is earned or paid-out
under an Award Agreement is subject to Section 409A and if the change in control definition contained in the Award Agreement (or other
agreement related to the Award, as applicable) does not comply with the definition of &ldquo;change in control&rdquo; for purposes of
a distribution under Section 409A, then any payment of an amount that is otherwise accelerated under this Section 15.3 will be delayed
until the earliest time that such payment would be permissible under Section 409A without triggering any penalties applicable under Section
409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">15.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<B>Outside Director Awards</B>. With respect to Awards granted to an Outside Director, in the event of a Change in Control, the Participant
will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the Shares underlying such Award,
including those Shares which would not be vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will
lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved
at 100% of target levels and all other terms and conditions met, unless specifically provided otherwise under the applicable Award Agreement
or other written agreement between the Participant and the Company or any of its Subsidiaries or Parents, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax
Withholding</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">16.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Withholding
Requirements</B>. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof) or such earlier time as any tax
withholdings are due, the Company (or any of its Parent, Subsidiaries, or affiliates employing or retaining the services of a Participant,
as applicable) will have the power and the right to deduct or withhold, or require a Participant to remit to the Company (or any of its
Parent, Subsidiaries, or affiliates, as applicable) or a relevant tax authority, an amount sufficient to satisfy U.S. federal, state,
local, non-U.S., and other taxes (including the Participant&rsquo;s FICA or other social insurance contribution obligation) required to
be withheld or paid with respect to such Award (or exercise thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">16.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Withholding
Arrangements</B>. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit
a Participant to satisfy such tax liability or withholding obligation, in whole or in part by such methods as the Administrator shall
determine, including, without limitation, (a) paying cash, check or other cash equivalents, (b)&nbsp;electing to have the Company withhold
otherwise deliverable cash or Shares having a fair market value equal to the minimum statutory amount required to be withheld or such
greater amount as the Administrator may determine if such amount would not have adverse accounting consequences, as the Administrator
determines in its sole discretion, (c) delivering to the Company already-owned Shares having a fair market value equal to the minimum
statutory amount required to be withheld or such greater amount as the Administrator may determine, in each case, provided the delivery
of such Shares will not result in any adverse accounting consequences, as the Administrator determines in its sole discretion, (d)&nbsp;selling
a sufficient number of Shares otherwise deliverable to the Participant through such means as the Administrator may determine in its sole
discretion (whether through a broker or otherwise) equal to the amount required to be withheld or paid, (e) such other consideration and
method of payment for the meeting of tax liabilities or withholding obligations as the Administrator may determine to the extent permitted
by Applicable Laws, or (f) any combination of the foregoing methods of payment. The amount of the withholding obligation will be deemed
to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined
by using the maximum federal, state or local marginal income tax rates applicable to the Participant with respect to the Award on the
date that the amount of tax to be withheld is to be determined or such greater amount as the Administrator may determine if such amount
would not have adverse accounting consequences, as the Administrator determines in its sole discretion. The fair market value of the Shares
to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;&nbsp;No
Effect on Employment or Service</B>. Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing
the Participant&rsquo;s relationship as a Service Provider with the Company or its Subsidiaries or Parents, as applicable, nor will they
interfere in any way with the Participant&rsquo;s right or the right of the Company and its Subsidiaries or Parents, as applicable, to
terminate such relationship at any time, free from any liability or claim under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;Date
of Grant</B>. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting
such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to each Participant
within a reasonable time after the date of such grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&nbsp;&nbsp;Effective
Date; Term of Plan</B>. Subject to Section <B>Error! Reference source not found.</B>3 of the Plan, the Plan will become effective upon
the later to occur of (i)&nbsp;its adoption by the Board or (ii)&nbsp;the business day immediately prior to the Registration Date. It
will continue in effect until terminated under Section 20, but no Incentive Stock Options may be granted after <FONT STYLE="background-color: yellow">10&nbsp;years</FONT>
from the date adopted by the Board and Section&nbsp;3.2 will operate only until the <FONT STYLE="background-color: yellow">10<SUP>th</SUP>
anniversary</FONT> of the date the Plan is adopted by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendment
and Termination of the Plan</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">20.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Amendment
and Termination</B>. The Administrator, in its sole discretion, may amend, alter, suspend or terminate the Plan, or any part thereof,
at any time and for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">20.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Stockholder
Approval</B>. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to comply with
Applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">20.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Effect
of Amendment or Termination</B>. No amendment, alteration, suspension or termination of the Plan will materially impair the rights of
any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and
signed by the Participant and the Company. Termination of the Plan will not affect the Administrator&rsquo;s ability to exercise the powers
granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Conditions
Upon Issuance of Shares</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">21.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Legal
Compliance</B>. Shares will not be issued pursuant to an Award unless the exercise or vesting of such Award and the issuance and delivery
of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to
such compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">21.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Investment
Representations</B>. As a condition to the exercise or vesting of an Award, the Company may require the person exercising or vesting in
such Award to represent and warrant at the time of any such exercise or vesting that the Shares are being acquired only for investment
and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation
is required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Inability
to Obtain Authority</B>. If the Company determines it to be impossible or impractical to obtain authority from any regulatory body having
jurisdiction or to complete or comply with the requirements of any registration or other qualification of the Shares under any U.S. state
or federal law or non-U.S. law or under the rules and regulations of the U.S. Securities and Exchange Commission, the stock exchange on
which Shares of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification
or rule compliance is deemed by the Company&rsquo;s counsel to be necessary or advisable for the issuance and sale of any Shares hereunder,
the Company will be relieved of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority,
registration, qualification or rule compliance will not have been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Intentionally
Omitted</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Forfeiture
Events</B>. The Administrator may specify in an Award Agreement that the Participant&rsquo;s rights, payments, and benefits with respect
to an Award will be subject to the reduction, cancellation, forfeiture, recoupment, reimbursement, or reacquisition upon the occurrence
of certain specified events, in addition to any otherwise applicable vesting or performance conditions of an Award. Such events may include,
without limitation, termination of such Participant&rsquo;s status as an employee and/or other service provider for cause or any specified
action or inaction by a Participant, whether before or after such termination of employment and/or other service, that would constitute
cause for termination of such Participant&rsquo;s status as an employee and/or other service provider. Notwithstanding any provisions
to the contrary under this Plan, </FONT>all Awards granted under the Plan will be subject to <FONT STYLE="font-family: Times New Roman, Times, Serif">reduction,
cancellation, forfeiture, recoupment, reimbursement, or reacquisition </FONT>under any clawback policy that the Company is required to
adopt pursuant to the listing standards of any national securities exchange or association on which the Company&rsquo;s securities are
listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Laws <FONT STYLE="font-family: Times New Roman, Times, Serif">(the
&ldquo;<B>Clawback Policy</B>&rdquo;). The Administrator may require a Participant to forfeit, or return to the Company, or reimburse
the Company for, all or a portion of the Award and any amounts paid thereunder pursuant to the terms of the Clawback Policy or as necessary
or appropriate to comply with Applicable Laws, including without limitation any reacquisition right regarding previously acquired Shares
or other cash or property. Unless this Section 24 specifically is mentioned and waived in an Award Agreement or other document, no recovery
of compensation under a Clawback Policy or otherwise will constitute an event that triggers or contributes to any right of a Participant
to resign for &ldquo;good reason&rdquo; or &ldquo;constructive termination&rdquo; (or similar term) under any agreement with the Company
or any Parent or Subsidiary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>39
<FILENAME>cm270_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Subsidiaries of 60 Degrees Pharmaceuticals,
Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Subsidiary &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdiction of Organization </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60 Degrees Pharmaceuticals, LLC &nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">District of Columbia </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60P Australia Pty Ltd &nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60P Singapore PTE, LTD &nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Singapore </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>40
<FILENAME>cm270_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation in the Registration
Statement of 60 Degrees Pharmaceuticals, Inc. (F/K/A 60 Degrees Pharmaceuticals, LLC) on Form S-1 Amendment No. 1 of our report dated
April 3, 2023 which includes an explanatory paragraph as to the Company's ability to continue as a going concern, with respect to our
audits of the financial statements of 60 Degrees Pharmaceuticals, Inc. as of December 31, 2022 and 2021, and for the each of the two years
in the period ended December 31, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also consent to the reference to us under the heading
&ldquo;Experts&rdquo; in the Prospectus, which is part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ RBSM LLP</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Las Vegas, Nevada</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">April 3, 2023</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>41
<FILENAME>cm270_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consent
of Director Nominee</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60
Degrees Pharmaceuticals, Inc. is filing a Registration Statement on Form S-1 (Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), in connection
with the initial public offering of common stock of 60 Degrees Pharmaceuticals, Inc. In connection therewith, I hereby consent, pursuant
to Rule 438 of the Securities Act, to being named as a nominee to the Board of Directors of 60 Degrees Pharmaceuticals, Inc. in the Registration
Statement, as may be amended from time to time. I also consent to the filing of this consent as an exhibit to such Registration Statement
and any amendments thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.45pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">/s/ Charles Allen</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name: Charles Allen</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.45pt"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>42
<FILENAME>cm270_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Exhibit 99.2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 231.65pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consent of Director Nominee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">60 Degrees Pharmaceuticals, Inc.
is filing a Registration Statement on Form S-1 (Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) with the Securities and Exchange Commission under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), in connection with the initial public offering of common stock of 60 Degrees
Pharmaceuticals, Inc. In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee
to the Board of Directors of 60 Degrees Pharmaceuticals, Inc. in the Registration Statement, as may be amended from time to time. I also
consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify; text-indent: 24.45pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; font-size: 10pt">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cheryl Xu</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Name: <FONT STYLE="font-family: Times New Roman, Times, Serif">Cheryl Xu</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>43
<FILENAME>cm270_ex99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: right"><B>Exhibit 99.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 231.65pt"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Consent of Director Nominee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">60 Degrees Pharmaceuticals, Inc.
is filing a Registration Statement on Form S-1 (Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) with the Securities and Exchange Commission under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), in connection with the initial public offering of common stock of 60 Degrees
Pharmaceuticals, Inc. In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee
to the Board of Directors of 60 Degrees Pharmaceuticals, Inc. in the Registration Statement, as may be amended from time to time. I also
consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4.55pt 0 0 60pt; text-align: justify; text-indent: 24.45pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Stephen Toovey</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stephen Toovey</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07/12/2022</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.2pt 0 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>44
<FILENAME>cm270_ex99-4.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-bottom: 0pt; text-align: right">Exhibit 99.4</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-bottom: 0pt"><B>Consent of Director Nominee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0.3pt 0 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">60 Degrees Pharmaceuticals,
Inc. is filing a Registration Statement on Form S-1 (Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;)
with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), in connection
with the initial public offering of common stock of 60 Degrees Pharmaceuticals, Inc. In connection therewith, I hereby consent, pursuant
to Rule 438 of the Securities Act, to being named as a nominee to the Board of Directors of 60 Degrees Pharmaceuticals, Inc. in the Registration
Statement, as may be amended from time to time. I also consent to the filing of this consent as an exhibit to such Registration Statement
and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Paul Field</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">Name:</TD>
    <TD STYLE="width: 45%">Paul Field</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>45
<FILENAME>cm270_ex107.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>60 Degrees Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Table 1: Newly Registered Securities</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Security</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Security</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Class</B></P></TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fee Calculation</B></P></TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Amount</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Maximum</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Maximum</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aggregate</B></P></TD><TD STYLE="white-space: nowrap">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center">Fee</TD><TD STYLE="white-space: nowrap; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registration</B></P></TD><TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Type</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Title</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Rule</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Registered </B><SUP>(1)</SUP></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Offering Price</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Offering </B><SUP>(1)</SUP></FONT></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Rate</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fee</TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 14%; text-align: left">&nbsp;&nbsp;Fees to Be Paid</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: left"><FONT STYLE="font-size: 10pt">Other</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: center">Units, consisting of one share of Common Stock, par value $0.0001 per share, and one Warrant to purchase one share of Common Stock</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center">457(o)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">1,219,512</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">6.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">7,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">0.0001102</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">826.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Equity</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, $0.0001 par value per share, included in the Units <SUP>(3) </SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">457(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left"><SUP>(6)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Equity</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Warrants included in the Units <SUP>(3) </SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">457(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left"><SUP>(6)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;&nbsp;Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Equity</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, $0.0001 par value per share, underlying the Warrants included in the Units <SUP>(4) </SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">457(o)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,219,512</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.0725</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">8,624,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0001102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">950.47</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Equity</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Overallotment Option Shares of Common Stock <SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">457(o)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182,927</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,125,002</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0001102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">123.98</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Equity</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Overallotment Option Shares of Common Stock underlying the Warrants <SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">457(o)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">182,927</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.0725</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,293,752</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0001102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">142.57</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Equity</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Representative&rsquo;s Warrants <SUP>(7)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">457(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left"><SUP>(6)</SUP></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Equity</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Common Stock, $0.0001 par value per share, underlying Representative Warrants <SUP>(2) (5)(6)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">457(o)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">84,146</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.765</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">569,248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0001102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">62.73</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Fees to Be Paid</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Equity</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Common Stock to be sold by Selling Stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">457(o)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,916,727</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6.15</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,787,872</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0001102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,299.02</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Total Offering Amounts</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">30,900,873</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0001102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,405.28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Total Fees Previously Paid</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">3,405.28</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Total Fee Offsets</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Net Fee Due</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">0.00</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457 under the Securities Act.
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), there is also being registered hereby
such indeterminate number of additional shares of common stock as may be issued or issuable because of stock splits, stock dividends and
similar transactions.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Includes an additional 15% related to the exercise in full of the over-allotment option by the underwriters.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>These shares of Common Stock and Warrants are included in the Units.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>The Warrant included in the Unit is exercisable at 115% of the Unit offering price.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">Includes shares that the underwriters have the option to purchase through exercise of the Underwriter Warrants.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD STYLE="text-align: justify">Represents common stock underlying the warrants (the &ldquo;Underwriter Warrants&rdquo;) issuable to the representative of the underwriters
to purchase up to an aggregate of 6.0% of the common stock sold in the offering at an exercise price equal to 110% of the public offering
price per security. Assuming exercise in full of the over-allotment option, consists of 84,146 shares of common stock issuable to the
representative of the underwriters.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(7)</TD><TD>No additional registration fee is payable pursuant to Rule 457(g) under the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>cm270_s1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_s1img01.jpg
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M Q$!_\0 ]    0,$ P$               @)"@$"!PL#!08$ 0 !! ,! 0
M            !08'" $"! ,)$   !@$# @,"!P4/# P,!P ! @,$!08' !$(
M$@DA$PHQ%$%182(R,Q5Q(S0U%H&1H;'!T5)BE3;6%S<X&N%"0V.3)&24EE<8
M6/!R@L)$M"5%M7:V.?%3<Z.S5(15974G=R969D=G>!D1  $"! ,$!@,*" L(
M P$!  $" P 1! 4A,09!41('87&!(C(3D3,(\*&QP=%"(Q0T%5)RDD.451<8
MX?&"LM)SDR14-19BHF.#)28V-\)31'1%_]H # ,!  (1 Q$ /P"?QH@@T00:
M((-$$&B"#1!!H@@T00:((-$$>#R%DFBXHJ$U?<E6RNT:DUQF9_/6NTRS.$@H
MEJ!BIE4>/WRJ2*9EE3@1,NXG4.(%* F$ T*D 2HR&\PG5]RI+8PJIN:TMTR1
M,J)D !F9GMP$=#A[-N),_4]ED'"V1*ADZE/7+AFA9:9-,YJ,!ZS$"NF*ZK8X
MJ-'[<3 )T%2D5*4P")=A 1RV4EN:2".@SC%LO%KO+'UBT5"7J;HQ_BC+6L0I
M0:((-$$&B"/*W:V5ZAU.S7>W2K2"JE.K\Q:;--/C"1E$P$!'N)27DG1B@)@0
M9,&JBAM@$P@7P\=M>E.TY453=*P.)]U02!M))D/?,H\WGVJ5ARI?(#2$3/4)
MDQKK^=/>YYS=PC,SG#O$F4R1C'#E@L:]7Q=BG#;203RWEA!1P9!A+7*;@TU;
M.YD)M!+WD(M@HV9,4!V5\TQ#K:MWI7E=I32%K1?=5*"JQ">-<R.%).(E/+"6
M>,5MU%KJ\:BK3;+,"FBXI) G,R^'&<)IG>V3WG\40KK-<A@?D_"DC6SF>DI^
MM7HDW=HMLT3.Z=2#V%J=UD[@7R4RBH?I;J'*4!$P> Z<C/,/EA<B;*'T-M.&
M0)0 !/(<1 '1G"&_I/75+_U 4ZR!CFJ<MY&?O0^#Z>'N+]QK/69)' F3&MLY
M)<=JY#.5;7F&[*)HV3 \B@U5"OL'5W>-T7%R"P.6WNQ8-T+F42 ?>4CD124*
M,1\X]'Z)LU(BZ6E0I;PO)"2%!:<YR$Y3G/MQB2.6]_U175*J&X()M*4D3(,P
M?ASBSU)7<$YO\=>26*,)84R9>L!8C<XKC\@M;70'@U^4R5<75AF6,TT=V@J!
MG0L*6WC&I?LY%4A.IWYJY3@=+IVY)Z.T9?;5455](55ER0&92#MELZ3V1IS/
MU1?K5=6*2W@A@-S)QD3CF<O=TP^[V/N2>>^5W;QQ-E[D>#F0R&\F[I6FMU>L
M$HQWDRIU>:5BZ_?G+5L@U:*.95),[=5PBDFD[4:F7*'WS<8JYAVBS676%316
M14Z-($L9RZ/=OA^:(N%PN6G6:JX@A\K.>!(SVYX[=L.ZZ9</&#1."*;A\8:(
M)&$A<F>=W$?AY)5.*Y-9SIV'GMZ9RCZH-K0$R92?:PB[1O++LOLJ*D2]+!5^
MB4_6)!^^!L AN(*]KT[?;Z5FQTRGWD>*6P=.,)-SOMHLP3]Y/AE:LI[1Z-\9
MSP_ES'6=\;U++F);5&WC&U[C/MJH6^(]Z"+GXDSA9J5\R!ZV:.O),NW.3YZ9
M!W*/AML.N"KHW[?4+I*I!;J4&2DG,*S(,*%-4T]8PFIHU^93K&"M^_WXR5N'
MQA^?KGCVD8KH@@T03$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#
M1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B".,QR@4=C%W^ -P\1]FLC'$9
M0$@3XLAG$&OU W<*/GK,"/$+&$V5SB?!LT*^1GL6X,9C=\PMR'05CC'14\E]
M#8Z14,W*&PE&347-X^20=-N^5275?5 >X!,Q1_V@^9"KG<SI.V*3]U4Q^D((
MD2,P2,.@#T9PDKLX=Q%QP4Y%-X>Z2*I..^9WD97<I-55#':U*:ZA:UK*#-$!
M,"9H)5QY$ETANM&*G,.YD$PTF6*L^K5!9=(2TLYY#KAH\D>8M1HV]"@N"O\
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M7<]%MDA#6NZLJ'7:_0XEC-VJ6F7<;(2ZZS6/D96&:?9T7&QJBKE4RX='40
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M(V4/"/F%B;G/QSHO(C$,@*D':V(-9^NN5DE9NA76.(1*S4>Q)I;"E*P3\XE
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MNJ!D<?BV1KY+[VT>[UVW<FN;CCG'><(I]!*J,HG-W%)_8+7 3,458%D <#3
M5L#>,<@B4RK":C4R%$! Y#>T;B?M Y::]IT,7EU"5E('D.I ""!*4\L<\#MB
MMCFE]8Z5J5.6]"^(*]8CBFK;GAE..ON1.^%W!@8XHOL'S?S;" X;F&H6:H6>
MG4 KE$Z9T']D%[#TZF*&;*%(<%I)4_EC\XH@.O)E[E%HMSZ_;/J9J<\3Q2Z!
M.9EU1M4*YA:E:%%5!XM 2QG,]/6=L2M^QSV3I;@.O,<C>1;RNSG)NV5Q:L0%
M<KSD)BN8:J$F=%::8MISRB)3EVL8H)I/G3< :M6J?NZ)U0454- W-3F>O6;C
M5DM?$W8T3*PK-:MA 'S0<I[-F42[R_T.-.$U56 :Y2<]T_C]V<)[]2SPAY9<
MNKIQ(?<:<%W7,3.BUG+C2W.:D2*,E NIZ5HZ\.@^&2DX\04?I1JYD^CK\$QW
MV\-UKDEJNQZ9>KA>7T,AX,\))D/HR2?3/"$OFO8;O=_JKUL86\4"1"1,S/5"
MBF3[N!\1^R?QCP+QPXQ91LW,N3Q2;'$A'1;*$54P#YLE-K35TL:SJ918GL+%
M@](6%;(J+ H]4!8_WM P&;#"=,W[7]1<+U5-LV(OE94K\X .Z$RV<0!/1"X4
MWJTZ)I[;0L..W?@(DG#@F23.<L0"1UY0U_V0^Q[G5KR7><GN?&*)^D,,/RZ-
MCQK0<DKL92:R5EEZHI)I7^PIH/Y47<)37)_?"G<'\Q[-*)G, E0/U2-S6YI6
MNKL[>F](NI+?EA/&C !($MF))^"<-+1&@K@Y<C>M2-*2I*Y\*LS/H]VZ)+O=
M)[>M+[C/%BR8<F!81&3( '%OPA?7" &4I^2&3%1)H5TL4@KC6;2B(Q\LD4?G
M-U05 !513$(0T1JNKT7>V;BTL^0H@/#\(3F2.K,3ZHD_5>FJ?4]K<HW$CSDS
M+1RD92D?=NB+9V<,+=W;MJ\E#M+=POSC-<:<KR[*L9PKL.:M2C6)59N31T/E
MNIHIV4"NY.K@816\LH#)1!SI["H5#HG?FA>>7VN+*BMH:MIN^-I) .!,Y32J
M6^78<8B30]MUII.ZFE>IG5VM2I*($Q(;1NE/XLH>%]0KVU,P\]</8DR%QUBD
M[9E[CY)VDQ\=JOVL8_O5&NK2*-,MJVXDE6T:-HA9* :KH-UUD0<HF73*;S03
M*:-N46N*31UWJ*6XDII*E#:2K8"A4YG_ &2)CKSPA[\Q]*OZDMR7J4?WA P3
MC/,F0D,XBO87IG?TQ;3EN*N$:+SUQU0UG\BW&APE.LU8K\2I..5%)D(NW2<6
MU;UB/D7*QU5CM)1LW$YSJ ("<QC3SJ&OY-W&N<U'5.TK]4I"B1(\1)'<PRFG
M;/LB);8US I?+M%**AJA*QAC+/'+?&RLHK.1:4FGLI<%B2S&K5YI*$=* NY)
M)MHAH@^*NN!U067*Z(<#GZC=1MQW'??5-JA;3C[BVI>45J(EE*9E+HE%GJ8%
M%,VEV9="$@DYSEC/IC7V>I_XZU'#W/6L9<JSN.1<<F,9HW*X5EJ"23N/M]&?
MHTI[9%4" !O=+;%MVA@5-XJ.VC@?';?5M_9_OE97Z==M3B2H4[QX2?#PY@;Y
MB*U\W;73T>H$UK9"?/:!(&?%M)ZY3A_3TR'$<<'\&GN?[#&%:WGE=:SVYJLN
MF8CM#%5/,\KM!:"50 .FC)O?M*5+ML"J3U(WB !J'^=FHUWO5YH$JG248X>@
MJ.[WND2,2/RLLWW;I[ZXX!Y]6J8W@#?[^424-1%$I0:((-$$&B"#1!!H@@T0
M0:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!#>O<OYPUS
M@9QBN&678L7^0)8HU##E7<K%Z['D66:+_9JBS;<%5(.MH$/(2)P\ ;H=&X'5
M)OS5KXIJ93H/?E@(8/,?6M+H;3+]T=*?KRTE#*)R*E$9Y'PG'(Y"($7#?C/E
M?N/<O8G'[F8F).4OEBDLAYOR4\$SMW!5-23)(76V/'"PF3^UI%9V#2/3$=CO
M'"1 #RRFZ671M/5U<DD=W,F*$:*TY<^9&M$,/%:VW:@N/K.(Q,R/=Z(V4V,<
M:TS$6/Z;C#'<*UK='H5<B:O5H1FGTH,(>(:$:M$Q'?J674*3S%53;G55,8YA
M$QA'3\"4I;\I(D!A'TGH+;2VJA8MM&D(I:=(2D#<D2'\/3&0=9CN@T01PKEZ
MT]@'8>HHA^8.^VMDF1F8U5,]T&0)D<)X',=HB"_W[^W"''C*RO+/$-?%OA/-
M$^<F0X:,:"2/QUEJ2$SARX(DB3RF=:R&<#N$O8FA* LEX LB739OU#P#ZXSX
MIRE+([Y]D4>]H#EH+-<O]165DIH'CB$"00Y(J*ICH!PD.O"%W>GG[C_Y2P1>
M"&7IOS;/4V#R4X]3DJ\^_3]0; L\F,9"NKXKR-2(8[N,*(B92-,HD7P:E >B
MRW 5#*6'1)8VSSA^>SUS+1<J9.CKR[_>T)^A4I6*LYHD<MDL=^$2M2'ZPWV
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MZLXR,#.-7]WOXTLSW@^4T*94R!9K)&,X@S@I04,W+*T*@1YG)4Q,4%!0!QU
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MK$.]+_WS_(K_ .\&'O\ LEC<=7;Y8_\ JK_EN_S515;6RB.82_QT?SA&SC;
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MIW I2E"I=_NM=>+W55M:M:W%/*D5$D@3P GL D(L59Z&DHK<U3TZ4@>4GBD
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M=<P-8&LQ *&#S9:P2JR39   >D3B<WS2F$%W3.G+CJR^4^GK6%&LJ' F8$^
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MZ.N+6>SSKJLU'8'-/UZN*JH? O:IO;Z.S Q#$SFU=,<PYM9.P4!XTRIE5JX
MX="OO*5UL!5.H!\2F$X?#IJUP*:IQ)\4_CBF&JAP:KKD+P5]?4>SCC9R\)WS
M:0X>\57;00%NOQWPXHD!1W "AC^"(( ;8-]C%$-/NEG]60?]D1]-]&K2YI2W
M.(,T&G3_ #85 80#;?X_U!UT"'.K*>P1%"]4DZ0#'_#9J(D]X5OV6W!=QV/Y
M"%9JJ2O2'M$/,<$'\P-(5]4$MMSVE7Q14_VI<;7;VAZPN.F70/+A)OI@VC@_
M*GD<]*)O=&V 8AJN =6WO#S(L0JUZMOF[^6R6V^'VZYK )ON*&4ODAL>RTE1
MOUP<'@^K@=N$3;R>S[GA^:   Z<Q()PBZR/ !M AM3NK\!:SW#>)%\PVX39,
M<F1!#W;"%L=D)O6,GPK-<(I)5P(>8C VILH>+DR /29LY\S83I$$'3HC5-;H
M_4+5SIE$)4KA6-GEGQ>C.&YJRR,ZALKM*H?WAM)*#T[NV->'V^>8&3^UWS>A
M\A6"'G8AM5;#*8FY)8P<%4;R,E2PFBQEV@W#(0 IK%4)%F$C'&$/PMF4I3 F
ML81N)K.P6W7VEU4]/);KC8=IG!D%*$P)_-&,C.45KTM>:W1FHD-O>J+A;=!V
M)!EVX;HVG-"OE1R;2ZGD*B3K&RTR\5R&ME4L$8KY[":KT_'H2<3)-50 -TG;
M)P0VP[&*(])@ P"&J*U+#M%5.T-2"FI844K!S!!(/7B,Q%M&GFGT!QH@MJ (
M(RD<L8]AKSCU@T00:((-$$4$0#VZR 3E!LGLBG47X]8C$X.LOQZ,-X@F.GT&
M#K+\?Z _H>'CK!,A/&71C&=A.P1899(NW4<I=_9U#MOX;^&^WP:RF:O"">PQ
MJ5H2 5$ *,A/:8B[=^WM!\H>>T]3L[\=\CEO;_&M07K1.,UMDV$#!)HK.%GL
MG:,93:OD1!+98  B<@WE3)^]$;H@DZ(4H):FGE/S%M.CUU%MNU*GZ90^G4DG
M"<L0 3P]F_"(JU[I*Y:B6+C;:@KX!@T") C:)F4Y]LS$;RCY=[]_!"&3P]5F
MG-;&U9@Q%O%5"6Q3(Y-K,2AT[%;U5]/5"\1#6+  W33CW(-2_P!:4-32NCY-
MZL?5<:Q5.JH5F6R&QZ%<,1BQ5<QK&DTJQ4!I.0$S,[L)QWT9PQ[VW=LR#6'6
M:(#.DY"QZXM6.1^2+=]B_%="9.!)]I2$)5W<7!I.G1D#")R0T2L[<[ 0QP+M
MMXG5/+3EW2NC3ZZ93^Q"4E3JCD.\ 1AMF0)1M]PZ[UG5(%Q\Y-*<^(R &>T]
M'R1.R[;?;_QKVY>-T!@FA.E+%,N7J]LR=D-ZS282F0\@23=JWD9M=HF=8T?$
ML6S5)G&,_,.#5DB4HF,H90YJL:MU1<-7WIR[UQE/!*=@3L_ABP.F-.TNFK8F
M@I\59J5O/NRAP'3:AQ0:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((
MH8=@$?DUD9P&&:^\=ST_T1L JTFAS96N=LVLY*OTP&RR?OM1JX%*VM-_.F'6
MHW49(+^Z1QQ .I\MUEW\@VIHY"<L1S U2*RN238J%?F.*V.+2.)MM&Q4U@<>
M(DF9QVU\]HCFFGE[I<T5"H"^UJ0EM(S0DJ 6I>/='#Q!)QF<.F(T_:3X)NN:
M7(QI(V^.67P=AQQ&VW)CQSYIDK5+BX%S7,?^\B4P+KV%X@+B1 3=81Z2H"/4
MJ3>Y_M!\SF] :2%GLG"U?+@T$AM. :2$E)4)9"71F1%+_9^Y9/\ ,C62[S<@
M7++3N%UY:OG+X@0D3GQ3F=V B?"S9(,T$6S=!)NW01201;H%*D@@DB0J:2*"
M1 *1-%),H%*4   *  &OF,%/*)4\2IQ1*E$F9XCG'U0:::8:2PPD(90D)2!@
M D8#"/I-[2_=#],-9 F9QZ 8SVB<:NWGXXEG?.?F YF_-^U5.1V7BN"K;F.4
MK>XRK=F3YWB*9&2*12_!T &WAIA7+[6I&T*G[\?++F6ZIS7%R"\2:LCLG$^;
MM Q=6B^VIP^3J941CG.*&4F\50$IO,LDK+2S^V&6, !U. LBSHJ@&^<4Q=A\
M0T\[<I*J-"D;OC,?07E0BGIM 6U-&CZ%32B2,YE:ISARXOL#[FND$*$QE$CR
M P&418/5"Q=4/A7BQ.."-0N;?+ETB(E0PE*^4J[NG>^6%(G]>=DC)LHTQAV$
MI5#%#VFT@ZC[S" )3G\D58]J5JF58+=4*2!6*?4E)VRD,_=MAO[TSJDJ7F]E
M?W45OLH.-\X,P4OU!U O]("+\T/9U^>8_2(_+M\.N:P ^>L#*41][,25)U?5
M,MJ)9\E1Z,ML-<=S?&KW%7< Y<TUZT!FF?--LM$6B =!%82_+$NL.NGMX>6L
MSGB[#\8"'P:2;LA35>KB^<<)>F(JYIVM=JUW<6'!)?G%P;BDF>&_")S?9@RW
M'Y>[;O&.1;O =2=)J+G%-A*(@*K.9QQ(NZX#94-Q, J13=JL3?Q%-4H_#IYV
M]U+]$E:)R D9[_=*+V\H+LW>- 6YYD\26T%!Z"-^[.'25/ -_$=M_9]S77/&
M6^).69(.!/0,\XA/^IQRXSL?(GCUA=D^(X5QEC*P7*?:)CU>X2V29QJUC$E0
M]A%S0M1!7P\?+6+\FFSJ%U!"$IS1,GME*7HBE7M179%1>Z*U,*^D896I0W!0
M21VR$*.]+OC5VUK_ "RS"Y9F39R\[CC&L2^.F($<J03";LTVB@H/@<&_Y0LN
MK;^N.&_LUZ:<"E-K=^:2!TY3AP^RS;G&Z.ON*DR"EI0"?Q9^C"):A?9X_'^G
MIP@$$SWQ;1(D)'.+5$P. @( ._RB&O-;?F*!)((R(C/"D@I/A.<0=_4Z=ML*
MA9X[N&XE@ 1KEQ>Q=-Y)QD8V#R(NW&*6.I64UDVY !%M9$$4XF47,  #U-HH
M8W4N<=6>Y$Z\4A#FC;H9I<,FB<2$[A/*6?P91 G-C2+:0F]6Y)G/OD;%=/7C
M&5O3$=R/[08R/;JRS._W]#(3-UXRR,DY^<Z@P.K*7O%:*BHB)U8=9928BT__
M %51VD78$4RZ3^>NBFZ6J:U?;T<*5]Q](&T8!73T],NF%'E1JA+],=-U:RIU
M(FE1_FS/O1,T X#\8?=#5=HFH&>PCKB[1&8-$$&B".LF%U6L9(ND1*"K6/>N
M$NH.HH*HMU%4Q$-PW+U$#</A#643+R&SX%* .^/)Y9;:4L9I03Z!&O#F/4\=
MS=G-3$>U1XZ&293$LQ;D'$LPLJ*+)^X;HE$Q+N G4\E,O4/2&YO'X=6TI^1F
MCONUFMJ:EY!4PE:\9 $[HKK4\U=2(JW6J9MM3:7" )"<AT2CXR^J%[G+7I6>
M1_'+R4SE%3WC$E@;)"41\"G5_+@GE@8/AZ@'61R+T(Z XW7J4E0!P4"8\U<V
M=6M'A<ID@]*99]D.J< _5$1.4\B5?%'-W&=4Q82X2D?!P><<:/9/\A(V5DUR
M-8XE\JMA<R,G7XATY5*F:3;/G2+<QP,LBFD!E2L?67(ZJM5*NXZ;J"]2-MEQ
M252GPC8G"1.>&'7#LTOS756U::&]-^6MSPE(P[<?@$*@]4I.RT/V^,7R-=G9
M:&<K\FZ*0LA 2[Z+76:+4;(:OE@]BW*"BK942$-MUB0VP#X[!IN\D*=A_6@9
MJF@XTEM14E8Z4G+'$3A5YI5[M)I]FIIEE*_.P*=V)V=$=UZ7"8F9WMU75W.S
M,Q.O0Y09);E>3<K(2[LK<M3QV9-N5U(N'*Y6Y#',($ W0 F$0#Q'6O.ZG8I]
M:K88:0TSP#NIR^='MRKJ'JO38>?6I;W%F8DD@0=MMQ#[AA#](0VU$*6PG 3
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M5IIM/5U_[Y!I+M5'P!%RJW1TJ$$A]C[^&OH==[+;M2Z21;[NM+= ]3M F<E
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MGT2GTPK\[0@NTJW 2E"00)RF2I0^*&\.VWV)>1W<GQFWS[8\M16%L-BJYIE
MLEKAIF^VZX-*@J:*62JU?)*P[6*I$ [149H++.R$,NDH1N@8I3'T[-:<X+3H
M2Y.V>W4X?K6UR64@-RGC/B 423G(##?O0=.\N[OJVC16U;P9H".Y/O$R)$I3
M$I';$B'(_ 28[;G8,YW<<YO(L3E1VK$Y+R"E<(FO/*NBY86J5I*#)DZB'C^5
M,B^9(Q'2H8CA1,X" @(>(!!]'JMS67-*V7NH;\M1>;2$D\6 ,YDR$R2=T276
M:=:TQH"MH6U^8"@\1RQF!AG$/CMP\$\Q]QW.B/&W'-L-3*>U:_QFY4MDJF_D
MJM3H&$,2%:6)Q6VCIHC/VI=>6%A$H'.D8QW"GWY-(%C:M#S$U/:M%6M5ZJFD
M.W92REK))5CU' #KRB#-&V.LU/6_<S"E(M\IJVCIW0[7W3/3P-N"7&"4Y-XB
MSU:,O0U ?5YKE2L7:GPL*_;PU@E&=?);:W(0#HZ!63"9D6Y'+)RD<Y4%A.5P
M82"48ZT%SH5J6_HT_=J=+7F \"O,*AQ;$E)2)SZY=$//5W+2FT_9E7.B6M2F
MU $2D3O(Q.4-[=NWASR-[N>5*'QAD<U62'POQJH$M+ISMG,]M\+A^D35@ Q8
M&BU=5\Q;KSUKL3P2-DE%TB(H(''J!% B(NG6FH;)RSIC>J"D95=JQ<L $$G>
M52.0&Z$/3=GO&M:I%KJ:A1MK*)SD3PC8)3AP/NK>GK9\#^-,GR<P_G2S9;J-
M(DZ['Y0JM]JD)#R[**LTNSKS.SUZ1KQP9.V+6:D6Z3IFNW*=-%7S2K'Z#$%L
M:#YX5>J[VSI^ZTS:&*ESAF%<6&Z12,>WT0M:SY84VG[<;I1NK6IN6R1!.1S,
M/,>EQY6W/-/%'+& [[/O;$\XQW6OQ]$>RKI=[)M,7W^+D)"$KRCMP=159A6Y
MV"D4FA1'=!JJFB'S$R $6\\=.45CU$BX6YL-TM4A1X1D%)5(GM&,/SE+>:NY
MV'RJYPN/-+P)SX<I'MCH.[QV-N1O<!Y@XVRYC_D(),3S[1O7KW6LER3Z5CL
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MNL6;8E"ONADA=0L822D@E()!'> (RB3>=_,6CY=:0=JBM!O+P**=$\RH2"B
M0>Z3.8EOV1#\[=G#FU<^>4,;6+"O+O:)#OSY"SQ<5U55':L&M)G=.HU20/\
M./9;_+'.V3,(B<I#+K[?>AU?GG!KVV\K=#_5+;Y;=U=9+-*TG )!$@X0"#-(
MQF"!LE'SWY.\OZ_FUKM3]P2M=M;>#M4[M,C,H!,Q(G8<>F-@O6X*)JT)#UJ
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MA0#C^,(8&](H7:>YV]/PQF / 1'IW\_*1?9^GJ6/:*P7;-Q2Z/2M(B/.3#?
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M;_YE>/\ _BV0OX7:/W/M(_K6X_V2?D@_?-UA^K:#\L_TH/Z1SRW_ ,RO'_\
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MT#L@5RR,N\-QI>OJW8V31._YB,J[>P,LT:I%4Q]D4B1E7+AHF@F4XG* ")@
M1$ ^'5R^9=SME3RQ-+2U3;E0EIJ:01/-,XK7HNWUC6O%+<IW$TZ724DSP!._
M;&S53^@&W^SY-4O9GY*9Y\(BS04E7>3D8OUZ1F(RWJH8V0DNWYC1M&QTC)N
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MMSC!*1F<Y@=,-L>DQB9>,PSS41E8B6BS.<N8L%-.3C7L8HNE^1$T10R)7J"
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M]2K^*?;_ ,U?4?1#Z?\ ;?C^3;6]3Z]7C\/SLXQ1>K'J_P"1E%9/ZO\ YO\
MI!^'_@WM_K_E_8_+KF/K5>+U/S<\XR]ZD>#UWSLOXXXHOZP?Q-],/Q1_M#?7
M_MOV/R;Z]*KU['K?"?%U;(WH_5+]5G\S+MC'6;?Y/+!_))]3_P#OA_)I[1_?
M!\GQ?)OI2MO^9-_:_"?4>+9ETQPU'J%?9\_SN48"XE?1GOYD7T!_FB>WZ8?C
M[^U_[[;7=J;U7_\ IY'[1GV=&_LCGM.:OL'_ ">W/W;X5HE^&D_>U]<7ZO\
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AHE^A_A'Q?)MI(;^SN?:LDY>'MCO=^VM_9<SGX_Y,?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>cm270_s1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_s1img02.jpg
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M$0'_Q #S  $  @(" P$!            !P@&"00% @,*"P$! 0 !!0$! 0
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M"1U=&:;##IC%:98[2C[884YN$,:H U)SSTA9@,^8MSG'U?212_)K%UQKVO\
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MUQAZ%R$?X<!')D#:><B&#QEJ"RA" +.,<N7N[NN:;SQO[6:+Q=[&R9FD9'2
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M-;]?;[KYGB<>DEAV;.J:DT54SJ!0^Q8&THZ[42=0['N3!,"%Z0+[YCN0)O/
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M757BNU=CGJEV^.V.34#E*9_"&1FD*UPMRKC())7AO+86UU92D2DIX G$6<L
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MVJ9V1M4LCLH;*_J[U.,6A$YNG(2R2(V?'GY]D#?*XXN)(]!&0DY+&+(P"P/
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M&,_%T9"&YV)K&MW%6C5RI;('M H:#Y-(T[>H5)V- TM:LX*9.89ZT:H-P,8
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M>*5^\7'JAMO+>O\ 2SR4]1%IZ1[T=./(3]#A%?SY.X1_>*5^\7'JAMO+>O\
M2SR4]1%IZ1[T=./(3]#A%?SY.X1_>*5^\7'JAMO+>O\ 2SR4]1%IZ1[T=./(
M3]#A%?SY.X1_>*5^\7'JAMO+>O\ 2SR4]1%IZ1[T=./(3]#A%?SY.X1_>*5^
M\7'JAMO+>O\ 2SR4]1%IZ1[T=./(3]#A%?SY.X1_>*5^\7'JAMO+>O\ 2SR4
M]1%IZ1[T=./(3]#A%?SY.X1_>*5^\7'JAMO+>O\ 2SR4]1%IZ1[T=./(3]#A
M%?SY.X1_>*5^\7'JAMO+>O\ 2SR4]1%IZ1[T=./(702OM&QZ+1>22=%N_O\
MJ%D;87=_2)UFPRTU&>J9D"AR3DJR@LI8C4IIJ; 3 X$'(@9SCKCZO,>ZZJ(+
M6UDN6:WKQ?'&YP!NC0EH) /%V88K%O>I&VL[.6\CWBWF,D43G@&]-"6-+@#Q
M,0:8]I?-A^V^YSX-#,=?1A5=6>G_ "^1!>3,O0*^ ]&A6N*@"1O1JERH>!B
MF1IS52@>"PY&/("2 #,%@  YSGICT8QUX1<QO8'UVP=EJ979SPG%@"C+>VK%
MN"!YQG. '93$F>4+.,9] NF?1PBXR=M<5AYR5(@6JE*<!QJA.G2GGGD%I_\
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M"Y.>822,18!A+SX>$4(ZC]@/2/2&SIY)Z#=+C;J>N"E7>F[LUAF4^53NE;=
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MB-_X*<(GT.?23[H+L^<1O_!3A$^ASZ2?=!=GSB-_X*<(GT.?23[H+L^<1O\
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MYZ8SRQ<]8VJW5M);#=O6VF1CFU,0H,P(J<=@JL>\ZV=;O;26S;NEO$UTL;F
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MTFO111D75O4JUN@+B4"#,ZN'0M2BA+L$(5!)43;CFX9$<<_"'!@0(P$G9QC
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M?)7J'=U+1^BZ<BJ!AK3838Z^-I:TDL!J\Z23"'L&F&Q\B12"5/!<O;V9$SM
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M-?0!"A;] WRF[896RRU4(S+]B'N>UK+G9Z52A RR%0Y*'@J('^8[*T:Q*H$
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M,8'C&<AZXQPBZA;%)2VCP6XQI_0&9<\LF"UK.XI1Y>0@+,$T8">F+%ES"6<
M64__ +7&!XSX?3CA%_'.+2=E2%.#Q''YI0*%:E 0M<VAP0)#ER,8RUB(I2J3
ME$F*TAA8@F%X%D98@YP+&,XSPBZ'A$X1.$3A%?+MU=Q78SME[%QW8;7F1"3J
MDXD[9/X Z'J10FU85E2 YQA\P;B1XP:0<'&1I%@,>M-RKPG$BQG @C(OU]>V
M?W,-=.Z-KHR7S0KV%.Y)P)6JT:M=E2;,VJ::Y38-61N2(RA8R<C-%@1C<XEA
M]5<4O0PO.!8,++(MB/"*"=E_ZD)Y_P!P1?SL@YN]W/OJ#\H_-*YK>_\ IVY_
M);\YJ^>W:O81NU8HJ77BZ1)WG22*+X>VXBC"O;FQV=U<RF#'#D!*1<[" W)Q
M%+GTLP63A!!D(<XR+'U<2C>W0LK9UPYI<&D8# FI X?=4)Z;8NU&\;9M<&%P
M<:FI RM+CLQX%16>]TISKJ-V8CE&N.62YZ?LU97\]JQZO*"HF].A#7)=J-,B
MC,O3-K@IFASS%3RP8;VUJ./2K,Y"H&63C!^=;+K+HF/#XJ7$;\KFE[>]S5!X
M:C@ P.U;B'=UL\D9CGS6DL>9KQ&ZOQLA!;49:'A+J$;,<%"LA[HUI25QM9Y8
M*X=(%2[%3FD%IPN;-BV$OL_3*-H)XT-(FN01^0&JVI4D=$JU0A_B2\&("T!Q
M_BR8>G\.,_69WE[FL+;<1PN!P+OSC@*$'#M=JG;"RV;NVT;8FOD#[ITMPQS3
MF#?S32:@C'#;VZ@; 5)#9WD*Z=5UYJ$M)391#ZJA]XR^+R5O?D"\Z9@H%YRR
MRQHD;9AJ*3ULOD)Q9IS%ZVK5X7$$C\?DF= <NC7XB9/S;N;8UY!KMR&A!PXM
M>"M:]I6';JSM$(,S.=D=&""*9><%6D&O& V.H!3MKIK"[H5TIS&F*0W5H4>L
MLO8756OGV.RJRXD]I%58[.-*F2Q)[;'AMRB;D$K=&] :B-(-R>0U*,^8,9H>
MG/DNLW&#(X:2\[&T@N!XLF(/:/!VE7!N[:$&6:XS6_,3.!#'#CQ&C@0<<H)K
MP$A6:UJW_2[!["6-0+M4:VH7J%BF FI+-)RU G[ZEADBPP+' ^M530TNI;2Y
MEYPM2+FU2[H_5! R<:2,80\S+35/&KI]JZ,QN;6E2,QH:?%H#3A!%11:Z_T0
MV-C'>ME$K7Y:Y6G*,PK3/4BHV$$--=E5"S;W&KA06?L)7#WKH7)9 R[B1[4W
M6N/,$]CC$"<R%R@)$W6BG,D<LKB8VG11XLQW.793C+P4I*1E$C/+,SS'&K7
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MK$DU^^-SV&W?S@C:*9FF/83P\;$BO86^O=WHK?2F2B*07D?-&5QKE<V7:&\
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MPTM[@M1 =%Z,@D)I!@<8&10=W$I;8;[JO1:6+1/82::[-';[TL0VI-ZX[AL
MBU$HF>+P&&FVQ'9'IT62-_E$C0H$BA(X$ 5A4K%P@F>#&2_#DBS+:(U=9,([
MC$N=MS66(=O)YIB-.FA<$ADZU5DVKTG@+$WQ!95]&1ZDG]Z5W+5VPB&0I1)U
MCBSLR)U2&DJQ*E.<G8R(BV)2Z9:CWL9M'JS=%L5,VUQ=_< 66V"1YE\1/(0+
MM6]7-6KK:QD*"W4(,-LR;X:_1\)H<Y+/4*#" ^,SJ7DBQ.W-I#[_ $&[MOTH
M"1S6RKGJWM.3UMKW7'<.!ZFV84@5UK:3G+D37:;KAR)*;H8%P3)WEI"1Y@Q"
M++,\OP\(J::T6)0[G04 U4WK5%UU+[Z[OEBR]CG]J7A$+RM[6FX:ZA5(3NEY
M-85J(ER1%-HA8&25,4>GD02$IA+@$7B!ZN9X2+61W9[&>+ TZVG).F)\NAL6
M[^.TB&M0%/0'R-L,6?:O=9*H1PP].<>WIV!U=W$Y;T2B\@XXX1N.N19SDB^?
MJY(#2D*:ZV55'?WQV.4GBH':Q&KXJY96_P 6$G$!'D<1]>DRQ41-?+&<:'U]
M#@M/GR>OA^OQPB@OA$X1.$3A%?'MU]Q38OME[&1S8?7F1"3JDPT[9/X Z*%(
MH3:T)RI"<XPZ8MQ(\8.3G!QD:18#&%3<J\)Q L9P((R+]?7MG=S'73NCZZ,M
M\T,]!3.:8*1IM*K794F%-:FFHDP35D;D:,H6,G(SA8$8W.)8?57%+T,+S@6#
M"P$5G-E_ZD)Y_P!P1?SL@YN]W/OJ#\H_-*YK>_\ IVY_);\YJ^=7<K7 &VVN
MLWH$V1IHHGFSA"5*MZ5MA[NG+0Q2;Q^6+4)B%*M;E _:Z5E&DP,!P,E9.\?I
M\/3,GZA:>/6CK6N7-3';L(/_ %I10MI5_P#9E\R]#2XL#L*TVM(!X=A-5'*K
MMLZ6K&-M8%%."-);99(YJ%X%/;%^&#D_2YB)B\ER_P WQ*L2R0-3Q&DI+<<A
M6+#D>41("?+\ >G+)TC3RT-,>QQ-<SJU(H:FM3484)V*^-?U8/+Q+B6AM,K<
MH#344;3*"#C4"M36J[)3V\=1EP&X@VK5."FZO*WJHE,FF<T3)5<&J&2H);6C
M0YH4[X6C=3X<]MI0T:H\L:H!6!%>9DL8PBJ.E6)IQ-C&MVG8TU:-O =G"J1K
MFI@DB3$R.?\ %;\9X+7D&F&8'$##A7$5Z<:6H9A8D+411L;)5L?$)^5)JXQ8
MLO2$2.)OSDE7V<YPRO!27V/&R75W5$G.RUH1)AY4&X$,8<CSU^&PT\2/C+0)
M)FNJW,<03QJ-K08[2 OHU75C%'*'$QV[FT=E;@0*,#G4J:#8'$K,9?H]K-/,
MR8Z35P<L42I53BYX<$<IEC0X@<*!2F(JE<&QR:7A$L9E\32G#  U,,L9^!Y\
M[(^O+DFG6<N8O94NRUQ/XGQ:8X45J+6-0ARB.3!N>@HTC\Y\<$$8@]@_@7NK
M_4#62E+.47)$(01'K!?,O3&U/+W-)6\HVD<V7%N4D:($QRB0N#+%SI<XIPG*
MR&L@D:L8?3C..N.(K"SMYO&(VTE-0"232NT-!-!7AHODVJ:A=V_BLK\T H2
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M JD-CR4"#UE\12L63 ><G",M(8G/ HR6(DS ;@U*R+<S7U%6<!QS_%IV:_\
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M\L:8"^1^?Q->WVFP-LHKD7MM"E5S-@=T!#HWN4?;5IR9R<23T"D!F< )R,O
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MN3>F[DFBG=&W/&[,>,^CR&EH.6M&X&N VJ39EJ#+;([D%7;&/443QNHZ2JE
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M$3IC]['^;'")TQ^]C_-CA$Z8_>Q_FQPB=,?O8_S8X1.F/WL?YL<(G3'[V/\
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M+W#GL#J:C>(^22X@4Y.,P0(*C&3L SCH;FTVYM"'&K&L:=IR@'#-4&N(X?\
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MIHO4,OD[&J>V9O3".7/H5;4P8'D)0 CRM"<0 (O+"(1%$5I]UJNHW%XP]PF
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M:#$]DKD3/.'58Y[6C8*G =@?]/>6>@3C+  LM.,LLL "RRP$B" LLL. %E@
M$& @   <8QC'HQC'3EW#M*S1W8*\_*-_Z$W_ -T9_P"KS[4=D)0]@JW&F(#
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MIP\!!G.<XY8?/:1SLMG4Y]X) #:X#:20* =LK*CMK^6UDO6EWBT1 <2ZF)V
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MN]PJ/RHV659'=K8Y:R.3MUA471T%JX3BELQ/6TXU\B;LI.(0H/9F%#D7TQC
M,XX11OM\NUK@#CVV-:(PEI..R.W*5[7S_/*'!H/4(G:6 LA7 W*?3!SV].78
ML!,ZRD 1C7H MHL'A$:F$=D)H\\(K2W!!Z;=^[M1E!%4 -;3,?[BSQ&WVN)5
MVN:+U[ID<+CB"?EM</9MB(P>Z2"WF)4I1%DIDKHA((=B X5F \1009(D;[>G
M;JF!VCUCPZ'UQ+M8MU>X[<EDU=&'HUO9Y6V 9=9I"N0:.V3*$XT3FBC[)LG$
M3&8E#ZR46M1*2,@S@9WBR11#K3K!6FW++0\H[GVF=/:AV&@[E$6HVI8K&:>2
MZDE[!UZJK:P)-*Z+DL60$QLN5Q*)6!'X^VE2/!7KP,.@D9B\P9O"*6=;=55]
MEEZZ7'W)^WWKOJE($7<\UUJS7I S4;"*=8+9J&QE=G1VS:0L:!MGA;93'X&O
MBB Y MD*4+P$PS&!GGEJ0Y$10MV_]'X5%EFM\9V5U4C\>E5C=Z2_H<S1ZX:G
M3M4@F%)PG4NRERN/HFJ4-!"YWK./S7U$X)80#;@.(2A SY@<9X16*A.C^CMP
M5Y1<BBU75;&M@]9NT'9]U7M7;O%8Z6SWW7-N4+<Z2N[P9FWV<$#G9U(W$RIB
MEJLS U>4[FE/P9_V<K "*E_<08:XJW2BD(?6]1/,;7S'MEZKSE^-A/;#I6<0
M5UE$SK1H<YC-9!NNJ7IK)ADC<^ABE>L3HS3&\\.,8,SY@A8(OF(3T*N44"OV
M!Q:M$$H$$I+BHJF46Q'2;^5FF'IB/;J"HA"^$BN+ RIP,2\./)"6 8OJ!SPB
M@CA%,= 7_<&KEO0B]J&G;Y7%IUX\$/<7E3 I$G5)E!6>AZ-83GQ)G-G<D^1$
M+$:@!B94G&(LT @"SCA%^LKV-.^K4'=BJLF'RPUCK7<NOV0@RSZHPJ"F0S)"
MD 60?957 5&Y4.4:6&YP):AQDQ4SGC\!GC($4>81;K+P_JAL3_=5T_ZG/-GH
MOWM;_I6_"M+O']Q77Z%RTHX^IC_)CDQG:O/2I6X;GH\7],:6B]'VU.XQ5,AB
M\0NNZHP5&SX75$FF$4.FS4G>V)0[DS%U9$$= 6<YN:)&:E094%A%D6<YZ:XZ
M@/&G6[(Y',80'O%*-)%<16I%-I P6V&DGQ)EW)-$R25I='&:YGAKLIH:902=
M@)J:*N>>[;5[;"W6R)=1MTQ*".M/S6^*2?EV84M'?595])FJ,25SB[:WR(Y7
M%'<LU[2K$Z%ZPD-4(3@F8S@7UO,7[<A$9E?%(V(QE[#AQVM(!(QP.-:&F"S_
M #9N72B".:%TPE;'(.,.;>X$@$D8C @EM<5DQ?<U8S!OT0'KC<::^$=RP>E8
MM0REXKD,DF;[8]?*+3BCRGEA,G.A+&RF05$<J695K FHS2\D9"(S..5C6&FL
M?-2>-"0,#*MJ2YN8&M: 9<34X;%:\WWX2\_$;,Q.D,E'4:&NR$9:9B<QH*#'
M:NFF/=CJ>O[)K^KIO3UNQ&4O[-6KK9C1)LP]GDU,GVQ)5,4B;8\0\]_%()RI
M+<$@E*\R/E+2D38("H0L@%TQ3)K<$4S89(Y&O(;F!H"S,:"HK4]O+6@Q5<6[
M5S/;ON(98G1M+PPC,0_(*N(=2C<,!FI4X+A23NJ,3:FDZIKURMT3.%[V/K>M
M)L[N4$(BEBW3K>U2-WDL%3)D<D/D#0V.C?&E"A*YJDY1!N"QE8Z&XQC/QVML
M:'$129:R-:3EHY\=26[:BM,"55'NX]Q:'3Q9Z1.>T!V9L<I #ME"02 0#5=A
M/=^;:A_;]H';A+0"IRL.Y'>BV9PK@3PS$HV4%N2-K9L/:%3[<\M2A=B5P/8Y
M1BG!N#%B?USR0A.\'V74YX]+BOA%660L&6HPS&E=O#P8]BO"J8-%M9=;FTPS
MT@B$A#J''(":;."G&-*8&E<%U\V[L<&A(9^>X:_6TD00^\SM:65W?Y+5L98I
MI=[> Q?((BWO;K+2T+*UQA@)&L6N[ADA#C.,$EB,-%C'/DFN11YJQ/HV3FP2
M6@%_" 2< !B2<.!50[M339 V>(N?#SI #R6QG .(#:DN. :*GA7KE/=UIR-P
MVC+&)JVPW."W(C9E*]U.D-;L3S!E+K8?Q8'M H<[RDB43EQ9Y, 8U(V9,H2>
MHAPH+.&$6,<^/UVW9''*&/,4E*FK06U=EI0FKJ'L"E,:I'NQ=22S6YD8)HB<
M*/(=1N>N8"C01LS&M<*+&XQW493Z_-626ZI62X2<S9V^: J./PI_@. RHBB8
M:.:R!<_.T@E:1*TKT[,B.-5&9P%/@1Q19.#,X%GE#-:?5S7PO+^>>QH!;CD%
M34DX8;?^BN2;N196/BN8Q'XO'(\N#L.<=E  #<<=G#MJO<D[R=. A#Q.)/2M
MO0A(HK2I+3JUNDRZ IE5K1VY9HJKJ+82+$\F/;(2,F8(#RE(WHY, M$5E5G/
MEYQC/T:_;\V9'QO:,C7-KEXP><HX:#'L\&*'=6ZYX0QS1/(D>Q],W$+&YCP5
M=Q2*9:XX+( ]V> .T1A+S!:!N"P9;+(_?S^X06/NU=$F10K6DUJ':&5TM<I0
MDB[XV ;'4"QK7-AZM.YDY#@KZ\> XK^W(G,:Z.*1[W!YRC+AS?QL:T(IB"*U
M5KS:G;(]DT\4<;3& XAV/.UR4:!4&HHX$ A2IJUO&\;0[$V97##4SPPU!'*.
MH.X819;DN:/7'DFZX^?)D21_:R'90I0"5(1>6B+))'X1H5.5 P>,G [UEJ+K
MR[?$UA%NV-C@[#'.*XBOO>X:\"Q]1T=NG6,<[Y0;ITTC', .'-FF!ICV_=%.
M%5^F7=S: PK;EPKRB9.HFFL\/G$A0,,VFE>L[I(3H5)BHLO6R"O"I,59,68@
MF&Y<B334.0K&T'B+&$P9818LFNMYN<Q1.YR%I-"6BM#3%M<P'#LQ"SHMV'<[
M:B>9O,W#FBK6N(&85%'4R$\&W J<6WN.PQ'') IG%56-&95!)-J? YS'QCBJ
MC*.6[8-S2JBXF]0C?E:,QJCQCH$2_.3LF8+Z>5Y@L9YDMU:,,)D8\2-,32,-
MLM*<.P5Q6&[093(!#)&Z-[9G-./Q82:UPVFF'_X5>97W3I:=;-8K8%0MA*==
MW%-MZK7254EAZZ07@EUB8U&'8VIT9$HPZ1DY!(VI;T)=TQ(G-*7C)60Y]',1
M^M2&=ABB=XJ>=QPJ_FQCEQPH0=NU9T6[D0MI!-,P7PYC#C4CYTX9\*&H(^*<
M"MB5#[25YL>^SMOK!,[NL<@;)5CJJGHO4,Q9Z<+5A::?-\;9C2%)JLYYCD<<
M$9CG@8 EDF*P "(0L"Z;:VO8KMSA#4L:&FO <PS4'; I7W5H[W3I[!C#<4$C
MR\9>$!CLI)[1(-/<5U:D_K1KW_?!A_G GEO5?NR?]$[X%<T/[YM?T[/G!;O^
M0PO1:<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB_+)_;&?\5.+?V8:X_I//.$6H+5OMN[MWU1K7:5,3"KX16.P\^>-?HZPS
MC:.M*2<KYGL.,8'Y16;3"9C-8TLL):E7.[<<F1B(/+$J,*$#'CQC."*HTHQM
M="+$DLQDZ^]&:S*/?%%8R6?'O$V')*R>X66="!PQ1/$ZPY1'#&!*0)L*2@6E
M@*38\DO'E9QC)%F^UE(;>ZW7*W178_XP"K/B#772>,2A3+7::%MZ!9$F";U^
MT0R?)'!R1"&QQ]_1&)T;>K\3:8+R\ +&#.,$7O>]@.X/-']%"))=NY4LE$:7
M)9>W1![LF[7U_C[FWIC<HI0B8%[RJ<6I<A1KQY*6EE%F%%G"\(\!'GJ18$KB
M]]!J"MW$$T>'B$26UY@GA%6-%AJGF2,]HL"9F ^R8=2(7-0[QIZ="ER<DAU$
MA*.7Y)$6 P>218"1<&:R7::Z9-DJQG^_[9F-;-^2A%S5UL6>2: M:(8#,EY
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MW,B4ESLM/6A+F-O9HS+7)2-2XD-P"C!&C$(&<>@//HTJVBE\8@!Y\9BT%Q+
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M*8NK?-I*[BI0.Y;,4AM<&.$%->)2PSEK<=8$RIQ;6@)JHAX(P,;24'(3'8C
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MY8;JUD8C+F=@0",KLU2*CBTK0C$&E*+*=H6I-F$):SC-+@[.S*0#0\:N4$'
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ME^D,,;*\DCY!%;O#%JRL'B20IG3-S@ICAC6:K()#Y@A#Q@7"*/EO<8W&7H9
MWG7&X%D2>K]?:;=Q)F"*I5!U>ZLO+5(:)9"%1#( ](9 WED2GE*BA 5*1%8P
MH,-QG.,D4';#["VOM3;\QOF\) AE=IS]6F<9A)4,9C$3P^N:=$G0Y=%C1$&A
MC9/::PI,$:E0%.$U4?D1IHAF#$+)%"G")PB<(G")C&<YQC&,YSG/3&,>G.<Y
M^IC&/W^$7VP_L^'[.H[W$YP[<3=:&GI(0G-022HJ5D2(90GW ! 5-LXL-M5
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MK[?\E9"9$E9:AK!H22]6C7RM$VIH<B025<WI2$*%8^H4R4M&ZJ4:-*446,X
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MS:4X,"3@< H/U[K0WL@WRO=T=TM .J2V$43Y7^-,AH)6AS>*]M*8TP<3@20
MNH_+5[HWZJ%7_>;KOWNY9\\NLWT5/3(>XK'G_P!<7H4?YA!R4_+5[HWZJ%7_
M 'FZ[][N//+K-]%3TR'N)Y_]<7H4?YA!R4_+5[HWZJ%7_>;KOWNX\\NLWT5/
M3(>XGG_UQ>A1_F$')3\M7NC?JH5?]YNN_>[CSRZS?14],A[B>?\ UQ>A1_F$
M')3\M7NC?JH5?]YNN_>[CSRZS?14],A[B>?_ %Q>A1_F$')3\M7NC?JH5?\
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M:R\,%IGVM*Z>$I"]OITI05@U*\.2<X)J9990RA]<"Z" T8SX2\Y/\0PD7W)
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MKIU.G":MTI>K'ATN;FF!Q1?6]KN,.KN'--E5ZEC48;T<>D<:3UJC/3C\)WK
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MC%Q63"\!",TH9%7#NK_UK=KG^W_6_P#-CAR(^M#[TW9_CT/P%05UR_?.Y_\
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M&M."4_(WS9EXUV@B*A,25<V/,R046A9X<XULXX0'ZJ(K E4)>'9NF@4Z!<Q
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M:H=?MLHO8^P$]K]TVQ8)I73?N[(((Y'HTCLWSZ12K:V(6!54+;5<DC#DEE\
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M/P%05UR_?.Y_^Y8/FN7PJ_MC/^*G%O[,-;_THGG)<4ZK7%3/=#A>NND-*4O
MJD)F.PL*/W#8U=@RYZDK;&(#"]FR*V8W4IABS.[AC\]='R+1E<2(;JF#[(4Y
M*.*\[.?"$BDR)]^^X(]*+'=5U(Q%XCUM67L384W8PSF5MSP(F_76GG\+#&9>
M%.K<(WB#/E,-QJ54 DX2HD\XHP ?XL82+C0SOL3J.-J5R?\ 6R!S6VD+FXIT
M]O/=DV.8^FP-PVO8]NQ0]S:E2QP;W9Q^'K/ZF:]GB$O/0&8\7\8'(QD6+L??
M,O6+*F%UCU70DIZC#?'DK*H>9!*'QL+61_<][W*+7K6@X],!4-:_/AC";@)I
M0\( X/ 8$_ZA%QQ]ZB8LK='8=6^O4-KZKH5):,D\-A1-BS^2N#:MJ39A^VHD
M!+O-9 H4R"1);$L&0FD#*.R IJ0%% 3@&9@9AA%)=3=^Z75?)$DP,U,J.2RQ
MFAZ"'1R4*I7*VZ0-#<3+[UE3DARY)TYPU+ \YO96 ] $)01*&Q*<,P8?,)$1
M<6*=^J=PLRC')JU7IJ12FE(+)H*1.+1=GNTYL]M$HAT=@:EF)EDO1+']KAB.
M.LQ^$[2>I<0ICUH_)/*(+ GP1:=-DKXENS]\VML%.T+ V2ZVYF\31\;HNT(F
M-A0JW4_S,)6YN0$)TY92<D(0B,R'S#QXR:9D1@Q"R10CPB<(G"+OHM%I).)(
MQP^'L3K)I5)71&RQ^/LB(]Q=WAV<#@)T3>WH4P##U*I0</ 0A#C.?3^]PB_2
MC_9]OV>%CU5:X_M'M4Q-TBV0=T12YA8E99*]GII L)P++<U9'@:=9-SB1^!:
MX!ZA38SDA/GIYAAA%]EB%"E;4I2-&2 A.2# "RP!P$. AQTQZ,8QPBY?")PB
M<(G"+3CK)_C#]QS_ (/:R_S&?R(MVO[M[P_5+/YJ@G='^^>]7U&P^8K#S[?9
M!5ML[#P&94_/#HW28*+3LTR8%D,$AFKM<C%*GPU*<IDTLC+-$4,<)C(@C6.J
MM&F,%U!@?FB)+,EU3LJMM_>-KXR</TE=HD[->N#C"Z-#3#^>C8$<[MZSKE9I
MM,#F=(J>[$9XC%V:(12 N.5.''R0FG)31@69#D@H\BGMB[K6LLA,:G- U6T7
M72M-7XWFWEL'*1UY$'"SHB]3&)LLD4&O6)(!Q.11Y6G4B2-JM,D5 +"8=@!Y
M)@R+OT/<FJ=Q6,<:3U3L &SIF1%'NNJA.@S&38-BP:9,,HE+/8D83"F'P>#%
M28_#'(];A<XHG!"8GPG.3 4&DE&$7&0]S.AI)59MEQY!8:!(J>J]B+:1)(2)
M.L12BUJ^<[!AP'QE*?"5I*)$VMP@.8 F@/3GXR4'J+Z[!%T#;W3Z$;V<3U/V
M2SHQ$V9G7ER2X%4$ @JDR9Q^BFO8.01AF,^$SM*O6Q5ZO&J38,1C3^<4)()3
ME1C&!D5@]7]T:;VQC,\DU>&OC2"LW-"W31NE!+-@]I+=8^GE+0Y =(P]R:,N
M"%>QJ?,SZLO-.2FEF$J2R3@9!PBA^*[]U/B/0HF"Z_;  (LY2<X43%6&KHZS
MXNB-K6Q_F[S.Z_R.5-T;2LJ9H;3W1<6[JFETP%:F&)*(Q85@9%T27NGT>_N#
M.D@%8;#62CD+G&HPQOD0KUHRTN$]EM;+;69Z^\;_ "YB6(I,")-*[*S*DDE"
M@5(C"%"@L8B_&1>U/W1Z8>5T=20NI]BI\FE8Z^:V%UB]>LHFU9,;1JY1;\+@
M@S7F8,YZ61KX>@5"4#-+ WH5*812A27D963"+I0]W[3PV41:+IG6:J#I+&(8
M_J%@&!M#\&'"P8:KG44B4B9#7XN5EOZUD2=%!J1O5MC>H.)+5*R?,QG!%FS'
MW%83,65&XQ6E=ALY55K'+2?%:RNVEQ2UC#K";7MRK"1V4W,DU4NJ-#+T#$>M
M]70A5JT" 'G+PH@9P+!%"L^[F]+PB.+BTT$./MNQZ)/GC&\ND58V*#67,&K7
MM?=+5%W1O%+%5GJ(\.)(U!):T]"H;$^0&(@KQ'XSC)%G-.=Q"! 8Y-&[ AA\
M0?8I)'.-UY%*\C^36B81IKM"*4RPLD*3J'%.6JE3=))8V@6MQ02"DB)62<#^
M*\?@(K$[7[GU;ITRL\BM)HF2YD<D,@>5[I&DD<]0C[#%@-YKXYN2R42:+I5B
MH@EQ -.V-XUKPN" S*=*;Y8NA%A+EW#Z-1(G$U$RV2^NK*"RS7Z--490X>X\
MGK26Q*&*5LA"YOC<VL37*G.<M9[0L5J24AS>HRJ.,3E%&B 102C[H<1GT@JT
M-2-@'%DF,]A,(EC/)F8\V11<:ZU9]64Y.0OL-E$ABLA7M*^%]$!+?E:G5>9@
MX"@T PEA(N O[L$3DDPKJ(T]4%ES>1.=R1N V#7^&R)K;"2P^:U%;]B164Q8
MAEL-1%D2\YSK#*=<B?7%O6-A7FA5)BC<E=2+B'=X>A(ZJEKM+"7(Z*+WZ.(J
M>;6)$C;IW(V<-/,=EV0KE;?-9%&V1H<H$XN)S<:C+585'J0EITY2@X7I(KFV
MCMA!X-5%,78VN UM>VT]QDYN7"C3LO<G")/]?2BQ"AHFS"]E4LSP>RQ[(@"6
M!, 29U*,)\8L9 1<_6W;&$[-)Y+F,0RS(.Z1IAKR7'1^S(\V1YY<H=:\=42>
MOI0VEMK\^HA() V(CPY)./)6)#R!E*22A8QU(J*T]W7%DOD#<=:&O5B5] '.
M"021KI&U(VF4%5^XSC8^U=?6I;/W%+* $E19T<86W&IQ-Z58N)$H4C/)"G*P
M9PBM/K)W#==MM+ D]=5&XOZQU8&!?+FUR<434%FEL2:I29#'!^9%#2].ZMN
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M=))@M601V$X1>?2*/)4[[7*"5,L8D*5J1JLM9;X1')JYMIJC)(A&HU/AZ8&
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M9$)0I"8$_P!7+.- 8H $W!%3/NK_ -:W:Y_M_P!;_P V.'(CZT/O3=G^/0_
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M*.,A'EJCAA#@UHXS&8^0H>UCRA6HBCT?J0<KL*P!,+%YN,"X1:\*WDW:]NE
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M[4BB$HK*MCFM6VRZ,M;&[HT(0FH;&EZ2=2UO:R%)P3L'R&<-Y#F,1'0_#@2
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MW1A\+GHJQU,,8 +DR,>FQKS+S-;5*HFG5-8#N)0M#7A/6R!NI^%N20,!8LH
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M73;+A#+0O-X-<7AH;5MF22VXO<-P%(':/F&/+<60H(6MC2:D&6,@I.FP 9>
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MEVB&S_1FE-BXW6-=(I$)S9'RRIG+"E*K,@DJX2U_3MK,C3I%IA9!:<)WD9+
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M!%A=OV9J0SP"7VC-RJ?GS5!\.LD-* A@LK=W25-=6G3Y.VQX*_S"ETW>*P;
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MLUTH-_4P2"1E\C RU%=*'-HA<H<%R2 @C:M<84!D8I8_1\U,TY :G1J%:46
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MCQ;IH6=/J2?1!['B'D>R%US$P)RJ5DV+/)]L>/VXT54]K&7#=C/A,+, 9D_
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MIX@FK];%!J*G=+1]>4OR9T $ILO.R:4RS^02@2BR:<?78G#!WB\. *L%>'Q
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MII>2V25Y:4+1*"HXI:CBE1K6:L*+-P$'BR(8<9(JF7#W6* KAF]<C#)8<^>
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M3!&P*DZT!9R9Q(5@&0+.,9ZD74PSN0:>3QZ9&%AM%>4KD"I@3-ZJ05W9<49
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MC;G/$3(1&R?8A+P8J"R8-."FS@ @!+(L.DO;PK66.<_7QNX;*B2FR5-PQJY
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MQDBC76@O>>Q]@Z77W7"[Z4UI$;8K"RTB^V&)?APB$D>Z+V7BUJICG==!Z_\
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MPU&<>'UHM$01=;**J*=AI:[<M2+FB<8N*VK<F$,MPBA9Y+E>L&MKA:T<D#+
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MK?DB?R_(2O,B314IW=$Y/D@\ #SAA#X ],>C''KKW&[^\Z-+R4]H?JV^DO\
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M)?\ 1)^2GZ<S0?[=W1\PEF^\7'KKW&[^\Z-+R4]H?JV^DO\ HD_)3].9H/\
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=L=VO&Y+BWU^"5X?;RQ@,%6DU<T T)Q[ J3@%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>cm270_s1img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_s1img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %[ H8# 2(  A$! Q$!_\0
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M7'C3P]<:E<VT5N\5Y);A8R2"%"X//UH ZZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#B?B9_PBUUH=OI?BF>2""\G5+>6-3E)>QR!@?CQ7F&M?\
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MBAO$BZ>@U9A@SY.>F,XZ9QQ0!YIXK32Y?'L.AZ5H.GWFJ:?IZ*9-5N-EO%$
M,!5)P2 >PKC]$#1_"CXCP%K<K'>+@6Q_= [N=G^SQQ7NFN^ O#'B6_COM6TJ
M*XND 7S,E20.@.#R*;%\/_#,&GZEI\.F)%::B5-S"C$*VWI@9X_"@"'X9?\
M)-M!_P"O8?S->:>$['1-;^('CEO&"02W<4[I"MVP&R %AE0?1=O(KVS3--M=
M(TV#3[&+RK:!=D:9)P/QK$UWX?>%O$E]]NU32(9KK !E!*LP'8X(S0!XUX]?
MP^/A7X?'AJXN9M)AU;:CW.[*G:V1\P'%=5XYU"SN_BC\.HK>YBF=)RS"-PV
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M>?H* -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SM4U_2-
M$V?VIJ=K9F3[@GE"EOIFN?\ '_C5O"G@]-=TZ."]#SQQKE\HRMGD$?2N'LK'
M2=<^-/BZ/Q3';R""VC6UCNB-JQX&2N?\\FN?\41^'(/@M<V_AC4+N]LH]7B#
M&XS\C<Y"Y XZ=* /8[C7=43Q5IEA%%I_V"YA$DK27&V<'!^ZG<<#]:T;KQ/H
M5C"9;K6+&*,2&(LTZ@;QU7KUKRO7_P#DX#P;_P!> _D]8?@OPQI6M:3\1+K4
M+59Y8KFX2$N,^5]\[E]#D#GVH ]C\1Z[=6>B6U_HAT^Y\Z55#W-P$C*'/(;N
M?:M34]9TS185FU._M[.-CA6GD"@GVS7S>TTDW[/6C*[%A'K01<GH,DX_6NQN
MX++6/VA[NS\3"-[&"R!L8;D_NV;"] >#U;\J /8[?4K&[L/MUO=P2VFTMYZ2
M I@=3GI5/3O$^A:O<M;:=J]E=3J,F.&96;\A7D5Y>^ ?#_@7Q%:65SJ5_I[Z
MAY4MM$Y14E);"HV,;./?( K&@A:Q^*'@<Q:9I6EAQA8]/N/-=D(',I  R?\
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M_P#Y)3JO^_#_ .C%KSK7Q=7WQ)\.6<MI87D$6B0/;6VI3F.!F*\G.""WM[4
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M$%GJ.E3@[B0 &90>>O?UKKM3_=_M$:(8NLFDRB7'H"V,_C0!Z=1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 445A:WXMTK0=4TO3;N1C=ZE.(((XQ
MD@G^)O0>] &[17+>)_'VC^%+V&SO4NYKB2)IS';0^84C'5V]!3M6\>:+I.D:
M;J):>YCU/'V..VB+O+D9X'T]: .GHK+\/>(+#Q/H\6J::[M;R$KAUVLK X((
M[$&M2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "O+/B'HFGVGC'PAJD-N!?7>N0K+,22Q
M 4X ST''05ZG44UK;W+1-/!'*T3;XRZ@E&]1GH: /*/$NH6>@_%;5KS6+B.W
MM;OPZT5L\IP'<-RH]_:L/22?#]M\+;_67^S64,-PDDDW"QLZDIG/3C%>X75A
M9WP07=I!<;#E?-C#;3ZC-.N+.UNX/(N;>*:'_GG(@9?R- 'FGPZMM3O? NNR
M:->I92WNKW,UC<O%YBA"P^8*>H.#6;XSD^)7@WPM=Z[-XQL[I+8H#$FFHI;<
MX7KSZU[!%%'!$L44:QQJ,*J#  ]A7G_QP_Y))K'^]!_Z.2@#H]-&O7>E6=RV
MHVNZ:!)#FU/4J#_>JU]FUS_H)6G_ ("G_P"*J;0/^1<TS_KTB_\ 0!6A4\B-
M_K$NR^Y&3]FUS_H)6G_@*?\ XJC[-KG_ $$K3_P%/_Q5:U%'(@^L2[+[D96@
MWMS?6<YNS&TL-S)#NC7:"%.,XR:U:X'0/%$6D?VI;:G!>B7^T)G39:.P*%N#
MD"MZR\9:3?ZA!8Q_:DGG)$8FMG0,0,GDBLJ=:#23>IOB\)5C5DXPT\EILF=!
M1116YPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445G7.LVMIK%
MGI<GF?:+L,8L+\ORC)R:3:6Y<*<INT5?K]VYHT444R HK \:ZK=Z+X0U'4+%
MD6ZA0&,NN0"2!R/QKE]:U#QMX2TE];O=6TO4+2W*M-;"V,3.I(!VMD\\T >C
MT5REAXK1;KQ%+JD\<%CI\T2QLPP0&C5L'U.35[2?&&BZS=O:6MRZW"(9/+GB
M:)B@ZL P&1[T ;M%<[9^.?#NH:E'86VH!Y96*1/L81R,.JJ^-I/L#2/X[\.I
MJ!LVO_F$GE&41L8@^<;3)C;G/'6@#HZ*X1?B!;:?XM\0Z;JTY6*SD@%LD4+.
M^UHPS$[0>,GK70WGBW0['3;6_EOD>"[_ ./?R@9&E_W57)/]* -JBL[1]=TW
M7[5KC3;I9D1MCC!#(WHRGD'ZUHT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >:^*?&'B)/%&J:5H)LH4TC3_ +=.URI8S=]@Y&!CO2W?
MCW4]5TOPC'H:6]O?^(0S%YE+K JKEB!QGGBJOQ(\+:AK.O+/;>&8]222S:!+
MF*[,#QR$\>8,@.@ZXYHN/!6L>'=-\%W6F6RZG=>'U=)[=) AE#K\Q4GC@^M
M'3>!_%4VM^'[NXU@V]O=V%Y+9W+*=J%D(&[GIG(KGOC3JVG77PJU:&WU"UEE
M9H,)',K$_O4[ UI>#O!C?\(EJ=GXELXR^KWTMY/:[\A Q!"DCJ1@=*Y#XL?#
MOPIH/PXU/4M,TB*WNXFA"2*6R,RJ#U/H30!ZWH'_ "+FF?\ 7I%_Z *T*S]
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M3->NT4 <9X/$M[XE\1:TMC-:65V8(X/-C*&8H&W2;3SSN Y]*[.BB@ HHHH
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MN)%/)SWQC\: /9M _P"1<TS_ *](O_0!6A6?H'_(N:9_UZ1?^@"M"@ HHHH
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MNH[..TN&>W$B3A/NMM)X89/.:[BB@"EI-A)ING1VTUY->2@EGGFQN=B<G@<
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M- #Z*\:\$> 7\3>#[#6;SQ5XCCN+H.SK%?,%&'9>/P%;_P#PJ2'_ *&[Q/\
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M@@,LIC##: .IQFN5^*7Q(T_Q!\/=1TR#2=8MY)FB(DN;0H@Q(IY)Z=* /9M
M_P"1<TS_ *](O_0!6A6?H'_(N:9_UZ1?^@"M"@ HHHH **** "BBB@ HHHH
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MK_H/V_\ WR_^%=/]AL_^?6#_ +]BC[#9_P#/K!_W[% ',?\ "T?!7_0?M_\
MOE_\*/\ A:/@K_H/V_\ WR_^%=/]AL_^?6#_ +]BC[#9_P#/K!_W[% ',?\
M"T?!7_0?M_\ OE_\*/\ A:/@K_H/V_\ WR_^%=/]AL_^?6#_ +]BC[#9_P#/
MK!_W[% ',?\ "T?!7_0?M_\ OE_\*Y_QU\0_"FI^ ]<L;+689KF>SDCBC56R
MS$< <5Z/]AL_^?6#_OV*/L-G_P ^L'_?L4 9O@X$>"- !&"--M__ $6M;5(J
MA5"J  !@ =J6@ HHHH **** "BBB@ HHHH *R/$'B;2?#%I'<ZO>):Q2OY:,
M_0M@G'Y"M>J6I:3IVKP+%J5E!=Q(V]5FC# ''49H ^;XKKP/J>FZKJFO^(]2
M?7_/F:-H9V /)\O8/3&*]X^'UU=7O@#1+F]N!<7,EJIDE#9W'W/KZ^]>-G6-
M2O[U3I/P_P##9M+A[@6AEC&YUA)W9Y'.!TKV?P)=F_\  VD7;06L!F@#^5:C
M$:9)X4=O\: *GQ$TV'5/#2POJ=OIURES'+:7%P0(Q,IRH;/8XKB?"/P_\5OK
M,%SKU_IQTR+47U399G<TLY'!SV7VKN/B$D,OADQ3>'6U_P R552S4X^;LQ/;
M'K7!^!? WBFS\01:A'>Q:'I:.&DTRWO&N?,']TYX7TH ]GHHHH X_P 2>"[O
M5]8.I:;K]WIDLMN;6X1%$B21GT4\*WN*AO/AS:#1=#L](OIM/NM$)-G<A0Y&
M?O;@>#G)KI-=UW3O#>D3:IJDXAM8<;FQDDDX  [FJ6J>,M%T?1K/5+NX<07H
M4VRI&S22[AD *.2<4 .\)^&8?"FC-8QSR7,LLSW%Q/( &EE<Y9L#I7,_'#_D
MDFL?[T'_ *.2NST76]/\0Z7'J.F3B:VD) ;!!!'!!!Y!'I7&?'#_ )))K'^]
M!_Z.2@#L] _Y%S3/^O2+_P! %:%9^@?\BYIG_7I%_P"@"M"@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,:4_\5E;C_IQ?_P!#6MFL+4=+OV\0
M0:K8M;DQP-"4FSW.<\5-N\0_\\]-_P"^GKGA)Q<DT]_\CEA-PE).+W?3T->B
MLC=XA_YYZ;_WT]3Z=<WLD]Q!?) LD04@PDD$'/K]*T51-VL_N-553=K-?(DU
M/2[36+%[.^B\R!R"5R1R#D'(K+_X0W2?[U]_X'2__%5T%%4X1;NT=E/$UJ<>
M6$FD</X3U-=,N-9L;^::.**]86_G;V)3IP3G(X%=,OB#2GFBA%Z@DE<)&I!&
MYCT R.M:5<OXRTC4]3.D3::BR/9WBW#HTFS( ]?\]:SM*G#36W^9UJ=#&8B]
M3W.;K=6NH^G5I?>=116"VJ>(%4L?#Z  9/\ IJ_X5:\/:U'K^CQW\:;-S,C)
MNW8*DCK5J:;L<L\+4A#VCLUMHT]_0U****LYPHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBN8\;+XN;3;<>#VLUO/._??:\;?+P>F>^<4
M >.>(=1T2[TV\TW1=&\2-IUKJ,MR-3M0&6%R"L@3/\'+=^]>U^"8M,@\%:1'
MHTKRZ<+=?(D?[S#U/OG->-06'Q.T*RGT!-8\-VBW3R-]G>YC#@R$E@H//<U[
M+X(TFZT/P5I.EWL<4=S;0".186W+D$]#WH QOBS?W=AX%G-K.ULDTT<%Q<H,
MF&)F 9OR_G7 Z3IWA_PEXU\.?\(7XADU&:_F\F\M3,)0\)4DR''W<8S7I7Q&
MUEM'\(3&*RAO+B[D2T@@G4&-W<X&[/:N7CT^S^'_ (UT VOAVPM[/5D%K-<1
M#,D=RP)PO/"\4 >J4444 >'?&6_N=2N;[3[O3]0&E:=:F2*2.!C'-<,.&9AP
M%4'\ZM_VC$]_\++^Y#VUDD4D1:X&P"01  G/KC@UZ_>6=OJ%I+:7<*36\J[7
MC<9##T-5[O0]+O\ 34TZ[L+>>SC 5(9(P54#@8':@#SSX>KJEQX2\32:!-;1
MS3:U<O92W"EHB-RY.!U'6N<^*5I\0XOA[J+Z]J6AS::&B\U+6%UD/[Q=N">.
MN*]NL[*UT^TCM;.WBM[>,82.)0JK^ K@_CA_R236/]Z#_P!')0!V>@?\BYIG
M_7I%_P"@"M"L_0/^1<TS_KTB_P#0!6A0 4444 %%%% !1110 4444 %%%% !
M1110 444T2(=V'4[3AN>GUH =12*P90RD$'D$=Z:\L<>-[JNXX&XXR: 'T4Q
MI8T=49U#-]T$\FGT %4;?_D,7O\ USB_]FJ]7-R6>LV?B.]OK.W@N(;E$4!Y
M=I4K[5E5DXV=KZ_YF-:3CRNU]>GHSI**Q/M?B+_H%VG_ ($?_6H^U^(O^@7:
M?^!'_P!:CVR[/[F+V\>S^YFW16;H^HSZA%<?:8%AF@F,+*K;AD 'K^-:57&2
MDN9&L)J<5)".H=&4]",&L'2?#)T.R^QZ?J=Q';AV<*R(V"3D\E:WZ*'%-W9O
M"O4A%PB]'NO38YXW-_9^*]/L)+YI[>X@FD8/&@(*[<8( ]370UR6M?;+?QUI
M-\+:XEL8K>5)&BC+X+=.!SU K6?Q#;(A=[6_55&23:/P/RJ(R2;3[G77H2G&
MG*"O>.MK;W>^VNQKT5#:745[9PW4#;H9D$B'&,@C(J:M3@::=GN%%%% @HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ H.<''6BD/W30!\U+<^ 8[#7D\91
M7#^*_M5QEV#E\Y.S81QCIUKW+X?_ &\^ -#.IES>&T0R%_O>V??&*\LT?5M=
MTMYX]6^'%[K4\5U(T%_-$ID*%LJ"2#T^M>SZ'?SZGHMK>W-A+833)N:UE^]$
M<]#0!A?$HZ*/ U\=>$QM/EV_9_\ 6^9D;-GOG%>4?#^;2I_%.CWFLW>NW<[7
M,UM8KJ#AHX)4"XSCHQ!./I7IGQ';2M0TN+2)M>LM-U7SH[BR^T./]8K97*^A
MZ5PVB>%]:TCQ)IZ^+]<TJ&VEU4W\%M;DF2YN6X&..%R: /<:*** .+\;^(_$
MF@"2YTO3K!M.MK9IY[F\F*[B#_JT YR1ZU6U/QWJ#:?X8CT>PA.J:^N^..[8
MA(5";F)QR>M0?$1]5NS-I,OA676=)N+8F&2U;YXKCHN[)& .N:R[O0_$FE67
M@76;BRGU2^T='COH("&D(=<9&3R1P#0!V?@CQ/-XHT6>>\MTMKVTNI+2YCC;
M*AT/)!/8Y%8'QP(/PEUCD?>@_P#1R4>#?!\EYX.UBU\0VDUM_;.H37;VPDVO
M&C,"H)4\'BN/^*7PP\->'/AYJ6J:=%=K=0M$$,EV[K\TBJ>"<'@F@#V30/\
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MU_S^ZW_X,7H_X4SX:_Y_=;_\&+T >B45YW_PIGPU_P _NM_^#%Z/^%,^&O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>cm270_s1img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_s1img04.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &] LH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#F/B%XBN/"O@?4M7M%5KF% (MXR S,
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MQL]2UC4/&NFZ=>VQ+0:3;,KAP,8'7.3]*@^(VNW/B7X!:'J]X%%S<7,9DV#
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MF@:??>'H';6-(=#:!"-Q48!'/IU_"@"O:>/=2N_'/B>5)4/AO0K5BVU!\\H
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MCA:!RA^65#@X8=\8XK9HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***A^UV_
MVO[+Y\?VC;O\K<-VWUQZ4 3457GO[.UE2*XNH8I)/N*[@%OIFGSW$%K"9;B9
M(HQU=V  _&@"6BF0S17$2RPR))&W1D.0?QI] !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4M)8FW(S28/_ &T:DFU*S94HTI474A%III;WW3\O(WZ***T.0**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BN;O?'_A73[V:RN]:MHKB%MLD;$Y4^AJ[;^*="N]*GU2VU2VFLH!F69'!
M"?7TH UZ*;'(DT22QL&1U#*1W!IU !1110 454?4[./4XM->X07DL9E2$GYF
M4=35N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*93.^YAD'/-;U;0;:NS"<'!V?]7"BBBJ)"BBB@ HHHH **** "BBB@ HHHH
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M".#S\[)$P.#^7ZFO1Z* ./\  ?A:_P!!M=1N]<FAN-7U.X,UR\7W  ,*HSV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]J^OZ)HEW:KJUW#:R3Y$,DPP#C&1NZ#M5#P!JUOK7@NPO+/3#IMJ5*PVW]U
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MFTJ7Q7I&J7\]S;Z+<;X[B=B[K"4W8)ZG&*F_X75X"_Z#7_D!_P#"@"O\(O\
M4^*O^P]<_P#H5>D5YC\%KJ&^TSQ'>6[[X)]:GEC;&,JQR#^1KTZ@ HHHH **
M** "BBB@ HHHH **** "BBB@#.U[_D 7_P#UP;^57H?]1'_NC^597BJZ2S\,
MWTKJ2/+VX'OQ_6M*UD$MG!(!@-&K#\162:]JUY+\V8J2]LUULOS9EZKX7T_6
M-1AO[@W$=S"AC22&4H0I^E5F\'V2J3]MU/@9_P"/MJZ.BJ=.#=['H1QN(C%1
M4W9;?U8XOP+K<#:-=1WU_&LD5[+&@GF&[:",=3FNH75M.=@J7]JS$X $RDG]
M:J2>%= FE:231[)W<Y9C"N2:Y+Q_H=GI.AP7FCZ5!#<1W2%I((!N5?R]<5E>
MI2AK9V]3O4,)CL5:+E%S?]VR=O\ @?B>B45S*>.]"V+NGGW8Y_T:3_"G?\)W
MH/\ SWG_ / :3_"M/:T^YQ?V?B_^?;^XZ2BN;_X3O0?^>\__ (#2?X4?\)WH
M/_/>?_P&D_PH]K3[H/[/Q?\ S[E]QTE%85EXPT;4+V*T@GD,TIP@:%U!/7J1
M6[51DI;,PJT:E%VJ1:?F%%%%49!1110 4444 %%%% !113'ECC9%>1%9SA0S
M %C[>M #Z*:98Q*(RZB0C(7/)'TIU !148GB,QA$J&4#)0,-P'TJ$ZG8*Y1K
MZV#@X*F5<@^G6@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!2N-*L[K4[34)8MUS:;_ "7W$;=PP>._%7:*
M* "BBB@ HHHH **** "BBB@ HHHH \[^*7Q(F\"6UM!9Z<]U>7J.8I,_)'MP
M,D=^O2O']$\6^'KN_76/'*ZOKFI Y2(P?N(AV 7.#^5?4,D<3C=*B,%'5@#B
MJULVG7L0EM3:SQGHT6UA^8H H>$M?L?$OAVWU+3;>2WM&)1(I$"%=IQT'2N;
M^)\(^QV5U+X:GUFWA+;VM;AHIX<XY4CJ#W_"N^5%1=J*%'H!BD>2./&]U7/]
MXXH \.T'XR>!O#-F]I9:%JEFSOOE1U#.[XQEB6R3Q78>%_B3?>,M3BBTKPS=
MPZ>&_?WMVX0*O^R!U/XUVKVVE2R>9)!9._\ >9%)JW%Y6S$6S:/[F,4 /HHH
MH Y"XT&_OOBA::O=1J=+L;%UMB6R1.S#)Q_N@\UG^//">KZCXCT'Q+H?D27F
MDLVZVF;:)E)!P&[=#^==_10!Q7@GPQ?6?]N:CX@B@^VZS/OEMT.]$C"[0I/?
MCK6O_P (3X6_Z%[3?_ 9?\*WJ* /-/@Y%'!9^)X845(H]<N%1%& H!P *]+K
MS?X1?ZGQ5_V'KG_T*O2* "BBB@ HHHH **** "BBB@ HHHH **** *]]8V^I
M6<EI=1^9#(,,N<507P[9HH59;P*!@ 7+\#\ZUZ*B5.$G=HSE2A)WDM3GH;86
M'BNWMX9KAHI+5W99)6<9##!YKH:Y?54O;?QE8ZA':W$]HELZ/Y(S@G/;\JTO
M[<;_ *!6H?\ ?K_Z]84IQ@Y1>FOGY'/1J1@YQ>FOGV7D:U(5### $>AJIINH
MQ:G;-/$DB!7:-ED&"".M7*Z8M25T=<9*24H[#/)B_P">2?\ ?(H\F+_GDG_?
M(I]%,J[[C/)B_P">2?\ ?(H\F+_GDG_?(I]% 7?<PM<C1-0T,JB@_;NP_P"F
M;UNUB:[_ ,?^A_\ 7]_[3>MNHC\3_KH=%;^%3]'_ .E!1115G,%%%% !1110
M 4444 %><_$RQGU'6O"EK;7+V\[7<C12J<;7$9*D^HR!7HU9>I:%:ZIJ>F7\
M[2"73I6EB"G@DC'- 'G4?B:74/&UA?R(MG=VFE7B7,4I)6.5",DXY*]#]#5_
MP[\0KC5]>M+!]4T259FVE+=)@YX[;AC\ZZS_ (1'3!XP/B90ZWS6_P!G=01L
M<>I'KVS["MI;>%&#+#&".X44 >;>+M*A\.ZKI_B&&$K"+Y6O+^.8F=M[$!,'
M@ID@8[ =*L:[X,T'5/%UA8VVG6T$Q<ZA?3JOSNH887/^TQY/H#6TWP_TJ363
M?S7%]-#YWVA;&2<FW63.=P3Z\X]:VH-&MX->N]85Y#<7,,<+!C\JJA)&/^^C
M0!HT444 %%%% !1110 4444 %%%% !1110 4444 (S!5+'H!FO,V^//@=6*F
MYO,@X/\ HY_QKTJ;_42?[I_E7FOP8TZQN/AM:23V5O+(9YLL\2L3^\/<B@!/
M^%]^!O\ GYO/_ 8_XT?\+[\#?\_-Y_X#'_&NY>V\/QN4D@TQ6'!5DC!%31Z7
MI$J!X[&Q=3T984(_E0!P'_"^_ W_ #\WG_@,?\:/^%]^!O\ GYO/_ 8_XUZ#
M_8^F?] ZS_[\+_A1_8^F?] ZS_[\+_A0!Y]_POOP-_S\WG_@,?\ &C_A??@;
M_GYO/_ 8_P"-=^^E:3&A>2PLE4=6:% !^E$>EZ1*@>.QL74]&6%"#^E ' ?\
M+[\#?\_-Y_X#'_&C_A??@;_GYO/_  &/^->@_P!CZ9_T#K/_ +\+_A34TO27
MW;+"R;:<'$*'!].E ' ?\+[\#?\ /S>?^ Q_QH_X7WX&_P"?F\_\!C_C7>?8
M-$\WROLFG^9_<\M,_EBG2Z;H\";Y;*QC7U>) /Y4 <#_ ,+[\#?\_-Y_X#'_
M !H_X7WX&_Y^;S_P&/\ C7H"Z5I+H'6PLF4\@B%"#^E,BT_19BPBM-/D*]0D
M:''Z4 <?I'QG\'ZWJ]KIEG/=-<W4@BC#0$ L3@9.:]!KQKXBVEM:?%SX>BVM
MXH0UR<B- N?G3TKV6@ HHHH **** "BBB@ HHHH 9,$,,@D.$*G<?;'-?-5]
M;^']'U1Y/AOKNMW.I;LI:VD1EA+>A.!Q^=>W^._$.I>'-%^U6&BS:HK92583
M\T8(X..XKQWP'\1M3T?PQ'%9>")[M]S_ .EVL&U6Y]AVZ4 =OX4\<^-(-8TG
M2?&?A]+1-0S'#>(<$N 2 R@G!./:N@\>_#VU\<BT>YU*\L_L@? MB/GSCKGZ
M5/X,_M#Q!X9TW4_%%@J:I'*\L:O'L:+DA3CL=IKK"0 2>@ZT ?+GAWP3X5U7
M0;J]U#QQ+874<DBBWDE4-&%) W \DG':O5_@20WP[5@LN3=29>1B=_3D9[5Y
MC?6WASQ)X\D>U\'R&RN6N&AG$\B?:Y(P2=J@XP3CIZU[E\/-:TO7/!UI<:3:
M"SMX\Q-; 8\IQU% '4T444 ?/.J>-[GQ'XC\0"Z\3WFA1:7.8;)+2!G0X8@O
M+@'CY1Z=:ZWQ?KVKW^H>#O#&GZP(AJ\0DN=0M!@NH Y3/0'DUB7/A3Q1X5UG
MQ;!I?AT:O9:_N:*8.O[HL22&R>GS'\A6AJW@CQ#H=KX(U32;7^T;S0H?*N;?
M> 7!P3MSZ<C\J .B\!:U=67_  D>BZUJ#72Z'/Q>S?>:(KN^;Z5I?\+4\"_]
M#-8_]]'_  JCX T#4&CU_5O$6GBVNM:N"7LV(;;$%V@''KS6O_PKKP?_ -"[
M8?\ ?N@#F?@S<0W>G^);FWD$D,VMW$D;KT92<@C\*]-KS/X-P16UCXFMX$$<
M46MW"(B]%4'  KTR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,7PU_P >=Y_U^S?^A5M5B^&O^/.\_P"OV;_T*MJLJ'\-?UW,,-_"C_75A111
M6IN%%%% &)KO_'_H?_7]_P"TWK;KC_'6IRZ7/H$R;-OV\;V<< ;2/Y$UO_\
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MKX=?#W2['P/I:ZUH<']J;6>?SXP7#%B0#^&*]#@@AM8$A@B2*)!A408 'L*
M.5\0^*]=TC5#:V'A&\U. (&^T13(JY/;!YJ[X7U_5=<%S_:7AZYTCRMNSSI5
M?S,YSC'IC]:JZ_\ #W1_$>IF_O9]128H$Q;W;1K@>P^M7/#7A#3O"@N!I\M[
M)]HV[_M-PTN,9QC/3K0!RGCM?^$B\>^'O!US(ZZ9<QRW5TB-@RA!E5)],BH_
M"=DO@_XGWWA:PED.D7-@+Z&%VSY+AMI ]JT?&^DZK;^)=$\6Z-8M?SZ=OAGM
M4(#21.,';GN*K^%['7-2\9ZGXRUC2Y+!?L@M+*R<CS"@.XEO<F@#L];75WL1
M'HKVT=R[A6EN%++&O<@ C)KA?A);7":!XEM7NWDN%UBYC-RXY+8 W8^O->A:
M;=2WVFV]U-:RVLDJ!F@E^]&?0^]<9X%L-3T/2?%,MQ83+-)JMU<V\3+S,I *
MD?7% ')^(_AYHGA71H+BUOKJ?Q:\RFRG,O[VXFW#("^F,Y]!6SJVC1^-_B4V
MBZXSOI^FZ9'.ULC%5>=S@D_0=*QM!U+Q#'J@USQ!X*UJ_P!:Y6.0(%CMT/\
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M:MXK2P\2VT$:QPQ:W<)&B]%4'  _"O3*\W^$7^I\5?\ 8>N?_0J](H ****
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M(**** "BBB@ HHHH **** *4VDV%QJ4&HS6L;W< (BE89*9ZXJ[110 4444
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M8:@?^6&_YOI]?:BZ\2Z+9:K%I=SJ5O%>RXV0L^&.>E<5XNL]*2Q@U#2IM/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $*O2*\O^"=HFGZ3XALHF9H[?6)XE+')(4X&3Z\5ZA0 4444 %%%% !1110
M4444 %%%% #9$\R)TSC<"*XZQ^'=A:QZ(LD[RMI<DC9(QYH9BX5O8-M/_ 17
M9TR:3R8'DVL^Q2VU1DGZ4 <KJ'@B.\LI4AOGM[O[=)>0W C5C&7X*X/!&/6H
M?^$!QID2+K-VNJQ3>?'?J "K8(("XV[<'IBHM!\:2:U#87$\%U9;[NXB:*2'
M E5%D(&<\8"C/N,4^+XFZ/*4Q9:F!-%YEN?LI_T@\95/4C- #(_AY^[/VG5[
MBYF?48;^260#+-&!Q[ X_"H+7X:-:31JFNW1LH+I;J&V*+@,'WX9L9;GU-:#
M?$?1?[+MKN.*]FGN)'B2RC@+3[T^^"O;&1FMW1-;M=>TT7MJ)47<4>.5"CQL
M.JL.QH QY?!44N@S:7]K<++J/V_?M&0?-$FW],5IZ[H2:V^FLTS1?8;Q+H8&
M=Q7/'ZUDS?$/2H+U[1K'6#(CF,LNGR%<YQP<=/>NDN[F2"PDN(+:2YD5-R0J
M0&<^G/2@#E]:\!K?ZS+J6GZE+ITES@7:I&KB7' (W [3CN*EU/P=<3723Z1K
M=UI>^)8;D1 /YRKG!);HV">1ZU5\+ZUX@UOP]KLCBW74X-2GM85)_=Q!=N,G
M'.,GZTO@?6+^\U#5-.O=5CU06NPBX$!A(8D@KM/4# Y]Z %OO 4DLTD=AKM[
M9:?<HJ7=JA#>=A0I.X\@D  D5>O/ ^EW6HZ-<JGEIIBB-8ATD11\BMZ@,%;Z
MBH_$OC>RT.XFL!!>3W20>;(]O 9%@!!PSD=!Q6=9>/X[/PSH\][:WU_?75FE
MQ(MG;E\ CECV H FU#X?FYUBXN[/6+BSMKN3S;BWCC1MS'J58C*YQVK4M-"B
MT*]UO55\ZY%ZD9-NB@MB-2,#U)S4^E^)[#5S:?9O,"7=JUS$[K@%58*P^H)&
M16;-\0--C^S"*SO[AYXS-LABW,D>XJ'(ST.,C% $7PZT"ZT32+N2]B>&6[N6
MDCA=MS0P#_5QGZ GCWKL:;&XDC5USM8 C(Q3J "BBB@ HHHH **** ,^ZT>V
MN[^.^+S1W$:%%>)]O![4'2^/^/\ OO\ O]_]:M"FOG8V.N#BH]G'5V,W2AJ[
M&?H,TL^DH\TC2.))%W-U(#L!^@K2KB?#&NG3=(^S:C;WYN%F<G%LQX)SUQ]:
MV?\ A*['_GVU#_P%>L*.(I^SC=ZV.:ABJ7LH\TK.W7_AC=HK"_X2NQ_Y]M0_
M\!7H_P"$KL?^?;4/_ 5ZT^L4OYOZ^XV^M4?YE_7R-VBL+_A*['_GVU#_ ,!7
MH_X2NQ_Y]M0_\!7H^L4OYOZ^X/K5'^9?U\C=HK"_X2NQ_P"?;4/_  %>C_A*
M['_GVU#_ ,!7H^L4OYOZ^X/K5'^9?U\C=HK"_P"$KL?^?;4/_ 5ZHZQXG672
M+F/3X-06[9,1,+9AAORI2Q-))NY,L71C%OFO_7H=715+2#<'2+0W>[[08AYF
M_KN[YJ[6T7=)F\9<T4^X4444R@HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!-J_P!T?E2X&,8XKR_Q]\5TT#4+/3=#\JZNC>""[9XV*1#^[G@;O\#6MX]\
M:ZAH%YI&C:'9Q76L:JY6)9B0B*,9)_.@#NJ*Y'P'XIOO$-K?VNL6T5MK&G7!
M@N8HC\O3*L/8BNNH \W^$7^I\5?]AZY_]"KTBO-_A%_J?%7_ &'KG_T*O2*
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MP;B>*)4DF(QO8#!/XU:HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0!]&45Y3_P *:OO^A\UO\A_C1_PIJ^_Z'S6_R'^- 'JU%>4_\*:OO^A\UO\
M(?XT?\*:OO\ H?-;_(?XT >K45Y3_P *:OO^A\UO\A_C1_PIJ^_Z'S6_R'^-
M 'JU%>4_\*:OO^A\UO\ (?XT?\*:OO\ H?-;_(?XT >K45Y3_P *:OO^A\UO
M\A_C1_PIJ^_Z'S6_R'^- 'JU%>/:I\)K_3])O+Q?'6M.T$+R!3C!P"<=:RO!
M'P\U+Q7X.T[7)O&NL027:,S1(00N'9>I/M0![M17E/\ PIJ^_P"A\UO\A_C1
M_P *:OO^A\UO\A_C0!ZM17E/_"FK[_H?-;_(?XT?\*:OO^A\UO\ (?XT >K4
M5Y3_ ,*:OO\ H?-;_(?XT?\ "FK[_H?-;_(?XT >K45Y3_PIJ^_Z'S6_R'^-
M'_"FK[_H?-;_ "'^- 'JU%>4_P#"FK[_ *'S6_R'^-'_  IJ^_Z'S6_R'^-
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MN-4\1CP_K.CR:9J,MO\ :H%\P.KQ]>HZ'':NYH **** "BBB@ HHHH ****
M"N&\8^"KSQ%XT\*ZU;W$4<.D3F25'!RXW(>/^^37<UY9XC^(_BWPX+FXNO!X
M6QBF,<<[7 _>#=A2!G//'% 'J=%4]*N;F\TFUN;RV^S7,L8>2'.=A/:KE !1
M110 4444 %%%% !112,P12S$!0,DGL* *FK6CW^CWMG&P5YX'C4GH"0163X$
M\/S^%O!6FZ+<RI+-:HRLZ=#EV;C\ZY_3OBKI^M?$B'PMI4:W-NT3L]X"0-RJ
M20OJ..M:WQ!\<6W@3PZ=1EC\^X=Q'!!G&\]_P !- '645F^']4.M^'M/U0QB
M(W=NDQ0'.W<,XK2H **** "BBB@ HHHH ***XSQ#XUO;+Q"GA[0]$FU+4_*\
MY]S".)4_WCP3[4 3S^%KF7XFVOB<31BVAL6MC'_$6)SGZ5UE<CH'Q#TC6?"U
MQKDY:QBM':*Z2;_EFZ]0".OM47@#Q]#X\&K2VUJT%O9W BC+_><$$Y([=* .
MSHHHH **** "BBB@ HHHH *P?&FAS>)?!VIZ-;R)'-=Q>6KOT!R#S^57->UF
M'P_HEUJEQ'+)';H6V1+N9CV %<AI?Q%O_P#A(=*TG7] DTUM74O8NLRR;@!G
M# =#R* .L\-:7)HOAG3=,F=7DM8%B9EZ$@=JU:\TU?XJSZ?/J5W;:%+<Z'I=
MP+:\N_-56#\ [4/) R*]"T^^AU/3;6_M\^3<Q+-'N&#M89&?SH LT444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7FWQP1_\ A 4N I,=M?02
MR8[*#C/ZBO2:9+#'/$T4T:21L,,CC((]Q0!Y#8:O9>)?CCHEUI,RSP6FD.TT
MB<@;EX!]^17L-4K#1]-TO?\ V?86UKOY;R8E3/UP*NT %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>cm270_ex3-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex3-1img01.jpg
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M P,# P,# P,# P,# P,# P,# P/_P  1" !U '@# 1$  A$! Q$!_\0 =0
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MFO ZE2+$1"5[-O"GENH1QS:ZG D-QY%=  \QB$>/$G5+8CW"[+XE;JFDH4R
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MU=1]]OJOE_A7P'9_3<P1L'ZK<[&YJ<O6W":(NB7ZZ@]^L<[-V[G J.7P9<B
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M3?+64F+%EM#DU^7T8Y:=M*1/ZK8-89FJAK9>I^+5F9.8@$N?;&R[#(>;2_\
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M38<6%(7+6-GQ4@^1D@5?F*!V=KKP_:J?7, ]CK'5V_P+,-,A;+57?XZAZI*
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M5UKU#F58C>*97G3=YN-R*)KV%>?*[SJ6G[QNNA.J8%!88ECJI+-?BO.6 O\
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M%7Z:4ZZN.DO^,]]_MJ1E2V_-ZV.=^K[_ "<I,7O^?RN\1\_@-5G5SVU/DNN
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/O_/R^ O#X"? 3X"? ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>cm270_ex10-20img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex10-20img01.jpg
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M   " @(# 0$            ("0<*!08#! L" 0$  @,  P$!
M!08$!P@" PD! !    <  0,$  0$!0$)     0(#! 4&!P@ $1(A$Q0),2(5
M%D%1,B.10C,7"O!A@:%2<H*3)!@1  $# @4" P4%!@0%!0$   $1 @,$!0 A
M,1(&00=1(A-A<3(4"(&1H2,5L<'10E)B\#,6%^'Q<H(DDJ)#4V,)_]H # ,!
M  (1 Q$ /P"\ER UF#PO'="V.RMI-Y7LYK;VT3+6%;I.I9PPC_$ZZ,>W7,1-
M5TH4>Q0$0]1Z[J>T2WZIBL\#Y(YJB5C&N8TN<I< $ S0G4] I.F!]TNC;+0O
MN3FES8TR&?Q$-T^W%?&S_P#) Q&IG8JN\$TL&SA9PBH*MAJHN4TPCU7K9NZ(
M@HY,60<+ V $1\3@DN<W;L3K44GT;\]J;$*N*M# 7MC\[PP[W::G3,9XJ^X=
M]^/VYVRJ;)O'1L9*?8#B37GWZ8Y_LO"ZY4<HO%V-*VAM3'%8A'+),]>F'1T6
MZ*EBF)-NUCVS4KIP5,W<Z93'_P!/R].AS/HVYI;*J&DN=>(Y99'1M)D&USV$
MM>A)"M4*#H0A&N%"3ZD+2^=[&LD:&J0'1N!1%'CF1I^[$>Z+_P A"FTN<2J#
MG$UFMO)4W,JL%@LJ<5!)6%ZF*5=BRNFS)^NJR?._(BSL@*(E\ \1'U[-=/\
M11S6ZLC-OK=[GS^BT;D+GE!Y0OF:#J[0*,!Y_JJM%(0&PU+P21Y87. ("^/0
M9^[7&'FOOXF"5ROVFE<2[%?ZPXFH^E3MQ:VQ.*IKR^.(^-D;#!T)S)1*$A=%
MX=,SDH$21 RRJ0ID[F$ Z#L^C7E<]XJ^.,N<;;U1O:R:-SVN,>XANYS X%S&
MD@OS"!<Q@RWZD:;THJB:*04LS@%$;B0"44CIE@LH[[2IJ5>0#)/*6P23[/K'
MK#^+>6UNVF2TN/EOTMFM$QR\2DFYLKYVW7(5@L)%DED# ( (@/59U_T]<BM]
MLGNUOO\ 3OHJ>H= XBWO7U&ZH!59M_N&#K^^=A9-%3N?/ZDY ;^44]BYY8/K
MD-R-CN/W'R7WZ7BE7\9%A03.6"BZ;%*/87>TP=>^7(+@!B-6\(I/IKJ]NX$!
M,>J9L/#3R'DTUKJ:HU-UB.UY;&8@[:%:&1ESR2@3XM<6Q77AEKL)Y#>'B*@:
MUKBXGH[1/'7]OACCQ?E56M+GF%<16CG[R1B6L@2PUB70LE4"07217-674LU1
M*$=.-T%P.FV<>VJHF!A* ]AZ>[SVQJ^,4OZH\/BZ>G+^7(6_U-8[,@(-/' R
MV\KL][9&^@E,D4L9>TIY2UJ=5USR'7/!0V":!C$24TV3.X"+CG3L2 GW,X*T
M;.7"S,"_UE!<Z1"F[@ AT@T5=%<'/;"',,90EX+&Y>!.&$Y4WS?_ , &O_#"
M_.!O.N$YUPFDR]<BR,T*!8(J >$8JJK1Y'<M"IR;A@JY.DFF9Y#+IG15(41$
M@G]>G;NAVGINW5THZ661P;61QO\ +F"9&M=T_P"K"=Q_FM/RZ&::R%[HX2X.
MWM,:;204!5=,L YPO^Y&?Y-\N:YQB?Y,C$-+2SUQU(6J&D5'B< OESE=H=.3
M:KCY)%GGB0@8Y?RD+V_B/5M<X^G.3A';>DYQ(876^KB$BB1I=F43:B[DS'BA
MPN<4[Q\1Y!?*KC,$E3^LT\PC+70N:TDA?*XE"T=3TR\<6 2J@#(ZPF\0,EY>
M12@/8# 'X%. @(" _P"'66*:.L^5D=3C="[X?ZCGX>.+<GD] [7?&BX49F'V
M :+H_+>JX#'Y=\:BO[!ML38KTHQ?+QD&TS(JB<$DM+(E4A8V5DO!4PM5SD7[
M$#\O\.M!UO;"UV_M8.=U+V"5S!M8'-,FY4SC^)#HN@Q75%S2&+FHXQ.Y_P ^
M<TVDM1%^+33I@$.?_P!Q>UT;E?&<*N$E+@- UUK*P]8N0S[ 7,@I:'X-EE8&
M!:C\&-;!%M'J:CUX[7,1(A^Z:8B'J?[+=@J/F7&9>=\U>(.,QQ.E<21O#&%P
M)V%#EM\<\*//NYKH.3R<;M+:A]7Z@:T,C<X*6@AJA2I0G1$&HP:+J*^VZ9H5
M9DHRUXS3M+7&,6GH&03C[!"I@W;N4GK<CA&,22(4KA=,!5(MW 2C_#UZ6YG?
M3.[D<4#*JZFTP5";A2'S. T ]3\<-=JBYA56F*LG8&M,FU'.\P("YC7_  AP
M='$"\\@;GDX+\F**UH6M0MSMM3DXZ/0]J-EHZN/4D(FS1!17<^[&V-IYND3
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MM)?>9G-(&?GK<P#J%5#]HTQ>G/*)U-VLKZ=THEBBC8 X'R@>52.@3JB9XSO
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M0VBVNI:%8K-23SLW*TYRY'17.HP\]+6B#CHZL(9S"+1!E"(MUC6!*.;=Q4*
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MP%3%(8PB4@]N_?IZ[H\[M'=SG=W[AU/IT=9<9W5!I03(&Z*T2':2%ZEHPO\
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M@?V/:$3]3;;Q*NGD$5)&#6R3-;LU(W N#S_80%77,98"T'(9*NJEBE9+LWN
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MY[<<IB.0QD;YM]T>JMH6B4'6PH"%?JJ\8Q!ZUN>@SZ#E1:5<)B1G%))'<KN
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-/Y]!$_+3VXGH5Q__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>cm270_ex10-20img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex10-20img02.jpg
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M   !! (# 0$             !@<("00% 0(#"@L! 0 # 0$!
M   ! @,$!080   '  $# P($! ('!  !+0$" P0%!@<( !$2(1,),11!(A46
M46$R%W$C@9&A0B08"K'A4C/PP='Q)1ER0R9BTE,T)U>7@I*BLH.35)34-475
M*&.CTT15E;7%5I;6-W<X2%@:$0 " @ % 04%" $$ @(" P$  1$"(3%!$@,$
M46$B,A-Q@9%2!?"AL<'1X4(4%?%B(S-RDE,&)#2"0V,6_]H # ,!  (1 Q$
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MF WJ/X>G?UZ Z?=-_$#^\GX"/B!O(/$1[]NP#]!'OZ?X] <_<H=S *A0$O\
M5Y=R]NP=Q_J ._IT![ (" "'J ^H#_(>@#H Z .@#H Z .@#H!*V^YU"B1"]
MBN]EA*C -!2(ZG+%+,H6(;'74]M$B[^07;MDCJJ>A0$P=Q^G5;6K7S-(9N-1
MK$>4W&E8@'1WS'3D$ ,53^XU1\.PAW ?/]6 .Q@'T_CU7U>+YD:>E<Y/RGXU
M)=O=Y XLGY>H>>F4\O?M]>W>8]>W3U>/YD5M5US-S5.0.&7F=9UBD:_FMQL<
MBD\<,X2L7>MSDHX;QPB#YPBPCI%PY.BS !%00+V* "/TZE<E&X3EE1X#J$3
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M3=O7Z!]1[]NW0 5P@;Q\52#Y&$A!\@[','81 @_0WU_#H#GWT?(I/<+Y&'L
M /<1_J]?3Z /B/K].X=N@/0! ?H(#ZB'H/?U#ZAZ?B'0'/0'0ZA$P[G,!0$0
M .X^HB(]@  ^HB(_0 Z Y\B^(G[_ )0 3"(>OH'J(^G0'A]XU$GN NF).P&
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M)Z"=>+AIKX%^!]<_Q;*I,/COXBG[N%4EL@@S)^7DN9+W5Y%P4AS)I^B28"!
M'Q_AU]3T?_37V?FSQ^INK\C<1C^2.E6YG/K#SILW&Q:LQC3+G&>3RV8Z2#]4
MR]ZVG(IJ%+OM$11$/MRH9]7;S"G]T!]HSE!\0#F40,0-]_C=7D8.K2G1CM:5
MSHXI8[8+;5=0W"@4BPT.'KL_<H*;F%235;A+:_>QM=FI6-:,G2S>&D7#!4WW
M/JF@B05%O;)V$9=ZIP\R#7<GN4% QK'KO>/WW7(6P(9!<-&HPNXYQ;TI!C"P
M8NX^R*0,*8[UW3U)5ZR0</O-%F!')"F7(*I1ZJ^12DB55O+02..<PZ8TXH\:
M]QY!W"K4^UZ]A.?Z?8&39C(-6J+^;H\#9[D[BH5H:=E6E2K+R='WG1A6;,D5
M$RJ*]S%$;.]4X>856\A>Z3SNXC9 YK[32^0&74Y6V5MI<JL67M;$HV"H/5&"
M3:TQ0-/NOO8!4TFB/W27FB!#^8F\ ,8L>I0@Q$^?W#9617B4^1>5GD6Z%^<+
M-2VR,$Q$\N;).[^ J"L5 3U9%=,710,(E%0H%\A'MUC;JJULZPRZX[64K(>G
M,-SRS8W5NC\[MS"?EJ#(QL5=(/V7\98:J^F8Q&:AT)^ F6<=,1?ZM%+E<-3J
MHE3<)=S)F, #VOQ<RY6U$01:CKF,]+;-8[%RH3X\9^W@TTZ+1X/5]MM4R@X=
M+0]>M<M-P&?T:LM&:S5%>U6]Y OGJSIT=1&.C68![1EG*0DN[7=FJQ@2JI5W
M6]P@\CY":;/\NN9F':,RHY*5Q\HF!WVDR]3BYYK-O8?7&.GR$RVMGZE*RY)&
M5B$J&D0AVB:*:H&'Q2*;TZLG;%VB"A&*D?(;HTW@7$'EY+1%'7QKE%M,#F$U
M3V$?)%L^70NH6V=SW+YF,L8RKA.V33&TQK%.?9'8H]_U X(&2! /=P?-:J3M
MJRRVQC.XQZQ\@&E3_&?(^;Z,%6E,/O7),F6VC,74*^;W>G9G;=U>\<Z;9X>R
MFE%6TO<8B\DCY609.&2356/?+(I&14;$.>*<][<CI"7V[2'$=YMK3\@-XC<1
MW?F S@:\''W!^3$ABCRMOHF14N=QH5%T^*Q34--BI@735NRG&-^D7AXR*%H#
M95E$'*JX%1P"B>JM=VC# */Y%P"*A%$DSE.4Q3E*)#AV JA1#N4Y0_@<OJ'\
MAZU(/;H Z .@ >@$G=+S4\YJ\Y=KU/1=4J-8BWTW8K)./4(Z&@XB-0,Y?24H
M_<G3;LV35 @F.<Y@ /YCT;A2!%8KOF1\BZ#%:AB%\K6F4"<6DFT5::I)$D8M
MTZAGIF$LT,J!$U&SM@X+V.DJ4BG8P#X]A 1A-64K(#P]2"H#YU,]9:=\:/(B
MM/Y-W$H)L:G,$?,@%9TDXC+5'*))MVI2"90SHBAR&$!]"A]!#KAZOJ/0A[=T
M-:^XZNEZ;^Q9IVV]F$Y'Y\__ "B4@HJ)IV#1 (4WB*X5U<Z0@4?'S*7S, IG
M /3\OT'K#_)1_P#U_>CK_P :O_D^X[#Q$I0"4B%LOQECE$W92LG21*4OU%18
MX%\.W?\ @/IU'^2__P _O(?TS##DQ]A;W\ /'ZO5CY3L_G8N7MCY>EXYLL@L
M*T?]M&.7<G$1$0V0=.B^2*B9V[Q8Q2B4#>X7N AUO3J:\NUNK3F<]89YUZ[+
M.LS&N1]C7)S<;S_S#<9>(N7R:5/L&^1^K7FZ::+%O+2E%R[)(B*6ESTF,E&+
MZNN[O/V:>8,FZ[])PWCDA.N+=P(E3#5\F^ZI#5O;[?T93+%'HA/1N+;Q1*/8
M.82DK&RM(O4K*9'LT]05M L QY8N8C;K6)EI5X&QK0-9;HNB222BIVJ17"9N
MQ"E O4N]N.SEMUC7\B^[>H>>ATB/D:P.4>,$B,- (RM&?773\QD$ZTC(&U^G
MYVW:/KB^SJ%BI-_9'SN+B'Z,BDU>LV+A[%',[0*=(AQ"JZM/^+)].PG(;Y3N
M,E@B*#88>'W9[7]5G<\K68SI,.OB43H,UJ-2F[A3V=.>KQR24^5VSKKQLX5;
M^:+-ZD!%CD(<BAG]NG8P^.R4FWB_DQX[2+9@Z7BM=@TC<@F'%NT_KV93K ^9
M;A,S<97:]3=-!/[D*R-EEIQB1BZ(+ILJD\17,8B"J:AI_M)3-;)+N*NK23>3
M'4><TL;:7%Q3/&VJJ,]JBN.KVT_MQRVI#7:9J):2\?1#6!ZHV,N_<E>I-B.4
MD%&(OU"M_?!0>P/[2CRO.-,R5QV>/:-S"_)-QSG;4XJS9CL+((K?GO&.T6B:
MQ^[0M)I>R(KP[*(K-LM$A&HQ\6E;)&P,FT6Y**J#E=RF B0#E$7]NJ<.MDX]
MWQ)?'98Z&]3Y^8R8.3R:M:UUI)<1YJO0&M0;S/'K>;6D+?[)ZB-%CCO 4N[.
MTMG":S!PS$47"9NQ3>8&(%Z=12_:F9CF\EMID\@Q":OM?AF\A<9)S3:=0ZQ/
MJBS2?Z#I]L@J%2HB8(W4%0I"3]D1.Z1(H4QDD52 H4?SAH[>'V@93D@]VO&L
M"I<Y1]22E[;7]1Q*&O=EM%3@G)KE6+?KU2KMS29L4?MHZJ*+UZPNB,122=':
M($22$5#E,L>EEM5>YDI.SA=@EMMVJV$YOX/Q(9:!(Y%6--P_7-297F$AZ](3
MU\N5(L5<A8_+(B2N$+/UAF:(KT^\L;M$C120=)M4R$%-+W!.Y-\K&*]Q! 9S
M\C>JH<;.+>V:C./J+D*/)S:L"YD[MGE.CWQZO%9S(W.CYMH,7!3<=9X^ J5Z
MT!A%$F7#=C+D;>Z=)$X%$#%S=FZI/-,E*<%F3AR:"YL<A.-6'35NW%QQRT%X
M6Y62TW&D43,[3<KC15YZ00QLLO 6^-LF?UN4L= <LYBP&8-C@A*I^PV%) YR
M!I5\BK.&U!J'&HO_ (\+5K%WP52_ZMJL[LYK=I6FO,SNMAI-4H\](8Q&6^1K
MM >RE>HT%"P[1].QT*,F8/MP.8CU(1,'<.KT=FI<003[25]WR_+V ![ (=Q*
M8!#Z@)BD_, ^@A^'5P>O0!T = '0 /0#>Z;JN>8S3I/0=5NE4SNCPI6PS-NN
MU@C:Q6XG[UPDR9%?S,NLV9-C/'ZZ:"8&. G44 H (CVZ RL[TBCZQ4XJ^9Q;
M:S>J3/IG<5^WT^<86.M3S1,XHG=1,U&J*LGR)'!#IF%,Q@ Y!#N/;H!;&^@_
M^C\0Z$-I*7D-)KVTYQA%2=7W5[7&4NF,74<P>V*7*]"/9NI9T5C&I+*,VCPR
M8.79@+Y& "E^HCVZY>HZJG3J;)LTXJ/ELJUU(R#\G7 D._?E%EG<.X" 2<D;
MU >P]A+$B _3\.N7_*]/]F:OIN92TIJ>)_E X"D$I3<I,O QQ$"!]]+" B'J
M/<P1  7M_/I_ENG^S*UX.2VD#HY-S9XN;O;3Y]D&TT?0;>6%=3BD) OUU7*<
M:U63077.FY:MQ,0GN@)NWX?X]^NKBZSI^9JM'XF3;IN2E7=^5$:.8>QWO(>3
MW!2FQVO*Y[F>_6/7Z9J'WG[*9,6[:F9]^]JW-14[;(617AIM2;(5HN87!D%V
M)Q2*B57Q5"_(FFFFU)E5U68C>&W."T7BL[ XV.04T5I <O+SQTXVWZ@486S_
M ))5BN1:,TVLM=@(]XM OB5I;]6;O9MBHWA3-XE5<52A_4X^1Q%I?XB'9MI'
M3DYR]-8<YQFY\=M(G:Q)QOR%<:.-^QU-W 1L;9()K;-<@JEI.:Z#7[%%O9*O
MNEXF5!9NHT.D99)9)PBJNW4 1NG6[UE%26*_-?%(K3I;)4$[>Y>5[4:WA]@N
M*%=6_MM6]BMT'$V&L9M,VQ9U[B5AF(>>8JD.FV6:$.[22.L58X)]6WJ8U)2;
MF-!,(?(YQD7GWT!^JWM$T%R"'C%;YYSFUQ:5*C:VJ,>VBXJZ69Y%-HRN14_,
M2K9@P>.#$3<.ET_0J2A%30^2J<,*K:E:#*<[>8+FI4DT5BS[1FUXJ?)?C1DU
MYNM.J\?,TVIJ:%L.91%MI%JL$NFNUCW$K1+>=%PNQ0.X9+.4R%<(K=^J.RLU
M$YAJ$F\F2]Y6[8XX]X7;[Y Q;*9LK)2LU6D04BNNWC92\7^XP5 ID<_59@9X
M+0T_9$%EB(_YRC1%42B4P=POR65:ML*)QR&'UBA<I(K.;@]C.6#3*&>8YW*V
ME#2T,[S^?D[9<X=*=L5C?Z' SL.>NU7+8EJQ9D;1<4H,FYCS+*.9 C@A1'+T
M[+Q)J$O;).;BN0RF<\D^0NZW#B'@<H9;"=&U+ABIRZW.4J\7&34E4Q"8IM0K
M=-JIK>RF8MK'3EML"ZLJFLU6?HL4RH)+I*&%P6\W=9>30A*5;,06'<W-:Y8V
M#B1BT:\C\KNVI9?R.T;=KO348J0DJL3CAID?BQH3/8BV,;%$-!NU\ET'8N'S
M9Z!(I-RBB +>+@M*I\B2T6!#JTDWDS#S3G#JVVVGB9B$K.-LBM.L6_FAG.G:
M32HR"%RM;N(EDBX*+BLXC[FA9:W&2.IQ,D,H8JC635:I-7+=NF($%<E%;<DO
MXJ039X%\@;;R$SS1E;V>O25RQ'D%L?'J=L=9:BSA;:;++&I&1-M09ING[>.E
M)J >M3OVR:@MT'PKE0$4A+UMQ6E1V$$YUW HB4H)"<Q^WC^;P((B<I?$53@!
M -XB(]N_<>WTZU!D%'R #!W ! ![" @/K_$!]0'H#GH Z QW1 .B8IA[%[E$
MP^(F_* ]S@   B F( AZ>OKT!1+H_P 05ZO'RV4_Y(F/)F?A*C6%:=(/,A:Q
M\V,P\/5H(L*K3FL[^O-8<<]G_<%=XV,W$Q53G "'[%$*?\DPHVR'BT^Q07Q=
M7!X*B(=^WX$[A_C^;H#Y&_F:^,;G-S'Y:S^EX5GM,G\_0RVBTZ*>V*WL:_(.
M91@E-'DTD6KM!4%D ?NR@)C=^Q/4!#TZX.2:\S;3AY82;53MMEUV+OQ+^>).
M!3><\8>+5'U&I5@FEY+DE&IT[X(LI@8*4C8,D1+MHJ:,B)C-5T#*)G]LP%,4
MP@/H/6%>'EF'5Y_F==^2KLW5J&H^XH&Y[_&!S/W/E)O.G9AE\!)U2\/F P#]
MW=X>/4>LHJ&2CT7!F;Y8#-E%5OS^)NWJ'KUY7)Q\ZZNSV6V[Y3CO.KEY>)\*
MJK5R[>PNDR5OM?#?XU<DIJ&:2UZW?-\EC*8UH-;?P2RJU\4(Y;LU!?OI>$B5
MX*(4<_>O#E<>0H("4A3',';W>&UZ\:E-./S>1Y-E/(^Q$0=OXM:'E.+<6-*X
M]7?4MZY"<<]:I>E9[F=AF<DK#6=+>WCQIR%KMZ>$&KH0#:ZUNV2JCN1=OY 6
M<J5 ?%8ODJ&S45K9MY^XBS=Y2R0L-/:7JY\HN7&IEPN[FI^C_%U6<,K!7C:A
MO'<_JKRT:=99;.&JK:W+M5!CV&C,$'AUSIL%%FC@"**$1[FO;DJTTDV_8*TL
MXMH,?D5&Y+Y5 L2S^-6C1H[</C,S'BV:/_>>?H6? -IQFJZ9&S<5=8VRW%BV
M2S_4'-U243DHMV^4%:+1(+=4541#*EG7V]Y')YV.CQDRS:L$L'%G4+YEKJT0
M;#XS<OXDW?.XRS4:>ON2ZUE3E&85_P LMN&&D:ML*;L[)_(LW1@9+13#[[Q3
M[J(S9V:3:P?857W"9P+C'>\<V'XS*K=:DA=:7A>-<T6.EVTKZHV"AYK8N1-@
MJ]IH>? ]D)M1_*LJ=&PSN!*[;LE4_921$3"1<>K<=_XL.)A>4RJI1M?-Q\^2
MD$.-U9D=9TKE-H6M9I!:_$T"1A-7SV>6SZ*C9JNP\G/*1J=BCJ33E",XB159
MME7[)L9R!P75 W"O4FT5?O7?H:*M9ESM>1(7A93-7@N:/*K5+71=5C*1N&(\
M6T*M;=(O68VBWRE@RTNIQUG96V*I-D?I5.<%G:&)R-&S95FB0#^2Y#& @=G3
MMM9/'M^!2RBT#F9#%/,\^23F82RI%:AR0SOCKJ&7/U0=$/.QF1U.:RO0JO&F
M<H?8G>4Z8492KE-!4J@(RR"ADS%$ZG5U9+D<E3C#*[HJ/R'<ZM(LF4:+5LYT
M3.N,U+SZ]RS.-+7KC(9"CJ+>T/(@&<HX=D:KK79H+$SE%(RI2*&$I>P .C<R
MH>"^T :)GP(IMXV7+5JIG=TQGCE@.\$Y(1=0G;#.I-M(WEHG/!%C0,Q?6"3A
MLMRN-FYY>=?G^U8.9.831^U;-FX'65\_DX[VY)JK;(C[Y_(F<(.L]P,JFJZ9
M7ZM5,SNV-\:*9R"@^3%\@):RSB-<V36*O9W%MBH:C9&\L*\?1Z@]O#H)NQR3
MEFT+).VJ!8]L)3JN1TXN.RO*34=I9M;4M4-Y<.(FU2'&KD#\>K2G2DG5]QY*
MW#3(W>!&,;U&%QS8]_:;W=5[(=Q+)22NE4Q^]E8I*':Q_LR"0M%TU2E!<Q=W
M;DW;6ON_,H66YGQUT&B[19-.DN5^_P"@4:9"R%@\&N2.3?VJI[:;?MG<.UK:
M]?SF%T-0M-9-A9LC2$R\.HBJ87 K*>)R[)0H!+7J0'0!T!P/T'_ >@(R<ON-
M-+YB<=-3XUZ)(6")IFN5W]MSTM5';=E8XY-)^QEH]Y%+/$7+$5FLK'(J&(ND
MHDH0HD,'8P],8PS T/QZ\#<]^.O O[ 9I:;M=(,USL%W>V*['B@E7DY97*"S
MU)I'PS-A&1S)-)LF0"ID[&\?(1$PB/5:UAMOS/\ ($^NK 1]WK#*X0+V DHN
M.EXY^0A';&4:MWC-P4AP4(55LY3424 IR@;U ?4.L>7@IRXVF8+\=[<=E:HR
M08;7DR"@.=T $A*!1*->AA*8"^A?RJM3)C_AV]!ZP_IT^5'7_<M\S,;^P=8]
MSR3SRA)@8IDU/;KD"0IP-]?,$F0%-Z?Q]>G].GRH+K'_ /(*>EX[7*98T+%&
M5&L1#MI&*QZ+N'AV#)XB@N4H.$$EF3=)8Z:@%#\HB/TZQ?#>G)-:O:NPY>7D
M?):9GO(3<T8BF1.]<<=Z@-SH&8<AN/C:[-H2H:>%C"B:CE&JQC2$N=2M2E>;
M.I6LO@5A4GT5*MDG(MGS< 6;+I'[%VJZJ\MQR)+/##[?B0J6:E9$?KS<\WY'
M[K1-;U[6<<QVM9SQZY/8.X@JKHS[1[!:C\E&F>Q#ZS1\@G3JRPK\=5V%$%5
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M4C9IMX#5@0C*.8JR<DI]NV3$Y6Z(%)YF["(E,8Y@F<?Z#_+_ +NI*73='&9
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M[=,$_=6.JJ)"%*)Q* %* K?MP*E[*?BF0$_;(!2@ )E OB4"E  +V*'T#Z=
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M@/$ZZ:9O$XB7Z  B @4QA^A""/\ 48?Y= =B*%.(@4#" % ?+MV+ZB(>/?\
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M[>(JF[B)>X (@(" ]N@,A%/V4B)]P'P#MW OB CW$1'Q[F[=Q'^(] >O0!T
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M>_0&"SA&,<=4\>V9QXN!*9R#!DW: X4(7L!U?9*43=A]0#\.X^OJ/0&T*0?
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MJ&L</&3]>E8^<@IEDWDH>9BGK>1C)2.>)%7:/X]^T46:O&;I X'343.8ARB
M@/;K5-64K(@VO4@.@#H Z .@#H Z A]SUTG>\AXC;OI7&"FDT'=JA1W,MG52
M/%+3Y).41>LB/E@K[9=LYL"L5"*NGA&21RJ.5&Y4P'\W4/+L!&SXB=UY=\B>
M'$!I7,^E/*1LCJ\7>+2;O*BZHKRPTF-EDQK<XXJ;A%NO&'>)+G0*L*27OI(^
M[X!W[C3CM."<I:@M4#K0%:WRVVNQTG@?N-EJ4_(5>?C8F+48SL._<1DHQ,I+
M-TA,W?-3IKHB<#B7N4?Q'KBZY6?%X4WB=W0^GZCWN/"RC_XUOD>XPUC+G66<
MSW[>7T*N23Z2@=5OU24OKFW5N3=EE4("1L;Z/EIPTG .C&1;HK>9 2_RR>).
MO!]..5OFJ]BUC([;UX<JVK[W'P&-^2SY#,LU:RTRN\-)V7H%)K39W+VZT9_7
M'V:O+A95C@,4@LE"-XES(1\7$I)>P98H]A5. !VZY^JY?&GPJ:1A I7@K3Q7
MJWV)S"_,S?A+VK5[I\A456;EJ^C7& D\2TZ?&$MTY8Y&+&5CI&#(@[:MI%PJ
MU#VPDCD3.4HF[%$ ZZNB]:[K=IZZ?#[SS.2[M:R4;2]CE),H9U\EOQ]Z5HXG
M98S,4#DCCD';)(RZ56I_(*\#19"AEF)%0HQL7+7BJ04K$1HNCI&=N%112$QS
M"0??KYU*:4Z]ISCD[1HNF,N=_%+#XJRP<9F^P8GRENMH *C$O[W 2.5HY+%L
M_P!F7I9P=S6T9XF@J'==VRA@48H>'< . ;NNYX^59 JHRG9^0L!P\^/??K'R
MDT:P3'*34JQBNI6#6]#<QF4042PL>TV.KI.)FKMFLW3[-<+%7(NNR5D3< J]
M9 5FH*7NH!UC>KKDWM+5V_R).3MXUG*+=EN-3',2MZ'6]/Y*::!+;9;U:*A"
MYZ5?)F]WI_&"3V2"M+^\V^34=.9&7A557K0RC9DFQ=+D,"""U,G$D^&7G&@-
M('7G&P<*<!E^>FH:=7[;+<V*G?+KE-H"E2-DB*!$U2UT.H35C35L<A,W/-4K
M ,>M8V[LDB[(V 3E35.X,$XZN:_<4-#QTTRU:#"_'0KHETGKW.T/GYR[R!"[
M6Z5_4[1:8/-LVY-UFJOK=,'!%&8L*4,S:(*.>P'<J) <W=4YQ&:6<U;R3:^Y
M R*-R!T&U:EQ$LE,VNXWK.MNYF\C<BG+;/WHE?4OU2B:3M3Q.M4S"X4\E6J]
M2\GDJ8S81\ZLY;3CEU&IO3-1))"?J6T[3HV!!X+HFX)TCBCL4MR/W"[6&6^1
M_2>*<Q7;5>4W-*MV2N+?MT2RCK16V<8Q1F+-%)5MD+*87,9\S,F4I0]DA$^H
MJVE,MXY \9:\.M\XX<#.0]NV"SO-,LOR3X4MH&>GO9TJ[!SC7<9FJN<;5SU%
M\6*8#D[=JT4*3[8TB5TT,Z66-[JIS6E.+:RI)EM),L7^2*RNF=<X>5U%T8M6
MTOY .,-#OPI*G(W=4YQ+62S"P>*IB"?V$C9JK'(+%/\ Y:A3^!@'R[=;6C">
MT)M9:FD^3SV$LVXII*"B0[GY(N"*7B905!<*%WZLJB7NH/FJJ5%$3" =Q I!
M'Z (]6(-+R3S2X<>>1N@?(-3;#G3NN.^,B6(:EFNCR]FAG3Y.EVF5MN:2V6S
M<)#V,#6Z;GIX8?\ ;ZS(I)ARX0]ERFN/YN;EJ\<,&B5&,YZ%7#WCWM]$S[XW
MN->76"/RWY%,TXR;OJT=<94SQ',29JY?-W%]XNV",(95.7C[!,V=G'-U2*?<
M5@8S[Y,1,"93\BXN1X6E*/N[":PL7GH6?8-R0S.F_%_1.2=)RM3)XZ'X]%C*
M3G*Z17,]'62&>/Z17: UEBJ/).R!.Z>V K-P"AU7A'J;LP"LJ(CW)JO$EK!.
M-V[/+4="+>;_ ,5,BXZY)C'%V:Y"LXBC0T5HEBB]>H=(<5>PE*R<626>M+P*
M;NT.IZ;?/WP'04 XF,/N_F, ]0GR))56#^V)6%+C(L0;&5.W0.LD*"QT4S*H
MB)3"DJ8@"HD)B&,0PIF$0[@(@/;N'IULIC',@]^I = '0!T = '0!T S.YZ]
M0L(S^QZSIUA85BBTR)6DIR7>M7#X&R8J$2:@W9M$UG;UXY>"FB@BD0RBBRA0
M#Q 1,%;6K139I(E1..12=ODA5>:_%GGRAB>FT39^2&HXM!2\7E6<R'[N8T?,
M<UFR2].R&1G8X2L)*9N,@O*'DR%<^+J6DED4$E6S<#*>?:E[<F_#/3(ON?DK
MD2SJ]AB=\YM\4M2S&=A9B@Y5Q TASHKR$.@Y7C)K9)+-&M)H$\5@=1*OV!NC
M4I)^K&.3E=MBL3@9(H& 1V2CE5W&W:OS*.5X7H:OA'H= _OQ\M=B_>E5<043
MRWK]J>RR,['N8]G7XKBAAT2_GCN6JKDH13&9KC]HHX(!TRNV#A'U514('1ZO
M&_Y()-N#+XT\I./?*;D:VTJ+U2DSEL6I%HI> 8]!O5I2XU>A%DFUKT/3M!9Q
M;=P%(F]&7K,41)B[.DHRBF39JJ;[UVX;$I5UM>>_ FR2P_EJ*;A(Q7:\K/E(
M=1CI9>E27*#-%(INH94S-MH#;CSGB6C)LB)I)(IE*I^G^][7F /4U?,XJ@<
MO3SV#B%&9:/UH5..P#]0#H [!_ /]70'/0!T = '0!T = '0!T = '0!T =
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M9G\OMOT]C-R.2?&IR-O#" D@A+!)9M.9^_:DEA*I_P ,LHS9Q[AV<K1,XD4
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MDXURV4#NF4Y[TON6.#*DD$C"=,AQ$HB8H"(D$#%$>WJ)1#T$!ZN#TZ .@#H
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M)VS@CD@')].Q1]0$H]C!W #%-V,0X?B40 Q1]!]>M2#(Z .@#H Z .@#H Z
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MJ#.)A6*$='-054,913V&C<A?(PB(]O7HDDH60;ERS?\ 4D /J A_'H#S]O\
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MYE,7N'\P'H#7'B$#JJ+&.8%%4Q3.)"E(50H$*FE[Y2AW7% A?R>0]@$1_EV
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M.F@HNK-.:\#HYE4DS^XL8/7MU/%9V36BP*MRYU)V=:D!T = '0!T = '0!T
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MY)F45D9Z>=CY")7,Y-O%W*@#W'N<.X]P$1M5-5AYD$@^K .@#H Z .@#H Z
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MNX 3L(]P[AW_ (= >;>2:.CF*DLF;LD*P=CE[BD @45>P&'_ "O(?ZOZ?Y]
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MA-V3#Z=K#"7@ZAQ[Y:[=H>*Z7H.1ZX29T^>T^V:/4*W&V.]S&7.,DB$U9RY
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MQ8D8B*0GY:/8_I;"3FV[))&5D&,8)US1[%Z]*=5% RJHH)G!/R-X^0V(%'T
M= '0!T = '0#"<C[YHN:Y;8[AE&.3^]Z!'-4T:IE]8EJS!RL]+OG";9%4\M;
MYZMP4?&1J9C.'2BKH#BBF)4@$X]5MO\ X0"KR5R?:>6G%[E#B$]QJUWCMHFN
MYV2TNM@W&TXZZ=W'>&3N/4I\=&QN5WO1$F%.K(U5DF1-PHV:,HTR3=$'"IW"
M@\3Z:[W)X]CDNKN-KR)%YGFU^U;E#D?)?1<RGLLDL0XP2.3E@K'(U]P]=Z=J
M5EJDM?',8E69Z<:K5:MQ=1!LV=K&(+X\B<2) " &'3CXVFNU*'\6_P RKB?#
MD'&]SKU'G_D&N-HXYZ;"#9.0DKJ.30J[[/SR6Q0#7(Z%3(Y"JKM+@Y9P\M-6
M"BKIE3ECL001=(JG-XB?QZ%5IV:U($%P]O\ R5LNJS=HY!\*=HR2\Z'%":\:
MW>[AA3_.J+6*PM(NZ+DF85S/M,O-ODFR4K+"NZ=.VC8SUT=R^<*D C9JG5*]
M7N<=Y:6XJ+O@Y4Y!]L7/W=TRBC3-WY/1(YP4&2[.,GZ[CN5T_-9:\M$UE3E?
M$LEKB)! DDF((/V4>V.G^4 Z<;W.UEE)#4.'F6:]:D!T = '0!T = '0!T =
M '0!T = '0!T = >)D$3*>Z*914$@IB?L'D9,?JF8?\ >)W_  'H#V#T] ^@
M= <=@'OW_$.P_P"'K_Z?H".&I<H^.N$SL'6]>VK.,TG[2HB,##6^T1,"^E4E
M7)8Y!RBV>+ X(T6>@5 J[CVD3*CXE/W].L>6U-KW3@!8W;8<RS)C&2-[O-?K
MK:>^\/#'E'A2#*I1<<>6EG<6V;E=/)!E%Q"9G;MVF4[=LU+[JIR)!Y=<KO55
MWVR995=LCK<-HRG/J:QT>ZZ72:?1YHT"E#VZ>L,5'U^97L@MT:VE%2RSDK69
M6GS.DBM"-Q4,M[A?;[]PZZZ6JJ5F%)42F\[1@V.U$5^0&CTO/:U9/U&!37N,
MPE#A+J+L14?L6Q43%=KF38+"9P= ABH%$#G$.X=[7=:J+9,E8.2+=?XK_'5<
M65-"M9]E=DA-927O%-?Q%HL<A"W\S))L[6L<"^9VE2.FGJ*;Y-?WB&,Y%'S4
M G@DH),MO \%4MZE^T?..X*\3XE($8O((Z.1!XL_]IC9KNU2^]<+BY7=>VC9
MB$%PLN(F.;MW,(CW[]^M/1XOE1/J\BP3,TO";B^187!,K:D6$I"BH2TWDIQ*
M0WD =PLX>@C]?Q$![#U'H\7RH>MR]K.W_)1Q?[>/]JFGCX&)X_N>[>/B851,
M !^Y>P#W6,/?Z@)A'Z]3Z/%\J'K<OS,X'A-Q='Q <H8F I4R 0]ENAR>"0%*
M0HD-9! 2@4@ (#Z& /7OZ=/1XNQ#UN7M9P/";BZ)_<'*6?N"JBL8_P"Y[OYJ
M*MQ(*)U3?N7R5%+VP[>7?\?XCW>CQ?*AZW)VL]/^2OC" D,&5M ,F<JB8A9[
ML7P,4Q3%\ +9 \2E\   #T  [?3OT]'B^5#UN3M8N<_XY8YELJYG\_IQ*W+/
M&*T:Z>HSEDD%%F*[A-VN@))B8D4D_=<H$.)B%*<1*'<W;N'4UI2KFJ@K:][^
M9R*V5R^E3=OK]_>PQ1N-78RD1$SR#ITV>E@9L6QYBNO104*24@)%PQ;K*,W
M*(@X;IJE JA /U+JG#["%9K(7J;=(!$P%^HB(E$>Y!./U4 ![]E!#T[A^'5B
M#A1DU5.0YT4S"G].Y"" AZ]@, E'R HB(@ ^G?UZ ZF8-3'$_MB4XB01,4Q@
M$? !*4!]?S% H]NP]P#\/H'0'8K- BA52E$#E\_$WD/H4X^0D^OJ0#>H!] Z
M R>WH(=Q]?\ #_TW0  =@[= <] '0'0R93" C]?Q[>G?T[!W$/7T_#H#J""9
M0.!2]O<]3B _F,/_ (A-]>_0'KT F;)-PU=8OIJPRL?"0L5&/).4EI1TVCV$
M=&,B>](OGDD]528LF35 H&6.L8A"D]?+^%+<E*N+*7!:EK5PKJQJ,FY#81NC
M.9E<8U>A:;&UI\2,L3NFS\5.)P;]8IW"+6338K&=,5%FI?<2,J0J2J0"8AC=
M47-T[R2P[BSOR3%G+-Q1-KR?3G$^UH=_J-R<5AP1M,I5B71ES,!45<ID<G^T
M(4%F"AVJA2N4O<;"=(Y2J&,4P!"Y^FM.W;AG")=^1)-9,V5<TC-[FI<4ZA=*
M=:'%&F3P%[_0)V)EQJ4FU:-Y!>%L[IFX42AI)M'.DW!D')DU443@8Q0[=7IR
M4O7=3RF;;;ED(YE+X[N:5ULDRE?:;MMXS>N(1<\WHNRWQB]@*TSEI-=)V:$S
MZXPB$A$)2WW)?U))NX RI?:!81*4O5+>BW-L0DVX0IJ[\>?!JS041+PF;OY2
M"?MRR$.\C]IV]6*=-GH^\C(,"I:89 0>$$!!3L"A@]##W[AU9<7$U*2@.4X>
M9N?_ %F?PM[) .43A@1(*:93;/NQR@0Q?$0,4VF"53\H 'YNX@ !_ .I]'B^
M5"7VYG0WQG<,"I*D3RF=-[H>*GN[3O*GD7N83%\C:>)^Q_+\P ( ;T[]^P=G
MH\78A+R&@KGPS\$ZW).U4J?J\M5U13-%YA/\BMUD\LJX-Y-M+L$ZQ2?WZC&Q
M*,4_:$.U(7R(B8.Y0[^O3TJ=A$O5CQ!\:'"X!,;^U$V4Q^P&$FS;L41*4@)E
M(/;3 _RR$* %+_24    .H]'B[$3+61L87XZ.(M<E$)J!SJTP\JU]X&LA';C
MOC5VU!=)1!46JJ.GE,V,HDH8!$GB/J/KW]>I7%QIRDI(EBY4X:X0JF9$['4C
MIG*<I@/R,Y&F$2G+XF+Y#JWD >O</7T,/<.P^O5VDU#R C4OCQXG(MEF25"M
MQ&;B/=Q*S8-TW\4#Q;]VB_>QPI#J'C]DZ>H$6.E_090H&$.X=4]'B^5 :MA\
M4?%*%F7R]9?<C*E39=Q).Y['ZORLY"PV-V)Q/H*HVA:?H370BQTJK;?>,>34
M5,91ZJ83',(B(C;;55VKR@L!BJ36(:HQE$90S/\ :<-7FE3CX-V!Y)DG7&,6
MG"MHA<LD9V=ZT+$I@W."XJ"JGW XF\A[SM6W;H#!I6?5^@UV+JE?"1+ PB2C
M:':2$H\E5(Z.!=11C$-WC\ZST8N(04*W9I'4/[#5)-(!$I0Z)0H K18-3'(H
MHF*BA$S(^9SF,)TS@ *$5+W BA% #U 0$.I "P:F(4ADBB!$Q1*/T,"(F WL
M]P[?Y("4.Q?Z>P= =C,D!,0Y2BF8AC&**8B4.Y_ZP\?4OB8?40[=O+U^OKT!
MD$(5,A2$#Q(0 *4H?0 #Z '^ = <]O41_CV_V= <] '0!T =^WU].@#H Z ;
MV_7VBT")&QZ!98:HU]NZ:L#S5@?MXR*(]D%OMV:#ETZ420*0RAN_YCE]>JVO
M6BFS21:M7;(;!+E)QE<@14G('%E3E$PD<%T2L 8?+T-X",H( 4WC] [AZ!U7
MU>/YD6]+D>56=?\ FCXO(F+Y[YBI3D[ 50VBUHQA[!V_S##)@"G8/P$1 /X=
M3ZO'\R'I<GRL5],VS&[_ "2\+0-7H%TEF[0TB:*JMKAIMRBV$QD3.CHQCURH
MF@"AA PB4.PCZ]%R<;P5E)6U+U\R8C]FV'C?!-7.8;IK>04H;I#KI+5+0]"K
M52?6& <E4;R";:.E9N*DWS!9-!5-44_\L4SB4PB ]AENKE/)9E1V*+)T2<KD
M6\S^6K<U5CM4&T._I[V,>UT\?'D!JW81B\,NXC?L&:1 3(DD;P(0 #L !TKM
MVK;Y0+KR*'8/(H#W[ '</J'8.P!_$.X=6!SW .W<0#N/8/7ZCV$>P?Q'L'0"
M!E=(IM?MU*HU@M,'#VS13V(E%K3UX1"<MBE58DE;!^B1YP]UVC"Q2Q%W(AZH
MD,43>A@ZAV2A-XLE)O%:"^[A_$/KV^OX_P /\>I(-+/6"%K46]F9Z7CH2*CD
M3N'LG*O&T?'-$""4IE7C]V=-JU1 Y@ 3G,4H"/4-PI>0&X/NV1(7UKE3C5\W
M;:>\1!PUSAW<J^WOKI Z!GB9V]0._+/*J&9%%4I0;^1T@ X!XCWZJN2C<)X@
MW4KJ= @+)#TN<OM.B;C8DRK5^JR\_$1EFFDC^_[9HV!<ODI%][OVBH *:?J)
M!   0'IOK.UO$&T<WFK1]CA:B^M, VLD^1^K$0+V5C6L[*IL"$6=K142=R1^
M_;LDU2^:B2)TRAZF.'<.]G:JA-XL"8L.VY55[A#9]8M3S>MWNR%#]O4>Q7*N
M0=RG!6,)&XPU;E95K+2Q3"0PB"")S& /R@/16JW":E 6<':H:?=R3.*EV,DY
MA'8QLTV9.F;E>)DOMT'(,9A!NLHXB9 S94J@-W!$EO X")?'L/163;2T J.I
M = '0!T = '0!T = 0;Y<5JIO<\U&C5O-ZQ?M:Y*5"6S-A6'$8S<*6=1]"K0
MC2T75VN<GM9_FC)\9\\=*F K3P!)M_QCA$BF'-5;7M2W6^WW%TVUI"(W9#G4
M;G_."+RN1E9.PM,E^,#*J-4/UIHBY9+-PU:W5G0+&W<>V99O,S;:N08R)"!Y
M+-A0 X^(%#KAJE5M6P<?;[=A5MMRRN5LC(/?^GZ\K0498('4XUCG<O,QK5P+
M.@Q'/^"AJ ^A$I/R6C&"M#*V!F853"1H)2%.;N4!]#CK1\==N2(/H3U5Y0J2
M9SJEFK835CCXA[4*S'MXTDE9+8]E7:;R,SRIMA!8Z\I;I>/0-[29"@H!?)<W
MLIG,5=43W-XDKOR*KMRP%]QE^(36X]L9E4]*P^I:9RPKB=;_ #-LOUR.T*<Y
M$,86J2C4B*X-*Q)22\"4R'BDXCCJ$\/85,F<T[U4YAQ.&1<;F=E5N%%HMJ=(
M+MGMHI-9L;M%9N9B9%Q-0S&56048JB"S=5-1\(&*(=RB @/TZT2A00.!U(#H
M Z .@#H Z .@#H Z .@#H Z .@#H Z .@#H Z ;C2J16="@'5:N4,TL58=_9
M*2L%)IF<Q$DFSD&TD@E*LOS(/(Y%VP34636*9(_@4#%.7R*-;536.1*;6137
MRL8L)O'ODHY@XF9W"MV?!NZ\?<YME39-F#'29+/&UVLEBT&$/'-TRV*-K,O-
MHUV)D@(8IRQKP6XG;F34/@O3EI^6 XA=HXD(SAJOS<^-^OYFW;(U^2X!['#3
MR<.L<\:YRVMDP5S2>ZH+>P[2:6UVS3:.%?=,4KQ8I/\ SC]K6SJJQZ?^L_D-
M,<Q5<0:/5'O);Y@::Y@XA.IV3DSDK:8A&;)*/8OVMCXB8@O8&[I%F#?[A::7
M>KG7_P!Y4S@?+OW'OLXC'()PY0YT!1*'J7+JA[)G2+9K5.*V8Z3AZT_ 0[2+
MKUOL=\>U@7.=L9YHDV3F*QD\=7#*+(MB*1[67>%12,#EJLF'/MW7FOE@M;)6
MU8B.&MUD8KFY\D''=F1RE0\YN&#ZW2HA7L,;67&[4.3<7F*@&WGV90;VTT8\
MP"!?1!W)+>V4I%.M.->*T9)E"U;K4!T = '0!T = '0!T = '0!T = '0!T
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M7!=(-G)JW0:?$MF:2IDTSOWOW+TY2G<"4%%9-NT8E'$X9$L.M" Z .@#H Z
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MS497&3CP5E)".C4C.%44@,H"!14[> "/6OJ\:S:1F(]MRAX\O8!U:6.PT1[
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MM2N7*"*W1KCSB)R'5X?(J'-X]'WB+A[!+0E+BK+I"R@7:3E'#Q*$G[(T8 9
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MQL6?)KCQ)5F+NK;;,Q)5)F>2JD7.O;G!1K![:E5"IA5T5)%XU,-C)YE,=B(
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M2L<>-2U$VJVN*LENL;J>9N9E>"B&]FE?U)O6ZR2?<.9-K#1IS',1,Q_$#*F
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M=D4P[%2* %* %*  224:$MRY%J9L@?MYHIF\3>0>10'L;OW[AW_'OZ_X]20
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ML4#( (E H>78?3K-5XKVF/%WD$B.0G(O'.,%+;W[:;=^RJBZEV%>;O6T#8K
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MF!? IBA9.Q_#P#MY=QZJ_IW GX*I5'JV[C'#X[^'1?'QQ.-+X]O$0G[F E
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MKF['>6TE5G%/DZ$Z+6XNQ.8^IRSNIS)S2L.XEXEN"QB+@4X@8!\0 0Z L7Z
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MDQA&)V*OU>JS^79],UFAMB,:;!2%7A7<34F23%.*!A ,UFQD8AG^E)%:F11
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M'3@UQ,XCRMOG..&'TW)9:^H1C:X2%:_5#.)YO#*.EHM)X:3DWX FR5>JB0"
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M5HVWB(*CE2.2YE,U>!I$E3*V_IM5-$J0%6=,TUJ]%%A2%3B$F\2)OLOLV21
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M\B_<-A\53@3R(80#OYW7<%.7I;IX6;S]YU=%SKI^IKR0FI+O>!TE)_(5E/\
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M5JZWJ]1SZ/<-&_:OM$F18XY@,1 PE55&U;*KF:S[2]JJ$L9T%+7[9FD?P!X
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M9YEJ#<!!!(! P"! [@<2F, _B F* %$ _ 0#Z==(/;H Z .@#H Z .@#H Z
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M3B&*$G)Q]8LT/-O&<:Y5,W;R*S:/=KK_ *>NX3%,JY0%(3AX^7EZ=%>ELFG
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M??S[F4 H !0 1[_3Q 1^@"/0'H1TW4!,2*E'W1[)_4!./8QNQ0$ $?RD$?\
M ._TZ ]^@#H Z .@.!$ #N/T_P !'_LZ YZ .@&_TRA5K4*99L]N<&C8ZC<(
M-[ V.&=]B-)"*D4E&[E$50[G(Z(4_F@8.PHK%(H42F* A%E-6B4X<C+PV(T*
M.IT&SWMAG6M/*>Q_2&&@Z53JJ_F$JM'B*$.VGIB?;O6ZDNBS  ?NB&;IOG(G
M5!$@G$.N7_AI_P!RKNDUVWNDZ3+[!VVV>9(^J\=5V=&H;BDH?:OXFM(56!5J
M;<Q%57#-]&0Z3 89 X++G43513 >YQ,4?S"(WK3@Y,:I04O2]'%\Q02U$I<]
M %J\U4ZS+5@J+= *Y*0$4_@?MF@$^U;?HSMHK'_;M@3+[9/;\2>(>(!V#K5\
M?&TDTH610\'%.I#VO(4UQ5ZVO44VS9NWJYZ_'+5H&3!0CEFV1A3LC18-6:R1
M3I$*F!4CE*)0 0#JR22A+PC\12L8R-BF+6.BX]C'1S%N5JQ8,&B#-DT:D+XD
M;-6K=--!N@4H=@(0H% /H'4Y9 U\U7H"T1SB'LD)$3T2[ @NHJ:C&<K&.?#L
M)/N6+]%=HMX"'IYE'L/4-)J'D!*/\DR:4@&%2ELWSZ3J<8N=S&U21IE<>5N/
M=*%5(J[8P3J-4C&;@R;@Y1432*/B<P"/8P]XV4:2A0ACKF-%HO'2HV#,++E.
M<L:YC%8ORQ(O17&<5>$JTG-U)P0Z=FB(EU"-XQM'SD_%J"R_5#(+J-&:R_M@
M"PD4+1\-96V$M0/W2JW!T^L0-3K$3&P=8K$-$P-<@XE!)M%0<-$L$&,=#131
M(I4V<9&,D$TFZ8!W(F4 ]>P".B22A9 58B!0$1'L !W$?X!U(.A54SB(%, B
M  /;U^@@ _C_ (AT!Z= '0!T = '0!T = '0&M>N%6I!%$OD<W8B8& ? IS?
M0ZQ@ ?;1('J8W8>P?@/1Y89@HGI/S0A;OE@MOQKK8;-M(J$E'=<8:J1\_4>J
MSD94H^RNEY:N$CTB1E??.7"[=J]%4R!RH@83=S]BXJ]X5G$-]A?:JMJ^<%]0
M?3_T?^D].MB@= :66$P@4@F,1$"F,J<AC$,4@!Y>15 ,4"'*( (#W  'U'TZ
MRYKNG&[5S+4MLNK:'Q!?+>_6<\L))BZ5LRQ(V.(T5+-W>#M*@_9OW I U-#I
M"I#MU"*@847 F./IV'\H]?"<M;5Y[<E7+=L9_4^GXWQ<E*O)M++(J\FSJN$P
M=+OCG%$@JIIB<H%+X%\B%.4/10H '80[>H!UHN6UFL(*<K7&VLS[=OA8(53X
MVN-9Q,53W8JU>1@ R?Y#7N?[@3Q,42]Q[=_P'MVZ^LZ'&MDUV?@>'U7.N:ZA
M1!455:UOVB_'A\M699EC.>:#4K/S(YL-96;G[F#"XP2*4O7WEFGZ)2'->")E
M;9285D:1@ 4F&(J2R"0^XEX 8W1%G11&V##P1C,D[-&YD:37.+5"U#BYI$=.
M9W4OCX9\A*2P=T/^Y.SWV6J$(F>.E-@J;MP@VS_)EX2%5))39'[9ZM+&.FT6
M7% 2**7M@M"*I--L1DEI>[6GE]H^Z9+*9MG]E=_$=B>W2IK15I:^Q9'*%BMU
M\"DMH=O-UAX:.E72ZB!I!=V5PW12()$%3"8"RU9\CB"W\%NRT'JI'+?F=O6O
M\9*EE3?#Z!G^Z\&,KYAV*5MM.N5E>UV2F;C06%SSF)<,+;&IS!)"N6!ZBP<E
M9-?L#&245(N8?,I\EU;:XDJMN,YF=2.8_(%YR&P*AN'M$M-7WW1.2V6R4O2:
MN]GLDS:P9I&7&UYLC1M9<KUF5U"P#7*L8+<V(12,3<I+-F3AN=N/G"Y+]Q#B
M,,QL<ZYA<I)7CSPJM%52P]A;N2?,W4^-5^1_M5.QM7@DVTINKR,OM8@:];FR
MC-*(+FA5WC5VHZ6F%'0 I(-P,=8;I\C4J(()V\$-JU[28WD51MMGJA<;SQYY
M%VC#S:%4:NM0XN_QT7$UZP1\\\I/ZG/MZI+(I6(6B[=N^=MS_;%4 _F<X=3Q
MW=YG0"1X,SDQM>B<XMDNIT5Y<O*>WX!36Y'1G2%<R'$X:NPD37F*;E$OV/Z[
M<'LM,2)4A 'B[I,QP,":?:..U;RWF\R79M):(B[Q^R*2M..?,MC.+*0F>S5[
MY0<F*;1U8EJSA(:M6:TY#6&S=R5)FD0&2+V7>F,X43#NB*HG3(';MU2D/=&7
M^H3AR,LVF[C.<COC$H,SEEHX_7#$>)O)-/E5#/W=-<MJ[B:.15[/FS%U+4>5
MF6TG2I71X,\G7U7:;9!=RB"Z*0K)*^W5-J%$)?>&Y<O,9?X[7B,GJ7!W$^1C
MB14HM0XX;,W^-G58J'_0&W*7#;\C^D21-.=1:B;K.M(J&-P;)TG7TU07=HN
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MA(YP^22#[1D#9H1,I2E(4I2]I_E?L@NX=*SD0%R36*S#U?@V-Y<W2M\_9?G
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MJW,:"KRS3Z/L=#K>E9Q;(2[4FWL0E*Y9JZ]1D(>5CS*'2*NS=H")%"^XD8#
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MV,%S?S@-EO\ EVH<FDDZ#]+T9@K]RRD'<>X RB)B?;'4:+(F.V5*(B8.XCY
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MX?=NE!,;W#'*'<1#U]>O.OS;N.Z;:M,8$K&RJLR\GB3SD=6O >.*FMZ9+/\
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MF)*%C7RA8U)X=5HR6_XE)('!2J%AU3CN)3CWCW(/FWDFV P@< 3)ZD$""8Q
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M5KC*UZ/89'#Q.C0$*[A$V%S:-(<(Z&1D3'2<&2!F4XD$0-Y&*8.PAV'OYO\
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MDC*(E,!E2_E]#'#L8=ZN:IO,@;W4N0R6?Z+3LFJ>>V35-4O%8LMV:5BNOJO
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M#N(&^H[OBJU&)7<X2T1.A$GME3(4HE*0A2%#M]"D(!2A^/T .M$H4$&1T =
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M0@)._</7L(>@CW$/P[= 91@\@[?3UZ Z>W_/_9_W] 'M_P _]G_?T >W_/\
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MV5+S&IC]SE-ZAY'$!\OP*H8A.Q *!2 9,I3#Z_U"/6M;JV$J09?5P'0!T =
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MK_,G8MJL&2\R*Y>8N\A8KR+O/KS8]L=Z>C-1$5!3!<\T"'A7M=536$(V,>)
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MSC(/;&'F+"R%$I"E'ZE#M]1'Z>@>H@ _3K8@[] '0!T = '0!T = '0!T =
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ML)A[_P _KUH0;'H#!D'B3%JJZ6=-6B2 >XJN\4320(D7U.)U5544T_R_B8P
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M*O(*WLN232,[2+:TD'+!9%5#]4(W;R;MBR%\U:.5E8M:6:,?NB(K DX(@X3
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MQ^%N=$(EPLI-I\652M%,^/\ XMQ%O2<HS2^:%L)D7I12>)1ERL4[<J\DY1,
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MLPKCJXL(TQ%742D\.^033,(H%[#V;ZI[=24FY:T'X.5-CXKF.J8""9,!4[J
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MFMO6BYAI5'R^KUZH9BROD5)4A*X)2[B7=V5C"+HN L3]PV19?:N#=BD3*?S
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M)C& /3OZ@;%%4%DDUB@(%5(50O?_ ,)@[E'_ $@/?H#UZ .@#H Z .@#H Z
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MV'7K-LG-/&M+FKC-0>&77(29[(:7^T#:2C#:7F$=<'L9:'U)BH:LO%V4@)_
M$TQ.W\Q1,<_@!ATHV[.9CL[!>JJDUJ)GCXNTW7F'\E+K0T6U@BZ!9<KXSU>H
MR GDD:YG2N2L;I;T31JW@T;1VG62T&>.#^T NBMDT#G4*B4>BC=:<BCM*C1&
MMNM'BMDY'0VZ8S!QS&#X=X?O>8530(6&:MFEXUO0H%K!(9]3EFR164O3,G7K
MAOOS%,:-3G7K=JV[J-G8$SVRVZ^4F(AO)D0*$9LGPC^$N1I[LQKJ_P!RSI5&
M6:*'=V&0FY[)MGD-44.X=+*.G[V;EDWJLH990WO*E.=;OXCVE^2L9EZ;?%\L
M"6IP2R?QD?&5+5Q-*1U!QSCQ":?NG!U%K(^OUDWS14M0=KOU5"NRV%RF[F"2
MJI#J"4A'!#>21!#J7Y*QYI(K:M6XRC Q=3RODEC''_CWP@M-=CK1H]U^1&$L
MN*[/2+E#2$\]I+#=G^_3&KS%2DH_]T1DK5*,^>M;([4.H@E^4PK*@Z BE+TL
MEMU;P*S+EGTCN5TSHK)@H=,P 815\!_RBJ>0%6(=0HHG  -Z?U%,/Y1^O73&
M$%2L3D_C^4;8^S;B)GD''13JA;CG')?3;#789$K+'(^FW =#_5'<N@4X1NG[
M#/(J-&2)U3/EV+MX]5 &R114POMPKHBU86+S(57HS5;A[\Y5@N0IK7,G(78F
M[AW)"=678,*OGF7JX:V023!PYCR14*K&KPA4NWBJL"I0*H<P]9RX;?FG\R)U
M)6[XQ8GYH_$C9)6-9!;GKO=VTO-.XQFC8CF+QR2,M'OWI4 >E(A)**&,B)Q(
MFLH/H ]NMGE0*K<QH.)S;Q2F;/F]SXAT.K1C6\<E[%'VRTS<?72*M\YC&-H@
MI2S[A9Y5! BC*SB2O%:0(JKE=OY0J22 @BW6,BM95OM7F<%JUE-]B-9O]G7S
M#Y N ,E3V:R9=Y:[[B.IE8H@9"9J%4HI-*I#N?%,$BJGI=NAE08.C&-]HE*+
MH$+XN#"%K/;9-9MP4+1T?5,O?R'Z_P!90*/U'_=#T /X?RZT!Z= '0$"/D.^
M0#*/CJPQMN.L5ZXV^-E+M"42MU*CM&2D_/V66(]=HI%<R[R-B8Y@R:QBJZJZ
MZY"B4@%(!Q-VZJ[0]O\ )Y =[A]R@SWF7QWS;DGER<TVI>HQ;B6C(ZQMBM)V
M'79/W,1*0TJW2.LU(\BI-@JB8R"BJ*GCYD.8#=^E;2N] DN<!$/3_P!'J _^
MDZL5NG:L+,2UI;+OH628M%3-W3N/>-FSTI3&^P7<(&1(Y$" *@" *CV$ 'L(
M?AUP]5Q<MTUQJ6Y@VZ=[+)/M/G=^1/D]Q+XLT"Z8MKU99\C=#N;=JXB,]<R;
M23>9ZY0CBQ@SLU8S*/9&H-)%R<KHC=,2./+U*3OW[?,K@NKWI98KXGMOK.)I
M3?:UFDGC[8/D^6U22%8C-FPCO:,<BB28I*)))M5'QET6B1C"HHLFT;F\/</X
MF. ?3H^F=DEE!#ZO@2PLI]Y>K_T[UU=3W-3D'$/FR+<6''T%P]H@@DHDK?X5
M1'VU/#N?L13^D.XE_AUZ/1\''Q7H[-[G.!Y?46]2[M7M+I.=,3M]0UO,N0V?
M<?*KS8R2AYM/U'7^,#]W#2>DUF-L-@9S\5M^2P%Q1?P4[;$(^+=Q#N/,BD[=
MLSF3;N>Y13+[#:W>!R<Z<)K1B&RC<<0)F?QRR/&RFUC2<3UOEOJ-68R&K1<E
M&ZKQ\M%I-L%XEX>%K"I%#UV]TVQ@^K[T)!Q]PUC?$ ]\51-U+O5*BB;3\":[
MH;64"G_Y^>35<DD)RZ9'D#+.8CY#67!BS*P%NN$I=9YI;+3$4NEZ)2TY!E'0
MK(D)8K,U+,(/P/[Q$W)6J:?MI"M?U++.,"J4N$.KP$TCD)IVO_((&N7JL3L9
MG7*Z2RZIP,' 6&(-5(JL9UG+B(2AUI.S3<:$!,PL@1\X0*C]Y^J.G)E5@$02
M34NDV[!J,&0JY'OV''GY.I3EY"+MJA0<RB.,F9\E&<012/@;!FG+*9TZHN=)
MN$<S4*PE9NC:77JR\4F%R$6;QH+E,=7R H4M=5Y-S\L)EU%EM>>@X&^2JVX\
M\^$U^=OEI7'*9R>T#!\ZKZAO?K=SL<!B=_L>K7^39*J#%6!K$W.&9P\0J(*D
M34AG2J7<RQ3%AW6]663>!-%"LGG \+#G_JS'=\7S2UT'/%$-CWS:>/SNBU*5
MG9^^9=-T&D7W1,X?6O2&LD^RIZ_O-5SXSI]!$!G*Q)9=L4X"9%R!++GENJS7
M<_LRFV(;\K$57?D:V]&Z0E.N=-RQ>:NW'3D+KL9%4\;L_CLPT;!XF/L3C+[?
MIB<I8,[T]%6*D?MY-]6UD58^23!,6_B;W"T_M?:"77'#)Y#8S7*_GQH%+^/_
M %!=+ \;H_*#<^,Q8N%K+K2;=;9>$NM&L%MN5;NRCJ:@&45#-IR(0\4V:KT'
M+%8J2B@F1'WI?+N59U>'N[2U5&Y/."3L1S=WR^2\%<<:P]32,I=\G)[ )F#A
MZWH"-TAZ;5;B\S^T[T6\KJ$S!S5H2RPKIP>$1(J^4AS)K [!<%$ /J8<8/W"
MO&FIMD-#0_D0Y332>3WNZ93A<=DUPY\3?!RT$JUNODK??U9U?['G]3T&I \:
M-Z\SAV+^,2_4FS[S=.O-4[<$.R13:5Y;6AX0V5NJU<5+R0]  /7Z!]>X_P"L
MWKW'K<H<] '0!T = '0!T = =%#^!!-]1 /0/XC_  ZK:RJN\$:[IR@P?/;/
M!5.Y[+GM2L-GEGT378";M$;%R$E,-%$47D8B5PY;,_ND%W:9C)+&*H(' "^8
MCZ>4_J''7G2M9*LXHNN.[4I8&H'E-QO-$S5C=[9DK6NU>TR57FII6YU]O%Q=
MO9" /H5\]=O06_7VA53%7*D0XD$X@)@ ?7K_ +_19MUGVXD^G<3R'.CAP! <
MEY18.1,Q%3$\=2K10,17Q[BL?WQ.<Y%""/D';OW[" ]N_67^0X9;36S3/]!Z
M5R056T6DW*D1^D4BTP-DH<HS=2S"V5^29NJR]C&0NFS^42ET3BS69M%6:GF?
MN!2@B/J';KHX.>O*MRRCL@HTZN'F,DZLW&;7-#HSX-;H-WL-'EG]BI],B]/K
M$M&FM:1"-?W@O6XZ65_6++6FA%$H]5P!_P!*,=0R1"JF\NKSQVM*<ON)6ZJG
M1DM4S@8I1+X"4X>1#)CW(8!]>X#V[#WZV*GKT = '0'FJ?VTS*?E#Q#N/F/B
M7MW#OW$ $>_;Z!^(^G0"/KFA4FVSEKK5;M]8GK!2';-C;H&&G(Z1FZJZD$%'
M#!O9(QHY6=PRT@BD=1N"Y$Q63*)B]P >H5DW&J LS& I3&'Z%*)A_P  #N/4
M@T#NR14<_CHI](,$9.6,^",CE':+=_)!&MP<R!XQDX4(XD4V*)@.N9(# D3\
MQO3J'9*)U!XQ-L@YXDL:%E8R3&$?*QLL1@]0?'BI!%N1PM&R2;,ZZC.31353
M.= P H4BI!$/S!U&Y2UJ@)Z$U*E69Q+-*Q:ZQ9'D"]%C.,X*:92SJ(= JJD+
M&10CW#E9D]*JD*8E5(F4% -Z_E'I6];9 R8[2Z3,3+VNQ5KK$I/QH><A"Q=A
MB9&59)D7(V6.ZCFKM1ZW*BY5(B<QTRE(L8"&$#>G4;ZSMG&275I)O)B50Y$8
M8YL)*FWV7(U[2>2"&&LHZ935;$$N+D&7Z22&)+B^5E >"")FX$]TJOY.PF$
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MK'[S/=S-9$K<KA63I3>P2+EP5BBU%R"(^U[_ ($3 LTM;:ZI8>T@O4BGZBX
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M\:_J+$J/N>RZ]Q.JIFH6&?>(24VU6!93E]VK.I4*H:74)!O.5'0:O7KK5IE
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M>/16,HJDX5,F)O#L,VNTE9+/M#33AB,XN<-KW&1.X:19-!U7 [MR3Y(:GO\
M9:/0+-4'+F":V<8.L4J%LLPZ@K2S>SD=2JDR6<IM%A;(.G:B0&."8#U2M+6Q
M=FEW$ULJZ)^T>K;L4O$)QFY+U:'O^R;M;-'Q*]T*I5NV/:K(+%LEAJD[!0WZ
M8,57ZJSC@D7TJD5ZX<*"@DF3S'Q H][[76KQ;P+*Z=E@ECH-[%6C<\8X/\?(
M:AXC>[?LT#E64YG,4R)8UIW.TB0C*JPA[E9)*-G;;58><:5$8E06S4DFB61<
M+MP _LG,8*39<:23Q7O(MA=B<H=O+D_%3D:XN>$:9C]?I])O-KD)K>9*@3-^
MW2]7*O3DK<9^9B\RL5G9O74U8W2#4$".?N'2KDC5JU(DDB4U:N%9/5%6Y<LD
M-\>V6VK$^$_%[*KRF#:Y4C$,^A[/&@HLH$'-?HB3U]7$?N").0:5Q9V+%$%"
M$.!&X=RAZ!UO3R(@F5U8!T = '0!T = '0!T = '0!T = '0' @!@[#]!Z K
M(YM:#S2Q>FZUR*RFVXRQSC!ZZ:X-\<M5&E9Z=VR%@XQE,6E@YT!*PQ3C.K#(
MK"XBH1HUCY$IERI++J&!R5-&C=T\(VEO#&'F,JW[YN&L7G5,YX_6.K9Y9^/^
M'9KJUV86^K_O%U8M#V"O6JS4+)I %G<(C7JRC#4]8TG)('+)'7>MP0]DJ:H*
M1-WC6((43CD-C=^=6G6+C'\?O)S(X^I5VK\IMYXNT;18.XP\M.3D-4MPM\;6
MY9K4'B$FP9H23)87) >O$%P,D9)0B9#>75O'"RG4.)PR)6\@HSF-:E!C>.VD
MY1B\=6XA2;D[AHV<N=94N$O]Q(F"FDA$;A224^%:1S%!5S*&.]74,] B*)?M
MU#&-V3?RQ]Y"SQR(V5#G'H"/%;C5S-TZM1E6S?0/V/4]MI[#R M%?Z#H[+.H
M#8ZQ8I,2.I:BEGGC0RK!7_,7B),CM!456XIKYJ]L&XADN)\.1:Z50BHF(!NQ
MR&[&(!@\R^H@ B >H%-V'M_'K8@Y%(@_4!'_ !$1_ 0[AW'ZCWZ !2*/;OY>
M@@/H(A]![A].W</Y= <%13)W A?$!^H (]N_\0 >X /0'H =@[= <] >)FZ9
MA$1\^XB01[*J%_H$3%#\I@[ (CZ_^+\>_;H#@6R F*<4R^11$2B'Y>PF_J_I
M[=_(1[CW^H] >A$R)E\2AV#OW'\>X_01'O\ 41[= =NP?P#_ %= <] '0!T
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MJW(&PP=7-?[E"9NSKC)6J45LZE&I)E.5N,I!QEMLDB\A'1F5=CW*LPZ1;*J
M0@>U[L7I1>%21)M,VY8YSJ->PG0*Q]R^Q_DI!1KW-M'= FVC'%HDF3I_'4*<
MAU?;D:]/2;6/=IHG7+]N>0:*,P,*QD"JZUMENB'D"5Z2#53^@"#[1A 02-V
MHCW[D.4@^(E !]"B'8 ZO:E;J+*2#W*V1*!0 G]/T]1[_00]1^H^@]4]'B^5
M ["BF(@(E[B4QCE$1$>QC=^X_P"WZ?3J?1XOE0EG3[5#\4RF[F _Y@ WYP[]
ME/S=_P X ;L _7MZ=75:I0E@#T*BD0WF5,I3B'B)@  ,)?3T$0]1 .P=N_TZ
MD'IT = '0!T = '0!T = <"8H!W$0  _$1  _A]?I^/0!W#U]0]![#ZAZ#V
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M.MY7AZC;*U:R1YT4GYZW/14X5BJY*H9NF\&*=.@:G7*D82 ?Q$X%'MW[#U.
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M,TR3@5O 0P3((KQM*;W!6#2<KO4\S4TBIETOR38 >1(P_99G@NCH$.J#?R[
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MVDNPB!L52:9OG7R><U.)5>AZ3G%LXVU/(JC"Y[&,:_5=,O=(LEDBM(WBN0\
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M1!(MB D'_B%O%'OV #"(AWT7)+B+? NZ62G0E$0_F)P\1#P-X]Q$H^7J(=P
MIA$ ]/Q[=:%#TZ .@/,QA 1#TZ ].@#H#5/CI-R]CH>X03E.!>W</<$WU+Y
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MJ5Q2>&!M?I.3CXO4O@.1[;!(YDP5!)01*=3R<$(HL8_Y0.<QQ$YC&,7Z^GJ
M=>D<AK5W%>JK OD>'KL.5R)!_-'P\>FYD7/HF10RC-HDZ?/W(B!?5194XB "
M8WK#LEGJ!/V>G9RHBZG;-5:8[%N0JSV8L<'7WAD$FI#""[R1EFY3)HH$ .YU
M%BD2*4/H4.W1PE+!N6T+5;&QAY 6$3+LVHLY&#64:1SYHV*5N 1[V*'P<-T
M^S6_R%4! ?:.'B;Q$.B::E9 V,I5J[.HHMYV%BYUNW4!9LA-,&<JDV6  *"R
M";]!P1-< +_Y@!YC^(]2#7RV?T6><?=3E-JLTZ!%NW*YEZY"R2Y$&HG^V2(L
M]8KJ@DW X@0G?Q)_N@'<>X#26#)V,Y9ZC+3[U%E0\SE/W-6**SCXMA!(6F,!
M=."L\T[*":IFE39NW!V#!)--FV<J?='%0Y$BIT:QFV%5C_J7E)89O,>VOOXV
M48IR40]:2,:]21<LGK!9LZ8O&JQ!41>LWC115%VV=$-Y$.!A#Q[=6334K%%#
M>]2##4?-DA.!U #VP R@B)0*F4W])E!,8 (!OP[_ %Z ] <IBG[H"'M^(J>8
MF  \  3"?OW\1+XAW[]^W0'5!VDY(51$0.0W])BF 2F^H?E,7N!NPA^'0'J*
MI03%3T$@=Q[E$#!X@'<3>0?E[  #T!X%?(' @D. @KV!,W<HD4$1[ !# 80,
M(CZ!V^H^G0&6'<0[CV]?X= <] '0!T = <&^@]_4.P^@_CZ= -3JV2YYL51?
M4G3J'4])ILD4BTA3[K78BSP+Y5N8BK41C9IH\:D7;KE Z2@% Z9_4!#JMJJV
M>@%E4ZY!U:N0M=KD%&5B"A(YI%P]=A6+.,B82-9()MV<9&Q[!%!DR9-$$RE3
M22(1,A0[  =2E"A9 4O4@8G=^.^4<E*>3/\ :*@SNM/2F&,ZG$.W#YFF63CC
M"9HY!Q'N6S@!3\A 0 P=P'KCZCH>GZK_ +MSQG!Q^!MQ<]^)[JQ,01 4^(C@
M <A"#Q^B0(C[@I@%EN @45%Q<#V\I[R_*N/D4.X  ]<G^#Z#LO\ ^S.C_(=1
MV4_]48A_B)X#'$YO["LCF44$YQ/:+KW 3   0O\ [,P 4@ 'H4/X]/\ "=!V
M7_\ 9D/K^=J'M^ ]W'_@=QDXO6>PWC$,T;TJR6>#0@)QXG-S\HF[C&;P)!%$
MK>9DY!%N<'! $3D[=^M^'Z9TO!96INPRER<U^2W(YM$C5['F&NRFW.]8S//-
M)9VO^WT%FR-\I6Y9;565AI;68>VX(J5S>\TVQ1[EQ$3DJY(B\<_\6B43BV.D
MFJJDIV>FEDV9C;_\N][;FPQ2+XR7^*<8'IUHV>OOHSE91&[VYZA=V,ZPN%PU
M!TK4UU[M*V1.SR)G8K"F0YWBGB4I (4M7P5M$MRM2RLZII:FAKO%RU5BQ+.H
M7BO;V]!5V=;D4CBBG)[/'&7,-M&43GD-!A(P]8&9AO9LQE90L<@\+&*2G9V=
MN"OD!IIPUXW-6X[-!O<1AD/+/432K'OU"Y-2/#MP.NYMGUQS2M2S?D70FS0U
M5NDE#2DBSE6B=? LHLW=11Q9J+>0M/NG7M]A<'$;;%NW:E2-AN%UT)-3SR,Q
M7?*[#2O(=IREBJC!<SJ*TJE4V,LL6:G)>NQBU,=.#Q,\_ 5'+1^J]3;G5.+,
MK8QA/UA_6JVY;VSVDS#D[EX565&6J]F9<?\ :6]OI?)"[\I:I>"<PZ"XM,-H
M^DQSB)OD6TDW](>^>?VF/<F2>0:A%&:P%*(AW(40TKP4HY4R3:SMF;64XB7*
M35UAZIQZV)K*:WO5$Y,2<M&\P*"QD*KLF<K-%*U::0*5+*TATB(Q[=!PR73=
MLG**!"G2$0$1MZ=>\A.,23?"[CBMB-GY"SIZ#I5#-N%^1U*TM[KOL9L<9(7I
M]%LHJ<EJZQCXUBO5599&+06=@HHH"JGB5+VTB$3)*HJII:AN7+-#6^(+R#+R
MQP.0?V2'X\<D+;:=5K]KH5S-5;O4+#J*,878<^;K>VZ7C8N4F6)I&->(D5+[
M$F]:G(D)"*+1LG!^59?N0.51N#&<4YI8XV:TC?-6@+#FTGDA*EK>J/K/4("C
MSK1&-FXZKUEE'P</$O'T,V3: Z]I1=NV3 B!DP$WD7%5$IPY-]0>'>75>1G)
MRR25PUB>E\O9X8$MI$TE,.(C'X_[KV:-$IQ;*';,T)1-V"DH\ @OY18B9W"Q
MQ33 KTJO.2SNWB>>/<2Z7C]H1O"=JT'1[;"YZSR.ER6C65E-/*!DS*1;22%#
MKBK6*CRIM9!Q'M#R,JY^XE),8]M]PN<4@ZE42E2X*MRY'3Q;%:MCC&^H5R1F
MI9UHFK7K7[5+33E)T\>6[07Z$C+)MCD03%O$L&J#=HS1 1!!JB1,IO$H $UJ
MJY$#T@D0! ?43  !Y&'N80*(B4#&_J, "/X]^K [@4I1$0#U'ZC^(^HCV$?J
M/J/0';H#$>!_E>?F4H$, CYE Q! ?3N;\2B7OW*("'8W;HW"D%!_&?FK\B6C
M_*KR5XSZMQX6K?$C/WEK;4G2B4V=KQX>'A%$BYO8@N;UZM$W8VELB*J+-$RJ
M*(&^@HD3/WQWK=-7,Z=@+^BCW !_B #_  ^H?P]>M@=3CZ=OQ[]_^WH#Y].7
M' #Y%I3D5JW(+A3\EUJQXE]C2/!P#2&$G9<\8SS1NR9+M:X\64L$17()ZV9_
M<)G3@U';=<5"@(@<#!@VM[EM KM7G/\ J$LBV7(+-KO'RG<TB\?4K^%1M-#T
MIS0X?2_[@1X,4Y>W$J5EJ</;EZRR2,FPCINOIG;@8YS![QB*%A^GGBV:5K?:
MVHAHF=6_G DLV9B//3XZ>7G%5NC+A'2NAQ.?S6D99%JG;B^8KGG632.=F<F9
M)JE,FR"0.F4G<1$GEUA_7MR-V>3R,R\GB]OV4\F<)S3>\7>R#W+=-B%Y2E.9
M*/=1;M:.;S4I$'.YC7A2NV2RD@R5#Q4#U  $!["'?HX>.W&HM /F(K-#T&W?
M#=S64::E1(+(6O*SFQ9]3HUAKBL9(:)G=9WV;L=BS6KZFUL1E*9<KX$8#!B_
M_27:J2J_M$2$0*KU%GBX[?OP)PA1F69UV4U7D1RHP>HT_=^1G&G&K9P%R/D:
MWR2%5ID?/P$XVU&K1[2G6)Q8:?*2GM$KS8T3. (F<NB+G '" >)30KMV:[5_
MJ3#AO1#.9AR6T9M0./+:9Y(7-_8F_P P.A\>[">R7J,6EK-D#.U:$RBZ#;3N
M46;J5A8R)1CDT#J$3<F4*EY'.90!/52\9>?;IA^Y-:JR;[$8E6U'D= OI?69
MCE+L=A;T_P"7E+BE%4>><TIE1W&,VFWPU-F*S;HM&LL365S&(2OO1JY7+1=B
MLD4$_P YE_>)V2G[=PI56F>P=7*MQY ;1JI+.UY(93G4C0.;=RR#3<?D[Q8'
MDPKG45=I2BPN7.\*7A3EC+C::N:.G8V>!T!D5UONUE%F1E$$IFUGV-LE>G&,
MR2W^.K1KWH%9Y0?W!TN>T\U!YH;QFM7FK.K&J2$93*M+0[>MUXZ\''0\>HVB
M?N3E3\4 ,(J=A,(@(]7X6VVVY*.)PR-'\>DN>SZ?\C6@6MVF:[NN<-]S-XV4
M8ND74/0<=JM8K.70Z#AX'O+Q:]75/)((H@5N55\X6(3S74.IHMJLWKJ0(OC5
M5V.G;%\QN?.I$[)C>MJAJ \D6GLKNHQ*S<9ZI773I%(XBF9RS(^$Y4S=A$Q>
MP]O7JE?$[1J6AUBVA%VKT3?$-5^.'B-:V^:R]BX! ^UK:=*R66LD\5+**AE5
MMRR@)/&3ROQ#C.K?K[B2;)A60D)=R]9-7:P&(U1(#BD6:V_*3O<M]I&;@D/]
MOMEX,RDC6YW1.$O)*V\F7' &HR;K]5T'AQ;I-2P/K'7=$8IBN2S0-FID3*E1
M7<")*@#L[$_N**G4Z*KFKT;(3A.-2Y2\ AL?-_&LOBD6"N:\.:,KOE\B6A@;
M1[#5M$82>><>JV#! Q6*"T%3F]EFTD? "M^[0Z8AW !O9MWTBN)"LTFEJ3RJ
M-]IUT8.7M2LT':6K"2DH=^ZKL@UE6K&7BU1)(P[I=BJNBA*QYS%*LW,;W2&,
M'<.PAUI6ZMD0+0![@ A]!]0_T]6 = '0!T = 1&YM<PLQX+<>[AR0U\)I6CT
MYS#1ZS&M,/U*?EYJQ/T8BOPT6@)TT474I*N4T@46,"1 -ZB'5+VM6-N.(,3@
MSS+S/GCQZJG(W)6\RQJ%I>3L4>*GV)6$M!S]:EW4'/P;PB:BS=PM&2;-1,ZJ
M1Q3.(=P'MU-;3@\+(EQ.&1,3JQ!6?\KFP7K$.*[J\9](?I,VG?:7%.)(2>96
ML1*/5T9)40[#^8B).X!V$1^G7C?6N1KIME7BWB>M]+HK7M9I-QJ?-2I\@'*9
M7[CV-E2, D0,AVC8WR,=51/OW[AYB!2F'U$._P#'KXVO_'QWX_Y-X'L^CQ?*
MCP4^0CE.@/MCL@D4(8Y%0/#,.PG*( /B/M=C!_,.N>>HT;2^X>CQK)1["S#X
MB^5>T;GRGO\ 6=(T4EFA8C%PFHZ/*Q8-O9?C:H^.57-[8%,!BI&^@_7OU]1]
M)SKC+VG!U[?H.FB9/#F/1Z=:?D,^+ ;+6(B4%U-\O571)%HD]5>&K>"I35?3
M<A[9B/CP\L7[EL1<%"(J>1B]C#U]-2B:5L9/GY'3^1^[UC..-S6W7'$ZMO\
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M6RG4[ J@XM4C%R]:N+QN >R^N.>6:;S^UR"/BH;Q1D)ZM.%R%\4Q*"G;P(
M4-Z-NJ;S(;ER3! >X (?00[_ .OJQ!ST = '0!T = '0!T G;*VF7$:\)7W#
M-K-JL'S:)=R2"KN,8R2S<Y6+Z08H.6BS]JV=^!E$2JIF43 Q0.43 /4-2F@5
MM<3]NY1\B>!U&TN/_MJ;?[Q;=-IDA9U(-PPSFFM*EN>A9VZO:=*/81DYEO7(
M&L$7;1))('#]T<@'6(4R@EHU=<:K7S QLQGN8[G5N3/&JW:SGMVLV<9YD^G9
M+N3',BU(5U=(E;RV4S/6Z'&6>6A%CMG-([%DXQ5DX_27OFF'W"7N=9^/)YU)
M43#R)B\6M^A>1^-5O1XZ.4@Y87U@I]XJRCA1ZO3M$HTR]J]XJSMZJBV4=&B9
M^,6*DL=-,SA R:OB7W #K6E]ZG4.)PR)%]7(#H#CL'\ _AT!ST = '0!T =
M<"4H_4 'Z_4 _'Z_Z^@.>@#H [!_#^7^C^'0!V[?3TZ .@#H Z Z'3*H'B;N
M)?Q#OZ& 0$HE-_$H@/TZ PUV!%_9 5%"E0$/ H#] ].X ?\ \PIA[ 'D @8
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M+CE^54B@V72G:TK?K%5:\SAYBZR;I8R[B5LSY%,CB8DUCG.'W"XF5\#>/?L
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M]:"86DK=;+)O[5>IAJ!Q%0&\G;IEXLF)NPF(8!$ $1ZUJHJDQ9IV;61), [
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M(*K=%4O37=55=O,\R-LMNN19<GX'[_0W;M]0]?Q]0 0[]A$/K].MRI[  !Z
M  'J/8/3ZCW'_6/0'/0!T!P8I3!V, &#^!@ 0]/4/0?3TZ  *!0[% "A_
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MY::P E'G);CK$L(B9DMNR&*BK/6GES@):0OU88QMAJ$>Z9-9"SPT@YD4FLM
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M: TD<<JC[0HV>O#^,G*^QC5\ODI&+NHN8Z;9-95!*)>1:X>9T2J+>'8I.X@
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M:%]U>5(T8+$3,<ZH@T. +7I9=X6>.0U/'/#M2X=W,:OO-"OFX9G?_CSPKCY
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M.8U&/D#*JHLGY(1\NY?P 3D4D@\,Q7-[K4RXD, =NK+=+G*</8"89A[!W_F
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M!7_J?X<2M7Y"*<P<I< JDP56*=BA4X-5VJ)EOMVP-#-DE0.H"AA(4!$ $P
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M>(^I1'L/;R+]#>(^H?P$._0'0S=,XB)O(1$P&_J$/4"^';T[=@[= >_0'40
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M@.ONIAW[J$#L/8?SE]!_@/KZ#Z] =O(H_0Q1_P!(?B "'^L!Z YZ .@#H Z
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M7C159NX2$0]#%,(=0FFI60-MU(*P?EQ9(/>(<P5=N"Q$[Q1CF$0 1*4)@/(
M 1[]Q#KYWZY7BKMY>30]/Z;?EK:U>)YI%!?$CC6/(K9GE+9S5:J4+5?T^=L;
M]Y[B=A5@17*>2"%46 6/WJ;3S$#& P)>IOJ4.O'Z?BX>K\EDJ]K_ "/4Y^7J
M^'AMS82OO'@YT<5:]@ULK=FKTQ"SN>WV4<IU$S-\D_DH^)CD$B*M9(&C=)!8
MZKA3S*LF ^9C&\NPAUU/Z=Q<;VNU'*P<_BSS*_4NIMXXLFL<AU_AJ8!_S1ZN
M*7VY6R6/'200% A5B^[=2%6*8_YNW?\ CZ]^M/I]+WZA\?'#59*\_#R^B^HO
M_+X^\LHYQ\MM*XC[AQ=FU@K;SC%>K"O4>2BTA%J%G<^C+#8*]1*/H\-84GB0
MLZ]'WFX,$)=%5)1-)FK[P&( ','OKEY./F]/D>#JCAV3Q[UG/Y&G^4/F1J?$
MC+,W<XC PLK>]$US+ZA)6"PM@E:WG5"LM]J](F+B:'"1:C.RS]Y9F[*+;$,*
M9UU#K*@)$1*.M^HHKKCKYWC[BB3<QH3ADN0^*Y]:&F>7O6JNWOK9S4Z\\9OW
M'VS\+!>%3-JHWEDV::L57GUZ=(=XQHX40,X$0*B4W<.\OGXZX6;E=S(-M,\F
M,(KMVC\XG=.K$3=Y2TPU&8U]X[.1PK=K%%.YR IQW1$CQ[>U342Q47:QRJQ'
MBZ8%$B8^:?D_L\3U?P99U:2;R9KJWRKP"WWDF<5K2(B7M[B8M%>C8YLWDP0G
M9VC-SN;Q#UR558IQ-AD:8DF;]519KK'8F(<JH%,FH4LUY^.[A3/L(::4Z,SH
M'DY@=HMT31*_J-7E;5/NK6R@(MJZ5$D^[HJY6UR;0,D= D3.+UE81!X1HNL9
M$"'$0[$.);KDH\-2#0<@-:<9VQS^MUX(P;_M>D0^2YXVF5U?TQ&<E8B6LLU.
MR3=GYNI%*J4RNR,D#<ATRN#MTT152!7S+'):U4E52V!F^0VO;1D>X<+*9734
M5_G>X["^R[1GDXREE;T19IEUTN#.2J@-%T:]#MEW=4[.@4*LH;W^R8%(4?*M
MKVK9*T0W!>M59-O1#:Z7R3V67V_EADV.OJ?!RO$O"*)IX1ENB#2[;5[C=V-G
MMK&!E7C=XW?5FC,J[4CQWW3),7H2;\%S'*FU!NXH^7=>*N(#JE5/5B$SWG!>
M>6EN?5;C8XK]*5B^$V3\LHA[;H5:96L-JW)M(R=#HTFV<GBT6M):1D08LL^:
M@+\5W*?VYT!14(M9.W(])12#9W_Y!7$C\>E:Y59!5DU]5UCC;;]BSC/Y80=Q
ME??T^AREGM4O:S +8SVBT9=H8CA4 15?J':MR>"SPGC:U[52E8LLJMS&2+&<
M\FWMMSBASTJ9#[^STFI6)\9L@8&K:0FH2.DWJK,I@5 B0.7)SH@)NR8 4/H'
M6E7*3*E<^Z['S7X^2>=;),'RZ?QRT<A*%C]CXYQM5E%M/B*=I]M;9M3+A"[$
M6?79V"\IRKYI+OXQ6$;,A0<*-DW(F3%<V3OR5AWB)T&;A&OT/F=HT;6^7>^4
M%&O2F,<,-3',[E1G$.J[M&H$HK.MN]OEHNV'ET4ZVO6SV84(!,K95([J*<F>
M"*3A,$F^S;B(1:$I5LR0U\VO3:WS*XCY#'!05\>W7/\ ?+%+N3$E%="+8LUK
M-3F85Y%B#C]%0J[IO9S ?L55P8Y"@(@4>KT=GBX@J,=S$V#FO@%+OO)JDI8S
M+9=EEKC$W7'V5IUE?Z#I&7A/Q%8EK'!:7#V'P@-)EY&<%:(A2PAV8%(0KERH
M=02EBSY%BH@$K(?<I6J\FVO'N\H,S-]/HM@U'&;.@BFP5?L:<_BX_1<]G&I1
M]I:QTM6PQSQ%TD(_>1[X2J%*LU4,K%>27%BSVQAF2X(8IR@8I@, ]^PA^/81
M ?\ 4(=NM2IVZ .@.ICE(43&'L !W'\?3_ .XCT!P10J@=R]_0>P]_X]@'\.
MX#W 0^G0'81 /KT(;24O(KX^27B7.<TN/S;((#>KEQS=H7ZJ7#^XE%C7DI8D
MOVRH[7)%-F[*U4]4B$DJY*"B@N_\L$P$"&'K'F:JE:WE69?CK;DPIF?.9.?$
M#=(+2X_)GWS(\MCW>0C1F4XA*JSBASQ*:R*"CXSA;=3M0#W%BCXF\C=OJ'7#
M;K^EI=\:H^PL^'F3AVQ_$=!3X#MB,[3ES_+[RS(],B!06)79Y4QT1#N4BB@[
MFCZAW_I*7L'6G'U/36<ND0/3Y-&6-_&3\<6C<,M=T:]7#G#LG*:'L5 9UJ/K
MFH1TK$H5.3)96THYGXM1YHET:.#.(Q,S<_DBD<"F'L8/KUM7FIR<B=*PE^96
MU;U\S;+1;_R(K=0NS7,H.J7/3-)5J$EH;JD4-*K*3<12(^03A&]AD_W7:ZHQ
M;)3LXH9E&H N=V]716 B7BD<P;N]5;;K^A"JVI6AML#WFE\A,N@=<H3*R-:O
M9#V1%BRLD$O 6-LYJMIFJC,,Y6!647=1L@E-0#DH(*""HD(!A*'?MU9--2LB
M!ZBO"&(F<J:P^X3S!+VC N0H 43 HB( =,Y!, "4?S (_3J0-E:= >0UYSRJ
M-*!=+!'7C]UI2%ZAF#1:J9Z:MQQ7K<MS>*2"+M@:TK'%I'"D@L!W)1*82=4M
M9U:24R!RD7:8F30\%0,!2D,)@,)2' H]DQ5. >Z<? WJ'?T*(C]0[W C-1TV
MIY#29J^W1XNTA(9)$/;9-%I&5E9)\Y180]?@8IL!G<Q89^5=(LV+1$HJ.'*Q
M"!V[B(5M95S T-TY5T+.[KQSSJYP.@0=OY,6AQ2Z,R4JWW49$VJ/HUET63@+
ME96;YQ7(.68UJHOC"V3=.5U5$NR15"=U E.5* G-1YFYKF5TNE*6@[U<7N5Y
MRRUO8']+K[&6B,GS^2=ND6$Q<73Z8BG/WKJ.BY"2)'1Z+^1-&QRZX(B'M K5
M\E4X>82EPLS6:#SKQFD/F\=#-K?IZI,2<<D)MQED3$V-C6L-35229Z)*.9"=
M@RO8^<\E#1S..!])O4VRQTVPE)W'-]3Q)QC)=4LW"S-=>^?&:5&:A8JKYIR!
MW!C+9M!:PXM6#Y-(Z!4Z[3K6BN\J3FS2XR$6,7(6:+:J/6K4$E%2LR^\L"13
M$$TUY^.V%9^!#JZYDD<-UZN;]CV;;;3X^R1-4U2G0=YK<=;XHL'9VL)8F*4A
M&DG(@CEZ6.D#-5BF.D"JGAW[>0]:IIJ5D5'5ZD!T = '0!T = '0!T = 01T
MK@NRT72]'T]MRFY=YQ,:9$1%=EXK,]"H$#"PD!",5V3*%IZDEE<Y8:VP,=TL
MZ5(@_P"ZCU8[@1]WQ,6CXTWNQ L;EPRS&XH3S(;%I=;877)H7$=)9UNS,TC:
M;G5?*\;QD7<Y.8A)F;7DDXR8DF1Y%DY9/U&<HZ3%;\R8I1Z:3E-HE.,C(V[A
M[FVXUG&Z5(6"^Y]4L*T+-=*H-;S)_6H2)0G\A7:.,^:236:JEB!W U]1BF";
M,@HD,!>QA'TZM:JLL<B# VKA]%[3I%)U%3=>1&8V'/*Y,5NJ-,JM5*AX6.3L
M2R9[!,D96;.[<L%CF6R"359X54JGVB8(D\2'5 ]?2KWEE9J>\:33.)4[<:#E
M'%EU;;W?,4BM"@=0VO2M@M25MTS1VE-OC;3(?.U'C6.B6[L]BO+1DJ]>?;M6
M<="L/M4">\LD)(=;2DO*F0HQDL<3'R 1_B8>M2#OT = '0!T = '0!T = '0
M!T = '0!T = <#]!_P !Z KQ^3'A](<\.)6B\;(G1I7)92XNJY)-KM#L7DD"
M2E=EF\H$1.Q,>\8OYBNS)2"BZ;I*%\R#^;N4!#JEZVM&W,&S^-'AHYX$\0\N
MXR/](DM5?Y\%D^XN#YNNS0=#8+#(SY6,2T=N7SQ*%BB/@0:@LLHH"1.PCZ!T
MHFI;\S<OL]Q+LVE71$_.KD$!/D<R72MQX\N\XRJ(:S5IE+;5GH-GDTR@DD&$
M>]4=.70.Y#_AUCD*G_Y?<!'Z]>!]?Z+EZO@7IYK ]7Z6J5=KVF"E&N?'5SFJ
M]A:V>$J->;2+ @(MP+H]?1:KH>I#$>H(E(+DCA,1*H0YQ*("(=NO Z3Z/UE.
M&UM)Q/7OU/3\=7;D?A]C_0S=%X(?(5I,U$3,]2Z65U#(&9QZ,;>ZVP8-6!_R
M*I(1Y/-JF80[?F H&[^OUZZ*_3NK221S_P"3^G_*B8_QQ<.>0G&_>[?=-/J4
M=&UFRYX>"0E(RT15@.69/9"R(-5&3$$UDTRI (F4[B'^'7I?1N*_%U-UR*&I
M3]IGUO/P\W3NO&TGG'82\Y54^H[/H[3$-/JZ,WD&I<>]ERC1;$6;K+=I69*]
MO:2[KJ3IJ^F4)MDZ40A'#YH\1;&%H[;-NWD94AB>CSQ_:FWR_B>-56]**]I4
MKLW&[D[;.&="IFARE;W?DJGKO&&I-!IEKI+*JU7CKQ/UPEDBKC8Y6P7%%LPN
M6E5V,4G),R7F=>4>(1Y"%*@8X4;6%E+<_<E^L%=EXC"$+;FW4>0.QS_)IA6\
M6"5A[-H7$_1,MELZTC'JO%:35LOM5.D[:&SN)*ZQ-LM>JU5!JZ91<&N!8=G&
MMTCI*'<%*L5:TV;3>+]VOW_N72LDDO>2%QUAJV;;/L64V[%,[U3-]*Y8S','
M,N3,YJ>8K5C,UKC)1$@Z@KK4I.:_>R>L9$FQ%A!+1#9^V<I&2#[EHB03"WO:
MJ]CG[?;#$K:C=I_C(TM6JF\6#6N/UGM67JU0U$V#EM4+RVJ>S8[#X]5ZENE5
MN<)5]9S&E-+TS?3T X/-?J\O(OP+:5I-PLDDF<%@23TX)K:>R=>W[9^P7K@H
MR0ML$S/2'6.?'WQCT&'9T"[\'-<HTY:-9C+I1YVDZ)2\HJE]ID6M1YYM8#V.
M1D]L83+$LK%*,VSIB=5VDL*I4@.?KW;MJ><F>UI2\F3;Y=0CZ-W#@3L7VZ(4
MS+M^LL!=')U2IEA6FPY39\YJ\XHB)%4U6O[O?QS(3!V.@+TH ;MY@-[YU]I:
MF5O8:GF0QT6Q[QP.=5')-"O$!F?(>6T31;=664"I7:-5SY??*.TD)=22L$9(
MNU5Y>U-U ;M&[A0K8JBA_$"=C9<TVM7;_%XD5:2:>J$ARZXIP^[:!.KTC/KU
M4=FU+,W6)7?D;5KA(TBJPN(SHR'ZTRM\=%69BCKD]",Y%TK6XAW'.DFDDL"R
MJR38JA3\F?+$.6U#T_<A6:7<S1\@.&M0;UC/J9QXRZS1&R5O"$N,M(W2(N,C
M0JIG>+"Q;U]RTT]U 3D<OHK>M,%C2K*O!&N_OWP%!-5JF<ZQ.II+PJ=_W$)M
M)K1B1UGXT'T%QION>\;=ATZLNHWA:XXST'+BQN4/ZY98F IEA:L(I_)W*CS-
MAJJVFV*9]Z=/'/V(G7$AQ$HHIB71<=U,-0](_<G<VHT1)N*XHZT]I''UDYY<
M\BZ/,YC1JE#VV&J*^5M8B^R$85B\=-[@W&@.6B:39-(T2!XXK43L40,(J+B*
MQCXK-*'#U(E=@RVB7_D9-[A&6&P\']VT.EYC>8]OA41%77"X>A#8WS5:!5W?
M1GTUHB-P(E!-GSD&#0D2X/"-/<=D;NWBR(-JX^6R::R]OM(&IM_%C6(+-.>O
M%+/Z4=> YC;3/WZG:T461Z-4*YOQ:^GM86QLI+-I,]ESUY$S+J/;)M@),B\9
ME(<ASKF+5*+;8;EH:#\;-3=!:\^/CYLM2R.]63+,=S?DK0[W?X=*O'@J3_<B
MK9I!TA[-&D9Z/F72!%Z6NFZ(R;.%FQ7*9S )1-X[JU:^#&4!&<B-EWF2V1[!
MK\">5VJY!DES@+#3B9Y+8&QKVRWJ%:)R,5:K$K<M?B)\N?4N:%-PP:)L4CJR
M+<KAP5<H(-2Q9-RWDLB5:%[1Q=0BY;3>>G!0D;'@T7Q3.MVU_5EF2_WS"JDO
MM7KF=4FJN9+VD"N5;9/+2BS82^(K)0BBXI"4Q#!1W5G5?RS)3:3[RS9$WDF4
MW8 \@$0[ (!V$1$![& I@$0]1[A]>MRIZ= <&'L41]/0!'U'L'H'XC^ = 57
M?+9L?-[%>+07C@7G:VC:\6]UUA-L8ZGFT&;@:*Z0D"RLW!TY%PB[FG0R"*")
M3HD<'3(KY D8!$Q,N3&U5IC^PT[R4G"*Z<A=!XKXI<^5E(BLYY!62FL933:9
M$(G:-X2<<*+ DDO'&<NPB))U&E07=,RK*E:KJF3 P^/8-$H49@E6?Z?^C^(=
M6*<GD97/\DO*FT<2L")IU6H;;19 UXKU>-755I% YFDH9<%W21XQ!XZ]Q($@
M[#[0D 1]1Z\+K^JO&U1$OX'7T*G%Y)3[]#YDKG\JTA:]?AM?G>'\@GH-8A7<
M%$S;2?M[-NE'N5DEA2>-@A09.P2.D'B<X!Z=^_?OUY3I:ZWJU?=B>S7BI:JL
MZ8O4?9O\Z>S)-T"$XF,5R)D*F15:2NBHG*4.P"(-8 Q -V^OJ(#T7/Z42UA]
MY2W2\3<['[BRCXO?DGT'F;M>G9];,,0RMM2\VC+:SEDWDXHA-JO+(G$*-$DI
MB+9"4Z*)A'^HPB8._P!/3KIZ;JGZJ>#=G[(CM.?GZ;9QVNDU1(>SDWE-9U[E
MJP'%.1-JXL<W\CPN-M$9<&K& L>?ZKB]CN$V"-%U7/YMXDE?Z1 7BO@Y<K-U
M&3^**[ R3@/?* >]:-\L\O:TD]&1GI&CWC?F7Q[LM1FI?C<OL&F\Q\XT^K\>
M]*G:3FVT25/@[=+KW.@3!EF3S]-T.R13N:CI)JH$N9!RL#1WV/[O4NRP2\L_
MH*V=<C14'5;*RJ9<5MVR6N=@V?)SFY5>/%RT[5'T3&Z9@^0U:M)QMHLFCPJZ
M%PUFQ4&QW-['5UBQ<-E95RR*LNY (XZJD6V_QDO2RENV;%;Q9W>\Z96OA=GK
M5L<W-2VMU+D16=7;M[JY0:75_3L=L"\2YL<0@\*@]MM??1[=07+E,9%!P(F,
M<%#&,:6TU5,K?SL;WC;<;@PRSBER,E>1NPW2\3GR7ZOQM_3K?K<K8*A8,FL6
M^[3F"-0DJBJZ_2YV3BJW$1TBUDG::\PW<-4Q!<&P EU9I+;:NK*%G?->4DPU
MGX^8-4PITNP<Q(\MI7(!B%5EH'']3G:)%+'$PD5:/+8P(H)!*/FJW3$!#P[C
M?D\U?:7K5--O1"!YV3#.%Y)?%9'.)AFQ0DN;-G;NDG*C-(')U.*^^DC&HE5.
M58'*TRY:)(J$[?YBA$A[F4(4VA09WF7E6A8O:.5?(?$[_ RULY@XW6L0E./-
MMK;RPR-^U.#KLQF>3R&0/X2R0;R.EU8^SK$EQD64BP29IG=*'0214'K*SMEA
M#)3AR0 Y0\?;+0G]%S7.[,RH>N\1_BL8/=,G924DDZ?S'R")G8Z+OG&&591Y
MVJH5,_Z!('+8(XY9N)=R[0$B DL<3>?S*M;M3XDI?[$IMWG62VS=]4D5.#F;
MH9W4SYW=>6%:Q?$\XSZ99F@96B2N]0,3#O63ABQ;@9E(9AG[J5=JI)E3^U2B
M3?T^(AUT<::26L"T[G.8_EAE.2^;6_.\ZPG#LEM&!PD!4:[)V>S:[*4ZUU&/
MB3HQ#IM%51.EV%*QMHNN-$0;"9ZV.HY#P,(%_-UT+U$HP)\&W7<3!(83!W[=
MOH/;MV'U_ 0[CZ]:E#OT = '0!T!BNGC=DD95PIX$+_ ICF,(_0I"E 3'.;M
MZ 'J/1N%($;&:AG<U89BH0]VJ\K;:Z!?W#5XV<C'UB@#G*@<B$U"MG2LC%N%
M$W)#%373(82F[]NW5%R4>">(%YU<&,Y,8J:G@ ";V^X 8P$+^(>IQ_*'6'.V
MEAF2E+2>11MO7)GDK0;K+N(32VPC%Z?,52G9TQA*K%.M'8%=QZY(15O;3.)9
M96&0.=%>8C@%NHF8O@/GW[?(WZCG74SN<2SZ;@Z?@=5-9M"DAQS<YV<S>,W'
MV,TBK<@:O)V:QV.6.P..>0=IB2QY)DRK^JM+! B6KQ;ZHF'[;W)5JFZ6 A_(
M_< []?%R<M^15=K0<77\7%QK=2J(2;E\CWRV9'QIH6\6CD#0XR3NTK"E+4(O
M'*H=5G&6))Z\K,X=\,BH1=%X@S,H=!,.P%+W-X@8.IX>1WZKTZVO$]IB^.U.
M!<MJT;CL_<^E[@ER%L6@?'/A')?<K"G(3\K@Q].TNUMXU",;K!#-Y>3G)$(U
MJ=1)J5M'1@C[9!$H@'KV#KWNF;]/<W+A_BSBYW-L%'^B-!QHU7D[R]XX0'*.
MH6FB91';!7U+SAV72%0&YQ[:H.U9$*J?4[2>R-9.1D;=&HM'2I(<L6E$>\*?
MB[,0WEI'+>&G"3^/<8N(PS'88<Q,]RO.Z4KR>M,%FVLM,9I^H[;4H]"2G&>8
MQTPNTKTQ;K*O$-9 :KGJ-V.NP;R+X4D#@@8?+LDJ8FF[:IOF$F\AQ6O+_CZ\
MT+3,K;WA0]ZR'-V^O7R&&MV<A(O-GK)20C[>QE#PY8B?B))H@J9NI'KN?>%%
M0I0$Q# #U*]Y.UPGVC9S7R1\+JZT=NIS:&T8I&T&DZI+QKFFZ$$U"9QH)URU
MF[3<*2IGE(FMJ$:+*.W2Z1$HU)!0[L4"E$>H]6@VN6NP7M5YL\6KK>+)GE9V
M.M2-EJE%<Z=*^:,O'P"^=L3M4Y*[P%ODXUG4[95HD[U(';^+>O&S7S#W3E[&
M[/5H-KA/M-&TY[\47,):K(KJB,;!4W)([?)F1EZQ<8Y(^(2SUW'Q^KPZ;F (
MXGZ.N[9* +UD1<J1/%10")G(8SU*"U77,WN9\U>,.Q:*CE&;ZQ#6:^/:4AHL
M-#-H^=:H6>EJ@U]ZP4^:?Q36"M[&-6>I)/1C'+H62Y_:7!-0!*$KDJW"(=6E
M.C&1YHZOMV6:7PNBLKNT' 5GD#RE@,+OT=-4YA9%TZ[)9]I&@.IFNR1I-@M%
MS"AL_!CXG(LGX.C*B'FF4HS;>XVN%KWD#SN^4.,.[U'95#WEVA=+'=;?F%;?
M)U*T2-2-I]1K#^Q6:JC9VT>G5UK#56#)1R\CQD$%!.F=OY>Z10A*VNL:Y,NJ
M6:W:$8>%W-<E@XKXQH')>[QS_7M4NFT5:!C:I47H2]_7RZY7-M(.JK1:NA,/
M#M(2FUP'S]9(#H-D0\U%>YB^5./D\+W8PX*I3@B1,]S[XA5QIF+V2VZN'1VB
MG2%\R@(QA8IM?0*U%LS/GZ]6:P\,^<R\LW2+XC&)$-*"K^0&_D @%_5H65+-
MQJA50G+'C]=<TSW6J?H["RTC73FC<ODX".FI*6N<JHJZ;*1==K+:."SO)5HH
MP<?<H?;$.S*W5,N"94S&!ZM=,R-EFVM41$X3\RWURQVVWK=+W'6F2?<I>2&4
M9*ZI%%E63W0:'D]HF&5=7K] A4):><R#.J0+AX_$R0K)IHG.MX&[%&*\J=9>
M<P2J6;:U19#GV@5+4Z76M"HDL6=J%OAF4_7I<C9XS*_BY ACMEQ:2#=J^:*#
MXB!TEDDU4C@)3E*8!#K1.5**M-.'F++J2 Z .@/,Z93B B =P'N ]@[_ $[>
MH_7Z= =B% A0*   !] *   !_     .@.W0#9ZA8G%2K<K9$8F1F"P\2]D%&
MT6D1=]_P*9WA?M4E54R**K%0,F!?0!,8HG,5,#&"E]R4J"4WH**MN)%] PSN
M48 RDW$4T6DV1SHK&:2"J2*BC<ZZ:#9%<Z)S"!CD33*80$0*7OX@K9;-SP7<
M);U9\F7);Y;N;N7<C=XS*H6.C-ZUGVBS]6@3/\_CWSI)@V4*LA[SAR\;G<',
MFX#U ! .WKU\_P!5U?*K-U<)MGK]-Q<,QM3:2S)9?$?\@O*CESR-T.B;59*S
M*U2HY0E:&4;!5.+@5#V$;6A!'<JOVRBKOVOLE?/V@[E[CV[]PZMT5[7O6S;:
M:9IU:KZ#:27L+I;E5N)MCTMG Z+7\(FM:LT=]_#0=P84I[I5EB8T#'.^B823
M24LLS%Q*?D)UD4E"-R@/D)0 >O9I3BNL4G;4\16LM6-QHO&'@#322>C:EB'&
M&F,CILXB3O-_I]#K<'XN3?8Q\6[F9Q%A'@X=G6\$2"<#*%,/CW'J_H\?8H$M
MYBQ9\3N'SUW'W!'C]ASMT>*2+'3#;/ZD[[Q"A$7#,S1TWBSB=@^32(JGV$Y%
M"D Q1'MWZ>AQ?*A+-/4L>X-7*U7EG2<TXY6NWTAXQ@=!85>J428FJI(K(+.(
MZ%LA6#55>'DA20,8K=?P5#P[^(>(=0N+A;:VJ4-ULTW(Y8<6^,X]NV!8P/J8
MH?\ O.ZH)NY0[C_]:A$1[?P[]3Z/%\J)W6[6=T^-W'>+>L'S'#,E8O&#U.29
MOVF?ULCA@_;F**#U!=O')JLWA%!#P6 P& ?IU/I<5?%"P(FW:Q16^W8W.Y[/
M*7>R41;.Y!%U6+)(V*9A4JD51=88Q[#R<L^=)1+=VF\'V13.J10C@ *'93L'
M4NU6EV,3#DW!IFD9C6FKBQ3\/5:Y'(1D&UD[/.(LV_\ D(@S9,C24TNF9PX4
M10* =U#'4$._J("(FZ423:2[PVVY9FK:+GK:N-;DZMU7;4]\BP<,K:XF8M*L
M/6\JLFVC%VD^=R$4Z1DEUDTVYB*F*N=0A2>0F* S-6MRC:0E+PS/!OIF:N:P
MG=6=RJCBF*MP=H6QM,1BM97:E7,P!RWG4UQBED2NR"AY%5$ 5_)_4(!T=ZI)
MS@]26FG#S-Y7K;5K?%M9VJ3T/9H202.LQF8!^SF(E\BFX4:**-)-@JX9.2)N
M$CD-X*&\3$, ]NP]2FFI61!MGK]A&ME';Y=%JU1+Y++K"":*29>XB=50W8B:
M:9>XB8P@4H=Q'TZEN%($VE=Z2[K;6ZM+-775/<QJDRUMK25CG5:5B4DCN#RJ
M4^W74BAC@23$WO@M[7I_5U&Y.N[0&+7M SVSQ;Z?J]OJUAAHY9\WEI>!F8J5
MCHUY&( [D6<H^CW+ALR>L6ZGN*I*F*HF0?(P 'KTW5:W3X0<5S2\TN,9(SM2
MO-+M,+$NUVDO,URQ0LY%QD@T;$=.6DE(1CMTU9/6S-0JITU3E.5(0,(>/KU5
M7JY:Q2!VJVAT#0&;]>A7.JVY!HN@T?N:M.Q4\BS=.VZ+INW=KQ+EXBW<N&2Y
M%4RG$#&3.4X!XB ]36U;9 ZU'/ZW492W343#-F4Q=IHL_9I7W%G<A.2*2'V;
M-Q(O7:BSI08]@0C=NB!@;M4"@F@1-,/ "JDV]6!>]6 = '0'3VR>GY"?E\?'
M\H?E\1[E[>GIXC]/X= =@ "@ %   /0  .P!_@ >@= <B/;U'H#421(A0A2R
M;5HY2#\Y2NFJ3DA1 0_/X*)*  @/X]NX?Z^H=:OS),&I",J"Y1_]4D&H0W@'
MK$QYR'*H;Q*("#<Q5"F/Z>G</+L ^H]1LX_E7P)W6[7 $B:BJ4I48*$.0#'
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M<^.+- Y.1%!ELS:W=Q9&*M,FI1*;=Q#ZLSSV">E2FD&$6C+L5EF?FDN5LAY
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MS-AK%%M+_C@:-RZ]7FG,)-]::32M2<U)*ES]MAHN)?+*MVKA7NBU< F8WM'
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MIL'$:6S*,@Z@RXV([U3--3N/ZK*VLR&CP^<R4-(U9&. E::1[N05 #JKNU'
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MN1-(F9&KR["148P-%5J=3</A>S;>-<-PFTDSI%^V<CU#K?=O>B*O;E6<R<&
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M:)/!;D444#Q\39;)ON9=M;$M2Y%HS1%F'O$\1$G<"^I@3[>?@"0 )C 4O?N
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M?)$J9,K5M7,LIZZBIQW /J(= <]_P_'H Z .@#H#@?H/^ _]G0%>7R<<UG7
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M%)>H>)K^.76#AF<= Q$1G%J:1C%@V19QT0V:UN0(B1FT;)>TU09E#\I4R?E
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MP@@W(3T*F4 TX[3@LD068]: .@#H Z .@#H Z .@#H Z .@#H Z .@#H [=
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M(%D:U:+ P;M"*RQZB](+UA&B*<>63.5TH555!$Q8=4XTADIM3&I(-L02%$/
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MP+M./8\?YG=%ZT<W:14C8[/G=Y-$ JF=(A556C<R7?R*(B(=A*/KU]-TU?\
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M'^J6NU-;Q;5K9-8OM=GMLLA"H5;0'C%.82?W"EH+RJT.JLJA'%205*D1NZ1
M8=7N:7E03Q)#\*-RG=JI5_C+L*2NC85L^FX'?'Z#$8UM8IO.)L8UC>&++\Y&
M3*]5E9C*D0*<4TC.C%(!2 4 OQ6;PT0;ER33ZV(#H Z .@#H Z ZF-X]OY]
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M3WTGY69%056$XJ&[N&V[@U;2>9E,VEAQ&B*M#?&KBIX4R3^)DN(D#9W3Y-R
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M._D4.PG'L3^H0\A,?L4 #N(B/0'@5Z4XE*0H&,8W81!0HIAV_J[J  ]CE_\
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M[5]A""[?HD.LDV33;K@'BJF<.MJ<+I"F4NXI^ LF_#;1VVHJ;<CI6 )Z\I6
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M->K,7'PL'!LDXV)BXYHDT8QL>D4 (R9-4"D210 Q>_;U'N(CW[CU9)54("C
M.W\/] =O_2CU(.>@#H Z .@#H#@PB =P#N/< [?XB ?[._0%9?RG<D.+''OC
MJ"_+"1O<12;[;H.H5J7S>&&9ND#?H]VWM]3M%9*F=-:/G:O.0+=ZU7*;T60
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MC5Q@0W+DG/UH0'0!T = '0!T = '8!^H=^@#MV^G0!T = '0!T = '0!T =
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MDK9\-A[1"T>65S-A>+(!SUNFR"U296BP$2$?NEH6#>'1DI%!H!#"HJDF9,/
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M6D4+/@*!?IW]>M <] '0!T = '0!T = '0!T = '0!T = '0!T = '0!T =
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MJ&CM58EL6D/+1*RB;2$=&<KM7[L?9-[:AD^_3R]1?CY=F&W/W'#MJU-)PS)
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M5RGTM*)A-%_=T'*P2]G)+.FT"S:A[;]L#,4.Y2@<YS#QVZ[I5-7;'V/]#?\
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M3>I>X"(=@$#  ^I3 8! 2F#T'H#E-,$R 0OT#O\ @4/J/?Z%  ] ]/IT!WZ
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M1ZUNX4IN(M>$!(79>1Z1!(*92H[#-I"4ICB<PBH1N"BIC=^W<XF'L ?PZO\
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MA*'^67L(   /U^OT S2)E3 I2>A"E I2_P "E#L4._\ (.@/3H Z .@#H Z
M.@#H"-7+'"D.1N)V_+AD$(::>A 6:B6)TV!TUJNE4.QQMVSZSKH@;W3$AK7
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MXL&=Y)8>/3I)]PCMF70%VA[O)PKTMGMMND+Q8$J[92RD6V7?.D2%8KB!_!!
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MR!L.I!%3E1>]%H\-1SYBG$+6&=NK""<H3+"2=MU85\RD/U(6RK-5%HQ?I)I
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M[Z1=0["P0KV88E SZ(92\>ZE&11.1(#/(YNNH\:A[ARE[J$+^80#ZCUS_P#
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MTBX]!N@F0YC'ZI6[2:4-/4O7C:?B(N<2,QL^9R%*Q#3N,,=<+=QLMNE2N?\
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MQQ#U.J;\QC@8YBE$0()O$H 4!)V$ ^H /8>KJ8QS!E]2 Z .@/%=9-%,3J*
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M]^A'NFEIK3IK+/\ ]*BG;:>BG#64E .*0QD<X1=G1?2)5 $HH)&,J ^GCWZ
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M'<?AUW48ZGW;>-S)6<)7ZDS>M(Z0T6T)0C5XK4:'&23A!JYG'H%8)*G*7W1
M#B2/1Z7Y2/5YKXMR;BX9=\?%)L&5U&XY7@,-;-CLHUC)H)>HM%)&[S Q[V8]
MN"(T1<$<$)"Q[A<RIS D7V_4P"(!U;^MTL+PYE?5Y.T26PL_C4XX.U(C7J!D
M-.<I5U[;Y)BWS"9LA(6JHN08KVJVN*C!6!O4*VL^=@5%_+F9-C^TIXG_ "*B
M$/@Z6KAUR)];E^9CI1F.\)9.S5FH1N1X^ZF;O5ANE/(C6V/VURIZ!45C3U:G
M&X&B9\$4)%%==-NN=R#5=)8Q"HJ%,)<'2MPJXEUU7/50K.!Q"<,>+!ECN2\=
M<L]TWM^7_LN-?'_+,4Q#%1]SVB"!D@]0* B =A]!$.M/ZG3_ "K[R'U/.XFS
MP,@O#GC&D'8G'C*BD*I[O@%68B7S\U%/(2^?@8WFL<0$0'MY#_'J/ZG3_*3_
M &NH^9G;_D]XQJG$YN/>8G-W[F]VMM#E,(@<OJ10YBF[%.8/IZ=QZG^IT_RC
M^UU'S,ZEX:\70.F?_EURGR3\"IG/5F!Q3(0YCD(7S$W9(ISB/C_3W'Z=/ZG3
M_*BCY^5N79CP9UD6<9)&N(K-J16J-%O7AWSR.K,6A&-7+U4PF4=JI(% #*'\
MA[CZ 'TZOQ\/'Q/=10VBMKVMA9X#H]:E Z .@#H Z .@#H Z X$Q0[]S 'CZ
MF[B =N_T[_P[] <] <&[]A[?7_7^/0AS&&8U>BS-.B4F,I;K2[JC5@5\H#UO
M8G-?243]CR6%=-FJFXDA1(3NF3Q.!#"(@ "/6/+R<-7'+;;[VO\ 4Z>#BY+K
M!2WV$466W\4-.=TB'K_)ZT/7]QE9UA36U9V&Y0SNRR$*E'&L+9(C99HLM^A?
M?-P.FN)2I&6'Q]>_7F6^I]$KNBLWC$[G]D6OTW-6S>W!#;37)7X_:Q-R5:GN
M=KB'F8F4>1LC$O>4UJ2>1LG%'%L]8JHEGC"0A3 /D(F$IS=_Q[]775=+S0JN
MT^_\?T,;*U7NLHD=K"-KXF[@]G:?@7)I_M$I3DF,G9X6L[-.W&4@XB6648,'
M<D#B07<%B%'")B)@ C^8.W\NNWCIQ7HHW..^WZD>HUHI#4*YQ<186O.M:Y&V
MJ.CIZ'7A;K5K3R:ML&<T'=T7<6G$RC<UJ9.XAO/HKJMFQ"F146]2)"(AZ39<
M.-79_P#M^I5N7(F<?XO<>'3V,5J^][9L\;E%BK[^HU6U<A9Z[5O*9Z)@GL-5
M"1D&P=LSL'+2#ECD9#)@Z4 G^84PF #=%Q\5Z[=S:KECEV?L6QJIT:)MITM@
MV4;+EL%R7%LY(J4BUQFG*9SI#V%-1%9V*:Q._H8@@/?OV[>O5Z\5:Q#MAWO]
M2%9I1@-I;U,8V:3E\DE+=7INXYU(UJ]/Z]7[4U;7[.9=J^.O4+:JWCG*DW6'
MXOT%"-7 D2*L3W4Q\TCJ%--E7D\,XKLT(3AR/PQ;$;M&R9G#E8R:*"1U7#GS
M5443(1,QE12$J'O','YO I2B81[ '?K0-RY/0&S-,>X%*3_,,K_YAB@*@E,F
M8Q@\P WY3"'8>X!WZ$')4&O83$\0*H)!$2'[%4 @"0I1\1['+V-V[?CT!C+(
MH(E*1/W0,;P3.=-0#K' G8"%6(<3&7(/D(#W[]@$1]._?J'"4Z 0U&TNBZ.W
MF'&<72M7>.KUEE:C87E2F(Z;9P=IAU&_ZU7GSU@Y=I-IN*.\2^X:',19(%0^
M@AVZ)IJ5D!QOMT_0"^:8!W'LFH=,#&'ZG/X"7S,/\1[]_P >I!P1LBD3VT@,
MD3Q$H%3.8H!W_$H /Y1_'T_$>_X] ->ZRFM2V@1&C3Z;V>FZPB\3IA)=V#J+
MISF28_ILM*5R+!LDFTG)IA_E.'JHJ.2(B9%(Y$U%"FILFVYMDMRDNP<YJW1;
M$,FB3P*)O,WJ)C'4'^I0YC")CJ'[>HCZCU<@RN@#H Z 3UB14.P6,D=-%<$U
MP:NE"'5(R<J-5DDG9D" (K@@H<#>'B;R[=NWXA#4J"5F4(_%GP=^2+C7R7Y-
M:1RWY-+Z]E^DR<LK0ZXXMLY.I2SV0L:TA&6DT',IHDJ!8FOF(R*Q:]RB4OU[
M=<]*OU5X8C-]I-K;K-R]I]!_725#H#Q.B10# (?U?7MZ?CW^O;OT!K3QZQ_,
M@+ FF;MZ%$?S!_ 0[?0/]O0&>V;@V2(B0>Y2% O<?J/;Z_\ ;T PW*K&T^1'
M'/;L'-+*0*FP97>\]:S94U54H=]9J^\CV$LY(F4WFUCGJB:JI.WDHD4Q2CW-
MU6ZFN/VC$$->)W)R;SWC?F>/[EBVMTODAC^>UC,YK)Z]F]LLC&^S%*B"5B-L
M&3W2/CG5.L%-M;:$(\2=NG[0\>DMV?D;"40ZHN3#'S ;GEUDE]8;IB&VXY4X
M6O:ERNK4KPNW%<[R+!_%4NU5R3T& OWW2;?RM4QBQ*K,I^:(&!XV>^)BBD0H
MIY-6<6U83AR,!M6*\3Z/\A]:H>K8G7;%BK?XQ'5-B:,CE;VW1LO,5_=&%=J$
M.,#"04PB-L3IJ#IE$N7!$1#W5B(J$,J(EN^/C59LO&2YL^]C:\9>+*3[DEP.
MR;D=F#[29+&/CWO,=JKR[4::F:S6+PUV;)+WQZK%HMCZ-6K3^\9[28QZDQ13
M>NE6"C)P4#=Q 3PMD8SN#\+[T%3J<S3J'3L!7Q'4!T/+?F7K.L.DX[+[:ZKL
M+FUNWU_>XW18NTEC?V]+59>COQ45_27*GVQ4A*X33*0_>E92C7=/W$^*\O4?
M7&:ZXA^;V5*4:'E[M5Y+6N2EIMM&VC$Y^'VWBA8K+"Z$VLUVJO(",BXV"MN2
M:3(NBLV$5-NI%11C*1_Z>H<K8I6MJ6::7:0W*@DUMS"5B/E0X1VV:8":E2W'
MSE1F]+ESNE2-HG6'2] N#V.^T!$&Z\Q:\_K3HS4#J%$4HUR(?T]C:-V5](9!
MI=PL3!+Y4.#AOM;$LV8XCR5K<I*LZK:)&$AYZ[-Z8ZJL=,6)I$.(")7GDJZ]
M%M]PY3*(H>(B43I@>MO^]/2( W/*OC)"6^6VK(N-['0H>]<U+!78OE2UCG#E
M+$J17'S"&K]UUR?"5CW,?'Z+*YM#K14>SA7(JR\DH@NZ3*5 Z@KI.T*6YQ+J
M:J<(:(W\V<?GKSR6T>RR-;M-0V[CU4,1=?&U/U[/Y*TU/991FT)/:!FNLNF<
M*_KMR:R>@-&\6>/G7#-"!:E2E6X)* =?K#DXO'-?-*S*'MS_ ,@L6X;?>GFM
M0UHSFYYAQ\SVU<$-0S;.GMN:V?D0=Y*V?4\[M[]E%SZ-T@7]E@H&*)5K#VAU
M(MVN\3#[DH+DA4=;O=V?>,RT*)SKFI>9+$-#'D34,:KZ=*RYYM^ IX/7="4F
M[FT0;2>I14)KCZY0LM ,IITLM'-'"#!R#,I <IE.8?'KLIY$">8>@ '\ #\>
M_P#M'U'JX.>@#H Z .@#H Z .@*ROE>M%EK7&2 C*^3M'ZIR,XOXC?7!'J,:
MLGFNK;G2ZG=6!'"BB:ZR=CB9 T6HBC^<R;T3&[IE.4U+U=H2!I/E>3:1W&+.
M6K1LD@S9\N.'S9-B@B*+9LS1W"G)(M$T6J0E2;(MR%*4A"^)   [ '6?,DN.
M-/\ 4"IY*4O3LTY+UKF]5IK+!S?->.VCY;KM<TN?FJ:K%0+JUP-]97ROVB+A
M9QL?[5:",W=QJZ)3/ ,D*)Q4(!!F]&GZE,7&OL@LMN,YE.U+R+D(CEW!"&SI
MRWPOY"-"M7/#E!QV>VF,66S?,<6N<TRNUSQ?0JLY!ZYE8_1F5SJZA&0I-746
M^.NN?VSLE$%:;'&Y9"KJL66-?'MH>+9[\?:^[M,CD<><8N3D7_>&KRLVC9K'
M':[1[M8%=_(WN21BA9&V@ZI .GJ/LD0*[550*1 HI%*%JT6W?C,!MMR\QPLT
ML6K\2^,>=V .-VL\BM<W2=MNT[;$9 I549.#T?3>]YFOU=6\SM5*V8QB3IK"
MH%( J%+'D+X=-SXZJR3;?W%14\EZ[$[MD,AQTAZ-^V[)RVB8B4V%&81AVS_-
M*"5&O+Z!=+JZ9+KINK7&1;$M?A?!18JTV0GVZQ6[!<R=+-67>XGW!8.2-,@E
M3(#E1\EXW1ZFA24OC?X_,,^<23\')/[11M<Y#L]'5@9?R.9U%_KAHY-ZL54_
MD^,CW[G.7RT6W:XS@G#)Y"BIL-;F'$+XA&FBIKJWB)U?BNK)+R95/UAFJOB^
M@L6C=^2131>-YI""620?>9"JF6%8!#R\NH_C3VDQ+>W(FAR&09-*SH%+SZK4
MI_M_(ZMN*2+2<39(-Y"#"*6J;^[WXQ&ZSV5H>:5J;75,FH;Q<'.2/1$KAXF0
M;7P?ASL*IO%:$8.2=2C.+G%'A[#Y0#N:7X]<@^'N<Y\\3,:8G'4-,W2O8O:V
M979G*0+#9:7:)%FH4ZA6Y?< @_E3* 1;PTKVID-RY9:]']O:'Q-Y (F/Y>!B
MB83JJB)P\A'L0YNXE+W_ "AUI5S62#8=6 = '0!T = '0!T = '0!T = <#]
M![_3L/?H"J_Y5ODOJOQF8C3=7F\RF]5>7G04\_@X&&EFM>31?I5V4LCI_)S;
MQJ]*S;IQD8=-,H(*F565*4/'MZUMO_C )@\0N0<)RNXT8SR1KE?E:I#;-2(J
M\,ZU-]AE8(9,ABNXMXJ1-))T=D^053(N0I2.$RE5 .Q^I4QCF"1X]Q >WU[=
M2"IWY7N0= XS9GDNG:)"3UDBVVH'81D+6V<>:1>SRE9E7404\R^63/7F)7C8
MOO.$BJG\!$/$0Z^<^N<74<\4X=LXY]QZO0=3P],K7NK-0EAWR4!4#Y?L$"8&
M6ON'6Z))<OUAG:I.NEJLT:IMRMVS*#+48HJ#%N_+,  C*G]U!8XMR"4YO+T\
MFGTS=6;M.R6)U<GU+I+X55O>A@?C_I'#3D[R7Y3_ /,G5*:_=SD7%V_%*S:I
M"4S*$2CVTFY)9E"PM2L:;.%=G@T4W*B!53D]P3"'<3#UO=7Z3BIZ6"?OR//Y
M^3BZFWAF$^R"?GP9ML>:?(G\B:&"Q;:,RV/SFHL*4QC7;QZQ+"Q5^DFR81\A
M*.7;YT@Y=-E#IG54,(@</7MVZ]OH'R>FK<C>]+'XK\CBLDK-+(M=^5+-Z96>
M*EVL\56XUM.:%R:XB3MWE3E!9U9).&V'+*O#.I)P[!R+=K#0\6W0;)$$B*9B
M&4\2G55.?JY[\:J[=I"C7(D-R*NTAA^W\9Y/.H*LIO>3_(B Q_9WKV%,\D92
MK16;:!-0<F1\T<-3,9BLR4&DFW6.18GLKF(?L IB&VZN[PM)OM_(TK-ZO=_%
M$/5N8W+-ZA9H.I/LO>V6)^52V<)&3N?SV9<D7RHU&A)V'L[EC7;%&')/U9W*
M*R#U<I1;OFS8$_\ AP,90+V=E"U96E4Y=M!FVFF:OEGR.:9E\[;<[8<F-UXQ
M\3LU3UIO0+ TQ%*_M9?7I:7L#V)<22H?K#^&BSMJ] NY1NM(/U2I)G]HB@ES
MW.MFIKN?W&CJGQRIA$S.2O)S:L=V*L9RH]B,^H5D9Y(PS+;[?2SS60:%H,S<
MUXK3LTU"U0XJ#C5M?UA!(U544(@RDI%U[0*F'P;]2[W3VJ-QEX-NNXE/R8U*
M>S*G5J9AI>O5\T[I--J;YW,,GLS8#0U@DSH+-<UIL?%3CV_:BY0+[<9#D0-[
MP^XNH IHG 9Y>3TXG4556X97NWY@\IG]=QF.CI'-(ZTVGY M2X9VV9M.8S#5
MZ_K%?;6YQ3[PTK#306K.L66+;PB:LA&BHY0D5NR95& &-X9KG;:2U<%MM?%W
M(V&6\W=PL"M)P2TR-%<;?9^:F[<3SZQ"UU. KB]5PFHOM+L>F1U#?RMD:-+>
M\JR*$:E$J/U6(OEA7 QB)"D>RY+7P48X%5MQG/0=_P"+M1^W@.:L=-NXE_,1
M'R+<F8*1DX.MM*HREGD62A,3RJD#'JKL6#Z0]LJKH4CF(HX4,IW_ #" ;U35
M4GF5+2^I = '0!T = '0!T!U,0#]NXB'8>_IV_@(?40$0^OX=AZ \?M6_F57
MVD_=)YB13P**A!4_K,4X@)@$W0&1T = ,=(\CL,B=38XC*[-E45L$JE[L5E\
MC>*\UO<@4Z2:Z9&E95DB2SM8[=0JI4TTQ4,F<! H_7JN^N[;J#=6K9\VI=CK
ME-M=^I]8MMO5*E6JU.33%A.38G7^R3+&1R[HJSDZ[W\B78/%0X"0HB<! #O5
M6VZ@S9[4*?6YRJUB=M=;@+%>Y(\138.;F(R/G;+*(L7$DXC*U".GB,C//&\>
MQ<+J BF;VTT3F'\I3"%@-/R&U3CE7HF'H'(/8J?E*-^D&[>NMI_4$LMF;"]C
MWK%1).!F4)J%F0*E(+H(JJ(*D(*IP1$3>?B.7(Z/P6DE88C?M^.7'5>P+4YK
M9-,_7VL6UFGM:#D3L9))&#?.3-&\H>,"]E<KM%W13))JIE,7W/J/YB@:M:\5
ML%N^+_4OZMNXPT/CRP8E[<WU[/[],O/LT6D+ 3'(;7'M5J!RMTVCU_48D;00
MT+)3#1,4G:Q53&62.<OH4Y@&_I5[_BQZMNXT;+XV<+9[:_W,UXY'O)I]GJ.:
M)5!UO=["DQ]<2E5)SR:HM7C6U.'YY==5P)G<LY2!58PE3+V+XO2K$8YSG]F/
M5MGA@AVO^3;&Q*!#.]@,0$_:\!WK9@(  8# 8I"78I4U , =C$ IOP[]A$!>
ME3_=_P"S_4>K;N.QN&^-G*4HNM? ">0I@&\[-_EG.02**D_]G?T4. ]Q$>_Y
M@ ?J "#TJ_[O_9_J/5MW"FJG&7-*9/0MA@W6E \@G)W;1M*ZWI4_$KKG]_L>
M2B)VS2$?) C]R?P*LF<I/3L'Y2]BXJJRLIE=[?XD/DLU& X6F9A6=4A6$/9"
MOT#0\[$6BO34(Z",L=8LT"\3>Q<_7I@J*J\;(("0R)Q* IN&JRJ"I#HJG(-K
M55LR@N4F1$R>)5%B /;N4AP3+Z"81[)IE(F43";U$  1[!W$>I2A0@<IL4DS
M%,!UC>)3E %%3*%_.83G-V/Y=CF,;U$.PC^/?J0=OLT?$Q.ZGB<# <H*&*!_
M,OB81 GCV$2A^';H#@69! P"JN)C%.43^8>7YB"0#"7Q]LQB%'L7N4?Y]_7H
M#U002;)@DD42D#U]1$QA'T]3&,(F,/I^/X= >W0!T = '0!T = '0!T Q^_Y
M#6=[S2V9';S2B<-;XE-N#R&.W;R\/),7B4K"V""?.4W",=8*_-Q[9ZS<'3$$
MU4  ![F'M6U=R AY?(:=L]%JE6Y(5NIZ>O6I^.G$G"<?8647(V6M.RO*S;T8
M<RZ/Z=+IK-BN5$O==(-G@=D5!*!>T;)JE;- <FUY)G%_=UEY=X5:TI5,X.82
M(FUGKBNED$UFR[.6DJTHJ$'-RD8JU(9HL\;KBU/^=("G_-U.Q0L\"5:)[SQO
MN(Y!K#FIN[]1XNR2%%E'LO3)5X5TTF:M*2<<XB)-Y 3<<X92\8K(QCE1%P5%
M8I%R&_S -XE[2ZJV9!B2/'/%7V5H8B.?P;+)T4HMN6B1*)HF .WAYEO8&S=P
MT8&0^Z07F&Y7#DJ@G!VH)C+>8G.)JOCJZ[- .^#0A4_; 3^'B!# 8"' Y0$1
M #>XF8.P";T .P!V  ] ZLE"A BQI7!#B3L5SEM%U#$ZO=+U/,F$;,6F57FD
MI61CHI%=O%L7)XZ48H&:1R+E0J*8)@4GN'-V\CG,:KXZ6<M8@7=LXR83=V]4
M86C-X*6C:1$IUZMQ9RKMXQI64B- 3JKM@S6;MI>J%5CVRPQCPKA@=PW25,D*
MA"F"/2KWDJS4QJ*#0,-RO6%*0II-.C[@OF]M9WRAN98[HJU5N4:FHE&V*&,R
M7:%;2<>@J8B)^P^V4Y@#^LW>VRN$K+(@:[6>$7%3<KLAHNNXO5[Y>6T 2JMK
M3-+3)99M6R.COBPK=>/E&148\'QQ7$A2AY+]E![G #!#I5N6#7..-T(ZD,3H
M<+%UNE<?<$L$/=*MG%?CW8.9&Y55*02I#9XJZ3.Q85*K/'YY,$D3*NG<H1%1
M0Z::9BJUVVW)8>FBTI+#-K$ETFD5+R\1,(G$#',8?4Q@ "B80  * F /7L !
MUJ5/7H Z .@#H Z .@#H Z .@#H Z !]?3H!M=,Q_,-CK:]/U6AU31:FY69.
M'-8ND!%V6"6<1ZPKLW(Q<NU=M$W;=41$JQ"E5* B &["(=5M56S MH6(CH"*
M80D.Q:1<1$M&T=%1<>T;L(^-CF:";=FP8,FB2+9HS:()E(FFF4I"%     .I
M2A0@;3J00,YX\$LYY\Y_4\TU&R76KP%1N+>\L7]%D(QC*+2K9DYC4V;TLJR?
M-UX]5N\.(@!0'R .O-ZNLWW-PZSI.990U%LL"KPW_37<0%">(ZQR'2 3"?Q3
MG:5X)F-W$0(4E6*F!2^7H %  ZMQ]*[<:M:WB:["&U,*KCVG0O\ TU?$!,5C
MI[+R015506;@NC9*FBJBFX*!%RE62K .?!0@>(E X!V$?X]4Y.C;=?$IGL(G
MNDFGP'^)G#_CSNVDWK*+WI=PD]$ID%2Y9K?'$*O'-(JORZ\RS,P&+AXL17!9
M<2J'.<X&3#MV >X]=7'PNE(NYPT)%ERTP[:.3L .72N>MCYM!WBEWZ(=53DK
M_;>;MTK1Y-K8((EACG.#W=:+A8VQQ[5W]LW?^3E1$H'5,B)TS\UER6P=5'M2
M+>%0]=34[MBW(OD+7*%"W7%X2"E\RT2M:M1KUGW+9[4KM7KQ6&TBQ;2C:30X
M^N8]5*2CIEXV?(*-#HN$7)ORE,!#$QOTW4WLK5A)+#')E_\ C;W;G[(&AJG"
M33J4[*\K>+.VRX<EU^6AA>\X[9->]L+J$&NNWJYYG!WRZ\"^AU%$G+,QQ%T*
M@G64.8J8DK_3ZR9W/+M)W<>+QQ/+5N$&F[38MSM-_P 3;R$QOT%F-;M#EAS
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MZF<_<>2O!W7'L!8XI?%4F4_,[LOR9BM)B^7R,/HE%VY\D5I*7*@S4/QK;Q\
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M0M.6 7YCB5@N^;18(ICYN4B*%!N>OJV>$+XEMJ2FVN16-6XS9%.0O$K4[:.
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M*-Z\M'@W#,]K;:6@\:"I%B>X0P&*;L(=O3T$/01 ?4.X?QZT(/;H Z .@#H
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M6.4324MCB[+/9]7J%B-5FK18XNJL_NKBN>%<0L:>%4K2@),G1'YVYPE'"#0
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M<*C%%;[I-H'VI/!F5X!$RN@9%_R?,"@ ^WW]0]1[^GY7S4WO#$HXG#(5G6Y
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MINB,M25&,YDQHML@T0!)L5-)HF1%%LDFD**222!11(DB CV(BF!/$B8  $*
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M@#H Z .@&8V?)J'LE?3J>F,AG*2#Z-E)NJ.C":OVQ.,67<M(2VM! R4E63O
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M.X=_X=^@.!,4!["8H#V[]A$ 'L'U'M_ .@.W< ^H]O\ O^G0!W[_ $]>@#H
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MHM^2SB%6T"-23LJE;E;2#9VYCY%! #1D,DX?BE[A@$QRIF*4 [B(!Z]?-_\
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MH)5!)Z@8!^O;Q, CZ>O0!^KLNX=C',7R$ICD)YE(8""H(' @F.!02#R$W82
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M\?7>I6Q]8(RD2< WB73.%LK25K-=<)#:BR*B3)PW,JC[K4Q#%[J%$*K?.*K
M>R/#,C\'E&R?GY@L42% YP%(P>)3>A!,(]BD QP$O<1  $H]Q .PCH5&NT.Q
MW^+?YZ;/\_;WN/GK]$PE_>O[<A2C9_17;*14E[RW1>1KU6T/(9RR103B$_M5
MG*CKN"Q0(8!JYE1D!TB2K(YB)E6 5%!4!)'MV65!$Z::QTD![*J)(G5(!C@4
M2AYE]?4.]LD!O;GM>8T"H.;[:K=%Q]1:2$9$K3A%@=M/U:9F65>BXI'[3WE7
M,F]FI%%N1NF4ZHG/_3X@80S]6@%Z:<BR.TV*CI-%VN50[9NL8J*KH$B&55^U
M(H)1<"DB03F\._B3\P^@#VNFFI60./UR,^^2C0<%-(+-@>E9%["\!B)Q2!^9
MIW^Y!B*P"3WO 4_,.W?N(=Y U6U;$QRFLQS]M$O+9:;3:(2B4&D1;MA'RUSN
ML\X4*RA63J5.DS;-6;!JYD)%P?R(TC&:ZY@$">(UM:/:P,UHW)B5S;D9QCX_
M2>=3LD;DH\T9JST9G8HQ.G5)[G6;V&_RL*JW$IY^6F9!K!^VV*FBBB1%4#F6
M Y1**N_^0&\V7G &9R?(UQ6* O?*-PV@:]9.2DZG:U8V;KK2P5,+VM$T. ;1
M4LK=++6,]<MIR1:NUHQ+[58J;959T8J0T=[RXB$!(ZQ\B<31+1J,-3*:WT"$
MPWC75.5VF6)>Z%KJK_*;A(2Z43_;F#4BY(UIL#B&@%WY$W2\8P\5$FYW1%C^
M'5/5OV(LJMO V&_\W-MRIC8[7F'#/0-ORVH99&ZI;M'6T2F97&1T8[K[NX2$
M9%QUU72>V1["5Q JKQ5@0Z+=RH#43&5*8"GS76.$+VD--.'FB=63W&2OV<9]
M=9BL2%,F+I2:S;Y:HR3MN_?U-]8X9C+KUM^]:!]JX=0YW@MS'3[%,*7< [=;
MIMJ7F0.1U(#H Z .@#H Z 3UIC@F8&4AQ6=MAEH]_& [CUDV\@T^_9+M/NHY
M=8AT4G[8%O-$QP[%.4!]>W88>*:!1E\2_P 3VG?'9IW(R\Z9R>E-OCM6*TBJ
MC  O9D$6D4QF59DUUM*5@?/$Y/05UW -%GC8  A!4$3 !RE+6BLE%H@%]H?0
M/41] ]1'N(^GU$?Q'JX,%VX40$PE( E*EY]S"4 ,8 5.!1,)R%2[BF!>Y^Q1
M$X>OH/1Y89@^%W!?@U^0>L?*=7>4UHR7.JWDK;EA<MN>V,VI9[-OVU5G+I8;
M.P2+"1SE]-OI%5M*IHKHBT(!?(1 X=O+KGZC=_6M\^$=DR37"RGRZDR^?_Q?
M<S=QY;;;J^49U4YFIW";K#N&E'VH5^ON'R4;5(N-=IN85ZJ"B#=)T@84P$1[
M^0CZ /;KP^3AY.1S9/W'H<?46XZS7*!U_B2^-OEWQ1Y>6/7=IIM.KE*G\;M=
M6([@+Y%6%T6;=3%7>M$W;"*3,85O;:*@*@"(=O\ ;W=)TBJDVK+.9[\"E^MO
MR)UM&W3#]RTG3KO:*M\@&?W4,;V6VT*E<6M3HLQ>:)1CV:NFN=\TG,;!7Z^W
M%I*%E%'B4+3G:KTXM0;-C*)%%41,8"]]VE:J7\9_ XL6^]D3.2'&KD%R\MW*
M_<4JI6<G?27#\.,O%VC7^YQL3=[2LIHZ&L7B=T]U5I5X&=P%_=UUM ,FZ+Q=
M^DR<.%W)&W8 ZI:[MF77A;3&PTFBKZCQ8Y7S5.^.CD#F.[W#BW,8:Y2TFW-=
M)OMYE91W%K0E R5A+;%?4YS*JY*&=R!IE\:&;-R)$]A+W%%@+#VQWD5:K,ZF
MUY%Y+>I&V:"YK?'?0++ SWPR6/C>U:UVE1CIA(;O+VR!G(?.7+99\Q8*6%HQ
M0%4RJP^PR%NH JD.'B:_J+9"S@HL<!VJUF+F%Y-\.KN3 KP&>Y=\96NY-99.
M8ID(]_1=,FGV)2%<SNP*H&]I[=7\539MO_E(J)?<*'2[D^\ IY5Z[(U@EIIP
MR-E#SCD6;CEQDRT.+.GQGV_ O=\FD']8;9O$ZY4M@EGCA.'P:SSSV::A2\->
M0L6D[:OHMP"<XLBU2<*  "FK5-*,Y+T6#]@Z7%_'[FAO_P =\KJO&F]P4%CW
MQ>2.(7^QWVD5A>!JNVI2N*FC:K+2JLU+>U8$HK-955NJ8IFZ)'#9/W"J+  6
MM=3CDLL/Q,S184PY/Y!NKWD'_9'8KKF>D\O>0]3M^(W6 AI&Z8_0]+O3VWT/
ME5A[=25<&8U:<)(?IULC16^Y69G]PG91L1(<YFTOM+-MJ,(18[\@<-(JYWQY
MOY4FSBM8WRZXZ:??2&$J3)"BQUP/7Y^P+D<+%0-&5%.S)2B@G 0!NS,H7P,0
M#%VO9-5MI)-6DG.J./D"CK79JO@E<J68Z'H?Z7RZXXWVS(9]7DGXUVC4+0V-
MDM-FD'[ETT8IMX]DW(<4R@==0.Y2%.(B)8M=6:C1E4XGO1B<O<@K.C6!A<Z3
MFUIL/*%*@6"@9QHM4G[EGL/4J[<E%&RXZ7=*_-UV-E<Y:2B994T,X6<R#ERV
M*1DF1=0IPK;;9S69)5G7+4ASJ_ 5G5ZUPGXCSN<6C?\ @3E>0:O7]+A(*(1?
MW:1W\8IFXS;:K-&DE6<JX-]X_L#E!PU,M]G8Y)-POW\$U4YLFJQ9/W?F5)19
M.UY=YC\:47!VZ/G-.Y9,<FD*K$MEWL<[MLA)S4D[KE$DK5(I.D(]Q8:C4I./
M=3:A5?,YF*Y@,HKZ&E>HZ0HAH#\6OB.XGL4QS'<WY!;=QKCLHA86$0FN/DA1
MX*0LC**K#>OA'3)+O1;RP&*,J@+PI6[=NL#D?,5/40'2M8K&L EQ78A6"A8N
M)7EI.?<1T;'L'$Y,G;J2\PLP9(,SRDH=HW:-#R,@*'NKF2123,J<PE(4.P!*
M4*$#==2 Z .@*JOF+R_FMKW#&RU+@9;9JJ;.-IKTE)_M2SI4JYV&A,BO?W%7
M:E:E7<<,7+O5#H'\4W+59PBD=)-4ASAWI=-PUHP/Y\=U/Y+43AQ@U6Y>6(;3
MR%AZ=]MH\NK,H6-^,@>1>+1D?,6%L91"?FXF$4;MG;LAU 562-^=00$YIJV\
M?XZ FSU8%4GRX3FFQ."U)EDYKH-EFM%B&3I"A03N;L2D25C(G6%F9HBJI'"*
MXD*)_),IRB)3"(!Z>%]9X5SJO&^P];Z2]G);EMI$=GO*UF\9O?[<0T!*E:<Q
MT<_Q]3E*_77N>R!+DKH1-1; V@W!&YWSIQ(%C52.4R( 0?MNYA 0#OUY'%T_
M)T_$Z\:M[_O/8ZBW%U%MU[+=W,A6REN?X1K)N$5RQ>JJ,&KM=VAEMN<"FNT=
MK.2-T3KQ#1,C<PJ]A*4%.Y?3N _7GOTO/RK=M9'%R<?#1PUD?0I\7)M.1XL1
MG]V6]Z3O:MQN+A^&F1KJ*L(L@E17:$7:O4DSQZ)FO<44_#N0?KW#KW_I?&NE
MX6U.[6?8?/=;;?S.^K;_ %(Z/,CCN3U>UG5>+.CU*#Y:<>.5NX73&KVWE2/X
M.2:6!ZQ?N\IU%E'O4/U;&=OBHLZ"@+^XV2623D6H&6;=Q]-+?9\E(G[?H<8S
ME NTZTHG"3:-BSVV8]EVB\W.7=TY2TJS-W4O#Y[H]RF]4K67*:8J!4VK"C1M
MT9)(,Y1Z0T8F\78NE#$\DU ESYK>5LO2VV>T9G<A0A+;/R3ZSN8WB/9OEEXG
M/\%<+3X0E=)#A17)>23NA.V+PKT<C?:2X136614"*5<"Y'P*B"ICQ"=HKY9)
MK>&V\VB;?(WBA$8]L.:'P#(W#FG<D\3O/ N[5N*9R$U4,_A9M\2]T+6;<>0D
M#N&%<I,>PGFRZGFJ=1,(]J@) \2=7M5U<+)X$).TV["+"+RU5'B9LZO(^B7N
M;A.%E3C.!L3(L)FSU=70F+;6:XE*;>^L5'9+6=A2 RIC4%[&\8MUU1C1ED2J
M#[BP#ER36K;\RA?>0HPCS2+_ "[+*%RVM/R6\<9;0E[".GTOC=>*58:Y3[9G
M-.@;JYRV091NHXU&.%'IV580N,<P.5Q]ZL+PR"OF95$X=\5R9U6<88//_4O:
MR<)YK,G1\>DEH6WP$ER;VFL&J>E2M<B^/K6'(Z!TV8L\-DI2NZ+/QHM_&-4C
M]"UYO*/V:I$R^<4@S^@^0&[>)/S6[$BEFO*O*CQX_%DH[Y%_D2;7!!<CZ4J?
M$B?SZ26.3Q>Y6E3KW&J,X9L)P6*SA+VRDR/5$0\5'#Q(BGJ =37_ ++$.(43
M(D./5DJ,Q\E_R01;>8A9E1UFO$Z-=1["0;.#*IU^KW*(LB1E$5@/[\*^DTD'
M9/(%6IU  _B<2AU"C=:<BSLMB2S1&EYQ8=/M'XW<3>/6RWFU<7<&Y)07)S2/
MUZ)J]EH^2T^FR,U<J5@];U<[$EBL$_+WJ1(>.CD'+A:OP1%%'RP]VI%<<)P?
MA]A#AK#,CU 0%@1Y=T+EA16S6M<C;GSSMV)[WPP4KR;ROKX8%HD:1&<E(FM&
MCA7IVA0F8Q+*W.M$ B9)9I(*QQW0@8B2DJ-^&4A6:E=I;UJ*:6Q\UL,R<[8[
MZH\;JP[Y17@GL+_8N])FS/<UPZ-<NP,"9WM>;NI^;]@YSF**+94Q0_)UI;=:
M\*,"H]V=M^7[#1;.MJ-EX[SV0+/IY2H1E$J6APFG1S%PZ2_;36Q2EBN$G59%
MRR0]S[Y5%NU!<W;V2$ .PZ>*%E.H)2]6 = '0!T = '0!T = '0!T!59\S\N
MT:_'GO%>,+YS,W=O0:O6(6'1=.Y^<F5M/ILDLV@V3 BKY9RPAXUT]5.0OBW;
M-E%3B4A#&"M[52BV3)2EPA12%FXW578#?^]:M>M/]9SV;HUKKDGH*U_IM'H-
M6AYJ[S&A75)P[4B,[B%$B(QYEE ;KRJKUN!"JB0XDYIKNP:VEFK-1\I4#Q)H
M%(8(?"(E=8242?VS(.6D!N3:3=6M9Y84VL4V6SRL:^FZ=*.GE9;W-%8L9'3H
MEC"/2 D0A1("?6KKQ0G.>6.905U1D4DLMP6/BG$NI6:)\]UN8YTDU--+M:]@
MB.@:$\A7,(HFDJY'+RQ;](6AO\R*50<)& PI 0Y83XUJQ$L7#^%R>.COENVN
M3SZSZC+YYR(EJ[48*"<:'59*'K^@4C):A>Y&ER\![IG56FIH5W-A/ LG2CI"
M%73_ #+>T!*^''[C:R:55_(8?:VLI-H<\HEN@ZNM/2L7Q-;G6ST_';G2LZDZ
MUG&U,GVZW7,:>$2_0280M?CT".4T5W<B_0:@8_O% 1ZFCHI5L44M6TXYLDML
M\_E%YY$<B<XY%3/(>#SO=8_CQ>.%,UF&>RSM:YUNIUB!>N:3B-K:TF1LF9Z3
M':I'/7KZ..XB!<Q[TSIP;[0RQR5\./9H$W6T:CF* SA><D?*52R0NM-[MRAJ
MK>^X9HT2^@^0''^[QN8,HA;8\7NK!ZF:[8*2OLVJDW&KH+PJ9GKA1JZ*X\T#
MJ^9/62[M=IK#!$KN4\18B\U_C,L9U%CYW&:-R-B+ S.U,X9H:#/X+*?VW?JN
MA*9!@JA&QDZV14'\RBCKVRF*!C=]K^:OM,E5N7V"4Y83<2;Y /BW:FD6AWT!
MH7*!_+($<)+N8!C;>,ERJU5>33= #*1+>QV)06,<JN %=.0]E$RBGY>KNR32
M>I T',SCVUG;=R(@N,.L6Z Y!\V*%"99K.45]6$F:DL(PJ%);[Y>CR<1-2.4
MM:-E3MTD9VDH@%C,FT9II'<B4W6%_-%6]S>)I3)^PA9SAS=&(UB=AX^(D,\N
M_"GB#CCK@E8E6[IR',2VL9I/]U8?<H<X%#7*[).ZW'P;JG+&679+2'ZLDD4W
MMJ$HZPX>:*8Z%L?)JR6J]Y;QDPI_77-;O7*R[9I7]!IJ"[AVI3,_@HYAJ/(5
MB[F&X@=-M#5R$=U\AS'\7"\B1/T _<-&DZU056Y:T'GLL1S53W>&DJ3?.,<5
MQC:N:TG*TBRYGI$GMAHQ!KXVQ"#NT3HL72T'#]R4#1_G"JD;-R 50J@]QZV2
M24+(@E\@J"Q/<#Z"(]OK] ] 'N(%'\P>OT_'J0>W0!T = '0!T = =?$HB B
M4O<._8>P=P[AV'L/U#N >O0';H#S4,F4IC* 'B4 ,81*)NP%$1 ?0!$1 ?I^
M/0$4WW.+BI&;7&<>9+9JTPUB:E0KT3 .V<^WB9.TF2%<M*8W=6(+1'5\,B4P
M_H9)(TM^0P?;]RF *6O3&M@.3:-]QJCVAO3;/=8J&GUG548N$%VL@9E$/+W*
MNH&CM;',(,E8>LKW"98JM8LL@NV%\N3P1\A$O?%<G3\=MJPL^Y_9%]MFIT,N
MT[1D56T&@9)9KQ7873M7)80SFF2!Q+8;6E68\)*Q.8IB*)CG91;+L998XD2
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MJ3+.:]=ZA;F9Y&J6>O6>/24,@>0KDLQG&)%RID5,V,\BEW;<K@$3E/[8F\_
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M;P(/?N4H]P$!_*'J _4!]/4!Z [ ';T#T /0 #\.@#H Z .@#H Z .@#H Z
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MD]&M(LDEG783.54S*J"90YQ'6BLE%B&Y<E@?5R Z .@#H Z .@#H Z .@#H
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M5.0%J5V:_9W(6*VW"K0,2O94+[I5657K+%$SN"B2(5JV0[=K'L3NCKHI$2[
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M1UX5J;M&:N;ZD,9>@R-0DDIJLSV>I4VD041 3D;8VZ+]-X9FNM]TV2*)A(4
MZY_ZLMMOQ/LT)=FTEHAS,^Q2!SNXZ=HZ4_:;/I.KJU5&T7*T#'K/F\/1HMS!
MU.N1,;&1D=&L:[ C(/'A6H^9EW[U=P<QC' "QZ5N/%V;;UUP$RDNP9JE<)ZY
M0..^@\::7K6Q5ZNZ#<+Y;Y"[Q,U7F^DQ3S3[.O;KFA"3*M<<Q[&/EW3QVB3W
M&PJMV[DR93=_ X5>]U==S$Y=QLZKC]ZP")F9JNZAM7(&8CJ@TJ&>9S=I3-JS
M3HHX.T0BW*$=2Z71XIBW1<(($>/W)7:S2,14^U2 3G*I1/DHMKL^Z"7M;3U>
M8YG$_#6?&[%*]FRDLA.V%66MMVO,^DW%BE8-"T:S2MXNDJV:*N';E&/4G)E9
M-H55114K1%,#F,8!$>SA35)LYL\65<3AD2556323%0YO$G<I>X>OYCF I0#Z
M]Q,8P '^/6I!T0<IN"F,3N!2G,3N;L &$HB B7U$! # (?XAT![&-X@(_CZ>
MG\N_J/\ 'TZ PQ?( (!YB81$0 $BB?U !$0'T'L/8!_U#T!Y"_9F*97W#^(!
MW$_KXAZE)Z]OIV,8 _Q'H#K]\U]/\P?4XI!_7ZJE-X&3#M_OE./80_CT!L$5
M$U$R'(<#$,'<IO(! 0 1#T$!$!#N'0'IY!_$/]?0'/?H#P37(H/Y3%[>OH @
M(AV[?7MZA]?QZ ]NX?Q#_7T  (#Z@/?H#GH Z QW+@K5/WCE$4BB'N& 0[IE
M'O\ G\?ZC]A].Q>YA[^@"/ITRQ G8:[52R%D35RP0E@_1WSJ,F"PDM'RAHF0
M9#XO6$H#)PM^GR#,P""K=;P7()1[D[AU":LI60%2 @( (?00 0_P'U#J08ZY
M0$#=_4#)F3$/IW _<!_[>LN:KO2$XS"4L^?SAU0:MK.P\CJA<HZ,L51KUWG9
M9A(IRH1+ZK2O[@>LSU\L017[Y>-? 85CK& I3*AW >W7R?'TE>7JWQ\UDN-O
MV'L7XN3IN)=36+.,NTL3_P"2[CBHY,W\I,@G)YF8M;J"*:A^WI_DI'*\(! '
MMZ#^/7I?X;Z?\]/BCD_R75?_  VCM.QN%/'0$54G))$A'*)V($?7EV<&QU2"
M3LDD\5-]Q[HB'8IC=S?0>M./Z3]/JX=ZS[4:5^H\K4NN/L_? D+HLA(9IB%M
ME:JX8HRF<9=89> /)HF?-%754J[B18)/F*3QBJZ9K_IY2*@1PF(IF$ -Z]^O
M7KQ<7!Q_\>B.+DM6]MRF6R /$SDKN&_\;.(FV3^N<?(V]\A('.K.]RM&AO(%
M*59NWA)G08*I28Z//3S6?A*2S?.V0K,W")7#8I5@ OD<*J]I4M8]W[F9-*[\
MR..&=2SJ%N.G1,.]8WFG9B^/^F6:2CH[1M >M(NFT>5G(6!DH&*L\[)2#9%-
MFX=)KIBY2%0I/<)Y:.]4X>8/*=YH<9ZS$:K.3NI1D;&8==H?.]>=+0UJ.3.[
M?8&L6_A(VTD0@%5XYK*Q\VT<(/A(,>=!PFH"_@8##G;GI52Y)2G!&\F>4V$P
M=S+GLOH<-'V\)^D5E:+4+(J(,[%HR:CF@P$K--(]S7X6:N**(BP9O7;9RX*8
M@E)V53\XIU%;MJ&BSX[(9[*^?6'ZE.<EV19"6J4+QFT!Q0[79;I6;55H9ZO&
MQT,I*/V#V=@(YLJ1*;E_LD&Y%%7CSP*NBD9%9$Q[+E6YSD46.&HZ"O+_ (Z,
MZ]?;3*:I6(2"RQ]%QVDO;(I(UAQ1'$\FQ/7C6V'L<;%3L(UGPDD1:.%6OVS@
MAA.FH<I%!+;U*$M-.-1K97ECD&C7O)8C*N3^6QA0VNU9G:*>]BQE9?5++6J6
M^DY?,J=*OE8PT)8:\=ZSF%'K5-Z19DB8A $AS&#+EY:*'.I.URUV#LPO)[ K
M7;V.60FGUZ4N<_*7*JP;%%&1"/L-BHJ:8WB&K\ZHQ1K-AF*L1S[C]FQ>KKH@
M14!*'LJ^$5ZE.$UBW"^W[D-1CH-/\?6VZ%O^+VV[Z@X@'EL@M[WK-#NZS!FK
ML4YA\XTB8J4&JG%&D)11-8T7%)"H=1PLH=3N(F[#V#3BN[IMZ.""=/6H#H Z
M .@#H Z .@#H!-VFW5NE1+NP6V<AJU 1Z9EI&<L$JQA8A@@4.YE'<C)+-F;<
M!$0 OF<H"(_7J&X4@VL=),Y9FUD(]=!XQ?-TG3-XU<(NFSILNF"J#A!PW.H@
MLBLD8#%,4P@8H@(#T334K(&?U(( \_>2T+Q;IV?7RQ7N0I$))V]S R01-10N
M,A8$U(&3<LXPK1PH4L<R1D4TEEW10\TP*7U ._7@_5^>W%R55&U;:=W1=.^=
MV<Q6I#[C[\QG#UKF%8)MO(8B.B^_*)2K63HUA8N3H(NE!9*)MHN%6CRB+,Y/
M\U,YQ4["(_7K'H^NV[7RRWC^Q;J.C=;.]'X![C?-%\<*(]C<A6(B/_AJ5S'M
MV_CV@1_CUZG^0X^QG&^.R4DB^-G.WC/RWE;I$8!H);Z]HK.%?V1,D+-PI(]M
M/JO$XX_NS3!B5P53[%01%/R] ZOQ];3DLJI,UOTO)3B7*XVL3UMWBX77EHMQ
M2S88.'_8N.1NS:Y>9>*7FG<1':#/3-0S*G4]D20CF1;1+.ZU*24@NZ%9-I'-
M42@B<70"&^ZUVZUB#G40YS$./+H^([YI6'<G+#5F5=K.#H\FJ5L3"*D:W%OL
MHAK(>EZ/$W.$*ZED$[I1IT&[U=5@<47<;($4*@@9,R9E;;/#=X)%H34K/4<O
M_P!:(<-OLY5\&Z599M%4]E?_ +EFPM3]I,4Z0=$9(6"J.6==6+=8YNZ5(F\/
M# _&/4$2N02$I@"WJ4[2JJWEH+Z0Y=\?(VI5"^*Z77G]-T"G3>@TB>KQY"T(
MV6DUF,;S-GMC!E7HZ2D_V[6XQZ@H^=&0 C8RH)G[*"!1MO4)Z,)-Y:"/OO/[
MB%F3J.8W?;JO"NYG-66QPZ -+)**R^6/GL5'H7Z*3A8*2/)5?[J<:@9RW!0J
M0+ 94$R 8Q:^K0@D RU*DS&>--5AK)"R>>2-4)>XVX,))%W R%.4BBS:5A9R
M#?W$5HY6+$5BJ /B) [@/\+;IKN78$I<(BCF^B[MO6.T+7,U_9N=Q.R286VO
M+WV'F+)*4K''D?*OZO.RE/:3=;;VZYW,B3%1-B1U'M8E&0\C'=G;_P"91/D:
ME1!:R2P_EJ1\A^8^[L:KKM.O4;G!=BIO-VD\,LWT"+A+'%YCH;G2F]%FX6VF
MKCF8?S+-]3JU:G9)5DA(G15EHH[<BQ$CF.6'>\QAG!"B5.1O=&YE7C)[KR1Q
M1U'4N3U&AJ<4T\0E7;*385BPQO+.[GRBG#=6#.4=NV[FIZ+$2P*I)N$?OX]J
MF<?9.H*@VW7KA:)T)>S")C4<-UN>UN-ZW'B9 ?V]=:G#X?G^XXW>IJ$EHVDK
M52UW*7SBT%NU58S3M[(K4ZV0+IVB@V?-1D&JR2(&2.053/\ D[@]F$3WF-Q_
MOO*M[R=U/&M>T3&= IF49C1YB?ELQR.U4&4::3HDT_>UZK/'\UI=U:NRLZ%!
MJR+INFV25!.1:G$X@ B::NSLZO0JXG#(L3?>8MU/9]H7 %/[!5O/V3+"0Q$P
M6!,0.*0&, F /7L'IZ]7<QAF"OWBOO\ M^QT/EP>U0V?2VEX3R>VW :,PJZ4
MW6*I8T,\A*C(5927&6EIR1;.9)Y8!!\LDJF4R20 0A!]1J]VW#S!1..1KX'7
M.1=8Y:Q/&/2I3.+M!:7@%WUJIZE2J).5!S0)[.+55*Q-5B[UN0N=JBIZ+F5;
MZV7BUD7C)RL#)PFJF _G"/\ DG"()>V>XD/Q=VIULE,M9)]@TB;_ )5IUVQG
M3HA@9T>-97FAR7VKMS#'>@#I:O3\*[8R; Y^YOMGI2"8YB"8TU<X/-!Q.&1)
MCJQ = '0!T #]!Z 2L_:H2L-4G\],1$)&*N"M?OYN48Q#3[I4WMHM0<R"S=$
M72JOH5,#>0@ ]NXAV&MK*N8-\Q<E=MRKD\?$PCV$I@,40[ (&*8/ZBF >X#Z
M=P'J4Y4H&9U((5<R=_TCC]7:%.9]5,]M06&\(UZRH7_3H'+$VE?.P<NEG$!-
MV)TV8/)H%4 \6XF_,4>_X=</5=7;@RKVG7TW3>O,N%!"+2.3U_@7DAK-=YA<
M<F=-@:S9G]UX\VB0S6US[.P,X%=W"M:3>*5-*K3CM]*$#W&JB ++#Z%4 1Z\
M'EY.JM/)QWA/&'DD=JZ+:H3]\#>9+RXWS8(K']))S0XNY=G<WGS&3O%8DF=6
M9VY30"2+I*QP+PEKFFRE=^Q;D3]H_B)5C"/J =NK\'-U=9=[NU6L(PCW&7)T
M2K96;PG(GAQ>Y/V7<=-TZB'C:-*4BDP4+(5_1X?4J);K+=G,@\6;KKS51HDE
M(A38E,$O)H"ZACN"]A].XAUZ_3._,H;TS.?GX*T3O,5G(S4=?U!;Y#)'C\:0
MK7]J&W%1#=&X! D&T%N!]5/GJ\:6:,Z I(8(E #B4$O<][L/EV].J\E+<=Y;
MG$Y_ ZZ[H-'9>4#+'-?Y%O\ <]0J-/P['Z7CTZ63EH56,2AI/3WTVS)^Y9YF
ML^]]@N]CT$R'^U(#<AA.H<0'JM.MY*<CI937VFU.G=^-76IM;CS5Q2U9[R'1
MIG("IT.<PZNJ.=$N\O6)>81R,7R!U(.Z2%2>MH]S::JX4;+BV=H"+!V9JJ4J
MHB0>KV^H)KP)E_ZK6L_<8,%SCS2$W'%.+DE-.;=I&J8,OMC/0&-,F(&@3]>B
MBP+(MA1E#H+1,:%L7E1<IH'<@5HF0?,W82=37K\*UVMO5R0^EPF?S'LA>7.$
MV*PIT^)T2$>69_3)30X2.<I/(1&?I<&[.TF;- 2$TBP93,'"N2 #MRW.HD@D
M8%3#X#Y=0OJ?$YA/ A])RJT.$B(D?S66T#G5QRQ3.+K!V',-1Q[<M"GD"562
M0<N%J YK#*KS5=L,HBT2DH)VM)/"$7:E,BY*4%"F$O;O/%UM>HO%4U#P^]_D
M5Y>%<6%LVC+YI<I[MQKWGA9$C9:I7,:W+1]*JNS/['7UG[V @*3D%FT2+?0$
MK^K-TV<Q/R<&A'%(1%PHJHX(1-,3]@'7FY]M-UFX2TU,JU=G@.WDUVW.UQ>F
MZQJ4I#Y[G$E%2DMD=0=U8K>Y42E-HP[YM;=9EQG54I6;?@W^]_2F:1 19B4B
MAP5,8H>?7JG9MMO:\NXLTJW26C-+GG.#C_4<;P&1T?DMF5VG=8RV:O\ 2[M!
MQ#NI1>RP=-B%[#;;91*>W"659,F,,@JY&/!4SDI$NQ2"(]@ZZ==2E$FFVEF:
M^@^2;5SD>UES P:3H5$U&*TBLR]!U(KW^W,_$K.9%6Y+1S1S(2#6"A&C92<>
M/(Q@Q74=I V%1K[0@H =6_R%/E8KTS>$^)9FGA>:W'&XT:L7FIZQ5[+6+[8W
MM-I<M J/7ZUBML:@+F2KD+#I,OU>0EHQ)(XN"D2\$ (/N&)V'M%OJ%&FH<P3
M_4<PW&!%?@[S?5T7C:RV#<;U55I"Q[-L.949]78=VR1NC2BWBPP]88P%7:%6
M>C/+0$2=59(J)CB! .<2AUGQ]=6B;LG ?2-?R1)9;G;QJ:P>56-;6ZN,3MLA
M/Q67+C]XF:V2M3CI>3M$.U(9IY-IROH0#U-TP7!)Z1PW%(J1SB4!T7U'C:G:
MX97^K?%3D)NN?(SQ'N[K-V=.W2FSKG7)V0K%!;IHSC1.5LL:LH@ZKDH^<Q!&
MM5GRN$3I RDSM71E0 @)B8W4_P"0I\K(?3<E:NUFL%/M)TMU3J)=U"@4Y0_,
M!3>9>X=_H<  #!Z?7KMI=74ZG.>GN?R_V_\ =U<&AM48>9@92)*Y<LRR<?(1
MJCMDJ9%ZT3D&#ED+MDH7MX/&HK^XF;N'@<H&^H=NGLS!2%\2OQ!2_P :5NY
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MJIWE\=6E5Y("GFL?S^R4R'SV6I%=6H\$2&&$JR<4Q91$,-<434K@PK.-,R"
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MH Z .@#H Z .@#H Z .@#H Z .@#H Z .@#H Z .@#H Z .@#H Z .@#H Z
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&#H Z __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>cm270_ex10-21img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex10-21img01.jpg
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M$0$#$0'_Q #3   ! @<! 0              " D" P0%!@<* 0L!  $#!0$
M               &!P@! @,$!0D0   % P," P8!" 8"$P    $" P0%$08'
M !(((0DQ01-187$B,A1"H5)B(S,5%@J!L7)#4QC"-9'!T>'QDJ+2TR0T9"5U
M)G8GMSD1  $"! 4!! 8%!P<)"0$   $" P 1! 4A,1(&!T%1,A,(87&!H2(4
MD<%",Q7PL=%2(S0)X?%B@I*R%G+"0U,D5"47&&-SLV1TM&6U-CG_V@ , P$
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MCT#E,(@!@$0\0 >H?'V:)$"?2 +05E (UC,1%JD70:((@%0A1$HF* @%1 1
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M@J!3;1ZZ;.KYSV?1O^ Y,K)E, _FG]<2JI/(CS:NWEY:6S5:0K05IG(XRU2
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M/"-R\[,G3T%P]XD8QC72[.+O>RX^5N11%0Z82;&VXJ,(A&N?3,43(&=R'KF
M>AQ3 ! =+3E6]5UMXRL]HH5A!JVT&?26F<CU^CK#*^5K9%EOWF,W==;LTBH3
M15;Y9"A/22[GCA.6$7+A1PGXO9)P3%9!R_,MY&[+L>S"I8Q:]T;<"W6+*0<L
MF2B;1!\U7<O%RH@N)EP,7Y]H%VA367C?CG9MYVJF[;D4'+@X%)(2L _ =(P)
M'9&3S.^9KS#[6Y.7MSCJC<;L%&&1J33*<0N: 525I(PR(&&<(G14/Q(YK)M,
M9W*I(Q5FY B(V.D$7R"Z4S:-PC&?<Q;URU$[=XFY82(HJ"0-I5D@-0#%#3:T
M["MB<B,M6-:A1*>"9:@1I61G(G&42&N5:CS"^6FKKM^4?@7U%&I[XFBA7CLH
M40H32"$ZYF79+"%4=XB_YA_EO'-@_O!8ML0EAM;L5C?5.#=:7FY%^D5XNW*8
MJ2KALUC2E(8U=@*"(==+?GV^U/SM&RVL@: 9#M,-!_#FV+9VMI7S=BF4+O;5
MP73(6L8)\-M"YC R'[64QB9>V%4<>.UO@"X<,63/Y(9SL[>-UV_'3\A)M9][
M&H1Z4PV*^;Q\:S: FV!)NW7* BH4YCFZB.ESM7A7:E50,UUW2IVI=90OX5$2
M*TA4O?##<J^=?FBW\BU=/M:II:>UTE6XR$.-A95X2E(4K*1FH83R'IA4./NW
M-Q[Q]8N1,=)L9ZYK>R<O''N!2X9<32:;:(.=Q%LH]]&MV*C-!FX,)PVU$QNH
MCIPK9QW8;10U= TDFF?D9=@2,!,_5#%[P\TW+F\-X6[=E:_3)N]L"DLJ2@
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MBO\ J2&3-,R>I^+#V"(]\Z\M>56W\97/C[C2WT53>*E*4_[*TE+;:DZM"PX
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MH]L_B]4XEAXC7=7UNOCO\1ILI\E?SJ=?;JB)_+)GJ_KRU>R77LB_#Q%:<_\
MLY^^?U13+_7_ 'E*)_32M=QO'\7J^SRUO-9_Z&<^O>R^B-&LT_@)S^]&4]>8
C]\2^G_<_#]/P_P"F_+K)].?Y>R.K\?\ YO\ =_Z/Y?7'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>cm270_ex10-21img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex10-21img02.jpg
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M$0$#$0'_Q "H   " @(# 0$             " <) @8!! 4* P$  @,! 0
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MJ^-=6LI!QY)6+(W<4K-(0+%N]5\<8]:^XW<:B=S)F/.US@M3DA!!&/B'&9%
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ML*,HO&6\20D,^8'-\3EQCC' X3JXS+1<BL<A-%@G@F,IJB.N<)_KFQJZ8/\
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MO84G]-Y,[P6)>.EDPI]EFK+AU028QVPR>Q<9HT2>>-[MV)LY47UVTD\,Y"
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,$(T(1H0C0A&A"__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>cm270_ex10-34img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex10-34img01.jpg
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M P,# P,# P,# P,# P,# P/_P  1" !6 (L# 1$  A$! Q$!_\0 K    @,
M P$!             P8$!0<  0(("@$  @,! 0              ! 4  @,!
M!A   @(! P,"! 0#!04)     @,!! 41$@8 (1,4!S%!(A5183(C<:$6@>%"
M) CPP6(S0['14G*B8R4F-A$  0,# @0$ @@%! $%     1$" P A!#$205$3
M!6%QH2*!!O"1L<'1,D(44F(C,Q7A\7*R@D-S)#06_]H # ,!  (1 Q$ /P#]
MZ?(^3\?XABF9SD^6IX3$*?4JLOWF>*N%B]874IID])^NQ9:(#'S*>N$@!36L
M,,L[^G"-S^5*)^Z7MZ]T+5RO&&S01V#ZDB@IF=!F KEI/?O^$]IZY+@9\A:]
MD$I:6A/::-/RQW[)_JP8TCH]% LM<GW(X*-I=(^38\+3B(%*9%I?D,1WD(FR
MN*RF![_'JA[5W)H4P2I_Q-0_)_S(UG5.))T[7LE]-#0D^YW +'G\'*<:T:Q^
M-YK)I@MG;19&*Y&#+7M'QGJQ[1W0?^A)]1KO_P".^9"%&*_TJ*WW9]NT&"W\
MGI)8RN%H5L"P!PAAN6)D$I@@U)!=ITGMU5_;,R-NY[0&^=0?)WS"2G0/UBK:
MA[G<'LTV6ZV>18K <03TJL,7N*0&!@@44;H(M)CXQUP]ORVMW;5;X7KCOE_N
MF&>ED,#7F^HT^@IFP7)\)R7$AF\+="]C6G86NRL2B#.HPU/@1*(F=C%S'\8Z
M%Q'ME<K%XBX0T-D8DV+D-QI@.JXA$*B_C5#C?<OAV5&"J9-DB5V<:)NIV4+.
M_O(!J U@"LW,D)D8B9W1&L=&9$K,:(2RJ&$I14G:,V)VQP;N\Q3V$P<S S^G
MX_'\(G_?UH+A:6&UJ3LOS7$XC.T^/6?N(Y&\M)UX5B<A8J%YS, W7TUV5%3!
M!.L$8[=._4<USHW$: 7\**CPYYH3D, Z8*:C6W#XT+E7.^/<277+-'D1BW#/
M%]OQ&1RLSX( VD<8ZO8E8C!QW+2)^72;#@DS\HMQ@I"^%6P\.?.!_;@$CF4T
MJ\XYFJ'(L-0SF+)YX_*("W3.S6?3<:&C$@3*U@%O24_@0Q/1AQIF.,;@C@4H
M:6-T3RQ_YA5?S#F.*X7C RF6'('79:13'[=0=D7"VQO\9&E&IBHB#;N^$$0Q
M\^JF*0,W[2BI;QM16!V[)[E.,?%V]4@FY06"FYHV Y-0SV./)I&W54JQ9KL5
MD:AT;2RJ"!OEE=DR8  ENUG_  ]^ASCNDGN"'"UZKEXDV#-^WGV]1%L5">=)
M[>=KN1_]3IW,RADP:WQ68NE;5):E8J6BB L(COH8_3,]NF8P8,R%V+(X-%E)
ML+<CQHO&[>]L@?DEK8$U7F+4*U[C3C*5JWEN/Y.NFDLVVGS7(4@"QW'(&V5P
MTAB/@&Z?RZ%D^6.WQ0F9TK-@/ @GZJ,;VB3,?LQ)(G+S<*>^-9I/(<1CLU6W
MS3RM&KD:)&LEF=2XH7H(UE$$LI4<:C/>/GTRF8QL $7Y W[J131/A>8WIN!(
MM?2U7_\ W])>/_E658G_ *A:-?(>UV719FI"UY7B]H9O:^#S5^2XHE?I(9\N
M[]'XGIT[[=D"/O,44C6NB%[CB$3C7J?DZ'K]]CBX%C_1A/W5EV"Q-)*$TTIH
ML*Q2=E&V&T5/OFZUG<E2)3W.U&/'Z<8CM,[IGY:=,.Y]WRPS*S1DNC;'D!@:
M$0 E#P732]>SR<_,BRY86S21L8] &E FUI4B]R3<^57&%HUK5[U;:F&JH0+\
M0B[Z1='(#DZV;O8[*)E=N602D*0J1,>Q$1?+3H,=Z[CW.-X[=DREL,Q8]2+(
M/:EN>M8O[OFNA=")YWQ_FV[E!"#:4\ZXRO@CN@MM7S+7BON3749$PLM^Y/HA
MY( "44C*HF($==_1F/F]\$<CILB1(V*+BYOK:MG=T[@QA+7N !0 \ @/K4VQ
M2R=5..?C'8&QE+5J2OU;AJ@#J"RJNY239;1;Z J2K"S(&1+"9,Q$QK$="_Y>
M23(=#(]& *H15^*BEA[@^8OC>^0,:;(2#]MP:)X1L3BLK6E94"0%K*U**F*K
M+@AU%?AL*78!UIA08P8Q.WY?#HS&[RZ4=+=N:#JE_N%#-R'2*I+G D NN?\
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MTQM!76I=E]F@A1,6#96$$"AB=9VC$3VCJ,QWY!BR(=O3LMP/2HPM+]_Z0/\
M>M%]MD,J</Q:K$3#HJM!PE.IPXFL84'_ ,<RSX?'I/WN:.'*E$FC6[CQL+FE
M/S YLG<26<4(X<!7GBRED&<5*Q](^TV(5$3I,-891].NL?3$_P .F&5(6#"V
MZ&![O0$4'EN)<P@E0S\:IUJO\>R5B556VW+.(K+2!=\?!+7%<BB?W-@%N[SV
MT[=^NX[1LWY-E'"]7R<[&E@V GJ6X'AK>F/(H"]FL/=KM@E^.JIDCW+4++WG
M!Q'P)<D,3'R[]4+ 8WM9^H6I0YWN4$I5CR2EDWQ7.B]%:%KM^5C)'698DQ%2
MHF8_<8>DQ_Y>@\9O[6*3JA-Q")_I5X';902J)1.$?_EL-VTGTBXG6)B9(9F"
MF8GOK)1U(3OA<!J7&NY+@Z11RHG+O']G85@;IU0<MEI5"%2UU<"'R*(6Q.JB
MW1);?K[=HF>W14((;M_50]QI7?'Q'QF8+-2+$DVN#(F"\#.ZXD2B)'Z?E,1,
M::=%Y#VF(+K75M?6II8>N 0%?]N(*==ND243\8F9UC2>AH,[',FT'W>5780U
MRG2LWY+B(I74W8;9Q\K**]"S1\I25ZT&D1?KKW RN+ [1]4::Z];30P9+P7%
M'IP\Z=8,\0B(=?W<O 4Q\ Y,WDF,OQ>#QY7!YK*\<R0B,PIEW#L2#K:IG_I6
MP>#!CY"41\=>EV0X%KC#^D$<M+&E,\+X7^\  E1Y&X]*>]9Z1=63QK%!6!?Z
MAR:'MFR5-4F)YQ[6BYC@%@BB?<KBOET$]1W%&D1.DZ=.?D I\T0H0/Z4^O\
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MA1?2:4?H4++$ZQ\8T\83\OQTZ!?@3LC;*P,W$G15^WZZ+BQ7SO$<5WFJ'/\
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MH**PT JB1RS%UYM5V,F-[S@8CHU\.%AO&)CEKY"%WMT07()\:.;DX7:&.9B
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M6>%6Q\)\CR)E:P1&3X(H\;U:#RCC7BQ;HR%%B<S>L8W$,&8:-Z^A=YUJK5F
M*2:I6+LD<1VB$GK\.ABR:(R,<PDL8KU&C20E^(]PL%U\Z&Z.43("')&%-]&V
M0Z^/G2V/N9Q.[3S#..WDY+(XFC9NSCK"LAB)L(K-;6%ZVW\>&[%LNKE7K% V
MO!1.A3IUJ.VS8LL;9XS&V5=KFN#@J* 2PD!?%*)';\R.9L4C?ZCM HXA>!3U
MJRL>Y'$L78N4,EDFU[6,54=E("AD[*<<-]E)-.;5FM3:A46VY!<*U+ZXW3'T
M@<B8R"5T+)F?V7KM*@*A(T5=0EZX[ RY(FY+6?T7BQ4!4)!0$KJ#PIC^[T[]
MB_CJQV)L8X:Y63E+UI [,&0H79((2RRM803%B4FL3"2B((9D625(B5(:0;^'
M$_"ET\<C<4R@>UP*7X_:*7N!\DN<CP%S,7UJ1"^0<IH5X!3UE%#$YW(8S'L:
M#V,F7LK5!(RC0"DM1B(TCIOE,BQL@8[3[@UOUD _?3+N/;Q@Y?[9A4[&./FY
M@=]]0P]P\2NNIUFQ9L"C!5^17KN,QMYM)%"VD6UC9J+23-H!82E21,D5%,QI
MIT+D/$+29"B.3X_"L1@Y2W;Q34<->-!7S6KC[%JM??<M6;?(1Q>*IUZ!>I1!
M\?K9J4/GUK(>%>L+;#7_ +6P#@/'],&?9@XHYOY>F'?!3?TK23 DE D 1FQ=
M0+*0OUA*]7?<*K357BIAN29N^X$63PV-J5/N]2@YKD_<;E:]D:"XI"U!#$K-
MIL*- $N^@N(YF6UNV1F.QRD=4/(<G(M!()X*@76U9CMC[.E=LC)0.)X\!9=?
MJKS:]S,(K',R5!>2OU%82IRBRRO1M$RO@;4,,L@VJ\:]F#2JNTYJ[?6%"B@%
M$4;>JP-=/._'+I.LV5S/<B$L3=M+2FT+;=<^246.VSODCA('4DF$++B[[>U=
M.(N;>-3N8\KG%\8HY;'MKC8S>2X_A\1Z^+ 5RN\FO4Z&.-ZEH:^8";D,V2(Q
M,CM.0'<0E8\+YY"P*X-:7$*A1H4GZA6.+VY^5E/QG,<YT39'N (7^D"XW5"!
MM/&_"EN<ER/B=GC-*YEF\Q;F;US#&3:./P]T\DW'9#-4F5XIS5QM>@",4VOL
M."9$L I:6A=#NQ79LDW3W1.B8'E^Y6AA( .T'53HBW5$K:*./-;)-%'LZ<8>
MX*#M:3M!UNIX"_,5G^*]P&V\"Z_/(\PQ%KB6>Y_7NH'CP91>&H4F4"L4L1+'
MD="C>D(\+I,YNZ;F0DI#K8XTV-E1F9CPQLW2<2[]8"D%JJ%%PH2_.F^7V/+Q
M\G]LZ),AN4W&(M_>>%:Q=%(ON'M'$UHN.]R2O7,AC,5A\GEEX&_@<-E;RV4E
MQ%_+TL=D7E7 [&MH,+0R:77=($U[Y$1*1F)%D=)AB)F0XQOG#WL#@27-#W!1
MR%CJFE)\OM_[4Q&6W68]S;JH8YS'&VB.:X(=446H>$]W,=E,[Q_$10L GDK<
MM7HW8OXPY4S&^OFNR[B!LSEJE7,!C7>F;*Y&2B%LV'.WHAF+.&2R22DNB#21
MM<&D/1-KR UQN%#24XI5Y^RR012R"4.?"UCG-0Z/1$.A10J$^E;'I^70^Y_,
MTG0UEWO5QW)<M]J^;\9P]*OD<EG,':QM3'VKOVU%X[&@G39D?$[T/J4[@ANP
MO'):Z=']IRX,'NN/DY+BR!LHW.&H!!N%M3_Y5[CC=I^8L/N>8[9C03!SBBH@
M-T\ZRO*^W?*'XSWB52Q]1-SFW*N'9' CZJJ1S0PG'.!8FRRS8;&U+*UC"VX'
M=J<B$$/U%$=7'=,?K8,A]T<&%.QY=_'))(6"W\0(IL_YAPVR]M87;FXN'.UR
MC5SI9I/^KVZ5>!P_F>/3&)QM3$^&I[M_ULG)LO,K,R/';_(&\BRJ;55,>8\L
M@;S:@B9BE@*!DSI]'6'^1Q)'R3EA<]V$Z-K. F:AVKK;6@?\CV\SG(F<1U,)
MT6T"P(: '!?KJOPO"?<-2^)XJY5PU/'<)YGR[+)R"\BJ]')<-GJW,$8MGH/3
M*;C;=">0I-B3/:R0,8+3OT5DYV(U\\A?(1/&UC%#=0&$@)R<U/C4E[CVN9\D
MT!.S(A8T@A-I"*G-=OK5F?#.97,4[&T44,11;Q/.<<.D[*7WLB]+4*PEJ@<'
M8#%8P*JF2>Z+3X\@!&@KF2\Y@3.;DC+RFO,@RBT!&M:UK038-8+E>)H;&SH"
MYKIG'>UX-M4'VT)>+LX#"^YO(?<FW1X]AL]9HVW6\?;R>0G!8M/%L%Q[0()>
M^LRGE*[6+E*]DPR&%$3NZ:P3MR(<&)[-N2V*3>RZ!S7N<$XH6N!-$=RSH3D=
MOB[..HW'"/#K;E>YRE/-/(4]^VU9CN/+S=BI;I7^40G/WD7I@KBV6:-2I46\
MC$&"V,901)@6L@V2CM\(#S ']R?A-7I1,1SA^HN'Z.:<5I)W%9)W8C4$<9LG
MB5/A9?2A\9X[R[C5&<&K[';Q49_-WHL.L7ANEB<SE<OEXK0F$2J+U([J4Q),
ME9K$IU&=L=.<N7&R,D92O#D;9 E@&_=1V=F19N7^[T>6,:1P!:T-]0 ?C2TW
MVWS8UZ^.^XXTL=. P&"/'%]P5@\7&(7=&S.&Q=*X@19D671DB?NT4@%SK$1'
M0F>U\\)V"Y>OW'TKA[DUH+T"J3]83TJXR'!^2L)ATK_'6"?),3FC3E..1;!U
M.M@*^(R-7S1E!97R=BXGU%>VF%S77 ID#C69[U;F%X<O[<-"<U=^-4;GPNB#
M'L+DCV6)T4N7U-O*N5_;S-88RR."Y!$Y=]&SC&OSV/\ O2Z]*+N4RF&55A5W
M&VWC@;N3-2?.XY;3G8<B?U]7>(GXS,>91$SB!=;)ZU1W<(Y6-@E:L;7;K&_T
ML*IT>T+::.54U9YG@Y'[<XOA*0],4)H7Z2^5^MSXJF\>Y^3?R7>:XD9B$P/D
M*--I+IX0['?#$6F/)DD<1^H2 *#X!+4>_O$3QC[(PQV/ENR#<J0X,">0V6/-
M:T'*\-1GN,4N/Y>QY'U5XJPO)UE*%E3-X=B+5#,4561>I;JE^N+5@<,#2-AP
M0R42&YCXLAV5"]S20YJ<$>H/H:68^>_&RW9>.4:\/!NBMD!!%N8)%+]/V\S%
MC.\?SG)^8V\X7%BN6L7CZN)I82B_,6ZUG'#E\H-5KVW74\7<:E*]P("6DR0D
MX"0V+HWPR1P,$0E #BTDJA:>//:*)?GXL$,F/V_'9$V<-WG<YQ*$&RZ D!:3
M*7L.RKQNKQE?,\O6II]M>1^W+F5J6,6Q_P!_N+MQR19,!Y5\GCQ EBN"E+!9
M.^)F(T+G[D<SN.3E2Q,#)\ID]B;N: -O@ FHN:>Y7SI)E=P?W%^/")7]QCS"
M 7('QMV"/GM.I/YETIYK>V**WW$:.6LXQ68R&+RV8/%(52MY+(XZOBJS;,VM
M[9JSE$8A*[4+"/*K4=8F9+H7*_\ FY#,C+_J&.-S& Z,:XDH/(N)%>;D[@Z7
MI$M#A"V4!>4KWO(/_$O('K0L;[9G0SV/R)<BRK\?A\ED<IC,:%7&5="R*+0O
MI9G)@DLEFZ"+%US:ZRE?C,AWDR5C,=ZL)$K6!_5F:QKE<2T!B)L8?:Q4NFOQ
MK:;N\LT3XRQH=(UH<03^E$0:#0*E:ON_+^?]W0W[<<S2I:&?CV_N[-FL?KV[
M=?E^KMKT&[:GO1/&LW[-IZB;/'3UKS^S_P"U_P"CX?/^753TTOM11RU_3\?X
M>/*JGI+?;N0\M$O\$1?"N_V=W_3W:3_X=VFG?\]-/CU9NW<-J;]Y1-=Z>Y/Y
MDUXIK5O9;32WEX>%<CQ:1IX]/EIMT_LZZY/;OY^U>?AX^5<'3VC:FU+:(GAX
M5W&S7MMW:1\--VG^'\]/PZ8^WBFOKQ^/.KA%LFZAGZ?2?)X=NZ-=_CV[]>VN
M[MNUZ@V=4;4Z]_\ EH%\=$7P2KLW[STEZG%-?2]>@\6V/'X]ND:;-NW3Y:;>
MVG7/Z>\:=2Z<_%./G4.[>=R]3CS^/&B=7J@3A0_VN_\ R_U=_P!/Z_S_ .+^
M?4J%$OI1.W4XVUKK=/;IX5SKA3C7!M7VINKS.S7OMU_/37Y]7&_@J5"BE47;
M?R\?#SM7K\/Y?W=5*<:@V[;)L]*YUP)PKM<ZX-MD1.'WI5?9X5W&[3MKI^6N
5G\NK5T)PKG?\]>_]_4KM==2I7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>cm270_ex10-34img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex10-34img02.jpg
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M$G))'#@JN$^4<S$ST6Y_Y#1Y*G4H2O'#RETM(LR06HJU0+9%BU+"JB.92=S
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M+:^GUS_+A+4#@7P5P&N9AD1%_L2;]L.0_<*C^X/[9\=\P^5?,N5^3_&OW/\
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MXRD#$-Q5 ;@V8U2&W_C_  ]F';P4?E7Q']YOCGR3_5M^]GP7@.]R'"?N5?\
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M2!8^-1E''A',.XL59CN+ X&(?[=],@2";&[_ -ZN/KA$3.B$3SU@'W9HQ/\
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M_P"[?/\ -K$1(R\.:'IKC9B!I[DGN0I$U>2%G01,>Y&TLSD$HZMXL8FZR$9
M!^FB:;>:R([.,WC"(L/%N>*,[H, (EC4%8PH>OO(QM4 GZC'C]-33:[/\5J<
MMK^G*((+8,A+4Q%9R9 S <@H:.,Q+@00,,)Y$.,YT.8F"TLT:OIQAIK#5C@I
MS2H:,:N[QLD8E=T&6D3;U1_[2G&,?0Z/"MO.!F@V"N9$(AP5A?EDL;U: .3N
M??"".BH(;:-C^SF5XSC[,^6D-Q^L5W_0JJX568#6+,UAU9@!U(\"?OT%=T@'
M-1+ '!\2"?Z,9_VZBM=!R,CZ9_AJ*M,I@B&87=1"U^%CYE6S%D;8JN<,NUNB
MDX(S_ ZB)279^:"S-$@B )VH0S;CG>23@,>IP-4G9"N.81%4EHLG?D$C\PY;
M'D2?'KJTM&$I#PHG465S447M11>U%%[44702#D:BR9 '2>*[N;ZGKTU%-,>2
MCJ+2C$RC>$Z>L$XZ=<')U%G1$< AK2LQ383O =D .W>P ]!;R##46@RH5K&Y
M%3?W$B1^VQQ'ZFVN';P9E'@//5*Y2$0YR3+5K&H:=7!=U$&4R_A."YJ+4)\#
MFZ]J(R;<!G]>XG!P?<2=2<8_(DR<^6J'ZL?:L6_Z>W_ME?6(T_P]B&-D,LY#
M[T;T$JI'KD\ Q\AYZZ%9 /CR7A-4B&?!,JY&ZSDP.8[8R!'/!@-0VA?R6S(=
MQ\#TU Q,N3%%Z=8B"(A\/L64M5 O[@227:G>C6EPPXV?]'FLQ O5O,:U.VER
MJM2U!M7O2,2)"!YC2.N7->S&SVQ,?RX<."PL7(?+D2BD#0P"OP0@JP2Q7K$M
MLUZ#F>:2/M6(A;HW& =WL@,$("MD$:%M@#"19>6W$*S=, #3J/P*>))?3V]F
MM>YN8S\!S$=)YZ]15M<NB0SR]VD*,DB[YBP4$[2.F3JC983F70ZZX1EX0 Z(
MGN\]7NB/OW;!BGX,+!-!&U:W3O-)-\IDY-Q4@2N*%:?MUU4YC:,$],ZK5/F5
MW-I5MOH8V70!)!Q9R@YI.:449K$=Z\;B<1S -KC*@]M;@^5=B"*"$&01/#PR
MI+C8[%/5@DZL661RD5R_4*MI9?U*X1TZ1P;):CXQ;GFI22SRVY+BPK+=@O5Q
M5@K22&W)<2JT<%:2=XW=2HV[&!TV299ETL(@'#BM<[H3N_E:JSCIX[:TA4X\
MB.FH"1B,E4JZY%R 5:'C6"4O(5B-2.)8.R9-RFO7PK#_ +KJPP?MUBTG5%_,
MX73V$(='<Z0-'3;_ -I7U?\ U%6J$W^H']]9(6LO+<_=_P#=9Z[0)TDKS?N!
M\A>)E$BYC)1@23@@>.-"KD(Q\7')$]8>7J<H#S29O<OC44]!Y"4;D+$2(U>6
MQ4N]WMNCDNL9J2OM[4R9E8@X7&#XZV(URR"YLZYUEIX%<BLUS#'^9<<SU:L>
MY+_>$S1QR,(WQL68#>#A@PR<'Z:OIPY+"%:*FM-:4O%WY*[2JS1%D:&:>W9@
MEG,L:R&)9)#)ODWA3N(SU48G3AR45W>I6)U*_J!$4M<@BPKF-GKO),F.XSQ
M;<N!@8'4:AA7$.1@K7;$\"]MY'G.(IB2TPLP]FRV 66"+:H>-AXDX&/LUC\G
M-9$HZM+XKM>:AN==]EE0'W<<3>ED:O,Y:5'P9%4(#DY*@>0UJ,*R'&2OY*2&
MK'-4I[9HTBX]Q$LC%9B5OPU;AP[;9$&Y45NJXQLZZV(B(88(@JG*KKQ'Y7-=
MF]I'N&;"()F=7WX'=550AI8\2$QH@&W/I'@!JM,99H:127:,B74C,EB>=K4:
M2TY08]XK*F)VC)"90@$OT;[2-;G73^ ?-8AK_&F$$]81WTDDM5U0U[-V-+LH
M"(VUHVG,JP[&>U(Y$?\ '&,:"(U'"*VBOR@)99DY)97NN))7&?S)$14V% T?
M;[2KD+Z1Y]3K73AR40-B2*/M60T@A/'LUB1UF"0PQ)+6E@20C+Q+-$5(8M(<
M>:XT'PB>/E52U:?#FEBM%)6:19[3.UO9)_B J0-7JTU98NRXD0.AR,=,>/74
M\&O^59\>C^=:V*PDE<JLDIAE=I*LL5L[[/B\NTM+F0$DEU.2?'&C1C ^(*X/
MI\6:62B/<EBM76PJR)#852BL1L9(HYG1D"KF1F\0"<$]<:WWJI"PGP)4LO'Q
M-$D<[QT;*MFO%):99$FDG$K"O&S-,>ZK^L D$9!'35&(D0Z;V\/5)[<1H?H
MG#P^W/%$>\@5YHL25BLSS+'W9'DF,02NEQD<L%>(2[5+8V G&!DZ+T]OR^:!
M?7O*B(W B1#C$9>Q.8I:_O.TXOV0]>)6+6HW7MF,@Q$=T-)$P8]!E?ZM Z<.
M2H9(>_/$5MR-F.E#-W'832-7#0HJK)A795=%&&/B?YLZ.!M8AYMEVYH1ZKX9
M)3,QB82BN\\A2F K"8LLD,5@2NB9_MN,L!AL^>-#C+2 8Y+)%L@QR]B:P=J2
M&*7$RRH'[RR/$%1I@-J! 1(<Q,0O3/UZZ)&9?Q'!6*8$/,>).3V-D?;0B/$:
M[',D![?0, )$:3^A2=#>1<RY_!;C"NOQ ,4/8>"&)YYM[QRR/"HC;?)W"K/'
M&K,D7\J]21CRUJ,I# +,I5>:667%*&EJ[5LR0S"2!%#) RE0TF0JMW,%G8?B
M(](U<Q/\:GY.?WKQ2J9:A)G:.=W+K-M[JIV\B-2GIP#U&>N?'692E+-9,1+]
M/]O>NAZ^(3$9^T:\97N["QW<55EN]O:!C<DA)S]>FMU@2+269"R%CQPKXY(F
M&:KW(27MF%NXS=WM;T[TP$<+]L#=(L(_+(Z9_$=5.$HDEO"Z/&V$@\3@CN[6
M[C?X:;>7B@1IF5BP>3 7\ME 8A3]FA1-@L<>55I@1J.12J>:MVVD>*=F<5-L
M;%.WO,'(2VBI4@^DU@>I\NFB]2?-2S;B$>IIQYJ"3\=) A8S1[T215#(J@-A
MU]4F !L.>IU.I-\T&,:B'GYO:HS'C##'W6M]N6S81&1HG5\I6$B H2,,.GE]
M^LF1)\6:/ 0;PY*(>$5&WU9W)BFED%AX\QU?</62.'LO^,8&,Y_%U.M=29XK
M)C5&0)SX+%?+7HFEQZB&W#.+3I$&:)D-=*\O<S@G!6Q)']O\,Z6NQ.KB5Z#T
M?0:K)0R-A6''1TW?AR=__EXZ#BNQ@HE03G'@"!]Q\?Z=19) 7@ !@=.G]6HK
MEKJ&&$I+NH@&N4"#8&!7  OATR<_Q^O741H-^#FJY94B7+%3DX Z')/D#@ZB
M++6_C7E=]HVQ]#X#"^'CYOYYU6:D-?X%TLWHR-I+$$=/^0G5H:OP-I_M97'W
M9]7V>&J30K@8C#@N:BUTX<E'5I68 F0,ES46"6#E=QJ+72,O&RYJ*E[_ ,O_
M "\-19,A'-4Q.I:50,,K#/CU&/''4#KJ*Y2  )R4VV;EW$!ADKDX\< X\ 2=
M1!U3,O"I#:^Z4;2<G<PP#GPQ@8('V:B*QD&EFN@@C(\-19)A'P%=&HI7T=9U
M^5NU>.HBVUUQ:<1X5 LH*Y/BV/ ^&<'468D2R3?@'B3G>/,Y C LD9#'\SL.
M$_""?%ONUJ&D6"4\@A;G7]-9H_PY+Z8MFK#7FBC7>K^MQF0%713L()ZC^'3[
M-/3Z;>!>-HJE,.0\4ZJ31(AW1&::P\+DY(W,*<.YFR0 29!K$7X<L41X^3B/
ML5][E(S,6=.21A'LD@6['3>4A>@A@,\,CP;1E0P+,P.W(TK$1-C?A3H]0W@R
ML.'8/N6=:]36PTE<#VEA(#,2OM8Y&$L(,T\@2.-ML.[U9VG/0]=&Z<.24E)R
M92S)<^U$?X=0DZ1E"]>TT#K-,TGLFDDKE4C$181B.;H-V5SN'49U<85OB,$O
M.<W_ "R7X=_M1L21@M28DB5I5G1W8@NP59C+*S$*KF$ DMM/AYG)>GMV.'S1
M:-QOHPZ,Y$4@8##^U!VK"PP&5I'78(JZR/*T:>GDD98XII&5!+M; *G?@XSC
MIH/3AR6#*^1Q^Q7)=%U$FFWR2)"_<!=BTD["1.CGHV^'8!U*@_;G1A7/DKE=
M7$Z9'%-DM<?(:Q9+D2I')',,QG"&ML7. <XD^FITY\E!=7+(HCOP2"1HH9XL
MHC2O(8F,L585',L8W%49ZQQC ^[.A6@ZH@^=Q[EU]B1T=S*/DZ>/_I*U7^I-
M[8_=?]\H(R8I9/W-_="&!E"I*<_..>W1QRMTC>5 4#?RELZE,*IU SS99]9E
M9'UF4AY8L1WLOSY<MIQ_?EX7@>5X^+V<M:]%!3L0>ZOIQT,O$I 3(QE=+DFW
MNC"LX)T.7Y;:>*2MLE8#.7ZG!7&'Y#-Q,-WD+',4;4]CXY0GJPB!&JT9.!KV
M.4,5<PR-[N.XLX=@?3CP].M0,R3JR70]-VVVW5!G:YF,\69LTK__ $FKV^76
MO<#QM%8I2U:U:VTRQ07:\?!\@;7M:%-;DT*MWRJOO(7.,:NR1C%QS5RK]-C+
MS 1<_B*:43=J<_QT5P\X_'0<KS\*$)'8>[')#Q[T;%A(@&::6=YD;N$_E+]F
M@&<I!BS+EC'$9+G*/\PH6.>K\2T4,L<-SDZ , EJFG(T=:#A9U7+-LL+)(,>
ML849P-9 ?!9TQU:N*YP_^8)5K3R\ES,E*(\]91/:R(U^45J:589WY"&U/,L/
MN;1,>P"14SD;!IF (BQP5H"M)\BGK4[L3\IL7B)X+=VS76:_[;]>XCOV./A>
M"O8A3L16.V&0 LO3IM.M%VPY(L96FCZ:$A&L-F.6+*97G[L=V6ER7*)7@J\Y
M9XVPL:07.4]O8K?I</* J1%96N)1L '>4Y8G&@O=FR%A M*0+JSY'R?,J]V+
MCIK-6,TY9J(I5HDIV>840QO6Y(K%@58AEG4]!U.J$[#DG*X;8TDV'\W46QX<
M,%X<9>@^/_.9:L=F?EKO)<LO&5W6.5K@W0IP[",(BSFPD8:*-LB-3@>)T:,!
M'$9I,&)F ^&H/W/BC#'\BFDY*MWK=.?D;?RZ*(&***HM3C.05_CAJB,*ADOU
M8E"O@&0>/CK2ZEL/3 XA,/P\12CD;WRN>WQ=P6IZ%.:.WRD53V-N2-+PL48*
M%*U7IT[2-LXR.61HY6B5SZ]Q;II6?G)[5S2SEO*A*\W+-8J37Q=GII\G3W]Z
M FM0F@O<//.T]3C]SV4CISK#!(LAV,[^GIUUA9,AI( .ILT3Q'+<Q'/Q$,[7
M^*-7V"M1KHI5[<_#6+%;BQ79&46^0M%'64AMJ@ @CIHD)2!$>#IDQH^FC)_S
MVQQX]RIHS\R).,OV!R\5>M\B[5=9&N8BJVOC;M.MAYJE-IB.>18W9HPH)*)E
M""64,:!7J_YC_!6U)OD<T#0F3E:\4U7@*7*E*T8L5>5L\P_ZA!QE? *4HJTI
M9RA&T'(U:)5OKMO#IUF(B[X@*WG;7(1WO<T%Y82IPEZ&DL$33&?F6YFNM"+E
M&(*PQ2QY<@]'3.?#628QSP*!N=U=N9"1() ; <."8W9^<CL--REWFU2SR7*2
MR-Q5..S/QE6E+9?@:49,3LD3/&A=P1W@P!T+5=P'P6!(2P"3W[/R&]2YBORG
MZB?D$W (E.C'!+%P%BS;X%Y;4PFK4+2O<DY !2&"G>JQ^9UO3J'B6D=)9Y?A
MI:XD/)<EQ]>Q9KB:O4FL<E8GN<%'^FUD@@ E(%^23<" /3MR,8U)G1#P\%F3
MMAFA+;_)*_"?J"6>2/=O\92FA(F58N'-*'WG(1=A);)%2STSM+#)&#C5U$RB
M3+V(.XG9&VN%.,39$2XM%L3V=Z^I?'Y;T_$<9)RLTL]B5^W/9EALQSF/OVGB
M=([M>K;2;V:(P#QH6/7&#K2<OC6+9QKQJ=@7X=ZE?=V,D*NBQKWIH;#C,82+
M(VR_6=@"Q/B.HUJ,9$N!Q25D0"(?A=+DDDVQR%"D\,3*8W ([DBJQ8KX,K+M
M*_8=,RB)9H.H"\0D6KUA^Y4223Q5Y+!R'B::2,LN5$K1$( OA@D# TJ8D9C!
M-W=*N;4'PGVJXN5KP$$!=TR0$X]5<TJE0,,]2"B$9/7(UNMA)SDRP.K8,GB5
M?&&[:G!Z25C_  1LM_YHTQ(1D "EZY1$#$'$G!%VIYTWF%HQ82Q6>-9(99LN
MTF8L1PD,VX,<>6@S$(@MYDQ7J8BS"(R2WEI2@KBN59,X8A21D07$;&_U#"3/
MX_\ )H>DL[8(\K>I$5D@A5","*%3&K@5J?I=0Z]8YLY!\PBQG^/VZ"=>L,/"
M@RA7$$<5.=%-)0J*C03798TC&T*3%7[+;1T(:12/MT6,92X*JY1B,3Q5LK3F
MN4R%=ZJQ9*] &E[YR/\ \=U^[IICI0 093>X"9_+6 ^3K8VT18D27:\K(R($
M ,FS>#C&?[L:0MX<EZCT81%%@K\G4*RX]7A@Y/U'CH*Z[*IY.C;""PP !UZ]
M<_T=-18 D9M(>%=5@5!++G SU _JU'56FV9Q& 4E96. 02!J(L'N.F[(9<%5
M9;\IPA]7@ .IR#G^G5(YIKC L^2$52Z1E\YCC8')QT8Y.X>9!\#Y:B (B(P1
ML3$+ZR ,X3) R !_3J(U1 =UQW7<GJ'1O+K_ +-6@E6=Q3_,/_+[]17*VT1\
M*\)%/\P_IU%H6V$8YKVY?[2_TC_GU$$F<K,<E[(/@0?#P.=12?E*EGP&>N,X
M^S4XHT[6I'3..1518Y;Z!D'\".NIP2\)&0+YJW4092,LT-"OJLL/Q;\#_P W
M(Z?>=4G(0A,>/()5R0M.U3MB7=',LH$7IW.GX4DQ^.,Y.5/0ZW 1)\>3+E>H
M3W=>D>F@RF078:N[/L0L?ZJ3-OBD $5!HQVP 998F-X?;LDP"/Y=;MC6(1-?
MF)+]W! VFY]2F+OJ(L1708>$!Y2_6':W+\/!:([U1 HZ]=P\>G4_[=!7?NJH
M!,CS+8\'^Y=1QM&X@-UW#PP03JW2<H$R_+#A6 @CH<CJ.FHB2&XE#3('2.Q4
M3$*T>>@W#^L@G455 @%T9QTA7FJ6065.X^T8!;T]5!/@2-5G.,3D5B4C+;7/
M_AE?10" 9B=T4[!5K@>M2P_ S#U#"]3YZ=#<%Y+797 1K6FJ"3?*0I:.I*2)
MP,1O7:I4:.5?JBJA&?/5@MDLQTZG_'Q^U9/E(91\YNVWJ#VHX#A#5G7BTO-)
M:@;D([1@FDW^SM5Z>QNZNUE+#ZZ&(1B7&:@,S:0?T](;OXK!TI_D$3BK5$U6
M,_'^'%&M:J69)%C?AHYK=:?8W9/;OJB8_&K */'KM%C@7[TV(Y.+MWJTGR&2
M7]*Y-:_=I3K9_5"%)CFJS@>AF9BBL?6!H,YR$M,4W,[?Z74".NT?WX(QTYNO
M:K5*=WEU,7Z(]=G!CH'AC;2;Y-+R[[3OGP[)&Q.8RN5\]9UV @%) B0PR5%%
M.=EDXAN0-N[/8I<9?NQ<G%"%XZ]!SMI?;Q%HR:3&FL3!E(.'#>)TQDK6E^+O
M:?CH7OR\C)?,,,G)MRT'MH5G:M:DF/&+%ZIH^\(P<?EJ<GQ)T466'))W] 2\
M9'4,21CGR6E821PYP5D$:-*"/P]U=T9/D ZG(T>)![TA1U^GKD"Y[$6)'-.9
M9$<,)%6(E60]H#CH1@8&]9%9QGZKI2Y_J(=X^:]3Z<_T.Z/'I?\ "5]%_P!0
M/N;/[S_O!-W*T;I^[/[DRQ[PN ?\]\[N9TE+*413D]" O70ZOTX]R-ZU_P"1
MGW#Y+Y8R6!8LBO;,[W45VVR)-&($D:./'1Q'$2OJQA03TQG4G&,CB5Q-=G+%
M'-%,EGO/$))(X*SF2.=(HXVFX;ERZ%9-^]64!AX'!T+JR[&74].G;3MIFL.Y
M+X$XG!#12>]@0(RRPB%1"T 1E:,6$;<LB ]P=^(+G)Z]/'1):91 )7+F+98&
M);N*[3B62XLC2QR[E=Q%#-Z6MSTU:>%Q&PDW1;\JN0R],Z"(QUMP=7#KR\,(
MDL. )4(\UYC*0>X*HILLC./RH&DD8L0RR%UPVXD^77J,Z8JKK,RYRRQ6I#<Q
M#RA(#^Z5YS/6CM<AWXZB05>Y9D60Q""!*\KPB9Y'':1SM&6(W ^/4:),")8'
M!:B21X@Q32I!M5$3W [3R(LDGJF80RLAB9V4[XVD(W#&2Q\CK(E$D!PSJS@'
M&:6/$C);D?#(1=8Y($85(Y P&W;A8R.OT\]'$*B&!P[TMXIV 2&#)4%<P<L7
M>1WN3WX8]['\V<T>_)V$&U7LL^Y3@$E4QCH3I:$1'),IP*^R -6$DI]XLIVC
MN8]F D381>BD(N[ZY\LZTA2!KQAF4+)7:)9D<2HI9%CE<%77%:&:3MN5"Y#,
MV>AP!]FAQD3(ZL A$2)R*&FM"*[5BCG2.:?CJ7^"#1YGB:GB-A <RE7DZ KC
M).@S\YY.C.8U@\60M:2'MSO%)%M%F2)NVT;1H(ZW%MW/%@DB2$@GRQCQSJHQ
M$I,<E8E+IZAYEI8^-IU[M6=88I.0A<25[$JQ-<D*QB-@#M#L@8@^D##8 P#C
M1Q5$%PZW DQ>6:#Y*'U5[#"VPRT!P[QU"K1.[RMV9U(E))&X*/N\]$4+@%DN
MC5D:(UD=A$L)B(,D[1QQG.P.Q=FCE(RQ8D_0C5K<:J[(@S+'O73*R4IMID)>
M[%)+&C/T".C@F-",[W&.N<Z'*(GFA71C1-JR\>W%-XVM+:F,+1EQ%%.\3,_;
M<V(>Y"2B.&.%&#X]>FML@1,XEP,2I69>W%9EC 2>2Q4AW1LZ.HDA5Y%7:P;\
MMR0 <X\]3%D64V#CS)3%WRYK*Z1*(:DB33'#UY8ZT[X@D?HKB9\G=EMQ\?+6
M+/+[5>OP"6&I,ZC/! C!@)6AC6:;"DR;%"JS;EV8C!(7TCH>N=,1KK$6!P[T
MC?;=#\RN+G'@2FPD=ZA=BJM%(LZ%O2&D [(!R<$&*0G'3P^FLF,=8B,L$2&X
MM-$9S $R.7%+;D#;;49=-B+<V8(+-OADPI(8^HLWTTS&(B,$'ZDROT3,00.[
MYE!R^F6<KU&8-I\0?\+74]1T.""/O&K=5<09:AF4.LK]Z)>A[N45",C<3C<B
MGQD4=1X_=I24S,8KJ5T4SI,B3K':%:(&FB5VC<NDTT32!6W2=M@ 9.FW?Y'
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MG$1+!9A?.0?3A[5&NN4N."&8F%PXR(I&$V\=O.'VAO2<]0<ZPW%5.9GFG55
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MN1&RB/?*FT%F5LC  )&-18G 61TG(IOD8K$D*;#L&4G&T!<@C/U/34X)6BD
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M- M6W3:J9(^(N59UN0V(I;\T4EEH\@,JITQTSI+1+D5ZWZS: Q>R&8XKYV_
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MR?Y=',I$,<ES*1H&D>5$)&_>E5T<0M7:T\?79W ]05^@'0-V5&//P\]"NQG
MC(,NOL)1C3N($C5*& YM$NG'SR=*O/\ RJW*\<5:KS?-32SS-L@ACJ\U;LV)
M)Y3Z(XNTN%)P-_34I'Y<43UG_P C,=WR67JST[LQN<;,MJ)YZ:R&.19NU/56
M-T@D,8 28IABI]6T@C36BL9GXA<8=>4WA"1$) A@3BB[1CC7W$RVA*MGN*L$
M*NN]H)ZIW!V5AA+#'H#U ^T: X)P134:[)62!$IE\1\DDL\KQ5:XO&V;D=%K
M#0V(^^T(C,LUA3!.S321XFGL*% '0GHHSJ%AFM1A.6$02W($JT\EQ\TTBQ7X
MY)Y8^0GAWP.9(Y*>V&_): 8$5N_E(O#J<9.JU <0@FH2).+JFK?XZY[>E2NU
M[4\-2Y''7A=VL+[-97*R*8U65^ZA#A/P8*GJ#HD;FP#,KLVTM(E(2$1E@BH0
MGN(ZX==]CN31!G4,TGM)RI5>A:(2Y!QUZ8SG6CHG'62-7>$#;RF7C(,!V%%I
M)'NMUA'/%*L-TJ94)2R7L2LO8(4>*G(\<CPT(%RX3/8IV&1&NL4E[J0&1&V_
ME,[J*X4]!X(.O7.>OV:*;9=B&*HQEJ#ODE,Y:**8H,[);[#()&9)'5@<8\-N
MI&L2<E\$.-LAN1%@P1L%>&O(Y5V> 6NTV"'?8L:;9%*K@J)-RDX\1]0=3JR[
M$>P"R0)S ;[46[QR$%4+]?"1&P"? #*KU/TUN(C'Q XE+73F(Z0, >2 L-$F
M!-7,VXML0*V5..I&%/ETU+) P50,@!)L60SAYGDLP_DF"Q8>N0IW*G9H[5C#
M JTJH<=01CRTOF>U,PD"'+.M!"8Y*TQ192C2F5 T8"J7(#H'WLS;2/H,>!U,
M1@5;"6'!#R!0I8@*FS:#D",R!NB!3ZC*1UW9Q@8QG3%1 B>]+7P$(>'$I'8*
M1V0YKJY=ZVUFWDB: B7<PW*O8]L<9\WZ:Q:02$:J35@.K:X+15Z[;G2&Y(!)
MXRR".SB)G;\+%E\\#(\-!E7J&+H?5EDP=-HY(9+%AHM^0R$AL=4P0'& /3D'
MKU&B0)B?",5F C)]99#V28X[K1C<]:4I$IZ[\&OC<!@L=LI/3'AK>N;Y+4:J
M1)Q+$]H514'T]<+!QZG[&2&PK*>G0J&ZCRT2(_&?,A7?ER$8Y%,8X[ "]N.0
M@A=R2Q=M94(W;8;'<*AFQD%EQ]F@6><E.1:( ?)-E>.6HX$K'\[M*# 8T7>F
M4WRM(<D@9\!D=1K"UJY(>\ZK&91,TDKS8FC6#;'""HW?GF;#1LPR !TSC[=7
M#&QCY6="NE*,'@'*4,Y8J0H<E?2BL%[@7Q"L<J/'J? :9<'B'20CU \L&04L
MJHQ(D0LCQRA/ I)7KWI4B))Q+F4@$KT.0!UT"4S/ IZ(C%R#FBX9(*T$<DF]
ME,>YUCP7W0BC6C  !(W1 D].I'D-48RY%:UQ?,/WHH8EDE:4A"#&P1HW.'C9
MFBEPIW*T;=1DX/VZP0^':@"(E,@Y*$C)$DDSEG*.DPVX]4D3,ZE@!D*Q/4>.
MC=678B"J(! ?Q)-+)A6GKC*QI(S=P$M))8K*[A4&QHT@2RW5OQ8R.@.=1M)+
M%F5=$9XHM(QLB\=\21 +TSN@C50K+C.?1U'UT0EPW!)=28GX0[%5V29*RPR1
M*%$[2=PH0X-J6".3U-E0 O0=-8T5C%\4U59;9)IQ:/<5Y3(*@LE2#%5JR ["
M5(>%'D."5!",Q'XAC'763;+L6S5 <2LKS:K-0JQLCLHL2%#)%VI%#1F5F4)+
M*N"JGKGP!\M*7 D!EV_1Y&%<VXR<]_)9Y8((F9.VCJ4C=2_4]QE.44@CS\M!
MTGM75E.4AB,%X1P2EX_;IAX)D.QF5P04)D5F8@-"4\/%@2!UU-,N15:S*.D9
M(=HHBK[TB:3!EQ&FR(*6Z#IZ\C/@3TUG'(HU<  )\5366/!F[,+%D8%'C$D0
MW.5Z(V0&"C(/B-6B/@Z\T<,+PEH]R2,%D1?2"9'VK&@7"Q,[$!>AZG5=RIQI
M?BI/!!(7 !AQ(\0BWC?$Z.4,3[AUE1A@]!D^6K0>I/E\%9[2$84PC)&1NW;B
M 2N[J>O53_$:BG5F!B RGV8DVJ($.3DDAR1UQ_:&!C48*X6B1:1 4-E4M,)8
MV18Q%VFB.T,6G"2!RV[.(NHQYZBW.1B''-6S5H/3M4J&RPZ^K!\ 2.GAJ(75
MEP 5H$:#I4KYV@%I(3+]/4!(2H)QXZBWJM_A^!51CB+LY@B!(ZJJE$&?[**0
MJ@>0&HL=8DZ<-7Q0L4,3V7W1(% <J " 2JH0/'KU)U2- F0\6"ZJ12+DQHA:
M612JY&%2('< 23G&23JU4S,-I#AN2FM>!<J(U)V.R$_B+912!@C=A23JE(3E
M('4H(L2J_P"7'('4H#(68(<]2I##!!'75K;KCQUH93$4A[B)$[$.2OYF=O\
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MXEW303Q]L?1]HZ=3C4,HMF%4KK)2%1'A'84W@DD,=XH \YC2;:!W'DB$T:Q
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M*LQ#K&WM$X]R+R&@$P64),L)1GC*HP* @AB>NX>&@I@<$;6+2U7@(=Y8YA(
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M;)GZCSU04Z6K%\U-0VYOSI:N,AI(R0VXDA8VZ>;=/L.K69T:R"[,JSG)W9+
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M2*=R!0"2,MT.F:X&&9=(^H3A?:+(1TQT@,PS'<M+% #/#+7BQ7BCY 3-)(J
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M((*9\/'46VJ$7 _,YI#O"%5<*-\LB)[F5D40-159%[\8)$A\!CQZZ@+99K#
MAE=7BK0Q(J@_EV4:.1IQ+$*RJH4(QPVQ<$ -USK>N1S*H0B,65EL*T61)$0.
M_- O<3((GA+LJYSN+%/OQK/S69B;O')4OVHXPDABB$4/H8O@X8'<A'DGV^&B
M5RC$%T,PG(XXK*?)0$K56C9#W?5$T;!AOV.F21^%A%(PZ^1.LW&-F.97;](H
MJZ,K+H@RUD ]B0RJL;UGVAVCVN\1_ \4]22)V)^I;'3QTM;$ .!Q3.\G9*,1
MM20P.KAQP11$+[$*AF%?D'&0?Q+-$]=OO6$-CZ9QK%0!ECDEMB6G,RR+-W\4
ME;8<N$)5CTPI)Z]? #.C:(\EWH!H@'-32'N122(@PFP'/I((FB9NAP>L2MJQ
M"'$!0SA$L4-<ABO0VJ\<G9AM"Q' X# QJ[2+"4QZD9"00?(C4( @0.2).$NB
M\<\_8EUVAW5HQ1O9CJT*=>KV/=1B07H99)[=]I?:2.?U">5C* Y+9)Z9THEQ
M9IK,IGBGO$UWJ*JVT0#W=6S52%P]A$$<B-+8G[<<;N1@%0/#&K7.NOG;$]*1
MU:2W#'@F4$2I)7%A%*)%9=@?5UC;N%NGB55AJ@"N5;N-W6T#.0)E$'',.A;,
M3&Y9[8 PP#X.,^.!]NMP,0?%DNK&<:CCA%>]N3)'&J#=:W2H.G7:.I<^"-@>
M!P='TP(<#!'.YAI<DZ5<(JQ:7:8'R8]B(ZLZ@)B3<H.Y</T.?/0)X2("7NW$
M# "HG5^] <I'''1$@4*)9C&A'B6B(+@_3&X:QBM;.<Y7#47B(GW\%E@H!) &
M3XGZ_P#EC5KJKOT^\X^_'7^K447M11>_F!\@&_K'3440\D<<[ YCD$>XH0V2
MDP V/Z3^$'.0?'45GLR5$=>97VL(FCV0NC1CMF-PJ]Z''G&7!.?MU2W6QFQ3
M(]<G &<G Z ?=]VK1;(0T' *(U$L !W+@Z#J0.G4L<#P\SJ*+I\%(*L'.%*D
M,"1Y9&HHQ6@^)*'^3<2A (9[*L#T!4U90P)\AM\=5^( >;@L7?Z>W_ME?5 G
M=W*LD+=@NL&9$*QO+%L;;U_F  /V:ZCU<L5X80L$HF.7%.JL@C,Z)$&$LJ1E
M"%]4BP(D[)D@)$[@8!]73QT(,=1X %,:XXCC^\)!RG W/UCFKE5*OM>;XREQ
MPE'+V:CUFKTYJ4B3T(5>M=2668%BW0+X#(QI-YS\+KUM.SHKE&4(1$SI<KYE
M6^%WU,Q6W )'H5*]>S#R,<-:",\+5X7]/:#L&]-5ALDL"T@'K+[2P4"XAIZ9
M+S-[=:;9:C\T^F^.6K(W1<3P-;W/%\WQDRQ\I/+)0DEO(]:6"-:K1,[1QLH=
M9"4&"<,3@Y#1:.!0XLX?)-)/C6.6[G'\5PM&I+RGQF]5O^_L+R''5.+]E#:X
MBLA"E5LS)+(<GMLDC ^HZ"38"Q.*ZNT.RZ %L0;\<6.?#%54/C-FF.&DJ]F%
M(:G"5+SU;4WNC>J<AS4UBX'BFC[\L:6X5/K4%%Z$;=% F*R_G<,E]Y;"-AJV
MQ:AF(& ?CGVIE\;I2T./7CGJ\7#(8*U223BK,ACOR04XTL\N6"=N(B:+"Q.\
MSA<Y<YP-I!:QP&D=T9&D_/:)U(;;NC&\]/#<$\//&J+J\5TH%I64$U86^Q5]
M?=3MEG?CF.U<Y&9!EAYZS;C.)&08+I[%XU[B(P!J_P"$J?RF[[#D>5M7)F@I
MQ<Q::S-;AB?ML>;F4[HXAER790JC\3$ =3K6W$.F\LRDO7#O/_L$Q$'Z)QR9
MM/OS6:CYRG%-1JV+QAFY>Z*%<6*1H73R$$"SVX)*G;_*M$[NA"J,=/+69"&&
MM!1M+F>/Y5^4I\;+-:CH2\C2NRK6D]H+W&A!/%';BA%-GKS'U['.YCYZHRJE
MA(HU>VON!Z426+')4S<C2AY!J)F;WH@BY(K 8I(O:U+L=:9;-DM)%68-8QMV
MESUZ#IJIV#2T"LV[:S;R'4B8F0P[?BKJ5TO//&985>/BKMY8%2)&FK23=9D9
M55I(=]63+#(!4^&JE(&#.'0JK+JK"881+HM)(IX1%&L,TT]%I:DT'9>6:4V3
MWTB>(F2P]= %+C<4P1D9.A1;4-62DS(@D>95//2K++*UF!FNRV*"L]A+$4O(
M+1E+0IEY(EL_F+W",') 8YT80@0XR4K$YG3G-%3VJZ5.0Y"22..K621)K,-=
M9VJM&+,MF-H(T=_>Q=LMV67N97&WQUIX0PR"U*,JYF$PTQF$MH7X>2KO.%L5
MJW(<?!+'!R4$$%KV<C+AFK1,P=#-)N++G&\ X\-:!$LEE"R2!4G[4]>6NTW)
MLLD A$ B%AHF5GC&P.590 <,V1@'6ZHU!W^U+F-DKF(_+35+=6RRYD24S6;!
MA$*0,)U'<1(TR ))O;28V+ENO49U@1C$O%,9*^3,\[Q02Q5Y1,TKP%8_=#;L
MJO#.@4B)!N"#&%0_TZM1(9/D7&)=M\<;4KUZ=61K<LU*9JT+4X(VNPP6XZQJ
MR6*SRJ&4N<DX&3D:7E.0D0#@K57ZUP#TBXFNS-)<NU:\4'%M/;:Y0K4;EF%J
M<-5K0]K4Q))E/2C*3^(9N$Y&0!R69/I.G-.^0OU^+1K5U!V*\2[HX8H#/,DL
ML2]NNI*":19Y4+!267&"/+1UFF%]EA#/%NQ4V+L<$K1W985CKJ*LR-$!V;K6
MEKK#9A42&O8+2+N5N@SN_#UU,5JR-M=F@AB#BJRS,\D<*0-+5F!1-B@Q/&8U
ME,BQKW JM,G4C&&!'346)Z]7AR1,6\<?2GD>K5W67BD-=/RRUBQOEG<%"Q=0
M-I_ZPQJ8%;Q>(&1D'[N*;Q13/:EVKC,BR*.A+P(%4H,D>!D7KT.L3T-XLE3R
MZ\Q_RC+P]RA8R(YU94?'=8,RJP;=)78$ CIT4_3PU>F,HMP1=!&)&"!M3R3&
M:4I&B+/VUF551K$14,98450!ASC#8\-%KB' _"N;O]Q9MZ8V0EI\9?+(=_\
M:KHYF5=P!W[1C=#F,KTZOW$V]W'D.FJF!&3#)+QWEDHO$RR=S @9<S$ I_5?
M_",QVDCJJE05W.,'"8V]?NT&0K,FEYEZZB5T]A"4,;)"/+VI-<E+/6278"';
MW"*BH.WAMF\( K*1CZZ/7"L0F_FP;OXKC^H67"ZD?\[4>KEAAX7X<O*EA,B^
MX:%8@PE5X$*JD/6,Q.#&H $7;Z$ =!X==4(2ED%G7#FJT9A[AAD!JTJ'T(J=
MT(WIB"@%H^HP6ZGSU-,HYC!"KD 2ZXI;V/;CCC:1H^VB]F%L[EXMPK[UPL1D
MCER1Z@1@=-5\D<2$L C'$D5R0/ D<<P/<WUT4.&;.1N3."0/#6Y:-'A\RR.I
MKQ\JL-C_ ! EE;TF<Q2LJ$@*5#LN(U](V,#T'GK"T2 '.2"L2H4A0[#*89NV
MCHN3(M!C&,.N-PD4^.J63,$>$^)<$@ 7*@+VX6"B+IZY;HSL"G *1+Y=,9U:
M9/3Z0;SOBKYOS*HV(F2DL*$Q(K!VDBD=1N52O15.=4$(Y89KC3=VDZKLDWPI
ML#1J=R%%D;\2^';<$??TU!VH<9$?J>Q9;Y:BK1XS8BJ\=ATD"@* BP!CD#"D
MAI%Z^/70;+&FU9\*[WID2=O*(S%I?W!9B1)&/J&7$48'A_=@?E^'3P_CH<IF
M6>2W9^6#KPU MVXKM@R1PO-%T>."5=W0X$FQ2,'(.1G602,1F@[8U1&.$B>U
M ]TPLQKD8W;4)4-^5NR/Q@^0'VZWU)YNNK&POB<%?'+Z&4$!IJ[/*  -UHV2
M/I@$U_(=/XZKJ3YH,9$ZI69\$(P2". N1'^?!'ECT#2S*B DD@;I' SX#/TU
M9G,C-&KOLL)K=X:>04)!N>PBE2W?L* &7U-"7,@C.<2;0A_#G..F=#6)US-)
MBV+IR8I)'KE&0Q]N$/(CQ2*AVB3U%2V"J."P\1GJ,ZM)1C75219A?J/NX=B*
M:/MSPM),)X&K\BA=%P!(8ZX5"%17RV[IY==0$KGSA&R6J8<O\D-.D\>25Q:>
M*)I<A6'=-PA@P&4#+5/5?$?3.J11,%S:?#FJLS+/NCC*.9Y0A,T<Y,KKC:@$
M2",;,>/3^.MBR0P? +(OIQUR_* ?C[%>&4*<I&K1@=UEC16&"$;<RJ"<L>OU
M.LR))<YJC781X!B<N[^Q*N6[BTS'+T2*P60''I:7 )R.IW;1XZBZ6R%>O3^-
MG]V:S1!!P>AU%TESZ?9U'\>FHHO:BB]J**K?%%)%$S*KV9'6%0N-[*AD*Y50
MH(121D]? ==3!3%6J0P1E((D!*$$'>!XE?[0^T:BL&42XS7<_P!>/+Z_UC46
MC9,AB5[46.Q<Z'Z$?: 1_0=113VL0N -J99<   ^9P,:BHR S3SXJ<?(N.<K
MN""X2O\ :S4F54Z],NQ _CJXQ)MBW-"NL@*+($^+01[U]9B]P D85,E<Q0]F
M$=D XV[@OJ);Q).NDU0S7BHRL)T\0G-2-A"))%_-6Q(CG(Z6%6-W4X.T$*P/
MTZZ#@"1')-45PG$F8\3JB[SU>O;M4H'LS7*%=+-IX^(DM5JL4H,Y%F>"!HHC
M*E<["6P67!\=+#3&P\ $]+U#=QGX9Y'D/N2**VE^:O[$(L=OCJ/,)FK$Y''V
M9J]R*W(VQXT@:%6)?=M7:<GIJI2&MP5SI=:4S/\ "2Y.'/%65[U:Q(]>*]4$
MTD%F]"46$%ZWNV43@ #",20<]1GJ-.2E08#0?S..:6!W/6F#^DYTY9?-,O=Q
M+-VXI(9"6$U8&-'>: RL8)8E9"\Z*T94D X*D'KTT,QB3J.:/"R^)#9/V(4W
M84L4TCDF662W'4B6I625&DM32A(YU:-D6.:57VL!N)!"YU:.=5DL,9%2IV:=
MF0RI^78@CL26:\*1*E18>EA)D"A8Y54@NGXQGPSG5=JJRN=1$; Q(?V)A&PE
M+@$1@R7ECE5 H6)*B,GIVC=ZG."1YZOYK+HZ-'EI6Y17C:18X 28$'6.Q67
M!0 LJH!TZ]-#O<2@(Y$AUU?30)4[HRS%?_"4!\X5N2L<Y56I0O06+-V5XKM@
MQUK@?FW6:"0(1(L3Q;@64AD_$#TU=42:PSG!#];MKCZC8\@[#CV+YS4^)_()
M3&>0YM'FX^D(.%>*6&Y*LUCDI+*OR7(\A#+;G_2H88*T,B;Y'K[B^3UUFZ$L
M,"N359U ^!"T_$5N5J<UR'(67H\;3LQ6#=J4KUJ_6Y"XU2!K5[V"5ZU?CID2
M%]I6/$LC@YR-7TH]J=HWMM D*C'Q%RX=8^+XKSN+5>).'KSP4+'%K:C>:RW+
M/;YI+QLWQ?X_D((KMBM&5:0Q]M6 VYQK%D!$.,UJ[<;C>D&0!T!L!D_-'<7\
M3OT4F"?HBW+7QOFZ-JP'CQ1NVN2L7T2)I.,F2W%)Q7*I&PC5(T;P'70@YP&:
M5RS7*?Q&Y!/5E"4EC_5;7(2*)Y.6[?'S*SR\?'6;CX/:.C;5K30M%@L ?2&.
MKT2Y%42 '*CQWPIN,AHR+3X6U=XKD^"L65ENOR,?(U^-I\EQ\TP)XG-&]..1
MC>==TS2F([I#C=IBL-%B&6Z9Z)]2/[,G_&?&;<7!?*>)D-&&+EZ\L?'^W-"U
M*DA]W%[B[-[*C/9WVV$T<MA9V8CHV/ =L298#@F[.C;0=S,CZH@$A^+L<.Y*
MY/BDM;E9R#Q"5GO?%IULBK"9^*D^/"M5L5^'KQ(J1U.8L56G;:0/S<G/36Z8
M28X'-<\V0$M!($^3XJ:<"U7XIQ_"2P4A"MRA'R/:G7M7+->_[JZT^XNMB:R(
M,X^PC&B'R$CS<%M R?#;,U>_3JQU&K6/U>E!-/8L)+\<JQ_*;W/QMQ-*)S%'
M;GK68HO1L+[>OCI<66'+$J>$9X8CYXIW7^.R\1R<O)AJTDKVOF\?(S<=#! ]
MVKRG(0S_ !^&:6!%[[PU:Z=0,=UV T2J4Y FP8NM;LUPG$;0B4&+XOB^" ;A
M.6@X'G."BDXQ:-^'G+$/)2VK+\H#RG(-R3QO559J5<I/.P[YES(H7*KMT*8(
MD3P=#B28@G-4M\:DDF@-B>+]/X_GODW*]ZO>L+S%A>5X&KQD->]/$8FDFJ6P
MV)$;\R+:&R I&(D@N,UDRD),?(F?R#X[8Y66U)'#P]V*[Q]7B >761I.'LT>
M8J\LG*\9$1)"Z6:Z+&3MW%E;+'J-'C*PEB,.Y&KO-9\!#I3=^)<E>Y'GKEZ3
MA&-WWLU0)!&GN'3FJO+TZ\R1\55CIT[?'0FM.7FFG:1R054X!55UVJ4KK2 <
MR<@K^/X#DH/DWZI-'Q7M'L6PYI21E%BO5>,>O#'4[-6Q!8I6*LOYC23!H]IV
M@8S9!&:'&<+(:ZR#'F,EK(8[0%.)5@[602D\@63:.1[;LJ'QVP'(/UZZI*V;
MBR'E;W)O7FE>9Y,*SQ">.0&80]M3%%(N5/BS-%X_9C691!P.2/09VQUG&43P
M49W([RR21D%;"J!M![L4M9>WT)]025NGCK0&#!9W.\E4/S3&(X/ADE\3F:/M
M@))$DLA'K"8C52-Q;KG#C&BL(1<>=<BR4]Y6:MP/ "X8-GQ^Y'0L\D*]V1NS
ML3;_ (@.@.1@!=HP,>?EH9)D7XE.52LLKZ6XNMG5$-&,I. .S!/ZS1)6;MLK
M)N9"20P"J-K=?(JW3[]+3+V^',+UFSG55LX3E("D8 DX=F*3VZ\(Q(CA@Y+&
M7N;DP,#MY P),Y/W:- R(\6:Y&ZE1=N)6B0)D>!2N2O&\BD2R+TV^E_0/M9?
M/[?KHD9RCD@]&#<5-80I2'>)2Y.=F/PD ,!@G.%ZY\M69F6:AJAGBN5_;B).
MY(J_EQ$9<#JT'%2-_P"E<?\ J^FDS;8"!@S_  3.TJI,9&TM)L,67%CC-JPR
M;BC*@+=QW4E21@%V8#IY#&F']R7U2UD?AQ1,D:AW"R21QM*DKLC[<EE2-\M@
M^E40?<=:=61$AI9)?8"LD,@6.6?MV0K-*)9-PIKMD$8QB0*['/EJOFLB$/,%
M*",((4,T[;J\"Q3E\NH#WRK32[>I*R+GP])&IBB*4Z_EPM+(YD#R5PQ?&]3+
M7=7'U+R1X4_3(U."GS4(I :<2$1]:5(8W"/\%* C,G\N\^)\]6 2,,4&9J.$
MY $=JS/R=Y'AJK/&D2LM^1=DF_=(L-7M>KRW=L]//!TFQ!Q":V?J%U(E&LQ8
ME\GQ2I#"\LJR. Z-)"J[@IVPTXY8ACQ+=V3!^N0-9X(M^[OLT&QM(PR; H.1
M@T<L;'TO3G8^1[R1JT2@_4OY>>H MS%L # '5J'!+2B@)MZ].O7./#&IP75J
MM@8CJD"38J58*5F>3TM')A,G;E"P4$CSR2!G[=6EHW76;KI /M].;<>]7WX*
M<U%$[KO)962!TV;8XK/7MDR]0O9Z/U^FJ1MO.R-Q!PP2&UQJYJ3[FF6MQ"<;
M)6%SLUDM4K4EL\B(XR'EFN9VLP8*X;'UU%T8V.,6U)EQ\!KC9*_;,CUYJS1S
M9ACB>)Y;"3%O47WC: >BY !.HN/Z@)]=JPXT@GCCQ38SO'*DD;#*1RHN1D8G
MV*Y(\-XV#:?(ZC(=5>JHRF")@*^:5I'65MH::R@D"C:K-)DRRD=?S9",L?,Z
MBO:U0W$)"QV8Y8*,G;24.C A97E+;@0)-NV,'[&(P!YG5AER9USC4!,$"6'W
MJ;QH#A\JL]=&F).,3,R2.H/\I#CP\M3CV+KU3L!'\+-\&2GFG$O'QOD%Y;LR
MN!_8@[9C('E^+K]=1-;2)%YG'@&]^:S!)8Y/_ECIJ+IJ)Z;?M)'] SJ*+OCX
M:BB\?[O<.IW@#SR/YNGV:BMN:HE@$KAMQ&U'1!D;4D9XVCL+GPFCV$!O !B/
M/45(&"B\"I'$[A8EK1P!G&VK%50Q]FOURJ2*<L3G<W75+6":M@DD# SD#.?
MY&3YZM97M11\77!TZ:BBF'8# QC!']/CJ+,HB6:T'Q)!)\BX^,YPXM_A.&RM
M:5TP?KO T6J0C8"< E]S4.C.<7ZFD_")(^++ZQ7*1,9)%DE:1=BL\ZQ[ 1A]
MJD#)R<Y'AIV5;!XXE>$V=UQIG9N1IN?#!N'),JG=59$""1.V[*9)1%DQHD8<
M$CUEE49^N-9,8B/\R-3NK8G3@Q[%F.7XCD9N?Y+DFDI-3YCC*53<W)\A7Y"J
M].O-7E84:VRE;#FXF%<':N6\=+3@&)'F3FIQKGFL'+\$GGEO1)=42+P\,%:U
M8F91!8D^.P\'VQQ\,/:L026#UZJFPY !8MH#%VXK+QU._P 4VM_'[%A9IH*7
MQ^C[SA;G$,M>K ?TUGMI92>H[UP7EE6-HI2_Y:*<*2PT>%9TZB"X*4NW1A8:
MX&.'S30?'P_(E:U;B4IOR7%<K!92H(+U.CQ"=FQ1K[J[0O7Y!DW%P0K,Y&,G
M14W7/7 3!!<(#B?A;<=#4K"Q'#)^A\#5Y)H5436KO!6N9DFMQ*L1BEEE3EW8
MN"-JHN/#4183E"6J.:T7QNG:I4:%3D*_'K++4K12S<<XC$D=#CA"EFP" '-R
M,#>-SMNPI8D:BU;;.Z0E/,!O8%J*Y69!@!L&W@18.T"J'<L1^)I8T&!XAM3)
M"1\=B:..> .Q+N=RMZI%+6J@!4>*L=^LW?J0YX?8NIZ<2-ONO[G_  E*OF%R
MIQUGD^4Y!FK5(K?)R7.W&S&&M^K7-_8BP7:0@X1>NYB!YZU1,QJ ')(>MU"S
MU*PE\6^27TN0IS5G=9FA+35ZZ1WXUH78KE=U-JJU:5V(EW,,J"QV,-;E/7YF
M"6JJC3#3$D]Z8PI4E-D):BDE$<K6(5FB#P0;>U+9E8DB**(@[BV ".IT"4V&
M#)G:[;J0U>)S(##O4..Y#C9#R-HVU6"'E(^':Q*]>&";DH<R*T$W?DADK.MC
MKAB1@=>HT*5AD&*]%3Z;109B,I$3YMPRX*%:W7CDE$D]4R5:,H,<DT:]B.5*
M*01,N]67*P@MN]1=L>&!K$9:2Z\^*;9DDQD,"<C]RG+<I))R,*VFAM5FBJM'
M,D<4%JU*D5@0\;-W<W U>>,YVC:Q\\C1HV2E( LF]YL*J=L+ 9:C(#%N0/)1
M-ZC4HS[[U&I(MZGQYEMSQ2K%<MJ@6"QVI4"3&5BN,K@C!&BRD(@G!US(Q;PA
M3JW*C+.XFA6)[/Z1&TAK13"_4MSUFAWR]9R958E%RRH1]IT$6R<#!:,20S+D
ML*36KT'=8V*-5+,L:I$=DL%EHY%FVRJ\2(\83JF0^5SG1>M*LM%B"LPV==V[
MC9,R!G( ]P"4/;JEK5)Y(VDDL\K[53+'MI2U9(IGL<B"<PL!(57.P8/4$ZT2
M!F<5WY^ET1C*0E-Q$GAP]B.IWN+M6^S7Y6N3:+<C6BCFAD>U ;MJE;EA=7*2
M11BB"I&[IDGIX J/B*X$H"6:(J3UK3QMWX7666<5U6>)TN3UKR1!(@C$2-)L
MZQ+F13T.CK6UIAIDYQ#G@@K$]2-+->2:-5:&*ITFB4K/.T2"NY8XBEDC8E=P
M 7&3D:7LF2\>"Z&SV?U%NBT2$&&+<^\(>K)'+'<8.=I[K2O'(T31322U?RG*
MD-$YA4,%;U8.=9AYPD;ZQ&<JQD"1[EHPK%X4C+%V,9<Y,A]O)&X5E+ DL67!
M)R--( K ((?!#S(%2%"CJ)"C2XS^7"[A2_J'1@3N/CTU >(4MKC;7*N982 ^
M"'[*I++$LFY5L[TF0@;P8.Q"ZC)*"5!D ]<ZU.9EB5G;40V] I@28A\\\>Y#
MUHPU.O.9I&<B6%3O'1'FSO4XR"K+T/AK/#M69T0D,24WAC'<LHH)4[%+@9)#
MQG.6 P=N[I]-0X'%.;.HQUBMY ESQQ]BJN0)MF96+;+,\O0@@-.](.#@> R<
M?=K49:2XY)'?;.O>M&PD /DW$OQ!7G@;=O69FVP"00[8TB67M,&BL,JJUB78
M 0^<@''EJB=1)YJ_I*Q@\O@KI8 JJ!W,86.-G4D[ @;M#8JIG:,YQT&H"07"
MS9MH5U=2!)GJ9NQDPJQL./D]#@EW.T]2#+)N89 P<>6EV$;M0S*[%=1M])KH
MD" 6/;@@9:^V)06,>Q6"1/%(QG=FW':P&%<9\3TQHZYYVL*3IB3[4 1$OHDD
M9)B,B,Q.<Y_#E\8&[^K5HKE5,[0YG5<O%'*R*P.&;MG (&"<GZ'5*SDH2545
M55RZJBP+N;"C!/'P-DE<96.LA^PM]"-"E5%^*PB2\X+*>Z^V1P0M?NLO7^95
M:(J"!XZ( P97V#,HDUI^S(\NP1E<*4\=QR,-U8 Y4C'U&/+4RQ694;B _/T,
M<M)^>)2LPJC0N"?3!(RYQ@L\ B(\.N(VSJ'(E",I0\(\H5Y39&P7)$-9=A(_
M$8TB4 X\>GCC5HM<R8N>:C/$\Y[2C!K6(W7H>L<<D4A9_KE<XQC)U,EI4&L5
MK&/)[\5:@6!QVY(9*\05HF&=S+  3U_%G6JY&,Q'@4G?0&-@?4L[\D"RP4^Z
M=FP6 G4+O*B)<>K\1Q,>@^S0]W&,)M'&*/LML90,VDY[.7L2)*Z-*\Y9M[2,
MY QM!:.)",8SC$(\]*I\TUVCIV%AARX=ZY+ H( W'=NSX''3[!K4(ZI:>#)V
MRP1#N'2\1 =/5T)']!(^FM2KB,7Q2T2+;&^2Z(0P=1N.Y5SCJ0J2)+GP^J#/
MV:&G*ATB3'%U";:L*AW"1^Y[IE;\*O-B'U8_D!(^W/GJ%,[>(MW'B+$A"3 "
M-@&WAR\:,%8"4HYC<Q!NK8=".F>H/TU%T)[>,,8N48D22I%VV,FU41NV5?:S
M%L*VT':Q \#UU%S=P"QM8NCNRK $%B/4<C!!"$;L''\OG]-4Z1ZTS$A@Q"L9
M0.VK^G$B2#/I)*Y&.OEUU'Q6:+94 B !!YJ8ACCR^-^01M?!7KG!Z =5/4:L
MX#!7N(BZF EAI+^]63QIVHAN.YBH R,LQ'@!C)8G5!2,Y"+-@ D?*Q;*" A@
MT=N;*L,,N_:#N! (_ -6NGM],=.DO*403]ON69QTSJ+J551L9WS7&_D^QC_6
M@U.*'8-$C 9*0R""!X'/]'740W;-1'10OD,D?]HY.HK=U'N()8H2</-O$?48
MRJYZCQQJ* .N0S0V(HIH6WI857@(93O0KG*XSOR? CIC5.MU1$R1+!BK<:MT
M;HP[5[&HJE5$1)#J.HEUW!^A_HU%3@9K2?#3CY3Q'VR6!_36D_KU"L6_I6'B
M*Y+ZW[<.L&_>N6;'3&067J,C70C;(1X+P_2ZKB3AL4X2&-@T;.56(S8(V[FV
M;3M8L",'S\-8)<NH-K >($N$DY3F*U7D;?'I)=>W4KRSW.UQLCU17GII<KL)
M5,K!-M0 GT@ENA\M E;($C!=/=;:J%<=$G)ECB$J2Y6:S'(K[O<\;2N/$,=^
M.L9*CB=H<[XH47J[,-JJ"2>FL1.JP2*YXKD;  "0#R7H>0X6=YJ4?*53*M:>
M]VC/"'6BL\\4]DRENTRK.#X=%0$MIL3\.D,R%/8URM-A,A(EVP^Y,4FK,(8(
MK<+[X"L")/"SR['VFQ$%8M(4ZH=OI^HSK*9JJC56*HDZ0JUY"A'-3Q9]U(UF
MO0WUFALI%^J"ZG^)[;J("%A4J2?,G!Z:BWQP4Z=B-JPFA>*QVZ:UL*RRI$]=
M6+*>V3ME;(#@]?#H-3(=J'7(R!U88)FX8)7>/='W(I&.S.-T\(C?!.?[M>H^
MA\=6B .'X'+M3)$3MV)'+[EC1T9,$EWNU!Z_20$'0],:!.<I3!(9BNIZ;$G;
M[H%_T_\ A*3_ #^O/R\_*<=7[<<UZQ=JQO(ID1.[RKAF9 ,G:F<8\#@^6CT0
M$J0>02/J^X,/5S0V$B _L7SGD/A=R;W-*A8H2*]N6>K[R=EN16^0FI6X;4ER
M>I/8LK6FADBCVF/QR3GH%[N'M04VM?%K9:[)&]%I))OEO)\@\BC?8;E+U#E*
M/%VW#+VJ2+6DK&,"0*)"W0ZOHCFGMIOI;2LUQB)/)\V49?C=RR[NB\#+$\W,
MI^D^XE7C^/L\U1H(D\,2!/\ '\='7*8((978#!P=3HCFF?ZQ/_#'O/W(E?BZ
MQ=A[/Z=R3P6;TMFQ:B2Y8DAD^+T^'J>[-M+%AC6Y-)+#(TK@;5\#UU.D.:O^
ML6?P#WE+1\0M0FDEFMQ7(UJMKA><NPSSR2B+D.%^/<3P]*2I.\+M'7BO<6\C
M+C,A7!^NM1KTR<%+;G?RW-72,0!J?-4U_BEF=.8M7%XKD)Y9:[)#*:M."S8X
M7Y'=Y8I6[-1/8QVX+'KWLXWKN+8.-25>HN^*1A(0D9<T=R/Q3D)CSK,G'-6Y
MH<]QSFR\O>X.'G?E%KDI+W$DQ21R7#3VQ,609>.)E=02-9Z(YHEFX,*]8 [G
MY(REPC4N:_4($IPI#ROS&[<81U_?6D^0W:4W&UY2U;+5ZBSE^C K(-PZG&H*
M0.*3CZE.-D;- >!=GS6?/$7GBY'U\9WHJOS,KR)6M8M7;/.O7M58KKV*,\B/
MQ59"D1!;IUVYZ:J\//5S79CZQ.ZO&L RB1F>/L5O&_#IX'DGCL<-)?-3Y76J
MW&BHSFI!S<\G*<5)7F-.-^0GK1UI:CA8H&V2%]HQU$D*XBR&HX(FI\/Y&K:I
M7))N.JSP<[+S9DOS)RDM7C[,W#>]XNKWZHIVK!?C5>*97KM$V/Q8)8]<R<.0
M69T"J18OJ'[T!4^&2UZE6:2&IR5JE-Q=F">]=K6SS5:E/(QGGJ-QW;X\2;R'
M4EW) QZ<:AJ!.HE=>'K$X-^6,.W]RTWQ_A7XM.32Q[*"I=L23<=4 C:6-6E%
MFW+9MB".:03O9!CC. @SU/0"XUB)=UR)RU2,N9)]Y6R:6%$BPQ=DGBKXB<JK
MQ,SNH$BC($1S]^=;(U!E7!#RRGMK&J';'!$F6<LVQ5&YB3@L<'50B(!NU#E7
MKQR2>1@)#8#*O:,:PNQQ&89^C22H.COT])/5/+1H0UN4C/=="9@ "O=UHT6"
M-(2T?I$<;L8XRQW!-VT')W9_CHG2'- W._E"V-0@",<76EXV0()PH$B_E>@'
M\QF[;;]JCT[$/3ZZ5M@)RU'!=[TS>RV]4M,0=1)SYAE3.RK0GF5 ID=@0#T/
M;F@&<_:6UH#!N#)&R\P<MQ4(VDD2))(PBM([*0VXL GF/MU.#(7U9) TA6H1
M'LL1LLRBCWI/SY&86)7>K(#&5V*%C8#Z^G&M1#ED>Z\T#4 [@_).5WCC"2F8
MS80%EDVL,#H00,]2>NE8>/<:,F9=[;[@QV$+6Q:(;O0=M4-6&7KDG&)97:(8
M)7U@8)&!HG4_-Z;<,TK.H6TC=.TI/@D['UJ<P@"1HQV]PA4"OWLY8LPP3@Z(
M<DEV*B9MR.<HVU9.L;$CI6L38)(!#9@Q_'46)RT5F7)#NF4G,8=RDS 022LR
M28'$Q[R[8V[1$/3YY^S40HW&4-;<4=)()))'96_,E+^ERN-QZ^ Z@:@0X[F1
MF8Z5<041Y2K;I88/^\8Q@6)K=P@1XV[DWXW>) ^IU MSO,-.&:%EC @8[NL%
M2Q8 _M&.H%"'KT![7]>HSADS" M)@2P5S3=J>6OL#K$\B[B2"VT; >F0/#.B
M1@\=3I ;DPWAV0 ,7/B[NS)>#,J*X#LRQN[B, M*JV!*J8/@%  S]!H:?. *
M'WF2*  H3'!% NS<_2")8P7 &[>0N2!GQZ:@6*YF0)69^5"-ZE!76-BEFWME
M+C:I6H+!RH]4>6K@%6PPSK$HZQR70VV]EM:C4(@B1EQ;S!DEA7"O_B:9.X>$
MC9/0^'I\]"G#2'=)VS-DX$AL5TMZ]N/^[E?/VQJ"!_VLZNH/-NQ,;K./<E6[
M> ^,;ANQ],]<:&2Y=8V7ZTE=7D[<IZ9W12)X^&X#K_#6Q6)1=UTY'3'4@[41
MFJ24@NX29AW>'5P=CG^R$D8-GRQG5FH!R_!7M;/\R+.,0?BE=NCW#4AG9)5K
M\?!7[;6)$6%J\TT;R@H,R"S(K2Y\]_705W8;@SB20![4XX:K)1MIO15(<30*
MDA=.U)$\9[N0.Z2'RI/5?$:M)[J>C;V2&/Y91J-[>"L@&X-7YEB? C!CZ?3S
MU2X--QT3P_"$Q:>M.<=KO!2<%SMVY/@!CST84AABE^L>2%W=R26+&T1O*H.<
MY$2*X\AU.<:$<"W(K<]U+0(B/)#M9;\HA5_$'*D98J <A3XH3_:'4:B;I_-!
MJ. ']J7<O/W:F\!8Q-.RCNR,^T1^ ,A&YW;ZD:K@Z+L9?Y[I\! XK,H-QV[E
M/0^I>JGH3T)QJUZ"%IJ& =L5V2/:%;.<L!C_ /9ZG% ZG5)D0V*\KE1C'U_K
M&-19G'4W8J]1:5$T)E(9?QK%+&C;<F,RA<2C R3&R@X\#J,M JJ&K-$BQQ"/
M"-7+L@ZQ) G;:-%( @2;Q..H/AJEN)TET=D?RC"^0)+$#R!)ZG5LM]<\ES.H
MJE<2&9<^O\/Z\_\ -J(*O!Q$#]=P_I(U,UF4-3%._B3;?DW$-U.V2PW0$YQ5
ME/@,GRU%FW"FR7*N2^OH\F]YGF>4,99(XFADA6$5X$E[:]SU.'9NI\M-\/8O
M'2EIB9=B/C<R1RN1C,EEL=2.L==L?;U?^K4XI6.[E*0\*S'(?'[5GE^<Y&..
MDT%RA4XZ%KUNWW*MBI1:A-)[>%3')E7R QP#U&ARJ!+NG.Y8U/A5E396:]7-
MAZ$=:E8M6IT[,\7'T^*VBNBHUVL3"^]V98S$Q4+OC.:Z(YE'IOZ!=@<1V)U8
M^/RWX+F(/CE&>Q\>YC@[J<?!/#6ISNUIX[,+.K=XRPR2&56**L>TKG.-; T0
M^*Q9,VV2MXR+HI_B0J\U++"O%P\,>1XOE1:[MIKU9./KPI'2JMVQ G'RJ6E"
M@@;W;<&W=)&1E$DK" X_XC:I)QE>22C7EJ<=QE7F9DCE9I^2XNWRL?(%$61!
M/86/DHHTRN]"@()S@2$C/,*I$"!F^2<_'X9J'$K5GJT:STZT4(6D9_SU@HQ1
MI:N>X&_W]D+ND/J!/GK:0ENY$$:1C$C/FM:.\RQPQQAE@]Q&'+8W,*P=?+"[
MF;'V:C)VFTV;:N#?IX=Z)CF*03X4'N0F$^/0"S4.[[?'6+O-$=@^Q=O87/3N
M9-E6W_M* ^3S04Y+]OD)&V?J$]?,49D=Q/R$J1A8PV\F29PO3H,$ZQ1N1"D!
MC[US_7-J9>IV2U<N'8@?UKBZTW&03BY1EYBX*=*"[4>K,EF#U2I=[S(E1<[<
M-N9#W$ZY;&ASGK([$I"&CVKM7EJG,/93CUN3HLEU/>>SE7C9+/&R=JY6BNMA
M7>&4;2=H&?#(ZZ+U^Q:XJ,'R#AUY":A[M/<P\8.6L,&A]K62"^E/VMBSWMD5
MR::==J$9(SK/5;!E.U6U>1XBS--2/+4(K;<<W)- \\9*T L0>QN5BI5)BZ$#
M^QG/74ZW8G-GM3O#*(EIT <'=TRFGI/'4$%^"=IN]V5J6:[2V51BTK5U[I]P
MD/\ /C\)&K%HY(FYV!VU?5,G&ILF^U)TY/BNPL<7)\?NM<A;XZK9(J@RWK%*
MR5K23QR%GD="/O.!J=8<ERKJNJ  69/(+56<2L+7<DBBF2V%B&:<T5Z2:6M:
M*R%8;$.,,I.0!D_31(2U!^U5*IPS\&61N\WQ*K6A%N*V>4LIQE,U)H&A6S(1
M.9FL/+'76"*NC&0NZ88QJ,]Q3K3K%6W-<];NH7>4XI)9JTB<F\Z32BTR</R,
ML-$6++P5GM6*\4L2!IU8M@^E,-U!&HK.S-U\)"3?F1X(I?E'!30MR4$]V2.4
M\7-5B@XRVG)VXN;MSU^+M4(9$7NT[%B)D#L5)<= =!-V.2[]GH\I1,18,03E
MRQYIC(:M6I';M,M*H:NZ)^5K]BU--/,]F*"432H%LR]HJ(^K!M&&(=>=CM#&
M0.K(\D%!\@XR>A#R\G(UX:\G%CE(H+;Q4[AJ3T!<2>W TKLCB,D;C@! #H1M
M:3,FI#5$QYA'5.0H2P/6JWN.MM>[U^BON(S-9J.L-IIDJ[M^U$C(!!.6# >&
MJZW8F+[Q/;BH#&,<^Y:"O /9 LZ;UE>P\=>*:15[LLAV*62,84R8S]FK%KR9
MD_70=SL! %M;'W*DQ)&D"DS. PQBN_K6'+61XD#MKC/C^+14C=X*_IN//]RS
MSPFQ* '*JKM6C#1E62.&OWT!&>H"]/Z].5[H0@(Z3AVKB[ST\[J[JB8C@ S/
ME[5=#5E0UPC9,K(5DVD"!O=PIDJ&]8GQL'A@]=+V3US,A@ZJCTTT1T&8/L_>
MFD$:Q2 Y](DCD:/;AD;LR0NI.2#N:7<#CP&-#70IKZ<-+OB/B5;8K1@.LMU,
M]QNT>T1E?<58@FQ7[:E3)XJ!G6(V R,6R1-[L)4Q!,@07.7)#1103(DHWQ 2
M2Q(%C,QVHAW [=F,L,ZVD*=J;:>MJ8 D-W*Y:&R$2B8[3&C !"I(.TX;)/I/
MF-9C8UFEOV9=3^@3.WZ_5&,7;3S]J>;1-Q\N$CBVW45V%=HO%5RT3%R)5QXD
M>.@2\%C]KKIU[8_1#;/B&Q;EV(.S7=*D;HVYB76(*-V2&(!DP?R@0,]<Z)&[
M5/0W!TK=LC5#7J?V?O2&9)1EIL!PN2!UZ>77IHJY\IB#!LUX),T$HCD14,<@
M960LS%D8="& '3^O455P^JJE:#I$20V;J]XG1989!^6UAV(\-Y@GXTXR/#!.
MH%FJ'3CI)<NK0G;F*DDAB4&U22""=I(\=G7U-_*.NK =^YTY _3QQQU!^YU<
M:I@M30EPQB3JP7 .7G'3K_[#^O68EX@\T*N73).;E"6:Z3=DK^6\J!B2-V/R
M%EQY'!!QHT+=,=+)?=TG>Q%0.GQ.^?!E4:VT#\P%54#?M.-^<NF,^**<ZS.0
MD76J:?I:HT$ZC$9Y+H5U>!%;8\A;8<;MU=9H5:4#(],G=V8\B<ZQDB<$.D2Q
M0HH+A$@H]E!&S*D<U> (A?.,H223C44!99SY55+UJWK [=FZA].=QAB%@MX_
MS"MC^.LSGH8J?B$N122O7(GCEW#"BR",8)6*'NMLZ^N0YP$\3XZ!.>H,A[B\
M6C2S,5=V<I+*&Z1JKXVX)#^ \>A&B0@S'L0JQKL$4J9MF.F=Q/\ #/76K/(N
MW*APS\E3"-SQ2>&$]SC[/>&ILS]<MNS_  T*-C!F1I1>O1V*^S,E2I(QE:$I
M>:H;,T7;J0[K';[\MAW$<<66ZD_A'75FUPS(%>T,]QYF\(&2!GFCE58Y;41D
M9N0@@)V1/<:O)-4EDK1O(JR54E0@2[L-C[="76G5II-#XRB _M10L06#6F5_
M08:RR;-LIC,*K X 1L.V(PV.GXL:@271-,C ETSA26:79'!."E3E'E$L9B9
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M(!(P,9/4YU2L$''@C_\ RZXR!Y XZ=-6J7-11$+A55O, DG[,D:BP)&-X?\
M38>]2R"K$?S*0/OU3(]UD,,5H/AO<C^1470 NL=IU!(P0D#LP)\LJIU?$'B$
MM9(';VF.8K*^O((T8C(8DJV\J<LWT/3P7PTYBR\7.(C$$#%&P!CW57\ =G*Y
MPO=;QP#TW/CP'CJP"0JVWED>1^U9^_\ &G?Y#S/,SFBJ\IPM3CIK5B&U<OU6
M@XFSQ,9XT)9BCK1%;A9U/1MOX<@'2H!MF=&./<NB(6['\Z[PZC@1CECP7SVS
M\%CDEY&"Y8BO"]3J16;4TO*/<BF/ 5?CPBIUO>1\?'2D7>9-P:7M':"3@C9V
M]H#D8+G2WVVG.1C(YXX'[N:U5W@[_)>XEGEXU8>1X#EN$M5*M6W0@J!^1$T5
MJBD5J2'WL4D21LV%81$9SDZQTY\D06P(=\%+_+:-R7)WEDJQ\<W,<1\D:6S5
MA_4H+7"0&K6XVA>[R"KQLD:J\A"@OW'C(;)U.G/DM1D)8C)"<5\+6N:E,<C"
MB<=Q?Q^E;BHUQ#&Y^.V.?BEN1)#%&J6K)Y)8W7J<(,CH-3I3Y(<KZHG3(XCL
M6G^/5[=;B(JUF3CY#!1]M2;CZ\L -/BZ:5%>W++/,ENYE,M(NQ2,#&03I@1$
M?*F*IURKE+B<D_GD*GMAL"5Y18'3#I)'MP3X>?7'4:U@QYM@EKK +A"!8./W
MI@6B-=XXWC-1XNQL5U*AHN5XU90_4L@VHV"2 1X:2\6K^9UZG9RV9A=* &D
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M3?%+#R2M;O5K?%";G;JTS%+Q]QI>9X6OPTU+]0BN"/VRBJ'0LGI9R#TZZW"
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M%BDC%BRJ=N [,\B$CZNQ)^TZN<8&3Q 9.;.ZV$M0E)V88HY9&C5'DS+B:/:
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MZ#2DJYF3KT&RNV]5,#:/SP,2SGWHW=N1F).U!@CS 7R_AK!B8ECFNH;P*)6
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M3&^2$><#\97TEB<=-,"0EY2JLB9, JG+D2=O_P!KDAD8&=(V$8R"RDI+@$>
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M [J?3#"J,9 R@(JCU.K9/4Y.A62E$!EB41,ZI9HD;U09BE=&WM,R*#86=9J
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MI1S34>5YJLZ\?\KH64DXVAR*7J/R*[)S359Q-!) E:M9)DCPNX+T./'5K(
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M?#^)*F2IS'RVO!7B_1ZYOR4I$ L<IR5.K*V)8J-&DY(8C:K!NIUC)'C%RTG
M6?XSYCR?)\EP''>TBHRMQBS\S7NU+LD<%\1\E+R=66SO2*E+[[CQ'427,LV_
M?X#1-(T:B<5FV !,0^E,H_G'R3]/^/-[;XQ*_,<,_P B$EJ6+CH/;37/94>'
MAFY7F*4L?(JB3=YXTG;T*0O7!&C=>4J.@V!(/;@@8_FW+3P<E9-;AWBJ2CCH
M(S>0WJMCC_E5?AAWXX[+7^6BGK3R2>J*J54*4+HR'3%#$F)RS7/W;PHE:,9A
M@W>6[UV3Y+S_ !U3EK=BOQUJ*A/\@AK-V>0@D:YP=OC*L5RQ&\DWMZS5KSM(
MK!MIC# CJ=7.PQ(;%*;2KKT]2QXR<X=W>O1?(^6:J)XI^%OV>)K\A9MRKVKJ
MV(>)Y_BX#,DG&<A;J0S3F\ R+8G ;#94$J!]8\@F?HX<S\%N>!Y'F!#\N'?J
MW;/'\WST5"O AB8IQ[(:L<\:E7%:U$Q,3^+8;!( UFR9LEJ*?V4Y;*,H5C5J
M+X\/<OGUKYQ?^4<=RD7'4X:BR<?R_.4F>2S%/>^.1PT8:%Y)HV5ZC'Y,&@DQ
MC/:P!USK"UN;9[R,1$ 1B3[S]BOFL\U/R9AH<K7GY#_-_P GXYU,4MR.+CJ7
MQVSR79N<=#/$[5YH8$CAW,K(J[FR=,0DU1/$,N1N:NE*LYRG(OV,FOR'F67X
M[QG)26H./KPU8^6;CXN6FX:;E:,W O,]3BK&UVMV*=E#V:Q!-A@JCJ0=!D22
MYP70&2(@^5//R=&6QR'(/>F^9TJ2<7^OT>)FX[C;<M**O<?@IZIGY&"_7E:>
MU*)5:+:W7TXUE-SOLG4(&+0YX_V(?X[R?RBY2^$ORK<=VY. ^76YIX>9DMR7
M'I3VVIM-&U2&$HREBI65_3U^H%QS"6GN9;?:?3U@&)P?CF_!:#GODD57A[MZ
MA-6FDKV(.)<O@1U.1L34ZYKVVEGK0HU1[1[Q:2-% &6&G'2$+3N+(43#1G+$
M\E@.)^7<ER4_&Q2)Q59[<'<N*M0REH3R?.T6D1X^23$LD/&1-"N'$Q=RC$+I
M?K'D$UN?3JJ9C3(FO2"3@X?DRB?E'R?VWQPVH/CZ6>4X2OS4J@-6J*L/(T*R
M<%[V_P C!'6LI[G+2Q)9G; *Q$ G4ZTN00?I*R"=18##)'Q?+><DN\A'%5XV
MM$>5_1:E2[8[UVB[_(^-X:&2>K6M>]E-FI=>0;XX0"@(R"1HAF1 2&92D(^-
ML<$3+\MYOC:O(/9K\38OPT^7EKI7HW$C-SXY\HK\%+-*9K!BC,IY-BZEU!9%
M8$==+R+EUTQXX8\0I6OEG,)5F'_NZ.2CQ/-V)E[2W!R%3AN1XV&N(YN,Y.Q6
MIR<C%,2P+ C!VX .MQL,8: ,-3K=YZ]\+Y82A5H [.??\$'9^0\OQ,(LV[W%
MRK!\TY:I945I)):/%PVGKU9/TV*[)=MI:-] CPQC"*S$>G6HVDEL%ES'Q#AB
MOJ>^S33M"<N!9[I4R-(8U;D5WPLY;.8B=H\@.F-$E 2DYS"N&^GTCM-,=)CG
MB^;]RDC&1T5FW&.*I$I.2745(-OX2#USY:V0@=61X+$?*82AK(P [EBS,67>
M QA2L<@/)+@$L<X.-8LF8 ,C((]][;00K&T=:S;4.S8+K^G!PPZX.23X=.F@
M3F9!BF ]XUS#$8(&4.\,89&43#D4)P<#-U&])\"<+_1K"W.B$8"0EB2!P0SV
M'D5U>,;)'+.HW GU%@ PPR@-@]/'5K7T-9EKU'X*Z*Y)W 6CC=BA*LRG"NOI
M638/0VT^1&TG4X+4MM"L"49$RY8*]&-412PQ "%XY%CPVS.[?@XZ@,<G_9J-
MP3%0!CI.#ED#8G>..H @(EI7@Q.?3V5L(N/^L.IU2)+;5QJ,Q(ZLN"9!.W-6
M R1,U!6)'X0_'H[$?<8P/XZF2Y,Z(2P);W+T%B1XHI3& Q9CMPPQL<@>/7J!
MK<):3@BRIKK@("3CV*<D[MRKPL@V2PQ2;CN_+D=3AU/@&3KC.LG''M2TMO6(
MF6K'/@I38"#)\&)))\@.I.H%G:[>%WF+*,LKL_=V>I8UCV@'&%QU^N>FH<DQ
M/8TQBXF7'<AY<QQ"< EG8 J1TSGKC'7IJAFF*FUL3@&4:$\BR6SVQD5Y&4$-
MZFE:(.H\,[!$#@=>O75HG].IND+3,ASV,O4Y7,(](],]J0>/4S0^W8'[%7J/
MMU00K=A3KTB9P[L5V)MD49 #B)3@'P<!F;:V/)O XU;X.@0V,).YDA&#25KD
MA)]5A)$B ]*;5SM0>.W(U,DQ]'6X(D7'<CZJH9;ZNBOVDN11;NNX1P5958?5
MF>8CI_9U11K]G794'D7)[.U=+EHU!  '4_9M #?=M\_IJPE1L(0\0D24K9X=
M[;$E>3<>C JJ$9RWI S@CP/0ZG!DS+851B^L_!=13-+^83DAV?: N^3=N61E
M QNCB_+'_0U%56WA5/K D_)&+5E1!^'L+/W@Q8;RQ4H%QX=<ZKBD+YZI2."+
MGCS7J%%[DBSL\D;KZ#&.B[00.X2?$:AS2^W8V:"6#HOA9GK\\'6O'&1QEFOL
M2)H4VVGR[[1_,-G3R.B5P$IB)R*Z5]YV>VE56TM>IW[6R9:S.Q4 &[MI@#&2
M0@)R0/Z],LO-5Q$SBF=:L)?<2P=A(XW-B)U58Y#--'$@ 1#N>8&0[1^'(&X:
M':?"W:GH;2+:@22 Z>&"8SN\QCD]Q,U8K/C:B@UX5E #+^9MAS] 6/EI4QU9
MY+T].WKHEJU'Q"(Q9962/,SY.PQR1H0A&"#96-ER?(@Z?C836(KS=VTAU)'4
M?.?FCXT!0[Q&*Y%ICD!EW1VNS&K ],.6R?/S&EK"UCC$HI;0Q.&2&"!6,K-7
M0PQO,$8!HA-#(7AC:)26,;1J,@=<GQU?4F1EA[4&L4]35&<3)L@0BXR(V"*T
M+B,3^N&-HD..0FB'H)Z'#?Q.LP@)8DY)C@J0)-Y=.BSP1?G.6,5?;'ZG"J0S
M]P>GIX'QZ:9[%0+R$3D5V8!VCS(D996AVL&)*-&R%QM^@.HS)3= 561E$N91
M^U%P1_X&]#L*5^U#%)EWW2YLPI%.ISG8CC) Z]<'QUBYC9#N"Z_ILI_2[IXM
M^7V_PE#S9%>K$CN9+WM$6+NS! ;<L4 4Q"3LR ENHV]?/ZZ7JM\#MFB>LT"S
MU$T.PF1C[$,\L/&RURL2""6W3J0FK5B_'R$ZPP1+$G<D@IPW8V>4X4#&X-D
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MEFM/!$\QF128+R23)))+)%-ATE9NI7&//1-.J '<E!N-$C@BV46IF+9.\[+
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M&[44$G]YOJ2'\OU(F_DF;:[_ ,K#Z8U$A4&WDX\BWNP5DUB=$@;>76[+36*
MD*%EC62M%&&'X^Y)+GPSY==4NG#;?438R;#DJ[%NG8JPRQ2M@Q<A6@#A$,TZ
MI,LR9+[4".I .>H^FH4"V@55V2=] ?O3*.W%9$79R46*M Q+1MB2.M"KC\MG
M4@$?75KE&@70.X=CR4I7[8SC=D$^./#^G4"4A#42.2[.^+&_']]6J-C/X=JR
M>>.OXOLU,UDC%#S1RV:]WM)N:!98"N?%9.TW<\,#!CQC[=1'K@P$G1"VC^(Q
M89@I*[OPG'49V]<$ZL9+$QXRJWGQ$HV_@EDD\?'NYZ>'3;C^.J;BF(SZK\&'
MV(:M;*RV9G7N;%MB)"VT1F44XW((4Y+9/].LKJ5U ;2-' #-=J3E(5;;G?8N
M(>N,;:_N,^!\2V-7V);Z8570F[Z2^7L78D[4,<><B)"N[&,X+-G&>GCJT:>Z
MT7=+3[748SE"PP<$],_86\1J#)#E;T+A!G=0CN00SHSN3/![8R1(K (UZ1(Z
M2AI1$S]\ECT7IC[=1TU5MA>#-V8ODK)9:@6VLMRM%$)>0K]TSQ2DFZZRJW;B
M9F4*R[>O3K]>FJ6K9=,#BX4ESN9W*K+*&<1@Y';+9W;NF<]".GAJ,E;8_4-6
M<,.]!!XTLN\C;03( ?J[#"KX_P QU:-.IME],^ ;'N[$XI/8.).Q&)ZDD<BP
MR?F1R /NPV0 ,H<_9XZI<SZ,9ZOA^]=MNJ0\<L$KN<VG[C.6:.6.;>RID?A#
M38'T U?8I]&WXOA^],/C1EM\\\$TK,ST'?NGJ0$/1 N? [OKK49Z'3T?3!=5
MU-;-$G+E[5KZZ!91-B5NV980(TW#UC;N9MPVD9SC&CRGH XKBPV@$M>K(CAS
M*<UWG@[LL<-65X2L4>V!8\XDBC4N06W2R=WU.?''72Q+EUW-/].D;1X]?L;2
M6[<W1DX=I;0$A1C%M9T2,R$;Q^ N&"%OL&=7&6@ZDYN-OUXXEL.2^=W^;XKC
M[OZ=8N?XI_TR7':D,")>OQ15/<WPHI5'GE0H.XRCN%5\6&B=7L7#LBSPY)]'
M+7B2>,O%) CS-/9>Q!'6AE6:1Y:LLF\D6H<D%<=2/IH<Y&1<8%EF%=+:+HZZ
MN(=G/ OCDC&FBC(AB%1R]4VZT,0JB[)#M)[W=FGC/:# LSH&Q$"?+&I$^$B9
MD3V%OABBZP/R**MO7M> %8UC_P#T=S[D15[4ZK.CK*D4]I& *.KI3DE_*W(S
M!0T\/=!\0&'35!&AMM>WEN-3,"6;D6S0:AEKJBMF6+C[!KY'1$E599">I]($
MY7RSHS=+M=*/XA'@49>58;E6>S.H3VE@DQP! OY#8! <[L_7R&M0LU/%LPL^
MK[(;2=$]6KJ@2R9L6;/%'"4I!)!L+B0-+W%CW.F>6XTCKG*)^7U^HS]-+Z?%
MI[67K*?TI^WY+'<_2GN\/-%6D%>ZM6E-0FD)2-.5I2I;XY9)%!9(DLJID(ZE
M,X!.JV\#*L'L7+]:_P#(S/=\EC.*^(WZ4?;GM5^16MR?QIZ\+RR368([O(+\
MI^2PRA\B>O/<GQ74=.TH# >&MS@8Y\5RLT0GPFW)P[<<WZ+.]3@?DO$U)$2I
M-!)R5R[QTE3F$*5*K5K,U*DJR IT9, ]3K"BTO)U.8BYF+GN%EXIIOT.;@;
MM6KL4N;%J&Y'(IH5K*F'W,;,ZD*3T SJ*++\E\0EY)^7]UR44DO-7OEJVL6[
MEFO6X[F^$XOCO?\ '\?!!(U>[2NH 5(5FB<@8(U%$]E@^206X>4EI<3[J/B:
M?Q\5*=NW922O/RL$G*\PTL]>K7KU^,K*O8@CC9@_J9^F#%$%RWQ+EKORB[R,
M4]6QQMO]&6".?D(Z]OCOTNY<FN]R./CK<_(07!:#/'$\8+@DY7IJ*OFN<3\1
MY&G:XAEX3@9H^)X>KPUQ8K$<4=&:/F?U&MSG'Q'C:LKV[]-R)(L@H8T)/B#'
MTX\E8V\KY,"V"W4=85S+6+")5N,WN5<-+:1H4C$MKZ%PFXKXCPTW&6H"0XK5
MVW.T,HR(+-EVA!%=_%.T,@9H]SHX!(;_ !L1B<#.2'5@0#Y:J<]!<K6TK.[H
MEN(^$1? ]BN:-A-6:*F&ABL33E;4;+(IF%XR#*.P*E[F[_LXUCI#\4@ @2CN
M"-5%4K  ';AS![ABJ+#*SF*.9)Q"EF4R1N64,SF1*J@A2B*#A?''UT8!@P2,
MK-9)Q8%UZPQ-2NPR,U;ES&?Y9(K%<1G_ *2D9SX:'U0\@V19=$EA4?\ %JZ@
M[!JTMWJR24+' 8G5F6-XV&/*+D3N(^_M$:&):K'0+K14SAW5]:SL*(^[<[2R
M%^[(R 2/+94"-O2#M7:0#T^FF%*KQ:3$ A5M,L<:#^\$=6.#<#^(G!WC/@,-
MJ#"2Q?Q[DFE],).>OOXHQ]GY:R_T8;&MSD)XC!<Y-D[1$4DTRP(5K89P6]0Y
M"$@=,=3G6$[MZ<8VF0$7Q[!Q/L3CC^W,4BBE67N3*A('12(RP!&3G<!H%^J)
MTR!':O2>GV461LE18+(ZR[<"!E[1BA2\.]FBK+#&4NS[T.5E%6:"63&?#^Y(
M_P"UK)@8QU<TG;?'=@"(TF%5DSVB.+*N*<"LTQ;M-8EEA1&ZE$0KW&SX9=7&
M/IG3%4=0 YA<R6XB(QDV;?'^U2X]5GCG[041PAX@DF6215(P'"X)C8#KCKJ7
MQ,(Z3BZZ7HML=T9[B(TB#P;F7S3ZL(6H94+"&E9I)7+&0N%ZG(.!OQC2:[R4
M<A+W*ZJH]41899@H?N13C&3X &/^G5PPMU<&9</U3<@BW9L=6 ?XI%G8^'8%
MU8 ('#EL> !STS_5IUF*\T'1#IND[RME0FP=/Q>.2/L!;'\-5FC'\[+!E"5"
M68;L;+,.?MVRU4_K[H_HU%BR)J.A\5;'"S7'VL :RV48G/K1B 5&/#P\]1N"
M)"@V8.V")C@/=EC#?B:OUZ].\TD8S]=ICS_'0I6B,F;).45&IW(+H>5HUBY!
MY4+H%GDVJ0#NCJ13+U/0?@(_CK,KQ&.IBF(1ZDC$8,JFKQAA%WU,T4K-@9];
M1@J$QG()QTSTZZ:C8.FP&?VI.S92$SXA[BNA(VCCE(/<C[P/J_F:5B/_ #1T
M(UA9^EF/Q8/VJH0O(Q", SLJ(A. V2%/7P 0'KJW1ND>:RGRD+"(Z\TD4;D\
MO%&0ZNK?X1J8;*]%S+.#CQP-*SF)L&9;KCTX")+D)5593,8.[7S9GGE#^X0*
M@@J1L0V>IW;.GWZ&KF#, /Q5O<AAC>9)ZTW_ .>',8L1H5]W89(P-V02N,]-
M3--;#S3[0![DOC<31LO=KJ8X1(0UF/KM*@J/^EJ+H3CKAI!8X?! YC6-)'GA
M5)8C-A9 Y&;30=LA?/<,Y\-6J$Q&0@V*[82K=XZS3F>%XK56>!<V$1U:5'C2
M4H?4-CMG&<D>&HC5G1;U#DD]CB9F[$[6^+L5JU+CH!4?D8*D]6;C[.\6JY>K
M/_>P^G"L'.3D^.J31L&ZC.F(8RBWQ6F^/5)*"58)+''RQ#EN.:JM>W4D[56*
MB2(I6A2/=(TBL26&[KU)U%QI;&=>XC#4,9-ES4CA8^Z98,31\F O?3*^XDV(
M21D>G9G[CJ'%=JSTN1#"4< 3ER"(ED1I8B9:Z[XJ40W6(Q^,2=<^8&W^O47"
MJB*XR!Q=U39:&RZ1QVH4.;Q8O)L!]HZQ=.HW=PG(^FK"WM!T+C.6(+?!4"6)
MEA*S1 HT;MOD$8(48(#G())U'P1+/39S!(F Y?(]Z(GG08D$D#;V4!18C)&_
MPZ^!U'8)7:T=.Z0)!90 26699#1K)!7EBDLB023,9F@G5BBMZMO;V]/KJEU
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MT4*",,<YR0.K:CJXU0,CH$1[$.V"QZ8ZGI@=.OATZ=#J!,"N(#$!U<5&$
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M !SK%OB@.Q->F4BFZ1<XU\>]$$NE69=J*8I'8*6] +@QRDN2,KCP!Z*?XZ7
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M,HDAV59A,8VR-Q6PV=Q\1GIJ)&%I-@BV"/A1:ZJ%</EG<@ A4:0G*+GKA?\
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M<8TL&4$TE:E'4DGPOX99BF]@#T8ZK)"W^\G7*5,(B4)0Q./''N5U?,=>#&&
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M')L_:CN,^04CS7)T)8+<,?%2)#R7)[:<=>K;]A6NM2S/=@NEB+2(LG:[$CL
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MR75;:0<9QY>'EC43PCJJ93F&#O\ [1)Q]//Q\]6RYQW+3T:?C^Y4YU&1!<Y
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M? @%G!. Q8,>]U1/(A$DJ@B,59?3@ ^#%_2#M]6W^.I",AYBJWFXJF-4 0!
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M<.VKE<[/$FM<^95VF!L\'E)8=Y1O^1)WFYJ*IS)B7G9OD=7DFFI59T/&\]R
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M#!O5X8/].#J(U)K-K0\R(4J%;/X_Y3CP\,:I,7 DX<OO4-V$*D^8(^F//5I
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M+C#!&_Y)7V=-%Y/DI9^-:"#B.1>*H6HS4N1AY:C:6HP,%F.BM,0NC K*9-Y
M(U2<&RF*A+1+JOBKI_AR5:E@MR1NVN2XGGN,Y#D)XZ?;L7/DO*U+]KD3"D8:
MK&HI1QB-&VKXG.K&,F'F3%U)IV0#$0B/<Z;+AIV9E)0R2()%MH0M9&*P"=7
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M\^FKSQ7+B)Q+@8KBDD!2[,H'I!;( QTQ]PU$.PR#D^;!3,;!0Y'I8X!R.O\
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MGHL<#W?-7K\P^-I1XRY#?FEB%OBZD:IQ/(K8MR<I++>X5*],QFP_ZE#4D=7
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MBW7+ ]/L(P2//4=5"B$&9\%W456^;V+IC#&/.<$,Q(\BAZ>7AJPEI1$RM?\
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M.^1 3/%!'-=GBM<='&DLKEDB 4 !1J2J$8:@<74URZPJ;PE\>X.F?(<12O\
M+W;5I6L-R/$Q\3.K$,(ZG?M6F>)L$I.TEHC?XX4#6(0U\4MZ@?\ -'^['Y)3
M2^.14SQUJ:_>Y"U3;BA!)99 BTN%BM\;QW'B&,!1"L5UGE;.^67U97)&MBD'
MBD1A9 _S >]-O\H\?,DG&2VN3E$M3YAQLEJQ;,\\E;Y;<JW;T3JR+$R5UKB.
M-<8V')ZZQ. B,"Z[<]C"RP2,C@1P'!%\;Q,'%7^6OP/-+)RLFR976NB11P7_
M '$>Y:L$"36%("=UE#&,8.2234(ZRW8FNL92D6#XE.Y#))N6=5 */'F*0J27
MJ4E9L+TP'#=/ 8UN58B'= IOE>3&08 ]JM-C8$?\M,R2Q 2LV-L<*L#N +,S
M:SH\&I=$7$<$=$99(#,(AD,,$22,C!CZB%.!C'AK"QU#K$VQ"&YBR$BXZ=,.
M$K2*<G !)N(P)'@5SJ1\5F@Y,Z!N+C6#: Y=+19D63"QJV"0/4<9Q@@GP&">
MNC]$<R@0]5LG%S >\J@V.[#(0]=)>S)&8I'<,7(<>D =0<],ZG1'-!GZM9*$
MH:(M*)&9XH2RSR&1BN UJ(KC).%L\<>H(R#J=$<UQY1>.GN^"/WSV7$<8[9R
M=S9."&Z>)P,@C6=(K\0Q76'^:E7&?A9R_?CQ4@^)9%:),57F4-%OB:4I'= :
M1@S Y-8>  RVKZ8GXR6=9&^L$3'0,'Y\'0);$5:8#K-$6*YSLQ2B&-WB?'Q.
MC5Q9H(.XI$*?J07D6P[XNF,9ECK1+$P=@$*JX!#9;<5/_)YZ6EXK&]B9%QEZ
M3&+9&)^*@N8(:B/%E>Y<LLID<[F/(4B4#XRH)8_: -$Z(XE)1W$AMCMQ'PD,
M_M=!O'"0\:*T4?9XQ"%WONW5JS;S.3B,_0'\6/3J"H<TNOEO[@(D+<>\8;US
M\GD.[/\ WC5&."W4;2V-#L@(+O>DVFFF<0'_ #"L(A_+9?\ K_\ [MF__!UA
M=&\ZVGQ9#YU%4-P8,PR"[G.HC0W1E)B K5/IF'UB_P!EV,ZI'C:\M+*J0"1'
M1AE)$:-U/4,KYR"#T(.=12ZTU $!T%)1AD#.2ZR;ZTV]7*CNU'5HFVC VG&&
M7P.K2\-W*<Q Q#%&K$(45%.<CN$D8)+^.<?=JD64-"Z.IQ_T6;_S<=/XYU.*
MQ=<0!@K(F(W]/Y0W_FLK8_CC5I?KGDJ\YZ_75(\2\04P(QO']CM@?;N3=_5J
M)@2TU:D+(WJD7ZC;G_EU%75/)0#D,&QX1]O'V9SG41(2U!U:'*5A'N8KO>3;
MNQ&'E4*[;,$!B%&3YXZZM*3W4HR,=(9#9/TU$'K'DN2+F%F\_4,?< =5Q6HV
M&1(;@K#"C=QB>O:DA_[,J(SX^C'PSY:ME!N)0D6#H*K4CJQUXD),5=8 J'H&
M:O"D".<= 0L8^[5)F-Q,02$66))).2?$D^.K9"GNC&3 !=)=V0*H)VE!D],!
M68D_<%.HRH;N1+,%P%2%*G(*J3]Y )_AGP^S5+<I:\^2(51V@V?!9!C5H<(B
M&"U?P%=_R.*/_P#D.0D!^UH1!CKTQAL_PU2W=<>E.+8&N2^OQH[J'0!C&2D@
MSTC=6R&4@>)7ZZ/T1FZ\6 201PD/FGM3;.QCE# .)%W+(R;>Y$\1/3\6!)GK
M]-!D&."]>+>I,A%3R]^29O0L,R.G<:1TPZMN(RHRPUJ$=19+VYR6%CX^H>1L
M<IV8I+=CB.+XX^Y$6V*O4Y&2:6:A8AKP7JEV=)"%DCE1U\0Q.B]$<RO,WEI2
M*S%+]OY^/;B_T3E;E..KS4/(QSB*BM^I5H\-S/&HD@-/MVYK372LLDW<=TZY
M#G.@SCI+)CHB-(O!+\DUH?!^!I$1T(A'6GX>*"=):G'6)6-2.+C5L0W):1NT
M[!A;=(89$,H0*>F<Y7<].C_D:^9!^:VM*C7IUN-IU\BIQU2G6J)N8.(:21QU
MPS#^01PA0O@ .FB0B) E%GMA/B5<J".&&,-G:C $X!.UG?.!]KZPRD8C:'I1
M+]ZJBF>2S!7V>G9;_,&209(EB*^&,J!G135^4;.+Y)._>REZE7M=(T3K=^3<
M.2=5U';L19Z&NT6-PZ#*$'W/X7+;?'^32Q<QU<L4Y21 2' @K/)7,M3CDR $
MXFI 3^825=F9O2)!'U*CQ4^&BU6^%VS2&^V1NW,[M3/V<AWHM7CAFLO%&4A8
MUA'%D?EK'''&07QZLLA/@/'5V2ULA0G]-..W;49:<<O,_#%>GW2%'58<$3QD
M20]Y]Y0-"Z893^6P/I_FSC(UA%OVYG9&Q_) \,VQ5474 =.D\.64Y<%@6'8D
MQUA4$#..C97RT<6\&4V^YZ[AF8@>\.C BEUQ(29*MYR5!R@,E1X@'\")D?)^
MH&@R.HNNB*=,3%\RZM1 V]B=H:"@6(7HF;S-]0,;B !K*OI8YJ]UV5YY9<HG
M=L0D ;G[FXW$BC3H7FDCC.U>A/CX:T@W2^GAULVD V6:B21-+8=0NYZZ=K\S
MN*6:PZ,V(]@0H0"<X#G;XC45QEUY@98*N24AWC@4I#)9*B'.?S+-&R\C[L =
M17QC'GG5):Z\5;GZ9GQ9^\/E^]9VS7;M*LK=E>U%('P22R7(R(QT&UFV]#Y$
MZ:C/6^#+G;R'4W48\ZXIWL5S9G:6>-7L33E(&(C"F.,'\L EF*Q9;^T2="G/
M4&;)=+:;<U"0=]3RRR89+%M\@L6.4Y:E3XN*:CP*4ARW*79'AAA>[27E)DIP
M&L\E@4.-D224DH-S;?(G68RTG4RX^YOZX&#:']KE5K\HXBW7BOUUYAQ-#1]G
M6/!<DMJ[^M\/)'QUBO"T0;V5E*C%7;#$]-N.NJ)>6KM=/Q]))TGJ9MPY^U"5
M?E_"3P6YJYY-TC7BV"'BK9L65O<U/3XXTJ\"SO9::[5>*4#!A=<-G1C>Y=ER
M+:],Y5/D6?N*;5OF7!F2&!IYC7:.%[<LG%3PU^-6WR-NC67D['K;C9OU.LT<
MG=4,2@&T9T&4M1=.U[[HU:=+MV_N4.0^=5%CAMU1-<IQW;G$VB]"XLUJW3@O
MVIQQT$4!-YUEHNLB$Y3H?/&LG$,G?J=6W-VG/!G_ ')4GRR":>.2:%ZQY'C>
M#L\=QE&O*_+7WYI+S(@JE8U:IV^.E=)=P61-IZ;NA86"$1%G8+E7V]>WJ ,X
M'P3#COD_"7/TPUI>0D2:#A[,DJ\1;>&@G*W9?TR#DI,".M<LV:CPM"22C#J3
MX:UUNQ,;3T\[NL7:].FS)GR]J,N?(;5"C\MY>2O%=I?';-UN)ACS#+-8XGA(
M1S"M:*RK-'9GC,,3A<Q@-T.@'%=#>7_33@&U:P>QN"4K\T@5_C$4$+O/\I:]
M;OU5?\SA0'DJ]FSA");"\Q5: *0A,9,N %VZW"6DNN?7'Z",9GQZP>QOFCN.
M^;\'R @,*<@9I9I8JM*GQ%BW=M-?JRW:,D:5&E'LK56E(RNY60;?4BZU*S4&
M9=#:W_4V&MM+1!=WS0]CYGQR0\?)Q=;D>0CGY'@*RI-P?(M;GH?(/?1Q7>(C
MB*O<0VZ1B"JP&_(SZ="1MW+Z6D6GQ/)FR^*=Q?.^#F/$5FM30?J;UE6.2M,W
ML/<\L_$55O$Y>*:6Y$Z&/K)&P 8=<ZB5V^[%]L:M+:@>+Y*O_,_&<@>'K5:_
M)VARLG(25@W$V#%9H-LBEY)!G\_C8K:B(LIW;SG&!JXG3/7V)^W:]6.G4WL2
M;C/E,G)T^/VUA4L7;/#/8@M4;M&P4Y6U;BMV:D3 K;BFL5)6SA, 8T;K=B##
M8&%'0U<27;G[41Q7,\;S'N/8S212OQ[7JOO^.L0/:IS+)'%=IN=R2UN^A4'(
M&X'4ZW8DSZ28@GJ# $Y<O:DR?+(#QWQZ_9C:I3Y>CRO-VXT]S:GB_3UH$HC1
M+# _<"!<N\>#X X.K%^!#9A<A^':/@5HZW.U^4YJ3A?9\I5DK\-3YZ2U8HNE
M<U>1DGBCA5BRJUH&N6"J6#)D@]-!A+2771$_ZC(U :- /:^K'L9EH%*K!-(Q
M)C$E9"T:]SH6M3*PP1E6VX_CG5MU)\G3NXOZ$ X? #[$N=6C$ZA2S+&\>W\)
M]:(Y8^)&POC'V:/^G#N7'G;KC*+9CYHB..4+5CC[HD6Y60/V28^Z*YGFA+Y.
MTQQ*>OGY: )_F&SL9,[:74JAM<M(S_<C0MF/CX#G<R&>%XW 8,J6GD4PGH8F
M<*/'=U.I.>H@\ET37]/Z=(.XA['<_!)FVR0I6+$K#4XV!BOI998*L#N0>H_F
MP/IHG6')<*4]9Y+YI^X<GJX=]H&X\K+M7HJ]Z2H JCRQLR?J3K%D]7L79],G
MHKGAG85\Y$?7=G\;,F,>';B[F?'SW8UAUT*:_J'D[8]Z[MZX^W']>HZ/]&?X
MOA^]2,9 DPV#&RC.#US]Q&/'44^C_F^'[USR'W#^GSU2W3MNE,SU._8HR$K'
M+(!N[<;R$9QD(-QZ^7341;JNJ '9"K<BP,G<PC?N)$1*\5M&=?:2!<89F0#=
M]OAJ($-H8SUZOA^]&YC=4DB9FC=%.73MNK@ 2QNFYBK1294_=J)J<-2FBX(D
MSX+)TQ]-OGJ(-FWUMCEV*:+N$SYQO(&/ID@9SY_CU$&S:^+7JX-E^]5 [?MV
M[OLSGIJU4O!#FRM:3,9&/[TKY_A[0V_3KN_JU%J.XU#IM^V:HU2VIQ_B'W-_
M]:=1'J\OM53';#&?'#N<?]D:G%*;O]2/=]JMV$[,=2R[L?P)QX_9J(T(Z^Q0
M(=0"Z[23T&<Y \_+409ST<%1+,8I(UV QE)'EDW@-$%V+&>V1ET>20*6R-N1
MXZBNB77?@RY%821*VXA99:]6281D2P5Y[,9?V_N!M601D$;\ ''AJ(TZ-46=
M$.AC9D)!*G!(.0?'J#YC5I.ZGI-B[KR^$G_XI]1#ICKLTY,IN,;/M1#_ %8_
MY-4G;(Z 1V+JMZ,X_"&3[]_G_#5I#BM9\#.[Y$BX'IJ6FZ]0<PLN".G3KJG3
M5N,)_P#;E]B^S5INRLBF-/[RZ/RQVQ_@DR21ZLF3/3Z?;IFV'4G&;LR\WL]X
M-I"4-.K42<VS#<BFW&KWHF>:<(#V63*;O#<<=&'UT.V?4ER;!.^C?\[GJC\E
M=(DKBS(TH8%.BL-BC:0<NV=JY'ATZGIJXVZ0 R>L.)*^6\M\HGI\ZG$14Q9C
MFI<',^^0M=V\WS(XO_!P=MC))QJ1//+'D$18.1K4;],G9>9O\TO;\D^K?-^&
MV)$#S-FW^IQ\&E.OQLE[D+D]FGR5WCU@KU997V35N)G<O+VU39U(\= )<NO1
M;*@C9UX_@"]7^9_&WD2JMF^7,*S-(.,G,<4UFK9NUZ,BAC/[EUKLIVHR!@1N
M.J[4]".@,M%P_*1<M0BOU(;U>K8CBFC7D*4]":>*:O%8AL1P3D/V)(YAM8@;
MNN-3)6<5Z:(L4D#[>S%.OAU;O%""G49*%.H^G71^MV)#>;8V[F.X=@(@,W+M
M5EE%DNUX!W%]Q):L*QDDCBA:Q7&]PZ,JB<,O0D>!(U.KV8+G;K]:L_Q!_=@C
MX5/M[9)/2G#$-B[GPTR %DZ%9QMZQ^(/GH,YZ;!VL5U(>0_W#\D@VQF"D)#)
MN;C>-D@*-A$DC8;S*,@E"J=,>>C58UMR7-]9)'J$P"<A\D;%#$99K05&=+%*
M59-TF4$40AQL7*GU^K&.NAR@8X(.WVT[#&W4&$@>/!6NNY8@>^LBQ7.[_CIB
MO<E$8C< *RE549(STSCH=83MVWG9;&8+1C%N..*N:2-D):([4<(D)VJD@F;8
MS-MZ]LQ$[<?S'.H_),,( 'EG[F0D9"13QH2I,%^&,F2)0B))4C.3--%G"P],
M9(!U%YXRF!(&1=CQ*),==JTJ8D:*7C:A)60*JM+(71"BLR&2-B<N&.?+PU%Z
M>H$5QL)PTCY(_<DKE41$W6+,L;.V'+H6=1C.P2%&V@^7W:BV9QF-+8E5&-G:
M3,H#L*I*%B2,=PLF1D$JWC]NHI"HPEKP8!#*YC!E*[,3-$KL=RSI#$'FC0+E
MHY-CG!.//RU8QP0=Q; ?F$?)*IY9&JDJRJ'2-P9,G8!<AR6QG( ^FM3B:Y&)
M*X]D#NC]3 Z8UR)8YG3P5DFYIF56.Y9YXW;<P222"":T2N.H1TAV_7)TT &0
M=QN1>8RAJBT6S^Y(9?CM*:]/?6[RM0\A6AK<S3I\BE6CRK5:YIJ;$<E*U*)'
MI[(I)$9>XB#/AH!I+NX9+?AEW?:$/7^+TJMZE;L6N1O24).&>HMN>"9*Z_'Z
MURMQU>+M4ZKF. 76RS$F3 8J"!H4@Q8KT\]]7MHPE.,B,L&X#M2X_$:Z1<9!
M1Y&?CA0DXDI-'.))X*U?Y'>YQHZJS5K$$%@S<@/S /$G:<ZN$#.0B.*\Q;^9
M*1&#R)]Y3>'X)PZJT45CE'2_%'4Y6*7DI&CYJG7Y;DN<HQ<J\<<:V.U<O2/N
M1$8-M\M4S%ETX[25E>!B'"KF^)\=4N6.2MO;N7>6GJ\M-8-F*%K!@X[D^,IU
MK @I;W5(N0D$KEU>4)'DXC .XUF0=<VXFB72DY^23CXW1AJT>W;Y>+D.%K\5
MQO&<O'>(O1U_C_'S0\9W/0(F(IVF@<8VE ".NKZ1YA E?&,3,@X%-^-^.4>.
MJ5ZU,3H9/\OREIKTTT9L\%?>?CIG1HSN/ZE8[K_09(Z]-7T3S"[>TW<-EMX5
MS!D;).&;#5S=-!\9JMP;?'K,ZV*DE&?C+,T32&Q9EY"O7L<I=GWX43V[5F0C
M!_!@?702F]YMI;VR,JR(B,6Q[TNE^*<1!/>Y!8[7<N<O4Y2Q"M^9(3:XN)^.
MVQL(^XD5B"221@,?FR$_;K48ZSI&:Y>ZVEFVC&4Y"0D[9X-WKGQ_XMQO%M1%
M3OD\38@F@21^/CABDCX9JL?;0<>#8_PO+%2TK%U*9!.M2K,0Y9DQZ;+3;*?#
M2![E?3^+TZD/&5Z\L]:7AJW#U:%BN]<3PG@I^0M\8ZV)JTB,8;W(M(<HJL5S
MT.JT'3JX+J62!>1RY(JO\!X&M-2EIK-'V>R+$W^!LR<FU:W;Y2*Q9]UQ4[03
M-;MRAS7:)=CDX)UA5+3M8?4R#Q+!AGBH2?&^"_3^ >-7,'QI$;BZD<M4?W<I
MEC5K2T^[$J6'8X@[65"[L]1JX^*>CBRH;^L[;ZG2=+.V#YLHTOCG"\<:35HK
MQ@X_CJ%6K#:O22P[>*MV[E-&01R;U#W7# AO'P.B]$\PK&^@:NKI+>Q+N"XE
M>!K+9,]F:XG 1<3)&9837JQ5._*(J#15X$6NTLF\ H2"3GKD:G2/,)*WU>F,
M)$PGY2.'%*X_BM&I6HU(+O*M%4I-Q'&F:Q2<TX[C\;6E  X[;)&ZUE+;LMD?
M?J^A+22XP"\S]9##PG$@+6\%\:J<1,G8L30K#Q:\<U<S-+6L1UK$]J*<JRH8
M9H9K4A4( @#8/30.U>GVNWE01*1!XIN(G2>65<21F]6_+WJA*226G7);$9PL
M@&/LZ:U&)D6&:YVYV\Z8ZY2!>1''O0+['224AA8C5HV.05*M'7W=0>K9'CIJ
M$,-"5&.2+1%$2%G<2">@V[>PC&R$QL=N<EFSH9LB'#)J.WF*AN ?"6PQ?%63
M2B&))F8F&)I=Y!ZE_<!@JQD[G+J#@^&>GGH4Y"1!&">V]FCT_7)R!$GWDA*[
M$16"B&!7;#40Y&V1Q'"D1>1,EHI',9.UO4!C/CJX2$7=<[<VQMMUP##2![E\
MO_<*-4'%!<X#<G(<]3F5ZSX'C@#(Z:&NUZ-#J463&74*P18;2.O61G'V QQI
MC_T3_3JUT]8V\V(?#@HAL$'Z'49:^LAR*D9!^9T/K*D?9C'CJ,I]9#D5#.HR
MGUD.1475)8Y8I 2DL3Q-@X.'&#YZC*?60Y%4FK7#2SKOCE9%=VC1 .Y$3(K@
M=,L9,%B>I&=10;N!P8HZ.%(95B5557[<N<D[Y+$:.[DMDEFE<Y^W5(W6'(JY
MNJ[@, QRX'W%1J(J$R?KJ(=OE]JYC[=1(2JD22^"[M/JZ_@*C_SANZ:M9Z,N
M85]=X(S+[B.25'@D1%BE[+"5@!&[2;6)C0]67'J'341@#"&/!=A0L0V1Z 0>
MF,X&"?$Y\=4FJP>GWJ#)G>W3"L1C[<@=/+SU%GHGBRBZE" 3UQGIGPZZB)"!
MB[JJ8EXPH."'W9/T'75I"_";%2DBC;).&])C.!GT2JCLISY' ^PD?9JD3:0,
M,^.*KBKP*54JZQKV?2)&9?\ #(4A]#G:H 8YQJ)Y$2>MG8R*SYRP QYXZ8Z=
M,ZB!?2;68LRC&A8]"!@=?XZB#3MI5V:R0RL:)@"=P.T9\_#./^741+SBW\OW
MJ 7\O']K+?P3Q'\=6D85F>2TWPR/?S]8&01YAM88Y]1]O(NP8\3ZL_<-;A,1
MS"W?L[#3.0D/#$GCP7V1 ']_7)V'W=A(Y6_!)W:\<9*X]0"MXY^NF6\)ERQ7
MDL_>/C@G-/=W'9(8PL;;&5'"YVGQ_,(&/II,XDGFN_L:9;3J"9!U$9=G>BYN
MW(LA96:+;N#JPV%\_@(SAMN/NU1+!TQ,NY68CI)!R%OD*QE]Z>*6E:F$V&3C
M^^TJK$&0[)&:?R/4#&B3K,(B1.!7F[9",Y$XC[\%GH?@U"E'QQXN_>K>TY6O
M//::<QWGXWC>/YGCN,HTIXX$CK20GDU9FEAG9L/A@2#K #D!=O;[N%&QC*0)
M$6'O1=7XGP-:6 11V:02I'#9>O+2A-KVL,]*I/9DAXV*>*<5[4@E:%QWV(9L
M:**2[.%/ZO5_!+X+6<=6K5*-:G K+#3JUZ<#-*\A->A5@HUBTCG)Q5K(#Y9S
MH<HF$M).2;JW<+ML=S$$1 .&#X8(?.Z.((Q#I#8#.F1)B21,#+XCV@(?^E@Z
M)T3P(7#E?]1N:YQ<1BSN<VS1+ 32QNV>T@D#)GU$M@KCRP!TT)=/>5'<W0M@
MPC&+-[4='"&@GL?X>NBQ[S&&E_Q'^(A W'P]1&,^/75-S3$!@1_*?DE/;'M>
M+D?^[/&<<I*_C -:)FQGIU+$_?H5$S.H:2<DIZM1/^H?5%NB^(XLW+)=($-A
M8X7<(&JLPR5R6VRCH#@X5A_'3U<2(",\9>]<G<3G=O:Y[61AM]400Y'?@,$R
M)4E-BA(XULRL,!5V1IW)% '0LY;./,^.ERP7?.!U_ABY/<$(UD%(RHEP)XU8
M+$DA(ZE 2[C:!@ZV*I''!)?U;9W & FSMB!R/:I5I%(60CTR"RT8*@[HIV@F
M_,SG#YD (Z]-0PE$8LRQZ=5$&R5X$HEF?'OS1LB5>ZU4^X3N0U2'C4" "PW;
M7U!@ (3U.!Z1X9.LQ!D6&:Z\IPT:0H3]A/4DDI*6;6PX#+DR%<C+8Q_9/D,:
MH@QDQ0HD"3JZJT8EF4J"8#5B?TJ,R/W5)7[&D!)\/'5=BU.;G!V2]YG2>3,,
MT82T%9'5=I#1K^8P5V7LRAMN3U)&"-1(V[JF$M$P3[$'*TD]3T#:#W%4B")E
MC$7((TP))&Y9$;8.GH'4==6Y)<YH0WNU'Y<8D \&#=O%,0G4G:,!F(&!ZF=6
MC8*/[3(Y!\,@D:O5+F4UTJ?X(Y$Y#@LE;^2UJ_/\+PSTI)([E2&O<F#0I/2Y
M#EEM2<#6$3I(DCVHZLS/ZAVUC'CN&IJES*YPW&U:1TX-R"5/\GX=EJN!\A [
M7'V87?C+49Y*ORT=3A:'M(Y"DLP3EI.WO*J))&#$YU<2!)Y8A;LV&ZF-1D##
M,8GC[%9/\HX:I 7DBO?E5[4EI?9$V.-2O\BY'BTIWX25D@LQ\O":ZQJ&'=<$
M';N80R&IXX)._:VTP>3.1P3:+YEPU1?:VS;X^>FW/)R$-RLQEXZYP7'U+EBO
M(8'GC6Q8I\O5F@0,>[',/ Y P^*8JW&JNO;1,NL(DD\,,\4 G[@_'5:\'GFG
M-%+52666G&D5BW2EAHM02 SK,)#>L+$GI4.V2I."18)&29A"J.WB;HQE8,"6
M<OWG%!4N>]WQWR'D;584*O#<W\CHU89J\T<DE?C:_&PU$EC8F2:>6V9(PRDY
MSXZW$3D'!R[4Q73MMWL9"J$-<@P) S''BN2_*W7XW4Y!J#)R[4.8W\5QJO;@
MXKD."RW(6I+VYEFX^K.R;F.=N<[>F-20G',_%(GTK=DP<P:,@<SD/8G\?S'@
M*:V+%Z2Q!!5FY4<BQJN_9L\/Q7$W^2=>WO!KJG)U8X&Z=Z6940$]!A=.S<U[
M0CJNTA@W[! 'YMQ]V O0X_E[LZKRL\_'P<?%8DJMQ4M":R+[U[,L<"F.VI]+
M/N$G7!.M5R$9.5S/4-W5N8P%3C2#F&Q)"5R_,..6J9[:35HS3^.64I;6EY1[
M/.P6Q S3-+'4%29.-*PEBI( &?(;C9$3)DYAC@@[F^$ZA#;/"QSEAPYA-7^;
M_&HK/*\;*;W=XVM>$SQ5(["--QU>M8MU4B68O8GCBL?A951FC=0<KC0]1RX)
MO;[NN<!5+49B.+\?BF\/S'BA M:S6YKC37GMUY%Y7AYJJQ6.+H3\Q8J-.Y9_
M<MQ5<SHN/5&R@X)P,K<]_01HF)&(.3#A[4C_ ,^<!=JTI^/K<I>EFN788^,I
M<=W[D\*\++S,<R+'*:C5O9PEAF4%7]) ;IJQ@7&:NK<;>R4:(QPE@ P;#%7W
M?EO'U8;TUBCRXJTUX9Z%NM3Q%?/.+1FHPH9Y8DA>:67;O;8!'NR?K>J7,IJS
M:RE7*$-(>+#O3I%]S$XC5EBCIQS[986KJ5L(\\9$17T.B9W18 8GU==&ZT-0
MCBY7(N])W1IF7AA%\^7L781@/F!I>W?K'TJK]L)-6W %RIZM(#T\<:W8)&+1
M++DUU1 >0!R^83))%F:;9^)H;"*&Z%)#)"PS@G:0H(R/KH$JS$.67IJ=U5N)
MRA6X,6=QS5\CQ2B<C';6=&[31(P\Q'AB2049@P/CTV^!UD"1+1S1I1A)A, A
M^(?$I=-/&NV)6&_;.)9/;1!9 T"%#V@=JD>6/P^6MF-D0[_%<G=7;</&$6D'
M&0'8BXHSVZVY&DB=D3NLJE2RC(9P22 3T'0]=#=/[41EMH1(<  >T*-G"Q+(
M@_EM( F-R*)SN! QM4E<XU,\%6ZB(4&,0!'LR04Y0UPJ#+2B)HP -R[7!D8_
MV?2.NM]*?8N&,5\P_<)<CC$Z;F;DY ?+MN]7MKGQ](4]/ :S*!CFO4>B1,-O
M.)SZA7S@C5)ZVB=F(9U[:=I;R'].HE33,%L%1&2S2]21E< GP!7/0>6HZL43
MD6#*[!U%OZ2WL_;V*$I*0RN,!DC9QGZKU'7!QJEH5=,-, E"&V!&J2=&:%&D
MP5R))YNS$HR ?4WW=/+5J:1FP3%).]VV5B3Z$4L3E7C55\>N,$=-5P=9ZL.U
M6HV549/J2;&?+JN?Z3J<63@N@>:J(P67S4@'[SGP_HU%=F,']JYJ)$WP&;KQ
M)Z]3UP3]N/#/W#41I5R->J*[TV@8ZY.3]GEUU:"(6/XCAWJR(D,>IV@,S $]
M1CZ>!.J3U7E]JB6R21G:6.5^N",Y'AJ(B[(P=@1GPQU^\_\ /J(?5CVJD_\
M/JUSKIB<]0R43.L$T : /%(7,K[@O;1%"@XZ9 +C[L?9JD3:3TDB9+JN"\L\
M$.4"=Z2(EB%';:=&9%)'J[85>OWC43T;(R+!T00%+>&<X)'GU^OGX:BS9;&I
MM3XJZ ^O_LM_'IT_H.HL0W-=D]$7=18L68;CC=C&3CJP 'W9.HI<'/L7%<;0
M.O177^)) \]6@5Q,1BM;\&9&^0UXI(VD04N1W+C*Y>,%&S_*5 /7Q&J1KK8]
M&R.+FN2^Q5)(XH7[Z"9HI)'65HU+,H7>%*GP9% 4G.7QD]=-3$IR>!:++R^Q
MW&UHJG#<1U3E)Q@"WOR3:JB.4FV(X4][9(N5>:0;'1U.X&%4)(\]V-+98<5T
MMM='=:NF_A9W[59-'(E:U''+VS&)%278&'6"9H_R>B KV\DCJ3JF=9W>WOE%
MZY,!VD+YKROR&]QW/GB?:5[O>J_'9(T1K*6[9Y3E5XJ2>.,*ZRQTF7>Z9]*;
MF ]/4T;(Z0)N67G[!I?7BR(B^:U+2R1QU^4G;]6'%1U8Z,<]F:S-!>O0RK-!
M9E@%8Q47ZNZNF!N4#)&NI6,6^"+ 6&<:7PEBSX8(.7YSP;3BFMB?OVJ4;O(:
MBV1!);KVI:U*S!W&L&V\51R0J,D!VEV0D:AMCP=UT3Z?9.MHZ 7_ &X+6<)R
M@Y*A5NQ07X*UJ,V:<7(U4J6'X>P[6N-L]E)I@RVJ4J.C$AF4C<!C&A",IN>*
M2NA?M)G;2DS#$ EL5*)9?T^)6AG*BDTCLH'0J@#MU=29 T@/U_CK>BQ\_BEX
M2T6PF?*) GN3TS1RLZ1IL$;2QY9%4[8H4E=NA.7 (QYY^FAQ@9%N*]+'<4[@
M'H@C2>(9&(Z?ILV]VDE,)2(""/\ +"6ZBMOC+=&S(&4>>#X:IL6XHD./]TI9
M)&WLN-C &XU*6U5(*E'584,; D/"-HPPZ8U5, 8/6!I1=[$3L,9!PI>W?N2N
MZJ2#!L)89P,1IMZ^6T#[M;USYKFV;:L52Z40+F\/9+@5QMRQ%7SN>*RH+?F1
M;A4JQMN1?5GO%NOAUSX:PL[2&ZC"8W1=SAB#A[%5V*TBC?!,P6P@)[JA"PSU
MC7.0,?76A.7 E:CL]K$@1KB Y^15T(4LJH $C>T%7& L2-355'V*HQJ:I' E
M ].,K#.(+F.?M14CR"LQW'K6J*_U.Z:1%&?'Q.KC(1DY728@L5&.+='*6PL4
M4EF-=^Q8A./1LCDSW))$=?4IPJ9&,YU)D&3C)9+L6S7@DD4DRG8\C0\:7*R'
M9)/(LC[C+%DYRW4CP.L!!C&[43(^%OBA7[L*S1=I(HI)!+(Z2O*618ED4%I1
MW3_BP3C[<ZL9@=J0WE%AME;$#I  Y^_XH+:GLP2 6CVDD$]-]R%I,8.#NSUU
MN\"-A$< ZFRCMYT&VP F,R'[$R1L]V;)[<5D@E<=R #U=R-/'>J#ITZ:&NA"
MR%P/3R#CVD++\A\6X&T+,UF@L]N2Y!R37Q)%)>J<G1DAEXXT+9S)5@BCA3*H
M0#EQYZBX=E%M,2+  6^T+.3? Z<7%UHIK$\G)4(N%@CNI.^ZIQW$<[7YV>IQ
MFZ$RPI')569"V[8ZYU8!)89KT<]UMZ80ZI.EP,CP&*83?$.&2'EX,VXX.>J/
M2NO[II+3R1<Y:YDW5MQ[F-R2W8>1G']L 8P=;Z4UYS=[DO*<Y'I.6[NY.3\3
MXN7CJ_<CN<@Y^00\XMBYR<[6;-F&KV%:^PQ[J"18E1XCM7:!C.T:Q*.DL<UN
MG;7S$;ZLB,"X=BD\_P 3X=9>44/;C'*1WKEFK%R,PAJ6^0L"[;Y/C8WS)7L-
M8'<P#D-DKXZN,)2#A5*RZ,M%DBSY(D?'>*%.QP]RW<Y"&]SR\O9-Z^QL6K9-
M:[*+$[A7]I,*ZR2*H]3#H,DC1ZXF(.KFNCL-Y11M^G:2):CP=45OAGQ20-.@
M;BVY"U-/RL?#\C)1@G'*(O&\A$T,8VK4O;(PZ''=D!.,]=9N.2=_J>S_ (C[
MBM)+\4X6Y>Y1Y86:QRE&MP5I19D$,=7BQ4]M-"NWMK<B->$F0@EC&I.<: H9
M[+=XD"0B",0<,'2=."XNI+[E)K-B5*?(43;EL1618JW.4IV;B>W,2A?=+04"
M7 R!CP  (*YG%>6E= %GXI<GPWB!1L<>LW*NL]*EP,\]BW&UJ?A^-XZS)QE>
M681,/;P0\VT,8P'C5<Y\#K!!!;BB<'X (W_)_&0)R$2?J,,7*5&6[%!R,DM/
MN3Q04.\T;+W'EACC69EW!9)!X$DYI=3:;:49BR<1H,/CP^"TES@N"OF66U3>
M0<ARO+7K,<I01R6>7XA^$N2JL8+1I9XM K1@@(XRI\=1,V5;6 U3B&<<.>2
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MJ\$@9RA+QDZ05R/\7WJV?M&TG5+HTD&#C)U"/U!5\22Q_@,9U$4Y*<A3(VC
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M7HJZ8Q)%0 ?%-HHT875A5&V=AI3&54)";4&2[L0K.$)RXZ'^&L2D007QU(D
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M(7S<N6P"<DY/@/)>OA]@T!.ZXR)8J+$*"3T \=1#N\GM7LC U.*%M9"NPF>
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M.V"KJKQBHRKGU2=P/V@ >C 8\/ ZO7;R77T4BN0@7P/% 2R2K(X,C+"LIED
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MQL\1\R3WQF*0X.ACBQ3)LV!6$<21[97!Z,F$$$S$N,X#[1TSK,8:+7CD5VX
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M'7R U@!AAQ*9    5;1;XZ[E6+=OD@5C0 8]]4=-J(O3>5Z?4:MVP5F$VQ!
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M[?\ 7J+J7!P%PKDNV?[UXX\?V?5NS]OX=7P2Q&(/(J>=C8\<;OL\1C5)Z)<
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M739$$A,Y&=FP]//,@CZ?Q.HA7 :?:AL8<CQPTJG_ +(Q_M&H$ DLJ_#^G/\
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MP%1*G1!/$%R0WBR,OVC&L$$%N*QZ?F3Q/V9(N[VH'8;X8@M2E/L,B^G<6+,
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M>GST3;-&EI8%)[^OJ^K"V()@)#$9>5&P C>T3=R5YZT.X.TBLZA(D",SLV2
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M9_35+NC*T=>1(T&X-(4C8(I,A9Y';&>I/4]/IH@LL.22OVFVICXB1-L'*N+
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MS1']/3G[2>Y;KX_'R]SCN+N74I)/?JUN3*4)&M1P06H8;U1&L%BL[QPR!6?
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MUEF6!7!^PA-4NA#<F9(;(<T3/+F:0X\7!\?IG[//.HC62:OO^T*CN?9_7_\
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MQ1JM$')!M-*6P-G60GXQK<PX\5#N+HPPG)@,,2OI,+QQ113%,. D/Y>))'<
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M/;@* @D%\_XG=DD^(\M1='ISY+K_ +B<ZDS?X?BU7>N :\D@V;G)Q^<IP"?
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M'7S\=6Q=N*#JOHF; &<$ MF,PC8CNK+O*2JUN-)SMPI?WE=&&.A&/#IJB#'
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M "&8')B#3;9N1T;2]0BXP;$8#+L6IKHEB)E818-B:2%FK[3Z[,MF9MQ]!ED
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MQM.9J%*Q=ISP4WGG2UQUV8W*BKR"SS05[5=$B0  *"'Q@:I=O8[G;U;.,)S
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MN9WK/%RMKAJ,*S<I4N044?EN8GO_ ">X>02E7I.8A%4]O-(P0C)! Z[E/5$
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MG :8S5(8',A *[';^.MQ8EB<%Y2^JR%L],9$ D9'[D]KUUDCK122K %VK/
M1T6K,F]S_P!VBIY]&QX:7-Q!;!>MV]1NV-<9N#IB?<J6K3BFTA3-=>,BC"S)
MN1EEWQ^/@3@ KGKU&=$A/4,>:JZKI;*=47+1C[<578ABVXC"0FPYW0H(XQ"8
M(8T"D*=NX[?4<X)\-9LL,<F0*=E&RO5(R!_;FBH:>Y:Z;HU3<D9"-DK$X<N5
M #MN!&0 I\?#6.K+DGJ]O&%9K!)!B1[T=QE9>X&D*QR&<X22.V""G8@Z=ZK5
M<#$()Z'J?+69S,L#@I1MXT B))U'[&0!JQQ1;W2"N0+! KHB&>5KP596*[MT
M;=<9PP(.=:%I 9@LT[:%$3$$D'FJGI+OL>K<PM66:/N1QR$9 DEC+C!WD!F^
MNC1GJ .#H!]/J+DREB#RXH^E'$\4K[]G;1!&"RDRJ)X(Q(O080HQ.",_UZ6L
M\Y3T0(Q$1P#(Q$6"LC;\L96$;/C*!S-(2GAX9Q]QUDLM#'N03UT->O)G)6&0
M(A&X8:484 #<<#PQJ.'5LE[T4]RC-++G"DH^,Q;1GM-LC<Y0D [5;QZ#1NK+
MD%S]SL*[]P=S.4A-F;!L%QJT*UZIWUMZTI[*]Z"^\O=*(W;BD_3%5,]PC!.>
MGEJNK(<$G;M17;&L:C&4026YJ^*&/VNSN'\RY6)ZKD]JQ5(1<9PS;SU/3 U5
MEAL(D6R72KJ^GB=#DR+_  53PJS1(KI(Y<2PO#%L2PP21#)&"-_9=7R ?4".
MNBF6FL'BRENWCN(QUDAGR[40./QVXHW+,+%6(JQ4,/SK%HQ9Z+WI)'VJ?P@#
MKK,;#(L0&0/Z=6X\4L2!P2E8)9Q,4>([I)4E=L[()(U0%XU_O)(G<C..IQD:
MD[""P2E6UUVRKEJ$02'9$&O@/)@D[H(UA0AT62:MF6PC+DLQV[<9VC[];C/5
M%SFFI^EU60Z9E(#V+D?'ND564G;#6,DX+D*YECNU8PA4@>DK,3]>GWZUJ#YA
M8_I%0IKJU3TUG X8OS_<KO90"-(A,2DD/&G?E#T6* 94C((W+C6+)Z, R)_3
MJLM4O@J+5-)""6<=[NE\ ^C<Y!QO1&  /F-2$]1Q93^FU_Q2^":*J12]Y9 6
MVR.%)&'?%=! F.HED RN>G0Z")&$B0F**(TOI)+E_@R#L5S'WFA838_5B6SM
M0AK$!#J6QA8QEFSXKX:+&PR+%<S<[44QB8:BY/#DNUE)DD4L(Q'#4Q$&G;N-
M(6+2 O/+%M)C!  !ZZW9+0 V+A'],@97SU.-,![<4+5HGMMVRQ:6>9&W*2JQ
MAV8N=@#D#/\ *<GRT+JD%F"(=A"R1LD9 F1/Q5QHX2,S;A(]A0B;%D5D0@@N
MN.JG;_Y'4ZLB6/-;^AJZ?3U%G?@IR1%9>\RD8DN2*JQ!(T,=:,J$4#H&9<>9
MT:3&!AP5T[*NBZ-T23*)RP1SUY)#*)$<@<;')&8QYO,DQC?=^)Y"VU<>'BVE
MHV&'>GY2,LT&:R,T>60L&E5)E0Y(;82J&9F8+D;6'@6&=;ZLN025NVC=9!R0
MS#W8HMXHPTJ(SLT$<#.0N5W3V9(RH89R55<D>(\_'02<778\2Y!2>&P[R3Q0
MA9)F^LZY_+,2$_EF15&6)&"#@==1PD95M:9XOJ0*P1^J579@32G8'!8"2T"W
M3&[(R/'KK>LF&C@N?/TVN9+REB7X<W1,T,3.D,;L8Y9N_P!W W96!HPBC^4J
MARQ/CD8U<;#$,&3'TL>CT7.EW?N2Z.HLIMP+-VUFXP*ZDC9MEL58UD9?_P"6
M2B I\/60?+692,CJ.:7A.72^@(_*#>+C@?<F-4+*L(2179;5A" K L=H=F4-
M@[4+8/U\M4G]MMXU5:(DD!_CBJK,$IJ1F4,KGC)1-#%@I-WH(GCW;\LK0S(0
MFWID^K1:2,4*VR5M<]09JY*/M/\ #6G[K)F^4:)HT8*$6/'<+*<G#>73IHEL
M]$],<0N7M]E'<0.LR&F8;#EBK8XHFGD+NC#L3$#! _O*^T^K^1S&,#QU4IM$
M$9E=73H>8S7(ZT,DTH,RIVKJP0OGHZN9>X47\+-3"#N9])SZ=58? &XAT*B^
M=LB)!@%Z6/N19W]UF@20O&N%9O<&'*J1D(RKD ]>NA5EI ID\.\?-!I6B-O?
MVHEEDDL2%UA59B8*&T>O\3*WMAG_ *Q^S33A<.Z,OJIL"VLHNI&%JNC8+U*]
M)TCE3(:)+TRAY4; ;OB,[ /#!SXC0Y1$CJXA=.-,8[452)$&&)PR+]R(%58$
MKA#NW2V#M554$-5ERR*@*B.$G!\SD8UCJRY+=$*ZZQ77+4'/$<>Y#R4T>=5;
M:%CH0@.\2,0&$3;B[=1DQX&WP/CJNL>Q59MHSL%I)!$0/<NFN)P)&+ J6](
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MH16\<T)(CPM!"2C;:\TZL'GRI983^8D4Z*0QF(&%)SC/33$)ZG!9<O<Q)W,
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MI]S_ '^/?;^-[?=_%V/\)VM_;_-V]S\?9Z[LY\]3_P!?P4_*[4>?^'+WC/\
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MUO<[8]W:_P U>[SL7NY[OY7>[V=^/3OSMZ8T*S1K#]1_8M#HX>7/X?VKB?\
M#E[/S?\ ?ASZL>Y_S!W<?9Y8^FI8SC5U/@G/R_Y4-)_PY.8<_P"^]CLOC?\
MK6-G;@[G<\\_A\/YO#1<?^I\$G+HOX-+=JG7_P"',P_MO]]K.!O]O^O>&.F>
M[ZL?=TUBS2WBZC>Q9CTV\6E4S_\ #E>W7W/^^UNVIVMW^8>YO_4N,[?;[O\
>/[SM9V]<?PTI?T-4-?5U.&9F['35;Z)>3R'W,O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>cm270_ex10-34img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex10-34img03.jpg
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MFV45U::I;>$=P+92F1D6X]V*;F^<?*F6?M_*OD1BA]H'<?(>5(B-I%;:SK=
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M-3&0D'X!+5XHE681F7+R1?(^WVY.Y86PLR;/RXZ;@.X3X Z1.>HC2[(7BO\
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MW4Q(1;FO1_\ ZY_-:>.@?->?;Q_^-L_CC/\ +&LB]0)"1(XJ6A646)(95.&
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MY:VQW:1@DD5C,GN"Q;>IK]$S^4DZ=&L:O",4F^T0KD7:0"/:;NM&=SY:>[#
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M)&/TF+9"^>CI1[4J[>W7L)Z<.0_%6<\H$L,:Q)''/=FKLL>0L4,+.Q9<CTX
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M;(<8*LP(/@.OD>OD?/QT@KD[N^N[3H?!_L1%8AK!!Z;&'0],8_\ EJ>"1;$
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MIJJQL98-RRJ=WICD,H\2 I!BD(_CUZZC0)2=O$HD ($# ,H1RB66N3$8P+B
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M0@+Y8&KPC&,1,X) E=UR"/V\4H3VY$7;,9)/;P>B""PO>=MH0%E=MS.#NSY
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M+ UD(D$H/=#@DY#[NNJ,E2]/VP#1#3_5Q/\ Q0O^6\V&(,E,AJZUIE%*(=[
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M$V&SX,-9].F8'<ESFSQYHHDEVQ"6:7U2QP[HY60*KE45R5/AD],ZTNJ0GIP
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M%!W#.?Q/_3PT)M6W%<]3O[%C*K8R/#..I'C^&A.LAU(&&3J(C0'(!Z?]Q/\
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MF6P!@ 88^7\=2D54FUV+,B]U,@Y'ATZ^1'_PU#+1]5$8&)P6*5ZE>H)Z]?/
M_P##4LD5W"%AF0X+_-3SH6NO<"R6D!EO4+0LT*LY:(F7)9H2X6B=9L; /\%'
M.I6&ZWJD$8,$&1&()3Q)7<#Y@?3/AH5*YZ,T4?RT*CXH;A1AR.HZ CH?Y_?0
M4RJLVRT@M@L<C:KCH6PF?/:Y =?P8>.H6@;>5?B)<+:="R  *N, >602?\=2
MD60_.B$94CZ@Z%JI(&V)[TH5*,>N?],_S<C_ *:A+C/7$D89I@+ZBQ.>F!]
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M0US(PR3T+@0(J. [U1/W$&6:,R;%!)^A/AK.NAH\&D,)(RI"R'N]QI^ZDN5
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MAOB@ET#$;>H!.<#P&#CQ^^A5TSTZWP11C QT'D-"7GFAR]5*Y*]"=V=HZ@C
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M9Q.0[)E>V^3YJ/#/CI:U."'1][OZQ-M0PR1JLE90=YZ)*5RPV@C(Z]0="B3
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M&4[$+N BX8QVH3(W4=2 .F?KI*U\$A<*F2#!W,DZM$XR,/*'6/!\-P7/X:9
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M;&D<47( &?/I_CC4+?6!*H XC\4-W8>E5)/UP0O7[C0JSE7"!@S!D"17ZO\
M3\ISG'IST^G4:$B$1.LF&6*(^[",HR?3N(_-MZ$C[YU/!+KB8N)+J?AXD/RC
MAQ#COF:81;L%037EZX;TY#8Q^.@I6ZA?.DPVY:P]K+U:9IDKUV9<3O>G3+0K
MVNS"I6P%=AVD;O$@@'+$:U1G&6 S7C[G 8YOBM())[<@B"/Z(]P38T<<0.V)
M'4':N7; 7QR=.D8:&'F2(5W"6K\O>A2';*WN%7_;V)'&T!>W#!39[! 7IA#,
MO\-9IV!B ?$K:9&6GBN3MR6HXX:IZ!JR+L"1LY5Y&!!9T<["@7/T/TSI!+G'
M--A&R$@> 3TJM9L3R=IK;5[3V:AV&1JLSQL@DIJH_P!M8<;@2H#D'4(LE8;,
M"74VBF%:1D64B7]HLWXRC]C=FR)C-"%6!7*KAA@,<=>O75XP,O$,ELVYLTDS
M+R='LR,K2;2P9[7)O&(*IL!8B838(VR1I"O<<^(. <#6D #)@E;J!E($*44<
M3I"LJ[HWDX]ER.ICEL*BCIU4N@8?PU A'B L<HF.:C$TU@0,T\20P\E8>=Y5
M3_5!:4)*)#AA()/TPO7'35DV)E#&>7!'9']CM*MWD[<3.U=T0(]QVBPAC",'
M!R!USC59DB/M'^H*],#U#/\ +ID?9I*N>01#[ET92J"8J$8AUV7AZ1C'55L;
M?XG5:?X8G@0K[B,3O+GQ.H*"UW/H!$<9LUWD89R'$X9)(4\8E/160^>3X::E
MP$_S*,FV5X96""!:FTQB185DG[[E8B7&T1E6R<]"=0KF(EYD>F8A)/W&:6&*
M9)(2#N[7<B,3ASD]YD#,H(P-I^VA5!B^D<%NJDDB11LL9,=<QR'NNI5U9PFU
M0FQP$QC.AU8@' JO7LN\JLZ+()D0!S@EA):<$9\ 5/3ZZ%&D:=/Y4>VKAY?7
M&T@'*&.56!40RX=6+#T@*70GR_QU4QB2YS0T8C_"B,RH\K(:DOZ7'DL+$)/=
M2S&DAPQR2,@CZD_;5QB65"8]*1AR/R5:W?\ 28Y2I9;DBQAB@E61[<0W,,%0
MLC@D?RTZRO\ 2,%R*MU9$'5(\.";L;EJ<F0TL<[5)9ED>TJINDAHR2,CY4AY
M&?H,^/AI"[? 2X2#CN7G'"<)>N7>-FLRR5_VWC?C%_W%@73?]T*=PS4566S/
M2D2=HR9\KW(RBY )QH4&0CGDK*>*O6YWDEY#C[-N]8EI6^'*"U+#'6[BBN4N
M86.LD5IF-@.5$BG PH.LTIS$BQ6F JD!Q+=JKN$F^2<CVZ]N[:JQ\E?X[NV4
MAL>[X^5ZW(?NB3R<A5@$$<\D"XC1'2NXRI8MH$YDL,TB<(QL) Q=5G(T>5DX
ME:AAY668W/FTMB[.P$E6.TM<UZL,L:*BUN3JKA2$.[)!.1T#.P%B<4+JKGNZ
M/,O1CDNU>)/*64L\G2@5Y[C5^ X<5H@*M9U6E-8,XL QY!4>7B"<R<#BA5-B
MU\BY \K.X^20U*]GA;8%=U298(/E$:K+3CAXVE$J_M0[ACC><NJ8]+%ETP2(
M!$SBESUOX<E=\+R'.GY/=AO38K->Y<1TIH9U]QQ1A:3CII6,*PFUM(D9]X;<
MVUD!&E=2?-7C&,<ES%H\YR''7HY;-ZP\E#L\G!/3"+%/%S%5.-J<?,JCNI-#
M)N8#((SNRO0P92EFNU4/3)'Q ?\ ,NE^2\;9Y)JO <8 ?;R/RIMK;6C"QXDP
M4N) E@5-\Z6U,KP8P55>@4]:K-&K:RF>J!HX9_UDDUN_))G/(1>^2*[<>M)Q
M#0P=NK%)\?%RQ:@B$'N &YE,"0MMS@#ITTX=5L,O8L5@@+)"'D!P[DAQ'[_;
MMK)-/;@NM8YY*MZ=L=J3_C563==$T$&ZQ-;@<*5&Q1YD'2R91DY/B5.Q+<7R
M?(<K)QO,++=%3GVD1>-6-H;$$$TGM@)9<"J*WN*TDC!F21%9"-W7,]2?-#<%
M<?'IKM?D:E2\W(UZ3<=4C6I)3%"/C;\4;.S62Z%;K-88DR!UPS?E/35XFR6/
M!T+T&3N!9)&0#9!MGZ,?_OT22@*HR2($\!_#3U"%)'E*PB4O&EL2D Y9!ZB1
M(025D QZ6P=2DV5Y" 5>( 42N8P_9KRU["EC%[42HLTQ28R*;2]F$[F&W8#M
M]7CJ"K&)CC6F5@VRHF3N24()8F*=P^V>0!%7KCM@9TV<@8@ K+"FP3)(P/<H
M=F9X8$WB%DJU9BTA544!X".X3T8[R%#$YZZ@Z-&'F3(C<B38Z/8K-G2:-]_H
M#RQGT,K#]-0"V49L;B!T\>FEITGZ6.:026005060XAVLTF0"#/-VPY4YVF4-
MU'7KTT*]&( .3I: @R7'9SF7LNS#8*\,$J"&K9B4'/;D,>T@Y?(R1JPE*(8'
M!1N-L9V:H1<,MPJP!G9D,<E.588&D1&E,C%([<7<*A>T4/W'\=!)D0Z2*HT@
MB8:1Q1I&95A.?4'C?((*JZ)@,@ZA0 2<#IG6@5P?)8>I/FN$^:M'V>#1&5MC
M\B, @N S0]'8=6 /AGP\-8KXU1 ->;XKU/IDI2@3(XL%Q UF*[FVA&<R)!PW
MW*6H6Z8JC6T_(.])R?ZC_P#D;_HN@K+9HT>#RHR$DL,] $P/Q&3J56$I"IH]
MJ#(H[3J#NRY!Z$=2N<:"IA5*<3*P.J1TN>XLP1[HX6HU&@E.QE6RMTM.G4[\
MFN ?# Q]=7CHPU?JQ[F^]<?<4[\3L^F!T=(:<1Y]7;_AYX>U7%1YG3,@\)9L
M= OZ>\]O(\3E>N=473C&,0>IGJ+=W#),G<VSI@$-W!D'Z[?Q_AH5WA/#-;[:
M?Y1_+0P1HCR4E10<A0-1@G0H!(,AX5&3?T"?7U> Z8./'[Z$ZR,(4F/Y/Q6V
M;:I;&<*21X:E<X:>H-.3K8/30M0E*. ."T=VY<?EZ[O#Z=/OXZ$NR%MI<!V6
MO7O'3" ')R.IZ8Z>(QH5.GT_Y0SY?T%,Z%-W1TCI9\<_M55?25IH)(TF<0QV
M'"1#/<<1/VX\8P7=NBY/CH43B?":>0?^BMQ&RJE6,R%9:K11I%&X[3(S6([#
MN"P16;:Q7!&!@_6$[3'4X&*>EZ@$-AHR#C'^9AC_ *:.*;&V(AH?QHIZ^.I2
M)DD$G-D-S@"-6VDC"C&<C&-N3T&?KH2JY6B+1/@?')3484 ^( '^&A7-D.:Z
M+XG_ /W/PV3M46)')'0CM0O*#GZ QY/V&A(W4KXP_8+3]GVKUAV6>.""1F=1
MSW(R.H<X1TCDL3 $9$:+,S';X8UHAH_)FR\M(:BTLW0Y8X3R4EB1W4B&NT+"
M<QHK]Q946-!T]4<9_$:9WJFN P?)9,@>*81)$8VBM R&9S)OLP=B3*$X(,>
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M&,A3Z0)$4;L9;'WUJ7$'4AP./84N%C?O'HTT=B2$2!WV3=MF#.(F/Z?AG:/
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M8B13LA8JQR[25))MRMU [9&/Q!TPS>&EEAE!K3-^*\YYCA[7+\R'6;:C</\
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M0=>6+-\TXY+3S,74+#9[;QI(C*56,#'I)* G+#/D?OJ1("!!S2[=O>):X2:
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MXDYD<@DY]).5!ZG! \1Y'4J"F-"%FA"S0A0DVA#N!PSHIQXELY3Z>!T(4CG
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MGZLU@/9J_M/#2S0U4JUV>6CS4W)5Q6L.!)4EFL+"DKKT:'TXSG.:SSX+?7;
MU=$N3\.:YI(>4J20P\E3YF*O8YVEOXVO>M"T)9(K[\G0K36;MR<5$@[.6)02
M X"@*":.?:DD1A<"0-(;@C"C\FEEHQ2S\BPCXFI(!7"21"*Q#R2R<?RL[V5C
MK+9S!W"(FFVIF-@PQJPA*>13)W52+QCAW!=[P$$D?QSC5M),[316)9TEM36T
M7D^U4$@'</<KE9T9]N3UP23DZ=7 Q=\UEN\9!A@%:2HZRK9D8I'7]B#(K9-E
MS/"TK2 #*X?PP,^.F)<(&+ZF3-*.RR0>YP6JVK>5+KM@1N^7&X8[H?&%'](Z
M8T8IB-)$T57MR;1W(88XP2-N6L"=%R/(IT'\M+M!,1V2C_J"T;<M*0/&N0^!
M*8OVI989*TYC25N/[CSQ0JQ[D]TN6B=E5]M;<,KZ0Q/VTJ F1JCD5L]2EMJK
M(P$6+'@HPS*C2$QJ8ZUJ61_2J]R6O$JHX4=.VTC[B/MK3V+F(44T&8^VKJ7K
M@DG\I5W9/43U)+*<_P -#>]8]V(B,1Q,DQ7D%>X%DBE+)<_5VA=O:]G>,;C/
M] P /+.JB<2=/%:84BN DP!8+4=A%KQR-N"I&XD5^AW+*RLV/HVW(SJ\09%A
MFIG,0&J7E2BVE6(2F4B%[,<:1B-7+/+( I+EAM49^A. <:"""Q41F)QU1R3,
MSINE6/*V=O*  ]8VB$L<:R;MP)$DQ+8P,#[ZCL5DQ(\9LLH14GCFX^0S2!V/
M;C5PR*B,G<(4'&3H*G@D'D]Q722'=$I>YN[L*,!+NN0F%QE@LT1D!89Q@^.@
M*,XL<D.6:*1Y%K0ABK48X8]FU#9LM, &;!2N)D8J&8@9Z9&=,F)@>)<YJK\-
MJ ",\&4>,Y3B[<ZPP<C#<:I9N-,:9JSN$DW1UU)CLO(BA8PI<!DD9,9RN-8'
M,3AFNB T0#R35>W2:[*L:P/!^W\?_N(NTW=+V7<M/*<,IP#G?C)U,)",GDFU
MF U:Q^4MW\$.I*R,+(JS2S/8LA)U6-A)"\YAEV3X(>-HQMP#@^&K3E C#S+G
MTPW,2#:<,>+K22D16F(L';+QJ3/M:5:;RB2.8/L+AEF>ODE<[,9/CJ82A$8Y
MK8CH]9)K$&V?N/[[VJS*R..VD0D$0GVN8Y)-[#&02<^>HE(2F",E"R:4A;/>
M5HX:O%0.R6,2-$D+/.9.V#(@C:$.%QU.XC5M57+X*4'O1.E9E4K TL2AVCEB
MC:*S%[A3M9%.'W @_4C5HB$L0%"A58UI-LH=C;I\7 $CIS)/7B:S(K1RS]O$
MLRNV\Y/I4C2JY").I-Z4U*%H4>!"RR2&2:&.QG*VI$3+M#D80JI =OZWSI\9
MQE@$B^N[0-&!?FG%=8V@)K.!WT5T9) X#RA'9^NT#KG\-66?;53KW G8W3=Y
M<74WLK.ZIV64M;M1.PPC@&![+ME?K".OFPZ:%N,B)F5> Q;VI"%JI5G"+$D$
MB#N1Q8]PW<4@M$/RH[Q@%3XXU9RS<%@^GT[CJ0  =U)I/_NA2'>1[!P3 8MG
M;VI(&ZX+!O GH1JJUD/@<BFS@[HE:-%VEY%DB$A9"X56?_TPX+#\NI53"/2-
M0 T'%N#\^]+QS1A26BF: U[,C[:[D,(0A'ZH!$!;><9\?X:@.Z3MZY5@ZV<L
M@6+%805^T0G^VCL!RG>$<<DVU&V' F1V Z>1(.K1B98!&YNC2 22 2HS-:[E
M98@SSFS.JHZF=EBDI)CO8*D@9/4Z7,29HYIIU2@##BI1V&K_ *9@#R(@WJ$V
MUU4.-J>HG*L\GY?J=,C3*41J+)1WD:/RB<P68Y*Y[C,KJG;6*1H))JL< ;M3
M%(RA+#H@51^;RSI4H3C8SO +8+8VUZS$1L/ 9!5P8!(9-@D;#R$NC2 +O*!G
M0 G:[QOGS\#YZOAP2T'OBS/'-)(C*;:QQ[8Y(0$E@=<,'53XC/T&A0P)?BJQ
MI6$U*$,K$U[,9C>'NA7AM/#"Y(_HB6,AE/CT.DV$B0 *I/IOXPY5GZO<0!98
MXD%ALQO%DOZATC\>RP^NG)@ &07G/SMH>_Q?9>,IVKL11(V1EE2<]W>6"Y]3
M9R,AO$:3;D.]=?TC"<QPTCYK@M)7<4%4AG8] ? >1.?'\<:$<.U8'RY3!&.H
M/UZ=?PQG0AN*GH0M,P498X'3_$XT(S0RT>]6+>K8&7K_ $,[(#C[LI&AU4R
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M*Q9Y8;,2=UEDC-A?S@%0>G33!.N.62:<L,T\EN?L/'&X9HVY$M[>,2A9:[U
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MQ)/'V960J%3<B>7CIXC$9)495QRP1:-7K8W+% L5BS)$YG8MWI:Q0B1"<8?
MP.G74]BBN1D2^2,XF2L)94@>S,L4:6D_+$\2[893#CHTFXJS?F(&-4L#@<G'
MS^]1M:YPW,IR'A,)_&)5KRTJTC%-R!JUX4@7>S+$6Q-R,D<:KL0R2R.S8"C+
M?;44XU!=GU2F,=U(P?4?-_7!;#"Y6]Y2$=F&0R312A0ZO&<K&Z+*OK!A# +C
M=Y8SJYD(YX+!"NRS^.)+<DE';CB@I<A%:!H\A'42D?931"5I[DZ0%<@R%VD4
MH5V KT)P-)ME$@,7*H0V!38BM):C,4AE@;DD0K&58) U:9I"DF>T%55&W+ %
MA@'2XR,2XS0DHG,D98"%XH%@CM/VU%B.P7C:*O83:')DI2!@K N23MSK3&7@
M$I(0*\AN15V@"=NU[;;.(-\7;L0863N';M431N6.Y<%2"=&N/,);SUM^51H\
MG3Y.8ST)+,\+KR*]RQ3L4H[$D%ATMFHMA(^_"K8!9 1].ASH,H$,X9,$9$.W
MA3ZSM8E=NWV2UKC7B9SL[H?N>I03AMKMACUVD]=1$UQ# AD=J7@>1:E<L@(C
MBM1CN5GFV+%;F+*,,F/2A(\2V.FIUPYA1\EDEH57CBFD1':_Q=95D0 K8MN)
MJD:%E/9FE50<="H\=&N',+E=&W])5LQ>&.G(\48R+S,^QFS)',Y>63:&W$*<
MYQI-<@)%UW+*3713(@B4H>)_U/@.S!4]^>#C18L7I6BA$-!3(M-[LDKVY9%I
M1Q4NTTTSV9)2% 4M@YU,Q!GCFD*2<U6DXZ#D7GK^PLFY,;*Q-7A9%"U9))(6
MP8%6165MV/4I'CJT3&4! G%"%QW(<1R,32<5:K<C!"8*#FD#+$768/"1(@*.
M$D'0*2 <Y&AJXE^*%<1]R5I8]I9 >1W=#A[-H!PK-@!S,J'=C\QSJ)],N7Q9
M2JM.5BDAL6:\[RTZ]J'A9+4L$JE.1K7OVVWQK$1A%:I9=HE \&'758:"'D<7
M0F45^[!++ WZ4DA1I(6Q%'V)]S/D>C<B9&<9'AIDNG+,HX(=6S*MENQ@;>+H
M6*SM$3$S=YPLBEEV.H[G@/KJ@D)X6<$(\;31R0N(\P2R6!&73,018T*=LXVJ
MS.7SYG&K6 F($5,92CB$=L*T('Z>Z16*H JN!UR<>)!.JQ$Y>&0\*O(1TN/,
M@JDTDR2Q.H LW<?ES@5,.<'.?4.GXZ> P;@E]BB@$,;A96[RI$J,8HW41.S$
MJ3YD..H\LZ@AQCQ0I9FD9RSI)^K'DH%7MSH=AV@ !'QTR-+-<0,,U,282$AF
M"Z+/.6&_9'(5,0#.@"E#,@EC<GH%,9+'/F!HJ! +\TRVZ=TA*PN0$-@CV"2,
M(#&9%3&R)>_&8?XR2*,?9=,256) %@K!8RUV/CY)E/7+]PHI4[3M?+IG!ZC:
M=14+)%B,E$IQAYB GI")BC/&DL4DDQ 96*82NH5QD>(<L!]] B(E^*EW#IF+
MN;P(AEDJP@;1EVBB8,D7_<@(&!H$ ^KBA'@K!X[!<;9 T?9:2!,+VP9HU+G)
M(5R<GZZM@A*"NIJSM)"C[VA!,JY61B[2;%)\8S)(<#P&>FJ$SU_X%LC#;?3&
M1/[^.#_8@80]R(A&60,DR@9#X1E#$?U.H.%.K=^2RQPD#P=1B9WK)*H06)H&
M61@VV7$M]UL1@'JH,9R1]M08"1<YJ]I!((R9;0]R6OLZQ=Y(I9 /R) C*O4_
M3'7\=6Q2E7W88)[D$%JK'*E;C6;]>N9)8=_(68W?MNH#/(H0'_MZCPU4Q$L)
M)]-]M!,JRQ*U5XOCH9A))P_%+'W3&K]J.4]EH0_<V.&'648/TTN=8 \(+NME
M?J6Y)\4HLW((<M+C-[R'B>,W!+3;/91&,1Q&,QSKD$++(F[*XQC)\AJ8U1(Q
MS2CZGN18=,@_<$-^/X_W1@BXSCXPCURP_;JOI,D=P@8[/2&1JX+/G*^&J]/Q
MLWA5+-_N9Q(LD-)[%85ZG&@VO_:N/*K7D&Y^.K.&95)#B22)WV[O+( U:5<1
M$GBK[/?WQE.N4@*1%XX#$\<>*W9XGB50A.&XTR=R'MXI0 E9$5I#Z5R-AZ9^
MNDQB9<,'3=UZC:=HU<H]>4B"&QTG^CBJK]OI]M67C*#GMH7_ -ODJXMF.56
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MR#UP(LC\=2M=E-,:!9&3V%G#CCGAFDXX4BL*T$C2 27P@SZ&9HU !\VR/O\
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M<$>/AG0&) .259*4(F$<@AQTK/>X]J\Y2..2UN!**-QA08<GIM<  $^!U,P
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M7FC-0Y4132MW ,CRSUT)4(SC8Q'A'%60.TJV/!0G_AG_ !U*O/RE&/@?P/\
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M5Z-]>#B];^]TY)!//9FWK' R6*V5:4$E3!(Z%3T!R/XC&E5'PDIEE)LL$W
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M#5P6K8W1.^%3%\?DDY+U:S$+%==T%BM R?IFNRQTK4,,LD=68)8]FK*?45&
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M!_L*]BB/AEN'G!9[+<%%Q)=N0I4/]O6FN1\F0 RH1&>@=&4E3+DX$E) B"X
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MC6.3B(%4X 8L,8(QJQ@1'4<EDL-D9&J1)$2S/A@F4^%02<CR,MNAQ9I3\_\
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M.Z3MJ,@ Y(!ZZ'(Q ![UI&WOM&F5DH1S<'X*:Q,7D"JYA$*@2-D J6!RI/\
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MVSX;"!],[QXYU/%9"3+$K%W;5V_YAGP\,]?'[:C@KPU_DR7;?V_W_P#+>/4
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M-OE]JZWIY>^1YQ?XA60KQ;(XXL( 5[8(9D&YV<;AG."Q.D' +L(R(.XC3HC
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M8J&K[/;S[X0>YO,BL,9\#G1.,8^4N%$M]N8EYQ ?L(^U A+JBN2J+'!$G:(
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MAL*KL*\Q$>=Q[,I52 "0Q"X& <GZ#0M)W5>O2)0T]X^]0$,Y9P:\XVL!GL2
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M<2RV(X*=.J]EKMA9N-O>SNUQ"_91I9J4#7]Z 2!65,$>>HTRY%7NNE?+5-G
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MJ[Y) EL5VG:-O#.<]-#KI':ON1N-638>QLUVUAQ#%:*MOVQ7R &7(Q87./$
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MT51E(.X ^':AW.;X:G&T]OE*$:)#Q5FO7>S%)))6?W<0DBC@DE[\4AZJZY#
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MF)!;FLB:%V4+(BHZ!WE;I%&&E:+>[_0["V!DD>6I!29U"1! &"FBX)9'##
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M49G!"]+XRC#Q7'TZ"-/N6E)!B#VR5FDJQUH9['9D"K#W9.N%&2 ,Y(U,H&#
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M=L)8DE93L%">1Y!(R1QE;B]R*)"K2-URP5NI]1STTR,P($'-;-S1*5XO(!I
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MGR_$V+4U.Q)76W3EH7(+%3DZ-N$&.T$M!_SQN"H4@@YT<>Q&]HMME$UAV!5
MWQN]-?*<CR''7H['RCX]S[3Q\+)6G?D^'X"SQM6BB^Z?V7QVPKA[,;-+88Q
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M#*S,2[N"LXH$#22;$<I6G7#N5V!PGZOI\!&5\3TU)6M*RE&DDAF!5IC1CKN
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MZ;CT7."WD/XZA:&$(D0S92("-T8,2.N0.@/4?ST)50G8";AC[EM'?*J 6R<
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M'0124T0EB2,AC"/#/^.GB$&<GXKSL+=W7O;#&!TO)CI+9HM0AH5="RGV< W
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M+X'0I2RF"[#R%<<?Q=*6*_1LRV%LP<?:J&>-&N)4KJ\=S)C*%P5Z, >@Q.2
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MOYK?N=P:("40"2?L357Y'P$E.:1;O%C<D4W>6W*LC5^1;M\3(_>_2 MRI)M
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M(D@/P3P@5B1NDWBY1E!5L E1G'3\W7^>IE+47*IM-M&V(M)(,9?+%,&HLM:
M!UW*EV1Y%(VR2KZXX\'&'Z%6^AU5;[]M&^0G(D$=R79)MX#)'&&BJJQ9!(24
ML2KE,YQNP#H4;BBO<-JDS/RXI>6LL5I5%B(DF]DM*V,I&C$JOA@]SS\,:DXA
M<[<[4;>(EJ,G+8M@M/M"RJ3&ID@I&21F(C!4I_I#Q!]7\=7E "(DEV[J5M(J
MD  &Q[@RC:C62#"O76W'-RDBS12;M\0F3;@D?ZA8@,#_ $L3G2U2BHW6"$)F
M!YC/^BK&6$+-*SAGG[]5Q-(2N39B,*"/KDM$K$ZG-= >FQ;QV2E+F0,5&-(Q
M&R>X"F2W-  ^5&R*JC[S]V;/34+5';QA0: 3I+X]Z05 L]98V/\ K\>HWG8,
M0NP*OG [LO\ Z8\],C,B.D<5R[:!M]Q"(+N0<>]6+T6"$O+62)/=3R3=R*4Y
MC?&&9&;;N67S^FEKI[C:QW$@9$AN2/!'$A,4B&0&/B^S_2K0E)7$T8/I[3E<
M#IY:$;?;1V[Z22Z(]2.0PG;&B)'-(0SR[6$;%RF'=URWETT#):4G;KH;!0,N
MR"2&Q"L0RD9?U21D@  R$8/\=2D7TQNAHD6#N@JH>9XR<+VI'5<9 =E.YS^(
MZ8TZ7\/N6:B_3<-H -,7#\<$A<J5RZCM*\IA@[\@,H;:J$QDCN=O 'VU%<SA
M!<SU;"4F_,WV):H8Q*KRN"T?=AC7;ABCD8&2,8&/#STXAPW!8MMA5[2MQ/\
MH2MM431O3:24@E>VZ!4WQ>6YAM.=1&(B&"T)A!4CAF@$ICPU\H=\LS$235Y#
MVS(SLD,<D3(JYP,:7=P4MBC7:_N9'R[*NZ@P*$JV8EVKM8=0"3U'@1I<)Z<E
MKW.VC0(Z"9/_ %P1N.6%I)2LJ@QW;[M'&NT!C'$Y"*,*.I\!JI+IOIW\LO\
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M)&J)\_4-M7YHRSY!#;X?\F=2$XF<@^#"2N1T/7_UAX:%IA?5. G$$ A\D/\
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M;JFR1C$$$*$WP+Y#,VUN,F/:C4&-9(@R&4"16P)E;>"H/U!&A-,NH&A@5@^
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MGHX(8HMK#LR"TQ9F/3]7NR!"!D[G(R!]M4,C(N<T_8QAMJ>A/PS,B6.>+?-
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M,V,XSCRSC)!\-&:V64T2K!LP'>M,OZ<^6]:21J@.,%"KEVV^>& _#4H--?3
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M4W5F=CN#S;!G75U+E#EJ*WJ&]*<XNFJ989()9*\D=,J[Q3!2T4RC,;?F(#9
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M"( Q?#BM$.35D-E9&':9&B4-B)PCH"$&Z1BKC()Z YU'%=2,X3\A!PX%U8,
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M= /(X(ZXT(558/:@JM$CJ6IUYF,C,^WNLD9C!;JP)8>/4ZO" EADN4?4;!G
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M!7SMVD@[60E6!/AXC4JL+.M:)1< _<L0;1M)R<G/\="W=.73,7S6;/H>IGB
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MHW$)^I;<"HZ&GQXLQX+LJ-LV^,BM)3NUX[B6/;K;A2.Y)#,(7BGF2*:=>W*
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M[D;*4WS"12#-&Z9':("K^8'.!J4VBF-5<8D1U@9C[TJD;]^/T1A@TLA1X>V
MKU)(\&%ST\<GKJ.U/1H7A$UH (R-04%%A*QDSVH67,;$AU"UCGKUR-"%.LC(
ME]S8"-$SF:-(/TYXQ$"H*DNZLBG^DY.A"I>2XBC<K<8MN&<>QBGV]^,K%V^8
M@FHE;,;8]Q!8KMC:""K@$^&A5E"$\9 $CF'5>_P_X[##0HT*\]*/C/V&C5F6
M1X[,;<(;\O'RF<23M/927E9S+.QW3AEW#TC0J]&K],?<%E7@>.XV_P 9R562
MZ)UJUZDBRW)I:M]:$K/7M\G"%1[UN59I@6WHRDJ Q5<:%R=W;1..FN+2$L<
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MTO<^>05N*>]QO$<ORM>'C_B_+6KS>VXZG6EY66WQ*5+1Y)XIQ:6[#(LB+D
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M=P-FPK+W,@''<6.5 6(P?+0N7NMI=;<9P TL.*&D4B32F/8#%<M"(';M6./
M7=U"E2C>)T+7M*ITU:)^9RH/&</MD20K4@9$697[+%U8L)5.UHGE4%&'3 T+
M2GWA#K&(UF1Q.NXOLD1X>F[,FX,A+9(P#G.A"\;_ +KAGY'A77\HI6#'(A]!
M!M%55V\9+&U<ECUP<:M&)EDLVX,0!JR=>6&)P\(ER.XDLF0<[AGTD_7PU,H2
MB'*BNZ<_# EP%KMO]OMU\OX^>JNGG=4:=%KF0SPXK:5MY;<>VQ1U#8]0.UBN
M?MNQG[:D8EAFL5UU9)Z67!$@KLC[9,MLC 5P0/61U!'T!U;IR2NH#6TO,@<G
M**="Q>QTJI-8D8C<!%617?*?U+AAGZZ.G,#')%=TZPSD5OC]J6KV565ZNR>>
MPT=7MU8Y!WY+4MBW ]=>F7W-4<KY;1D:6Z9*W;VEX?)6-=$:JMF,O^I+-#(D
MC[FC:(A6C(Z%<$_QT%*EU(YE&CA,S;5;8 "20/+[#IJ%?KRF&N)D!DZR2NX&
MQ@2/*0CQ&[\PZ^)&I"1"XQF>F2"M&I_MA@$RDN=V?#_)D>:_;5^G,XC):VW5
MD?,3$]JCV/20%&?>=Y2#C;" H_PQ_CI@T1#2\R59&V+B62%8C :547]/>6'F
MQQ^7[]-+D8ZO#DJ@O68#SE"6,=OTCU]SJ,^"8&6Q]0=2(&0>.2*WKK,;/,4X
M(7EZJH;& <XS_CY8U4Q,<#FG[:Z-0(D6<J*Q. ^WIMMTW_[2O=(4#/0[7(.H
M3-[9"S3IX/\ 8H=A1*Q52(H>\9@/4$"@[3]3Z]3*$HYJFWLA7+_<9'+CBJFW
M/8J68HV@(IR5;DENT64M1DBBW57:,C/:LV&2/<#Z=X+= 3JTI0TAO,F7CHQZ
MLL*R</;DK&M*DR4RJRM[EJ\%5T6(1-)9J?N(28F02)F,L2=NU7]+$-TTM(G$
M&KJAF*/V^W(Y(]3 !O ^&,?]-7>'3;\RSZBS/@A2(Q=FRNT_4X_B<],:H"MF
MUN,91K? E:2,$$-M9#8@4X(;KMF)\//;J<RP6S<TV6$F(PTIX0NY8A/' W=.
M@4>G'\-7Z4N*Y1V\Z^ #KN/[?P.GR.%O2":=X@.0H.V!W&,GJ5:,'2VY+5L8
MRD9-V?:O<(H'K&-708>2ZT1+H4*QL\3!6#;,[QCJ0?/0MF146B9R8C6C$[O7
M1V6W%-O<H6A C4!4)523@G!'74H57/%9-J)X]H2%;9D9G _4FC<,2&ZL=QZ?
M_#4U,"39D^"XWJ&SW-^XA90!I +XLO/K?.\A2^4<;Q9]C+5EA^,07*8:6/D+
MB\M>GK6;D7( V>.HT_CU2)9I5F5!*&QN1@"S)&O2=(Q6*BG=5;Z,)G!^?8FZ
M'S2E,J)%QEVURMF[)07CZUNE.SI)QEGE'>":J>S$D52J^]7D8HV!N)(TE=_K
M1J.FP^)0J?/OCDLUFJD-]N[0XZX9(_8&Q%/8XN2W #!'W)A/ M=XIV9#$DJ[
M2P.A,A.-@>.2[NG,W)\7QMV"C:J>_$T\=:ZT'=$$B030RLT$CQ*)8I@P&<X^
MFI5TRT#8=GAD:7-6.65YJ[]I(PRQDB'!.%/GDZA"E7IO',@%DJNZ=E."=YD5
MF8M_F+'PSX:$*VK4BT:[GZ>RNL9NI[I'#7;<6T^*F!!D_7:=(LL#B,3CJ ]B
MM#%WY%=%R-7XAZ=_.\SVO]MUC^*5]W<]_=QZ6^9@[CTW]>AQXC&DP^L8ZP/?
M^"K>)Z@QFW8(_:4BM7XI^MV.=Y8OV7W[/B= '/>3?OV?-">YC=G/J\=,_P!U
MRC[_ ,$DB7 S]@C]I3_M?B9C7N<]S*)ZNU[7XGQ<BB/NG&_W7S2($=O'CZL9
MT?[KE'W_ ()<18^)M;NA]DDLE;XOV7$7-<P2#=#G_C-56)S3[#,J?+6C5C)G
MHI*ALX)T?[KL_KV*S6/G9[H_>M15?C>V8KSG.$[?2A^*TEK_ .LV[]0?,F.T
M18QZ?'&ECKZ\!'7W_@I F^)FW='[TDU;XYEL\SS8?W,6"GQJJ8.WVAD8;Y8H
M[^[[_E^^G/N=.4'[R_R96.ILY>X?>I25OCIFM%>9Y=91QK]M8?C-%HV86N.V
M&Q)+\L1EW#.X!2H^I.J_[KE'W_@DD6O@;?8(?]3HK5_BY:7M\O\ ($C]W.3O
M^.\%)9'^SBW!B_RB-BA.<'H=OB- ^J?*/O\ P4Q%K%S;[1#_ *ES7R*K_;GV
M/'_\BYSF!'^T\V*8I?%:+1"M^RW#SYNGBOF2Y!XS>%# .).J'=Z=7LZ[C0(^
M_P#!9;Q5A]0;.QQ'VY2^:SY'4_MB3RZV.?\ D\=MN?;$O_$1-VN?_P""<S[/
M,$?S:"I/)^PFP5WR1KTQ+ZCD+_W7*/O_  68C9<#9[ /MDN*XZO_ &J_X_2$
M',?W!/.K_P 37C'F^-V5^82SCXXW[9+\?C'RII:_&MQ'=#1P/)1$1SO+A09_
MW7*/O_!5(V?ZK?\ ZQ_ZE:-!_:O_ (CRQ@Y7E3\?_P"+<!E1P#A/VK;RWM!Q
M[S?)3:_<#)W^R=O<$P&<YR#_ '7*/O\ P70L%7TT>H9]+!L _9Q4[-;^U)Y+
MY#[_ )GYBEX5>:%OW/QFQ+&]D\7Q'[_)/_\ I;#3B^1+Q?8]PD>]3@88 D!G
M[^C*.OO_  5-O])U!TC+J<,/Q9=1'6_MG^^(:?-?)3<_Y/3]T.-^,N*9Y;]B
MXG]V%MHOEIIK!^V=KW!G!7\NT>!TF7U;%@'[_P %>?0Z^)E]1W=G>V2JN8K?
MVL-SY+^X<U\P2'VD7[C[7XQW.*/,B3A_;]@1?+HJR_(FC]J%[677*E<N #$?
MK&\8B[\_P5+Q5CU39J;E'+WJ7"P?VG-M.URORE.0]A\H$PY?X_-+RHMFEPH^
M1GGC?^2Q1-S0C_;S2&!*?",@;CJ_^ZY1]_X+(!LN)L]H'V20KU;^T 7X9['F
M_E$BGXP@XG]F^+B&POQ?W%#9)R_L/E\]I^.[_9]%K:W^5L;M/I^J8X1]_P""
MLVQYS]P^]<O;K_V[W52O+_W #)\FXUIPOQV^W.V:_P#Q_P"3KPL-9K'RA;]*
MF$+-#*HL3^E%>/MLKK'CY1]Y^Y &QYS?N'WIJG7_ +*&?B_V_EN>7_<_'A$8
M/C]U_C(N>SE/!M8$/R9.*//&IN$8.)Q)@R'N[03_ '7_ '!'3PQ_#ES14-C]
M/^T9]#7R'FQ[7YHR0_VT]K6]IR7RKO;/[=GBQQ_"6/WTXM<W_P 32@U?G_=+
M.RFUN;!81 ]T$'I0=?67$=/?^"=MQM^I^P;-;<A]I4./A_M?^X\%[7DOENWV
M\HL'BN$Y0VQP[?*7_;V^0K/SXG9XODADZ2$3.XDWE%+8F1MT^$1?O_!4O&UU
MGJ&SJ/C@/^ID3D*_]LD2N&Y?G+$0X2']M>U\=AIWVICYB?<^UCB^4WBE^3Y/
MLQZVV*!C<A.)CU6\0#]Y^Y:]L!TX](V=/',1^],\9#_;S]ZJ>RY'YK^[>VI=
MX5^%Y0Q"(O8_:?\ D[6N>$)LK-W]N\ %/]3$>W5)_4:O"(MW_@D7BGZB.LV=
M7!F$6SPS*](A@^+]YMG*\ML]QQV=W <3^3M6.[@O\EVA?KGIX?;5?]S_ (?Z
M]BV-9SL]T/O0H8?C_<;;R7,$]IMXCX3BPO?[-T ,4^0,,B+)7:,%\ ].NH_W
M7*/O_!6D)\#/W1^TI85N!Q#_ .]<YN[4>-_QGA^IQ'W>^)/EO1BV<[.@7'CU
MT][.4?>?N56LYV-W1^]3FK\)[C]/EN8[_P"M_H_'>'*]OKOWC_E ;&WPSUV^
M'3.I_<Y1]Y^Y#6<[/=#[T):_QO>W:Y;F3-VJVW/Q_C5._8,YS\F:(]/X?32Q
MU]>(CI[_ ,$-9SL]T?O3L=;@/9QE.:Y8S_N.45OC'%"8'LOO&^/Y<RF 2>!*
M@D^7U!U]>0T=_P""&LYV-W1^]*I7^.]D[N6Y,2;Z6XGX]QK3";<O=VK+\G64
MG':QU"X\//0>OKP T]_X(:SG9[H_>A>W^-B5_P#W?G'_ %)NX?\ CM*+KM7O
M95/E$W7MXS@XTS]SE'WG[E8"6DN9OW1^]+15_C^R'9RW+@>ZFR%^/4F0MNCV
M;R/DZN*IAW=O([>[[Z'LY1]Y^Y5:SG9[H_>G(H.%*Q[N4YA)=PWC]BX^1<;>
MH!;Y'$,$^/3/TT/9RC[S]RM$2XF?M$?L*\C_ +I0?'QRO 8Y/E&3]LL]\3<%
M D9?W/\ Z1J_(I(PNSPP"WCG5H=;\@C[_P %GWP)A'&8Q/E /O<A>835_CG?
MCSRW*X[3]@2?'JW;$6[UA63Y/W20?-@#CRSJ9G<-X@&[_P %:D4,.F;->G%A
M'[9,H)7X#)W\QRFWR$?QNL?\9/E8/3\- ,FQ%;]\OL"I(;36=<K=3XO&/V24
MC!P88=GE>1;H>LG 5T;.#Y+\E==,?P>$5]3L,ON;)*M&UT'IRMU</#'[9)B"
M#@]LW?Y7D V].UV^ K%-FWU__P RKUW:=$V:?&(:N\_<RPR&!:5VK_+#_J2W
M)0?%?96?>\IRQI^WL=TC@:@_1V)[G<#\D( V8\_#2I=9\ -/?^"*QA^Y*UG_
M $PR]DE5]CXE^X<KV>3YO]QW<5[GL<'#[@S?[O\ ;_8%/D1 FSWM_:R,YW==
M)F[C2(MWG[ENI&Q8L9OW#[U9UH^",$':NW4CVGI+QD$L@.YMWN"W+0L9PV<[
M\-X9\M-PY1]Y^Y,(H_[IM?@PC_U)N.O\?+?I<MR2OM._'QZNW3/]/=^3H/'Z
M>6L_CX"/O/W*H&R_5;_]8_\ 4BSP\"(U_P#<N39\C.[A*J G W;=O/R.JX\<
MYZZT@QTC"#]\ON6>T;3_ +,K>H^/AC]LE!8N#P-][D0F/ZN*B*?;&SF1)G/\
M-/B9:<H>^7W+;MQ+2'E=I;]-?_4AB'XZ6Z\CSRC'4)PW'O'GZJTG/))_AK-,
MSZN(CI[SR[E-HJ8ZI6OVQC]DE"6O\=)&.7YU!@X#?'>.E_$AA\HAQ_+5WCI\
M0@_?)_DR5$;=@QEJ[@_S9+1U_C>1MY?F0W3J/CE-O\&^4J/'4Q=O#I;VHF*/
MSF>IN0^PM[U=1U_BNP8YCG1)C];M?&^/8$^6>_\ *E(_^PZ:K,SU!Q#WG[E6
MH;5O&;7X.(_9)0:M\5Q%MYCY(?\ <+M ^-\6,R=F?;O)^5D"/9NSD'KC43/Z
M17[Y?<GVC:X:C9[!'_J5:D'Q[;8QROR/9V9.]GX_Q1/;\_\ ^900<ZC]S_N"
M+<,3]R3,4N-1F[X81^]1LP?$_P#>=[E.9'_M[=\R<#QY'M-L/?R'^1B/N&39
MMP=P;PSI)UOE%N\_<G[H0Z$>N;>FX;"'+LDZC2K_  OW$13E_DY;MMA9?CM0
M4Q-[&3M9=/E#;K8X[/:PH/;QCRU#V<H^_P#!5:KZ<.9]%AD _P TQ)7^(=S*
M\OS_ '>VFU1\=I[/],8WN_RC?G'CZ?'4_NME'W_@J6#9] Z#9U.& ?/O;X_%
M;CK_ !<[=_+\ZO\ F'_'.+9!]?4_RE&(_$:A[.4?>?N5=L*&#FWK/AA%^S\S
M(;0?%Q,/;\IR[KW!W#^PT(B9-DF!B+Y',@]&[ZZ;6_YA%WYG[ET9"_G;I[H?
M]2>2+@,-LO\ *^723B*>/XE.;WC'^/VUNB2QPK]IG_TK/8*_SRN_^L/^I=[\
M$@^,CG*/=Y/D'E[5W</V*E&PA]G)O[1E^12Q%PGV&3C.N3/K?D$??^"9LA2\
MNB;'P=Q'[U[A8K?$_<V,\QR_:[UWV8/QNJ8 W<Z]?^5A6 ?QZ $?3II,/K7.
MH1T]_P""TST-X<TN:_Q[$9GY>^)]PVK4^.U"=V#L+O\ \H#9QG V_P <:O\
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=6C^3,[V"^[9O"X7&,C6>6OJ!V\XY\U>''_*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>cm270_ex10-34img04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex10-34img04.jpg
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M+#1T6T%-H22<-9U9M>!!TT"/47!5!RE[!/Z@8P/FKIV:H.W;!QH5';/XY?\
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MSQ!FS9*1C1HU524762*!<\T<)\"DAL#F[7EN[U+9K3BNG)M(SG[1,QFZ;BG
MNV9;6HZZ:)L59U%V[I4 ,2_:EJ35K6B-W3R0<*3<M(*F=K^PH$1(YHX3X%(K
M*8]JK3'VV<QU'UY:93X0[=Y(7G5..^E(Q +;UEID3?(:Z-"$J\HX+7*FRA$F
M\@B?_K;MTNJJF'L "BYNZ?!*EMJMFNUQ>RXSJ]B@-=L">1VUQ*Q3%7B?J-&<
MC*39>.'7-EFS>#>MOQ:P1C#6]3][8RBD4$G,(+ ,BH51HD@JYNZ? HZ^ "AS
MK%YP35</Z<U2AT?X^,AXBO%>JW%.^2K^Z2%-L<Z-AL@PLC7CBZS^:@; 9O\
M@F!5\D*BPF(=,?4+&6M5/@NQ+/XU*M]SF"[8S8*!TW29=O\ O59DK%T?E#K-
M[9(9U),I.CXU58R8=>\E[=X[A\#!U]V_ QS+/&0N%#&.Z,<UA"!@>6=MT?XY
M<'XT9HUVBZMRYHG,-6MDIH36TM:?9H;D'4Z!?(6STJ1A8MX:P1&OU:@QB[-R
MB(I1YI-=)U[7K)9H W)#=-\!5#JW<<SN^AUG,HRD9_9*%?;++PT9)*;'L4OE
MTZZM>=9K<+ 1&*B8O)*M<54Y15(_[P^?B06J(QR*K@5ZIMN??CJM^.];-^BI
M2]U1^:+?=/J3ET@6]D9:YT-!="Z(POU.JG01G"Q:S*1_/ )JQ];<(F>*"V1;
M%;IQB)5FZI*28KG'M7G,>G\[VZ2F[).:!JMQVK1Y[-+_ *=DKN4O-JLCZ29-
MXVT9]:ZC>$J[5:N$;!-&QWQ4EF$2W!9,PE "E2VK\''UB!A*U$ \")KL1&P4
M8$C)R4U(!'1+-%@R!_,S+M_,2[T&S<OW73M==RX/ZG54.<QC"&W\ \ \ #Z?
M7P*UN6/BWYVY)ZTZ<[&S=[H3O3>IG4LZN4?9K.TEJM7"V.VEO-E:U2/0A6$@
M5*7M*9'!32#M\HT2(""!B)"8#2(B)LI94/U$1_T^4>>+YL?ALV;Y-]!PZ]Y'
ML&69R;-<_NU$L$7I<)9GXR*5BL]8L\=(P,A76K\[)=!6$417^XF4WVS@!3"!
MSAYG+&TF%%KG_*7=HHBD"/3O+JPJ&$#?<9ZR@4@ 41 WJG477N]1#T^OIYGD
ME*33^-W_ "Y_67&'<.!=/W[<.=+;1\DG;1+3<'3G&E_U7)HS>>VVI-THEO-T
MB/B/NHR%@24/]YVF'V2'$/4WH4;&,Q-K6JY/79AY7N_;?JU_YYU/6LXCN?ZC
MBD5%U+E;0=774DX^Z3&D&M\)=2,GU!=-S2,^+-9FD";A &J9S*BKZHD3,1.L
M3X+2-LPI,O+;JT6CB_6TABFQ=A9#VA*L9CCG:0UJEW?,)++;(_HT"]1:*5&5
MKMHL^.11VLDHX1>0S!Z]; W<&(V5"7W3X%(2O.?^@WN00>8+U/;7;>'/,VF/
MC)/A[I=:!K6E*]PVCK=C8H9U$OH)Y-H3E=L:-:>_O#9X:&-'"YBR +]WZKTJ
MI\"DN9F*L=BF[^,KC_5Z5;T'N/2^GY+]JY W%I9V&=Z9QW,\K251B72L6JQ:
M7]DK,GE".S&48@B'V0$3_P WEONG;P*/K\=D#ML3OM.6U..T$\?GG%]5Y<K\
MM-\DZ[@\9,Q.1W8TS5[I/V6^6>8KZ%JLE=E"HO8=BF=,'R"BC8X-RB V)N=_
M@4>/.\4Z5S;+^N>9,:LT3F6CV+HK7MER7:KK6+'8J6[RGIK0Y#49A_$/(%RP
M =,HT]/3E?%HLNFK'*H,I,R*K9=N52HU+3ACI>(8YM;:_=>9JUJ6;97N7.-<
MBJI0M)ALTAL+VF.H3A)85IVW72ZV;1*=?\[:V%1T]<)DGCOGC9PJW.H#T%%$
MA6OB>>Y[!L,-I-]KBW,]EM?&][U2/GX^4#3'E@XRAJ%"03*JN&0# A&ZLACU
M4/*K.54EHD6CTK8CG\Q,6LKAL4^V??&]EK?HJZ](7^EYS799[5[)GV=YYB);
M-3*O5X&X75O?+_?;#-1[FMOY[5-.GXUD>169,XE@S:MC(%([5<NG:UK6Q.2C
MXYGN;R+V5I\7+,'LBR+'.SR%ON=B2.T(N1P4B;2R6*89MU/O)@/W$DR*B'T$
MWM$0&ASO / / / P)A* F#^ #_I]/[1]/IZB >!5!:^V^C.>M,O2/3F7Y&ED
MJ','2?5%?+D5RLD_HV;5KFQ>I+/JGKZD^T1JTL]T"&N;4(^3ABM6:,P@X9@F
MY3(5T8ENNU[EZ"A:'T_#7*B9"&^8WQC2NUZ5&Q<I<&N:2U.OD!HSM2BV=VHK
M,V8)VBV7+Y"/6D6@(H3*+ALY3;,?55(@OQ/!OF[=5P/.-6V_!J9@2ZD?A,CO
M.HO]HM%RA:Z",+1(ZYGS^HMZDFO+LWT\BH]$LW)*GCXI)H3[B#PZP@D-2OQS
MK&:N>KYIF^ATDE"7Z"YL@.F,6:N'#LL\WCX]C1V^P95>6+WVI)7O-9O08EP1
MPT B+^/?G**"*K!4ZY4VO4?[1_VCX!ZCZ^OJ;U_3]1$/_21'T]? Q]?_ "(W
M_I9O_#\# AZA[1]3%^H"!A$P" _00, B/N 0_@/J'@?-9N@X^V#A!%<$EDG"
M0+))J@DX1'U172 Y3 FLD/U*8/0Q1_0? ^OZ"!OXAZ@ _P 0 ?U\#E[S?V_\
MP?\ A>!Q_4?4?3U]/3U] ]?3_9X!X!X!X!X!X!X#?:I&Z--T*=A\GML/1+Y)
M$9,H:Y3E="VM*R@X?M4IF9:UA1VP9STXQ@S.3QK=VL1B:0!$7('0!1,X4Y9M
MTCU1,7#-N7I_< G9_4>T.ELGIO6<+F5'BIBW\_\ ..'M-(GI2*I2T3)Y8E=R
M:\[<4I:31C#QCAK"/7*#4BYDSDB%!F/:^_Z9&?$S>4YVKP,5TYLV[XCT34FE
M.:ND[5-Y)F/0"G]3U"=?/E7]+C%[QAYGQ&22:QS-WY4A7 J0@J#YZ/,]=TCL
M'"(9EN%8ME WJYZY7)["87**RS>X]B53S>>F(?<HC4'G[A:)&T5N_-J\QETY
M8B]??OK,DS:LTA2346JI"\;[9:MEH6A0^B?C+:K@6WZ5SMITI'1PQ$-9['G+
MQ@XA[Q#18KN2Q;._T&PPLV=F111)BYD%6R9A(D41"6W@<O>;^W_F#_PO />;
M^W_F#_PO QZCZ^OK]? !$1#VC^@_P\# ?0/:'Z!^@?V>O]G@'@'@'@'@'@'@
M'@'@'@'@0Y[?T/3LKRRA73+KBVJ4G_B4Y8H]D([K$59DK'1-6Z!SS++C7DBR
MQP2@GCN%N2BJ4@D15= Z( 0I1/[R24DSW7-GZXS'3L?N^6[%4UZE;>@,3R.'
MY=',(666T^E6J9;)[/9IS27KP;E 6RBTT9FQM%8L&T/'Q5>_ZZDZ.X4,DFU/
M+S9M%LLVJ]/<]Z&]3GKCSI<J6ZB[FC$MH4MUR?::H:\YE+2,>Q31C$+- +,Y
M>O2)FJ:*#M2%(\*DB+DR2:!,(?J/J( (_P"D 'T_U>H?3RC/K]?=^H_Z?KZ?
MZ@'Z%]?]'Z^  /IZ^@ 'J/N'T*7ZC^GJ/T^H^G@8'Z_K]?\ 0;ZA_L'U#P.'
MVD_<!_87W ("!@#T$! IBA^GI^A3B'_+X'T]?^[_ +OX^!CP#P#P#P#P#P#P
M#P/FJ8I$SG,(%(4HF.8QBD*5,OU.8QS>A2%*0!$1'Z 'U\"DE>@P5]N/18[G
M\A'%]QRWI>K:#G5^KU7A*Q7]);Y18:G8*;1,G@-$L&^VV$@:AGJ%D<RAA:5Y
M!W+SBJ[MPJ47*A07";WVB,VS!U1NE%;WW'R?8MKV_DVJ\:UNY1MEJT14:EF5
M'K>@Q$38)>N&TMW*3=JL=ATZ3F91-%ZT:$.1LT;^U-(ZZJX*2 NF':OON!X!
M1<4Z4YW?4S-V]6C-547SZ7V;-MED,W@(J-AJJ]1J&Q4ES'TQO9&*<M)Q*LB\
M&041;LW9CLP<(N@4E3R_7+KUSB=]TAV[GV7)>!:71)W5AIZ>?0FT;=T"YRI]
M876?U SR66:4.B57.Q!=<'3AN,A+)-$W+I=B^,0;UB'A1X!X!X!X!X&1 0_7
MP,> > > > > > >!$KN+3<=RKFC19O=NAI?E?.IYDA2)/<JXY;L;-3%[<K^T
MMU*U)NZW;6L1/2)%3MFSPS!4S914%$A(L5,Y1*G1[M'QBX/_ $EF=D^4ZV1&
MS8;.5.[9#8;C%TI>P8A S^.GJ[.K5*AUO"X#/"4>\Y5?Q6>).XMPX>*NFKH[
MC[K9 "31-''_ !B?#373\-5RD]^1U5KG%MUD[;G,!#5>RVLM[L5@HMISB=<Z
M?87672;I-Q8XS1)ERX7;JQAW$J_,Y*;U2*0K0T6I/./)5MOEHZDC>E.DI>7G
M7-<F'&-PDEC4119^MT)DZ=TW((^3D,S;7>&H#J5=*NG3(MD9H2,@\66?JG*J
MKY5.!QYBUIQVE:#):&:.#5-VV70>A=18PKX\G UZU:(XCFT;28.251;*2S&@
M42O0T(9]]I$L@X8*.BI)E6 A0EAX!X!X&?0?3U_AX!Z#]/\ 3X&?:/U_T?K]
M0_\ #\#CX&1 0#W#] _7U^G@'I] 'Z>@_H/J'I_;_;X&?:;^S_G#_P /P#VF
M_L_YP_\ #\# @(?KX&/ / / / K?^1/9./:U5Z!DO3_7E5Y9>3E[SO9JJI*R
MM28SEI6PC2*MH,2BT0N$+.L58!&[P<7^X_:1(NHB HE53!4QO)/!$%M?Z_\
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M2;/B34M(05>++V*.B7<!7U;)-1+IJQ([<)&760,'H4HE,(30\"E7Y_7JD?\
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MCJ%N=.AJW6FL%H,]CV9;!^VVY%\^C'ECJY%KAEY9))C'NT&PIO125!0J:8>
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M['DR>MM-F[A)MK1 2XS]IU:^TR7.Y.\$[>.A/P46C=)RDLY7ANMU/D'ZMU7
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M /35?<2Q(F,,N5-=6/8(J*D(H<Y0"3/@'@1SR[D7FC%-9U?=<IQ6AT37]R=
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MIA!R2H>QZS<-_P#@^!MI/G>FV78Z_M-WE[->)BAM)9ME=0L+B)#.\L=6*&/
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M.EI8;'L&48P9,(YN@T8,FJ#)DU:D!)JU9M$B-VK5JB7T(BW;()E(0I0  *4
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MC 1]BD(HJJ,G-2[[W'^T\!+R;D>C<?T*(@ &$/YP ?7T-]/4/]OFE<? / /
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M#SCJAU5Q+Q*+@#E<)1DDK$G>L$URJ& Y4CD P&'U]?4?+0W']W.>?^V%2_\
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M-V.]M'TD#5O68BLHPJ]E<2,JLF2)^_6T[''#(-TUSN6(OVX+ID%9,#/,P[_
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M3FN4C;1DN,WZ,KM.W>ZK7.H1.?RD]W %LB*IBGY'[=&,9%]**/(]!)(5FQ0
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MOY*P>\X1#TV2@'<C9K1#W*+S&*0FSVUM/,(Z*?1265,3F(,8Y!THZ<B)B?\
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M.^.;GM+?[KGUPTJ.>7NN4!E7*<M'L'(25@;2K\LA*S4O_P"*V'BVK&%7 %%
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M4 8P[N1A&:RB"8%(8[1'U#T3(  K/3Z^OJ;ZB(^GO-[?4?U_E]?;_P W@9\
M\ \!N*9CN29S/W6UY]EV>T:T:5-%L>B6.H4VO5N<O<^4% +,W"5AX]F^L<F
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MS =9LS9-U'40=?CJ*XS+]\13.8'90E1(R425(N9,Z*H$%IM?3^'Z?P_U?P\
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MC]Y>&CW1BIN7(#]E%51,BA@.HF!JIQT(Z-;D=)M6+%NF]<.';TC=JW2(]=O
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M7+<]7SS(*DZDT(5M9-(M\%389S+N4EET8QL_G7K)!R^,W;*JBD03'*BD=0P
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M6>W)!/\ >J63E>E9\L^23%=CA[_)'ET1"*66()D(2=U^7MAW1DS FX>,1*H
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M["K@\?(U^\5 [*39E77:'>QQ5DC*D!%8=!^O / /0H?[I0*/\1#^/_<(> >
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MKSLZ(J5G9.CG2**[AFH+7L_J]=)%PQ<*HO&J@-]H,1%=B[*<JJ9O0R2@& P
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M M7TSBW,,?-4;6*\X2_>EW=>O'+43::3H\6JX3456<,V<H4JQ% -[5"F-/\
MYV5W'5F_9]2XX&(T[G[CC$=.A\HT_M)2E:-K(F@ AY7G3C95.:+L-L:J%B+Q
M8&?)CJN0*.LWB"2%%&?=LR6&39E^V#A5/Z:_!ZL:>=EX?5;[CJ6+ L<T38'F
M*7'NC1;GK183^[U["6;%>3YOWQL?'QNJFRD;7+<LNJPO)1T.W9VA2J%D#OD&
M:24F9F5(A%P?@]7_ #3X?4YHX$6VR_F72*;L5F4^0.X6"C5U=AL&NS-FQSDY
MO#R:I&\E7:YLCAQ8^6&07UA)H51U&0UICOW!O(?@'9LGBHI_:"_A=:O_ #37
ML^I<<%FW*\E0W>-5Z*SS29;4H6G+R%)=S]DKT?3+5&S%;<F:.ZM9Z)&U*@H4
M25KC<R+<L4,)%F;M2HF^P!3E.?T^FZ.71QF,LN:YX5\V2YOFU9;F-CS2HWRX
MQU;LNQ7$U S*(>I/E75ON)(A]/'@HW\-HZ23<DAXQ=P8RYD4@(D/J?U^GGH#
M1U/M[EJ^7R_9A2M?@;1?\TK]DM=IJT/'69U(JUJG21H6V3=0$D#^-I#"M39?
MP7QZXI*_C/C%;G]%C%((2/J=IKEYK$#=*A-Q=EJMHB8^>KE@A'B,C$3<+*MD
MGD=*1KYN8R+EF\:K%.0Y1]! ?[? WW@'@'@8,(  "(^@>XO^L?Y@_E#^T3?I
MX'G^Y\^.#3JO<NCW>ZY6UMM+Z.QW3(/L6M1%]KKB'[+W5]K\A:<NU[-(M%]7
M'F*/8?/9:29./RGL 5LZ=,2II**L3R:V8A/:D#B.6;-Q6_LFQ3U-L^Z:OVCT
M_C5,OE9>Z_(7"QX7AT-7W-$H;:/N=DKZKS7)#+H8KR=L?H$:V'\^040<F09$
M5=6(I3Z=NP?3>@25%SO*^>ZEM.)*?^77K\;8]KA,J7N\Y799G)47,I!*1IUP
M<CG+B79$D[&=-#[TD@@A'E*9JL^(HFQ':=XNVR>TZQ5)S6Z^VRS6.[>?^^KK
MHS6X-EPJ<ME5+S,UQR*.KCI%E:)F1FM-QV.&+D2-DV 04LNHN=%TU(W<2I35
MM.5.,]<R:\<KL+K76C.B<"Y'TMF&=VB-LT/)R.ZK;5<:>2GS#.!3<?E5-K Y
MI2"!*IRQVRHS[_[;<%6B NE+7A!!><2\H[12^4,;S?4[KJO/]TSVS[X[G:EE
M=US*5B+.QTK:KMH-9D)N</4KN+I6)@K"B5%)FY8_:<JN"K%7*"1@1&BMOU-S
M=L,Q1.5:OG+Z];Q)9CW'@6]7FQZ==Z&QL4?GN=6)>7LID7Q(FE1DFN@@8H,F
M+9F"AU#G 3E+[1\3 ^D^AU'(]?,]/T+!\T;\_9(K+Q>::?8-]AH=IG-*DZ^<
M-9W";H9*0\?/=%L<6T/#1B2TJT9P< 985%B'?/P\:VA8?'C6I)EG&Y:2NP=Q
M5;Z(ZVZ"W[-X]^S>1KTV9WBS-6--L2\8^*FZCR:#&U[^I44SD3.+>93.<A3F
M,'B%3[\H/ / / / / / JPOE[^3EM\HF646B9;G:OQNN,O<RFE:6_&)<68MM
M"-L)G22+X\\ULL7:&UE"(:L(Y".<Q[F.47<*J <#?8)K[EI_A7G8_P S-C.K
M;7P/G]>Q[,+[K%JC.H,^FG->SFH3UTL+*"2HFG,7LLM%5UC(/THI%X[;)*K"
M0$B**I@(@)@\DI+7?Y8_#-EPGAS58O:,ZT'+)JU=-VN?A*CI%0F:5.#!-\_S
M:$-.MHN?;LI%6,D9*+73(L*)"&.V.!1-Z>OB"-CRT=5_';WO;_D>WVZ5?C3I
M.=IMD[:O-H@;?'9+;5ZM*UF3V]W*L+&TL 1X11X%U%JE<E=_=!#\<?N"8"_7
MR,[WO([FFF\7H?Q]KF9SD@1EW'5Y.5-7Z]-V(8:!>8/T!3RV2P#"L'I8&K-+
M';(]JXD7AD&B!W1/<?Z^:;4LRJ.Y4;D68S'-X7M.O:?&:#\L5H3G8&O]1S,6
MAKT)I-IN. ,'S>KMVMMGK1:*M+-)6G/SS;?/SJ$D'$FG+OQ2:#&=Q_LW8[M8
M^>?E,U'-9O3,8UBJ=?53J*ER4]%VO)6NC1^<<S\Q7^P4BSC:HNN?DTC4(NM2
MT!,$4,@@R7<B*XHF0$H%3GTE_P!!VWXN.F],8-[;&;WL_.V]:W2J0Z>+O+#F
MP:!0IN7SK,(4C=0_XMDI-*-'LE4VIA(>PE<JH_54 \J[C>=6&K3W&?BC7S*)
MD)BB,.ON*[;7PIE9G+#&0F5PM!L:36R.?Z?C)%*#J,5%3#$IWKC[+1!-8@&.
M #Y$-[L?,6EV#K*.SS#;G,3V=:/W5AW=O3*=ES&61;8>OB-3SXS:&I6XJSL?
M7YF0UJ8S*N-FM90BI619,U)%=9TU9 4AP97XY<;T6G]FVN:N.<V(E!L51ZFF
M)'+;S3KPWKG %M?=31UN9YMCEILS+^BKM3NIFQD+BN>.4>+IR$"#EF=M&';M
MP$+$LO@.H5L^M&YXW6,C:ZETOL%CU6W0_1B^@5-Q7<I:1+2BX7744J7!2TVS
ML$5F53A7#YB^11!N_D'W^ZJ)@-1$#K*3-T[J5IYWK>5[-6;5EN9=&T'#;3!\
M^:O#9G8^H>@<"OV>V/35-<>4V-SZM8UGD1=95F,@O*@O/6"557 AP8MCOH-U
M@4?,SEVUS<(RI7NH9U1OBQPKFRPQ,_0+;691;;J,KL%IM%1B*T\A6LO8W^91
M$VTCEU6#=TW_ #9+\5JHJ<JI2@IE]<+E/QQ\>4PN=:>MI.I\MY=@;^=@^=]6
MTV7Q*##(JW":I8] J-0HTY;F!:HXCSHM()TW0"9L)&B"@$;$<.FXW%)0F%<@
M>JOC+K^&5R_5"G5CB'H2IV&L7N#=UF\1_/U61Y[@LC2TRMS*+:=AI@EXBFIF
M*+U%N\(JL\ R21Q<IEHN!$?4?4/T$ '_ )@\*QX!X!X!X!X%>&DJRJ7R=\N)
M68A#41WR1U2AG)G %,U#9@OV!N; 5#WC[ GCY.@[_'_]2BQ!^!/^']_R;Q#2
M6QZO[?=/F;HUZL=]R:K6G<.6KO7-284"RO4T'^18EA\C&V6LQLA"I,=/AH/3
M\T-'23&/,Y*[!NJU]Y!434\!OH/$MO2E;SWMK%QL5&VN2Z_7V;G7-*GSS<+$
MOHM.@>7G'*=8K5NYY3OCJW5BU[/3DW4BF#NRLG<"3\)2279@#MJ@[PZ.5XQI
M_..:?$3E^OMWTKJ47U7KVK;$:E5^?L%-HL_L.0]7V2=C7$K!,9:(KM3K-_VM
MA7FCETY39G543!)4Z8^\ L.C6W=HV>/)99?D=6@'FVY9XD% ;0TN)ZL=X!7R
M<.X>6AS$(6$8TQBHJ*E,W!?T,8OM^GC45<\X8I;,8V;,Y]_<;9=>*OCVY[VS
M*\]ORV"WJ-TO0+3MND4MTI4TX6)4M$[N$-C56SY@#NP0]<CV#F3^T=(CM9%Z
MJV?H)+\8Z._QRRZ'4=(?ZG=*SU!V;IC[G/8+7A\Q1YN])RF2U:^6%?6#1M<K
MD-5&3*Q0DU6Z@]D8R$/,Q=?02;(*IIIK*('9^0;1J'*SD'S'9LKVR?I5_?4?
M4MNN62<ZZQJ!YR(S*Y0%EH620EAS^DS4/_>%?;55V2*KJ2>MD(&O-ESF527<
MLC%2(473!]JN4_9>9X*.NL'L<G\F^[];(Z,XK4\A583"+_SUI3>FW!QH:##^
MFRJ \O,;2@8)/3OR2+19 4?QT!4\@:>>Q/8-3H&;3M&SC1H]GRQP=PGC^ST^
M1H=B@I:>TC NN,>V/5LIK$-*1C$^@R]*SS()M0P197S-T>8:(M5%5'GM\"U#
ME2N;++7/M3:LT6@ZS1M]ZL:73.4=;H]X9GG:54.?,7RJ0N436DY:F3L.UL]Z
MHTD+99ZD!GS-JFX*3[:J2A[ [O5O]Y+>P<0!H(0MDE&7>&=3KASE5!OJD7 5
M%ED^P0SJ:M_O=V\T+'-9ZQM$%)!TLU9$%TD4P@/J801F<Z72MC[N@)0N4;I5
MT.?:QK.'X.F]YQU2E4%5M90K,OK>N3&CS=,K^=1E+FO[O(NNU"-;R"[E\8%G
MPH"5XW_&;P[7QJE?$QW:"-E%SYX7M'L4N,^\Z)V1,O#>KA^$C!&0$4QK2%M_
M>"1_M$4P: 0$_P#A^SQ L-\H/U\ #ZAZ_P#DPE_T^H>H#_WO CEV)+SE>Y&Z
MGL%8EG\!9H'G';YJN3T2\7CI6#GXK,[,_AYB+D&QB.6$C&2+=-=!=,P*)*D*
M8H@(!X)V/RS6OR8?(L=JV,?NSK8PF;HB(FWK1A$1%,HB(C^_?41\K%R^A_DI
M^1%0OM/W5UL)?00]I=]TD@" ^@B _;L!1, B ?0?4/IX+E[\/C3ZMNU$^#+,
MNO\ 7'6B[[:<]Q[9M1OCF1LQ9O2;M#4+2M'<20$L=PD )(2T?5X?VMP=N2E,
MFV(B!BA[?2-;DW:7W?4G&SS6(;)2I;"+.RY\B>H(RP6ZU4V7S:7Q]]94J=)2
MJMUBY-)O6)RNV1T@W=,95!H"I5R*-E5R ?VE2*5Z-P%K2H?2'>WY(PSVQ?N1
M("\2>CTZ.J4PI"E=J324;/O9IO%/%X0D>X%XFFJ91K]A3[H$$AO0&9YP[9RG
MH#^M8-[/46@:;2-!WZK2>4/=-J\U=2T_!M<L^3R&GN8<AHN68U.=<UTKP%CM
M/QVA'14S+J>GW#9G.(FM0\L1T/A%BI4KHU>V7,)FA0<H6#F;I&7BM2-8BYHZ
MC,B<.^F&<FLQ;RSC]P;BBV.<%EP<)"F4P*IB;/FX[-? ,3B?<N'ZYS_4-ROU
MKSC**IHUOUBE5U"U:/6GE=L;;.-.MV;&E8FQR1(&/G8BQLZXE)>]-#[+=N_3
M(H80]#GZ1-I:2K+7<L?Z ]RF/T&F/=+C8_\ =Y"AM+'#N+4RC@19.#NW4$B[
M/)(I)-9)JJIZI^J:+I YO0BJ8F*:B4Z1<N-/V'-,_P WD[^O@^=H6?1YMM88
M* 8-]!L,*%IHF,P?[R=)*0M\]42?NT@Z<+,XZ%9/(X5%%CO?8@#&E[Y5L.><
MES6;8M(7+5NN<,FNAJ?D3^^0E7-7\^J-'I]QN 2MU7B9..=SS)WH,+$,&Z30
M$GS]][E%FK5)9P0EF4L/R[96A)Y4>CT"PW6NZ9C?.FZ-CN;!%5F^251Z:UDF
M-TZ$R[.'+*2<ZU=Z79S&6M<>V?L$XAH!/8LY6533$6?/,N_ZSI&H9_5BT"0B
M<SV?3M]Q7$-;3L\9)-[UIW-KFTMM!AYFFIL6TC3XN;+GUD7KSPSM\,@WA5!<
M),3KM2+"U@_A1X!X!X!X&0]?KZ#Z>@>O@4#?))_F <!^/#>$N=ELDONZZ3$P
ML;.Z"WJ4U#5&+H+>PLF<M5XIQ*61HX3GYR9A'A7ID6A00:HG2!58%#BF26DS
M2W+E'IK->Q^>\RZ0R)68/0-2KYYN(;6&,4B)N,79R+Z%G(*88',JD22@9V,<
MLUCHJ+-5CHB=!51(Q#C5-5VS5^/6E*@M5Z\I*%DK%:L%;H,#)I5R]6>18SFI
M6J$J%;A6\3GQ5YE<EEMTBP9)B=!1$CE=/U,0#B/DF(G:73I-_C:X5,BBK_AT
MJ*0+$2^V11Y<$52%^ATT3I'L0G343-_T!]!*8/T]0\G)CP+)RV_%3\>]T;,8
MZR\TU639-79'A8\T_?VS)^5+WB>/F&3*VM6\_ N@5-^3'/"N&#GZ?=2/Z!XC
M'&-A.J3>%\Z8?S="2]6PS/8/-X&<EB34K$09I(6CR818-HU-T8DD_D#)*I1S
M))("IB0A4R!_+YH?.<E<2Y,S!1XX31H.>M+ 5G#5R"8S<T=U:="M(EBZ;0:?
M$I2DL^DK-;)S[,9!Q+8R95%_MMT$TBB!0[U:W[)K7>-:S:&LIRV_!XZI2FKQ
MLM!SM>9TV/O45-S5;=KS<[&QT!)LWD57GBJB[!RZ0;@@8JIR' 2@#)L>_.6I
M.FVZ]-M ?-:U2X?/+*[)-4.^PDY/UC7YT:OD%IH%6F:VRL.A5S6+1_XK*Z\A
MFSQ"3D!^PF;[GT\#43GR-\D5:N0UAFKW:Q4G)_2*RM5:_C.R7/0*W8<B=,V.
MI15[H%(H=DMM'7HS^1;(OU95HU; =RC]M50JJ9C!("-Z&QR6P>,Z7;W-!+#9
MF@1>G1=XD8J=C4'M(FX]O*0LLA R$8WLIUY=HZ1_$9?A?G.55DTDD3*J$((,
M[6^_.6;AG\WHU?O,^\9U_3XW$):GO,RTV#UY#7YA!I(0>9_W-6"I16IGMTQ%
M2*4@T:_M/_%CCF=E-^.FJJ067S?K'GYVA@DBPOA)!KT]/OJGBC^.KEJ?-;?8
MHF!F[)*P;UZV@U&]1DXF,K4A^0WFSQZR+ADNW,4'"1TR@T++ICC.H]16V@,9
MYRAT9I2ZU6E9,:)IS]A>[!E%3=V$V/U#3W]?<9S+VZFUM1V_&G0DK^6BY7>+
M&9_F*.C"$M\ZT2EZS2:_HN>6!G9J?:&0OH>7:%<(_=(DX69/&CQB\1;2$5+1
M4BU6:/63I)%VR>(*H+IIK)G(4%IX!X!X'(2B'U'T\#CX'C-_S%GR2]<\D=B8
MME6&W:I5^GM<=I.XQ1)O,Z3;)ZO:BCH.EUXMGKMHGHIW.PJBD%$D9K-T%RM7
M+-9PW6340<KIJ9F12LK_ )C+Y>E2^W_$K6D_J @=+",4*</3^!3#2# 4!#]?
MIY+D6^?!)\MG??:'?T7B?1NV,KUFBF+:A;E*ZTS?.:H92=K;FIDA7)I2K5F*
ME?LL_P!T6'[(+ D<3_S%-Z!Z.:M9V#U92O8V5QNH2.7M(;2[&K7]+I>,7&]5
M:B2,WG%'U6_LX*0K%&M-D;*@LTD5F=KB3NW"+5Q'1@RC8CQP@HI[0GF8[-XE
M6;V^@ < 'W#Z 4Q1'W#_ &  AZ"/G0?/[Z1@*<I@4]3>A!( F$3>[[9O8/I]
M?:8?0WI^G\?./G]/O$4ZIT/D6J6VG.*]0K];))KM>^X4RN1LKD'<;EU\QC^I
M('27MGLKA$X4&NV!U55HJ-DSF3),K+(H)^H+  ]8FXL/'I6O9?C?]"FTJVQ-
M/#3M)JF244TD94A;-I5V.[)5:JP^RDIZR4P>/5^V)_:F'VQ$QB_3RAS?:7T$
M1+Z>XX*#ZD'ZJ>@ !OH'^_\ 0 _M\!H=5VZC8W(9:QN83H+ZYJ-7QVJ+0\&[
MEFS:X7%O,.*^2P.6_HG!1#T81=,'2O\ P_O>TG^\8 \#<36DQT#I%&S96JWY
M_(:!"7.>0MD/3I.1H%:3I!8+[T=>KB@7]MJTU9 GBA"MG _<DA:N02_\0F\!
MQOMD R@^T ,J  H/M$!4 /7T WT 3>GN']?[? T]@@(ZSP,O6I4'8Q$[&/X>
M32824E#NU(Z3:*L7B365AW;"6C%SMEC 1=JNBX1,/N3.4P 8 ^-4JE:HM9@:
M;38**K%4J\2P@:[7H1DC'1$+#1C<C2/C8YBW*1%JT:-TP*0A0]  /XCZCX"@
M\"L_Y3OCWG?DBP*K8G =%77G!S6]0@=$7LM1CG4RA8&\1&3,4,)-13*R5-TM
M^(>8"08*@\]C>0:(G,F?T 2DF+6$TBMJ4VE5"GJSDQ9U*I5Z_6U;+8G /+!8
M58*(:19YV==@  ZF9<S47#I3_IKJ&-_'PI!=%T":U?GS=<MK:C!&Q:5CFG4"
MOKRJZS:*0F[E29NNQ2\FX;H.G"$<D_D4S+G325.1(#"4AA "B'@8;_Y5KY+4
M6S9,UOY4$Y$4TS@73KU_*8A *(^HY2 " ^GK]/+;'++M)_Y5OY)S']JETY42
M+Z%'[G]Y=\.7U$?02^A<J]_J4/J/T]/[/%KRR],D%RYI?'OP1V;CC0I>CO\
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ML,@*AW+CP@O1:%_@]Y'_ /&5^<A^O_QD,S_\Q?R\N/"%11?TWF>,Z>O?/:O
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M=/@>@K+'&#>&>6!E4G8X&TW1*L)5B0DFEDGJ_$5-W,A7AB7%K:E>(N'#$TB
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M_P!+C>EY^ZVF-:[1TI7:=4Y33<_SNN4F%HM3SF^-=1I]0KU$1?2IK% R%]:
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M#U[]U3<5B7,\DXTGHI*1L>WFXI62A7;8C^/.[8G7;*$*L)B_4EVE/X5YV?\
M,96'H53EBIYIBV)/-AI]TGK-/;VX)CTAI$+4,LH\ C*'>+VMH0R.3V20EW!
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ME5;,K2(+^IK6FV>-F2T<S/#P7_6# Z60%4H""7O, @ ."("'U$!  ^HB/\/
MCI=NM^:\WC+U-WG9:1687-+U5\PO,S*R2J$/7]'N98\U<H;B4(W49.;>_P#W
M9J!HYN=9TW,X3!8B8G* AM] Z5P[*;A6Z#H^C5^H6RU_M1XF*E3/A!%O/V!.
MIUU]/R+1DXB:E&V:UJA%1CF679-Y*2]6K8ZJX"F MKG75_.3/2Y+('>MU=GH
M$,[E8R3B':CQM'MYV!J*5_G:H-I<-$ZD>Z0=#7+-O84CXTLUB!_,5;D;@*@
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M4KUECL'LV]2V N+,M%S80%<0EIH(D+!/5=FM'R<I4HT'R)7<8F)%%BHG /\
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M?KZ?V^GZ^!Q\"J7Y@N\,GX.YCC+-LV%R_0U'VJZ?W(RN>1LS$P#1RTG:E:+
M_>RTE*MW14FQ&-=.FE]@@.2N%"'3.F8@'#.67+%I,THJ@O\ -B9!7(6%@6_$
M>OV!*#B8R)0F[9NU0E[+(IQC5-JB\FI=S2W+J3E%"D]RSE10RJZ@F4.(G,8?
M,^9'!GG+"N_YM#*IR9K]6'A:_,F=@G8>OG5-L=,5;-$YZ6;1RKE1F%)12721
M%X*AT_<0%  0$0]?7QYD<#G>JF];#GV:W+)L_M;J49V7;K1*4K-6D?5[!,LI
MJQP56EKI)QKR4AXQ[%UT&51K[Y]]V15:H&;LEO8<QB"7SI;;;6K0HNJVW.Z@
M^K]TDW6ER=CC6$W 5"7G*E6%*S6)"TNGNA69D@I$TB-D&D<9JP</U$R/)!1-
MLD(J' /,9]3'#:$?7^BLEMNLQ&,5FQ?O]ML&+MNA8%[$L7+^GS>7/;2A4&5B
MA[BV(I 2:CN8<IBFB@LHH+<Y5O0$SD,9CG&>RP]1F[<B/L^P@9$@%,")44S$
M  ]1*)4O9[ ]/KZ#Z>;'T3 B)"$3(1(HE]Q4BD GH  4! $RE#T]@>@" ?IX
M# 0$#G&0ZK(M(NM79_?.CYBT72VZ&XBYVT1X*4*-BF\17[9=%"K1])KT-"S)
M&-5AS"W:&!-U^.F9P=VJJ$@1^@>H@(!_I 0_3_7X$.=![OYVS=.Z&EI6_6-:
MBW1YG<JPS;)-,U&5DKI!P*EGNL)5XF@5>PR5H_NUA"%4LSIDDLQ@5U2-7:R;
MLWV EPEPYS?>W*\+5<WO(:86;INIYV78ZY9JO7;+9(F-QD%X-DYUZZN(F*<C
M1,ZCY*R,FKJ1EBM"-UU3E.  W="@N"X.--=/8E7-D4P2=N(Q6F(8Y8-_=QS^
M"L#2 :9'5IB,@IZXJW9Q%ITQ1K&2,NB59!)^HZ23-]PZ12>AA7%UO4T5)^0S
MF*_QFJRD-.WZ-+B<)6KCI<7<,;U:AV>O9Q<%'7]-ZN2I7*H0=FF<MDV4:\=A
M.,6CEDDT8.553$!$_HN)2X308/6<HQ:R<<Z;/HY^V0>,7S-=%TS>LW21%VKQ
MFZ;G5;NFCI!0ITU"&,0Y# 8HB @/E5VO / / /\ 1_ ?U\#H,HJ+C5'ZT=&Q
M[!:4>&D)-5DR;-%9)^<A$SOGZB"29WCPZ:92BJH)CB4H!Z^@>!W_  (ZZS@/
M*6C6F"M>\8W@5\MCE-G3*U8=:H&?6:>637=.W$;4H*3M\8]?K J^?+J(,&YC
M>Y58YB$]QC"(-LYY7^/**MC&AK<[<:QUUFXY::C:4OD6(-K9)Q#0%".9>+K:
M]?)-/8Y 6YP4720,D3V&]3!Z#Y*@.-G'-?*=3GH76L@PSG^N68D$Z8UC1LZS
M+.H65) 32)0=HPEKJ<*U7-%2R %!3[*QDUB!Z#ZA]/*(TZ[Q1H^D:Y/:C&VS
MEULK)R-??M0O_*]BO5D6&H+ XJ(W"6A^A:36KVM4G)"GB%I&%.M'@4GVQ R9
M3!F8RO28KV!#S/!6Z3SBS2$GJG)KB8MVEH[+.3A>2-,:SJNKMZDQH!- C9MG
MUVC*URS&HT:A#J+QJK3[L806ZA3)'.4TK/C'A]5*QKR3U<Q;9FT9[OR(V0Q=
MRL]R--/A9]_YK-XYKTI4G3NE'/TH=2!=.ZQ-O&"RJ E45;.5"G$WO$?+66Z8
M\/JABI#XK;A)R-EEW5DXD+*7)EJ<9:I!CQ)<HAU-Q>XI(I;!&NSQ76#,I8[1
MOL I)MD@2067.HL4I%EE3GX9=+J3.V-JZ%R_^/;999"6;26@<7JHST-FE>GO
MQ^*;@R4G87&'T1)9(RFU8_JQHK+_ -W+V 8GAU7)E5V0-$B$.!" 4)Y75G;/
MQ-"[P?@J;R/>H;<9EURD^EF+O3Y*0D,RY<LF67MQ*:X+=]>74;;7&_7B+BV]
MHL3%"0DFW[2H@X< JHF""[A98_;#'/&/NI#[3O'F<V>\;N\L[2,M.0].PE:/
MN6+V.+5>UNVW^GQL15XF[HKH2+3[!9VC0K**GH]9%=M)%B6"Q12,FZ!UT&8K
M@WD" HDWF=?P#/J]2K%:(Z[S,5 1[V$=/+?$1QX:+LG[_%R#2QMI=A"JJL4U
MD7B9BLG"S?\ \0K*D/*@+65Y2YXG93.9:6R>G.%\CC8*$S=JWC31T358.K2$
M;,5:!;0L:NSAI&!J\W#,W\6R>MW36.D&R;IL1)P4%/*':BZ15H6SVJYQL*R;
M6F[(P#:USI"'-(SC:JMGC2MM7JRBB@?C0C>1< @F0"$(9PJ?T$ZAS""I] ^@
M>@>@>GI_H]/T]/\ 5X'+U']?4?7^WP*O/E.^/6]?(IEF69U1NH+SS$YSS56&
MAR,S3F<F_3L[5M&/(Q-J[;0]IJ+U.8@%7?YT4X,Y400=D]3HG$2G3DQ8LN@X
MY2'A(>(6DG\PM%14=&JR\JJ5:4E5&#-%J>2DEB%(15^^,D*JQ@  ,H81 /*$
M9L5/=Z'DFH4%@C$.']VSRZU)@C/D44@E'UCK4I#,@FB(D46/%?DO2_D 0IC_
M &O=[0$WH'@>(JU?Y87KNTUV+5>#R;#WYNN@F^EL^MMLH]4;Q#1$4FS.$I@9
M5+LUI-8Z)#.'KERFHH*RAOJ*295,\H>/,/@(^7WE(CE3COO^K9HPG2QTK.UQ
ME?M)I,>]L'X#%!^:9J\94KG2Y@6BJ:B*#TY#K+MDD?>FF(BFFJ=PONU+.^H(
MGXC;WBO25OA]2ZLO& W'&;S?Z75] M]?GK?H!9NH15F5@\QS26NK]E'UZ6:J
M2*K*N)^]5!4XD2(85"W=0K5T>B,;](;C8:3DLCSR&G<'V;D9SG-$Y@[-?U+5
MKK/R42O7M-V)W%<K5>,;QV1Q24FUKZ;6'DI5T69=E<.44?MH@H.SV.=UN,G;
M9/&(.UTMMJ/$=_Y*N,5?>..U&S:I25AMD7=X>VT]*F8,Z;6"/6?HNF+I%R$8
MHW*9%X3[XD.T.U&WBI A;Y/V*2B=22867Y!YKK5^XAN4^RB3$=GEBX[>\SR$
M)"J..=?4+ZVF9!1Z@"IRLRQ_\OY/WA$OGGRPSG*9J:]W'VEF/R^DSM&QBI93
M+TBFHV/+['RA UK6*'PAV]5KUJ.8<T= 9WKR<CKMFEL,D'E>FI2!H'V"0$=^
M;"_OLDYDE7B9")HAWQBHUVBY;9*E+5GMSEWJ5%A+R= 7R;7^7[NJP8/7ZE&D
M-:M.57W,[I*1[)%P\;5R2LN=JP,@[,G]M@YE&*BXIM_O+)7>-[6>?+DWU_N2
MX7ZK9=?<TZ;B\T85:AR,S)O@L$72<G5SF?K&HQLQ2%H*/B+>L8?7\89<B;14
MQ5$CF#T,WB%G_93R#//M$78CFSVW['N&$7O6<.EYR]R7/-OY]P2,?5ZG\BJ6
M"SMKC<5:"V8R2LPY?N(H[&1L >T89O&"5FFH2/Q+BS1,]Y]Y4YYME[B9^F8O
MKS_2[O'GFK/8/_+1JEJN-_P'$JC,V)D,M8J9D%G?UEJD]E?Q%W,;540!!/[W
MVD@E)E%MW"P:GT'"Z13*U!9?4+548[";;"&GD):\P4A3F$C<_P"J8^=]$QDJ
MQ:E#MDGT<4(QVBK]M,3+-ES>42"\ \ \#(?J'^L/ JDFLW^4%7Y5H/2(;7*$
MU^-!OF(,9C+SJ0XV5Y:1JCYLY2&*/6#6 UK6T$[=^C*%E2,4H8@MC)BI[B'S
M]W-_VIK?<M:\TKS5?YI.A6*]<!YA_2=>M-JFZ[U'1Y+]EJ=8FK0^-'O*!ID4
M\>N6T&U>.6C-F=ZEZK&3$GO.4@B F 0QU-C.6QX&/[D]M_\ C)[-_P"<GT'_
M ,QSSE4N91TS%MK)=*4H?%=E*1.YU,YS#E&@@!2$L,:8YA'^G/H!2@(CXJ5?
MI_\ ;M[@J-N7Q_VB;3EEH.F= Z+;K>ZAXA[-*5JK/N8-NSUI895C')KR!8T]
MSO<4Q 4DE3BHZ]P%$B2IB=INX=),/T'L]4Z*T/FDM>&>99VST'JBBWQ*T3K:
MG0D_3I_D[1J?!66Z5YS8HYS&4BRZ/86T;#J3;9!=5TD#I%--$Y%AQU,9RF)B
M-T_0E4A*YHU=8#GR=+IFC9_<\=^&I:E4"(AKE(TBRPW8U+UFK2\3"-"UF_$4
MF;@:V0"\W%LW2SAFO'*@Y!$$%?:$QQF+N)NOZLUI[DUY?7[6AT>DS00T>R,&
M7R+5+?8&T1UVAF.;IX/<.#5Z%(1HV*1N[&*CHH-U262EH15 R<))F!^X;)@9
M)13IK?O7>BA3+%IA:'I\*D;>J,CH<3\7=R)%.+M9(2PUZZU;J&48==1YK\TU
M.8MELN+3.B(JVBSF-&'M,>V&039I,@9@.=>_<FM;]Q\HRRVS.]@RN%I$MILO
MFN<;Q\IC*O0Y=ADV\6[IUYRUM*\\-%KQ9['+QS.NV.__ )S:H3<N=XTBG1@4
M(=(I@ ]UB=^]=4FOB$L-S3O/0-9G6.D1E4F\WY5OU4B+K^Y&CH6V*4.P5;8V
M"2\S=[M,O[E_5D*T&=DGRC5[// &140(FX1,I<5A].==CUC#_CIH%<JV8:7I
MO3+34]QQ_31SV@K://91I3G=-&DM4U:[5XK^-5DVT<J]"<9,OOIGL3A]'E Z
M;5P9TBC3'O39'>9._P#/5N@\UN\/C7.^^-J-T!\5LGPGC5 ME236OU TZMZ#
MI\?!26UHPCR6B\[8Z=$:NE9G,O(N$&;=**<E=BV=?8:&E<.![.";AJ%;J+\@
M/,C^0J.@VJC9I\;FT9/:M&BJ%9YNEJW9;0, E8JOK3R,<O&+6.V0F=2KENQ%
M4RROVB)& %%T2*7^[W+O]SI<Z:>E?-+Z1Z"W[GG>\1?V3)$XBRSVY9_&T;.L
M^YTRB2MKZMYXG/.K$^<VRZ3Q+E/6JQ.D&H1[,JX,?NBFR;K.T<2-J07QGP=U
MK/ '(L%H"4LVL<?A5%3,RG3J'FHV#4C07J$5+ N4CA&1B:>JP;+)* "B)TA(
M;^8H^7']L$;$Y/*H\ \ \ \ \"J[Y2VU/(SX$G+&C74Y:"^37CH]9EYH(Y)]
M%.)&[/64K^ROGOM6:*OHPQDW (F 5$?H<!  ])(9[K]?AAWU[B]%G;E@V>=#
MU+=<3Z=T?4;%/5:.V.-:511*M9CE%0>/9 +W-63;'39O"%KD8!V3:K#(N5FY
M%7C,KUH)4\<*OJQT#\A.,Q!2IY5F^_Y_9<\C6Z"B,;4Y3:<*H&H:;3H<I1_#
M;1I+S,N)W\5$I"MW%@5_E*!R@ 6$^4'@'@'@'@'@'@'@'@'@'@'@'@'@9+Z>
MH>OZ>!3W(]\;31>;_D.UR\0N=3%GY-ZOLF#TI6M05EC*>WI3E+#TJ[>]!8O;
M'+S#EI16VMJRUD5;O&:*K*,6^U^,3_B%EZ! $^1#15=L'D8^M8RVL[?HA_E2
MO7:=3;/,G/5S<KM.E*S'.*M_>&WKC75I>8=JUY5K^_@U4:1ZSI%(KE4B"2PW
MT5\K&U:%B4[MM$@\ZB&W/W%K'L3=*^\CIF=8:8?^]36,Z>43,YPDO'FJM4E8
M/!++,QLRJ24<'-(Q13D.DDY^^L7!:9.:U>J-7T^;+GF%-M-E-$2,C;M/@)6]
MMJ94GL.XE5'[;.:_:*<[LMB=NCLVI$',Q&-&J2ZKDYUC(D;+45ST+MKJ+6*5
MRC1XUIE-!WC:LWZMUFUW1:MV>R9E+4CEVVQE$KEDS^K/;'$S+>M] 2]N@9EF
MJZD7"L=7'2PI"NLHW7) X69=V:7KNC?&/)UR&I<1CG='.VMZE;X)[&34AH-2
MNU#SRD75G&P-F+-M(%:M)NK2LT.5:+,Z6%N"@*E _M(L;A[J??$-TDPQ>0F.
M<9I'8<7VO3Z0PK5&O8..=IK+K51HZ@1VHV1]>%2:?2]3;6\8QU(-HVM.T)5J
MX.Q1511,!6HF+R_N<'TS@.7[I7XQW"--!K99)]7I!0%W]5LD>]>0%QJ+QS]E
MN#MS5+;$OHTZP)D*L9J)P* & /*'[ ?0/0/H']GH'@8\ \#  !0] #T#U]?^
M4? SX!X!X!X&"B!_4"C[A*/H;T_@/^L?I_#P,^!6I\GVI_(+D.+4^S?'1C%8
MVW5WFE1\1=:]9H]"6+%YXM7+ Y7F8R,<7>AE<.RV1JP1.8':IDT53#]H0]3D
MDWN2;W*)%^U_\TPM]4N$<[:^OZ?;SFNF]/\ D<]#*C_M\S>9J^$?U[_FHG\O
M$ME.-:&S;.9:-;N3N<XH;5DFU6?()N3O':NZ+*-&A$#&%14 $R9/4P (@'B\
MS5Z1.@Y/+4=.Y?HVF\]TW8Y'=;W9<R@K)9X:CSC+.'D#F5KUN5=J(VY@^DEX
MJ3AJ"_(0D> G.\21*H %4^X7:E+8\6XGIQG1+=DO+-6.RK4_<WA+'0<EA#M*
M=5 :&M-L<%DHEL*-9K17Z R#\WHU9@LG]XY/>7UDY8X[9U&A/G_ *:\JU/2.
M/".8%M1WTVW&KXL#B'9::]1C<U>2:/X'W6+70I)P1O!J* 4DLX.";453B!?)
MSX<1U'%+^/UE*VJ!DZ3QU&3-'B3S]RB7]8Q9I(U*#3= Q6F;,R<1Z:\%&(/3
M%047=%2236,5,X@<Q2BY\.,!/Q"7QG6&SQ-'KK+AZ;NL]:[-186IQ,9A,C8Y
M>YTMH#^XU2,A&;961>V*L,A!9^S33,NU3$!4*4!#QSX\0@>?9'BC;'M[JTQ@
M'*E!U"CZ5ME'=Y8ZA\7G;@YKF*Z)+9[):.WB4ZW$3(U.9>18+_>%E]EF*P(G
M5,8/<*,\9WP6DGE4AQY$BM8<+<\X1:DQ/-L^6ELF7S*,";M*C-:=C:2N\J1V
MYY6<6CDSOFL<8RBRC<!723$G\_CFQXP.<-L_*$1;"S,)J."1MRVN1@FJ3N.T
M"BMY[4Y>.F5<Q@"L$T)<KJWRZ$^T-7D#(E7<&=M08>HG0!(DGJ=.-9F*30YU
M=V''[A97U,J.H9Q9KE&(.G<E4Z_=JS,V9BT9/3QSUV[@XV3=2:#5G(IF;JJ&
M2 B;@IDS"!RB4+CGAE^V8E3 VCK@C2*ZMLE)RZPZ+4^3X*<1L<U%V.JPX7K4
M*G5BW:ZYE3$)MXW;_<I->>,RR4L^7:M"2CA1@B199LX^W;#2[/U/4+?3,5HX
M8 .ZV;?,/D.HT\5E[!7(=@QR[+H_.[G,.Y>2G6;J%L$ZTM=V@XZ*C#H%:R<@
M8QG"S5JDHJ"PA67RP9-8M%S>I4>DS]NK-_AN0YE*QC,Q4+<W+#M5683RF8I6
M5.$'$S?:Y5$XD5KD];NVP5](%Q(F[,T<E3<R6=[/>QM<L_1='PR]<:Z7DD%I
M,!KUPJ&BV;1\LFUB4W)WM=CS6"WY_5IR5LU,+;'=PB4V3=V(KIJ/037*FHFJ
M0JU3Z*(&]?:/KZ?KY1GP#P#P#P$%HB.8-J^K9]:3H3:J5!0DZO8=&)74J[5U
M43D23F59:S@$;"*I**E*5P*B1@$P![OJ'@=II T:?297&%B:C,J2S9C-PMN8
M1T+*B_;NFZ"\7-QLZB@X_.079BFHW<)JG*=+V&(82^G@)W'L9J^*UR7@ZXXF
M9F2M5LG+_>[E:'C>0MM\O=D.A^\6JSOVK6/9*OE&C)LS;(-F[9E'QK-LS:HH
MMFZ*1 0]OZPPJCZ IF4_;GY+4SL%$J4X>,I5\GZO4K9J#M@RSJL7>\P%9DZ7
M2I^YN)5I^"TE'[58Y';=0Q2)N$#J8RZF&,UE,1(<S/\ 4*3J"5M7I$R6<0H]
M]M>8659)E(-4V%YHSX(NVP29G[5K^<:$DO5NHNA]QN98ARD4-[#>FPX(?S !
M@^H#^@^OZ_P_\#P,^@^8GJ81MF @M$TZE96PKDE=Y!]&,K7=:EG<(LQK]CL9
MW-NO,NC!5B.6:UJ*F'3!K(2C@J:CUP1)@S*/W'"R28";S43$Q<; O?0?^[]/
M[?U_3RAF[/T#CM-G[S6;)>H>.F,QSG^]K1&PDD'1*30#JO4FL]9WC!DZ8PX2
M?[:Y.R:K*%?/46JZJ"*B2*AR@D[=UQSO2<\SG5;!I4<UHFM5@MVSR890UJG'
M%GIG],-[H[N#.!@8*3L3>IPU2=)2,E).&B+*+:*D.[41 Y?4/O-=8\[UJW5.
MD3NIUM"?O#6DOJW^%^Y2\"LSTQ^ZBLS<RMOB&#ZGUE+2Y5FJUK@R;]G^^N2"
MDQ^^?^7P$/%=^\>S>VM><XG;JY(;,]NT_F[.FM(RV+@\OE4CI&6L]28V,E?&
MIOIVNL(AV=Z@D_.9L+94JGH9,Q0EP)@C^H_ZQ\HQX!X!X!]/4/40 !$ #U$
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MMB94R@7^;W'$WH'I]?7P/R%VC&0%JV']NDOJW1'_ /%SW^*91_\ 5'E<W8_
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M.H.5L.[)RASB?0U+:WO.7=FJ-N6A'#ARS,$W2IYG8(9PB\9G3<(D4<-!;NB
M/L=,'"[90!36. A6?_F"F#6(^'?J*+BF;2,BHQAB<<QCHYL@QCX^/:;=FC1J
MP8LVQ$D&C)JW(1)-),I2$3 "@ %#T\D[$G8_-2SO_P"*+G/_ ,D.B?\ [V0_
MD9?J2_)5T/O_ #.3!M-Q)VWEZW6+=<KUT/ERU>93TGIG.F<U!2PZFSI!OP5)
MJ,T2IP1E)N+4:N$B.?V]1JJDO]XB?FFY(#1.R-)N'>_$>8XI=HA'E>]IZF?4
M[%"PT/.2VM6MESK_ '_T:KP,A+0<DM#U:NTQY$2,@M&*-W[U>P-VQ3$!%4!B
M;VFT'Y(U-,JDO"XW&W''=*H^\\!Q=K971IG\W*!E74O3,#G+J+F8>)G+6-,N
M[RO0<XPF(&439SD =9(3@FL8HIT*]K\G<E3<)O&W;9SK<:U&U3;>IL\30J]K
MSV0@F]*YFMETAY*PS=PG[A"5YA:IUA3E6T;"F6(^G9D#(QZ*C<!< L2*Z6Z0
ME(3)<"6QF71A+MV!J63Y%D5LFH1M*ITU#3X*4OTW?7E9D%4VDI*T_**S+R+)
M@Y,+9>61;(N .@90ABN+^_ZS5>X:-D?]<.[;F,SQ=K&C'H[RMU5I,R6FYEJ>
M+56.M"]P91[20,\L,-H#M!9DF5M&I+ "A$OJ )A3LP^3;IW^[F</7-,JMIWF
MY_'WN_3MTRR_U6IT=3C+<\DOU-@#9]+(.(FN.F-=>Q5QD8F,:6X\@Z?3U:;N
M!=';2"I!EI9?Y/\ (+KFGTS+)A[N%QR_GW5.G.@,_4Z)OU"S.,W/!:CDF)Q<
MQ4LSZ;K;BFN\ORG3;GMI)L$OW6#8JJUF/8-Q CV23<"+6S?'_P!!6;J;CCG_
M 'RYM8]K:=(H3:7F58AHM'PLVZ9RTO !;()@NHLJQ@[FE#%EV2 J*?9:OB$]
MY@*!AJDVYU76XGO"]Y6-C&QYBAQC$;%5LR1KT P>-=%;ZK-T]XHE;2-S3LC_
M %*P8HHD074!LU.;W$((B(@%.C#Y2>E8VB+'KUL>[!LUTX6DND]$RHF5,"6S
MC;8H/:<[SBY5-U1J[7(FU2%2I]7T&7=)0\^G)3#IU1C+?E*HOSE\EI98:M\E
M>E4:O[2G4MLL>U8=S_V'C>=7;?<;JN6VKH:V8OJ'.<CIU@JF7U%G439K?]0R
MK10:GG#QT!^2A2@<N#-BN&;EV 76\9WS0-/Y3Y^TC5;+0;CHMZRFGVNT6C,7
M;!]1YR0G8I&1+(0#N+<.HEPFLT<)_D'9'%B9V"OX_HA]L JI+B(C^O@8\ \
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M8I-M^3#-V"#:45-*J+1R2"2,BL](FH,FH= I2NUGJ0$,*QO<<Y?3U$?-CO\
MU_M'_:/_ (?F)PQG;^L@'U$0$1'Z?P]1]/H/J ^GKZ>H#_']?-Q%14#YG224
M435.F0ZJ(F%)0Q2B9(3E$AQ3$0]2"<@^@B'ZA]/ ^GH'Z^GU_M\ \ \ \ \
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M>5(YHM8_IZE./A4^O / XF-[?3Z&'U]1_E*)OH'IZB/IZ_3Z^!D! P (?H(
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MN5U>U#67.BSCMVL^?K3UKM"M0C(]LH0C1&.AV(I^U9=XZ6,$LO00_4!#P,>
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MS*S+U?1B8C;,G)GOB?!ZKQ]! #!^AO40]0$/I_#Z#]?J'GIB;BT8\H/ / /
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MQ:'%6-Y=IE_)N9SIS4>>M+KM%E(U[#L$H11+,',K7Y1XDLHFDLF1PU<^\3)
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M0<5BBTK&[W0Y]WFT+,6JRVFRV6+.W96>3BY>?.DB^?BJ5!P2/,R8(HMTQ(W
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M['CEPQ_HO8!B<NA;>WT/$J]@A:_)1+VYVF8L4A 7^.O\//$:J+H1$"5I._\
M ;E<H$.H()W%.P-SO(LZU:D,Q0O&M\+1G<60N(ZNV%.M4=O+R*4:[RZ\MAM*
MLG=6M:_J:OJ!+,UHA:0,J^+^.@4B ^!N+=OO6LUQ'DW3V92?.]0E#\JQ71VJ
M.M.K=WG:_-6!7-86]AGE5A*[<:\\J$#,*K/4U)MU(2KAD!6Z23)T=0ZA >*A
M=*7)38<5SG4JLTJB73&"#KF:Q@MGK:QT>^T:%I4CL..7(ZJBC66?QK*\-9&,
M>)I,S^QI(-UDA%%%10)J^ >O@'@'@'@9$HA^O_?#P,>!5U\L?27:O,//U+N_
M"^((;UK-@U^OTF6JBM$MNAGC:=)5JU2CR;0K]-F(.1*H69AV;;\E9?\ '2!Q
M[1*)SD])-[A06W^5G_,DK% $OC+;JF* E%4>7=N*<?0?J!O=J9 #Z_Z \ER-
MU"?*'_F0'$] I3'QI-(^#=3\(UG79>9MA3_%AWDJT;2STQQU-8Y/Q&*ZBOO$
MA@)[?<(" #XN1ZK-=U'&8F:IN#Z1HY:-:^BD+93\VC&\[-5.PW)[%P:DA8(R
ME6N+!M^W6MK!G.X;$0=H20D3.JU 3)&,30V>;RN25607Y\S@8F&=9%2Z2X4H
M<'%23.-I]+GR2L=1RD<&9A$E2DR5MX"*17"CD_XRIU ]?<8<Y9XX_NF@M[==
MJI0Z_.VFW3C*#@JU7;!;)IZZ%50S.N56//*V*6!FU27?NFT0P)]Q;[*2AB@8
MH>@F,4!8YXY?MFQ]J=;:Y?ZA5;[3I5&<J%WKD';JI-MTW"+>9KEEC&LS!RJ"
M+M%N[21D(QZDL4JJ9%"E. &*4WJ :C4;]94B"9U51$")D.H;VD.H;VID,H?V
MII%.H<P$((@4 $P_H "/@-UD&OYOOF;577\AM#:ZYQ=F;F0J]H9LY2/;RS1G
M(O8ATL1E-,8V5;?9DHY=$2K()F]R8_3T]!$'(]0 WM_C_P OI]0]?U_3]/ 0
M<'J%$L>@WK*X:=3?7W-86EV&[0)6<D@K!1&BDL)Z6]4=N6:,<^3G2U20]GXR
MRPI"U,54"&]H"&UNUUJ.;U&PWZ^V.(J-+J<0\GK)9IYZC'Q$-$,$A6=OGSM8
MQ2)))D#T /J8YA I0$P@ @AZ]ON.6K0'.4P5^AGFDL,YK^MR='4(_866(SJU
M.?PJ_:)F*D631S#,Y)V IE3=%2<$.4P'3*)3>@(NK]B\PW.NZ%;8#9Z6M6LJ
MKA;K?9UZ[>PT7 T15O,.66@?F3K&,2E,^E4J^^_!GF7Y,0^,T6*W<JF3,  E
M)_OKCVJ4@NA6G=JK6*V-[+F"B5C8V6"M+;05*Z2WIU!]0I2#:WN/G5:@JG+$
M07C4S'BUDG9?5NJFH8'VR#8,QWW.JYK>-W2&T/-K<G(*UNX5]59:(F"14J^@
MY$6BCA%NL;\*7C'#=0!( E52,'\/ <GP#P#P,B81_4? QX$3NALHXLG9NG6S
MIW),$NMJM4Y7\IH4OJ>8U.^VR;EYEZ_=P=(JPR\!.3SI(JJKU\=LV**#1N1T
M[6!-!-=4H1MC</\ A_D4]GF8W!>%UF/-$ZK$;;+ML:RA-KEEECXEI9EHNUN_
MZ53082S6,=(K_9 RB@&.4OI]P0)Y- \FE=(\V7['G<FSWF1IT'9+<ZR%G)TV
M#DU].2O\?'NIZ7SAIF,O1K1;U;*RK\>I(R$*\KBJ@PQ#.%D@9"90<93CE$X7
MM@5_S]@X4YKKL($I\F<]EU5UVAM]6C4:7$\VLJO=,VE 5BFEZF6U%YO7B'-8
MD?MK-4G<B4J"H)*HE$?8H4O#\7&9_=*VE%K6+4;/<QL^C:_W=N,-ET["Q+6T
M2=JAN=W\+:X:7!*-K]?=PQN>7KBUDE1EBMF,05LZ5<&<BDB@8QS%%'H\(_NG
MX%HXRU)XDL68TS8)GN^5M.9ZBS2@JK:5LYY:L[:=A\<._<*LGS-/F*1F(RNX
M@JU<J/1D6[9C3C%,9P+(?KYSGH]2_P!V7;W%P=9[R+STWT3,\+?]3VT^AR;"
MQ;AE&=J9SR4^?_:KSB"96+4ZBS+S6YCXYXR<.H])261.DY.((E(H8"%]O2/2
MW&N>5R7W&MBJWQ;IRV]4B%^0"PW4U"<KZYO58"D\S3+)XK7ID&+[7+'&J<RJ
MLM$1KL_"@DO96Q91)B[:%!1TF=(OMYST.IC,QAE-=NVEB3B7QX46UI.K+_?Y
M>[%_6+2?D)"PM\TY E"VQCHC"/+:)!Y,$YN7&PMK[%,6@2*RBJQ95NDD"PJD
M*7R>3U=\Y7[AM93X[("<C[!$S?0.N3$5;0K);7&RN?\ *LBPM!:6DBA32V-H
M[YT60G"5)NW33C"NBJ@P3(4J'VR@ !TP]-S1>6642)7X5B\;A-,<TR*LTQ:F
MKF>DI\9"9@,]K+A)Q*BDHZ03B\RI="K/VSN2'6,L+ 7:RJIS*JJ#[?;Z.ETH
MZ43$3,V2>?SH@\ \ \"&W9O!/-/?-7HM/Z4J,M:8;.K@%TK182T355=I/UF"
ML7*QKQY"N6ZSN$G8U7[+M 1 QBE*)#IG #>!+V-CV41&L(B,;),HV+9M8^/9
MH@)46C%B@FU:-40$1$$F[=(I"@/J/H'@('9LTCMHR'4<?F)!_$P^JY]<,ZEY
M6*!N:4C8JZ0$A79%_& \27:#(M&DB=1#[I#I?<*'N*8/4/ \VQO\JMR]]HA6
MW4/1*(%'T %HO+G'_"* E*3T)4T1]_T#^;U$!_L\#2.?\JC@AO3\3K?<4?H;
MU_(I6=.OJ/\ N?\ B-NS] +_ !_M_P!'@6UW/C>AY7\;=5XND:]N&]U+/:E2
MJE"3&1L*4SVAO8JG:&%EIVH5IE8;%6ZFQG:3<6365(0[I1$I6?M.DX()DCI2
M=(LP5^MW2VQXU?<;V+).X+'&WW*;7EDI*4GFOG//E) +C!*5^1NEE9+]87!"
M6LC!LJ=9JVCSPT45PLH8[4Y?M%1E]TIS=TD'9:':9[:9_84N;>\F)YK>N1MY
M2@%,5Y\?"SE.6:'*9VM7E)4>I&_Y4=H<#)>\5@;)+1+LHG)^24P)D7W2<W=)
MLD,YWZK+P-KS;%^Z:?J57VWK#2V]O/S;RU:*I-T7KG08[1[UFTMG=FZO>$.X
MKUA@(Q>'F$I!)=-1B *MSIJJIC.;NDYNZ5J>P99=K57>-]OJT#=)W0N8;K!Z
M(]I5T4K:&CVRFW+*[)E&K0,L$4\1IP:HRK5U5E4T6SE./7E8T6:2A"+D.733
MZU;DW64=ET;2]"Z2:W^AZPI,LKEEZV(5> >O<\<5R8KM3R-._N++.3D5GM.3
MFUWWXC1LU<OY59PY76][IP!PZV2<1O<L!\^<:FG<+)7^9(KD;&9J1HY8U'/\
M=@G+]]&?U-'M;2L:_7%^Z_:PE7R2T,V>)0C8$6K4YUSG#26+BW6W^ \Q8)5^
MDXJK0_/%<I,'-N7>'15NA-C7S*!C8//7EOJDQ?FZ#)A7G,4C+&CB.G+5U,HH
M+J?\-!-'P%+$8YIEHZ9P>U7>1FYZ Y.RF_1"FJV!A 5Y]N6S[5#TZ)F9R'JU
M<]&$15:=4X)Z+D?M-T32<LFV; L5DLJ(3O\ < B(>XHC_'T$/^4? SX!X!X
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ME'Z?K[3&#_G\H/41_41'P#U$?U$? QZB'Z#X&?4?[1_VCX!ZC_:/^WP,> >
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MNU+LB$NZKEOJ]@:U]\[C)YS!S\3+-X638%,H_CI=9@[73C'S$A1,LDN*9TP
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M"^OH4 ]?]'_A^/)Z? VL F4#BI]?>(>T1$QA#T]0'_=$PE#]/[/.@Y^ > >
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M >!UW3=L[;JM7B2+AJX(9%=NX3(J@NDH'L.@LDJ4R:J2I1]IBF 2F ?00]/
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M<[0Y+2JRSTG/7M>CK+4X65@X><5C)YD\F8-O/PCRS1XNX5ZX:33=)V10[0"
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M&_TAV;A/JI-C&WNGOGCQUC-M:I-8]E:(MPX>.CK,P3130;)&44_F,!"@/U$
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M\KW5U4K'CGQG9)F\C<>?=A:3C9KP3=262P/[E'QM;?,D O<<F5%@5D[<_86
M?NE*F(>W$Y97ICG4WNX_4I-CD]QNM8WB=J-DIEN/@LCLNX['E%IM7+.D5O7Z
ML[WBQ3][L.<7R]6 [BE0U3KUILKPR4Q''_<IIJW8,G":"::QE==*?OB.7*--
M^PJESP"80_F]/=]0'T_01 ?3W!_8!O3U_P!'KYZAGP#P#P#P*V?EN3B9K@_9
M<\D+G0J'(ZLG6Z/6)[2K+_252">_J*.M9&K^9*PE%DCK1=7="F5-NJ<YB_H
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M:WYO>HQ5^T164;MI=)V1#T0^R4"I:> #^@AZB'J AZ@/H(>O]@_P'P,
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M;4-W,,%EXF6L$-0Z R<2Z[(ZC+]V>.4FRJZ"22Z@3 \ \ \ \ \ \ \ \ \
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M9X<J3V^\T].IRQ;=7K\XLHWVRMX3(9-DC7'D6N!Q1:G5<@^3 H)@EZ'+)_\
M;^G_ .^O],_)>7+M,'&N+Z6DNA9W<:G-230CSL+$>C(V'L'.'6ZQCTNE\CS7
M+&A5J16B\F9 C;G*4XK,0BB(J,CB4$78I@(F&?\ UNC_ -W^V?D1C.[]81@I
M.#RU1Q]WD+:QYU"RV125'E><=Q@>#>G":E>U,QW^G;S1*_T]*JT9L\+7BJ41
ME&SS.MN%23+A<9,1(LU114O_ -?T^G[O]L_).6>TPL?Y<VX<>8]+3>EN92SW
M;<]RG=N@HNA<X=6QE5@%Y7*\THZ-3F9>Q94ZF':*$MGXG,_08^XS5P!_QP4
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MG=Q+PZ<G*D'_ ,5:+P"G,5:6?&_?))E6<;#,9#/Y]I@O&M0U6UUJ;;DI:/\
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M,(2SL;3,KD1=%EG;95HFF)VI3"8OF<O,O[8BO;]%T1C<_';U'%-,D6R2G4'
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M2NNAURBU>"O-P26=IOU4[5;(R,;3UB(H^1(L8'CA;U5(!A_F !\M!SO / /
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MD2^RHJ5R@253N<:3T]8JI\?. ZAJ6FLQZ4UOJ-P\V]@6*IFTW+G'&ZUI%[P
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MD!02^!\AU*D$U/\ N6&5<!HRE!4U 8/]FFOQ!I!+$G4C2Y[!^W_TX#@9]0$
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M"M-5G0?K"V/1V\VWB1C/M( W*NG/.73W]P!<%1.)3?;]@E] ]?7RA8> > >
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MV*:S6C(N(^FUK4(UF5^V*",@Q58@X39J?;3,/7S^EMYH*DQE'SC4HW%=B^Y
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M(_@#^-[ #0>POKZC[?7]1]?3]/7^/K_T?=_S^ #Z_3U_T>W]/3_1[?3Z?[/
MX?R^\W_JST#W>OKZ^G\/7U\#EX!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X!X
M!X!X!X!X!X!X!X',WN]/YOT]?]'_ ('@</ / / ZZ_X_L4^_Z>SV#]S_ '_7
MV>G\W^Y_-Z>G]GF<^7EGF_;6HAM=O^SP_JVQ_P!Y/^#7^O/W,_\ 5?\ 7W]R
MW]8?NWVTO=^^_P!2C^]_E_9]G_B;^;V^GI]//#R^AWY8WW[?T:^ZM+HFS?\
M9?\ I]?\!7I_H_P]_P#VODY?0?RP[>X^_O<O_=7_ /\ Z$^G_P!+SYR_X/\
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?.5>^DF]]I7?3^'H(?P$/3T$/X>GI]/3SU(/ / __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>cm270_ex10-34img05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cm270_ex10-34img05.jpg
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M6P@"&Q$QO-^@R$A\^D/JWK8O&O5O6O&MB\?'>M?IK>_EE&N P& P& P& P&
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M;ZFK99NCQSVE8*X69:%4,%ED-Y[8^6C%8(T*W ;007L2C[0X@@PU0484$7"
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M/V6!.Y%I_7\ ^,#LEWU\W63[B-@Q^8QNPR:AG7M36_2TTG$?ATITQHE4RN!
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M/6_.M^=Z^/C>M_+>O.MZW\OE@:X# 8# 8# 8# 8% _<"8.HY_73)4?/E5HK
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MYPK#E:(0&4,T.MN5/L*L?G*<3>["9,\:B-=*"VI \/4P9TZ$38O=A'C:AEK
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MN66.!S>/65!H98T07"<HG/XI'IM%W 11J<2Z.2IH1OS&M&G." X@2MK7E&;
M/6A V+QOXZPKM?G?\=_SW@/._P"._P"> \[W\][P-H)"8)XU>DY.E9A $QBK
MT!^X&G*&884G$;Z?J;(*,.&((//IT(8MZUYWOR&Y@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8I?<OLFMV(
MZFX/8'<U <F-Q[NML)P@MX5__<-LNPF**40(\C=&D-H5J,^&1&4'D.*E%LPX
MAQ<"4@5.A)RC"#R2H#;ML^WU<()61)O=1YL6_P!_:9IVDNNG4U(RH7.W6&FY
M@]2YN?(2E:)2@9ZS>90CESVPK2SB'Q.2TK21E:VJ2Z-.%+C<Z7]RS8W<]\6%
M2W<O-=ESWI2E:GK"OJ?BR=2[R!@<N?4=I2,B2*5!$T(_=S<I+L-Q4+4"=,V#
M*2H2M 4:WLP>ROJ4<W]@T_0MVUK_ '49>HIKTY'Y=6;:I8: U6!"6UKF3K&6
M3] 7_-1V;8*TV+P>$@^W3)T0&U A;6]*U(D9PQ(2BB,H],UPDIRGZIJ!O<#G
M=MJFMH+6[<ZJB@DJW-%!HLU1A,X*B@"& I0M):]&C"'>]!$+>M;WA4DX# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8%/ZC[TY4O2^K1YDJZTTDGNVF@.8[#A93'(D0F;3$\)([(-)7Q>UI
MXX^"8'Y<2C6:0*U.R#S-:W\-;WH+@8&+OW!:J]J:?26N'3W%%-&)94U1Z0(Z
MS';-K.=>.0HXI<6\^0Z94+;,8T-U2!<RD_U3!%'?3,](="#ZMZV'B4N9@X\C
MWNOM,4KMEY[?N($]JUHTE 33YU-I]SIY\9V4Z;R"16$3,S'LM_9 .CB<89IR
M+-)<$!) 2=@UHDP/6UQS6?L-1SH: /'&#OSJHZ01E2(, !";:ELEEQQ:F.N2
M:3:;&-\F3DWK3-Q@U7L[RG&,!'U!AUK8?.@Y^];_ +O9.\.C*(;;:Z+00='R
MY0MB5:QTA6-:39?!+/M"RYK6CB].[A)Z\>DA4*(_ H5YX9 N C)+"N$ X.M
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M5KTI"Y/OR S11YY6Q!\@,&'>A;WN)9P& P& P& P& P& P& P& P& P& P&
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E P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
